

American Heart Journal

An international publication for the study of the circulation

George E Burch *Editor*

Thomas D Giles *Assistant Editor*

James A Cronvich *Assistant Editor*

International Editorial Board

Walter H Abelmann *Boston Mass*

R P Ahlquist *Augusta*

James K Alexander *Houston Texas*

John B Barlow *Johannesburg South Africa*

Giorgio Baroldi *Milan Italy*

Lotfy L Basta *Tulsa Okla*

Henry W Blackburn *Minneapolis*

Thomas M Blake *Jackson Miss*

S Gilbert Blount Jr *Denver*

Bernardo Boskis *Argentina*

Eugene I Chazov *Moscow U.S.S.R*

Henri Chevalier *Paris*

Te-Chuan Chou *Cincinnati*

J M Criley *Torrance Calif*

Arthur C DeGraff *New York*

Lewis Dexter *Boston*

James E Doherty *Little Rock*

Jesse E Edwards *St Paul*

Robert H Fick *Syracuse N Y*

Marv Allen Engle *New York*

Ali M Fakhro *Bahrain*

M Irené Ferrer *New York*

Nancy C Flowers *Louisville*

Nicholas J Fortum *Baltimore Md*

Martin J Frank *Augusta Ga*

Julian Frieden *New Rochelle N Y*

Meyer Friedman *San Francisco*

Peter C Gazes *Charleston*

Ja ques Genest *Montreal Canada*

Allan V N Goodyer *New Haven Conn*

Mervyn S Gotsman *Jerusalem Israel*

Robert L Grosson *Omaha*

Dale Groom *Oklaoma City*

Rolf M Gunnar *Chicago*

Warren G Guntheroth *Seattle Wash*

E. William Hancock *Stanford Calif*

Herbert N Hultgren *Palo Alto Calif*

Mohamed Ibrahim *Cairo Egypt*

Thomas N James *Birmingham Ala*

L E January *Iowa City*

James N Karnegs *Minneapolis*

John A Kaster *Philadelphia*

Nodar N Kipshidze *Tbilisi U.S.S.R*

Richard Langendorf *Chicago*

John H Laragh *New York*

J Lequime *Brussels Belgium*

Maurice Lev *Chicago*

R J Linden *Leeds*

F Loogen *Dusseldorf Germany*

Hugh A McAllister Jr., *Washington D C*

Dan G McNamara *Houston*

George E Maha *West Point Pa*

Rashid A Massumi *Dallas Calif*

Clifford V Nelson *Portland Me*

Satoshi Ohta *Japan*

Eckhardt G J Olsen *London*

Victor Parsonnet *Newark*

Morton Lee Pearce *Los Angeles*

Alfred Pick *Chicago*

Hubert V Pipberger *Washington D C*

Ray Pryor *Denver Colo*

E W Reynolds *Madison Wisc*

Robert C Schlant *Atlanta Ga*

Peter J Schwartz *Milano*

Ralph C Scott *Cincinnati*

Walter Somerville *London*

Borys Surawicz *Lexington*

John Thomas *Nashville Tenn*

Hironori Toshima *Kyushu Japan*

William H Wehrmacher *Chicago*

Hein J J Wellens *Maastricht*

The Netherlands

Douglas P Zipes *Indianapolis Ind*

VOLUME 96

JULY DECEMBER 1978

July 1978

American Heart Journal

Copyright © 1978 by The C V Mosby Company

Contents

Editorial

Surgical versus medical treatment in disease of the left main coronary artery 1

Ian M Graham MB MRCPi Dublin Ireland

Clinical communications

The error in indirect blood pressure measurement with the incorrect size of cuff 4

L A Geddes ME PhD and S J Whistler BS West Lafayette Ind

Distinctive echocardiographic pattern of posterior wall endocardial motion in aortic stenosis 9

J M Sheppard MD Abid A Shah MD James A Sbarbaro MD and Harold L Brooks MD Chicago Ill and Milwaukee Wis

Unusual complications of coronary bypass surgery 17

Agop Aintablian MD Robert I Hamby MD Robert J Kramer MD and George Wisoff MD New Hyde Park and Stony Brook NY

Intravascular hemolysis in the late course of aortic valve replacement: Relation to valve type size and function 24

Jon Dale MD and Erik Myhre MD Oslo Norway

continued

Vol. 96, No. 1 July 1978 The American Heart Journal is published monthly by The C V Mosby Company 11830 Westline Industrial Drive St Louis Mo 63141

Annual subscription rates

	US	PUAS Mexico	Canada other countries
Institutional	\$37.00	\$43.50	\$44.50
Personal†	\$4.00	\$9.50	\$31.50
Student resident†	\$19.20	\$5.00	\$26.70

(Postal Union of the Americas and Spain)

Single copies are \$4.00 postage and handling charges should be made by check draft post office or money order payable to this journal

Instant (tutorial) (multiple reader) subscriptions are available to public and private libraries, schools, hospitals, academic city county state provincial and national government bureaus and departments and all commercial and private institutions and organizations

†Person 1 subscriptions and all student rate subscriptions must be in the names of billed to by individuals. All student rate requests must indicate matriculation status and name of institution. Subscriptions may begin at any time

Second class postage paid at St Louis Mo and additional mailing offices.

Printed in the USA copyright © 1978 by The C V Mosby Company

The appearance of codes at the bottom of the first page of an original article in this journal is the copyright owner's consent that copies of the article may be made for personal or internal use of the person or internal use of specific clients. This consent is given on the condition that the copier pay the stated per copy fee through the Copyright Clearance Center, Inc., 27 Congress St., Salem, N.H. 03079.

Arterial thrombosis in essential thrombocythemia 31

Shafkat Hussain M.D. Joel M. Schwartz M.D. Sandor A. Friedman M.D. and Segundina N. Chua M.D. Brooklyn N.Y.

Blind study on the relations between the extent of coronary atherosclerosis and the strength of the myocardial contraction as measured by invasive and noninvasive tests 37

Isaac Starr M.D. George Karreman M.D. Thomas Bering B.A. and James C. Shelburne M.D. Philadelphia Pa.

Comparison of heart rate and blood pressure response to amyl nitrite isoproterenol and standing before and during acute beta adrenergic blockade with intravenous propranolol 47

Andreas P. Niarchos M.D. Paris Tahmooressi M.D. and Robert C. Tarazi M.D. Cleveland Ohio

Variations in the critical cycle length inducing rate dependent bundle branch block 54

Shinji Kinoshita M.D. Sapporo Japan

Effects of bundle branch block on experimental A V reentrant tachycardia 62

Fernando Amat y Leon M.D. F.A.C.C. Alison Blasdel B.S. Steve Teague Kenneth M. Rosen M.D. F.A.C.C. and Pablo Denes M.D. F.A.C.C. Chicago Ill.

Myocardial infarction in young vs old male rats Pathophysiologic changes 70

Bernard C. Wexler Ph.D. Cincinnati Ohio

Effects of verapamil on ventricular rhythm during acute coronary occlusion 81

Joseph D. Fondacaro Ph.D. Jaak Han M.D. Ph.D. and Myung S. Yoon M.D. Albany N.Y.

Case reports

Acute idiopathic pericarditis and calcific aortic stenosis unusual fatal disease combination 87

Charles E. Wheatley M.D. Ann Arbor Mich.

Isolated dissecting aneurysm of the renal artery 92

Asad A. Bakir M.D. Suresh K. Boddy J. J. Brown D. L. Davies R. Fraser D. Edmund J. Lewis M.D. Chicago Ill.

Review

The treatment of low renin (primary) hyperaldosteronism 97

J. B. Ferriss D. G. Beevers K. Boddy J. J. Brown D. L. Davies R. Fraser D. Kremer A. F. Lever and J. I. S. Robertson Glasgow Scotland

Fundamentals of clinical cardiology


Pericardial constriction 110

J. V. Hirschmann M.D. Seattle Wash.

Appraisal and reappraisal of cardiac therapy

Infective endocarditis New diagnostic techniques 123

Michael H. Miller M.D. and Joan I. Casey M.D. F.R.C.P.(C) Bronx N.Y.



Varian

Medical Group Varian Associates
611 Hansen Way Palo Alto CA 94303

Annotations

Preventing thromboembolism after myocardial infarction Effect of low dose heparin or smoking 129

Peter A Emerson MD FRCP FACP (Hon) London England

Of how non invasive is non invasive? 130

George E Burch MD Neu Orleans La

Another link between the left stellate ganglion and the long QT syndrome 130

Richard S Crampton MD FACC Charlottesville Va

Roll over test 132

George Marshall MD Kansas City Mo

Letters to the Editor

Dissertation on a Roast Pig Updated 134

Myron R Schoenfeld MA MD FACP Scarsdale N Y

Setting the record straight on TAPVC 134

Maurice Lee MD Chicago Ill

More on jugular venous pulse (JVP) tracings and cannon waves 134

J Tenczer MD and L Littmann MD Budapest Hungary

Additional angiocardiograms for Tetralogy of Fallot 135

Byan Siassi MD FACC Iraj Aryanpur MD FACC and Jamu G Shakibi MD FACC Tehran Shemiran Iran

Book reviews

Book reviews 137

Books received

Books received 138

Announcements

Announcements 138

(Information for authors on page 13)

Burdick's new EK-7:

Today's intelligent answer for computerized ECGs



ECG ANALYSIS 05/10/77 15 15 15
BURDICK COPY , MILTON WISC
PAT 999999 ROOM 6-7 NAME CRUC AGE 59 NY 604 LBS
BING NO HEART DISEASE NEWS NONE

NORMAL STATUS RATION DATE 66

CONSISTENT WITH ANTERIOR INTERACTION

THERE IS A QS PATTERN IN V2 WITH R IN V4 MORE
THAN 87 MM (TYPE 3)
THERE IS AN R IN V4 R2 PLUS RS IN V3 V4 OR V5 (TYPE 1)
THERE IS A QS PATTERN IN LEAD III WITH R WAVE PRESENT
LEAD TO THE RIGHT ON THE CHEST (TYPE 1)

FRONTAL PLANE ANGLES IN DEGREES

QRS	P	T	ST	
28	44	69	4	52

Burdick's new 3-channel automatic electrocardiograph

At the touch of a button the EK 7 provides cost efficient ECGs for computer analysis ready for your review

Burdick designed the EK 7 acquisition system to use the interpretive potential of computer programs already in service even though they may be many miles from your office clinic or hospital. Thus the Burdick EK 7 gives you the greatest freedom of computer service choice

Burdick's EK-7 records, translates, and transmits ECGs automatically

Access to computer facilities can be as automatic as activating one button. Manual operation is also possible with a built in telephone handset. Patient identification and statistics are set manually and transmitted automatically.

For immediate examination, you get scratch resistant smudge free tracings produced on Burdick's easy to read BlueTrace 3 channel paper.

Burdick and computer-assisted electrocardiography help meet your needs

When you invest in an EK 7 you invest in your practice.

Computer assisted electrocardiography substantiates and augments your diagnosis, increases speed and volume of ECGs administered. For your review, you get computer generated ECG interpretation in minutes.

A Burdick trained dealer will help you select the instrumentation options best for you and teach your staff the proper techniques. For more information call our toll free number (800) 356 0701.

Within Wisconsin (608) 868 7631. Or write The Burdick Corporation, Milton, Wisconsin 53563.

BURDICK

American Heart Journal

Copyright © 1978 by The C V Mosby Company

Contents

Editorial

- Coronary stenosis Ischemic or non ischemic factor? 139
Giorgio Baroldi MD Rome Pisa and Milan Italy

Clinical communications

- Infective endocarditis in heroin addicts Epidemiological observations and some unusual cases 144
Michael Lange MD John S Solaki MD John R Middleton MD Purnendu Sen MD Rajendra Kapila MD Marmaduke Gocke MD and Donald B Louria MD FACP Newark NJ
- The temperature course in acute myocardial infarction 153
R Lofmark MD R Nordlander MD and E Ornnus MD Huddinge Sweden
- Systolic flutter of the mitral valve 157
Karl C Sze MD Navin C Nanda MD and Raymond Gramiak MD Rochester NY
- The management of anticoagulation during noncardiac operations in patients with prosthetic heart valves A prospective study 163
Richard E Kathol MD Stanton P Nolan MD and Lockhart B McCurre MD FACP Charlottesville Va

continued on page 7

Vol 96, No 2 August 1978 The American Heart Journal is published monthly by The C V Mosby Company 11830 Westline Industrial Drive St Louis Mo 63141

Annual subscription rates

	US	PUAS Mexico	Canada other countries
Institutional	\$37.00	\$43.50	\$44.50
Personal†	\$24.00	\$30.50	\$31.50
Student, resident†	\$19.20	\$25.00	\$26.70

(Postal Union with Americas and Spain)

Single copies are \$4.50 postpaid. Remittance should be made by check, draft, post office or express money order payable to this Journal.

Institutional (multiple reader) subscriptions are available to public and private libraries, schools, hospitals, and clinical city county state provincial and national government bureaus and departments and all commercial and private institutions and organizations.

†Personal subscriptions and all student subscriptions must be in the names of billed to and paid by individuals. All student rates require a statement indicating training status and name of institution.

Subscriptions may begin at any time.


Second class postage paid at St Louis, Mo and additional mailing offices.
Printed in the USA copyright © 1978 by The C V Mosby Company

The appearance of a code at the bottom of the first page of an original article in this journal indicates the copyright owner's consent that copies of the article may be made for personal or internal use or for the personal or internal use of specific clients. This consent is given on the condition that the copier pay the stated per-copy fee through the Copyright Clearance Center Inc. P.O. Box 765, Schenectady, NY 12301 518-374-4430 for copying beyond that permitted by Sections 107 or 108 of the U.S. Copyright Law. This consent does not extend to other kinds of copying such as copying for resale or for general distribution for advertising or promotional purposes, for creating new collective works or for resale.

The Medtronic 8950 and 6951 unipolar and bipolar tined leads feature four integral silicone rubber tines that protrude from the lead body just proximal to the tip electrode. These tines were designed to provide better acute lead stability and reduce chronic lead dislodgement by latching onto the papillary musculature or the trabeculae of the right ventricle. The large surface area provided by the tines should also enhance the stability afforded by fibrosis.



The newest members of the Tenax™ family of self anchoring leads – the 6961 and 6962 unipolar and bipolar leads – feature shorter smaller tines and small tip diameter (8 French approximately 10 French with tines folded) enabling the physician to use the more common cephalic approach. Though small the soft pliable tines are still long enough to become securely anchored in one or more of the interstitial spaces formed by the trabeculae of the right ventricular chamber. The leads ring tipped electrode provides optimum energy to the heart with impedance matching and current drain characteristics. Its durable space-wound multilayer conductor is designed to provide a longer life time to match the potential long effective service life of lithium powered pulse generators.



ME **E PACING LEADS**

Intend
Medtronic Implantable pacemaker leads are designed to be used with 1 or more of the
generators set to a cardiac pacing system (see product labeling) and all directions
app. at end

[illegible]

August 1978

Contents

Clinical communications

Infective endocarditis in heroin addicts Epidemiological observations and some unusual cases 144

Michael Lange MD John S Salaki MD John R Middleton MD Purnendu
Sen MD Rajendra Kapila MD Marmaduke Goeke MD and Donald B Lourie
MD FACP Newark NJ

The temperature course in acute myocardial infarction 153

R Lofmark M.D R Nordlander M.D and E Orinius M.D Huddinge Sweden

Systolic flutter of the mitral valve 157

Harl C. Sze M.D., Nalin C. Nanda M.D. and Raymond Gramiak M.D. Rochester N.Y.

The management of anticoagulation during noncardiac operations in patients with prosthetic heart valves. A prospective study 163
Richard E Aethols MD, Stanton P Nolan MD, and Lockhart B McGuire MD, FACP, Charlottesville, Va.

continued on page 7

Annual subscription rates

Vol 90, No August 1978 The American Heart Journal is published monthly by The C V Mosby Company 11830 Westline Ind. trail Dr • St Louis MO 63141

2.8

PUAS
Mexico

Canada other
countries

Inst tot onal	\$37 00	\$43.50	\$44 50
Personalit	\$74 00	\$39 50	\$31.50
Student, read att	\$19 20	\$35 0	\$ 8 20

(Postal Union of the Americas and Spain)

Single copies are \$4.50 postpaid. Remittances should be made by check, draft, post office order or express money order payable to this Journal.

Institutional (multiple reader) subscriptions are available to public and private libraries, schools, hospitals, and clinics, city to city, state, provincial and national government bureaus and departments and all commercial and private institutions and organizations.

1 Personal subscriptions and all student rate subscriptions must be in the names of billed to and paid by individuals. All subscription requests must indicate mailing status and name of institution.

Serve d less postage paid at St. Louis, Mo and additonal mailing offices

Printed in the USA copyright © 1988 by The C.V. Mosby Company

The presence of a code at the bottom of the first page of an original article in this journal indicates that copyright was transferred to certain types of specific clients. This consent is given on the condition that the copiers pay the stated per-copy fee through the Copyright Clearance Center Inc. P.O. Box 765, 222 Rosewood Drive, Danvers, MA 01923. This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale.

A reminder
LANOXIN®
(digoxin)



125 mg
yellow
imprinted



25 mg
white
imprinted & scored



5 mg
green
imprinted & scored

Complete literature & a table on request from Professional Services Dept. PML



Burroughs Wellcome Co
Research Triangle Park
North Carolina 27709

Organized left atrial mural thrombus demonstrated by coronary angiography 166

Paul R Cipriano MD and Diana F Guthaner MD Stanford Calif

Idiopathic familial myocardiopathy in three generations A clinical and pathologic study 170

Richard S Ross MD Bernadine H Bulkley MD Grover M Hutchins MD John S Harshey MD Richard A Jones MD Henry Kraus MD Jerome Liebman MD C Michael Thorne MD Sidney B Weinberg MD A Ashley Weech MD and Alexander A Weech Jr MD Baltimore Md

Occurrence and significance of echocardiographically demonstrated tricuspid valve prolapse 180

Jeffrey A Werner MD Nelson B Schiller MD and Richard Prasquier MD San Francisco Calif

Rapid sensitive detection of myoglobinemia by improved counterimmunoelectrophoresis in cases of acute myocardial infarction 187

Katsuhiko Hiramori Tetsuya Sumiyoshi Saeko Motegi Takashi Honda Shinichi Kimoto Kohichiro Hirosewa Hsueomi Kawai Akira Kondo Masaru Iwasa and Ka uo Mvoshi Tokyo and Tokushima Japan

The importance of R on T phenomenon 191

Te Chuan Chou MD and Frank Wenzke MD Cincinnati Ohio

Experimental and laboratory reports

Postextrasystolic aortic pressure pulse response in coronary artery disease 195

Robert J Hamby MD FACC Agop Aintablian MD Gerald Roberts MD and Robert J Kramer MD New Hyde Park Jamaica and Stony Brook N Y

Peripheral hemodynamics in anephric patients with hypertension 203

John A Wyden MD Altin Sellers MD Kouichi Nagasawa MD Teruo Takano MD Marsha Groseth Robertson BA and H J C Suan MD PhD Los Angeles Calif

Effect of probucol in hyperlipidemic patients during two years of administration 213

William B Parsons Jr MD Madison Wisc

Antihypertensive effect of cardiovascular Ca^{2+} antagonist in hypertensive patients in the absence and presence of beta adrenergic blockade 218

Amzoo Aoki Shuta Kondo Akihiro Mochizuki Tadashi Yoshida Setsuko Kato Kazuaki Kato and Kiyoharu Takakawa Nagoya Japan

Circulating catecholamines and systolic time intervals in normotensive and hypertensive patients with and without left ventricular hypertrophy 227

Daniel Cousineau MD MSc Léonard Lapointe MD FRCP(C) and Jacques de Champlain MD PhD Montreal Quebec Canada

A reminder
LANOXIN®
(digoxin)



0.125 mg
yellow
imprinted



0.25 mg
white
imprinted & scored



0.5 mg
green
imprinted & scored

Complete literature available on request from Professional Services Dept. PML



Burroughs Wellcome Co.
Research Triangle Park
North Carolina 27709

Case reports

Electrophysiologic histologic correlation of the cardiac specialized conduction system in two cases of single ventricle and levotransposition of the great arteries 235

John Schatz M.D. John Fenoglio M.D. and Ehud Kronegrad M.D. F.A.C.C.
New York N.Y. and Washington D.C.

Pleural effusion as a manifestation of Dressler's syndrome in the distant post infarction period 243

W. Roger Dombey M.D. and Michael E. Whitcomb M.D. Boston Mass

Clinical pathologic conference

Pompe's disease presenting as hypertrophic cardiomyopathy with Wolff Parkinson White syndrome 246

Bernadine H. Bulkley M.D. and Grover M. Hutchins M.D. Baltimore Md

Fundamentals of clinical cardiology

Mitral valve repair for significant mitral insufficiency 253

Jerome Harold Kay M.D. Pablo Zubiate M.D. Michael A. Mendez M.D. Neal Vanstrom M.D. and Taro Yokoyama M.D. Los Angeles Calif

Appraisal and reappraisal of cardiac therapy

Infective endocarditis Part II Current therapy 263

Joan I. Casey M.D. and Michael H. Miller M.D. Bronx N.Y.

Annotations

Hypertension and the cerebral circulation—its relevance to the elderly 270

John V. Jones Ph.D. M.R.C.P., and David I. Graham Ph.D. M.R.C.Path., Oxford England and Glasgow Scotland

Intramural ramification of the left bundle branch 271

L. Rossi L.D.Path.Univ Milan Italy

Of the myocardium and myotonia atrophica (dystrophica myotonia) 272

George E. Burch M.D. New Orleans La

Mutton's law 273

Herbert L. Fred M.D. Houston Texas

Letters to the Editor

Steroids in myocardial disease 274

Salatore J. Giordanni Jr Pharm.D. New York N.Y.

Diagnosing magnesium deficiency 274

Carlo Tommaso M.D. and Joseph Tucci M.D. Providence R.I.

Lymphatic drainage of the brain and catarrhea 274

A. G. Gordon London England

Exaggerated impendante waveform—a noninvasive assist 275

A. Leach M.D. and L. E. Schnitzer B.A. RT A.R.D.M.S. Marshalltown Iowa

Reply 275

Marcos U. Ramos M.D. Boston Mass

No Matter How You Look At It...



with the experience of over 155,000 valves and now into its 10th clinical year, the Bjork Shiley Cardiac Valve Prosthesis continues to be the choice of cardiologists and surgeons for valvular replacement. Certainly a major reason is durability—exhibited both in vitro and in vivo. Life cycle testing indicates a projected wear life of 794 years, and the structural integrity of the valve is further substantiated by excellent clinical experience. On a continuing basis, Shiley provides updated material about the Bjork Shiley valve. If you are not currently receiving this information and would like to, please let us know.

**Shiley**

an integral member of the open heart team

Contents continued

Sensing the cardiac electrogram 275

M B Raber P Eng Winnipeg Manitoba Canada

Reply 276

Seymour Furman MD and Philip Hurzeler PhD Bronx N Y

Ischemic myocardial disease and alterations in the ECG 276

David Halbersleben MD Chestnut Hill Mass

The O point and diastolic impedance waveform 277

Zuhdi Lababidi MD Columbia Mo

Reply 279

Marcos U Ramos MD Boston Mass

Book reviews

Book reviews 280

Books received

Books received 281

Announcements

Announcements 282

(Information for authors on page 15)

ISORDIL[®]

(isosorbide dinitrate)

HELPS THE HEART IN THE CONTROL OF ANGINA PECTORIS*

The established use of Isordil in the management of angina pectoris for more than two decades has often been ascribed only to the vasodilatation it produces in the coronary arteries. Recent investigations, however, suggest that an even more important effect of this agent is to dilate peripheral arteries and veins. Arterial dilatation lowers impedance to left ventricular ejection, reducing afterload. Venous dilatation leads to venous pooling and a fall in right and left ventricular filling pressure, thus reducing preload.

With afterload and preload reduced, the amount of energy expended and oxygen consumed by the heart should be decreased. Isordil can thus reduce myocardial oxygen requirements and relieve or prevent attacks of angina pectoris.

to abort or prevent
acute angina attacks

ISORDIL[®] SUBLINGUAL
Sublingual Tablets 2.5 mg and 5 mg

ISORDIL[®] CHEWABLE
Chewable Tablets 10 mg

for more accurate
titration of dosage to
prevent angina attacks

ISORDIL[®] TITRADOSE[®]†
Oral Tablets with E-Z Split[®] scoring
5 mg, 10 mg, and 20 mg

to provide
sustained
prophylaxis
against angina

ISORDIL[®] TEMBIDS[®] Capsules
Sustained Action Capsules 40 mg

Indications: Based on a review of this drug by the National Academy of Sciences—National Research Council and/or other information, FDA has classified the indications as follows:

Probably effective: When taken by the sublingual or chewable route, Isordil Sublingual and Chewable Tablets are indicated for the treatment of acute anginal attacks and for prophylaxis in situations likely to provoke such attacks.

Possibly effective: When taken by the oral route, Isordil is indicated for the relief of angina pectoris (pain of coronary artery disease). It is not intended to abort the acute anginal episode, but is widely regarded as useful in the prophylactic treatment of angina pectoris.

Final classification of the less than-effective indications requires further investigation.

Contraindication: Idiosyncrasy to this drug.

Warnings: Data supporting the use of nitrates during the early days of the acute phase of myocardial infarction (the period during which clinical and laboratory findings are unstable) are insufficient to establish safety.

Precautions: Tolerance to this drug and cross tolerance to other nitrates and nitrites may occur.

Adverse Reactions: Transient vasodilation with flushing. Headache is common and may be severe and persistent. Transient episodes of dizziness and weakness as well as other signs of cerebral ischemia associated with postural hypotension may occasionally develop. This drug can act as a physiological antagonist to norepinephrine, acetylcholine, histamine, and many other agents. An occasional individual exhibits marked sensitivity to the hypotensive effects of nitrite and severe responses (nausea, vomiting, weakness, restlessness, pallor, perspiration and collapse) can occur even with the usual therapeutic dose. Alcohol may enhance this effect. Drug rash and/or contact dermatitis may occasionally occur.

Consult directions circular before prescribing.

May we send you reprints, detailed information and/or professional samples?

IVES LABORATORIES INC.

New York, New York 10017

DEDICATED TO IMPROVING THE QUALITY OF LIFE THROUGH MED[®]

For S. Pat. Nos. 383647 and 0224591

TEMBIDS — TRADE MARK FOR



Contents

Editorial

Venous thromboembolism after stroke 283
Charles Warlou M.D. M.R.C.P. Oxford England

Clinical communications

Atrial flutter Electrocardiographic vectorcardiographic and echocardiographic correlation 286
Olga Zonerach M.D. F.A.C.C. Samuel Zonerach M.D. F.A.C.C. Jai J. Rhee M.D. and David Jordan Ph.D. Stony Brook and Jamaica N.Y.

Hemorrhagic myocardial infarction associated with aortocoronary bypass revascularization 295
J. T. Lee M.D. Gerald M. Laurie M.D. George C. Morris Jr. M.D. and William L. Winters M.D. Houston Texas

Long term follow up of aneurysmectomy for recurrent ventricular tachycardia or fibrillation 303
Magdi Sami M.D. Bernard R. Chastman M.D. Marthal G. Bourassa M.D. Denis Charpin M.D. and Michel Chabot M.D. Montreal Quebec Canada

Coronary ectasia Incidence and results of coronary bypass surgery 309

Agop Ainalabian M.D. Robert I. Hamby M.D. Irwin Hoffman M.D. and Robert J. Kramer M.D. New Hyde Park and Stony Brook N.Y.

continued on page 7

Vol. 96 No. 3 September 1978 The American Heart Journal is published monthly by The C V Mosby Company 11830 Westline Industrial Drive St. Louis, Mo. 63141

Annual subscription rates

	U.S.	PUAS Mexico	Canada other countries
Institutional	\$17.00	\$43.50	\$44.50
Personal	\$ 4.00	\$30.50	\$31.50
Student, resident	\$19.20	\$25.70	\$26.70

(Postal Union of the Americas and Spain)

Single copies are \$4.50 postage paid. Remittances should be made by check, draft, post office or express money order payable to this Journal.

Institutional (multiple user) subscriptions are available to public and private libraries, schools, hospitals and clinics, city, county, state, provincial and national government bureaus and departments and all commercial and private institutions and organizations.

Personal subscriptions and all student rate subscriptions must be in the names of individuals and paid by individuals. All student rate requests must indicate training status and name of institution.

Subscriptions may begin at any time.

Second class postage paid at St. Louis, Mo. and additional mailing offices.

Printed in the U.S.A. copyright © 1978 by The C V Mosby Company

The appearance of a code at the bottom of the first page of an original article in this journal indicates the copyright owner's consent that copies of the article may be made for personal or internal use on the personal or internal use of specific clients. This consent is given on the condition, however, that the copier pay the stated per copy fee through the Copyright Clearance Center Inc. P.O. Box 65, Schenectady, N.Y. 12301 518-3 4-4430 for copying beyond that permitted by Sections 107 or 108 of the U.S. Copyright Law. This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale.



Study of the temporal effects on conduction and refractoriness of the His Purkinje system in man 316

C Pratap Reddy MD Anthony N Damato MD Masood Akhtar MD Malkiat S Dhatt MD Joseph A Gomes MD James R Foster MD Staten Island N Y

Hypertrophic cardiomyopathy in the aged 326

Norman Krasnow MD and Richard A Stein MD Brooklyn N Y

Experimental and laboratory reports

Effects of rapid digitalization on total and regional myocardial performance in patients with coronary artery disease 337

Jack Ferhaz MD Michael DelVicario MD and Wilbert S Aronow MD Long Beach and Irvine Calif

Non invasive assessment of left internal mammary-coronary bypass patency using the external Doppler probe 347

Alberto Benchimol MD Philippe Reyns MD Sergio Altare MD Kenneth B Desser MD and Karen McCullough Phoenix Ariz

Assessment of perhexiline maleate in angiographically proven intractable angina A double blind trial 350

Y Afzal Mir MB MRCP DCH and E M Kafetzakis MD Manchester England

Comparative influence of ouabain norepinephrine and heart rate on myocardial oxygen consumption and inotropic state in dogs 355

Robert C Boerth MD PhD Karl E Hammermeister MD and J Richard Warbasse MD Baltimore Md and Nashville Tenn

Cardiac dose response relationship for intravenously infused glucagon in normal intact dogs and men 363

Thomas C Smitherman MD Roger C Osborn Jr MD and James M Atkins MD Dallas Texas

Comparison of rhythm and rate induced myocardial O₂ consumption changes before and after coronary occlusion 372

Alexandros C Kralios MD Theofilos J Tsagaris MD and Hiroshi Kuida MD Salt Lake City Utah

Case reports

Echocardiographic diagnosis of left ventricular mural thrombi occurring in cardiomyopathy 381

Neil E Kramer MD FACC Ramesh Rathod MD Kamal K Chaula MD FACC FRCP(C) Ramesh Patel MD and William D Toune MD FACP FACC Chicago Ill

Infective aneurysm of the left ventricle angiographic and echocardiographic features 384

Franklin B Saksena MD FACP FACC FRCP(C) Neil E Kramer MD FACC William D Toune MD FACP FACC Mushtaq Khan MD Robert Gamble MD Jairo B Cruz MD and Sukjit Gill MD Chicago Ill

Review

Spirololactone 389

Hermann R Ochs MD David J Greenblatt MD Gunther Bodem MD and Thomas W Smith MD Boston Mass and Bonn Venusberg W Germany

Fundamentals of clinical cardiology

Diabetic angiopathy—its lessons in vascular physiology 401

Donald E McMillan MD Santa Barbara Calif

A reminder
LANOXIN®
 (digoxin)



0.125 mg
 yellow
 imprinted



0.25 mg
 white
 imprinted & scored



0.5 mg
 green
 imprinted & scored

Complete illustration of a tablet on request from Professional Services Dept., PML.



Burroughs Wellcome
 Research Triangle Park
 North Carolina 27709

Appraisal and reappraisal
of cardiac therapy

Complications due to cloth wear in cloth covered Starr Edwards
aortic and mitral valve prostheses—and their management 407
*Anilkumar Shah M.D. Martin Dolgin M.D. David A. Tice M.D. and Naresh
Trehan M.D. New York N.Y.*

Annotations

Spontaneous changes in the severity of angina pectoris 415
David Short Ph.D. F.R.C.P. and Mary Stouers M.B. B.S. Aberdeen Scotland

Of discoveries 416
George F. Burch M.D. New Orleans La.

The carbon copy pain of myocardial infarction 417
David Short Ph.D. F.R.C.P. and Mary Stouers M.B. B.S. Aberdeen Scotland

The effect of a new beta blocking agent levo bunolol on
exercise induced or augmented ventricular arrhythmias 417
William Shapiro M.D. and Janet Park Dallas Texas

Letters to
the Editor

Truncus arteriosus in a family 419
*Sandra C. Brunson M.D. Dov B. Nudel M.D. Norman Gootman M.D. and
Behinde Aftalion M.D. N.W. Hyde Park and Stony Brook N.Y.*

Serum myoglobin tests by RIA 420
James C. Roberts Jr. M.D. Rolling Hills Calif.

Nocturnal angina 421
Richard M. Luceri M.D. Flushing N.Y.

Quality of early FCG tracings 421
J. B. Alevy M.D. La Tour de Peil. Switzerland

Hypertension control: an alternate view from Gimbels 421
*Michael H. Alderman M.D. Arthur W. Seligmann M.D. and Toni K. Davis M.S.
N.W. York N.Y.*

Reply 422
*David L. Sackett R. Brian Haynes Edward S. Gibbon D. Wayne Taylor Robin
S. Roberts Arnold L. Johnson and Kilgore S. Trout Hamilton Ontario Canada*

Smoking and the causes of CHD 423
Christ Aratanis M.D. Athens Greece

Reply 423
Philip R. J. Burch Ph.D. Leeds England

More on BP measurement and cuff size 423
Warren G. Guntheroth M.D. Seattle Wash.

Oral ISDN—long acting nitrate 424
Noemi Pascal M.D. Monheim W. Germany

Book reviews

Book reviews 425

Books received

Books received 426

Announcements

Announcements 426

(Information for authors on page 13)

8 things to look for in a new cardiograph:

Versatility

The EK 5A is ideal for routine ECGs, exercise tolerance testing procedures, ECG data phone transmissions, surgery and emergency departments and ICUs. It's also compatible with other instrumentation in multiple use situations. That means cost effectiveness for you.

State of the art electronics

The Burdick EK 5A produces high fidelity, consistently accurate ECGs. Patient is protected with isolated circuitry. Automatic lead coding and fast lead switching save time and reduce paper usage. Exceeds minimum frequency response recommendations of the AHA.

Solid return on investment

The Burdick EK 5A electrocardiograph is an income producing center that quickly pays for itself. With special tax savings and depreciation advantages available, as few as 27 ECGs can cover your actual net cost of the EK 5A.

Proven in service dependability

Backed by years of electrocardiograph manufacturing experience. Ready for rigorous use day after day. Every Burdick EK 5A is live patient tested before passing final inspection, added assurance for you.

ECG technician training seminars

Burdick has conducted more than 750 technician training seminars for over 35,000 nurses and technicians nationwide, demonstrating proper technique that contributes to accurate, consistently high quality ECGs, builds confidence in taking electrocardiograms. Your staff, too, is well come. Ask us for details.

Local dealer service


Service is readily available through Burdick trained and authorized local dealers. Proper installation, careful analysis of environmental interference problems and provision of loaner equipment are all part of Burdick's service after the sale.

Ease of operation

Well arranged panel and easy top-loading paper save time and reduce labor costs. Fewer retakes, more top quality ECGs. Your staff will appreciate its attractive appearance, compactness and light weight.

A warranty you can trust

Enjoy the security gained from purchasing the best in ECG instrumentation. Know that it's backed by Burdick, with more than 64 years of ethical, warranted service to the medical profession.



If your electrocardiograph can't offer you all these advantages and benefits, it makes good sense, diagnostically and financially, to buy one that does—the Burdick EK 5A. Ask your participating Burdick dealer about special tax advantages and trade-in allowances available to you. Convert your old cardiograph into a partial payment on a Burdick EK 5A, and start taking advantage of its

many benefits. And now Burdick's new BlueTrace/200 ECG paper will give you distinct blue tracings that contrast clearly with a red grid on bright white paper.

For a demonstration or more information, call toll free (800) 356-0701. Within Wisconsin, (608) 868-7631. Or write to The Burdick Corporation, Milton, Wisconsin 53563.

BURDICK

Contents

Editorial	Population screening for myocardial ischemia 427 <i>Coeffrey Rose D.M. FRCP FRCM London England</i>
Clinical communications	Reproducibility of a consensus panel in the interpretation of coronary angiograms 430 <i>Miguel E Sanmarco MD Samuel H Brooks DSc and David H Blankenhorn MD Los Angeles and Downey Calif</i>
	Coronary artery fistulas emptying into left heart chambers 438 <i>Djordje T Arani MD FACC David G Greene MD FACC and Francis J Klocke MD FACC Buffalo N.Y.</i>
	Arterial hypoxemia following the administration of sublingual nitroglycerin 444 <i>Ercument A Kopman MD Glenn R Weygandt MD Spomenko Bauer MD and Thomas B Ferguson MD St Louis Mo</i>
	Echocardiographic evaluation of porcine heterograft valves in the mitral and aortic positions 448 <i>William E Harston Jr MD Rose M Robertson MD and Gottlieb C Friesinger MD Nashville Tenn</i>

continued on page 7

Vol 96 No 4 October 1978 The American Heart Journal is published monthly by The C V Mosby Company 11830 Westline Industrial Drive St Louis Mo 63141

Annual subscription rates

	US	All Foreign countries
Institutional	\$40.50	\$49.00
Personal	\$20.50	\$24.00
Student, resident	\$20.40	\$23.90

Single copies are \$4.50 postage paid. Remittance should be made by check or draft payable to the post office or express company. Payment may be made by money order payable to this journal.

Institutional (multiple reader) subscriptions are available to public and private libraries, schools, hospitals, and in city, county, state, provincial, and national government, business, and departmental and all commercial and private institutions and organizations.

Personal subscriptions and all student rate subscriptions must be in the names of individuals and paid by individuals. All institutional requests must indicate training status and name of institution.

Subscriptions may begin at any time.

Second class postage paid at St Louis, Mo and at additional mailing offices.

Printed in the USA. Copyright © 1978 by The C V Mosby Company.

The appearance of a code at the bottom of the first page of an original article in this journal indicates the copyright owner's consent that copies of the article may be made for personal or internal use or for the personal or internal use of specific clients. This consent is given on the condition however that the copier pay the stated per copy fee through the Copyright Clearance Center, Inc., P.O. Box 6, Schenectady, N.Y. 12301 518-344-4430, for copying beyond that permitted by Sections 107 or 108 of the United States Copyright Law. This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works or for resale.

INDERAL[®]
(propranolol hydrochloride)
**PERFORMANCE IN
CARDIAC ARRHYTHMIAS**

EFFECTIVE ALONE OR IN COMBINATION



The predictive value of anginal chest pain as an indicator of coronary disease during exercise testing 458

Donald A Weiner MD Carolyn McCabe BS David C Hueter MD Thomas J Ryan MD and William B Hood Jr MD Boston Mass

Perioperative myocardial infarction related to coronary bypass surgery 463

Juan S Lam MD William L Proudfit MD William C Sheldon MD FACC Carlos Alosilla MD Daniel F Phillips MD and Floyd D Loop MD FACC Cleveland Ohio

An evaluation of range gated pulsed Doppler echocardiography for detecting pulmonary outflow tract obstruction in d transposition of the great vessels 467

Jose C Aretas MD Stanley J Goldberg MD Silja E C Spitaels MD and Volkert H de Villeneuve MD Rotterdam The Netherlands and Tucson Ari

Blood pressure levels in acute myocardial infarction 475

Thomas C Gibson MB FRCP Burlington Vt

The effect of aging on ventricular contractile performance 481

F Urthaler MD A A Walker BS and T A James MD Birmingham Ala

The prevention and reversal of digoxin intoxication with specific antibodies 486

T Hess G Scholtysik and W Riesen Berne Switzerland

Transmural gradients of experimental myocardial ischemia Limited correlation of ultrastructure with epicardial S T segment elevation 496

John J Lamberti Helayne Siler BS Joel Houell BS Kenneth Kampman MD and Seymour Glagov MD Chicago Ill

Dose independent pharmacokinetics of digoxin in humans 507

Hermann R Ochs MD David J Greenblatt MD Gunther Bodem MD and Jerold S Harmatz Bonn Venusberg W Germany and Boston Mass

Origin of the basal systolic murmurs in mitral stenosis A study with intracardiac phonocardiography 512

Tadashi Kambe MD Shohachi Suzuki MD Tadayuki Kato MD Norio Hibi MD Yoichi Fukui MD Takemi Arakawa MD Kunya Nishimura MD Arata Niwa MD and Nobuo Sakamoto MD Nagoya Japan

The noninterference of aluminum hydroxide gel with quinidine sulfate absorption An approach to control quinidine induced diarrhea 518

John A Romankiewicz Pharm D Marcus Reidenberg MD Dennis Drayer PhD and John E Franklin Jr MD New York N Y

Noninvasive diagnosis of ischemic cardiomyopathy by fluoroscopic detection of coronary artery calcification 521

Allen D Johnson MD Stuart L Laiken MD and Ralph Shabetai MD La Jolla and San Diego Calif

Echocardiographic detection of a subannular aortic aneurysm 525

Barry R Alter Maj MC Robert L Treasure Col MC Hal A Martin Lt Col MC Stephen H Humphrey Capt MC Joseph P Murgu Lt Col MC and George M M Granahan Jr Col MC Fort Sam Houston Texas

Case reports

A reminder
LANOXIN®
(digoxin)



0.125 mg
yellow
imprinted



0.25 mg
white
imprinted & scored



0.5 mg
green
imprinted & scored

Complete literature available on request from Professional Sales Dept. PML



Butterfly logo of Burroughs Wellcome Co.
Research Triangle Park
North Carolina 27709

The predictive value of anginal chest pain as an indicator of coronary disease during exercise testing 458

Donald A. Weiner MD Carolyn McCabe BS David C. Huebler MD Thomas J. Ryan MD and William B. Hood Jr MD Boston Mass

Peroperative myocardial infarction related to coronary bypass surgery 463

Juan S. Lim MD William L. Proudft MD William C. Sheldon MD FACC Carlos Alosilla MD Daniel F. Phillips MD and Floyd D. Loop MD FACC Cleveland Ohio

An evaluation of range gated pulsed Doppler echocardiography for detecting pulmonary outflow tract obstruction in d transposition of the great vessels 467

Jose C. Areias MD Stanley J. Goldberg MD Silja E. C. Spitaels MD and Volker H. de Villeneuve MD Rotterdam The Netherlands and Tucson Ariz

Blood pressure levels in acute myocardial infarction 475

Thomas C. Gibson MB FRCP Burlington Vt

The effect of aging on ventricular contractile performance 481

F. Urihater MD A. A. Walker BS and T. N. James MD Birmingham Ala

The prevention and reversal of digoxin intoxication with specific antibodies 486

T. Hess G. Scholtysik and W. Riesen Berne Switzerland

Transmural gradients of experimental myocardial ischemia Limited correlation of ultrastructure with epicardial S-T segment elevation 496

John J. Lambert Helayne Siler BS Joel Houell BS Kenneth Lampman MD and Seymour Glagor MD Chicago Ill

Dose independent pharmacokinetics of digoxin in humans 507

Hermann R. Ochs MD David J. Greenblatt MD Gunther Bodem MD and Jerold S. Harmat Bonn Germany and Boston Mass

Origin of the basal systolic murmurs in mitral stenosis A study with intracardiac phonocardiography 512

Tadashi Kambe MD Shohachi Suzuki MD Tadayuki Kato MD Norio Hibi MD Yoichi Futui MD Takemi Arakawa MD Kin'ya Yishimura MD Arata Miwa MD and Nobuo Sakamoto MD Nagoya Japan

The noninterference of aluminum hydroxide gel with quinidine sulfate absorption An approach to control quinidine induced diarrhea 518


John A. Romankiewicz Pharm D Marcus Reidenberg MD Dennis Drayer PhD and John E. Franklin Jr MD New York N Y

Noninvasive diagnosis of ischemic cardiomyopathy by fluoroscopic detection of coronary artery calcification 521

Allen D. Johnson MD Stuart L. Laiken MD and Ralph Shabetai MD La Jolla and San Diego Calif

Echocardiographic detection of a subannular aortic aneurysm 525

Barry R. Alter Maj MC Robert L. Treasure Col MC Hal A. Martin Lt Col MC Stephen H. Humphrey Capt MC Joseph P. Margo Lt Col MC and George M. McCranahan Jr Col MC Fort Sam Houston Texas



with the experience of over 155,000 valves and now into its 10th clinical year, the Bjork Shiley Cardiac Valve Prosthesis continues to be the choice of cardiologists and surgeons for valvular replacement. Certainly a major reason is durability—supported by a wealth of excellent clinical experience substantiating the structural integrity of the valve. On a continuing basis, Shiley provides updated material about the Bjork Shiley valve. If you are not currently receiving this information and would like to, please let us know.



Shiley

of the open heart team

Shiley Sales Corp.
17600 Gillette Avenue
Irvine, California 92714
(714) 979-0504
Cable SHILEYSLS1RIN
Telex 88 5585
Mailing Address
P.O. Box 11707
Santa Ana, CA

Ventricular pre excitation and prolonged Q T interval syndromes
in a patient with mitral valve prolapse 529

David M Mirus MD and Stanley W Erwin MD Memphis Tenn.

Fatigue dyspnea and abdominal swelling in a 13 year old boy 533

Noble Fowler MD Keith E Bore MD Scott Dunbar MD and Richard Meyer MD Cincinnati Ohio

Echocardiography in ischemic heart disease Present status and
future prospectives 543

Barry Massie MD Jack J Kleid MD and Nelson Schiller MD San Francisco Calif

Intravenous nitroglycerin 550

James E Cottrell MD and Herman Turndorf MD New York N Y

Coronary artery spasm—diagnostic and therapeutic implications 554

Attilio Vasseri A L Abbate S Chierchia and O Parodi Pisa Italy

Effect of transducer placement on echocardiographic mitral valve
motion 555

W Markiewicz MD Haifa Israel E London and R L Popp MD Stanford Calif

Hazards of cardiac catheterization in children with primary pulmonary
vascular obstruction 556

John F Keane MD Donald C Fyler MD and Alexander S Nadas MD Boston Mass

Of atherosclerosis in infants and children and viral infections 558

G E Burch MD New Orleans La

Statistics marathoning and CHD 560

Thomas J Bassler MD Inglewood Calif

Reply 560

Paul Wiley PhD New York N Y

Acid gas induced MI 561

M Puletti MD G F Jacobellis MD V Greco MD and F Pozzar MD Rome Italy

Pathogenesis of myocardial infarction 561

Professor M J Davies Professor W B Robertson Professor N Woolf and Dr A Popple London England

Reply 562

Giorgio Baroldi MD Pisa Italy

Orthostatic hypertension in normotensives and borderline hypertensive
patients 563

Professeur Ag M Safar Paris France

Chest thumping to terminate ventricular tachycardias 564

Donald Forester MD New York N Y

Reply 564

Benjamin Befeler MD Miami Fla

Clinical pathologic
conference

Fundamentals of
clinical cardiology

Appraisal and reappraisal
of cardiac therapy


Annotations

Letters to
the Editor

VOLUME INFUSED 0 0 0 0

AIR IN LINE
OCCLUSION
INFUSION COMPLETE
LOW BATTERY
DOOR OPEN
MALFUNCTION

NOT OPERATING
RATE NOT 000
NOT CHARGING
SET 0000 VOLUME
AUDIO OFF



WHEN YOU HAVE QUESTIONS THE 960 PROVIDES ANSWERS

From the Innovator of Volumetric Infusion and pump diagnostics — an infusion pump that COMMUNICATES WITH THE NURSE. A liquid crystal display panel spells out changes in operating status or alarm event con

ditions as they occur. No guesswork. The 960 provides all of the features of the IMED Model 922 — the leader in Volumetric Infusion Pumps — and more — with emphasis on safety — accuracy — simplicity.



IMED CORPORATION 9925 CARROLL CANYON ROAD SAN DIEGO CA. 92131
CALL TOLL FREE 800/854 2033 CALIFORNIA RESIDENTS CALL 714/565 4633

Contents continued

Observations on Q fever endocarditis 564

W P G Turck MBChB FRCP E Hong Kong

Reply 566

Mark M Applefeld MD Baltimore Md

Book reviews

Book reviews 567

Books received

Books received 567

Announcements

Announcements 568



(Information for authors on page 15)

(Index to Advertisers on page 54)

VOLUME INFUSED 0 0 0 0

AIR IN LINE
OCCLUSION
INFUSION COMPLETE
LOW BATTERY
DOOR OPEN
MALFUNCTION

NOT OPERATING
RATE NOT 000
NOT CHARGING
SET 0000 VOLUME
AUDIO OFF



WHEN YOU HAVE QUESTIONS THE 960 PROVIDES ANSWERS

From the Innovator of Volumetric Infusion and pump diagnostics — an infusion pump that COMMUNICATES WITH THE NURSE. A liquid crystal display panel spells out changes in operating status or alarm event con-

ditions as they occur. No guesswork. The 960 provides all of the features of the IMED Model 922 — the leader in Volumetric Infusion Pumps — and more — with emphasis on safety — accuracy — simplicity.



IMED CORPORATION 9925 CARROLL CANYON ROAD SAN DIEGO CA. 92131
CALL TOLL FREE 800/854 2033 CALIFORNIA RESIDENTS CALL 714/565 4633

Contents**Editorial****Coronary heart disease—the doctor's dilemma 569***George V. Mann, Sc.D., M.D., Nashville, Tenn.***Clinical communications****Adverse reactions to methyldopa with particular reference to hypotension 572***D. H. Lawson, M.D., F.R.C.P. (Ed.), D. Gloss, M.S., M.P.H., and H. Jick, M.D., Waltham, Mass.***Common pulmonary vein atresia 580***Marion K. Ledbetter, M.D., David H. Wells, M.D., and Dean M. Connors, M.D., Madison, Wis.***Prolonged benefit of nitroglycerin ointment on exercise tolerance in patients with angina pectoris 587***Dennis L. Aarhus, M.D., Richard E. Umbach, M.D., Laurence S. Cohen, M.D., F.A.C.C., and Rene A. Langou, M.D., F.A.C.C., New Haven, Conn.***An evaluation of the results of left ventricular aneurysmectomy. Use of a simplified method for analysis of the left ventriculogram 596***Harold Smulyan, M.D., Robert H. Eich, M.D., Lewis W. Johnson, M.D., Frederick B. Parker, M.D., James L. Potts, M.D., and Gerald P. Tracy, M.D., Syracuse, N.Y.**continued on page 7***Annual subscription rates**

V. 196, No. 5, November 1978. The American Heart Journal is published monthly by The C. V. Mosby Company, 11550 Westline Industrial Drive, St. Louis, Mo. 63141.

	U.S.	All foreign countries
Institutional		
Personal	\$40.50	\$49.00
Student resident†	\$ 5.50	\$34.00
	\$70.40	\$8.90

Single copies are \$4.50 postpaid. Remittances should be made by check, draft, post office or express money order payable to this Journal.

Institutional (multiple-reader) subscriptions are available to public and private libraries, schools, hospitals, and clinics, city, county, state, provincial, and national government, business and departmental, and non-commercial and private institutions and organizations.

Personal subscriptions and all student subscriptions must be in the names of individuals and paid by individual. All student rate requests must indicate training status and name of institution. Subscriptions may begin at any time.

Second class postage paid at St. Louis, Mo., and additional mailing offices. Printed in the U.S.A. Copyright © 1978 by The C. V. Mosby Company.

The appearance of a code at the bottom of the first page of an original article in this journal indicates the copyright owner's consent that copies of the article may be made for personal or internal use, or for the personal or internal use of specific clients. This consent is given on the condition, however, that the copier pay the stated per-copy fee through the Copyright Clearance Center, Inc., P.O. Box 65, Schenectady, N.Y. 12301, 518-344-4330, for copying beyond that permitted by Sections 107 or 108 of the U.S. Copyright Law. This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale.

An Endocardial Tined Ventricular Lead

The Medtronic® 6950 and 6951 unipolar and bipolar tined leads feature four integral silicone rubber tines that protrude from the lead body just proximal to the tip electrode. These tines were designed to provide better acute lead stability and reduce chronic lead dislodgement by latching onto the papillary musculature or the trabeculae of the right ventricle. The large surface area provided by the tines should also enhance the stability afforded by fibrosis.



A Small, Durable Endocardial Tined Lead.

The newest members of the Tenax™ family of self anchoring leads—the 6961 and 6962 unipolar and bipolar leads—feature shorter, smaller tines and small tip diameter (8 French, approximately 10 French with tines folded) enabling the physician to use the more common cephalic approach. Though small, the soft pliable tines are still long enough to become securely anchored in one or more of the interstitial spaces formed by the trabeculae of the right ventricular chamber. The lead's ring tipped electrode provides optimum energy to the heart with improved sensing and current drain characteristics. Its durable space-wound multifilar conductor is designed to provide a longer flex life to match the potential long effective service life of lithium powered pulse generators.



Many of the common problems associated with endocardial leads are caused by the design of the lead itself. The Tenax® leads are designed to minimize the risk of these problems by providing a more durable, self-anchoring lead.

PACING LEADS

ME Medtronic
Tined leads are designed to be used with Medtronic pulse generators as part of a cardiac pacing system (see product labeling for specific directions regarding applications).
Contraindications
Endocardial pacing leads are contraindicated in the presence of tricuspid valvular disease.

Myocardial leads are contraindicated for a patient whose myocardium is thin walled, suffused with fat, or infarcted in the area of electrode placement.
Myocardial leads may be contraindicated in the case of high risk patients with a low tolerance to general anesthesia.
Atrial leads are contraindicated in the absence of a right atrial appendage.
Warnings
An implanted lead constitutes a direct, low resistance current path to

Coronary artery to pulmonary artery fistulas 605

Abdulmassih S Iskandrian MD Demetrios Kumbiris MD Charles E Bemis MD and Bernard L Segal MD Philadelphia Pa

Migraine and the mitral valve prolapse syndrome 610

George I Litman MD and Harley M Friedman MD Akron Ohio

Experimental and laboratory reports

The ventricular A wave a new echocardiographic index of late diastolic filling of the left ventricle 615

John A Ambrose MD Jose Meller MD Michael V Herman MD and Louis E Teichholz MD New York NY

Leukocyte function after aortic valve replacement 624

Bernt Aarstein MD and Jon Dale MD Oslo Norway

Quinidine pharmacokinetics in patients with cirrhosis or receiving propranolol 627

Kenneth M Kessler MD William C Humphries Jr MD Martin Black MD and James F Spann MD Philadelphia Pa

Left ventricular function in β thalassemia and the effect of multiple transfusions 636

Basil S Levis MD MRCP FCP(SA) Eliezer A Rachmilewitz MD Noga Amitai BSc David A Halon MB ChB and Mervyn S Gotsman MD FRCP FACC Jerusalem Israel

Hemodynamics of essential hypertension in young subjects 646

Fetnat M Fouad MD Robert C Tarazi MD Harriet P Dustan MD and Emmanuel L Bravo MD Cleveland Ohio

Case reports

Congenital tricuspid incompetence simulating pulmonary atresia with intact ventricular septum a report of two cases 655

William Berman Jr MD Victor Whitman MD Paul Stanger MD and Abraham M Rudolph MD Hershey Pa and San Francisco Calif

Exposure of concealed right bundle branch block in Wolff Parkinson White type B by pacing from the vicinity of the A V node 662

Otto L Garcia MD Agustin Castellanos MD Ruey J Sung MD and Henry Gelband MD Miami Fla

Review

Intraventricular conduction disturbances A review of prevalence etiology and progression for ten years within a stable population of Israeli adult males 669

Yardena Siegman Igra MD Joseph H Yahini MD FACC Uri Goldbourt MA and Henry N Neufeld MD FACC Tel Aviv and Tel Hashomer Israel

Fundamentals of clinical cardiology

Serum myoglobin in acute myocardial infarction A clinical study and review of the literature 680

Ajit P Varki MD David S Roby MD Harley Watts MD and Jacob Zatuchni MD Philadelphia Pa

A reminder
LANOXIN®
(digoxin)



0.125 mg
yellow
imprinted



0.25 mg
white
imprinted & scored



0.5 mg
green
imprinted & scored

Complete literature available on request from Professional Services Dept., PMA.



Burroughs Wellcome Co.
Research Triangle Park
North Carolina 27709

Contents continued

Coronary artery to pulmonary artery fistulas 605

Abdulmassih S Iskandrian MD Demetrios Kimbiris MD Charles E Bemis MD and Bernard L Segal MD Philadelphia Pa

Migraine and the mitral valve prolapse syndrome 610

George I Litman MD and Harvey M Friedman MD Akron Ohio

Experimental and laboratory reports

The ventricular A wave a new echocardiographic index of late diastolic filling of the left ventricle 615

John A Ambrose MD Jose Meller MD Michael V Herman MD and Louis E Teichholz MD New York N Y

Leukocyte function after aortic valve replacement 624

Bernt Klarstein MD and Jon Dale MD Oslo Norway

Quinidine pharmacokinetics in patients with cirrhosis or receiving propranolol 627

Kenneth V Kessler MD William C Humphries Jr MD Martin Black MD and James F Spann MD Philadelphia Pa

Left ventricular function in β thalassemia and the effect of multiple transfusions 636

Basil S Lewis MD MRCP FCP(SA) Eliezer A Rachmilewitz MD Noga Amitai BSc David A Halon MB ChB and Verlyn S Gotsman MD FRCP FACC Jerusalem Israel

Hemodynamics of essential hypertension in young subjects 646

Fetnat M Fouad MD Robert C Tarazi MD Harriet P Dustan MD and Emmanuel L Bravo MD Cleveland Ohio

Case reports

Congenital tricuspid incompetence simulating pulmonary atresia with intact ventricular septum a report of two cases 655

William Berman Jr MD Victor Whitman MD Paul Stanger MD and Abraham M Rudolph MD Hershey Pa and San Francisco Calif

Exposure of concealed right bundle branch block in Wolff Parkinson White type B by pacing from the vicinity of the A V node 662

Otto L Garcia MD Agustin Castellanos MD Ruey J Sung MD and Henry Gelband MD Miami Fla

Review

Intraventricular conduction disturbances A review of prevalence etiology and progression for ten years within a stable population of Israeli adult males 669

Yardena Siegman Igra MD Joseph H Yahini MD FACC Uri Goldbourt MA and Henry N Neufeld MD FACC Tel Aviv and Tel Hashomer Israel

Fundamentals of clinical cardiology

Serum myoglobin in acute myocardial infarction A clinical study and review of the literature 680

Art P Varkis MD David S Roby MD Harvey Watts MD and Jacob Zatzehni MD Philadelphia Pa

Burdick's EXTOL Training seminar. We want you to get the most from your investment.

When you decide on the Burdick EXTOL system for your coordinated exercise tolerance test procedures you'll be making an investment in both quality and dependability. And like any other investment you make, it pays to make the best use of your EXTOL system.

That's the reason Burdick developed the EXTOL technician training program for you and your medical team.

Burdick's one day seminar includes an introduction to EXTOL procedures, a review of heart physiology and its relation to

coronary artery disease, as well as protocols, team duties, artifact interpretation and emergency procedures. All to help you get full utilization from the EXTOL system.

During the workshop session your medical team and others will be working with a complete Burdick EXTOL system very much like the one you see here. The system includes a treadmill, electrocardiograph, cardiac monitor and defibrillator. Each component has been designed and built for compatibility in the system and individual use in other procedures as needed.

EXTOL's engineered compatibility provides the capability to help track down clinically unsuspected coronary disorders with time saving techniques and procedures.

In planning your investment consider EXTOL, the system Burdick backs with training seminars.

For full details call toll free 800 356 0701. Within Wisconsin 608 868 7651. Or write The Burdick Corporation, Milton, Wisconsin 53563.

BURDICK

The most meaningful and productive use of the EXTOL system is to use it by people who understand it.



Contents continued

**Appraisal and reappraisal
of cardiac therapy**

**Infective endocarditis Part III Prevention of bacterial
endocarditis 689**

Franklin Louy MD and Neal H Steigbigel MD FACP New York NY

Annotations

Conflicts in coronary care 696

Michael F M Hourke Sydney Australia

Of the venous pumps and congestive heart failure 697

G E Burch MD New Orleans La

**Renal vein renin and saralasin testing in renovascular
hypertension 697**

F P McCarthy MRCP and G S Stokes MD Sydney NSW Australia

Towards more selective resuscitation 698

Richard Prattfield MA MRCP London England

**Letters to
the Editor**

Neurologic-cardiologic interrelationships 700

Brooks A Mick MD Findlay Ohio

Nitroprusside reversal of ergotamine induced ischemia 700

*Thomas L Whitsett MD William S Myers MD and James M Hartsuck MD
Oklahoma City Okla*

**Evaluation of the hemodynamic effects of hyaluronidase in patients
with acute myocardial infarction 700**

*Maria Ray MD Luigi Tatazi MD Jorge A Salerno MD and Piero Bobba
MD Pavia Italy*

Testing antianginal therapy In favor of current practice 701

William Shapiro MD Dallas Texas

Prolonged repolarization and hypomagnesemia 702

*Dr Shinde Suresh N MD and Dr G S Sainani MD FRCP FACP PhD
Poona India*

CPK MB elevations in hypothermia 703

Peter R Maggs MD Boston Mass

Reply 703

C Jeffrey Carlson MD and Elliot Rapaport MD San Francisco Calif

**Recourse to a computer for teaching the proper use of
nitroglycerin 703**

*Stephen H Rabinowitz MD Bernard Loun MD and Warner V Slack MD
Boston Mass*

Potential hazard of the programmable pacemaker 704


Laurence Gould MD and C V Ramana Reddy MD Brooklyn NY

RAPID RELIEF NOW

acts almost as fast as nitroglycerin

PROLONGED PROTECTION AFTER

duration of action up to two hours



ISORDIL® SUBLINGUAL AND CHEWABLE (isosorbide dinitrate)

Sublingual Tablets 2.5mg and 5mg

Chewable Tablets 10mg

Highly stable tablets for aborting or preventing attacks of angina pectoris*

***Indications** Based on a review of this drug by the National Academy of Sciences—National Research Council and/or other information FDA has classified the indications as follows

Probably effective. When taken by the sublingual or chewable route Isordil Sublingual and Chewable Tablets are indicated for the treatment of acute anginal attacks and for prophylaxis in situations likely to provoke such attacks.

Final classification of the less than effective indications requires further investigation

Contraindication Idiosyncrasy to this drug

Warnings Data supporting the use of nitrates during the early days of the acute phase of myocardial infarction (the period during which clinical and laboratory findings are unstable) are insufficient to establish safety

Precautions Tolerance to this drug and cross tolerance to other nitrates and nitrites may occur

Adverse Reactions Cutaneous vasodilation with flushing. Headache is common and may be severe and persistent. Transient episodes of dizziness and weakness as well as other signs of cerebral ischemia associated with postural hypotension may occasionally develop. This drug can act as a physiological antagonist to norepinephrine, acetylcholine, histamine, and many other agents. An occasional individual exhibits marked sensitivity to the hypotensive effects of nitrite and severe responses (nausea, vomiting, weakness, restlessness, pallor, perspiration and collapse) can occur even with the usual therapeutic dose. Alcohol may enhance this effect. Drug rash and/or exfoliative dermatitis may occasionally occur.

Consult direction circular before prescribing

May we send you reprints, detailed information and/or professional samples?

IVES LABORATORIES INC.

New York, New York 10017

DEDICATED TO IMPROVING THE QUALITY OF LIFE THROUGH MEDICINE



Heart rate correction of pre ejection period 705

David H Spodick M.D D.Sc Worcester Mass

Reply 706

D Burckhardt M.D and E Raeder M.D Basel Switzerland

Book reviews

Book reviews 707

Books received

Books received 708


Announcements

Announcements 708

(Information for authors on page 15)

Index to Advertisers on page 62

for Life™
MEDTRONIC



ACEMAKE

Pacing for Life™ Warranty

The Pacing for Life™ Warranty provides this assurance to the patient who receives Medtronic Xyrel™-VL or Xyrel™-VP pulse generators. If the pulse generator fails to function within normal tolerances for any reason (including exhaustion of the battery or other component) Medtronic will provide for the patient a functionally comparable Medtronic® pulse generator at no charge. In addition, if the failure is due to a defect in materials or workmanship, Medtronic will reimburse the patient for up to \$450.00 of reasonable uninsured medical expenses incurred in connection with the replacement.

This same warranty will apply to any Medtronic® replacement pulse generator supplied pursuant to its terms.



Contents

Acknowledgment to reviewers

Acknowledgment to reviewers 709

Editorial

The role of acute myocardial infarction in sudden cardiac death—a statistician's nightmare 711

T Logeart *MB ChB* and P Thompson *MB BS FRACP FACC*
Hedlands Western Australia

Clinical communications

Radionuclide assessment of ventricular performance during propranolol withdrawal prior to aortocoronary bypass surgery 714

Laurence A Reduto *MD* Harvey J Berger *MD* Alexander Geka *MD* Graeme Hammond *MD* Laurence S Cohen *MD* Alexander Gottschalk *MD* and Barry L Zaret *MD* New Haven Conn

Electrophysiological studies in four patients with atrial flutter with 1:1 atrioventricular conduction 723

Brian M Kennelly *MB ChB PhD MRCP FACC* and Geoffrey K Lane
BSc MB BS MRACP Cape Town South Africa

continued on page 7

Vol 90 No 6 December 1978 The American Heart Journal is published monthly by The C V Mosby Company 11530 Westline Industrial Drive St Louis Mo 63141

Annual subscription rates

	US	All Foreign countries
Institutional	\$40.50	\$49.00
Personal	\$25.50	\$34.00
Student, resident	\$20.40	\$28.90

Single copies are \$4.50 postpaid. Remittances should be made by check, draft, post office or express money order payable to this journal.

Institutional (multiple reader) subscriptions are available to public and private libraries, schools, hospitals, and libraries. Institutional rates are given on the condition however that the subscriber and all commercial and private institutions and organizations must be in the names of the institution. All student rate subscriptions must be in the names of the student and the name of the institution. Subscriptions may begin at any time.

Second class postage paid at St. Louis, Mo. and additional mailing offices.
Printed in the U.S.A. Copyright © 1978 by The C V Mosby Company

The appearance of a code at the bottom of the first page of an original article in this journal indicates the copyright owner's consent that copies of the article may be made for personal or internal use or for the personal or internal use of specific clients. This consent is given on the condition however that the copier pay the stated per copy fee through the Copyright Clearance Center Inc., P.O. Box 65, Schenectady, N.Y. 12301 518-3 4-4330 for copying beyond that permitted by Sections 107 or 108 of the U.S. Copyright Law. This consent does not extend to other kinds of copying such as copying for general distribution for advertising or promotional purposes, for creating new collective works, or for resale.

A reminder
LANOXIN[®]
(digoxin)



0.125 mg
yellow
imprinted



0.25 mg
white
imprinted & scored



0.5 mg
green
imprinted & scored

Complete literature available on request from Professional Services Dept. P&L



Burroughs Wellcome Co.
Research Triangle Park
North Carolina 27709

Leukocyte intracellular cations in hypertension Effect of antihypertensive drugs 731

Matthew A Aronoy M.B. B.S. Ibrahim M. Khatir M.D. Linda L. Yao M.S. and Edward D. Freis M.D. Washington D.C.

Significance of P wave terminal force in presumably healthy middle aged men 739

Kolbjørn Forfang M.D. and Jan Eriksen M.D. Oslo Norway

Clinicopathologic study of the conduction systems in 10 patients with Kawasaki's disease (mucocutaneous lymph node syndrome) 744

Huayoshi Fujiwara M.D. Chutchi Kauai M.D. and Yoshihiro Hamashima M.D. Kyoto Japan

Exercise tests atrial pacing and myocardial lactate extraction in relation to coronary arteriography in young patients with angina pectoris 751

M. Rajasalmi M.D. and J. Takkinen M.D. Oulu Finland

Effect of verapamil on normal sinoatrial node function and on sick sinus syndrome 760

Hugo A. Carrasco M.D. Abdel Faenmayor P. M.D. Juan S. Barbasa M. M.D. and German Gonzalez M.D. Mérida Venezuela

Protection of ischemic myocardium by whole body hypothermia after coronary artery occlusion in dogs 772

Dana R. Abendschein Ph.D. Wilis A. Tucker Jr. M.D. Ph.D. and Charl s F. Babbs M.D. M.S. Ph.D. West Lafayette Ind.

Ouabain induced Wenckebach conduction block in canine Purkinje fibers The role of cycle length and time dependent changes in membrane potential 781

Gary J. Anderson M.D. and Joseph Reuser Ph.D. Philadelphia Pa.

Case reports

Endocardial fibroelastosis Myocardial and vascular alterations associated with viral like nuclear particles 791

Stephen M. Factor M.D. Bronx N.Y.

Teflon felt embolism of coronary arteries after cardiac surgery A case report 802

Carlos D. Bedetti M.D. Ralph D. Steuers M.D. and Harold A. Dunsford M.D. Pittsburgh Pa.

Clinical pathologic conference

Complex congenital heart disease A multiplicity of therapeutic options 806

Lewis P. Scott M.D. Roma S. Chandra M.D. and William C. Roberts M.D. Washington D.C. and Bethesda Md.

Fundamentals of clinical cardiology

Coagulation for cardiologists 811

Stanford Wexler M.D. and Sanford N. Gitel Ph.D. New York N.Y.

Appraisal and reappraisal of cardiac therapy

Diuretics 824

Philip D. Lief M.D. Bronx N.Y.



No Matter How You Look At It...

with the experience of over 155,000 valves and now into its 10th clinical year, the Bjork Shiley Cardiac Valve Prosthesis continues to be the choice of cardiologists and surgeons for valvular replacement. Certainly a major reason is durability—supported by a wealth of excellent clinical experience substantiating the structural integrity of the valve. On a continuing basis, Shiley provides updated material about the Bjork Shiley valve. If you are not currently receiving this information and would like to, please let us know.

 **Shiley**
an integral member of the open heart

Shiley Sales Corp.
17600 Gillette Avenue
Irvine, California 92714
(714) 979-0504
Cable SHILEYSLIRIN
Telex 68 558
Mailing A
P.O. Box
San

Annotations

Sequential atrioventricular pacing with a single bipolar electrode catheter 828

R W Wald MD FRCPC M B Waxman MD FRCP(C) and J F Bonet MD Toronto Ontario Canada

A reevaluation of intravenous quindine 829

Elaine Woo MD and David J Greenblatt MD Boston Mass

Of testing treating and charging 832

George E Burch MD New Orleans La

Favorable effects of prolonged nitroglycerin infusion in patients with acute myocardial infarction 833

J P Derrida MD R Sal MD and P Chiche MD FACC Paris France

Letters to
the Editor

Main determinant of ECG voltage measurements 835

David Bennett MD MRCP Oxford England

Reply 835

Hironori Toshima MD and Yoshinori Koga MD Kurume Japan

Lactate production after left ventricular angiography in coronary artery disease 835

Odoardo Visoli MD PhD Francesco Cucchini MD Stefano Bongrani B.S.D and Roberto Ferrari MD Parma Italy

Unusual cystic endocardial lesions 836

Solange Abu Nassar MD and John T Flynn MD New York N Y

Silent or asymptomatic myocardial ischemia 838

Joseph P Liss Jr MD FACC Hartford Conn

Reply 838

Peter F Cohn MD Boston Mass

Retrograde Wenckebach effect in VT 839

Leon Pordy MD New York N Y

Lenegre's disease in youth 839

P A Matheu MD FACC T Marsano MD and A Ostroff MD Rochester N Y

Book reviews

Book reviews 841

Announcements

Announcements 842

Index

Author index 845

Subject index 852

Information for authors on page 13

Index to advertisers on page 52

Editorial

Surgical versus medical treatment in disease of the left main coronary artery

Ian M Graham MB MRCP
Dublin, Ireland

To the outside observer the wholesale acceptance of coronary artery bypass grafting by the very country that scrupulously protects its citizens from the introduction of unproven new medications remains an extraordinary paradox. That the reasons extend far beyond a simple consideration of what is good for the patient has been made abundantly clear by Preston's penetrating analysis. Happily coronary artery surgery relieves angina pectoris in the majority of cases although the placebo effect of a thoracotomy is difficult to measure and unsuccessful operations may be associated with early symptomatic improvement.¹ It is assumed but not proven that coronary artery bypass grafting is actually superior in terms of pain relief to discarded and obsolete procedures such as denervation, induced pericarditis, coronary sinus ligation or arterialization and internal mammary occlusion or implantation. With the increasing tendency to offer operation to subjects with mild or even no symptoms the need to know whether this major procedure with its attendant morbidity and mortality actually prolongs life becomes ever more urgent.

If coronary artery surgery prolongs life one might expect this to be most readily demon-

strable in conditions which carry a poor prognosis and are readily amenable to surgical treatment such as left main coronary artery stenosis. Many studies suggest that surgical treatment prolongs life in left main stenosis but how good is the evidence? One way to judge this is to draw up a list of design criteria and apply these to available studies. Such a list might be

- 1 Precise diagnostic criteria
- 2 Prospective trial design
- 3 Randomly allocated concurrent controls
- 4 Stratified prognostic allocation
- 5 Predetermined starting times for observations of mortality and morbidity with details of the method of handling patients who die before surgery
- 6 Statement of the nature of the comparison is surgery being compared with no haphazard or optimal medical treatment?
- 7 Statement of medical treatment given to surgical patients before and after operation
- 8 Adequate sample size and duration of follow up

If one applies these criteria to five of the studies frequently quoted in reviews of surgical treatment of left main stem stenosis,²⁻⁶ the results are interesting (see Table I). Although we have written previously about one of these publications this table is not intended as a criticism of the papers themselves which are mostly carefully written observational studies. It is however a vigorous criticism of those who quote such

From the Cardiac Department, St Vincent's Hospital, and the Irish Heart Foundation, Dublin, Ireland.

Received for publication May 9, 1978.

Reprint requests: Dr Ian Graham, Director of Research, Cardiac Department, St Vincent's Hospital, Elm Park, Dublin 4, Ireland.

significant left main lesions *Circulation* 54 (Suppl III) 3 107 1976

- 12 Murphy M L Hultgren H N Detre K, Thomson J and Takaro T Treatment of chronic stable angina. A preliminary report of survival data of the randomized Veterans Administration cooperative study *N Engl J Med* 297 621 1977
- 13 Special correspondence. A debate on coronary bypass *N Engl J Med* 297 1464 1977
- 14 Mulcahy R Hickey N and Graham I Natural history of post infarction angina pectoris (Abstr) *Br Heart J* 38 87, 1976
- 15 Wilhelmsson C Vedin J A Elmfeldt D Tibblin G and Wilhelmsen L Smoking and myocardial infarction *Lancet* 1 415 1975

- 16 Mulcahy R Hickey N Graham I and McKenzie G Factors influencing longterm prognosis in male patients surviving a first coronary attack *Br Heart J* 37 158 1975
- 17 Multicentre International Study Improvement in Prognosis of myocardial infarction by longterm beta adrenoceptor blockade using practolol, *Br Med J* III 735 1975
- 18 Berglund G Wilhelmsen L Sannerstedt R Hansson R Andersson G Silvertsson R Wedel H and Wikstrand K J Coronary heart disease after treatment of hypertension *Lancet* 1 1 1978

Information for authors

Most of the provisions of the Copyright Act of 1976 became effective on January 1 1978. Therefore all manuscripts must be accompanied by the following statement signed by each author: "The undersigned author(s) transfers all copyright ownership of the manuscript entitled (title of article) to The C V Mosby Company in the event the work is published. The author(s) warrants that the article is original, is not under consideration by another journal, and has not been previously published. Authors will be consulted when possible regarding republication of their material."

Table 1 Design criteria fulfilled by five studies of left main coronary artery disease

Reference	Design Criteria*								Total fulfilled
	1	2	3	4	5	6	7	8	
Lavine et al 1972	+	-	-	-	-	-	-	-	1
Demots et al 1975	+	-	-	+	-	-	-	-	2
Cohen and Gorlin 1975	+	-	-	-	-	-	-	-	1
McConahay et al 1976	+	-	-	-	-	-	-	-	1
Oberman et al 1976	+	-	-	-	-	+	-	-	2

See text paragraph 2 for explanation of design criteria

studies as if they were controlled trials proving the benefits of surgery. They are not. They may provide suggestive evidence indicating the need for a properly designed prospective study, but they cannot provide proof of the benefits or otherwise of surgical treatment. Fortunately, the VA study¹¹ approaches more closely to the ideal and suggests that coronary artery bypass grafting prolongs life in the small sub group of symptomatic patients with left main stenosis, poor left ventricular function, and disease of the right coronary artery. This study has generated lively criticism,¹² some scientific and some clearly prejudiced. Despite possible difficulties with randomization, a relatively high surgical mortality rate and the problems of coping with the 17 per cent of patients who received surgical treatment after starting in the medical group, it must be stressed that this study is infinitely superior in design to anything which preceded it. It is interesting to read surgical enthusiasts, who presumably have justified their commitment to surgical treatment on the basis of inadequate earlier studies protesting against the first attempt at a truly scientific experiment.

A particular problem with most studies of the surgical treatment of left main stenosis is the lack of information about medical treatment given to either medically or surgically treated patients. With aggressive risk factor modification and exercise programs the great majority of angina subjects can be managed satisfactorily.¹⁴ There is increasing evidence that subjects with proven coronary disease who stop smoking live longer than those who continue.^{15, 16} The place of beta

blockade remains controversial although some believe that it prolongs life, at least after myocardial infarction.¹⁷ There is a suggestion that anti-hypertensive treatment postpones the development of overt coronary heart disease.¹⁸

These studies are every bit as open to criticism as the quoted studies of coronary artery surgery, and do not refer specifically to left main stenosis which may be resistant to medical treatment. If some or all of these findings are correct, however, there are important implications. Trials of surgical treatment should include full details of medical treatment given to all groups of patients. More importantly, rehabilitation and risk factor modification are free from morbidity and mortality and carry substantial additional health benefits.

It is the author's belief that the time for rationalization (in the literal sense) of research into the treatment of coronary artery disease is long overdue. Massive observational studies of surgical treatment are unlikely to yield useful information, but selective controlled studies will. Too little is known about medical treatments which are promising, risk free, and logical.

REFERENCES

1. Preston T A. Coronary artery surgery. A critical review. New York 1977. Raven Press.
2. Block T A, Murray J A and English M T. Improvement in exercise performance after unsuccessful myocardial revascularization. *Am J Cardiol* 40: 673 1977.
3. Preston T A. Coronary artery surgery. A critical review. New York 1977. Raven Press chapter 2.
4. Johnson W D, Hoffman J F Jr and Shore R T. Myocardial revascularization in the absence of cardiac symptoms. *Am J Cardiol* 39: 268 1977.
5. Lavine P, Kimbirs D, Segal B L and Linhart J W. Left main coronary artery disease. *Am J Cardiol* 30: 791 1972.
6. Demots H, Bonchek L I, Rosch J, Anderson R P, Starr A and Rahmootola S H. Left main coronary artery disease. *Am J Cardiol* 36: 136 1975.
7. Cohen M V and Gorlin R. Main left coronary artery disease. *Circulation* 52: 275 1975.
8. McConahay D R, Killen D A, McCallister B D, Arnold M, Reed W A, Crockett J E and Bell H H. Coronary artery bypass surgery for left main coronary artery disease. *Am J Cardiol* 37: 885 1976.
9. Oberman A, Kouchofios N T, Harrell R R, Holt J H, Russell H O and Rackley C E. Surgical versus medical treatment in disease of the left main coronary artery. *Lancet* 2: 591 1976.
10. Graham I M, Hickey N, Mulcahy H and Daly L. Surgical versus medical treatment in disease of left main coronary artery. (Letter to the Editor). *Lancet* 1: 137 1977.
11. Takaro T, Hultgren H N, Lipton M J and Detre K M. The VA cooperative randomized study of surgery for coronary arterial occlusive disease. II. Subgroup with

- significant left main lesions *Circulation* **54** (Suppl III) 3 107 1976
- 12 Murphy M L, Hultgren H N, Detre K, Thomsen J and Takaro T Treatment of chronic stable angina. A preliminary report of survival data of the randomized Veterans Administration cooperative study *N Engl J Med* **297** 621 1977
- 13 Special correspondence: A debate on coronary bypass *N Engl J Med* **297** 1464 1977
- 14 Mulcahy R, Hickey N and Graham I Natural history of post infarction angina pectoris (Abstr) *Br Heart J* **38** 973 1976
- 15 Wilhelmsson C, Vedin J A, Elmfeldt D., Tibblin G., and Wilhelmsen L. Smoking and myocardial infarction *Lancet* **1** 410 1975
- 16 Mulcahy R., Hickey N, Graham I and McKenzie G Factors influencing longterm prognosis in male patients surviving a first coronary attack *Br Heart J* **37** 158 1975
- 17 Multicentre International Study Improvement in Prognosis of myocardial infarction by longterm beta adrenoreceptor blockade using practolol, *Br Med J* **III** 735 1975
- 18 Berglund, G, Wilhelmsen L, Sannerstedt R, Hansson H, Andersson O., Silverstam R, Wedel H and Wikstrand K J *Coronary heart disease after treatment of hypertension* *Lancet* **1** 1 1978

Information for authors

Most of the provisions of the Copyright Act of 1976 became effective on January 1 1978. Therefore all manuscripts must be accompanied by the following statement signed by each author: "The undersigned author(s) transfers all copyright ownership of the manuscript entitled (title of article) to The C V Mosby Company in the event the work is published. The author(s) warrants that the article is original, is not under consideration by another journal, and has not been previously published. Authors will be consulted when possible regarding republication of their material."

The error in indirect blood pressure measurement with the incorrect size of cuff

L A Geddes, M E, Ph D

S J Whistler, B S

West Lafayette Ind

When the auscultatory (Korotkoff) method is used to measure blood pressure indirectly the accuracy is dependent on many factors the most important of which is the relationship of the width of the bladder in the cuff to the size of the member to which it is applied. Cuff width is that dimension measured along the member, Fig 1 illustrates the terminology applied to blood pressure cuffs and presents a listing of the sizes presently available. The aspect ratio (length to width) of most of these cuffs is about two to one. The cuff width for human application has been specified by several cardiology groups.¹⁻³ The most recent of these reports specified the correct cuff width as 20 per cent wider than the diameter of the arm. Because arm diameter is difficult to measure accurately, this recommendation can be restated in terms of the arm circumference as follows: cuff width should be $1.2/\pi = 0.382$ or about 40 per cent of the arm circumference. This means that for a typical adult subject with a 30 cm arm, the cuff width should be 12 cm. In the most recent¹ recommendations for cuff width it is stated that a cuff of 12 to 14 cm is adequate for the 30 cm adult arm. The length of the bladder is such that it should half encircle the arm.

It is well known by pediatricians that the measurement of blood pressure in children^{4,5} requires that special attention be given to use of

the correct cuff width in relation to the size of the member to which it is applied. The use of a cuff that is too narrow provides falsely high, and the use of a cuff that is too wide provides falsely low values for indirect blood pressure. Similarly in adult subjects it has been found⁶⁻¹⁰ that the standard 12 cm wide cuff gives falsely high values for pressure when applied to large arms. In fact, Orma and associates¹¹ described the situation as "cuff hypertension." It has been shown by Trout and colleagues¹ and by King and co-workers¹² that by increasing the arm circumference by wrapping with cotton or sponge rubber falsely high values for indirect pressure are obtained. Moreover Neussel and collaborators¹³ have shown that the loose application of a standard cuff to the adult arm provides a falsely high value for indirect blood pressure.

To reduce the error encountered when a standard cuff is applied to a large arm several investigations¹⁴⁻¹⁶ have advocated the use of a longer, rather than a wider bladder in the cuff. They reasoned that a long bladder would allow better transmission of the pressure in the bladder to the underlying artery. However widespread support for this suggestion has not been forthcoming. At present the length of the bladder is such that it encompasses about one half of the member circumference.

From all of these reports it is clear that the width of the cuff in relation to the circumference of the member to which it is applied, importantly affects the values obtained for indirect blood pressure. However there are few reports which specify the magnitude of the error to be expected when the incorrect cuff size is used either because the correct size is unavailable or because of a lack of knowledge of the correct size. This paper

From the Biomedical Engineering Center, Purdue University, West Lafayette, Ind.

Supported by grant HL 18947-01, National Heart, Lung and Blood Institute, Bethesda, Md.

Received for publication Apr 26 1977

Accepted for publication Dec 19 1977

Reprint requests: L A Geddes, Ph D, Director, Biomedical Engineering Center, Purdue University, in title for Interdisciplinary Engineering Studies, West Lafayette, Ind 47907.


presents data which illustrates the amount of error to be expected when the cuff width departs from the optimum which is recommended to be 40 per cent of the circumference of the member to which it is applied

Methods and materials

To illustrate the order of error to be expected with cuffs which are too small and too large blood pressure was measured indirectly in a group of 52 healthy adult subjects using three standard cuffs (9, 12 and 18 cm wide) applied to the upper arm. The arms ranged from 21.5 to 36 cm in circumference. Resting blood pressure was measured with each of the three cuffs using the auscultatory method. During deflation of the cuff (at the rate of about 3 mm Hg per heart beat) the first sound (Phase I) heard with a stethoscope placed at the antecubital fossa indicated systolic pressure. The cessation of sound (Phase V) signaled diastolic pressure. In order to illustrate the effect of cuff width on indirect blood pressure readings, the systolic and diastolic pressures obtained on each subject with the 12 cm cuff were taken as reference pressures. In almost all cases it was found that this width was very nearly 40 per cent of the arm circumference. The systolic and diastolic pressures obtained with the 9 and 18 cm cuffs were expressed as ratios of the systolic and diastolic reference pressures. These ratios were then plotted versus the ratio of arm circumference to cuff width. A linear regression line was determined for the data points for systolic diastolic and the combined pressures. A previous study¹ showed that there exists a hyperbolic correlation between the indirectly measured pressure and the ratio of cuff width to arm circumference. A consequence of this fact is that there is a linear relationship between indirect pressure and the ratio of arm circumference to cuff width.

Results

Fig 2 presents the values for the ratio of measured pressure to the reference pressure (12 cm cuff) versus the ratio of arm circumference to cuff width for systolic and diastolic pressures. Fig 3 presents the distribution of ratios for arm circumference to cuff width for the three cuff widths applied to the 52 subjects. Note that for both systolic and diastolic pressures the use of cuff that is too narrow (i.e. arm to cuff ratio greater than 2.48) resulted in a higher indirect



CUFF DESIGNATION	WIDTH (cm)	LENGTH (cm)
Newborn	2.3	6.0
	2.5	5.0
	3.0	6.8
	3.5	10.5
	3.7	7.6
Infant	4.5	11.5
	5.6	11.6
Child	8.3	15.7
	9.4	21.3
Adult	11.9	21.9
	12.4	25.9
Large Adult	15.2	32.1
	15.5	31.3
	18.0	36.0
Thigh	18.6	40.2

Fig 1 The meaning of cuff width and length and the cuff sizes presently available

pressure. Similarly with a cuff that was too wide (i.e. arm to cuff ratio less than 2.48) the measured pressure was lower. An arm circumference to cuff width ratio of 2.48 is the same as a cuff width to arm circumference ratio of 0.403.

Discussion

Of considerable importance in interpreting the data in Fig 3 which shows the histograms for the ratio of arm circumference to cuff width among the 52 subjects. For the 12 cm cuff the mean ratio of arm circumference to cuff width was 2.30. The reciprocal of this value is 0.435, which is very close to the 0.4 value recommended as optimum for obtaining accurate indirect blood pressure values. It is not coincidental that this group of subjects possessed arms which provided this value. For the 9 cm cuff the mean value for the ratio of arm circumference to cuff width was 3.02, which corresponds to a cuff width to arm circumference ratio of 0.33. This cuff is therefore too narrow for these subjects and provided a combined indirect pressure reading of 5.7 per cent above the reference value obtained with the 12

The error in indirect blood pressure measurement with the incorrect size of cuff

L A Geddes, M E, Ph D

S J Whistler, B S

West Lafayette Ind

When the auscultatory (Korotkoff) method is used to measure blood pressure indirectly, the accuracy is dependent on many factors, the most important of which is the relationship of the width of the bladder in the cuff to the size of the member to which it is applied. Cuff width is that dimension measured along the member, Fig 1 illustrates the terminology applied to blood pressure cuffs and presents a listing of the sizes presently available. The aspect ratio (length to width) of most of these cuffs is about two to one. The cuff width for human application has been specified by several cardiology groups.¹⁻¹³ The most recent of these reports specified the correct cuff width as 20 per cent wider than the diameter of the arm.¹ Because arm diameter is difficult to measure accurately, this recommendation can be restated in terms of the arm circumference as follows: cuff width should be $1.2/\pi = 0.382$ or about 40 per cent of the arm circumference. This means that for a typical adult subject with a 30 cm arm the cuff width should be 12 cm. In the most recent¹ recommendations for cuff width it is stated that a cuff of 12 to 14 cm is adequate for the 30 cm adult arm. The length of the bladder is such that it should half encircle the arm.

It is well known by pediatricians that the measurement of blood pressure in children¹⁴ requires that special attention be given to use of

the correct cuff width in relation to the size of the member to which it is applied. The use of a cuff that is too narrow provides falsely high, and the use of a cuff that is too wide provides falsely low values for indirect blood pressure. Similarly in adult subjects it has been found¹⁵ that the standard 12 cm wide cuff gives falsely high values for pressure when applied to large arms. In fact Orma and associates¹² described the situation as 'cuff hypertension'. It has been shown by Trout and colleagues¹ and by King and co workers¹³ that by increasing the arm circumference by wrapping with cotton or sponge rubber, falsely high values for indirect pressure are obtained. Moreover Neussel and collaborators¹¹ have shown that the loose application of a standard cuff to the adult arm provides a falsely high value for indirect blood pressure.

To reduce the error encountered when a standard cuff is applied to a large arm, several investigations¹³⁻¹⁵ have advocated the use of a longer, rather than a wider bladder in the cuff. They reasoned that a long bladder would allow better transmission of the pressure in the bladder to the underlying artery. However widespread support for this suggestion has not been forthcoming. At present the length of the bladder is such that it encompasses about one half of the member circumference.

From all of these reports it is clear that the width of the cuff in relation to the circumference of the member to which it is applied importantly affects the values obtained for indirect blood pressure. However there are few reports which specify the magnitude of the error to be expected when the incorrect cuff size is used either because the correct size is unavailable or because of a lack of knowledge of the correct size. This paper

From the Biomedical Engineering Center, Purdue University, West Lafayette, Ind.

Supported by grant HL 18947-01 National Heart, Lung and Blood Institute, Bethesda, Md.

Received for publication Apr 26 1977

Accepted for publication Dec 19 1977

Reprint requests: L A Geddes, Ph D, Director, Biomedical Engineering Center, Purdue University, Institute for Interdisciplinary Engineering Studies, West Lafayette, Ind 47907.




Fig 4 This illustration shows the error expected for indirect blood pressure when the cuff width deviates from a value which is 40 per cent of the member circumference. The ends of each bar represent a +5 per cent (right) and a -5 per cent (left) error in indirect blood pressure measurement.

was applied to the arms of human subjects and the readings obtained were compared either with direct arterial pressure or with the values obtained relative to one size of cuff. Accordingly the data presented in the papers by Erlanger, Robinow and colleagues,⁹ Day, Ragan and Bordley,¹⁰ Trout and associates,¹¹ Simpson and co-workers,¹² King,¹³ Kivols and collaborators,¹⁴ and Burch and Shewey¹⁵ were plotted in the manner shown in Fig 2 to represent the ratio of indirect to direct (or reference 12 cm cuff) pressure versus the ratio of arm circumference to cuff width. Linear least squares lines were obtained for each set of data. From the slope of this relationship is revealed the percentage error expected when the cuff width deviates from 40 per cent of the arm circumference. In those papers where the least squares line did not pass through the ratio of cuff width to arm circumference equal to 0.4, a proportional adjustment was made without altering the slope of the regression line. Thus the data from all of these reports were represented by straight lines passing through the 0.4 point on the axis representing arm circumference to cuff width ratio. Then the values for the ratio of cuff width to arm circumference corresponding to a plus five and minus five per cent error were identified for each subject. Using these minimum and maximum cuff to arm ratios the ranges of member circumference for a ± 5 per cent error in indirect blood pressure measurement (with respect to the AHA recommended cuff size) were calculated for the 2.5, 3.5, 4.5, 6.5, 9, 12, 15 and 18 cm cuffs. Fig 4 presents the result of this analysis and shows the cuff widths that are appropriate for members ranging from 5 to 55 cm. The cuff widths chosen

represent those that have been described in the literature or sizes that are presently available. The illustration points out that use of a cuff that is narrower than the recommended width results in an overestimation of pressure and the use of a cuff that is wider than that recommended results in an underestimation of pressure.

Cuff widths corresponding to the centers of the black bars in Fig 4 represent a cuff width to arm circumference ratio of 0.4. The extremities of the bars represent the extreme value of member circumference which will produce a ± 5 per cent error in measured pressure for a given cuff.

In order to relate the information obtained in this study to present practice, we calculated the range of arm circumference for each of the cuffs provided by the two largest manufacturers of sphygmomanometers. The limits of arm circumference were based on obtaining a ± 5 per cent error in blood pressure measurement. It was found that one manufacturer provides cuffs that are based on the American Heart Association criterion, i.e. optimum cuff width equals 40 per cent of the member circumference. The limit marks on the cuff provided by this manufacturer are in good agreement with the ± 5 per cent error in blood pressure found in this study, with the exception of the thigh cuff which indicates that it is applicable to larger members than we would recommend. It was found that the other manufacturer provided cuffs which were centered about a ratio for cuff width to member circumference equal to 0.345, i.e. slightly less than that recommended by the AHA. However, for all cuffs the range of arm circumference limits coincided very well with the ± 5 per cent criterion presented in this paper.




Fig 2 The ratio of measured indirect pressure to reference (12 cm cuff) pressure versus the ratio of arm circumference to cuff width for the 62 subjects




Fig 3 Distribution of the ratio of arm circumference to cuff width for the 52 subjects

cm cuff. Likewise, the mean ratio of arm circumference to cuff width for the 18 cm cuff applied to the subject was 1.54. The reciprocal of this figure is 0.67, i.e. the cuff width was 67 per cent of the arm circumference. This cuff was therefore too wide and provided combined indirect pressure readings which were 10 per cent below the reference values obtained with the 12 cm cuff.

The American Heart Association recommends that the cuff width should be 12 times the arm

diameter, i.e. 40 per cent of the arm circumference. However, it is not always possible to select a cuff width which is exactly 40 per cent of the arm circumference. In practice the cuff is usually narrower or wider than this optimum value. The magnitude of error to be expected with a cuff width that is not optimal can be estimated from the type of relationship presented in Fig 2.

In addition in the published literature there are several reports in which a range of cuff widths

Distinctive echocardiographic pattern of posterior wall endocardial motion in aortic stenosis*

J M Sheppard MD
Abid A Shah MD
James A Sbarbaro MD
Harold L Brooks MD
Chicago Ill and Milwaukee Wisc

In aortic stenosis (AS) the prolonged ejection time¹ and slowly rising arterial pressure pulse² reflect the abnormal manner in which blood is ejected from the left ventricle. Thus a slow prolonged rise in the arterial pulse (which primarily results from a slow volume rise in the proximal arterial tree) might be expected to produce a slow prolonged decrease in ventricular volume provided no shunt or mitral regurgitation is present. In this regard we have noted a characteristic saw toothed pattern of posterior wall endocardial motion on M mode echocardiography in aortic stenosis in which the left ventricular (LV) posterior wall endocardium has a nearly constant systolic rise lasting until the abrupt onset of its posterior motion (see Fig 1). This contrasts with the normal pattern in which despite distortion by movement of the left ventricle as a whole during late systole and early diastole the endocardial rise gradually plateaus in systole more clearly reflecting the rapid and slow phases of LV ejection.

From the Sections of Cardiology The University of Chicago and The Medical College of Wisconsin Milwaukee

This work was supported in part by United States Public Health Service Training Grant HL-05613 and United States Public Health Service SCOR in Ischemic Heart Disease HL-1648 and RCDA HL-70132.

Received for publication May 19 1977

Accepted for publication Aug 31 1977

Reprint requests: Dr Harold Brooks, The Medical College of Wisconsin Milwaukee County Medical Complex 8700 West Wisconsin Avenue Milwaukee Wisc 53226.

Presented in part at the 56th Annual Session of the American College of Cardiology Las Vegas, Nevada 34 Feb, 1977

In this study we have examined the endocardial motion in four distinct groups of patients: those with aortic stenosis; those with severe hypertension; those with coronary artery disease with aortic ejection murmurs but no aortic valve gradient (designated herein as aortic sclerosis -AScl); and those with no demonstrable heart disease. The patients with aortic stenosis and hypertension were matched in terms of systolic pressure load and degree of left ventricular hypertrophy. The study was also designed to determine whether the abnormal pattern could be reproducibly recognized by different observers thus providing a practical non-invasive marker in the assessment of aortic stenosis.

Methods

Patient populations Group A consisted of 33 of 41 consecutive patients with hemodynamically proved aortic stenosis who were studied at our Echocardiography laboratories between June 1973 and July 1976. Of the 41 patients with AS 33 had suitable M mode echocardiographs and cardiac catheterization performed within 72 hours during the 3 year period. Four patients (12 per cent) had technically unsuitable recordings and four did not have echocardiography performed. Patients with other valvular lesions were included in the study (see Table I). Two cases (No 4 and No 12) were in atrial fibrillation; the remainder were in sinus rhythm at the time of study. Patient age ranged from 23 to 72 years with a mean of 56 years. Group A was divided into patients with valve areas $< 1 \text{ cm}^2$ (AS $< 1 \text{ cm}^2$)

Conclusion

The data in this report, and those presented in the published literature, show that the use of a cuff that is too narrow overestimates and one that is too wide underestimates indirect blood pressure. A cuff width to arm circumference ratio of 0.34 overestimates blood pressure by about 5 per cent, a cuff width to arm circumference ratio of 0.50 underestimates blood pressure by 5 per cent. For the same degree of mismatch, the error is greater when the cuff width is narrower rather than larger.

Summary

This paper shows the error to be expected when blood pressure is measured indirectly with a cuff that is too wide or too narrow for the member to which it is applied. A cuff that is too narrow overestimates and a cuff that is too wide underestimates blood pressure.

REFERENCES

1. Barker M H (and committee) Standardization of blood pressure readings. Joint recommendations of the American Heart Association and the Cardiac Society of Great Britain and Ireland. *AM HEART J* 18 95 1939
2. Bordley J, Connor C A R, Hamilton W F, Kerr W J and Wiggers C J. Recommendations for human blood pressure determination by sphygmomanometers. *Circulation* 4 503 1951
3. Kirkendall W M, Burton A C, Epstein F H and Freis E D. Recommendations for human blood pressure determinations by sphygmomanometer. *Circulation* 36 980 1967
4. Woodbury R A, Robinow M and Hamilton W F. Blood pressure studies on infants. *Am J Physiol* 122 472 1938
5. Robinow M, Hamilton W F, Woodbury R A and Volpito P P. Accuracy of clinical determinations of blood pressure in children. *Am J Dis Child* 58 102 1939
6. Day R. Blood pressure determinations in children. *J Pediatr* 14 148 1939
7. Moss A J and Adams F H. Auscultatory and intra arterial pressure. A comparison in children with special reference to cuff width. *J Pediatr* 66 1094 1967
8. Hansen R L and Stuckler C G. The non hypertension or small cuff syndrome. *Clin Pediatr* 5 579 1966
9. Erlanger J. A new instrument for determining the minimum and maximum blood pressure in man. *Johns Hopkins Hosp Rep* 12 53 1904
10. Ragan C and Bordley J. The accuracy of clinical measurements of arterial blood pressure. *Bull Johns Hopkins Hosp* 69 504 1941
11. Pickering G W, Roberts J A and Sowry G S C. The aetiology of essential hypertension. The effect of correcting for arm circumference on the growth rate of arterial pressure with age. *Clin Sci* 13 267 1954
12. Trout K W, Bertrand C A and Williams M H. Measurement of blood pressure in obese persons. *JAMA* 162 970 1956
13. Orma E, Karvonen M H and Keys A. Cuff hypertension. *Lancet* 2 51 1960
14. Berliner K et al. Blood pressure measurements in obese persons. *Am J Cardiol* 8 10 1901
15. King G E. Errors in clinical measurement of blood pressure in obesity. *Clin Sci* 32 223 1967
16. Kvols L K, Rohlfing B M and Alexander J K. A comparison of intra arterial and cuff blood pressure measurements in very obese subjects. *Cardiovasc Res Cent Bull* 7 118 1969 and Personal communication 1975
17. Nussel W F. The importance of a tight blood pressure cuff. *AM HEART J* 51 905 1956
18. Karvonen M H. Effect of sphygmomanometer cuff size on blood pressure measurement. *Bull WHO* 27 805 1962
19. Simpson J A, Jamieson G, Dickhaus D W and Grover R F. Effect of cuff bladder on accuracy of measurement of indirect blood pressure. *AM HEART J* 70 208 1965
20. Steinfeld L, Alexander H and Cohen M L. Updating sphygmomanometry. *Am J Cardiol* 33 107 1974
21. Geddes L A and Tvey R. The importance of cuff width in the measurement of blood pressure indirectly. *Cardiovasc Res Cent Bull* 14 69 1976
22. Burch G E and Shewey L. Sphygmomanometric cuff size and blood pressure recordings. *JAMA* 225 1215 1973

Distinctive echocardiographic pattern of posterior wall endocardial motion in aortic stenosis*

J M Sheppard MD
Abid A Shah MD
James A Sbarbaro MD
Harold L Brooks MD
Chicago Ill and Milwaukee Wis

In aortic stenosis (AS) the prolonged ejection time¹ and slowly rising arterial pressure pulse^{2,3} reflect the abnormal manner in which blood is ejected from the left ventricle. Thus a slow prolonged rise in the arterial pulse (which primarily results from a slow volume rise in the proximal arterial tree⁴) might be expected to produce a slow prolonged decrease in ventricular volume provided no shunt or mitral regurgitation is present. In this regard we have noted a characteristic saw toothed pattern of posterior wall endocardial motion on M mode echocardiography in aortic stenosis in which the left ventricular (LV) posterior wall endocardium has a nearly constant systolic rise lasting until the abrupt onset of its posterior motion (see Fig 1). This contrasts with the normal pattern in which despite distortion by movement of the left ventricle as a whole during late systole and early diastole the endocardial rise gradually plateaus in systole more clearly reflecting the rapid and slow phases of LV ejection.

From the Sections of Cardiology, The University of Chicago and The Medical College of Wisconsin, Milwaukee.

This work was supported in part by United States Public Health Service Training Grant HL-05633 and United States Public Health Service SCOR in Ischemic Heart Disease HL-17648 and RCDA HL 70-132.

Received for publication May 10, 1977.

Accepted for publication August 11, 1977.

Reprint requests: Dr Harold Brooks, The Medical College of Wisconsin, Milwaukee County Medical Complex, 8700 West Wisconsin Avenue, Milwaukee, Wis. 53226.

Presented in part at the 76th Annual Session of the American College of Cardiology, Las Vegas, Nevada, March, 1977.

In this study we have examined the endocardial motion in four distinct groups of patients: those with aortic stenosis; those with severe hypertension; those with coronary artery disease with aortic ejection murmurs but no aortic valve gradient (designated herein as aortic sclerosis—AScl); and those with no demonstrable heart disease. The patients with aortic stenosis and hypertension were matched in terms of systolic pressure load and degree of left ventricular hypertrophy. The study was also designed to determine whether the abnormal pattern could be reproducibly recognized by different observers, thus providing a practical non-invasive marker in the assessment of aortic stenosis.

Methods

Patient populations. Group A consisted of 33 of 41 consecutive patients with hemodynamically proved aortic stenosis who were studied at our Echocardiography laboratories between June 1973 and July 1976. Of the 41 patients with AS, 33 had suitable M mode echocardiographs and cardiac catheterization performed within 72 hours during the 3 year period. Four patients (12 per cent) had technically unsuitable recordings and four did not have echocardiography performed. Patients with other valvular lesions were included in the study (see Table I). Two cases (No 4 and No 12) were in atrial fibrillation; the remainder were in sinus rhythm at the time of study. Patient age ranged from 23 to 72 years with a mean of 56 years. Group A was divided into patients with valve areas $< 1 \text{ cm}^2$ (AS $< 1 \text{ cm}^2$)




Fig 1 Diagram comparing the typical posterior LV endocardial motion in hypertensive patients and normals with that in aortic stenosis. The method of calculating the value XY is illustrated.

and those with areas greater than or equal to 1 cm^2 ($AS \geq 1 \text{ cm}^2$).

Group B consisted of 33 of 52 consecutive patients with severe untreated hypertension who had suitable M mode echocardiograms recorded in our laboratories between July, 1974 and November, 1976. Of the 52 patients 12 had normal posterior wall thickness (less than or equal to 11 mm) on echocardiography. Of the remaining 40 33 were selected without knowledge of the ratio diastolic LV posterior wall thickness (hd) LV internal diameter ratio (Dd), with those of the 33 patients in Group A, thus providing a basis for comparison of the pressure loads in both groups. The validity of this echocardiographic index has previously been described by Grossman and colleagues.⁴

Mean hd Dd was 0.342 ± 0.014 in Group A and 0.343 ± 0.013 in Group B. Mean peak systolic

pressures were $188 \pm 59 \text{ mm Hg}$ in Group A (intraventricular) and $181 \pm 44 \text{ mm Hg}$ in Group B (arm cuff). Thus patients in both Groups A and B had a similar mean systolic pressure load and degree of left ventricular hypertrophy. Mean age of the 33 patients was 42 years with a range of 29 to 62 years. None of the patients had evidence of associated valvular or ischemic heart disease and none had evidence of left ventricular failure.

Group C comprised 12 randomly selected patients with Grade 2/3/6 harsh ejection murmurs and who on diagnostic cardiac catheterization had minimal ($< 10 \text{ mm Hg}$) or no transaortic valvular peak systolic gradients and normal cardiac outputs. Most of these patients were elderly (mean age, 61 years) and had coronary artery disease with angiographically demonstrated coronary narrowings of ≥ 75 per cent lumen diameter in one or more arteries. Such

Table 1 Clinical echocardiographic and hemodynamic data in 33 patients with aortic stenosis

Table 1 Clinical echocardiographic and hemodynamic data																		
Pt	Age/ sex	BP (mm Hg)	Other lesions	LVF	Echocardiographic data										Hemodynamic data			
					Dd (cm)	Ds (cm)	hd (cm)	hs (cm)	Sd (cm)	hdi Dd	Mean XY (cm)	Abn En	FS	PSGr (mm Hg)	AVA (cm ²)	LVS/ LVEDP	LVS	
1	54/F	80/60	MS3+ MR1+ AR1+	-	35	25	15	18	18	0.43	0.07	+	29	80	0.6	160/10	-	
2	51/M	125/65	AR2+	-	47	36	16	20	19	0.34	0.0	+	23	100	0.6	225/40	-	
3	72/M	190/60	AR3+	-	61	45	18	24	22	0.29	0.32	-	26	10	1.9	200/18	-	
4	43/F	98/65	AR2+ MR2+ TR1+	-	40	22	11	17	11	0.27	0.40	-	40	30	1.1	130/11	-	
5	45/M	140/70	MS1+ AR3+	-	58	38	11	22	11	0.19	0.70	-	34	10	2.1	140/10	-	
6	50/F	140/60	AR3+ MS1+	-	61	39	17	30	20	0.78	0.27	+	36	30	1.7	180/11	-	
7	70/F	150/90	MR1+	-	34	22	15	21	16	0.44	0.07	+	35	70	0.5	224/22	-	
8	38/F	130/90	MS2+	-	42	28	15	21	14	0.36	0.30	-	33	40	1.2	170/12	-	
9	70/F	130/60	AR+ MS2+	+	50	40	13	18	16	0.26	0.03	+	20	50	0.6	175/18	-	
10	59/F	150/80	AR2+ MS2+ TS1+	-	50	33	14	22	14	0.28	0.27	-	34	10	2.2	190/06	-	
11	65/F	130/90		-	33	21	14	18	17	0.45	0.20	+	36	90	0.6	230/19	-	
12	63/M	110/60	AR2+ MS2+	+	63	50	13	20	14	0.21	0.10	+	21	30	1.5	140/15	+	
13	60/M	100/60		-	42	28	13	16	13	0.31	0.27	+	33	25	1.4	170/25	-	
14	68/F	140/70		-	50	38	17	22	16	0.34	0.13	+	24	75	0.9	270/20	-	
15	23/M	140/70	MS1+ AR2+	-	36	25	18	25	16	0.90	0.07	+	70	53	0.7	200/19	-	
16	52/F	150/80	AR1+	-	42	25	16	21	23	0.38	0.07	+	40	80	0.6	240/08	-	
17	59/M	130/60	AR2+	-	57	40	14	18	13	0.25	0.23	+	30	15	1.8	145/16	-	
18	48/M	110/5	↑	-	50	40	14	16	13	0.78	0.10	+	20	30	1.2	142/14	-	
19	26/M	110/0		-	36	18	13	20	15	0.36	0.13	+	50	50	1.0	160/18	-	
20	61/M	110/70		-	40	30	15	22	15	0.37	0.10	+	20	55	0.8	230/32	-	
21	66/M	130/80	MS1+	-	38	31	17	21	18	0.45	0.07	+	18	70	0.5	200/30	-	
22	53/M	170/90	AR2+	+	51	40	14	20	14	0.27	0.20	+	21	40	0.4	180/40	-	
23	65/F	100/15		-	45	35	15	20	16	0.33	0.10	+	22		0.6		-	
24	48/F	165/80		-	42	30	17	22	16	0.40	0.10	+	29	95	0.5	200/20	-	
25	58/M	105/90	MS9+ MR1+ AR1+	-	42	30	14	21	14	0.33	0.10	+	29	42	0.8	187/15	-	
26	55/M	105/85		-	42	31	18	23	20	0.42	0.23	+	26	100	0.7	210/35	-	
27	70/F	130/90	MR1+	-	46	32	19	21	17	0.41	0.78	+	30	90	0.8	230/22	-	
28	66/F	130/80		+	40	30	17	26	17	0.47	0.40	+	20	105	0.4	230/15	-	
29	63/M	100/80		+	50	40	17	21	16	0.37	0.10	+	20	110	0.25	270/45	+	
30	65/M	130/90	AR1+	-	53	42	18	21	16	0.34	0.07	+	21	40	0.5	180/30	+	
31	68/M	125/10		+	50	42	19	28	17	0.38	0.17	+	16	30	1.1	175/18	-	
32	33/F	120/90	AR9+	-	51	32	11	15	11	0.27	0.65	-	37	20	1.3	140/10	-	
33	62/M	120/90		-	46	32	17	20	17	0.42	0.17	+	20		0.6		+	

Abbreviations: BP = blood pressure determined by arm cuff method; MS = mitral stenosis; MR = mitral regurgitation; AR = aortic regurgitation; PSGr = peak systolic gradient; AVA = aortic valve area; LVS = left ventricular systolic pressure; LVEDP = left ventricular end diastolic pressure; LVS = left ventricular segmental thickness; Pt = patient; M = male; F = female.

↑ = estimated at surgery.

† = aortic prosthesis.

Me n XY = mean of the measurements for XY by the 3 observers; Abn En = abnormal endocardial appearance as assessed by a majority of observers; one of the 3 observers; LVP = left ventricular failure; Ld = posterior wall thickness in diastole; Ls = posterior wall thickness in systole; Dd = left ventricular internal diastolic dimension; Ds = left ventricular internal systolic dimension.

patients were designated as having aortic sclerosis. Four of these patients had a history of previous anterior myocardial infarction and one previous inferior infarction.

Group D consisted of 30 patients selected as normal controls. All had a negative history for heart disease, normal cardiovascular findings and

normal electrocardiograms. Blood pressure was less than or equal to 140/90 mm Hg. Mean patient age was 53 years with a range of 16 to 85 years.

Echocardiographic technique. Echocardiograms were performed using a Unirad echocardiographic ultrasonoscope and strip chart recorder.

Table 11 Analysis of posterior wall endocardial motion by 3 independent observers

	PW endocardial pattern—inspection alone							Assessment by distance 11						
	Observer 1		Observer 2		Observer 3		Agr %	Observer 1		Observer 2		Observer 3		Agr %
	AbnEn	NI	AbnEn	NI	AbnEn	NI		AbnEn	NI	AbnEn	NI	AbnEn	NI	
AS < 1 cm ²	19	1	16	4	20	0	84	19	1	20	0	20	0	97
AS ≥ 1 cm ²	5	8	5	8	8	8	67	9	4	9	4	8	5	72
HT	4	29	3	30	2	31	90	3	30	3	30	2	31	86

Abbreviations: PW = posterior wall; AbnEn = abnormal posterior wall endocardial appearance (see text); NI = normal posterior wall endocardial appearance; Agr % = interobserver agreement rate; AS < 1 cm² = aortic stenosis valve area less than 1 cm²; AS ≥ 1 cm² = aortic stenosis valve area greater than 1 cm²; HT = hypertensive patients.

A 2.25 MHz ultrasound transducer with a pulse frequency of 1538/sec was utilized. The recordings and standard measurements were performed as described by Feigenbaum.⁶ The patients were studied in the supine or left lateral position. Particular care was taken to clearly delineate posterior wall endocardium and epicardium. Posterior wall thickness measurements were taken at the peak of the R wave, from the anterior edge of endocardium to the anterior edge of the epicardium. Fractional shortening (FS) was calculated using the formula

$$FS = \frac{Dd - Ds}{Dd}$$

where Dd = LV internal dimension in diastole and Ds = LV internal dimension in systole. All echocardiographic measurements were made without knowledge of the catheterization findings.

Hemodynamic assessment. Full right and left heart catheterization was performed in all patients with significant aortic murmurs and/or other findings suggesting significant aortic valve disease. This comprised all of groups A and C. Aortic valve area was calculated by the Gorlin hydraulic formula.⁷ Valve area was estimated at surgery in two of the patients in whom the aortic valve could not be crossed. LV failure, defined by Standard Clinical Criteria and/or an LV ejection fraction at catheterization of less than 45 percent, was present in 6 out of 33 cases. Coronary arteriography was performed in 34 of the 45 patients. Significant arterial lesions were present in 18 cases (six with aortic stenosis and all 12 of the aortic 'sclerotic group'). Nine had segmental abnormalities on left ventricular angiography, including four patients with aortic stenosis and five with aortic sclerosis. Segmental abnormalities were not present in cases without significant

coronary artery disease. In the group with aortic valve area < 1 cm², nine patients had pure aortic stenosis and 11 had associated lesions (including eight with aortic regurgitation).

Posterior wall endocardial motion assessment. To evaluate the ability to recognize the characteristic saw tooth pattern in an unbiased fashion, echocardiograms from the aortic stenotic (Group A) and hypertensive (Group B) patients showing only the left ventricle were mixed and independently analyzed by three physicians unaware of the diagnoses or catheterization findings. In this way assessment could not be biased by the presence of increased aortic root echoes (present in 29 out of 33 cases of AS). Assessment in Groups C and D could not be similarly blinded as the normal wall thickness in these groups allowed immediate differentiation from the group with aortic stenosis. Analysis was then made in the following ways.

1 To assess whether the appearance could be recognized by visual impression alone, the three observers graded appearances in Groups A and B as either (a) positive if the abnormal motion was definitely or probably present or (b) negative if it was either definitely or probably not present. Interobserver reproducibility and degree of prediction for aortic stenosis were assessed.

2 In an attempt to evaluate endocardial motion in a simple yet objective way, the recordings in Groups A and B were again mixed and lines were drawn tangential to the endocardium at the point of its maximal rate of rise and at its maximal rate of fall (lines AB and DC in Fig 1). The vertical distance between the point of intersection (X) of these lines and a line joining the peaks of the endocardium was measured (1Y in Fig 1) and corrected for scale expansion. Each observation involved averaging at least two




Fig. 2 Values (means with standard errors) of XY in normals, hypertensive patients (HT), aortic sclerosis (A.Scl) and aortic stenosis with (a) valve area greater than or equal to 1 cm² (AS ≥ 1 cm²) (b) valve area less than 1 cm² (AS < 1 cm²) and (c) after aortic valve replacement (post op). = Paired t test comparing AS with HT. Note decreasing values for XY with increasing severity of stenosis. A value of XY of 3 mm or less can be seen to differentiate aortic stenotic patients from the other groups.

measurements of XY. A low value of XY was expected if the endocardium had the abnormal saw toothed appearance (see Fig. 1). These results were again assessed for ability to predict AS and for agreement in predictions between the observers.

3 The pattern of endocardial motion in the records from Group C (patients with aortic sclerosis) and Group D (age matched normals) were assessed as above by one observer. The effect of heart rate on mild exercise (heart rate 110 to 120) was assessed in 10 of the normal patients. To assess the possible effect of changing paper speed upon the abnormal endocardial appearance recordings were made at various speeds in five of the normal patients.

4 Endocardial motion was assessed at varying intervals ranging from 3 days to 18 months postoperatively in 11 of the 15 patients who underwent aortic valve replacement.

5 Serial LV dimensions were recorded at 15 msec intervals in selected aortic stenotic (valve areas < 1 cm²) and hypertensive patients thus allowing graphs of LV dimension against time to be drawn. A sonic pen digitizer and a computer were utilized in measurement and analysis of the dimension changes. The time (T) between that point in the latter part of ejection at which shortening in LV internal dimension had fallen to half its maximal rate to the point at which end

systole occurred was measured in 13 patients with significant aortic stenosis and 13 patients with hypertension who were selected without knowledge of the posterior wall endocardial appearance on the basis of matching hd Dd ratio. End systole was defined as the point at which the shortest LV dimension occurred. This method of analysis of serial LV dimension was chosen to determine whether significant shortening in LV dimension (i.e. at half the maximal rate) was occurring at a relatively later stage in systole in aortic stenosis as suggested by the abnormal endocardial appearance. The remaining seven patients with AS < 1 cm² could not be accurately analyzed because of segmental abnormalities (two cases), paradoxical septal motion (left bundle branch block type) (two cases), technical problems (two cases) and insufficiently clear left side of septum (one case).

Results

Ninety nine observations by both visual assessment and by calculation of XY were performed in the aortic stenotic and hypertensive groups (one by each of the three observers). In the other groups one observation per patient by both methods was performed.

Assessment of endocardial motion by inspection alone. The abnormal motion was assessed as being present in 55 out of 60 (92 per cent) of




Fig 3 Preoperative and one year postoperative echocardiograms in a patient with severe aortic stenosis and moderate aortic regurgitation (Case No 2). Note that after aortic valve replacement the abnormal endocardial motion returned to the normal pattern.

observations in AS with valve area $< 1 \text{ cm}^2$ and 21 out of 39 (54 per cent) with a valve area $\geq 1 \text{ cm}^2$. These compared to only 9 out of 99 (9 per cent) of hypertensives, 0 out of 12 (0 per cent) of the aortic sclerotic group, 1 out of 30 (3 per cent) of normals, and 1 out of 11 (9 per cent) of post aortic valve replacement cases. Table II shows the breakdown of observations in Groups A and B by each observer. When the observations were paired to assess interobserver agreement rate agreement in prediction was demonstrated in 84 per cent of predictions in AS $< 1 \text{ cm}^2$, 67 per cent of predictions in AS $\geq 1 \text{ cm}^2$ and 90 per cent in the hypertensive patients.

Assessment by use of Distance XY. Fig 2 shows the mean values for XY in the different patient categories. There was a highly significant statistical difference ($p < .001$) both between the mean values for XY in AS $< 1 \text{ cm}^2$ and AS $\geq 1 \text{ cm}^2$ and between AS $< 1 \text{ cm}^2$ and hypertensive patients. A value for XY of 30 mm or less was taken to indicate the presence of the abnormal motion, as this value best distinguished the group with AS $< 1 \text{ cm}^2$ (see Fig 2). When assessed in this way the abnormal motion was present in 59 out of 60 observations (98 per cent) of AS $< 1 \text{ cm}^2$ and 29 out of 39 (67 per cent) of AS $\geq 1 \text{ cm}^2$, contrasting with 8 out of 99 (8 per cent) of hypertensives, 1 out of 12 (8 per cent) of the aortic

sclerotic group, 5 out of 30 (17 per cent) of normals, and 1 out of 11 (17 per cent) of the post valve replacement group. Interobserver agreement in prediction was found in 97 per cent of AS $< 1 \text{ cm}^2$, 72 per cent of predictions in AS $\geq 1 \text{ cm}^2$ and 86 per cent in the hypertensive patients. The poor interobserver agreement in predictions in the patients with AS $\geq 1 \text{ cm}^2$ reflected the mean value for XY in this group which was intermediate between AS $< 1 \text{ cm}^2$ and hypertensive patients.

Mean fractional shortening was 28 per cent in the aortic stenotic group and 32 per cent in the hypertensive patients, the similar finding suggesting that over all LV dysfunction did not cause the abnormal motion. The mean fractional shortening in the AS group was similar to that of reported adult patients with AS.¹⁰ Increasing heart rate in the 10 normal patients did not influence the value for XY significantly (mean XY = 0.42 cm). Changing paper speed did not influence the value of XY.

Echocardiographic assessment following aortic valve replacement. Fifteen of the 20 patients with aortic valve area $< 1 \text{ cm}^2$ underwent aortic valve replacement. In 11 of these repeat tracings were obtained ranging from 3 days to 18 months postoperatively. As noted above, in nearly all cases the endocardial pattern returned to normal.

(including, the study performed 3 days postoperatively) Fig 3 shows representative echocardiograms before and 18 months after valve replacement

Serial LV dimension study The mean value for T (the time between shortening at half maximal rate and end systole) was significantly decreased ($p < 0.05$) in the group with AS ($< 1 \text{ cm}^2$ as compared to the hypertensive group (37 msec compared to 97 msec). Thus shortening in LV dimension at half the maximal rate occurred much closer to end systole in the group with AS ($< 1 \text{ cm}^2$).

Discussion

This study clearly differentiates the posterior wall endocardial motion in patients with significant aortic stenosis from that in hypertensive aortic sclerotic and normal patients. The change appears to be related to the aortic valve narrowing since similar degrees of hypertrophy and pressure load were present in the aortic stenotic and hypertensive groups. Evidence for this conclusion is further corroborated by the fact that the abnormal motion disappeared after aortic valve replacement. Age and generalized myocardial dysfunction were not considered causative since the abnormal motion was not usually present in the age matched normals and fractional shortening was similar in hypertensive and aortic stenotic patients. In the 10 normal patients in whom heart rate was increased by exercise to rates varying from 110 to 120 per minute a shorter plateau in the endocardial motion was compensated by an expected increase in the AB and CD slopes secondary to increased rate of shortening and relaxation during exercise thus resulting in a normal mean value for XY. Associated valve lesions also did not influence the characteristic saw tooth appearance. Similar endocardial appearances are present in echocardiograms of aortic stenosis in the previous literature where the left ventricle is shown.

M mode echocardiography provides an opportunity to examine posterior wall endocardial motion in great detail with its high sampling rate capabilities. This motion to some extent reflects over all cardiac function in the absence of coronary artery disease.¹² A localized cause for the abnormality was unlikely as significant coronary artery disease was present in only 6 out of 33 cases of aortic stenosis and posterior wall segmental

abnormalities on LV angiography (that region likely to be visualized on M mode echocardiography) were present in only two cases. Production of the abnormal posterior wall endocardial appearance by abnormal whole heart swing was also considered unlikely since the cases with aortic stenosis had no evidence of abnormal whole heart swing elsewhere in the left ventricle and since the endocardial changes were reflected in changes in over all LV dimension.

It thus appears that the abnormal endocardial motion is a reflection of an over all change in the ejection pattern in aortic stenosis. The resumption of the normal pattern following aortic valve replacement parallels the decrease in ejection time¹ and normalization of the carotid pulse character² usually seen after aortic valve replacement. The appearance after valve replacement was identical to the normal pattern (see Fig 3) and thus unlikely to be caused either by abnormal heart swing or as compensatory to the abnormal septal motion seen after cardiac surgery (see Fig 3) where some residuum of the abnormal pattern would be expected.

The value XY probably effectively differentiates the abnormal pattern because of the constancy of the endocardial rise in aortic stenosis until abrupt posterior endocardial motion occurs (which results in a saw toothed endocardial pattern). This appearance taken in conjunction with the serial dimension study suggests that shortening is occurring later in systole in aortic stenosis to compensate for diminished ejection in the early rapid ejection phase. Diminished left ventricular compliance secondary to left ventricular hypertrophy lowers the DC slope this affects XY to a lesser degree however as evidenced by the normal values for XY in hypertensive patients whose LV hypertrophy and systolic loads were comparable to the aortic stenotic patients. Despite the small values of XY involved the clear separation between the aortic stenotic and all other groups usually allowed confident characterization of the endocardial appearance. In those normal cases where the value for XY was abnormal it is possible that an abnormal degree of anterior late systolic heart swing was responsible. Values for XY were generally borderline in these cases (four of five cases classified as abnormal had values of XY = 3 mm).

The abnormal pattern is most helpful in the

diagnosis of significant aortic stenosis on M mode echocardiography, particularly in view of the high rate of detection of significant AS using the value XY. As all of our patients with significant AS had a wall thickness of 13 mm or greater (see Table I), and wall motion was assessed as abnormal in nearly all of the observations we feel the absence of both features essentially excludes significant AS in the adult age group. As has been noted by others, we found increasing degrees of wall thickness with more severe degrees of aortic stenosis.¹⁰⁻¹³ We strongly suspect significant aortic stenosis when the combination of the abnormal motion, a posterior wall thickness greater than 14 mm, normal or decreased LV size, and thickened ill defined aortic valve cusps are all demonstrated. These guidelines are especially useful considering present difficulties in diagnosing aortic stenosis using M mode echocardiography¹⁸, the sign being particularly helpful in aortic regurgitation where the association of aortic stenosis is sometimes difficult to determine, and in patients with aortic 'sclerosis' where aortic root echoes may be thickened and the carotid pulse misleading.

Conclusion

Posterior wall endocardial motion was studied by M mode echocardiography in varying degrees of aortic stenosis documented at cardiac catheterization and compared to hypertensive patients with matched systolic loads and normal controls. In 20 patients with valve area $< 1 \text{ cm}^2$ a distinctive 'saw toothed' pattern of motion consistent with the slowly rising arterial pulse of AS was seen (114 out of 120 observations). When the aortic valve area was $\geq 1 \text{ cm}^2$ the saw toothed pattern was seen less commonly (47 out of 78 observations, 13 patients) and was rarely seen (1 out of 24 observations, 12 patients) with coronary artery disease, aortic ejection murmurs but insignificant aortic valve gradients (aortic 'sclerosis'). The abnormal pattern was seen in only 8 per cent of 33 hypertensive patients with hypertrophy and pressure loads comparable to the 33 aortic stenosis patients and 10 per cent of 30 age matched normals. Following aortic valve replacement the pattern reverted to normal in nine of 11 patients restudied suggesting that the phenomenon is a dynamic response to fixed outflow obstruction

rather than a permanent anatomic (mural) abnormality. With echocardiographic evidence of left ventricular hypertrophy associated with typical aortic root abnormalities, this characteristic pattern is a most helpful sign in the diagnosis of aortic stenosis.

REFERENCES

1. Katz L N and Feil H S. Clinical observations on the dynamics of ventricular systole III. Aortic stenosis and insufficiency. *Heart* 12 171 1925
2. Mason D T, Braunwald E, Ross J Jr and Morrow A G. Diagnostic value of the first and second derivative of the arterial pressure pulse in aortic valve disease and hypertrophic subaortic stenosis. *Circulation* 30 90 1964
3. Epstein E J and Coulshed N. Assessment of aortic stenosis from the external carotid pulse wave. *Br Heart J* 26 84 1964
4. McDonald I G, Feigenbaum H and Chang S. Analysis of left ventricular wall motion by reflected ultrasound: application to assessment of myocardial function. *Circulation* 46 14 1972
5. Grossman W, Jones D and McLaurin L P. Wall stress and patterns of hypertrophy in the human left ventricle. *J Clin Invest* 56 56 1975
6. Feigenbaum H. *Echocardiography* 2nd ed. Philadelphia 1976. Lea & Febiger p 287
7. Gorlin R and Gorlin S G. Hydraulic formula for calculation of the area of the stenotic mitral valve, other cardiac valves and central circulatory shunts. *AM HEART J* 41 1 1951
8. Assad Morell J L, Tajik A J and Guiliani E R. Echocardiographic analysis of the ventricular septum. *Progr Cardiovasc Dis* 17 219 1974
9. Johnson G L, Meyer R A, Schwartz D C, Korfhagen J and Kaplan S. Left ventricular function by echocardiography in children with fixed aortic stenosis. *Am J Cardiol* 38 611 1976
10. McDonald I G. Echocardiographic assessment of left ventricular function in aortic valve disease. *Circulation* 53 860 1976
11. Feigenbaum H. Echocardiographic examination of the left ventricle. *Circulation* 51 1 1975
12. Quinones M A, Gaasch W H and Alexander J K. Echocardiographic assessment of left ventricular function with special reference to normalized velocities. *Circulation* 50 42 1974
13. Ludbrook P, Karlner J S, London A, Peterson K L, Leopold G R and O'Rourke R A. Posterior wall velocity: an unreliable index of total left ventricular performance in patients with coronary artery disease. *Am J Cardiol* 33 475 1974
14. Benchemol A and Matsuo S. Ejection time before and after aortic valve replacement. *Am J Cardiol* 27 244 1971
15. Bennett D H, Evans D W and Raj M V J. Echocardiographic left ventricular dimensions in pressure and volume overload: their use in assessing aortic stenosis. *Br Heart J* 37 971 1975
16. Segal, H L, Konecke L L, Nobuyoshi K, Kotler M N and Linhart J M. Echocardiography: Current concepts and clinical application. *Am J Med* 57 267 1974

Unusual complications of coronary bypass surgery

Agop Aintablian M D
Robert I Hamby M D
Robert J Kramer M D
B George Wulsoff M D

New Hyde Park and Stony Brook N Y

Since the advent of coronary bypass surgery each year an increasing number of patients are subjected to this procedure with good results.¹ Reported complications of saphenous vein bypass surgery have included pulmonary emboli and myocardial infarction or postoperative appearance of pathologic new Q waves associated at times with deterioration of the left ventricular function due to closure of the graft or trauma caused by left ventricular apical venting.²⁻⁴ A few case reports described post bypass appearance of new systolic⁵ or continuous murmurs due to normal or stenosed graft⁶ or to anastomoses of the graft to coronary vein⁷ and in one case to a coronary atero-venous fistula.⁸ Other complications include false aneurysm of the vein graft,⁹ intimal tear with or without dissecting aneurysm of the aorta¹⁰ and transmyocardial left to right shunt.¹¹

Here we report five cases, three of whom developed post bypass apical thrombus, one developed a moderate degree of new mitral regurgitation and in the other patient there was stagnation of angiographic contrast material around the distal anastomatic site. To our knowledge these complications have not been described.

From the Department of Medicine, Division of Cardiology, Long Island Jewish Hillside Medical Center, New Hyde Park, N.Y., and Department of Medicine, School of Medicine, Health Sciences Center, State University of New York at Stony Brook, Stony Brook, N.Y.

Received for publication May 11, 1977

Accepted for publication August 19, 1977

Reprint requests to Agop Aintablian, M.D., Division of Cardiology, Long Island Jewish Hillside Medical Center, New Hyde Park, N.Y. 11040.

Material

Between December 1969 and February 1977, 900 patients underwent saphenous vein bypass surgery. Postoperative angiograms were performed in 585 patients. Among these patients in three (Cases 1, 2, and 3) postoperative angiograms showed new apical thrombi which were not present prior to surgery. In one patient (Case 4) there was stagnation of angiographic material around the distal anastomatic site of the vein graft to the diagonal branch of the left anterior descending artery. The fifth patient (Case 5) developed new mitral regurgitation.

Operative Technique

All patients had reversed saphenous vein aorto-coronary bypass utilizing total cardiopulmonary support. Priming solution was 5 per cent dextrose in one third normal saline. Flow rates were 40 to 55 ml/Kg using a bubble oxygenator with mean arterial pressures of at least 50 mm Hg. The left ventricle was vented through the right superior pulmonary vein. None of these patients had apical venting. Moderate hypothermia was achieved by cooling the patient to 32° C. After total cardiopulmonary bypass the ventricle was occasionally electrically defibrillated and aorta was intermittently clamped for the distal anastomoses.

Case 1

A 65 year old white female who had documented anterior wall myocardial infarction 14 months and double saphenous vein bypass surgery four months earlier was admitted to the hospital for the second time in August, 1976 with recurrent




Fig 1 Pre and postoperative left ventricular angiograms of Case No. 1 as viewed in the right anterior oblique projection. Prior to surgery (*Pre op*) she had prolapsed mitral valve and apical akinesis (arrow in end diastole) postoperatively (*post op*) not only prolapsed mitral valve remained unchanged (upper arrow) but the patient also developed apical thrombus (lower arrow)

angina pectoris. On her first admission in April 1976 she gave a history of typical angina pectoris initially on exertion then at rest and nocturnally for the last three months not well controlled with long acting nitrates and propranolol. Her blood pressure was 140/80 mm Hg with a regular heart rate of 75 per minute. Physical examination was within normal limits except for a systolic ejection murmur Grade II/V1 and a S gallop best heard at the apex. The electrocardiogram revealed regular sinus rhythm and pathologic Q waves in Leads I, aV, V to V consistent with anterior wall infarction. Chest x ray revealed minimal cardiomegaly. The first cardiac catheterization and coronary angiography revealed normal cardiac output and normal pressures in the right heart with slight elevation of pulmonary wedge pressure (15 mm Hg) and left ventricular end-diastolic pressure (16 mm Hg). The left ventricular angiogram revealed akinesis of the apex of the left ventricle with a prolapsed mitral valve (Fig 1 *pre-op*). The coronary angiograms demonstrated over 50 to 75 per cent narrowing of the right coronary artery at the crux, slight irregularities of the circumflex artery and 80 to 90 per cent proximal narrowing of the left anterior descending artery with good distal run-off. On the day of cardiac catheterization she underwent saphenous vein bypass graft surgery to the right

coronary and the left anterior descending arteries. Her postoperative course was uneventful except for mental depression. She was discharged two weeks after surgery on no medication and remained asymptomatic for three months. On her second admission for recurrent angina pectoris a repeat left heart cardiac catheterization and left ventricular angiogram revealed again apical akinesis with a prolapsed mitral valve however there was a new large apical filling defect (Fig 1 *post op*) which was not present prior to surgery. The saphenous vein bypass graft angiograms revealed a patent graft to the left anterior descending artery and closure of the graft to the right coronary artery. A year after surgery she continues to have occasional exertional angina despite antianginal therapy.

Case 2

A 44 year old white male with history of exertional precordial pain for one year sustained a transmural inferior infarction three months prior to admission. In the last three months he continued to have precordial pressure radiating to the left arm occurring only on exertion and excitement relieved by sublingual nitroglycerin. Because of these symptoms and his job as a truck driver he was advised to take a treadmill stress




Fig 2 Pre and postoperative left ventricular angiograms of Case No 3 as viewed in the right anterior oblique projection. Prior to surgery (*pre-op*) the left ventricular contraction is normal (A and B). Postoperatively (*post-op*) not only is there deterioration of left ventricular contraction but also new apical thrombus (arrow in D).

test during which he developed 8 mm ST segment depression and angina pectoris at a heart rate of 133/minute (70 per cent of predicted maximum). On admission he was comfortable with a blood pressure of 130/80 mm Hg and a regular pulse rate of 85 per minute. He looked older than his age with extensive graying of his hair. On physical examination the only positive finding was the presence of an S gallop. His electrocardiogram showed an old inferior wall infarction. Cardiac catheterization performed on December 8, 1976 revealed normal cardiac output and normal pressures in both left and right heart. The left ventriculogram revealed an inferior wall aneurysm. Selective coronary angiograms showed almost complete occlusion of the right coronary artery at its midportion with a good distal run-off. The left anterior descending artery had a 70 to 80 per cent proximal stenosis with good run-off. The circumflex artery was almost completely occluded proximally with good distal delayed filling. Because of his symptoms and the findings on coronary angiography he underwent left anterior descending and right coronary bypass surgery. Bypass graft to the marginal branch could not be performed. His postoperative course was uneventful and ten days after surgery a postbypass graft angiogram showed patency of both grafts but the left ventriculogram revealed a new apical filling defect consistent with

apical thrombus not present prior to surgery. Four months after surgery he was asymptomatic on no therapy.

Case 3

A 56-year old white male with a 3 week history of progressive resting and nocturnal angina not well controlled with antianginal drugs was admitted for coronary angiography and possible bypass surgery. He was found to have hypertension 6 months earlier for which he received Dyazide. Physical examination on admission was entirely within normal limits. His chest x ray and electrocardiogram did not reveal any abnormalities. Cardiac catheterization done on January 4, 1977 revealed normal cardiac output and normal pressures in the right and left heart except for slight elevation of left ventricular end-diastolic pressure (16 mm Hg). The left ventricular wall motion as well as valvular functions were all normal. Selective coronary angiograms demonstrated almost complete proximal occlusion of the right coronary artery with good run-off. The left anterior descending and circumflex arteries also showed over 70 per cent proximal stenosis with fair run-off. A similar lesion was noted on the diagonal branch of the left anterior descending artery. Four days later he underwent saphenous vein bypass surgery to the above mentioned arteries. On the fourth postoperative day he




Fig 3 Selective saphenous vein opacification to the diagonal branch of the left anterior descending artery. *A* In right anterior oblique projection upper large arrow points to patent graft and lower large arrow points to the leakage of angiographic material around distal anastomotic with good visualization of native vessel (small arrows). *B* The angiographic material continued to stagnate around the anastomotic site while the bypass graft and coronary artery already has been emptied. *C* The graft (upper large arrow), the native vessel (small arrow) and the extravasated angiographic material (lower large arrow) are seen in left anterior oblique projection.

complained of severe retrosternal pain and lightheadedness and his electrocardiogram revealed a new anterior wall infarction. He was digitalized and treated as an acute myocardial infarction. One month after surgery and just before discharge he had bypass angiograms which revealed deterioration of left ventricular contraction with impaired movement of the lower anterior and apical segment. There was also a new apical filling defect consistent with thrombus (Fig 2). The saphenous vein grafts were patent to the left anterior descending, right coronary and left circumflex arteries but the graft to the diagonal branch of the left anterior descending artery was closed.

Case 4

A 65 year old white female was admitted for evaluation because of refractory exertional angina. Her resting electrocardiogram was normal. Cardiac catheterization performed on October 7, 1976 revealed normal left ventricular contractile pattern, normal cardiac output and normal pressures in the left and right heart. Coronary angiograms revealed a severe degree of proximal stenosis of all three coronary arteries and also of the diagonal branch of the left anterior descending artery. She underwent triple saphenous vein bypass grafts with five distal anastomoses: the graft to the posterior descending artery and two marginal branches of circumflex artery was a "snake" (side-to-side) graft. Her postoperative course was uneventful and her electrocardiogram remained normal. Angiogram two weeks after bypass revealed no

change in the normal left ventricular contractile pattern and normal left ventricular end diastolic pressure. The bypass grafts to the left anterior descending artery and its diagonal branch were patent but there was leakage with stagnation of angiographic material around the distal anastomotic site of the graft to the diagonal branch (Fig 3). The snake graft was closed.

Case 5

A 52 year old white male with a history of angina for 11 years which required two admissions for coronary insufficiency in the last two years was admitted for coronary angiography because of progressive angina not well controlled with high doses of propranolol and nitrates. He had a history of hypertension for twenty years treated with Aldomet. On admission his electrocardiogram and physical examination was normal and his blood pressure was 150/90 mm Hg. On cardiac catheterization, cardiac output, right and left heart pressures and left ventricular contractile pattern were all normal. There was no evidence of any mitral regurgitation (Fig 4). His coronary angiogram showed 70 to 80 per cent narrowing of the main left, left anterior descending and right coronary arteries. The circumflex artery was irregular. He underwent triple saphenous vein graft surgery. Prior to discharge left heart catheterization and post bypass angiogram were performed which showed normal left ventricular end-diastolic pressure with normal motion of the left ventricular walls but there was significant mitral regurgitation.




Fig 4 Comparison of pre and postoperative left ventricular angiograms of Case No 5 As shown in D there is significant angiographic evidence of mitral regurgitation (arrow) which was not present prior to surgery

Because of possible catheter induced mitral regurgitation the catheter was repositioned and repeat left ventriculogram again demonstrated moderate degree of mitral regurgitation. Bypass angiogram showed patent grafts to all three arteries but there was significant stenosis of the right coronary artery at its anastomotic site (Fig 5). Auscultation at this time failed to reveal any heart murmur. Six months after surgery he is completely asymptomatic and does not have murmur.

Discussion

The most common complications of saphenous vein bypass surgery are related to the stenosis or occlusion of the vein grafts with subsequent myocardial infarction or deterioration of the left ventricular contraction, whereas unusual complications are seldom related to the occlusion of the graft but rather due to surgical technique. Karpman³ noted that a high percentage of patients with a patent bypass graft to the left anterior descending artery have a systolic murmur. Bauman and Tsagans described a continuous murmur in two patients which appeared after

bypass surgery and they speculated that the murmur was produced by turbulent flow related to the graft. In our previous report⁴ as well as that of Vieweg and associates⁵ the continuous murmur was due to a fistula between coronary artery and right ventricle or between the vein graft and coronary vein. Although we noted small false aneurysms of the vein grafts at the distal anastomotic site with patent grafts in two patients on their two week postoperative angiograms none of them had late repeat graft angiograms to evaluate any deterioration in these structures. However, Baltaxe and Levin⁶ described a case with false aneurysm of the vein graft whose initial patent graft was occluded during a second study eight months after surgery. According to these authors the occlusion of the graft was caused by the compression of false aneurysm upon the bypass graft.

Post bypass formation of the apical thrombi in Case 1 and 2 probably is related to the trauma



Fig 5 Selective specification of vein graft (black arrow) to the right coronary artery of Case 5. The white arrow points to the significant stenosis just distal to the anastomotic site probably this significant stenosis by causing papillary muscle dysfunction resulted in mitral regurgitation

caused by the vent introduced through the right pulmonary vein to the endothelium of the apex of the heart with subsequent fibrin deposition and formation of the thrombus, whereas in Case 3 apical thrombus may have been due to postoperative anterior wall infarction. None of these patients had left ventricular apical venting. It is conceivable that patients with left ventricular apical venting who develop localized apical contractile abnormalities due to stab wound may develop apical thrombus. However, none of our 104 early saphenous vein bypass cases in whom apical venting technique was used, demonstrated apical thrombus. It is well known that diffuse left ventricular dysfunction or multiple infarctions predispose to apical thrombus.¹¹ Since none of the first two patients had diffuse left ventricular dysfunction or multiple infarctions, it is improbable that apical akinesia in Case 1 and inferior wall aneurysm in Case 2 played any role in the genesis of apical thrombus. Nevertheless, these abnormal wall movements were present prior to surgery and did not predispose to the formation of thrombus. In our Case 4 patient, as a result of improper and incomplete suturing of distal anastomosis, there was leakage of angiographic material probably on the epicardial surface surrounding the anastomotic site, without compromising the flow to the distal vessel. Although this patient continued to be asymptomatic six months after surgery, we advised recatheterization a year after

surgery to re evaluate the patency of the grafts.

New post bypass significant angiographic mitral regurgitation in our fifth patient was most likely due to papillary muscle dysfunction. Although the bypass graft to the right coronary artery was patent, there was significant stenosis just distal to the anastomotic site of the graft, possibly sufficient to compromise the blood supply of the papillary muscle. Lack of systolic murmur in the presence of significant angiographic mitral regurgitation, as in our case, is uncommon. In a few series not only was the intensity of the murmur poorly correlated to the degree of angiographic mitral regurgitation in patients with left ventricular dysfunction,¹⁴ but silent mitral insufficiency of significant magnitude has been described in patients with coronary¹⁵ and rheumatic heart disease.¹⁶

Although our five patients had rare complications after bypass surgery and were asymptomatic, these complications should be considered in the entire spectrum of bypass surgical complications, because they are potential future sources of morbidity for these patients.

Summary

Five patients after coronary bypass surgery developed unusual complications. Three developed new apical thrombi which are thought to be due to the trauma of the left ventricular vent or deterioration of the left ventricular contraction. Significant new mitral regurgitation in one patient probably is secondary to papillary muscle dysfunction as the result of stenosis distal to anastomoses. The leakage of angiographic material around distal anastomotic site is due to technical error. Although these unusual complications are very rare, however, they should be considered as potential source of morbidity in asymptomatic patients who leave the hospital after bypass surgery.

REFERENCES

- 1 Chatterjee K, Matloff J M, Swan H J C, Ganz W, Sustata H, Magnusson P, Buckbinder N, Hems M, and Forrester J S. Improved angina threshold and coronary reserve following direct myocardial revascularization. *Circulation* 51 and 52 (Suppl I) 181 1975.
- 2 Stile G R, Lindesmith G G, Tucker B L, Hughes R K, and Meyer B W. Long term follow up of patients with coronary artery bypass grafts. *Circulation* 54 (Suppl III) III 32, 1976.
- 3 Aintablian A, Hamby R I, Hoffman I, Hartstein M L, and Wsoff B G. New Q waves after bypass grafting. Correlations between graft patency, ventriculogram and

- surgical venting technique *J Electrocardiol* 9:371 1976
- 4 Shaw H A, Keng Y, Pritchett C L C, Warren S G, Oldham H N and Wagner G S Ventricular apical vents and postoperative focal contraction abnormalities in patients undergoing coronary artery bypass surgery *Circulation* 55:34 1977
- 5 Karpman L The murmur of aortocoronary bypass *Am Heart J* 83:179 1972
- 6 Vieweg W V R, Folkert, L T and Hagan A M Saphenous vein graft from aorta to coronary vein with production of continuous murmur A complication of coronary artery bypass surgery *Chest* 68:377 1975
- 7 Bauman D J and Tsagara T J Continuous heart murmur following aortocoronary bypass surgery *Chest* 64:269 1973
- 8 Tabrah F, Aintablian A and Hamby H I Coronary arteriovenous fistula complicating aortocoronary bypass surgery *Am Heart J* 85:534 1973
- 9 Baltaxe H A and Levin D C Angiographic demonstration of complications related to the saphenous aortocoronary bypass procedure *Am J Roentgenol Radium Ther Nucl Med* 119:484 1973
- 10 Amburn D, Dreifus, L M, Adam A, Beanco G and Linhart J W Dissection and rupture of the ascending aorta Unusual complications of aortocoronary bypass surgery *Chest* 68:313 1975
- 11 Bouchow I B, Lyengar R and Jude J R Injury to ascending aorta by partial occlusion clamp during aortocoronary bypass *J Thorac Cardiovasc Surg* 73:303 1977
- 12 Ibrahim F, Kinard J A, Schwartz E L and Shetrich E B Transmyocardial left to right shunt complicating acute inferior wall myocardial infarction after aortocoronary bypass *Surgery* 77:285 1975
- 13 Hamby R I, Wisoff H G, Davison E T and Hartstein M L Coronary artery disease and left ventricular mural thrombi: Clinical, hemodynamic and angiographic aspects *Chest* 66:488 1974
- 14 Cheng T M Incidence of ventricular aneurysm in coronary artery disease: An angiographic appraisal *Am J Med* 50:340 1971
- 15 Forrester J S, Diamond G, Freedman S, Allen H N, Parnley W M, Matloff J and Swan H J C Silent mitral insufficiency in acute myocardial infarction *Circulation* 44:877 1971
- 16 Schurr V, Vogelpeol L, Neilen M, Swanepoel A and Beck W Silent mitral incompetence *Am Heart J* 61:723 1961

Intravascular hemolysis in the late course of aortic valve replacement Relation to valve type, size, and function

Jon Dale, M D
Erk Myhre, M D
Oslo Norway

Implantation of prosthetic material into the heart induces intravascular hemolysis¹ The discovery that the serum lactate dehydrogenase (LDH) levels reflected the rate of red cell break down² made quantitative evaluation of hemolysis in larger groups of patients possible Thus, a first order correlation was found between LDH values and red cell half life in patients with prosthetic heart valves³ This makes the enzyme levels more useful for quantitation of intravascular hemolysis than most other parameters,⁴ although it gives a rather rough estimation of red cell destruction⁵

After aortic ball valve implantation a significant hemolysis frequently develops⁶ and although it is usually well compensated anemia represents a problem in some patients^{1, 7-10} For unknown reasons the degree of hemolysis varies considerably between patients with the same valve type⁹ The rate of red cell breakdown is, however, to some extent dependent upon the type and size of ball valve⁹ and it may be aggravated by valvular or paravalvular leakage^{11, 12} Hemolysis has been reported to be moderate after aortic disc valve implantation^{11, 13} but most comprehensive studies on intravascular hemolysis have been performed within the first year after valve implantation

The present investigation was done to study the degree and significance of chronic intravascular hemolysis in the late course of aortic valve replacement, and to reveal the importance of

factors that might influence red cell destruction Hemolysis induced by two series of Starr Edwards ball valves and the Lillehei Kaster and Björk Shiley disc valves was compared

Materials and methods

Included were 315 patients with four types of prosthetic aortic valves and 64 healthy individuals

Single Starr Edwards aortic ball valves were implanted in 253 patients from 1967 to 1970 Two series were used first type 1200 with silastic ball and metal cage thereafter type 2300 with hollow Stellite ball and cloth covered cage¹⁴ Two types of aortic disc prostheses the Björk Shiley and Lillehei Kaster valves were implanted in 196 patients from 1971 to 1973 according to randomization¹⁵ Both valves have free floating discs and they differ mainly with regard to the shape of the cage The Lillehei Kaster valve is constructed to open slightly more while the Björk Shiley prosthesis has a larger orifice^{14, 16, 17} The disc of the Lillehei Kaster valve closes against the metal of the ring while the contact between disc and cage is more limited in the Björk Shiley prosthesis

The patients with ball valves were examined on average three and a half years after the operation and 169 of the 175 patients still alive reported for examination¹⁸ Similarly 146 of the 152 patients alive with disc valves were studied the mean time since the implantation being more than two years¹³

The normal material of 64 healthy subjects mostly hospital personnel was selected to match the patient groups with regard to age and sex distribution

From the Institute for Thrombosis Research and Medical Department B Rikshospitalet University Hospital Oslo Norway

Received for publication May '6 1977

Accepted for publication Oct 31 1977

Reprint requests to: Dr J Dale Institute for Thrombosis Research Rikshospitalet Oslo 1 Norway

Table I Number of patients with each of the four valve types. Mean age at operation and time since operation and occurrence of leaks, arrhythmias and mitral valve disease

	Ball valves Starr Edwards type		Disc valves	
	1200	2300	Lillehei Kaster	Björk Shiley
No. of patients	50	111	72	74
Men	37	86	46	49
Women	13	33	16	25
Time since operation months	50.6	37.2	25.1	25.7
Age at operation years	51.5	52.4	53.3	54.6
No. of patients with Leakage suspected	2	6	3	2
Leakage operated	0	3	3	2
Arrhythmias	11	24	7	3
Mitral disease	12	29	14	16

Table II Hemoglobin concentrations in healthy subjects and in patients with different types of aortic valve prostheses

	Hemoglobin (Gm./dl.)		Compared with normal
	Mean	S.D.	
Healthy subjects	14.9	1.1	
Patients with valve			
Starr Edwards type 1200	14.7	1.4	N.S.
Starr Edwards type 2300	13.8	1.8	p < 0.005
Lillehei Kaster	14.9	1.3	N.S.
Björk Shiley	14.1	1.2	N.S.

The methods used were whole blood red cell and reticulocyte counts and creatinine levels were determined by routine methods. LDH measurements were done in serum according to Wroblewski and LaDue¹ using commercial reagents (Kabi AB Sweden). The results are given in international units (IU) defined as the amount of enzyme that transforms one μ mol of NADH per minute at 25° C. The content of free haptoglobin was determined by Tarukoski's method.¹⁴ Plasma hemoglobin was measured in 66 unselected patients with Starr Edwards aortic ball valves. For this test blood was carefully collected in plastic tubes and mixed with EDTA in a final concentration of 0.005 M. Plasma was prepared by centrifugation at 300 \times g for 10 minutes, the plasma pipetted off and centrifuged in new tubes at 2000 \times g for 30 minutes. Plasma hemoglobin was determined by the method of Crosby and Furth.¹⁵ This method gave reproducible results; the coefficient of variation between duplicate samples being 5.0 per cent. The plasma heme levels were expressed in terms of oxyhemoglobin standards determined with the cyanmet hemoglobin method.¹⁶

Day to day variation of plasma LDH levels

were studied by determination on two consecutive days in 17 healthy subjects and 15 patients with ball valves.

Student's *t* test was used for statistical evaluation of the results.

Results

Blood samples from a total of 315 patients were analyzed (Table I). The mean time since operation differed between the four groups of patients being more than four and a half years in those with the oldest ball valve type. A slightly higher mean age at operation in the last part of the period reflects the trend that valve replacement was gradually offered to older patients. The sex distribution was similar between the two groups with ball valves, while a higher proportion of men had Lillehei Kaster than Björk Shiley valves despite randomization.

Eight subjects with ball valves and five with disc valves had diastolic murmurs suggesting valvular or paravalvular leakage or leaks had been demonstrated by angiography. During the period three patients with ball valves and five with disc valves had been reoperated because of leakage. Mitral disease not considered serious enough to require valve replacement was equally divided between subjects with the four valve types, while continuous arrhythmia was more frequent in those with prosthetic ball valves.

The mean whole blood hemoglobin concentration was significantly reduced in patients with the Starr Edwards valves of type 2300, although two thirds of them received iron substitution (Table II). Four had levels lower than 10 Gm./dl., their anemia representing a clinical problem. One male patient who had received more than 60 transfu-

Intravascular hemolysis in the late course of aortic valve replacement Relation to valve type, size, and function

Jon Dale M D
Erk Myhre, M D
Oslo Norway

Implantation of prosthetic material into the heart induces intravascular hemolysis¹⁻⁴ The discovery that the serum lactate dehydrogenase (LDH) levels reflected the rate of red cell breakdown made quantitative evaluation of hemolysis in larger groups of patients possible Thus a first order correlation was found between LDH values and red cell half life in patients with prosthetic heart valves⁵ This makes the enzyme levels more useful for quantitation of intravascular hemolysis than most other parameters⁶ although it gives a rather rough estimation of red cell destruction⁷

After aortic ball valve implantation a significant hemolysis frequently develops⁸ and although it is usually well compensated anemia represents a problem in some patients⁹⁻¹¹ For unknown reasons the degree of hemolysis varies considerably between patients with the same valve type⁹ The rate of red cell breakdown is however, to some extent dependent upon the type and size of ball valve,⁸ and it may be aggravated by valvular or paravalvular leakage¹² Hemolysis has been reported to be moderate after aortic disc valve implantation¹¹⁻¹³ but most comprehensive studies on intravascular hemolysis have been performed within the first year after valve implantation

The present investigation was done to study the degree and significance of chronic intravascular hemolysis in the late course of aortic valve replacement and to reveal the importance of

factors that might influence red cell destruction Hemolysis induced by two series of Starr Edwards ball valves and the Lillehei Kaster and Björk Shiley disc valves was compared

Materials and methods

Included were 315 patients with four types of prosthetic aortic valves and 64 healthy individuals

Single Starr Edwards aortic ball valves were implanted in 253 patients from 1967 to 1970 Two series were used first type 1200 with silastic ball and metal cage thereafter type 2300 with hollow Stellite ball and cloth covered cage¹⁴ Two types of aortic disc prostheses the Björk Shiley and Lillehei Kaster valves were implanted in 196 patients from 1971 to 1973 according to randomization¹⁵ Both valves have free floating discs and they differ mainly with regard to the shape of the cage The Lillehei Kaster valve is constructed to open slightly more while the Björk Shiley prosthesis has a larger orifice¹⁶⁻¹⁷ The disc of the Lillehei Kaster valve closes against the metal of the ring while the contact between disc and cage is more limited in the Björk Shiley prosthesis

The patients with ball valves were examined on average three and a half years after the operation and 169 of the 175 patients still alive reported for examination¹ Similarly 146 of the 152 patients alive with disc valves were studied the mean time since the implantation being more than two years¹⁸

The normal material of 64 healthy subjects mostly hospital personnel was selected to match the patient groups with regard to age and sex distribution

From the Institute for Thrombosis Research and Medical Department
Rikshospitalet University Hospital Oslo Norway

Received for publication May 26 1977

Accepted for publication Oct 31 1977

Reprint requests to Dr J Dale Institute for Thrombosis Research
Rikshospitalet Oslo 1 Norway

Table VI Reticulocyte and erythrocyte counts and mean corpuscular hemoglobin in healthy subjects and in patients with different aortic valve prostheses

	Reticu- lytes (per cent)		Erythro- cytes (per μ l)		MCH (pg)
	Mean	S.D.	Mean	S.D.	
Healthy subjects	0.48	0.17	490	0.42	30.4
Patients with valve					
Starr Edwards 1200	1.02	1.09	5.02	0.46	29.3
Starr Edwards 2300	1.86	1.55	4.65	0.59	29.1
Lillehei-Kaster	0.19	0.38	4.95	0.52	30.1
Björk-Shiley	0.59	0.37	5.04	0.49	30.0

lysis was studied in three patients with disc valves. LDH fell from 493 to 293 in one patient but remained at the preoperative level of 220 and 229 in two others. In two other patients a thrombus on the valve that had left the discs in a semi-open position was removed in both after a rapid development of congestive failure. One had a preoperative LDH value of 1380 U/L but simultaneously increased transaminases indicated LDH leakage from damaged liver cells. After closure LDH was only 226 U/L. In the other a level of 180 U/L was not influenced by the operation.

The influence of the size of the valves on the degree of hemolysis was evaluated in patients without leaks (Table IV). The orifice diameters were smaller in the ball valves than in the disc prostheses and smallest in type 2300 because of the double cloth covering of the ring. The Björk-Shiley prosthesis is even more advantageous in this respect than is apparent from the table since the average annulus diameter was slightly smaller than in the Lillehei-Kaster valves used. The degree of hemolysis caused by smaller and larger valves within each of the four groups was compared (Table IV). The ball valves termed smaller were of size 10A or less corresponding to an inner diameter of 15.5 mm in type 1200 and 14.3 in type 2300 while the orifice diameter was 18 mm or less in both disc valve groups. A significant difference in LDH levels was only found in patients with Starr Edwards valve type 2300; the smaller valves causing more hemolysis than the larger ones.

Table VII Plasma hemoglobin levels in 64 healthy subjects and in 66 patients with Starr Edwards aortic ball valves

	Plasma hemoglobin (mg/dl)	
	Mean	S.D.
Healthy subjects	4.7	2.0
Patients with valve		
Starr Edwards 1200	5.8	3.0
Starr Edwards 2300	15.4	15.8

The day to day variation of LDH levels expressed as the coefficient of variation was 19 per cent in healthy subjects and 28 per cent in patients with aortic ball valves.

Free haptoglobin was not found in plasma in the majority of patients with ball valves; only four had levels slightly higher than 15 mg/dl (Table V). Unbound haptoglobin was absent or low also in most patients with disc valves especially in those with Lillehei-Kaster prostheses.

Normal mean red cell counts were maintained by an increased erythrocyte production in patients with Starr Edwards valve 1200 and with both disc valve types as reflected by increased numbers of circulating reticulocytes (Table VI). In those with type 2300 however the hemolysis was not fully compensated for even with a considerably increased red cell production. The differences in red cell and reticulocyte counts between the groups with valve types 1200 and 2300 were highly significant ($p < 0.001$).

Plasma hemoglobin was determined only in ball valve patients since they had the most pronounced hemolysis (Table VII). The intravascular liberation of hemoglobin was not rapid enough to increase the plasma level in patients with valve 1200 while a slightly higher mean concentration appeared in those with the newer ball valves. A good correlation was found between LDH and plasma hemoglobin levels in patients with valve type 2300 (Fig. 1).

Continuous intravascular hemolysis did not seriously affect renal function in the ball valve patients since the serum creatinine levels exceeded the upper normal limit of 1.3 mg/dl slightly in only six of them; the highest recorded value being 1.8 mg/dl.

Table III Serum LDH concentrations in healthy individuals and in patients with different types of aortic valve prostheses

	Serum LDH U/L		Compared with normal
	Mean	SD	
Healthy subjects	131.2	26.6	
Patients with valve			
Starr Edwards type 1200	343.7	227.3	$p < 0.001$
Starr Edwards type 2300	553.2	308.0	$p < 0.001$
Lillehei Kaster	230.0	54.7	$p < 0.001$
Björk Shiley	196.0	50.4	$p < 0.001$

Table IV Relation between serum LDH and size of the prosthetic aortic valves of different types. Mean orifice diameter of each valve group

	Orifice diam eter (mm)	Serum LDH (U/L)					
		Smaller valves		Larger valves			
		Mean	SD	Mean	SD		
Patients with valve							
Starr Edwards 1200	16.4	314	134	332	217	NS	
Starr Edwards 2300	14.7	554	281	444	224	p < 0.05	
Lillehei Kaster	18.2	232	48	228	55	NS	
Björk Shiley	18.4	193	55	198	48	NS	

sions during a three year period was finally reoperated because of the anemia but died post operatively. Another man had also received several transfusions but only with temporary benefit. A moderate anemia persisted in several patients with valve type 2300 in spite of iron administration. The tendency towards anemia was less in individuals with valve series 1200 and did not constitute a problem in any patient. In this group anemia was prevented by iron administration and the mean hemoglobin concentration did not deviate from normal. The mean hemoglobin levels were also normal in both groups of patients with disc valves and none of them were anemic 25 per cent possibly because they received iron substitution.

Table V Distribution of haptoglobin levels in the groups of patients with different types of aortic valve prostheses. Normal range 30-180 mg/dl

Patients with valve	Per cent distribution of haptoglobin		
	< 15 mg/dl	16-50 mg/dl	> 51 mg/dl
Starr Edwards 1200	95	5	
Starr Edwards 2300	98	2	
Lillehei Kaster	70	17	13
Björk Shiley	43	33	24

The mean serum LDH levels (Table III) indicated significant intravascular hemolysis in all four groups ($p < 0.001$). The ball valves caused considerably more hemolysis than did the disc valves, the difference between individuals with Starr Edwards valve type 1200 and the Lillehei Kaster valves being highly significant ($p < 0.001$). Considering the ball valves type 2300 caused more hemolysis than did type 1200 ($p < 0.001$) explaining the stronger tendency towards anemia. In 36 of the patients with ball valves LDH values higher than 500 U/L indicated a red cell breakdown of more than twice the normal. In eight per cent of the patients including three of the four most anemic ones, LDH levels above 1000 U/L reflected a fourfold increase of red cell destruction.

A highly significant difference in LDH levels between the two groups with disc valves ($p < 0.001$) demonstrated that the Lillehei Kaster valves were more traumatic to red cells than the Björk Shiley prostheses. The hemolysis was however, moderate in both groups and erythrocyte turnover of twice the normal rate was indicated in only one patient, while LDH values below the upper normal limit of 184 U/L were found in 23 per cent of the patients with Lillehei Kaster and in 46 per cent of those with Björk Shiley valves.

The relation between hemolysis and leaks was studied. The mean LDH was 917 U/L in the eight ball valve patients with diagnosed or suspected leaks and in four higher levels than 1000 U/L were found. In the five patients with disc valves who had diastolic murmurs the mean LDH value was 217 U/L. The effect of closure of paravalvular fistulae upon the degree of hemo-

sent a problem in spite of well functioning valves and adequate iron substitution and may even require replacement of the valve. This study demonstrates that severe anemia may develop in a few patients with hemodynamically satisfactory valves of type 2300 but hardly with any of the three other valves studied.

Free haptoglobin is important to prevent iron loss by the urine. Haptoglobin combines with hemoglobin in plasma^{1, 23} the complex is brought to the reticulo endothelial system where iron is made available for reutilization²⁴. When the hemoglobin binding capacity is exceeded free hemoglobin passes the glomerular membrane and iron is lost²⁵. The binding capacity of haptoglobin is limited^{26, 27} and was exceeded even in a considerable proportion of the patients with disc valves. Iron deficiency and anemia may therefore develop also in some patients with such valves unless iron is substituted.

The increased red cell breakdown in patients with valve 2300 was not fully compensated for even with a considerably accelerated cell production while the mean corpuscular hemoglobin was normal most probably because of iron administration. This demonstrates that the limiting factor in the prevention of anemia was the formation of new cells and not the incorporation of iron.

Increased hemolysis known to accompany valvular or paravalvular leakage^{28, 29} occurred only in some of our patients with leaks. Nevertheless this complication should be suspected when the degree of hemolysis changes in a valve patient. To what extent shear stress due to turbulence or direct mechanical trauma due to squeezing of blood through the aperture is responsible for the accelerated red cell breakdown is difficult to evaluate.

Small amounts of hemoglobin accumulated in plasma in some patients with ball valves in spite of the rapid elimination of liberated pigment from blood depleted of free haptoglobin. Red cells also contain considerable amounts of adenosine diphosphate (ADP)³⁰ which is a platelet aggregating substance and therefore a potential inducer of thrombosis. Luckily however the degradation of free ADP proceeds so rapidly³¹ that the nucleotide does not appear in concentrations known to affect platelet behaviour.

The hemoglobin that is filtered through the glomerular membrane is reabsorbed by tubular

endothelium^{32, 33} and converted to ferritin³⁴ and hemosiderin³⁵. Renal hemosiderosis as well as hemosiderinuria is characteristic in abaptoglobinemic patients^{36, 37}. The present study demonstrated however that intravascular hemolysis did not seriously reduce the kidney function even several years after valve implantation.

Summary

The degree of intravascular hemolysis was evaluated in 315 patients in the late course of aortic valve replacement. Starr Edwards aortic ball valves of series 2300 caused significantly more hemolysis than did those of series 1200 as estimated from the serum lactate dehydrogenase levels. Smaller valves of series 2300 caused a higher degree of hemolysis than did the larger ones. Aortic disc valves induced a more moderate red cell destruction than did the ball valves. The Lillehei-Kaster significantly more than the Björk-Shiley prostheses. Crushing of red cells is thought to be a more important cause of hemolysis than shearing forces in turbulent blood. Hemolytic anemia represented a problem only in some patients with Starr Edwards valve type 2300 although iron substitution was necessary also in some with other prostheses since the hemoglobin binding capacity of haptoglobin was exceeded in several patients. Valvular or paravalvular leakage was associated with stronger hemolysis in some patients and should be suspected whenever the rate of red cell destruction increases. Longstanding intravascular hemolysis did not seriously affect renal function.

REFERENCES

1. Rodgers B M and Sabiston D C Jr Hemolytic anemia following prosthetic valve replacement, *Circulation* 39 (Suppl. 1) 155 1969.
2. Brodeur M T H, Sutherland D W, Koler H D, Starr A and Griswold H E Red blood cell survival in patients with aortic valvular disease and ball valve prostheses. *Circulation* 32 570 1965.
3. Yacoub M H and Keeling D H Chronic haemolysis following insertion of ball valve prostheses. *Br Heart J* 30 676 1968.
4. Garcia M C, Clarysse A M and Alexander C S Hemolytic anemia due to progressive enlargement of silastic ball component of aortic prosthesis. *Circulation* 38 50, 1968.
5. Eysters E Traumatic hemolysis with hemoglobinuria due to ball variance. *Blood* 33 391 1969.
6. Myhre E and Rasmussen K Mechanical hemolysis in aortic valvular disease and aortic ball valve prosthesis. *Acta Med Scand* 185 543 1969.
7. Myhre E, Rasmussen K and Andersen A Serum lactate dehydrogenase activity in patients with prosthetic




Fig 1 Relation between plasma hemoglobin concentrations and serum LDH levels in patients with Starr Edwards aortic ball valves of series 2300. Coefficient of correlation = 0.894

Discussion

The results confirm our earlier finding that intravascular hemolysis is more pronounced in patients with Starr Edwards valve type 2300 than with the older type 1200.¹ The mean LDH values in the two groups were quite similar to those measured within one year after operation,¹ indicating a rather constant degree of hemolysis in the late course of valve replacement. The trend that the smaller valves of type 2300 caused more hemolysis than the larger ones has also persisted. The difference in the degree of hemolysis between patients with the two ball valve types was however not entirely due to the difference in opening area alone. Thus the hemolysis was significantly greater in the group with large 2300 valves than in that with small valves of series 1200 although the mean inner diameter was larger in the former group.

The red cell membranes may be ruptured in two different ways either as a result of direct trauma by the impact of the ball or by shearing forces induced by turbulent blood flow.¹ The stronger hemolysis caused by smaller than larger valves of type 2300 is probably related mainly to crushing. Similarly a stronger direct trauma inflicted upon a higher number of red cells by the ball of this valve may be the cause of the more extensive hemolysis found in patients with valve 2300 than in those with type 1200 although larger peak systolic gradients across the former valve¹

indicate a higher rate of shear stress. However, aortic stenosis with much higher gradients and considerable turbulence of the blood induces only a slight hemolysis even when combined with aortic insufficiency.¹ It is therefore inconceivable that shearing forces should be a main determinant for red cell destruction after prosthetic valve implantation.

Significantly more hemolysis in patients with Lillehei-Kaster than in those with Björk-Shiley valves has not been reported before although a more moderate difference has appeared in a previous study.¹¹ Moderate intravascular hemolysis has been found to accompany implantation of both disc valve types.^{11,13} Turbulence may occur by passage of blood through the smaller as well as the larger aperture of the disc valves. Although the disc is able to open more in the Lillehei-Kaster valve an angiographic investigation has demonstrated that it rarely moves maximally. Turbulence is important for arterial thrombus formation¹⁴ and thrombi that disturb the movements of the disc represent a dangerous complication for the patient.¹¹ The slightly brisker hemolysis caused by Lillehei-Kaster than by Björk-Shiley valves is, however most probably due to mechanical crushing because of the more extensive contact between disc and cage in the former type.

Frank hemolytic anemia which occurs in some patients with aortic ball valves^{1,10} may repre-

Arterial thrombosis in essential thrombocythemia

Shafkat Hussain MD*
Joel M Schwartz MD**
Sandor A Friedman MD***
Segundina N Chua MD****
Brooklyn NY

Much recent investigation into the pathogenesis of thromboembolic diseases and atherosclerosis has centered on the role of platelet adhesion and aggregation in initiating the thrombotic process. A great deal has been learned about platelet function in normal and disease states¹ and under the influence of a variety of drugs.² By contrast less attention has been paid to the effects of thrombocytosis on the vascular tree. The purpose of this report is to describe our clinical and laboratory observations in ten patients with essential thrombocythemia followed for considerable periods of time.

Subjects and methods

The ten patients with essential thrombocythemia had platelet counts consistently in excess of 875 thousand per cubic millimeter in the absence of any identifiable cause such as surgical or functional asplenia, hemolysis, chronic blood

loss, inflammation, chronic infection, and malignancy. The platelet count at the time of diagnosis in nine of the patients exceeded 1 million per cubic millimeter. The hemoglobin concentration was normal or low in all patients and none of the patients presented evidence for leukemia or myelofibrosis in the peripheral blood or in the bone marrow.

Aggregation of platelets by adenosine diphosphate (ADP) and epinephrine was measured by the method of Born and Cross,³ using a model 3001 Chronolog aggregometer attached to a Beckman 10 inch laboratory recorder. At the time of the studies, the patients had not ingested aspirin, antithrombotics, or anti-inflammatory agents for one week or more. The blood was collected into plastic tubes containing one tenth volume of 3.8 per cent sodium citrate. The patient's platelet rich plasma, prepared by centrifugation at $150 \times g$ and $22^\circ C$ for five minutes, was diluted with his own platelet poor plasma to a concentration of 200 to 300 thousand per cubic millimeter and was allowed to stand at room temperature for 30 minutes. Then 0.05 ml of a solution of aggregating agent was added to 0.45 ml of the plasma in a small tube containing a Teflon coated magnet and the mixture was stirred continuously at $37^\circ C$. The final concentrations of ADP were 5 and 20 μM and of epinephrine were 50 and 100 μM . These were minimum concentrations which consistently produced 60 to 100 per cent aggregation of platelets in normal subjects. The concentrations of epinephrine used were not sufficient to mask the platelet defect induced in normal subjects by the ingestion of aspirin.

Platelet aggregation was quantified by assum-

From the Divisions of Hematology and Peripheral Vascular Disease, Department of Medicine, Conely Island Hospital, and the Department of Medicine, State University of New York Downstate Medical Center, Brooklyn, NY.

Received for publication June 9, 1977.

Accepted for publication October 31, 1977.

Reprint requests: S. Hussain MD, Conely Island Hospital, 2601 Ocean Parkway, Brooklyn, NY 11235.

Assistant Professor in Medicine, State University of New York Downstate Medical Center and Chief, Division of Hematology, Conely Island Hospital.

Clinical Associate Professor in Medicine, State University of New York Downstate Medical Center and Chief, Division of Hematology, Conely Island Hospital.

Associate Professor in Medicine, State University of New York Downstate Medical Center and Chief, Department of Medical Services and Division of Peripheral Vascular Diseases, Conely Island Hospital.

Formerly Fellow, Division of Hematology, Conely Island Hospital.

- heart valves A parameter of intravascular hemolysis *AM HEART J* 80 463 1970
- 8 Myhre E Rasmussen K and Dale J Quantitative aspects of hemolysis in aortic valvular disease and ball valve prostheses *Acta Med Scand* 189 101 1971
 - 9 Myhre E, Dale J and Rasmussen K Erythrocyte destruction in different types of Starr Edwards aortic ball valves *Circulation* 42 515 1970
 - 10 Santinga J T Flora J D Batsakis J and Kursh M M Hemolysis in patients with the cloth covered aortic valve prosthesis *Am J Cardiol* 34 533 1974
 - 11 Nitter Hauge S Sommerfelt S C Hall K V Frøysaker T and Efskind L Chronic intravascular hemolysis after aortic disc valve replacement Comparative study between Lillehei Kaster and Bjørk Shiley disc valve prostheses *Br Heart J* 36 781 1974
 - 12 Lillehei C W Kaster R L Coleman M and Bloch J H Heart valve replacement with Lillehei Kaster pivoting disc prosthesis *N Y State J Med* 74 1426 1974
 - 13 Bjørk V O Olin C and Rdonguez L Comparative results of aortic valve replacement with different prosthetic heart valves *J Cardiovasc Surg* 13 268 1972
 - 14 Dale J Arterial thromboembolic complications in patients with Starr Edwards aortic valve prostheses *Am HEART J* 91 653 1976
 - 15 Dale J Arterial thromboembolic complications in patients with Bjørk Shiley and Lillehei Kaster aortic disc valve prostheses *AM HEART J* 93 715 1977
 - 16 Bjørk V O Holmgren A Olin C and Oenforss C O Clinical and haemodynamic results of aortic valve replacement with the Bjørk Shiley tilting disc valve prostheses *Scand J Thorac Cardiovasc Surg* 5 177 1971
 - 17 Kaster R L Lillehei C W and Starek P J K The Lillehei Kaster pivoting disc aortic prosthesis and a comparative study of the pulsatile flow characteristics with four other prostheses *Trans Am Soc Artif Intern Organs* 16 233 1970
 - 18 Wroblewski F and LaDue J E Lactic dehydrogenase activity in blood *Proc Soc Exp Biol Med* 90 216 1955
 - 19 Tarukoski P H Quantitative spectrophotometric determination of haptoglobin *Scand J Clin Lab Invest* 18 80 1966
 - 20 Crosby W H and Furth W F Modification of the benzidine method for measurement of hemoglobin in plasma and urine *Blood* 11 280 1956
 - 21 Crosby W H Munn J I and Furth W F Standardizing a method for clinical hemoglobinometry *US Armed Forces Med J* 5 693 1954
 - 22 MacCallum R N Lynch E C Hellums J D and Alfrey C P Fragility of abnormal erythrocytes evaluated by response to shear stress *J Lab Clin Med* 85 67 1975
 - 23 Dale J and Myhre E Mechanical fragility of erythrocytes in normals and in patients with heart valve prostheses *Acta Med Scand* 190 127 1971
 - 24 Kloster F E Herr R H Starr A and Griswold H F Hemodynamic evaluation of a cloth covered Starr Edwards valve prosthesis *Circulation* 39 (Suppl 1) 119 1969
 - 25 Slater S D Sallam I A Bain W H Turner M A and Lawrie G D V Haemolysis with Bjørk Shiley and Starr Edwards prosthetic heart valves a comparative study *Thorax* 29 624 1974
 - 26 Huhmann W Böttcher D Dalichau H Lichtlen P and Horst H Left ventricular hemodynamics after aortic valve replacement with a Lillehei Kaster prosthesis (Abstract) *Seventh European Congress of Cardiology* p 92 1976
 - 27 Stein P H and Sabbah H N Measured turbulence with its effects on thrombus formation *Circ Res* 35 608 1974
 - 28 Goldsmith H L Blood flow and thrombosis *Thromb Diath Haemorrh* 32 35 1974
 - 29 Ben Zvi J Holdner F J Chandraratna P A and Samet P Thrombosis on Bjørk Shiley aortic valve prosthesis *Am J Cardiol* 34 638 1974
 - 30 Spencer F C Reed G E Claus R H Tice D A and Reppert E Cloth covered aortic and mitral valve prostheses *J Thorac Cardiovasc Surg* 68 92 1970
 - 31 Latham W The renal excretion of hemoglobin Regulatory mechanisms and the differential excretion of free and protein bound hemoglobin *J Clin Invest* 38 659 1959
 - 32 Laurell C B and Nyman M Studies on the serum haptoglobin level in hemoglobinemia and its influence on renal excretion of hemoglobin *Blood* 12 493 1957
 - 33 Keene W R and Jandi J H The site of hemoglobin catabolism *Blood* 26 705 1965
 - 34 Murray R K Connel G E and Pert J H The role of haptoglobin in the clearance and distribution of extracorporeal hemoglobin *Blood* 17 45 1961
 - 35 Eysters E Mayer K and McKenzie S Traumatic hemolysis with iron deficiency anemia in patients with aortic valve lesions *Ann Intern Med* 68 995 1968
 - 36 Owen J A de Gruy G C and Smith H Serum haptoglobins in hemolytic states *J Clin Pathol* 13 478 1960
 - 37 Arrigoni M G Danielson G K Mankin H T and Pluth J R Aortic valve replacement with cloth covered composite seat Starr Edwards prosthesis *J Thorac Cardiovasc Surg* 65 376 1973
 - 38 Wallace H W Kennepp D L and Blakemore W S Quantitation of red blood cell destruction associated with valvular disease and prosthetic valves *J Thorac Cardiovasc Surg* 60 842 1970
 - 39 Schottenfeld M Wisheart J D Ross J K Lincoln J C R and Ross D N Cloth destruction and hemolysis with totally cloth covered Starr Edwards prostheses *Thorax* 26 159 1971
 - 40 Dale J Myhre E and Rasmussen K Elimination of hemoglobin and lactate dehydrogenase from plasma in normals and patients with intravascular hemolysis *Scand J Clin Lab Invest* 29 343 1972
 - 41 Dale J Reduced platelet adhesiveness in patients with prosthetic ball valves Relation to adenosine diphosphate and mechanical trauma *AM HEART J* 94 562 1977
 - 42 Rørvik T O Holmsen I and Stormorken H The release of ADP from red blood cells *Thromb Diath Haemorrh* 19 77 1968
 - 43 Bishop C Rankine D M and Talbott J H The nucleotides in normal human blood *J Biol Chem* 234 1233 1959
 - 44 Holmsen H and Day H J Adenine nucleotides and platelet function *Ser Haematol* 4 28 1971
 - 45 Brashear R E and Ross J C Disappearance of adenosine diphosphate in vivo *J Lab Clin Med* 73 64 1969
 - 46 Bunn H F and Jandi J H The renal handling of hemoglobin *J Exp Med* 129 925 1969
 - 47 Sears D A Anderson P H Foy A L Williams H L and Crosby W Urinary iron excretion and renal metabolism of hemoglobin in hemolytic diseases *Blood* 28 708 1966
 - 48 Leonardi P and Ruol A Renal hemosiderosis in the hemolytic anemias Diagnosis by means of needle biopsy *Blood* 16 1029 1960

Table 1 Clinical data in nine patients with essential thrombocythemia

Case	Age (yrs)	Sex	Presenting symptoms	Hepato megaly	Spleno megaly	Con current factors	Total dose of busulfan (mg)	Time to 1st remis sion (days)	Duration of 1st remis sion (months)	Status
1 A F	■	M	Bleeding from inguinal herniorrhaphy site 10 painful blue toes	0	0	—	104	27	40	Died in remission of a heart attack 41 months after diagnosis
2 E F	46	F	3 painful blue toes of 1 foot	+	+	Smoker	484	90	87	Alive in busulfan induced 2nd remission 109 months after diagnosis
3 S G	68	F	1 painful blue toe	■	+	HBP† Diabetes	216	90	7	Alive in busulfan induced 2nd remission 61 months after diagnosis
4 J S	71	M	Bleeding after dental extraction	0	0	HBP	144	36	26	Alive in relapse 44 months after diagnosis Refuses further treatment
5 C S	67	M	1 painful blue toe	■	+	Smoker	960	90	39	Alive in busulfan induced 2nd remission 43 months after diagnosis
6 R J	80	F	Coma CVA†	0	0	Smoker	—	—	—	Died without regaining consciousness 3 weeks after diagnosis
7 M H	59	M	Nerve deafness	+	+	ASHD†	407	150	■	Alive in remission 23 months after diagnosis
8 E E	72	F	1 painful blue toe	0	+	HBP PAD†	130	50	2	Alive in busulfan induced 2nd remission ■ months after diagnosis
9 M D	66	M	Dizziness	0	+	—	436	144	14	Alive in remission 19 months after diagnosis
10 S R	6	M	1 painful blue toe	+	+	—	—	—	—	Alive has not achieved remission 4 months after diagnosis Takes busulfan haphazardly

■ spleen in top left Enlargement documented with the use of radioisotope scan

†Abbreviations: PAD = peripheral arterial disease with claudication HBP = hypertension ASHD = atherosclerotic heart disease CVA = cerebrovascular accident

were relieved as the platelet count reverted toward normal. Nevertheless palpable pulsations did not reappear in occluded arteries of medium and larger size. One patient (Case 10) took busulfan haphazardly. Four months after diagnosis the platelet count and the spleen size were still increased and the great toe was painless but remained dusky in color.

Busulfan was discontinued after the platelet

count decreased to the normal range. The duration of the remissions bore no apparent relationship to the total dose of busulfan administered, the initial height of the platelet count, or the time required to achieve the initial normalization of the platelet count. In five patients (Case 2, ■, 4, ■, and 8) the platelet count increased to greater than 750 thousand/cubic millimeter after 2 to 87 months. One of these patients (Case 4) refused

ing that the light transmission through the patient's platelet rich and platelet poor plasma sample represented 0 per cent and 100 per cent aggregation, respectively. The maximum percent improvement in light transmission was considered equivalent to the maximum percent of aggregation achieved. Maximum aggregation occurred 1 to 5 minutes after addition of ADP or epinephrine.

Spontaneous aggregation of platelets was detected by continuous stirring of 0.50 ml of plasma at 37° C for a period of 15 minutes.

Leukocyte alkaline phosphatase was determined by a histochemical technique⁴ and serum levels of vitamin B12 and unbound vitamin B12 binding capacity by a radioimmunoassay method.⁵ ADP was purchased from Sigma Chemical Company, St Louis, Mo., and epinephrine from Park, Davis and Company, Detroit, Mich.

Clinical presentation and laboratory data

Ten patients with essential thrombocythemia (Table I) and 40 patients with polycythemia vera were diagnosed at this institution during a nine year period (1968 to 1977). The ages of the patients with essential thrombocythemia ranged between 46 and 83 years, the mean age was 69 years. Sex distribution was nearly equal.

The presenting complaint in six of the patients was painful blue toes which were cyanotic, cold, and tender. Posterior tibial pulses in the affected lower extremities were absent in two of the six patients (Case 2 and 8) when they were first seen and three patients (Cases 1, 3, and 8) actually lost peripheral pulsations shortly after the diagnosis and while under our observation. Bleeding occurred in only two patients and in each instance it was post surgical rather than spontaneous. Evidence of modest splenomegaly palpable in five instances was obtained in seven patients and of hepatomegaly in three patients.

Table II reveals laboratory data obtained at the time of diagnosis. The platelet counts ranged between 0.88 and 2.26 million per cubic millimeter. Large platelet clumps and giant forms were regularly observed in films made from finger stick blood. Nine patients had modest yet unequivocal, leukocytosis due mainly to an absolute increase in band forms and segmented neutrophils. Only one patient was anemic (Case 4) and hypochromic erythrocytes were apparent in the peripheral smear. The circulating erythro-

cytes in all the other patients were normochromic and displayed mild variation in size and shape, target cells and Howell Jolly bodies were not observed. The aspirated bone marrow specimens were often hypercellular and they always demonstrated hyperplasia of megakaryocytes and the presence of large platelet clumps. The relative proportion of myeloid and erythroid elements was normal in each case. Iron was depleted in two patients M.D., (Case 9) who was not anemic, and J.S., (Case 4), whose hypochromic anemia corrected completely after the oral administration of iron. The leukocyte alkaline phosphatase scores were variably increased, normal or decreased. The serum unbound vitamin B12 binding capacity was increased in only two of the six patients tested.

Platelet function studies are summarized in Table III. Epinephrine induced platelet aggregation was absent or markedly decreased (less than 40 per cent of maximum) in seven of eight patients studied when the platelet count was 750 thousand per cubic millimeter or greater and in all six patients studied at the time of diagnosis. The aggregation of platelets by ADP was decreased less consistently than the aggregation by epinephrine. Correction of the abnormal platelet responsiveness to epinephrine was achieved in some (Cases 5, 7, 8, and 10) but not all cases as the platelet count decreased toward the normal range (Fig 1). Spontaneous aggregation of platelets could not be detected in the four subjects who were studied (Cases 7, 8, 9 and 10). Platelet factor III was normally available in all patients and at all stages of the disease.

Clinical course

One patient (Case 6) presented with coma and died after three weeks without regaining consciousness. Her cerebrospinal fluid was neither bloody nor xanthochromic. The elevated platelet count was reduced to normal within 12 hours of diagnosis by plateletpheresis, and it was maintained at a low level thereafter by the administration of a single 0.4 mg per kilogram dose of nitrogen mustard intravenously and by daily busulfan by mouth. Eight patients received oral busulfan alone at a starting dose of 2 to 4 mg per day. Busulfan was uniformly effective in decreasing the platelet count to the normal range and in shrinking the size of the spleen. The ischemic symptoms and the incipient gangrene of the toes

Table III Platelet functions

Case	Date	Platelets ($\times 10^3$ / cu mm)	Platelet aggregation		Platelet factor III avail- ability
			ADP	Epinephrine	
1 A F	11/68	170	—	—	—
2 E F	4/68	101	—	—	—
	9/74	04	N	N	N
	11/75	08	N	N	N
	4/76	22	—	—	—
3 S G	11/75	030	N	A	N
	1/77	032	N	A	N
	9/73	133	—	A	N
4 J S	11/75	075	D	A	—
	10/73	101	—	—	N
5 C S	10/74	035	N	N	N
	9/76	080	D	D	N
	10/76	040	N	N	N
	6/74	118	N	D	N
6 R J	6/74	150	D	A	N
7 M H	6/75	030	—	N	N
	10/75	030	—	N	N
8 E E	6/75	118	D	A	N
	3/76	049	N	N	N
9 M D	11/7	103	A	A	N
	5/76	055	D	A	N
10 S R	1/77	048	N	D	N
	5/77	065	N	N	N

Aggregation of 60 percent or more was considered normal (N) and less than 60 percent was decreased (D). Absence of detectable aggregation is not due to (A).

Surprisingly three patients lost pulses in tibial and larger peripheral arteries shortly after thrombocythemia and digital infarction were found. Occlusion of these larger arteries could reflect synergism between the thrombocythemia and concurrent risk factors i.e. diabetes mellitus, hypertension and peripheral arteriosclerosis. Indeed the patient who developed popliteal artery occlusion had diabetes mellitus (Case 3) and another patient who lost pedal pulses had a history of intermittent claudication (Case 8). In the case of AF (Case 1) age 83 the loss of all dorsalis pedis and posterior tibial pulses may have occurred because of the superimposition of platelet thrombi on pre-existing atherosclerotic plaques. However E F (Case 2) was 46 and premenopausal when she was first seen and she had no significant risk factors for arteriosclerosis. The finding that she lacked a palpable pulse in a posterior tibial artery at the time of diagnosis suggests that thrombocythemia per se may lead to the occlusion of medium size arteries.

In contrast to the findings in secondary throm-




Fig 1 Platelet aggregation by epinephrine. Left panel: No aggregation of J S (case 4) platelets at the time of diagnosis; platelet count 133 million/cubic millimeter (A) normal aggregation in control subject (B). Right panel: Aggregation of C S (case 5) platelets during remission in October 1974 (C), relapse in September 1976 (D), second remission in October 1976 (E). See Table III for platelet counts.

bocythemia qualitative disorders of platelet function frequently accompany the thrombocytosis of myeloproliferative disorders.¹⁻¹³ The test that is abnormal most consistently at the time of diagnosis of essential thrombocythemia is epinephrine induced aggregation of platelets. Our study confirms the nearly universal impairment of the platelet response to epinephrine reported by Spaet and associates¹ and Neemeh and colleagues.¹² The relationship between clinical thrombosis and the qualitatively abnormal platelets in this disorder is unknown. Since thrombosis of digital arteries was observed at a broad range of platelet counts (0.88 to 2.26 million per cubic millimeter) factors other than the mere height of the platelet count may have played a role e.g. prior compromise of the circulation by disease in the blood vessel wall, enhanced release of vasoactive amines by platelets and unusual stickiness of the platelets with a tendency to form large aggregates. We are not aware of any published data on the release reaction of platelets in essential thrombocythemia or on platelet hyperaggregability in this disorder in response to aggregants. In contrast to the findings reported by Preston and colleagues¹² none of the four patients whom we have studied showed spontaneous aggregation of platelets in vitro.

Although statements in the literature indicate that a proportion of patients with essential thrombocythemia undergo a transition to polycy-

Table 11 Laboratory data at the time of diagnosis

Case	Hgb (Gm / 100 ml)	PCV (%)	MCHC (%)	WBC ($\times 10^3$ / cu mm)	Absolute neutro phils ($\times 10^3$ / cu mm)	Platelets ($\times 10^3$ / cu mm)	LAP*	Bone marrow aspirate				Serum†		
								Cellu larity	Mega karyo cytes	Iron	ME*	B12 (pg / ml)	UBBC (pg / ml)	Uric acid (mg / 100 ml)
1	12.6	36	35	12.8	10.2	172	N*	I*	I	2+	27	236	—	5.8
2	15.9	46	34	13.6	10.4	101	D*	I	I	3+	38	168	—	7.1
3	13.7	41	33	42.9	29.6	226	D	I	I	2+	41	625	2715	7.4
4	10.2	33	30	19.8	16.0	133	N	—†	—	—	—	800	313	—
5	15.2	46	33	11.6	7.8	101	—	N	I	2+	17	400	—	4.1
6	13.4	38	35	17.3	14.1	118	I	I	I	3+	50	—	—	9.0
7	16.2	49	33	17.2	11.5	150	I	I	I	2+	41	327	2813	7.6
8	12.0	36	33	7.5	5.2	118	D	N	I	3+	28	125	927	7.4
9	14.9	44	33	11.7	9.0	103	I	I	I	0	25	180	1035	5.3
10	13.7	39	34	12.7	11.0	0.88	I	N	I	4+	25	640	619	10.6

Abbreviations: LAP = leukocyte alkaline phosphatase ME = ratio of myeloid to erythroid cells I = increased N = normal D = decreased
†Normal serum B12 150 to 900 pg/ml unbound B12 binding capacity (UBBC) 850 to 1550 pg/ml uric acid 4 to 7 mg/100 ml

‡Patient refused to permit aspiration of bone marrow

further therapy Remission was induced in the remaining four patients by retreatment with busulfan which was then discontinued The duration of the second remissions has varied between 8 and 51 months and none of the patients has again relapsed

The nine patients who survived the initial presentation of their disease have been followed for a period ranging from 4 to 109 months Five patients have been followed for more than three years One patient (Case 1) died of a myocardial infarction at the age of 86 while in remission To date, none of the patients has shown evolution to another myeloproliferative disorder

Discussion

Essential thrombocythemia has generally been regarded as a disorder dominated by recurrent hemorrhages, most commonly epistaxis and gastrointestinal bleeding and by hypochromic iron deficiency anemia⁶⁻¹¹ Thrombosis of large veins has often been reported⁶⁻⁹ Yet none of the ten patients in the present series conform to this description Our patients suffered much more from the sequelae of arterial occlusion than from hemorrhage, and none endured venous thromboses Indeed only two of ten patients experienced unusual bleeding (Case 1 and 4) In both hemorrhage appeared in areas of operative wounds and was self limited

We cannot satisfactorily explain the differences between the clinical manifestations of our

patients and the patients reported in the other series⁶⁻¹¹ Although Preston¹ has hypothesized that patients with essential thrombocythemia and a relatively low platelet count are more likely to develop thrombosis whereas hemorrhage predominates in patients with relatively high platelet counts, a review of the data available in the published reports⁶⁻¹¹ does not substantiate this suggestion Nor is it likely that different diagnostic criteria have been applied to the patients in this series The relative incidence of essential thrombocythemia and polycythemia vera of 1:4 found in our population is similar to the ratio recently found by Lewis and colleagues¹² in a large series of patients with myeloproliferative disorders

The preeminence of the digital infarction observed in the present series and in a few selected cases previously reported^{8,9,13,14,15} probably relates to the great potential for vasoconstriction of peripheral arterioles and to clumping of a large number of platelets which ultimately occlude the already narrowed lumen Shortened survival of platelets has been reported in three essential thrombocythemia patients who had ischemic symptoms in the fingers and toes¹⁵ whereas the survival of platelets in three patients without these symptoms was normal¹⁵ The platelet survival data are consistent with a process of consumption of platelets in the course of the presumed thrombosis in the digital arteries

Table III Platelet functions

Case	Date	Platelets ($\times 10^9$ / cu mm)	Platelet aggregation		Platelet factor III analaly bilitv
			ADP	Epinephrine	
1 A F	11/68	172	—	—	—
2 F F	4/68	101	—	—	—
	9/74	045	N	N	N
	11/75	085	N	N	N
3 S G	4/72	276	—	—	—
	11/75	030	N	A	N
	1/77	039	N	A	N
4 J S	9/ 3	133	N	A	N
	11/ 5	075	D	A	—
5 C S	10/ 3	101	—	—	N
	10/74	035	N	N	N
	9/ 6	080	D	D	N
	10/76	040	N	N	N
6 R J	6/74	118	N	D	N
7 M H	6/ 5	150	D	A	N
	10/75	030	N	N	N
8 E I	6/75	118	D	A	N
	3/76	042	N	N	N
9 M D	11/75	103	A	A	N
	5/76	055	D	A	N
10 S R	1/77	088	N	D	N
	5/77	065	N	N	N

Aggregation of 80 percent or more was considered normal (N) and less than 50 percent was decreased (D). Absence of detectable aggregation was indicated by (A).

Surprisingly three patients lost pulses in tibial and larger peripheral arteries shortly after thrombocythemia and digital infarction were found. Occlusion of these larger arteries could reflect synergism between the thrombocythemia and concurrent risk factors, i.e. diabetes mellitus, hypertension and peripheral arteriosclerosis. Indeed the patient who developed popliteal artery occlusion had diabetes mellitus (Case 3) and another patient who lost pedal pulses had a history of intermittent claudication (Case 8). In the case of AF (Case 1) age 88 the loss of all dorsalis pedis and posterior tibial pulses may have occurred because of the superimposition of platelet thrombi on pre-existing atherosclerotic plaques. However E F (Case 2) was 46 and premenopausal when she was first seen and she had no significant risk factors for arteriosclerosis. The finding that she lacked a palpable pulse in a posterior tibial artery at the time of diagnosis suggests that thrombocythemia per se may lead to the occlusion of medium size arteries.

In contrast to the findings in secondary throm-




Fig 1 Platelet aggregation by epinephrine. Left panel: No aggregation of J S (case 4) platelets at the time of diagnosis; platelet count 1.33 million/cubic millimeter (A); normal aggregation in control subject (B). Right panel: Aggregation of C S (case 5) platelets during remission in October 1974 (C); relapse in September 1976 (D); second remission in October 1976 (E). See Table III for platelet counts.

bocythemia qualitative disorders of platelet function frequently accompany the thrombocytosis of myeloproliferative disorders.^{17,18} The test that is abnormal most consistently at the time of diagnosis of essential thrombocythemia is epinephrine-induced aggregation of platelets. Our study confirms the nearly universal impairment of the platelet response to epinephrine reported by Spaet and associates and Neeme and colleagues. The relationship between clinical thrombosis and the qualitatively abnormal platelets in this disorder is unknown. Since thrombosis of digital arteries was observed at a broad range of platelet counts (0.88 to 2.26 million per cubic millimeter), factors other than the mere height of the platelet count may have played a role, e.g. prior compromise of the circulation by disease in the blood vessel wall, enhanced release of vasoactive amines by platelets, and unusual stickiness of the platelets with a tendency to form large aggregates. We are not aware of any published data on the release reaction of platelets in essential thrombocythemia or on platelet hyperaggregability in this disorder in response to aggregants. In contrast to the findings reported by Preston and colleagues,¹ none of the four patients whom we have studied showed spontaneous aggregation of platelets in vitro.

Although statements in the literature indicate that a proportion of patients with essential thrombocythemia undergo a transition to polycy-

themia vera^{10 11} or to myelofibrosis^{12 13} we have not observed such a transition. The course of essential thrombocythemia has been benign once the platelet count was reduced to the normal range, and relapses have responded well to retreatment with busulfan. Because arterial thrombosis has been such a common presentation of essential thrombocythemia in our experience, and inasmuch as the response to myelosuppressive therapy has been so good, we believe that essential thrombocythemia should be suspected and platelet counts should be performed in every patient with occlusive arterial disease involving small size vessels. Screening for essential thrombocythemia may also be important in patients with disease in larger vessels when the common risk factors which predispose to arterial thrombosis are not apparent, e.g., in the non diabetic patient with peripheral arterial disease and in the non diabetic normotensive patient with symptoms of cerebral ischemia.

Summary

The course of essential thrombocythemia has been observed in ten patients ages 46 to 83, of whom nine were followed for a period of 4 months to 11 years. In contrast to the experience with essential thrombocythemia recorded in the literature, manifestations of arterial thrombosis were far more common than hemorrhage. In six of the ten patients, the presenting complaints were ascribable to incipient gangrene of the toes and several of these patients additionally developed occlusion of tibial and larger arteries while under our observation. All patients with incipient gangrene showed marked clinical improvement accompanying busulfan induced reduction and normalization of the platelet count. Relapses in five patients after 2 to 87 months responded well to retreatment with busulfan. No patient has shown evolution to another myeloproliferative disorder. Essential thrombocythemia should be considered in the differential diagnosis of occlusive arterial disease.

The authors wish to acknowledge the expert technical assistance of Ms Norma Tan BSc.

REFERENCES

- 1 Weiss H J Platelet physiology and abnormalities of platelet function. N Engl J Med (Medical Progress) 293:531-541, 580-588, 1975

- 2 Packham M A and Mustard J F Drug induced alteration of platelet function in platelets: production function, transfusion and storage. Edited by Baldwin M G and Ebbe S. New York 1974. Grune & Stratton Inc. chap 24 p 265
- 3 Born G V R and Cross M J The aggregation of blood platelets. J Physiol 168:178-193
- 4 Kaplow L S Cytochemistry of leucocyte alkaline phosphatase. Use of naphthol as phosphates in azo dye coupling techniques. Am J Clin Pathol 39:439-1963
- 5 Gottlieb C, Lau K E, Wasserman L R and Herbert V Rapid charcoal assay for intrinsic capacity (IF) Gastric juice unsaturated B12 binding capacity antibody to IF and serum unsaturated B12 binding capacity. Blood 25:875-1965
- 6 Gunz F W Hemorrhagic thrombocythemia. A critical review. Blood 15:706-1960
- 7 Ozer F L, Truax W E, Miesch D C and Levin W C Primary hemorrhagic thrombocythemia. Am J Med 28:807-1960
- 8 Silverstein M N Primary or hemorrhagic thrombocythemia. Arch Intern Med 122:18-1968
- 9 Spaet T H, Lejnieks I and Gaynor E Defective platelets in essential thrombocythemia. Arch Intern Med 124:135-1969
- 10 Lewis S M, Szur L and Hoffbrand A V Thrombocythemia. In Clinics in Hematology edited by O Brian J R. London 1972. W B Saunders Company Ltd p 339
- 11 Jamshidi K, Ansari A, Windschitl H E and Swann W R Primary thrombocythemia. Genetics 28:121-1973
- 12 Preston F E, Emanuel I G, Winfield D A and Maha R G Essential thrombocythemia and peripheral gangrene. Br Med J 3:548-1974
- 13 Vreeken J and Van Aken W G Spontaneous aggregation of blood platelets as a cause of idiopathic thrombosis and recurrent painful toes and fingers. Lancet 2:1394-1971
- 14 Berme R, Boneu B, Guirand B and Pris J Asymptomatic and recurrent painful toes and fingers in thrombocythemia. Lancet 1:432-1972
- 15 Winfield A, Branchot I and Kuttu J Platelets in the myeloproliferative syndrome. In Clinics in hematology edited by Videback A. London 1975. W B Saunders Company Ltd p 373
- 16 Harker L A and Finch C A Thrombokines in man. J Clin Invest 48:964-1969
- 17 McClure P D, Ingram G I C, Stacey R S, Glass V H and Matchett M O Platelet function tests in thrombocythemia and thrombocytosis. Br J Hematol 12:478-1966
- 18 Zucker S and Mielke C H Classification of thrombocytosis based on platelet function tests. Correlation with hemorrhagic and thrombotic complications. J Lab Clin Med 80:385-1972
- 19 Neeme J A, Bowe E J W, Thompson J H Jr, Didsheim P and Owen C A Quantitation of platelet aggregation in myeloproliferative disorders. Am J Clin Pathol 57:336-1972
- 20 Wetherley Men G The myeloproliferative disorders. In Blood and its disorders edited by Hardisty R M and Weatherall D J. Philadelphia 1974. J B Lippincott Company chap 26 p 1180

Blind study on the relations between the extent of coronary arteriosclerosis and the strength of the myocardial contraction as measured by invasive and noninvasive tests

Isaac Starr MD*
George Karreman MD**
Thomas Bering BA***
James C Shelburne MD***
Philadelphia Pa

During the past several years records of the carotid pulse derivative and the force ballistocardiogram have been secured in a series of over 76 cardiac patients admitted to the hospital for diagnostic cardiac catheterization and coronary angiograms the invasive and noninvasive tests having been performed within a few days of one another Great care was taken that the data to be compared were secured blindly ie Dr Shelburne's cardiac catheterization team remained ignorant of the findings of Dr Starr's ballistocardiographic team and vice versa until the data were assembled for statistical analysis many months later

As most of the information sought was physiological one would expect its magnitude to be influenced by abnormalities in the emotional state of the subjects at the time of the tests so we feared that the excitement inherent in invasive tests would put an interfering variable into the

results which would make it difficult or impossible to demonstrate the physiological abnormalities of interest We planned to circumvent or minimize this difficulty by identifying those subjects who had reacted emotionally to the rigors of cardiac catheterization and eliminating their data After thus elimination correlations of interest were sought by means of a computer in the data of the stable remainder who had undergone cardiac catheterization without emotional reaction detectable by our methods

A preliminary report¹ has been made A study of the significant relationship between the degree of coronary sclerosis and the presence of cardiac incoordination has already been published² Studies of the strong relation between coronary sclerosis and cardiac strength discovered in our data by the computer will now be presented

Subjects

Although inpatients at the University Hospital, all our subjects were ambulatory Age averaged 52 years ($\sigma \pm 12$ years) for the men 55 years ($\sigma \pm 12$ years) for the women

Divided according to the chief diagnosis 52 per cent were patients with typical coronary heart disease suffering from angina previous cardiac infarctions, or both with coronary narrowing demonstrated by angiogram 4 per cent were patients clinically suspected of coronary heart disease but without noteworthy coronary obstruction demonstrated by angiogram 23 per

From the Departments of Therapeutic Research Physiology (Bockus Institute) and Medicine School of Medicine University of Pennsylvania

Received for publication May 24 1977

Accepted for publication July 18 1977

Reprint requests Isaac Starr MD University of Pennsylvania School of Medicine 361 Gates Memorial Pavilion University Hospital Philadelphia Pa 19104

Department of Therapeutic Research, University of Pennsylvania

Department of Physiology Bockus Institute

Medical and Graduate University of Pennsylvania

Department of Medicine Cardiovascular Section University of Pennsylvania

Table 1 Two methods of dividing our data into two groups (a) those stable during catheterization, and (b) those excited by the procedure, by differences between the pulse rates and the systolic blood pressures at the invasive and noninvasive tests made on each subject

	(a) The stable group					(b) The excited group				
	No	Mean pulse rate—difference per min	σ	Mean syst BP—difference mm Hg	σ	No	Mean pulse rate—difference	σ	Mean syst BP—difference	σ
Method 1 (empirical) Limits of normal differences in pulse rate and systolic BP at the 2 tests were taken as 10 per minute and 10 mm Hg	29	10	± 7	03	± 9	45	54	± 16	73	± 31
Method 2 (from a previous experiment) Limits of normal differences in pulse rate and systolic BP were 18 per minute and 32 mm Hg	51	13	± 7.1	41	± 16.2	24	13.6	± 23.9	26.7	± 31.8

cent had valvular heart disease in all probability rheumatic, without coronary narrowing, 15 per cent had valvular heart disease chiefly aortic, with coronary obstruction in addition, 6 per cent had miscellaneous diagnoses such as patent ductus IHSS, atrial septal defect, and constrictive pericarditis

Patients in unstable clinical states were not admitted to this study the data of the few such cases studied inadvertently have been omitted Thus no data secured from patients suffering from acute cardiac infarction acute temporary arrhythmia, congestive failure recent operative procedures, or febrile episodes were included in the final analysis In two cases the entrance of the catheter tip into the ventricles caused asystole and ventricular tachycardia respectively despite the fact that appropriate therapeutic measures resulted in the rapid return of normal rhythms the data obtained on these patients were not used

In a few cases some of the data sought routinely was not secured and this accounts for the small differences in numbers found in the tables

Methods

In the invasive test catheterization was performed by standard techniques³ Blood pressure was taken from a catheter in the aorta or brachial artery Cardiac output was estimated by the dye dilution method the dye being injected into the pulmonary artery while samples were

taken from the central aorta Ejection fractions were calculated from ventriculograms Dr Shelnburne estimated the degree of coronary sclerosis from the angiograms by the method of Friesinger Page and Ross⁴ in which the three main coronary branches are rated separately, zero indicating normal patency 1 to 4 various degrees of narrowing and 5 occlusion The sum of the three scores we have called the coronary rating a value of 15 indicating maximal arteriosclerosis and zero no sclerosis

The noninvasive tests were performed by Dr Starr's group after the subjects had been lying supine for ½ hour or longer in the comfortable hammock of the ULF ballistocardiograph⁵ Force ballistocardiograms (Bcg)⁶ records of the carotid pulse, and of its first time derivative (PD) were then secured⁴, followed by estimations of blood pressure by the auscultatory method After calibration the average vertical I J amplitude (Bcg amp) was measured from each record, as was the average maximum slope of the front of the carotid pulse (PD max)⁴

Detection of those excited by invasive procedures The pulse rate and systolic blood pressure obtained on each subject during the noninvasive test were compared with those values found during the invasive test so that the differences could be compared with the normal scatter of those values found when two similar noninvasive tests are made on the same subject on different days To our surprise the latter were not to be found in the Biological Handbook⁷ and we

Table II Clinical composition of the 76 patients studied and the number judged to be excited at catheterization by excessive differences in pulse rate and (or) systolic blood pressure at the invasive and noninvasive tests. Normal limits used in this study were 18 per minute and 32 mm Hg so this is the less rigorous of our two methods of detecting excitement.

	Number of subjects		
	Not excited by cath	Excited by cath	Total
A Coronary heart disease			
1 Typical cases of coronary heart disease with angina pectoris, cardiac infarction or both	10	11	39
2 Cases with chest pain or abnormal ECGs, coronary heart disease suspected but not demonstrated by angiogram	2	1	3
3 Coronary heart disease complicated by valvular disease chiefly aortic	7	4	11
B No coronary heart disease			
1 Valvular heart disease chiefly RHD	11	7	18
2 Congenital heart disease patent ductus and atrial septal defect	2	0	2
3 Others	1	1	2
IHBS			
Constrictive pericarditis	0	1	1
postop			
Total	51	25	76
		33%	

were forced to fall back on our own data and experience. The fluctuations of pulse rate and blood pressure on different days are recorded on the chart of every hospital patient and from long experience with these we estimated that the normal scatter of heart rate and systolic BP observed on different days would be about 5 per minute for pulse rate and 5 mm Hg for systolic pressure. So as a first trial we eliminated all our subjects whose pulse rate at catheterization differed from that at the noninvasive test by 10 per minute or more, the blood pressure by 10 mm Hg or more, or both. This left a remainder of 29 patients who had taken cardiac catheterization in their stride: their average differences in pulse rate and systolic BP in the invasive and noninvasive

Table III Items correlated with one another in this study

Measured at noninvasive test	Measured at catheterization
Age	Pulse pressure (brachial or aortic)
Body surface area	Mean systolic BP (brachial or aortic)
Pulse pressure	R ventricular systolic pressure
Mean blood pressure	R ventricular diastolic pressure
PD max (carotid artery)	R ventricular pulse pressure
Heart rate	R ventricular mean BP
Bcg amplitude	Wedge pressure
Bcg amp + BSA	Heart rate
Bcg amp + BSA \times mean BP	Cardiac index
Pulse pressure \times mean BP	Stroke volume index
Bcg amp + BSA \times PD max	Ejection velocity index
Systolic BP	Stroke volume \times mean BP
Diastolic BP	Ejection velocity \times mean BP
	Coronary rating (amount of coronary sclerosis)

tests in the excited and nonexcited groups are given in Table I.

The stable group thus selected consisted of 20 males and nine females whose average ages were 52.5 and 56.6 years and it was composed of 16 cases of typical coronary heart disease, one case of probable coronary heart disease, seven cases of typical rheumatic valvular disease, one case of valvular heart disease with coronary obstruction also, and four miscellaneous cases, chiefly congenital heart disease. Thus the diagnostic composition of these 29 stable subjects was essentially the same as that of the entire series tested in this study.

Later seeking to compare this very stable group with a larger group selected by a less rigorous method of detecting those excited by catheterization, we used the data assembled to control an experiment on digitalis action made a few years ago⁸ in these subjects: the normal limits (20%) of differences between estimates of pulse rate and blood pressure made on the same subject on different days were 18 per minute and 32 mm Hg.

By eliminating those in whom differences of pulse rate and BP at the invasive and noninvasive tests exceeded these limits, we obtained a sample of 51 stable subjects whose diagnoses are given in

Table 1 Two methods of dividing our data into two groups (a) those stable during catheterization and (b) those excited by the procedure by differences between the pulse rates and the systolic blood pressures at the invasive and noninvasive tests made on each subject

	(a) The stable group					(b) The excited group				
	No	Mean pulse rate— difference per min	σ	Mean syst BP— difference mm Hg	σ	No	Mean pulse rate— difference	σ	Mean syst BP— difference	σ
Method 1 (empirical) Limits of normal differences in pulse rate and systolic BP at the 2 tests were taken as 10 per minute and 10 mm Hg	29	10	± 7	0.3	± 9	45	5.4	± 16	7.3	± 31
Method 2 (from a previous experiment) Limits of normal differences in pulse rate and systolic BP were 18 per minute and 32 mm Hg	51	13	± 7.1	4.1	± 16.2	24	13.6	± 23.9	26.7	± 37.8

cent had valvular heart disease, in all probability rheumatic, without coronary narrowing, 15 per cent had valvular heart disease, chiefly aortic with coronary obstruction in addition, 6 per cent had miscellaneous diagnoses such as patent ductus IHSS, atrial septal defect, and constrictive pericarditis.

Patients in unstable clinical states were not admitted to this study, the data of the few such cases studied inadvertently have been omitted. Thus no data secured from patients suffering from acute cardiac infarction, acute temporary arrhythmia, congestive failure, recent operative procedures, or febrile episodes were included in the final analysis. In two cases the entrance of the catheter tip into the ventricles caused asystole and ventricular tachycardia, respectively, despite the fact that appropriate therapeutic measures resulted in the rapid return of normal rhythms, the data obtained on these patients were not used.

In a few cases some of the data sought routinely was not secured and this accounts for the small differences in numbers found in the tables.

Methods

In the *invasive test* catheterization was performed by standard techniques.³ Blood pressure was taken from a catheter in the aorta or brachial artery. Cardiac output was estimated by the dye dilution method, the dye being injected into the pulmonary artery while samples were

taken from the central aorta. Ejection fractions were calculated from ventriculograms. Dr Shelburne estimated the degree of coronary sclerosis from the angiograms by the method of Friesinger, Page, and Ross,⁴ in which the three main coronary branches are rated separately, zero indicating normal patency, 1 to 4 various degrees of narrowing and 5, occlusion. The sum of the three scores we have called the coronary rating; a value of 15 indicating maximal arteriosclerosis and zero no sclerosis.

The *noninvasive tests* were performed by Dr Starr's group after the subjects had been lying supine for $\frac{1}{2}$ hour or longer in the comfortable hammock of the ULF ballistocardiograph.⁵ Force ballistocardiograms (Bcg),⁶ records of the carotid pulse, and of its first time derivative (PD) were then secured,⁷ followed by estimations of blood pressure by the auscultatory method. After calibration the average vertical I J amplitude (Bcg amp) was measured from each record as was the average maximum slope of the front of the carotid pulse (PD max).⁸

Detection of those excited by invasive procedures. The pulse rate and systolic blood pressure obtained on each subject during the *noninvasive test* were compared with those values found during the *invasive test* so that the differences could be compared with the normal scatter of those values found when two similar noninvasive tests are made on the same subject on different days. To our surprise the latter were not to be found in the Biological Handbook⁹ and we

Table VI Correlations of the cardiac strength—coronary sclerosis relationship in various divisions of our data. Subjects whose pulse rate differed by more than 18 per minute or whose systolic pressure differed by more than 32 mm Hg or both in the invasive and noninvasive tests are regarded as excited by catheterization

	n	r	Levels of significance	
			P = 0.01	P = 0.05
I. In patients not excited by catheterization the stable group				
a. Those with coronary heart disease only	27	-0.57	0.49	
b. Add those with both coronary and valvular heart disease	34	-0.43	0.39	
II. In patients excited by catheterization				
a. Those with coronary heart disease only	11	-0.48		0.60
b. Add those with both coronary and valvular heart disease	16	-0.43		0.51
III. Stable and excited patients combined				
a. Those with coronary heart disease with and without complicating valvular heart disease	49	-0.38	0.34	
b. Add those with valvular heart disease only (all our data except for miscellaneous cases)	67	-0.09		0.24

written consent to assume the risk. The observations recorded in the invasive study were made soon after the minor operation required to insert the catheters had been performed under local anesthesia in an operating room atmosphere. No sedatives were given routinely to our subjects but they were used occasionally if required. Questioned after such invasive tests many patients had no complaints but others found the procedure so frightening and so disagreeable that they refused to undergo it again.

In three of our cases the pulse rates during catheterization exceeded those of the noninvasive tests by 31 per cent, 34 per cent and 63 per cent in three more the systolic BPs exceeded the controls by 31 per cent, 41 per cent or 54 per cent in these the excitement was easy to identify. But the logical placement of the line best fitted to

Table VII Accuracy of estimates of the amount of coronary sclerosis in 29 patients stable during catheterization

Using

(a) Shelburne's Angiogram I (first reading)

(b) Shelburne's Angiogram II (second reading)

(c) Simple regression degree of coronary obstruction =

$$9.24 - 0.009 \left[\frac{\text{Bcg mm}}{\text{BSA (M}^2\text{)}} \times \text{mean BI mm Hg} \right]$$

(d) Multiple regression degree of coronary obstruction =

$$19.2 + 0.104 \text{ Age (year)} + 12.5 \text{ BSA (M}^2\text{)} - 0.008$$

$$\left[\frac{\text{Bcg mm}}{\text{BSA (M}^2\text{)}} \times \text{mean BP mm Hg} \right]$$

Comparisons	Mean difference	σ
Angiogram 1 vs Angiogram 2	+0.1	27
Angiogram 1 vs value predicted by Simple Regression†	+0.2	39
Angiogram 1 vs value predicted by Multiple Regression†	+0.2	34

Where 1 mm. = 2.5 (10⁵) dyne

† Data from Angiogram I was used to compute both formulas

divide our data into two groups excited and not excited presented difficulties. Our aim was to work on groups of patients in whom the differences in pulse rate and blood pressure at invasive and noninvasive tests did not exceed those which are found when normal subjects are tested by duplicate noninvasive tests made on different days. Both groups of stable subjects described in Table I meet these criteria.

The cardiac strength/coronary sclerosis relationship. The significant correlations of greatest interest identified by the computer in the data on our 29 most stable subjects have been placed in Table IV. One of them stands out. When the Bcg is calibrated in the standard way [15 mm = 275 (10⁵) dynes] the product of several measurements

$$\frac{\text{Bcg amp (mm)}}{\text{Body surface area (M}^2\text{)}} \times \frac{\text{Systolic blood pressure (mm Hg)} + \text{diastolic (1) BP (mm Hg)}}{2}$$

correlates strongly ($P = 0.02$) with Shelburne's blind estimate of the degree of coronary artery sclerosis and this is the strongest of the hundreds of correlations calculated. This relation seemed of such obvious clinical and physiological interest that the remainder of this paper has been devoted

Table IV Correlations between items measured at the noninvasive test and the amount of coronary sclerosis measured by angiogram in 29 very stable subjects who underwent cardiac catheterization without excitement

Measurement	Number	Correlation coefficient	Probability of significance
Bcg amp (BSA) \times mean BP	27	-0.43	0.02
Age	29	0.37	0.04
Bcg amp / BSA	27	-0.37	0.05
Pulse pressure \times mean BP	29	-0.36	0.05
Body surface area	27	0.37	0.06
Pulse pressure	29	-0.32	0.08
Mean blood pressure	29	-0.32	0.08
Systolic blood pressure	28	-0.33	0.09
Bcg amp	29	-0.26	0.17
PD max	28	-0.27	0.16

Table II In Table I the average values secured by our two methods of detecting the emotional reactors can be compared. In both our stable samples the scatter of pulse rate and systolic BP differences in the two kinds of tests is less than that expected in duplicates, and the diagnostic composition of the two stable groups closely resembles that of the series as a whole. We find no relation between excitement at catheterization and clinical differences.

The statistical analysis was supervised by Dr Karremman and largely conducted by Mr Bering. The first such study was made on the sample of 29 very stable subjects, secured by the more rigorous method of eliminating emotional reactors. The data enumerated in Table III were placed on cards and fed to an IBM Unicol 360 system computer which was programmed to correlate each item with the 26 other items measured a total of 351 different correlations. For those whose coefficients were larger than 0.3 regression equations were computed also.

When the computer is used in this way the results contain much spurious correlation i.e. correlation between two variables which are not mathematically independent. For example both cardiac index and stroke volume index are listed in Table III and the computer estimates that the correlation between them, $r = 0.87$ is strong. But in this computation the same estimate of stroke

Table V Physiological measurements made during cardiac catheterization not correlating significantly with the degree of coronary sclerosis (i.e., $P > 0.10$) in cases without emotional reaction to catheterization

	Number	Correlation coefficient	Level of significance ($P = 0.05$)
RV systolic pressure	29	-0.31	0.10
RV pulse pressure	28	-0.36	0.12
Ejection velocity index	27	0.25	0.20
Cardiac index	27	0.22	0.26
RV diastolic pressure	28	-0.22	0.27
Ejection fraction	20	-0.24	0.30
Ejection velocity index \times mean BP	27	0.28	0.38
Stroke volume index \times mean BP	27	0.16	0.56
Stroke volume index	27	0.18	0.63
Wedge pressure	29	0.17	0.63
LV end diastolic pressure	29	0.02	0.90

volume is used twice, once by itself, again as a factor in the calculation of the cardiac index and so it is found on both sides of the regression equation. For this reason the two variables are not mathematically independent and although their correlation cannot be explained by chance this fact is of little or no physiological interest. Such spurious correlations have not been recorded in the tables.

Hundreds of other correlations, not significant for $P = 0.05$, and of no apparent physiological interest have also been omitted from the tables. Significant correlations of interest but not pertinent to this present study will be reported later.

Results and discussion

Dangers in the comparison of results secured in invasive and noninvasive tests. Both types of tests were done with the patients lying supine after a comparable rest period but here the resemblance ceased. The noninvasive tests were performed on patients resting comfortably after reassurance that the test they were about to undergo was completely innocuous and that they could go to sleep if they wished as many of our subjects have done. The invasive tests were performed after a warning required by the hospital's legal staff that the procedure was not without danger, and after each patient had given

Table VI Correlations of the cardiac strength-coronary sclerosis relationship in various divisions of our data Subjects whose pulse rate differed by more than 18 per minute or whose systolic pressure differed by more than 32 mm Hg or both in the invasive and noninvasive tests are regarded as excited by catheterization

		Levels of significance	
		$P = 0.01$	$P = 0.05$
I In patients not excited by catheterization the stable group			
a	Those with coronary heart disease only	27 -0.52	0.49
b	Add those with both coronary and valvular heart disease	34 -0.41	0.39
II In patients excited by catheterization			
a	Those with coronary heart disease only	11 -0.48	0.60
b	Add those with both coronary and valvular heart disease	15 -0.43	0.51
III Stable and excited patients combined			
a	Those with coronary heart disease with and without complicating valvular heart disease	49 -0.38	0.34
b	Add those with valvular heart disease only (all our data except for miscellaneous cases)	67 -0.09	0.24

written consent to assume the risk. The observations recorded in the invasive study were made soon after the minor operation required to insert the catheters had been performed under local anesthesia in an operating room atmosphere. No sedatives were given routinely to our subjects but they were used occasionally if required. Questioned after such invasive tests many patients had no complaints but others found the procedure so frightening and so disagreeable that they refused to undergo it again.

In three of our cases the pulse rates during catheterization exceeded those of the noninvasive tests by 31 per cent, 34 per cent and 63 per cent in three more the systolic BPs exceeded the controls by 31 per cent, 41 per cent or 54 per cent in these the excitement was easy to identify. But the logical placement of the line best fitted to

Table VII Accuracy of estimates of the amount of coronary sclerosis in 29 patients stable during catheterization

Using

(a) Shelburne's Angiogram 1 (first reading)

(b) Shelburne's Angiogram 2 (second reading)

(c) Simple regression degree of coronary obstruction =

$$9.21 - 0.009 \left[\frac{\text{Bcg mm}^2}{\text{BSA (M)}} \times \text{mean BP mm Hg} \right]$$

(d) Multiple regression degree of coronary obstruction =

$$19.2 + 0.104 \text{ Age (year)} + 12.5 \text{ BSA (M)} - 0.008$$

$$\left[\frac{\text{Bcg mm}^2}{\text{BSA (M)}} \times \text{mean BP mm Hg} \right]$$

Comparisons	Mean difference	σ
Angiogram 1 vs Angiogram 2	+0.1	2.7
Angiogram 1 vs value predicted by Simple Regression†	+0.2	3.0
Angiogram 1 vs value predicted by Multiple Regression†	+0.2	3.4

Where 15 mm. = 275 (10³) dynes

†D ta from Angiogram 1 was used to compute both formulas

divide our data into two groups (excited and not excited) presented difficulties. Our aim was to work on groups of patients in whom the differences in pulse rate and blood pressure at invasive and noninvasive tests did not exceed those which are found when normal subjects are tested by duplicate noninvasive tests made on different days. Both groups of stable subjects described in Table I meet these criteria.

The cardiac strength/coronary sclerosis relationship. The significant correlations of greatest interest identified by the computer in the data on our 29 most stable subjects have been placed in Table IV. One of them stands out. When the Bcg is calibrated in the standard way [15 mm. = 275 (10³) dynes] the product of several measurements

$$\frac{\text{Bcg amp (mm)}}{\text{Body surface area (M)}} \times \frac{\text{Systolic blood pressure (mm Hg)} + \text{diastolic (1) BP (mm Hg)}}{2}$$

correlates strongly ($P = 0.02$) with Shelburne's blind estimate of the degree of coronary artery sclerosis and this is the strongest of the hundreds of correlations calculated. This relation seemed of such obvious clinical and physiological interest that the remainder of this paper has been devoted

Table IV Correlations between items measured at the noninvasive test and the amount of coronary sclerosis measured by angiogram in 29 very stable subjects who underwent cardiac catheterization without excitement

Measurement	Number	Correlation coefficient	Probability of significance
Bcg amp /BSA \times mean BP	27	-0.43	0.02
Age	29	0.37	0.04
Bcg amp /BSA	27	-0.37	0.05
Pulse pressure \times mean BP	29	-0.36	0.05
Body surface area	27	0.37	0.06
Pulse pressure	29	-0.32	0.08
Mean blood pressure	29	-0.32	0.08
Systolic blood pressure	28	-0.33	0.09
Bcg amp	29	-0.26	0.17
PD max	28	-0.27	0.16

Table II In Table I the average values secured by our two methods of detecting the emotional reactors can be compared. In both our stable samples the scatter of pulse rate and systolic BP differences in the two kinds of tests is less than that expected in duplicates and the diagnostic composition of the two stable groups closely resembles that of the series as a whole. We find no relation between excitement at catheterization and clinical differences.

The statistical analysis was supervised by Dr Karreman and largely conducted by Mr Bereng. The first such study was made on the sample of 29 very stable subjects, secured by the more rigorous method of eliminating emotional reactors. The data enumerated in Table III were placed on cards and fed to an IBM Univac 360 system computer which was programmed to correlate each item with the 26 other items measured a total of 351 different correlations. For those whose coefficients were larger than 0.3 regression equations were computed also.

When the computer is used in this way the results contain much spurious correlation i.e. correlation between two variables which are not mathematically independent. For example, both cardiac index and stroke volume index are listed in Table III and the computer estimates that the correlation between them $r = 0.87$, is strong. But in this computation the same estimate of stroke

Table V Physiological measurements made during cardiac catheterization not correlating significantly with the degree of coronary sclerosis (i.e. $P > 0.10$) in cases without emotional reaction to catheterization

	Number	Correlation coefficient	Level of significance ($P = 0.05$)
RV systolic pressure	29	-0.31	0.10
RV pulse pressure	28	-0.36	0.12
Ejection velocity index	27	0.25	0.20
Cardiac index	27	0.22	0.25
RV diastolic pressure	28	-0.22	0.27
Ejection fraction	20	-0.24	0.30
Ejection velocity index \times mean BP	27	0.28	0.38
Stroke volume index \times mean BP	27	0.16	0.56
Stroke volume index	27	0.18	0.63
Wedge pressure	29	0.17	0.63
LV end diastolic pressure	29	0.02	0.90

volume is used twice, once by itself, again as a factor in the calculation of the cardiac index and so it is found on both sides of the regression equation. For this reason the two variables are not mathematically independent and although their correlation cannot be explained by chance this fact is of little or no physiological interest. Such spurious correlations have not been recorded in the tables.

Hundreds of other correlations not significant for $P = 0.05$ and of no apparent physiological interest, have also been omitted from the tables. Significant correlations of interest but not pertinent to this present study will be reported later.

Results and discussion

Dangers in the comparison of results secured in invasive and noninvasive tests. Both types of tests were done with the patients lying supine after a comparable rest period but here the resemblance ceased. The noninvasive tests were performed on patients resting comfortably after reassurance that the test they were about to undergo was completely innocuous and that they could go to sleep if they wished as many of our subjects have done. The invasive tests were performed after a warning required by the hospital's legal staff that the procedure was not without danger and after each patient had given




Fig 1 Does the formula used measure cardiac strength? Comparison between the formula's product used to measure cardiac strength in this study and accurate estimates of left ventricular power secured in a series of simulated systoles in experiments performed on cadaver RR. Note the very strong correlation $r = 0.99$. A level of $r = 0.51$ is significant for $P = 0.005$. The line shown is the regression for estimating cardiac power from the formula. Obviously the formula provides a good estimate of cardiac strength. This was true in three other cadavers also.

(Table IV). The product of pulse pressure and mean pressure attains significance and this is to be studied further. One also recalls that the pulse pressure itself correlates significantly with cardiac work in cadaver experiments.¹

The correlations of the coronary rating with pulse pressure with mean pressure and with systolic pressure miss significance by very narrow margins (Table IV).

These simple relations between aspects of the pulse and the coronary rating are of great interest because of the ease with which the measurements needed to estimate the amount of coronary sclerosis from the regression could be made by any doctor. But before testing our abilities to calculate the coronary rating from data secured by simple noninvasive methods two possible difficulties were investigated.

Does the degree of excitement during the invasive test affect the cardiac strength/coronary sclerosis relationship? Table VI gives the results of a study of our data divided into stable and excited groups by our less rigorous method. The relationship strong in the group of coronary cases not excited by catheterization remains equally strong when those excited by catheteriza-




Fig 2 Comparison of two readings of 11 coronary angiograms made by Dr. Shelburne about 6 months apart so that at the time of the second estimate he had forgotten the result of the first. Note that when coronary sclerosis is absent or minimal and when it is very severe the two readings agree well but when sclerosis is moderate the two estimates are sometimes far apart.

tion are added. Apparently the obstructive abnormalities visualized by the angiogram are due to lesions of such a stable character that they are not influenced by excitement as might have been expected from the fact that so many coronary obstructions cannot be dilated by a probe at necropsy. Despite our original misgivings in studies of the cardiac strength/coronary sclerosis relationship in catheterized patients we have the right to neglect excitement as a factor in the latter measurement.

Does the type of heart disease affect the cardiac strength/coronary sclerosis relationship? The results recorded in Table VI answer this question in the affirmative. In data from cases of coronary heart disease the relation is strong but if data from cases of valvular heart disease are added the correlation loses its significance. What seems like a very interesting relation when coronary heart disease is studied by itself does not necessarily hold for other types of heart disease.

On estimating the degree of coronary sclerosis from data secured by noninvasive methods. By

to its study. Contrasting with this finding is the list of items, measured during the invasive tests, which have been placed in Table V and in which the lack of correlation with coronary sclerosis is the feature of interest.

Physiological meaning of the formula's product From knowledge of the general theory of the ballistocardiogram,⁵ the formula (1) can be readily interpreted. Bcg amp is the resultant of the initial forces of the cardiac contraction. The inclusion of body surface area compensates for differences in body size in different subjects. Mean blood pressure measures the load encountered by the ejecting heart.

The relation of our formula (1) to more familiar aspects of cardiac performance can be expressed as follows, whereas

$$\text{work} = \int P Q dt \quad (2)$$

where $Q = dv/dt = \text{ejection flow in cm}^3/\text{sec}$,
and $P = \text{arterial blood pressure}$

$$\text{power} = d(\text{work})/dt = d/dt \int P Q dt \\ = P Q = \text{pressure} \times \text{flow} \quad (3)$$

$$\text{derivative of power} = d(\text{power})/dt \\ = d/dt (P Q) = (dP/dt)Q + P(dQ/dt) \quad (4)$$

From our formula (1) we have

$$Bcg \times \bar{P} = (dQ/dt)\bar{P} \quad (5)$$

when, as in these experiments, the vertical I J distance of the Bcg is measured and the acceleration of the body's center of gravity is being recorded.

One notes that the right side of (5) is essentially similar to the second term of the right side of (4) so the relationship of formula (1) to other aspects of cardiac performance is mathematically described.

Certain implications of this relationship should be pointed out. It is not unlikely that the first term in the right side of formula (4) is considerably smaller than the second term during early ejection. This means that our formula (1) puts a heavy emphasis on the fast components of the heart's activity. Its product is proportional to the time derivative of cardiac power.

The mathematical demonstration that our formula (1) is theoretically related to the derivative of cardiac power does not deny that it may also be proportionally related to other more familiar aspects of cardiac function when systoles vary in strength. This has recently been explored in data secured in cadaver experiments some years ago.¹¹ In such models all the measurements needed to set up formula (1) can

be made, so we were able to calculate its product for each of 43 simulated systoles in four cadavers. In addition, the Newtonian work of the left ventricle in these simulated systoles could be estimated instant by instant and so with an accuracy not yet attained on living men or animals. Cardiac power could be approximated by dividing work by ejection duration which was recorded very accurately. But an accurate estimation of the derivative of power involved a second differentiation of the recorded volume curve which could not be performed with enough accuracy to make the effort worthwhile.

Fig 1 shows the relation between the formula's product and left ventricular power in 14 simulated systoles in cadaver RR. The correlation is strong, $r = 0.92$, whereas $r = 0.51$ is significant for $P = 0.05$. The correlation between the formula's product and Newtonian work is also significant, $r = 0.62$, but the relation is not as strong as that with power. When the 43 systoles simulated in these four cadavers are considered together, the correlation between the formula's product and left ventricular power is strong, $r = 0.73$ that with left ventricular work only a little less so, $r = 0.65$, a level of 0.40 being significant for $P = 0.01$.

Evidently our formula is related to many aspects of cardiac strength and one should have no hesitation in using it for comparative measurements. So the results in Table IV show clearly that, as coronary sclerosis increases, the strength of the resting cardiac contraction diminishes and we believe this to be the first experimental demonstration of this important relationship.

Other significant relations with coronary sclerosis The other aspects of cardiac function identified by the computer as correlating significantly with the coronary rating (Table IV) lend support to this conception. Although Bcg amplitude of itself does not correlate significantly with the amount of coronary sclerosis detected in this study when a factor to correct for differences of body size is added, significance is attained (Table IV). That age proves to be significantly correlated with the degree of coronary arteriosclerosis in our data will surprise nobody, the fact that this familiar relation is present testifies that our sample is a good one.

Several aspects of the blood pressure either correlate significantly with the degree of coronary sclerosis or miss significance by a narrow margin.

solely to the fact that the elaborate methods used to measure cardiac function in invasive testing are too inaccurate to permit the detection of abnormal relationships easily demonstrated by simple methods in the quiet of noninvasive testing.

Despite such misgivings there is a physiological conception^{1, 2, 3} which provides a satisfactory explanation for this apparent contradiction in our findings. Evidence from animal experiments^{4, 5} shows clearly that as the myocardium is weakened experimentally a reduction of the acceleration of ejected blood manifests itself first reduction of ejection velocity and displacement follow later. So our findings are in accord with the view that in cases such as ours suffering from symptoms but still ambulatory resting cardiac function has deteriorated to the point where ejection acceleration is reduced but not to the point at which noteworthy reductions of cardiac output, ejection velocity or both manifest themselves.

This laboratory has long been interested in the higher dynamic cardiac functions and the information sought during noninvasive tests reflects our belief in the clinical importance of such measurements.^{2, 3} By means of the force Bcg and the pulse derivative one secures information about much higher frequency aspects of the heart's performance than is contained in the studies of cardiac output and ejection velocity made during the invasive tests. The measurements of high frequency performance recorded in Table IV identify important abnormalities of cardiac function at a stage of coronary heart disease when the lower frequency measurements in Table V do not. Early weakness of your automobile can be readily detected by an inability to accelerate normally at a time when normal speed and distance traveled are unaffected. So our findings can be interpreted as additional evidence that the heart behaves in accordance with Newtonian principles and that the evidence of cardiac weakness will appear first as an inability to accelerate the blood or in still higher derivatives such as the jerk of the contraction at a time when cardiac output is still normal.

Summary

Invasive tests based on cardiac catheterization and noninvasive tests based on the ballistocardiogram

(Bcg) and pulse derivative (PD) were performed within a few days of each other on 76 cardiac patients. To eliminate those who reacted emotionally to the invasive test only those whose pulse rates and systolic blood pressures were reasonably similar in the two tests were admitted to this study.

Two methods of detecting excitement during catheterization were devised and tried the first more rigorous than the second. The first method identified over one half of our subjects as excited during catheterization after these had been eliminated. 29 stable subjects remained who had withstood the rigors of catheterization without excitement detectable by our methods. In these 29 stable patients each of 13 items of physiological interest measured during the noninvasive test and each of 14 measured during the invasive test were correlated with all the others by means of a computer a total of 351 correlations.

In these stable subjects four items measured at the noninvasive test correlated significantly with the amount of coronary sclerosis rated by angiogram.

$$\frac{\text{Bcg amplitude}}{\text{Body surface area}} \times \text{mean blood pressure} \times \text{age}$$

$$\frac{\text{Bcg amplitude}}{\text{Body surface area}}$$

and pulse pressure \times mean pressure. In four other items significance was missed by a narrow margin.

Correlations between the coronary rating and physiological measurements made at the invasive test such as stroke volume, cardiac output, ejection fraction, ejection velocity and LV end diastolic pressure were very poor and did not approach significance.

In cases of coronary heart disease the cardiac strength/coronary sclerosis relationship is strong in both the stable group and in those excited during catheterization. But the same relation does not hold in cases of valvular heart disease.

Mathematically the product Bcg amp/BSA \times mean blood pressure is proportional to the first time derivative of cardiac power. Using data secured several years ago¹⁰ when systoles differing in strength were simulated in cadaver experiments the formula's product was also found to be strongly correlated with both cardiac work and power. So our data indi-

means of regression equations derived from any of the significant correlations, such as equation C in Table VII, one could calculate the degree of coronary sclerosis for any patient from measurements made at noninvasive tests, and more accurate information could be secured by incorporating the most promising items into a multiple regression equation, such as equation D (Table VII).

Before comparing estimates made by such equations with the coronary rating estimated from the coronary angiograms, one should know the reproducibility of the latter measurement. In our studies duplicate angiograms were not attempted, but Shelburne restudied the films taken at 19 of our angiograms after a lapse of time sufficient to abolish his recollection of his original readings.

Comparisons of his first and second estimates are found in Fig 2. When the amount of sclerosis was large, or when it was absent or minimal, Shelburne's two readings were very consistent, but in the middle range he sometimes missed badly. But the average difference between his first and second reading was only 0.1 coronary unit ($\sigma = 2.7$), and this we found encouraging. The scatter of such ratings in tests in which everything is duplicated will certainly be larger than this.

In Table VII estimates of the coronary rating made by simple and multiple regression equations can be compared with Shelburne's estimates from the angiogram, and a large part of the differences can be accounted for by the errors inherent in the latter estimates. Thus when a simple regression equation, C in Table VII is used to compute the coronary rating of our most stable patients with coronary heart disease the difference between such estimates and Shelburne's first readings of the angiograms averages only +1.4 coronary units. But when the same equation is used for the cases of rheumatic valvular heart disease the average error of the estimate is -4.2 units and this difference cannot be explained by chance. Such difficulties greatly handicap the use of such equations to diagnose coronary sclerosis.

The reason for the difficulty seems plain. When estimating the coronary rating by such regression equations one is attempting to measure the severity of the lesions of coronary artery disease from the abnormalities of cardiac performance which accompany them. But while the severity of

coronary heart disease is strongly correlated with cardiac weakness in cases suffering from coronary heart disease, and this seems well worth knowing, this is not true of our cases of RHD, many of whom have hearts as weak as those with advanced coronary heart disease but although coronary sclerosis was found by angiogram. So, clinicians should remember that, if the heart beats strongly, the presence of advanced coronary heart disease is most unlikely. But they must also remember that coronary arteriosclerosis is only one of many causes of cardiac weakness, and that an attempt to diagnose its presence and extent from cardiac weakness alone would often result in serious errors.

Why are measurements of cardiac function made by invasive testing so often completely unrelated to the degree of coronary arteriosclerosis? The contrast between Tables IV and V is one of the most interesting and unexpected of the findings of this blind study. Judged by the physiological data secured during cardiac catheterization, coronary sclerosis has no effect on cardiac function (Table V). Judged by the data secured by noninvasive testing (Table IV) coronary sclerosis is accompanied by cardiac weakness manifest in many ways.

One possible explanation of the discrepancy lies in the belief that the simple measurements of pressures and forces made during noninvasive tests are more accurate and are made under more reproducible conditions than the much more complicated measurements of circulatory function attempted during invasive tests. In the noninvasive tests the long procession of pulses and ECGs taken at each test provides evidence of the stability of the cardiac performance at the time of the test. The absolute accuracy of the noninvasive methods has been studied in mechanical mathematical electrical and cadaver models^{1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100}, while not of high accuracy these methods are surely accurate enough to identify the extremes of abnormality.

No comparable information is available about either the accuracy or the consistency of estimations of cardiac output, ejection velocity, ejection fraction etc. made in the invasive studies largely because the rigors of such tests discourage work on the healthy and the repeated testing of the sick.

So one cannot deny that the difference in the results recorded in Tables IV and V might be due

Comparison of heart rate and blood pressure response to amyl nitrite isoproterenol and standing before and during acute beta-adrenergic blockade with intravenous propranolol

Andreas P Niarchos MD
Parvys Tahmoore MD
Robert C Tarazi MD
Cleveland Ohio

Propranolol a beta adrenergic blocking drug has been used extensively in the treatment of angina pectoris cardiac arrhythmias, and hypertension.¹⁻⁴ Numerous other beta blockers are now under investigation and most of them will probably be available to the practicing physician in the near future. Since beta blockers affect sympathetic nervous activity it is important for the clinician to be able to test in every day practice whether sufficient drug has been given or if the administered beta blocker has been eliminated after its discontinuation. The appropriate test therefore should be simple non invasive and easy to reproduce. To date the heart rate response to various physiological maneuvers (standing up passive head up tilt hyperventilation Valsalva) and to pharmacologic agents (nitroglycerin isoprenaline) before and during acute or chronic propranolol administration has been used for this purpose. Fitzgerald has suggested that heart rate increase following sublingual administration of nitroglycerin before and after propranolol may be used as a test of adrenergic beta blockade but the specificity of this test has recently been questioned by other investigators.⁵

It was suggested that amyl nitrite rather than nitroglycerin may be a more appropriate drug to

study heart rate response before and during beta adrenergic blockade since a greater heart rate peak may be achieved over a shorter period of time in comparison with nitroglycerin. In the present study the heart rate response during amyl nitrite inhalation was compared to that observed with standing up and isoproterenol infusion before and during acute adrenergic beta blockade with intravenous propranolol.

The results indicate that neither amyl nitrite inhalation nor the assumption of upright posture during intravenous propranolol can be used to assess the degree of beta adrenergic blockade because heart rate responses to both procedures are determined to a great extent by the parasympathetic nervous system.

Patients and methods

Six patients with mild essential hypertension and three normal volunteers were investigated. Six were male and three female their ages ranging from 21 to 59 years, mean 39 years. Informed consent was obtained from all subjects. None of the patients was receiving oral propranolol or other beta blockers at the time of the study or during the two weeks prior to it.

All subjects were allowed to rest in the supine position until heart rate and blood pressure were stabilized usually within 20 minutes. Heart rate was recorded continuously (Lead II of the ECG) and blood pressure was measured by a mercury sphygmomanometer. After control values were obtained the subject was asked to stand up while the ECG was recorded. The highest heart rate

From the Research Division, Cleveland Clinic Foundation, Cleveland, Ohio.

Received for publication June 13, 1977.

Accepted for publication December 9, 1977.

Present address and reprint requests: Andreas P. Niarchos, MD, Cardiac Vascular Center, The New York Hospital-Cornell Medical College, 525 East 68th St., New York, N.Y. 10021.

cate that, as coronary obstruction increases, the strength of the resting cardiac contraction diminishes

Our data have important diagnostic implications, if the heart of any patient is beating strongly, the presence of severe coronary heart disease can be ruled out. But if the heart is beating weakly, the presence of significant coronary heart disease cannot be safely inferred, for coronary heart disease is only one of many causes of cardiac weakness

We are indebted to Dr A. Noordergraaf for advice and assistance in the theoretical aspects of this study

REFERENCES

- 1 Starr I and Shelburne J C Emotional alterations in the circulation during cardiac catheterization (Abstr.) *Physiologist* 19:377 1976
- 2 Starr I and Shelburne J C A comparison of 3 methods of detecting ventricular incoordination in man and the relation of their results to the amount of coronary arteriosclerosis in Proceedings of the Fourth World Congress on Ballistocardiography and Cardiovascular Dynamics Amsterdam April 1973 *Bibl Cardiol* 35:109 1975
- 3 Grossman W Cardiac catheterization and angiography Philadelphia 1974 Lea & Febiger Publishers
- 4 Friesinger G C Page E H and Ross R S Prognostic significance of coronary angiography *Trans Assoc Am Physicians* 83:78 1970
- 5 Starr I and Noordergraaf A Ballistocardiography in cardiovascular research Amsterdam and Philadelphia 1967 North Holland Publishing Co and J B Lippincott Company
- 6 Starr I and Ogawa E A clinical study of the first time derivative of the brachial pulse normal standards and abnormalities encountered in heart disease *AM HEART J* 65:482 1963
- 7 Altman P L and Dittmer D B editors Biological Handbook Respiration and Circulation Bethesda MD 1971 *Fed Am Soc Exper Biology*
- 8 Starr I and Luchi R J Blind study on the action of digitoxin in elderly women *AM HEART J* 78:740 1969
- 9 Starr I Askovitz S I Feder W and Schild A Studies made by simulating systole at necropsy VII Clinical methods of estimating the work of the left ventricle *Circulation* 12:1005 1955
- 10 Starr I and Schnabel T G Jr Studies made by simulating systole at necropsy III On the genesis of the systolic waves of the ballistocardiogram *J Clin Invest* 33:10 1954
- 11 Starr I Studies made by simulating systole at necropsy VIII Significance of the pulse pressure *Circulation* 14:1117 1956
- 12 Starr I Relation of the ballistocardiogram to cardiac function *Am J Cardiol* 2:737 1958
- 13 Starr I Progress towards a physiological cardiology A second essay on the ballistocardiogram *Ann Intern Med* 63:1079 1965
- 14 Starr I Verdouw P D and Noordergraaf A Clinical evidence of cardiac weakness and incoordination secured by simultaneous records of the force *Bcg* and carotid pulse derivative and interpreted by an electrical analogue *AM HEART J* 85:341 1973
- 15 Rushmer R F Initial ventricular impulse A potential key to cardiac evaluation *Circulation* 29:268 1964
- 16 Noble M I N Trenchard D and Guz A Studies of the maximum acceleration of blood in the ascending aorta of conscious dogs Proceedings of the First World Congress Ballistocardiography and Cardiovascular Dynamics Basel and New York 1968 S Karger AG p 243
- 17 Starr I Studies made by simulating systole at necropsy XI On the higher dynamic functions of the heart and their reflections in the pulse wave *Circulation* 17:569 1958
- 18 Starr I The place of the ballistocardiogram in a Newtonian cardiology and the new light it sheds on certain old clinical problems *Proc R Soc Med* 60:13 1967

Table II Heart rate increase (Δ %) with the various stimuli before and after 1 v propranolol (10 mg)

	Standing up		Amyl nitrite		Isoproterenol 0.03 μ g/Kg/min	
	Before	After	Before	After	Before	After
Heart rate (beats/min mean \pm SD)	21.65 \pm 7.39	12.44 \pm 7.40	57.2 \pm 24.00	36.11 \pm 18.40	25.44 \pm 9.74	2.22 \pm 5.66
p value	ns		p < 0.01		p < 0.01	

hypertensive patient Heart rate increase with standing correlated with the increase produced by amyl nitrite ($r = 0.723$ $p < 0.05$) but no correlation was observed in the heart rate increase produced by standing and isoproterenol ($r = 0.163$) or amyl nitrite and isoproterenol ($r = 0.229$). The relative potency for heart rate and blood pressure responses of the three stimuli is shown in Table III.

2 Blood pressure response to amyl nitrite before and during beta blockade with propranolol (Table IV). Before propranolol the control average mean arterial pressure in the nine subjects was 107 ± 19 falling to 74 ± 9 mm Hg ($p < 0.01$) following amyl nitrite inhalation. Isoproterenol infusion ($0.03 \mu\text{g/Kg/min}$) and intravenous propranolol produced a small fall in blood pressure (Table IV). After propranolol amyl nitrite inhalation was followed again by a significant decrease in blood pressure ($p < 0.05$) while isoproterenol infusion produced again insignificant changes in blood pressure with the exception of Case 6 who exhibited a greater decrease (bv 30/20 mm Hg) in blood pressure.

3 Correlation between blood pressure and heart rate responses. Before propranolol the increase in heart rate after amyl nitrite inhalation correlated with the observed fall in blood pressure ($r = 0.607$) but the correlation did not reach statistical significance probably because of the small number of subjects studied. After propranolol the r value was 0.417.

In Fig 2 the average per cent change in systolic blood pressure is plotted against the average per cent change in heart rate before and after amyl nitrite before and during acute beta blockade with propranolol. This graph shows that the baroreceptor reflex remained functioning when amyl nitrite was given after pretreatment with intravenous propranolol. In Fig 3 the difference in heart rate and blood pressure responses between the normal subjects ($n = 3$) and the

hypertensive patients ($n = 6$) is shown. It is clear that the hypertensive patients had a smaller heart rate increase following amyl nitrite prior to and during beta blockade despite a greater decrease in blood pressure. However because of the small numbers of subjects involved no statistical analysis was attempted.

4 Side effects. Amyl nitrite inhalation was associated with the following side effects: coughing, dizziness, feeling faint and headache. No side effects were observed during isoproterenol infusion.

Discussion

Amyl nitrite administration as test of adrenergic beta blockade. As suggested previously, amyl nitrite inhalation proved to be the most potent stimulus for heart rate increase in comparison to standing up and isoproterenol infusion (Table IV). However a great variation in individual heart rate responses was observed both before (from 27 to 97 per cent) and during beta blockade (from 10 to 60 per cent). These changes probably reflected the different degree of blood pressure decrease and varying sympathetic and vagal participation in the individual patient. It is known that other factors such as age and the presence of hypertension^{1,2} probably sex¹³ uremia and autonomic neuropathy¹⁴ or cardiac disease¹⁵ may affect the degree of cardioacceleration produced by hypotension. All these factors may exist in the heterogeneous population of patients who require treatment with beta blockers (coronary heart disease, cardiac arrhythmias, hypertension) and they per se may determine heart rate responses to amyl nitrite as well as the degree of beta blockade. Furthermore the unpleasant and occasionally serious side effects of amyl nitrite together with the inherent effects of the method of its administration (cough, hyperventilation) which separately may influence cardiovascular responses¹⁶ will make amyl nitrite




Fig 1 Heart rate responses to three different procedures before and after intravenous propranolol. The greatest variability in heart rate response was observed with amyl nitrite. B = before propranolol, A = after propranolol. — each line represents two patients. ● — mean change.

observed within a two minute period of standing was noted and the subject returned to the supine position again. Following another control period amyl nitrite was given to the subject to inhale (three deep breaths) and the maximal rise in heart rate and fall in blood pressure were recorded. Amyl nitrite was given in the supine position in order to avoid the nitrite syncope. When the effects of amyl nitrite had passed, and both heart rate and blood pressure had returned to control levels, with the subject in the supine position, isoproterenol was given by infusion at three dose levels, 0.01, 0.02 and 0.03 $\mu\text{g}/\text{Kg}$ of body weight/minute, as previously described.¹⁰ Heart rate and blood pressure were recorded with each dose level of the infusion. When again heart rate and blood pressure had returned to control levels (usually within 10 minutes after stopping the infusion) propranolol 10 mg was given slowly intravenously with the patient in the supine position. All the above procedures (standing up, amyl nitrite inhalation and isoproterenol infusion) were repeated 10 to 15 minutes after propranolol when the maximal bradycardic effect was observed.

Standard statistical methods were used to calculate averages, standard deviations and errors, correlation coefficients and the statistical significance of the results.¹⁰ During the analysis of the results heart rate and blood pressure changes produced by the 0.01 and 0.02 $\mu\text{g}/\text{Kg}/\text{min}$ isoproterenol dose and pressure changes with standing up were small and therefore they will not be discussed further.

Table 1 Heart rate response to stimuli before propranolol

	Heart rate (beats/min \pm SD)		p value	% increase in HR	
	Control	Response		Mean \pm SD	Range
Standing up	77 \pm 15	94 \pm 18	$p < 0.05$	21.66 \pm 7.39	11-33
Amyl nitrite inhalation	76 \pm 12	118 \pm 19	$p < 0.001$	57.22 \pm 24.0	9-97
Isoproterenol 0.03 $\mu\text{g}/\text{Kg}/\text{min}$	74 \pm 11	94 \pm 13	$p < 0.005$	25.44 \pm 9.74	11-43

Results

1 Heart rate response to standing up, amyl nitrite inhalation and isoproterenol infusion before and after propranolol

A Before the administration of propranolol heart rate was significantly increased by all three procedures (Table 1). The greatest heart rate increase (57 per cent) occurred following amyl nitrite inhalation ($p < 0.001$), isoproterenol 0.03 $\mu\text{g}/\text{Kg}/\text{min}$ produced a 25 per cent increase ($p < 0.005$), while the least potent stimulus for heart rate increase was standing up (21.6 per cent, $p < 0.05$). Great individual variability in heart rate increase was observed with all procedures (Table 1, Fig 1) especially following amyl nitrite inhalation (range 27 to 97 per cent increase). There was no correlation between the heart response to standing with that produced by amyl nitrite ($r = 0.441$, $p > 0.05$) or between standing and isoproterenol infusion ($r = 0.371$, $p > 0.05$) but a significant negative correlation was observed between amyl nitrite and isoproterenol increase in heart rate ($r = -0.832$, $p < 0.01$).

B After propranolol administration (Table II and Fig 1) the increase in heart rate produced by the above procedures was diminished. Heart rate increase with amyl nitrite was significantly decreased but not completely abolished by propranolol from 57 per cent to 36 per cent (by 42 beats/minute, $p < 0.01$). Heart rate increase with standing up was decreased by propranolol from 21 to 12 per cent (by 8 beats/minute) but not significantly. The response of heart rate to isoproterenol infusion (0.03 $\mu\text{g}/\text{Kg}/\text{min}$) was completely blocked by propranolol in eight subjects but isoproterenol given after propranolol still produced a 20 per cent increase in heart rate in one




Fig 2 Normal baroreceptor reflex function before (B) and after (A) adrenergic beta blockade with propranolol following amyl nitrite administration. Propranolol did not affect the slope of the line relating the per cent change of heart rate to per cent change in systolic blood pressure.

This finding suggests that parasympathetic withdrawal is also a major mechanism for heart rate increase with standing at least during acute beta adrenergic blockade. In two similar studies oral practolol⁶ and oral propranolol⁷ decreased significantly but did not abolish completely heart rate increase after standing.

The heart rate increase produced by isoproterenol infusion was completely abolished by propranolol in eight subjects but a 20 per cent increase in heart rate was observed in one patient even after propranolol. Isoproterenol increases heart rate by direct cardiac stimulation and by reflex vagal withdrawal as a result of the decrease in blood pressure because of peripheral vasodilation.²¹ In the present study vagal withdrawal probably contributed to the heart rate increase in the single patient who was not blocked by propranolol since he exhibited a marked fall in blood pressure (by 30/20 mm Hg) while blood pressure changes were negligible (a 5 mm Hg average mean blood pressure fall) in the remaining subjects.

Difference in heart rate response between normal and hypertensive subjects. Another interesting observation of the present study was the greater heart rate increase following amyl nitrite administration which occurred in the normal subjects as compared with the hypertensive patients although the latter exhibited a greater hypotensive response following amyl nitrite administration (Fig 3). This finding would




Fig 3 Differences in heart rate and blood pressure response to amyl nitrite between normal (●—●) and hypertensive (○—○) subjects. Heart rate increase was greater in the normals despite a smaller decrease in blood pressure.

suggest that decreased parasympathetic inhibition existed in the hypertensive patients of the present study as has been reported previously in borderline²² and established²³ hypertension. Since however the number of normal subjects who took part in the present study is rather small further investigations are needed to substantiate the observed differences in heart rate response between normal and hypertensive subjects during amyl nitrite induced hypotension.

Conclusions

The findings of the present study confirm that the increase in heart rate produced by the three procedures investigated is diminished but not completely abolished during acute beta blockade with intravenous propranolol because of varying degrees of vagal participation in heart rate control. A varying degree of participation in heart rate control by the individual components of the autonomic nervous system may explain the different degrees of correlation in heart rate changes among the three procedures (Table V). Thus the negative correlation in heart rate increase between amyl nitrite and isoproterenol (before propranolol) would mean that the greater the increase in heart rate via the parasympathetic the lesser via the sympathetic as shown in

Table III Relative potency of the three stimuli for heart rate and blood pressure response

	Heart rate		Blood pressure
	Sympathetic	Para sympathetic	
<i>Before propranolol</i>			
Amyl nitrite	++	++	++
Isoproterenol	+++	+	++
Standing	++	++	+
<i>During propranolol</i>			
Amyl nitrite	-	++++	+++
Isoproterenol	-	(+)	+
Standing	-	++++	+

Symbols + = effective - = absent (+) = occasionally effective

the least appropriate test for estimating the degree of beta blockade in routine clinical practice. Similar conclusions were reached by other investigators⁸ regarding the usefulness of nitroglycerin administration.

Amyl nitrite, however, may still be used to study baroreceptor function,¹⁷ since it is a potent and quick acting hypotensive agent. Because of its other hemodynamic effects the drug has been used for the evaluation of cardiac murmurs.¹⁸

From the clinical standpoint, the results of the present study do not favor the usage of amyl nitrite as a test for the detection of the degree of beta blockade, but nevertheless they do confirm that the amyl nitrite induced acute hypotension in the presence of beta blockade is transient and without deleterious hemodynamic consequences as has been documented by other investigators¹⁸ and by ourselves (unpublished observations) with the more commonly used peripheral vasodilators.²⁰

Mechanism of the tachycardia following baroreceptor hypotension. The relative participation of the two components of the autonomic nervous system in the heart rate increase that results from baroreceptor hypotension is now better understood.^{21,22} It has been shown^{22,23} that the cardioacceleration during acute baroreceptor hypotension is due to an increased sympathetic stimulation, and also a withdrawal of the parasympathetic tone. The reduction in blood pressure after amyl nitrite administration is mainly due to the vasodilatory effect of the drug on the arteriolar smooth muscle.²⁴ It has been suggested that the tachycardia which accompanies the fall in blood pressure after amyl nitrite is mainly due

Table IV Blood pressure changes (averages \pm SD, mm Hg) with the various procedures

	Control	After	p value*	% change
<i>Before propranolol</i>				
Amyl nitrite	107.38 \pm 19	73.97 \pm 9	$p < .001$	-30
Isoproterenol	114 \pm 27	103 \pm 21	ns	-11
0.3 μ g/Kg / mm				
<i>Propranolol</i>	113 \pm 24	106 \pm 25	$p < .025$	-5.6
<i>After propranolol</i>				
Amyl nitrite	106.22 \pm 25	81 \pm 18	$< .005$	-26.6
Isoproterenol	102 \pm 18	97 \pm 14	ns	-9.4

*paired t test

ns = not significant

to reflex withdrawal of the parasympathetic tone at least in normal subjects²² because the drug had negligible effect on the heart rate when given after atropinization. The finding of the present study, however, that propranolol blocked the effect of amyl nitrite on the heart rate significantly would support the view that the heart rate response is mediated to a significant degree by sympathetic activation. A direct effect of amyl nitrite on the heart (sinus node) is very unlikely.²⁵ Nitroglycerin induced tachycardia is similarly the result not only of sympathetic stimulation alone,²⁶ but also of parasympathetic withdrawal.²⁷ Therefore heart rate response to both agents can not be used as a specific test for beta adrenergic blockade.

Atropine was not used in the present study because our aim was to explore heart rate responses in the absence of atropinization as they occur in clinical practice. It was initially reported²⁸ that atropine did not modify the increase in heart rate produced by nitroglycerin but this finding does not exclude the possibility that atropine administration may effect heart rate response following hypotension in the presence of beta blockade when the sympathetic-parasympathetic balance on heart rate may be altered.^{29,30} Indeed it has been shown³¹ that the combination of atropine and propranolol can almost completely abolish the heart rate increase produced by amyl nitrite.

Mechanism of tachycardia with standing and during isoproterenol infusion. In the present study heart rate increase with standing was decreased by propranolol but not significantly

- 16 Brown E B Jr Physiological effects of hyperventilation *Physiol Rev* 33 445 1953
- 17 Pickering T G Gribbin B and Sleight P Comparison of the reflex heart rate response to rising and falling arterial pressure in man *Cardiovasc Res* 6 277 1972
- 18 Perloff J K Calvin J DeLeon A C and Bowen P Systemic hemodynamic effects of amyl nitrite in normal man *AM HEART J* 66 460 1963
- 19 Mroczek W J Lee W H Davidov M E and Finnerly F A Jr Vasodilator administration in the presence of beta adrenergic blockade *Circulation* 53 985 1976
- 20 Tarazi R C Dustan H P Narchos A P and Bravo E L Vasodilating drugs—Contrasting hemodynamic effects (Abstract) *Circulation* 52 11 1975
- 21 Huggins C B Vatner J F and Braunwald E Parasympathetic control of the heart *Pharmacol Rev* 25 119 1973
- 22 Braunwald E Regulation of the circulation (First of two parts) *N Engl J Med* 290 1124 1973
- 23 Thames M D and Kontos H A Mechanisms of baroreceptor induced changes in heart rate *Am J Physiol* 218 251 1970
- 24 Vatner J F Huggins C M Franklyn D and Braunwald E Autonomic components of reflex tachycardia induced by hypotension *Physiol* 15 994 1972
- 25 Goodman L S and Gilman A Eds The Pharmacological Basis of Therapeutics New York, 1965 MacMillan Publishing Co Inc
- 26 Leon D F Shaver T A and Leonard J J Reflex heart rate control in man *AM HEART J* 80 729 1970
- 27 Pickering T G Gribbin B Petersen E S Cunningham D J C and Sleight P Effect of autonomic blockade on the baroreflex on man at rest and during exercise *Circ Res* 30 172 1972
- 28 Levy M N Sympathetic-parasympathetic interactions in the heart *Circ Res* 29 437 1971
- 29 Green J H and Heffron P F The inter relationship between sympathetic activity and the heart rate *Arch Intern Pharmacodyn* 169 15 1967
- 30 Warner H R and Russel R H Effects of combined sympathetic and vagal stimulation on heart rate in the dog *Circ Res* 24 567 1969
- 31 Dollery C T Paterson J W and Conolly M E Clinical pharmacology of beta receptor blocking drugs, *Clin Pharmacol Ther* 10 765 1969
- 32 Dunlop D and Shanks R G Selective blockade of adrenoceptive beta receptors in the heart *Br J Pharmacol Chemother* 32 701 1968
- 33 Julius S Pascual A V and London R Role of parasympathetic inhibition in the hyperkinetic type of borderline hypertension *Circulation* 44 413 1971
- 34 Julius S Randall O S Esi M D Kashima T and Bennett J Altered cardiac responsiveness and regulation in the normal cardiac output type of borderline hypertension *Circ Res* 36 and 37 (Suppl. I) 1 199 1975
- 35 Korner P I Shaw J, Uther J M West M J, McRitchie R J and Richards J G Autonomic and non autonomic circulatory components in essential hypertension in man *Circulation* 48 107 1973
- 36 Rosenbluth A and Freeman N E The reciprocal reservation in reflex changes in heart rate *Am J Physiol* 98 430 1959

Table V Correlation coefficients between heart rate increase (beats/minute) with the three procedures before and after propranolol

	r value	p value
<i>Before propranolol</i>		
Standing amyl nitrite	-0.441	ns
Standing isoproterenol	0.371	ns
Amyl nitrite isoproterenol	-0.832	p < .01
<i>After propranolol</i>		
Standing amyl nitrite	0.723	p < .05
Standing isoproterenol	0.163	ns
Amyl nitrite isoproterenol	0.229	ns

Table III This finding is in agreement with the classical view that heart rate responses are the result of sympathetic-parasympathetic balance.³⁰ The positive correlation in heart rate increase between standing and amyl nitrite (after propranolol) may be explained by the fact that in the absence of the sympathetic nervous system the magnitude of heart rate increase is mediated via the parasympathetic by both procedures (Table IV). It is obvious therefore that neither amyl nitrite inhalation nor standing can be used for the assessment of beta blockade, since heart rate responses to both procedures are determined to a great extent by the parasympathetic nervous system.

Summary

Heart rate responses to three different procedures (amyl nitrite inhalation, standing up and isoproterenol infusion) were studied before and during acute adrenergic beta blockade with intravenous propranolol in three normal and six hypertensive subjects. Propranolol decreased but did not completely abolish the heart rate increase produced by amyl nitrite and standing probably because of vagal participation (withdrawal) in heart rate increase produced by baroreceptor hypotension (amyl nitrite) and on assuming the upright posture.

Heart rate responses to amyl nitrite varied greatly from patient to patient (from 27 to 97 per cent), but the drug proved to be the most potent stimulus for heart rate increase as a result of its marked hypotensive effect. However this vasodilator induced acute hypotension was well tolerated and without deleterious hemodynamic consequences despite the presence of beta blockade.

Different degrees of correlation in heart rate increase were observed with the three procedures, reflecting probably the varying sympathetic-parasympathetic participation in reflex heart rate control. It is concluded that from the clinical stand point, neither amyl nitrite administration nor standing up can be used as a test to assess accurately the degree of beta blockade, because both procedures activate vagal withdrawal which increases heart rate regardless of the degree of beta blockade.

REFERENCES

- Morell H F. Propranolol. *Ann Intern Med* 78:913 1973.
- Leading article. Current status of propranolol hydrochloride (Inderal). *JAMA* 225:1380 1973.
- Niarchos A P and Tarazi R C. Hemodynamic effects of beta blockers in hypertension. In: Regulation of Blood Pressure by the Central Nervous System, edited by G Onesti, M Fernandes and K E Kum. Philadelphia 1976: WB Saunders Company.
- Fitzgerald J D, Rowlands D J and Davies E T L. Heart rate response to certain physiological maneuvers: proposed measure of degree of beta receptor blockade. *Br Heart J* 33:614 1971.
- Fitzgerald J D. A new test for the degree of adrenergic beta receptor blockade. *Internat J Clin Pharmacol* 4:125 1970.
- Ekus K J, M Shanks R G and Walsh M J. Observations on the effect of β adrenoceptor blocking drugs on glyceryl trinitrate tachycardia. *Br J Clin Pharmacol* 1:19 1974.
- Hansson L. Beta adrenergic blockade in essential hypertension. Effects of propranolol on hemodynamic parameters and plasma renin activity. *Acta Med Scand (Suppl.)* 550:1973.
- Zweifler A J and Hansson L. Heart rate responses during treatment of hypertension with propranolol. The clinical usefulness of the nitroglycerin test. *Clin Pharmacol Ther* 19:403 1976.
- Frohlich E D, Tarazi R C and Dustan H P. Hyperdynamic beta adrenergic circulatory state. *Arch Intern Med* 123:1 1969.
- Croton R E and Cowen J. Applied general statistics. New York 1941: Prentice Hall Inc.
- Bristow J D, Honour A J, Pickering G W, Sleight P and Smyth H S. Diminished baroreflex sensitivity in high blood pressure. *Circulation* 39:48 1969.
- Gribbin B, Pickering T G, Sleight P and Peto R. Effect of age and high blood pressure on baroreflex sensitivity in man. *Circ Res* 29:424 1971.
- Bunag R D, Walaszek E J and Mueing N. Sex differences in reflex tachycardia induced by hypotensive drugs in unanesthetized rats. *Am J Physiol* 229:652 1975.
- Lazarus J M, Hampers C L, Lowrie E C and Merrill J P. Baroreceptor activity in normotensive and hypertensive uremic patients. *Circulation* 47:1015 1973.
- Goldstein R E, Beiser G D, Stampfer M and Epstein S. Impairment of autonomically mediated heart rate control in patients with cardiac dysfunction. *Circ Res* 36:571 1975.




Fig 1 Case 1 Rate dependent right bundle branch block. Three strips are not continuous. Shaded areas in the diagrams represent the refractory period of the right bundle branch for the anterogradely conducted impulse. Impulse conduction within the right bundle branch is indicated by solid lines whereas impulse conduction within the left bundle branch is indicated by dashed lines. Time intervals are expressed in hundredths of a second. S = sinus impulse or beat. RBB = right bundle branch. LBB = left bundle branch.

second examination (i.e. a period of 64). This indicates that the critical CL inducing RDBBB varied within a month though it was invariable throughout one examination.

Case 3 In this case findings similar to those in Case 2 were seen. The electrocardiograms showed rate dependent right BBB which were taken from a 20 year old man with an otherwise normal heart. The critical CL inducing RDBBB during the first examination (a period of 91) was considerably longer than that during the next examination (a period of 84). These examinations were made at an interval of a week. This indicates that the critical CL inducing RDBBB varied within a week. During either examination however the critical CL allowing recovery was longer than the critical CL inducing RDBBB by a period of 5.

Case 4 In Case 4 the critical CL inducing RDBBB varied even in a continuous recording. The electrocardiogram showed rate dependent right BBB which was recorded from a 64 year old man with an otherwise normal heart. As shown in Fig 3 the critical CL inducing RDBBB fluctuated between periods of 125 and 130 in a continuous 17 minute recording. The critical CL allowing recovery also fluctuated in parallel with the critical CL inducing RDBBB. Therefore when reversion to normal conduction occurred within a very short time after RDBBB was induced the critical CL allowing recovery was always longer than the critical CL inducing




Fig 2 Case 1. The critical cycle length inducing bundle branch block, and the preceding cycle length in a 10-minute recording. When normal conduction is maintained the shortest cycle length is indicated by open circles. When bundle branch block is induced the cycle length between the last normal conduction and the initial bundle branch block is indicated by solid circles. The critical cycle length inducing bundle branch block which is indicated by the dashed line is independent of changes in the preceding cycle length.

RDBBB and the difference between them was constant (a period of 5). However the shortest critical CL allowing recovery in the continuous recording (i.e. a period of 130) was considerably shorter than the longest critical CL inducing RDBBB (i.e., a period of 135). This case indicates that the critical CL inducing RDBBB varied within only a few minutes.

Variations in the critical cycle length inducing rate dependent bundle branch block

Shinji Kinoshita, M D
Sapporo Japan

It has been demonstrated that in many patients with tachycardic RDBBB (rate dependent bundle branch block), the critical CL (cycle length) allowing reversion to normal conduction is considerably longer than the critical CL inducing RDBBB.^{1,2} On the other hand it has been reported that in RDBBB, the refractory period of the blocked bundle branch varies under certain conditions.^{1,3,4} In order to disclose the mechanism of maintenance of RDBBB it seems important to know whether the comparatively long critical CL during recovery is due to variation in the bundle branch refractory period or due to another mechanism. In the present report five patients with tachycardic RDBBB will be presented in whom variations in the critical cycle lengths inducing RDBBB and allowing recovery are investigated.

Case Reports

Case 1 Fig 1 represents portions of long recordings showing rate dependent BBB (bundle branch block) which were taken from a 33 year old man with an otherwise normal heart. The three strips in Fig 1 are not continuous. In Case 1 the critical CL inducing RDBBB was an invariable value i.e. a period of 91 * which was independent of changes in the preceding CL. The critical CL allowing reversion to normal conduction was

another invariable value, i.e. a period of 98 * which was considerably longer than the critical CL inducing RDBBB. In Case 1, extending over two years, the critical CL inducing RDBBB and the critical CL allowing recovery were both invariable.

Fig 2 shows the relationship between the critical CL inducing RDBBB and the preceding CL in a 10 minute recording including the upper two strips in Fig 1. The dashed line in Fig 2 indicates that, independent of changes in the preceding CL, the critical CL inducing RDBBB is invariable, in which the preceding cycle lengths range between periods of 91 and 103. The middle strip in Fig 1 shows that although the cycle lengths between two sinus beats of the BBB type, i.e. the intervals S₁ S₁, S₁ S₂, and S₂ S₂ are all within the same range as the above, the critical CL allowing reversion to normal conduction is distinctly longer than the critical CL inducing RDBBB.

Case 2 The electrocardiograms which were recorded from a 69 year old man with essential hypertension showed rate dependent left BBB. Electrocardiographic examination was made three times at intervals of about a month. During any of the three examinations the critical CL allowing recovery was longer than the critical CL inducing RDBBB in the same recording and the difference between them was a period of 5. However, the critical cycle lengths inducing RDBBB during the three examinations were different from one another which were periods of 71, 84 and 73. Therefore the critical cycle lengths allowing recovery during the first and third examinations (i.e. periods of 76 and 78) were shorter than the critical CL inducing RDBBB during the

From the Second Department of Medicine Hokkaido University School of Medicine Sapporo Japan

Supported in part by a grant from the Education Ministry of the Japanese Government

Received for publication June 14 1977

Accepted for publication Jan 13 1978

Reprint requests: Shinji Kinoshita M D the Second Department of Medicine Hokkaido University School of Medicine Sapporo Japan

* These numbers represent hundredths of a second

These numbers represent hundredths of a second




Fig 4 Case 5 Rate dependent right bundle branch block showing variations in the critical cycle length inducing bundle branch block. The four trips are not continuous. In the bottom trip the sinus rhythm is slowed owing to pressure on the eyeball. Time intervals are expressed in hundredths of a second.

that unidirectional block in the bundle branch is the main mechanism of maintenance of RDBBB for the following reasons.

The possibility exists that the beat of seemingly complete BBB configuration might be caused not by true complete BBB but by markedly slow antegrade conduction into the bundle branch. If the beat of seemingly complete BBB configuration is caused by slow antegrade conduction the transition from normal configuration to complete BBB configuration will usually be gradual. Namely increasing grades of incomplete BBB patterns will usually be seen. However in only a few cases of RDBBB such gradual transition can be seen. In most cases of RDBBB including the present cases the transition is sudden without showing incomplete BBB patterns which makes unlikely the presence of slow antegrade conduction into the bundle branch. Even in the cases showing gradual transition due to slow antegrade conduction if unidirectional block in the bundle branch is not present bundle branch Wenckebach periods will usually be seen and therefore BBB will usually not be maintained.⁵

Transient depression of atrioventricular (A-V) conduction through the His-Purkinje system following rapid driving has been defined as the fatigue phenomenon. When such depression causes A-V block of the 2:1 type occurs before complete recovery of conduction. How-

ever in most cases of RDBBB after shortening of only one CL RDBBB can be maintained for a long time and thereafter reversion to normal conduction occurs without showing 2:1 BBB. Therefore it seems unlikely that "fatigue" of the blocked bundle branch is the main mechanism of maintenance of RDBBB, namely in most cases of RDBBB the refractory period of the blocked bundle branch appears to vary within a comparatively narrow range even when BBB is maintained. The presence of a fatigue of the blocked bundle branch was suggested in a few cases of RDBBB. However it appears to me that in these cases too RDBBB was maintained not because of fatigue but because of unidirectional block in the bundle branch. If unidirectional block were not present in these cases RDBBB could not be maintained and 2:1 BBB would occur.

Thus the critical CL inducing RDBBB appears to show the refractory period of the blocked bundle branch for the anterogradely conducted impulse. Therefore the observations in the present report suggest that independent of variations in the bundle branch refractory period the critical CL allowing reversion to normal conduction is considerably longer than this refractory period. This suggests the presence of concealed retrograde conduction to the blocked bundle branch as illustrated in the diagram below the middle




Fig 3 Case 4 Fluctuations of critical cycle lengths inducing bundle branch block and allowing reversion to normal conduction. When bundle branch block is induced, the cycle length preceding the initial bundle branch block is indicated by solid circles. Conversely, when reversion to normal conduction occurs, the cycle length preceding the initial normal conduction is indicated by solid triangles. During the period from the solid triangle to the next solid circle, normal conduction is maintained. During this period, the shortest cycle length preceding normal conduction is indicated by open circles. Accordingly, the critical cycle length inducing bundle branch block during this period will be found between the open circle and the solid circle, or at the solid circle. Variations in this critical length are indicated by the solid line. On the other hand, during the period from the solid circle to the next solid triangle, bundle branch block is maintained. During this period, the longest cycle length preceding bundle branch block is indicated by open triangles. Therefore, the critical cycle length allowing recovery during this period will be found between the open triangle and the solid triangle, or at the solid triangle. Variations in this critical cycle length are indicated by the dashed line. The critical cycle length inducing bundle branch block fluctuates in parallel with the critical cycle length allowing recovery.

Case 5 In this case the critical CL inducing RDBBB varied from cycle to cycle. Fig 4 represents portions of long recordings showing rate dependent right BBB which were taken from a 36 year old man with paroxysmal supraventricular tachycardia. The four strips in Fig 4 are not continuous. Cycle lengths at rest ranged between periods of 77 and 130. When the CL at rest was shorter than a period of 100, the following sinus beat was always of right BBB configuration as shown in the top strip of Fig 4. When on the other hand the CL was prolonged beyond a period of 127, the following sinus beat was always of normal configuration as shown in the bottom strip of Fig 4. The longest CL during pressure on the eyeball (Aschner's test) was a period of 772. These findings indicate that Case 5 was also one of tachycardic RDBBB. However, the critical CL inducing RDBBB fluctuated between periods of 100 and 127. As a result, when the CL varied between periods of 100 and 127, the following sinus beat was sometimes of the right BBB type and at other times of normal configuration as shown in the second and third strips of Fig 4. In the second strip, reversion to normal conduction occurs despite the fact that the CL at recovery (a period of 101) is shorter than the CL preceding that (a period of 104). Besides, in the third strip, RDBBB is induced despite the fact that the CL

at induction (a period of 111) is longer than the CL preceding that (a period of 110). These facts indicate that the critical CL inducing RDBBB varied within a very short time, occasionally even from cycle to cycle. Therefore, even within a very short time, a fixed difference between the critical CL inducing RDBBB and the critical CL allowing recovery could not be disclosed.

Discussion

The present report demonstrates that critical CL inducing RDBBB was invariable in Case 1, extending over two years, and that in the other cases it varied within a comparatively short period. However, when RDBBB was maintained for only a few cycles, the critical CL allowing reversion to normal conduction was always longer than the critical CL inducing RDBBB here in all cases except Case 5. In Case 5, such a distinct difference in CL could not be disclosed because the critical CL inducing RDBBB varied from cycle to cycle.

It is known that when RDBBB is initiated it is almost always maintained for some time. There are several possible mechanisms by which RDBBB could be maintained—(1) slow antegrade conduction, (2) fatigue of the bundle branch, (3) unidirectional block, and (4) combination of (1) and (3) or of (2) and (3). However, I believe

In other words "true unidirectional block is considered to be present at the site of RDBBB. Similarly in all other cases except Case 5 RDBBB was maintained even when the CL was shortened below the bundle branch refractory period for the anterogradely conducted impulse.

If repeated retrograde conduction as mentioned above maintains RDBBB it is expected that when the CL is shortened below the refractory period for the retrogradely conducted impulse retrograde conduction to the blocked bundle branch will not occur in succession. Fig 5 represents portions of a recording after exercise in Case 5. The middle and bottom strips are continuous but the top and middle strips are not continuous. In Fig 5 the sinus beat of a normal configuration often appears despite the fact that the CL here is far shorter than the critical CL inducing RDBBB at rest. This can probably be explained by shortening of the CL below the refractory period for the retrograde impulse which will result in 2:1 retrograde conduction to the RBB as illustrated in the diagrams below the strips. When an anterograde sinus impulse falls after the RBB refractory period because of both anterograde and retrograde block of the preceding sinus impulse it will become a beat of normal configuration—for example the sinus beats S and S' in the top strip. When on the other hand the anterograde impulse falls in the RBB refractory period despite both anterograde and retrograde block of the preceding impulse it will become a beat of the right BBB type—for example the beats S and S' in the top strip. In the middle strip the sinus impulse following such bidirectional block becomes sometimes the beat of a normal configuration and at other times the beat of the right BBB type although the CL is almost invariable in this strip. This can be explained by the fact that the RBB refractory period for the anterograde impulse considerably varies from cycle to cycle in this case as mentioned above. In the bottom strip of Fig 5 the CL increases beyond a period of 60 (i.e. one half of 120). After that all the sinus beats are of the right BBB type until the CL reaches a period of 111. Here retrograde conduction to the RBB seems to occur in succession as illustrated in the diagram below the strip probably because the CL becomes longer than the refractory period for the retrograde impulse though it remains shorter than that for the anterograde impulse. Such features after exercise

reinforce the conclusion that true unidirectional block is present at the site of RDBBB. Thereafter features similar to those shown in Fig 4 were also seen in this recording namely, when the CL increased beyond the period of 111 the sinus beat was sometimes of normal configuration and at other times of the right BBB type because of considerable fluctuation in the RBB refractory period for the anterograde impulse and when the CL was prolonged beyond the longest refractory period of 127 owing to pressure on the eyeball all the sinus beats were of normal configuration.

The above mentioned finding in Case 5 is similar to pseudobradycardia dependent BBB alternans observed in recently reported cases of Cohen and colleagues⁷ in which a change from alternans to persistent BBB occurred as the cycle lengthened. However the disappearance of BBB with further increase of the CL proved the tachycardia dependence of the conduction defect. The phenomenon in their cases was also explained by a transition from a bidirectional 2:1 block into a sustained unidirectional block in a bundle branch. However unidirectional block postulated by them was not "true" unidirectional block namely they postulated that the bundle branch refractory period for the retrograde impulse was equal in length to that for the anterograde impulse.

In Case 5 in the present report paroxysmal supraventricular tachycardia occasionally occurred in which the CL was a period of 34 and all the beats were of right BBB configuration. It seems that although 2:1 retrograde block at the site of RDBBB occurred here all the anterograde impulses fell in the refractory period because the sum of two cycle lengths (i.e. a period of 68) is much shorter than the refractory period for the anterograde impulse. This indicates unidirectional block alternating with bidirectional block as illustrated by the diagram below the early portion of the top strip of Fig 5. Recently the presence of 2:1 block in the ventricular conduction system was suggested in concealed bigeminy⁸ and intermittent parasystole⁹. Such 2:1 block and the above mentioned alternating unidirectional block appear to be governed by the same mechanism.

In the other cases in the present report when the CL was shorter than the critical CL inducing RDBBB the beat of a normal configuration could not be found even after exercise. The probable reason for this is that in these cases the




Fig 5 Case 5 Electrocardiogram after exercise in the same patient as in Fig 4. The lower two strips are continuous. *Thickly shaded areas* in the diagrams represent the refractory period for the retrogradely conducted impulse i.e. the period showing bidirectional block during which both the anterograde impulse and the retrograde impulse are blocked. *Thinly shaded areas* represent the period showing unidirectional block during which the anterograde impulse is blocked but the retrograde impulse is conducted. The deflection marked with a in the middle strip is an artifact. Abbreviations are the same as in Fig 1.

strip of Fig 1. In Case 1 the critical CL inducing RDBBB was a period of 91 as mentioned above. This indicates that the refractory period of the right bundle branch (RBB) is the period of 91. In the middle strip of Fig 1, the sinus impulse labelled S_1 is blocked within the RBB because the preceding CL S_1 is shorter than the refractory period of the RBB. However, after a period of 6 from that time the sinus impulse S_2 conducted from the left bundle branch penetrates retrogradely into the blocked site of the RBB. Consequently the subsequent sinus impulse S_3 is again blocked within the RBB despite the fact that the CL S_3 is longer than the refractory period of the RBB. In the same way the subsequent sinus impulses S_4 and S_5 are blocked within the RBB in succession. Thus retrograde conduction to the blocked RBB maintains RDBBB until the CL is prolonged beyond a period of 97 (i.e., the RBB refractory period of 91 plus the period of 6). If the sinus impulse S_6 were not conducted retrogradely to the blocked RBB the subsequent sinus impulse S_7 would not be blocked within the RBB and as a result RDBBB would not be maintained. Moe, Mendez and Han⁴ de-

monstrated experimentally that functional bundle branch block was maintained owing to such repeated retrograde conduction. The feature mentioned above does not indicate 'true' unidirectional block, namely this can be explained without any difference between the refractory period for the anterogradely conducted impulse and that for the retrogradely conducted impulse.

However, even when the CL is shortened below the above mentioned refractory period of the RBB RDBBB is also maintained as shown in the bottom strip of Fig 1. Therefore, we must assume that even in such rapid rhythm retrograde conduction to the blocked RBB occurs in succession. The relationship represented in Fig 2 suggests that the expected decrease in the refractory period with shortening of the preceding CL did not occur here. In the recent electrophysiological study by Denes and colleagues⁵ the same feature was also demonstrated in four of five patients with RDBBB. These facts suggest that the RBB refractory period for the retrogradely conducted impulse is not equal in length to that for the anterogradely conducted impulse, namely that the former is considerably shorter than the latter.

changes in the preceding CL the critical CL inducing RDBBB was invariable extending over two years. In the other patients the critical CL inducing RDBBB varied within a comparatively short period. However when RDBBB was maintained for only a few cycles the critical CL allowing reversion to normal conduction was always longer than the critical CL inducing RDBBB here in all patients except one. In one patient such a distinct difference in CL could not be disclosed because the critical CL inducing RDBBB varied from cycle to cycle.

These observations suggest that independent of variations in the refractory period of the blocked bundle branch the critical CL allowing reversion to normal conduction was considerably longer than this refractory period in all patients. The possible mechanisms by which RDBBB could be maintained are discussed. The most probable mechanism appears to be true unidirectional block in the affected bundle branch in which the refractory period for the retrogradely conducted impulse is shorter than that for the anterogradely conducted impulse.

REFERENCES

1. Fleck C, Zipes D P and McHenry P L. Rate dependent aberrancy. *Circulation* 48 714 1973
2. Depes P, Wu D, Dhingra R C, Amat y Leon F, Wyndham C and Rosen K M. Electrophysiological observations in patients with rate dependent bundle branch block. *Circulation* 51 244 1975
3. Wallace A C and Laszlo J. Mechanisms influencing conduction in a case of intermittent bundle branch block. *Am Heart J* 61 548 1961
4. Narula O S and Runge M. Accommodation of A V nodal conduction and fatigue phenomenon in the His Purkinje system. In Wellens H J J, Lie K I and Janse M J editors. *The conduction system of the heart*. Leyden 1976. Stenfert Kroese p 529
5. Rosenbaum M B, Nau C J, Levi R J, Halpern M S, Elizar M V and Lazzari J O. Wenckebach periods in the bundle branch. *Circulation* 40 79 1969
6. Moe G K, Mendez C and Han J. Aberrant A V impulse propagation in the dog heart: a study of functional bundle branch block. *Circ Res* 16 761 1965
7. Cohen H C, D'Cruz I, Arbel M R, Langendorf H and Pick A. Tachycardia and bradycardia-dependent bundle branch block alternans: clinical observations. *Circulation* 55 942 1977
8. Kinoshita S. Concealed ventricular extrasystoles due to interference and due to exit block. *Circulation* 52 230 1975
9. Kinoshita S and Tanabe Y. Second degree entrance block in intermittent ventricular parasystole. *Chest* 67 236 1975
10. Lightfoot P R. Intermittent parasystole with concealed extrasystolic bigeminy during myocardial infarction. *Am Heart J* 93 229 1977
11. Kinoshita S. Intermittent parasystole originating in the ventricular path of ventricular extrasystoles. *Chest* 72 201 1977

Copyright information

The appearance of a code at the bottom of the first page of an original article in this journal indicates the copyright owner's consent that copies of the article may be made for personal or internal use or for the personal or internal use of specific clients. This consent is given on the condition, however, that the copier pay the stated per copy fee through the Copyright Clearance Center Inc. P.O. Box 765, Schenectady, N.Y. 12301 518-374 4430 for copying beyond that permitted by Sections 107 or 108 of the U.S. Copyright Law. This consent does not extend to other kinds of copying, such as copying for general distribution for advertising or promotional purposes, for creating new collective works, or for resale.




Fig 6 Diagrams to illustrate the relationship between the cycle length and the impulse conduction in rate dependent bundle branch block. Thickly shaded areas represent the refractory period for the retrogradely conducted impulse. Thinly shaded areas represent the period showing unidirectional block. Impulse conduction in the affected bundle branch is represented by solid lines whereas impulse conduction in the contralateral bundle branch is represented by dashed lines. BB = bundle branch. S = sinus impulse.

CL would not be shortened below the refractory period for the retrograde impulse.

In conclusion, "true unidirectional block in the affected bundle branch appears to be the most probable mechanism by which RDBBB can be maintained. Diagrams in Fig 6 illustrate the relationship between the CL and the conduction of the anterograde and retrograde impulses at the site of RDBBB. Thickly shaded areas in the diagrams represent the refractory period for the retrograde impulse (RPR), i.e. the period showing bidirectional block, during which both the anterograde impulse and the retrograde impulse are blocked. Thinly shaded areas represent the period showing unidirectional block, during which the anterograde impulse is blocked but the retrograde impulse is conducted. The sum of the periods of bidirectional and unidirectional block corresponds to the refractory period for the anterograde impulse (RPA).

Diagram A in Fig 6 indicates that when the CL S_1 , S_2 following normal conduction is longer than the RPA the anterograde impulse S_2 passes through the bundle branch.

Diagram B shows that when the CL S_1 , S_2 is slightly shorter than the RPA the anterograde impulse S_2 is blocked within the bundle branch. After some delay the retrograde impulse is conducted to the blocked bundle branch. Here the retrograde impulse falls after the RPA. Thus when the subsequent cycle lengths (including the

CL S_1 , S_2) are slightly longer than the RPA bundle branch block is maintained because of repeated retrograde conduction. However, this does not indicate true unidirectional block, namely, the feature shown in diagram B can be explained without any difference in length between the RPA and the RPR.

Diagram C indicates that even when the cycle lengths S_1 , S_2 and S_3 are both shorter than the RPA the retrograde impulses S_2 and S_3 are conducted to the blocked bundle branch in succession because these impulses fall in the period of unidirectional block. Thus, RDBBB can be maintained for a long time.

Diagram D shows that when the retrograde impulse falls in the period of unidirectional block shortly after the RPR its conduction time within the bundle branch may be markedly prolonged in some cases. If such a retrograde impulse falls after the refractory period in the region above the site of RDBBB this impulse may possibly re enter the ventricles after passing through the contralateral bundle branch although in the cases in the present report such re entrant extrasystoles were not found. In my recently reported case of intermittent ventricular parasystole¹¹ the presence of re entrant ventricular extrasystoles due to a similar mechanism was demonstrated.

Diagram E demonstrates that when the retrograde impulse S_2 falls in the RPR but the sum of the cycle lengths S_1 , S_2 , and S_3 is longer than the RPA the anterograde impulse S_3 passes through the bundle branch despite the fact that these cycle lengths are both far shorter than the RPA.

Diagram F shows that when the CL is further shortened the anterograde impulses S_1 and S_2 fall in the RPA. Thus bundle branch block is again maintained as the result of 2:1 retrograde conduction. In cases in which the RPR is considerably shorter than one half of the RPA whenever the retrograde impulse falls in the RPR the subsequent anterograde impulse will fall in the RPA. In such cases therefore when the CL is shorter than the RPA, the anterograde impulse is always blocked within the bundle branch whether the retrograde impulse is blocked or not.

Summary

In five patients with tachycardic RDBBB (rate dependent bundle branch block) variations in the critical CL (cycle length) inducing RDBBB were investigated. In one patient independent of

changes in the preceding CL the critical CL inducing RDBBB was invariable extending over two years. In the other patients the critical CL inducing RDBBB varied within a comparatively short period. However when RDBBB was maintained for only a few cycles the critical CL allowing reversion to normal conduction was always longer than the critical CL inducing RDBBB here in all patients except one. In one patient such a distinct difference in CL could not be disclosed because the critical CL inducing RDBBB varied from cycle to cycle.

These observations suggest that independent of variations in the refractory period of the blocked bundle branch the critical CL allowing reversion to normal conduction was considerably longer than the refractory period in all patients. The possible mechanisms by which RDBBB could be maintained are discussed. The most probable mechanism appears to be a true unidirectional block in the affected bundle branch in which the refractory period for the retrogradely conducted impulse is shorter than that for the anterogradely conducted impulse.

REFERENCES

- 1 Fisch C, Zipes D P., and McHenry P L. Rate dependent aberrancy. *Circulation* 48:714 1973
- 2 Denes P, Wu D, Dhingra R C, Amat y Leon F., Wyndham C and Rosen K M. Electrophysiological observations in patients with rate dependent bundle branch block. *Circulation* 51:244 1975
- 3 Wallace A G and Laszlo J. Mechanisms influencing conduction in a case of intermittent bundle branch block. *AM HEART J* 61:548 1961
- 4 Narula O S and Hunge M. Accommodation of A-V nodal conduction and fatigue phenomenon in the His-Purkinje system in Wellens H J J., Lie K I and Janse M J editors. *The conduction system of the heart*. London 1976. Stenfort Kroese p. 529
- 5 Rosenbaum M I, Nau G J, Levi R J, Halpern M S, Elizari M V and Lazzari J D. Wenckebach periods in the bundle branch. *Circulation* 40:79 1969
- 6 Moe G K, Mendez L and Han J. Aberrant A-V impulse propagation in the dog heart: a study of functional bundle branch block. *Circ Res* 18:261 1965
- 7 Cohen H C, D Cruz J, Arbel E R, Langendorf R and Pick A. Tachycardia and bradycardia-dependent bundle branch block alternans: clinical observations. *Circulation* 55:749 1977
- 8 Kinoshita S. Concealed ventricular extrasystoles due to interference and due to exit block. *Circulation* 52:230 1975
- 9 Kinoshita S and Tansbe Y. Second degree entrance block in intermittent ventricular parasystole. *Chest* 67:276 1975
- 10 Lightfoot P R. Intermittent parasystole with concealed extrasystolic bigeminy during myocardial infarction. *AM HEART J* 73:229 1977
- 11 Kinoshita S. Intermittent parasystole originating in the reentrant path of ventricular extrasystoles. *Chest* 72:401 1977

Copyright Information

The appearance of a code at the bottom of the first page of an original article in this journal indicates the copyright owner's consent that copies of the article may be made for personal or internal use, or for the personal or internal use of specific clients. This consent is given on the condition, however, that the copier pay the stated per copy fee through the Copyright Clearance Center, Inc., P.O. Box 765, Schenectady, N.Y. 12301, 518-374-4430 for copying beyond that permitted by Sections 107 or 108 of the U.S. Copyright Law. This consent does not extend to other kinds of copying, such as copying for general distribution for advertising or promotional purposes, for creating new collective works, or for resale.

Effects of bundle branch block on experimental A-V reentrant tachycardia

Fernando Amat y Leon, MD, FACC*

Alison Blasdel, BS**

Steve Teague***

Kenneth M Rosen, MD, FACC****

Pablo Denes MD, FACC*****

Chicago Ill

Most cases of ventricular preexcitation reflect the presence of an anomalous A V pathway, which may be located in either the right or left A V rings, or within the atrioventricular septum.^{1,3} In patients with preexcitation, circus movement paroxysmal tachycardias (PSVT) usually involve the normal pathway as antegrade limb and anomalous pathway as retrograde limb.^{2,3} In patients with circus movements involving retrogradely conducting anomalous pathways, it has been suggested that development of functional bundle branch block ipsilateral to the anomalous pathway produces a slowing in the rate of parox-

ysmal tachycardia.⁴⁻¹⁰ It has been additionally suggested that the presence or absence of this slowing during bundle branch block could be used as a diagnostic sign for lateralization of anomalous pathways.⁴⁻¹²

Recently Pritchett and co workers,¹³ further elucidated this phenomenon. They studied 15 patients with left free wall anomalous pathways, three patients with right free wall anomalous pathways and four patients with presumptive septal preexcitation. Ventriculo atrial conduction times were increased during paroxysmal tachycardia when functional bundle branch block occurred ipsilateral to the location of an anomalous pathway. Contralateral functional bundle branch block did not affect V A conduction during PSVT in these patients. In patients with septal anomalous pathways, neither right or left bundle branch block appeared to affect V A conduction times during PSVT. Since the occurrence and lateralization of functional bundle branch block could not be controlled in the above study it was not possible to look at the effects of both right and left bundle branch in all patients.

In the present study we extend the observations of Pritchett and colleagues¹³ by systematically examining the effects of ipsilateral and contralateral bundle branch block on experimentally induced A V reentrant paroxysmal tachycardia in dogs. The experimental model utilized an anomalous pathway simulator so that the effects of bundle branch block could be examined utilizing multiple anomalous pathway locations in the same dog.

From the Cardiology Section Department of Medicine Abraham Lincoln School of Medicine University of Illinois College of Medicine and West Side Veterans Administration Hospital Chicago Illinois. Supported in part by National Institutes of Health grant HL16794 01 United States Public Health Service training grant HL 05879 06 Basic Institutional Support West Side Veterans Administration Hospital (MRIS No 1878) Veterans Administration grant 0363 01 and Chicago Heart Association grant A76 59 Chicago Illinois.

Received for publication Oct 3 1977

Accepted for publication Nov 2 1977

Reprint requests Fernando Amat y Leon MD Cardiology Section University of Illinois Hospital P O Box 6998 Chicago Ill 60680

Research Associate West Side Veterans Administration Hospital Assistant Professor of Medicine Cardiology Section Abraham Lincoln School of Medicine University of Illinois College of Medicine Chicago

Graduate Student in Physiology and Biophysics at the University of Illinois Medical Center

Senior Medical Student Abraham Lincoln School of Medicine University of Illinois

Professor of Medicine and Chief Cardiology Section Abraham Lincoln School of Medicine University of Illinois College of Medicine

Associate Professor of Medicine Cardiology Section Abraham Lincoln School of Medicine University of Illinois College of Medicine Chicago




Fig 1 Schematic representation of the seven anomalous pathway locations. Anterior, lateral, and posterior views of the heart are shown. Anomalous pathway locations both atrial and ventricular are represented by closed circles. AR = anterior right LR = lateral right AL = anterior left LL = left lateral PL = posterior left S = posterior septum PR = posterior right RA = right atrium LA = left atrium

Methods and materials

Seventeen mongrel dogs weighing from 14 to 21 kilograms were premedicated with morphine sulfate (2 mg /Kg intramuscularly) and anesthetized with Nembutal (30 mg /Kg intravenously). Ventilation was maintained with endotracheal intubation and a Harvard Respirator. Autonomic blockade was achieved by bilateral cervical vagotomy and propranolol administration (1 mg /Kg intravenously). The chest was opened through a midsternotomy and the heart suspended in a pericardial cradle.

Close pairs of plunge bipolar electrodes (Teflon coated stainless steel wires of 0.003 inch diameter) were positioned at seven contiguous atrial and ventricular sites around the A V ring in order to simulate the atrial and ventricular insertions of anomalous pathways. The following anomalous pathway sites were utilized (Fig 1) (1) anterior right (AR) at the right atrial appendage and underlying right ventricular outflow tract (2) posterior right (PR) at the posterior right atrium and contiguous right ventricle (just to the right of the intra atrial and intraventricular grooves) (3)

lateral right (LR) at a midpoint between AR and PR (4) septum (S) at the posterior atrioventricular septum (the atrial septal site was reached by plunging electrodes through the posterior free wall of the right atrium and lodging them in the posterior septum—the corresponding ventricular septum was reached by plunging electrodes through the posterior interventricular septum and lodging them 1 to 2 cm deep in the posterior septum) (5) anterior left (AL) at the left atrial appendage and underlying left ventricle (6) posterior left (PL) at the posterior left atrium just above the coronary sinus and the adjacent left ventricle (7) left lateral (LL) at midpoint between AL and PL. Special attention was paid to positioning the electrodes close to the A V ring at a distance of 1 cm.

A 5F bipolar electrode catheter was introduced into the left carotid artery and advanced behind the non coronary cusp of the aortic valve for His bundle recordings. His bundle potentials were validated by atrial and His bundle pacing. Standard electrocardiographic Leads I II III His bundle electrograms right atrial electro-

Table 1 Cycle length of A V reentrant PSVT with and without bundle branch block (mean \pm SEM in msec)

AP site	Control (N = 7)	RBBB (N = 7)	P	Control (N = 10)	LBBB (N = 10)	P
AR	281.5 \pm 8.3	318 \pm 9.5	< 0.001	281.5 \pm 7.4	281 \pm 8	NS
LR	276.5 \pm 9.4	303 \pm 12	< 0.001	275 \pm 9	274 \pm 6.4	NS
PR	266 \pm 8	289 \pm 9.3	< 0.01	267.5 \pm 5	261 \pm 9	NS
S	271 \pm 10.5	273.5 \pm 11	NS	273.5 \pm 8	278 \pm 6.5	NS
PL	277 \pm 11	276 \pm 10	NS	275 \pm 6.7	309 \pm 6.3	< 0.001
LL	289 \pm 10.5	285 \pm 10	NS	269 \pm 9	307 \pm 7.7	< 0.01
AL	286 \pm 10.5	286.5 \pm 11	NS	280 \pm 7.5	312.5 \pm 7.6	< 0.001

Abbreviations: AP = anomalous pathway; RBBB = right bundle branch block; LBBB = left bundle branch block; AR = anterior right; LR = lateral right; PR = posterior right; S = septum; PL = posterior left; LL = lateral left; AL = anterior left; NS = non significant; P = P value.

grams local ventricular electrograms and stimulus artifacts were simultaneously displayed on an oscilloscope and recorded on a multichannel recorder (Electronics for Medicine DR 8 White Plains, N Y) at paper speeds of 100 and 200 mm/sec.

The electronic anomalous pathway simulator was schematically depicted in a previous publication.¹⁵ Local electrograms recorded from the ventricle were preamplified by a multichannel recorder and filtered and differentiated by input circuitry. The resulting signal was used to trigger a crystal controlled digital timer programmable to a specific pathway delay between 1 and 999 msec. When the preset time was reached the timer triggered a pulse generator adjusted to deliver an above threshold stimulus to the atrial stimulating electrodes. Thus the relevant features of this anomalous pathway simulator include ability for ventricular sensing, retrograde conduction with programmable conduction time, and atrial stimulation.

Experimental protocol

A V reentrant tachycardias were induced in each of the dog at all seven sites with a programmed anomalous pathway conduction time of 100 msec. This conduction time was chosen since it allowed induction of paroxysmal tachycardia with a cycle length comparable to that seen in patients with Wolff Parkinson White syndrome and PSVT. Recordings were obtained during each tachycardia at a paper speed of 100 mm/sec. The following subintervals were measured: (1) S-A interval, from the stimulus artefact to the first high frequency electrogram of the low septal right atrium recorded from the His bundle

recording catheter. This interval reflected intra atrial conduction time from the atrial stimulation site to the low septal right atrium. (2) A-H interval, from the first high frequency deflection on the low septal right atrial electrogram to the His bundle electrogram. This interval reflected A-V nodal conduction time. (3) H-V_L interval from the His bundle electrogram to the first high frequency deflection of the local ventricular electrogram recorded from the tested ventricular sensing site. This interval reflected conduction time from the His bundle to the sensing site. (4) V_L-S interval from the sensed ventricular electrogram to the stimulus artefact. This interval was 100 msec reflecting programmed delay of the anomalous pathway simulator.

After control values were obtained right bundle branch block was produced in seven of the dogs by inserting a needle through the right ventricular wall and traumatizing the second portion of the right bundle branch.¹ Similarly in another group of 10 dogs left bundle branch block was induced by traumatizing the main left bundle branch with a needle introduced through the left ventricular wall at the apex of the heart.¹⁷ A V reentrant tachycardia was again induced in all dogs at all sites after a stable bundle branch block was produced. Measurements of tachycardia cycle length and subintervals were determined.

At the termination of each experiment the heart was excised and the exact location of the plunge wires were verified. Lugol's solution was used to identify the intraventricular conducting system and to verify the interruption of the traumatized bundle branch.

All the intervals given represent the average of




Fig 2 Induced A V reentrant tachycardia (PSVT) Representative example from the anterior right location before (Panel A) and after (Panel B) right bundle branch block was produced. Shown are electrocardiographic leads I, II, III, HBE = His bundle recordings, RA = right atrial electrogram, V_L = local ventricular electrogram, S = stimulus artifact. Paper speed is 100 mm/sec and time intervals are at 1 sec. Values for the different components of the cycle length (CL) of supraventricular tachycardia before and after RBBB are shown in the right column.

10 consecutive measurements. Statistical analysis was performed using the Student t test for paired data and analysis of variance.

Results

Cycle length of tachycardias (Table 1) The effects of right bundle branch block on the cycle length of A V re-entrant tachycardias in seven dogs at all sites is presented in Table 1. Cycle length of tachycardias was significantly increased only with the three right sided anomalous pathway locations increasing by a mean of 37 ± 3 msec ($P < 0.01$) with the anterior right site by 27 ± 3 msec ($P < 0.01$) with the lateral right site and by 23 ± 4 msec ($P < 0.1$) with the posterior right site. Cycle length of tachycardias utilizing septal and left sided pathways were not significantly changed. Fig 2 is a representative

example of one of the experiments conducted with an anterior right anomalous pathway.

The effects of left bundle branch block on the cycle length of A V re-entrant tachycardias in 10 dogs at all sites is presented in Table 1. After left bundle branch block cycle length of PSVT was significantly increased only with the three left sided pathway locations increasing by a mean of 34 ± 2.6 msec ($P < 0.01$) with the posterior left site by 38 ± 4.6 msec ($P < 0.1$) with the left lateral site and by 32.5 ± 3.3 msec ($P < 0.01$) with the anterior left site. Cycle length of tachycardias utilizing septal and right sided locations were not significantly changed. Fig 3 is a representative example of one of the experiments conducted with a left lateral anomalous pathway.

Subintervals The cycle length of A V re-

Table 1 Cycle length of A V reentrant PSVT with and without bundle branch block (mean \pm SEM in msec)

AP site	Control (N = 7)	RBBB (N = 7)	P	Control (N = 10)	LBBB (N = 10)	P
AR	281.5 \pm 8.3	318 \pm 9.5	< 0.001	281.5 \pm 7.4	281 \pm 8	NS
LR	276.5 \pm 9.4	303 \pm 12	< 0.001	275 \pm 9	274 \pm 6.4	NS
PR	266 \pm 8	289 \pm 9.3	< 0.01	267.5 \pm 5	261 \pm 9	NS
S	271 \pm 10.5	273.5 \pm 11	NS	273.5 \pm 8	278 \pm 6.5	NS
PL	277 \pm 11	276 \pm 10	NS	275 \pm 6.7	309 \pm 6.3	< 0.001
LL	289 \pm 10.5	285 \pm 10	NS	269 \pm 9	307 \pm 7.7	< 0.01
AL	286 \pm 10.5	286.5 \pm 11	NS	280 \pm 7.5	312.5 \pm 7.6	< 0.001

Abbreviations: AP = anomalous pathway; RBBB = right bundle branch block; LBBB = left bundle branch block; AR = anterior right; LR = lateral right; PR = posterior right; S = septum; PL = posterior left; LL = lateral left; AL = anterior left; NS = non significant; P = P value

grams, local ventricular electrograms and stimulus artifacts were simultaneously displayed on an oscilloscope and recorded on a multichannel recorder (Electronics for Medicine DR 8 White Plains N Y) at paper speeds of 100 and 200 mm/sec.

The electronic anomalous pathway simulator was schematically depicted in a previous publication.¹⁶ Local electrograms recorded from the ventricle were preamplified by a multichannel recorder, and filtered and differentiated by input circuitry. The resulting signal was used to trigger a crystal controlled digital timer, programmable to a specific pathway delay between 1 and 999 msec. When the preset time was reached the timer triggered a pulse generator adjusted to deliver an above threshold stimulus to the atrial stimulating electrodes. Thus, the relevant features of this anomalous pathway simulator include ability for ventricular sensing, retrograde conduction with programmable conduction time and atrial stimulation.

Experimental protocol

A V reentrant tachycardias were induced in each of the dogs at all seven sites with a programmed anomalous pathway conduction time of 100 msec. This conduction time was chosen since it allowed induction of paroxysmal tachycardia with a cycle length comparable to that seen in patients with Wolff Parkinson White syndrome and PSVT. Recordings were obtained during each tachycardia at a paper speed of 100 mm/sec. The following subintervals were measured: (1) S A interval from the stimulus artefact to the first high frequency electrogram of the low septal right atrium recorded from the His bundle

recording catheter. This interval reflected intra atrial conduction time from the atrial stimulation site to the low septal right atrium. (2) A H interval from the first high frequency deflection on the low septal right atrial electrogram to the His bundle electrogram. This interval reflected A V nodal conduction time. (3) H V₁ interval from the His bundle electrogram to the first high frequency deflection of the local ventricular electrogram recorded from the tested ventricular sensing site. This interval reflected conduction time from the His bundle to the sensing site. (4) V₁ S interval from the sensed ventricular electrogram to the stimulus artefact. This interval was 100 msec reflecting programmed delay of the anomalous pathway simulator.

After control values were obtained right bundle branch block was produced in seven of the dogs by inserting a needle through the right ventricular wall and traumatizing the second portion of the right bundle branch.¹⁷ Similarly in another group of 10 dogs left bundle branch block was induced by traumatizing the main left bundle branch with a needle introduced through the left ventricular wall at the apex of the heart.¹⁸ A V reentrant tachycardia was again induced in all dogs at all sites after a stable bundle branch block was produced. Measurements of tachycardia cycle length and subintervals were determined.

At the termination of each experiment the heart was excised and the exact location of the plunge wires was verified. Lugol's solution was used to identify the intra-ventricular conducting system and to verify the interruption of the traumatized bundle branch.

All the intervals given represent the average of

Table II H V₁ during PSVT with and without bundle branch block (mean \pm SEM in msec)

AP site	Control (N = 7)	RBBB (N = 7)	P	Control (N = 10)	LBBB (N = 10)	P
AR	39.5 \pm 3	87 \pm 3	< 0.001	37.5 \pm 2.4	37 \pm 2.5	NS
LR	37 \pm 2.4	69 \pm 5	< 0.001	34.5 \pm 2	35 \pm 2	NS
PR	40 \pm 2.4	63 \pm 4.7	< 0.001	38 \pm 3	38 \pm 2.6	NS
S	40 \pm 2.7	43.5 \pm 4.6	NS	37.5 \pm 3	42.5 \pm 3	NS
PL	37 \pm 1.5	43 \pm 1.8	NS	35.5 \pm 3	85.5 \pm 5	< 0.001
LL	41 \pm 3.5	48 \pm 3.4	NS	38 \pm 2	80 \pm 2.6	< 0.01
AL	40 \pm 3	36.5 \pm 7	NS	36.5 \pm 2.5	79 \pm 3.6	< 0.001

Abbreviations AP = anomalous pathway RBBB = right bundle branch block LBBB = left bundle branch block NS = non significant P = P value

sites. With left bundle branch block AH decreased by 12 ± 5 msec ($P < 0.05$) 15 ± 5 msec ($P < 0.05$) and 13 ± 4 msec ($P < 0.05$) with tachycardias respectively utilizing the left posterior lateral and anterior sites. SA intervals did not change significantly after either right or left bundle branch block.

Discussion

In patients with preexcitation A V reentrant tachycardias (PSVT) usually reflect circus movement with the normal pathway as antegrade limb and the anomalous pathway as retrograde limb.^{2,3} The cycle length of the tachycardia is determined by A V nodal conduction time. His Purkinje conduction time conduction through ventricular muscle anomalous pathway conduction and intra atrial conduction.

It has been suggested that the development of functional bundle branch block during PSVT ipsilateral to the location of an anomalous pathway results in lengthening of the cycle length of PSVT.⁴ This lengthening is thought to be due to an increase in the size of the reentrant pathway by addition of transseptal conduction time. Coumel and associates⁵ has suggested that the presence or absence of this lengthening in cycle length could be used as a sign for lateralization of anomalous pathway location. Thus in 1972 Coumel and Waynberger⁶ reported a patient with left ventricular preexcitation and A V reentrant PSVT in whom the development of functional left bundle branch block was accompanied by an increase in PSVT cycle length of 20 msec. PSVT cycle length was not changed by functional right bundle branch block. This observation was later corroborated by other reports from Slama Coumel and Bouvrain⁷ in 1973 Coumel and Attuel⁸ in 1974 Spurrell and colleagues⁹ in 1974 and Neuss and Schlepper¹⁰ in 1975. This phenomenon

has also been used to predict and locate concealed retrogradely conducting anomalous pathways.¹¹

More recently Pritchett and co workers¹² have extended these observations by analyzing the changes in V A conduction during episodes of A V reentrant paroxysmal tachycardia when functional bundle branch block develops. They reported 15 patients with left free wall anomalous pathways, three patients with right free wall anomalous pathways and four patients with septal preexcitation. Ventricle atrial conduction times were prolonged during A V reentrant tachycardia when functional bundle branch block developed ipsilateral to the location of an anomalous pathway. Functional bundle branch block contralateral to anomalous pathway did not prolong V A time. In patients with septal anomalous pathways neither bundle branch block altered V A time during PSVT.

Our results substantiated these clinical observations. We utilized a canine model of preexcitation with an anomalous pathway simulator characterized by unidirectional conduction (ventricle to atrial) programmable conduction time and predetermined location along the A V ring. A V reentrant tachycardias were easily induced using the normal pathway for antegrade conduction and the anomalous pathway (simulator) for retrograde conduction. Following experimentally induced bundle branch block ipsilateral to anomalous pathway locations cycle length of A V reentrant PSVT was significantly increased. With experimental bundle branch block contralateral to anomalous pathway location cycle length of PSVT was not changed. Cycle length of PSVT utilizing septal anomalous pathways was not changed by either right or left bundle branch block.

To further understand these results one can




Fig 3 Induced A V reentrant tachycardia. Representative example from the left lateral location before (Panel A) and after (Panel B) left bundle branch block was produced. Values for the different components of the cycle length of PSVT are shown in the right column.

trant PSVT in these experiments is the sum of the following subintervals: S-A, A-H, H-V₁, and anomalous pathway delay (V₁-S). Any significant change in cycle length of PSVT should be explainable on the basis of changes in subintervals.

Mean H-V₁ intervals during tachycardia before and after right and left bundle branch block are presented in Table II. With right bundle branch block, H-V₁ interval significantly increased with tachycardia utilizing the three right sites: H-V₁ increased by a mean of 48 ± 2.4 msec with the anterior right location ($P < 0.01$), by a mean of 32 ± 4 msec with the lateral right ($P < 0.01$) and by a mean of 23 ± 4 msec with the posterior right location ($P < 0.01$). There was no significant differences in H-V₁ with septal and left sites. With left bundle branch block, H-V₁ interval was

significantly increased with tachycardia utilizing the three left sided sites. Thus, H-V₁ increased by a mean of 50 ± 4.6 msec with the posterior left location ($P < 0.01$), by a mean of 42 ± 5 msec in the left lateral ($P < 0.01$) and by 42.5 ± 5 msec in the anterior left ($P < 0.01$). His Purkinje conduction time (conventional H-V interval) was not altered by either right or left bundle branch block. Therefore, the changes in H-V₁ represented increases in intraventricular conduction time.

There were compensatory decreases in A-H intervals for the increases in H-V₁ with bundle branch block occurring ipsilateral to anomalous pathway location. Thus, with right bundle branch block, A-H decreased by 8.5 ± 3.2 msec ($P < 0.05$), 14 ± 2.6 msec ($P < 0.05$) and 8 ± 2.6 msec ($P < 0.05$) with tachycardias respectively utilizing the right anterior, lateral and posterior

Summary

The effects of bundle branch block on experimental A V reentrant tachycardia (PSVT) were studied in 17 dogs using an anomalous pathway simulator (APS). The APS was a programmable digital electronic circuit with ability for ventricular sensing, retrograde conduction with programmable conduction time and atrial stimulation. Close bipolar electrodes were positioned at seven contiguous atrial and ventricular sites (V_1) along the A V ring these being anterior lateral and posterior right (AR LR PR) septal (S) and posterior lateral and anterior left (PL LL AL) Right (R) (seven dogs) and left (L) (10 dogs) bundle branch block (BBB) were produced with transcatheter needle. After BBB cycle length (CL) of A V reentrant PSVT was significantly increased only with ipsilateral sites. Thus with RBBB CL of PSVT increased by 37 ± 3 msec 27 ± 3 msec and 23 ± 4 msec ($P < 0.001$) at AR LR and PR sites respectively. With LBBB CL of PSVT increased only with left sided sites. Thus CL increased by 34 ± 2.6 msec 38 ± 4.6 msec and 32 ± 3.3 msec ($P < 0.001$) with PL LL and AL sites respectively. PSVT CL and septal site did not change significantly after either R or LBBB. The increase in CL was explicable in terms of corresponding increases in intraventricular conduction time (H V_1). There were slight compensatory decreases in A H intervals for the increases in H V_1 . These studies confirm findings suggested by clinical electrophysiological observation.

We are indebted to Ms Lore U Foley for her secretarial assistance.

REFERENCES

- Bouneau J P, Moore M J, Spear J F and Sealy W C. Basis of static and dynamic electrocardiographic variations in Wolff Parkinson White syndrome. *Am J Cardiol* 32:37 1973.
- Durrer D and Wellens H J. The Wolff Parkinson White syndrome anno 1973. *Eur J Cardiol* 1:34 1974.
- Gallagher J J, Gilbert M, Svenson R H, Miller H, Sealy W C, Kasell J and Wallace A G. Wolff Parkinson White syndrome. The problem, evaluation and surgical correction. *Circulation* 51: 67 1975.
- Durrer D, Schöo L, Schwenburg R M and Wellens H J. The role of premature beats in the initiation and the termination of supraventricular tachycardia in the Wolff Parkinson White syndrome. *Circulation* 36:644 1967.
- Wellens H J. Contribution of cardiac pacing to our understanding of the Wolff Parkinson White syndrome. *Br Heart J* 37:235 1975.
- Coumel P and Wajnberger M. Les tachycardies par rythme réciproque au cours du syndrome de Wolff Parkinson White. *Coeur Med Interne* 11:77 1972.
- Slama R, Coumel P and Bouvaire Y. Les syndromes de Wolff Parkinson White de type A: mappements ou latents en rythme sinusal. *Arch Mal Coeur* 66:539 1973.
- Coumel P and Attuel P. Reciprocating tachycardia in overt and latent preexcitation. *Eur J Cardiol* 1:423 1974.
- Spurrell R A, Krikler D M and Sowton E. Retrograde invasion of the bundle branches producing aberration of the QRS complex during supraventricular tachycardia studied by programmed electrical stimulation. *Circulation* 50:487 1974.
- Neuss H, Schlepper M and Thormann J. Analysis of reentry mechanisms in three patients with concealed Wolff Parkinson White syndrome. *Circulation* 51:75 1975.
- Wellens H J and Durrer D. The role of an accessory atrioventricular pathway in reciprocal tachycardia. *Circulation* 52:58 1975.
- Barold S S and Coumel P. Mechanisms of atrioventricular junctional tachycardia. Role of reentry and concealed accessory bypass tracts. *Am J Cardiol* 39:97 1977.
- Fitchett E L, Tonkin A M, Dugan F A, Wallace A G and Gallagher J J. Ventriculo atrial conduction time during reciprocating tachycardia with intermittent bundle branch block in Wolff Parkinson White syndrome. *Br Heart J* 38:1058 1976.
- Scherlag H J, Helfant R H and Damato A N. A catheterization technique for His bundle stimulation and recording in the intact dog. *J Appl Physiol* 25:425 1968.
- Scherlag H J, Kosowatz B D and Damato A N. A technique for ventricular pacing from the His bundle of the intact heart. *J Appl Physiol* 22:584 1967.
- Teague S, Denes P, Amat y Leon F and Rosen K M. Effect of anomalous pathway location on rate of canine experimental A V reentrant tachycardia. *Am J Physiol* 233:H44 1977.
- Rosenbaum, M B, Elizari, M U and Lazzari J. Los Hemibloques. Buenos Aires, 1967. Paidós p 93.
- Rosen K M, Rahmtoola T, H S, Suno M Z and Gunnar R M. Bundle branch and ventricular activation in man. *Circulation* 43:193 1971.
- Denes P, Wu D, Dingra R, Amat y Leon F, Wyndham C, and Rosen K M. Electrophysiological observations in patients with rate dependent bundle branch block. *Circulation* 51:744 1975.
- Narula O J, Javier H P, Samet P and Marmamba L. Significance of His and left bundle recordings from the left heart in man. *Circulation* 42:383 1970.
- Lewis T and Rothschild M A. The excitatory process in the dog's heart Part II. The ventricles. *Phil Tr R Soc B* 206:181 1915.
- Wilson F N and Hermann G R. Bundle branch block and arrhythmia block. *Arch Intern Med* 25:153 1970.
- Wilson, F N and Hermann G R. An experimental study of incomplete bundle branch block and of the refractory period of the heart of the dog. *Heart* 8:229 1971.
- Rodriguez M I and Sodi Palares D. The mechanism of complete and incomplete bundle branch block. *Am Heart J* 44:715 1952.

look at the determinants of PSVT cycle length with our experimental model PSVT cycle lengths equals the sum of the following subintervals (1) S A, conduction time from the atrial stimulating electrode to the low septal right atrium (from His bundle catheter) This was a function of anomalous pathway atrial site and independent of cycle length This was unchanged by experimental bundle branch block (2) A H, from low septal right atrium to the His bundle electrogram, a measure of A V nodal conduction time This was partially a function of conduction times in the rest of the circuit (3) H V₁, from His bundle electrogram to the onset of the ventricular electrogram at the ventricular sensing electrode (close to the A V ring) This was a function of ventricular site and independent of cycle length H V₁ encompassed H V (from His bundle electrogram to the onset of ventricular activation), and V V₁ conduction time from onset of ventricular activation to the ventricular sensing site (4) V₁ S from ventricular sensing site to the atrial stimulus This was a programmed function in this series of experiments and was 100 msec

In these experiments bundle branch block ipsilateral to an anomalous pathway location significantly increased H V₁ during PSVT Contralateral bundle branch block had no significant effect When analyzed, it was demonstrated that the increase in H V₁ reflected an increase in V V₁ and not H V The lack of change in H V was consistent with prior experimental work which demonstrated that conduction times in both bundle branches to the onset of ventricular activation in the ipsilateral chamber were essentially equal^{18,20} The increase in V V₁ with bundle branch block ipsilateral to an anomalous pathway reflected change in sequence of ventricular activation Ventricular activation was initiated in the contralateral ventricle proceeded across the ventricular septum and then invaded the ipsilateral ventricle The change in V V₁ with bundle branch block ipsilateral to an anomalous pathway thus reflected primarily the addition of transseptal conduction time With bundle branch block contralateral to an anomalous pathway the activation sequence of the ventricle with the anomalous pathway was essentially unchanged since its bundle branch was intact, resulting in no change in V V₁

The magnitude of increase of V V₁ with ipsilateral bundle branch block during PSVT was

similar for both right bundle branch block (range of 23 to 48 msec) and left bundle branch block (range of 42 to 50 msec) It is interesting to note that our values correlated very closely with calculated transseptal conduction times of 40 msec reported in dogs by Lewis and Rothschild²¹ and of 30 to 40 msec as reported by Wilson and Hermann²² in 1920, and of 40 msec reported by Rodriguez and Sodi Palares²³ in 1952

The failure of H V₁ (and of necessity V V₁) to increase cycle length of PSVT with septal anomalous pathways suggested that the septal location (postero basal) sensed ventricular activation arriving simultaneously from both ventricles, so that delay in the input of one or the other ventricle did not increase V V₁ This is presumably the reason for the clinically observed failure of bundle branch block to increase V A conduction time, during spontaneous PSVT in patients with septal anomalous pathway

In previous work¹⁶ utilizing the anomalous pathway simulator, we demonstrated that A H interval was a function of programmed anomalous pathway delay (V₁ S) As programmed V₁ S was decreased, A H increased This reflected a compensatory increase in A V nodal conduction time, as the cycle length of PSVT was decreased due to the decrease in V₁ S In the present study the decrease in A H during PSVT with bundle branch block ipsilateral to anomalous pathway site was compensatory for the increase in V V₁, which presented itself to the A V node as a total increase in retrograde conduction time (increase of H V₁ with a fixed V₁ S of 100 msec) The decrease in A H was of small enough magnitude, so that it only partially offset the increase in H V₁ with resultant increase in cycle length of PSVT with ipsilateral bundle branch block

Although in our experimental model increase in intraventricular conduction time was responsible for the slowing in cycle length of PSVT it is worth emphasizing that in patients with PSVT and functional bundle branch block a detailed analysis of subintervals is necessary¹¹ For instance it is possible that the decrease of A H might be of such magnitude to completely offset the lengthening in ventriculo atrial conduction time resulting in no change in cycle length of PSVT Changes in H V might also occur with functional bundle branch block complicating PSVT in patients¹¹




Fig 1 Changes in adrenal and thymus gland weight of young vs old Sprague Dawley rats subjected to an acute myocardial infarction by two subcutaneous injections of isoproterenol and autopsied at regular intervals during Days 1 and 2 while myocardial necrosis is on going on Day 3 when myocardial necrosis reaches a zenith and on Day 8 when myocardial repair is essentially complete. Each point depicted represents the Mean \pm Standard Error $n = 24$ for each of the control groups $n = 6$ for each of the experimental groups. The same protocol was followed in Figs 2 through 7




Fig 2 Changes in serum creatine phosphokinase (CPK)

chardes PAS stain for glycoprotein von Kossa stain for calcium Verhoeff van Gieson stain for elastic tissue and frozen sections cut at 10 μ m were stained with Sudan black B for lipids

The data was evaluated statistically by analysis of variance and Student's *t* test according to the statistical methods and tables cited by Snedecor

Results

General observations Young and old male rats subjected to an isoproterenol induced myocardial infarction exhibited the characteristic sequence of readily observable changes and signs of shock which have been described in detail. Within minutes of receiving the isoproterenol young and old rats exhibited tachycardia dyspnea anuria and prostration

Survival Four hours after the first injection of isoproterenol all of the young males survived

Snedecor G W. *Statistical Methods*, 6th ed. Cedar Falls, Iowa, 1967: Iowa State College Press.

while 81 per cent of the old males survived. Twenty four hours later 86 per cent of the young and 76 per cent of the old animals remained alive

On Day 2 the same syndrome of anuria and prostration observed on Day 1 was promptly re-established after the administration of isoproterenol. All of the young males survived while only 60 per cent of the old males survived. By Day 3 however survival of the old males increased to 83 per cent despite the fact that myocardial infarction was most severe on this day. By Day 8 when both gross and histopathologic evidence indicated that the myocardium had undergone repair survival of old males had increased to 100 per cent

Gravimetric observations

Changes in heart weight The average body weight of the 15 month old males ranged from 150 to 200 grams more than their young male counterparts and concomitantly their hearts were substantially heavier than the young rats. The absolute weight (as well as the ratio of heart weight to body weight) of both the young and old rats increased appreciably within 4 hours after the first injection of isoproterenol. The heart weights of the young and old rats continued to

Myocardial infarction in young vs old male rats Pathophysiologic changes

Bernard C Wexler, Ph D

Cincinnati Ohio

For several years, we have been investigating the induction of acute myocardial infarction in rats by means of the potent beta adrenergic stimulating agent, isoproterenol.¹⁻⁴ The pathophysiologic changes in these animals during the acute phases of myocardial necrosis and repair mimic those which occur in patients, e.g., changes in serum enzymes, lipids, catecholamines, steroids, etc. In earlier investigations we had also demonstrated definite electrocardiographic evidence of myocardial ischemia in isoproterenol treated rats.⁵ By regulating the dose of isoproterenol, we can induce a myocardial infarct of equal size and severity in young and old rats. In this report we describe the salient pathophysiologic differences between young and old rats during acute myocardial infarction.

Materials and methods

A total of 400 adult male Sprague Dawley rats were used in these investigations: 200 young males, 90 days of age, weighing 310 to 350 grams, and 200 old males, 15 months of age, weighing 500 to 580 grams.⁶ Both young and old rats were injected subcutaneously with isoproterenol at a dose level of 50 mg per 100 grams of body weight (Day 1). A representative number of animals were killed 4, 8, 12 and 24 hours after the first injection.

From the May Institute for Medical Research of the Jewish Hospital of Cincinnati, Ohio and the Departments of Medicine and Pathology, University of Cincinnati College of Medicine, Cincinnati.

Supported in part by grants from the Southwestern Ohio Heart Association, the National Institute on Aging (AG 58-1) and the National Heart, Lung and Blood Institute (HL-21418). N.I.H.

Received for publication Oct. 10, 1977.

Accepted for publication Nov. 7, 1977.

Reprint requests: Dr. B. C. Wexler, May Institute for Medical Research, 421 Ridgeway Ave., Cincinnati, Ohio 45229.

The authors wish to express their gratitude to Mr. Charles E. Rast, General Manager, ARS/Sprague Dawley, Madison, Wisc., for graciously providing the old male rats used in this investigation.

Tion. On the following day (Day 2), the second injection of isoproterenol (same dose) was given and animals were killed 4, 8, 12, and 24 hours later. On Day 3, 24 hours after the second injection of isoproterenol had been given and when myocardial necrosis reaches a zenith, two additional groups of young and old rats were killed. On the eighth day after the first injection of isoproterenol (Day 8) when myocardial repair is usually completed, the remaining young and old isoproterenol treated rats were killed. Two groups of young and old rats (injected with 0.9 per cent saline) served as baseline controls. The sequential temporal autopsies provided us with a dynamic analysis of the pathophysiologic changes that occur in young vs old rats during acute myocardial infarction.

Blood was withdrawn from the abdominal aorta of each animal by means of a heparinized syringe. Plasma was separated by refrigerated centrifugation and analyzed by automated methods in our Auto Analyzer (Technicon) for creatine phosphokinase (CPK), transaminases (SGOT, SGPT), lactic dehydrogenase (LDH), triglycerides, free fatty acids, total cholesterol, glucose and blood urea nitrogen (BUN).⁷ Circulating corticosterone (Compound B) levels were measured by the fluorometric method of Guillemain and associates⁸ as an index of adrenal secretory activity. Total myocardial hexosamine as an index of cardiac mucopolysaccharide content was analyzed by the method of Boas.⁹

For histopathologic analyses, organs and tissues were embedded in paraffin, sectioned at 3 μ m and stained with Hematoxylin and Eosin for routine examination. Hale stain for mucopolysac-

All of these automated procedures are detailed in the manual published by the Technicon Co., Automation in analytical chemistry, Technicon Medical Inc., New York.




Fig 1 Changes in adrenal and thymus gland weight of young and old, Sprague Dawley rats subjected to an acute myocardial infarction by two subcutaneous injections of isoproterenol and autopsied at regular intervals during Days 1 and 2 while myocardial necrosis is on going on Day 3 when myocardial necrosis reaches a zenith, and on Day 8 when myocardial repair is essentially complete. Each point depicted represents the Mean \pm Standard Error $n = 24$ for each of the control groups $n = 6$ for each of the experimental groups. The same protocol was followed in Figs 2 through 7.




Fig 2 Changes in serum creatine phosphokinase (CPK)

chandes PAS stain for glycoprotein von Kossa stain for calcium Verhoeff van Gieson stain for elastic tissue and frozen sections cut at 10 μ m were stained with Sudan black B for lipids.

The data was evaluated statistically by analysis of variance and Student's *t* test according to the statistical methods and tables cited by Snedecor.*

Results

General observations Young and old male rats subjected to an isoproterenol induced myocardial infarction exhibited the characteristic sequence of readily observable changes and signs of shock which have been described in detail. Within minutes of receiving the isoproterenol young and old rats exhibited tachycardia dyspnea anuria and prostration.

Survival Four hours after the first injection of isoproterenol all of the young males survived

while 81 per cent of the old males survived. Twenty four hours later 86 per cent of the young and 76 per cent of the old animals remained alive.

On Day 2 the same syndrome of anuria and prostration observed on Day 1 was promptly re-established after the administration of isoproterenol. All of the young males survived while only 60 per cent of the old males survived. By Day 3 however survival of the old males increased to 83 per cent despite the fact that myocardial infarction was most severe on this day. By Day 8 when both gross and histopathologic evidence indicated that the myocardium had undergone repair survival of old males had increased to 100 per cent.

Gravimetric observations

Changes in heart weight The average body weight of the 15 month old males ranged from 150 to 200 grams more than their young male counterparts and concomitantly their hearts were substantially heavier than the young rats. The absolute weight (as well as the ratio of heart weight to body weight) of both the young and old rats increased appreciably within 4 hours after the first injection of isoproterenol. The heart weights of the young and old rats continued to

Snedecor G W Statistical methods, 6th ed., Cedar Falls Iowa, 1967 Iowa State College Press.




Fig 3 Changes in serum glutamic oxaloacetic transaminase (SGOT)

rise on Day 1. On Day 2 when cardiac necrosis and interstitial edema become manifest, the hearts of both the young and old rats continued to show a dynamic increase in weight; the young rats exhibited the most sustained and greatest increase in absolute weight ($p < 0.001$). After 8 days, although gross and histopathologic evidence indicated that the heart damage was repaired, the absolute heart weight of the young and old rats remained above normal. The dynamic changes in heart weight in young vs old rats are essentially identical to those already described in this journal.⁸

Changes in adrenal and thymus gland weights
The weight of the adrenal and thymus glands also underwent dynamic changes. Both the young and old rats manifested an acute increase in adrenal size on Day 1 and an even greater increase on Day 2, remaining enlarged throughout the period of acute myocardial infarction and repair (Fig 1). Analysis of variance demonstrated a statistically significant over all greater increase in the adrenal weight of the old rats. Despite the stress of acute myocardial infarction initially, the thymus glands of the young rats increased in size and weight and then became progressively involuted (Fig 1) concomitant with increased adrenal size and increased adrenocortical activity (see below).




Fig 4 Changes in serum glutamic pyruvic transaminase (SGPT)

The thymus glands of the old rats which were naturally involuted at the outset, manifested none of the dynamic changes exhibited by their young counterparts (Fig 1).

Kidney weight
The kidneys of the old rats were considerably heavier than the young rats, i.e., 1.685 ± 12 mg vs 1.227 ± 8 mg. Despite initial anuria (Days 1 and 2) followed by copious diuresis (Days 3 to 5), there were no dynamic or statistically significant changes in the weight of the kidneys of either the young or old rats.

Congestive heart failure
Using hydrothorax, i.e., amount of fluid aspirated from the chest cage as an index of the severity of congestive heart failure, we found that the old animals manifested much more severe failure than the young animals, e.g., an average of 4 cc of chest fluid in young rats vs 8 cc in old rats. The old rats manifested persistent anuria and 1 to 2 cc of chest fluid until Day 8, after which the anuria and hydrothorax were subsequently relieved; young rats began to diurese copiously on Day 3 with virtually complete clearance of chest fluid by Day 5.

Blood chemistry

Enzymes

Creatine phosphokinase (CPK)
During the acute necrosis phase, CPK levels rose steeply to a

peak level in both young and old rats as early as 4 hours after the first injection of isoproterenol and then promptly declined almost to normal levels (Fig 2) Following the second injection of isoproterenol CPK levels rose again in the old but not in the young rats CPK levels were normal throughout the myocardial repair phase 1e Days 3 to 8 (Fig 2)

Glutamic oxaloacetic transaminase (SGOT) SGOT levels rose markedly in both the young and old rats during the acute necrosis phase of myocardial infarction (Fig 3) The young rats exhibited a steeper rise and higher levels than their older counterparts returning to normal levels during the repair phase

Glutamic pyruvic transaminase (SGPT) SGPT levels rose steeply and significantly ($p < 0.001$) in the young rats during the acute stages of cardiac necrosis and returned to normal during the myocardial repair phase (Fig 4) The older rats exhibited much less SGPT activity during this same period (Fig 4)

Lactic dehydrogenase (LDH) Young and old rats displayed an acute and marked increase in LDH LDH reached a zenith in young males 4 to 12 hours after the first injection of isoproterenol then decreased only to rise again after the second injection of isoproterenol LDH levels remained elevated in the older rats on Days 1 and 2 (Fig 5) LDH levels returned to normal in the young and old during the repair phase (Days 4 through 8)

Lipids

Triglycerides Changes in serum triglyceride levels occurred in opposite directions in young vs old rats (Table I) After a delayed rise young rats displayed elevated levels of serum triglycerides during the acute stages of cardiac necrosis and repair (Days 3 to 8) after an acute rise triglyceride levels progressively decreased in old rats during this same period (Table I)

Free fatty acids Free fatty acids became acutely elevated in both young and old rats much more so in the young rats (Table I) However the free fatty acid levels in the young rats promptly returned to normal and remained so throughout the experiment whereas the free fatty acid levels in the old rats remained well above normal ($p < 0.001$) (Table I)

Total cholesterol Prior to treatment the older rats had considerably higher ($p < 0.001$) blood cholesterol levels than their young brothers (Table I) Circulating cholesterol levels rose in




Fig 5 Changes in serum lactic dehydrogenase (SLDH)

both young and old rats on Day 1 remained slightly elevated in the young rats but were reduced to subnormal levels in the old rats ($p < 0.001$)

Glucose Acute and transitory hyperglycemia occurred in both the young and old rats 1e on Day 1 in the old and Day 2 in the young (Table I)

Blood urea nitrogen (BUN) The young animals showed an abrupt increase in BUN levels during the acute myocardial necrosis phase on Days 1 and 2 (Table I) The old rats which had elevated BUN levels at the outset manifested a greater increase in their BUN levels in response to the stress of acute myocardial necrosis (Table I)

Adrenal steroids

Corticosterone (Compound B) Prior to treatment the Compound B levels of the old rats were double those of the young rats During the first day of acute myocardial necrosis the old rats showed only a slight increase in circulating Compound B levels returning to normal levels for the duration of the experiment (Fig 6) The young animals manifested an initial drop in circulating Compound B levels (Day 1) followed by a progressive and super normal increase in Compound B levels (Day 2) ($p < 0.001$) reaching a

Table 1 Changes in serum lipids, glucose and blood urea nitrogen in young vs old male Sprague Dawley rats during the acute necrosis and repair phases of an isoproterenol induced myocardial infarction

	Triglyc (mg %)	Free fatty acids mEq / L	Total chol (mg %)	Glucose (mg %)	BUN (mg %)
<i>Young rats</i>					
Controls	59 ± 4 (12)	538 ± 85 (10)	39 ± 5 (11)	165 ± 8 (11)	23 ± 0.6 (11)
Day 1 Isoproterenol 1st inj					
4 hours later	52 ± 4 (5)	1097 ± 105* (6)	40 ± 5 (5)	157 ± 6 (5)	27 ± 6.8 (5)
8 hours later	58 ± 7 (6)	423 ± 49 (5)	47 ± 5 (6)	155 ± 7 (6)	36 ± 4.8 (6)
12 hours later	87 ± 6* (5)	528 ± 35 (5)	77 ± 5* (5)	138 ± 10** (5)	31 ± 4.8 (5)
24 hours later	132 ± 3* (6)	506 ± 30 (6)	60 ± 3** (6)	143 ± 5** (6)	34 ± 5.6 (6)
Day 2 Isoproterenol 2nd inj					
4 hours later	117 ± 9* (5)	611 ± 41 (5)	62 ± 3 (5)	295 ± 21* (6)	27 ± 2.3 (6)
8 hours later	115 ± 10 (6)	611 ± 50 (6)	55 ± 6 (6)	233 ± 36 (6)	31 ± 4.7* (6)
12 hours later	85 ± 5* (5)	377 ± 42* (5)	50 ± 4 (5)	149 ± 5** (5)	37 ± 2.8 (5)
24 hours later	120 ± 7* (6)	470 ± 38 (6)	77 ± 8* (6)	148 ± 6* (6)	33 ± 6.3** (6)
Day 3	102 ± 8* (6)	294 ± 42 (6)	56 ± 4 (6)	134 ± 3* (6)	21 ± 1.0 (6)
Day 6	77 ± 8 (6)	338 ± 21* (6)	43 ± 5 (6)	156 ± 5 (6)	22 ± 0.9 (6)
<i>Old Rats</i>					
Controls	136 ± 16 (12)	199 ± 12 (12)	109 ± 11 (11)	149 ± 7 (12)	27 ± 3.1 (11)
Day 1 Isoproterenol 1st inj					
4 hours later	195 ± 25 (6)	549 ± 69 (6)	96 ± 16 (6)	212 ± 15 (6)	27 ± 0.5 (6)
8 hours later	162 ± 24* (6)	419 ± 57 (6)	115 ± 14 (6)	209 ± 15 (6)	27 ± 1.0 (6)
12 hours later	127 ± 16 (5)	410 ± 38 (5)	133 ± 21 (5)	139 ± 6 (5)	37 ± 5.4 (5)
24 hours later	118 ± 14 (6)	433 ± 39* (6)	132 ± 22 (6)	121 ± 8 (6)	37 ± 10.0 (6)
Day 2 Isoproterenol 2nd inj					
4 hours later	76 ± 6 (5)	402 ± 29* (6)	138 ± 16 (6)	134 ± 6 (6)	43 ± 8.5 (6)
8 hours later	59 ± 4 (6)	435 ± 35 (6)	92 ± 9 (6)	148 ± 11 (6)	24 ± 3.0 (6)
12 hours later	50 ± 3 (6)	556 ± 31 (6)	102 ± 11 (6)	132 ± 4 (6)	24 ± 4.8 (6)
24 hours later	62 ± 5 (6)	536 ± 26* (6)	102 ± 3 (6)	121 ± 4 (6)	23 ± 1.6 (6)
Day 3	62 ± 8 (5)	376 ± 25 (5)	59 ± 11 (5)	123 ± 5 (5)	25 ± 0.8 (5)
Day 6	74 ± 12 (6)	206 ± 14 (6)	83 ± 7 (6)	135 ± 6 (6)	26 ± 1.0 (6)

* p < 0.001 ** p < 0.05

Mean ± Standard error (n) = number of samples.




Fig 6 Changes in circulating corticosterone (Compd B)

peak on Day 3 when cardiac necrosis was most advanced receding daily but remaining well above normal until the close of the experiment (Fig 6)

Myocardial glycosaminoglycans

Total hexosamine Measurement of total hexosamine is a good index of the dynamic ground substance changes which occur in the heart during the acute stages of necrosis and repair. Myocardial hexosamine levels in both the young and old rats rose in parallel, reached a peak on Day 2 when myocardial necrosis was becoming established and remained elevated despite resolution of cardiac damage by Day 8 (Fig 7)

Gross and histopathologic observations On gross inspection the hearts of the old vs young rats appeared to have myocardial infarcts of equal severity i.e. confluent areas of myocardial necrosis involving the apex left ventricle and occasionally the right ventricle. All of the animals displayed grossly visible fatty livers without any discernible differences between old and young rats. In addition to the greater increase in weight the adrenal glands of the old rats were markedly more hemorrhagic than those of the young rats and concomitantly the adrenal glands of the old




Fig 7 Changes in total myocardial hexosamine

rats displayed much more extensive cortical lipid depletion. The thymus glands of the young rats which became significantly enlarged on Day 1 were cystic and gelatinous (gross) and contained considerable colloid (histologically). There were striking differences in the myocardial histopathology between young vs old rats. On Day 3 when isoproterenol induced myocardial necrosis reached a maximum the hearts of the young rats manifested extensive white blood cell infiltration and large areas of through and through necrosis (Fig 8) whereas the old rats manifested much less white blood cell infiltration but much greater interstitial edema and ground substance accumulation (Fig 9). On Days 4 through 8 when the process of myocardial repair was on going the hearts of the young rats exhibited persistent white blood cell infiltration and active fibrosis (Fig 10) whereas the hearts of the old rats manifested complete clearance of white blood cells but persistence of the myocardial edema and extra ground substance (Fig 11). By Day 8 when myocardial repair was essentially complete the hearts of the young rats showed virtually total resolution of the earlier extensive damage but persistent fibrosis which was limited to the endo

Table 1 Changes in serum lipids, glucose and blood urea nitrogen in young vs old male Sprague Dawley rats during the acute necrosis and repair phases of an isoproterenol induced myocardial infarction

	Triglyc (mg %)	Free fatty acids mEq /L	Total chol (mg %)	Glucose (mg %)	BUN (mg %)
Young rats					
Controls	59 ± 4 (12)	538 ± 85 (10)	39 ± 5 (11)	165 ± 8 (11)	23 ± 0.6 (11)
Day 1 Isoproterenol 1st inj					
4 hours later	52 ± 4 (5)	1097 ± 105 (6)	40 ± 6 (5)	157 ± 6 (5)	27 ± 6.8 (5)
8 hours later	58 ± 7 (6)	423 ± 49 (5)	47 ± 5 (6)	155 ± 7 (6)	36 ± 4.8 (6)
12 hours later	87 ± 6** (5)	528 ± 35 (5)	77 ± 5* (5)	138 ± 10* (5)	31 ± 4.8 (5)
24 hours later	132 ± 3 (6)	506 ± 30 (6)	60 ± 3** (6)	143 ± 5* (6)	34 ± 5.6 (6)
Day 2 Isoproterenol 2nd inj					
4 hours later	117 ± 9* (5)	611 ± 41* (5)	62 ± 3* (5)	295 ± 21* (6)	27 ± 2.3 (6)
8 hours later	115 ± 10* (6)	611 ± 50* (6)	55 ± 3 (6)	253 ± 36* (6)	31 ± 4.7* (6)
12 hours later	95 ± 5 (5)	377 ± 42 (5)	50 ± 4 (5)	149 ± 11* (5)	37 ± 2.8* (5)
24 hours later	120 ± 7* (6)	470 ± 38 (6)	77 ± 8* (6)	148 ± 6** (6)	33 ± 6.3** (6)
Day 3	102 ± 8* (6)	294 ± 42* (6)	56 ± 4 (6)	134 ± 3* (6)	21 ± 1.0 (6)
Day 8	77 ± 8 (6)	338 ± 21 (6)	43 ± 5 (6)	156 ± 5 (6)	22 ± 0.9 (6)
Old Rats					
Controls	136 ± 16 (12)	199 ± 12 (12)	109 ± 11 (11)	149 ± 7 (12)	27 ± 3.1 (11)
Day 1 Isoproterenol 1st inj					
4 hours later	195 ± 25* (6)	549 ± 69 (6)	96 ± 16 (6)	212 ± 15 (6)	27 ± 0.5 (6)
8 hours later	162 ± 24 (6)	419 ± 57 (6)	115 ± 14 (6)	209 ± 15 (6)	27 ± 1.0 (6)
12 hours later	127 ± 16 (6)	410 ± 38 (5)	133 ± 21 (5)	139 ± 11 (5)	37 ± 5.4 (5)
24 hours later	118 ± 14 (6)	433 ± 39 (6)	132 ± 22 (6)	121 ± 8 (6)	37 ± 10.0 (6)
Day 2 Isoproterenol 2nd inj					
4 hours later	76 ± 6 (5)	402 ± 29 (6)	138 ± 16 (6)	134 ± 6 (6)	43 ± 8.5 (6)
8 hours later	59 ± 4 (6)	455 ± 35 (6)	92 ± 11 (6)	148 ± 11 (6)	24 ± 3.0 (6)
12 hours later	50 ± 3 (6)	556 ± 31 (6)	102 ± 9 (6)	132 ± 4 (6)	24 ± 4.8 (6)
24 hours later	62 ± 5 (6)	536 ± 26 (6)	102 ± 3 (6)	121 ± 4 (6)	23 ± 1.6 (6)
Day 3	62 ± 8 (5)	376 ± 25 (5)	59 ± 11 (5)	123 ± 5 (5)	25 ± 0.8 (5)
Day 8	74 ± 12 (6)	206 ± 11 (6)	83 ± 7 (6)	135 ± 6 (6)	26 ± 1.0 (6)

* p < 0.001 ** p < 0.05
Mean ± Standard error (n) = number of samples.



Fig 10 Heart of a young rat on Day 6 when myocardial repair has commenced. White blood cells persist and there is intense fibroplasia (Hematoxylin and eosin original magnification $\times 125$)



Fig 11 Myocardium of an old rat on Day 6. The intermuscular spaces persist, there are few white blood cells and no active fibrosis. accumulations of edema and ground substance are still present (Hematoxylin and eosin original magnification $\times 135$)

second injection of isoproterenol (Day 2) when the process of myocardial necrosis is acutely activated. Paradoxically the survival rate of the old rats improved on Day 3 when the necrosis activated 24 hours earlier by the second injection of isoproterenol reaches a zenith. The explanation for this paradox may be that once necrosis is fully established the chances for arrhythmia become less. Apparently acute myocardial necrosis is more lethal in old than in young rats. It should be emphasized that although the area of

myocardium infarcted appeared to be equal in the young and old rats, the older rats received a larger total dose of isoproterenol because they were considerably heavier than their younger counterparts. We¹⁸ and others^{14, 17} have found that the cardiac stimulating effect of isoproterenol is related to body weight, i.e. much greater myocardial necrosis is produced by isoproterenol in heavy vs light rats. The half life and cardiac stimulating effect of catecholamines is prolonged by temporary sequestration in adipose tissue.



Fig 8 Left ventricle of a young male Sprague Dawley rat illustrating the extensive necrosis which reaches a zenith on the third day of an isoproterenol induced myocardial infarct (Hematoxylin and eosin original magnification $\times 125$)




Fig 9 Myocardium of an older rat showing the extensive intermuscular spaces which appear on Days 2 and 3 of a drug induced infarct. These spaces are filled with edema and stain very positively for mucopolysaccharide. Note the relative absence of white blood cells which are conspicuous in the younger rats (Hematoxylin and eosin original magnification $\times 75$)

cardium (Fig 12). By direct contrast, the old rats displayed no endocardial fibrosis but persistence of the intramyocardial pools of edema and extraground substance (Fig 13).

Discussion

Our findings demonstrate that the pathophysiologic changes which attend acute myocardial infarction and repair are different in old vs young rats. This is in keeping with the general clinical

experience that the pathophysiologic course of a myocardial infarct is different in young vs old patients.¹¹⁻¹³ Despite the dose regulated induction of myocardial infarcts of equal size (gross observation) and signs of shock and prostration of equal severity in young and old rats, the survival rate was distinctly different. Only a few young rats died but a considerable number of the old rats succumbed. Mortality among the old rats was particularly high immediately after the




Fig 10 Heart of a young rat on Day 6 when myocardial repair has commenced. White blood cells persist and there is intense fibroplasia (Hematoxylin and eosin, original magnification $\times 125$)



Fig 11 Myocardium of an old rat on Day 6. The intermuscular spaces persist; there are few white blood cells and no active fibrosis. accumulations of edema and ground substance are still present (Hematoxylin and eosin, original magnification $\times 135$)

second injection of isoproterenol (Day 2) when the process of myocardial necrosis is acutely activated. Paradoxically, the survival rate of the old rats improved on Day 3 when the necrosis activated 24 hours earlier by the second injection of isoproterenol reaches a zenith. The explanation for this paradox may be that once necrosis is fully established the chances for arrhythmia become less. Apparently acute myocardial necrosis is more lethal in old than in young rats. It should be emphasized that although the area of

myocardium infarcted appeared to be equal in the young and old rats, the older rats received a larger total dose of isoproterenol because they were considerably heavier than their younger counterparts. We⁸ and others¹¹ have found that the cardiac stimulating effect of isoproterenol is related to body weight, i.e. much greater myocardial necrosis is produced by isoproterenol in heavy vs light rats. The half life and cardiac stimulating effect of catecholamines is prolonged by temporary sequestration in adipose tissue




Fig 12 Heart of a young rat on Day 8 when myocardial damage is essentially resolved. There is little or no evidence of the extensive earlier damage in the myocardium proper. Persistent and extensive fibrosis is limited to the endocardium (Hematoxylin and eosin, original magnification $\times 125$).

Therefore, although the older rats received a larger total dose of isoproterenol, our main purpose which was to maintain the area and severity of myocardium infarcted as equal as possible between young vs old rats, appears to have been achieved.

Of particular interest are the specific pathophysiologic differences between the old rats and their younger brothers. For example, despite the greater accumulation of ground substance and edema in the old rats, their absolute heart weight did not increase as greatly as the hearts of the young rats. This difference in dynamic changes in heart weight has been a consistent observation in our comparison of the response of young vs old rats to acute myocardial infarction.⁸ Although the adrenal glands of the old rats were much larger than those of the younger rats and showed more intense hypertrophy, hemorrhage and lipid depletion, their circulating Compound B levels were much lower than young rats. This would suggest decreased steroidogenic capacity of the old rats during acute stress. The initial dynamic increase in thymus size and weight in the young rats concomitant with little or no adrenal glandular hyperplasia and reduced Compound B levels followed by supernormal levels of Compound B has been our consistent experience.¹¹ We believe that these pathophysiologic conditions are indicative of a temporary reduction in adrenal steroidogenesis in young rats which permits the unusual thymic hypertrophy. Further, we have evidence which suggests that during

the early stages of myocardial ischemia, glucocorticoid steroidogenesis is impaired, consistent with the hypotensive shock. At the same time, adrenal cholesterol steroid precursor material is actively being converted into mineralocorticoids, e.g., aldosterone. The potent sodium retaining activity of aldosterone would account for the concomitant anuria and congestive failure i.e. the observed hydrothorax condition. The subsequent thymus gland involution, adrenal glandular enlargement, and increased glucocorticoid, e.g., Compound B levels concomitant with lowered aldosterone levels, would account for the restoration of blood pressure, diuresis and relief of the hydrothorax condition. It would appear from the nature of the gravimetric and histopathologic changes of the adrenal and thymus glands of the old rats as well as their reduced Compound B levels that the old rats were unable to synthesize glucocorticoids as efficiently as the young rats. This could account for their higher mortality rate and more profound heart failure e.g., more severe and persistent hydrothorax.

The use of serum enzymes as an index of acute myocardial infarction is equally as reliable in experimental as well as in clinical application. Although both the young and old rats manifested a dynamic rise and fall in serum CPK, SGOT, SGPT and LDH levels it appeared that the young rats showed a much more vigorous increase in SGOT and SGPT levels whereas the old rats responded with more prolonged increases in CPK and LDH. Because of the disparate nature of




Fig 13 Heart of an old rat on Day 8 showing unresolved damage consisting of intermuscular spaces of edema and mucopolysaccharide accumulation and lack of fibroblastic repair there is no endocardial fibrosis in these old rats (cf Fig 12) (Hematoxylin and eosin original magnification $\times 125$)

these serum enzyme changes it can only be suggested that the temporal nature of the myocardial necrosis must be different between young and old rats. Similarly the dichotomous changes observed in circulating lipid levels between the young and old rats during acute myocardial infarction and repair also indicates a distinct difference in metabolic requirements between young vs old rats. Although the young and old rats exhibited dynamic hyperlipemia initially the free fatty acid levels remained elevated in the older rats whereas total cholesterol fell to subnormal levels. This rise and fall in circulating lipids is characteristic of rats subjected to an isoproterenol induced myocardial infarction. We believe that this dynamic lipid mobilizing effect is related to the energy requirements of the failing myocardium and is not due to isoproterenol *per se*. Further this acute mobilization of lipid during the myocardial ischemia and necrosis phases is concomitant with a transient fatty liver condition. That so much lipid is metabolized by the liver at this time of acute cardiac need that there is insufficient protein to transport the excess lipid from the liver to the failing myocardium leading to temporary stasis and the fatty liver condition. This fatty liver condition could also contribute to the excess circulating aldosterone and congestive heart failure which occurs at this time because of the impaired hepatic conjugation of adrenal steroids.

Although the Compound B levels of the older rats were double that of the younger rats prior to the induction of myocardial infarction it is apparent that their pituitary-adrenal axis was unable to respond as effectively as the young rats to the acute stress of myocardial infarction. I.e. very slight increase in Compound B levels in old vs a substantial increase in Compound B in young rats. We⁸ and others¹² have found the adrenocortical system becomes less responsive to stress with increasing age.

One of the most salient features of this investigation is the distinct difference in the histopathology of the myocardium between young vs old rats. Although the amount of damage in the hearts of young and old rats appeared to be equal by gross inspection histopathologic examination demonstrated a much greater and more persistent myocardial infiltration by white blood cells in the hearts of the young rats. The hearts of the old rats exhibited copious and persistent edema and ground substance i.e., mucopolysaccharides. This latter observation is in keeping with our present finding of much greater quantities of total myocardial hexosamine in the old rats and our previous findings of accumulation of myocardial mucopolysaccharide antecedent to myocardial repair.¹³ The marked endocardial fibrosis in the young rats vs little or no endocardial fibrosis in the old rats is remarkable and suggests that the degree of endocardial ischemia as a stimulus for fibroblastic activity was distinctly different

between young vs old rats or that ground substance metabolism and fibroplasia is fundamentally different between young and old rats

Summary

Young (90 days) and old (15 months) male, Sprague Dawley rats were subjected to an acute and massive myocardial infarct by giving them two injections of a large dose of isoproterenol. The animals were autopsied at sequential time intervals to ascertain the similarities or dissimilarities in the pathophysiologic events which attend acute myocardial infarction and repair in young vs old rats. Although the signs and severity of hypotensive shock appeared to be equal, mortality was higher in the old rats, especially during the acute necrosis phase. The older rats also manifested more severe and persistent congestive heart failure, i.e., hydrothorax. Serum enzymes (CPK, SGOT, SGPT and LDH) lipids (triglycerides, free fatty acids and cholesterol), glucose, and BUN levels manifested a dynamic rise and fall concomitant with the induced myocardial necrosis and repair phases with distinct differences in these metabolic changes between young and old rats. Despite initially higher circulating levels of corticosterone in the old vs young rats the older animals manifested little or no increase in circulating corticosterone levels during the acute stress of myocardial infarction. This apparent lack of adrenocortical responsiveness was accentuated by the concomitant finding of greatly hypertrophied, hemorrhagic and lipid depleted adrenal glands in the old rats vs a dynamic increase in circulating corticosterone levels and alterations in the weight of adrenal and thymus glands of the young rats. During the myocardial repair phase, the young rats manifested extensive endocardial fibrosis whereas the old rats displayed little or no endocardial fibrosis but copious and persistent myocardial edema and ground substance in keeping with their higher concentration of cardiac hexosamine. The pathophysiologic course of events which attends myocardial necrosis and repair is quite different in young vs old rats and may be related to the degree of responsiveness of the pituitary-adrenal axis which changes with age.

The author is indebted to D. Conatser, E. Domingo, W. Goodhue, G. Williamson and J. Wexler for their technical assistance and expertise.

REFERENCES

1. Wexler B C and Kittinger G W. Myocardial necrosis in rats: serum enzymes, adrenal steroid and histopathological alterations. *Circ Res* 13:159 1963.
2. Wexler B C and Kittinger G W. Steroids produced *in vitro* by adrenal glands of normal and arteriosclerotic rats during and after drug induced myocardial necrosis. *Circ Res* 16:322 1965.
3. Wexler B C, Kittinger G W and Judd J T. Responses to drug induced myocardial necrosis in rats with various degrees of arteriosclerosis. *Circ Res* 20:18 1967.
4. Saroff J and Wexler B C. Isoproterenol induced myocardial infarction in rats: distribution of corticosterone. *Circ Res* 27:1101 1970.
5. Wexler B C. Serum creatine phosphokinase activity following isoproterenol induced myocardial infarction in male and female rats with and without arteriosclerosis. *Am Heart J* 79:69 1970.
6. Wexler B C, Judd J T, Lutmer R F and Saroff J. Metabolic and histopathological consequences of a fatty liver during the acute stages of myocardial infarction in rats. *Br J Exp Pathol* 52:565 1971.
7. Wexler B C. Acute enzyme and metabolic changes in arteriosclerotic vs nonarteriosclerotic rats following isoproterenol induced myocardial infarction. *Angiology* 22:251 1971.
8. Wexler B C and Greenberg B P. Effect of exercise on myocardial infarction in young vs old male rats: electrocardiographic changes. *Am Heart J* 85:343 1974.
9. Cuileman R, Clavton G W, Lipscomb H S and Smith J D. Fluorometric measurement of rat plasma and adrenal corticosterone concentration. *J Lab Clin Med* 53:830 1959.
10. Boas N F. Method for the determination of hexamines in tissues. *J Biol Chem* 204:553 1953.
11. Wedgewood J. Heart failure in old age. *Postgrad Med* 52:179 1972.
12. Agress N S, Rosin E Y, Adolph R J and Fowler N O. Significance of chronic sinus bradycardia in elderly people. *Circulation* 46:924 1972.
13. Harris R and Piracha A R. Acute myocardial infarction in the aged: prognosis and management. *J Am Geriatr Soc* 18:893 1970.
14. Zeman F D and Rodstein M. Cardiac rupture complicating myocardial infarction in the aged. *Arch Intern Med* 105:431 1960.
15. Astrand P O. Human physical fitness with special reference to sex and age. *Physiol Rev* 36:307 1956.
16. Rona G, Chappel C I and Kahn D S. The significance of factors modifying the development of isoproterenol induced myocardial necrosis. *Am Heart J* 66:389 1963.
17. Balazs T, Sahasrabudhe M R and Grace H C. The influence of excess body fat on the cardiotoxicity of isoproterenol in rats. *Toxicol Appl Pharmacol* 4:613 1962.
18. Riegle G D. Chronic stress effects on adrenocortical responsiveness in young and aged rats. *Neuroendocrinology* 11:1 1973.
19. Judd J T and Wexler B C. Myocardial connective tissue metabolism in response to injury. I. Histologic and chemical studies of mucopolysaccharide and collagen in rats after isoproterenol induced infarction. *Circ Res* 25:201 1969.
20. Judd J T and Wexler B C. Myocardial connective tissue metabolism in response to injury. II. Investigation of the mucopolysaccharides involved in isoproterenol induced necrosis and repair in rat hearts. *Circ Res* 26:101 1970.

Effects of verapamil on ventricular rhythm during acute coronary occlusion

Joseph D Fondacaro Ph D
Jaok Han M D Ph D
Myung S Yoon M D
Albany New York

In the past several years verapamil has received considerable attention for use as an antiarrhythmic agent. It has been shown that verapamil prevents the development of ventricular fibrillation during coronary artery ligation in dogs. Zipes and associates demonstrated a slowing of the sinus node discharge rate and depression of A V conduction when verapamil was administered to dogs. They also showed that verapamil lengthened the effective and functional A V nodal refractory periods. Tse and Han recently reported that verapamil suppresses ouabain induced increase in automaticity in canine Purkinje fibers. Verapamil was shown to prolong PR interval without affecting the QRS or QT interval in patients with ischemic heart disease. Also in this report verapamil increased the degree of A V block and decreased ventricular rates in patients with atrial flutter or fibrillation. More recently this drug has been shown to suppress both accelerated idioventricular rhythm and repetitive ventricular response induced by digitalis in dogs.

The present study is designed to study the effects of verapamil on ventricular rhythm and some electrophysiologic parameters in the ischemic ventricle of dogs. The parameters to be

studied were selected as representing the mechanisms responsible for the genesis of ventricular arrhythmias during acute coronary occlusion.

Methods

Experiments were performed on mongrel dogs anesthetized by an intravenous injection of sodium pentobarbital (30 to 35 mg/Kg body weight). Under artificial respiration the chest was opened in the midline and the heart was cradled in the opened pericardium. A femoral artery was cannulated to record the arterial pressure and a femoral vein for administration of the drug. Complete A V block and the resultant idioventricular rhythm were produced in most dogs by destroying the bundle of His with an electrical cautery knife as previously described.¹ In experiments in which ventricular conduction time or fibrillation threshold was studied only the sinoatrial node was destroyed by crushing. For reversible coronary occlusion the left anterior descending artery was dissecting free for a few millimeters near its origin and an occluding snare was applied around the vessel. The artery was occluded about 5 minutes before each observation of specific parameters and the occlusion was released immediately following each observation. Verapamil was administered intravenously in a dose of 0.2 mg/Kg body weight over a period of about 2 minutes and 5 to 10 minutes were allowed for the drug to take effect before coronary occlusion.

The bipolar stimulating and recording electrodes were small steel hooks with an interelectrode distance of 2 to 3 mm. A pair of stimulating electrodes was attached to the anterior septal margin of the right ventricle just outside the area

From the Department of Medicine (Cardiology) Albany Medical College (Union University) and the Electrocardiography Laboratory Albany Medical Center Hospital, Albany, N.Y.
supported by Grant HL-18,966 from the National Institutes of Health, and a grant from the American Heart Association, New York Chapter.

Received for publication Oct 18, 1977

Accepted for publication Dec 9, 1977

Reprint requests: Jaok Han, M.D., Dept. of Medicine, Albany Medical College, Albany, N.Y. 12241.




Fig 1 Effect of verapamil on idioventricular rate during acute coronary occlusion See text

of expected ischemia. A pair of recording electrodes was attached to a site well within the area of expected ischemia at a distance of 50 mm from the site of stimulating electrodes. Lead II electrocardiograms and local electrograms of the potentially ischemic site were recorded photographically by an Electronics for Medicine recorder at a paper speed of 100 mm per second. The artifact of stimuli delivered to the stimulating electrodes was recorded on the Lead II electrocardiograms.

Patterns of basic and premature stimuli were programmed by using a variable interval generator. The output of the interval generator triggered a Tektronix pulse generator which delivered rectangular pulses of variable duration and intensity. These stimuli were also displayed on an oscilloscope and the intensity was determined by means of a Tektronix current probe amplifier. The basic and premature stimuli applied through the stimulating electrodes were 2 msec in duration and twice the diastolic threshold. Ventricular conduction time was measured using an oscilloscope on which sweep was triggered by the basic and premature stimuli and which displayed the stimulus artifact and the response at the recording electrodes. Conduction time between the sites of stimulation and recording could be determined directly from the oscilloscope screen.

Ventricular fibrillation threshold was determined by the method of Han.⁷ This was to apply a train of rapid square pulses across the vulnerable period following every twelfth basic ventricular response. The rapid pulses were 3 msec in duration and occurred at 10 msec intervals (100 per second). The train was started at 80 to 100 msec




Fig 2 Effect of verapamil on ventricular conduction time of basic and premature beats during acute coronary occlusion. The values are means \pm SE. See text.

after the basic response and its duration did not extend the absolute refractory period of the first premature response evoked by the train. The intensity of the rapid pulses was gradually increased until fibrillation resulted. The fibrillation threshold was then defined as the minimum current in milliamperes (mA) which induced fibrillation. Defibrillation was immediately accomplished by DC countershock and at least 15 minutes were allowed for recovery before the subsequent test was made.

Results

The effect of verapamil on idioventricular rate was studied in five dogs with complete A-V block during acute coronary occlusion. Fig 1 shows the results of a typical experiment in this series. Tracing A shows an idioventricular rate of 84 beats/minute during coronary occlusion before verapamil. Tracing B shows that the idioventricular rate is slowed to 48 beats/minute during coronary occlusion following pretreatment with verapamil. The mean value of idioventricular rate




Fig 3 A and B Effects of two successive ventricular premature beats on the postextrasystolic rhythm are shown on these Lead III electrocardiograms recorded during coronary occlusion (CO) before verapamil (A) and after verapamil (B) V = the last of a series of 12 basic beats V = first premature beats and V = second premature beats See text

in the five dogs was 968 ± 86 beats/minute before verapamil and it decreased significantly to 776 ± 50 beats/minute after administration of verapamil ($P < 0.05$)

Six separate experiments were performed to study the effect of verapamil on ventricular conduction time during coronary occlusion. Conduction time over a distance of 50 mm from the stimulating site to the recording site within the ischemic area was measured for the basic and earliest possible premature beats. Fig 2 shows the results of this series of experiments. The mean conduction time of basic beats during coronary occlusion was 88.0 ± 8.1 msec before verapamil and it was significantly reduced to 64.6 ± 2.8 msec after administration of the drug ($P < 0.03$). The mean conduction time of premature beats during coronary occlusion was 119.6 ± 13.2 msec before verapamil and it decreased significantly to 83.6 ± 6.0 msec after the drug ($P < 0.03$). The results indicate that verapamil is effective in improving conduction of basic and premature beats in the ischemic ventricular myocardium.

Fig 3 shows the typical changes in ventricular rhythm following the introduction of two closely coupled premature beats during acute coronary occlusion. In panel A before verapamil administration the ventricle was paced at a cycle length of 400 msec after the last of a series of 12 basic beats (V₁) the first premature beat (V₂) was introduced at the earliest possible V₁V₂ interval of

215 msec and the second premature beat (V₃) at variable V₂V₃ intervals. Ventricular pacing was then interrupted for about 1.5 seconds after the premature V₁ and V₂ to observe ventricular rhythm. As shown in the upper tracing three rapidly repetitive beats occurred following the premature V₂ induced at the earliest possible V₂V₃ interval of 170 msec. We have concluded from our earlier studies^{1,2} that these repetitive beats are most likely due to reentry resulting from depressed conduction in ischemic areas of the ventricle. In the lower tracing the premature V₁ with a longer V₂V₃ interval of 230 msec did not produce the rapidly repetitive beats but was followed by an idioventricular escape beat with an escape interval of 805 msec.

Panel B of Fig 3 depicts the same experiment as in panel A but after pretreatment with verapamil. As shown in the upper tracing rapidly repetitive beats could not be induced during coronary occlusion by the premature V₂ and V₃ of the same intervals as in panel A. In the lower tracing the escape interval of idioventricular beat following the premature V₂ was lengthened to 1090 msec. The results indicate that verapamil was effective in abolishing rapidly repetitive beats of the re-entrant mechanism and in increasing the escape interval of latent idioventricular pacemakers (or decreasing automaticity) during coronary occlusion.

The same experiment as illustrated in Fig 3




Fig 1 Effect of verapamil on idioventricular rate during acute coronary occlusion. See text

of expected ischemia. A pair of recording electrodes was attached to a site well within the area of expected ischemia at a distance of 50 mm from the site of stimulating electrodes. Lead II electrocardiograms and local electrograms of the potentially ischemic site were recorded photographically by an Electronics for Medicine recorder at a paper speed of 100 mm per second. The artifact of stimuli delivered to the stimulating electrodes was recorded on the Lead II electrocardiograms.

Patterns of basic and premature stimuli were programmed by using a variable interval generator. The output of the interval generator triggered a Tektronix pulse generator which delivered rectangular pulses of variable duration and intensity. These stimuli were also displayed on an oscilloscope and the intensity was determined by means of a Tektronix current probe amplifier. The basic and premature stimuli applied through the stimulating electrodes were 2 msec in duration and twice the diastolic threshold. Ventricular conduction time was measured using an oscilloscope on which sweep was triggered by the basic and premature stimuli and which displayed the stimulus artifact and the response at the recording electrodes. Conduction time between the sites of stimulation and recording could be determined directly from the oscilloscope screen.

Ventricular fibrillation threshold was determined by the method of Han.⁷ This was to apply a train of rapid square pulses across the vulnerable period following every twelfth basic ventricular response. The rapid pulses were 3 msec in duration and occurred at 10 msec intervals (100 per second). The train was started at 80 to 100 msec




Fig 2 Effect of verapamil on ventricular conduction time of basic and premature beats during acute coronary occlusion. The values are means \pm SE. See text

after the basic response and its duration did not extend the absolute refractory period of the first premature response evoked by the train. The intensity of the rapid pulses was gradually increased until fibrillation resulted. The fibrillation threshold was then defined as the minimum current in milliamperes (ma) which induced fibrillation. Defibrillation was immediately accomplished by DC countershock and at least 15 minutes were allowed for recovery before the subsequent test was made.

Results

The effect of verapamil on idioventricular rate was studied in five dogs with complete A-V block during acute coronary occlusion. Fig 1 shows the results of a typical experiment in this series. Tracing A shows an idioventricular rate of 84 beats/minute during coronary occlusion before verapamil. Tracing B shows that the idioventricular rate is slowed to 18 beats/minute during coronary occlusion following pretreatment with verapamil. The mean value of idioventricular rate

in decreasing idioventricular automaticity under conditions of myocardial ischemia. It has been previously demonstrated that idioventricular automaticity is increased during myocardial ischemia thus increasing the likelihood of ventricular arrhythmias.⁴ Verapamil clearly prevents this increase in automaticity and thereby reduces the probability that this mechanism could lead to cardiac arrhythmias.

Another concept proposed for the genesis of ventricular arrhythmias is the mechanism of reentry.⁵ Because of slowed conduction or unidirectional block through the ischemic area reentrant activity may be initiated in the ischemic ventricle resulting in ventricular premature beats. This may in turn set up a series of rapidly repetitive beats which degenerate into fibrillation. Verapamil abolished rapidly repetitive beats in all nine of the cases in which it occurred prior to drug administration (Table 1). In fact the repetitive beats and fibrillation were not observed at any time following verapamil in dogs thereby suggesting that verapamil reduces the possibility of reentrant activity. The suppression of ventricular automaticity and reentrant activity by verapamil as shown in this study support the findings of Foster and colleagues.⁶ However the arrhythmias in our study were produced by experimental coronary artery ligation as opposed to ouabain induced arrhythmias in the study cited.

One way in which verapamil may suppress the reentry mechanism is by altering myocardial conduction. If conduction of an impulse through an area of ischemia was improved by a drug potential unidirectional block would be eliminated. Conversely if slowed conduction was further delayed by this drug areas of bidirectional block could result. Both of these conditions would tend to break the reentrant pathway. From the studies presented here dealing with conduction time as measured through ischemic areas verapamil improved impulse conduction in all experiments (Fig. 2). These findings suggest that verapamil abolishes re-entrant activity by improving conduction through areas of potential unidirectional block and preventing the establishment of re-entrant pathways. Our results show that verapamil prevented the occurrence of tachyarrhythmias during coronary occlusion in all nine cases where it had occurred during

control occlusion prior to its administration. Ventricular tachyarrhythmias occurring soon after coronary occlusion such as in studies of the present design are thought to be due to reentry mechanisms rather than to increased automaticity. Because verapamil suppresses the reentry mechanism by improving myocardial conduction the incidence of arrhythmias was significantly reduced.

Han⁷ has reported that acute coronary artery ligation lowers ventricular fibrillation threshold thereby making the ventricle more vulnerable to fibrillation. In the present study, verapamil significantly increased ventricular fibrillation threshold during coronary occlusion (Fig. 4). This finding is also expected to decrease the likelihood of ventricular tachyarrhythmias during myocardial ischemia.

The mechanism of action of verapamil as inhibitor of the slow current (or slow response) has been well documented^{8,9} and the results of this study may be explained by this effect. Besides slowed conduction acute myocardial infarction causes increased levels of catecholamines locally and release of potassium ions from dead and dying cells. The increased levels of extracellular K⁺ could decrease the resting membrane potential of fibers in the ischemic zone and effectively prevent the normal action potential or fast response from occurring leaving only the slow response operable. Due to the presence of these partially depolarized fibers increased catecholamine levels and depressed conduction, a situation now exists in which arrhythmias can be initiated by both increased automaticity or reentry. These have been referred to as slow current dependent arrhythmias.¹⁰ Our results suggest that verapamil prevents the development of these slow current dependent arrhythmias by specifically inhibiting calcium current which is the major component of the slow current channel. This direct inhibition of the calcium current may account for some of our observations especially suppressed reentrant activity and decreased incidence of tachyarrhythmias. However, verapamil may also affect other ion fluxes either directly or indirectly as a result of its action on calcium. This perhaps may explain the improvement of myocardial conduction and the increase in ventricular fibrillation threshold that has been observed. This indirect effect may also explain




Fig 4 Comparison of ventricular fibrillation thresholds determined during acute coronary occlusion (C.O.) before and after verapamil administration. The values are means \pm SE. See text.

was carried out in 15 dogs and the results of these experiments are summarized in Table I. Rapidly repetitive beats were observed in nine dogs during coronary occlusion before verapamil, and the repetitive beats degenerated into ventricular fibrillation in seven dogs. Following pretreatment with verapamil, the repetitive beats and fibrillation were observed in none of the 15 dogs during coronary occlusion. Using the idioventricular escape interval as an index of automaticity, it can be seen that verapamil decreased idioventricular automaticity in 12 out of 15 dogs during acute coronary occlusion.

The effect of verapamil on ventricular fibrillation threshold was studied in eight dogs during coronary occlusion and the results are shown in Fig 4. The mean value of fibrillation threshold during coronary occlusion was 9.3 ± 1.5 ma

Table I Effects of verapamil on ventricular rhythm during acute coronary occlusion (15 experiments)

Occurrence of rapidly repetitive beats (re entry)		Occurrence of fibrillation		Change in automaticity
Before verapamil	After verapamil	Before verapamil	After verapamil	After verapamil
9/15	0/15	7/15	0/15	Decrease 12/15 No change 3/15

before verapamil, and it increased markedly to 29.5 ± 2.8 ma after verapamil administration ($P < 0.01$). Our previous studies^{1,2} showed that fibrillation threshold is significantly reduced in the ventricle during acute coronary occlusion. The present results indicate that verapamil is effective in reversing the effect of myocardial ischemia in lowering ventricular fibrillation threshold.

Discussion

Enhanced automaticity and re entry are two major mechanisms for the genesis of cardiac arrhythmias. The likelihood of these events occurring in the ventricle are markedly increased during coronary artery occlusion. Myocardial ischemia increases the electrophysiologic inhomogeneity of the ventricular myocardium and it is this increased inhomogeneity that most likely results in the abnormal electrical events which can lead to ventricular premature beats and fibrillation.³ This study attempts to demonstrate the effects of a new antiarrhythmic drug verapamil on electrophysiologic parameters in the ventricle during acute myocardial ischemia. In this way, the effects of this drug on important electrophysiologic parameters of myocardium such as automaticity and conduction could be determined and its efficacy as an antiarrhythmic agent can be evaluated.

In the present study verapamil clearly decreased idioventricular automaticity during acute coronary occlusion. Whether automaticity is measured as idioventricular rate (Fig 1) or in terms of idioventricular escape interval (Fig 3 and Table I) verapamil was consistently effective.

in decreasing idioventricular automaticity under conditions of myocardial ischemia. It has been previously demonstrated that idioventricular automaticity is increased during myocardial ischemia, thus increasing the likelihood of ventricular arrhythmias.⁸ Verapamil clearly prevents this increase in automaticity and thereby reduces the probability that this mechanism could lead to cardiac arrhythmias.

Another concept proposed for the genesis of ventricular arrhythmias is the mechanism of reentry.⁹ Because of slowed conduction or unidirectional block through the ischemic area, reentrant activity may be initiated in the ischemic ventricle, resulting in ventricular premature beats. This may in turn set up a series of rapidly repetitive beats which degenerate into fibrillation. Verapamil abolished rapidly repetitive beats in all nine of the cases in which it occurred prior to drug administration (Table I). In fact, the repetitive beats and fibrillation were not observed at any time following verapamil in dogs, thereby suggesting that verapamil reduces the possibility of reentrant activity. The suppression of ventricular automaticity and reentrant activity by verapamil as shown in this study support the findings of Foster and colleagues.⁸ However, the arrhythmias in our study were produced by experimental coronary artery ligation as opposed to ouabain-induced arrhythmias in the study cited.

One way in which verapamil may suppress the reentry mechanism is by altering myocardial conduction. If conduction of an impulse through an area of ischemia was improved by a drug, potential unidirectional block would be eliminated. Conversely, if slowed conduction was further delayed by this drug, areas of bidirectional block could result. Both of these conditions would tend to break the reentrant pathway. From the studies presented here dealing with conduction time as measured through ischemic areas, verapamil improved impulse conduction in all experiments (Fig. 2). These findings suggest that verapamil abolishes reentrant activity by improving conduction through areas of potential unidirectional block and preventing the establishment of re-entrant pathways. Our results show that verapamil prevented the occurrence of tachyarrhythmias during coronary occlusion in all nine cases where it had occurred during

control occlusion prior to its administration. Ventricular tachyarrhythmias occurring soon after coronary occlusion such as in studies of the present design are thought to be due to reentry mechanisms rather than to increased automaticity. Because verapamil suppresses the reentry mechanism by improving myocardial conduction, the incidence of arrhythmias was significantly reduced.

Han⁷ has reported that acute coronary artery ligation lowers ventricular fibrillation threshold, thereby making the ventricle more vulnerable to fibrillation. In the present study, verapamil significantly increased ventricular fibrillation threshold during coronary occlusion (Fig. 4). This finding is also expected to decrease the likelihood of ventricular tachyarrhythmias during myocardial ischemia.

The mechanism of action of verapamil as an inhibitor of the slow current (or slow response) has been well documented^{1-3, 10} and the results of this study may be explained by this effect. Besides slowed conduction, acute myocardial infarction causes increased levels of catecholamines locally and release of potassium ions from dead and dying cells. The increased levels of extracellular K^+ could decrease the resting membrane potential of fibers in the ischemic zone and effectively prevent the normal action potential or fast response from occurring, leaving only the slow response operable. Due to the presence of these partially depolarized fibers, increased catecholamine levels and depressed conduction, a situation now exists in which arrhythmias can be initiated by both increased automaticity or reentry. These have been referred to as slow current dependent arrhythmias.¹¹ Our results suggest that verapamil prevents the development of these slow current dependent arrhythmias by specifically inhibiting calcium current, which is the major component of the slow current channel. This direct inhibition of the calcium current may account for some of our observations, especially suppressed reentrant activity and decreased incidence of tachyarrhythmias. However, verapamil may also affect other ion fluxes either directly or indirectly as a result of its action on calcium. This perhaps may explain the improvement of myocardial conduction and the increase in ventricular fibrillation threshold that has been observed. This indirect effect may also explain

the slowing of idioventricular automaticity. Our preliminary microelectrode studies indeed show that verapamil decreases the slope of phase 4 spontaneous diastolic depolarization of canine Purkinje fibers.

There has been a recent report¹ stating that because of its specificity for calcium verapamil may adversely effect excitation-contraction coupling resulting in hemodynamic depression. However, considering our results and those of others and until such time as appropriate clinical trials are complete, verapamil must be considered as a potentially useful antiarrhythmic agent.

Summary

The effects of verapamil on electrophysiologic parameters of the ventricle were studied during acute coronary occlusion in anesthetized open chest dogs. Those parameters measured in the study were idioventricular automaticity, ventricular conduction, and fibrillation threshold. The incidence of rapidly repetitive beats and fibrillation induced by two successive premature beats was also studied. Verapamil significantly decreased idioventricular automaticity (in five dogs), improved conduction through the ischemic area (in six dogs), and increased fibrillation threshold of the ischemic ventricle (in eight dogs). The drug was effective in abolishing rapidly repetitive beats and fibrillation induced by closely coupled premature beats during acute coronary occlusion. Rapidly repetitive beats occurred in nine out of 15 dogs and these repetitive beats were degenerated into fibrillation in seven dogs before verapamil. Following pretreatment with the drug, rapidly repetitive beats and fibrillation occurred

in none of the 15 dogs. The results indicate that verapamil can be very effective against ventricular arrhythmias occurring in association with myocardial infarction.

The authors wish to thank Rosalyn Grote and Susan Jones for their technical assistance and Oksana Cnupka for the preparation of this manuscript.

REFERENCES

1. Kaumann A J and Aramendia P. Prevention of ventricular fibrillation induced by coronary ligation. *J Pharmacol Exp Ther* 164:326, 1968.
2. Zipes D P and Fischer J C. Effects of agents which inhibit the slow channel on sinus node automaticity and atrioventricular conduction in the dog. *Circ Res* 34:184, 1974.
3. Tee W W and Han J. Effects of manganese chloride and verapamil on automaticity of digitalized Purkinje fibers. *Am J Cardiol* 36:50, 1975.
4. Heng M K, Singh B N, Roche A H G, Norris H M and Mercer C J. Effects of intravenous verapamil on cardiac arrhythmias and on the electrocardiogram. *Am Heart J* 90:487, 1975.
5. Foster P R, King R M, Nicoll A DeB, and Zipes D P. Suppression of ouabain induced ventricular rhythms with aprindine HCl. *Circulation* 53:315, 1976.
6. Han J, Goel B G, Yoon M S, and Rogers R. Effects of procainamide and lidocaine on ventricular automaticity and re entry during acute coronary occlusion. *Am J Cardiol* 34:171, 1974.
7. Han J. Ventricular vulnerability during acute coronary occlusion. *Am J Cardiol* 24:857, 1969.
8. Han J. Mechanisms of ventricular arrhythmias associated with myocardial infarction. *Am J Cardiol* 24:800, 1969.
9. Han J, Goel B G, and Hanson C S. Re-entrant beats induced in the ventricle during coronary occlusion. *Am Heart J* 80:778, 1970.
10. Zipes D P, Besch H R, and Watanabe A M. Role of the slow current in cardiac electrophysiology. *Circulation* 51:761, 1975.
11. Cranefield P F, Wit A L, and Hoffman B F. Conduction of the cardiac impulse. III. Characteristics of very slow conduction. *J Gen Physiol* 59:227, 1972.
12. Weidman M. Heart Electrophysiology. *Ann Rev Physiol* 36:155, 1974.

Acute idiopathic pericarditis and calcific aortic stenosis unusual fatal disease combination

Charles W. Wheatley M.D.*

Ann Arbor, Mich

Acute idiopathic pericarditis with effusion is rarely fatal unless it complicates chronic myocardial disease. Acute epimyocarditis and the impedance to ventricular filling due to pericardial tamponade further decreases the low cardiac output due to primary myocardial valvular hypertensive or atherosclerotic heart disease. Treatment of acute pericarditis with effusion in the presence of chronic myocardial disease may be very difficult. This presentation of a fatal case illustrates these truths.

Case report

■ N, a 47-year-old white male Michigan National Guard, man worked 36 consecutive hours on May 11 and 12, 1973, despite shortness of breath to help his company prepare for weekend maneuvers. He was fatigued and febrile the following day. Dyspnea and cough productive of white frothy sputum developed after he walked 30 feet. His oral temperature rose to 103°F during the next 5 days. Dyspnea with cough at rest and a constant aching anterior chest pain which was aggravated by deep inspiration, chest wall movement and the supine position appeared. Tetracycline, penicillin and hydrochlorothiazide were prescribed because of basilar rales and precordial blowing aortic and apical diastolic murmurs. An electrocardiogram showed left ventricular enlargement. He was admitted to hospital on May 23, 1973.

An illness from which he recalled no symptoms forced his absence from school for 1 year at age 17. Inactive rheumatic heart disease with mitral stenosis was diagnosed at age 22 after a systolic murmur with a diastolic rumble was heard and cardiac fluoroscopy showed cardiac calcification. An electrocardiogram was normal at that time but tracings in 1971 showed left ventricular enlargement. In 1972 snow

shoveling caused chest fullness which disappeared with rest. Caught palpitations, mild shortness of breath and fever appeared in February 1973 but remitted after 3 days of bedrest. Dizziness or syncope never occurred although he intermittently performed strenuous work.

Admission physical examination showed a chronically ill, pale, mildly diaphoretic and moderately dyspneic white male with temporal muscle wasting who was unable to recline below 60 degrees due to aggravation of his chest pain and dyspnea. The blood pressure was 105/50-45 both arms sitting; temperature 99.8°F (oral); heart rate 90/minute; respiratory rate 22/minute. Neck venous distention at 60 degrees was minimal; venous waves paradoxical; pulse and Kussmaul's sign were absent in all positions. Bilateral harsh carotid and subclavian transmitted systolic murmurs were present. Carotid upstrokes were delayed but equal. Eye, ear, nose and throat examinations were normal. There were fine wet rales over the left lateral chest and bilateral basilar decreased vocal fremitus.

The left border of cardiac dullness was 15 cm beyond the midsternal line, 2 cm beyond the midclavicular line and the point of maximum impulse was diffuse in the sixth intercostal space. The heart sounds could not be heard at the base and were greatly reduced along the left sternal border and at the apex. Extra sounds were not heard. A regular rhythm at 68 beats per minute was present with occasional premature beats. A harsh crescendo-decrescendo systolic murmur at the base became more high pitched along the lower left sternal border and radiated to the apex, infraclavicular and interapical areas. A high pitched early and mid-diastolic decrescendo murmur was present along the left sternal border. A pericardial knock and continuous friction rub were heard at the third and fourth intercostal spaces, left sternal border and at the apex. A slightly tender liver with a total height of 14 cm was palpable 3 cm below the right costal margin but the spleen and kidneys were not palpable. Abdominal masses, bruits, and tenderness were absent. The dorsalis pedis pulses were diminished but the other peripheral pulses were bounding and equal. Peripheral edema, cyanosis, clubbing and skin or nail changes to suggest bacterial endocarditis were absent.

Elevation of leukocyte counts from 11,000 to 23,000/mm³ with left shift and toxic granulation suggested infection but repeat cultures of urine, stool, and blood for bacteria (including *M. tuberculosis*), fungi, yeasts, and viral agents were

From the University of Michigan Medical Center, Ann Arbor, Mich.

Received for publication May 20, 1977.

Accepted for publication July 28, 1977.

Reprint requests: C. W. Wheatley, M.D., Division of Cardiology (H-4), University of Michigan Medical Center, Ann Arbor, Mich. 48109.

Clinical Instructor in Internal Medicine, University of Michigan Medical Center.




Fig 1 ECG before pericardiectomy

negative Sputum cultures grew *Candida albicans* and *Klebsiella* species Hemoglobin 11 gm per cent plasma hemoglobin 36 mg per cent serum iron 37 μ g per cent total iron binding capacity 330 μ g per cent serum haptoglobin less than 20 units suggested hemolysis and iron deficiency Screening tests for thyroid and renal disease lupus erythematosus and rheumatoid arthritis were negative Immunoglobulin electrophoresis showed elevated IgA Abnormal enzyme values were serum amylase 135 units glutamic oxalacetic transaminase 147 to 202 units glutamic pyruvic transaminase 246 units lactic dehydrogenase 318 units with increased fast fractions 1 2 Serum total bilirubin was 2.8 mg per cent Electrocardiograms showed left atrial depolarization abnormality first degree atrioventricular block left ventricular enlargement and ST elevation suggestive of pericarditis (Fig 1) Admission chest x ray showed massive water bottle enlargement of the cardiac silhouette typical of pericardial effusion and mild venous congestive changes (Fig 2)

Right heart catheterization findings (Table I) showed greater elevation of pulmonary artery diastolic pressure than severely elevated right atrial and ventricular diastolic pressures which suggested that left ventricular failure was a major cause of the low cardiac output After CO₂ and dye contrast right atrial angiograms demonstrated a large pericardial effusion (Fig 3) pericardiocentesis yielded a sero sanguineous fluid The patient remained very weak anorectic and tachypneic despite this procedure and an 8 lb diuresis induced by digitalis and diuretics Pericardiectomy with removal of a large sanguineous effusion was performed

Pericardial fluid and tissue cultures were negative for all pathogens The oral temperature was 100.5° F at 4 P.M. for three consecutive days after surgery and then remained normal Dyspnea and orthopnea improved shortly after surgery but severe dyspneic episodes were precipitated later by activity such as use of bed pan Despite a 25 lb weight loss pulmonary congestion increased and bilateral fluffy infiltrates

were seen on chest x ray Pulmonary embolism could not be differentiated from edema by perfusion lung scan

Due to intractable congestive heart failure the patient was transferred to the University of Michigan Hospital on July 2 1973 for possible aortic valve replacement Admission physical examination confirmed previous findings and revealed an erythematous area over the hard palate and several vesicular lesions on the left buccal mucosa Urinary output and orthopnea improved after hyperalimentation which was discontinued after central venous pressure reached 22 cm H₂O He was treated for suspected septicemia with penicillin G 10 million units daily and streptomycin 10 Gm daily Thirteen days after admission the diastolic blood pressure dropped to 30 mm Hg and short episodes of substernal pressure like chest pain occurred

Left heart catheterization (Table I) showed mild mitral insufficiency 65 mm Hg gradient across a heavily calcified aortic valve and a hypertrophic moderately hypokinetic left ventricle The severely calcified stenotic aortic valve was replaced with a Starr Edwards ball prosthesis but primary closure of the aorta was unsuccessful and a Dacron prosthetic graft was used to replace the ascending aorta Pulmonary edema developed during parallel cardiopulmonary bypass Return to full bypass and furosemide did not produce diuresis ventricular fibrillation developed and defibrillation was unsuccessful

Tissue findings

A Surgical The pericardium was 4 cm thick Soft brown papillary excrescences were seen Microscopic sections showed marked fibrosis and scattered inflammatory infiltrate composed mostly of lymphocytes with fibrin attached to one surface

B Autopsy (Limited to thorax with transdiaphragmatic liver biopsy) Chronic calcific aortic valvulitis Normal mitral valve Fibrous epicarditis and myocarditis (Fig 4) Biventricular myocardial hypertrophy (Fig 5) with focal fibrosis



Fig 2 Admission chest x ray before pericardiectomy

and necrosis of myocardium and absence of inflammatory interstitial infiltrate. Pulmonary edema and pulmonary arterial embolus. Chronic passive congestion of liver with central lobular necrosis and fatty infiltration. Granulomatous mediastinal lymphadenopathy.

Discussion

Acute idiopathic pericarditis is usually benign although frequently recurrent. This is not true if other chronic myocardial disease is present. Liu and Garcia¹¹ review¹ of the literature to 1965 reported 12 fatal cases of acute idiopathic pericarditis. Cardiac tamponade was thought to be the cause of death in five but severe chronic myocardial disease was present in six others. Aortic stenosis with myocardial hypertrophy was present in one of these six cases. An additional fatal case of idiopathic pericarditis complicating calcareous aortic stenosis and cardiac hypertrophy was reported by Kirschner and associates² in 1971. Their patient also had acute subendocardial (zonal) infarction without extension to the outer one-half of the myocardium. Search of the English literature since 1965 did not reveal additional cases of this fatal combination of diseases.

Before the advent of CO and dye contrast



Fig 3 CO right atrial angiogram. Large pericardial effusion separates CO in right atrium and right heart border.

Table 1 Catheterization findings

Site	Before pericardiectomy pressure (mm Hg)	After pericardiectomy pressure (mm Hg)
1 Right atrium	40/30 Mean = 30	Mean = 18
2 Right ventricle	100/20 RVED = 30	80/10 RVED = 20
3 Main pulmonary artery	110/65 Mean = 70	100/30 Mean = 45
4 Left pulmonary artery wedge	—	25
5 Brachial artery	—	150/40
6 Ascending aorta	—	85/40
7 Left ventricle	—	150/10 LVED = 28

angiography and echocardiography the diagnosis of pericardial effusion in the presence of other cause for the enlargement of the heart was often made at autopsy.¹ When two diseases that affect myocardial function are known to be present determination of the degree that each disease contributes to the low cardiac output may be extremely difficult.^{1,4} The contribution that acute epimyocarditis makes to myocardial dysfunction is speculative although myocardial biopsy may have demonstrated myocarditis. Pericardial effusion with or without tamponade may mask the changes on physical examination that




Fig 1 ECG before pericardiectomy

negative Sputum cultures grew *Candida albicans* and *Klebsiella* species Hemoglobin 11 gm per cent plasma hemoglobin 3.6 mg per cent serum iron 37 μ g per cent total iron binding capacity 330 μ g per cent serum haptoglobin less than 20 units suggested hemolysis and iron deficiency Screening tests for thyroid and renal disease lupus erythematosus and rheumatoid arthritis were negative Immunoglobulin electrophoresis showed elevated IgA Abnormal enzyme values were serum amylase 135 units glutamic oxalacetic transaminase 147 to 202 units glutamic pyruvic transaminase 246 units lactic dehydrogenase 318 units with increased fast fractions 1.2 Serum total bilirubin was 2.8 mg per cent Electrocardiogram showed left atrial depolarization abnormality first degree atrioventricular block left ventricular enlargement and ST elevation suggestive of pericarditis (Fig 1) Admission chest x ray showed massive water bottle enlargement of the cardiac silhouette typical of pericardial effusion and mild venous congestive changes (Fig 2)

Right heart catheterization findings (Table I) showed greater elevation of pulmonary artery diastolic pressure than severely elevated right atrial and ventricular diastolic pressures which suggested that left ventricular failure was a major cause of the low cardiac output After CO and dye contrast right atrial angiocardigrams demonstrated a large pericardial effusion (Fig 3) pericardiocentesis yielded a sero-sanguineous fluid The patient remained very weak anorectic and tachypneic despite this procedure and an 8 lb diuresis induced by digitalis and diuretics Pericardiectomy with removal of a large sanguineous effusion was performed

Pericardial fluid and tissue cultures were negative for all pathogens The oral temperature was 100.5 F at 4 P.M. for three consecutive days after surgery and then remained normal Dyspnea and orthopnea improved shortly after surgery but severe dyspneic episodes were precipitated later by activity such as use of bed pan Despite a 25 lb weight loss pulmonary congestion increased and bilateral fluffy infiltrates

were seen on chest x ray Pulmonary embolism could not be differentiated from edema by perfusion lung scan

Due to intractable congestive heart failure the patient was transferred to the University of Michigan Hospital on July 2 1973 for possible aortic valve replacement Admission physical examination confirmed previous findings and revealed an erythematous area over the hard palate and several vesicular lesions on the left buccal mucosa Urinary output and orthopnea improved after hyperalimentation which was discontinued after central venous pressure reached 22 cm H₂O He was treated for suspected septicemia with penicillin G 10 million units daily and streptomycin 1.0 Gm daily Thirteen days after admission the diastolic blood pressure dropped to 30 mm Hg and short episodes of substernal pressure like chest pain occurred

Left heart catheterization (Table I) showed mild mitral insufficiency 60 mm Hg gradient across a heavily calcified aortic valve and a hypertrophic moderately hypokinetic left ventricle The severely calcified stenotic aortic valve was replaced with a Starr Edwards ball prosthesis but primary closure of the aorta was unsuccessful and a Dacron prosthetic graft was used to replace the ascending aorta Pulmonary edema developed during parallel cardiopulmonary bypass Return to full bypass and furosemide did not produce diuresis ventricular fibrillation developed and defibrillation was unsuccessful

Tissue findings

A Surgical The pericardium was 4 cm thick Soft brown papillary excrescences were seen Microscopic sections showed marked fibrosis and scattered inflammatory infiltrate composed mostly of lymphocytes with fibrin attached to one surface

B Autopsy (Limited to thorax with transdiaphragmatic liver biopsy) Chronic calcific aortic valvulitis Normal mitral valve Fibrous epicarditis and myocarditis (Fig 4) Biventricular myocardial hypertrophy (Fig 5) with focal fibrous



Fig 2 Admission chest x ray before pericardiectomy



Fig 3 CO right atrial angiogram. Large pericardial effusion separates CO in right atrium and right heart border.

and necrosis of myocardium and absence of inflammatory interstitial infiltrate. Pulmonary edema and pulmonary arterial embolus. Chronic passive congestion of liver with centrilobular necrosis and fatty infiltration. Granulomatous mediastinal lymphadenopathy.

Discussion

Acute idiopathic pericarditis is usually benign although frequently recurrent. This is not true if other chronic myocardial disease is present. Lau and Garcia's review of the literature to 1965 reported 12 fatal cases of acute idiopathic pericarditis. Cardiac tamponade was thought to be the cause of death in five but severe chronic myocardial disease was present in six others. Aortic stenosis with myocardial hypertrophy was present in one of these six cases. An additional fatal case of idiopathic pericarditis complicating calcareous aortic stenosis and cardiac hypertrophy was reported by Kirschner and associates in 1971. Their patient also had acute subendocardial (zonal) infarction without extension to the outer one-half of the myocardium. Search of the English literature since 1965 did not reveal additional cases of this fatal combination of diseases.

Before the advent of CO, and dye contrast

Table 1 Catheterization findings

Site	Before pericardiectomy pressure (mm Hg)	After pericardiectomy pressure (mm Hg)
1 Right atrium	40/30 Mean = 35	Mean = 18
2 Right ventricle	100/20 RVED = 30	85/0 RVED = 20
3 Main pulmonary artery	110/65 Mean = 75	100/30 Mean = 45
4 Left pulmonary artery wedge	—	95
5 Brachial artery	—	150/40
6 Ascending aorta	—	85/40
7 Left ventricle	—	150/10 LVED = 28

angiography and echocardiography the diagnosis of pericardial effusion in the presence of other cause for the enlargement of the heart was often made at autopsy. When two diseases that affect myocardial function are known to be present determination of the degree that each disease contributes to the low cardiac output may be extremely difficult. The contribution that acute epimyocarditis makes to myocardial dysfunction is speculative although myocardial biopsy may have demonstrated myocarditis. Pericardial effusion with or without tamponade may mask the changes on physical examination that




Fig 1 ECG before pericardiectomy

negative Sputum cultures grew *Candida albicans* and *Klebsiella* species Hemoglobin 11 gm per cent plasma hemoglobin 3.6 mg per cent serum iron 37 μ g per cent total iron binding capacity 330 μ g per cent serum haptoglobin less than 20 units suggested hemolysis and iron deficiency Screening tests for thyroid and renal disease lupus erythematosus and rheumatoid arthritis were negative Immunoglobulin electrophoresis showed elevated IgA Abnormal enzyme values were serum amylase 135 units glutamic oxalacetic transaminase 147 to 202 units glutamic pyruvic transaminase 246 units lactic dehydrogenase 318 units with increased fast fractions 1 2 Serum total bilirubin was 2.8 mg per cent Electrocardiograms showed left atrial depolarization abnormality first degree atrioventricular block left ventricular enlargement and ST elevation suggestive of pericarditis (Fig 1) Admission chest x ray showed massive water bottle enlargement of the cardiac silhouette typical of pericardial effusion and mild venous congestive changes (Fig 2)

Right heart catheterization findings (Table I) showed greater elevation of pulmonary artery diastolic pressure than severely elevated right atrial and ventricular diastolic pressures which suggested that left ventricular failure was a major cause of the low cardiac output After CO and dye contrast right atrial angiocardigrams demonstrated a large pericardial effusion (Fig 3) pericardiocentesis yielded a sero sanguineous fluid The patient remained very weak anorectic and tachypneic despite this procedure and an 8 lb diuresis induced by digitalis and diuretics Pericardiectomy with removal of a large sanguineous effusion was performed

Pericardial fluid and tissue cultures were negative for all pathogens. The oral temperature was 100.5 F at 4 p.m. for three consecutive days after surgery and then remained normal Dyspnea and orthopnea improved shortly after surgery but severe dyspneic episodes were precipitated later by activity such as use of bed pan Despite a 25 lb weight loss pulmonary congestion increased and bilateral fluffy infiltrates

were seen on chest x ray Pulmonary embolism could not be differentiated from edema by perfusion lung scan

Due to intractable congestive heart failure the patient was transferred to the University of Michigan Hospital on July 2 1973 for possible aortic valve replacement Admission physical examination confirmed previous findings and revealed an erythematous area over the hard palate and several vesicular lesions on the left buccal mucosa Urinary output and orthopnea improved after hyperalimentation which was discontinued after central venous pressure reached 22 cm H₂O He was treated for suspected septicemia with penicillin G 10 million units daily and streptomycin 10 Gm daily Thirteen days after admission the diastolic blood pressure dropped to 30 mm Hg and short episodes of substernal pressure like chest pain occurred

Left heart catheterization (Table I) showed mild mitral insufficiency 65 mm Hg gradient across a heavily calcified aortic valve and a hypertrophic moderately hypokinetic left ventricle The severely calcified stenotic aortic valve was replaced with a Starr Edwards ball prosthesis but primary closure of the aorta was unsuccessful and a Dacron prosthetic graft was used to replace the ascending aorta Pulmonary edema developed during parallel cardiopulmonary bypass Return to full bypass and furosemide did not produce diuresis ventricular fibrillation developed and defibrillation was unsuccessful

Tissue findings

A Surgical The pericardium was 4 cm thick Soft brown papillary excrescences were seen Microscopic sections showed marked fibrosis and scattered inflammatory infiltrate composed mostly of lymphocytes with fibrin attached to one surface

B Autopsy (Limited to thorax with transdiaphragmatic liver biopsy) Chronic calcific aortic valvulitis Normal mitral valve Fibrinous epicarditis and myocarditis (Fig 4) Biventricular myocardial hypertrophy (Fig 5) with focal fibrosis

stolic expansion and output the consequences are lower pulmonary capillary and left atrial pressures than would result if the pericardium were not present. Pericardiectomy by permitting greater pulmonary blood flow may be followed by increased left heart failure.

The clinician faces a dilemma when surgery is considered for acute pericarditis with effusion in the presence of left ventricular hypertrophy due to aortic stenosis. Surgery may relieve the dominant cause for the low cardiac output if tamponade is present but if the chronic myocardial disease is the major cause for the low cardiac output surgery may tip the balance unfavorably although valve replacement may correct the primary cause of the chronic myocardial disease.

Summary

Acute idiopathic pericarditis with massive pericardial effusion complicated left ventricular enlargement due to calcific aortic stenosis and led

to intractable congestive heart failure and death during aortic valve replacement in a 42 year old white male. This unusual combination of acute and chronic diseases is lethal due to their combined deleterious effect upon myocardial function.

REFERENCES

1. Lau H. Y. and Garcia R. Acute idiopathic pericarditis. *AM HEART J* 69:677 1965
2. Kirschner R. H. Archer F. L. Page M., et al. Clinical pathologic conference. *AM HEART J* 81:554 1971
3. Case Records of the Massachusetts General Hospital. *N Engl J Med* 258:1004 1958
4. Burch G. E., and Phillips J. H. Methods in the diagnostic differentiation of myocardial dilatation from pericardial effusion. *AM HEART J* 64:266 1962
5. Lange R. L. Compressive cardiac and circulatory disorders. Clinical and laboratory correlation. *AM HEART J* 74:419 1967
6. Lange R. L. Botticelli, J. T., Taagaras T. J. et al. Diagnostic signs in compressive cardiac disorders. *Circulation* 23:763 1966
7. Berglund, E. Sarnoff S. J. and Isaacs J. E. Role of the pericardium in regulation of cardiovascular hemodynamics. *Circ Res* 3:133 1955



Fig 4 Visceral pericardium (top right) and epicardium with fibrinous epicarditis and myocarditis



Fig 5 Gross specimen left and right ventricular enlargement

indicate antecedent ventricular failure. Pulsus paradoxus may not be produced by tamponade in the presence of aortic stenosis due to the failure of transmission of respiratory variations in left ventricular systolic pressure to the arterial system.¹⁰ X ray findings of clear lung fields and a massively enlarged cardiac silhouette (Fig 1) suggest tamponade but changes on physical examination that indicate ventricular enlargement point more accurately to the cause of the greatest hemodynamic abnormality. Pericardiectomy removes a lax effusion, but unless tamponade is present more severe congestive failure may follow. Lange and colleagues¹¹ found that abnormal hemodynamic changes in nine patients with lax effusion did not improve after pericardiectomy in contrast to improvement in similar parameters in nine patients with tamponade. Berglund and associates¹² state that the left ventricle stressed from outflow obstruction as in aortic stenosis dilates and produces increased pericardial pressure which limits right ventricular dia-

tomy removes a lax effusion, but unless tamponade is present more severe congestive failure may follow. Lange and colleagues¹¹ found that abnormal hemodynamic changes in nine patients with lax effusion did not improve after pericardiectomy in contrast to improvement in similar parameters in nine patients with tamponade. Berglund and associates¹² state that the left ventricle stressed from outflow obstruction as in aortic stenosis dilates and produces increased pericardial pressure which limits right ventricular dia-

stolic expansion and output the consequences are lower pulmonary capillary and left atrial pressures than would result if the pericardium were not present. Pericardiectomy by permitting greater pulmonary blood flow may be followed by increased left heart failure.

The clinician faces a dilemma when surgery is considered for acute pericarditis with effusion in the presence of left ventricular hypertrophy due to aortic stenosis. Surgery may relieve the dominant cause for the low cardiac output if tamponade is present but if the chronic myocardial disease is the major cause for the low cardiac output surgery may tip the balance unfavorably although valve replacement may correct the primary cause of the chronic myocardial disease.

Summary

Acute idiopathic pericarditis with massive pericardial effusion complicated left ventricular enlargement due to calcific aortic stenosis and led

to intractable congestive heart failure and death during aortic valve replacement in a 42 year old white male. This unusual combination of acute and chronic diseases is lethal due to their combined deleterious effect upon myocardial function.

REFERENCES

1. Lau H Y and Garcia R. Acute idiopathic pericarditis. *AM HEART J* 69:677 1965.
2. Kirschner H H, Archer F L, Page M, et al. Clinical pathologic conference. *AM HEART J* 81:554 1971.
3. Case Records of the Massachusetts General Hospital. *N Engl J Med* 288:1004 1958.
4. Burch G E and Phillips, J H. Methods in the diagnostic differentiation of myocardial dilatation from pericardial effusion. *AM HEART J* 66:766 1962.
5. Lange R L. Compressive cardiac and circulatory disorders. Clinical and laboratory correlation. *AM HEART J* 74:419 1967.
6. Lange R L, Botucelli, J T., Tsagaris T J., et al. Diagnostic signs in compressive cardiac disorders. *Circulation* 23:63 1966.
7. Berglund E, Sarnoff S J and Isaacs, J P. Role of the pericardium in regulation of cardiovascular hemodynamics. *Circ Res* 3:133 1955.

Isolated dissecting aneurysm of the renal artery

Asad A Bakir, M D
Suresh K Patel, M D
Melvin M Schwartz, M D
Edmund J Lewis, M D
Chicago Ill

Isolated dissecting aneurysm of the renal artery is a rare entity that gives rise to severe loin pain and hypertension, and is associated with a high incidence of vascular occlusion and renal infarction. It is not clear if the disease occurs primarily or if it is an unusual complication of fibromuscular dysplasia. Most reported cases have been in middle aged males. This report is a presentation of two new cases and a review of the pathology, treatment, and prognosis.

Case reports

Case A A 44 year old Caucasian man was admitted with bilateral dull flank pain and retro orbital and occipital headache. He had been well until six months before admission when he developed severe left flank pain which radiated into the left groin. There was no hematuria. His blood pressure was 180/100. A urinalysis and an IVP were reported to be normal. Three months before admission he had severe right flank pain radiating into the right groin. Two months before admission he was started on chlorothiazide to control hypertension which had not been present in the past.

The blood pressure was 150/106. There was marked fundal arteriolar narrowing but no cardiomegaly, costovertebral tenderness or abdominal bruits. Peripheral arm and leg pulses were present strong and of equal volume bilaterally. The urine had a trace of protein with no significant sediment. BUN, serum creatinine and electrolytes were normal. Twenty four hour creatinine clearance was 49 ml/minute. Renin levels were 1.4 ng/ml/hr from the inferior vena cava 2.1 from the right renal vein and 7.1 from the left renal vein.

Radiography (See Figs 1 and 2)

Surgical procedure There was no gross evidence of athero-

From the Departments of Medicine, Radiology and Pathology at Rush Presbyterian-St. Luke's Medical Center, Chicago, Ill.

Received for publication June 28, 1977

Accepted for publication July 18, 1977

Reprint requests: Edmund J. Lewis, M.D., Director, Section of Nephrology, Rush Presbyterian-St. Luke's Medical Center, 1733 West Congress Parkway, Chicago, Ill. 60612.



Fig 1 Case A. Selective left renal arteriogram. The right kidney was 14.5 cm in diameter. Dissecting aneurysm (small arrow) of the anterior division of the left renal artery. Distally the anterior division is occluded (small black arrow head) while the posterior division (large arrow) is patent. There is a cyst in the upper part of the left kidney (large black arrow head) and there are bite deformities along its lateral margin (open arrow heads).

sclerosis of the aorta or the renal arteries. Immediately distal to the aneurysm of the left renal artery, the anterior division of the artery was completely occluded. Within the kidney, this segment gave rise to two branches that had maintained their patency by collateral flow (Fig 1). The left main renal artery, the aneurysm at its bifurcation and the occluded anterior division were all excised and a Dacron tube graft was placed.



Fig 2 Case A Selective right renal arteriogram. The right kidney was 12 cm. in diameter. Dissecting aneurysm (large arrow) of the anterior division of the right renal artery is noted. The thin translucent line (small arrows) indicates dissection. A posterior and an inferior division were patent. Note the string of beads appearance along the anterior branch.

Histopathology The surgical specimens showed marked fibrous intimal thickening and disruption of the internal and external elastic lamina with aneurysm formation. There were areas of hemorrhage in the outer media and the inner adventitia. Areas involved by the dissecting hemorrhage showed disorganization and fragmentation of the smooth muscle bundles with interposition of a homogeneous material staining Alcian blue positive.

Subsequent course The patient presented a month later with a severe right flank pain. Surgery was performed on the aneurysm of the right renal artery (Fig 2). Dissection was noted to have proceeded into the renal hilum and had separated the intima from the remainder of the arterial wall. This artery was excised at a point proximal to the aneurysm and replaced with a Dacron tube graft.

The patient was discharged on chlorothalidate for control of mild hypertension. Two months after his second surgical procedure he was readmitted complaining of severe epigastric and right lumbar pain. A right renal arteriogram showed narrowing at the anastomotic site between the right renal artery and the patent graft. The kidney size was diminished, presumably due to ischemic atrophy. Renin levels by radium



Fig 3 Case B Selective right inferior renal arteriogram. There is absence of the nephrographic phase over the upper part of the right kidney and a prominent testicular artery (arrow) is seen arising from the right inferior renal artery and supplying retrograde flow to the upper part of the right kidney.

immunoassay were 0.9 ng/ml/hr from the right renal vein, 0.9 from the left renal vein and 0.5 from the inferior vena cava. Blood pressure on diuretic therapy has since ranged between 130 to 105 systolic and 90 to 106 diastolic and the BUN has been normal.

Case B A 50-year-old Caucasian man was admitted for evaluation of renovascular hypertension. Seventeen years earlier he had been told that he had "hypertension" and received therapy intermittently.

Two months before admission his blood pressure was found to be 200/120. An IVP was normal except for a ring of calcification in the vicinity of the right kidney. A month later renal angiography showed a significantly diminished size of the right kidney as compared to the previous IVP, a loss of the nephrographic phase in the upper half of the right kidney and a late deformity of the lateral border of the left kidney (Fig 3).

On admission there was no loin pain or hematuria. The blood pressure was 190/130. There was mild fundal arteriolar narrowing, a fourth heart sound at the apex and a Grade I/IV systolic ejection murmur at the left lower sternal border. There was no cardiomegaly, costovertebral tenderness or abdominal bruits. Peripheral arm and leg pulses were normal. The urine was unremarkable. The BUN was 27 mg/dl, serum creatinine 1.5 mg/dl, and creatinine clearance 81 ml/minute.



Fig 4 Case B Selective left superior renal arteriogram. An aneurysm is seen with a thin radiolucent line (arrow) suggestive of dissection. One of the branches of the artery distal to the aneurysm is completely occluded (black arrowhead). There is a diminution of the nephrographic phase in the shape of a bite deformity over the lateral border of the kidney (open arrowheads).

Renin levels were 3.8 ng/ml/hr from the aorta, 4.3 from the inferior vena cava, 8.6 from the right superior renal vein, and 3.5 from the left superior renal vein. An autotransplantation was performed. The left kidney was placed in the left groin. Radiography (See Figs 3 and 4). Histopathology (See Fig 5).

Subsequent course Postoperatively, hypertension persisted and proved difficult to control. Three months later he was admitted with a blood pressure of 190/130. Angiography failed to show new dissection or infarcts. Renin levels were 3.1 ng/ml/hr from the inferior vena cava, 7.3 from the right superior renal vein, and 2.5 from the left renal vein. Ten months later, arteriography showed ischemic atrophy of the lower half of the autotransplanted kidney. The BUN was 40 mg/dl, the serum creatinine 2.9 mg/dl, and the creatinine clearance was 26 ml/minute. The blood pressure was controlled but labile.

Discussion

Clinical features (Table I). In addition to the two patients reported here, detailed observations of this phenomenon have been described in 16



Fig 5 Section of the resected left superior renal artery from Case B. The internal elastic membrane is disrupted at the site of the dissection (asterisk). In this region, the damaged media and intima have formed a reactive proliferating mass of spindle cells. A small hematoma left from the original dissection is seen pushing against the external elastic membrane (arrow). (Elastic Von Giessen stain, original magnification 20x).

cases.¹⁻² The mean age of the 18 patients is 52 years. Fourteen of the 18 cases were males. Six patients were Caucasian as well as our own two patients; race was not mentioned in the remaining ten. Loin pain occurred in 11 out of the 18 patients, and was severe in eight. Hypertension was present in 14 cases, while prior history of hypertension was recorded in only two cases. Abdominal bruits were not found in four cases where they were sought. Microscopic hematuria was described in four cases. Gross hematuria occurred in only two patients, one of whom had cystitis.

The phenomenon occurs predominantly in the right renal artery. This artery, alone, was affected in ten reported cases, and there was bilateral involvement in five others (Table I). There appears to be a predilection for the superior branch on the right.¹ No satisfactory explanation has been offered for this right-sided predominance. The dissection tends to extend beyond the bifurcation of the renal arteries.

Hypertension pre-existed in six of the 18 cases. Conversely, hypertension is a common consequence once dissection has occurred (Table I). Atherosclerosis was absent in nine out of 13 reports and in three cases,¹ it was mild, involving only the aorta.¹ Trauma was described in two out of the 18 cases.

The major consequence of dissecting renal aneurysms is vascular occlusion with subsequent infarction. This occurred in 12 out of the 18

Table 1 Characteristics of sixteen cases of isolated dissecting aneurysms of the renal arteries

Series	Age	Sex	Past history of hypertension	Low pain	Gross hematuria	Trauma	BI	Renal artery(s) involved	Infarction	Intimal rent	Atherosclerosis
1. Watson, 1956											
A	52	M	-					Right	-		-
B	49	F		++				Both	+	-	-
2. Liebow & Cline 1956	57	M	+	++	+		200/150	Both	+	+	++
3. Gillilan & Smart 1956	47	M	-	++			19/120	Left	+	+	+
4. Henry & Burke 1963											
A	66	P	-		-		230/80	Right	+	-	Mild
B	72	M	-				120/80	Right	+	-	Mild
C	80	F	-				180/90	Right	+	+	++
6. England 1960	49	M	-	+	-		210/130	Right	+	+	
6. Rosenblum 1960	66	M						Right	+	-	
7. Kincaid Smith et al 1970											
A	47	M	(-) 2 mo	++	-		200/125	Right	+		-
B	43	M	(-) 8 yr	+	-		140/130	Right	+		-
C	44	M	(-) 3 yr	++	+		200/130	Left	+		-
D	39	M	(-) 3 yr	++	-		260/180	Left			
E	49	F	-	++	-		210/130	Both			
8. Perry 1971	27	M			-		180/120	Right	-		-
9. Kaufman et al 1973	67	M					7/130	Right	-		-
Current Series, 1971											
A	44	M	(+) 6 mo	++	-	-	150/110	Both	+	+	-
B	50	M	+		-	-	19/134	Both	+	+	-

For to admission. Abbreviation and symbols M = male F = female ++ = present + = severe - = absent.

patients. This complication is considered rare in classic fibromuscular dysplasia. Rupture of the renal artery did not occur in any of the reported cases.

Radiographic features. Many typical radiographic features of this phenomenon are demonstrated in Figs 1 to 4. A characteristic feature of dissecting aneurysms is a thin radiolucent line that indicates partial separation of the intima brought about by the dissection. This line was seen in both of our cases (Figs 2 to 4). Loss of the nephrographic phase and peripheral bite deformities indicate renal infarction. Collateral vessels often with retrograde flow are frequently seen supplying ischemic parts of the kidney (Fig 3).

Pathology (Table 1). The histopathology of the involved renal arteries in our two cases showed marked intimal fibrous thickening, intimal tears, medial degeneration with dissecting hemorrhage in the outer media and disruption of both the internal and external elastic lamina.

Similar medial changes have been described in most of the reported cases.^{1-9,11} The dissecting hemorrhage occurred in the outer media or

between the media and the adventitia in nine cases (Table 1 1 3 5-7B 9) in addition to our own two cases. Renal arterial dissections in general for example those secondary to trauma also occur along this plane of least resistance.¹²

The histological changes in the renal arteries are similar to those found in fibromuscular dysplasia. It has therefore been suggested¹³ that a dissecting renal aneurysm forms when there is a disruptive involvement of the internal elastic lamina by fibromuscular dysplasia. If this is true then dissecting aneurysms are a very uncommon complication of fibromuscular dysplasia.¹⁴ The few cases of dissecting aneurysms that have been described in fibromuscular dysplasia have also shown a predilection for males. This sexual bias contrasts with the experience in classic fibromuscular dysplasia, a disease that affects females three times as often as males. Alternatively, isolated dissecting aneurysm may be a primary pathologic event leading to secondary changes in the vessel wall similar to those described in fibromuscular dysplasia.¹⁵

Treatment and prognosis. In 40 per cent of the

Table II Treatment modalities in ten patients with isolated dissecting aneurysm of the renal artery

Patient	Treatment	Follow up (mo)	B P
3	Nephrectomy†	48	C
7A	Nephrectomy*	12	C
7B	Nephrectomy	12	C
7C	Antihypertensive medication	36	C
7D	Antihypertensive medication	10	C
7E	Antihypertensive medication	4	C
8	Nephrectomy	?	C
9	Tube Graft	12	C
Current series			
A	Tube Graft*	16	C
B	Autotransplant*	18	C

†Not known whether or not followed by antihypertensive agents
 *Followed by antihypertensive medication
 C = Controlled

reported cases, renal arterial dissection was an incidental autopsy finding and had not been suspected prior to the patient's demise.¹⁻⁴

In patients diagnosed during life, various management approaches have been taken, including nephrectomy, vascular surgery and antihypertensive medication (Table II). Duration of follow-up has varied in these reports and therapeutic effectiveness has been variable. Frequently, antihypertensive therapy is needed after surgical intervention. The decision to undertake nephrectomy must be made in the light of the experience that the disease is bilateral in a third of the cases. While the postoperative course in two out of three cases of renal revascularization was unsatisfactory, surgery for impending vascular occlusion may be appropriate. Medical management alone has been effective in controlling hypertension in some patients (Table II).

Summary

We report two cases of an unusual cause of the acute onset of hypertension in spontaneous dissecting aneurysm localized to the renal artery. Also reviewed are 16 reported cases from the literature. The mean age of the 18 patients was 52 years. The majority of these patients were males (78 per cent). Hypertension was a presenting sign in 14 (78 per cent) but was not usually a pre-existing feature. Loin pain often severe occurred

in eleven patients (61 per cent), whereas gross hematuria was recorded only in two (11 per cent). The right renal artery was involved in ten cases (55 per cent), the left in three (17 per cent), and both in five cases (28 per cent). Atherosclerosis of the renal arteries and the aorta was absent in 69 per cent, and mild in 23 per cent. There has been no report of renal artery rupture, however, vascular occlusion occurs frequently. Medical and surgical approaches to the management of this phenomenon have been reported and are reviewed.

Dr D Munson and M Weinberg of the Department of Cardiovascular Surgery, Rush Presbyterian St Luke's Medical Center, carried out the revascularization procedures in Case A. Dr F Merkel of the Department of General Surgery, Rush Presbyterian St Luke's Medical Center performed the renal autotransplantation in Case II. The renal assays were done at Dr I D Rennie's laboratory at Rush Presbyterian St Luke's Medical Center. Ms Helan Ivan and Ms Janet Iapichino did the secretarial work.

REFERENCES

1. Watson A J. Dissecting aneurysms of arteries other than the aorta. *J Pathol Bacteriol* 72:439 1956
2. Liebow J M, Chene T, Post R F and Persky L. Isolated bilateral simultaneous dissection of the renal arteries. *Am J Med* 21:151 1956
3. Güllüan H S and Smart W R. Dissecting aneurysm of the renal artery. *Arch Surg* 73:737 1956
4. Henry L and Burke W D. Isolated dissecting aneurysm of the renal artery. *Angiology* 14:269 1963
5. Englund G W. Primary dissecting aneurysm of the renal artery. *Am J Clin Pathol* 45:427 1966
6. Rosenblum W I. Isolated dissecting aneurysm of the renal artery. *J Urol* 95:135 1966
7. Hare W S C and Kincaid Smith P. Dissecting aneurysm of the renal artery. *Radiol* 97:255 1970
8. Perry M D. Hypertension and dissecting aneurysm of the renal artery. *Arch Surg* 102:216 1971
9. Kaufman J J, Coulson W F, Lecky J W and Popjak G. Primary dissecting aneurysm of the renal artery. Report of a case causing reversible renal hypertension. *Ann Surg* 177:259 1973
10. McCormack L J, Poutasse E F, Meaney T F, Noto T J and Duxan H P. A pathologic arteriographic correlation of renal arterial disease. *Am Heart J* 72:188 1966
11. Kincaid, Q W, Davis G D, Hallermann F J and Hunt J C. Fibromuscular dysplasia of the renal arteries. *Am J Roentgenol* 104:271 1963
12. Lang E K. Arteriographic diagnosis of renal infarcts. *Radiology* 88:1110 1967
13. McCormack L J. Morphological abnormalities of the renal artery associated with hypertension. In: Hypertension. Mechanisms and management. Onesti G, Kim K E, Meyer J H, Editors. New York 1973. Grune & Stratton Inc.
14. Harrison E G, Hunt J C and Bernatz P F. Morphology of fibromuscular dysplasia of the renal artery in renovascular hypertension. *Am J Med* 43:97 1967
15. Watson A J. Dissecting aneurysms due to trauma. *Scot Med J* 1:326 1956

The treatment of low renin ("primary") hyperaldosteronism

J M Ferriss
D G Beavers
K Boddy
J J Brown
D L Davies
R Fraser
D Kremer
A F Lever
J I S Robertson
Glasgow Scotland

In previous papers we reviewed the clinical biochemical and pathological features and the differential diagnosis of low renin hyperaldosteronism (primary hyperaldosteronism). This paper describes the surgical and medical management of the condition.

Primary hyperaldosteronism exists in a number of forms. Most commonly it is associated with a unilateral adrenocortical adenoma^{1,2} but in some cases an adrenal tumor is not found, the adrenal glands then usually showing bilateral hyperplasia of the zona glomerulosa. Rarely all the abnormalities are reversed by glucocorticoids³ while low renin hyperaldosteronism has also been described associated with a malignant adrenocortical or ovarian tumor.

Several forms of treatment are available. These include adrenal surgery and drugs such as the mineralocorticoid antagonist spironolactone and the potassium conserving diuretic amiloride while rarely glucocorticoids such as dexamethasone are effective. This paper describes our results with treatment and also reviews the experience of others. Previous reports have described the responses to spironolactone^{1,2} adrenal surgery⁴

and amiloride^{5,6} in some of the patients in the present series.

Patients and methods

All patients had a mean outpatient diastolic blood pressure of 100 mm Hg or more, an elevated plasma aldosterone concentration (normal up to 18 ng/100 ml) on at least one occasion and with a concurrent plasma renin concentration below the mean of the normal range (less than 44 microunits per ml of International Standard Renin). Fuller details of these patients are given in a preceding paper.¹ Blood pressure readings were obtained in the outpatient department and hypotensive drugs other than those specified were not used. Blood pressure and biochemical values obtained from the onset to the fourth week of treatment were excluded from the analysis as were all postoperative biochemical values in the four patients who underwent total adrenalectomy. Blood pressure readings within one standard deviation of the means found in a population study⁷ when matched for age and sex were defined as normal.

Surgery Sixty-four patients (39 females) underwent adrenal surgery. A single adrenocortical adenoma was found in 48 and unilateral adrenalectomy was usually performed. A tumor was not identified in 14; total adrenalectomy was undertaken in four of these; sub-total adrenalectomy (all of one gland and about three quarters

From the Medical Research Council Blood Pressure Unit and the University Department of Medicine, Western Infirmary, Glasgow and the Scottish Universities Research Heart Centre, East Kilbride, Scotland.

Received for publication May 21, 1976.

Reprint requests: Dr J I S Robertson, MRC Blood Pressure Unit, Western Infirmary, Glasgow G11 6TY, Scotland.

B - ADENOMA & NON-ADENOMA GROUPS




Fig 1 The mean fall in systolic and diastolic blood pressure (with SEM) in patients with primary hyperaldosteronism during treatment with spironolactone and after adrenal surgery. Continuous lines represent patients with adenoma, broken lines those in the non adenoma group. All changes were statistically significant while the fall in diastolic pressure was significantly greater among adenoma patients with each treatment (see text).

of the other) was carried out in six while in four one adrenal gland only was removed. In this group was one patient in whom a renal carcinoma was also found and nephrectomy was performed. Because renal carcinoma may itself contribute to hypertension,³² data from this patient were excluded from the following analysis. The adrenal lesion in two further patients proved difficult to classify; each lesion showed some histological features of an adenoma and some of a macronodule.¹ There was not a significant difference in the mean duration of follow up between the groups with and without an adrenocortical adenoma (84 and 68 weeks respectively, $t = 0.64$, $0.6 > p > 0.5$).

Spironolactone. Ninety five patients (56 females) were treated with spironolactone for a minimum period of four weeks (range 1 to 96 months, mean 9.7 months). These patients received 50 to 400 mg daily (usually 300 to 400 mg daily, smaller doses being used only when the

hypotensive response was satisfactory). A pathological diagnosis was subsequently available in 51 patients: a unilateral adrenocortical adenoma was found in 37, while in 14 a tumor was not identified; the adrenal glands usually showing bilateral hyperplasia of the zona glomerulosa.

Amiloride. Eighteen patients (11 females) were treated with amiloride, increasing to 40 mg daily in divided doses for 6 to 8 weeks. Eight of these patients subsequently underwent adrenal surgery and a unilateral adenoma was found in each. A direct comparison between the effects of amiloride and spironolactone (400 mg daily) was made in each case. Patients were initially treated with amiloride (15 cases) or spironolactone (3 cases) and plasma levels of renin, angiotensin II and aldosterone together with total exchangeable sodium and potassium were measured on a fixed normal intake of sodium and potassium before and during each treatment. Therapy was with drawn for 6 to 8 weeks between each drug treatment. Fuller details of this protocol appear elsewhere.³³

Dexamethasone. Nineteen patients (9 females) in the present series received dexamethasone 0.5 mg four times daily for 14 days. Nine subsequently underwent adrenal surgery and a unilateral adenoma was found in six; a tumor was not identified in three; the adrenal glands showing hyperplasia of the zona glomerulosa in each. Blood pressure and plasma electrolytes were measured before and on the seventh and fourteenth days of treatment. Plasma renin concentration was measured before and during treatment in 14, while plasma aldosterone was measured before and during treatment in 13 cases.

Other methods. Plasma (and serum) electrolytes, blood urea, plasma concentrations of renin, angiotensin II and aldosterone, total exchangeable sodium, total exchangeable potassium, total body potassium and total body water were measured as described previously,^{1, 33} where sampling conditions are also outlined. Statistical calculations were made on a Hewlett Packard 9810A calculator.

Results

Adrenal surgery. There was a significant fall in systolic and diastolic blood pressure after operation in both the adenoma and non adenoma groups. The mean blood pressure fall after opera-

Table 1 Comparison of variables before and after adrenal surgery (paired t test) Mean values (\pm S.E.M.)

	Before treatment	After operation	No of pairs	t	p
Systolic BP (mm Hg)	204 (13.6)	150 (4.1)	63	-13.01	< 0.001
Diastolic BP (mm Hg)	114 (1.7)	102 (2.3)	63	-11.29	< 0.001
Plasma sodium (mEq/L)	140.8 (0.4)	139.0 (0.3)	56	-9.3	< 0.001
Plasma potassium (mEq/L)	4.9 (0.08)	4.4 (0.06)	46	14.01	< 0.001
Plasma tCO ₂ (mEq/L)	30.1 (0.5)	24.5 (0.4)	51	-8.66	< 0.001
Blood urea (mg/100 ml)	32.3 (1.1)	46.6 (1.7)	33	8.31	< 0.001
Plasma renin (μ units/ml)	23.2 (0.3)	63.5 (0.9)	40	.91	< 0.001
Plasma angiotensin II (pg/ml)	8.4 (1.2)	1.3 (.2)	11	4.06	< 0.01
Plasma aldosterone (ng/100 ml)	43.0 (4.9)	9.0 (0.8)	30	-6.69	< 0.001
NaE (mEq)	307.6 (100.5)	260.4 (100.1)	19	-6.5	< 0.001
NaE (mEq/kg BW)	4.9 (1.2)	39.5 (1.0)	19	-6.98	< 0.001
K _E † (mEq)	237.0 (11.3)	260.4 (128.3)	18	2.53	< 0.05
K _E (mEq/Kg BW)	34.6 (1.8)	38.4 (1.0)	18	2.08	0.1 > p > 0.05
Total body water (liters)	36.9 (1.8)	35 (1.0)	15	-0.99	0.4 > p > 0.3

NaE = exchangeable sodium
 †KE = changeable potassium

tion in the adenoma group was 48/26 mm Hg and among non adenoma patients 40/15 mm Hg (Fig 1) (adenoma v non adenoma systolic t = 0.95 NS diastolic t = 2.66 p < 0.05) Blood pressure fell to the defined normal level after operation in 27 patients in the adenoma group (56 per cent) and in two patients in whom an adenoma was not found (15 per cent)

After operation (Table 1) there was a significant fall in plasma sodium total exchangeable sodium and in plasma tCO₂ and aldosterone concentrations There was a significant rise in plasma and total exchangeable potassium in blood urea and in the plasma concentrations of renin and angiotensin II A small fall in total body water was not statistically significant There was a significant inverse correlation among individual patients between preoperative blood urea and the fall in blood pressure after operation (systolic r -0.35 p < 0.01 diastolic r -0.36 p < 0.01)

Spironolactone There was a highly significant fall in mean systolic and diastolic blood pressure during treatment with spironolactone (Table II) The mean blood pressure fell during treatment was 53/29 mm Hg in the adenoma group and 45/19 mm Hg among patients in whom a tumor was not found at operation (Fig 1) The fall in systolic pressure did not differ significantly between the two pathological groups (t = 1.04 0.4 > p > 0.3) but the fall in diastolic pressure was significantly greater in the adenoma group (t = 2.65 p < 0.02) (Fig 1) Blood pressure fell to normal during treatment with spironolactone in 17 patients in the adenoma group (46 per cent) and in seven patients in whom a tumor was not found (50 per cent)

No evidence of escape of blood pressure from control was seen in any patient in up to eight years of therapy Temporary withdrawal of spironolactone in patients whose blood pressure had been well controlled resulted in a rise of blood

B - ADENOMA & NON-ADENOMA GROUPS




Fig 1 The mean fall in systolic and diastolic blood pressure (with SEM) in patients with primary hyperaldosteronism during treatment with spironolactone and after adrenal surgery. Continuous lines represent patients with adenoma broken lines those in the non adenoma group. All changes were statistically significant while the fall in diastolic pressure was significantly greater among adenoma patients with each treatment (see text)

of the other) was carried out in six, while in four one adrenal gland only was removed. In this group was one patient in whom a renal carcinoma was also found and nephrectomy was performed. Because renal carcinoma may itself contribute to hypertension²⁴ data from this patient were excluded from the following analysis. The adrenal lesion in two further patients proved difficult to classify, each lesion showed some histological features of an adenoma and some of a macronodule. There was not a significant difference in the mean duration of follow up between the groups with and without an adrenocortical adenoma (84 and 68 weeks respectively $t = 0.64$, $0.6 > p > 0.5$).

Spironolactone Ninety five patients (56 females) were treated with spironolactone for a minimum period of four weeks (range 1 to 96 months mean 37 months). These patients received 50 to 400 mg daily (usually 300 to 400 mg daily smaller doses being used only when the

hypotensive response was satisfactory). A pathological diagnosis was subsequently available in 51 patients = unilateral adrenocortical adenoma was found in 37, while in 14 a tumor was not identified, the adrenal glands usually showing bilateral hyperplasia of the zona glomerulosa.

Amiloride Eighteen patients (11 females) were treated with amiloride increasing to 40 mg daily in divided doses, for 6 to 8 weeks. Eight of these patients subsequently underwent adrenal surgery and a unilateral adenoma was found in each. A direct comparison between the effects of amiloride and spironolactone (400 mg daily) was made in each case. Patients were initially treated with amiloride (15 cases) or spironolactone (3 cases) and plasma levels of renin, angiotensin II and aldosterone together with total exchangeable sodium and potassium, were measured on a fixed normal intake of sodium and potassium before and during each treatment. Therapy was withdrawn for 6 to 8 weeks between each drug treatment. Fuller details of this protocol appear elsewhere.³

Dexamethasone Nineteen patients (9 females) in the present series received dexamethasone 0.5 mg four times daily for 14 days. Nine subsequently underwent adrenal surgery and a unilateral adenoma was found in six; a tumor was not identified in three. The adrenal glands showing hyperplasia of the zona glomerulosa in each. Blood pressure and plasma electrolytes were measured before and on the seventh and fourteenth days of treatment. Plasma renin concentration was measured before and during treatment in 14 while plasma aldosterone was measured before and during treatment in 13 cases.

Other methods Plasma (and serum) electrolytes, blood urea, plasma concentrations of renin, angiotensin II and aldosterone, total exchangeable sodium, total exchangeable potassium, total body potassium and total body water were measured as described previously^{1,2,3} where sampling conditions are also outlined. Statistical calculations were made on a Hewlett Packard 9810A calculator.

Results

Adrenal surgery There was a significant fall in systolic and diastolic blood pressure after operation in both the adenoma and non adenoma groups. The mean blood pressure fall after opera-

Table 1 Comparison of variables before and after adrenal surgery (paired t test) Mean values (\pm S.E.M.)

	Before treatment	After operation	No of pairs	t	p
Systolic B.P. (mm. Hg)	204 (3.6)	159 (4.1)	63	-13.01	< 0.001
Diastolic B.P. (mm. Hg)	114 (1.7)	100 (1.3)	63	-11.29	< 0.001
Plasma sodium (mEq/L)	147.8 (0.4)	139.0 (0.3)	56	-9.30	< 0.001
Plasma potassium (mEq/L)	2.9 (0.08)	4.4 (0.08)	56	14.01	< 0.001
Plasma tCO ₂ (mEq/L)	30.1 (0.5)	24.5 (0.4)	53	-8.69	< 0.001
Blood urea (mg/100 ml)	30.3 (1.1)	40.6 (1.7)	53	8.32	< 0.001
Plasma renin (units/ml)	23.9 (0.3)	63.5 (0.9)	40	7.91	< 0.001
Plasma angiotensin II (pg/ml)	8.4 (1.2)	1.3 (2.0)	11	4.06	0.01
Plasma aldosterone (ng/100 ml)	43.0 (4.9)	9.0 (0.8)	30	-6.69	< 0.001
NaE (mEq)	393.6 (106.5)	2007.4 (100.1)	19	-6.75	< 0.001
NaE (mEq/Kg BW)	47.2 (1.1)	39.5 (1.0)	19	-6.88	< 0.001
KE† (mEq)	230.2 (11.3)	2606.4 (123.3)	18	9.53	< 0.001
KE (mEq/kg BW)	34.6 (1.8)	38.4 (2.0)	18	2.08	0.1 > p > 0.60
Total body water (liters)	17.7 (0.7)	30.2 (2.2)	15	-0.99	0.4 > p > 0.3

NaE = exchangeable sodium

KE = exchangeable potassium

tion in the adenoma group was 48/26 mm Hg and among non adenoma patients 40/15 mm Hg (Fig 1) (adenoma v non adenoma systolic $t = 0.95$ N.S. diastolic $t = 2.66$ $p < 0.05$). Blood pressure fell to the defined normal level after operation in 27 patients in the adenoma group (56 per cent) and in two patients in whom an adenoma was not found (15 per cent).

After operation (Table 1) there was a significant fall in plasma sodium total exchangeable sodium and in plasma tCO₂ and aldosterone concentrations. There was a significant rise in plasma and total exchangeable potassium in blood urea and in the plasma concentrations of renin and angiotensin II. A small fall in total body water was not statistically significant. There was a significant inverse correlation among individual patients between preoperative blood urea and the fall in blood pressure after operation (systolic $r = -0.35$ $p < 0.01$ diastolic $r = -0.36$ $p < 0.01$).

Spironolactone There was a highly significant fall in mean systolic and diastolic blood pressure during treatment with spironolactone (Table II). The mean blood pressure fell during treatment was 53/29 mm Hg in the adenoma group and 45/19 mm Hg among patients in whom a tumor was not found at operation (Fig 1). The fall in systolic pressure did not differ significantly between the two pathological groups ($t = 1.04$ $0.4 > p > 0.3$) but the fall in diastolic pressure was significantly greater in the adenoma group ($t = 2.60$ $p < 0.02$) (Fig 1). Blood pressure fell to normal during treatment with spironolactone in 17 patients in the adenoma group (46 per cent) and in seven patients in whom a tumor was not found (50 per cent).

No evidence of escape of blood pressure from control was seen in any patient in up to eight years of therapy. Temporary withdrawal of spironolactone in patients whose blood pressure had been well controlled resulted in a rise of blood

Table II Comparison of variables before and during treatment with spironolactone (paired *t* test)
Mean values (\pm S.E.M.)

	Before treatment	During spironolactone	No of pairs	<i>t</i>	<i>p</i>
Systolic BP (mm Hg)	198.6 (2.45)	146.1 (2.82)	95	-20.45	< 0.001
Diastolic BP (mm Hg)	121.5 (1.12)	97.3 (1.50)	95	-17.96	< 0.001
Plasma sodium (mEq/L)	142.4 (0.27)	138.2 (0.31)	83	-10.61	< 0.001
Plasma potassium (mEq/L)	3.2 (0.07)	4.6 (0.05)	85	15.91	< 0.001
Plasma tCO ₂ (mEq/L)	28.6 (0.40)	23.9 (0.33)	74	-11.2	< 0.001
Blood urea (mg/100 ml)	33.4 (1.2)	48.6 (2.1)	80	11	< 0.001
Plasma renin (μ units/ml)	26.8 (1.4)	129.5 (16.9)	45	6.12	< 0.001
Plasma angiotensin II (pg/ml)	10.2 (0.75)	57.4 (19.2)	16	2.49	< 0.05
Plasma aldosterone (ng/100 ml)	31.2 (5.0)	41.7 (5.0)	19	1.67	0.2 > <i>p</i> > 0.1
NaE* (mEq)	2969.4 (82.7)	2464.9 (72.7)	36	-10.50	< 0.001
NaE (mEq/Kg BW)	44.5 (1.0)	37.9 (0.9)	36	-8.18	< 0.001
KE† (mEq)	2347.0 (107.5)	2551.2 (107.1)	36	2.90	< 0.01
KE (mEq/kg BW)	35.1 (1.4)	39.4 (1.3)	36	4.65	< 0.001
Total body water* (liters)	38.5 (1.3)	35.9 (1.4)	28	-4.73	< 0.001
Extra cellular fluid* (liters)	19.3 (0.79)	16.6 (0.82)	13	-4.31	< 0.01
Plasma volume (liters)	3.07 (0.21)	2.80 (0.24)	10	-2.27	< 0.05

NaE = exchangeable sodium
 †KE = exchangeable potassium

pressure towards pretreatment levels. There was an inverse correlation among individual patients between pretreatment blood urea and the fall in blood pressure during spironolactone (systolic $r = -0.25$, $p < 0.02$; diastolic $r = -0.14$, NS).

Spironolactone corrected the plasma electrolyte abnormalities in every case regardless of the hypotensive response. The changes which occurred during treatment are summarized in Table II. There was a significant decrease in plasma and total exchangeable sodium in total body water, extracellular fluid and plasma volumes and in plasma tCO₂ concentration. There was a significant increase in plasma and total exchangeable potassium in blood urea and in plasma concentrations of renin and angiotensin II. Plasma aldosterone was measured before and

during treatment in 19 patients; levels rose in 13 but fell in six. Overall the mean change was not significant. Aldosterone secretion rate was measured in two patients and values during treatment were unchanged.

Changes in plasma concentrations of renin, angiotensin II, and aldosterone were similar in patients with and without an adrenocortical adenoma. These responses are reported in more detail elsewhere.²

The side effects included epigastric discomfort, gynecomastia, Raynaud's phenomenon, menstrual irregularities, lassitude, cutaneous pigmentation, excessive sweating, and impotence. However, these unwanted effects were generally minor and in only three patients were they severe enough to lead to withdrawal of the drug.

Table III Comparison of variables before and during treatment with amiloride (paired t test) Mean values (\pm S.E.M.)

	Before treatment	During amiloride	No of pairs	t	p
Systolic B.P. (mm Hg)	184 (4.4)	151 (6.8)	18	-5.18	< 0.001
Diastolic (mm Hg)	114 (1.7)	101 (.8)	18	-4.53	< 0.001
Plasma sodium (mEq/L)	149.6 (0.4)	139.6 (0.5)	18	-7.0	< 0.001
Plasma potassium (mEq/L)	3.2 (0.2)	4.5 (0.1)	18	10.01	< 0.001
Plasma tCO ₂ (mEq/L)	30.1 (0.7)	25.7 (0.5)	18	-6.43	< 0.001
Blood urea (mg/100 ml)	30.1 (1.6)	36.4 (4.0)	18	4.10	< 0.001
Plasma renin (μ units/ml)	33.8 (3.3)	72.0 (13.3)	17	3.16	< 0.01
Plasma angiotensin II (pg/ml)	10.4 (1.0)	22.5 (4.5)	16	3.09	< 0.01
Plasma aldosterone (ng/100 ml)	25.0 (3.6)	38.5 (6.4)	16	2.49	< 0.05
NaE (mEq)	2800 (127)	2529 (101)	17	-5.13	< 0.001
NaE (mEq/Kg BW)	47.9 (1.1)	37.0 (0.8)	17	-5.21	< 0.001
KEt (mEq)	2240 (159)	2840 (149)	17	3.43	< 0.01
KE (mEq/Kg BW)	37.0 (1.5)	40.9 (1.3)	1	2.5	< 0.05
Total body water (liters)	38.2 (1.9)	37.3 (1.9)	16	-0.88	0.4 > p > 0.3

NaE = exchangeable sodium

KE = exchangeable potassium

Amiloride Eighteen patients were treated with amiloride and blood pressure fell in all except one. There was a highly significant fall in systolic and diastolic blood pressure for the group during treatment (Table III). The mean fall in patients with a proved adenoma was 40/22 mm Hg. No patient in the non adenoma group underwent adrenal surgery but quadric analysis placed five patients in this diagnostic category among these the mean fall was 18/12 mm Hg. The fall in systolic pressure was significantly greater in the adenoma group ($t = 2.46$ $p < 0.05$) but the difference in diastolic response was not statistically significant ($t = 1.71$). Diastolic pressure fell to normal levels during amiloride in four patients with a confirmed adenoma (50 per cent) but in only one of five in the predicted non adenoma group.

Other significant changes (Fig. 3) included a fall in plasma and exchangeable sodium and a rise in plasma and exchangeable potassium and in

blood urea while mean values of plasma renin, angiotensin II and aldosterone also rose.

Three patients noticed excessive flatus in the first three weeks of treatment but this symptom became less prominent as therapy continued. Two complained of transient lassitude. No other side effects were encountered.

Comparison of adrenal surgery and spironolactone Forty four patients followed after appropriate adrenal surgery had been previously treated with spironolactone as described. There was a significant correlation among individuals between the blood pressure response to each treatment (systolic $r = 0.66$ $p < 0.001$ diastolic $r = 0.60$ $p < 0.001$). The correlation was particularly close for patients in the adenoma group (systolic $r = 0.87$ $p < 0.001$ diastolic $r = 0.75$ $p < 0.001$). However data from only 10 non adenoma patients were suitable for this comparison and one patient behaved atypically in that she failed to alter her blood pressure during

Table II Comparison of variables before and during treatment with spironolactone (paired t test)
Mean values (\pm S E M)

	Before treatment	During spironolactone	No of pairs	t	p
Systolic BP (mm Hg)	198.6 (2.45)	148.1 (2.82)	95	-20.45	< 0.001
Diastolic BP (mm Hg)	121.5 (1.12)	97.3 (1.50)	95	-17.96	< 0.001
Plasma sodium (mEq/L)	142.4 (0.27)	138.2 (0.31)	83	-10.61	< 0.001
Plasma potassium (mEq/L)	3.2 (0.07)	4.6 (0.05)	85	15.91	< 0.001
Plasma tCO ₂ (mEq/L)	28.6 (0.40)	23.9 (0.33)	74	-11.2	< 0.001
Blood urea (mg/100 ml)	33.4 (1.2)	48.6 (2.1)	80	11	< 0.001
Plasma renin (μ units/ml)	26.8 (1.4)	129.5 (16.9)	45	6.12	< 0.001
Plasma angiotensin II (pg/ml)	10.2 (0.75)	57.4 (19.2)	16	2.49	< 0.05
Plasma aldosterone (ng/100 ml)	31.2 (5.0)	41.7 (5.0)	19	1.67	0.2 > p > 0.1
NaE* (mEq)	2969.4 (82.7)	2464.9 (72.7)	36	-10.55	< 0.001
NaE (mEq/Kg BW)	44.5 (1.0)	37.9 (0.9)	36	-8.18	< 0.001
KE† (mEq)	2347.0 (107.5)	2551.2 (107.1)	36	2.9	< 0.01
KE (mEq/Kg BW)	35.1 (1.4)	39.4 (1.3)	36	4.65	< 0.001
Total body water* (liters)	38.5 (1.3)	35.9 (1.4)	28	-4.73	< 0.001
Extra cellular fluid (liters)	19.3 (0.79)	16.6 (0.82)	13	-4.31	< 0.01
Plasma volume (liters)	3.07 (0.21)	2.80 (0.24)	10	-2.27	< 0.05

NaE = exchangeable sodium

†KE = exchangeable potassium

pressure towards pretreatment levels. There was an inverse correlation among individual patients between pretreatment blood urea and the fall in blood pressure during spironolactone (systolic $r = -0.25$, $p < 0.02$; diastolic $r = -0.14$, NS).

Spironolactone corrected the plasma electrolyte abnormalities in every case regardless of the hypotensive response. The changes which occurred during treatment are summarised in Table II. There was a significant decrease in plasma and total exchangeable sodium in total body water, extracellular fluid and plasma volumes and in plasma tCO₂ concentration. There was a significant increase in plasma and total exchangeable potassium in blood urea and in plasma concentrations of renin and angiotensin II. Plasma aldosterone was measured before and

during treatment in 19 patients; levels rose in 13 but fell in six. Overall, the mean change was not significant. Aldosterone secretion rate was measured in two patients and values during treatment were unchanged.

Changes in plasma concentrations of renin, angiotensin II and aldosterone were similar in patients with and without an adrenocortical adenoma. These responses are reported in more detail elsewhere.²

The side effects included epigastric discomfort, gynaecomastia, Raynaud's phenomenon, menstrual irregularities, lassitude, cutaneous pigmentation, excessive sweating and impotence. However, these unwanted effects were generally minor and in only three patients were they severe enough to lead to withdrawal of the drug.




Fig 4 Relationship between concurrent estimates of total exchangeable potassium (K) and total body potassium (K*) in patients with primary hyperaldosteronism Δ = untreated \bullet = taking spironolactone \circ = taking amiloride \blacksquare = postoperative

measurements of total exchangeable and total body potassium, whether the patient was untreated, taking amiloride or spironolactone, or had been subjected to surgery, thus justifying the use of exchangeable potassium as a measure of potassium status. Total body potassium estimates were systematically slightly higher than exchangeable potassium estimates.

Dexamethasone. Blood pressure and plasma electrolytes were unchanged in all of 19 patients during dexamethasone 2 mg daily for two weeks. No consistent changes in plasma renin or aldosterone concentrations were observed.

Discussion

Adrenal surgery. Conn and associates¹ have reviewed the literature and Conn has subsequently described his personal experience of patients following the removal of an aldosterone-secreting adenoma. Blood pressure was reported as normal in 60 per cent to 70 per cent and hypertension was ameliorated in most of the remainder. Other reports have been in general agreement,²⁻⁴ although we found that postoperative blood pressure fell to a normal level in only 50 per cent of cases.²² This expanded series is in general agreement with our earlier report.

The effect of surgery on the blood pressure in non-adenoma cases is less satisfactory. Persistent

hypertension has been reported,^{4, 23, 24} although some fall in blood pressure may occur.²⁵ We have previously shown that blood pressure may occasionally fall to normal following surgery,³ but this expanded series again confirms that a smaller hypotensive response occurs in the non-adenoma group.

Debate continues on the choice of operative approach. This may be posteriorly through the eleventh rib (bilaterally if necessary) or anteriorly through a transverse upper abdominal incision.²¹ The amount of adrenal tissue which should be excised from patients without tumor is also uncertain. Total adrenalectomy removes the site of aldosterone production with rare exceptions,⁴ but the patient is thereafter dependent on corticosteroid replacement. By preserving a remnant of one gland it is hoped to avoid the need for replacement therapy while curing the aldosterone excess (corticosteroid replacement was not necessary in any of the six patients so treated in the present series). However, recurrence of hyperaldosteronism after extensive adrenal surgery has been reported.²⁶ Less extensive adrenal surgery also leads to a smaller fall in blood pressure.^{11, 27} It is suggested that if surgery is to be worthwhile in such patients, removal of one adrenal and at least three quarters of the other should be undertaken. It is of interest that complete excision of




Fig 2 Mean systolic and diastolic blood pressure (\pm SEM) in eight patients with an aldosterone producing adenoma untreated while taking spironolactone untreated while taking amiloride and after adrenal surgery

spironolactone but had a considerable fall (mean 78/38 mm Hg) following total adrenalectomy. When this patient was excluded there was a significant correlation between the fall in diastolic pressure with the two forms of treatment (systolic $r = 0.33$ NS diastolic $r = 0.72$ $p < 0.05$).

The mean fall in blood pressure was again slightly greater during spironolactone treatment than after adrenal surgery both in the adenoma group (mean fall 52/27 and 46/24 mm Hg respectively) and in the group in whom an adenoma was not found (mean fall 45/20 and 36/16 mm Hg respectively). However these differences did not reach statistical significance.

Both forms of treatment corrected the abnormalities of plasma electrolytes and renin concentration. However the changes were slightly but consistently greater during spironolactone possibly due to a greater shrinkage in extracellular and plasma volumes with this treatment.

Comparison of adrenal surgery and amiloride
Eight patients treated with amiloride subsequently underwent adrenal surgery and a single adenoma was found in each. The hypotensive effects of amiloride spironolactone and adrenal




Fig 3 Mean systolic and diastolic blood pressure (\pm SEM) in 18 patients with primary hyperaldosteronism (both with and without adenoma) untreated while taking spironolactone untreated and while taking amiloride

surgery are compared in Fig 2 all three treatments produced a highly significant fall in mean systolic and diastolic blood pressure although values were slightly higher during amiloride than during spironolactone or after operation. There was a positive correlation between the blood pressure response to amiloride and that following adrenal surgery although with the small numbers involved this did not reach significance (systolic $r = 0.417$ diastolic $r = 0.673$). The fall in plasma and exchangeable sodium and the rise in plasma and exchangeable potassium were not significantly different during each treatment.

Comparison of spironolactone and amiloride
Both treatments produced a significant fall in systolic and diastolic blood pressures although the hypotensive effect of spironolactone was significantly greater with the doses used (Fig 3). There was a significant positive correlation among individuals between the fall in blood pressure with each form of treatment (systolic $r = 0.607$ $p < 0.01$ diastolic $r = 0.576$ $p < 0.02$).

Relationship between total exchangeable and total body potassium
As shown in Fig 4 there was a close correlation between concurrent

tion of a peptic ulcer necessitating withdrawal of the drug.¹¹ This woman subsequently did well on amiloride. Although there is little information on whether spironolactone can induce peptic ulceration, we have previously reported a patient with no history of dyspepsia who developed a gastric ulcer during spironolactone treatment; this healed rapidly following withdrawal of the drug and epigastric symptoms have not recurred.¹

Amiloride Amiloride is a pyrazine carbonyl guanidine which appears to act on sodium reabsorption in the distal renal tubule independently of aldosterone.¹² When administered in five day courses amiloride was reported to correct the electrolyte abnormalities but not the hypertension in a patient with an aldosterone producing adenoma. We have shown that prolonged treatment in a patient unable to tolerate spironolactone also reduced blood pressure to normal.⁶ The present findings confirm that amiloride can control the hypertension of primary hyperaldosteronism with or without an adrenocortical adenoma as well as correcting the electrolyte abnormalities.

Comparison of surgery, spironolactone and amiloride This study again confirms the close correlation between blood pressure levels during spironolactone and after adrenal surgery,¹³ especially in the adenoma group. Thus spironolactone is useful in predicting the blood pressure level after adrenal surgery. Although numbers are still small a similar correlation seems to be emerging between the blood pressure responses to amiloride and surgery.

The fall in both systolic and diastolic pressure during spironolactone was again slightly greater than the blood pressure fall after adrenal surgery. In the doses used spironolactone was also more effective than amiloride and indeed the latter treatment was also slightly less effective than adrenal surgery. We do not know whether these differences reflect the dosage of amiloride used or whether the drug is inherently less effective.

Dexamethasone Dexamethasone was ineffective in correcting the abnormalities in all 10 patients studied in this series. This confirms that glucocorticoid remediable hyperaldosteronism is an uncommon variant. However Griebink and associates¹⁴ have recently shown that treatment for longer than 14 days may sometimes be neces-

sary for aldosterone suppression in contrast to earlier cases.¹⁵ Probably glucocorticoid treatment should be continued for at least four weeks when screening for this condition.

Newton and Laragh¹⁶ administered glucocorticoids for five days to patients with primary hyperaldosteronism. Aldosterone excretion fell in three, rose in one and was unchanged in another. Slaton and colleagues¹⁷ reported that dexamethasone for three days suppressed aldosterone excretion significantly in six of fourteen patients with aldosterone producing adenoma, although smaller increases occurred in four others. These findings are in general agreement with our own.

The cause of glucocorticoid remediable hyperaldosteronism is as yet unknown. A specific adrenocortical biosynthetic block has not yet been identified.¹⁸

Adrenocortical carcinoma We have not encountered a single example of adrenocortical carcinoma producing aldosterone excess in our series of 136 patients with low renin hyperaldosteronism despite prolonged follow up in most cases and surgical exploration in 79. When recognized or suspected prompt surgical excision is required.¹⁹

It has been suggested that long term spironolactone treatment in patients with primary hyperaldosteronism is unsafe because an underlying adrenal carcinoma may be overlooked.²⁰ Crane and co-workers²¹ reported a blood pressure fall to normal during spironolactone treatment in one of two such patients. However these rare cases should be recognizable preoperatively: a large tumor may be palpable or displace the kidney on excretion pyelogram or renal arteriography; fever, severe muscle weakness and abdominal pain are common features and excessive secretion of adrenocorticosteroids other than aldosterone may be found.²²⁻²⁴

Management of the individual patient In patients with primary hyperaldosteronism associated with an adrenocortical adenoma in whom preoperative spironolactone has reduced blood pressure to normal or near normal, removal of the tumor bearing gland is usually the treatment of choice. However when surgery is contraindicated or refused long term treatment with spironolactone is an acceptable alternative. Should the patient be unable to tolerate spironolactone, amiloride may be substituted although it is

both glands has largely replaced sub total adrenalectomy in the surgical treatment of Cushing's disease.^{41, 44}

Spirolactone Spirolactones are synthetic steroid compounds with an added lactone ring. These compounds block the renal effects of aldosterone and deoxycorticosterone by competitive inhibition.^{45, 46} In patients with primary hyperaldosteronism spirolactones cause urinary sodium excretion and potassium retention,^{47, 48} and when treatment is prolonged, blood pressure falls.^{30, 5} There is also a good correlation between level of blood pressure during spirolactone treatment and after appropriate adrenal surgery.^{40, 37, 34}

Spark and Melby⁴⁰ reported a fall in blood pressure to normal in each of 20 patients with an aldosterone producing adenoma but in two further patients with low renin hyperaldosteronism and histologically normal adrenal glands, blood pressure was unaltered during treatment with spirolactone. However, a satisfactory hypotensive response to spirolactone has been reported in some patients without an adrenocortical tumor.^{30, 1, 33}

This larger series confirms our previous report² that spirolactone produced a significant fall in blood pressure in patients both with and without adenoma. However, blood pressure did not return to normal in all patients even in the adenoma group. This observation was not unexpected as the removal of the cause of secondary hypertension does not always result in a fall of blood pressure to normal.⁴⁹ Although the fall in systolic blood pressure did not differ significantly between the pathological groups, the fall in diastolic pressure was significantly greater in the adenoma group.

Plasma electrolyte abnormalities were corrected in all cases, irrespective of the blood pressure response. Hyperkalemia was rare in the absence of renal impairment and resolved spontaneously when the dose of spirolactone was reduced or stopped.⁵¹ However potassium supplements were not needed and should be avoided during treatment with spirolactone. The increase in blood urea during treatment may result from a decrease in glomerular filtration rate as a result of shrinkage in plasma and extracellular fluid volumes.²

In the two patients in whom aldosterone secretion rate was measured before and during spirolactone

treatment no appreciable change occurred. This failure of aldosterone secretion to increase despite several simultaneous potential stimuli (increases in plasma renin, angiotensin II and potassium concentrations and in exchangeable and total body potassium with a decrease in plasma and exchangeable sodium) suggests autonomy of the adrenal adenomata in these patients. Others describe a rise in aldosterone secretion⁴⁰ and excretion³⁰ during spirolactone, suggesting a variable degree of autonomy of such tumors. Although changes in plasma aldosterone during treatment may not accurately reflect aldosterone secretion rate,² contrasting changes in plasma aldosterone during spirolactone might suggest variable adrenal autonomy, with spontaneous fluctuations. However, the fall in plasma aldosterone levels observed in some patients might also result from a direct inhibition of aldosterone synthesis by spirolactone, an effect previously shown in the rat adrenal *in vitro*.^{37, 38} Spirolactone reduced the rise in aldosterone induced by other diuretic drugs in normals.⁴⁹ Such an effect was suggested by Sundsfjord and colleagues⁴⁰ who described a fall in plasma aldosterone and in aldosterone secretion in one patient with primary hyperaldosteronism treated with spirolactone. In the entire present series spirolactone did not cause a significant rise in plasma aldosterone (Table II) while amiloride did (Table III); this could well reflect in part an inhibitory effect of spirolactone on aldosterone biosynthesis.

By controlling hypertension and correcting electrolyte abnormalities treatment with spirolactone or amiloride should increase the safety of subsequent adrenal surgery. It has also been suggested that by activating the renin angiotensin system spirolactone may reduce the risk of temporary hypoadosteronism in the postoperative period.⁴¹ However Bravo and colleagues⁴ have been unable to confirm this and suggest that spirolactone may actually contribute to postoperative hypoadosteronism by direct inhibition of aldosterone synthesis.

Side effects encountered were similar to those reported previously.^{21, 32} Contrary to the experience of others,^{40, 41} the drug has been well tolerated in the great majority. Epigastric discomfort was usually overcome by taking the drug with or after meals. One patient experienced exacting

We are grateful to G D Searle & Co High Wycombe England and to Merck Sharp & Dohme Hoddeston England for financial support

REFERENCES

- 1 Ferriss J B, Beavers D G, Brown J J, Davies D L, Fraser R, Lever A F, Mason P, Neville A M, and Robertson J I S. Clinical biochemical and pathological features of low renin ("primary") hyperaldosteronism. *Am Heart J* 95:375 1978
- 2 Ferriss J B, Beavers D G, Brown J J, Fraser R, Lever A F, Padfield P L, and Robertson J I S. Low renin ("primary") hyperaldosteronism: differential diagnosis and distinction of sub groups within the syndrome. *Am Heart J* 95:641 1978
- 3 Conn J W, Knopf R F, and Nesbit R M. Clinical characteristics of primary aldosteronism from an analysis of 145 cases. *Am J Surg* 107:159 1964
- 4 Brown J J, Chinn R H, Davies D L, Dusterdieck G, Fraser R, Lever A F, Robertson J I S, Tree M, and Wileman A. Plasma electrolytes, renin and aldosterone in the diagnosis of primary hyperaldosteronism: with a note on plasma corticosterone concentration. *Lancet* 2, 55 1968
- 5 Davis W W, Newsome H H, Wright L D, Hammond W H, Easton J, and Bartter F C. Bilateral adrenal hyperplasia as a cause of primary aldosteronism with hypertension, hypokalaemia and suppressed renin activity. *Am J Med* 42:642 1967
- 6 Katz F H. Primary aldosteronism with suppressed plasma renin activity due to bilateral nodular adrenocortical hyperplasia. *Ann Intern Med* 67:1035 1967
- 7 Laragh J H, Ledingham J G G, and Sommers S C. Secondary aldosteronism and reduced plasma renin in hypertensive disease. *Trans Assoc Am Physicians* 80:168 1967
- 8 Grun C E, McBryde A C, Glenn J F, and Cunnella J C. Childhood primary aldosteronism with bilateral adrenocortical hyperplasia: plasma renin activity as an aid to diagnosis. *J Pediatr* 71:377 1967
- 9 Rhamy R K, McCoy R M, Scott H W, Fishman L M, Mikelakis A M, and Liddle G W. Primary aldosteronism: experience with current diagnostic criteria and surgical treatment in fourteen patients. *Ann Surg* 167:18 1968
- 10 Duller A, Barth C, Roscher S, Vecsei P, Dhoni G, and Wolff H F. Hochdruck und Aldosteronismus bei soliden Adenomen und bei nodularer Hyperplasie der Nebennierenrinde. *Klin Wochenschr* 47:688 1969
- 11 Ferriss J B, Brown J J, Fraser R, Kay A W, Lever A F, Neville A M, O'Murchaigh I G, Robertson J I S, and Symington T. Hypertension with aldosterone excess and low plasma renin: pre-operative distinction between patients with and without adrenocortical tumour. *Lancet* 2:995 1970
- 12 George J M, Wright L, Bell N H, and Bartter F C. The syndrome of primary aldosteronism. *Am J Med* 43:343 1970
- 13 Baer L, Sommers S C, Krakoff L H, Newton M A, and Laragh J H. Pseudo primary aldosteronism: an entity distinct from true primary aldosteronism. *Circ Res* 26 and 27(Suppl 1):203 1970
- 14 Biglieri E G, Schambelan M, Slaton F E, and Stockigt J R. The intercurrent hypertension of primary aldosteronism. *Circ Res* 26 and 27(Suppl 1):195 1970
- 15 Sutherland D J A, Ruse J L, and Landau J C. Hypertension increased aldosterone secretion and low plasma renin activity relieved by dexamethasone. *Can Med Assoc J* 95:1109 1966
- 16 New M I and Peterson R E. A new form of congenital adrenal hyperplasia. *J Clin Endocrinol Metab* 27:300 1967
- 17 Mura K, Yoshimura K, Coto K, Katsushima I, Maebashi M, Demura H, Iino M, Demura R, and Torikai T. A case of glucocorticoid responsive hyperaldosteronism. *J Clin Endocrinol Metab* 28:180 1968
- 18 Giebink J S, Gotlin R W, Biglieri E G, and Katz F H. A kindred with familial glucocorticoid-suppressible aldosteronism. *J Clin Endocrinol Metab* 36:710 1973
- 19 Foye L V, Feichtmeir T V. Adrenal cortical carcinoma producing solely mineralocorticoid effect. *Am J Med* 19:966 1955
- 20 Brooks R V, McSwainy R H, Prunty F T G, and Wood F J Y. Potassium deficiency of renal and adrenal origin. *Am J Med* 23:391 1957
- 21 Zimmermann H, Moran W H, Rosenberg J C, Kennedy B J, and Frey R J. Physiologic and surgical problems in the management of primary aldosteronism. *Ann Surg* 180:653 1973
- 22 Crane M G, Harris J J, and Herber R. Primary aldosteronism due to an adrenal carcinoma. *Ann Intern Med* 63:494 1965
- 23 Neville A M, Symington T. Pathology of primary aldosteronism. *Cancer* 19:1854 1967
- 24 Harrison J H. In discussion. *Ann Surg* 164:509 1966
- 25 Biglieri E G, Slaton P F, Schambelan M, and Kronfeld S J. Hypermineralocorticoidism. *Am J Med* 45:10 1968
- 26 Altman S L, Dominguez C, Lopez Gomez A, and Lieber A L. Primary adrenocortical carcinoma causing aldosteronism. *Cancer* 24:602 1969
- 27 Filipceki S, Feltyowski T, Poplaska W, Lapinska K, Krus, S, Wocla B, and Januszewicz W. Carcinoma of the adrenal cortex with hyperaldosteronism. *J Clin Endocrinol Metab* 35:275 1972
- 28 Ehrlich E N, Dominguez O V, Samuels L T, Lynch D, Oberhelman H, and Warner N E. Aldosteronism and precocious puberty due to an ovarian androblastoma (Sertoli cell tumor). *J Clin Endocrinol Metab* 23:308 1963
- 29 Todesco S, Terribile V, Borsatti A, and Mantero F. Primary aldosteronism due to a malignant ovarian tumor. *J Clin Endocrinol Metab* 41:809 1975
- 30 Brown J J, Chinn R H, Ferriss J B, Fraser R, Lever A F, and Robertson J I S. Effets d'un traitement prolongé par la spironolactone sur les electrolytes, plasmas matiques et la pression sanguine des malades atteints d'hyperaldosteronisme primaire. *Acta Nephrol Hypertol Necker* 131:19 1970
- 31 Brown J J, Ferriss J B, Fraser R, Lever A F, and Robertson J I S. Spironolactone in the treatment of hypertension with aldosterone excess. In: The medical uses of spironolactone. G M Wilson ed. Amsterdam 1971. Excerpta Medica p 77
- 32 Brown J J, Davies D L, Ferriss J B, Fraser R, Haywood E, Lever A F, and Robertson J I S. Comparison of surgery and prolonged spironolactone therapy in patients with hypertension, aldosterone excess and low plasma renin. *Br Med J* 2:29 1971
- 33 Ferriss J B, Brown J J, Fraser R, Haywood E, Davies D L, Kay A W, Lever A F, Robertson J I S, Owen K, and Pearl W. Results of adrenal surgery in patients with hypertension, aldosterone excess and low plasma renin concentration. *Br Med J* 1:135 1975

slightly less effective with the doses discussed. The evidence suggests that when there is an unsatisfactory hypotensive response to spironolactone in adequate dosage (300 to 400 mg daily), a significantly greater fall in blood pressure after adrenal surgery is unlikely. Amiloride also seems unlikely to be effective and hypertension must be controlled with other conventional hypotensive drugs. However, irrespective of the effects on blood pressure, electrolyte abnormalities are invariably corrected by spironolactone, amiloride or appropriate adrenal surgery.

In those patients in whom an adrenocortical tumor is not found effective adrenal surgery necessitates a total or a sub total adrenalectomy. This exposes the patient to the risks of postoperative adrenal insufficiency while with more conservative surgery there is a risk of recurrence of hyperaldosteronism. For these reasons the alternative of long term spironolactone is probably the treatment of choice for most such patients. Should the patient be unable to tolerate spironolactone, amiloride may be substituted.

Glucocorticoid remediable hyperaldosteronism responds to dexamethasone, 1 to 2 mg daily, usually within one week, although up to four weeks of treatment may be required. All patients with primary hyperaldosteronism should be screened for this condition especially those in whom an adrenocortical adenoma is not identified preoperatively. Dexamethasone 2 mg daily could theoretically lead to adrenal suppression when used for several weeks. Others^{17, 18} have administered dexamethasone 2 mg daily in divided dosage for two weeks followed by dexamethasone 1 mg daily thereafter. In responsive cases blood pressure will fall and electrolyte abnormalities are corrected. Aldosterone values also fall while plasma concentrations of renin and angiotensin should rise. Even with this regime it would seem prudent to test the adrenal response to synthetic ACTH at the end of this period.

When an adrenocortical carcinoma is diagnosed or suspected prompt surgical excision is required.

Summary

Sixty four patients with low renin (primary) hyperaldosteronism underwent adrenal surgery. A unilateral adrenocortical adenoma was found in 48, no tumor was identified in 14, the adrenal

glands then usually showing hyperplasia of the zona glomerulosa. The adrenal lesion in two further patients was difficult to classify. There was a significant fall in systolic and diastolic blood pressure after operation in both the adenoma and hyperplasia groups, although the fall in diastolic pressure was significantly greater in the adenoma group. Blood pressure fell to an arbitrary normal level in 56 per cent of patients with adenoma and in 15 per cent of patients in the hyperplasia group.

Ninety five patients with primary hyperaldosteronism received spironolactone for a minimum period of four weeks. There was a significant fall in mean systolic and diastolic pressure during treatment in both the adenoma and hyperplasia groups. However, the fall in diastolic pressure was again significantly greater in the adenoma group. There was a significant positive correlation between the fall in blood pressure during spironolactone and following adrenal surgery.

Eighteen patients also received amiloride preoperatively and again there was a significant fall in systolic and diastolic blood pressure although levels were slightly higher than during spironolactone or after subsequent adrenal surgery. Nineteen patients received a two week course of dexamethasone without effect on blood pressure or the electrolyte abnormalities.

It is suggested that removal of the tumor bearing gland is usually the treatment of choice for patients with an aldosterone producing adenoma, provided preoperative spironolactone has reduced blood pressure to normal or near normal. However long term spironolactone is an acceptable alternative. For patients in the hyperplasia group long term spironolactone is usually the treatment of choice. If this drug is not tolerated amiloride may be substituted. If preoperative spironolactone does not produce a satisfactory hypotensive response adrenal surgery is unlikely to do so and hypertension should be controlled with other conventional hypotensive drugs. All patients with primary hyperaldosteronism in whom an adrenocortical adenoma is not identified preoperatively should be screened for the rare glucocorticoid remediable variant. Dexamethasone 1 to 2 mg daily for two to four weeks will reverse the biochemical abnormalities and reduce blood pressure. When an adrenocortical carcinoma is suspected prompt surgical excision is required.

- 71 Brown J J, Fraser R, Lever A F., and Robertson J I S. Aldosterone: physiological and pathophysiological variations in man. *Can Endocrinol Metabol* 1397 1972.
- 72 Silen W, Biglieri E U, Slaton H, and Galante M. Management of primary aldosteronism: evaluation of potassium and sodium balance technique of adrenalectomy and operative results in 24 cases. *Ann Surg* 164 600 1966.
- 73 Brooks R V, Felix Davies, D, Lee M H, and Robertson I W. Hyperaldosteronism from adrenal carcinoma. *Br Med J* 1 100 1972.
- 74 Brown J J, Ferriss J B., Fraser R., Lever A F., and Robertson J I S. Aldosterone excess and adrenal carcinoma. *Br Med J* 1 686 1972.
- 75 Boddy K, King P C., Tathill P, and Strong J A. Measurement of total body potassium with a high sensitivity shadow shield whole body counter: calibration and sources of error. *Phys. Med Biol* 16 275 1971.

34. Kremer D, Beevers D G, Brown J J, Davies D L, Ferriss J B, Fraser R, Lever A F, and Robertson J I S. Spironolactone and amiloride in the treatment of low renin hyperaldosteronism and related syndromes. *Clin Sci Mol Med* 45 213s 1973
35. Brown J J, Fraser R, Kremer D, Lever A F, Morton J J, and Robertson J I S. A comparison of the effects of amiloride with those of spironolactone in the treatment of primary hyperaldosteronism and essential hypertension. In *Physiologie Pathologie et Traitement de l'hyperaldosteronisme* N Meyer ed Paris 1975 Laboratoires MSD pp 135 157
36. Bangham D R, Robertson I, Robertson J I S, Robinson C J, and Tree M. An international collaborative study of renin assay: establishment of the International Reference preparation of human renin. *Clin Sci Mol Med* 48 135s 1975
37. Hamilton M, Pickering G W, Roberts J A F, and Sowry G S C. The aetiology of essential hypertension 1. The arterial pressure in the general population. *Clin Sci* 13 11 1954
38. Editorial. Renal tumours and hypertension. *Br Med J* 3 327 1968
39. Conn J W. The evolution of primary aldosteronism 1954 1967. *Harvey Lect* 62 257 1968
40. Spark R F, and Melby J C. Aldosteronism in hypertension: the spironolactone response test. *Ann Intern Med* 69 685 1968
41. Flanagan M J, McDonald J H. Heterotopic adrenocortical adenoma producing primary aldosteronism. *J Urol* 98 133 1967
42. Kawasaki T, Omai T, Tanaka K, Matsunaga M, and Emoto K. Remission of recurrent hyperaldosteronism resulting from sub total adrenalectomy of adenomatous hyperplastic adrenal glands. *J Clin Endocrinol Metab* 33 474 1971
43. Orth D N, and Liddle G W. Results of treatment in 108 patients with Cushing's syndrome. *N Engl J Med* 285 243 1971
44. Besser G M, and Edwards C R W. Cushing's syndrome. *Clin Endocrinol Metab* 1 451 1972
45. Kagawa C M, Cella J A, and Van Arman C G. Action of new steroids in blocking effects of aldosterone and deoxycorticosterone on salt. *Science* 126 1015 1957
46. Liddle G W. Sodium diuresis induced by steroidal antagonists of aldosterone. *Science* 126 1018 1957
47. Salassa R M, Mattox V R, and Power M H. Effect of an aldosterone antagonist on sodium and potassium excretion in primary hyperaldosteronism. *J Clin Endocrinol Metab* 18 787 1958
48. Conn J W, Louis L H, Fajans S S, Streeten D H P, Johnson R D, Moorhouse J R, Crane M G, Berker A F, and Ramirez E. Metabolic effects in normal men and in primary aldosteronism of a synthetic aldosterone antagonist. *J Lab Clin Med* 52 805 1958
49. Bolte F, Verdy M, Marc Aurele J, Brouillet J, Beauregard P, and Genest J. Studies on new diuretic compounds: spironolactone and chlorothiazide. *Can Med Assoc J* 79 881 1958
50. Mobley J E, Headstream J W, and Melby J. Primary aldosteronism: preoperative preparation with spironolactone. *J A M A* 180 1036 1962
51. Flanagan M J, Ganit C J, and McDonald J H. Primary aldosteronism. *J Urol* 88 111 1962
52. Brown J J, Davies D L, Lever A F, Peart W S, and Robertson J I S. Plasma concentration of renin in a patient with Conn's syndrome with fibroid lesions of the renal arterioles: the effect of treatment with spironolactone. *J Endocrinol* 33 279 1965
53. Gwinup G, and Steinberg T. Differential response to thiazides and spironolactone in primary aldosteronism. *Arch Intern Med* 120 436 1967
54. Brown J J, Chinn R H, Dusterdieck G O, Fraser R, Gleadie R H, Lever A F, Robertson J I S, and Tree M. Hypertension and hyperaldosteronism with low plasma renin concentration: analysis of a series of 87 patients. *Proc R Soc Med* 62 1258 1969
55. Crane M G, and Harris J J. Effect of spironolactone in hypertensive patients. *Am J Med Sci* 260 311 1970
56. Pickering G W. Hypertension: causes, consequences, and management. Edinburgh 1974. Churchill Livingstone p 12
57. Erbler H C. Stimulation of aldosterone production in vitro and its inhibition by spironolactone. *Naunyn-Schmiedeberg Arch Pharmacol* 273 366 1972
58. Erbler H C. On the mechanism of the inhibitory action of spironolactone SC 9376 (Aldidene) on the production of corticosteroids in rat adrenals in vitro. *Naunyn-Schmiedeberg Arch Pharmacol* 277 139 1973
59. Erbler H C. The effect of saluretics and spironolactone on aldosterone production and electrolyte excretion in man. *Naunyn-Schmiedeberg Arch Pharmacol* 288 145 1974
60. Sundsfjord J A, Marton P, Jørgensen H, and Ankvaa A. Reduced aldosterone secretion during spironolactone treatment in primary aldosteronism: report of a case. *J Clin Endocrinol Metab* 39 734 1974
61. Monimoto E, Takeda R, and Murakami M. Does prolonged pre-treatment with large doses of spironolactone hasten a recovery from juxta glomerular adrenal suppression in primary aldosteronism? *J Clin Endocrinol Metab* 31 639 1970
62. Bravo E L, Dustan H P, and Tarazi R C. Selective hyperaldosteronism despite prolonged pre- and postoperative hyperreninaemia in primary aldosteronism. *J Clin Endocrinol Metab* 41 611 1975
63. Editorial. Management of primary and secondary hyperaldosteronism. *Br Med J* 3 427 1969
64. Kremer D, Brown J J, Davies D L, Fraser R, Lever A F, and Robertson J I S. Amiloride in primary hyperaldosteronism with chronic peptic ulceration. *Br Med J* 2 216 1975
65. Bull M B, and Laragh J H. Amiloride: a potassium sparing natriuretic agent. *Circulation* 37 43 1968
66. Lent A F, Smith A J, and Wilson G M. Clinical Evaluation of Amiloride: a potassium sparing diuretic. *Clin Pharmacol Ther* 10 50 1969
67. Brann C H, Campbell R G, Hashim S A, and Van Italie T H. Use of amiloride in preoperative management of a patient with primary aldosteronism. *Am J Med* 45 480 1968
68. Newton M A, and Laragh J H. Effects of glucocorticoid administration on aldosterone excretion and plasma renin in normal subjects in essential hypertension and in primary aldosteronism. *J Clin Endocrinol Metab* 28 1014 1968
69. Slaton J F, Schambelan M, and Biglieri F G. Stimulation and suppression of aldosterone secretion in patients with an aldosterone producing adenoma. *J Clin Endocrinol Metab* 29 270 1969
70. New M I, Siegel F J, and Peterson R F. Deoxymethasone suppressible hyperaldosteronism. *J Clin Endocrinol Metab* 37 93 1973

rare in developed countries. Untreated this disorder tends to have one of four outcomes: (1) progressive cardiac compression from effusion and constriction leading to death within several months; (2) development of fatal tuberculosis elsewhere; (3) apparent resolution with later occurrence of tuberculosis in other organs; (4) apparent resolution with possible late constriction.⁸ Several untreated patients with bacteriologically proved tuberculous pericarditis have had delayed constriction which on histologic and bacteriologic examination showed no evidence of its tuberculous etiology.⁹ This discovery emphasizes the frequent difficulty in delineating the etiology of pericardial constriction but it is unlikely that tuberculosis is currently responsible for a substantial proportion of cases in the United States.

The frequency of constriction with or without effusion that occurs in treated tuberculous pericarditis has ranged from 50 to 65 per cent.⁹ It may develop during therapy or years after apparent bacteriologic cure. In one retrospective study four of 18 patients (22 per cent) receiving corticosteroid therapy in addition to antituberculous agents required pericardiectomy compared to five of ten patients (50 per cent) treated without corticosteroids.⁹ There are however no prospective controlled studies that examine whether corticosteroid therapy reduces the incidence of subsequent constriction in this or any other form of pericarditis.

Fungal. Patients with disseminated coccidioidomycosis uncommonly have pericardial involvement apparently by spread from an underlying myocardial abscess. This may rarely progress to constriction.¹⁰ One case has occurred a year following apparently uncomplicated acute coccidioidomycosis.

Histoplasma capsulatum can cause an acute pericarditis characterized by a prodrome of fever, malaise, rhinorrhea and cough lasting several weeks followed by chest pain and frequently by pleural effusion. The illness tends to last about ten weeks. Histoplasmosis has been demonstrated by serologic changes but has not been cultured. Pericardial constriction has occurred three years following acute pericarditis in one case in which organisms were demonstrated histologically but not by culture in the resected pericardium.¹¹ Because histoplasmosis is so common in the

Table 1 Causes of constrictive pericarditis

Hereditary
Mulibrey nanism
Infections
Bacterial
Mycobacterial
Fungal
Viral
Parasitic
Connective tissue disorders
Rheumatoid arthritis
Systemic lupus erythematosus
Polysarthritis nodosa
Metabolic
Uremia
Trauma
Blunt or penetrating thoracic trauma
Surgery
Radiation therapy
Neoplastic
Benign or malignant pericardial tumors
Metastatic malignancy

United States this disease may be a more frequent cause of pericardial constriction than is currently recognized in addition mediastinal fibrosis an exuberant fibrosing response to histoplasma mediastinal node infection may involve the pericardium and cause constriction.¹²

Viral. Several viruses especially Coxsackie B¹³ can apparently cause acute myopericarditis and are probably responsible for most cases of acute benign nonspecific pericarditis.¹⁴ Only rarely however has the virus actually been grown from the pericardial fluid.¹⁵ Instead a viral etiology has been inferred from serologic changes or isolation of the organism from stool or pharynx at the time of the pericarditis. In some of these cases pericardial constriction has occurred several weeks to years following the acute event.^{16,17} An epidemic of Coxsackie pericarditis was apparently responsible for a sudden upsurge of pericardial constriction over a three year period in Vancouver British Columbia. Infectious mononucleosis an infection from Epstein Barr virus has caused a case of pericardial constriction with effusion.¹⁸

Parasitic. Perforation of an amebic liver abscess into the pericardium causes a purulent pericarditis that may rapidly constrict.¹⁹ Dracunculosis²⁰ rupture of an echinococcal cyst into the pericardium²¹ and filariasis²² have rarely caused pericardial constriction.

Pericardial constriction

J V Hirschmann, MD

Seattle Wash

Definition and terminology

When involved by inflammation, extensive fibrosis, calcification or neoplasm, the pericardium may become rigid and impede filling of the enclosed cardiac chambers. The usual term for this condition, *chronic constrictive pericarditis*, is somewhat inaccurate since inflammation may be absent. *Pericardial constriction*, however, is especially felicitous since it suggests both constriction of and constriction by the pericardium its contraction and its compression of underlying structures. The two layers are frequently fused but sometimes the constriction is mainly from the visceral pericardium (epicardium), often with a tense effusion. Usually labeled *effusive-constrictive pericarditis*, *pericardial constriction with effusion* is appropriate for this condition, where cardiac compression by both pericardial fluid and a rigid pericardium can cause somewhat different clinical and hemodynamic findings.

Etiology (Table 1)

Most cases probably originate as pericardial inflammation with exudation of fluid into the pericardial sac. This is resorbed and the visceral and parietal pericardial layers then fuse. Several disorders may cause the initial inflammation but in most cases no underlying etiology is evident clinically or histologically. Instead nonspecific fibrous tissue sometimes accompanied by calcification has replaced the original inflammatory process.

From the Department of Medicine, University of Washington School of Medicine and the Veterans Administration Hospital, Seattle, Wash.

Received for publication Apr 27, 1977

Reprint requests: J V Hirschmann, MD, Medicine Dept, VA Hospital, 4430 Beacon Ave, South Seattle, Wash 98108.

Hereditary

"Muhbrey" nanism (dwarfism) found mostly in Finland, is an autosomal recessive disorder whose name is an acronym from *muscle, liver, brain and eye*, the principal organs involved. Its diagnosis requires the presence of short stature plus at least two of the following four features: yellow dots in the ocular fundi; clinical evidence of pericardial constriction; fibrous dysplasia in the long bones; and a slightly increased basilar skull angle with a long shallow J shaped sella turcica. Almost all patients have had clinical evidence of pericardial constriction; eight of 26 reported cases have had surgical confirmation with resected tissue showing non specific fibrosis.

Infections

Bacterial. A wide variety of bacteria— aerobic, anaerobic and higher bacteria like *Actinomyces* and *Nocardia*—can cause purulent pericarditis by several mechanisms: (1) contiguous spread from adjacent mediastinal, pulmonary or pleural infections; (2) introduction of organisms by penetrating trauma including surgery; (3) contiguous spread from an underlying myocardial abscess; (4) hematogenous involvement during bacteremia. Acute pericardial constriction can occur over several days to weeks in this setting, cardiac compression resulting from the combination of a thickened adherent pericardium and purulent material in varying stages of organization. Surgical drainage is usually necessary for survival with pericardiectomy the optimal procedure. Rarely, chronic constriction may occur months to years after apparent recovery from acute purulent pericarditis if other drainage procedures were used.

Mycobacterial. Tuberculous pericarditis is now

the commonest underlying malignancy probably because they so often receive mediastinal irradiation and because their frequent long term survival allows the fibrosing process to develop

Neoplastic

Sometimes the neoplastic process rather than its treatment causes pericardial effusions and constriction. Primary pericardial tumors both benign² and malignant³ have led to constriction. Malignancy of other organs most commonly breast or lung carcinoma, malignant melanoma, leukemia or lymphoma may cause cardiac compression by a large effusion or through neoplastic pericardial thickening.

Clinical features^{4,5} (Tables II and III)

Population involved. Pericardial constriction occurs in all decades of life with most series reporting an average age in the thirties. Almost all have an unexplained male predominance of about 3:1. There seems to be no racial predisposition except in association with tuberculous pericarditis which has a higher incidence in blacks.^{6,7}

Symptoms. The onset is typically insidious, symptoms frequently being present for months to years before the diagnosis is established. The most common and usually earliest complaint is exertional dyspnea, a consequence of several possible mechanisms: limited diaphragmatic excursion from ascites; restrictive lung disease from the pleural effusions; pulmonary venous hypertension. In addition, the arteriovenous oxygen difference increases abnormally on exercise because tachycardia cannot maintain an adequate cardiac output in the face of a stroke volume that is decreased and relatively fixed by the rigid pericardial shell. Increased ventilation creating the sensation of dyspnea is necessary to ensure full oxygenation of the abnormally desaturated blood arriving in the lungs. Orthopnea, present in a minority of patients, may be related to either the ascites or the pulmonary vascular congestion. Paroxysmal nocturnal dyspnea is quite uncommon, perhaps because the rigid pericardium which inhibits diastolic filling prevents the increased venous return occurring with recumbency from reaching the pulmonary vasculature. Similarly, frank pulmonary edema is rare.

Ascites, a prominent early finding, often

without accompanying peripheral edema results from a combination of factors. The increased systemic venous pressure causes portal hypertension and impedes hepatic lymph return. In addition, the decreased cardiac output reduces renal perfusion, resulting in increased sodium retention. The varying contribution of these factors determines whether the ascitic fluid is high in protein (from protein rich lymph) or low, both circumstances having been described.^{8,9}

Peripheral edema alone or with ascites is usually present as a manifestation of the increased systemic venous pressure and sodium retention. Typically most prominent in the lower extremities, it may occasionally occur in the face.¹⁰

Constitutional symptoms of weakness and fatigue are common, and some patients describe weight loss and anorexia. These may be the effects of hepatic congestion and a low cardiac output. Amenorrhea may occur in females.

Unless the inflammatory process is still active, chest discomfort is uncommon, but abdominal pain in the right upper quadrant may occur from hepatic enlargement. Other uncommon symptoms include dizziness or syncope and dysphagia, which is probably due to left atrial impingement on the esophagus.

Unusual clinical features

Localized constriction. The process causing constriction usually affects the pericardium diffusely and equally. Occasionally, however, there may be a localized area of constriction, most often in patients with previous inadequate pericardiectomies, but rarely without prior surgery.¹¹ The clinical presentation has most commonly resembled infundibular pulmonary stenosis, usually with right ventricular hypertrophy and failure and a calcified constricting band evident on chest roentgenogram. Others have resembled mitral stenosis—from a constricting band in the atrioventricular groove¹² or pulmonary veins—and aortic stenosis—from constriction at the aortic root.¹³ In most of the cases, these unusual features have been associated with clinical evidence of typical pericardial constriction.

Protein losing enteropathy. The markedly elevated systemic venous pressure may obstruct lymphatic drainage from the small intestine, rarely causing substantial gastrointestinal pro-

Table II Symptoms

Symptom	Approximate incidence
Dyspnea	85%
Peripheral edema	70%
Abdominal distention	65%
Weakness fatigue	30%
Orthopnea	30%
Paroxysmal nocturnal dyspnea	10%

Table III Signs

Sign	Approximate incidence ¹¹
Distended neck veins	95%
Hepatomegaly	90%
Ascites	70%
Peripheral edema	70%
Pulse pressure less than 35 mm Hg	50%
Third heart sound	40%
Pulsus paradoxus	35%
Cyanosis	25%
Splenomegaly	10%

Connective tissue disorders

Clinical and necropsy studies indicate that pericarditis, usually asymptomatic, is common in rheumatoid arthritis.¹ A few develop pericardial tamponade, more have pericardial constriction with at least 46 cases reported.²² There is a male predominance, and most patients have had moderate or severe arthritis for several years, usually with subcutaneous nodules and a positive rheumatoid factor. The pericardial constriction has no distinctive features, although many have an accompanying pericardial effusion.

Although pericarditis and effusions are frequent in systemic lupus erythematosus, pericardial constriction is rare. It has occurred, however, with both spontaneous²³ and drug induced²⁴ forms. It has been associated with polyarteritis nodosa,²⁵ but for unknown reasons probably does not occur from the pericarditis of acute rheumatic fever.²³

Metabolic

Pericarditis occurs in the terminal stages of both acute and chronic renal failure.²⁶ Untreated patients usually die shortly after its appearance, but it typically responds well to dialysis. About 10 to 15 per cent of patients on maintenance chronic hemodialysis develop this disorder, some early in

the course, but many only after months of conventional dialysis. The prominent manifestations are pain and fever, the major complications tamponade and constriction. The latter has occurred from six weeks to 11 months after the acute pericarditis, with an average of about six months. The pathogenesis of uremic pericarditis is unknown. Hemopericardium from the uremic coagulation abnormalities may be an important factor, in some cases perhaps exacerbated by systemic heparinization during hemodialysis.

Trauma

The presence of blood in the pericardial sac seems to elicit inflammation which can sometimes evolve into fibrosis and pericardial constriction. Whole blood injected into the pericardial sac of dogs is rapidly absorbed, leaving minimal if any, inflammation, pericardial thickening and scarring. When superficial myocardial or epicardial injury is inflicted with a knife and bleeding occurs, however, pericardial constriction may develop over many months.²⁷ These results suggest that the formation of adhesions in the pericardial cavity requires damage to the mesothelial lining. This probably decreases both the mesothelial capacity to absorb blood and the normal mesothelial fibrinolytic activity. Since injection of the lipid fraction of blood into the pericardial sac can produce constriction,²⁸ the lipid components of the blood may be the most important factor in the development of inflammation and eventual constriction. Alternatively, the traumatic pericardial injury may cause an immunologically mediated inflammation analogous to the post pericardiectomy syndrome.²⁹

One or both of these mechanisms may be involved in the constricting process sometimes observed months to years following penetrating or blunt thoracic trauma.³⁰ Unusual etiologies include foreign bodies (needles) in the myocardium³¹ and cardiac surgery, with constriction occurring several weeks postoperatively.³²

Radiation³³

Patients receiving therapeutic mediastinal radiation may develop pericardial constriction with or without pericardial effusion several months to years later. In some a preceding episode of symptomatic acute pericarditis has occurred. Most have received a minimum of 4,000 rads to the heart. Hodgkins disease or other lymphomas are

Table VI Hemodynamic differentiation of pericardial constriction and cardiomyopathy

	Pericardial constriction	Cardiomyopathy
Left ventricular diastolic pressure—right ventricular diastolic pressure	< 6 mm Hg	> 6 mm Hg
Right ventricular diastolic pressure	$\geq \frac{1}{2}$ of right ventricular systolic pressure	< $\frac{1}{2}$ of right ventricular systolic pressure
Pulmonary artery systolic pressure	< 50 mm Hg	> 50 mm Hg

ascent in the jugular pulse as ventricular filling is abruptly terminated by the rigid pericardium. With normal sinus rhythm the x descent may also be prominent.¹⁰

The apical impulse is often inapparent because of a reduced stroke volume and the insulating and confining effect of the thickened pericardium. When the apical impulse is detectable there may be systolic retraction. Coincident with rapid left ventricular filling an outward thrust may occur causing an early diastolic apical impulse.¹¹ The heart sounds are often distant although clear loud sounds do not exclude the diagnosis.

A characteristic early diastolic sound or "pericardial knock" is present in many patients. Phonocardiographic¹² and angiographic¹³ studies indicate that it occurs from the abrupt halt in ventricular filling coincident with the steep upstroke of the early diastolic dip. It is best heard at the center of the precordium, is snapping in quality (often louder than S₁ or S₂) and can increase in intensity on inspiration. It occurs from 0.09 to 0.13 sec following E, the shorter the interval the more severe the constriction. It therefore occurs earlier than S₁ and later than the opening snap of mitral stenosis. A pericardial friction rub is very unusual.

The chest examination may reveal dullness to percussion and decreased breath sounds from pleural thickening or effusions present in about 60 per cent. Rales from pulmonary vascular congestion are uncommon.

Hepatomegaly occurs early from hepatic engorgement and is present in nearly all patients. With prolonged disease cardiac cirrhosis may develop and occasionally cause a decreased liver size. Splenomegaly may occur from portal hypertension.

Laboratory findings

Routine laboratory data are usually unhelpful. The hematocrit may be decreased perhaps from

the effects of chronic illness or the underlying disease. The white count is usually normal¹⁴ as is the sedimentation rate.¹⁵ Urinalysis may show proteinuria varying from trace to 4+ in those with associated nephrotic syndrome. Hypoalbuminemia may be present because of hepatic dysfunction, increased urine loss with the nephrotic syndrome or from protein losing enteropathy. Bilirubin and liver function tests may be normal or show the changes characteristic of hepatic congestion: bilirubin below 5 mg/100 ml and often predominantly unconjugated; transaminase mildly elevated (40 to 80 u) and rarely above 200; prothrombin time and alkaline phosphatase slightly increased.¹⁶ Liver biopsy usually shows evidence of hepatic congestion and sometimes cardiac cirrhosis but may be normal.¹⁴

Chest roentgenograph (Table IV)

Pericardial calcification present in one half of cases may be inapparent on posteroanterior roentgenographs but detectable on lateral or oblique projections. While pericardial calcification can occur without causing myocardial compression¹⁷ its presence with the clinical features of pericardial constriction is virtually diagnostic. The most frequent sites of calcification are in the coronary sulcus between the left atrium and ventricle along the left heart border and on the sternal or diaphragmatic surfaces of the right ventricle.¹⁸ The presence of calcification probably reflects the duration rather than the cause of the pericardial constriction.

The cardiac silhouette may be decreased or demonstrate a diminution in size on serial films. An increased cardiac silhouette however is common and may occur from the pericardial thickening itself or the presence of a concomitant pericardial effusion. The left atrium may appear enlarged. There is frequently evidence of pulmonary vascular congestion and often manifestations of increased systemic venous pressure. a

Table IV Radiographic abnormalities

Abnormality	Approximate incidence %
Pleural thickening or effusion	55%
Pericardial calcification	50%
Enlarged cardiac silhouette	40%

tein loss by bulk loss of lymph into the bowel lumen, often accompanied by diarrhea. The hypoproteinemia that results when gastrointestinal loss exceeds hepatic production reduces the intravascular osmotic pressure and thus further encourages the formation of peripheral edema. Small intestinal biopsy has demonstrated lymphangiectasia—dilated submucosal lymphatic vessels—and small bowel roentgenography may show the typical findings of that disorder: mild dilatation, diffusely thickened jejunal and ileal mucosal folds, and dilation, flocculation, and segmentation of the barium column.⁶² There may also be gastrointestinal loss of lymphocytes (mostly T cells) in the lymph that results in impaired cell mediated immunity: delayed allograft rejection, cutaneous anergy, and poor *in vitro* lymphocyte proliferative responses.⁶³ The protein losing enteropathy, the lymphangiectasia, and the lymphocytopenia with impaired cellular immunity disappear following pericardiectomy, although sometimes only after several months.

Nephrotic syndrome. The nephrotic syndrome has occurred with pericardial constriction and abated weeks to months following pericardiectomy.⁶⁴⁻⁶⁶ Renal biopsies have shown focal or diffuse membranous glomerular thickening without hypercellularity.⁶⁷⁻⁶⁹ One case showed, in addition, diffuse tubular dilatation with focal interstitial scarring and round cell infiltration.⁶⁷ The pathogenesis of this syndrome is uncertain. The association of the nephrotic syndrome with renal vein thrombosis suggests that increased renal vein pressure may be responsible in both circumstances. In most cases however renal vein thrombosis is a complication, not a cause, of the nephrotic syndrome.⁶⁹

Physical examination. Many patients look chronically ill, the decreased muscle mass a sharp contrast to a protuberant abdomen and the prominent peripheral edema. This appearance

Table V Electrocardiographic abnormalities

Abnormality	Approximate incidence %
Flattened or inverted T waves	95%
Low QRS voltage	65%
Notched prolonged P wave	50%
Persistent atrial fibrillation	25%

frequently suggests a venous systemic disease such as metastatic malignancy or a primary liver disorder.

The patients are afebrile unless the underlying inflammatory process is still active. The rhythm is atrial fibrillation in about 25 per cent and atrial flutter in about 5 per cent. These arrhythmias presumably arise from the stretch and distortion of the atrial conduction system by an increased atrial pressure, but may also be due to inflammatory or fibrotic involvement of the sinoatrial node. Hypertension is very uncommon, and the pulse pressure is often low (less than 30 mm Hg), reflecting the decreased stroke volume. Pulsus paradoxus, an inspiratory decrease of greater than 10 mm Hg in systolic pressure, is uncommon unless there is an associated pericardial effusion, presumably because the rigid pericardial shell is relatively unaffected by changes in intrathoracic pressure.

Examination of the jugular venous pulse is the single most important physical observation. Unless the patient has undergone vigorous diuretic therapy, which can reduce the systemic venous pressure to normal, the jugular venous pressure is virtually always elevated. Frequently the veins are distended to the mandibular angle in the upright position. Inspiratory distension of the cervical veins (Kussmaul's sign) indicating an increased inspiratory venous return that the encased right ventricle is unable to accept is present in a minority of patients. The high venous pressure may obscure this sign as well as the pulse waves.⁷⁰ When visible the jugular waves often show a rapid y descent occurring at the time of tricuspid valve opening. This results from the brisk but brief inflow of blood into the right ventricle from the high right atrial pressure. The presence of a rapid y descent excludes the diagnosis of tricuspid stenosis,⁷¹ which also has the clinical features of a high systemic venous pressure. The rapid y descent is followed by rapid

contractility have varied dp/dt V_{max} and measurements of circumferential fiber shortening have been normal " or decreased " The differences may in part reflect the degree of myocardial fibrosis and atrophy present

With exercise²¹ the cardiac output is subnormal in relationship to the increased oxygen consumption The AV O₂ difference widens abnormally The stroke volume fails to increase because of limitations to diastolic filling There is a marked elevation in right ventricular diastolic pressure but the difference between left and right diastolic pressures remains low and essentially unchanged "

The angiographic findings may include increased extraluminal soft tissue thickness along the lower right heart border straightening and immobility of the right atrial border superior vena caval dilatation and left atrial enlargement While coronary arteriography is not routinely indicated unless it is necessary to exclude the presence of ischemic heart disease it does show extension of the heart shadow beyond the ventricular epicardium as delineated by the coronary arteries This finding indicates percardial thickening and/or fluid "

Features of percardial constriction with effusion²²

Patients having percardial constriction with effusion tend to be somewhat younger than those with percardial constriction alone The most frequent causes are idiopathic (many presumably viral) radiation therapy uremia neoplasm or rheumatoid arthritis The duration of symptoms is typically weeks to months rather than years and unlike percardial constriction alone there is frequently a preceding history of acute percarditis with fever pleuritic chest pain and percardial friction rub The symptoms are similar—dyspnea abdominal distension and ankle edema most prominently—but some physical features differ Paradoxical pulse is more common but Kussmaul's sign and the diastolic knock are unusual While there are T wave flattening and inversion and frequently low voltage abnormal P waves and atrial fibrillation are generally absent The cardiac silhouette is usually enlarged on chest roentgenogram and percardial calcification is rare The catheterization results show a generally higher right atrial

pressure that decreases to the usual level seen in percardial constriction following percardiectomy The x descent is predominant or equal to the y descent predominant y descent is not seen until percardial fluid is removed At operation there is extensive thickening of both visceral and parietal percardial layers with the percardial space generally containing several hundred c c of fluid often bloody always high in protein and frequently tense As with percardial constriction alone there may be underlying myocardial atrophy Percardial constriction with effusion can develop into percardial constriction alone over a period of weeks to months and in fact may be a common stage in the evolution of percardial constriction.

Complications

Myocardial fibrosis Perhaps in part from disuse percardial constriction can cause myocardial fiber atrophy and fibrosis In 11 patients dying with chronic percardial constriction muscle fiber thickness was uniformly reduced throughout both ventricles The muscle atrophy seemed related to neither the duration of symptoms nor the thickness of the percardium " Some patients may have replacement of muscle fibers by fibrous tissue at times causing electrocardiographic changes typical of a myocardial infarction in the affected area " Myocardial atrophy or fibrosis may also be responsible for the refractory cardiac failure occasionally following percardiectomy when the myocardium appears unable to handle the increased volume load

Cardiac cirrhosis "

The increased systemic venous pressure of percardial constriction almost always causes severe hepatic congestion which when prolonged can lead to cardiac cirrhosis In this entity there is central atrophy with fibrous bridging between central vein areas The hepatic congestion seems to cause some cellular destruction promoting a reparative fibrogenesis in the damaged centrilobular areas Clear differentiation from simple hepatic congestion is impossible by clinical or biochemical features alone cardiac cirrhosis may have no associated abnormalities in liver function tests and its presence does not seem to increase the incidence of portal hypertension splenomegaly ascites or esophageal varices Perhaps the

widened right upper mediastinum from an enlarged superior vena caval shadow and distended azygous vein⁷⁶⁻⁷⁸ Pleural effusions, present in about 60 per cent, are usually bilateral, when unilateral, they are typically, though not uniformly, right sided Pleural thickening or scarring from the original inflammatory event may also be visible On fluoroscopy the cardiac pulsations are usually, but not always, diminished or absent

Electrocardiogram⁷⁹⁻⁸² (Table V)

The electrocardiogram is rarely normal Atrial fibrillation is present in about 25 per cent, atrial flutter in 5 per cent Paroxysmal supraventricular tachycardia and both supraventricular and ventricular extrasystoles occasionally occur The P wave is often notched and prolonged (> 0.10 sec) resembling "P mitrale," and presumably occurring from left atrial hypertension and enlargement The P-R interval is usually normal The QRS complex often shows decreased voltage, at times confined to the limb leads Some patients may show abnormal Q waves characteristic of myocardial infarction These patients have myocardial fibrosis in the involved area at autopsy⁸³ The QRS axis is usually normal but some show right axis deviation (> 100 degrees) with or without evidence of right ventricular hypertrophy ($R/S > 1$ in V_1) These features are unexplained, since ventricular hypertrophy is not a pathologic feature of the disease Left axis deviation and left ventricular hypertrophy are rare A pattern of incomplete right bundle branch block occasionally occurs

The most common findings, seen in nearly all patients are nonspecific T wave changes—low flat biphasic or inverted T waves in leads where they are normally upright In a minority there is accompanying ST segment depression These changes may represent myocardial involvement from subepicardial penetration of the primary pericardial inflammatory process myocardial atrophy and fibrosis simultaneous involvement of the myocardium and pericardium by the same pathologic process impairment of coronary flow or unrelated coronary artery disease⁸⁴

Echocardiography usually demonstrates an unexplained paradoxical motion of the interventricular septum similar to that seen in right ventricular flow overload syndromes such as

atrial septal defect⁸⁵⁻⁸⁷ Evaluation of pericardial thickness is usually difficult and unhelpful but the echocardiogram is sensitive in detecting any fluid in those with associated pericardial effusion It may also be useful in assessing ventricular size and function

Cardiac catheterization⁸⁸ and angiography⁸⁹

The most important diagnostic procedure is cardiac catheterization, best performed on both right and left sides of the heart and employing angiocardiography Since all diastolic expansion is restricted by the rigid pericardium, all diastolic pressures are elevated and approximately equal, even following exercise The difference between right and left diastolic pressures rarely exceeds 5 to 6 mm Hg Thus, the diastolic pressures in the left and right atria and ventricles and the pulmonary artery are nearly equal

The right atrial pressure usually shows no respiratory variation, but an inspiratory increase (Kussmaul's sign) may be present in some severe cases In sinus rhythm the a and v waves are approximately equal and followed by rapid x and y descents because of the high filling pressure This gives the typical M or W wave form Concurrent with the right atrial y descent is a deep diastolic dip in the right ventricular pressure as rapid filling begins This pressure quickly rises to a plateau as the rigid pericardium impedes further filling This dip and plateau pattern, resembling a square root sign is also present in left ventricular diastolic tracings

Substantial pulmonary hypertension is rare most pulmonary arterial systolic pressures being less than 45 mm Hg The pulmonary capillary wedge pressure tracing has a wave form similar to that of the right atrium Unless vigorous diuresis has caused hypovolemia the ventricular filling pressures are elevated typically to levels between 12 and 25 mm Hg depending on the severity of constriction Pulsus paradoxus occurs in a minority of patients more frequently in those with an associated pericardial effusion

In most cases⁹⁰ the cardiac index and stroke index are low normal or decreased The left ventricular end diastolic volume is reduced in all but mild cases and reflects the severity of constriction The ejection fraction is usually normal but may sometimes be substantially diminished⁹¹ Isovolumic and ejection indices of

existence for 5 to 15 years with repeated paracentesis¹ a procedure apparently unattended by any significant or deleterious hemodynamic consequences despite the removal of large quantities of fluid.^{2,3} An occasional patient has survived for several decades without surgery one of Paul Dudley White's cases having had symptoms for 44 years.⁴ Although some patients respond to vigorous diuretic therapy the treatment of pericardial constriction is pericardiectomy whose delay may risk the development of myocardial atrophy and fibrosis. The surgical mortality rate is small (5 to 10 per cent^{5,6}) and the outcome excellent with about 80 to 90 per cent obtaining complete symptomatic relief. Few derive no benefit.

The basic requirement for surgery is a thorough decortication with the removal of both visceral and parietal pericardial layers from the right and left ventricles. Resection over the left ventricle should proceed at least as far posterolaterally as the phrenic nerve.^{7,8} The approach has varied including median sternotomy which most surgeons favor and left thoracotomy the important point is obtaining excellent exposure. It is probably wise to free the left ventricle first to avoid pulmonary congestion when release of the right ventricle increases pulmonary blood flow and volume. Calcification may require bone cutting instruments and in places may so invade the myocardium that removal is impossible. The necessity of decorticating the atria and vena cava in the absence of obvious constricting bands is debated.^{9,10} This procedure increases the risk and is probably unimportant in most patients.

Hemodynamic measurements immediately following pericardiectomy may show normal values in all chambers normal left atrial and ventricular values with improved but still abnormal right atrial and ventricular measurements or no immediate changes.¹¹ Over the next few days however central venous pressure begins to fall and ordinarily reaches normal levels within four weeks. The pulse pressure increases as stroke volume becomes normal. Cardiac catheterization studies two to five months following surgery demonstrate satisfactory hemodynamic indices in almost all patients. These findings suggest that in some patients there may be reversible myocardial impairment requiring several days to abate following pericardiectomy.

Electrocardiographic abnormalities often resolve postoperatively. The frequently abnormal P wave usually reverts to normal low voltage increases most flat or inverted T waves become upright and right axis deviation disappears. Those with the pattern of incomplete right bundle branch block have no change and atrial fibrillation typically persists.¹²

A few patients have persistently abnormal hemodynamic values following surgery. Probably the most common reason is incomplete pericardiectomy.¹³ Some patients however have substantial myocardial atrophy and fibrosis.¹⁴ They may die shortly after surgery from unremitting cardiac failure the pericardiectomy had the effect of increasing pulmonary blood flow which the left ventricle cannot effectively accept. Others survive surgery but have derived little or no benefit from it. Which patients will not respond to decortication is unpredictable significantly diminished left ventricular function which may persist postoperatively does not preclude improvement in symptoms or other hemodynamic measurements.¹⁵ Hence virtually all patients should receive surgical therapy with the recognition that in a very small number the results will be unimpressive or even catastrophic.¹⁶

REFERENCES

- 1 Roberts W C and Spray T L. In Spodick H editor. Pericardial diseases, Philadelphia 1976 F.A. Davis Company.
- 2 Hancock J W. Subacute effusive-constrictive pericarditis, *Circulation* 43 183 1971.
- 3 Perheentupa J, Autio M, Leisti S, Raitta C., and Tuuten L. Mulhrey nanum: an autosomal recessive syndrome with pericardial constriction. *Lancet* 2 351 1973.
- 4 Voorhes, M L, Husson M., and Blackman M S. Growth failure with pericardial constriction. The syndrome of mulhrey nanum. *Am J Dis Child* 130 1146 1976.
- 5 Rubin R H and Moellering R C Jr. Clinical microbiologic and therapeutic aspects of purulent pericarditis, *Am J Med* 59 68 1975.
- 6 Boyle J D, Pearce M L and Guze L. Purulent pericarditis: review of literature and report of eleven cases, *Medicine* 40 119 1961.
- 7 Andrews H W S, Pickering G W and Sellors T H. The aetiology of constrictive pericarditis with special reference to tuberculous pericarditis together with a note on polyserositis. *Q J Med* 41 291 1948.
- 8 Harvey A M and Whitehill M R. Tuberculous pericarditis. *Medicine* 16 45 1937.
- 9 Rooney J J, Crocco J A and Lyons H A. Tuberculous pericarditis. *Ann Intern Med* 72 73 1970.
- 10 Carson T J, Murray G F, Wilcox B R and Starek

only clue is a small liver, but definitive diagnosis requires a liver biopsy

Differential diagnosis

Unexplained exertional dyspnea, ascites, peripheral edema, or pleural effusions should suggest pericardial constriction. The diagnosis is missed with striking and disconcerting regularity. Hepatic cirrhosis, metastatic malignancy, and Meigs syndrome in females are among the most frequent mistaken diagnoses. Careful examination of the jugular venous pulse, which is elevated in pericardial constriction but normal or low in these other disorders, should prevent such errors.

Most difficult to distinguish from pericardial constriction are the cardiomyopathies, particularly the restrictive forms resulting from such processes as diffuse fibrosis following myocarditis, idiopathic hypertrophy, or infiltrative diseases like amyloidosis, hemochromatosis, or sarcoidosis. In the absence of pericardial calcification or some manifestation of the systemic disorder causing the cardiomyopathy, the sometimes strikingly similar clinical and hemodynamic findings may make clinical differentiation impossible without exploratory surgery. Both cardiomyopathies and pericardial constriction may have clinical features of increased systemic and pulmonary venous pressures, the S_4 of left ventricular failure may be mistaken for a 'diastolic knock,' and the electrocardiographic findings may be identical. Cardiac catheterization in restrictive cardiomyopathy may also show increased systemic and pulmonary venous pressures displaying the M or W configuration and an early diastolic dip and plateau pattern of ventricular pressure.²⁰ While certain findings on catheterization may help to distinguish these disorders sometimes even this procedure is inconclusive and surgical exploration becomes necessary.

Findings favoring a cardiomyopathy are episodes of acute pulmonary edema, a prominent apical impulse displaced well to the left, an audible S_4 , and electrocardiographic evidence of left ventricular hypertrophy or bundle branch block.²¹ Of the hemodynamic findings (Table VI) the difference between right and left diastolic pressures is the most reliable point in the differential diagnosis but even it may be misleading.²² In the cardiomyopathies the diastolic

pressures in both ventricles may be elevated but because the heart is not encased in a rigid shell as in pericardial constriction, they are very unlikely to be equal. In restrictive cardiomyopathy the reduction in diastolic compliance is greater in left than right ventricle giving a higher left ventricular diastolic pressure and a difference between the two of greater than 8 mm Hg. Exercise enhances this difference. This value is almost always less than 6 in pericardial constriction even with exercise. Other differential points include the pulmonary artery systolic pressure which is usually less than 50 mm Hg with pericardial constriction, but greater in the cardiomyopathies. In addition, left ventricular systolic function is usually normal in pericardial constriction, but abnormal in the cardiomyopathies.

Several noninvasive techniques reflect these differences. Echocardiography or radionuclide angiography showing a small left ventricular cavity with good ventricular function in a patient with predominantly right-sided failure should suggest pericardial constriction and the need for cardiac catheterization. Systolic time intervals will usually show a short pre-ejection period (PEP), a long left ventricular ejection time (LVET) and a low PEP/LVET ratio (less than 0.5).²³ Simultaneous jugular venous pulse tracing and phonocardiography demonstrate that the interval from the aortic component of the second sound to the peak of the jugular venous V wave is usually less than 0.03 sec in pericardial constriction greater in cardiomyopathies.¹⁰⁰

These noninvasive tests are helpful but not completely reliable in differentiating the two disorders. In perplexing cases cardiac catheterization or even exploratory surgery is necessary to exclude the eminently treatable entity of pericardial constriction. Noninvasive techniques may be more dangerous to the patient than invasive ones if they result in a missed or significantly delayed diagnosis.

Treatment

Since no reported large series of untreated patients exists, the natural history of pericardial constriction is uncertain. Young children seemed less capable of prolonged survival than adults, most dying within one to three years after the appearance of massive ascites. Adults could survive, albeit frequently with a *valetudinarian*

existence for 5 to 15 years with repeated paracentesis¹⁰¹ a procedure apparently unattended by any significant or deleterious hemodynamic consequences despite the removal of large quantities of fluid.¹⁰² An occasional patient has survived for several decades without surgery, one of Paul Dudley White's cases having had symptoms for 44 years.¹ Although some patients respond to vigorous diuretic therapy the treatment of pericardial constriction is pericardiectomy whose delay may risk the development of myocardial atrophy and fibrosis. The surgical mortality rate is small (5 to 10 per cent¹⁰³) and the outcome excellent with about 80 to 90 per cent obtaining complete symptomatic relief. Few derive no benefit.

The basic requirement for surgery is a thorough decortication with the removal of both visceral and parietal pericardial layers from the right and left ventricles. Resection over the left ventricle should proceed at least as far posterolaterally as the phrenic nerve.¹³ The approach has varied including median sternotomy which most surgeons favor and left thoracotomy the important point is obtaining excellent exposure. It is probably wise to free the left ventricle first to avoid pulmonary congestion when release of the right ventricle increases pulmonary blood flow and volume. Calcification may require bone cutting instruments and in places may so invade the myocardium that removal is impossible. The necessity of decorticating the atria and vena cava in the absence of obvious constricting bands is debated;¹⁴ this procedure increases the risk and is probably unimportant in most patients.

Hemodynamic measurements immediately following pericardiectomy may show normal values in all chambers, normal left atrial and ventricular values with improved but still abnormal right atrial and ventricular measurements or no immediate changes. Over the next few days however central venous pressure begins to fall and ordinarily reaches normal levels within four weeks. The pulse pressure increases as stroke volume becomes normal. Cardiac catheterization studies two to five months following surgery demonstrate satisfactory hemodynamic indices in almost all patients. These findings suggest that in some patients there may be reversible myocardial impairment requiring several days to abate following pericardiectomy.¹⁵

Electrocardiographic abnormalities often resolve postoperatively. The frequently abnormal P wave usually reverts to normal, low voltage increases, most flat or inverted T waves become upright and right axis deviation disappears. Those with the pattern of incomplete right bundle branch block have no change and atrial fibrillation typically persists.

A few patients have persistently abnormal hemodynamic values following surgery. Probably the most common reason is incomplete pericardiectomy.¹⁶ Some patients however have substantial myocardial atrophy and fibrosis.¹⁷ They may die shortly after surgery from unremitting cardiac failure. The pericardiectomy had the effect of increasing pulmonary blood flow which the left ventricle cannot effectively accept. Others survive surgery but have derived little or no benefit from it. Which patients will not respond to decortication is unpredictable, significantly diminished left ventricular function which may persist postoperatively does not preclude improvement in symptoms or other hemodynamic measurements.¹⁸ Hence virtually all patients should receive surgical therapy with the recognition that in a very small number the results will be unimpressive or even catastrophic.¹⁹

REFERENCES

1. Roberts W. C., and Spray T. L. In Spodick D. H., editor. Pericardial diseases, Philadelphia 1976 F.A. Davis Company.
2. Hancock, E. W. Subacute effusive-constrictive pericarditis, *Circulation* 43: 183 1971.
3. Perheentupa J., Autio S., Leisti E., Rastia C. and Tuuttila L. Mulibrey nanism, an autosomal recessive syndrome with pericardial constriction, *Lancet* 2: 351 1973.
4. Voorhes M. L., Husson G. S. and Blackman M. S. Growth failure with pericardial constriction. The syndrome of mulibrey nanism. *Am J Dis Child* 130: 1146 1976.
5. Rubin R. H. and Moellering R. C. Jr. Clinical, microbiologic and therapeutic aspects of purulent pericarditis. *Am J Med* 58: 68 1975.
6. Boyle J. E., Pearce M. L., and Guze S. B. Purulent pericarditis: review of literature and report of eleven cases. *Medicine* 40: 119 1961.
7. Andrews H. W., Pickering G. W. and Sellors, T. H. The etiology of constrictive pericarditis with special reference to tuberculous pericarditis together with a note on polyserositis. *Q J Med* 41: 91 1948.
8. Harvey A. M. and Whitehill M. H. Tuberculous pericarditis. *Medicine* 16: 45 1937.
9. Rooney J. J., Crocco J. A. and Lyons, H. A. Tuberculous pericarditis. *Ann Intern Med* 72: 73 1970.
10. Carson T. J., Murray G. F., Wilcox B. R. and Starek

only clue is a small liver, but definitive diagnosis requires a liver biopsy

Differential diagnosis

Unexplained exertional dyspnea, ascites, peripheral edema, or pleural effusions should suggest pericardial constriction. The diagnosis is missed with striking and disconcerting regularity. Hepatic cirrhosis, metastatic malignancy, and Meigs's syndrome in females are among the most frequent mistaken diagnoses. Careful examination of the jugular venous pulse which is elevated in pericardial constriction but normal or low in these other disorders should prevent such errors.

Most difficult to distinguish from pericardial constriction are the cardiomyopathies, particularly the restrictive forms resulting from such processes as diffuse fibrosis following myocarditis, idiopathic hypertrophy, or infiltrative diseases like amyloidosis, hemochromatosis, or sarcoidosis. In the absence of pericardial calcification or some manifestation of the systemic disorder causing the cardiomyopathy, the sometimes strikingly similar clinical and hemodynamic findings may make clinical differentiation impossible without exploratory surgery. Both cardiomyopathies and pericardial constriction may have identical features of increased systemic and pulmonary venous pressures, the S_4 of left ventricular failure may be mistaken for a 'diastolic knock' and the electrocardiographic findings may be identical. Cardiac catheterization in restrictive cardiomyopathy may also show increased systemic and pulmonary venous pressures displaying the M or W configuration and an early diastolic dip and plateau pattern of ventricular pressure.¹⁴ While certain findings on catheterization may help to distinguish these disorders, sometimes even this procedure is inconclusive and surgical exploration becomes necessary.

Findings favoring a cardiomyopathy are epistolic apical impulse displaced well to the left, an audible S_4 , and electrocardiographic evidence of left ventricular hypertrophy or bundle branch block.¹⁵ Of the hemodynamic findings (Table VI), the difference between right and left diastolic pressures is the most reliable point in the differential diagnosis but even it may be misleading.¹⁶ In the cardiomyopathies the diastolic

pressures in both ventricles may be elevated but because the heart is not encased in a rigid shell, as in pericardial constriction, they are very unlikely to be equal. In restrictive cardiomyopathy the reduction in diastolic compliance is greater in left than right ventricle, giving a higher left ventricular diastolic pressure and a difference between the two of greater than 6 mm Hg. Exercise enhances this difference. This value is almost always less than 6 in pericardial constriction even with exercise. Other differential points include the pulmonary artery systolic pressure which is usually less than 50 mm Hg with pericardial constriction, but greater in the cardiomyopathies. In addition, left ventricular systolic function is usually normal in pericardial constriction but abnormal in the cardiomyopathies.

Several noninvasive techniques reflect these differences. Echocardiography or radionuclide angiography showing a small left ventricular cavity with good ventricular function in a patient with predominantly right-sided failure should suggest pericardial constriction and the need for cardiac catheterization. Systolic time intervals will usually show a short pre-ejection period (PEP), a long left ventricular ejection time (LVET) and a low PEP/LVET ratio (less than 0.5).¹⁷ Simultaneous jugular venous pulse tracing and phonocardiography demonstrate that the interval from the aortic component of the second sound to the peak of the jugular venous V wave is usually less than 0.03 sec in pericardial constriction, greater in cardiomyopathies.¹⁸

These noninvasive tests are helpful but not completely reliable in differentiating the two disorders. In perplexing cases cardiac catheterization or even exploratory surgery is necessary to exclude the eminently treatable entity of pericardial constriction. Noninvasive techniques may be more dangerous to the patient than invasive ones if they result in a missed or significantly delayed diagnosis.

Treatment

Since no reported large series of untreated patients exists, the natural history of pericardial constriction is uncertain. Young children seemed less capable of prolonged survival than adults, most dying within one to three years after the appearance of massive ascites. Adults could survive albeit frequently with a valetudinarian

- 7 Evans W and Jackson F Constrictive pericarditis Br Heart J 14 53 1952
- 58 Chesler E Mitha A ■ Matson R E and Rogers M N A Subpulmonic stenosis as a result of noncalcific constrictive pericarditis Chest 69 475 1976
- 59 Bergh N P, Krause F and Lander E Some aspects of diagnosis and treatment of chronic pericarditis Acta Chir Scand 128 683 1964
- 60 Mounsey P Annular constrictive pericarditis Br Heart J 23 325 1955
- 61 Wilkinson P Pinto B and Senior J R Reversible protein losing enteropathy with intestinal lymphangiectasia secondary to chronic constrictive pericarditis N Engl J Med 273 1178 1965
- 62 Peterson V P and Hastrup J Protein losing enteropathy in constrictive pericarditis Acta Med Scand 173 401 1963
- 63 Kump D A Jaffe R B Waldmann T A and Weinstein M A Constrictive pericarditis and protein losing enteropathy An imitator of intestinal lymphangiectasia Am J Roentgenol 124 365 1975
- 64 Nelson D L, Blaese R M, Strober W, Bruce R M and Waldmann T A Constrictive pericarditis intestinal lymphangiectasia and reversible immunologic deficiency J Pediatr 86 548 1975
- 65 Pastor B H and Cahn M Reversible nephrotic syndrome resulting from constrictive pericarditis N Engl J Med 282 872 1960
- 66 Blainey J D, Hardwicke J and Whitfield A G W The nephrotic syndrome associated with thrombosis of the renal veins Lancet 2 1208 1954
- 67 Daugherty G W, Broadbent J C and Brown A L Jr Chronic constrictive pericarditis associated with nephrotic syndrome report of a case Proc Staff Meet Mayo Clin 37 282 1962
- 68 Kark R M, Pirani C L and Pollack V E Nephrotic syndrome in adults a common disorder with many causes Ann Intern Med 48 151 1958
- 69 Liach F, Arieff A E and Masaryk S C Renal vein thrombosis and nephrotic syndrome a prospective study of 35 adult patients Ann Intern Med 83 8 1975
- 70 Gibson R Atypical constrictive pericarditis Br Heart J 21 583 1959
- 71 Wood F C, Johnson J, Schnabel T ■, Ruo P and Zinsner H F The diastolic heart beat Trans Assoc Am Physicians 64 95 1951
- 72 Mounsey P The early diastolic sound of constrictive pericarditis Br Heart J 17 143 1955
- 73 Deslats D T, Grollman J H Jr and MacAlpin R N Cineangiographic demonstration of the diastolic snap in constrictive pericarditis Radiology 86 1036 1966
- 74 Dunn G ■, Hayes P, Breen K J and Schenker S The liver in congestive heart failure a review Am J Med Sci 285 174 1973
- 75 Mathewson F A L Calcification of the pericardium in apparently healthy people electrocardiographic abnormalities from apparently healthy persons with calcification of the pericardium Circulation 12 44 1955
- 76 Plum G E, Bruwer A J and Clagett O T Chronic constrictive pericarditis roentgenologic findings in 35 surgically proved cases Proc Staff Meet Mayo Clin 32 55 1957
- 77 Heinz R and Abrams H L Radiologic aspects of operable heart disease IV Appearances of constrictive pericarditis Radiology 69 84 1977
- 78 Cornell S H., and Rosen N P Roentgenographic findings in constrictive pericarditis. Analysis of 21 cases, Am J Roentgenol 102 301 1963
- 79 Lazarides D ■, Avgoustakis G ■, Lekos D and Michaelides G B Evaluation of radical pericardectomy for constrictive pericarditis (a clinical hemodynamic and EKG study of 170 cases) J Thorac Cardiovasc Surg 51 821 1966
- 80 Levine H D Myocardial fibrosis in constrictive pericarditis-electrocardiographic and pathologic observations Circulation 48 1268 1973
- 81 Chesler E Mitha A ■ and Matson R E The ECG of constrictive pericarditis-pattern resembling right ventricular hypertrophy Am Heart J 91 470 1976
- 82 Avgoustakis D., Lazarides D., Athanassades D., and Michaelides G The electrocardiogram in constrictive pericarditis before and after radical pericardectomy Chest 57 460 1970
- 83 Gibson T C, Grossman W., and McLaurin L P Echocardiography in patients with constrictive pericarditis Circulation 50(Suppl III) 86 1974
- 84 Pool P E, Seegren S C, Abbas A S., Charun Y., and Kraus R Echocardiographic manifestations of constrictive pericarditis Chest 68 684 1975
- 85 Shabetai R In Grossman W editor Cardiac catheterization and angiography Philadelphia 1974 Lea & Febiger Publishers
- 86 Figley M M and Bagshaw M A Angiographic aspects of constrictive pericarditis Radiology 69 46 1957
- 87 Deutsch V, Miller H, Yehuda J, H. Shem Tov A., and Neufeld H N Angiography in constrictive pericarditis Chest 63 379 1974
- 88 Lewis B S and Gotman M S Left ventricular function in systole and diastole in constrictive pericarditis Am Heart J 86 23 1973
- 89 Vogel J H K, Horgan J A and Strahl E L Left ventricular dysfunction in chronic constrictive pericarditis Chest 59 484 1971
- 90 Gaasch W H, Peterson K L and Shabetai R Left ventricular function in chronic constrictive pericarditis Am J Cardiol 34 107 1974
- 91 Montero A C, Smith W G, Takezawa H, Lewis J M and Alexander J K Hemodynamic response to exercise in constrictive pericarditis Circulation 34(Suppl III) 72 1966
- 92 Ramsey H W, Sbar S and Elliott L P The differential diagnosis of restrictive myocardial pathology and chronic constrictive pericarditis without calcification value of coronary arteriography Am J Cardiol 25 635 1970
- 93 Hancock E W Constrictive pericarditis clinical clues to diagnosis JAMA 232 176 1975
- 94 Dines D E, Edwards J E and Burchell H B Myocardial atrophy in constrictive pericarditis Proc Staff Meet Mayo Clin 33 97 1958
- 95 Kotin P and Hall E M Cardiac or congestive cirrhosis of the liver Am J Pathol 27 561 1951
- 96 Meaney E, Shabetai R, Bhargava V, Shearer M, Weidner C, Mangaraj L M, Smalling H and Peterson K Cardiac amyloidosis constrictive pericarditis and restrictive cardiomyopathy Am J Cardiol 38 54 1976
- 97 Nody A C, Bruno M S, DePasquale N P and Benstock P A Fulminating idiopathic hemochromatosis presenting as constrictive pericarditis Ann Intern Med 83 373 1975
- 98 Scully R E, Goldblum J J and McNeely B U Case

- P J K The role of surgery in tuberculous pericarditis
Ann Thorac Surg 17 163 1974
- 11 Hageman J H D Esposo N D and Glenn W L L
Tuberculosis of the pericardium A long term analysis
of forty four proved cases N Engl J Med 270 327
1964
 - 12 Schwartz E L Waldmann E H Payne R M
Goldfarb D Kinard S A and Diethrich E H Coccid-
iodal pericarditis Chest 70 670 1976
 - 13 Larson R and Scherb R E Coccidiodal pericarditis
Circulation 7 211 1953
 - 14 Picardi J L Kauffman C A Schwarz J Holmes J
C Phair J P and Fowler N O Pericarditis caused by
Histoplasma capsulatum Am J Cardiol 37 82 1976
 - 15 Wooley C F and Hosier D M Constrictive pericar-
ditis due to Histoplasma capsulatum N Engl J Med
284 1230 1961
 - 16 Goodwin R A Nickell J A and Des Prez R M
Mediastinal fibrosis complicating healed primary histo-
plasmosis and tuberculosis Medicine 51 227 1972
 - 17 Hirschman S Z and Hammer G S Coxsackie virus
myopericarditis: a microbiological and clinical review
Am J Cardiol 34 224 1974
 - 18 Koontz C H and Ray C G The role of Coxsackie
group B virus infection in sporadic myopericarditis AM
HEART J 82 750 1971
 - 19 Kagan H and Bernkopf H Pericarditis caused by
Coxsackie virus B Ann Paediatr 189 44 1957
 - 20 Howard E J and Maier H C Constrictive pericar-
ditis following acute Coxsackie viral pericarditis AM
HEART J 75 247 1968
 - 21 Cooper D K C and Sturridge M F Constrictive
pericarditis following Coxsackie virus infection Thorax
31 472 1976
 - 22 Robertson R and Arnold C H Acute constrictive
pericarditis J Thorac Cardiovasc Surg 49 91, 1965
 - 23 Wilson D R Lenke E C and Patterson J F Acute
constrictive pericarditis following infectious mononu-
cleosis Circulation 23 257 1961
 - 24 Lamont N McE and Pooler N R Hepatic amoebias-
is a study of 250 cases Q J Med 27 389 1958
 - 25 Kinare S G Parulkar G B and Sen P K Constric-
tive pericarditis resulting from dracunculosis Br Med
J 1 845 1962
 - 26 Halliday J H Jose A D and Nickls R Constrictive
pericarditis following rupture of a ventricular hydatid
cyst Br Heart J 25 821 1963
 - 27 Charan A and Sinha K Constrictive pericarditis
following filariasis Indian Heart J 25 213 1973
 - 28 Franco A E Levine H D and Hall A P Rheuma-
toid pericarditis report of 17 cases diagnosed clinically
Ann Intern Med 77 837 1972
 - 29 Thadani U Iveson J M I and Wright V Cardiac
tamponade constrictive pericarditis and pericardial
resection in rheumatoid arthritis Medicine 54 261
1975
 - 30 Yurchak P M Levine S A and Gorlin R Constric-
tive pericarditis complicating systemic lupus erythema-
tosis Circulation 31 113 1965
 - 31 Sunder S K and Shah A Constrictive pericarditis in
procainamide induced lupus erythematosus syndrome
Am J Cardiol 36 960 1975
 - 32 Harkavy J Vascular allergy Ann Intern Med
67 709 1941
 - 33 Harrison M B and White P D Chronic constrictive
pericarditis a follow up study of 37 cases Ann Intern
Med 17 790 1942
 - 34 Comty C M Wathen R L and Shapiro F L In
Spodick D H editor Pericardial diseases, Philad-
phia 1976 F A Davis Company
 - 35 Sbokos C G Karayannacos P E Kontas A
Kambylakis J and Skalkas G D Traumatic hem-
pericardium and chronic constrictive pericarditis Am
Thorac Surg 23 225 1977
 - 36 Ehrenhaft J L and Taber R E Hemopericardium
and constrictive pericarditis J Thorac Surg 24 35
1952
 - 37 Tabatznik B and Isaacs J P Postpericardiotomy
syndrome following traumatic hemopericardium Am
Cardiol 7 83 1961
 - 38 Goldstein S and Yu P N Constrictive pericar-
ditis after blunt chest trauma AM HEART J 69 54
1965
 - 39 Kishon Y Pauzner Y Dalith F and Neufeld H N
Foreign body in the myocardium as a cause of constrictive
pericarditis Thorax 22 238 1967
 - 40 Simon J S and Pluth J R Constrictive pericarditis
Ann Thorac Surg 21 440 1976
 - 41 Cohn K E Stewart J R and Fayardo L F Heart
disease following radiation Medicine 46 281 1967
 - 42 Wender C and Acker J F Jr Constrictive pericar-
ditis associated with hemangioma of the pericardium
AM HEART J 72 255 1966
 - 43 Anderson J A and Hansen B F Primary pericardial
mesothelioma Danish Med Bull 21 195 1974
 - 44 Paul O Castleman B and White P D Chronic
constrictive pericarditis a study of 53 cases Am
Med Sci 216 361 1948
 - 45 Chambliss J R Jaruszewski E J Brofman B L
Martin J P and Feil H Chronic cardiac compression
(chronic constrictive pericarditis) a critical study of
sixty one operated cases with follow up Circulation
4 816 1951
 - 46 Detering R A Jr and Humphreys G H Factors in
the etiology of constrictive pericarditis Circulation
12 30 1955
 - 47 Dalton J C Pearson R J and White P D Constrictive
pericarditis a review and long term follow up of
cases Ann Intern Med 45 445 1956
 - 48 Gimlette T M D Constrictive pericarditis Br Heart
J 21 9 1959
 - 49 Wood P Chronic constrictive pericarditis Am J
Cardiol 7 48 1961
 - 50 Portal R W Besterman E M M Chambers R J
Sellers T H and Somerville W Prognosis after
operation for constrictive pericarditis Br Med J 1 563
1966
 - 51 Conti C R and Friesinger G C Chronic constrictive
pericarditis clinical and laboratory findings in 11 cases
Johns Hopkins Med J 120 262 1967
 - 52 Dayem M K A West F M Bentall H H Goodwin
J F and Cleland W P Investigation and treatment of
constrictive pericarditis Thorax 22 242 1967
 - 53 Wychulis A R Connolly D C and McGoon D C
Surgical treatment of pericarditis J Thorac Cardio-
vasc Surg 62 608 1971
 - 54 Cortes F M and McDonough M T In Cortes F M
editor The pericardium and its disorders Springfield
1971 Charles C Thomas Publisher
 - 55 Fewell J W Cohen R V and Miller C L In Cortes
F M editor The pericardium and its disorders Spring-
field 1971 Charles C Thomas Publisher
 - 56 Hall H W Foulk W T, Butt H R, and Stauffer M
H Chronic constrictive pericarditis simulating primary
hepatic disease Proc Staff Meet Mayo Clin 31 627
1956

Infective endocarditis New diagnostic techniques

Michael H. Miller MD
Joan I. Casey MD FRCP (C)
Bronx, N. Y.

Recent reviews of infective endocarditis (IE) have documented changes in predisposing factors, etiology, and the clinical characteristics of this infection.¹ Although atypical or unusual manifestations of IE are often stressed, the majority of cases may be diagnosed using clinical criteria and blood culture results. In the past several years, new diagnostic tests have been used in assessing patients with IE. While some of these tests may provide clinically useful information, it is important to critically evaluate these techniques and to determine which patients would benefit from such studies. Blood cultures, positive in approximately 80 per cent of patients with IE, continue to be the most definitive study. Blood culture results will be compared in terms of sensitivity and specificity to newer diagnostic techniques.

Blood cultures

Infectious endocarditis and other intravascular infections, such as mycotic aneurysms and infected arteriovenous fistulas, are characterized by bacteremia which is continuous. In contrast, positive blood cultures persist for less than 30 minutes in patients who have a low inoculum of bacteria, since organisms are effectively cleared by the reticuloendothelial system.² The rapid removal of pathogenic bacteria from the blood has also been demonstrated when larger inocula are given to experimental animals. The persis-

tent bacteremia seen with IE is due to organisms which are constantly seeded into the blood from vegetations. Blood cultures in patients with endocarditis should therefore be drawn in a way that will not only document bacteremia but also indicate its persistence.

The use of proper techniques in obtaining blood cultures cannot be overemphasized. At least three cultures should be obtained over a period of hours to days in patients with suspected endocarditis. More than six blood cultures are rarely necessary. The timing of the cultures will often depend on the severity of the illness and the need for rapid institution of therapy. Alternative venipuncture sites should be meticulously prepared with a 2 per cent iodine solution followed by 70 per cent alcohol to remove the iodine. Arterial samples offer no advantage over antecubital vein cultures.³ Several milliliters of blood are inoculated into each of two liquid media; routine blood sets consist of an aerobic and an anaerobic bottle. The amount of blood to be inoculated is specified by each manufacturer. The aerobic bottle is under a partial vacuum and should be routinely aerated after blood collection. Blood culture sets are generally adequate for the isolation of aerobic and anaerobic bacteria. Routine subculturing and incubation for up to 21 days is necessary when cultures are negative, since IE occasionally is caused by slow growing or nutritionally fastidious organisms.

Since the reported incidence of negative cultures in patients with IE is about 15 per cent,⁴ modification of the procedure outlined above may be indicated in some patients. In patients who have received antibiotics (a common cause of negative cultures), an effort should be made to

From the Division of Infectious Diseases, Department of Medicine, Montefiore Hospital and Medical Center, and the Albert Einstein College of Medicine.

Received for publication February 24, 1978.

Reprint requests: Michael H. Miller MD, Department of Medicine, Division of Infectious Diseases, Montefiore Hospital and Medical Center, Box A, NY 10467.

- records of the Massachusetts General Hospital (Case 16 1976) *N Engl J Med* 294 886 1976
- 99 Armstrong T G Lewis H S and Gotsman M S Systolic time intervals in constrictive pericarditis and severe primary myocardial disease *Am HEART J* 85 6 1973
 - 100 Lisa, C P Good G and Tavel M E The jugular pulse in pericardial constriction its differentiation from that of cardiomyopathy *Am HEART J* 84 409 1972
 - 101 Somerville W Constrictive pericarditis with special reference to the change in natural history brought about by surgical intervention *Circulation* 38 (Suppl V) 102 1968
 - 102 Zitrnik R S Solov'yev V V, Marshall H W and Parkin T W The immediate hemodynamic effects of abdominal paracentesis in two patients with chronic constrictive pericarditis *Proc Staff Meet Mayo Clin* 39 101 1964
 - 103 Smith G W and Muller W H Jr The evolution and current concepts of the surgical treatment of constrictive pericarditis *Progr Cardiovasc Dis* 4 316 1962
 - 104 Harken D E In Spodick D H editor Pericardial diseases Philadelphia 1976 F A Davis Company
 - 105 Ebert P A In Sabiston D C and Spencer F C editors Gibbons surgery of the chest Philadelphia 1976 W B Saunders Company
 - 106 Viola A R The influence of pericardiectomy on the hemodynamics of chronic constrictive pericarditis *Circulation* 48 1038 1973
 - 107 Lazarides D P, Avgoustakis D G Lekos D and Michaelides G B Evaluation of radical pericardiectomy for constrictive pericarditis a clinical hemodynamic and electrocardiographic study of twenty cases, *J Thorac Cardiovasc Surg* 51 821 1966
 - 108 Kloster F E Crislip R L Briston J D Herr R H Ritzmann L W and Griswold H E Hemodynamic studies following pericardiectomy for constrictive pericarditis *Circulation* 32 415 1965

Information for authors

Most of the provisions of the Copyright Act of 1976 became effective on January 1 1978. Therefore, all manuscripts must be accompanied by the following statement signed by each author. The undersigned author(s) transfers all copyright ownership of the manuscript entitled (title of article) to The C V Mosby Company in the event the work is published. The author(s) warrants that the article is original is not under consideration by another journal, and has not been previously published. Authors will be consulted, when possible regarding republication of their material.

Appraisal and reappraisal of cardiac therapy

edited by Arthur C. DeGraff and Julian Frieden

Infective endocarditis New diagnostic techniques

Michael H. Miller MD

Joan I. Casey MD FRCP (C)

Bronx, N.Y.

Recent reviews of infective endocarditis (IE) have documented changes in predisposing factors, etiology and the clinical characteristics of this infection. Although atypical or unusual manifestations of IE are often stressed, the majority of cases may be diagnosed using clinical criteria and blood culture results. In the past several years, new diagnostic tests have been used in assessing patients with IE. While some of these tests may provide clinically useful information, it is important to critically evaluate these techniques and to determine which patients would benefit from such studies. Blood cultures positive in approximately 85 per cent of patients with IE continue to be the most definitive study. Blood culture results will be compared in terms of sensitivity and specificity to newer diagnostic techniques.

Blood cultures

Infectious endocarditis and other intravascular infections such as mycotic aneurysms and infected arteriovenous fistulas are characterized by bacteremia which is continuous. In contrast to positive blood cultures persist for less than 30 minutes in patients who have a low inoculum of bacteria, since organisms are effectively cleared by the reticuloendothelial system. The rapid removal of pathogenic bacteria from the blood has also been demonstrated when larger inocula are given to experimental animals. The persis-

tent bacteremia seen with IE is due to organisms which are constantly seeded into the blood from vegetations. Blood cultures in patients with endocarditis should therefore be drawn in a way that will not only document bacteremia but also indicate its persistence.

The use of proper techniques in obtaining blood cultures cannot be overemphasized. At least three cultures should be obtained over a period of hours to days in patients with suspected endocarditis. More than six blood cultures are rarely necessary. The timing of the cultures will often depend on the severity of the illness and the need for rapid institution of therapy. Alternative venipuncture sites should be meticulously prepared with a 2 per cent iodine solution followed by 70 per cent alcohol to remove the iodine. Arterial samples offer no advantage over antecubital vein cultures. Several milliliters of blood are inoculated into each of two liquid media; routine blood sets consist of an aerobic and an anaerobic bottle. The amount of blood to be inoculated is specified by each manufacturer. The aerobic bottle is under a partial vacuum and should be routinely aerated after blood collection. Blood culture sets are generally adequate for the isolation of aerobic and anaerobic bacteria. Routine subculturing and incubation for up to 21 days is necessary when cultures are negative, since IE occasionally is caused by slow growing or nutritionally fastidious organisms.

Since the reported incidence of negative cultures in patients with IE is about 15 per cent, modification of the procedure outlined above may be indicated in some patients. In patients who have received antibiotics (a common cause of negative cultures) an effort should be made to

From the Division of Infectious Diseases Department of Medicine, Montefiore Hospital and Medical Center and the Albert Einstein College of Medicine.

Received for publication February 24, 1978.

Reprint requests: Michael H. Miller MD, Department of Medicine, Division of Infectious Diseases, Montefiore Hospital and Medical Center, Bronx, N.Y. 10467.

inactivate antibiotics which may have been carried over into the culture flask from the patient's blood. The addition of a beta lactamase (penicillinase) to the medium may be helpful in patients who have received penicillins or cephalosporins. Care should be taken not to overinoculate the blood culture bottle. Antibiotics in the blood will be diluted by the larger volume of liquid culture medium decreasing their activity. The presence of cell wall deficient forms should be sought in patients who have received agents whose primary activity is on the cell wall. Such drugs include the penicillins, cephalosporins, and vancomycin. Since cell wall deficient forms of bacteria will not grow on ordinary media a hypertonic medium such as broth with 10 per cent sucrose should be used in addition to the routine blood culture bottles. Organisms requiring special growth factors not present in standard media are sometimes seen on Gram stain from patients with IE. The use of enriched medium may permit the isolation of these organisms.⁶ Although thioglycollate or other anaerobic blood culture media will usually support the growth of anaerobes routine subculturing and the incubation of bottles for many days are especially important when anaerobic endocarditis is suspected. Patients with gastrointestinal disease or prosthetic valve endocarditis account for most cases of anaerobic IE. Fungal endocarditis is another important cause of culture negative endocarditis. Candida species are more often associated with positive cultures than other fungi such as histoplasma or aspergillus species. The fungemia associated with candida endocarditis may not be continuous and often many days are required for the isolation of this pathogen. The use of biphasic medium⁷ and the aeration of bottles facilitate the isolation of these pathogens. Routine aeration of one bottle may also facilitate the isolation of some bacteria such as pseudomonas species. Fungal endocarditis should be suspected in the presence of drug addiction, following prosthetic valve replacement and in patients with intravenous or urinary catheters who have received parenteral antibiotic therapy. The presence of large emboli in culture negative IE also suggest a fungal etiology and the histologic and bacteriologic examination of material removed at embolectomy may provide a diagnosis.

The examination of peripheral leukocytes for

the presence of bacteria may be useful in some patients with IE.⁸ False negative results, however, are not uncommon,¹⁰ and the differentiation of bacteria from artifacts may be difficult.

Echocardiography

Echocardiography has been used in assessing patients with IE. Vegetations have been documented on the aortic, mitral, and tricuspid valves. The sensitivity of this procedure is related to the size of the vegetation.

In some clinical settings, echocardiography is a useful diagnostic procedure. Patients with aortic insufficiency of unknown etiology may be diagnosed as having IE by the demonstration of vegetations on the aortic valves.¹¹ This technique may also be useful in patients with culture negative fungal endocarditis. The sensitivity of this procedure however, in diagnosing patients with IE is relatively poor. In one study, only one third of patients with clinically and bacteriologically documented IE had positive results.¹² Echocardiography does not distinguish between active and inactive cases,¹³ and false positive results may occur.¹³

Echocardiography is also useful as a prognostic indicator and may identify patients who require surgical intervention. Individuals with IE who have vegetations large enough to be documented by this technique have a poor prognosis. These patients more frequently require surgery for congestive heart failure and have higher mortality rates than those without this finding.¹ There is also a strong association between the presence of vegetations on echocardiography and embolic phenomena.¹² Premature closure of the mitral valve in IE with acute aortic insufficiency¹⁴ demonstrated by echocardiography and is associated with a poor prognosis.¹ This finding may indicate the need for early valve replacement. Echocardiography indicates the nature of the pre-existing cardiac lesion in up to one half of cases.¹⁵ It also may define the extent and nature of damage secondary to the infectious process.¹ This and other information provided is important when surgical intervention is being considered.

Cardiac catheterization

Cardiac catheterization of patients with IE may document unsuspected or clinically unsuspected intracardiac complications define the extent and

hemodynamic significance of valve damage or identify the infected valve

In patients with active endocarditis quantitative differences in bacterial counts done on samples obtained through catheters from sites proximal and distal to the suspected lesion may indicate the site of infection. This technique may be most useful in right sided endocarditis where murmurs indicating tricuspid or pulmonary valvulitis are often absent. In patients with endocarditis who deteriorate despite medical therapy immediate valve replacement may be indicated. Cardiac catheterization with cineangiography has been useful in these patients in demonstrating complications such as mycotic aneurysms or ventricular septal defects.

Patients with residual valvular damage may also benefit from catheterization prior to surgery. A retrospective study of 19 patients with bacteriologically inactive endocarditis was recently reported by Mills and associates.¹ In this study catheterization with cineangiography was performed to clarify an uncertain diagnosis or to confirm a diagnosis suspected on clinical grounds. Direct inspection at the time of cardiac surgery or pathologic examination was used to document the anatomical diagnoses. Catheterization was often useful when the diagnosis was unclear. Three patients were thought to have combined mitral and aortic insufficiency. The severity of each lesion could be determined in two and the third patient was shown not to have mitral insufficiency. The clinical diagnosis of mitral stenosis in two patients was shown by catheterization to be incorrect. The relative contribution of valvular insufficiency to heart failure was determined in two patients: one with emphysema and another with pericarditis.

Two serious complications resulted from these studies. One patient developed pulmonary edema and another a fatal arrhythmia. Bacterial vegetations were not demonstrated in any patient by cineangiography and four patients had false positive tests indicating valvular insufficiency. In patients with clear cut mitral insufficiency, catheterization data provided little additional information. Paravalvular lesions (five mycotic aneurysms and one fistulous tract) were present in six patients. Cineangiography demonstrated only three of these defects. These authors conclude that cardiac catheterization is helpful when

several valves are involved with infection when a paravalvular lesion is present or to determine the relative contribution of valvular insufficiency to heart failure.

Serologic tests

Serologic tests used in the assessment of patients with IE can be divided into those which suggest a particular etiologic agent or myocardial involvement and those tests which show a heightened immunologic state. Serologic tests may be useful in diagnosis of culture negative endocarditis and in following the course of therapy.

Rheumatoid factor (RF) is present in the blood of approximately 50 per cent of patients with IE in whom symptoms have been present for six weeks or more. RF is an IgM directed against the Fc portion of IgG and its presence may interfere with IgG mediated opsonization of bacteria. The presence of RF correlates with active disease and titers fall rapidly with adequate therapy.

The presence of glomerulonephritis due to the deposition of immune complexes has been found with IE of a number of bacterial etiologies. A recent paper documenting the presence of circulating immune complexes (CIC) in patients with IE is of considerable interest. The possible diagnostic value of this test in culture negative endocarditis has been stressed. In this study 97 per cent of cases with IE had circulating immune complexes as compared to 10 to 40 per cent of control groups. Moreover the patients with CIC unrelated to endocarditis had lower titers than those with endocarditis. As with RF titers of CIC are related to duration of disease. Although titers do diminish with adequate therapy, persistent CIC levels do not necessarily indicate a poor therapeutic response. The sensitivity of this test was better than that of the simpler measurement of complement levels, the latter being decreased in only 41 per cent of cases of IE. Tests which measure CIC have potential usefulness in culture negative endocarditis but these tests are difficult to perform and are not available in most laboratories.

Tests used for the determination of specific etiologic agents include those which demonstrate the presence of an antibody directly such as immunoprecipitation tests and complement fixation tests.

inactivate antibiotics which may have been carried over into the culture flask from the patient's blood. The addition of a beta lactamase (penicillinase) to the medium may be helpful in patients who have received penicillins or cephalosporins. Care should be taken not to over inoculate the blood culture bottle. Antibiotics in the blood will be diluted by the larger volume of liquid culture medium, decreasing their activity. The presence of cell wall deficient forms should be sought in patients who have received agents whose primary activity is on the cell wall. Such drugs include the penicillins, cephalosporins and vancomycin. Since cell wall deficient forms of bacteria will not grow on ordinary media, a hypertonic medium such as broth with 10 per cent sucrose should be used in addition to the routine blood culture bottles. Organisms requiring special growth factors not present in standard media are sometimes seen on Gram stain from patients with IE. The use of enriched medium may permit the isolation of these organisms.⁶ Although thioglycollate or other anaerobic blood culture media will usually support the growth of anaerobes, routine subculturing and the incubation of bottles for many days are especially important when anaerobic endocarditis is suspected. Patients with gastrointestinal disease or prosthetic valve endocarditis account for most cases of anaerobic IE. Fungal endocarditis is another important cause of culture negative endocarditis. *Candida* species are more often associated with positive cultures than other fungi such as *histoplasma* or *aspergillus* species. The fungus associated with *Candida* endocarditis may not be continuous and often many days are required for the isolation of this pathogen. The use of biphasic medium and the aeration of bottles facilitate the isolation of these pathogens. Routine aeration of one bottle may also facilitate the isolation of some bacteria such as *Pseudomonas* species. Fungal endocarditis should be suspected in the presence of drug addiction following prosthetic valve replacement and in patients with intravenous or urinary catheters who have received parenteral antibiotic therapy. The presence of large emboli in culture negative IE also suggest a fungal etiology and the histologic and bacteriologic examination of material removed at embolotomy may provide a diagnosis.

The examination of peripheral leukocytes for

the presence of bacteria may be useful in some patients with IE.⁹ False negative results, however, are not uncommon,¹⁰ and the differentiation of bacteria from artifacts may be difficult.

Echocardiography

Echocardiography has been used in assessing patients with IE. Vegetations have been documented on the aortic, mitral, and tricuspid valves. The sensitivity of this procedure is related to the size of the vegetation.

In some clinical settings, echocardiography is a useful diagnostic procedure. Patients with aortic insufficiency of unknown etiology may be diagnosed as having IE by the demonstration of vegetations on the aortic valves.¹¹ This technique may also be useful in patients with culture negative fungal endocarditis. The sensitivity of this procedure, however, in diagnosing patients with IE is relatively poor. In one study, only one third of patients with clinically and bacteriologically documented IE had positive results.¹² Echocardiography does not distinguish between active and inactive cases¹³ and false positive results may occur.¹³

Echocardiography is also useful as a prognostic indicator and may identify patients who require surgical intervention. Individuals with IE who have vegetations large enough to be documented by this technique have a poor prognosis. These patients more frequently require surgery for congestive heart failure and have higher mortality rates than those without this finding.¹⁴ There is also a strong association between the presence of vegetations on echocardiography and embolic phenomena.¹⁵ Premature closure of the mitral valve in IE with acute aortic insufficiency is demonstrated by echocardiography and is associated with a poor prognosis.¹⁶ This finding may indicate the need for early valve replacement. Echocardiography indicates the nature of the pre-existing cardiac lesion in up to one half of cases.¹⁷ It also may define the extent and nature of damage secondary to the infectious process.¹⁸ This and other information provided is important when surgical intervention is being considered.

Cardiac catheterization

Cardiac catheterization of patients with IE may document unusual or clinically unsuspected intracardiac complications, define the extent and

abnormality may have some localizing value²³

One recent study correlated pathologic findings with ECG abnormalities in 24 patients with IE involving the aortic valve²⁴. Eighteen of 21 patients with aortic valve endocarditis had prolonged P R intervals unrelated to digitalis. Four developed complete heart block. Deep infection with aneurysm formation was present in 16 of these 18 patients. Four patients who developed left bundle branch block with normal P R intervals had aneurysms of the intraventricular septum. Four of 24 patients had evidence of a myocardial infarction with multifocal ventricular ectopic beats and two of these had coronary artery emboli on postmortem examination.

It is important to obtain serial ECGs in patients with the diagnosis of infective endocarditis. Electrocardiographic evidence of an infarction or heart block is associated with a poor prognosis. New conduction defects indicate abscess or aneurysm formation and may suggest the need for surgical intervention.

Conclusions

The rational use of techniques introduced in the past several years for assessing patients with suspected or proven IE requires careful patient selection. With the exception of cardiac catheterization these tests are noninvasive and therefore not associated with significant morbidity. The general availability of many of these tests is limited and the sensitivity and/or specificity may be less than more conventional studies. Serologic studies measuring circulating immune complexes, teichoic acid antibodies, and antiheart antibodies often require the sending of samples to reference laboratories. Gallium scans, cardiac catheterization and echocardiography may require the transfer of patients to hospitals with facilities for such studies. Despite these limitations the use of one or more of these tests in individual patients may provide information crucial to the diagnosis or management of patients with infective endocarditis.

REFERENCES

- Weinstein L and Rubin R H Infective endocarditis—1973 *Prog Cardiovasc Dis* 16:239 1973
- Benson P B Brennan E S and Warren J V Observations on the sites of removal of bacteria from the blood in patients with bacterial endocarditis *J Exp Med* 81:9 1945
- Leacock J L Ellis C A Turchik J B and Weinstein

- L Transient bacteremia associated with sigmoidoscopy *N Engl J Med* 289:477 1973
- Goshi K Cluff L F and Norman P S Studies on the pathogenesis of staphylococcal infection VI Mechanism of immunity conferred by anti alpha hemolysin *Bull Johns Hopkins Hosp* 112:31 1963
- Cannady P B and Sanford J P Negative blood cultures in infective endocarditis: a review *South Med J* 69:1470 1976
- Caveux P Acar J F and Chabbert Y A Bacterial persistence in streptococcal endocarditis due to thiol requiring mutants *J Infect Dis* 124:247 1971
- Roberts H D and Washington J A Detection of fungi in blood cultures *J Clin Microbiol* 1:309 1975
- Roberts G D Horstmeier E Hall M and Washington J A Recovery of yeast from vented blood culture bottles *J Clin Microbiol* 2:18 1975
- Powers H L and Mandell H L Intraleukocytic bacteria in endocarditis patients *JAMA* 227:232 1974
- Carlson B E and Anderson H R Value of Granulocyte examination for bacteria *JAMA* 235:1460 1976
- DeMara A M King J F Salel A F Caudill C C Miller R R and Mason D T Echography and phonography of acute aortic regurgitation in bacterial endocarditis *Ann Intern Med* 82:379 1975
- Wann L S Dillon J C Weyman A E and Feigenbaum H Echocardiography in bacterial endocarditis *N Engl J Med* 295:135 1976
- Chandrasekaran P A N and Langevin E Limitations of the echocardiogram in diagnosing valvular vegetations in patients with mitral valve prolapse *Circulation* 58:436 1977
- Mann T M Laurin L Grossman W and Craige E Assessing the hemodynamic severity of acute aortic regurgitation due to infective endocarditis *N Engl J Med* 293:108 1975
- Roy P Taky A J Cushman E R Schattenberg T T Chau G T and Frye R L Spectrum of echocardiographic findings in bacterial endocarditis *Circulation* 53:474 1976
- Pazin G J Peterson K L Griff F W Shaver J A and Hg M Determination of site of infection in endocarditis *Ann Intern Med* 82:746 1975
- Symbas P N Baldwin B J Schlant R C and Hurst J W Unusual complications of bacterial endocarditis *Br Heart J* 33:664 1971
- Mills J, Abbott J Utley J R and Ryan C Role of cardiac catheterization in infective endocarditis *Chest* 72:576 1977
- Bayer A S Theofilopoulos A N, Eisenberg R Dixon F J and Guze L B Circulating immune complexes in infective endocarditis *N Engl J Med* 295:100 1976
- Nagel J C Tuaron C U Cardella T A, and Shearman J N Teichoic acid serologic diagnosis of staphylococcal endocarditis *Ann Intern Med* 82:13 1975
- Crowder J C and White A Teichoic acid antibodies in staphylococcal and nonstaphylococcal endocarditis *Ann Intern Med* 77:87 1972
- Kozinn P J Galea R S Taschdjian C L Goldberg P L Protzman W, and Kozinn M A The precipitin test in systemic candidiasis *JAMA* 235:68 1976
- Das S K and Cassidy J T Importance of heart antibody in infective endocarditis *Arch Intern Med* 137:591 1977
- Wiseman J Rouleau J Rigo P, Strauss H W and Pitt B Gallium-67 myocardial imaging for the detection of bacterial endocarditis *Radiology* 120:135 1976

Staphylococcus aureus cell walls contain the antigenic moiety ribitol teichoic acid. The determination of an antibody response to teichoic acid using immunoprecipitation tests such as counter immunoelectrophoresis (CIE) or double diffusion in agar may be useful in patients with IE due to this organism. CIE is more rapid and sensitive than agar diffusion and has been proposed as an aid to early diagnosis of this infection.⁹ The latter is relatively sensitive and more specific than the CIE. These tests have most potential usefulness in patients who have received antibiotics active against *Staphylococcus aureus*. In some studies antibodies to teichoic acid may be found in as many as 90 per cent of patients with IE due to this organism. There is a correlation with adequate therapeutic response and fall in titer. A number of problems exist with this diagnostic test. Teichoic acid antibodies may be found in uninfected drug addicts and the presence of antibodies does not necessarily indicate endocarditis in patients with staphylococcal sepsis.¹ False positives occur in some patients with IE due to a streptococcal species.⁹ Furthermore, the absence of a standardized commercially available antigen limits the availability of this test.

Serologic tests may also be useful in cases of culture negative fungal endocarditis. In patients with Candida endocarditis blood cultures will be positive in 50 to 75 per cent of cases. Serologic tests include immunoprecipitation and agglutination. The usefulness of these serologic tests has been questioned since significant titers may occur in noninvasive disease and false negatives may occur in invasive candida infection.

In patients in whom the clinical diagnosis of endocarditis due to candida is suspected serologic tests may give additional supportive evidence especially when combined with echocardiography. Serologic studies available for the diagnosis of less common fungal etiologies such as aspergillus or histoplasma species are of limited use. As with candida infections a single high titer or a changing titer may be helpful in certain circumstances.

Coxiella burnetii, the agent of Q fever, is an unusual cause of infective endocarditis and may be suspected in patients with culture negative disease where there is a history of animal contact.¹ An increase in the complement fixing antibody titer is required to diagnose this infec-

tion. Similarly, *Brucella* species may cause culture negative endocarditis in patients with animal exposure and may be diagnosed serologically.

The presence of antiheart antibodies measured by indirect immunofluorescence has been reported in nine out of 13 (62 per cent) patients with subacute endocarditis.¹ Antibody titers were associated with congestive heart failure and titers fell with adequate therapy. Antiheart antibodies may be seen in a variety of cardiac disorders and this test is unlikely to be useful in diagnosing or following patients with endocarditis.

Gallium scans

The radiopharmaceutical Gallium 67 citrate localizes in areas of inflammation and in many neoplasms. Scintigraphy with gallium may be helpful in localizing occult infective foci such as intra abdominal abscesses. This diagnostic procedure has recently been evaluated in ten patients with acute bacterial endocarditis and in an additional patient with a myocardial abscess.¹ Scanning demonstrated accumulation of the isotope within the heart in six of the IE cases and in the single patient with a myocardial abscess. The resolution of this procedure is not sufficient to determine which valve is infected and there is a delay of at least 48 hours before scans become positive. With 40 per cent false negative results the sensitivity of this procedure is considerably less than blood cultures. The potential usefulness of gallium scans in patients with subacute infective endocarditis or culture negative endocarditis has not been determined.

Electrocardiography

The relative importance of the electrocardiogram (ECG) in the assessment of patients with IE has recently been stressed.¹ However there has been no comprehensive study of ECGs in patients with this infection. ECG changes are not diagnostic of endocarditis and often consist of partial or complete heart blocks and premature ventricular contractions indicating myocarditis or the involvement of the conduction system with infection or inflammation. The anatomical relation of the non coronary cusp of the aortic valve and the mitral annulus with the conduction system accounts for the frequency of conduction abnormalities and the type of the conduction

Preventing thromboembolism after myocardial infarction Effect of low dose heparin or smoking

When patients with myocardial infarction were kept in bed for several weeks thromboembolic complications were thought to be the cause of death in some 4 per cent of patients. Although most cardiologists think that such complications are less common now that patients with myocardial infarction are mobilized more quickly a third of such patients still develop evidence of leg vein thrombosis, as detected by the I-fibrinogen uptake test and a proportion of these undoubtedly develop fatal pulmonary embolism. Another serious thromboembolic complication is cerebral embolism from thrombi on the ventricular wall.

It is recognized that heparin therapy in full dosage effectively prevents thromboembolic complications after myocardial infarction but this benefit has to be weighed against the possible hemorrhagic complications of the treatment. Studies which were undertaken to define those patients in whom the risk of thromboembolism would be greater than the risk of the hemorrhagic complications of the anticoagulant therapy indicated not unexpectedly that thromboembolic complications were more likely in the elderly, in those in heart failure and in those with a significant dysrhythmia. Unexpectedly it was also found that leg vein thrombosis after myocardial infarction was significantly more common in non-smokers than in smokers.

Deciding which patients should be given full dose heparin prophylaxis was a nice exercise in clinical judgment to which the technique of decision theory has been applied but these niceties of clinical decision making have been made less necessary by the advent of low dose heparin prophylaxis. This has been shown to be effective in preventing thromboembolic complications after surgery and several studies have now shown that low dose heparin prophylaxis is also effective in preventing leg vein thrombosis and so presumably pulmonary embolism after myocardial infarction.

The lower incidence of leg vein thrombosis after myocardial infarction in smokers compared to non smokers to which the reported health benefit of smoking. It is a dubious one however because the smoker is more likely to be suffering from a myocardial infarction in the first place.

Why being a cigarette smoker should confer any protection against leg vein thrombosis after myocardial infarction is not known. It is interesting that a decreased incidence of leg vein thrombosis has also been reported in smokers after gynecological operations.

One possible explanation is that smokers are likely to be more fit people especially when they have had to stop smoking after admission to a coronary care unit and start their own involuntary postoperative or postmyocardial infarction mobilization earlier.

The practical conclusion to be drawn from these observations is that low-dose heparin prophylaxis should probably be given to all patients with myocardial infarction and certainly to those with an increased risk of thromboembolic complications that is the elderly, those with varicose veins or a previous history of thromboembolism, those in cardiac failure or a dysrhythmia and those who are non-smokers. Five thousand units of heparin are given intravenously and 7,500 subcutaneously as soon as possible after diagnosis and then 7,500 units subcutaneously every 12 hours until the patient is mobilized.

The only disadvantages of giving low-dose heparin prophylaxis are the cost and trouble and the occasional problem of bruising at the subcutaneous injection sites. Such bruising can be minimized by careful attention to the injection technique. Seven thousand five hundred units of heparin in 0.3 ml is drawn up into a tuberculin syringe and injected subcutaneously into the anterior abdominal wall near the iliac crest using a new fine gauze needle (i.e. not the one which was used for drawing up the heparin). The nurses should be told to insert the needle vertically and to resist their overwhelming instinct to rub the site of the injection. There is evidence from a small controlled trial that calcium heparin is less likely to cause bruising than sodium heparin but the difference is probably marginal.

Peter A Emerson M.D. FRCP F.A.C.P. (Hon)
Westminster Hospital
London SW1P 2AP
England

REFERENCES

1. Hilden T, Inversen K, Raaschov F, and Schwartz M. Anticoagulants in acute myocardial infarction. *Lancet* 2:37-1961.
2. Murray T S, Larimer A R, Cox F C, and Lawrie J D V. Leg vein thrombosis following myocardial infarction. *Lancet* 2:79-1971.
3. Handley A J, Emerson P A, and Fleming P R. Heparin in the prevention of deep vein thrombosis after myocardial infarction. *Br Med J* 2:436-1972.
4. Summons A V, Sheppard M A, and Cox A P. Deep vein thrombosis after myocardial infarction: predisposing factors. *Br Heart J* 35:623-1973.
5. Handley A J and Teather D. The influence of smoking on deep vein thrombosis after myocardial infarction. *Br Med J* 3:302-1974.
6. Marks P and Emerson P A. Increased incidence of deep vein thrombosis after myocardial infarction in non smokers. *Br Med J* 3:332-1974.
7. Emerson, P A, Teather D and Handley A J. The application of decision theory to the prevention of deep

Miller and Casey

- 25 Hutter A M and Moellering R C Assessment of the patient with suspected endocarditis J A M A 235 1603 1976
- 26 Roberts N K and Somerville J Pathological significance of electrocardiographic changes in aortic valve endocarditis (Abstr) Br Heart J 31 393 1969
- 27 Rubinstein E Nonoguchi E R Simberloff M & Holzman H and Rahal J J Fungal endocarditis Analysis of 24 cases and review of the literature Medicine 54 331 1975

Preventing thromboembolism after myocardial infarction Effect of low dose heparin or smoking

When patients with myocardial infarction were kept in bed for several weeks thromboembolic complications were thought to be the cause of death in some 4 per cent of patients. Although most cardiologists think that such complications are less common now that patients with myocardial infarction are mobilized more quickly a third of such patients still develop evidence of leg vein thrombosis, as detected by the I-fibrinogen uptake test and a proportion of these undoubtedly develop fatal pulmonary embolism. Another serious thromboembolic complication is cerebral embolism from thrombi on the ventricular wall.

It is recognized that heparin therapy in full dosage effectively prevents thromboembolic complications after myocardial infarction but this benefit has to be weighed against the possible hemorrhagic complications of the treatment. Studies which have undertaken to define those patients in whom the risk of thromboembolism would be greater than the risk of the hemorrhagic complications of the anticoagulant therapy indicated not unexpectedly that thromboembolic complications were more likely in the elderly in those in heart failure and in those with a significant dysrhythmia. Unexpectedly it was also found that leg vein thrombosis after myocardial infarction was significantly more common in non smokers than in smokers.

Deciding which patients should be given full dose heparin prophylaxis was a nice exercise in clinical judgment to which the technique of decision theory has been applied but these niceties of clinical decision making have been made less necessary by the advent of low-dose heparin prophylaxis. This has been shown to be effective in preventing thromboembolic complications after surgery and several studies have now shown that low-dose heparin prophylaxis is also effective in preventing leg vein thrombosis and so presumably pulmonary embolism after myocardial infarction.

The lower incidence of leg vein thrombosis after myocardial infarction in smokers compared to non smokers is the first reported health benefit of smoking. It is a dubious one however because the smoker is more likely to be suffering from a myocardial infarction in the first place.

Why being a cigarette smoker should confirm any protection against leg vein thrombosis after myocardial infarction is not known. It is interesting that a decreased incidence of leg vein thrombosis has also been reported in smokers after gynecological operations.

One possible explanation is that smokers are likely to be more fit people especially when they have had to stop smoking after admission to a coronary care unit and start their own involuntary postoperative or postmyocardial infarction mobilization earlier.

The practical conclusion to be drawn from these observations is that low dose heparin prophylaxis should probably be given to all patients with myocardial infarction and certainly to those with an increased risk of thromboembolic complications that is the elderly those with varicose veins or a previous history of thromboembolism those in cardiac failure or a dysrhythmia and those who are non-smokers. Five thousand units of heparin are given intravenously and 7500 subcutaneously as soon as possible after diagnosis and then 7500 units subcutaneously every 12 hours until the patient is mobilized.

The only disadvantages of giving low-dose heparin prophylaxis are the cost and trouble and the occasional problem of bruising at the subcutaneous injection sites. Such bruising can be minimized by careful attention to the injection technique. Seven thousand five hundred units of heparin in 0.3 ml is drawn up into a tuberculin syringe and injected subcutaneously into the anterior abdominal wall near the iliac crest using a new fine gauge needle i.e. not the one which was used for drawing up the heparin. The nurses should be told to insert the needle vertically and to resist their overwhelming instinct to rub the site of the injection. There is evidence from a small controlled trial that calcium heparin is less likely to cause bruising than sodium heparin but the difference is probably marginal.

Peter A. Emerson MD FRCP FACP (Hon)
Westminster Hospital
London SW1P 2AP
England

REFERENCES

1. Hilden T, Inversen K, Raasehov F., and Schwartz M. Anticoagulants in acute myocardial infarction. *Lancet* 2:327 1961.
2. Murray T S, Lorrimer A R., Cox F C. and Lawrie T D V. Leg vein thrombosis following myocardial infarction. *Lancet* 2:797 1970.
3. Handley A. J., Emerson P. A. and Fleming P. R. Heparin in the prevention of deep vein thrombosis after myocardial infarction. *Br Med J* 3:436 1972.
4. Summons A V, Sheppard M. A. and Cox A. F. Deep vein thrombosis after myocardial infarction: predisposing factors. *Br Heart J* 35:673 1973.
5. Handley A. J., and Teather D. The influence of smoking on deep vein thrombosis after myocardial infarction. *Br Med J* 3:302 1974.
6. Marks P. and Emerson, P. A. Increased incidence of deep vein thrombosis after myocardial infarction in non smokers. *Br Med J* 3:237 1974.
7. Emerson P. A., Teather D. and Handley A. J. The application of decision theory to the prevention of deep

- vein thrombosis following myocardial infarction *Q J Med* 43 389 1974
- 8 An International Multicentre Trial Prevention of fatal postoperative pulmonary embolism by low doses of heparin *Lancet* 2 45 1976
 - 9 Steffensen K A Coronary occlusion treated with small doses of heparin *Acta Med Scand* 186 519 1969
 - 10 Warlow C Beattie A G Terry G Ogston D Kennure A C F and Douglas A S A double blind trial of low doses of subcutaneous heparin in the prevention of deep vein thrombosis after myocardial infarction *Lancet* 1 934 1974
 - 11 Emerson P A and Marks P Prevention of thromboembolism after myocardial infarction Effect of low dose heparin or smoking *Br Med J* 1 18 1977
 - 12 Clayton J K Anderson J A and McNicol G P Preoperative prediction of post operative deep vein thrombosis *Br Med J* 2 910 1976
 - 13 Whitehead M L and McCarthy T G In Hakkar V and Thomas D P editors Heparin chemistry and clinical use London 1976 Academic Press p 361

Of how non-invasive is non-invasive?

When a treadmill exercise test is obtained along with echocardiogram (ECHO) Holter monitoring vectorcardiogram (VCG) apexcardiogram carotid pulse tracing and jugular phlebogram as well as with routine urinalysis ECG EPA of the chest SMA 12 and often repeats of the same etc the special procedures are considered non-invasive But how non-invasive are they psychologically and economically? All experienced physicians know how disturbing the mere mention of the existence of a slight murmur can be to a patient Some patients never recover from such a casual remark Unfortunately the terms invasive and non-invasive are now used and interpreted to mean only physical

invasion This is inadequate consideration People have minds too Disturbance of mind and thought can be even more troublesome crippling and invasive than casual considerations might suggest Remember always patients are people with minds as well as bodies And finally remember that the unnecessary use of these non-invasive studies definitely does invade the pocketbook

George E Burch MD
Tulane University School of Medicine
and Charity Hospital of Louisiana
New Orleans La

Another link between the left stellate ganglion and the long Q-T syndrome

Electrical alternation of the T wave associated with emotional or physical stress is characteristic of the long Q-T syndrome and often precedes life threatening arrhythmias This phenomenon has been experimentally reproduced in animals by stimulating the left stellate ganglion Moreover blockade of the right stellate ganglion which permits dominance of the left cardiac sympathetics not only lengthened the Q-T interval in long Q-T syndrome but also evoked T wave alternans and ventricular arrhythmias Excessive sympathetic stimulation of the heart via the left stellate ganglion resulting from a congenitally low activity of the right cardiac sympathetic nerves has been suggested as the pathogenetic mechanism The important role of the left stellate ganglion in cardiac arrhythmias has been recently demonstrated Furthermore in a patient with long Q-T syndrome at left stellatectomy after failure of medical treatment manipulation of the left stellate ganglion consistently produced ventricular tachycardia thus confirming this ganglion's modulation of dangerous ventricular arrhythmias This report describes temporary abolition of T wave alternation during blockade of

the left stellate ganglion in a patient with Romano-Ward syndrome

A 26 year old white housewife had fainted two to three times yearly for 15 years during pleasant and unpleasant emotion After negative neurologic and EEG examination at age 20 she took phenytoin for a time At age 21 she fainted upon hearing in the next room the voice of an old friend who had visited unexpectedly Before each faint she noted heart pounding and had the urge to run away Asymptomatic long Q-Tc interval was found in the patient's mother (0.2 sec) maternal grandmother (0.47 sec) and son (0.47 sec) In the patient's sister (0.4 sec) and father (0.44 sec) Q-Tc was normal Another maternal uncle and his son had childhood syncope which disappeared in adult life Three maternal aunts died suddenly at 2 years at 30 years with childhood cyanosis and at 33 years in sleep with presumed brain hemorrhage At age 23 after uneventful induced labor for toxemia of pregnancy at another hospital the patient was abruptly separated from her newborn son because of suspected tuberculosis She lapsed into hysteria fainted and convulsed whenever she




Fig 1 Upper precordial bipolar lead shows Q-T interval alternans of 0.8 and 0.61 sec and T wave alternans of opposite polarity which preceded ventricular tachycardia. Center and lower panels continuously record ventricular R-on-T ectopy tachycardia and transient fibrillation succeeding another episode of Q-T and T alternans.

heard babies brought to other mothers to nurse. She became cyanotic and pulseless with dilated pupils and required DC shock for ventricular defibrillation. R-on-T ventricular ectopy was then identified during hysterics. Although the first serum potassium was 3.4 and calcium 3.9 mEq/L, these rose to 4.6 and 4.8 mEq/L with treatment while the Q-T interval remained prolonged. Treatment also included lidocaine and propranolol. After each of six episodes of alternans of the Q-T interval and T wave she had ventricular ectopy tachycardia, flutter or fibrillation (Fig 1). She also had paroxysmal A-V junctional tachycardia. Upon entry to this hospital the cardiovascular examination, serum electrolytes and echocardiogram were normal but Q-T interval and T wave alternans prolonged Q-T interval, and occasional ventricular ectopy were seen. Although left stellate ganglion blockade with 8 ml of 1 per cent lidocaine induced left Horner's syndrome, suppressed alternation of the Q-T interval and T wave and shortened the Q-T interval to a constant value, alternans reappeared 16 hours after blockade (Fig 2). After 24 hours of propranolol and phenytoin treatment the T wave alternans disappeared. A 24-hour ECG tape showed prolonged Q-T interval but no alternans of Q-T and T wave and no ventricular ectopy. The husband was taught basic life support. During the ensuing 3 years she has never fainted; she takes extra propranolol 40 mg for palpitation. The Q-Tc has ranged from 0.49 to 0.52 sec during daily propranolol 120 to 160 mg, and phenytoin 300 to 400 mg therapy. Recently when a late systolic murmur without click appeared, a second echocardiogram showed prolapse of the posterior mitral leaflet. An audiogram was normal.

The abolition of T wave alternation during left stellate blockade and its later return in the present case together with the production of T wave alternans by both stimulation of the left stellate ganglion in animals and by blockade of the right




Fig 2 Left panels show Leads I, II, and III after left stellate blockade shortened Q-T from 0.59 to 0.52 sec. Right panels simultaneously record Leads I, II, and III with Q-T interval alternans of 0.55 and 0.67 sec and T wave alternans of 0.2 and 0.4 mV 16 hours after left stellate blockade (1 mV = 1 cm).

stellate ganglion in man demonstrates the crucial role of the left stellate ganglion in this phenomenon. The left stellate ganglion has been successfully excised to prevent syncope, ventricular fibrillation, and death in 11 cases of long Q-T syndrome. The prospective assessment of the influence of left

stellate blockade and subsequent antsympathetic drug treatment may assist in identifying first those patients in whom the left stellate ganglion clearly modulates dangerous arrhythmias. Second, the disappearance of T wave alternans during increasing doses of propranolol and phenytoin supports the antsympathetic merit of these drugs in long QT syndrome. The rationale for excision of the left stellate ganglion as specific therapy for long QT syndrome is supported by the finding that left stellectomy raises the threshold for ventricular fibrillation i.e. it reduces vulnerability to ventricular fibrillation. The suppression of alternation of the T wave, one of the characteristic ECG signs of long QT syndrome, by blockade of the left stellate ganglion links this ganglion again to an imbalanced cardiac sympathetic innervation with left dominance as the major pathogenetic mechanism for the syncope and ventricular arrhythmias seen in long QT syndrome and possibly for the long QT syndrome itself.

Richard S. Crampton MD FACC
Professor of Medicine
School of Medicine
158 Medical Center
University of Virginia
Charlottesville Va 22901

Roll over test

The etiology of hypertension induced by pregnancy is unknown. Recently several papers have suggested that the possible mechanism for hypertension may involve factors that regulate the utero-placental blood flow. The utero-placental unit represents a system in which blood flow is highly critical. It would seem logical to search for a self regulatory hemodynamic mechanism such as that demonstrated in the renin-angiotensin-prostaglandin regulatory mechanism in the kidney.

One hundred randomly selected normal primigravida women between 28 and 32 weeks gestation were subjected to the roll over test as described by Gant and associates. The patient was placed in the left lateral recumbent position and a blood pressure was taken at 5 minutes and again at 15 minutes. The subject was then turned to the supine position and the blood pressure was measured immediately and 5 minutes later with the patient still supine. An increase in diastolic pressure of 20 mm Hg or more was considered a positive roll over test. Auscultatory blood pressure measurements utilizing the onset of the first (systolic) and fifth (diastolic) sounds of Korotkoff were used when recording the blood pressure.

Twenty-five women had a positive test. Thirteen of those 25 women developed pre-eclampsia requiring magnesium sulfate therapy. Eight had transient hypertension during labor requiring no therapy. Four had no evidence of hypertension during pregnancy. A false positive rate for the 25 women with a positive "roll over test" was 16 per cent. Seventy-five women had a negative roll over test. Sixty-eight of those women

REFERENCES

- 1 Schwartz P J and Malliani A. Electrical alteration of the T wave: clinical and experimental evidence of its relationship with the sympathetic nervous system and with the long QT syndrome. *Am Heart J* 89:43 1975.
- 2 Moss A J and McDonald J. Unilateral cervicothoracic sympathetic ganglionectomy for the treatment of long QT interval syndrome. *N Engl J Med* 285:900 1971.
- 3 Schwartz P J and Periti M and Malliani A. The long QT syndrome. *Am Heart J* 89:378 1975.
- 4 Schwartz P J, Stone H L and Brown A M. Effects of unilateral stellate blockade on the arrhythmias associated with coronary occlusion. *Am Heart J* 82:589 1976.
- 5 Coyer B H, Pryor R, Hirsch W M and Blount S G. The prolonged QT syndrome: in vivo evidence of probable etiology at left stellate ganglionectomy. *Chest* (in press).
- 6 Schwartz P J. Experimental reproduction of the long QT syndrome. *Am J Cardiol* 41:374 1978.
- 7 Schwartz P J, Snebold N G and Brown A M. Effects of unilateral cardiac sympathetic denervation on the ventricular fibrillation threshold. *Am J Cardiol* 37:1034 1976.

had no evidence of hypertension during pregnancy. Seven had evidence of transient hypertension during labor requiring no therapy. A false negative test was present in 10 per cent of the 75 patients with a negative roll over test. In no case did a patient with a negative test develop pre-eclampsia. The "roll over test" is recommended as a routine test for every pregnant patient between 28 and 32 weeks gestation for the early diagnosis of hypertension of pregnancy.

George Marshall MD
St Luke Hospital
Wornall Rd at 44th St
Kansas City Mo 64111

REFERENCES

- 1 Aiken J W and Vane J R. Intrarenal prostaglandin release attenuates the renal vasoconstrictor activity of angiotensin II. *J Pharmacol Exp Ther* 184:679 1971.
- 2 Gant N F, et al. A study of angiotensin II pressor response throughout preeclamptic pregnancy. *J Clin Invest* 52:2682 1973.
- 3 Gant N F, et al. The nature of pressor responsiveness to angiotensin II in human pregnancy. *Obstet Gynecol* 43:854 1974.
- 4 Gant N F, et al. A clinical test useful for predicting the development of acute hypertension in pregnancy. *Am J Obstet Gynecol* 120:1 1974.
- 5 Jaffe B M, et al. Renal concentrations of prostaglandin F in acute and chronic renal ischemia. *Biochem Biophys Res Commun* 49:794 1972.
- 6 Longro A J, et al. Dependency of renal blood flow on

- prostaglandin synthesis in the dog *Circ Res* 32 712 1973
- McGiff J C and Itskovitz H D Prostaglandins and the kidney *Circ Res* 33 419 1973
- Ryvan W L, Coronel D M and Johnson R J A vasodepressor substance of the human placenta *Am J Obstet Gynecol* 105 1201 1969
- Speroff L An autoregulatory role of prostaglandin in placental hemodynamics: their possible influence on blood pressure in pregnancy *J Reprod Med* 15 181 1975
- Speroff L Hypertension in pregnancy: role for prostaglandin *Contemp Obstet Gynecol* 7 27 1976
- 11 Terrago N A et al. Prostaglandins and the regulation of uterine blood flow in pregnancy *Nature* 244 57 1974
- 12 Venato H C et al. Uterine prostaglandin E secretion and uterine blood flow in the pregnant rabbit *J Clin Invest* 55 193 1975
- 13 Weinberger M H et al. The effect of supine and lateral recumbency on plasma renin activity during pregnancy *J Clin Endocrinol Metab* 36 991 1973
- 14 Hellman L M and Pritchard J A Williams obstetrics fourteenth edition New York 1971 Meredith Corporation

Letters to the Editor

Dissertation on a Roast Pig Updated

To the Editor

Consider the following points

1 Even ordinary abdominal and pelvic surgical procedures are associated with a small but appreciable incidence of acute myocardial infarction in the perioperative period

2 Coronary bypass surgery a more formidable procedure than abdominal and pelvic surgery and hence representing an even greater degree of cardiac stress and carried out in patients with known poor coronary reserve a priori would be expected to be associated with a considerably higher incidence of acute myocardial infarction This in fact is the case an incidence of 11 to 20 per cent being reported in several series of cases

3 The diagnosis of acute myocardial infarction in a patient who recently has undergone heart surgery is difficult Because any but the most obvious cases would tend to escape identification in such a situation it seems probable that this reported incidence of 5 to 20 per cent really underestimates the magnitude of the problem (the iceberg effect)

4 Diminution in the frequency of angina pectoris when myocardial infarction supervenes is a well known clinical phenomenon Ischemic tissue is painful dead tissue is not

5 The main clear cut benefit of coronary bypass surgery is relief of angina pectoris Prolongation of survival has not been proven except perhaps in those comparatively few cases of main left proximal left anterior descending or triple vessel coronary artery occlusion with good distal runoff

6 I have informally surveyed several cardiac surgeons at different hospitals about the in hospital mortality rate of those instances of proven acute myocardial infarction that complicated coronary bypass surgery Their unanimous opinion confirmed my own impression that death is quite unusual surprisingly so inasmuch as the patients would be expected to be at high risk

7 Myocardial infarction during or following cardiac surgery occurs in a setting unusually favorable for survival The vital signs are continuously monitored and maintained at hemodynamically optimal levels Adequate oxygenation is assured Fear and pain are dampened (and thus the release of catecholamines diminished) by analgesics and soporifics The slightest unfavorable turn is instantly detected by the ever vigilant medical and nursing staffs and appropriate corrective measures taken No physical activity of any kind is permitted Such an ideally controlled environment stands in contradistinction to the chaos that follows those crucial but medically unattended first few hours following a myocardial infarction at home Such a difference very well may explain the markedly low perioperative mortality rate of acute myocardial infarction complicating cardiac surgery

Considering all of these factors one is led to speculate that coronary bypass surgery may accomplish the relief of angina pectoris not so much by improving coronary perfusion (which of course may be an added benefit) but primarily by inducing a relatively benign form of myocardial infarction Conceivably by converting electrically unstable ischemic tissue to electrically inert infarcted myocardium the incidence of

arrhythmias may be reduced and survival increased too If the induction of controlled myocardial infarction indeed is the mechanism surely there must be a better way to accomplish this same end!

Myron R Schoenfeld M.A. M.D. F.A.C.P.

2 Overhill Road
Scarsdale N.Y. 10583

Setting the record straight on TAPVC

To the Editor

I was surprised to read the letter of Dr. Allen Rathnam in the May 1977 issue of the Journal (AM HEART J 93 6:6 1977) regarding the exchange of letters between Dr. Bharati and Dr. Van Praagh concerning TAPVC I do not ordinarily engage in polemics as I believe this is a waste of time But the remarks of Dr. Rathnam are ill advised and I believe he has missed the main point of Dr. Bharati's remarks to Dr. Van Praagh

Dr. Van Praagh said in his paper that This is the largest series of TAPVC published to date This was a misstatement of fact Of course any author can choose any references he or she wants to quote in his or her paper but he or she must not misstate a fact And of course Dr. Van Praagh as a gentleman and scientist saw the point and said so

I don't understand the term research trainee that Dr. Rathnam uses that itself is a misstatement of fact Dr. Bharati is the Associate Director of the Congenital Heart Disease Research and Training Center

Maurice Levi M.D.
Director

Congenital Heart Disease Research
and Training Center
627 S Wood St
Chicago Ill 60619

More on jugular venous pulse (JVP) tracings and cannon waves

To the Editor

We have read with interest the paper by Drs. Berman and Waxman (AM HEART J 91 643 1976) drawing attention to the diagnostic value of the jugular venous pulse tracings (JVP) in cardiac arrhythmias. JVP is a sensitive and non-invasive method in detecting P waves concealed in the T wave and especially in the QRS complex Cannon waves can be frequently observed in sinus tachycardia with prolonged atrioventricular (A-V) conduction time atrial tachycardia atrial flutter all junctional rhythm disturbances ventricular extrasystoles ventricular tachycardia and ventricular escape rhythm

We agree with the authors that cannon waves are not commonly produced in A-V association due to sinus tachycardia with first degree A-V block This is even more true for




Fig 1 Top and bottom ECG Lead II JVI and phonocardiogram tracings from 54 year-old male patient with moderate aortic regurgitation and 1st degree A V block accompanied by frequent episodes of high grade A V block

cannon waves due to both A V association and A V dissociation on one tracing. We would like to present a case with frequent cannon waves on tracings showing both A V association and A V dissociation. The variable hemodynamic consequences of the changing time relations of atrial and ventricular contraction were sensitively reflected by the JVP. The ECG standard Lead II JVP and phonocardiogram were recorded from a 54 year old man suffering from ankylosing spondylitis with moderate aortic regurgitation and first degree A V block with frequent episodes of high grade A V block.

Returning to Drs. Berman and Waxman's case, we can find no hemodynamic cause responsible for the increase in amplitude of wave 12 called a small cannon wave by the authors.

J Tenczer MD
L Littmann MD
3rd Department of Medicine
Semmelweis University of Medicine
Mező Imre ut 17
1430 Budapest Hungary

Additional angiocardiograms for Tetralogy of Fallot

To the Editor

In the majority of children with tetralogy of Fallot a good quality biplane right ventricular angiocardiogram or cineangiogram is adequate for definition of anatomy. At times however due to presence of additional anomalies a more

special projection will have to be obtained. In our institution we have studied 325 children with tetralogy of Fallot in a 3½ year period and despite adequate preoperative biplane angiocardiograms in four instances the following anomalies were discovered during surgery: origin of the right pulmonary artery from the ascending aorta; origin of the right pulmonary artery from the descending aorta; interrupted left pulmonary artery at the hilus of the lung; and absent pulmonary valve with supralvalvular pulmonic stenosis. To avoid unpleasant surprises we have concluded that additional angiocardiograms from aortic root, left ventricle and 40-degree elevated left anterior oblique (LAO) right ventricular projection must be obtained. As it is obviously impractical to subject all children with the diagnosis of tetralogy of Fallot to all of the above studies we therefore recommend the following guidelines:

In all cases of tetralogy one must primarily obtain a good quality biplane right ventricular angiocardiogram (or cineangiogram) and while the child is still on the table the following points must be ascertained:

- 1 Left ventricle should be visualized (lateral or levo phase)
- 2 Mitral aortic continuity should be present (lateral)
- 3 Main pulmonary artery and right and left branches must be seen in sequence with equal concentration of contrast material and continuous with each other
- 4 Ventricular septum must be identified
- 5 It is mandatory to locate both semilunar valves
- 6 Attempts must be made to see the coronary arteries (not always possible on right ventricular angiogram)

Although institutional policies may differ we believe that if all the above points are checked out with certainty additional

Dissertation on a Roast Pig Updated

To the Editor—

Consider the following points

1. Even ordinary abdominal and pelvic surgical procedures are associated with a small but appreciable incidence of acute myocardial infarction in the perioperative period.

2. Coronary bypass surgery is a more formidable procedure than abdominal and pelvic surgery and hence representing an even greater degree of cardiac stress, and carried out in patients with known poor coronary reserve a priori would be expected to be associated with a considerably higher incidence of acute myocardial infarction. This in fact is the case—an incidence of 5 to 20 per cent being reported in several series of cases.

3. The diagnosis of acute myocardial infarction in a patient who recently has undergone heart surgery is difficult. Because any, but the most obvious cases would tend to escape identification in such a situation it seems probable that this reported incidence of 5 to 20 per cent really underestimates the magnitude of the problem (the iceberg effect).

4. Diminution in the frequency of angina pectoris when myocardial infarction supervenes is a well known clinical phenomenon. Ischemic tissue is painful, dead tissue is not.

5. The main clear-cut benefit of coronary bypass surgery is relief of angina pectoris. Prolongation of survival has not been proven, except perhaps in those comparatively few cases of main left, proximal left anterior descending or triple vessel coronary artery occlusion with good distal runoff.

6. I have informally surveyed several cardiac surgeons at different hospitals about the in-hospital mortality rate of those instances of proven acute myocardial infarction that complicated coronary bypass surgery. Their unanimous opinion confirmed my own impression that death is quite unusual, surprisingly so inasmuch as the patients would be expected to be at high risk.

7. Myocardial infarction during or following cardiac surgery occurs in a setting unusually favorable for survival. The vital signs are continuously monitored and maintained at hemodynamically optimal levels. Adequate oxygenation is assured. Fear and pain are dampened (and thus the release of catecholamines diminished) by analgesics and soporifics. The slightest unfavorable turn is instantly detected by the ever vigilant medical and nursing staffs, and appropriate corrective measures taken. No physical activity of any kind is permitted. Such an ideally controlled environment stands in contradistinction to the chaos that follows those crucial, but medically unattended first few hours following a myocardial infarction at home. Such a difference very well may explain the markedly low perioperative mortality rate of acute myocardial infarction complicating cardiac surgery.

Considering all of these factors, one is led to speculate that coronary bypass surgery may accomplish the relief of angina pectoris, not so much by improving coronary perfusion (which, of course, may be an added benefit) but primarily by inducing a relatively benign form of myocardial infarction. Conceivably, by converting electrically unstable ischemic tissue to electrically inert infarcted myocardium, the incidence of

arrhythmias may be reduced and survival increased too. If the induction of controlled myocardial infarction indeed is the mechanism, surely there must be a better way to accomplish this same end!

Myron R. Schoenfeld, M.A., M.D., F.A.C.P.
2 Overhill Road
Searsdale, N.Y. 11653

Setting the record straight on TAPVC

To the Editor—

I was surprised to read the letter of Dr. Allen Rathnam in the May 1977 issue of the *Journal* (*AM HEART J* 93:6:1911) regarding the exchange of letters between Dr. Bharati and Dr. Van Praagh concerning TAPVC. I do not ordinarily engage in polemics as I believe this is a waste of time. But the remarks of Dr. Rathnam are ill advised, and I believe he has missed the main point of Dr. Bharati's remarks to Dr. Van Praagh.

Dr. Van Praagh said in his paper that "This is the largest series of TAPVC published to date. This was a misstatement of fact. Of course any author can choose any references he or she wants to quote in his or her paper but he or she must not misstate a fact. And of course Dr. Van Praagh, as a gentleman and scientist, saw the point and said so.

I don't understand the term "research trainee" that Dr. Rathnam uses that itself is a misstatement of fact. Dr. Bharati is the Associate Director of the Congenital Heart Disease Research and Training Center.

Maurice Lee, M.D.
Director
Congenital Heart Disease Research
and Training Center
627 S. Wood St.
Chicago, IL 60612

More on jugular venous pulse (JVP) tracings and cannon waves

To the Editor—

We have read with interest the paper by Drs. Berman and Waxman (*AM HEART J* 91:643, 1976) drawing attention to the diagnostic value of the jugular venous pulse tracings (JVP) in cardiac arrhythmias. JVP is a sensitive and non-invasive method in detecting P waves concealed in the T wave and especially in the QRS complex. Cannon waves can be frequently observed in sinus tachycardia with prolonged atrioventricular (A-V) conduction time, atrial tachycardia, atrial flutter, all junctional rhythm disturbances, ventricular extrasystoles, ventricular tachycardia and ventricular escape rhythm.

We agree with the authors that cannon waves are not commonly produced in A-V "association" due to sinus tachycardia with first degree A-V block. This is even more true for




Fig. 1 Top and bottom ECG Lead II JVP and phonocardiogram tracings from 54 year-old male patient with moderate aortic regurgitation and 1st degree A V block accompanied by frequent episodes of high grade A V block

cannon waves due to both A V association and A V dissociation on one tracing. We would like to present a case with frequent cannon waves on tracings showing both A V association and A V dissociation. The variable hemodynamic consequences of the changing time relations of atrial and ventricular contraction were sensitively reflected by the JVP. The ECG standard Lead II JVP and phonocardiogram were recorded from a 54 year old man suffering from ankylosing spondylitis with moderate aortic regurgitation and first degree A V block with frequent episodes of high grade A V block.

Returning to Drs. Bertman and Waxman's case we can find no hemodynamic cause responsible for the increase in amplitude of wave 12 called a small cannon wave by the authors.

J. Tenczer M.D.
L. Littmann M.D.
3rd Department of Medicine
Semmelweis University of Medicine
Mező Imre ut 17
1430 Budapest Hungary

Additional angiocardiograms for Tetralogy of Fallot

To the Editor

In the majority of children with tetralogy of Fallot a good quality biplane right ventricular angiogram or cineangiogram is adequate for definition of anatomy. At times however due to presence of additional anomalies a more

special projection will have to be obtained. In our institution we have studied 325 children with tetralogy of Fallot in a 7½ year period and despite adequate preoperative biplane angiocardiograms in four instances the following anomalies were discovered during surgery: origin of the right pulmonary artery from the ascending aorta; origin of the right pulmonary artery from the descending aorta; interrupted left pulmonary artery at the hilus of the lung and absent pulmonary valve with supraventricular pulmonary stenosis. To avoid unpleasant surprises we have concluded that additional angiocardiograms from aortic root, left ventricle and 40-degree elevated left anterior oblique (LAO) right ventricular projection must be obtained. As it is obviously impractical to subject all children with the diagnosis of tetralogy of Fallot to all of the above studies we therefore recommend the following guidelines:

In all cases of tetralogy one must primarily obtain a good quality biplane right ventricular angiogram (or cineangiogram) and while the child is still on the table the following points must be ascertained:

- 1 Left ventricle should be visualized (lateral or left phase)
 - 2 Mitral aortic continuity should be present (lateral)
 - 3 Main pulmonary artery and right and left branches must be seen in sequence with equal concentration of contrast material and continuous with each other
 - 4 Ventricular septum must be identified
 - 5 It is mandatory to locate both semilunar valves
 - 6 Attempts must be made to see the coronary arteries (not always possible on right ventricular angiogram)
- Although institutional policies may differ we believe that if all the above points are checked out with certainty additional

Dissertation on a Roast Pig Updated

To the Editor

Consider the following points

1 Even ordinary abdominal and pelvic surgical procedures are associated with a small but appreciable incidence of acute myocardial infarction in the perioperative period

2 Coronary bypass surgery a more formidable procedure than abdominal and pelvic surgery and hence representing an even greater degree of cardiac stress and carried out in patients with known poor coronary reserve a priori would be expected to be associated with a considerably higher incidence of acute myocardial infarction This in fact is the case an incidence of 10 to 20 per cent being reported in several series of cases

3 The diagnosis of acute myocardial infarction in a patient who recently has undergone heart surgery is difficult Because any but the most obvious cases would tend to escape identification in such a situation it seems probable that this reported incidence of 5 to 20 per cent really underestimates the magnitude of the problem (the iceberg effect)

4 Diminution in the frequency of angina pectoris when myocardial infarction supervenes is a well known clinical phenomenon Ischemic tissue is painful dead tissue is not

5 The main clear cut benefit of coronary bypass surgery is relief of angina pectoris Prolongation of survival has not been proven except perhaps in those comparatively few cases of main left proximal left anterior descending or triple vessel coronary artery occlusion with good distal runoff

6 I have informally surveyed several cardiac surgeons at different hospitals about the in hospital mortality rate of those instances of proven acute myocardial infarction that complicated coronary bypass surgery Their unanimous opinion confirmed my own impression that death is quite unusual surprisingly so inasmuch as the patients would be expected to be at high risk

7 Myocardial infarction during or following cardiac surgery occurs in a setting unusually favorable for survival The vital signs are continuously monitored and maintained at hemodynamically optimal levels Adequate oxygenation is assured Fear and pain are dampened (and thus the release of catecholamines diminished) by analgesics and soporifics The slightest unfavorable turn is instantly detected by the ever vigilant medical and nursing staffs and appropriate corrective measures taken No physical activity of any kind is permitted Such an ideally controlled environment stands in contradistinction to the chaos that follows those crucial but medically unattended first few hours following a myocardial infarction at home Such a difference very well may explain the markedly lower perioperative mortality rate of acute myocardial infarction complicating cardiac surgery

Considering all of these factors one is led to speculate that coronary bypass surgery may accomplish the relief of angina pectoris not so much by improving coronary perfusion (which of course may be an added benefit) but primarily by inducing a relatively benign form of myocardial infarction Conceivably by converting electrically unstable ischemic tissue to electrically inert infarcted myocardium the incidence of

arrhythmias may be reduced and survival increased too If the induction of controlled myocardial infarction indeed is the mechanism surely there must be a better way to accomplish this same end

Myron R Schoenfeld M A M D F A C P
2 Overhill Road
Scarsdale N Y 10533

Setting the record straight on TAPVC

To the Editor

I was surprised to read the letter of Dr Allen Rathnam in the May 1977 issue of the Journal (AM HEART J 93 676 1977) regarding the exchange of letters between Dr Bharati and Dr Van Praagh concerning TAPVC I do not ordinarily engage in polemics as I believe this is a waste of time But the remarks of Dr Rathnam are ill advised and I believe he has missed the main point of Dr Bharati's remarks to Dr Van Praagh

Dr Van Praagh said in his paper that This is the largest series of TAPVC published to date This was a misstatement of fact Of course any author can choose any references he or she wants to quote in his or her paper but he or she must not misstate a fact And of course Dr Van Praagh as a gentleman and scientist saw the point and said so

I don't understand the term research trainee that Dr Rathnam uses that itself is a misstatement of fact Dr Bharati is the Associate Director of the Congenital Heart Disease Research and Training Center

Maurice I et al M D
Director
Congenital Heart Disease Research
and Training Center
627 S Wood St
Chicago Ill 60612

More on jugular venous pulse (JVP) tracings and cannon waves

To the Editor

We have read with interest the paper by Drs Berman and Waxman (AM HEART J 91 643 1976) drawing attention to the diagnostic value of the jugular venous pulse tracings (JVP) in cardiac arrhythmias JVP is a sensitive and non invasive method in detecting P waves concealed in the T wave and especially in the QRS complex Cannon waves can be frequently observed in sinus tachycardia with prolonged atrioventricular (A V) conduction time atrial tachycardia atrial flutter all junctional rhythm disturbances ventricular extrasystoles ventricular tachycardia and ventricular escape rhythm

We agree with the authors that cannon waves are not commonly produced in A V association due to sinus tachycardia with first degree A V block This is even more true for

Book reviews

Pregnancy Hypertension By Emanuel A. Friedman MD and Raymond H. Nuff ScD Littleton Massachusetts 1977 PSG Publishing Company Inc 400 pages. Price \$40.00

This book is intended primarily for obstetricians and gynecologists but should interest internists, general practitioners and cardiologists for many reasons. The book provides the reader with the viewpoint of the obstetrician. Hypertension is an important problem in itself. Hypertension offers special difficulties in the pregnant patient. The book also summarizes very well the Collaborative Perinatal Project supported by the National Institute of Neurological Diseases and Blindness (now the National Institute of Neurological Diseases and Stroke). The book is primarily a statistical report concerning such variables as age, risk factors, diagnostic factors, standards, choice of groups, interrelationship of variables during pregnancy. Fourteen university hospital institutions participated initially and two discontinued prior to completion of the study. The practicing physician will find this to be a useful reference source but will find the book rather difficult to read even though it represents the results of an important and extensive study. Unfortunately none of the larger hospitals for the indigent patients were included in the study in spite of difficulties they would have brought to view.

Medical statisticians will find this to be a useful source of information on hypertension and pregnancy. The influence of drugs and other aspects of therapy for hypertension on the fetus and fetal mortality is another important aspect of the book. Medical libraries of the world should include the book among their files. Obstetricians and others who manage hypertension will want to own a copy for reference. The data and statistical analyses are extensive and well presented.

Correlative Atlas of Vectorcardiograms and Electrocardiograms By Doctors C. V. Ramana Reddy and Lawrence A. Gussel New York 1977 Futura Publishing Company 994 pages

The stated purpose for the preparation of this book was to provide the reader with electrocardiograms and vectorcardiogram recorded simultaneously from adults with various types of heart disease and to correlate those recordings with a clinical summary of the patient. To this end the authors have achieved their goal. Thus, as he would in practice, the reader is permitted to interpret the ECG and VCG together. This approach is certainly the preferable one and illustrates how much the ECG and clinical findings contribute to the interpretation of the VCG. The authors' interpretation of the electrocardiograms and vectorcardiograms follow each clinical presentation.

Although the first chapter deals with the normal vectorcardiogram and electrocardiogram, it is not adequate preparation for proper understanding of the material presented in this book. Therefore the reader should acquaint himself with the fundamentals of VCG and ECG before reading the book.

The illustrations are of good quality. The Frank VCG lead system is used throughout the book. The appendices contain differential diagnoses of various vectorcardiographic patterns

and would serve as a useful reference for analysis of complicated vectorcardiograms. This book will be of value to trainees in cardiology and practicing cardiologists and hopefully will stimulate clinicians to use electrocardiography and vectorcardiography in a complementary fashion.

Auscultation of the Heart third edition By Abe Ravin MD Lane D. Craddock MD Phillip S. Wolfe MD and David Shander MD Chicago 1977 Year Book Medical Publishers Inc 287 pages

The third edition of *Auscultation of the Heart* contains the same fundamental principles of auscultation as the first edition and now includes the systolic click postoperative cardiac sounds and correlations with echocardiography. Except for these additions, the third edition is essentially the same as the first. This is surely expected for heart sounds are not expected to change nor is the use of the stethoscope. The main shortcoming of this book is the failure to emphasize continuously for learners the relationship of the heart sounds to various simultaneous cardiac events, especially the hemodynamic events. The relationship to the ECG is relatively simple and adequate for timing but heart sounds represent mechanical and hydraulic phenomena rather than electric. For beginners, the importance of auscultation is not limited to the mere detection of the various sounds, murmurs, rales, etc. but an understanding of the situation responsible for them and in turn the clinical significance.

The book contains a brief discussion of sound, the stethoscope, graphic recording, normal sounds and abnormal sounds as produced by various types of cardiac disease. The authors have produced a useful book about a neglected subject. That this book is useful and a success is attested by the fact that a third edition appears.

The Hypertrophied Heart Edited by Prof. Dr. Ruthard Jacob Darmstadt 1977 Dr. Dietrich Steinkopff Verlag 277 pages.

This paperback volume contains the papers presented at the Erwin Ruch Symposium held in Tübingen in September 1976. The 33 brief papers produce a book of 277 pages. The range of the discussions is wide, being concerned primarily with the biochemical, physical, chemistry, morphology and physiologic correlations with cardiac hypertrophy and the normal myocardium. The relation of ultrastructure of the sarcomere to myocardial contraction is discussed within the limits of existing knowledge. This symposium not only summarizes very well the existing knowledge of myocardial hypertrophy but also indicates the limited information available. The investigators plunge into a discussion of myocardial hypertrophy but they fail to define it adequately. This only adds to the extent of the problems involved. Regardless, this book contains a good collection of brief papers that should interest all physicians, biochemists, biophysicists, morphologists and pathologists. This is an interesting book to read and study. Myocardial hypertrophy is an important and common problem in medicine.



Fig 1 Normal anteroposterior (left) and lateral (right) projections of the right ventricle seen in angiocardigram of a patient with tetralogy of Fallot



Fig 2 Angiocardigraphic view showing a 40 degree elevated LAO right ventricular projection in a patient with tetralogy of Fallot. See text for explanation

angiocardigrams are not necessary. Nevertheless in our opinion one is obliged to continue and complete the study if any of the points in the checklist cannot be satisfied with certainty or if any of the following points exist

1 Uncertainty regarding the ventricular septum (left ventricular injection)

2 Major difference or discrepancy in the size or dye concentration of the main right or left pulmonary arteries (40 degree elevated LAO projection)

3 Suspicion of right left and main pulmonary artery junctional stenosis (40 degree elevated LAO projection)

4 Reversed tapering of the right or left pulmonary artery branches (40 degree elevated LAO projection)

5 Main right or left pulmonary artery transverse diameter equal to or larger than the aortic root diameter above the sinus of Valsalva (aortic root injection and 40 degree elevated LAO projection)

The standard anteroposterior and lateral projections of the right ventricle in a patient with tetralogy of Fallot (Fig 1) is compared with the 40 degree elevated LAO right ventricular projection in Fig 2. Note that the main and left pulmonary artery junctional stenosis is not evident on the anteroposterior and lateral projections whereas it is easily noted on the latter view (Fig 2)

Byan Siasst MD FACC

Iraj Arjandpur MD FACC

Jamr G Shalibi MD FACC

Department of Pediatric Cardiology

Queen Pahlavi Cardiovascular Center

P.O. Box 33-473

Shahanshahi Park

Pahlavi Road

Tehran Shemiran

Iran

Editorial

Coronary stenosis Ischemic or non-ischemic factor?

Giorgio Baroldi M D
Rome Pisa and Milan Italy

An entity can be defined only when all the pertinent variants have been recognized and their meaning has been understood. However, the rule is to postulate most of our definitions on a limited number of often misinterpreted findings. After all, most of the history of medicine is the history of errors.

For millennia the earth remained the center of the universe—an unquestionable objective fact documented already from the first primitive man by looking every morning at the rise of the sun and its course from east to west. A few, by looking at the stars, questioned this undeniable fact and despite the Inquisition were right. Today a boy of the elementary school could present a lecture in the school of Padua circa 1600 confirming the well grounded hypothesis of Copernicus just by showing a slide of our planet seen from the moon.

Every morning in the autopsy room we can see—as did Morgagni—the first primitive pathological again in Padua—atherosclerotic plaque stenosing the lumen of the coronary arteries in most of the people dying from so called coronary

heart disease (CHD). This is an objective fact which led to the present definition of CHD, namely an absolute or relative (to an increased metabolic demand) reduction of the nutrient flow to the myocardium. The obvious corollary is that the coronary arteries are functionally speaking end arteries. This is another well documented fact since CHD occurs even in the presence of collateral as is demonstrable by cineangiography.

Let us look at the stars for a moment attempting to profile as far as we can the universe of CHD in relation to its natural history. The first need is a selection of pure cases which really belong to the CHD natural history, trying to avoid the frequent error of including cases associated with other diseases (cardiac and non cardiac) or that have undergone surgery or have been exposed to too prolonged intensive care. What are we observing in these cases? Pertinent findings or the results of an association or iatrogenic effects alias experimental pathologic models?

The second need for a correct valuation of the functional meaning of the lesions is to study a control population. In spite of the obvious limitations at present only a postmortem investigation may achieve this goal. In fact all the *in vivo* information belongs to a population selected by a disease. For instance, non CHD patients with normal coronary angiograms cannot be considered as controls, since the disease may change the CHD natural history.

From the Consiglio Nazionale delle Ricerche Program in Preventive Medicine + Atherosclerosis Project, Rome CNR Istituto di Patologia Clinica Medica, University of Pisa and Institute of Pathological Anatomy, Medical School, University of Milano.

Received for publication August 5, 1977.

Reprint requests: Giorgio Baroldi, MD, Via Igia 41, Labors, 20121 Milano, Italy. Tel. 02/58100. Fax 02/58100.

Books received

Malpractice A Trial Lawyer's Advice for Physicians By Walter G. Alton Jr. LL.B. Boston 1977 Little Brown & Company 230 pages Price \$9.95

The Marathon Physiological Medical Epidemiological and Psychological Studies Edited by Paul Milvy New York 1977 New York Academy of Sciences 1090 pages Price \$75.00

Doppler Ultrasonic Assessment of Venous Disease By Robert W. Barnes M.D. Henry E. Russell and Michael R.

Wilson Iowa City 1976 The University of Iowa Hospitals 232 pages

Periphere Angiodysplasien By Robert A. Schoberer Berne Switzerland 1977 Hans Huber Publishers 262 pages Price 58 Swiss francs or 58 Deutschmarks

Moderne Kardiologie die ischämische Herzkrankheit im Elektrokardiogramm By Rassoul A. Parsi and Herbert Semmler Jena Germany 1977 VEB Gustav Fischer 157 pages

Announcements

XXIV annual meeting on Thrombosis and Haemostasis

The 24th annual meeting of the International Committee on Thrombosis and Haemostasis will be held at the University of Leuven Belgium on July 20 through 22 1978. The different subcommittees will meet on Thursday July 20 (morning and afternoon sessions) and on Saturday July 22 (Thursday evening and Friday morning are devoted to plenary sessions on the design of clinical trials in thrombosis). All meetings are open and interested physicians and scientists are welcome. Further information and registration forms can be obtained from the office of the Secretary General Dr K. M. Brinkhous Preclinical Educational Bldg 228 H Chapel Hill NC 27514 or from Dr M. Verstraete and Dr J. Vermeylen Center for Thrombosis and Vascular Research Dept of Medical Research Campus Gasthuisberg Herestraat 49 3000 Leuven Belgium.

Vascular Disease course

A course entitled Vascular Disease—Mechanisms and the Basis for Therapy will be presented at Hilton Head South Carolina on August 16 through 19 1978. Co-directors for the program are Robert Lefkowitz and Andrew Wallace. Sponsorship is by the Council on Clinical Cardiology of the American Heart Association. For further information contact Administrator Postgraduate Programs American Heart Association 7320 Greenville Ave. Dallas Texas 75231 Telephone (214) 750 5441.

Circulation Annual Scientific Meeting

The Council on Circulation Annual Scientific Meeting will be held in Snowmass Colorado on August 17 through 21 1978 under the sponsorship of the Council on Circulation of the American Heart Association and the Colorado Heart Association. Philip Schmidt is course director. For further information contact Administrator Postgraduate Programs American Heart Association 7320 Greenville Ave. Dallas Texas 75231 Telephone (214) 750 5441.

Third Canadian Summer Workshop in Electrocardiography

The Third Canadian Summer Workshop in Electrocardiography will be held at the Sheraton Centre Hotel Toronto Ontario Canada on July 3 through 7 1978. The workshop will be conducted by Henry J. L. Marriott M.D. of the Rogers Heart Foundation. The workshop is acceptable for 21½ prescribed hours by A.A.F.P. and for credit toward Category 1 of the A.M.A. Physician's Recognition Award. Fee for the workshop is \$120 U.S. funds. For further information contact Program Chairman Rogers Heart Foundation St. Anthony's Hospital St. Petersburg Fla. 33705 Telephone (813) 894 0790.

Fifth European Congress of Anaesthesiology

The Vth European Congress of Anaesthesiology will be held in Paris France from September 4 through 8 1978. Title of the congress which will be held in the Palais des Congrès: Haemodynamics in Anaesthesia and Intensive Care. For further details please contact Congres Anesthesie P.M.V. B.P. 246 92205 Neuilly Sur Seine France.

VI Asia Pacific Congress on Diseases of the Chest (The Heart and Lungs)

The VI Asia Pacific Congress on Diseases of the Chest dealing with medical and surgical aspects of heart and lung diseases and sponsored by the International Academy of Chest Physicians and Surgeons (Affiliate American College of Chest Physicians) will be held in Bombay India from November 18 to 22 1979. The Congress is being hosted by the Indian Chapters of the American College of Chest Physicians and will be organized by the Western India Chapter. Many international physicians and surgeons in the field of heart and lung diseases will participate in the plenary sessions symposia and free papers. For further information please contact Dr Aspi R. Bhatnagar Secretary General VI APCDC L.D. Ruparel Medical Centre Dr Anne Besant Road Worli Bombay 400025 India.

Table I Frequency of maximal lumen reduction

Source (No)	Lumen reduction (%)										Total			
	< 50		50-69		70-79		80-89		≥ 90		≤ 69		≥ 70	
	No	%	No	%	No	%	No	%	No	%	No	%	No	%
AMI (70)	7	9.8	3	4.2	15	21.4	22	31.4	23	32.8	10	14	60	86
OMI (30)	1	3.3	0	0.0	5	16.6	5	16.6	19	63.3	1	3	29	97
SUD (95)	5	5.2	9	9.4	21	22.1	26	27.3	34	35.7	14	15	81	85
SFD (107)	12	11.8	14	13.7	8	7.8	27	26.5	41	40.2	26	25	76	75
NCA (100)	17	17.0	17	17.0	11	11.0	24	24.0	31	31.0	34	34	66	66
AD (97)	28	28.8	31	32.0	19	19.6	13	13.4	8	8.2	59	61	38	39
$\chi^2 = 73.66$ $P < 0.001$														

In all the groups the frequency of a stenosing plaque its degree of lumen reduction length and type (concentric eccentric and semilunar) as well as the behavior of the collaterals have been estimated.

From a study of this type the first main point in discussing the meaning of a plaque is the very high frequency of severe stenosis in the control groups (Table I) 66 per cent of the non cardiac atherosclerotic patients (NCA) and 39 per cent of the normal people (AD) had at least one vessel with a lumen reduction higher than 70 per cent a frequency significantly inferior in respect of the CHD groups but nevertheless too high for a linear cause-effect relation between stenosis and ischemia. In terms of lumen reduction per se the ischemic role of a severe stenosis becomes questionable as does any presumed cause which too often does not result in the expected effect. This is particularly true if we note that a severe multi vessel involvement does not show any significant divergence between CHD and NCA groups and this also can be observed in the AD group (Table II). Even if the controls are regarded as possible CHD candidates if they had survived still the fact remains that at the time of death despite the severe coronary damage they were not CHD patients. Furthermore it is very unlikely that in people living a normal life or stressed by a disease episodes of increased metabolic demand of the myocardium may not occur.

Other findings which do not fit with the concept of a linear relation between stenosis and ischemia are

(1) In acute cases at the first episode (AMI and SED) death occurs independently from the degree of severe obstruction (same frequency of

Table II Frequency of severe stenosis (≥ 70%) vs number of main involved vessels

Source	≤ 69 ≥ 70		1		2		≥ 3		Total	
	No	%	No	%	No	%	No	%	No	%
AMI	10	14.3	28	40.0	24	34.3	8	11.4	70	100
OMI	1	3.3	10	33.3	12	40.0	7	23.3	30	100
SUD	14	14.7	39	41.1	26	27.4	16	16.8	100	100
SED	26	24.5	21	20.1	27	26.5	28	27.4	102	100
NCA	34	34.0	26	26.0	16	16.0	22	22.0	100	100
AD	59	60.6	2	2.7	13	13.4	3	3.1	97	100
Total	144	29.1	146	29.6	120	24.3	84	17.0	494	100

stenosis with different lumen reduction superior to 70 per cent) and the number of involved vessels (Table I and II)

(2) The lack of a relationship between the infarct size and the degree and number of the severe obstructive lesions (Tables III and IV). According to the classic view ischemia should be proportional to the grade of severity of the coronary damage and one would expect to find a maximal infarct size in the presence of severe multivessel involvement a supposition not confirmed by the facts.

(3) Most of the cases already at the first episode show chronic even multiple obstructions preexisting from a long time (months or years) prior to the onset of the disease. This is a long lasting clinically silent period in people living a normal stressful style of life.

(4) Allowing for some discrepancies which will be discussed further no significant difference was noted as far as the length and types of stenosis in the different group was concerned. All these




Fig 1 Cast of the coronary arteries A anterior view B posterior view Double occlusion (o) of the anterior descending branch and occlusion (o) of the right coronary artery in a 65 year old man without CHD and with normal myocardium Brain hemorrhage was the cause of death

The following selective criteria have been adopted in our study

1 *Acute myocardial infarct (AMI)* Subjects who die within 25 days from the onset of a clinically documented cardiac infarct with an unequivocal coagulation necrosis not associated with massive and extensive fibrosis As a histologic landmark of early coagulation necrosis only a polymorphonuclear cell infiltration was accepted Cases with other cardiac and non cardiac diseases as well as cases having undergone surgical procedure of any type or that had prolonged resuscitation maneuvers were not included

2 *Old myocardial infarct (OMI)* People with the identical characteristics of the previous AMI group, but with the non healed coagulation necrosis associated with a massive scar with an extension greater than 5 per cent of the left ventricular mass Such an arbitrary distinction is suggested by the fact that a scar independent of its size is a non pathognomonic end result of any irreversible myocardial damage However it sounds reasonable to assume that a large scar in people dying from an acute infarct likely represents a previous one

3 *Sudden unexpected coronary death (SUD)* Apparently healthy subjects, in normal activity, without a history of CHD and other disease, who die suddenly (within 10 minutes) in the presence of witnesses and without medical assistance and resuscitation attempts of any type The unique postmortem findings are atherosclerotic lesions of the coronary arteries and/or non inflammatory irreversible damage of the myocardium

4 *Sudden expected coronary death (SED)* Same as in the previous SUD group the only difference being a history of minor symptoms (episodes of mild chest pain dyspnea etc) retrospectively suggestive of a possible latent CHD

5 *Non cardiac atherosclerotic patients (NCA)* Patients who die from other non cardiac diseases (brain hemorrhage pneumonia etc) without history symptoms or signs of CHD and with normal myocardium

6 *Accidental death (AD)* Healthy people dying from violent death before any medical assistance without resuscitation attempts and without a record of previous significant diseases as well as negative autopsy findings in the myocardium and other organs

epiphenomenon likely secondary to the infarct.¹ On the other hand there is no morpho-functional proof that collaterals may suddenly lose their compensatory function as the primary event in infarct and sudden death. Keeping in mind that by cineangiography a correct valuation of the anastomotic system is unobtainable² and that the capillary like makeup of these vascular structures does not support the concept of a possible spasm of the collaterals.

A last argument seems worthy of discussion. If we admit that at a certain critical point of lumen reduction/length a stenosis is bypassed by its own functioning anastomoses the same mechanism proposed for the secondary thrombus formation may explain the aggravation of a stenosis. In fact the frequently observed progressive deposition of laminar mural thrombi within a plaque can be the result of the redistribution of flow by the collaterals. Any time for any reasons an increased peripheral resistance in the depending vascular area ensues a further hypostasis within the stenosis (where there is already a critical hemodynamic situation because of the reduction of the proximal flow counterbalanced by the distal retrograde collateral flow) can be expected. This hypostasis plus other thrombogenic factors (reduced fibrinolytic activity of the atherosclerotic wall irregular and serpiginous course of the stenotic lumen and others) may explain the secondary thrombus deposition. A hypothesis supported by the frequent occlusion of a stenosis after an aortocoronary bypass the latter can be considered an equivalent of collaterals at very high pressure. If so the worsening of a stenosing plaque becomes a meaningless fact in the ischemic sense. The higher incidence of stenosis greater than 90 per cent in chronic patients (OMI Table I) the trend of triple vessel involvement in the latter (OMI and SED Table II) and the higher incidence of concentric plaque in infarcts may be more the secondary effects of the flow redistribution than the indication of an increased ischemia.

In science the main needs are the discovery of new facts the discrimination between facts and appearances the formulation of well grounded working hypothesis and the admission of our ignorance. Despite innumerable theories and proposed pathogenic factors CHD still is undefinable. The natural histories of atherosclerosis and CHD are not synonymous. Because of the collaterals the ischemic effects of the chronic stenosis

as well as the acute event at its level seem more a preconceived postulate than an objective fact. Obviously we have to explain why most of the CHD patients have severe atherosclerotic obstructive lesions the basic question being do we face a simple association or the atherosclerotic plaque act by an unknown mechanism. On this subject long lasting controversies can be anticipated and these controversies are necessary with one condition that they do not become tedious useless and often misleading repetition among people looking only at one image and not trying to see the universe. We must keep in mind that CHD is a more complex phenomenon in which several pathogenic mechanisms are likely interacting as suggested by the different types of myocardial necrosis found in the disease.¹³

REFERENCES

- 1 Burch, G E. Changing concepts in cardiovascular therapy. A quarter century perspective. *AM HEART J* 93:413 1977.
- 2 Baroldi, G. and Scorsazzi, G. Coronary circulation in the normal and pathological heart. Washington D.C. 1967. U.S. Government Printing Office. American Registry of Pathology. Armed Forces Institute of Pathology.
- 3 Baroldi, G. Radice, F. Schmid, C. and Leone, A. Morphology of acute myocardial infarction in relation to coronary thrombosis. *AM HEART J* 87:65 1974.
- 4 Baroldi, G. Mariani, F. and Falzi, G. Degree of coronary artery obstruction at autopsy in patients with coronary heart disease compared with control population (in press).
- 5 Doerr, W. The pathogenesis of cardiac infarction. A few comments on some unanswered questions. *Virchows Arch (Pathol Anat.)* 373:1-7 1977.
- 6 Khouri, M. M. Gregg, D. E. and Lowensohn, H. N. Flow in the major branches of the left coronary artery during experimental coronary insufficiency in the unanesthetized dog. *Circ Res* 23:99 1968.
- 7 Baroldi, G. Acute coronary occlusion as a cause of myocardial infarct and sudden coronary heart death. *Am J Cardiol* 16:859 1965.
- 8 Baroldi, G. Coronary thrombosis: facts and beliefs. *AM HEART J* 91:683 1976.
- 9 Baroldi, G. Significance of arterial obstructive lesions in early diagnosis of coronary heart disease. In: *Early diagnosis of coronary disease. Advances in Cardiology*. P. Halonen and A. Louheja eds. Basel 1973. S. Karger pp 49-66.
- 10 Aldridge, R. M. and Trimble, A. S. Progression of proximal coronary artery lesions to total occlusion after aorta-coronary saphenous vein bypass grafting. *J Thorac Cardiovasc Surg* 62:7 1971.
- 11 Griffith, L. S. C., Achuff, S. C., Conti, R., Humphries, J. C., Brawley, R. K., Gott, V. L., and Ross, R. M. Changes in intrinsic coronary circulation and segmental ventricular motion after saphenous vein coronary bypass graft surgery. *N Engl J Med* 288:590 1973.
- 12 Baroldi, G. Different types of myocardial necrosis in coronary heart disease: a pathophysiological review of their functional significance. *AM HEART J* 89:749 1975.

Table III Lack of correlation between the extension of cardiac infarct (% total left ventricular mass) and the degree of obstructive coronary damage

Lumen Reduction (%)	No	< 49			50-69			≥ 70			Total
Number of vessels	~	1 (%)	2 (%)	3 (%)	1 (%)	2 (%)	3 (%)	1 (%)	2 (%)	3 (%)	%
Infarct size (%)											
< 10	2 (7)	1 (35)	~	~	~	1 (35)	~	8 (27)	10 (34)	7 (24)	29 (100)
11-20	1 (5)	~	~	~	~	~	~	8 (40)	0 (45)	2 (10)	20 (100)
21-30	~	1 (4)	~	~	~	~	~	13 (52)	6 (24)	2 (8)	25 (100)
31-40	1 (9)	~	1 (9)	~	1 (4)	1 (4)	1 (4)	3 (27)	5 (45)	1 (9)	11 (100)
41-50	~	~	~	~	~	~	~	6 (50)	5 (41)	1 (8)	12 (100)
> 50	~	~	~	~	~	~	~	1 (33)	1 (33)	1 (33)	3 (100)
Total	4	2	1	~	1	2	1	39	36	14	100

Table IV Infarct size vs number of main coronary arterial vessels with severe stenosis

In farct size (%)	> 70% stenosis in			Total	< 70% ste noses to normal	Total
	1 (%)	2 (%)	3 (%)			
< 20	16 (32.6)	19 (38.7)	9 (18.3)	44	5 (10.0)	49 (100)
> 20	23 (45.0)	17 (33.3)	5 (9.8)	45	6 (11.7)	51 (100)
Total	39	36	14	89	11	100
$0.2 < r < 0.3 \quad \gamma = 2.49$						

conditions may be explained only by an adequate compensatory function of the collaterals

The continuously repeated claim is that the collaterals do not exist or are meaningless or cannot develop in time when needed. The presence of anastomoses between the coronary arteries is no proof of their functional efficiency or readiness in an emergency. The conditions which determine their responsiveness, particularly as far as time is concerned, are at the moment still not adequately known. From one of the few solid experiments we know that in a relatively short time (less than one week) the normal collaterals may reach a size capable of compensating for a severe stenosis. In fact the occlusion of the latter is not followed by infarction, ventricular fibrillation, electrographic changes or impairment of the cardiac dynamics. By cineangiography and postmortem injection a dramatic increase in collateralization can be documented.

From postmortem tridimensional casts of the coronary arteries we know that the normally existing collaterals (abundant everywhere) enlarge in diameter and increase in length in the

presence of a severe obstruction. These changes are proportional to the degree and number of the stenoses, independently of the presence or absence of CHD. In other words, infarct and sudden death cases show the same collateral enlargement as in non-CHD subjects with the same degree of coronary damage. This sounds logical since an anatomical structure (collateral network) responds to a functional stimulus (pressure gradient) on a physical basis. This enlargement per se is already indicative of a compensatory function. Furthermore, all the previously mentioned conditions (very frequent severe coronary damage without CHD, absence of correlation between degree/number of stenoses and mortality (and likely morbidity) as well as size of infarct, preclinical long-lasting silent period) are the proof that collaterals are sufficient and behave in man as in the quoted experiments. What does an emergency mean in the natural history of CHD? Is it a vascular emergency or something else? And if it is a vascular emergency by which mechanism? At present we know only that the infarct and sudden death cases occur.

(1) With low frequency (about 7 per cent) in the absence of a demonstrable acute occlusion and without or with minor atherosclerotic lesions, in no one instance is an occlusive thrombus seen in a normal artery.

(2) In the presence (93 per cent) of severe often multivessel old obstructive damage associated with highly enlarged collaterals. When found an acute occlusive factor (thrombus and/or rupture of atheroma plus intimal hemorrhage) is always located at the level of the severe stenosis and therefore apparently already bypassed by the anastomotic flow. This fact suggested that the occlusive cause in this condition is a non-effective

Studies of street drugs A total of 31 samples of drugs obtained from addicts were cultured on sheep blood agar and Sabouraud's medium in order to identify microbial contamination. Included were seven samples of cocaine, 12 samples of white heroin and 12 samples of brown heroin.

Results

Of a total 80 cases of alleged endocarditis reviewed, 42 were accepted as having infective endocarditis. In 19 of the 42 cases there was an unequivocal history of parenteral drug abuse. Eleven cases occurred in the year 1975, four in 1972 and two each in 1973 and 1974. Another 12 addicts were strongly suspected of having right-sided endocarditis but failed to meet our criteria. An additional addict was seen in 1974 who had intravascular sepsis from the liver that mimicked right-sided endocarditis.

Ten (52% per cent) of the 19 cases in which endocarditis was linked to drug abuse were diagnosed clinically as having pure right-sided (tricuspid) endocarditis. Four patients had isolated aortic or mitral valve disease. One patient (No. 4) had had a mitral valve prosthesis implanted several years previously because of rheumatic valvular disease. Two patients with underlying heart disease had been treated for subacute bacterial endocarditis due to alpha-hemolytic streptococci several years earlier.

Coagulase-positive staphylococci were the etiological agents recovered in 13 (68.4 per cent) of our cases. *Candida* species accounted for three (15.8 per cent). *Pseudomonas aeruginosa* was recovered in one patient (5.3 per cent) and two patients (10.5 per cent) showed *Streptococcus viridans* on repeated blood cultures. In four of our 1975 patients with cultures positive for coagulase-positive staphylococci, the organism was sent to the Center for Disease Control, Atlanta, for phage typing. Two of these organisms were classified as non-typable, one as 29 and one as WH1. The incidence of staphylococcal infection in 1975 showed no significant variation from the total incidence over the years reviewed (63.6 per cent vs. 68.4 per cent).

Complications of the endocarditis seen among our patients included glomerulonephritis and uremia (one), hemiplegia (one), intracerebral

Of these three occurred in 1972, two in 1973, two in 1974 and six in 1975 (see Table 1).



Fig. 1. Case No. 13. Chest x-ray on day of admission. Diffuse bilateral infiltrates with possible necrotizing cavitation.

bleeding (one), pericarditis (one), renal infarction and mesenteric occlusion (one), osteomyelitis and mucopurulent conjunctivitis, each occurred once in patients with staphylococcal endocarditis.

A total of three (15.8 per cent) deaths occurred in our series. Two of these (cases No. 4 and No. 6) were infected with *Candida* species and are discussed below. The third patient had fulminating tricuspid endocarditis due to *Pseudomonas aeruginosa*. Because of the fulminating course and the grave prognosis associated with right-sided endocarditis due to this bacterium, this case deserves special emphasis.

Case reports

Case No. 13. A 44-year-old male was admitted on May 21, 1975, with a 5-day history of fever, cough with putrid sputum production and progressively increasing dyspnea. He denied shaking chills, hemoptysis or chest pain. He admitted to drinking heavily and smoking one pack of cigarettes per day. He stated that he had vomited several times during his illness. He denied heroin use.

Physical examination revealed an acutely ill male. Vital signs showed respiratory rate 36/minute, temperature 102°F, heart rate 170/minute and blood pressure 140/90 mm Hg. Cardiac auscultation revealed no murmur. Auscultation of the chest showed scattered bilateral rhonchi with diminished breath sounds bilaterally over the bases.

Total white blood count was 18,000/mm³ with 79 per cent

Infective endocarditis in heroin addicts Epidemiological observations and some unusual cases

Michael Lange, M D
John S Salaki, M D
John R Middleton, M D
Purnendu Sen, M D
Rajendra Kapila, M D
Marmaduke Gocke, M D
Donald B Louna, M D, F A C P
Newark N J

Infective endocarditis is a well recognized complication of parenteral drug abuse in which early diagnosis and prompt therapy leads to a significant decrease in mortality^{8,9,11,12}. It is generally accepted that pure tricuspid valve involvement is found to a significantly higher degree in parenteral drug users than in the non addict population^{3,4}. Coagulase positive staphylococci are the most frequently isolated etiological agents in the addict population with Gram negative organisms and candida species occurring regularly although less frequently^{5,8,10,13,17,20}.

It had been widely assumed that contamination of the illicit drugs during addition of diluting substances, the use of non sterile diluent water, the sharing of injection paraphernalia by several people without an attempt at sterilization between use and the egregiously unhygienic injection techniques of the addicts account for the high frequency of sepsis in the parenteral drug user^{3,4,6}. However, Tuazon and associates^{16,18} studied 100 samples of street heroin and 100 items of injection paraphernalia obtained from infected addicts, and failed to isolate a single colony of staphylococci despite frequent isolation of other bacterial and fungal contaminants^{16,18}.

From the Departments of Preventive Medicine and Community Health and Medicine New Jersey Medical School Newark N J

Received for publication June 7 1977

Accepted for publication July 5 1977

Reprint requests Donald B Louna M D Department of Preventive Medicine CMDNJ 100 Bergen St Newark N J 07103

During the year 1975 we observed a significant increase in the number of heroin addicts with infective endocarditis in our hospital. This increase appeared to coincide with the appearance in the street market of large quantities of 'brown' heroin of Mexican and East Asian origin²¹. We investigated the possibility of a relationship between our observed increase in the number of cases of endocarditis and the appearance of this new heroin source.

Methods

Patient selection The medical records of all patients suspected of having infective endocarditis at Martland Medical Center Newark, N J were reviewed from January, 1972 through December, 1975. The records of all heroin addicts with evidence of sepsis admitted during the same time period were also reviewed. In order to be included in our series as a bona fide addiction related case of infective endocarditis the following criteria had to be met: (1) definite history of parenteral drug abuse, (2) multiple blood cultures growing the same organism, (3) significant cardiac murmur or multiple pulmonary emboli on admission or developing during hospitalization and (4) oral temperature greater than 101° F (38.3° C). Organisms were identified by standard laboratory techniques. Antibiotic susceptibility testing was done by the Kirby Bauer disc technique. Minimum inhibitory concentrations by tube dilutions were obtained in several instances.

Table 1 Number of cases of endocarditis according to year of occurrence

Organism	1972	1973	1974	1975
Coagulase positive staphylococcus	4(2)	1	1(1)	7(3)
Candida		1	1	1
Pseudomonas				1(1)
Streptococcus				2
II hemolytic streptococcus		(1)		
No organism recovered	(1)		(1)	(1)
Total	4(3)	2(1)	2(2)	11(5)

Numbers in brackets ref. 16 highly suspected but not definitely confirmed cases.

negative Serum hepatitis B antigen test was negative. Anti nuclear antibody was present in a titer of 1:80. The electrocardiogram showed no abnormalities. Chest x ray revealed small focal areas of opacity in both lung fields (see Fig. 3) and lung scan showed multiple bilateral filling defects. Three initial blood cultures were negative and repeated blood cultures over the next month (total $\times 17$) were negative. Sputum culture showed normal flora. An intradermal test with intermediate PPD (5 TU) was positive but sputum showed no acid fast bacilli on smear or culture. Liver scan was negative.

During hospitalization afternoon temperatures daily rose to 101 to 105.6 F and chills persisted. On July 8, 1974, he coughed 75 cc of red frothy blood and complained of sharp left sided chest pain. Auscultation revealed decreased breath sounds at the left base. Cephalothin 3 Gm every 6 hours and gentamicin 80 mgm every 8 hours were given and this resulted in partial defervescence over the next five days but he continued to have pain and decreased breath sounds over the left chest. A mid systolic click became audible at the apex. The patient denied abdominal tenderness or pain. High fever readings returned on July 14, 1974 and continued daily thereafter. Hemoptysis recurred on July 22, 1974. Liver and bone marrow biopsies were performed and these showed no significant abnormalities and were negative on culture. Chest x ray revealed focal bilateral nodular infiltrates, some with central cavitation (Fig. 4).

On July 25, 1974, he experienced massive hemoptysis and died. Autopsy revealed bilateral septic pulmonary emboli and abscesses. Heart and cardiac valves were normal but the liver showed multiple abscesses, the largest being 3.5 inches in diameter. The largest abscess had eroded into the inferior vena cava and vegetations were found in this area within the inferior vena cava. Cultures from aspirated pus of lung and liver abscesses yielded *Staphylococcus aureus*.

Comment: This to our knowledge is the first such case reported. It is unique in two respects. First, staphylococcal liver abscesses have not been noted as a consequence of addiction. Second, despite multiple staphylococcal pulmonary emboli, all blood cultures using routine and hypertonic media were unrevealing. This is surprising since the lung, unlike the liver and spleen, is ineffective in reducing microbial populations arriving hematogenously. When first seen by the arriving



Fig. 4 Case No. 20. Chest x ray three weeks after admission. Several new fluffy infiltrates representing septic emboli have appeared.

infectious disease team, a diagnosis of tricuspid endocarditis probably due to *Staphylococcus aureus* was made. However, the negative cultures, persistent fever, increasing diffuse pulmonary infiltrates, and positive tuberculin test prompted a presumptive diagnosis of disseminated tuberculosis. Even in retrospect the correct diagnosis could not readily have been made. Presumably a repeat liver scan in the face of the persistently elevated alkaline phosphatase and studies of serum antistaphylococcal antibodies might have been helpful.

Of the three cases of *Candida* endocarditis, one (No. 4) developed infection with *Candida parapsilosis* on a mitral valve prosthesis and died before adequate therapy could be instituted. The second (No. 6) had previously documented rheumatic carditis with both aortic and mitral valve disease and had been treated successfully four years earlier for subacute bacterial endocarditis due to *Streptococcus viridans*. This patient died during a surgical attempt to insert an aortic valve prosthesis. He was found to have a large myocardial abscess extending from his aortic valve from which *Candida* species was recovered. The third patient with *Candida* endocarditis (No. 10) also had previously documented rheumatic heart disease. She presented initially with a left-sided hemiplegia. Multiple blood cultures were positive for *Candida parapsilosis*. The patient improved on amphotericin and 5-fluorocytosine but left the hospital before finishing therapy. Three weeks later she was readmitted again started on antifungal therapy and again signed out prematurely. Six weeks later she returned complaining of fever and malaise. Blood cultures at this time failed to show *Candida*. Nevertheless, antifungal therapy was again started and she felt improved. After 4 weeks of therapy, she again signed out against medical advice. She



Fig 2 Case No 13 Chest x ray 72 hours after admission. New fluffy infiltrates have developed bilaterally representing septic emboli.



Fig 3 Case No 20 Chest x ray on day of admission showing bilateral infiltrates.

neutrophils hematocrit was 47 per cent blood sugar 120 mgm per cent blood urea nitrogen 26 mgm per cent Alkaline phosphatase bilirubin and liver enzyme concentrations were all within normal limits. Urinalysis was normal. Blood gases revealed pO_2 34.4 mm Hg pCO_2 65 mm Hg HCO_3^- = 27 meq/L pH 7.24.

Sputum gram stain showed many polymorphonuclear leukocytes with Gram positive cocci in pairs and chains and a few Gram negative rods. Smears for acid fast bacilli were negative.

ECG showed sinus tachycardia. Chest x ray revealed diffuse bilateral infiltrates more pronounced on the right side (Fig 1).

The patient was intubated and given oxygen. A presumptive diagnosis of aspiration pneumonia was made and treatment was started with clindamycin and gentamicin, the latter being given because of the presence in sputum stain of gram negative rods. On the third hospital day a repeat chest x ray showed new infiltrates in the upper lung fields (Fig 2) and the initial sputum specimens showed on culture normal flora plus a few pseudomonas organisms. The patient was again queried about drug abuse and admitted to intermittent heroin use. Blood cultures showed *Pseudomonas aeruginosa* and diagnosis of combined embolic and aspiration pneumonia was made. Carbenicillin was added to the regimen but relentless deterioration continued. On May 28 1975 he developed a pneumothorax and died. Postmortem examination revealed right sided tricuspid endocarditis with multiple foci of embolic pneumonia.

Comment This was a marvelously instructive case. The history of alcoholism and the fetid sputum virtually estab-

lished a diagnosis of aspiration pneumonia. When new infiltrates appeared after hospitalization the possibility was entertained of continued aspiration in the hospital or iatrogenic pneumonia secondary to administration of oxygen via an apparatus with a reservoir nebulizer. However the presence of pseudomonas organisms in the original sputum together with new infiltrates suggested the proper diagnosis of embolic pneumonia from vegetations on the tricuspid valve.

The case of intravascular sepsis mimicking right sided endocarditis is so extraordinary it also merits particular emphasis.

Case No. 20 A 17 year old man was admitted on June 21 1974 with a 4 month history of intermittent chills night sweats non productive cough chest pain and 25 lbs weight loss. He admitted using heroin for the past 4 years and had had four previous admissions for overdose since 1970. His chills developed in the evening occurred every 24 hours during the month prior to admission and were associated with left anterior chest pain leg pains and diaphoresis. Physical examination revealed an acute and chronically ill appearing male. Vital signs showed a rectal temperature of 101 heart rate of 108/minute respiratory rate of 24/minute and blood pressure of 110/72 mm Hg. No cardiac murmur was audible and physical examination revealed no abnormalities.

Laboratory studies showed a hemoglobin ranging from 10.1 to 7.2 gm per cent white blood count of 10.6 to 18.3 mm³ with a differential count of 84 per cent segmented cells 14 per cent lymphocytes and 2 per cent monocytes. Alkaline phosphatase concentration was 116 international units per 100 ml. Urinalysis L F (11) preparation blood sugar smears for malaria and latex agglutination slide test for rheumatoid factor were

Table 1 Number of cases of endocarditis according to year of occurrence

Organism	1972	1973	1974	1975
Coagulase positive staphylococcus	4(?)	1	1(1)	7(3)
Candida		1	1	1
Streptococcus pseudomonas				1(1)
Streptococcus viridans				2
B hemolytic streptococcus		(1)		
No organism recovered	(1)		(1)	(1)
Total	4(3)	2(1)	2(2)	11(5)

Numbers in brackets refer to highly suspected but not definitely confirmed cases.

negative Serum hepatitis B antigen test was negative. Anti nuclear antibody was present in a titer of 1:80. The electrocardiogram showed no abnormalities. Chest x ray revealed small focal areas of opacity in both lung fields (see Fig 3) and lung scan showed multiple bilateral filling defects. Three initial blood cultures were negative and repeated blood cultures over the next month (total $\times 17$) were negative. Sputum culture showed normal flora. An intradermal test with intermediate PPD (5 TU) was positive but sputum showed no acid fast bacilli on smear or culture. Liver scan was negative.

During hospitalization afternoon temperatures daily rose to 101 to 105.6 F and chills persisted. On July 8 1974 he coughed 75 cc of red frothy blood and complained of sharp left sided chest pain. Auscultation revealed decreased breath sounds at the left base. Cephalothin 3 Gm every 6 hours and gentamicin 80 mgm every 8 hours were given and this resulted in partial defervescence over the next five days but he continued to have pain and decreased breath sounds over the left chest. A mid systolic click became audible at the apex. The patient denied abdominal tenderness or pain. High fever readings returned on July 14 1974 and continued daily thereafter. Hemoptysis reurred on July 27 1974. Liver and bone marrow biopsies were performed and these showed no significant abnormalities and were negative on culture. Chest x ray revealed focal bilateral nodular infiltrates some with central cavitation (Fig 4).

On July 25 1974 he experienced massive hemoptysis and died. Autopsy revealed bilateral septic pulmonary emboli and abscesses. Heart and cardiac valves were normal but the liver showed multiple abscesses, the largest being 3.5 inches in diameter. The largest abscess had eroded into the inferior vena cava and vegetations were found in this area within the inferior vena cava. Cultures from a purulent pus of lung and liver abscesses yielded *Staphylococcus aureus*.

Comment: This to our knowledge is the first such case reported. It is unique in two respects. First staphylococcal liver abscesses have not been noted as a consequence of addiction. Second, despite multiple staphylococcal pulmonary emboli, all blood cultures using routine and hypertonic media were unrevealing. This is surprising since the lung unlike the liver and spleen is ineffective in reducing microbial populations arriving hematogenously. When first seen by the arriving



Fig 4 Case No 20 Chest x ray three weeks after admission. Several new fluffy infiltrates representing septic emboli have appeared.

infectious disease team a diagnosis of tricuspid endocarditis probably due to *Staphylococcus aureus* was made. However the negative cultures, persistent fever, increasing diffuse pulmonary infiltrates and positive tuberculin test prompted a presumptive diagnosis of disseminated tuberculosis. Even in retrospect the correct diagnosis could not readily have been made. Presumably a repeat liver scan in the face of the persistently elevated alkaline phosphatase and studies of serum antistaphylococcal antibodies might have been helpful.

Of the three cases of *Candida* endocarditis one (No 4) developed infection with *Candida parapsilosis* on a mitral valve prosthesis and died before adequate therapy could be instituted. The second (No 6) had previously documented rheumatic carditis with both aortic and mitral valve disease and had been treated successfully four years earlier for subacute bacterial endocarditis due to *Streptococcus viridans*. This patient died during a surgical attempt to insert an aortic valve prosthesis. He was found to have a large myocardial abscess extending from his aortic valve from which *Candida* species was recovered. The third patient with *Candida* endocarditis (No 10) also had previously documented rheumatic heart disease. She presented initially with a left sided hemiplegia. Multiple blood cultures were positive for *Candida parapsilosis*. The patient improved on amphotericin and 5-fluorocytosine but left the hospital before finishing therapy. Three weeks later she was readmitted again, started on antifungal therapy and again signed out prematurely. Six weeks later she returned complaining of fever and malaise. Blood cultures at this time failed to show *Candida*. Nevertheless antifungal therapy was again started and she felt improved. After 4 weeks of therapy she again signed out against medical advice. She

Table II Endocarditis in heroin addicts

Case No	Age	Sex	Drug	Organism	Valve	Underlying disease	Presentation	Treatment	Outcome
1	26	F	Heroin	Staph CP	Tricuspid	None	Fever Hemoptysis Multiple pulm emboli Abscess of right antecubital fossa	Methicillin Vancomycin	Recovered
2	36	M	Heroin	Staph CP	Tricuspid	None	Fever Multiple pulm emboli	Methicillin Keflin	Recovered
3	46	M	Heroin	Staph CP	Tricuspid	None	Malaise fever Multiple pulm emboli and right sided effusion	Penicillin Methicillin Keflin	Recovered
4	17	M	Heroin	Candida nonalbicans	Mitral prosthesis	RHD age 8 Mitral valve prosthesis	Chills fever congestive heart failure	Keflin Gentamicin Amphotericin	Died
5	22	M	Heroin	Staph CP	Tricuspid	None	Chest pain & fever hemoptysis—RLL infiltrate & empyema	Keflin Clin damycin	Recovered
6	34	M	Heroin	Candida nonalbicans	Aortic	RHD with AI and MI 1970 SBE with streptococcus viridans	Fever Left sided hemiplegia Osler node	Amphotericin B	Died during open heart surgery
7	24	M	Heroin	Staph CP	Tricuspid	None	Fever Septic emboli	Oxacillin Cefazolin	Improved Signed out against medical advice
8	21	M	Heroin	Staph CP	Tricuspid	Diabetes	Fever chills cardiac murmur mucopurulent conjunctivitis	Cefazolin	Did well but had intermittent renal insufficiency
9	50	F	Heroin	Staph CP	Aortic & mitral	RHD hypertension cirrhosis SBE in 1971	Fever mental confusion Roth spots	Methicillin Cefazolin	Recovered in hospital developed renal infarct and mesenteric occlusion
10	26	F	Heroin	Candida	Aortic & mitral	RHD	Left hemiplegia harsh systolic & early diastolic murmur	Amphotericin B and 5 fluoro cytosine	Improved signed out against medical advice x 3 lost to follow up

Abbreviations used CP = coagulase positive AMA = against medical advice RHD = rheumatic heart disease W = white B = brown AI = aortic insufficiency MI = mitral insufficiency SBE = subacute bacterial endocarditis IVC = inferior vena cava

was lost to follow up for the next 7 months at which time she returned for cardiac catheterization. Although she had evidence of cardiac failure she had no fever and her erythrocyte sedimentation rate was 17 mm/hour (Westergren). Candida precipitins were negative whereas they had been positive during the first admission. The echocardiogram showed damaged mitral and aortic valves but no evidence of any vegetations.

The two patients with *Streptococcus viridans* endocarditis were a couple sharing both heroin and injection paraphernalia. The husband was on hemodialysis for "heroin induced

nephropathy" and developed the endocarditis 4 months after he had started dialysis. The wife had been hospitalized in 1972 with an intracranial hemorrhage. No cardiac murmur was noted and cerebral arteriogram showed diffuse arterial spasm but no evidence of an aneurysm. She was readmitted in 1975 in coma with a hemorrhagic cerebrospinal fluid. This time the cerebral arteriogram demonstrated an aneurysm in the circle of Willis and cardiac auscultation showed an aortic insufficiency murmur. The patient was treated successfully for her alpha streptococcal endocarditis and subsequently the cerebral aneurysm was removed surgically.

Table 11 Continued

Case No	Age	Sex	Drug	Organism	Valve	Underlying disease	Presentation	Treatment	Outcome
11	25	F	Heroin	Staph CP	Tricuspid	None	Fever chills x 5 days multiple pulm emboli developed in hospital $\frac{1}{2}$ right murmur at left sternal border	Cephalothin and Gentamicin Cefazolin	Did well Cardiac cath. 3 months after cure showed pul regurgitation and mild tricuspid regurgitation
12	33	M	Heroin	Staph. CP from pericardial fluid and skin abscess	Tricuspid	Diabetes Obesity	Skin abscess x 2 wks Right axilla fever and rigors pleuritic pain & right pulm infiltrates	Cefazolin & Gentamicin	Pericardiectomy Died 1st day postop
13	44	M	Heroin	Pseudomonas aeruginosa	Tricuspid	None	Fever cough, pleural pain	Cefazolin Gentamicin	Progression of pulmonary emboli Died
14	17	M	Heroin	Staph CP	Aortic	None	Back pain & fever x 3 days Osteomyelitis of vertebrae	Oxacillin Cefazolin	Recovered
15	42	M	Heroin	Staph CP	Mitral	None	Fever & rigors splenomegaly $\frac{1}{2}$ apical systolic murmur	Cefazolin	Improved—signed out against medical advice
16	34	M	Heroin	Staph CP	Mitral	RHD Alcoholism hypertension	Recurrent septic arthritis in L ankle	Cefazolin	Improved
17	31	M	Heroin Cocaine	Strep viridans	Aortic	Uraemic (on hemodialysis)	Fever ascites right pleural effusion	Streptomycin Penicillin	Recovered
18	25	F	Heroin	Strep viridans	Aortic	Intracranial hemorrhage 1971	Drowsy confused bloody CSF	Penicillin Streptomycin	Berry aneurysm successfully removed recovered
19	25	M	Heroin	Staph CP	Tricuspid	None	Fever multiple pulmonary emboli	Cefazolin Gentamicin	Improved—signed out against medical advice
20	17	M	Heroin	Negative blood cultures x 16 autopsies Staph CP from liver abscess and IVC vegetations	No valvular involvement	None	Fever & chills cough, chest pain 25 lbs wt loss	Methicillin Cephalothin Gentamicin	Died

Results of cultures of drugs

Although we found frequent contamination of street drugs on culturing neither cocaine nor brown or white heroin yielded a single colony of *Staphylococcus aureus*. Neither did we isolate any strains of *Streptococcus viridans*, candida or *Pseudomonas aeruginosa*. The bacterium most often recovered from the drug specimens was *Bacillus subtilis* and the fungi found most frequently were aspergilli (see Table II).

Discussion

In May 1975 an editorial in the *New York Times* noted that on the basis of increasing numbers of arrests for heroin related felonies it had become apparent that increasing quantities of heroin were becoming available on the street market in both the regular white form of European origin and a newer brown form originating in Mexico.¹ Brown heroin had first made its appearance in 1973-74 at a time when the ban

Table III "Street drug" culture results

7 samples of cocaine	- Streptomyces B Subtilis x 2 Aspergillus sp Pleosporum sp
12 samples Brown Heroin	- Aspergillus sp x 3
12 samples White Heroin	- Pleosporum sp x 2 Streptomyces B Subtilis

on poppy growing in Turkey resulted in a significant decrease of the traditional supply. Although less purified, the brown heroin was noted to be more potent. It was felt that a "new heroin epidemic" was a serious and likely possibility in the near future.

The marked increase in the number of cases with heroin associated endocarditis diagnosed in our hospital during this period corresponds closely to the above listed dates. We observed a decrease in the number of cases in 1973 and 1974 (two definite for each year and one and three suspected respectively), followed by a steep rise in incidence in 1975.*

We wondered whether there might be a relationship between the increase in septic complications observed in our addict population and the more frequent use of brown heroin. It was felt that the more unrefined impure heroin originating from Mexico was possibly more heavily contaminated with pathogens. The results of our cultures of samples of cocaine, white and brown heroin did not, however, lend credence to this hypothesis. Despite our finding of heavy contamination of street drug samples we failed to recover a single isolate of *Staphylococcus aureus* the pathogen responsible for 63.6 per cent of the infective endocarditis cases in 1975. We failed in addition to isolate any of the other organisms causing endocarditis in our addicts namely candida, pseudomonas or alpha streptococcus. We were unfortunately unable to obtain the injection paraphernalia used by the couple suffering from *Streptococcus viridans* endocarditis.

Others have also failed to recover offending organisms from the drugs and injection paraphernalia used by addicts. Although the isolation of strains of pseudomonas and candida has

occurred,¹⁶ only a single isolation of *Staphylococcus aureus* from heroin¹⁷ has been made to date. The drugs and paraphernalia¹⁸ may not be the source of the offending organisms. Tuazon and colleagues¹⁹ reported that on culturing nose, skin, and throat of drug addicts 33 per cent were found to be carriers of *Staphylococcus aureus* as compared to only 11 per cent in controls. Moreover, when studied within the first 3 days after initiating therapy for addiction associated staphylococcal endocarditis, 100 per cent of patients showed identical phage type staphylococci from nose, throat, or skin as grew from the initial blood cultures.¹⁹ Interestingly, these authors also found similar increases in staphylococcal carrier rate among diabetics on chronic insulin injection therapy.¹⁹

Available present data, therefore, suggest that heroin injection increases staphylococcal carriage and that self inoculation during nonsterile injection of skin contaminating staphylococci accounts for frequent staphylococcal bacteremia and consequent endocarditis.

Since the majority of our addicts had been using heroin for several years this hypothesis does not fully explain the marked increase in incidence in 1975. Heroin was used on a periodic rather than on a daily basis by many of our addicts. If we assume that each intravenous injection carries a certain constant percentage risk it might follow that if increased availability of heroin on the street led to greater frequency of injections among the addicts a greater number of cases of staphylococcal sepsis and hence of endocarditis would occur. It might also be that in some undefined manner the injection of brown heroin increases the carrier state of staphylococci even more than does white heroin.

The criteria for establishing the diagnosis of tricuspid endocarditis remain somewhat controversial. It is primarily a clinical diagnosis made on the basis of repeated positive blood cultures, multiple pulmonary infiltrates, fever and a history of parenteral heroin use.* Different series vary considerably in the proportion showing a typical tricuspid insufficiency murmur.²⁰⁻²²

That the above listed criteria for diagnosing tricuspid endocarditis can be present without actual involvement of the tricuspid valve is shown by our patient No. 20. This patient who

(11 definite and five suspected)

had an intermittent murmur multiple pulmonary emboli fever and a history of heroin abuse but whose blood cultures were consistently negative was found to have multiple staphylococcal liver abscesses that had eroded into the inferior vena cava. Hence the infection was peripheral to the right side of the heart the tricuspid and pulmonary valves were found to be totally normal at autopsy despite continuing evidence of multiple sites of embolic pneumonia. To our knowledge this case is unique.

In order to establish the diagnosis of tricuspid endocarditis more clearly cardiac catheterization has been utilized to obtain blood for bacteriologic culture above and below the tricuspid valve thereby establishing the definite anatomic level at which infection is present.^{12,13} The risk of embolization as a direct consequence of such catheterization however makes this a dangerous procedure that should be undertaken only in cases of persistent infection or unsatisfactory clinical response after a trial of appropriate medical therapy.

Our series supports the increasingly frequent reports of a favorable outcome for right sided endocarditis caused by staphylococci when a high level of suspicion is maintained and appropriate antibiotic therapy is begun immediately after the diagnosis is seriously suspected.¹⁴ This is in marked contrast to the right sided endocarditis produced by pseudomonas infection a disease that continues to have a bleak prognosis. Indeed in a local epidemic described by Arbulu and colleagues¹⁵ and by Reyes and co workers¹⁶ which occurred in Detroit a relatively favorable outcome was only achieved after surgical excision of the tricuspid valve. Medical therapy for six weeks frequently resulted in relapse following discontinuation of the antibiotics. Currently recommended medical therapy includes gentamicin carbenicillin and polymyxin given together.¹⁷

Left sided endocarditis caused by staphylococci on the other hand remains a disease with a serious prognosis if the aortic valve is involved. The disease is particularly severe if the causative organisms are strains of candida or pseudomonas. On the other hand if the left sided disease is caused by *Streptococcus viridans* treatment is usually successful.

Of the eight patients with left sided endocarditis five had a history of previous rheumatic heart

disease. In one patient this had led to the insertion of a mitral valve prosthesis. All three of our candida cases occurred in this group giving further support to the observation that candida usually colonizes previously damaged heart valves.¹ Of the 13 patients with staphylococcal endocarditis nine occurred on the right side of the heart. Of four patients with staphylococcal infections involving left sided cardiac valves two had a history of previous rheumatic heart disease. In only two patients therefore did staphylococci colonize left sided cardiac valves presumed to be normal.

It has been observed that platelets are aggregated in vitro by various bacteria and that large numbers of viable clumped bacteria can be found within the aggregated platelet mass.^{18,19} Of the bacteria studied staphylococci showed the greatest promotion of aggregation.^{20,21} It is unknown if there are specific factors that cause these platelet-staphylococcal aggregates to settle out predominantly on the right sided heart valves.

The presumed transmission of *Streptococcus viridans* by shared paraphernalia has to our knowledge not been reported previously. There is one instance in which enterococci caused endocarditis in both husband and wife using heroin.²² This is of particular interest in view of a recent paper²³ reporting isolation of enterococci from the paraphernalia of heroin addicts with enterococcal endocarditis. The narcotic samples we studied unfortunately did not include the drugs used by the husband and wife with streptococcal endocarditis. However it still seems likely the shared needles and drugs accounted for the conjugal aortic valve endocarditis.

Conclusion

The reason for the sharp increase in the number of cases in 1975 in our series remains obscure. We could not implicate the drugs and there was no evidence of a point source. Several organisms were involved and phage typing of four of the seven 1975 cases of *Staphylococcus aureus* infection revealed at least three different phage types. Since the drug samples were from addicts other than those who developed endocarditis and since we did not study the paraphernalia from the patients with endocarditis drug or paraphernalia contamination is still a possibility. If however

there was no point source and drug contamination could not be demonstrated, an intriguing possibility is that the brown heroin modifies host defenses or microbial carriage rates more than white heroin

Summary

The total number of cases of heroin induced endocarditis occurring over a four year period were reviewed in order to explain an increase in the number of cases in the last year studied (1975). Brown heroin was noted to be used more frequently by addicts during the period of increased incidence. Cultures of street samples of brown and white heroin as well as cocaine were obtained in order to elucidate a possible relationship between the increased use of brown heroin and the increased number of endocarditis cases. Despite frequent contamination of both white and brown heroin, none of the common endocarditis causing pathogens were isolated from the samples.

Staphylococcus aureus, the most common etiological agent, frequently resulted in tricuspid endocarditis. That the accepted criteria for tricuspid endocarditis may be present without actual cardiac valve involvement is demonstrated by a most unusual case of hepatic vasculature infection.

REFERENCES

- Hussey H H and Katz E Infections resulting from narcotic addiction Am J Med August 1960 p 186
- Olson R A and Romansky M J Staphylococcal tricuspid endocarditis in heroin addicts Ann Intern Med 67 755 1962
- Louria D H Hensle T and Rose J The major medical complications of heroin addiction Ann Intern Med 67 1 1967
- Cherubin C E The medical sequelae of narcotic addiction Ann Intern Med 67 23 1967
- Cherubin C E Baden M Kavaler F Lerner S and Cline W Infective endocarditis in narcotic addicts Ann Intern Med 69 1091 1968
- Jaffe R B and Koschmann E H Intravenous drug abuse Pulmonary cardiac and vascular complications Am J Roentgenol 109 107 1970
- Ramsey R G Gunnar R M and Tobin J R Endocarditis in the drug addict Am J Cardiol 25 608 1970
- Lewis R J Infections in heroin addicts JAMA 223 1036 1973
- Menda K H and Gorbach S L Favorable experience with bacterial endocarditis in heroin addicts Ann Intern Med 78 25 1973
- Dreyer N P and Fields B N Heroin associated infective endocarditis A report of 28 cases Ann Intern Med 78 699 1973
- Arbulo A Kafi A Thoms N W and Wilson R F Right sided bacterial endocarditis New concepts in the treatment of uncontrollable infection Ann Thorac Surg 16 136 1973
- Reyes M P Palutke W A, Wynn R F and Lerner A M Pseudomonas endocarditis in the Detroit Medical Center 1969 1972 Medicine 52 173 1973
- Banks T Fletcher R and Ah N Infective endocarditis in heroin addicts Am J Med 55 444 1973
- Gilroy J Andaya L Thomas V J Intracranial mycotic aneurysms and subacute bacterial endocarditis in heroin addiction Neurology 23 1193 1973
- Curtis J Richman B L and Feinstein M A Infective endocarditis in drug addicts South Med J 67 4 1974
- Tuzson C U Hill R and Sheagren J N Microbiologic study of street heroin and injection paraphernalia J Infect Dis 129 327 1974
- Khan M Y Hall W H and Gerding D N Staphylococcal endocarditis in narcotic addicts Diagnosis and treatment Minn Med March 1975 p 244
- Tuzson C U and Sheagren J N Staphylococcal endocarditis in parenteral drug abusers Source of the organism Ann Intern Med 82 788 1975
- Pazin G J Peterson K Griffin F W Sharer J A and Ho M Determination of site of infection in endocarditis Ann Intern Med 82 746 1975
- Tuzson C U Cardella T A and Sheagren J N Staphylococcal endocarditis in drug users Arch Intern Med 135 1555 1975
- Kreek M J Khun E and Joseph H A new heroin epidemic? (Editorial) Ann Intern Med 83 420 1975
- Mills J and Drew D Serratia marcescens endocarditis A regional illness associated with intravenous drug abuse Ann Intern Med 84 29 1976
- Reiner N E Gopalakrishna K V and Lerner P I Enterococcal endocarditis in heroin addicts JAMA 235 1861 1976
- Lutgens W F Endocarditis in main line opium addicts Arch Intern Med 83 653 1949
- Lutembacher R Endocarditis infectieuse secondaire des cardiaques Presse Méd 26 546 1918
- Hussey H H Kelber T F Schaefer B F and Walshe B J Septicemia and bacterial endocarditis resulting from heroin addiction JAMA 126 535 1944
- Weinstein L and Schlesinger J J Pathoanatomic pathophysiology and clinical correlations in endocarditis (Part 1) N Engl J Med 291 832 1974
- Clawson D C and White J G Platelet interaction with bacteria I Reaction phases and effects of inhibitors Am J Pathol 65 367 1971

The temperature course in acute myocardial infarction

R Lofmark M D
R Nordlander M D
E Ornnus M D
Huddinge Sweden

Most patients with acute myocardial infarction (AMI) develop fever during the first days of their disease. In earlier days when the temperature course was an important factor for diagnosing AMI several studies were performed where temperature was correlated to the clinical course.¹⁻³ A more detailed analysis of the temperature course was performed by Eckerstrom⁴ and by Forsman.⁵ However in all these studies AMI was diagnosed mainly by clinical signs partly by electrocardiograms (ECG) but not by serum enzymes.

The main reason for measuring the temperature in patients with AMI today is to diagnose complications.⁶ For this purpose the normal temperature course must be known. Most patients become afebrile in the beginning of the second week.^{7,8} However some patients run another temperature course and they present a difficult problem: still only infarction fever or a complicating infection or an early post myocardial infarction syndrome (PMI syndrome)? Though exceptional with proper techniques the infection may be a septicemia as a consequence of different catheters used in the coronary care unit (CCU) and this possibility makes a correct diagnosis—especially urgent. Yet patients with prolonged infarction fever or early PMI syndrome should ideally not undergo an empirical treatment by high dose antibiotics. With this background we studied a consecutive series of AMI patients retrospectively to find some

guidelines for our handling of fever problems in AMI.

Materials and methods

The temperature recordings of 192 consecutive patients with AMI were studied.^{*} The patients had been admitted to the CCU because of prolonged chest pain, frank pulmonary edema or syncope. The diagnosis of AMI was based upon (1) appearance of a pathologic Q wave and/or appearance or disappearance of a localized ST elevation followed by a T inversion and/or (2) two raised SGOT (ASAT) values with a maximum about 24 hours after onset of symptoms in association with lower SGPT (ALAT) values, (3) findings at autopsy of myocardial necrosis of an age corresponding to the onset of symptoms.

Seven patients died during the first two days and were excluded as their temperature recordings could not be further analyzed. Another 25 patients (Table I) were excluded due to treatment with antibiotics during the first ten days because of a diagnosed or suspected infection. Left for study were 160 patients of whom eight had two AMIs during the hospital stay. Thus the study will include 160 patients with 168 AMIs.

Results

Eighteen patients (11 per cent) did not have fever on any day of their hospital stay.

As can be seen from Fig. 1 only four patients (3 per cent) had a temperature above 38.2° C in the first hospital morning.

In 145 of the 160 AMI cases with fever (97 per

The temperature was measured rectally every morning in hospital and fever was defined as a morning temperature above 37.0° C.

From the Department of Medicine, Karolinska Institute at Huddinge Sjukhus, Huddinge, Sweden.

Received for publication Jan. 7, 1977.

Accepted for publication Oct. 20, 1977.

Reprint requests: R. Nordlander, Department of Medicine, Huddinge Hospital, S-141 86 Huddinge, Sweden.




Fig 1 Temperature in the first morning in hospital One hundred fifty AMI cases with fever

Table 1 Patients ($n = 25$) primarily excluded due to treatment with antibiotics during the first ten days because of a diagnosed or suspected infection

Diagnosed or suspected cause of fever besides AMI	No	Temperature course atypical for AMI*
Urinary tract infections	11	3
Upper respiratory infections	2	0
Pneumonias	3	3
Operation/wound infections	5	4
Septicemia(?) + pulmonary emboli	1	1
Tuberculosis (treatment)	1	1
Fever of unknown cause	2	1

Regarding Temperature course atypical for AMI: see text

cent) the temperature reached its maximum on day 2 to 5 in hospital. The remaining five patients had their maximal temperatures on day 6, 9, 9, 14 and 20.

Eight patients had two temperature maxima in all cases due to a reinfarction.

Only one (1 per cent) of the patients with fever had a morning temperature above 39.0°C (Fig 2) during hospital stay.

On the eighth day 43 patients (26 per cent) had fever (Fig 3). These patients had higher SGOT

maxima than the rest of the series (259 ± 134 v 138 ± 77 IU/L, $m \pm SD$, $p < 0.001$). On the eleventh day 18 patients (11 per cent) still had fever. All of these had had intravenous catheters during the CCU period, five of them had also had catheters in the aorta, the heart or the bladder.

For clinical reasons seven of the 18 patients had, after the eleventh day, been given a tentative treatment with high dose antibiotics parenterally and eleven had not. Only two of the seven treated patients responded with a normalized temperature in due time. One of them was the only patient with a morning temperature above 39.0°C and his maximum occurred on day 20. In one of the five non responders antibiotics were discontinued and no other treatment started. His temperature gradually fell to 37.0°C in 24 days in hospital. After 14 days only seven patients (4 per cent) had fever (Fig 3).

From a maximum on day 2 to 5 the temperature generally fell gradually with minor oscillations. In order to study this part of the curves the consecutive morning temperatures after day five were analyzed. Generally the morning temperature was either lower or unchanged compared to the morning before. In some patients however an increase in temperature occurred in some mornings after day five and the sum of these increases in each patient was analyzed. In nine patients (6




Fig 2 Maximal morning temperature recorded during hospital stay One hundred fifty AMI cases with fever

per cent) this sum exceeded 0.6°C . Eight of these nine patients reached a second temperature maximum.

These results indicate that the ordinary temperature course after AMI is characterized by (1) a temperature below 38.2°C in the first hospital morning (2) a morning temperature maximum occurring on day 2 to 5 in hospital (3) a maximal morning temperature below 39.0°C (4) if any temperature increase occurs from one morning to the next after day five the sum of these increases is not more than 0.6°C .

Lastly the temperature recordings from the 25 patients excluded due to treatment with antibiotics (Table I) were compared to the findings above. Thirteen of these patients (52 per cent) had a temperature course which would have been considered atypical for AMI. The other twelve patients with ordinary AMI fever generally had urinary or upper respiratory tract infections as the cause of antibiotic treatment.

Discussion

Naturally it is impossible to present a normal AMI temperature course and conclude that all other courses indicate a complication. The aim of the present investigation was to find some guidelines for the practical handling of fever in AMI.

The results indicate that a concomitant cause of fever besides the AMI should at least be

considered if the temperature (1) is above 38.2°C in the first hospital morning (2) if it reaches its maximum before day two or after day five (3) if it reaches a maximum above 39.0°C and/or (4) if it increases more than 0.6°C after day five in one or more steps.

These findings are partly in accordance with those of earlier series. Forssman¹ found that the temperature is generally not elevated during the first 12 hours after onset of symptoms and the maximal temperature is generally reached on day 2 to 5.^{1,2} Maximal morning temperature seldom exceeds 39.0°C .¹ Worth noting is that all patients with AMI do not have fever. In Eckerstrom's series³ 20 per cent of the patients did not have fever and the corresponding figure in this series was eleven per cent. This difference is probably due to different diagnostic criteria.

In Eckerstrom's series³ 55 per cent of the patients were afebrile after one week and 94 per cent after two weeks. The corresponding figures in the present series were 74 per cent and 96 per cent.

Forssman¹ found a correlation between the duration of fever and the maximal temperature and a tendency towards this was seen also in this study.

Patients with fever for more than one week had higher SGOT maxima than the rest of the series which corresponds to Woodhead's finding of an association between peak SGOT and the area




Fig 3 Duration of fever after AMI in all 168 cases

below the temperature curve, but not with maximal oral temperature

According to Kossowsky and associates⁶ fever of long duration could indicate an early PMI syndrome. The 11 patients in this study with fever for more than ten days and who were not treated with antibiotics were further examined with history, cardiac physical examination, sedimentation rate, and chest x ray but in no case did the examinations support a diagnosis of an early PMI syndrome.

Conclusions

A concomitant cause of fever besides the AMI should at least be considered if the temperature (1) is above 38.2° C in the first hospital morning (2) if it reaches its maximum before day two or after day five (3) if it reaches a maximum above 39.0° C and/or (4) if it increases more than 0.6° C after day five in one or more steps.

Summary

The rectal temperature course was studied retrospectively in 192 consecutive patients with acute myocardial infarction (AMI). The ordinary temperature course after AMI was characterized by four points:

1 The morning temperature on the first day in hospital was seldom above 38.2° C (in four of 150 cases).

2 The maximal morning temperature was seldom recorded before day two or after day five in hospital (in five of 150 cases).

3 The maximal morning temperature seldom reached above 39.0° C (in one of 150 cases).

4 The morning temperature seldom increased more than 0.6° C after day five in one or more steps (in nine of 150 cases).

Seventy-four per cent of the patients were afebrile after one week, and 96 per cent after two weeks. Patients with higher SGOT (ASAT) maxima had longer duration of fever. Eleven per cent of the patients did not have fever at all.

REFERENCES

- 1 Billings F T, Kallstone B M, Spencer J L, Ball C O T and Meneely C R. Prognosis of acute myocardial infarction. *Am J Med* 7: 356 1949.
- 2 Chambers W N. Acute myocardial infarction. *N Engl J Med* 235: 347 1946.
- 3 Eckerstrom S. Clinical and prognostic aspects of acute coronary occlusion. *Acta Med Scand (Suppl)* 139: 1 1951.
- 4 Forssman O. Myocardial infarction and adrenal function. *Acta Med Scand (Suppl)* 150: 1 1954.
- 5 Gibson T C. The significance of fever in acute myocardial infarction. A reappraisal. *AM HEART J* 87: 439 1974.
- 6 Kossowsky W A, Epstein P J and Levine R S. Post myocardial infarction syndrome. An early complication of acute myocardial infarction. *Chest* 63: 35 1973.
- 7 Levine S A and Rosenbaum F F. Prognostic value of various clinical and electrocardiographic features of acute myocardial infarction. *Arch Intern Med* 68: 913 1215 1941.
- 8 Woodhead R L. Fever in relation to serum enzyme changes in acute myocardial infarction. *AM HEART J* 88: 813 1974.

Systolic flutter of the mitral valve

Karl C Sze MD
Navin C Nanda MD
Raymond Gramiak MD
Rochester NY

Diastolic flutter of the mitral valve is a well recognized echocardiographic finding frequently observed with aortic incompetence. In contrast systolic flutter of the mitral valve is distinctly uncommon and has received little attention. This report presents 11 cases of systolic flutter of the mitral valve which were identified from approximately 6 000 studies in our laboratory during the past 3 1/4 years. The echocardiographic features are correlated with the clinical presentation and in six cases with available pathological specimens. The association of systolic flutter of the mitral valve with the presence of mitral regurgitation and coexistent bacterial endocarditis is emphasized. Our findings differ from a previous report which suggested association of systolic flutter with ruptured chordae tendineae and apparently did not evaluate as a causative factor the role of bacterial endocarditis which had occurred in some of their patients.

Materials and Methods

Echocardiographic records were examined for all patients indexed with the finding of systolic flutter of the mitral valve. Eleven previously identified cases out of approximately 6 000 studies performed in the past 3 1/4 years were confirmed by two independent reviewers. Hospital records were reviewed in these 11 cases.

From the Department of Medicine (Cardiology Unit) and Radiology Unit, University of Rochester School of Medicine and Dentistry, Rochester, NY.

Supported in part by contract HL 05600 from the National Heart and Lung Institute, National Institutes of Health, Bethesda, Md.

Received for publication 14 1977.

Accepted for publication Aug 31 1977.

Reprint requests to Dr. Karl C. Sze, MD, Cardiology Unit, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642.

The results of the above study prompted us to examine 59 other patients with mitral regurgitation studied in the same period. All of them had adequate echocardiographic studies and confirmation of mitral valve lesions by surgery and/or pathology. The valvular lesions consisted of papillary muscle dysfunction (four cases) and papillary muscle rupture (three cases) due to ischemic heart disease, bacterial endocarditis involving the mitral valve (four cases), mitral valve prolapse with associated idiopathic chordae tendineae rupture (10 cases), severe mitral valve prolapse with elongated but intact chordae tendineae (seven cases), isolated rheumatic mitral regurgitation (eight cases), and rheumatic mitral regurgitation with associated stenosis (23 cases). In addition, 70 cases of angiographically proven mitral regurgitation and 50 recent cases of clinically diagnosed mitral regurgitation were also reviewed.

All echocardiographic examinations were performed using a Picker echograph and a 2.0 or 2.25 MHz collimated transducer. Continuous records were made on 35 mm film at an effective speed of 125 mm/sec by means of a Fairchild oscilloscope record camera and a dual beam oscilloscope acting as a slave. Echocardiographic recordings of the cardiac valves and chambers were obtained by standard methods. Mitral valve echoes were also recorded at 2X magnification in some cases demonstrating systolic flutter. Additional high speed recordings at 375 mm/sec were performed to clarify subtle flutter of the mitral valve.

Mitral valve echocardiograms were examined for amplitude, frequency, and predominant location of the systolic flutter. Evidence of mitral valve prolapse, flail mitral leaflet(s), rheumatic mitral valve disease, and shaggy thickened




Fig 1 Systolic flutter of the mitral valve in a patient with mitral valve prolapse and healed bacterial endocarditis (Case 5). The flutter is seen predominantly on the prolapsing mitral segment and has a frequency of 40 Hz in this record.




Fig 2 Mitral valve echocardiogram demonstrating larger amplitude, higher frequency (80 Hz) systolic flutter. This record is from the same patient as Fig 1.

echoes suggestive of bacterial vegetations. Measurements of the systolic flutter were averaged over four cardiac cycles.

Mitral valve prolapse was diagnosed if records demonstrated a distinct steplike posterior motion of the mitral leaflet in midsystole or holosystolic sagging of at least 3 mm posterior to the mitral C point.^{5,6}

A flail mitral leaflet was diagnosed by erratic, bizarre undulations of either leaflet in diastole, paradoxical anterior motion of a portion of the

posterior mitral leaflet in diastole, or linear structural echoes from the mitral leaflets detected in the left atrial cavity behind the aortic root.^{3,7,8}

Results

All eleven patients with systolic flutter of the mitral valve (nine males and two females, aged 46 to 74 years) had murmurs of mitral regurgitation. None had a clear history of antecedent acute rheumatic fever. Based upon echocardiographic findings, mitral valve prolapse was present in 10 cases and flail mitral leaflet(s) in seven cases (Table I). Mitral regurgitation was demonstrated in each of the seven patients who underwent left ventricular angiography. In all 11 patients the systolic flutter of the mitral valve was of high frequency, ranging from 30 to 100 Hz with a mean of 66 Hz. The maximum amplitude of the flutter varied from 2 to 6 mm, with a mean of 4.5 mm. In six patients the systolic flutter was predominantly recorded on the prolapsing portion of the mitral leaflet. Figs 1 and 2 illustrate typical examples of the systolic flutter. In two patients with flail mitral leaflets the flutter was prominently seen in mitral segments echoed in the left atrium behind the aortic root (Fig 3). The high frequency flutter was superimposed on a coarser undulating movement of the valve in these two patients. Echoes from the usual mitral valve recording position failed to show systolic flutter in one of these two patients. Undulating movements of this type (< 25 Hz) were not seen in any other patients in this group.

Nine of the 11 cases had prior or concurrent




Fig 3 Left Mitral valve echocardiogram from Case 2. There are shaggy echoes and coarse diastolic undulations (arrow) consistent with bacterial vegetations and chordae rupture. Systolic flutter is not seen. Other records showed classical mitral valve prolapse. Right Aortic root echocardiogram. Coarse and fine flutter of prolapsing mitral elements are recorded in systole within the left atrial cavity. These findings were absent prior to bacterial endocarditis.

Table 1 Findings in patients with systolic flutter

Table 1 Findings in patients with systolic flutter									
Patient	Clinical SBE	Echo				Surgical/Pathological			
		Systolic flutter				Chordae rupture	SBE	Myxoid degeneration	Other
		Fre quency	Ampli tude	MVP	Flail leaflet				
		(Mean) (Hz)	(Max) (mm.)						
1 ML	+	80	5	S	+	+	+	+	Billowing leaflets. Cleft posterior leaflet Moderate aortic insufficiency
2 WS	+	60	5	S	+	+	+	+	Billowing leaflets
3 IS	+	100	6	S	0				Not available
4 AH	+	80	3	S	0				Not available
5 WH	+	70	5	S	0				Not available
6 NF	+	80	3	H	+	+	+	+	Partial fusion to ventricular wall
7 ISK	+	40	3	S	0	0	0	+	Billowing thin posterior leaflet
8 JO	+	80	5	S	+	0	+	+	
9 CR	+	30	4	0	+				Not available
10 JB	0	80	6	S H	+	Flail billowing posterior leaflet confirmed by angiography			
11 SD	0	30	5	S	+	+	0	+	Elongated chordae billowing posterior leaflet

Abbrev: + = present; 0 = absent; H = hysteric; Max = maximal; MVP = predominant mitral valve prolapse pattern; S = step-like displacement in mid systole; SBE = subacute bacterial endocarditis.

bacterial endocarditis at the time of echocardiographic study documented by multiple positive blood cultures in an appropriate clinical setting including fever, heart murmur of mitral regurgitation and no other apparent source for the sustained bacteremia. The infecting organism was an alpha streptococcus in eight patients and *Staphylococcus aureus* in the remaining patient

(Case 9). Two patients (Cases 6 and 8) had two episodes of alpha streptococcal endocarditis. Echocardiograms showed shaggy thickening of the mitral valve highly suggestive of bacterial vegetations in two patients. Multilayering with some thickening was observed in four patients while no evidence for bacterial endocarditis was present in the remaining three patients.




Fig 4 *Upper panel* Mitral valve echocardiogram prior to bacterial endocarditis (Case 1) Note the typical prolapse pattern and absence of systolic flutter *Lower panel* Mitral valve echocardiogram following bacterial endocarditis Note the development of high frequency systolic flutter Other records obtained with higher gain settings demonstrated shaggy thickening and diastolic instability highly suggestive of bacterial endocarditis with chordae rupture

In two patients with auscultatory evidence of mitral valve prolapse echocardiograms obtained prior to the development of bacterial endocarditis showed no evidence of mitral systolic flutter One of them demonstrated typical mitral valve prolapse (Fig 4 *upper*), while the other showed some posterior displacement in systole, but was not definitive for valve prolapse Subsequent echocardiograms during and following treatment for bacterial endocarditis showed development of systolic flutter as well as shaggy thickening of the mitral leaflets which appeared to be flail (Figs 3 and 4, *lower*) A typical mitral valve prolapse pattern became evident in the second patient

Pathological findings were available in five of nine patients with bacterial endocarditis (Table I) In all five patients the mitral leaflets were reported to be flexible and generally redundant

Although large vegetations were not present in any patient the histological findings showed areas of fibrosis and vascularization consistent with healed bacterial endocarditis in four and myxoid degeneration in all Interestingly, in the patient without obvious evidence of scarring it was difficult to find the systolic flutter which was localized to a small portion of the mitral systolic segment Pathological findings were unavailable in three patients who remained asymptomatic following cure of their endocarditis Two patients had systolic flutter of the mitral valve without any history of bacterial endocarditis In one patient the flutter was limited to a few vibrations in early systole and was difficult to locate Both patients had severe mitral valve prolapse with flail posterior leaflets demonstrated by echocardiography and confirmed by angiography In one

patient pathological examination showed very thin mitral leaflets with elongated and ruptured chordae tendineae. There was advanced myxoid degeneration with no evidence for bacterial endocarditis.

Systolic flutter of the mitral valve was not noted in any of 179 other patients with mitral regurgitation studied in the same period. These included four patients with bacterial endocarditis involving the mitral valve. Mitral regurgitation was judged to be mild or minimal in two instances.

Discussion

Our study indicates that systolic flutter of the mitral valve is relatively rare and is always associated with an abnormal mitral valve. All patients with this finding had mitral regurgitation due to mitral valve prolapse or chordae rupture and all but two had associated bacterial endocarditis. The regurgitant jet of blood across the edge of the incompetent mitral leaflet(s) during systole apparently generates the vibrations recorded by echocardiography. This is supported by the fact that the systolic flutter was most prominently recorded from the prolapsing or flail portion of the mitral valve in over half the instances. In addition to the regurgitant blood flow the characteristics of the mitral leaflets are also important for the development of flutter. Pathology has shown scarring superimposed on flexible redundant mitral leaflets in cases where the systolic flutter has been easily recorded. The flexibility allows motion of the leaflets to occur whereas the stiffness imparted by the scarring process apparently enables the thickened structure to vibrate rapidly in the presence of turbulence resulting from the high velocity regurgitant jet. In addition the thickened leaflet is a strong reflector of ultrasound thereby making recording of the phenomenon more likely. In the two patients where pathology demonstrated very thin ballooning mitral leaflets without any scarring the flutter was difficult to locate, limited to a small portion of the mitral systolic segment and was noted to have a somewhat lower frequency.

The genesis of systolic flutter of the tricuspid valve has also been attributed to a similar mechanism. It has been reported in patients with congenital left ventricular-right atrial communication and is probably due to the passage of a left ventricular jet of blood into the right atrium

through a deformed and thickened tricuspid valve. It does not occur when the shunt is above the valve level or in tricuspid insufficiency.

Marked thickening rigidity and calcification of the mitral leaflets would be expected to restrict systolic flutter. We have not observed systolic flutter of the mitral valve in any of our patients with echocardiographic features of rheumatic mitral valve disease. In the literature, a patient with mitral stenosis and only a slightly thickened valve demonstrated systolic flutter following closed mitral commissurotomy complicated by possible chordae rupture. The setting of a new regurgitant jet across a somewhat thickened but apparently flexible valve is consistent with our postulation of the requirements necessary for the development of systolic flutter.

Based upon a small number of cases Meyer and colleagues considered systolic flutter to be a specific and not uncommon finding for ruptured chordae tendineae. However our findings demonstrate rupture of the chordae tendineae is not necessary for the causation of high frequency systolic flutter. Two of our patients with systolic flutter had intact chordae tendineae demonstrated at surgery. Three additional patients with systolic flutter lacked echocardiographic evidence of a flail mitral leaflet were asymptomatic following cure of their endocarditis and were considered unlikely to have had chordae rupture although definitive proof was lacking. Furthermore systolic flutter is uncommon (13 per cent) in patients with ruptured chordae tendineae or papillary muscles in the absence of bacterial endocarditis. Interestingly three of four patients reported by Meyer and associates² who underwent surgery had prior bacterial endocarditis.

When endocarditis is suspected detection of flutter may serve as a clue to its location since other diagnostic features of a vegetation may be absent or in some instances difficult to distinguish from multilayered echoes of mitral valve prolapse. It should be emphasized that high speed recording (125 mm/sec) and image magnification may be needed for delineating subtle flutter.

Summary

Systolic flutter of the mitral valve was observed in 11 cases during the past 3 1/2 years. All patients had mitral regurgitation due to mitral valve prolapse or flail leaflets and nine of the 11 (82 per cent) had prior or concurrent bacterial

endocarditis. Systolic flutter is uncommon in the absence of endocarditis and was observed in only two of 15 patients (13 per cent) with proven chordae tendineae or papillary muscle rupture without histological and pathological evidence of infection involving the mitral valve. Systolic flutter was also not seen in a large number of patients with mitral regurgitation due to other causes. It is postulated that the regurgitant jet of blood across the edge of a structurally abnormal but flexible mitral leaflet is important for the development of flutter.

We are thankful to Dr Paul Yu for reviewing this manuscript and to Mrs Beth Nestorowycz for her secretarial help.

REFERENCES

- 1 Nanda N C, Gramiak R and Manning J A. Echocardiography of the tricuspid valve in congenital left ventricular-right atrial communication. *Circulation* 51:269 1975.
- 2 Meyer J F, Frank M J, Goldberg S and Cheng T O. Systolic mitral flutter: an echocardiographic clue to the diagnosis of ruptured chordae tendineae. *Am Heart J* 93:3 1977.
- 3 Roy P, Tajik A J, Giuliani E R, Schattenberg T T, Gau G T and Frye R L. Spectrum of echocardiographic findings in bacterial endocarditis. *Circulation* 52:474 1975.
- 4 Gramiak R and Nanda N C. Mitral valve. In: *Cardiac Ultrasound*, edited by Gramiak R and Waag R C. St. Louis: The C V Mosby Company, 1977, p 47.
- 5 Shih P M and Gramiak R. Echocardiographic recognition of mitral valve prolapse (Abstr). *Circulation* 42 (Suppl III): III 45 1970.
- 6 Markiewicz W, Stoner J, London E, Hunt E A and Popp H I. Mitral valve prolapse in one hundred presumably healthy young females. *Circulation* 53:464 1976.
- 7 Burgess J, Clark R, Kamigaki M, Cohn K. Echocardiographic findings in different types of mitral regurgitation. *Circulation* 48:97 1973.
- 8 Duchak J M Jr, Chang E and Feigenbaum H. Echocardiographic features of torn chordae tendineae (Abstr). *Am J Cardiol* 29:260 1972.
- 9 Nanda N C. Clinical applications of echocardiography. *Mod Concepts Cardiovasc Dis* 45:135 1976.
- 10 Wann L S, Dillon J C, Weyman A E and Feigenbaum H. Echocardiography in bacterial endocarditis. *N Engl J Med* 295:135 1976.

Information for authors

Most of the provisions of the Copyright Act of 1976 became effective on January 1 1978. Therefore all manuscripts must be accompanied by the following statement signed by each author: The undersigned author(s) transfers all copyright ownership of the manuscript entitled (title of article) to The C V Mosby Company in the event the work is published. The author(s) warrants that the article is original, is not under consideration by another journal, and has not been previously published. Authors will be consulted when possible regarding republication of their material.

The management of anticoagulation during noncardiac operations in patients with prosthetic heart valves

A Prospective Study

Richard E. Katholi MD*
Stanton P. Nolan MD
Lockhart B. McGuire MD FACP
Charlottesville Va

In a previous study of thromboembolism and hemorrhage among patients with prosthetic heart valves undergoing noncardiac operations there was significant perioperative bleeding when anticoagulation was maintained during such operations. Also among patients with mitral valve prostheses there was significant perioperative thromboembolism when anticoagulation was discontinued.

The need for some means of managing patients with thrombogenic caged ball or caged disc cardiac valves who require subsequent noncardiac operations was the impetus for this prospective study of 45 operative procedures performed among a group of 235 patients on chronic anticoagulation with prosthetic valves. Because in the earlier study there had been no adverse effect from the interruption of anticoagulants for three to five days among patients with only aortic valve prostheses, simple interruption was employed in the present study for such patients. For patients with mitral caged disc prostheses either alone or in combination with an aortic or tricuspid prosthesis, restoration of anticoagulation with heparin was used in the early postoperative period to prevent thromboembolism.

Methods

The following protocol for the management of anticoagulation during noncardiac operations was used. For patients with isolated aortic valve prostheses warfarin was discontinued in time to produce a normal prothrombin time on the day of operation and oral anticoagulation was resumed two days after operation. (One patient with an aortic valve prosthesis also received heparin early after operation because of a presumed increased risk of thromboembolism). Patients with mitral or combined prostheses underwent rapid reversal of their warfarin effect with parenteral vitamin K during the 24 hours before operation and received intravenous heparin beginning 12 hours after operation. Heparin anticoagulation was maintained by either intermittent or continuous intravenous infusion to produce a partial thromboplastin time of one and one half to two and one half times the levels of normal controls. When adequate surgical hemostasis was assured usually three days after operation oral anticoagulation with warfarin was resumed and the heparin was stopped when the prothrombin time reached a therapeutic level.

A noncardiac operation was classified as major if a body cavity or bone was entered and otherwise as minor. There were 23 major operations which included hysterectomy (eight), pulse generator change (five), bowel resection

From the Departments of Internal Medicine and Surgery, University of Virginia Hospital, Charlottesville Va.

Received for publication June 16, 1987

Accepted for publication August 10, 1987

Reprint requests: Lockhart B. McGuire MD, Division of Cardiology, Department of Internal Medicine, University of Virginia Hospital, Charlottesville Va 22908.

Present address: University of Alabama, Birmingham, Alabama 35294. (Dr. Katholi) or Medical Research Service, Department of Veterans Affairs Medical Center, Durham, North Carolina 27705. (Dr. McGuire).

Table 1 Thromboembolism or hemorrhage in patients with prosthetic valves during subsequent noncardiac operations

Patient group	Aortic valve only	Mitral & combined valves
Number	18	21
Operations		
Major	10	13
Minor	9*	13
Total	19	26
Management	Stop warfarin	Stop warfarin add heparin
Thromboembolism	0	0
Hemorrhage	1†	2

*Two dental extractions were performed with anticoagulation maintained

†This patient received heparin early after operation

(four), cholecystectomy (three), subtotal gastrectomy (two), and craniotomy (one). There were 22 minor operations which included biopsy or excision (nine), dental extraction (five), arteriography (four), mastectomy (two) and hemorrhoidectomy (two).

Results

Thirty nine patients have undergone 45 noncardiac operations under this protocol. Table I summarizes the experience in terms of perioperative thromboembolism and hemorrhage. There were no deaths. Thromboembolism did not occur among the patients with isolated aortic valve prostheses despite the discontinuation of anticoagulation for three to five days. There was an incisional hematoma which occurred in a patient who received heparin early after operation because of an increased risk of thromboembolism. In this case the bleeding was minor and easily controlled. Dental extractions were performed on two patients with prosthetic aortic valves without the cessation of anticoagulation and there were no complications. Both had chronic atrial fibrillation and were the only patients in the aortic group with this arrhythmia.

When heparin was administered to patients with mitral or combined prosthetic valves early after operation no thromboemboli occurred. Sixteen of these 21 patients (76 per cent) had chronic atrial fibrillation. One patient developed an abdominal incisional hematoma but did not require transfusion or discontinuation of anticoagulant therapy. One patient developed vaginal

cuff bleeding after a vaginal hysterectomy and required transfusion, ligation of the bleeding site and brief interruption of heparin.

Discussion

The major problem for patients with mitral caged ball or caged disc prostheses undergoing noncardiac operations has been thromboembolism when anticoagulants are discontinued. Under these circumstances the risk is increased when there is atrial fibrillation.¹

Others have reported that a hypercoagulable state is not associated with the interruption of warfarin therapy.² The absence of thromboembolism during the short term withdrawal of warfarin from patients with aortic prostheses in this and our previous study¹ supports that observation. However, it has also been observed that minor procedures performed in accessible areas such as dental extractions, can be safely accomplished with maintenance of warfarin.³ Our experience with the continuation of anticoagulation during dental procedures has also been favorable.

In this study heparin was administered to patients with mitral prostheses in the early postoperative period in order to avoid the previously observed problem of thromboembolism. The advantage of heparin when compared to warfarin is the rapid reversal of its anticoagulant effect by protamine sulfate if major bleeding should occur. The result from the use of heparin in these patients was the avoidance of thromboemboli; however, hemorrhage did occur in three patients. This incidence of hemorrhage (10 per cent) in our patients is similar to a previous report¹ in which anticoagulation was started soon after an operative procedure. Since these bleeding episodes occurred when the partial thromboplastin time was in the appropriate therapeutic range,⁴ future consideration might be given to the use of lower doses of heparin. It is probable also that the increasing use of non thrombogenic mitral xenografts will minimize this difficult management problem in the future.

Summary

Based on previous thromboembolic complications associated with the interruption of anticoagulation during subsequent noncardiac operations in patients with nonbiological mitral prostheses a protocol was developed for this high risk

group. We report the successful management of 26 such operations in which anticoagulation was interrupted for 12 hours and then rapidly restored by means of heparin in the postoperative period. Since an earlier study suggested no adverse effect from the interruption of chronic anticoagulants for three to five days among patients with isolated aortic valve prostheses, simple interruption was again employed during 16 subsequent noncardiac operative procedures in this group with no complications. There were three episodes of hemorrhage observed in patients receiving therapeutic doses of heparin postoperatively but only one required blood replacement.

REFERENCES

1. Kathol, R. E., Nolan, S. P., and McGuire, L. B. Living with prosthetic heart valves. *Am HEART J* 92:162, 1976.
2. Kudoh, T. Surgery of the patient on anticoagulants following prosthetic valve replacement. *Jpn J Thorac Surg* 28:187, 1975.
3. Michaels, L. Incidence of thromboembolism after stopping anticoagulant therapy. *J.A.M.A.* 216:593, 1971.
4. McIntyre, H. Management during dental surgery of patients on anticoagulants. *Lancet* 2:99, 1966.
5. Coon, W. W., and Wilks, P. W. Hemorrhagic complications of anticoagulant therapy. *Arch Intern Med* 133:386, 1974.
6. Salzman, E. W., Deykun, D., Shapiro, R. M., et al. Management of heparin therapy. *N Engl J Med* 292:1046, 1975.

Organized left atrial mural thrombus demonstrated by coronary angiography

Paul R. Cipriano, MD
Diana F. Guthaner, MD
Stanford Calif

A variety of uncommon cardiovascular abnormalities have been demonstrated by coronary angiography, including cardiac tumors,^{1,2} vascular malformations,³ and coronary arterial fistulas.^{4,5} This communication describes an angiographic abnormality which has a characteristic appearance, was observed during selective coronary angiography in three patients with mitral stenosis, and was due to organized mural thrombus that was adherent to the wall of the left atrial appendage.

Clinical features of the patients

Table I summarizes the clinical features of the three patients with mitral stenosis in whom an organized left atrial mural thrombus was demonstrated by selective coronary arteriography. The patients ranged in age from 67 to 75 years and had typical symptoms and findings of mitral stenosis on cardiac examination. There was no history of a thromboembolic event in any of the three patients. Patients No. 1 and 3 had atrial fibrillation. Chest radiographs demonstrated multichambered cardiac enlargement in each patient and mitral valvular calcification in patients No. 1 and 2. Echocardiographic studies were made in patients No. 1 and 2 and revealed findings typical of mitral stenosis but no evidence of intra atrial thrombi. At cardiac catheterization the mean diastolic pressure gradient across

the mitral valve ranged from 5 to 15 mm Hg and the area of the mitral valve orifice ranged from 0.6 to 0.9 square centimeters.

Coronary angiographic findings

Selective coronary angiograms of these elderly patients were obtained prior to replacement of the mitral valve to exclude the possibility that their valvular disease might be complicated by coronary artery disease. Coronary arteriography did not demonstrate coronary arterial luminal narrowing in any of the three patients. However, one (patient No. 2) or two (patients No. 1 and 3) small arteries, approximately 1 mm in diameter, were observed to arise from the circumflex coronary artery, course superiorly and terminate in a collection of radiographic contrast medium in the left atrial appendage (Fig. 1, A-C). The collections of radiographic contrast medium were small in patient No. 2 and large in patients No. 1 and 3. These collections were inhomogeneous in density and had irregular shapes and borders. The contrast material appeared to flow from these collections into the lumen of the left atrium in the region of the appendage. Because of the features just described these vascular channels were considered to represent small coronary arterial-left atrial fistulas.

Anatomic findings

At operation a single thrombus was found within the left atrial appendage of each patient. These thrombi ranged from less than 1 cm to 5 cm in length and were adherent to the wall of the left atrial appendage. In each patient the thrombus was removed and the mitral valve was replaced. Microscopic examination of the atrial

From the Cardiovascular Section, Division of Diagnostic Radiology, Department of Radiology, Stanford University School of Medicine, Stanford, Calif.

Received for publication June 16, 1977.

Accepted for publication June 30, 1977.

Reprint requests: Paul R. Cipriano, MD, Department of Radiology, S076 Stanford University Medical Center, Stanford, Calif. 94305.




Fig 1 A through D A C Selective left coronary artery angiograms demonstrating coronary artery fistulas which terminate in a large or small collection of radiographic contrast medium in the left atrial appendage A Patient No 3 right anterior oblique view two atrial coronary artery fistulas (arrows) B Patient No 2, left anterior oblique view one atrial coronary artery fistula (small arrow) the collection of radiographic contrast medium is small (large arrow) C Patient No 1 left anterior oblique view two atrial coronary artery fistulas (arrows) D Histologic section showing organizing thrombus that was removed from the left atrial appendage of patient No 2 (Hematoxylin-eosin stain original magnification $\times 63$)

thrombi showed various stages of organization (Fig 1D). The organizing areas of the thrombi had sinuses which contained red blood cells and the organized areas of the thrombi were dense with fibrous tissue. Arterioles or venules were not present within the thrombus but a few small vascular channels were observed that were composed only of a single layer of endothelial cells. There was no correlation between the size of the thrombus (Table I) and the size of the collection of radiographic contrast material observed during coronary angiography (Fig 1 A C).

Discussion

Non atherosclerotic cardiovascular abnormalities that are demonstrated by coronary angiography such as cardiac tumors, vascular malformations, and large coronary artery fistulas are uncommon but frequently have characteristic angiographic appearances. These features differ from those observed in this study.

To our knowledge, arteriographic abnormalities due to cardiac tumors have been reported only in three cases: a myxoma,¹ a hamartoma,² and a hemangioma.³ A small amount of radiographic contrast material was observed in a left

Table 1 Patients with organized left atrial mural thrombus demonstrated by selective coronary angiography

Patient No	Age/sex	Cardiac symptoms	Murmurs	ECG	Chest radiograph	Echo cardiogram	Mitral valve gradient (mm Hg)/ orifice (cm ²)	Length of thrombus
1	67M	DOE and palpitations	MS MR	AF LAD	IPE RVE LAE LVE MV Ca	LAE MS	15/0.6	5 cm
2	69F	DOE PND palpitations	MS MR	1° AV block PVCs LAE	PVH RVE LAE MV Ca	LAE MS	18/0.6	5 cm
3	75F	DOE orthopnea palpitations	MS MR TR	AF IRBBB	PVH RVE LAE LVE	—	5/0.9	< 1 cm

Abbreviations and symbols — = data not available AF = atrial fibrillation AV = atrioventricular DOE = dyspnea on exertion ECG = electrocardiogram IPE = interstitial pulmonary edema IRBBB = incomplete right bundle branch block LAD = left axis deviation LAE = left atrial enlargement LVE = left ventricular enlargement MR = mitral regurgitation MS = mitral stenosis MV Ca = mitral valve calcification PND = paroxysmal nocturnal dyspnea PVCs = premature ventricular contractions PVH = pulmonary venous hypertension RVE = right ventricular enlargement TR = tricuspid regurgitation

atrial myxoma, presumably within the tumor, during selective right coronary angiography.¹ A hamartoma² and a hemangioma³ have been demonstrated in children by ascending thoracic aortography. Both of these tumors were located at the apex of the heart. Both tumors were supplied by enlarged, tortuous branches of the left anterior descending coronary artery; these branches terminated in a dense mass of vessels that emptied slowly into the coronary venous system but did not communicate directly with the left ventricular chamber.

Among coronary vascular malformations, drainage of all left coronary arterial flow into the left ventricle through thebesian veins⁴ has been recognized by means of coronary angiography. Coronary angiograms demonstrated multiple, tortuous epicardial arteries terminating in an intense myocardial collection of contrast material which drained directly into the left ventricular chamber without filling any coronary veins or the coronary sinus.

Large coronary arterial fistulas may be composed of a single vessel or many vessels and may involve one or more coronary arteries.⁵⁻¹³ Coronary arterial fistulas communicate with the right heart more often than with the left heart or with the pulmonary circulation.¹⁴ The small coronary-left atrial fistulas observed in this study appeared to empty directly into the left atrium without having demonstrable venous drainage. These fistulas were small and could not have produced congestive heart failure or myocardial

ischemia due to shunting of blood from the coronary arteries to the left atrium.

An angiographic abnormality similar to the one which we have observed has been demonstrated at operation to be due to a ventricular¹⁴ and to an atrial¹⁵ mural thrombus. The small vessels that we observed in the excised portions of the atrial thrombi were too small to account for the collections of radiographic contrast material that were observed during coronary angiography. Therefore, we presume that these collections were present within vascular channels located either in the most basal portions of the thrombi or in the immediately subjacent areas of the left atrium. Microscopic studies have demonstrated that cardiac mural thrombi may be invaded by new vessels as they become organized.¹⁶⁻¹⁷ Thus, it is possible that these ingrowing vessels form dilated vascular channels in an effort to resorb the thrombus.

The following conclusions can be drawn from the data reviewed above: (1) small arterial fistulas that terminate at the site of an adherent organized mural thrombus in the left atrial appendage may be observed incidentally during selective coronary angiography in patients with mitral stenosis; (2) the angiographic features of this vascular abnormality can be distinguished from those of cardiac tumors, vascular malformations, and coronary artery fistulas that are not associated with organized thrombus; (3) the vascular abnormality demonstrated by coronary angiography may be the only indication of the

presence of a left atrial thrombus (4) this abnormality may be present in thrombi that are not revealed by echocardiography and are not manifest clinically by systemic emboli and (5) the size of the collection of radiographic contrast material in the left atrial appendage is not proportional to the size of the thrombus

Summary

Small coronary artery fistulas terminating at the site of adherent organized mural thrombi in the left atrial appendage were observed during selective coronary angiography in patients with mitral stenosis. The angiographic features of this abnormality can be distinguished from those of cardiac tumors, vascular malformations and coronary artery fistulas that are not associated with organized thrombus. This coronary angiographic abnormality may indicate the presence of left atrial thrombus that is not revealed by echocardiography and is not manifest clinically by systemic emboli. The size of the collection of radiographic contrast material in the left atrium is not proportional to the size of the thrombus.

REFERENCES

- 1 Marshall W H, Steiner R M and Wexler L. Tumor vascularity in left atrial myxoma demonstrated by selective coronary arteriography. *Radiology* 93:815 1969
- 2 Franciosi R A, Gay R M and Ah Tye P. Vascular hamartoma of the heart in a child. *Am Heart J* 79:676 1970
- 3 Sulayman M and Cassels D E. Myocardial coronary hemangiomatous tumors in children. *Chest* 68:113 1975
- 4 Kinsard M A. Hypoplasia of the coronary sinus with coronary venous drainage into the left ventricle by way of the Thebesian system. *Chest* 68:384 1975
- 5 Gasul B M, Arcilla R A, Fell E H, et al. Congenital coronary arteriovenous fistula. Clinical, phonocardiographic, angiocardiographic and hemodynamic studies in five patients. *Pediatrics* (Suppl.) 31:560 March 1960
- 6 Neufeld H N, Lester R C, Adams P, et al. Congenital communication of a coronary artery with a cardiac chamber or the pulmonary trunk (Coronary artery fistula). *Circulation* 24:171 1961
- 7 Uphaw C H. Congenital coronary arteriovenous fistula. Report of a case with an analysis of seventy three reported cases. *Am Heart J* 53:399 1962
- 8 Dedichen H, Skalleberg L and Chappelen C. Congenital coronary artery fistula. *Thorax* 21:121 1966
- 9 Gobel P L, Anderson C F, Baltaxe H A, et al. Shunts between the coronary and pulmonary arteries with normal origin of the coronary arteries. *Am J Cardiol* 25:655 1970
- 10 Eke H and Hillestad L. Arterio-venous fistulae of the coronary arteries. A report of six cases. *Scand J Thorac Cardiovasc Surg* 5:34 1971
- 11 Reddy R, Gupta M and Hamby R I. Multiple coronary arteriovenous fistulas. *Am J Cardiol* 33:304 1974
- 12 Silverman J F, Obrez L and Krus J P. Coronary artery fistula. Diagnosis and evaluation by selective contrast and radioisotopic coronary arteriography. *J Can Assoc Radiol* 25:310 1974
- 13 Herschman A, Natarajan N, and Reddy R. Multiple fistulas between the coronary arteries and the left ventricle. *Radiology* 122:302 1977
- 14 Grollman J H, Hoffman R B, Price J E, et al. Abnormal vascularity in left ventricular mural thrombus demonstrated by selective coronary arteriography. *Radiology* 113:591 1974
- 15 Standen J R. Tumor vascularity in left atrial thrombus demonstrated by selective coronary arteriography. *Radiology* 116:49 1975
- 16 Mitchell J H A and Schwartz C J. Arterial disease. Oxford 1965. Blackwell Scientific Publications pp 151 154
- 17 Farrer Brown G. Normal and diseased vascular pattern of myocardium of human heart II. Pattern seen with fibrosis of the left ventricular free wall. *Br Heart J* 20:537 1968

Idiopathic familial myocardopathy in three generations A clinical and pathologic study

Richard S Ross MD
Bernadine H Bulkley, MD
Grover M Hutchins, MD
John S Harshey MD
Richard A Jones, MD
Henry Kraus MD
Jerome Liebman, MD
C Michael Thorne MD
Sidney B Weinberg MD
A Ashley Weech MD
Alexander A Weech Jr MD
Baltimore Md

Hypertrophic or non dilated cardiomyopathy frequently has a familial incidence¹⁻⁴ and demonstrates an autosomal dominant mode of inheritance. In contrast in congestive or dilated cardiomyopathy it is rare to find families in which more than one member is affected⁵ and virtually all cases of congestive cardiomyopathy are considered sporadic. This report describes clinical and morphologic features of an idiopathic non hypertrophic myocardopathy which differs from sporadic idiopathic congestive cardiomyopathy both by its clinical presentation and its occurrence in three and possibly five generations of a single family (Table I). The autosomal dominant pattern of inheritance for the cardiac abnormalities in this family and the lack of distinctive structural abnormalities in the hearts of the three direct line descendants which were studied at autopsy suggest the possibility of a

genetic metabolic abnormality of myocardium as a causative factor in this family and in some sporadic cases of idiopathic myocardopathy.

Case report

On March 29 1973 approximately one year after the unexpected death of her son a previously healthy 44 year old mother of three collapsed suddenly while playing tennis. She was brought into a local hospital in ventricular fibrillation was converted to sinus rhythm by electroshock but died four days later having not regained consciousness. She was known to have had a systolic murmur since childhood first evaluated when she was three years old and believed to be functional. Because of vague chest pain an evaluation 10 years before her death revealed a systolic murmur in the pulmonic area a normal sized heart and borderline abnormalities of the ST segment on electrocardiogram (ECG). One year before her death an ECG during exercise showed nonspecific ST segment abnormalities and premature ventricular contractions. Although she denied any symptoms other than occasional chest pain over the eight year period before her death she had had two unexplained fainting spells.

At autopsy her heart weighed 380 grams had a globular configuration mild acute fibrinous pericarditis and left ventricular dilatation and hypertrophy. There was no disproportionate septal hypertrophy. The mitral valve showed thickening and rolling of its margins (Fig 1) with chordal shortening but no commissural fusion. The left ventricular endocardium was involved by a diffuse endocardial fibroelastosis (Fig 2). Histologic examination of myocardium showed scattered fibrosis prominent perinuclear lipofuscin accumulation in muscle cells. Basophilic degeneration present in moderate degree was evident by light microscopy which by

From the Cardiovascular Division of the Department of Medicine and the Department of Pathology The Johns Hopkins Medical Institutions Baltimore Md

Supported by Grant P50 HL 17655-07 from The National Institutes of Health Public Health Service Department of Health Education and Welfare and the Stetler Research Fund for Women Physicians

Received for publication June 20 1977

Accepted for publication July 30 1977

Reprint requests to Dr Bernadine H Bulkley Cardiovascular Division The Johns Hopkins Hospital Baltimore Md 21205



Fig 1 Views of left side of the heart of the index case (No 4) showing the globular configuration of the left ventricle endocardial fibroelastosis especially prominent in the left ventricular (LV) outflow area and rolling of the margins of the mitral valve leaflets secondary to mitral regurgitation A Outflow tract of left ventricle AV = aortic valve B Opened left atrium (LA) and left ventricle




Fig 2 Histologic sections from heart shown in Fig 1 A Marked endocardial fibroelastosis The endocardium is approximately five times thicker than normal and contains prominent elastic lamellae stained black (Verhoeff van Gieson stain original magnification $\times 375$) B Myocardium showing strongly PAS positive intracellular material characteristic of basophilic degeneration (BD) (Periodic Acid Schiff stain original magnification $\times 125$) C lower panel Transverse section of myocardial cell with basophilic degeneration (Toluidine blue stain original magnification $\times 750$) D The rolled margin of the mitral valve showing changes characteristic of long standing mitral regurgitation (Verhoeff van Gieson stain original magnification $\times 25$)

ultrastructural examination consisted of circumscribed fibrillar deposits within the central portion of the myocardial cells. No other abnormalities could be seen within myocardial fibers with or without basophilic degeneration and serial section studies of the atrioventricular conducting system showed no abnormality of the specialized conduction tissues. The extramural and intramural coronary arteries were normal. Other organs and tissues showed no abnormalities. Death was attributed to ventricular fibrillation arising in a heart with mitral insufficiency and left ventricular dilatation hypertrophy and endocardial fibroelastosis of unknown etiology.

Methods

Medical genealogical study The sudden unexpected death of this 44 year old woman approximately one year after the sudden death of her previously healthy 20 year old son suggested that a heritable cardiac disorder might exist within some segment of this family. To explore this hypothesis a detailed family tree was constructed and medical information was sought

Table I Clinical data in five generations

	Patient number age & sex	Clinical history	Pre cordial murmur	Chest x ray	Electrocardiogram			Echo cardiogram	Clinical course
					Short PR (< 12)	PVC	ST segment abnormalities		
Generation I	1 52F	Active unrestricted life	+	?	?	?	?	-	Sudden death due to fatty degeneration of the heart
Generation II	2 57F	Occasional heart attacks because of heart of someone who drank too much coffee over 2 years PTD otherwise well	+	?	?	?	?	-	Sudden death due to acute cardiac dilatation
Generation III	3 60F	Wolff Parkinson White syndrome active unrestricted life spell 1 month PTD premonition of death	0	?	+	+	?	-	Sudden death
Generation IV	4 44F	Vague chest pains x 8 yrs palpitations mild dyspnea on exertion 2 years PTD	+	Upper limits of normal heart size	0	+	+	-	Sudden death
	5 49F	Active life no symptoms	0	Normal	+	+	+	Slight LV dilatation EF = 49%	Alive and well
Generation V	6 20M	None until fatigue flu like syndrome 4 days before death	+	?	?	?	?	-	Acute heart failure and unexpected death
	7 23F	None except for occasional vague chest pain active life	+	Normal	+	+	+	Normal EF = 48%	Alive and well
	8 24F	Active unrestricted life	+	Upper limits of normal heart size	+	+	+	Slight LV dilatation EF = 41%	Alive and well Mild LV dilatation and decreased contractility at cardiac catheterization
	9 26F	Active unrestricted life	+	Normal	+	+	+	-	Alive and well

Symbols and abbreviations ? = unknown + = present 0 = not present -- = not done LV = left ventricle EF = ejection fraction PTD = prior to death

on relatives of the deceased woman including offspring, parents and grandparents on both sides of each family. Heart disease and cardiac deaths were preponderant in one segment of the family and could be traced back five generations in a direct line. A detailed historical search of this branch of the family was undertaken which

included interviews of family members in three generations, review of medical records and death certificates in all five generations and prospective medical examinations including electrocardiograms and chest x rays in all living family members. Living family members who demonstrated any cardiac abnormality underwent




Fig 3 Family tree. Case numbers refer to patients in text and on Table I. Numbers below circles and squares refer to individuals age as of 1976 or age at time of death.

further evaluation including exercise stress test
ing echocardiography cardiac fluoroscopy and
in one instance cardiac catheterization

Autopsy studies Complete autopsies were obtained on three first degree relatives in three different generations with cardiac disease. The hearts were reviewed grossly and by light microscopy. Histological stains performed included hematoxylin and eosin, Congo Red, Periodic acid-Schiff, phosphotungstic acid hematoxylin, Verhoeff's elastin and sudan IV. Electron microscopy was performed on formalin fixed tissue from two of the three hearts. Conduction system was examined by a method described previously and adapted from Hudson.

Results of a genealogical study

Family tree The family tree of the segment of the family under study is shown in Fig 3. The generations are designed I to V and clinical details of corresponding family members with definite or probable cardiomyopathy are summarized in Table 1. The proband, the 44 year old woman (Case 4) is in the fourth generation of the family.

Generation I The earliest recorded ancestor with cardiac disease in this family (Generation I)

was the proband's great grandmother who died before the turn of the century at age 52 of fatty degeneration of the heart which was apparently a clinical diagnosis. Little is known about her clinical details except that she had a long standing heart murmur and died at an unexpectedly early age. Family records indicate that all her siblings (the exact number is not clear) lived into their 70's or 80's.

Generation II The second generation of this family consisted of four children and two of them died cardiac deaths. One, a son, died in his early 20s also before 1900 of clinically diagnosed valvular disease of the heart. The other, a daughter (Case 2) died at age 57 of acute cardiac dilatation and chronic myocarditis and had a history of what were probably premature ventricular contractions. The other two members of Generation II were apparently well living into old age.

Generation III Seven offspring comprised the third generation of this family. The mother (Case 3) of the index case was the third born of these seven siblings. During a hospitalization approximately 20 years before her death, she was noted to have a Wolff Parkinson White syndrome but led a generally vigorous active life. At age 60 she died suddenly in her sleep. In retrospect there was




Fig 4 A Histologic sections of myocardium from mother of index case (No 3) showing extensive basophilic degeneration of the myocardium (Periodic acid Schiff stain original magnification $\times 125$) B Longitudinal section of muscle cells shown in A with basophilic degeneration (Toluidine blue stain original magnification $\times 7.0$)

some suspicion that she may have had a premonition of death and one month before her death she suffered a transient spell resembling petit mal. At autopsy the only significant abnormality was in her heart which had four chamber dilatation and a focally thickened and grayish white left ventricular endocardium. The valves were minimally thickened and the coronary arteries widely patent. Myocardium showed severe focal replacement fibrosis, extensive basophilic degeneration (Fig 4) and prominent perinuclear lipofuchsin deposits present in many cardiac muscle cells. Except for basophilic degeneration no other abnormalities of myocardial fine structure could be seen by electron microscopic examination of previously formalin fixed myocardium. Death was attributed to a myocardial disease of unknown etiology.

Although details of all her siblings are not available she, like her mother, had a brother who died in his early twenties of 'acute myocarditis and mitral insufficiency after three months of cardiac symptoms and associated systemic emboli. Another brother died shortly after birth of "apnea neonatorum" but it is not known whether cardiac disease was present. There was no known cardiac disease in the other four members of this generation.

Generation IV The fourth generation of this family consists of the three offspring of Case 3, the 60 year old woman who died in her sleep and includes the index case (Case 4) reported above who was the second oldest of her children. The first member of this generation also a daughter (Case 5), has clinical findings similar to those of other family members including a short PR interval, nonspecific ST-T wave changes, and exercise related premature ventricular contractions. By echocardiogram she has a mildly dilated left ventricular cavity (5.5 cm) and no evidence of asymmetric hypertrophy. She remains clinically well and asymptomatic at age 49. The third child in this generation a 43 year old male physician is well without evidence of cardiac abnormality by physical examination, electrocardiogram, electrocardiographic stress test or echocardiogram.

Generation V Eight offspring of these three children comprise the fifth generation of this family and four of the eight have evidence of a cardiac abnormality similar to that present in the previous generations. Within this fifth generation was the 20-year old son (Case 6) of the index case who died unexpectedly approximately one year before his mother. This young college student had been in excellent general health and had recently passed a physical examination for admission to the lacrosse team. Four days before his death he complained of unusual fatigue and subsequently developed a flu like illness. Twenty four hours after admission to the college infirmary he died unexpectedly with left sided congestive heart failure. At autopsy his heart weighing 540 grams showed biventricular dilatation and hypertrophy, focal fibrosis and a thinned gray white endocardium. The posterior tricuspid leaflet was adherent to the septal endocardium and the mitral valve had nodular thickening and rolling of its free margin. The coronary arteries were normal. Death was attributed to congestive heart failure caused by primary myocardial disease with endocardial fibroelastosis of unknown etiology.




Fig 5 Rhythm strips taken during or after electrocardiographic exercise stress tests in the index case (A) and her sister (B) and from their respective daughters (C and D)




Fig 6 Chest radiograph (A) from Case No. 6 the niece of the index case. Her cardiac silhouette has never been enlarged however by echocardiogram (B) her left ventricle is slightly dilated and at cardiac catheterization her left ventricle was moderately hypodynamic. Shown in C are frames from her left ventricular cineangiogram at end systole (ES) and in C lower panel at end diastole (ED). MV = mitral valve, LV PW = left ventricular posterior wall.

his deceased young man had two younger siblings. His sister (Case 7) is an asymptomatic young woman who has had a precordial systolic murmur since birth, nonspecific ST and T abnormalities, and exercise aggravated focal premature ventricular contractions. On several occasions she has had a short QT interval (< 12 sec) with a normal QRS complex. Her heart is normal sized by chest radiograph and by echocardiogram, the left

ventricular cavity size is at the upper limits of normal. The third sibling in this family is a young brother who is entirely free of any detectable cardiac abnormality by examination, chest radiograph, rest and stress electrocardiogram, echocardiogram, and Thallium 201 myocardial perfusion scan. Also within the fifth generation of this family are the three children of Case 5, the sister of the index case, two of whom have evidence of a similar myocardial disorder including systolic

murmurs, short PR intervals and minor ST segment abnormalities on electrocardiogram. One of these two sisters (Case 8) also had a normal cardiac silhouette by chest radiograph and like her mother, aunt, and cousin (Case 7) multifocal premature ventricular contractions worsened by exercise. By echo she has a mildly dilated and hypodynamic left ventricle with an ejection fraction of 41 per cent and no evidence of asymmetric hypertrophy (Fig 6). She was the only family member to undergo cardiac catheterization which demonstrated normal pressures, a slightly enlarged left ventricle and generalized moderately impaired over all left ventricular contractility. The two other members of Generation V are offspring of the unaffected brother of the index case and both are free of cardiac abnormalities by physical examination and noninvasive laboratory studies including electrocardiograms, chest radiographs and echocardiograms.

Therapy In two members of Generation V (Cases 7 and 8) anti arrhythmic therapy was instituted. After three baseline ECG stress tests and 24 hour Holter monitoring anti arrhythmic agents were started and repeat stress tests were performed. Propranolol had little effect on the arrhythmias. Both quinidine and diphenylhydantoin (Dilantin) were effective in suppressing the in exercise multifocal premature ventricular contractions and in decreasing postexercise extrasystoles. Because of side effects related to quinidine dilantin was chosen for long term therapy in both patients. Dilantin in a dose of 300 mg a day has been well tolerated and repeat stress tests at six months and one years time have continued to show that ectopy is suppressed during and diminished after maximal exercise compared to the pretreatment studies.

In contrast to these two patients anti arrhythmic therapy was unsuccessfully instituted in one member of generation IV (Case 5). Quinidine was not tolerated and resulted in syncope and Dilantin and procainamide had no effect on the frequency of her premature ventricular contractions.

Discussion

A similar type of myocardial disease distinctive both in its clinical presentation, its course and its morphology developed in several members of at least three and possibly five generations of an otherwise healthy family. The clinical manifesta-

tions of this familial myocardial disease are distinct from the usual forms of sporadic congestive cardiomyopathy. Rather than being the chronic debilitating disorder lasting for a few years usually seen with idiopathic congestive cardiomyopathy, this familial myocardial disease ran a relatively long but benign subclinical course with those affected appearing healthy, vigorous and asymptomatic. With most dilated congestive cardiomyopathies murmurs, electrocardiographic abnormalities and arrhythmias become manifest along with symptoms of heart failure and signs of cardiac dilatation and do not precede them. In the patients described here however precordial murmurs were most often detected in the first few years of life and conduction and rhythm disturbances were detected without associated heart failure or gross cardiac dilatation. Even in the family members who died suddenly, symptoms during life were minimal and signs of heart failure were present if at all, for only a brief time before death. The clinical picture of this myocardial disease also suggests that the same disorder may occur with variable severity in different affected family members. Although two family members died prematurely in their 20s and 40s respectively, one lived into her 60s suggesting that the disorder can be compatible with a normal or near normal life span.

The familial pattern of this myocardial disease suggests an autosomal dominant mode of inheritance. Of the 11 direct descendants of the mother of the index case six had evidence of cardiac abnormalities. It is not clear however whether this disorder has a sex predominance. Although female sex predominates in the affected family members, women predominate in the offspring. It is of note however that the one affected male who had the most severe form of the disease with death at age 20 also had congestive heart failure terminally. The direct line descendants in Generations II, III and V each had a brother dying in his early 20s of cardiac failure. In Generation III there was also a male sibling who died at birth but cardiac disease was not documented. Although detailed medical records or autopsy information are only available on one of the three likely affected males, one might wonder whether the cardiac abnormalities in this family were manifested in a milder form in the affected females.

The overall picture of the familial myocardial disease described here with autosomal dominant

inheritance and variable penetrance associated with murmurs, electrocardiographic abnormalities, a paucity of symptoms and sudden cardiac death appears superficially similar to the pattern of hypertrophic cardiomyopathy but echocardiographic, cardiac catheterization and morphologic studies indicate that it is rather more akin to a congestive dilated type of cardiomyopathy. Nonetheless, morphologic observations on the family members from three different generations reaffirm the clinical impression that it comprises a most unusual form of dilated cardiomyopathy. The three hearts studied at autopsy showed similar morphologic abnormalities that varied only in degree. Left ventricular hypertrophy and dilatation, endocardial fibroelastosis and relative mitral insufficiency with secondary rolling and shortening of the leaflet margins was most prominent in the heart of the 20 year old, intermediate in that of the 44 year old mother and most mild in his 61 year old grandmother, suggesting again that the disease in its most severe form led to early death but in its milder form was consistent with a near normal life span. The complex of morphologic features in these three hearts resembles both the idiopathic endocardial fibroelastosis of children and the idiopathic dilated cardiomyopathy of adults. Although the latter is rarely familial, endocardial fibroelastosis of children 'may be inherited in an autosomal recessive pattern. Unlike the familial myocardial degeneration described here, idiopathic endocardial fibroelastosis usually manifests itself within the first few years of life with symptoms of heart failure and at times conduction disturbances and leads to death within a matter of months to a few years. Some patients have been reported to live to the second decade but these represent a distinct rarity.

Although the cause of endocardial fibroelastosis is unsettled, it may be a consequence and not a cause of left ventricular dilatation resulting from an underlying myocardial weakness.¹¹ Endocardial fibroelastosis is known to exist in a secondary phenomenon in a variety of congenital and acquired diseases associated with ventricular dilatation, particularly when present early in life. Similarly, the endocardial fibroelastosis present in the three hearts under study may be a response to long standing mild ventricular dilatation as was documented angiographically in one clinically asymptomatic family member.

An unusual morphologic feature of the myocardial

disease in this family is the marked basophilic degeneration seen in the hearts of the grandmother and present to a moderate degree in the mother. Basophilic degeneration^{10, 11} is a focal myocardial disorder characterized by the deposition of a glycogen like granular substance within the central portions of myocardial fibers. A mild degree of basophilic degeneration is present in over 80 per cent of hearts, particularly with advanced age, but there are certain disease entities in which basophilic degeneration exceeds that expected from age alone and may in such instances be related to myocardial dysfunction. In myxedema heart disease in which there is a generalized myocardial hypodynamic state (generally believed to be sufficient for diminished metabolic demands), basophilic degeneration of myocardium is generally increased¹² and may be related to abnormal glycogen metabolism. Some patients with sporadic and familial idiopathic congestive cardiomyopathy¹³ have also been reported to have extensive basophilic degeneration of myocardium but as in our patients it is uncertain whether the degenerative changes in myocardium are morphologic manifestations of an underlying metabolic defect causing muscle weakness or are unassociated or secondary changes.

Another feature distinguishing this familial cardiomyopathy from the sporadic congestive cardiomyopathy is the degree of myocardial fibrosis. In idiopathic congestive cardiomyopathy, fibrosis is usually minimal and limited mainly to the interstitium. Frank replacement fibrosis unassociated with coronary artery disease is unusual although it may be seen in some rare myocardial diseases such as that associated with scleroderma.¹⁴ The degree of myocardial fibrosis present in these three hearts exceeds that usually seen in idiopathic myocardial disease. The fact that the fibrous endocardial fibroelastosis and basophilic degeneration appear to become more prominent with age suggests that none of these is the primary disorder although they may in fact reflect an underlying primary myocardial disturbance.

The arrhythmias and repolarization abnormalities, the major clinical manifestations of this myocardial disease, showed a striking similarity among affected family members. Familial arrhythmias and conduction disturbances have been reported in a variety of settings. Families

with isolated repolarization abnormalities such as the long QT interval associated with sudden death have been reported.⁴ Idiopathic ventricular tachycardia has been described in siblings without detectable heart disease themselves who were part of a family with hereditary congestive myocardiopathy.⁵ There have also been reports of congenitally malformed conduction systems associated with sudden death in several family members with otherwise normal hearts,⁶ and the mitral valve prolapse syndrome which may be associated with arrhythmias and sudden death in some families may be transmitted as an autosomal dominant trait.^{7,8}

The finding of a pre excitation syndrome in at least five of these family members described here may be important. Since the first report of the Wolff Parkinson White syndrome⁹ it has been recognized to be associated with certain congenital disorders including Ebstein's anomaly, atrial septal defect, ventricular septal defect and tetralogy of Fallot.¹⁰ Although a number of reports have associated familial cardiomyopathies with Wolff Parkinson White syndrome,¹¹⁻¹⁴ almost always the cardiomyopathy is of a hypertrophic variety. A recent echocardiographic study demonstrated associated cardiac abnormalities in almost one quarter of patients with Wolff Parkinson White syndrome including two patients with hypertrophic cardiomyopathy and one with congestive cardiomyopathy.¹⁵ Since Wolff Parkinson White syndrome was first described other variants of the Wolff Parkinson White syndrome have been recognized as related pre excitation syndromes including the short PR interval with a normal QRS duration (Lown Ganong Levine syndrome) which is prevalent in the family described here. Whether the pre excitation syndrome associated with idiopathic cardiomyopathy results from a specific nodal bypass tract or from intranodal abnormalities related to the underlying myopathic process is uncertain.

Clinical and pathologic cardiac findings in this family raise questions about idiopathic non hypertrophic cardiomyopathy which are worthy of consideration. First congestive cardiomyopathies may be familial and using the ECG as a screen one may be able to detect subtle subclinical abnormalities in the myocardium of first degree relatives of patients with seemingly sporadic congestive cardiomyopathy. Only a

detailed family search and prospective clinical evaluation of all living family members uncovered the striking inheritance pattern of the disorder described here. Secondly, this family demonstrates that dilated cardiomyopathy like hypertrophic cardiomyopathy, may be subclinical, have a benign course and go virtually unrecognized during life. And thirdly, the findings in this family point out that the class of disorders deemed idiopathic dilated cardiomyopathies are a heterogeneous group likely to be of multiple etiologies and pursuing varied clinical courses. That dilated cardiomyopathies may be associated with an autosomal dominant pattern of inheritance and a relatively homogeneous clinical and pathologic expression suggests that a unitary biochemical defect yet to be discovered may lead to an intrinsic weakness of myocardial contraction.

Summary

A peculiar non hypertrophic myocardiopathy is described which occurred in three and possibly five generations of a single family. Clinical features included systolic murmurs, electrocardiographic abnormalities and sudden cardiac death with a paucity of symptoms of cardiac dysfunction. Pathological studies in three generations showed a striking similarity of cardiac findings including globular and dilated ventricles, endocardial fibroelastosis and mitral valve thickening. Myocardium in two showed basophilic degeneration and fibrosis. A retrospective genetic analysis and a prospective clinical evaluation of living family members suggested an autosomal dominant mode of inheritance with variable penetrance. The cause of this heritable myocardiopathy is presumably a mutant gene; the biochemical defect to which the mutant gene gives rise remains unknown.

REFERENCES

1. Brent L B, Aburano A, Fisher D L, Moran T J, Myers J D and Taylor W J. Familial muscular subaortic stenosis. An unrecognized form of idiopathic heart disease with clinical and autopsy observations. *Circulation* 21:167-190.
2. Braunwald E, Lambrew C T, Rockoff S D, Ross J Jr and Morrow A G. Idiopathic hypertrophic subaortic stenosis. I. A description of the disease based upon an analysis of 64 patients. *Circulation* 30 (Suppl 4):3-1964.
3. Evans W. Familial cardiomegaly. *Br Heart J* 11:68-1949.
4. Teare D. Asymmetrical hypertrophy of the heart in young adults. *Br Heart J* 20:1-1958.

- Treger A Blount S G Jr Familial cardiomyopathy AM HEART J 70 40 1965
- Kariv I Kreisler H Sherf L Fridman S and Rosenthal T Familial cardiomyopathy A review of 11 families AM J Cardiol 28 693 1971
- Battersby E J and Jenner G G Familial cardiomyopathy AM J Med 30 387 1961
- Shabetai R Shum I Heritable and familial aspects of myocardial diseases in Myocardial Diseases Fowler N O ed New York 1973 Crune M Stratton Inc chapter 8 pp 213 231
- Anselmi A Suarez J A Anselmi G Moleiro F de Suarez C and Ruesta V Primary cardiomyopathy in identical twins AM J Cardiol 35 9 1975
- Ridolfi R L Bulkley B H and Hutchins G M The cardiac conduction system in progressive systemic sclerosis Clinical and pathologic features of 35 patients AM J Med 61 661 1976
- Hudson R H B The human pacemaker and its pathology Br Heart J 22 143 1960
- Bulkley B H Rousseau J Strauss H W and Pitt B Idiopathic hypertrophic subaortic stenosis Detection by Thallium 201 myocardial perfusion imaging N Engl J Med 293 1113 1975
- Bulkley B H Hutchins G M, Bailey I Strauss H W and Pitt B Thallium 201 imaging and gated blood pool scans in patients with ischemic and idiopathic congestive cardiomyopathy A clinical and pathologic study Circulation 55 753 1977
- Thomas W A Randall R V Bland E F and Castleman B Endocardial fibroelastosis A factor in heart disease of obscure etiology A study of 70 autopsied cases in children and adults N Engl J Med 251 327 1954
- Lee M H Liebman J Steinberg A G Perron F V, and Whitman V Familial occurrences of endocardial fibroelastosis in three siblings including identical twins Pediatrics 52 407 1973
- Hutchins G M and Vile S A The progression of interstitial myocarditis to idiopathic endocardial fibroelastosis AM J Pathol 66 483 1977
- Black Shaffer H Infantile endocardial fibroelastosis A suggested etiology Arch Pathol 63 281 1957
- Black Shaffer B and Turner M E Hyperplastic infantile cardiomegaly A form of idiopathic hypertrophy with or without endocardial fibroelastosis and a comment on cardiac "atrophy" AM J Pathol 34 745 1958
- Davies J N P Some considerations regarding obscure diseases affecting the mural endocardium AM HEART J 59 600 1960
- Manion W C Basophilic mucoid degeneration of the heart Med Ann D C 34 60 1965
- Rosai J and Lescano I F Basophilic (mucoid) degeneration of myocardium A disorder of glycogen metabolism AM J Pathol 61 99 1970
- Brewer D B Mixoedema An autopsy report with histochemical observations on the nature of mucoid infiltrations J Pathol Bacteriol 63 503 1961
- Bulkley B H Ridolfi R I Salver W R and Hutchins G M Myocardial lesions of progressive systemic sclerosis A cause of cardiac dysfunction Circulation 53 493 1976
- Jervell An and Lange Nielsen F Congenital deaf mutism functional heart disease with prolongation of the Q T interval and sudden death AM HEART J 54 59 1957
- Karhunen P Luomanmaki K, Heikkila J and Eisalo A Syncope and Q T prolongation without deafness The Romano-Ward syndrome AM HEART J 80 870 1970
- Sacks H S Matson R and Kennelly B M Familial paroxysmal ventricular tachycardia in two sisters AM HEART J 87 217 1974
- Brink A J Tornator M and Van Der Walt J J Hereditary dysrhythmic congestive cardiomyopathy (In preparation)
- Green J R Jr Korovetz M J Shanklin R R DeVito J J and Taylor W J Sudden unexpected death in three generations Arch Intern Med 124 359 1969
- Barlow J B Bosman C A, Pocock W A and Marchand P Late systolic murmurs and non ejections (mid late) systolic clicks An analysis of 90 patients Br Heart J 30 703 1968
- Wells A N Mims J W Ludbrook P A and Sobel B F Echocardiographic detection of mitral valve prolapse Exclusion of false positive diagnosis and determination of inheritance Circulation 52 1091 1975
- Wolf L Parkinson J and White P D Bundle branch block with short P R interval in healthy young people prone to paroxysmal tachycardia AM HEART J 6 680 1930
- Schaebler G L Adams P Jr and Anderson R C The Wolff Parkinson White syndrome in infants and children Pediatrics 24 585 1959
- Newman B J Donoso M and Freiberg C K Arrhythmias in Wolff Parkinson White syndrome Progr Cardiovasc Dis 9 147 1966
- Gallagher J J Gilbert M Svenson R H Kealy W C Kasell J and Wallace A G Wolff Parkinson White syndrome (A problem evaluation and surgical correction Circulation 51 767 1975)
- Westlake R E Cohen W and Willis W H Wolff Parkinson White syndrome and familial cardiomegaly AM HEART J 64 314 1969
- Chandra M S Kerber R Brown D D and Funk D C Echocardiography in Wolff Parkinson White syndrome Circulation 53 943 1976

with isolated repolarization abnormalities such as the long QT interval associated with sudden death have been reported.^{1,22} Idiopathic ventricular tachycardia has been described in siblings without detectable heart disease themselves who were part of a family with hereditary congestive cardiomyopathy.²³ There have also been reports of congenitally malformed conduction systems associated with sudden death in several family members with otherwise normal hearts,²⁴ and the mitral valve prolapse syndrome which may be associated with arrhythmias and sudden death, in some families may be transmitted as an autosomal dominant trait.²⁵

The finding of a pre excitation syndrome in at least five of these family members described here may be important. Since the first report of the Wolff Parkinson White syndrome²⁶ it has been recognized to be associated with certain congenital disorders including Ebstein's anomaly, atrial septal defect, ventricular septal defect and tetralogy of Fallot.^{27,28} Although a number of reports have associated familial cardiomyopathies with Wolff-Parkinson White syndrome,²⁹⁻³¹ almost always the cardiomyopathy is of a hypertrophic variety. A recent echocardiographic study demonstrated associated cardiac abnormalities in almost one quarter of patients with Wolff Parkinson White syndrome including two patients with hypertrophic cardiomyopathy and one with congestive cardiomyopathy.³² Since Wolff Parkinson White syndrome was first described, other variants of the Wolff Parkinson White syndrome have been recognized as related pre excitation syndromes, including the short PR interval with a normal QRS duration (Lown-Ganong-Levine syndrome) which is prevalent in the family described here. Whether the pre excitation syndrome associated with idiopathic cardiomyopathy results from a specific nodal bypass tract or from intranodal abnormalities related to the underlying myopathic process is uncertain.

Clinical and pathologic cardiac findings in this family raise questions about idiopathic non hypertrophic cardiomyopathy which are worthy of consideration. First congestive cardiomyopathies may be familial and using the ECG as a screen one may be able to detect subtle subclinical abnormalities in the myocardium of first degree relatives of patients with seemingly sporadic congestive cardiomyopathy. Only a

detailed family search and prospective clinical evaluation of all living family members uncovered the striking inheritance pattern of the disorder described here. Secondly this family demonstrates that dilated cardiomyopathy like hypertrophic cardiomyopathy, may be subclinical have a benign course, and go virtually unrecognized during life. And thirdly the findings in this family point out that the class of disorders deemed 'idiopathic dilated cardiomyopathies' are a heterogeneous group likely to be of multiple etiologies and pursuing varied clinical courses. That dilated cardiomyopathies may be associated with an autosomal dominant pattern of inheritance and a relatively homogeneous clinical and pathologic expression suggests that a unitary biochemical defect yet to be discovered may lead to an intrinsic weakness of myocardial contraction.

Summary

A peculiar non hypertrophic cardiomyopathy is described which occurred in three and possibly five generations of a single family. Clinical features included systolic murmurs, electrocardiographic abnormalities, and sudden cardiac death with a paucity of symptoms of cardiac dysfunction. Pathological studies in three generations showed a striking similarity of cardiac findings including globular and dilated ventricles, endocardial fibroelastosis, and mitral valve thickening. Myocardium in two showed basophilic degeneration and fibrosis. A retrospective genetic analysis and a prospective clinical evaluation of living family members suggested an autosomal dominant mode of inheritance with variable penetrance. The cause of this heritable myocardiopathy is presumably a mutant gene, the biochemical defect to which the mutant gene gives rise remains unknown.

REFERENCES

1. Brent L B, Aburano A, Fisher D L, Moran T J, Myers J D and Taylor W J. Familial muscular subaortic stenosis. An unrecognized form of idiopathic heart disease with clinical and autopsy observations. *Circulation* 21: 167, 1960.
2. Braunwald E, Lambrew C T, Rockoff S D, Ross J Jr and Morrow A G. Idiopathic hypertrophic subaortic stenosis. I. A description of the disease based upon an analysis of 64 patients. *Circulation* 30 (Suppl 4): 3, 1964.
3. Evans W. Familial cardiomegaly. *Br Heart J* 11: 68, 1949.
4. Teare D. Asymmetrical hypertrophy of the heart in young adults. *Br Heart J* 20: 1, 1958.




Fig 1 An example of the M mode echocardiographic pattern of the normal tricuspid valve showing the smooth gradual anterior motion during systole of the valve between the C and D points

Table I Echocardiographic pattern of tricuspid valve prolapse

Patient group	Description
I	Consecutive patients without mitral valve prolapse or congenital heart disease
II	Mitral valve prolapse (with adequate visualization of tricuspid valve)
III	Marfan's Syndrome patients with mitral valve prolapse
IV	Marfan's Syndrome patients without mitral prolapse

systolic portion of the valve. This could almost always be done in only one interspace and with one type of angulation in any given patient.

Drawing on the experience of Markiewicz and colleagues¹ DeMaria and others² we decided on the criteria listed in Table II for the demonstration of the pattern of tricuspid valve prolapse. Points 4a and 4e are strict criteria that resulted from several years of experience with the mitral prolapse pattern. This seems to be essentially analogous with that of tricuspid valve prolapse as suggested by others¹ and confirmed in the present study. Fig 1 is an illustration of normal tricuspid valve motion by M mode echocardiography, while Figs 2 through 4 are reproductions from some of our patients illustrating the criteria for an abnormal pattern as stated.

Data analysis. Groups were looked at individually for absolute incidence of tricuspid valve prolapse. Group I, containing the largest number

Table II Criteria

Echo must demonstrate

1. Maximum valve excursion where systolic portion is optimally seen
2. Complete visualization of tricuspid valve during systole
3. Exclude congenital heart syndromes
4. Pattern analogous to mitral prolapse patterns
 - a. Distinct midsystolic reversal of established anterior motion
 - b. Late systolic pattern acceptable only if posterior movement is 2 mm or greater from a horizontal line drawn connecting C and D points
 - c. Pansystolic
 - d. Early systolic posterior displacement acceptable only if pansystolic
 - e. Pattern seen on at least three non extrasystolic beats

of patients exhibiting the pattern of tricuspid valve prolapse was further analyzed for age, sex and associated clinical characteristics. Patients with mitral and tricuspid valve prolapse were compared to patients with mitral valve prolapse alone and p values were obtained using the χ^2 analysis.

Results

Occurrence. Table III is a summary of our findings. Group I patients revealed not one case of isolated tricuspid valve prolapse in 500 consecutive patients. This finding was somewhat surprising in view of published reports of as high as 15 per cent incidence of angiographically demonstrated isolated tricuspid prolapse.

Following completion of the analysis of this

Occurrence and significance of echocardiographically demonstrated tricuspid valve prolapse*

Jeffrey A. Werner, M.D.
Nelson B. Schiller, M.D.
Richard Prasquier, M.D.
San Francisco, Calif.

Systolic prolapse of the mitral and tricuspid valves has been described both by angiography and noninvasively by echocardiography.¹⁻³ The occurrence of prolapse of each valve individually as well as simultaneously has also been reported and speculation as to possible etiologic associations offered.¹⁻⁴ However, the infrequent occurrence of the pattern of tricuspid prolapse as diagnosed by routine M mode echo in our laboratory coupled with the high incidence of this disorder reported angiographically¹ prompted us to investigate this finding more fully.

Materials and methods

Patients We investigated a total of 562 patients by M mode echocardiography utilizing either a Picker EV X coupled with a Honeywell 1856 fiberoptic strip chart recorder or a Smith Kline Ekoview 20 A interfaced with an Irex strip chart recorder. Two patients were additionally studied using the prototype of a 32 element phased array, 80 degree sector scanner developed by Varian Associates.

There were four groups of patients (Table I). In Group I were 500 consecutive patients who had

echocardiograms in our noninvasive laboratory and in whom the systolic portion of the tricuspid valve could be adequately visualized. Excluded from this group were patients with mitral valve prolapse and patients with known congenital heart disease, including Ebstein's anomaly. In Group II were 59 consecutive patients with echocardiographically proven mitral valve prolapse. Six patients were discarded from this group due to inability to adequately visualize the systolic portion of the tricuspid valve according to criteria described below. Group III (six patients) and Group IV (three patients) both had Marfan's syndrome, but with (III) and without (IV) mitral valve prolapse, respectively.

Two patients with mitral and tricuspid valve prolapse underwent additional examination using the two dimensional real time sector scanner described above. Their tricuspid valves were imaged in a transverse section through the base of the heart by directing the echo beam in the manner described by Henry and associates.¹⁰

Criteria Patients were examined using standardized technique. Patients were placed in the left lateral decubitus position and the transducer initially placed in the standard interspace.* The tricuspid valve was then imaged in most cases, by inferior and slight medial angulation once the level of the aortic valve was visualized. In some cases the valve was best imaged by visualizing the mitral just below the AV ring and then angulating almost directly medially until good tricuspid valve imaging was accomplished. If both of these failed other interspaces were tried. The objective was adequate visualization of the entire

From the Department of Medicine, Cardiovascular Division and the Cardiovascular Research Institute, University of California, San Francisco.

This work was supported in part by NHLBI Program Project Grant HL 06285.

Received for publication June 12, 1977.

Accepted for publication Aug. 12, 1977.

Reprint requests: Jeffrey A. Werner, M.D., Division of Cardiology, Harborview Medical Center, 325 9th Avenue, Seattle, Wash. 98104.

Presented in part at the American Heart Association Meetings, November 15, 1976, Miami Beach, Florida.




Fig 4 Mitral and tricuspid valve echoes taken from the same echocardiogram of a patient with mitral and tricuspid valve prolapse demonstrating marked similarities in prolapse pattern

small also suggests the apparent rarity of the pattern of tricuspid valve prolapse occurring by itself

Age and sex distribution There were a total of 17 males and 36 females in Group II (Table IV). This ratio of female predominance is typical with mitral prolapse. Of the males three of 11 had mitral valve prolapse and tricuspid valve prolapse—whereas fourteen of 42 had mitral prolapse alone—a difference that was not statistically significant. Eight of the 11 females had both findings compared to 28 to 42 with mitral valve prolapse alone. Again this difference was not significant. However when both sexes are taken together and compared for age patients with mitral valve prolapse and tricuspid valve prolapse had a mean age of 57 years (± 15) whereas patients with mitral valve prolapse alone had a mean age of 37 (± 16) years. This proved to be a significant difference at the p less than .05 level.

Clinical features Correlations of the typical clinical features of mitral valve prolapse to the presence or absence of the additional finding of the pattern of tricuspid valve prolapse are shown in Table V. Group II patients alone were considered because this group had the greatest number

Table III Echocardiographic pattern of tricuspid valve prolapse

Patient group	Finding	% TVP
I	Consecutive patients with out mitral valve prolapse or congenital heart disease	0% (0/500)
II	Mitral valve prolapse (with adequate visualization of tricuspid valve)	21% (11/53)
III	Marfan's Syndrome patients with mitral valve prolapse	87% (4/6)
IV	Marfan's Syndrome patients without mitral valve prolapse	0% (0/3)

of patients with tricuspid valve prolapse for analysis. One patient with mitral valve and tricuspid valve prolapse had atypical chest pain. Six of eleven with both findings had a systolic click and/or systolic murmur and three of eleven of these patients had a history of palpitations. There was no statistically significant difference between these patients and patients exhibiting mitral prolapse alone.




Fig 2 Example of late systolic prolapse demonstrating distinct mid-systolic reversal of established anterior motion as well as greater than 2 mm of movement posterior to the CD line




Fig 3 The pattern of pansystolic prolapse with greater than 2 mm of posterior systolic movement

study group, we have seen an occasional case of isolated tricuspid prolapse by echo but these instances were not apparently naturally occurring. One case each with the pattern of tricuspid valve prolapse has been seen: (a) following a right ventricular wound, (b) with tricuspid valve vegetations, (c) with a large pericardial effusion and (d) in a patient with mitral regurgitation due to apparent chordal rupture.

Group II patients revealed 11/53 or 21 per cent of patients with mitral valve prolapse who also had the pattern of tricuspid valve prolapse. Group III Marfan's patients with mitral valve prolapse, revealed four of the six (67 per cent) to have an analogous pattern of tricuspid valve prolapse on echo. None of the Group IV patients with Marfan's syndrome and no mitral prolapse had the tricuspid pattern. This group although very




Fig 6A Two-dimensional sector scan taken in the short axis through the base of the heart of a normal individual. The frame was taken in early systole and demonstrates that the commissure of the septal and mural leaflets of the tricuspid valve lies slightly above the level of the bellies and ring attachment and is oriented toward the right ventricular outflow tract

Fig 6B Early systolic two-dimensional scan taken from a patient with M mode echo pattern of pansystolic tricuspid prolapse. Note that the commissure is located slightly below the level of the ring attachment and that there is an extra set of echoes coming from the septal leaflet

studies on several patients the absence of any cases of isolated tricuspid valve prolapse in 500 consecutive patients and validation of the echo cardiographic pattern by right ventricular angiogram in two patients: one in and one outside (Fig 5) the study lent credence to our techniques and findings. Furthermore two tricuspid valve prolapse patients were also studied by two-dimensional echocardiography and were felt to have a

pattern consistent with prolapse of the tricuspid valve toward the right atrium during systole (Fig 6)

Our study population is intended to investigate a different group of patients from those with congenital heart disease. We expect that the findings and clinical applications likewise would not be similar. These patients frequently have right ventricular enlargement which can actually




Fig 5 RV angiogram and M mode echo in same patient demonstrating tricuspid valve prolapse

Table IV Echocardiographic pattern of tricuspid valve prolapse Age and sex distribution—Group II patients

	MVP and TVP	MVP only	P
Age (yrs)	57 ± 15	37 ± 16	< 05
Male	27% (3/11)	33% (14/42)	NS
Female	73% (8/11)	67% (28/42)	NS

Discussion

The present study of 562 patients represents one of the largest group of patients in whom the pattern of tricuspid valve prolapse has been systematically sought. Our finding of 21 per cent occurrence of tricuspid valve prolapse in patients with mitral valve prolapse is less than half of the previously reported incidence of this association in both an angiographic series and a small echographic series.¹ The true incidence of spontaneously occurring tricuspid valve prolapse however, can probably never be known because of absence of indications for right ventricular angiography in most patients coupled with the significant potential for artifact inherent in the echocardiographic detection of this type of anomaly. The latter problem has been eloquently dealt with in mitral prolapse by Markiewicz and colleagues² and by Weiss and associates.³ When

Table V Echocardiographic pattern of tricuspid valve prolapse Clinical features—Group II patients

	MVP + TVP	MVP only	P
a Atypical chest pain	9% (1/11)	10% (4/42)	NS
b Click and/or murmur	55% (6/11)	71% (30/42)	NS
c Palpitations	27% (3/11)	33% (14/42)	NS

analogous criteria for transducer placement and angulation, as well as strict diagnostic criteria, are applied to the analysis of the tricuspid valve our experience suggests that reproducible findings can be achieved. However the tricuspid valve remains more difficult to image adequately and inherently involves more transducer angulation. Hence tricuspid valve imaging is unavoidably subject to more hazardous interpretation and therefore requires very careful extrapolation to clinical application. Nevertheless with experience adequate and reliable visualization of the tricuspid valve and its anomalies is becoming easier and use of standardized technique in each laboratory should minimize such errors. In our laboratory we often found that patients that had the pattern of tricuspid valve prolapse could sometimes have this pattern normalized with other transducer angulations. However repetitive




Fig 5A Two-dimensional sector scan taken in the short axis through the base of the heart of a normal individual. The frame was taken in early systole and demonstrates that the commissure of the septal and mural leaflets of the tricuspid valve lies slightly above the level of the bellis and ring attachment and is oriented toward the right ventricular outflow tract.

Fig 5B Early systolic two-dimensional scan taken from a patient with M mode echo pattern of pansystolic tricuspid prolapse. Note that the commissure is located slightly below the level of the ring attachment and that there is an extra set of echoes coming from the septal leaflet.

studies on several patients the absence of any cases of isolated tricuspid valve prolapse in 500 consecutive patients and validation of the echocardiographic pattern by right ventricular angiogram in two patients, one in and one outside (Fig 5) the study lent credence to our techniques and findings. Furthermore two tricuspid valve prolapse patients were also studied by two dimensional echocardiography and were felt to have a

pattern consistent with prolapse of the tricuspid valve toward the right atrium during systole (Fig 6).

Our study population was intended to investigate a different group of patients from those with congenital heart disease. We expect that the findings and clinical applications likewise would not be similar. These patients frequently have right ventricular enlargement which can actually




Fig 5 RV angiogram and M mode echo in same patient demonstrating tricuspid valve prolapse

Table IV Echocardiographic pattern of tricuspid valve prolapse Age and sex distribution—Group II patients

	MVP and TVP	MVP only	P
Age (yrs)	57 ± 15	37 ± 16	< .05
Male	27% (3/11)	33% (14/42)	NS
Female	73% (8/11)	67% (28/42)	NS

Discussion

The present study of 562 patients represents one of the largest group of patients in whom the pattern of tricuspid valve prolapse has been systematically sought. Our finding of 21 per cent occurrence of tricuspid valve prolapse in patients with mitral valve prolapse is less than half of the previously reported incidence of this association in both an angiographic series and a small echocardiographic series. The true incidence of spontaneously occurring tricuspid valve prolapse however can probably never be known because of absence of indications for right ventricular angiography in most patients coupled with the significant potential for artifact inherent in the echocardiographic detection of this type of anomaly. The latter problem has been eloquently dealt with in mitral prolapse by Markiewicz and colleagues¹ and by Weiss and associates.² When

Table V Echocardiographic pattern of tricuspid valve prolapse Clinical features—Group II patients

	MVP + TVP	MVP only	P
a Atypical chest pain	9% (1/11)	10% (4/42)	NS
b Click and/or murmur	55% (6/11)	71% (30/42)	NS
c Palpitations	27% (3/11)	33% (14/42)	NS

analogous criteria for transducer placement and angulation as well as strict diagnostic criteria are applied to the analysis of the tricuspid valve our experience suggests that reproducible findings can be achieved. However the tricuspid valve remains more difficult to image adequately and inherently involves more transducer angulation. Hence tricuspid valve imaging is unavoidably subject to more hazardous interpretation and therefore requires very careful extrapolation to clinical application. Nevertheless with experience adequate and reliable visualization of the tricuspid valve and its anomalies is becoming easier and use of standardized technique in each laboratory should minimize such errors. In our laboratory we often found that patients that had the pattern of tricuspid valve prolapse could sometimes have this pattern normalized with other transducer angulations. However repetitive

Rapid sensitive detection of myoglobinemia by improved counterimmunoelectrophoresis in cases of acute myocardial infarction

Katsuhiko Hiramori*
Tetsuya Sumiyoshi*
Saeko Motegi*
Takashi Honda*
Shunichi Kimata
Kobuchiro Hiroseawa*
Hisaoaki Kawanishi*
Akira Honda**
Masaru Iwaasa**
Kazuo Miyoshi**
Tokyo and Tokushima Japan

Kass and Reinhart reported in 1956 that myoglobin (Mb) can be detected in the blood or urine of patients with acute myocardial infarction (AMI). However, this has not been applied to clinical diagnosis because of the absence of a rapid and sensitive method for detection of Mb. Occasional AMI is difficult to diagnose at an early stage by means of electrocardiogram or measurement of serum enzyme activity. A technique that can detect and provide an estimate of myocardial infarction size during the early stages should be useful.

The counterimmunoelectrophoresis (CIE) technique for Mb, although simple and rapid, lacks sufficient sensitivity for AMI diagnosis. Thus, we tried to improve the sensitivity of the Mb detection method by using water-soluble non-ionic polymer dextran, which had been reported

to enhance specific antigen-antibody reaction,^{1,2} and applied this modified CIE method to clinical cases.

Subjects and materials

We studied 48 patients admitted to our coronary care unit with AMI. Blood samples were collected venally after admission. The blood was left to coagulate and was then centrifuged at 4°C. An aliquot of sodium azide was added to the serum samples, which were then stored at -40°C and freeze-thawed only once. Materials used were agarose dextran of molecular weight 195,000 and Coomassie Brilliant Blue obtained from Nakarai Chemicals Ltd. and anti-human Mb serum obtained from the Behring Institute. The veronal buffer had a pH of 8.6 and an ionic strength of 0.05. An MP-4 camera and type 105 film from the Polaroid Corporation were used.

Methods

A CIE plate of 1.5 mm thickness was composed as shown in Table 1. Pairs of wells were made on the plate with the distance between the wells of each pair being 6 mm, center to center. The sample (10 µl) was applied to the well on the cathode side, and the anti-serum was applied on

From the Heart Institute of Jpn. Tokyo University Medical College and the First Department of Internal Medicine, Tokushima University School of Medicine, Tokushima, Japan.

Received for publication July 15, 1977.

Accepted for publication February 17, 1978.

Reprint requests to: Katsuhiko Hiramori, MD, National Cardiovascular Center, 5-1-1 Fushimi, Suita City, Osaka 565, Japan.

*The Heart Institute of Japan, Tokyo Women's Medical College.

**The First Department of Internal Medicine, Tokushima University School of Medicine.

© 1978 by W.B. Saunders Company 0002-8736/78/0018-0040\$01.50/0

enhance the ability to image the tricuspid valve. In addition, the attendant anatomical and physiological alterations frequently lead to increased valvular excursion, multiple echoes and altered structural relationships that would totally have redirected the viewpoint and purpose of the study.

The remaining risk in this work lies in the possibility that a 'new disease' may have been discovered. Our findings are strongly against this. The pattern of tricuspid valve prolapse did not occur as an isolated finding. When it did occur, it was always associated with mitral prolapse and in a greater percentage in patients with an underlying connective tissue disorder (Marfan's). The one significant finding of increasing occurrence with age, when taken together with the above, may provide a biological glimpse of the natural history of myxomatous degeneration. Such a relation between the patterns of mitral and tricuspid prolapse had been suggested to us clinically in a patient with apparent endocarditis and mitral regurgitation from chordal rupture who also had tricuspid valve prolapse on the echo. That such an association exists, although uncommon, could suggest an etiologic clue to the underlying pathology.

In summary, the echocardiographic pattern of tricuspid valve prolapse is rare. Its occurrence is almost always accompanied by mitral valve prolapse and likely represents part of the same clinical spectrum.

Summary

Echocardiograms from 562 patients were examined for evidence of the pattern of tricuspid valve prolapse. Criteria for the diagnosis can be established similar to those applicable to mitral prolapse. In 500 consecutive patients without mitral valve prolapse, there were no cases of isolated tricuspid valve prolapse. Eleven of 53 (21 per cent) patients with mitral valve prolapse also had tricuspid valve prolapse. Four of six (67 per cent) patients with Marfan's syndrome and

mitral valve prolapse also had tricuspid valve prolapse. The occurrence of this echocardiographic pattern as an isolated finding as well as associated with mitral valve prolapse was significantly less than previous angiographic reports. Patients with both these findings tended to be older than those with mitral valve prolapse alone but clinically differed in no other way. Use of standardized technique can minimize errors in diagnosis.

The authors wish to thank Patricia Hart for the schematic drawing of Figs 6A and 6B and Mrs Sylvia T. Smith and Mrs Kathleen G. Hecker for their assistance in the preparation of this manuscript.

REFERENCES

1. Gooch A S, Maranhao V and Scamporrino G. Prolapse of both mitral and tricuspid leaflets in systolic murmur-click syndrome. *N Engl J Med* 28: 1718-1719, 1972.
2. Maranhao V, Gooch A S and Yang S S. Prolapse of the tricuspid leaflets in the systolic murmur-click syndrome. *Catheterization Cardiovasc Diag* 1: 81, 1975.
3. Chandraratna P A, N. Lopez J M and Fernandez J J. Diagnosis of tricuspid valve prolapse by echocardiography (Abstr.). *J Clin Ultrasound* 2: 225, 1975.
4. Chandraratna P A, N. Lopez J M and Fernandez J J. Echocardiographic detection of tricuspid valve prolapse. *Circulation* 51: 823, 1975.
5. Markiewicz W, Stoner J, London M and Hunt S. Mitral valve prolapse in one hundred presumably healthy young females. *Circulation* 53: 464, 1976.
6. DeMaria A N, King J F and Bogen H G. The variable spectrum of echocardiographic manifestations of the mitral valve prolapse syndrome. *Circulation* 50: 33, 1974.
7. Nanda N C, Gramiak R and Manning J A. Echocardiography of the tricuspid valve in congenital left ventricular-right atrial communication. *Circulation* 51: 268, 1975.
8. Weiss A N, Mims J W and Lundbrook P A. Echocardiographic detection of mitral valve prolapse. *Circulation* 52: 1091, 1975.
9. Popp R L, Filly K, Brown O R and Harrison D C. Effect of transducer placement on echocardiographic measurement of left ventricular dimensions. *Am J Cardiol* 35: 537, 1975.
10. Henry W L, Maron B J, Griffith J M, Redwood D R and Epstein S E. Differential diagnosis of anomalies of the great arteries by real time two dimensional echocardiography. *Circulation* 51: 283, 1975.

Table 1 Immunelectrophoretic plate composition

Agarose	1.5 Gm
Veronal buffer (pH 8.6 ionic strength 0.05)	50 ml
Distilled water	50 ml
Sodium azide	0.1 Gm
Dextran (molecular weight 195 000)	3.0 Gm

cal application of this effect especially in the antigen or antibody excess zone has been suggested. We managed to improve CIE sensitivity for detecting Mb using this effect.


From a previous study¹ of serially collected blood samples from 21 AMI cases we have observed that in all patients there was an apparently elevated serum Mb level (above 150 ng/ml) within four hours from the onset of AMI. Peak Mb concentration value averaged 1146 ± 823 ng/ml while peak concentration occurred at 10.3 ± 4.8 (mean \pm SD) hours. Mb decreased exponentially by a half time of 6.7 ± 1.3 hours.

Hibway and Blaker reported that CIE sensitivity to Mb was 2000 ng/ml. Since most myocardial infarction patients show values lower than this figure the method is not sensitive enough for the detection of myocardial infarction. Our improved method is sufficiently sensitive thereby with the exception of small myocardial infarctions the diagnosis can be ascertained at bedside from blood samples taken within 10 hours from disease onset.

In regard to the specificity of our method we studied 51 cases with heart disease other than AMI. Only two of these were 1+ and \pm the former being a resuscitated Adams Stokes patient and the latter a severe angina pectoris case. Since it is well known that myoglobinemia is found in many other skeletal muscle diseases patients must be thoroughly checked for skeletal muscular damage. We were impressed by the fact that the specificity of this method was sufficient for AMI diagnosis in a clinical setting.

Summary

A counterimmunoelectrophoresis technique for detection of serum myoglobin (Mb) was improved using non ionic polymer dextran. Precipitin lines were graded according to their strength which



Counter Immunoelectrophoresis

Fig 3 Myoglobin levels of precipitin lines divided into five classes according to line strength. Myoglobin levels were measured by radioimmunoassay. Mean \pm SD ng/ml of myoglobin of each class is written at the bottom. The phrase 'before stain' in the figure means the detected precipitin line before staining on the photograph.

was ascertained by radioimmunoassay data. By this method serum Mb in concentrations of 500 ng/ml before stain and of 200 ng/ml after stain were detected. Electrophoretic time was 60 minutes. Among 32 cases of acute myocardial infarction (AMI) whose blood samples were collected within 24 hours after disease onset precipitin lines were detected in 25 cases (78 per cent) before stain and 31 cases (97 per cent) after stain. Considering the early peak concentration time (approximately 10 hours) of serum Mb after AMI onset diagnosis becomes more rapid and exact with this method especially in severe cases.




Fig 1 Immunoprecipitation enhancement. Precipitin lines on the simple agarose plate (top) and on the agarose-dextran plate (bottom) of the same serum sample (left side)

the anode side. The CIE was performed at 3 mA / cm constant current for 60 minutes in an electrophoretic chamber filled with the same veronal buffer at room temperature. For easy detection of the precipitin line a photograph of the plate enlarged two and a half times was taken with an Mp 4 camera. Subsequently the plate was deproteinized and stained with Coomassie brilliant blue as usual. The Mb level of each serum sample was measured by radioimmunoassay able to detect 1 ng / ml of Mb.⁶

Results

Precipitin lines easily visible as sharp lines concave toward the antibody reservoir were graded according to line strength — no line ± questionable line 1+ not sharp but easily visible line 2+ sharp line 3+ sharp thick line. Fig 1 reveals the effect of 3 per cent (W/V) dextran and Fig 2 shows precipitin line examples. The mean \pm SD ng / ml of Mb levels measured by radioimmunoassay of each of the five above mentioned classes was 43 ± 37 , 118 ± 91 , 320 ± 159 , 1032 ± 933 and 2794 ± 2062 respectively. Class differences were statistically significant. Fig 3 presents these relationships.

The sensitivity of this improved serum Mb CIE was approximately 200 ng / ml. Before staining with Coomassie brilliant blue Mb above 500 ng / ml was detected on the photograph. Forty eight samples in all which revealed precipitin lines




Fig 2 Graded precipitin lines by improved counterimmunoelectrophoresis: top 1+ middle 2+ bottom 3+

stronger than 2+ also showed the lines before staining.

Among the 48 cases admitted to our coronary care unit 31 cases (65 per cent) revealed positive precipitin lines of Mb of more than 1+ strength. Among 32 cases whose blood samples were collected serially within 24 hours after AMI onset precipitin lines stronger than 1+ were detected in 31 (97 per cent). In enlarged photographs before staining 25 showed precipitin lines.

These 32 cases were divided clinically into two groups—severe and less severe—of 17 and 15 cases respectively. Among the 17 severe cases 14 showed precipitin lines before staining. Of three negative cases two were sampled within four hours of the onset and one had a recurrent myocardial infarction that was thought to be small using other laboratory data.

Discussion

The effect of specific antigen-antibody reaction enhancement by water soluble non ionic polymers such as dextran and carbowax has been known since 1968⁷ although the mechanism of this effect was not ascertained.⁸ However clinical

The importance of R on T phenomenon

Te Chuan Chou M D
Frank Wenzke M D
Cincinnati Ohio

Early premature ventricular beats interrupting the T wave have long been considered hazardous in patients with organic heart disease. They often lead to the development of ventricular tachycardia and fibrillation. In patients with acute myocardial infarction they are of particular concern and call for prompt institution of suppressive therapy. However, some recent data showed that the R on T phenomenon alone was not related to the development of ventricular tachycardia. The purpose of this study is to re-examine the role of early premature ventricular contractions in the genesis of ventricular tachycardia in a group of unselected patients.

Methods

Forty four consecutive patients in whom the onset of ventricular tachycardia was recorded were studied. They consisted of both hospitalized and clinic patients at the University of Cincinnati Medical Center Hospitals. The electrocardiograms were obtained by either the conventional electrocardiograph bedside monitor in the Cardiac Care Unit or Holter monitor. They were observed by the authors during a 3 year period but do not represent the total number of such patients in this institution during this period. Although a much larger number of patients with ventricular tachycardia was seen, they were not included in this study unless the onset of the tachycardia was demonstrated and their electrocardiograms met all of the following criteria:

- 1 The basic rhythm was sinus in origin
- 2 The paroxysm consisted of three or more abnormal and wide QRS complexes which were different in morphology from those of the sinus beats
- 3 The tachycardia had a rate greater than 110/minute
- 4 There was no premature P wave preceding the onset of the tachycardia
- 5 In addition one or more of the following findings should also be present during the paroxysm of tachycardia:
 - A Atrioventricular dissociation
 - B Fusion beat
 - C Capture beat or
 - D Isolated premature ventricular contraction in the same lead having the same QRS morphology as that of the tachycardia

Cases with supraventricular tachyarrhythmia such as atrial fibrillation, atrial flutter or paroxysmal atrial tachycardia as the basic rhythm were excluded because the possibility of aberrant ventricular conduction was more difficult to rule out in their presence.

The electrocardiographic analysis consisted of the determination of:

- 1 The coupling time or R-R interval which is the duration from the preceding R wave of sinus origin and the R wave of the premature ventricular contraction (R) initiating the tachycardia
 - 2 The Q-T interval of the normal sinus beats
 - 3 The prematurity index or $R-R/Q-T$ a prematurity index of less than 1.0 is considered to be the equivalent of the R on T phenomenon
 - 4 The rate of the ventricular tachycardia
- If more than one episode was recorded in the same patient, the episode with the shortest R-R interval was used, realizing that such a selection

From the Division of Cardiology, University of Cincinnati College of Medicine, Cincinnati, Ohio.

Supported in part by a grant from the Southwestern Ohio Chapter of the American Heart Association.

Received for publication July 28, 1977.

Accepted for publication Sept. 7, 1977.

Reprint requests: Dr. T. Chuan Chou, Division of Cardiology, 31 Bethesda Avenue, Cincinnati, Ohio 45229.

The authors wish to acknowledge the advice of Dr Susumu Sugai, Associate Professor, Kanazawa Medical College

REFERENCES

- 1 Kiss A and Reinhart W. Über den Nachweis des Myoglobins im Serum und im Harn nach Herzinfarkt. *Wien Klin Wochenschr* 68:154, 1956
- 2 Hibrav N and Blaker R G. Improved estimation of urinary myoglobin by counterimmunoelectrophoresis as compared with the double immunodiffusion technique. *Clin Chem* 21:765, 1975
- 3 Ceska M and Grossmüller F. Immuno precipitates in agar-dextran media. *Experientia* 24:391, 1968
- 4 Ceska M and Linden A M. The enhancement of immunoprecipitation using antisera from early stages of immunization. *Immunology* 20:123, 1971
- 5 Harrington J C, Fenton J W II and Pert J H. Polymer induced precipitation of antigen-antibody complexes. "Precipitin reactions." *Immunochem* 8:413, 1971
- 6 Miyoshi K, Kawai H, Yagita M, Kondo A, Iwasa M, Nagata J, Hiasa M, Harada T, Ohno F and Saito S. Myoglobin levels in serum and urine determined by radioimmunoassay in cases with myocardial infarction. The 41st annual meeting of the Japanese Circulation Society, April 1977, Kyoto, 1978. The Japanese Circulation Society
- 7 Hiramori K, Sumiyoshi T, Haze K, Motegi S, Ohi K, Koeda T, Honda T, Nakajima M, Takahashi S, Sekiguchi M, Kondo M, Kimata S, Hiroseawa K, Kawai H, Kondo A, Iwasa M and Miyoshi K. The kinetics of serum myoglobin in acute myocardial infarction patients and its clinical usefulness measured immunologically. The 41st annual meeting of the Japanese Circulation Society, April 1977, Kyoto, 1978. The Japanese Circulation Society

Monitor lead




Fig 1 Ventricular tachycardia initiated by a late premature ventricular contraction which interrupts the P wave of the following sinus beat. Retrograde capture of the atria is probably present beginning with the second complex of the tachycardia. In the top strip premature ventricular contractions with the R on T phenomenon are not associated with the development of ventricular tachycardia. (Isolated premature ventricular contractions having the same QRS T morphology as that during the tachycardia are also present but not shown)

sinus P wave. One of such cases is illustrated in Fig 1.

Twenty five of the patients also had isolated premature ventricular contractions with different coupling time. In 14 their R R/Q T ratio was smaller than the R R/Q T ratio of the ventricular ectopic beats initiating the ventricular tachycardia. In four the premature ventricular contractions interrupted the preceding T wave without the development of ventricular tachycardia while the ventricular tachycardia of these patients was initiated by a premature ventricular contraction appearing later in the cycle (Fig 1).

Discussion

In 1949 Smirk reported 17 patients with interruption of the T wave by a premature ventricular complex. Three of the patients died suddenly. Later he described a larger series of patients with various types of heart disease and the R on T phenomenon, which he regarded as a poor prognostic sign. Lown and associates subsequently emphasized the danger of early premature ventricular beats in patients with acute myocardial infarction. Examples were given to illustrate

the precipitation of ventricular tachycardia by early premature ventricular contractions in contrast with the absence of such event with late premature ventricular contractions. Dolara⁴ described three cases of ventricular tachycardia and fibrillation initiated by early premature ventricular contractions. Gutierrez and colleagues reported 26 episodes of ventricular tachycardia or ventricular fibrillation in 12 patients in whom the R on T phenomenon was demonstrated. In the experimental animals electrical stimuli applied to the ventricle during a period of the T wave (the vulnerable period) are effective in inducing rapid repetitive responses and ventricular fibrillation.⁵ This is particularly true in the presence of severe myocardial ischemia. It is now a general clinical practice to regard the R on T phenomenon as one of the indications for prompt initiation of suppressive therapy in patients with acute myocardial infarction.

Bleifer and associates⁶ studied the relationship of the R on T phenomenon to the development of ventricular tachycardia in ambulatory patients with ischemic heart disease using the Holter monitor. None of the 34 cases who had the

Table I Clinical diagnosis in the 44 patients with ventricular tachycardia

Diagnosis	No of patients
Coronary artery disease	20
Acute myocardial infarction	6
Cardiomyopathy	5
Hypertensive heart disease	5
Idiopathic ventricular tachycardia	3
Mitral valve prolapse	2
Rheumatic heart disease	1
Heart disease of uncertain etiology	8
Total	44

may increase the relative frequency of the R on T phenomenon in the group. In patients who had isolated premature ventricular contractions in the same tracing, their prematurity indices were also calculated.

The following clinical data of the patients were obtained: age, sex, clinical diagnosis, cardiac drug or drugs (including digitalis, quinidine, procainamide, lidocaine, propranolol) received at the time of ventricular tachycardia, presence or absence of electrolyte imbalance.

Results

Among the 44 patients with ventricular tachycardia, 23 were male and 21 were female. Their age ranged from 14 to 85 years with a mean age of 55 years. The types of associated heart disease are listed in Table I. Twenty of the patients had coronary artery disease with eight of them having acute myocardial infarction at the time of the electrocardiographic recording. Others had cardiomyopathy, hypertensive heart disease, mitral valve prolapse, rheumatic heart disease, heart disease of undetermined etiology, and idiopathic ventricular tachycardia. Seventeen patients were receiving no cardiac drug at the time of the paroxysmal ventricular tachycardia. Seventeen patients were taking digitalis, but in only one of them digitalis was considered the possible cause of the arrhythmia. Fifteen patients were receiving one or more of the other cardiac drugs with or without digitalis. There was no evidence of electrolyte imbalance in the entire group except the patient with possible digitalis intoxication had a serum potassium level of 3.1 mEq/L.

In addition to the criteria (paragraphs 1 to 4) described under *Methods* for the electrocardio-

Table II Distribution of the prematurity index (R R/Q T) of the premature ventricular contractions initiating ventricular tachycardia

Prematurity Index (R R/Q T)	No of patients
< 10	6
10-1.19	12
1.20-1.39	13
1.40-1.59	7
1.60-1.79	3
1.80-1.99	1
2.0-2.1	2
Total	41

graphic diagnosis of ventricular tachycardia. A V dissociation was present in 32 patients. One patient had ventricular capture beats and six patients had fusion beats. Another patient had both capture and fusion beats. All but one of these eight cases also had evidence of A V dissociation. Twenty-two patients had premature ventricular contractions with similar morphology in the same lead that recorded the ventricular tachycardia. In 10 of these patients evidence of A V dissociation was not demonstrated.

In one half of the 44 patients the paroxysm consisted of five or more ventricular complexes. In the entire group the ventricular rate varied between 115 to 300/minute with an average rate of 160/minute. The coupling time of the premature ventricular contractions initiating the tachycardia (R R interval) had a range between 0.20 to 0.80 sec. The prematurity index (R R/Q T) was between 0.6 and 2.1. Only six patients had an index less than 1.0 and, therefore, the R on T phenomenon. One of these patients had acute myocardial infarction, one had Prinzmetal angina. The other four patients had cardiomyopathy, mitral valve prolapse, organic heart disease of unknown etiology, and idiopathic ventricular tachycardia, respectively. Four cases had an index of 1.0. All of them had coronary artery disease with two having acute myocardial infarction. The distribution of the patients with different degrees of prematurity of the initiating premature ventricular contraction is depicted in Table II. It is apparent that relatively late premature ventricular contractions were responsible for the onset of ventricular tachycardia in the majority of instances. Indeed, in 16 cases, the ventricular tachycardia began after the onset of the next

Experimental and laboratory reports

Postextrasystolic aortic pressure pulse response in coronary artery disease

Robert I Hamby MD FACC

Agop Aintablian MD

Gerald Roberts MD

Robert J Kramer MD

New Hyde Park Jamaica and Stony Brook N Y

The greatest interest in aortic pressure-pulse contour change after extrasystolic beats has been in hypertrophic subaortic stenosis.¹ Here the postextrasystolic beat manifests a decrease in pulse pressure when compared to beats preceding the extrasystole. It had generally been our impression that the normal postextrasystolic response is accompanied not only by an increased pulse pressure but also by an increased systolic pressure as well. During a previous study of the effect of postextrasystolic potentiation in patients with coronary artery disease,² we observed that it was unusual that the postextrasystolic beat generated a systolic pressure higher than in preceding beats. Beck and associates³ in patients with varying types of heart disease observed a postextrasystolic increase in the left ventricular systolic pressure. Such responses were seen in left ventricular outflow obstruction, myocardial failure and in the volume overloaded left ventricle. Furthermore, Beck observed that the systolic pressure response after an extrasystolic beat was different in left and right ventricles in normals.³ In view of the observations of Beck and co-workers as well as our continued interest in postextrasystolic potentiation we evaluated the

postextrasystolic aortic pressure-pulse contour in a consecutive series of patients with coronary artery disease and related the response of the systolic pressure to left ventricular function.

Material and methods

One hundred consecutive patients referred for angina pectoris underwent a complete evaluation including a complete history and physical examination, standard 12 lead electrocardiogram, posterior-anterior and lateral chest x-ray films and a complete right and left heart catheterization including left ventricular angiogram and selective coronary arteriography. Excluded were all patients without demonstrable coronary artery disease or with valvular heart disease. The diagnosis of a prior myocardial infarction on the electrocardiogram was made on the basis of accepted criteria,⁴ while cardiomegaly on x-ray was diagnosed by a radiologist. Hemodynamic studies were performed by methods and criteria previously published.²

After completion of hemodynamic studies a pigtail catheter (Cordis F 8) was positioned in the ascending aorta for obtaining the pressure-pulse contours which were recorded simultaneously with an electrocardiogram. Aortic pressure was obtained with a balanced Statham strain gauge transducer (P2JDb) and recorded on an Electronics for Medicine recorder (Model DR 16) at a paper speed of 25 or 100 mm/sec with 100 or 40 msec time lines. The aortic pressure pulse was recorded while single ventricular extrasystoles were induced by a catheter in the right ventricle. The time between the R wave of the last

From the Department of Medicine Division of Cardiology, Long Island Jewish Medical Center, New Hyde Park, N.Y., Queens Hospital Center, Flushing, N.Y., and School of Medicine, Health Sciences Center, State University of New York at Stony Brook, Stony Brook, N.Y.

Received for publication July 11, 1977

Accepted for publication July 15, 1977

Reprint requests: Robert I. Hamby MD, Division of Cardiology, Long Island Jewish Medical Center, New Hyde Park, N.Y. 11040.

R on T phenomenon alone developed ventricular tachycardia. However, there was a substantial incidence of ventricular tachycardia when both the R on T phenomenon and pairing of the premature ventricular contractions occurred. In patients with acute myocardial infarction de Souza and co workers¹⁰ failed to find any significant difference between the mean coupling interval of the premature ventricular contractions initiating ventricular tachycardia and those that did not initiate tachycardia. More recently, Winkle and co workers¹¹ studied 23 ambulatory patients with various types of heart disease who had a total of 94 episodes of ventricular tachycardia. The R on T phenomenon was observed in only 15 per cent of the episodes.

Our data show that in only six of the 44 unselected patients the ventricular tachycardia was initiated by an early premature ventricular contraction. In a substantial number of patients (16) the ventricular tachycardia was precipitated by very late premature ventricular contractions appearing after the onset of the next sinus P wave. These findings were observed in both patients with acute myocardial infarction and patients with other types of heart disease. The results from this and the other studies raise considerable doubts as to the relative importance of the R on T phenomenon in the genesis of paroxysmal ventricular tachycardia.

Two proposed electrophysiological mechanisms are most commonly used to explain the production of premature ventricular contractions and ventricular tachycardia. One of them is the reentry theory. There is a local area of impaired excitability and conductivity in the ventricular myocardium which is depolarized by the impulse of the basic cardiac rhythm only after a considerable delay. When it is finally activated it generates a wave of excitation which finds some of its surrounding myocardium being now excitable resulting in a premature ectopic beat. A circus movement may be established causing repetitive tachycardia. It is believed that this mechanism is responsible for the appearance of early premature ventricular contractions as these premature ventricular contractions are related to the preceding complex and are initiated as soon as the tissue recovers from its excitability.¹² The second theory suggests that there is an enhanced automaticity of the His Purkinje fibers. This mechanism

is probably responsible for those premature ventricular contractions with relatively long coupling time, as time should be allowed for the Purkinje fibers to be repolarized before they begin their diastolic slow depolarization. Since most of our cases of ventricular tachycardia began with a late premature ventricular contraction it is possible that increased automaticity of the Purkinje fibers is a more important mechanism in the initiation although not necessarily perpetuation, of the ventricular tachyarrhythmia.

Summary

The onset of ventricular tachycardia was examined in 44 patients with various types of heart disease. In only six patients (14 per cent) the ventricular tachycardia was initiated by an ectopic ventricular complex interrupting the T wave. The findings suggest that the importance of R on T phenomenon may have been over emphasized.

The authors wish to thank Dr. Noble O. Fowler for reviewing the manuscript and his helpful suggestions.

REFERENCES

1. Smirk F H. R waves interrupting T waves. *Br Heart J* 11:23 1949.
2. Smirk F H and Palmer D G. A myocardial syndrome with particular reference to the occurrence of sudden death and of premature systoles interrupting antecedent T waves. *Am J Cardiol* 6:620 1960.
3. Lown B, Fakhro A M, Hood W R and Thorn G W. The coronary care unit. New perspectives and directions. *JAMA* 199:166 1967.
4. Bleifer S B, Karpman H L, Sheppard J J and Bleifer D J. Relation between premature ventricular complexes and development of ventricular tachycardia. *Am J Cardiol* 31:400 1973.
5. Dolara A. Early premature ventricular beats repetitive ventricular response and ventricular fibrillation. *Am Heart J* 74:352 1967.
6. Gutierrez M R, Changfoot G H and Perez D I. Significance of T wave interruption by premature beats as a cause of sudden death. *Can Med Assoc J* 98:144 1968.
7. Bleifer S B, Sheppard J J, Karpman H L and Bleifer D J. Relationship of the R on T phenomenon to the development of ventricular tachycardia. (*Abstr*) *Circulation* 43 and 44 (Suppl II):142 1971.
8. Han J and Goel H G. Electrophysiologic precursors of ventricular tachyarrhythmias. *Arch Intern Med* 129:749 1972.
9. de Souza N, Bassett J K, Kane J J, Murphy M L and Doherty J E. Ectopic ventricular premature beats and its relationship to ventricular tachycardia in acute myocardial infarction in man. *Circulation* 50:599 1974.
10. Winkle R A, Derrington D C and Schroeder J S. Characteristics of ventricular tachycardia in ambulatory patients. *Am J Cardiol* 39:497 1977.




Fig 3 Four series of extrasystolic beats (A,B,C,D) with progressive lengthening of the coupling interval (numbers below each figure) demonstrating a response typical for group I after the postextrasystolic beat with lengthening of the coupling interval.

Table 1 Clinical profile and angiographic findings

Groups	IA		IB		IIA		IIB	
	No	(%)	No	(%)	No	(%)	No	(%)
Number	45		40		12		3	
Age (yrs) (Mean \pm 1 SD)	54 \pm 8		54 \pm 6		57 \pm 11		53 \pm 3	
Sex (M/F)	37/8		31/9		11/1		3/0	
Duration of symptoms (Mean \pm 1 SD)	33 \pm 11		30 \pm 11		39 \pm 21		40 \pm 0.8	
Congestive heart failure	1	(2)	0	(0)	8	(67)	3	(100)
Cardiomegaly (by x ray)	1	(2)	2	(5)	6	(50)	3	(100)
Myocardial infarction (by ECG)	21	(47)	14	(35)	8	(67)	3	(100)
Coronary artery disease								
Number of vessels								
Single	9	(20)	12	(30)	1	(17)		
Double	16	(36)	10	(25)	0	(0)		
Triple	20	(44)	18	(45)	11	(83)	3	(100)
Abnormal left ventricular contractile pattern	30	(67)	25	(62)	12	(100)	3	(100)

assistance of a statistician utilizing a program mable calculator and either the chi square statistic or the unpaired Student t test

Results

The 100 coronary artery disease patients studied manifested four distinct patterns of aortic systolic pressure in the immediate postextrasystolic beat. Contractions preceding the extrasystolic beat were designed as control beats. Group IA consisted of 45 patients demonstrating a lower systolic pressure (<5 mm Hg) in the postextrasystolic beat as compared to control (Fig 1A arrow). After two to six beats the pressure returned to levels observed prior to the extrasystolic beat. Group IB consisted of 40 patients demonstrating a systolic pressure in the postextrasy-

stolic beat essentially equal (± 5 mm Hg) to control (Fig 1B arrow). Group IIA contained 12 patients who showed an increase in the systolic pressure (>5 mm Hg but almost invariably 10 or more) as compared to control (Fig 2A arrow) with return either immediately on the second beat to control levels or gradually over the next two to four beats. In four patients pressure generated in the second postextrasystolic beat was less than control but all subsequent beats were similar to control. The response in these four patients represented a transition to group IIB response where in all three patients the increase in postextrasystolic systolic pressure was followed by four to six beats demonstrating pulsations (Fig 2B). The coupling index observed in groups IA and IB were 0.32 ± 0.07 and 0.33 ± 0.07 .




Fig 1 A and B Aortic pressure-pulse response after an extrasystole in group IA (A) and group IB (B). The arrow points to the postextrasystolic beat. Note in A that the systolic pressure in the postextrasystolic beat is less than in beats preceding the extrasystole, while in B the postextrasystolic pressure is the same as that of the beats preceding the extrasystole.

conducted sinus beat and the extra systole (R_1 , Ex) was determined (coupling interval). The time between R_1 and the first sinus conducted R wave (R_2) after the extra systole was then determined (R_1 , R_2). The latter interval (R_1 , R_2) comprises the coupling interval and the compensatory pause. The coupling index was defined as R_1 , Ex/ R_1 , R_2 . A value close to 0.5 msec would represent an interpolated beat.

Left ventricular cineangiograms were then obtained in the right anterior oblique position by injecting 0.50 to 0.75 ml/Kg of 75 per cent sodium meglumine diatrizoate over a two second interval using a power injector (Viamonte Hobbs) via a pigtail catheter positioned in the left ventricle. A grid of known dimensions was positioned at the approximate location of the left ventricle and a short film strip was taken to permit correction of errors due to magnification. This was followed by selective coronary angiography performed in




Fig 2 A and B Aortic pressure-pulse response after an extrasystole in group IIA (A) and IIB (B). The arrow points to the postextrasystolic beat which in both cases has a higher systolic pressure as compared to beats preceding the extrasystole. Note furthermore in B that following the first postextrasystolic beat there is pulsus alternans.

multiple projections using the Judkins technique.

Left ventricular volumes were obtained using the area-length method³ and regression equation of Kasser and Kennedy⁴ by techniques previously described.² The left ventricular end diastolic volume index and ejection fraction determined in 20 patients with normal left ventricles using this method were 69 ± 19 ml/M² and 0.68 ± 0.10 respectively. An abnormal left ventricular contractile pattern was defined as localized absence (akinesis) or diminished (hypokinesis) wall movement or generalized hypokinesis.⁷

All data were analyzed statistically with the

All three patients in group IIB had a history of congestive heart failure as well as cardiomegaly, on x ray and electrocardiographic evidence of both anterior and inferior myocardial infarctions (Table I).

Selective coronary arteriography (Table I) revealed that 83 per cent of the patients in group IIA had triple vessel coronary artery disease as compared to 44 and 45 per cent in groups IA and IB respectively ($p < 0.01$). Left ventricular angiography revealed that all patients in group IIA had an abnormal left ventricular contractile pattern as compared to 67 and 62 per cent in groups IA and IB respectively ($p < 0.025$). Triple vessel disease and an abnormal left ventricular contractile pattern were present in all three patients in group IIB (Table I).

The mean left ventricular end diastolic pressure for groups IA and IB were 14 ± 6 and 12 ± 7 mm Hg respectively which for both groups was significantly ($p < 0.025$) less than the 19 ± 9 mm Hg observed in group IIA. The mean left ventricular end diastolic pressure for the three patients in group IIB was 31 mm Hg. The mean heart rates and mean aortic pressures at the time of study revealed no significant group differences. Although not specifically measured the postexercise systolic beat demonstrated a lower diastolic and a wider pulse pressure when compared to the control thus absolute group mean values for these parameters could not be evaluated. Comparing groups IA and IB with each other for cardiac output (Fig 4) stroke volume (Fig 5) end diastolic volume (Fig 6) and ejection fraction (Fig 7) showed no significant differences. However when comparing these two groups with the patients in group IIA significant differences were revealed. Two thirds of the patients in group IIA had an abnormal cardiac output (2.5 L/min/M^2) with a mean value of 2.2 ± 0.6 (L/min/M^2) as compared ($p < 0.01$) to 2.8 ± 0.5 and $2.9 \pm 0.5 \text{ L/min/M}^2$ in groups IA and IB respectively (Fig 4). Similarly the stroke volume was $30 \pm 10 \text{ ml/M}^2$ in group IIA which was significantly ($p < 0.005$) less than observed in groups IA and IB (Fig 5). The mean end diastolic volume (ml/M^2) observed in group IIA was 102 ± 28 as compared ($p < 0.001$) to 69 ± 11 observed in group IA and 65 ± 12 found in group IB (Fig 6). Finally all the patients in group IIA had an abnormal ejection fraction (< 0.5) the group mean being 0.30 ± 0.08 (Fig 7) which was




Fig 6 End-diastolic volume in the four groups of patients. Each point represents an individual patient with the horizontal bar being the mean for each group. N = number of patients.

significantly ($p < 0.001$) less than 0.57 ± 0.11 and 0.59 ± 0.11 observed in groups IA and IB respectively. All three patients in group IIB had abnormally low cardiac outputs (Fig 4) and ejection fractions (Fig 7) as well as abnormally high ($> 100 \text{ ml/M}^2$) end-diastolic volumes (Fig 6).

Discussion

The present study confirms the findings reported by Beck and associates¹ on patients with




Fig 4 Cardiac output in the four groups of patients. Each point represents an individual patient with the horizontal bar being the mean for each group N = number of patients

respectively, which was not significantly different to 0.36 ± 0.04 in group IIA. The mean coupling index in the three patients of group IIB was 0.34. In two patients in group IA and three patients in group IB, changing the coupling index with pace maker induced extrasystoles did not change the response i.e. they still had a group I response (Fig 3) whereas in one patient in Group IIA a coupling index greater than 0.4 produced variable responses. The response to two or three consecutive extrasystoles was variable in groups IA and




Fig 5 Stroke volume in the four groups of patients. Each point represents an individual patient with the horizontal bar being the mean for each group N = number of patients

IB whereas such beats did not alter the distinct postextrasystolic pressure response in groups IIA and IIB.

The ages of the patients studied and duration of their symptoms in each of the four groups described above showed no significant difference (Table I). A history of congestive heart failure was significantly ($p < 0.001$) more frequent in group IIA as compared to both groups IA and IB (Table I). Similarly, enlarged heart on x ray was more frequent ($p < 0.005$) in group IIA when compared to either group IA or IB (Table I). Eleven patients (83 per cent) in group IIA had electrocardiographic evidence of a prior myocardial infarction as compared to 21 (47 per cent) and 14 (35 per cent) in groups IA and IB respectively ($p < 0.01$). The location of the infarction by electrocardiogram was not different in the three groups of patients (IA, IB and IIA).

All three patients in group IIB had a history of congestive heart failure as well as cardiomegaly on x ray and electrocardiographic evidence of both anterior and inferior myocardial infarctions (Table I)

Selective coronary arteriography (Table I) revealed that 83 per cent of the patients in group IIA had triple vessel coronary artery disease as compared to 44 and 45 per cent in groups IA and IB respectively ($p < 0.01$). Left ventricular angiography revealed that all patients in group IIA had an abnormal left ventricular contractile pattern as compared to 67 and 100 per cent in groups IA and IB respectively ($p < 0.025$). Triple vessel disease and an abnormal left ventricular contractile pattern were present in all three patients in group IIB (Table I)

The mean left ventricular end diastolic pressure for groups IA and IB were 14 ± 6 and 12 ± 7 mm Hg respectively which for both groups was significantly ($p < 0.025$) less than the 19 ± 9 mm Hg observed in group IIA. The mean left ventricular end diastolic pressure for the three patients in group IIB was 31 mm Hg. The mean heart rates and mean aortic pressures at the time of study revealed no significant group differences. Although not specifically measured the postextrasystolic beat demonstrated a lower diastolic and a wider pulse pressure when compared to the control thus absolute group mean values for these parameters could not be evaluated. Comparing groups IA and IB with each other for cardiac output (Fig 4) stroke volume (Fig 5) end-diastolic volume (Fig 6) and ejection fraction (Fig 7) showed no significant differences. However when comparing these two groups with the patients in group IIA significant differences were revealed. Two thirds of the patients in group IIA had an abnormal cardiac output (2.5 L/min/M^2) with a mean value of $2.2 \pm 0.6 \text{ (L/min/M}^2)$ as compared ($p < 0.01$) to 2.8 ± 0.5 and $2.9 \pm 0.5 \text{ L/min/M}^2$ in groups IA and IB respectively (Fig 4). Similarly the stroke volume was $30 \pm 10 \text{ ml/M}^2$ in group IIA which was significantly ($p < 0.005$) less than observed in groups IA and IB (Fig 5). The mean end diastolic volume (ml/M^2) observed in group IIA was 102 ± 28 as compared ($p < 0.001$) to 69 ± 11 observed in group IA and 65 ± 12 found in group IB (Fig 6). Finally all the patients in group IIA had an abnormal ejection fraction (< 0.5) the group mean being 0.30 ± 0.08 (Fig 7) which was




Fig 6 End-diastolic volume in the four groups of patients. Each point represents an individual patient with the horizontal bar being the mean for each group N = number of patients

significantly ($p < 0.001$) less than 157 ± 0.11 and 159 ± 0.11 observed in groups IA and IB respectively. All three patients in group IIB had abnormally low cardiac outputs (Fig 4) and ejection fractions (Fig 7) as well as abnormally high ($> 100 \text{ ml/M}^2$) end diastolic volumes (Fig 6)

Discussion

The present study confirms the findings reported by Beck and associates¹ on patients with




Fig 7 Ejection fraction in the four groups of patients. Each point represents an individual patient with the horizontal bar being the mean for each group. N = number of patients.

various types of heart disease. The 'normal' response after an extrasystole (a decrease or no change in aortic systolic pressure) was noted in 85 per cent of our patients with coronary artery disease (groups IA and IB). This contrasts sharply (Fig 8) with the 15 patients in groups IIA and IIB. Here the postextrasystolic beat had a higher aortic systolic pressure than did beats preceding the extrasystole and these patients had a clinical picture characterized by a history of congestive heart failure, cardiomegaly and

evidence of prior transmural myocardial infarction (Table I). Angiographically, the majority of these patients had triple vessel coronary artery disease and all had abnormal left ventricular contractile patterns. The findings in these 15 patients contrast sharply with the 85 patients (Group IA and IB) who demonstrated a 'normal' response to an extrasystole. Only two had a history of congestive failure and only seven had radiologic evidence of cardiomegaly. Less than half had evidence of a transmural myocardial infarction. In these 85 patients angiography demonstrated that less than half had triple vessel disease and two thirds had an abnormal left ventricular contractile pattern.

The hemodynamic findings (Figs 4 to 7) clearly separated patients in groups IA and IB from those in group IIA and IIB and are probably the basis for the differences observed in the postextrasystolic beat. The patients in groups IIA and IIB were characterized by abnormally low cardiac outputs, stroke volumes and ejection fractions. In addition, 60 per cent had increased end diastolic volumes as well. This contrasts with the patients in groups IA and IB. Here the majority had normal cardiac outputs, stroke volumes and end diastolic volumes and ejection fractions.

The factors which determine aortic systolic pressure include stroke volume and aortic impedance. The interplay of these two factors probably determines as well the variable aortic systolic pressure response after an extrasystole, noted in the present study. It is well known that the postextrasystolic beat may demonstrate evidence of increased myocardial contractility. This response to an extra systole has been termed postextrasystolic potentiation. It has been observed that the magnitude of potentiation after an extrasystole is directly dependent on the coupling interval and subsequent lengthening of the compensatory pause. Our failure to demonstrate a change in the response of the postextrasystolic beat with alterations of the coupling index in five patients in group IA and IB suggests the postextrasystolic potentiation may not be playing a critical role in determining systolic pressure in the postextrasystolic beat. Katz¹⁰ in a review of postextrasystolic potentiation, presented several examples (Figs 9 and 16 in ref 9) of no increase in systolic pressure in the postextrasystolic beat and ascribed this to the absence of any potentiation. In the one patient tested in group IIA the coupling index was found to be a




Fig 8. Aortic pressure-pulse response after an extrasystole taken at a slow paper speed to demonstrate the four responses observed. Arrow (X) is the postextrasystolic beat whereas the small arrows are subsequent beats. IA and IB are similar to Fig 1 and IIA and IIB are similar to Fig 2.

factor in determining the increase in systolic pressure in the postextrasystolic beat suggesting that such a response may be partly dependent on postextrasystolic potentiation. It has previously been shown that potentiation is more readily demonstrated in the presence of myocardial dysfunction and not easily discernible in the non-failing heart.⁸ We previously observed that the increase in stroke volume of the postextrasystolic beat was significantly greater in patients with unpaired left ventricular function than in patients with normal left ventricular function. Therefore the patients in groups IIA and IIB all of whom had the greatest impairment in left ventricular function probably had a significantly greater increase in stroke volume in the postextrasystolic beat than did patients in groups IA and IB. Thus the changes in stroke volume present in the postextrasystolic beat may in part explain the distinct difference in the level of the systolic pressure attained after the extrasystole.

The interplay of aortic run off and aortic impedance may further contribute to the systolic pressure level attained in the postextrasystolic beat. During the compensatory pause after the extrasystole increased run off occurs as reflected by a progressive decrease in aortic diastolic pressure. As a result of this fall in aortic pressure the aortic wall stiffness will decrease, resulting in an overall decrease in aortic impedance. Thus the increase in stroke volume associated with postex-

trasystolic potentiation will normally be counterbalanced by a decrease in aortic impedance.

The difference in response noted in patients in group IA and IB may be explained on the degree of responsiveness of aortic impedance. Aortic arch and carotid baroreceptors also influence aortic impedance as a result of the decrease in aortic pressure during the compensatory pause.¹¹ Under such circumstances one would anticipate increased impedance. In the patients in group II the response of the vascular bed to the compensatory pause is probably different than in patients in group I. The decreased cardiac output and stroke volume in group II is probably associated with a higher peripheral vascular resistance than in group I patients in whom both the mean cardiac output and stroke volume were normal (Figs 4 and 5). Therefore the increased aortic impedance already present in the patients in group II and the reported increased stiffness of the vascular walls and lack of response to vasodilatory stimuli present in such patients¹² would tend to maintain a high level of aortic impedance during the compensatory pause. Under these conditions an increase in the stroke volume in the postextrasystolic beat could result in the observed increased systolic pressure in group II patients. Finally it has been observed that augmentation of contractility, as a result of postextrasystolic potentiation is enhanced in the presence of increased aortic impedance.⁸ This

enhanced contractility would further increase the stroke volume in the postextrasystolic beat of the patients in group II

The different responses (Fig 8) after an extra systole are best explained by the variations in each group of postextrasystolic potentiation and decreased aortic impedance. The differences in response between group I and group II patients clearly separate two distinct hemodynamic groups. It is thus evident that the distinctive characteristic of the aortic pressure-pulse after an extrasystole may be clinically useful in suggesting the presence of significant left ventricular dysfunction. Such an approach has been found useful in our non invasive section, and will be reported separately. Furthermore, with increasing use of arterial cannulation and right heart pressure monitoring during acute myocardial infarction the response to an induced extra systole may be useful in defining the need for inotropic or reduced afterloading measures.

Summary

The response of the aortic systolic pressure after an extrasystole was evaluated in 100 consecutive patients with coronary artery disease. The patients were divided into four groups depending on the response of the first postextrasystolic beat. Group IA (45 patients) had lower systolic pressure whereas group IB (40 patients) had a similar systolic pressure in the postextrasystolic beat as compared to beats preceding the extrasystole. Group IIA (12 patients) and group IIB (3 patients) demonstrated an increased systolic pressure in the first postextrasystolic beat with subsequent beats in group IIB also demonstrating pulsus alternans. Congestive heart failure and cardiomegaly were significantly more frequent in group II as compared to group I patients. In group IIA and IIB triple vessel disease was present in 83 and 100 per cent respectively as compared to 44 per cent in group I patients. Left ventricular end diastolic pressure (mm Hg) was 14 ± 6 and 12 ± 7 in group IA and IB respectively as compared to 19 ± 9 ($p < 0.025$) in group IIA and 31 in group IIB. Comparing groups IA and IB with each other for cardiac output, stroke volume and end diastolic volume and ejection fraction revealed no significant difference. The cardiac output ($L/min/M^2$) was 2.2 ± 0.6 for group IIA as compared ($p < 0.01$) to 2.8 ± 0.5 and 2.9 ± 0.5 in groups IA

and IB. Stroke volume (ml/M^2) and ejection fraction were 30 ± 10 and 0.30 ± 0.08 respectively, for group IIA, which is significantly less as compared to group I patients. The end diastolic volume (ml/M^2) in group IIA was 102 ± 28 which is significantly ($p < 0.001$) higher as compared to group IA and IB. All patients in group IIB had an abnormal cardiac output and diastolic volume and ejection fraction. Thus the differences in response between group I and group II patients to an extrasystole clearly define two distinct hemodynamic groups. The responses observed to an extrasystole are best explained by variable response of each group to postextrasystolic potentiation and aortic impedance.

The authors would like to thank Dr. Irwin Hoffman for his critical review of this manuscript and the assistance in preparing this manuscript given by Brenda Hamby.

REFERENCES

1. Brockenbrough E C, Braunwald E and Morrow A G. A hemodynamic technique for the detection of hypertrophic subaortic stenosis. *Circulation* 23:189 1961.
2. Hamby R I, Antablian A, Wusoff B G and Hartstein M L. Response of the left ventricle in coronary artery disease to postextrasystolic potentiation. *Circulation* 51:428 1975.
3. Beck W, Wheeler E and Schurr V. Postextrasystolic ventricular pressure responses. *Circulation* 44:523 1971.
4. Masnie E and Walsh T J. Clinical vectorcardiography and electrocardiography. Chicago: Year Book Medical Publishers Inc.
5. Sandler H and Dodge H T. The use of single plane angiocardiograms for the calculation of left ventricular volume in man. *Am Heart J* 75:325 1968.
6. Kasser I S and Kennedy J W. Measurement of left ventricular volume in man by single plane cineangiography. *Invest Radiol* 4:83 1969.
7. Herman M V, Heinle R A, Lein M D and Gerlin R. Localized disorders in myocardial contraction: Asynergy and its role in congestive heart failure. *N Engl J Med* 227:222 1967.
8. Hoffman B F, Bartelstone H J, Scherlag H J and Cranefield P F. Effects of postextrasystolic potentiation on normal and failing hearts. *Bull N Y Acad Med* 41:498 1965.
9. Katz L N. Effects of artificially induced paired and coupling beats. *Bull N Y Acad Med* 41:428 1965.
10. Leary B M and Taylor M G. Alterations with age in the viscoelastic properties of human arterial walls. *Cir Res* 18:278 1966.
11. Hainsworth H and Karm F. Inotropic responses of the left ventricle to changes in aortic arch pressure in anesthetized dogs. *J Physiol* 223:213 1972.
12. DeGeest H, Levy M N and Zieske H Jr. Carotid sinus baroreceptor reflex effects upon myocardial contractility. *Cir Res* 15:327 1964.
13. Zelis R, Mason D T and Braunwald E. A comparison of the effects of vasodilator stimuli on peripheral resistance vessels in normal subjects and in patients with congestive heart failure. *J Clin Invest* 47:960 1964.

Peripheral hemodynamics in anephric patients with hypertension

John K. Vyden MD
Alvin Sellers MD
Koichi Nagasawa MD
Teruo Takano MD
Marsha Groseth Robertson BA
H.J.C. Swan MD PhD
Los Angeles Calif

Anephric patients undergoing chronic hemodialysis therapy are anemic may have hypertension and are found to have a high cardiac index.^{1,2} Neff and colleagues have shown that the high cardiac index is not responsible for the hypertension since restoration of the cardiac index to normal by blood transfusion raises rather than lowers the arterial blood pressure. Since these workers showed that hypertension in this clinical setting is related to an inappropriate level of systemic vascular resistance relative to the cardiac output the present study of peripheral hemodynamics in anephric patients with hypertension was undertaken to see how they differ from normal.

Methods

Subjects Four patients of mean age 32 years (range 21 to 44 years) who were anemic and hypertensive were studied 6 to 12 months following bilateral nephrectomy. Blood samples were drawn for plasma renin determinations 1 to 2 weeks after bilateral nephrectomy and renin was absent from the mixed venous blood. They

were free from any significant complicating generalized systemic disease. All medications were withdrawn at least 7 days prior to the study. All four patients had arteriovenous shunts in position allowing vascular access for hemodialysis and were studied in the 24 hour period after dialysis when they were judged to be in optimal fluid and electrolyte balance. In the results described data collected in limbs with an A-V shunt were excluded since it was found that the presence of the shunt distorted vascular measurements made in that limb. None had clinically detectable edema or evidence of congestive heart failure at the time of study. The patients remained hypertensive despite the absence of edema and progressive ultrafiltration hemodialysis to attain dry weight.

Ten staff members of mean age 34 years (range 18 to 51 years) acted as controls. They had normal blood pressure and underwent the same peripheral vascular studies as the anephric, hypertensive patients described above.

I Systemic measurements In four anephric hypertensive patients cardiac output was determined under standard laboratory conditions by an indicator dilution technique using indocyanine green. Arterial blood pressure was measured with a Statham strain gauge transducer. Plasma renin activity was measured by the method of Boucher. Total blood volume, red blood cell mass, and plasma volume were determined following injection of labelled serum albumen.

II Peripheral vascular studies Peripheral vascular studies were performed with the patients

From the Department of Cardiology Cedars-Sinai Medical Center and the Department of Medicine University of California, Los Angeles, Calif.

This study was supported in part by Contract No. PH-43 68-1333, Myocardial Infarction Research Program, National Institutes of Health.

Received for publication: June 22, 1977

Accepted for publication: September 30, 1977

Reprint requests: Publication Office, Department of Cardiology, Cedars-Sinai Medical Center, 800 Beverly Blvd., Los Angeles, Calif 90048.

enhanced contractility would further increase the stroke volume in the postextrasystolic beat of the patients in group II

The different responses (Fig 8) after an extra systole are best explained by the variations in each group of postextrasystolic potentiation and decreased aortic impedance. The differences in response between group I and group II patients clearly separate two distinct hemodynamic groups. It is thus evident that the distinctive characteristic of the aortic pressure-pulse after an extrasystole may be clinically useful in suggesting the presence of significant left ventricular dysfunction. Such an approach has been found useful in our non-invasive section, and will be reported separately. Furthermore, with increasing use of arterial cannulation and right heart pressure monitoring during acute myocardial infarction, the response to an induced extrasystole may be useful in defining the need for inotropic or reduced afterloading measures.

Summary

The response of the aortic systolic pressure after an extrasystole was evaluated in 100 consecutive patients with coronary artery disease. The patients were divided into four groups depending on the response of the first postextrasystolic beat. Group IA (45 patients) had lower systolic pressure, whereas group IB (40 patients) had a similar systolic pressure in the postextrasystolic beat, as compared to beats preceding the extra systole. Group IIA (12 patients) and group IIB (3 patients), demonstrated an increased systolic pressure in the first postextrasystolic beat with subsequent beats in group IIB, also demonstrating pulsus alternans. Congestive heart failure and cardiomegaly were significantly more frequent in group II as compared to group I patients. In group IIA and IIB triple vessel disease was present in 83 and 100 per cent, respectively, as compared to 44 per cent in group I patients. Left ventricular end diastolic pressure (mm Hg) was 14 ± 6 and 12 ± 7 in group IA and IB respectively, as compared to 19 ± 9 ($p < 0.025$) in group IIA and 31 in group IIB. Comparing groups IA and IB with each other for cardiac output, stroke volume, end diastolic volume and ejection fraction, revealed no significant difference. The cardiac output ($L/min/M^2$) was 2.2 ± 0.6 for group IIA as compared ($p < 0.01$) to 2.8 ± 0.5 and 2.9 ± 0.5 in groups IA

and IB. Stroke volume (ml/M^2) and ejection fraction were 30 ± 10 and 0.30 ± 0.08 respectively, for group IIA, which is significantly less as compared to group I patients. The end diastolic volume (ml/M^2) in group IIA was 102 ± 9 , which is significantly ($p < 0.001$) higher as compared to group IA and IB. All patients in group IIB had an abnormal cardiac output, end diastolic volume and ejection fraction. Thus the differences in response between group I and group II patients to an extrasystole clearly define two distinct hemodynamic groups. The responses observed to an extrasystole are best explained by variable response of each group to postextrasystolic potentiation and aortic impedance.

The authors would like to thank Dr Irwin Hoffman for his critical review of this manuscript and the assistance in preparing this manuscript given by Brenda Hamby.

REFERENCES

1. Brockenbrough E C, Braunwald E and Morrow A G. A hemodynamic technique for the detection of hypertrophic subaortic stenosis. *Circulation* 23:189 1961.
2. Hamby R I, Aintablian A, Wsoff B III and Hartstein M L. Response of the left ventricle in coronary artery disease to postextrasystolic potentiation. *Circulation* 51:428 1975.
3. Beck W, Chesler E and Schnire V. Postextrasystolic ventricular pressure responses. *Circulation* 44:570, 1971.
4. Massey E and Walsh T J. Clinical vectorcardiography and electrocardiography. Chicago: Year Book Medical Publishers Inc.
5. Sandler H and Dodge H T. The use of single plane angiograms for the calculation of left ventricular volume in man. *AM HEART J* 75:325 1968.
6. Kasser I S and Kennedy J W. Measurement of left ventricular volume in man by single plane cineangiography. *Invest Radio* 4:83 1969.
7. Herman M V, Heinle R A, Lein M D and Gorlin R. Localized disorders in myocardial contraction: Asynergy and its role in congestive heart failure. *N Engl J Med* 227:222 1967.
8. Hoffman B F, Bartelstone H J, Scherlag H J and Cranefield P F. Effects of postextrasystolic potentiation on normal and failing hearts. *Bull N Y Acad Med* 41:498 1965.
9. Katz L N. Effects of artificially induced paired and coupling beats. *Bull N Y Acad Med* 41:428 1965.
10. Leary B M and Taylor M G. Alterations with age in the viscoelastic properties of human arterial walls. *Circ Res* 18:278 1966.
11. Hainsworth R and Karim F. Inotropic responses of the left ventricle to changes in aortic arch pressure in anesthetized dogs. *J Physiol* 223:213 1972.
12. DeGeest H, Levy M N and Zieske H Jr. Carotid sinus baroreceptor reflex effects upon myocardial contractility. *Circ Res* 15:327 1964.
13. Zelis R, Mason D T and Braunwald E. A comparison of the effects of vasodilator stimuli on peripheral resistance vessels in normal subjects and in patients with congestive heart failure. *J Clin Invest* 47:960 1968.

Table II Forearm hemodynamics in 4 patients with anephric hypertension and 10 normal subjects

Measurement	Anephric hypertension	Normal	P
Forearm blood flow (ml/100 c.c./min)	712 ± 165	366 ± 031	<0.05
Forearm vascular resistance (mm Hg/ml/100 c.c./min)	235 ± 16	284 ± 35	NS
Forearm venous capacitance	395 ± 013	397 ± 029	NS

Mean ± SEM

NS = not significant

largest digital pulsation amplitude measured was accepted as the reading. Skin temperatures of the digits were measured using 24 channel temperature measurements by tape application of a thermal probe.

Digital blood flows, pulsation amplitudes and skin temperatures were all recorded at rest and after the use of a standard vasodilator technique which consists of having the patient ingest 30 c.c. of 43 per cent ethanol. At the same time the patient was surrounded by an electric blanket to produce body heating and the limbs were subjected to 5 minutes of reactive hyperemia as described above. Readings were taken approximately 30 minutes after these interventions.

The difference in the data obtained from normal subjects and anephric patients with hypertension was evaluated statistically by the Student's *t* test.

Results

I Systemic hemodynamics In all four patients hypertension was present (Table I). Postoperatively in two patients there was no circulating renin activity while in two patients levels of 25 to 38 ng/100 ml/3 hours were found. When these determinations were repeated no circulating activity was detected. All four patients were anemic (hemoglobin—5.6 to 7.0 Gm/100 ml). In the three patients in whom cardiac index was measured the range varied from 4.11 to 5.32 L/min/M² while systemic vascular resistance varied from 1.015 to 1.510 units.

II Peripheral Hemodynamics

(1) Forearm blood flow vascular resistance and venous capacitance Mean forearm blood flow in patients with anephric hypertension was

Table III Oscillometric findings in 4 patients with anephric hypertension and 10 normal subjects

Measurement	Anephric hypertension	Normal	P
Above elbow (c.c.)	0.96 ± 0.07	0.45 ± 0.02	< 0.05
Wrist (c.c.)	0.26 ± 0.03	0.25 ± 0.01	NS
Finger (mm)			
Before vasodilation	1.00 ± 0.20	2.02 ± 0.34	< 0.05
After vasodilation	3.81 ± 0.68	4.57 ± 0.38	NS
Above knee (c.c.)	1.23 ± 0.08	0.84 ± 0.05	< 0.01
Below knee (c.c.)	1.18 ± 0.07	0.83 ± 0.08	< 0.01
Ankle (c.c.)	0.35 ± 0.03	0.37 ± 0.01	NS
Toe (mm)			
Before vasodilation	0.96 ± 0.11	1.00 ± 0.11	NS
After vasodilation	2.13 ± 0.36	4.77 ± 0.51	< 0.05

Mean ± SEM

NS = not significant

712 ml/100 c.c./minute which was significantly higher than that of 366 ml/100 c.c./minute found in normal control subjects (Table II). Mean forearm vascular resistance of 235 mm Hg/ml/100 c.c./minute found in anephric hypertensives was not significantly different from that of 284 mm Hg/ml/100 c.c./minute found in normal control subjects. Mean forearm venous capacitance was almost identical in both groups being 397 c.c./100 c.c. in normal subjects and 395 c.c./100 c.c. in the anephric hypertensive group.

(2) Oscillometry Mean pulsation amplitude of 0.96 c.c. above the elbow was significantly higher in patients with anephric hypertension than that of 0.45 c.c. in normal subjects (*p* < 0.05). Pulsation amplitudes at the wrist were identical in both groups (Table III). Mean finger pulsation amplitude before vasodilation was 1.00 mm³ in anephric patients and this was less (*p* < 0.05) than 2.02 mm³ found in normal subjects. After standard vasodilation finger pulsation amplitudes were similar in the two groups.

The pattern of findings of the upper limbs were nearly repeated in the lower limbs, in that the mean pulsation amplitudes above and below the knee were 1.23 c.c. and 1.18 c.c. respectively in anephric hypertension. This was significantly higher (*p* < 0.01) than the values of 0.84 and 0.83 c.c. found in normal subjects. Pulsation amplitudes when measured at the ankle were similar to both groups of patients (Table III). When oscillometry was performed on the toes no significant differences between the two groups were found before vasodilation. After vasodilation the pulsa-

Table 1 Characteristics of patients with anephric hypertension

Patient	Sex	Age	Reason for nephrectomy	Blood pressure (mm Hg)	Hemo globin (Gm / 100 ml)	Hema tocrit (Gm / 100 ml)	Cardiac index L./min / M ²	Systemic vascular resistance (units)	Pre operative renin (ug / 100 ml)	Post operative renin (ng / 100 ml / 3 hours)
S W	F	21	Transplantation	230/100	6.1	23	—	1 105	—	0.25
W H	M	22	Malignant hypertension	180/120	6.0	15	4.81	—	8 470	0
F A	M	35	Transplantation	170/100	5.6	13	4.11	1 510	—	0.38
E C	M	44	Transplantation	160/100	7.0	20	5.32	1 015	500	0

postcubital and supine in a quiet room at 68° F using a pneumatic plethysmograph. After resting for 20 minutes oscillometry was performed above the elbow at the wrist, the upper thigh, above and below the knee, and at the ankle. The greatest pulsation amplitude in a given area was compared to that produced by a 1 cc standard injection of air into the cuff. The accepted reading was the greatest pulsation amplitude in a given area upon 10 mm Hg decrements of arterial blood pressure determined by sphygmomanometer. Observations were not made in the limb in which the arteriovenous shunt was present since measurements made in such a limb were distorted by the presence of the shunt. Venous occlusion plethysmography was used for the measurement of limb blood flow and venous capacitance. The plethysmographic cuff was placed around the mid limb to measure limb blood flow, the second cuff connected to a cylinder of compressed air which was placed around the arm just above the elbow which allowed immediate pressure increase by sudden inflation of 30 mm Hg. Forearm blood flow was calculated from the change in mean circumference during venous occlusion expressed in ml/100 cc of tissue/minute. During the recording blood flow to the hand was occluded by the use of a third cuff inflated to supra systolic levels of pressure. Venous capacitance was determined by an equilibration method described by Mason and Braunwald.¹ During these measurements the forearm was elevated above the level of the heart. Repeated determinations of limb blood flow and venous capacitance were undertaken to insure a relatively steady state. When a steady state was considered to be present three successive measurements of limb flow and venous capacitance were undertaken averaged and utilized as the true measurement.

Vascular resistance was defined as the mean arterial blood pressure measured in the arm by the auscultatory method divided by the forearm blood flow. Mean arterial blood pressure was calculated by using the formula: mean arterial pressure = diastolic blood pressure + $\frac{1}{3}$ (systolic - diastolic blood pressure).

The reactive hyperemia response was determined in the forearm after release of 1 and 10 minutes of arterial occlusion. Following restoration of the circulation to the ischemic limb blood flow determinations were made at 5, 15, 30, 60 and 90 seconds after one minute of arterial occlusion. The test was then repeated occluding circulation to the limb for a period of 10 minutes and forearm blood flow was measured 5, 15, 30, 60, 90, 120, 180, 240 and 300 seconds after release.

Forearm active hyperemia was determined by having the patient open and close a hand grip of 30 pounds tension once a second for 30 seconds. Upon completion of this exercise circulation to the hand was once more occluded by supra systolic blood pressures and forearm blood flow was measured as described above. The results described in the above active and reactive hyperemia reactions are the average of two measurements.

Digital blood flow was measured in a similar fashion using a specially designed recording cuff sealed with plethysmographic sealing compound. The digits used were the index finger and the second toe. Venous occlusion was achieved by a 30 mm Hg cuff pressure applied at the wrist and ankle. Calibrations were performed by injecting 0.01 ml of air into the system. Vascular resistance was calculated as the ratio of mean arterial blood pressure to digital blood flow. Oscillometric evaluation of digital pulsations was performed with digital cups in positions described above. The

Table II Forearm hemodynamics in 4 patients with anephric hypertension and 10 normal subjects

Measurement	Anephric hypertension	Normal	P
Forearm blood flow (ml/100 cc/min)	712 ± 165	366 ± 0.31	<0.05
Forearm vascular resistance (mm Hg/ml/100 cc/min)	235 ± 16	284 ± 35	NS
Forearm venous capacitance	395 ± 0.13	397 ± 0.79	NS

Mean ± SEM

NS = not significant

largest digital pulsation amplitude measured was accepted as the reading. Skin temperatures of the digits were measured using 24 channel temperature measurements by tape application of a thermal probe.

Digital blood flows, pulsation amplitudes and skin temperatures were all recorded at rest and after the use of a standard vasodilator technique which consists of having the patient ingest 30 cc of 43 per cent ethanol. At the same time the patient was surrounded by an electric blanket to produce body heating and the limbs were subjected to 5 minutes of reactive hyperemia as described above. Readings were taken approximately 30 minutes after these interventions.

The difference in the data obtained from normal subjects and anephric patients with hypertension was evaluated statistically by the Student's *t* test.

Results

1. Systemic hemodynamics In all four patients hypertension was present (Table I). Postoperatively in two patients there was no circulating renin activity while in two patients levels of 25 to 38 ng/100 ml/3 hours were found. When these determinations were repeated no circulating activity was detected. All four patients were anemic (hemoglobin 5.6 to 7.0 Gm/100 ml). In the three patients in whom cardiac index was measured the range varied from 4.11 to 5.32 L/min/M, while systemic vascular resistance varied from 1.015 to 1.510 units.

2. Peripheral Hemodynamics

(1) Forearm blood flow, vascular resistance and venous capacitance Mean forearm blood flow in patients with anephric hypertension was

Table III Oscillometric findings in 4 patients with anephric hypertension and 10 normal subjects

Measurement	Anephric hypertension	Normal	P
Above elbow (cc)	0.96 ± 0.07	0.45 ± 0.02	< 0.05
Wrist (cc)	0.26 ± 0.03	0.26 ± 0.01	NS
Finger (mm ²)			
Before vasodilation	1.00 ± 0.20	2.02 ± 0.34	< 0.05
After vasodilation	3.81 ± 0.68	4.57 ± 0.38	NS
Above knee (cc)	1.23 ± 0.08	0.84 ± 0.05	< 0.01
Below knee (cc)	1.18 ± 0.07	0.83 ± 0.08	< 0.01
Ankle (cc)	0.35 ± 0.03	0.37 ± 0.01	NS
Toe (mm ²)			
Before vasodilation	0.96 ± 0.11	1.00 ± 0.11	NS
After vasodilation	2.13 ± 0.36	4.7 ± 0.51	< 0.05

Mean ± SEM

NS = not significant

712 ml/100 cc/minute which was significantly higher than that of 366 ml/100 cc/minute found in normal control subjects (Table II). Mean forearm vascular resistance of 235 mm Hg/ml/100 cc/minute found in anephric hypertensives was not significantly different from that of 284 mm Hg/ml/100 cc/minute found in normal control subjects. Mean forearm venous capacitance was almost identical in both groups being 397 cc/100 cc in normal subjects and 395 cc/100 cc in the anephric hypertensive group.

(2) Oscillometry Mean pulsation amplitude of 0.96 cc above the elbow was significantly higher in patients with anephric hypertension than that of 0.45 cc in normal subjects (*p* < 0.05). Pulsation amplitudes at the wrist were identical in both groups (Table III). Mean finger pulsation amplitude before vasodilation was 1.00 mm² in anephric patients and this was less (*p* < 0.05) than 2.02 mm² found in normal subjects. After standard vasodilation finger pulsation amplitudes were similar in the two groups.

The pattern of findings of the upper limbs were nearly repeated in the lower limbs in that the mean pulsation amplitudes above and below the knee were 1.23 cc and 1.18 cc respectively in anephric hypertension. This was significantly higher (*p* < 0.01) than the values of 0.84 and 0.83 cc found in normal subjects. Pulsation amplitudes when measured at the ankle were similar to both groups of patients (Table III). When oscillometry was performed on the toes no significant differences between the two groups were found before vasodilation. After vasodilation the pulsa-

Table IV Digital blood flow, vascular resistance, and temperature in 4 patients with anephric hypertension and 10 normal subjects

Measurement	Anephric hypertension	Normal	P
Finger blood flow (mm ³ /sec)			
Before vasodilation	213 ± 0.42	0.97 ± 0.91	NS
After vasodilation	271 ± 95	147 ± 19	NS
Toe blood flow (mm ³ /sec)			
Before vasodilation	0.89 ± 0.07	1.65 ± 0.05	<0.01
After vasodilation	6.12 ± 0.96	9.35 ± 0.91	<0.05
Finger resistance (mm Hg/mm ³ /sec)			
Before vasodilation	74 ± 22	22 ± 24	<0.05
After vasodilation	4.88 ± 1.50	5.85 ± 1.15	NS
Toe resistance (mm Hg/mm ³ /sec)			
Before vasodilation	150 ± 11	52 ± 37	<0.01
After vasodilation	24 ± 18	91 ± 24	<0.01
Finger temperature (°C)			
Before vasodilation	29.7 ± 0.7	29.7 ± 0.7	NS
After vasodilation	35.2 ± 0.5	35.9 ± 0.1	NS
Toe temperature (°C)			
Before vasodilation	25.9 ± 0.8	25.9 ± 0.8	NS
After vasodilation	31.7 ± 1.5	33.7 ± 0.4	NS

Mean ± SEM
NS = not significant

tion amplitude was 2.13 mm³ in patients with anephric hypertension and 4.77 mm³ in normal subjects ($p < 0.05$)

(3) *Digital blood flow* Mean finger blood flow in patients with anephric hypertension was not significantly different from that seen in normal subjects both before and after standard vasodilation (Table IV). Mean toe blood flow before vasodilation was 0.89 mm³/sec in anephric patients and 1.65 mm³/sec in normal subjects ($p < 0.01$). After vasodilation anephric patients had a mean toe blood flow of 6.12 mm³/sec which was still significantly lower than the figure of 9.35 mm³/sec ($p < 0.05$) observed in normal subjects.

Mean vascular resistance in the finger before vasodilation was 74 mm Hg/mm³/sec in anephric subjects, while in normal controls resistance was only 22 mm Hg/mm³/sec ($p < 0.05$) (see Table IV). However, standard vasodilation abolished the difference between these groups. Mean vascular resistance in the toe before vasodilation was significantly higher in anephric patients reaching a level of 150 mm Hg/mm³/sec while in normals the figure was 52 mm Hg/mm³/sec ($p < 0.05$). After vasodilation the anephric patient had a resistance of 24 mm Hg/mm³/sec

Table V Comparison of minute resistance level produced by hyperemic methods in 4 patients with anephric hypertension and 10 normal subjects

Measurement	Anephric hypertension	Normal	P
10 minute reactive hyperemia			
Minimal resistance (mm Hg/ml/100 ml/min)	2.28 ± 0.39	1.75 ± 0.13	NS
30 lbs/30 sec active hyperemia			
Minimal resistance (mm Hg/ml/100 ml/min)	3.25 ± 0.40	3.46 ± 0.58	NS
1 minute reactive hyperemia			
Minimal resistance (mm Hg/ml/100 ml/min)	3.36 ± 0.44	4.06 ± 0.38	NS

Mean ± SEM
NS = not significant

and in normal subjects resistance was 9.1 mm Hg/mm³/sec ($p < 0.01$)

Mean finger and toe temperatures both before and after vasodilation were not significantly different between the two groups (Table IV)

(4) *Reactive hyperemia* Five seconds after release of the cuff in the one minute reactive hyperemia reaction mean forearm blood flow was 41.5 ml/100 cc/minute in patients with anephric hypertension. This was significantly greater than the 20.4 ml/100 cc/minute recorded in normal control subjects ($p < 0.001$) (Fig. 1). This increase in forearm blood flow was maintained at the 15, 30, and 60 second post occlusion observation periods. After 90 seconds however there was no significant difference between the two groups. Five and 15 seconds after cuff release in the 10 minute reactive hyperemia reaction the forearm blood flow in anephric patients was 58 and 57 ml/100 cc/minute. However in the normal subjects the levels were 38.2 and 40.7 ml/100 cc/minute respectively ($p < 0.01$ and $p < 0.0025$). Thirty seconds after cuff release there was no significant difference between the two groups. The values in the two groups remained essentially the same at the 60, 90, 120, and 180 second periods of observation. After 180 seconds the difference between the two groups became significant, being 7.84 ml/100 cc/minute in the hypertensive patients and 8.08 ml/100 cc/minute in the normal patients ($p < 0.025$). Increase in forearm blood flow in the




Fig 1 Mean 10 minute hyperemia reaction in 10 normal subjects and five patients with anephric hypertension. Forearm blood flow at 5 and 15 seconds after cessation of circulatory arrest is greater in patients with anephric hypertension. The increase seen in 180 to 300 seconds may reflect the greater resting forearm blood flow seen in anephric hypertension.

anephric patients was maintained at both 240 and 300 second observation periods.

In the one minute reactive hyperemia reaction a significant and marked increase in flow occurred in the anephric patients when compared to the normal subjects. This increase in flow was seen at the 5, 15, 30, and 60 second periods of observation after cuff release (Fig 2).

(5) Thirty second/thirty pound active hyperemia reaction. Five and 15 seconds after cuff release in this reaction no significant differences were found between the hypertensive and control groups. However, at 30 seconds after cuff release the blood flow in normal subjects, which had reached its maximum 15 seconds, started to fall and reached a level of $18.4 \text{ ml}/100 \text{ cc}/\text{minute}$. Conversely, in the anephric patients the level of forearm blood flow continued to increase, reaching a level of $39 \text{ ml}/100 \text{ cc}/\text{minute}$, which was significantly greater than that seen in normals ($p < 0.001$). Sixty seconds after cuff release mean forearm blood flow started to fall in anephric patients and reached a level of $28 \text{ ml}/100 \text{ cc}/$

minute. This was still significantly greater than that of $15.2 \text{ ml}/100 \text{ cc}/\text{minute}$ in the normal controls ($p < 0.0025$). This increase in forearm blood flow was maintained at the 90, 120, and 180 second observation periods, and it was only at 240 seconds after cuff release that the difference between the two groups became insignificant (Fig 3).

Discussion

While essential hypertension is usually characterized by a normal cardiac output and increased systemic vascular resistance, patients with hypertension associated with end stage renal failure appear to have a high cardiac output and normal or only slightly increased systemic vascular resistance. This is similar to the hemodynamic pattern seen in young patients with labile essential hypertension.^{1,4,5} While bilateral nephrectomy has been found to be effective in many uremic patients with uncontrollable hypertension, this is not always the case as is seen in the four patients included in this study.^{1,4} Thus




Fig 2 The mean 1 minute reactive hyperemia reaction in 10 normal subjects and five patients with anephric hypertension. A marked increase in forearm blood flow is seen between 5 to 60 seconds after cessation of circulatory arrest.

nearly all patients with high renin have their hypertension lowered by nephrectomy, fewer patients with low or normal renin uremic hypertension will respond.

Anemia In contrast to young patients with essential hypertension, anephric patients with hypertension are invariably anemic and their hematocrits rarely exceed 25 per cent. Patients with severe anemia alone usually have an increased cardiac output at rest while their blood pressure is normal, unless other complicating diseases are present.¹² The systemic vascular resistance is correspondingly low. An important factor here is the decreased viscosity of blood for even if the caliber of the vessels (i.e. their geometric factors) were normal, the reduced viscosity would lead to lower resistance.¹² Patients with anephric hypertension reported in this study and elsewhere¹ have a systemic vascular resistance that falls within the normal range, but for the degree of anemia and cardiac output present it is far too high.^{12, 13}

While anemic patients with normal kidney and normal arterial blood pressure may be theoretically preferable as control subjects in such a

study as this a survey of hospital population showed that few such patients exist except where complicated by other multiple disease processes.

Anemia and forearm blood flow In 1909 Hewlett and Van Zwailuwenburett¹⁴ reported that in patients with anemia comparable to that seen in the present study, the anemia per se has no effect on the forearm blood flow. Verel and Duff¹⁵ also showed that when the level of hemoglobin exceeded 4 Gm/100 ml, the limb blood flow was within the normal range. It was only in subjects with hemoglobin values below 4 Gm/100 ml that the rate of blood flow was persistently increased. These observations suggest that in anemia patients the oxygen demands in the limb are met initially by greater extraction of oxygen and that flow rates only increase when little further oxygen extraction is possible.

When a plethysmograph is placed as high as possible in the forearm, Grant and Pearson¹⁶ observed that 85 per cent of the tissue enclosed is muscle and the remainder is bone and skin. Since the degree of anemia observed in the present study has little effect upon resting muscle blood flow, one can reason that the elevated resting




Fig 3 Mean 30 second/30 pound active hyperemia reaction in 10 normal subjects and five patients with anephric hypertension. The peak forearm blood flow is seen at 15 seconds in normal subjects that is delayed until 30 seconds in patients with anephric hypertension. Thirty to 180 seconds after the release of the circulatory arrest the cessation of work by the limbs forearm blood flow is greater in patients with anephric hypertension.

forearm blood flow was in fact due to the hypertension. This agrees with Abramson and Fierst⁷ who found a greater limb blood flow in patients with hypertension as compared with normal subjects. From these observations it would appear therefore that the vessels in skeletal muscle are less constricted than other vessels in the body so that at rest blood flow through the muscles is increased.⁷ The findings of normal resting limb vascular resistance agree with earlier findings of Stead and Kunkel.

Anemia and venous tone. While the needs of the organism are apparently served by maintaining right heart filling pressures through the mechanism of generalized increase in venous tone the compensatory response of the veins in patients with chronic anemia is usually not observed until the hemoglobin level is under 5 Gm/100 ml.⁸ The finding of normal venous tone in patients with anephric hypertension is in keeping with the finding in other patients with essential hypertension that the widespread arteriolar constriction is not associated with generalized constriction of veins.⁹

Pulsation amplitudes. On oscillometric ex-

amination one sees increased pulsation amplitudes in the areas above the elbow and above and below the knee. However more distally at the wrist and ankle there is no difference between the pulsation amplitudes seen in patients with anephric hypertension and normal controls. This increased proximal pulsation amplitude may be related to the degree of anemia present which often gives a clinical impression of a large pulsation amplitude which sometimes is said to be collapsing in character.¹⁰

Pulsation amplitudes observed in the digits are somewhat paradoxical. In the fingers of patients with anephric hypertension before vasodilation the mean pulsation amplitude was diminished (Table III) while after standard vasodilation pulsation amplitudes are similar to those seen in normal control subjects. However pulsation amplitudes are normal in the toe before vasodilation. After standard vasodilation one sees a diminished pulsation amplitude in the toe of patients with anephric hypertension. Why vasodilatory stimuli can overcome the vasospasm present in the fingers in patients with anephric hypertension but are unable to do so in the toes




Fig 2 The mean 1 minute reactive hyperemia reaction in 10 normal subjects and five patients with anephric hypertension. A marked increase in forearm blood flow is seen between 5 to 60 seconds after cessation of circulatory arrest.

nearly all patients with high renin have their hypertension lowered by nephrectomy; fewer patients with low or normal renin uremic hypertension will respond.

Anemia. In contrast to young patients with essential hypertension, anephric patients with hypertension are invariably anemic and their hematocrits rarely exceed 25 per cent. Patients with severe anemia alone usually have an increased cardiac output at rest while their blood pressure is normal, unless other complicating diseases are present.¹² The systemic vascular resistance is correspondingly low. An important factor here is the decreased viscosity of blood, for even if the caliber of the vessels (i.e., their geometric factors) were normal, the reduced viscosity would lead to lower resistance.¹ Patients with anephric hypertension reported in this study and elsewhere^{1, 2} have a systemic vascular resistance that falls within the normal range but for the degree of anemia and cardiac output present it is far too high.^{12, 13}

While anemic patients with normal kidney and normal arterial blood pressure may be theoretically preferable as control subjects in such a

study as this a survey of hospital population showed that few such patients exist except where complicated by other multiple disease processes.

Anemia and forearm blood flow. In 1909 Hewlett and Van Zwaluwenburet¹⁴ reported that in patients with anemia comparable to that seen in the present study the anemia per se has no effect on the forearm blood flow. Verel and Duff¹⁵ also showed that when the level of hemoglobin exceeded 4 Gm/100 ml the limb blood flow was within the normal range. It was only in subjects with hemoglobin values below 4 Gm/100 ml that the rate of blood flow was persistently increased. These observations suggest that in anemia patients the oxygen demands in the limb are met initially by greater extraction of oxygen and that flow rates only increase when little further oxygen extraction is possible.

When a plethysmograph is placed as high as possible in the forearm Grant and Pearson¹⁶ observed that 85 per cent of the tissue enclosed is muscle and the remainder is bone and skin. Since the degree of anemia observed in the present study has little effect upon resting muscle blood flow, one can reason that the elevated resting

whereas in the anephric hypertensive group forearm blood flow continues to increase creating a significant difference in the levels of flow. At 60 seconds after cuff release the mean forearm blood flow starts to fall in anephric hypertensive patients but the increase in forearm blood flow is maintained at 90, 120 and 180 seconds of observation. Since Stead and Kunkel¹⁰ and Abramson and Fierst¹¹ have obtained normal flows after reactive hyperemia in hypertension it would seem that one more possibly this as seen in patients with anephric hypertension may be influenced by the degree of anemia present which would tend to increase blood flow.

In addition there may be other factors present influencing the results obtained in these patients. The precise state of their sodium balance cannot be defined, and some degree of peripheral and autonomic neuropathy may be present. All of these factors in varying degree could participate in alterations in hemodynamic control.

Summary

Peripheral hemodynamics were examined in a group of four anephric patients with hypertension and the results were compared with a group of 10 normal subjects. Measurements of systemic hemodynamics in these anephric patients showed increased arterial blood pressure and a modest increase in cardiac index. Renin blood levels were negligible. Mean forearm blood flow was significantly higher in the anephric patients. This was probably a reflection of the increased arterial blood pressure since mean forearm vascular resistance was within normal limits. Mean forearm venous capacitance was also within normal limits.

Oscillometric examination showed markedly increased pulsation amplitudes proximally in the limbs of anephric patients while at the wrist elbow fingers and toes pulsation amplitudes were either normal or diminished.

Skin blood flow as reflected in both fingers and toes was significantly diminished in anephric patients while skin temperature was normal. While this may indicate normal capillary blood flow in anephric hypertension constriction at the precapillary network level as seen by the increased resistance occurring in the skin is present. Changes in the 1 and 10 minute reactive hyperemia and 30 pound/30 second active hyperemia reactions showed that in anephric patients a

greater time period of increased levels of flow was obtained in all three reactions.

These data suggest that the difference seen between anephric and normal subjects in their peripheral vasculature in part result from the hypertension, severe anemia and other factors which may be present.

REFERENCES

1. Neff M S, Kim K E, Persoff M, Onesti G, and Swartz C. Hemodynamics of uremic anemia. *Circulation* 43:676 1971.
2. Hampers C L, Zollinger J, Skillman J J, Gumpert T W, Bailer G L, and Merrill J P. Hemodynamic and body composition changes following bilateral nephrectomy in chronic renal failure. *Circulation* 40:367 1969.
3. Mason H T and Braunwald E. The effects of nitro glycerin and amyl nitrite on arteriolar and venous tone in the human forearm. *Circulation* 32:755 1965.
4. Sannerstedt R. Hemodynamics responses to exercise in patients with arterial hypertension. *Acta Med Scand* (Suppl.) 45:55 1966.
5. Lund-Johansen P. Hemodynamics in early essential hypertension. *Acta Med Scand* (Suppl.) 482.
6. Onesti G, Swartz C, Ramirez O, and Brest A N. Bilateral nephrectomy for control of hypertension in uremia. *Trans Am Soc Artif Intern Organs* 14:361 1968.
7. Dustan H P, and Page I H. Some factors in renal and renovascular hypertension. *J Lab Clin Med* 67:948 1964.
8. Vertes V, Cangiano J L, Berman L B, and Gould A. Hypertension in end-stage renal disease. *N Engl J Med* 280:978 1969.
9. Seto D, Fritz W, Nakamoto S, and Kolff W J. Effect of bilateral and of sodium and water content on hypertension. *Trans Am Soc Artif Intern Organs* 9:35 1963.
10. Nakamoto S, Poutasse E F, and Kolff W J. Cause of renal hypertension after bilateral nephrectomy and transplantation. *Ann N Y Acad Sci* 120:607 1964.
11. Kolff W J, Nakamoto S, Poutasse E F, Straton R A, and Figueroa J E. Effect of bilateral nephrectomy and kidney transplantation on hypertension in man. *Circulation* 29:1123 1964.
12. Burton A C. Physiology and biophysics of the circulation. In Year Book Medical Publishers Incorporated, Chicago 1972 p 93.
13. Vanter E F, Higgins C B, and Franklin D. Regional circulatory adjustments to moderate and severe chronic anemia in conscious dogs at rest and during exercise. *Circ Res* 30:731 1972.
14. Hewlett A W, and Van Zantenburek J G. The rate of blood flow in the arm. *Heart* 1:87 1969.
15. Verel D, and Duff R S. Circulatory adjustments of voluntary muscle in anemia. *J Appl Physiol* 14:225 1959.
16. Grant H T, and Pearson R S. The blood circulation in the human limbs. Observations on the differences between the proximal and distal parts and remarks on the regulation of body temperature. *Clin Sci* 3:119 1938.
17. Abramson D I, and Fierst S M. Resting blood flow and peripheral vascular responses in hypertensive patients. *AM HEART J* 23:84 1947.

requires further investigation. The tendency for hypertensive ulcers to form on the lower limb may, in part, be a reflection of the inability of the pulsation amplitudes in the lower limbs to respond to vasodilatory stimuli such as reactive hyperemia, heat, and alcohol ingestion.² Inasmuch as hypertensive ulcers are usually of an ischemic nature, it is assumed either that the organic changes in the arterioles or small arteries produce an area of relatively poor arterial blood supply in which minor injury can initiate an ulcer or that occlusion of the arterioles or small arteries cause an area of infarction of the skin which breaks down to form an ischemic ulcer.⁴

Digital blood flow. Skin blood flow can be quantitated by the measurements of blood flow in the digits. In patients with anephric hypertension one sees diminished skin blood flow before vasodilation in the toes, due, in part to markedly increased resistance in both sets of digits. These findings of increased skin resistance and normal or diminished muscle resistance agree with the results of Brod¹⁵ who found a similar state in the peripheral vasculature of patients suffering from essential hypertension. After standard vasodilation one sees diminished resistance in the fingers in patients with anephric hypertension (Table IV). However, by contrast, a state of diminished blood flow and elevated resistance continues in the toe, indicating a difference in reactivity between upper and lower digits of uncertain cause.

Skin blood flow is regulated through the vaso-motor nerves in the interest of body temperature regulation.¹⁶⁻¹⁷ The fact that under given environmental circumstances the blood flow through the skin is of the same order in normal subjects and in subjects with hypertension may mean no more than that the mechanism of the dissipation of heat from the body is the same in the two groups. Stead and Kunkel¹⁸ obtained similar blood flows through the hand at 43° C in normal subjects and in subjects with essential hypertension. By contrast, in acute nephritis, hand blood flow after releasing sympathetic tone was larger in the phase of hypertension, while in pheochromocytoma it was smaller.

Digital temperature. Since digital temperature is a reflection of capillary blood flow, the finding that both before and after vasodilation the skin temperature is essentially identical in both normal subjects and in patients with anephric

hypertension may indicate that capillary blood flow is within normal limits in anephric hypertension.² However, since digital blood flow is markedly reduced at rest, this tends to indicate excessive resistance at the pre capillary arteriolar level.

Reactive hyperemia. When the reactive hyperemia reactions are considered, the results are similar to that obtained in other types of hypertension. Pickering⁹ and Prinzmetal and Wilson¹⁰ have shown that with circulatory arrest lasting up to 10 minutes the rate of blood flow increased to the same extent in subjects with benign essential hypertension, malignant hypertension, and chronic nephritis with hypertension as in subjects with normal arterial blood pressure. This was confirmed by Conway,¹¹ who added patients with renal vascular disease and primary hyperaldosteronism. In the present study, 5 and 15 seconds after the release of the cuff in the 10 minute reactive hyperemia reaction blood flow in the anephric hypertensive patients was greatly increased above normal. This increase may reflect a need for greater blood flow because of anemia to repay the oxygen debt present in the limb. The increase seen in this reaction at 180 seconds to 300 seconds of observation is probably a reflection of the higher resting forearm blood flow in anephric patients (Fig. 1).

In the one minute hyperemia reaction an increase is seen in forearm blood flow at 5, 15, 30 and 60 seconds of observation which may once more represent repayment of the oxygen debt and the need for greater blood flow to achieve this. Conway¹¹ found that the average minimal resistance obtained during reactive hyperemia was greater in hypertensive patients than in normal subjects. However this was not seen in the present study (Table V) where resistances in both the 10 minute reactive hyperemia, 1 minute reactive hyperemia and 30 seconds reactive hyperemia responses are not significantly different from one another. This difference may once more reflect the influence of anemia but it is an area in which further study is indicated.

Active hyperemia. When both groups of individuals were subjected to the 30 pound/30 second active hyperemia reaction there was no significant difference early after cuff release (Fig. 3). However, at 30 seconds after cuff release the blood flow in the normal group which had reached the maximum at 15 seconds starts to fall

Effect of probucol in hyperlipidemic patients during two years of administration

William B Parsons Jr MD

Madison Wise

Probucol a new cholesterol reducing agent is a bis phenol with a chemical structure unlike presently recognized lipid lowering drugs (Fig 1) It lowers serum cholesterol in mice rats dogs and monkeys without significantly affecting triglycerides¹⁻⁴ The drug has shown no adverse effects in animals with one notable exception an apparent species specific sensitization to epinephrine induced ventricular fibrillation in dogs⁴

In most hypercholesterolemic humans probucol has reduced serum cholesterol without important side effects or toxicity⁵⁻⁷ Triglyceride levels have been unchanged⁸⁻⁹ widely variable¹⁰ or somewhat reduced¹¹

The mechanism of probucol's cholesterol lowering action remains undetermined It has no effect on incorporation of mevalonate into cholesterol Cyclic precursors of cholesterol (desmosterol and 7 dehydrocholesterol) do not accumulate in serum of animals or man¹² Studies on incorporation of acetate *in vivo* (rats mice) and *in vitro* (rat liver slices) gave inconclusive results One study which used larger than usual doses (2 g per day) in patients with familial hypercholesterolemia showed reduction of cholesterol synthesis increased fecal excretion of bile acids and reduced intestinal absorption of lipids¹³

In the present clinical study ambulatory outpatients with several types of hyperlipoproteinemia received probucol for two years without accompanying dietary alteration

From the Jackson Clinic and Fund in Madison Wise

Received for publication Aug 3, 1977

Accepted for publication Sept 19, 1977

Reprint requests: William B Parsons Jr MD 7331 E O'Brien Dr (Suite 205) Scottsdale, Ariz. 85251




Fig 1 Structural formula for 4,4'-[isopropylidenebis(2,6-di-tert-butylphenyl)] bis(2,6-di-tert-butylphenol) (DH 581)

Subjects and methods

The subjects of this study participating with informed consent were 31 men and 31 women ages 32 to 66 years (mean 55 years) whose serum cholesterol levels exceeded 255 mg/100 ml before treatment All were ambulatory outpatients from the author's private practice None had received lipid lowering drugs in the preceding 60 days The participants were instructed to eat their usual unrestricted diets but to avoid gaining weight

During a baseline period of placebo administration three blood samples were drawn at weekly intervals for lipid determinations Probucol was then administered orally in doses of 500 mg (two tablets) twice daily Subsequent cholesterol and triglyceride determinations were performed after two weeks four weeks and then at four week intervals always after an overnight fast

After one year of probucol administration 11 subjects were removed from the study and given other medication because their mean serum cholesterol levels had been reduced by less than 10 per cent from baseline values One other

- 18 Pickering G W *High blood pressure* New York 1968 Grune & Stratton Inc p 182
- 19 Stead E A Jr and Kunkel P Nature of peripheral resistance in arterial hypertension *J Clin Invest* 19 25 1940
- 20 Sharpey Schafer E P Venous tone Effects of reflex changes humoral agents and exercise *Br Med Bull* 19 145 1963
- 21 Wood J E *The veins—normal and abnormal function* Boston 1965 Little Brown & Company p 175
- 22 Evans W *Diseases of the heart and arteries*, Edinburgh and London 1964 E and S Livingston Ltd p 643
- 23 Allen E V Barker N W and Hines E A Jr *Peripheral vascular disease* Philadelphia 1966 W B Saunders Company
- 24 Fairbairn J R II Juergens J L and Spittell J S Jr *Peripheral vascular disease* Philadelphia 1972 W B Saunders Company p 381
- 25 Brod J Physiological comparison of labile and essential hypertension *Circ Res* 26 and 27 (Suppl 1) 11 63 1970
- 26 Lewis T and Pickering G W Vasodilation in the limbs in response to warming the body with evidence for sympathetic vasodilator nerve in man *Heart* 16 33 1931
- 27 Pickering G W The vasomotor regulation of heat loss from the human skin in relation to external temperature *Heart* 16 116 1932
- 28 Winsor T, and Hyman C *A primer of peripheral vascular diseases*, Philadelphia 1975 Lea & Febiger Publishers
- 29 Pickering G W The peripheral resistance in persistent arterial hypertension *Clin Sci* 2 209 1936
- 30 Prinzmetal M and Wilson C The nature of the peripheral resistance in arterial hypertension with special reference to vasomotor tone *J Clin Invest* 15 63 1936
- 31 Conway J A vascular abnormality in hypertension A study of blood flow in the forearm *Circulation* 27 590 1963

Copyright information

The appearance of a code at the bottom of the first page of an original article in this journal indicates the copyright owner's consent that copies of the article may be made for personal or internal use, or for the personal or internal use of specific clients. This consent is given on the condition, however, that the copier pay the stated per copy fee through the Copyright Clearance Center Inc P O Box 765 Schenectady N Y 12301 518 374 4430 for copying beyond that permitted by Sections 107 or 108 of the U S Copyright Law. This consent does not extend to other kinds of copying such as copying for general distribution for advertising or promotional purposes for creating new collective works or for resale.




Fig 2 Effect of probucol in 43 hyperlipidemic individuals during two years of administration. Code (mean serum cholesterol levels, mg/100 ml) A = 250 or less B = 251-350 C = 351-400 D = 401-450 E = 451-500 F = 501 or higher

or less in both years of treatment compared to six of 17 (35 per cent) of these individuals at base line

Triglyceride levels Mean serum triglyceride levels for HL types characterized by hyperglycemia (IIB IV V) were lower during probucol administration but reduction of these lipids in individuals was inconsistent and quite variable

Side effects Three patients complained of anal pruritus which did not prevent continuation of therapy One patient had mild diarrhea and another reported softer than usual stools without diarrhea both unproved while continuing medication Three patients had irritable bowel symptoms (gas bloating abdominal distress) which persisted in two of them despite substitution of placebo tablets

Toxicity No abnormalities attributed to probucol were noted in tests of hepatic renal or hemopoietic function No drug related effects occurred in associated diseases including coronary disease diabetes hypertension and gout

Comment

The patients in this study showed reduction in their elevated serum cholesterol levels notably in Types II and IIB III but in other types also without dietary restriction No serious side effects or toxicity occurred confirming other reports of few if any symptoms or adverse effects related to probucol None of the reported clinical trials have revealed any reactions in humans like the




Fig 3A Effect of probucol in 32 patients with Type II hyperlipoproteinemia (HLL) Code for mean serum cholesterol levels same as in Fig 2




Fig 3B and C Effect of probucol in 12 patients with Type IIB HL Code for mean serum cholesterol levels same as in Fig 2 (lower) Effect of probucol in five patients with Type IV HL Code for mean serum cholesterol levels same as in Fig 2

species specific sensitization to epinephrine induced ventricular fibrillation in dogs^{2,3} Polachek and associates⁴ unfortunately were not able to obtain appropriate studies to exclude paroxysmal arrhythmia during hospitalization in their patient who had experienced dizziness and palpitation after each of three 500 mg doses in the first few days of therapy They attributed this reac

Table I Changes in mean serum cholesterol levels (\pm S E) during first year of probucol therapy

HL type	No	Baseline average 3 values	Months of therapy												
			½	1	2	3	4	5	6	7	8	9	10	11	12
II	32	298 ± 7	245 ± 8	240 ± 7	240 ± 7	252 ± 8	237 ± 8	241 ± 7	236 ± 6	236 ± 6	235 ± 6	239 ± 6	244 ± 5	234 ± 6	231 ± 5
IIB	12	305 ± 11	262 ± 15	259 ± 13	246 ± 15	256 ± 15	260 ± 14	253 ± 17	254 ± 10	249 ± 12	247 ± 13	244 ± 9	247 ± 13	246 ± 13	257 ± 19
IV	5	265 ± 5	239 ± 20	225 ± 20	214 ± 19	222 ± 17	228 ± 14	226 ± 14	228 ± 17	220 ± 20	215 ± 11	240 ± 16	232 ± 19	228 ± 14	233 ± 15
V	1	409	378	340	384	346	290	280	392	328	266	254	384	304	237

Table II Changes in mean serum cholesterol levels (\pm S E) by six month periods

HL type	No	Baseline average 3 values	1 6 months	7 12 months	13 18 months	19 24 months
II	32	298 ± 7	242 ± 6	238 ± 5	244 ± 8	239 ± 7
IIB	12	305 ± 11	256 ± 12	247 ± 11	247 ± 15	248 ± 13
IV	5	265 ± 5	226 ± 16	228 ± 14	225 ± 15	230 ± 19
V	1	409	344	339	275	285

patient left the study after one year for personal reasons. Probucol therapy continued for a second year in the remaining 50 patients, whose results are the subject of this report.

Cholesterol was measured by the N 24 Auto Analyzer method in which isopropanol extraction precedes the automated determination.¹⁶ Triglycerides were determined by a modification of the Lofland method.¹⁷ After paper electrophoresis by the method of Lees and Hatch,¹⁸ patterns of hyperlipoproteinemia (HL) were categorized by the Fredrickson Lees Levy classification.¹⁹

Results

Cholesterol levels Probucol administration resulted in prompt and sustained reduction of mean serum cholesterol levels in patients with Type II HL (32 patients), Type IIB HL (12 patients), Type IV HL (five patients), and Type V HL (one patient) as shown in Tables I and II. In every group the mean reduction after two weeks approached but did not equal that at subsequent intervals. The first year's mean reductions were sustained through the second year of probucol therapy without evidence of escape (Table II).

In HL Types II and IIB the mean cholesterol

Table III Changes in mean serum triglycerides (\pm S E) by six month periods in HL Types IIB IV and V

HL type	No	Baseline average 3 values	1 6 months	7 12 months	13 18 months	19 24 months
IIB	12	223 ± 17	213 ± 23	198 ± 22	180 ± 21	191 ± 19
IV	5	427 ± 42	414 ± 78	477 ± 102	361 ± 72	409 ± 83
V	1	1227	1151	654	609	772

values for each six month period of treatment (Table II) were significantly lower than for the baseline period ($p < 0.1$). Differences between mean values at baseline and after two weeks were also significant in these groups ($p < 0.05$). Reductions in Types IV and V HL showed similar trends which in smaller numbers of participants failed to achieve statistical significance.

Fig 2 shows the distribution of average serum cholesterol levels in individuals at baseline (three values) and throughout each of two years of probucol therapy omitting the one patient with Type V HL. Thirty of 49 (61 per cent) in the first year and 31 of 49 (63 per cent) in the second year had mean cholesterol levels of 250 mg/100 ml or less. Only 6 per cent (three of 49) had mean levels higher than 300 mg/100 ml in each year of therapy compared to 31 per cent (15 of 49) at baseline.

Fig 3 depicts individual results in HL Types II IIB and IV. Probucol reduced the average cholesterol level in Type II HL to 250 mg/100 ml or less in 23 of 32 (63 per cent) in the second year. All five patients with type IV HL and 11 of 12 with Type IIB HL (94 per cent of these two groups combined) had average levels of 275 mg/100 ml

- 13 Brown H B and DeWolfe V G The additive effect of probucol on diet in hyperlipidemia *Clin Pharmacol Ther* 16 44 1974
- 14 Salel A F Zelis R Sodhi H S et al Probucol A new cholesterol lowering drug effective in patients with type II hyperlipoproteinemia *Clin Pharmacol Ther* 20 690 1974
- 15 LeLorier J Dubreuil Quidoz E Lussier-Cacan S et al Additive effects of a lipid lowering diet and probucol on plasma cholesterol concentrations in patients with familial type II hyperlipoproteinemia *Arch Int Med* 137 1479 1977
- 16 AutoAnalyzer method for determination of total cholesterol in serum Technicon Method N 21 Tarrytown N Y 1964 Technicon Instruments Corp
- 17 Lofland H II Jr Semiautomated procedure for the determination of triglycerides in serum *Anal Biochem* 9 393 1964
- 18 Lees R S and Hatch F T Sharper separation of lipoprotein species by paper electrophoresis in albumin containing buffer *J Lab Clin Med* 61 518 1963
- 19 Fredrickson D S Levy R I and Lees R S Fat transport in lipoproteins An integrated approach to mechanisms and disorders *N Engl J Med* 276 32-44 94 103 148-156 215-226 273-281 1967
- 20 Levy R I Drug therapy of hyperlipoproteinemia *JAMA* 235 2334 1976

tion which necessitated withdrawal of the drug, to hypersensitivity

The ultimate goal of lipid reduction is to lessen the incidence of atherosclerotic disease and its serious—often fatal complications. Conclusive evidence of such benefit is difficult to demonstrate even in long term clinical trials involving large numbers of participants. Like most of the established lipid lowering drugs, probucol has reduced experimental atheromas in animals. Also like older drugs in this category, its ability to prevent or retard atherosclerosis has not been established.

In the absence of definite guidelines from field trials, the decision to treat or not to treat hyperlipidemia will continue to depend on clinical judgment. Clinicians should welcome the availability of probucol, a new and distinctive cholesterol reducing agent with convenient twice daily oral dosage and virtual freedom from side effects or adverse reactions. The drug appears to be most effective in Type II and Type IIB HL but it can reduce cholesterol levels in other groups. Its inconsistent activity regarding triglyceride levels is not an important drawback, inasmuch as these lipids are most amenable to reduction by appropriate diet which is generally recommended as the first measure in a regimen for hyperlipidemia. Other investigators have demonstrated an additive effect on cholesterol levels by combining probucol therapy with dietary modification.¹⁻¹¹

Further studies are needed to delineate probucol's effect in familial Type II HL both as a single agent and in combination with diet and other drugs (cholestyramine, niacin) presently recommended for this syndrome with a high incidence of premature myocardial infarction and sudden death.¹² Because its mechanism of action is likely to differ from drugs currently used for this disorder, probucol may improve the success of combination therapy in familial Type II HL in which hypercholesterolemia is often resistant to treatment.

Summary

Probucol, a new cholesterol lowering agent was administered to ambulatory outpatients representing several classes of hyperlipoproteinemia (HL) for two years without dietary restriction. In 32 patients with Type II HL and 12 with Type IIB HL, statistically significant reduction in mean serum cholesterol levels occurred within

two weeks and persisted throughout two years of therapy at constant dosage (500 mg twice daily). In smaller numbers of patients with Type IV HL (five patients) and Type V HL, (one patient) similar trends in mean serum cholesterol were observed but failed to achieve statistical significance. Mean triglyceride levels were generally lower during probucol therapy but varied widely between individuals. The drug was well tolerated with no toxicity and few side effects (mild diarrhea, gas bloating, anal pruritus). Probucol should be a valuable addition to the therapeutic armamentarium for hypercholesterolemia.

James T. Lowe Ph.D. and Harold L. Taylor Ph.D. of The Dow Chemical Company Indianapolis, Indiana, generously furnished supplies of probucol for this study. Richard A. Stein Ph.D. (Armour Research Center, Scottsdale, Arizona) performed the statistical analyses. The author gratefully acknowledges these important contributions.

REFERENCES

1. Barnhart J W, Sefranka J A, and McIntosh D D. Hypocholesteremic effect of 44 (isopropylidenedithio)bis(2,6-di-*t*-butylphenol) (probucol). *Am J Clin Nutr* 23:1229, 1970.
2. Molello J A, Gerbig C G, and Robinson V B. Toxicity of 44 (isopropylidenedithio)bis(2,6-di-*t*-butylphenol) probucol in mice, rats, dogs, and monkeys. Demonstration of a species specific phenomenon. *Toxicol Appl Pharmacol* 24:590, 1973.
3. Marshall F N, and Lewis J E. Sensitization to epinephrine induced ventricular fibrillation produced by probucol in dogs. *Toxicol Appl Pharmacol* 24:594, 1973.
4. Kritchevsky D, Kum H K, and Tepper S A. Influence of 44 (isopropylidenedithio)bis(2,6-di-*t*-butylphenol) (DH 581) on experimental atherosclerosis in rabbits. *Proc Soc Exp Biol Med* 136:1216, 1971.
5. Kritchevsky D. Newer hypolipidemic agents. *Fed Proc* 30:835, 1971.
6. Duncan C H, and Best M M. The additive effects of clofibrate and probucol (DH 581) on rat serum cholesterol. *Atherosclerosis* 17:161, 1973.
7. Kalama Z, Daquisto M, and Kornett G S Jr. Biphenyl (probucol). A new hypocholesteremic agent. *Curr Ther Res* 13:692, 1971.
8. Danowski T S, Vester J W, Sunder J H, et al. Endocrine and metabolic indices during administration of a lipophilic bisphenol probucol. *Clin Pharmacol Ther* 12:929, 1971.
9. Miettinen T A. Mode of action of a new hypocholesteremic drug (DH 581) in familial hypercholesterolemia. *Atherosclerosis* 15:163, 1972.
10. Polacek A A, Katz H M, Sack J A, et al. Probucol in the long term treatment of hypercholesterolemia. *Curr Med Res Opin* 1:323, 1973.
11. Harris R S Jr, Gilmore H III, Bricker L A, et al. Long term oral administration of probucol [44 (isopropylidenedithio)bis(2,6-di-*t*-butylphenol)] (DH 581) in the management of hypercholesterolemia. *J Am Geriatr Soc* 22:167, 1974.
12. Nash D T. Probucol, a new cholesterol lowering drug. *J Med* 6:305, 1975.

- 13 Brown H B and DeWolfe V G The additive effect of probucol on diet in hyperlipidemia *Clin Pharmacol Ther* 16 44 1974
- 14 Salel A F, Zelis R Sodha H S et al Probucol A new cholesterol lowering drug effective in patients with type II hyperlipoproteinemia *Clin Pharmacol Ther* 20 690 1974
- 15 LeLone J Dubreuil Quidoz S Lussier Cacan S et al Additive effects of a lipid lowering diet and probucol on plasma cholesterol concentrations in patients with familial type II hyperlipoproteinemia *Arch Int Med* 137 1479 1977
- 16 AutoAnalyzer method for determination of total cholesterol in serum Technicon Method N 24 Tarrytown NY 1964 Technicon Instruments Corp
- 17 Lofland H B Jr Semiautomated procedure for the determination of triglycerides in serum *Anal Biochem* 9 393 1964
- 18 Lees R S and Hatch F T Sharper separation of lipoprotein species by paper electrophoresis in albumin containing buffer *J Lab Clin Med* 61 518 1963
- 19 Fredrickson D S Levy R I and Lees R S Fat transport in lipoproteins An integrated approach to mechanisms and disorders *N Engl J Med* 276 37 44 94 103 148-156 215-226 273-281 1967
- 20 Levy R I Drug therapy of hyperlipoproteinemia *JAMA* 235 2334 1976

Antihypertensive effect of cardiovascular Ca^{2+} -antagonist in hypertensive patients in the absence and presence of beta-adrenergic blockade

Kyuzo Aoki
Shuta Kondo
Akihiro Mochizuki
Tadashi Yoshida
Setsuko Kato
Kazuaki Kato
Kiyoharu Takikawa
Nagoya Japan

Altered cardiac and vascular smooth muscle functions are considered major contributing factors in the development of hypertension. Muscle functions are controlled, at least in part by the intracellular ionic environment, especially the distribution of Ca^{2+} in the cell. It is known that Ca^{2+} is regulated by cell membranes and sarcoplasmic reticulum. Recently it has been reported that in spontaneously hypertensive rats (Okamoto Aoki hypertensive strain SHR) the ability of the vascular smooth muscle membrane to retain Ca^{2+} and the ATP dependent Ca^{2+} uptake sarcoplasmic reticulum are reduced.^{1,2} Also, decreased vascular smooth muscle relaxation³ may lead to hypertension. These findings suggest that abnormalities of Ca^{2+} flux through cell membranes, Ca^{2+} uptake and release by sarcoplasmic reticulum in the cardiovascular muscle cells may play a role in the development and persistence of hypertension.

Calcium antagonists inhibit influx and release of calcium from sarcoplasmic reticulum. They antagonize the Ca^{2+} ion function responsible for

excitation and contraction in the electromechanical coupling, thus blocking contraction of myocardial and vascular fibers and inducing their relaxation. This has a negative inotropic effect on the myocardium and a vasodilatation result.^{4,5} These actions, reduction of myocardial contraction and vasodilatation can be expected to lower elevated blood pressure. Therefore Ca^{2+} antagonists are of interest in the management of hypertension.⁶

Nifedipine, a Ca^{2+} antagonist with distinct coronary vasodilating properties was studied in normotensive volunteers and in hypertensive patients as to its hypotensive action, its cardiovascular effects and its influence on plasma renin. Changes of heart rate and plasma renin activity induced by nifedipine and the effect of beta blockade (propranolol) were measured to examine the significance of a combined administration. Also the mechanism of action of nifedipine in the control of the vascular system is discussed in comparison with that of other Ca^{2+} antagonists such as verapamil.^{7,8}

Materials and method

Four normotensive healthy male volunteers (Table I) aged 34 to 45 years (38.5 ± 5.4 years) (mean \pm SD) and 24 hypertensive patients (10 hospitalized and 14 outpatients) participated in this study. The patients consisted of 16 males

From the Second Department of Medicine Nagoya City University School of Medicine Nagoya Japan

Received for publication Aug 19 1977

Accepted for publication Nov 21 1977

Reprint requests Kyuzo Aoki Second Department of Medicine Nagoya City University School of Medicine Mizuho-ku Nagoya Japan 467

0002-8703/78/0296-0218\$00.90/0 © 1978 The C

Table I Effects of Ca^{2+} antagonist (nifedipine) and beta blockade (propranolol) on blood pressure heart rate and PRA* in normotensive group

Treatment	Case No.	Nifedipine 10 mg						Nifedipine 30 mg						Nifedipine 30 mg and Propranolol 0.2 mg/Kg body wt					
		Blood pressure (mm Hg)		Heart rate (beats/min)		PRA (ng/ml/h)		Blood pressure (mm Hg)		Heart rate (beats/min)		PRA (ng/ml/h)		Blood pressure (mm Hg)		Heart rate (beats/min)		PRA (ng/ml/h)	
		B	1 hour	B	1 hour	B	1 hour	B	1 hour	B	1 hour	B	1 hour	B	1 hour	B	1 hour	B	1 hour
	1	S 114	112	64	70	0.8	1.3	130	110	54	66	0.6	1.4	110	100	68	64	0.4	0.3
		D 72	68					80	70					64	60				
	2	S 176	178	64	66	3.1	3.8	114	106	62	78	3.5	12.2	120	108	62	78	3.7	2.1
		D 80	79					60	64					76	68				
	3	S 116	120	68	68	0.9	1.5	100	97	64	62	0.9	2.4	114	98	70	58	4.4	4.3
		D 80	82					64	60					72	68				
	4	S 120	170	70	72	0	1.3	110	110	68	64	0.4	0.4	130	110	66	66	0.4	0.3
		D 80	76					70	70					80	70				
	SV	119.0	170.0	66.5	69.5	1.25	1.98	113.5	104.5	67.0	67.5	1.35	4.10	118.5	104.0	66.5	66.5	2.23	1.73
	±SD	5.2	6.5	3.0	3.0	1.2	1.7	17.5	8.5	5.9	7.2	1.45	5.46	8.7	5.9	3.4	8.4	2.13	1.86
	p value	> 0.1	ns	> 0.1	ns	< 0.001	*	> 0.1	ns	> 0.1	ns	> 0.1	ns	< 0.01	*	> 0.1	ns	> 0.1	ns
	DM	78.0	74.5					68.5	66.0					73.0	66.5				
	±SD	4.0	6.0					8.7	4.9					6.8	4.4				
	p value	> 0.1	ns					> 0.1	ns					< 0.05	*				
Average of paired % change of control value																			
	SV	101		101		9.6		93		110		93		88		101		76	
	±SD	2		5		25.0		6		17		10.4		3		18		16	
	DM	96						97						91					
	±SD	3						8						4					

Abbreviations: PRA = plasma renin activity; B = before treatment; 1 hour = 1 hour after treatment; S = systolic blood pressure; D = diastolic blood pressure; M = mean; 1u = standard deviation of the mean; * = statistically significant; ns = not statistically significant.

† Case 1 = 41 years, male; Case 2 = 34 years, male; Case 3 = 34 years, male; Case 4 = 45 years, male.

and eight females mean age 45.9 ± 9.3 years (from 29 to 63 years). The average blood pressure was 119.0 ± 5.3 mm Hg (from 114 to 126 mm Hg) systolic and 78.0 ± 4.0 mm Hg (from 72 to 80 mm Hg) diastolic in the normotensive and 176.3 ± 23.8 mm Hg (from 150 to 240 mm Hg) systolic and 109.5 ± 15.1 mm Hg (from 90 to 150 mm Hg) diastolic in the hypertensive group. Systolic blood pressure of 150 mm Hg or higher and diastolic blood pressure of 90 mm Hg or higher on at least three separate measurements in the hospital (Nagoya City University Second Department of Medicine) were criteria for admission to the trial.

Blood pressure was measured on four different occasions at rest in the supine position. Arterial blood pressure was measured by auscultation. Heart rate was measured at the cardiac apex pulse rate or from a simultaneously recorded

electrocardiogram. The results are values averaging four readings.

Ten hypertensive patients (Table II) were hospitalized at Nagoya City University Hospital. They were selected from the total of 24 cases according to clinical history, physical status, measurements of routine urinalysis, hematocrit, white blood cell, red blood cell, serum glucose, sodium, potassium, chloride, bicarbonate, calcium, cholesterol, protein, creatinine, clearance, regitane test and rapid sequence intravenous pyelogram. Their clinical diagnosis and findings are summarized in Table II. They consisted of seven essential and three secondary hypertensive subjects (one female and 9 males) mean age 44.9 ± 10.7 years (from 29 to 63 years). Blood urea nitrogen 16.7 ± 6.7 mg/dl (7 to 27 mg/dl); SV, + RV, in electrocardiogram 4.87 ± 2.17 mV (2.1 to 9.4 mV); cardiothoracic ratio in chest

Antihypertensive effect of cardiovascular Ca^{2+} -antagonist in hypertensive patients in the absence and presence of beta-adrenergic blockade

Kyuzo Aoki
Shuta Kondo
Akihiro Mochizuki
Tadashi Yoshida
Setsuko Kato
Kazuaki Kato
Kiyoharu Takikawa
Nagoya Japan

Altered cardiac and vascular smooth muscle functions are considered major contributing factors in the development of hypertension. Muscle functions are controlled, at least in part by the intracellular ionic environment especially the distribution of Ca^{2+} in the cell. It is known that Ca^{2+} is regulated by cell membranes and sarcoplasmic reticulum. Recently it has been reported that in spontaneously hypertensive rats (Okamoto Aoki hypertensive strain SHR) the ability of the vascular smooth muscle membrane to retain Ca^{2+} and the ATP dependent Ca^{2+} uptake sarcoplasmic reticulum are reduced^{1,2}. Also, decreased vascular smooth muscle relaxation³ may lead to hypertension. These findings suggest that abnormalities of Ca^{2+} flux through cell membranes, Ca^{2+} uptake and release by sarcoplasmic reticulum in the cardiovascular muscle cells may play a role in the development and persistence of hypertension.

Calcium antagonists inhibit influx and release of calcium from sarcoplasmic reticulum. They antagonize the Ca^{2+} ion function responsible for

excitation and contraction in the electromechanical coupling, thus blocking contraction of myocardial and vascular fibers and inducing their relaxation. This has a negative inotropic effect on the myocardium and a vasodilatation result^{4,5}. These actions reduction of myocardial contraction and vasodilatation can be expected to lower elevated blood pressure. Therefore, Ca^{2+} antagonists are of interest in the management of hypertension¹.

Nifedipine a Ca^{2+} antagonist with distinct coronary vasodilating properties, was studied in normotensive volunteers and in hypertensive patients as to its hypotensive action its cardiovascular effects and its influence on plasma renin. Changes of heart rate and plasma renin activity induced by nifedipine and the effect of beta blockade (propranolol) were measured to examine the significance of a combined administration. Also, the mechanism of action of nifedipine in the control of the vascular system is discussed in comparison with that of other Ca^{2+} antagonists such as verapamil^{6,7}.

Materials and method

Four normotensive healthy male volunteers (Table I) aged 34 to 45 years (38.5 ± 5.4 years) (mean \pm SD) and 24 hypertensive patients (10 hospitalized and 14 outpatients) participated in this study. The patients consisted of 16 males

From the Second Department of Medicine Nagoya City University School of Medicine Nagoya Japan

Received for publication Aug 19 1977

Accepted for publication Nov 21 1977

Reprint requests Kyuzo Aoki Second Department of Medicine Nagoya City University School of Medicine Mizuho-ku Nagoya Japan 467

0002-8703/78/0296-0218\$09.00/0 © 1978 The C




Fig 1 Changes of blood pressure with 10 and 30 mg of nifedipine (Ca^{2+} antagonist) and combined administration of 30 mg of nifedipine and propranolol (β blockade) in normotensive volunteers. Values are mean \pm standard deviation.

pressure decreased significantly after 10 mg of nifedipine from 172.9 ± 17.1 to 130.3 ± 15.7 mm Hg ($p < 0.001$) in systolic and from 112.9 ± 13.8 to 86.6 ± 14.6 mm Hg ($p < 0.01$) in diastolic pressure (25 per cent and 23 per cent reduction respectively) ($n = 7$). After administration of 30 mg nifedipine blood pressure decreased somewhat more, namely from 166.9 ± 17.6 to 122.0 ± 13.8 mm Hg ($p < 0.001$) or 27 per cent and 28 per cent reduction ($n = 9$). Combined administration of nifedipine and propranolol produced a 32 per cent decrease in systolic and a 30 per cent decrease in diastolic values one hour after medication ($n = 8$) (Table III and Fig 2).

Heart rate increase by nifedipine and its inhibition by propranolol. Ten mg nifedipine slightly increased heart rates of normotensive patients from 66 ± 6 to 68 ± 6 beats/minute and with 30 mg it changed from 62.0 to 67.5 beats/minute one hour after medication. Combined administration of nifedipine and propranolol induced no significant changes (Table I, Fig 3). In hospitalized hypertensive patients it increased significantly with 10 mg and 30 mg of nifedipine from 66.3 to 80.3 beats/minute ($p < 0.001$) ($n = 7$) and 70.0 to 82.2 beats/minute ($p < 0.01$) ($n = 9$) respectively (Table III, Fig 3). Combined administration of nifedipine and propranolol decreased the heart rate from 67.5 to 65.5 beats/minute ($n = 8$) one hour after administration. Therefore propranolol seems to inhibit a nifedipine induced increase in heart rate associated with a decrease in blood pressure.

Effect of nifedipine on blood pressure and heart rate. After administration of either nifedipine alone or with propranolol normotensive




Fig 2 Hypotensive effect of 10 mg and 30 mg of nifedipine (Ca^{2+} antagonist) and combined administration of 30 mg of nifedipine and propranolol (β blockade) in hypertensive patients. Values are mean \pm standard deviation.

patients showed slight changes in both systolic and diastolic pressure within 5 minutes. Decrease continued reaching the lowest levels after 60 minutes (Fig 1).

Fall of both systolic and diastolic pressure starts within 5 minutes in hypertensive patients, decreases for one to two hours, reaching relatively rapidly almost normotensive levels. Then blood pressure increases gradually and reaches near pretreatment values within six to ten hours (Fig 2).

In normotensive patients heart rate increases rapidly to reach the highest rate within 30 minutes and returns to the initial rate after two hours. In contrast the heart rate increases rapidly to reach the highest within 30 minutes and gradually decreases, however it remains slightly elevated for ten hours in hypertensive patients (Fig 3).

Hypotensive effect and heart rate increase. In 24 hypertensive patients (total of hospitalized and outpatients) nifedipine (30 mg) lowered both the systolic and diastolic blood pressures significantly and increased the heart rate as shown in Table IV. The differences in both blood pressure and heart rate are statistically significant.

Plasma renin activity increase by nifedipine and its inhibition by propranolol. Plasma renin activity in normotensive subjects increased from 1.3 to 2.0 ng/mg/hour ($p < 0.02$), 276 per cent after 10 mg nifedipine and from 1.4 to 4.1 ng/mg/hour ($p > 0.1$), 237 per cent after 30 mg of nifedipine. On the contrary it decreased from 2.2 to 1.7 ng/ml/hour ($p > 0.1$) after the combined administration of nifedipine and pro-

Table II Hospitalized hypertensive patients

Case No	Initial	Age (years)	Sex	Clinical diagnosis	Urinalysis protein sugar	Blood urea nitrogen (mg/dl)	ECG findings			CTR (%)	Ocular fundus Scheie
							SV ₁ + RV ₅ (mV)	ST depression (mV)	T		
1	R R	63	M	Ht essential	(-) (-)	14	25	< 0.1	Flat	52	H S
2	I K	56	M	Ht essential	(-) (-)	14	52	> 0.1	Flat	50	H S
3	M I	38	M	Ht essential	(-) (-)	17	53	Normal	Normal	51	H S
4	T O	43	M	Ht essential	(-) (-)	27	94	LV strain pattern		61	H S
5	T I	47	M	Ht essential	(-) (-)	12	45	< 0.1	Normal	44	H S
6	H N	54	M	Ht essential	(-) (-)	12	72	Normal	Flat	68	
7	K N	36	F	Ht essential	(-) (-)	14	21	Normal	Normal	50	H S
8	T K	35	M	Ht ch nephritis	(+) (-)	26	50	> 0.1	Flat	50	H S
9	Y N	29	M	Ht renal arterial stenosis	(-) (-)	7	40	Normal	Normal	49	H S
10	S K	48	M	Ht diabetes mellitus	(-) (+ +)	24	36	< 0.1	Inverted	50	H S
Mean \pm SD		44.9 \pm 10.7				16.7 \pm 6.7	4.9 \pm 2.2			53.1 \pm 7.9	

Abbreviations Ht = hypertension M = male F = female ch = chronic

x ray 53.1 \pm 7.9 per cent (44 to 68 per cent) ocular fundus in Scheie H₁ to H₄ (Table II)

All medications were discontinued at least two weeks prior to admission to the study. In four normotensive volunteers (Table I) and in ten hospitalized hypertensive patients (Table II) blood pressure, heart rate and plasma renin activity were determined as follows: (1) they received sublingually 10 mg of nifedipine (Adalat, Bayer), (2) after one week of administration the dose was increased to 30 mg nifedipine sublingually (3) after one more week a combination of nifedipine and propranolol 30 mg and 0.2 mg/Kg body weight was administered. The drugs were given after at least 30 minutes bed rest when the steady state had been established. Blood pressure and heart rate were measured before and after administration at 10 minute intervals during the first hour and 30 or 60 minute intervals for the subsequent 10 hours. However, for normotensive subjects checks were stopped four hours after administration of the drugs. Plasma renin activity before and up to 4 hours were determined.

Fourteen patients were seen at our outpatient clinic. They had bed rest for one hour to establish the steady state. Then, nifedipine was given sublingually in a dose of 30 mg. Blood pressure, heart rate and plasma renin activity were checked up to four hours after administration. One week later they again visited our cardiovascular laboratory and were allowed to rest in the

supine position for one hour. Blood samples were taken for plasma renin activity. Five minutes later 40 mg of furosemide were given intravenously. The patients remained in the upright position for one hour and then blood again was collected.

Plasma renin activity was determined by a slight modification of the method of Haber and associates¹⁵ using Dainabot Kit. Renin activity was expressed in ng of angiotensin I generated per ml of plasma per hour.

For statistical analysis, *t* tests for paired data were applied and percentage averaged changes were calculated for each paired data.

Results

Antihypertensive effect of nifedipine and combined administration of nifedipine and propranolol. Following administration of 10 mg of nifedipine blood pressure in normotensives (*n* = 4) changed from 119.0 \pm 5.3 to 120.0 \pm 6.5 systolic and from 78.0 \pm 4.0 to 74.5 \pm 6.0 mm Hg diastolic for one hour after administration. The administration of both 10 mg and 30 mg of nifedipine did not produce statistically significant changes in blood pressure in the normotensive group. However, blood pressure fell significantly (12 per cent in systolic *p* < 0.01, 9 per cent diastolic *p* < 0.05) following combined administration of 30 mg of nifedipine and 0.2 mg/Kg body weight of propranolol (Table I and Fig. 1).

In hospitalized hypertensive patients' blood

Table III Effects of Ca²⁺ antagonist (nifedipine) and beta blockade (propranolol) on blood pressure heart rate and PRA* in hospitalized hypertensive patients

Treat ment	Nifedipine 10 mg						Nifedipine 30 mg						Nifedipine 30 mg and Propranolol 0.2 mg/kg body wt					
	Blood pressure (mm Hg)		Heart rate (beats/ min)		PRA (ng/ml/h)		Blood pressure (mm Hg)		Heart rate (beats/ min)		PRA (ng/ml/h)		Blood pressure (mm Hg)		Heart rate (beats/ min)		PRA (ng/ml/h)	
	B	I	B	I	B	I	B	I	B	I	B	I	B	I	B	I	B	I
Case No†	B	I	B	I	B	I	B	I	B	I	B	I	B	I	B	I	B	I
1	S	170	150	72	90		150	110	88	84	0.3	4.0						
	D	130	110				130	94										
2	S	188	170	79	80		170	140	66	80	0.5	1.0	154	170	66	60	0.7	0.1
	D	100	80				100	80					96	74				
3	S	200	130	87	96		186	130	10	100			196	110	64	70		
	D	120	80				170	90					120	80				
4	S	180	110	82	54		150	100	67	0			150	94	82	56	0.8	0.6
	D	100	80				110	60					90	68				
5	S	190	142	66	90		190	140	10	84	(1.4)		190	122	76	70	17.9	11.5
	D	130	104				130	90					130	80				
6	S	172	130	78	80		156	128	70	80	0.3	3.2	170	136	76	79	4.0	1.7
	D	110	87				108	84					110	90				
7	S	160	120	67	72		160	110	64	6	2.9	4.2	160	110	64	64	2.4	1.5
	D	100	80				100	80					100	70				
8	S						190	120	79	86	0.2	0.3						
	D						120	80										
9	S						150	170	16	90			150	112	87	78	4.5	2.4
	D						100	80					90	70				
10	S												200	174	60	54	1.3	0.7
	D												130	60				
SM 172.9 130.3 66.3 80.3 166.9 177.0 0.0 82.2 1.2 2.5 171.3 116.0 67.5 65.5 4.5 2.8																		
± SD 17.1 10.7 8.6 14.1 17.6 13.8 4.7 9.1 1.3 1.8 21.1 12.5 9.9 8.4 6.1 4.0																		
p value < 0.001 s < 0.001 s < 0.001 s < 0.01 s ns < 0.001 s ns ns																		
DM 112.9 86.6 113.1 80.9 108.3 140 108.6 92																		
± SD 13.8 14.6 1.3 10.6 16.6 9.2																		
p value < 0.01 s < 0.001 s < 0.001 s																		
Average of paired % change of control value																		
SM 75 121 73 117 39.3 66 98 57																		
± SD 7 19 12 12 5.6 9 8																		
DM 77 2 9 70 12																		
± SD 6 9 12																		
No of cases	(7)		(7)		(9)		(9)		(5)		(8)		(8)		(7)			

Abbreviations: PRA = plasma renin activity; M = mean; SD = standard deviation; of the mean; s = statistically significant; ns = not statistically significant; S = systolic blood pressure; D = diastolic blood pressure; SM = mean of systolic blood pressure; DM = mean of diastolic blood pressure.

*Age of patients (M ± SD): 44.9 ± 10 years (range from 29 to 63 years) (n = 101).

tively. Systolic blood pressure did not change and diastolic pressure slightly increased by propranolol administration alone.¹⁰ Heart rate decreased from 69 ± 3 beats/minute to 57 ± 1 in normotensive volunteers and was 64 ± 1 beats/minute to

56 ± 2 in hypertensive subjects respectively. The time course of plasma renin activity changes with nifedipine reaching the maximum value between one and two hours after administration and returns to initial levels within three




Fig 3 Heart rate increase with nifedipine in normotensive volunteers and hypertensive patients. Combined administration of nifedipine and propranolol does not result in an increase in heart rate. Propranolol may inhibit the increase of the nifedipine induced increase in heart rate. Hypertensive patients = (—) normotensive volunteers = () Values are mean \pm standard deviation

pranolol (Table I). In hypertensive patients plasma renin activity increased from 1.2 to 2.5 ($n = 5$) ($p > 0.1$) 393 per cent after 30 mg of nifedipine and decreased from 4.5 to 2.6 ng/ml/hour ($n = 7$) ($p < 0.1$) 52 per cent after the combined administration (Table III). These results indicate that a nifedipine induced increase of plasma renin activity is completely inhibited by propranolol.

The time course of plasma renin activity changes is shown in Table IV. Nifedipine causes increase of plasma renin activity for two hours followed by a gradual decrease, corresponding with a persisting decrease in blood pressure (Table IV). As the result of furosemide and the upright posture the plasma renin activity is significantly increased (Table IV).

Discussion

Our previous studies have shown that nifedipine is a potent antihypertensive agent.¹² Klutsch and colleagues¹³ Kobayashi and associates¹⁷ and Murakami and co workers¹⁸ have also reported on the hypotensive effect of nifedipine. In this study this is again confirmed. Higher doses (30 mg) are more effective than lower doses (10 mg).

Calcium antagonists (nifedipine, verapamil and others) have been investigated for their hypotensive effect.^{11, 16, 18} The pharmacological action of verapamil is thought to block primarily the slow inward calcium current in ventricular fibers¹⁹ and Ca^{2+} influx associated with excitation.²⁰ Similarly, the negative inotropic action of nifedipine seems to block the slow calcium inward

current.²¹ Hemodynamic effects of nifedipine are summarized by the following: (1) marked reduction in arterial pressure,^{12, 14, 16, 18} (2) increase in heart rate,¹ (3) decrease in peripheral vascular resistance,^{18, 21} (4) increase in coronary blood flow,²¹ and (5) increase in cardiac output and stroke volume.²² (6) Diuresis, urea clearance and electrolyte clearance, are increased by nifedipine in hypertensive patients due to an increase in the glomerular filtration rate and renal plasma flow.¹⁶ Nifedipine has a controlled negative inotropic action by antagonizing the excitation-contraction coupling. Thus cardiac function and peripheral vascular resistance are reduced.

Hypertension is generally associated with increased cardiac function and elevated peripheral vascular resistance; therefore it seems logical to reduce both cardiac activity and vascular tone, when managing hypertensive patients. Considering these points, Ca^{2+} antagonists can be assumed to be logical drugs for the treatment of essential hypertension, especially the severe forms.

Besides lowering blood pressure, nifedipine increases the heart rate. This transient increase can be apparently inhibited by propranolol. It has been shown that vasodilators such as nifedipine,¹ verapamil,^{13, 16} diazoxide,¹ PDP,¹ and hydralazine¹ increase the heart rate probably by enhancing sympathetic discharge via the vasoreceptors.²³ The most common side effect of nifedipine was the effect on the vessels and heart which were headache (4.5 per cent), facial flushing (3.1 per cent), giddiness (1.7 per cent) and palpitation (5 per cent). These side effects were almost abolished or inhibited by the combination administration of nifedipine and propranolol. The combined administration of nifedipine and propranolol for the treatment of hypertension may therefore be recommended. Propranolol alone was given intravenously (0.2 mg/kg body weight) in 11 normotensive healthy men and in 13 patients with essential hypertension (mild) and their blood pressure and heart rate was measured before propranolol and 5, 15, 30 and 60 minutes after propranolol. Blood pressure (mean \pm SEM) was $120 \pm 3/66 \pm 3$ mm Hg and $114 \pm 3/71 \pm 2$, $112 \pm 3/72 \pm 3$, $114 \pm 4/72 \pm 3$, $114 \pm 3/71 \pm 2$ mm Hg in normotensive healthy volunteers and was $145 \pm 4/93 \pm 3$ mm Hg and $146 \pm 4/99 \pm 4$, $142 \pm 4/97 \pm 3$, $143 \pm 4/98 \pm 3$ and $148 \pm 4/98 \pm 3$ mm Hg in hypertensive subjects respec-

in both normotensive and hypertensive patients

The antihypertensive effect of nifedipine is enhanced and prolonged by propranolol. The observed increase in heart rate and plasma renin activity with nifedipine is inhibited by propranolol probably by inhibiting the cardiovascular effects of the activity of the sympathetic nervous system.

The results of this study indicate that oral administration of nifedipine is very effective in lowering arterial blood pressure in hypertensive patients especially when combined with propranolol.

Administration of nifedipine with beta blockade resulted in satisfactory management of hypertension with minimal adverse drug reactions which could be possibly attributed to the preparation especially in the management of hypertensive emergencies including hypertension associated with acute myocardial infarction and coronary insufficiency.

We wish to thank Dr. H. J. Knobloch and Prof. K. Hotta for assistance in preparation of the manuscript.

REFERENCES

- 1 Jones, A. W. Altered ion transport in large and small arteries from spontaneously hypertensive rats and the influence of calcium. *Circ Res* 34 and 35 (Suppl. 1) 117-124.
- 2 Holloway, E. T. and Bohr, D. F. Reactivity of vascular smooth muscle in hypertensive rats. *Circ Res* 33: 678-193.
- 3 Aoki, K., Ikeda, N., Yamashita, K. and Hotta, K. ATPase activity and Ca²⁺ interaction of myofibrils and sarcoplasmic reticulum isolated from the hearts of spontaneously hypertensive rats. *Jap Heart J* 15: 475-1974.
- 4 Aoki, K., Ikeda, N., Yamashita, K., Tazumi, K., Sato, I., and Hotta, K. Cardiovascular contraction in spontaneously hypertensive rat. Ca²⁺ interaction of myofibrils and subcellular membrane of heart and arterial smooth muscle. *Jap Circ J* 38: 1115-1974.
- 5 Aoki, K., Yamashita, K. and Hotta, K. Calcium uptake by sub-cellular membranes from vascular smooth muscle of spontaneously hypertensive rats. *Jap J Pharmacol* 26: 621-1976.
- 6 Moore, L., Hurwitz, L., Davenport, G. R., and Landon, E. J. Energy dependent calcium uptake activity of microsomes from the aorta of normal and hypertensive rats. *Biochim Biophys Acta* 413: 437-1975.
- 7 Wei, J. W., Janus, R. A., and Daniel, E. Calcium accumulation and enzymatic activities of subcellular fractions from aortas and ventricles of genetically hypertensive rats. *Circ Res* 39: 133-1976.
- 8 Cohen, M. L. and Berkowitz, B. A. Decreased vascular relaxation in hypertension. *J Pharmacol Exp Ther* 195: 396-1976.
- 9 Fleckenstein, A., Tritthart, H., Döring, H. J., and Hyon, K. Y. BAY 1040 ein hochaktiver Ca²⁺ antagonistischer Inhibitor des elektro-mechanischen Koppelungsprozesses in Warmblüter Myokard. *Arzneim Forsch* 22: 99-1972.
- 10 Grün, G. and Fleckenstein, A. Die elektromechanische Entkopplung der glatten Gefäßmuskulatur als Grundprinzip der Koronarrelaxation durch 4-(2-Nitrophenyl)-2,6-dimethyl-1,4-dihydropyridin-3,5-dicarbonsäuremethyl-ester (BAY 1040 Nifedipine). *Arzneim Forsch* 22: 334-1972.
- 11 Kroneberg, G. Pharmacology of nifedipine. Second International Adalat Symposium. New Therapy of Ischemic Heart Disease, ed. by W. Lochner, W. Braasch, and G. Kroneberg. Berlin 1975. Springer Verlag, p. 17.
- 12 Aoki, K., Yoshida, T., Kato, M., Tazumi, K., Sato, I., Takikawa, K., and Hotta, K. Hypotensive action and increased plasma renin activity by Ca²⁺ antagonist (Nifedipine) in hypertensive patients. *Jap Heart J* 17: 479-1976.
- 13 Brittinger, W. D., Schwarzbeck, A., Wittenmeier, K. W., Twittenhoff, W. D., Siegar, B., Buber, W., Ewald, R. W., Henning, G. E., Fabricius, M., and Strauch, M. Klinisch experimentelle Untersuchungen über die blutdrucksenkende Wirkung von Versamil. *Deutsch Med Wochenschr* 95: 181-1970.
- 14 Bender, V. Die Behandlung der tachycarden Arrhythmien und der arteriellen Hypertonie mit Versamil. *Arzneim Forsch* 20: 1310-1970.
- 15 Haber, E., Koerner, T., Sage, L. H., Kuman, B., and Pernode, A. Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects. *J Clin Endocrinol Metab* 29: 1243-1969.
- 16 Kiutsch, V. K., Schmid, P., and Grosswendt, J. Der Einfluss von BAY 1040 auf die Nierenfunktion des Hypertonikers. *Arzneim Forsch* 22: 377-1972.
- 17 Kobayashi, T., Ito, Y., and Tawara, I. Clinical experience with a new coronary active substance (BAY 1040). *Arzneim Forsch* 22: 380-1972.
- 18 Murakami, M., Murakami, E., Takekoshi, N., Tsuchiya, M., Kuri, T., Onoe, T., Takeuchi, N., Funatsu, T., Hara, S., Ishise, S., Mifune, J., Maeda, M. Antihypertensive effect of 4-(2-Nitrophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid dimethyl ester (Nifedipine, Bay 1040), a new coronary dilator. *Jap Heart J* 13: 128-1972.
- 19 Kohlhardt, M., Bauer, B., Krause, H., and Fleckenstein, A. Differentiation of the transmembrane Na⁺ and Ca²⁺ channels in mammalian cardiac fibers by the use of specific inhibitors. *Pflügers Arch* 335: 309-1972.
- 20 Fleckenstein, A. and Grün, G. Prinzipien zur Wirkung von Ca²⁺ Antagonisten auf die bioelektrische und mechanische Funktion glatter Muskelzellen. *Vascular Smooth Muscle*, ed. by E. Betz. Berlin 1972. Springer Verlag, p. 69.
- 21 Hashimoto, K., Taira, N., Chiba, S., Hashimoto, K., Endoh, M., Kokubun, M., Kokubun, H., Iijima, T., Kimura, T., Kubota, K., and Oguro, K. Cardiohemodynamic effects of BAY 1040 in the dog. *Arzneim Forsch* 22: 15-1972.
- 22 Schneider, K. W. and Jesse, R. Der Informationswert der Änderung der zentralen Hamodynamik nach Applikation eines O-Nitrophenyl-1,4-dihydropyridinderivates. *Arzneim Forsch* 22: 373-1972.
- 23 Mroczek, W. J., Lee, W. R., Davidov, M. E., and Finnerty, F. A. Vasodilator administration in the presence of beta adrenergic blockade. *Circulation* 53: 985-1976.
- 24 Glimore, E. Weil, J., and Chidsey, C. Treatment of essential hypertension with a new vasodilator in combination with beta adrenergic blockade. *N Engl J Med* 282: 521-1970.
- 25 Ueda, H., Kaneko, Y., Takeda, T., Ikeda, T., and Yagi, S.

Table IV Decrease of blood pressure, increase of heart rate and PRA* by Ca²⁺ antagonist (30 mg of nifedipine) and increase of PRA by 40 mg of furosemide in the upright position in hypertensive group

		Nifedipine 30 mg						Furosemide 40 mg upright position	
		Before	30 min	1 hour	2 hours	3 hours	4 hours	Before	1 2 hours
Systolic Blood pressure mm Hg	M	176.3	145.2	125.2	124.0	119.6	120.8		
	SD	23.8	16.6	15.5	16.1	15.8	5.8		
	p value		< 0.02 s	< 0.001 s	< 0.001 s	< 0.001 s	< 0.001 s		
Diastolic	M	109.5	88.4	79.6	79.9	72.8	76.8		
	SD	15.1	7.4	11.2	12.7	10.0	10.1		
	p value		< 0.05 s	< 0.001 s	< 0.001 s	< 0.001 s	< 0.001 s		
Heart rate beats/min	M	73.3	85.2	84.1	82.2	72.2	77.4		
	SD	10.1	15.0	10.0	10.9	10.0	10.2		
	p value		< 0.05 s	< 0.001 s	< 0.001 s	> 0.1 ns	> 0.1 ns		
Plasma renin activity ng/ml/h	M	1.75	2.87	2.95	2.99	1.60	1.37	2.32	3.43
	SD	2.45	4.13	4.01	4.90	1.55	2.26	5.38	5.80
	p value		> 0.1 ns	< 0.01 s	< 0.05 s	> 0.1 ns	< 0.05 s		< 0.01 s
No of patients		(24)	(5)	(21)	(20)	(5)	(8)		(17)

See Tables I to III for explanation of abbreviations

hours, while decreased pressure persisted (Table IV Fig 2) Propranolol inhibits this increase of plasma renin activity but does not inhibit the decrease of blood pressure. Negative correlations between changes of plasma renin activity and blood pressure levels following administration of nifedipine, are noted. However there is a positive correlation when nifedipine and propranolol are combined. These results suggest that plasma renin activity changes may be caused mainly by renin release from the kidney due to increase of sympathetic discharge by vasodilators. However renin release is controlled by a number of factors including vascular receptors, muscular tone, sympathetic nervous system, perfusion pressure to the renal arterioles and its wall tension, so a conclusion with regard to the effect of nifedipine on plasma renin activity may not be drawn.

Summary

The effect of the administration of a cardiovascular Ca²⁺ antagonist (nifedipine) on arterial blood pressure, heart rate and plasma renin activity was investigated.

Blood pressure of normotensive healthy volunteers (n = 4) does not change significantly by administration of 10 mg (from 119/78 to 120/75 mm Hg) and 30 mg (from 114/69 to 105/66 mm Hg) of nifedipine. When nifedipine (30 mg) is

administered with propranolol (beta blockade), a slight decrease of systolic and diastolic blood pressure was observed (from 119/73 to 104/61 mm Hg). Blood pressure of hypertensive patients is significantly lowered by 10 mg of nifedipine from 172.9 to 130.3 mm Hg (25 per cent reduction) systolic and from 112.9 to 86.6 mm Hg (23 per cent) diastolic (n = 7). Thirty mg nifedipine had a slightly stronger hypotensive effect, namely 27 per cent reduction in systolic and 28 per cent in diastolic values (n = 9). Combined administration of nifedipine and propranolol resulted in lowering initial blood pressure by 32 per cent and 30 per cent reduction in systolic and diastolic (n = 8) respectively.

The heart rate of normotensive patients hardly changes with administration of 10 and 30 mg of nifedipine and combined medication. But in hypertensive subjects it is significantly increased by nifedipine from 66.3 to 80.3 (p < 0.001) by 10 mg and from 70.0 to 82.2 beats/minute (p < 0.01) by 30 mg. On the contrary combined administration of nifedipine and propranolol causes no increase or only a slight decrease in heart rate (from 68 to 66 beats/minute).

Plasma renin activity of normotensive and hypertensive subjects is increased by 30 mg of nifedipine. Combined administration of nifedipine and propranolol decreases plasma renin activity.

Circulating catecholamines and systolic time intervals in normotensive and hypertensive patients with and without left ventricular hypertrophy

Daniel Cousineau MD MSc*
Léonard Lapointe MD FRCP(C)*
Jacques de Champlain MD PhD*
Montreal Quebec Canada

An increase in heart rate and myocardial contractility is present in a large subgroup of patients with borderline and established hypertension and it has been suggested that the underlying mechanism for these augmented cardiac functions is an exaggerated adrenergic drive to the heart. The recent development of sensitive radioenzymatic assays for the precise measurement of catecholamines (CA) has led to the discovery that circulating CA levels are increased in a large proportion of patients with essential hypertension. It has been proposed that the population with essential hypertension is composed of two distinct subgroups: hyperadrenergic patients (those with CA above normal levels) and normoadrenergic patients (those with CA levels within normal range). Heart rate in the hyperadrenergic group was found to be higher than in the normoadrenergic group whereas the mean heart rate

from the latter group was identical to that of normotensive subjects. There is a possibility that these two groups of hypertensive patients with normal and high levels of circulating CA might represent separate clinical entities.

In the present study the ventricular performance of normotensive and hypertensive patients (with or without left ventricular hypertrophy [LVH]) was evaluated with systolic time measurements and related to their basal circulating CA levels.

Methods

Fourteen normotensive patients (eleven males and three females) aged 22 to 50 years (mean 36.8 ± 2.7 years) and 43 hypertensive patients (20 males and 18 females) aged 23 to 52 years (mean 39.3 ± 2.0 years) were studied between 100 and 200 P.M. Patients had received no medication for at least 2 months prior to the study.

Patients were diagnosed as having essential hypertension after exclusion of known causes of hypertension. Hypertensive patients were subdivided into two groups according to the presence or absence of left ventricular hypertrophy (LVH) determined by electrocardiogram, chest x-rays and echocardiography. Seven hypertensive patients had evidence of LVH but no signs of left ventricular failure while 36 patients had no LVH. Mean age values did not differ significantly between patients without LVH (38.9 ± 1.9 years) and those with LVH (41.2 ± 3.2 years).

Phonocardiogram, electrocardiogram and

From the Department of Physiology and Faculty of Medicine, Université Laval, and the Department of Cardiology, Hôpital Sainte-Justine, Montreal, Quebec, Canada.

These studies were supported by grants from the Medical Research Council of Canada and from the Quebec Heart Foundation.

Received for publication August 4, 1979.

Accepted for publication October 31, 1979.

Reprint requests: Daniel Cousineau, MD PhD, Department of Physiology, Faculty of Medicine, 616 Avenue de la Université, Montréal, Québec, Canada H3C 3J7.

Full names of the Medical Research Council of Canada.

Member of the Division of Cardiology, Hôpital Sainte-Justine, Montreal, Quebec.

J. C. de Champlain, Professorship in Cardiovascular Research, Department of Physiology, Université de Montréal.

- Observations on the mechanism of renin release by hydralazine in hypertensive patients *Circ Res* **26** and **27** (Suppl II) 201 1970
- 26 Page I H and McCubbin J W Renal vascular and systemic arterial pressure responses to nervous and chemical stimulation of the kidney, *Am J Physiol* **173** 411 1953
- 27 Thames M D and Kontos H A Mechanisms of baroreceptor induced changes in heart rate *Am J Physiol* **218** 201 1970
- 28 Ninomiya I and Iwasawa H Summation of baroreceptor reflex effects on sympathetic nerve activities *Am J Physiol* **216** 1330 1969
- 29 Ebner F Survey of the results of world wide clinical trials with nifedipine (Adalat®) in First International Nifedipine Adalat Symposium New Therapy of Ischemic Heart Disease eds Hashimoto K Kimura E and Kobayashi T Tokyo 1973 University of Tokyo Press pp 282 290
- 30 Aoki K Tazumi K Yoshida T Hato E Sato I and Takikawa K Serum dopamine β hydroxylase activity in essential hypertension *Clin Sci Mol Med* **51** 1976




Fig. 2 Correlation between the logarithm of plasma catecholamines and pre-ejection period. Patients are those illustrated in Fig. 1. For the HT + LVH group intercept differs significantly when compared with NT or HT groups ($P < 0.1$).

interval index LVETI did not differ significantly between normotensive and hypertensive patients without LVH but mean PEP and PEP/LVET values were significantly higher and LVFT value significantly lower in hypertensive patients with LVH.

Correlation coefficients between logarithm of plasma CA and systolic time intervals, heart rate and blood pressure for the three groups of patients are given in Table II. Within each group there were good correlations between plasma CA and PEP or PEP/LVET values. In hypertensive patients with LVH the intercept of the regression line between plasma CA and PEP was significantly higher than in hypertensive patients without LVH, indicating a relationship between circulating CA and higher PEP values (Fig. 2). Correlations were poor between plasma CA and LVET, systolic or diastolic blood pressure in the three groups of patients. For the group of hypertensive patients without LVH there was a good correlation between plasma CA and heart rate (Fig. 3).

When hypertensive patients were subdivided into normoadrenergic (circulating CA levels within the normotensive range) and hyper-

Table II Correlation coefficients between logarithm of circulating CA and systolic time intervals, heart rate and blood pressure in normotensive (NT) and hypertensive patients without LVH (HT) or with LVH (HT + LVH).

	PEP	LVET	PEP/ LVET	Heart rate	Systolic blood pressure	Diastolic blood pressure
NT (n=14)	-0.88	-0.2	-0.58	0.97	3.1	3.65
HT (n=36)	-0.71	-0.87	-0.45	0.38	-0.28	-0.30
HT + LVH (n=7)	-0.72	-0.193	-0.594	-0.403	-0.06	0.332

adrenergic (circulating CA levels above normal range) groups significant differences were observed in some cardiac functions. Mean heart rate was significantly higher in the hyperadrenergic group than in normotensive subjects but was not different in the group of normoadrenergic patients. Mean PEP and PEP/LVET values were significantly higher for the normoadrenergic group when compared with normotensive pa-


Table 1 Mean values of circulating CA, systolic time intervals, systolic time interval index, heart rate, and blood pressure in normotensive (NT) and hypertensive patients without LVH (NT) or with LVH (HT + LVH)

	CA (ng/ml)	PEP (msec)	LVET (msec)	LVETI (msec)	PEP/ LVET	Heart rate (beats/ min)	Systolic blood pressure (mm Hg)	Diastolic blood pressure (mm Hg)
NT (n = 14)	305 ± 0.15†	88.2 ± 3.0	292.4 ± 5.8	412.2 ± 3.9	306 ± 0.10	70.9 ± 2.4	119.3 ± 3.4	61 ± 2.5
HT (n = 36)	434 ± 0.30*	90.2 ± 2.3	278.5 ± 4.5	418.3 ± 2.6	325 ± 0.05	85.1 ± 2.7**	155.5 ± 3.8**	99.1 ± 2.5
HT + LVH (n = 7)	524 ± 104	117.1 ± 6.8*	272.3 ± 9.0*	414.7 ± 7.3	442 ± 0.32	83.6 ± 5.1**	180.0 ± 12.5	105.7 ± 3.1

†Mean ± SEM

P < .05

P < .01 versus values in normotensive subjects

**Fig 1** Circulating catecholamines at rest in normotensive subjects (NT n = 14), hypertensive patients without left ventricular hypertrophy (HT n = 36), and hypertensive patients with left ventricular hypertrophy (HT + LVH n = 7). The shaded area at the bottom of each rectangle represents the average levels for all values of each group.

carotidogram pulse tracing were recorded simultaneously after resting supine for 20 minutes. All tracings were made at a paper of 100 mm/sec on a three channel Schwarzer recorder. Ten consecutive cardiac cycles were analyzed to determine the average heart rate, Q-S interval and left ventricular ejection time. The Q-S interval was measured from the beginning of the Q wave to the first rapid deflection of the second heart sound. The left ventricular ejection time (LVET) was measured from the onset of the rapid stroke of the carotid pulse to the nadir of the dicrotic notch. The pre-ejection period (PEP) was calculated by subtracting LVET from the Q-S interval. The corresponding systolic time interval index (LVETI) was calculated from LVET value according to the formula: $LVETI =$

$LVET + 16 \times \text{heart rate (females)}$, $LVETI = LVET + 17 \times \text{heart rate (males)}$.¹⁰ PEP and PEP/LVET do not depend to a significant extent upon the heart rate and no correction was made.¹¹ Blood pressure was determined by indirect sphygmomanometry. At the end of the resting period, 7 milliliters of blood were sampled from a brachial vein in a non-heparinized tube for the determination of circulating catecholamines.

The same tests were repeated two weeks later for 10 of the patients (five normotensive and five hypertensive subjects).

Circulating CA levels were measured by the radioenzymatic method of Coyle and Henry,¹² modified for measurements in plasma.⁸ The principle of this technique is based on the conversion of the norepinephrine and epinephrine to tritiated normetanephrine and metanephrine in the presence of catechol O-methyl transferase and tritiated S-adenosylmethionine as a labelled methyl donor. The technical details for this method have been previously described.⁸

For statistical evaluation the Student's *t* test and the Pearson *r* test and covariance analysis were used.

Results

Mean values for circulating CA, systolic time intervals, systolic time interval index, heart rate and blood pressure for normotensive patients and the two groups of hypertensive patients are given in Table 1. The mean circulating CA level was significantly higher for the two groups of hypertensive patients with or without LVH (Fig 1). Mean values for systolic time intervals (PEP, LVET, PEP/LVET) and the systolic time in




Fig 4 Heart rate prejection period and PEP/LVET (Mean ± SEM) in hypertensive patients without left ventricular hypertrophy subdivided in two groups: a normoadrenergic group (circulating CA within the normotensive range 17 patients) and a hyperadrenergic group (circulating CA levels above normal levels 19 patients)

Table III Mean values of circulating CA systolic time intervals systolic time interval index heart rate and blood pressure in normoadrenergic hypertensive patients (circulating CA levels within the normotensive range) and hyperadrenergic hypertensive patients (circulating CA levels above the normotensive range)

	CA (ng/ml)	PEP (msec)	LVET (msec)	LVETi (msec)	PEP/ LVET	Heart rate (beats/min)	Systolic blood pressure (mm Hg)	Diastolic blood pressure (mm Hg)
Normoadrenergic group (n = 1)	96 ± 0.18	96.8 ± 2.7	297.3 ± 5.4	417.8 ± 4.1	.331 ± 0.04	63 ± 3.0	15.6 ± 5.2	100 ± 3.3
Hyperadrenergic group* (n = 19)	508 ± 0.30	84.4 ± 3	264 ± 4.3	417.5 ± 3.3	.319 ± 0.06	93.0 ± 1.9	153.7 ± 4.3	97.7 ± 2.9

P < 0.05

P < 0.01

†Age 38.4 ± 5 yrs

‡Age 41.9 ± 1 yr

have previously reported that 40 to 50 per cent of hypertensive patients had circulating CA levels above the highest value found in normotensive subjects and we have proposed the classification of hypertensive patients into hyperadrenergic or normoadrenergic groups based on whether resting circulating CA levels were above or within the normal range. In the present study and as

previously reported hyperadrenergic hypertensive patients were found to have higher heart rates than normotensive or normoadrenergic hypertensive patients. Moreover circulating CA levels were closely correlated with heart rate in hypertensive patients. The normoadrenergic group of hypertensive patients was also found to have significantly higher PEP and PEP/LVET




Fig 3 Correlation between the logarithm of plasma catecholamines and heart rate in hypertensive patients without left ventricular hypertrophy (HT; $n = 36$)

tients, but were not significantly different in the hyperadrenergic group (Fig 4)

When normoadrenergic and hyperadrenergic groups were compared heart rate was found to be significantly higher in the latter group, while PEP and PEP/LVET were significantly lower. LVET was also significantly lower in the hyperadrenergic group but LVETI was not different. Mean diastolic and systolic blood pressure values were similar for both groups (Table III).

Circulating CA, systolic time intervals, heart rate, and blood pressure tests were repeated two weeks later under identical conditions in five normotensive and five hypertensive patients. Mean circulating CA levels of both groups were identical in the first and second study and circulating CA levels remained significantly higher in hypertensive patients (Fig 5). Systolic time intervals, heart rate, and blood pressure were also similar in both series (Table IV).

Discussion

Systolic time intervals such as PEP and PEP/LVET, have proved to be good index of myocardial contractility in the healthy human and in patients with hypertensive disease.^{11,12} The sympathetic system is probably the most impor-

tant factor regulating the position of the force-velocity and ventricular performance curves under physiological conditions.¹ The measurement of circulating CA is highly stable and reproducible when determined under standardized conditions.⁸ Circulating CA, systolic time intervals, blood pressure, and heart rate were similar in the same patients tested at the beginning of the study and after a two week interval. Moreover, circulating CA levels were found to increase in conditions known to activate the sympathetic system such as tilting¹³ and dynamic exercise,¹⁰ thus supporting the validity of circulating CA as an index of sympathetic activity. In the present study, circulating CA levels were inversely related with PEP or PEP/LVET, therefore suggesting a good correlation between myocardial contractility and circulating CA. This finding is in agreement with our previous studies in which coronary sinus CA were correlated with myocardial contractility directly determined with the dP/dt of left ventricular pressure.¹¹ The validity of this correlation is also supported by the observation that infusion of CA in the human shortens PEP and PEP/LVET.¹⁴ Since part of the neurally released CA diffuses into the circulation, circulating CA may give a relative indication of the amount of physiologically active CA present at the receptor. Good correlations between circulating CA and myocardial contractility further support that the measurement of circulating CA provides a good index of sympathetic activity in the human under standardized conditions.

In hypertensive patients with LVH, the mean PEP value was significantly higher than in hypertensive patients without LVH. The prolongation of PEP in hypertensive cardiopathy is secondary to a diminished rate of isovolumic left ventricular pressure rise.¹ This could explain the inverse relationship between circulating CA levels and higher PEP values in hypertensive patients with LVH during a period of altered myocardial contractility.

When the group of hypertensive patients without LVH was taken as a whole, there was no significant difference for the mean PEP or PEP/LVET value when compared with normotensive subjects, in agreement with previous studies.¹ However, when these hypertensive patients were further subdivided according to their circulating CA levels, significant differences appeared. We




Fig 4 Heart rate pre-ejection period and PEP/LVET (Mean \pm SEM) in hypertensive patients without left ventricular hypertrophy subdivided in two groups: a normoadrenergic group (circulating CA within the normotensive range 17 patients) and a hyperadrenergic group (circulating CA levels above normal levels 19 patients)

Table III Mean values of circulating CA systolic time intervals systolic time interval index heart rate and blood pressure in normoadrenergic hypertensive patients (circulating CA levels within the normotensive range) and hyperadrenergic hypertensive patients (circulating CA levels above the normotensive range)

	CA (ng/ml)	PEP (msec)	LVET (msec)	LVFTI (msec)	PEP/ LVET	Heart rate (beats/min)	Systolic blood pressure (mm Hg)	Diastolic blood pressure (mm Hg)
Normoadrenergic group† (n = 17)	996 \pm 018	968 \pm 2	297.3 \pm 5.4	417.8 \pm 4.1	331 \pm 004	76.3 \pm 3.0	151.6 \pm 5.2	100.7 \pm 3.3
Hyperadrenergic group‡ (n = 19)	558 \pm 030	844 \pm 3.4	264.7 \pm 4.3	417.5 \pm 3.3	319 \pm 006	93.0 \pm 1.9	153.7 \pm 4.3	91.7 \pm 2.9

P < 0.05

P < 0.1

†Age 38.4 \pm 2.5 y ans

‡Age 41.9 \pm 1.1 y ans

have previously reported that 40 to 50 per cent of hypertensive patients had circulating CA levels above the highest value found in normotensive subjects and we have proposed the classification of hypertensive patients into hyperadrenergic or normoadrenergic groups based on whether resting circulating CA levels were above or within the normal range. In the present study and as

previously reported hyperadrenergic hypertensive patients were found to have higher heart rates than normotensive or normoadrenergic hypertensive patients. Moreover circulating CA levels were closely correlated with heart rate in hypertensive patients. The normoadrenergic group of hypertensive patients was also found to have significantly higher PEP and PEP/LVET

Table IV Mean values of circulating CA, systolic time intervals, heart rate, and blood pressure in five normotensive and five hypertensive patients repeated at an interval of two weeks under identical conditions

	CA (ng/ml)	PEP (msec)	LVET (msec)	Heart rate (beats/min)	Systolic blood pressure (mm Hg)	Diastolic blood pressure (mm Hg)
Normotensive						
1st study	274 ± 02	97.3 ± 6.0	294.0 ± 6.4	66.7 ± 1.0	112.5 ± 3.2	71.2 ± 3.1
2nd study	268 ± 03	92.2 ± 5.8	295.7 ± 10.4	68.2 ± 4.1	111.2 ± 3.1	71.2 ± 4.3
Hypertensive						
1st study	436 ± 04	106.4 ± 15.4	269.0 ± 14.3	84.0 ± 6.5	151.0 ± 9.0	96.0 ± 6.8
2nd study	435 ± 05	103.4 ± 10.9	278.8 ± 13.6	83.2 ± 7.8	152.0 ± 12.4	93.0 ± 7.0




Fig 5 Circulating catecholamines in five normotensive and five hypertensive patients measured at an interval of two weeks. Bars represent mean ± SEM. $P < 0.05$

values than the group of normotensive patients while these values were not significantly different in the hyperadrenergic group.

When normoadrenergic and hyperadrenergic groups were compared, PEP and PEP/LVET were significantly lower in the hyperadrenergic group. Since mean diastolic blood pressure was similar in both groups it is then likely that lower PEP and PEP/LVET values in the hyperadrenergic group reflect an enhanced myocardial contractility in these patients.

These findings are in good agreement with a previous study where approximately 40 per cent of hypertensive patients were found to have higher heart rates than normotensive patients and similar values for PEP and PEP/LVET.⁷ According to these authors 'normal PEP and PEP/LVET in this group of patients designated hyperkinetic essential hypertension,' would indicate in the presence of an elevated diastolic blood pressure an increased rate of rise in ventricular pressure and they suggested that these augmented cardiac functions were secondary to

an exaggerated adrenergic drive to the heart. High levels of circulating CA observed in our study for this group of patients further substantiated this hypothesis.

The hyperadrenergic group of hypertensive patients probably correspond to high renin hypertensive patients, since high circulating CA levels were recently observed in a group with mild high renin essential hypertension.⁸ This group of high renin hypertensive subjects also had lower PEP and higher heart rate values.

The increased chronotropic and inotropic myocardial activity induced by sympathetic stimulation is associated with an increased myocardial oxygen consumption.^{23,24} High levels of circulating CA in hyperadrenergic hypertensive patients could have a deleterious effect on a myocardium already subjected to an increased afterload. A greater incidence of sudden deaths and cardiac diseases have been reported in individuals with rapid heart rate.²⁵ It is therefore possible that higher circulating CA levels might contribute to a higher incidence of cardiovascular disease in the group of hyperadrenergic hypertensive patients.

Circulating CA levels then appear to be a good index of sympathetic activity in man as suggested by good correlations with myocardial contractility index such as PEP and PEP/LVET. Moreover basal circulating CA levels are highly reproducible when repeated under standardized conditions. A large subgroup of patients with essential hypertension are characterized by increased chronotropic and inotropic myocardial functions and elevated circulating CA levels thus suggesting that they constitute a separate clinical entity.

Summary

Circulating catecholamine (CA) levels were measured in normotensive and hypertensive patients with or without left ventricular hypertrophy (LVH) and were related with systolic time intervals, heart rate and blood pressure. The pre-ejection period (PEP) and the ratio PEP/LVET were correlated with circulating CA in normotensive and hypertensive patients. For a given circulating CA level, the PEP was higher in hypertensive patients with LVH than in those without LVH. This is probably secondary to a diminished myocardial contractility in these patients. Heart rate was related with circulating CA in hypertensive patients without LVH. When hypertensive patients without LVH were divided into normoadrenergic (circulating CA levels within normotensive range) and hyperadrenergic (circulating CA above normal range) groups, the hyperadrenergic group was found to have significantly higher heart rate than normotensive patients while the heart rate of the normoadrenergic group was similar to that of the normotensive group. PEP and PEP/LVET were significantly elevated in the normoadrenergic group when compared with normotensive subjects but were not different in the hyperadrenergic group. These differences in chronotropic and inotropic myocardial activity between these two groups of hypertensive patients with normal and high levels of circulating CA suggest that they are separate entities.

The authors are most grateful to Ms Diane Papin and Jo Anne Le Guernier for their skilful technical assistance and to Ms Marie Colette Renaud and June Manson for their efficiency in preparing the manuscript.

REFERENCES

- Julius S and Esler M D. Autonomic nervous cardiovascular regulation in borderline hypertension. *Am J Cardiol* 36 685 1975.
- Ibrahim M M, Tarszi R C, Dustan H P and Bravo E L. Cardioadrenergic factor in essential hypertension. *Am Heart J* 88 724 1974.
- Filer M D, Julius S, Zweifler A, Randall O, Harburg E, Gardiner M and De Quattro V. Mild high renin essential hypertension. *Neurogenic human hypertension*. *N Engl J Med* 295 405 1977.
- Engelman K and Portnoy B A. Sensitive double-isotope derivative assay for epinephrine and norepinephrine: normal resting human plasma levels. *Circ Res* 26 53 1970.
- De Quattro V and Chan S. Raised plasma catecholamines in some patients with primary hypertension. *Lancet* i 806 1972.
- Louis W J, Doyle A E and Anavekar S. Plasma norepinephrine levels in essential hypertension. *N Engl J Med* 288 399 1973.
- De Quattro V, Mura Y, Lurvey A, Cosgrove M and Mender R. Increased plasma catecholamine concentrations and vas deferens norepinephrine biosynthesis in man with elevated blood pressure. *Circ Res* 36 118 1975.
- De Champlain J, Farley L, Cousineau D, and Van Amerongen W R. Circulating catecholamine levels in human and experimental hypertension. *Circ Res* 38 109 1976.
- Lütold B F, Bühler F F and Da Prada M. Dynamik von Plasmacatecholaminen und B-Adrenozeptor-Funktionen. *Schweiz Med Wochr* 105 1734 1976.
- Weissler A M and Garrard C L. Systolic time intervals in cardiac disease I and II. *Mod Concepts Cardiovasc Dis* 40 (11) 1 1971.
- Harris, W S, Schoenfeld C D and Weissler A M. Effects of adrenergic receptor activation and blockade on the systolic pre-ejection period, heart rate and arterial pressure in man. *J Clin Invest* 48 1 51 1967.
- Kumar S and Spodick D H. Study of the mechanical events of the left ventricle by atrumatic techniques: comparison of methods of measurement and their significance. *Am Heart J* 80 401 1970.
- Talley R C, Meyer J F and McNay J L. Evaluation of the pre-ejection period as an estimate of myocardial contractility in dogs. *Am J Cardiol* 27 384 1971.
- Weissler A M. Current concepts in cardiology. Systolic time intervals. *N Engl J Med* 288 321 1977.
- Coyle J T and Henry D. Catecholamine in fetal and newborn rat brain. *J Neurochem* 21 61 1973.
- Martin C E, Shaver J A, Thompson M E, Reddy P S and Leonard J J. Direct correlation of external systolic time intervals with internal indices of left ventricular function in man. *Circulation* 44 419 1971.
- Ahmed S S, Levinson G E, Schwartz C J and Ettinger P O. Systolic time intervals as measures of the contractile state of the left ventricular myocardium in man. *Circulation* 46 559 1972.
- Braunwald E, Ross J Jr and Sonnenblick E H. Mechanism of contraction of the normal and failing heart. *N Engl J Med* 277 853 910 967 1012 1967.
- Christensen N J and Brandborg O. The relationship between plasma catecholamine concentration and pulse rate during exercise and standing. *Eur J Clin Invest* 3 299 1973.
- Von Euler U S. Sympathoadrenal activity in physical exercise. *Med Sci Sports* 6(3) 185 1974.
- Yamaguchi N, De Champlain J and Nadeau R A. Correlation between the response of the heart to sympathetic stimulation and the release of endogenous catecholamines into the coronary sinus of the dog. *Circ Res* 36 667 1975.
- Raab W, Silva P de P and Starcheska Y K. Adrenergic and cholinergic influences on the dynamic cycle of the normal human heart. *Cardiologica* 33 350 1958.
- Salzman S H, Wolfson M, Jackson B and Schechter E. Epinephrine infusion in man: Standardization, normal response and abnormal response in idiopathic hypertrophic subaortic stenosis. *Circulation* 43 137 1971.
- Weissler A M, Harris W S and Schoenfeld C D. Systolic time intervals in heart failure in man. *Circulation* 37 149 1968.
- Krasnow N, Klett E I, Yurchak P M, Hood W B and Gorlin R. Isoproterenol and cardiovascular performances. *Am J Med* 37 514 1964.

- 26 Sonnenblick F H Ross J Jr Covell J W and Kaiser G A Velocity of contraction as determinant of myocardial oxygen consumption *Am J Physiol* **209** 919 1965
- 27 Berkson D M Stanler J Lindberg H S Miller W A Stevens E L Soyugene R Tolich T J and Stamler

R Heart rate an important risk factor for coronary mortality—ten year experience of the Peoples Gas Company epidemiologic study (1958-1968) in Atherosclerosis. Second International Symposium June 1970 New York 1970 Springer Verlag p 38

Information for authors

Most of the provisions of the Copyright Act of 1976 became effective on January 1 1978. Therefore all manuscripts must be accompanied by the following statement signed by each author: "The undersigned author(s) transfer all copyright ownership of the manuscript entitled (title of article) to The C V Mosby Company in the event the work is published. The author(s) warrants that the article is original is not under consideration by another journal, and has not been previously published. Authors will be consulted when possible regarding republication of their material."

Electrophysiologic-histologic correlation of the cardiac specialized conduction system in two cases of single ventricle and levotransposition of the great arteries

John Schatz MD*

John Fenoglio MD

Ehud Krongrad MD FACC

New York NY and Washington DC

Electrophysiologic delineation of the specialized cardiac conduction system (SCS) during open heart surgery has been found to be a valuable technique for locating the cardiac conduction system in patients with various forms of congenital heart disease. This technique was found useful particularly in patients in whom extensive intraventricular repair is carried out during open heart surgery. In such patients the use of this technique assumes special clinical importance. The technique is especially helpful in patients in whom the specialized conduction system is known to vary in location such as in patients with single ventricle and therefore enables surgical repair of this complex anomaly considered until recently inoperable. Although in recent years many studies reported observations on recording specialized conduction system electrograms in man during cardiac catheterization as well as during open heart surgery we are unaware of previous reports correlating the location of specialized conduction system electrograms obtained during open heart surgery under

direct vision with histologic verification of the underlying conducting tissue.

The purpose of this report is to present the electrophysiological observations in two cases with single ventricle (type A) obtained during open heart surgery and to verify these findings with histological examination of the specialized conduction system.

Case reports

Case 1 L.S. was known to have levotransposition of the great arteries and a large interventricular communication documented by cardiac catheterization in early life. Because of congestive heart failure and to protect the pulmonary vascular bed from developing pulmonary vascular disease pulmonary artery banding was carried out at 14 months of age. At age 13 years she was referred for elective surgical closure of the intraventricular defect. Throughout the patient's entire life she had maintained a normal sinus rhythm (Fig. 1).

During open heart surgery the patient was placed on total cardiopulmonary bypass and a ventriculotomy was performed. Inspection of the intraventricular anatomy showed both A-V valves to enter a large single ventricular chamber. There was also a subaortic infundibular chamber which was connected to the other ventricular chamber via a bulbous ventricular foramen.

Intraventricular delineation of the specialized conduction system was then carried out as previously described demonstrating specialized conduction system electrograms between the bulbous ventricular foramen and the pulmonary valve. Identification of the specialized conduction system was carried out during sinus rhythm and also during atrial pacing at 92 beats per minute with 1:1 atrioventricular conduction (Fig. 2). The longest interval from specialized conduction system electrogram to the initial deflection of the QRS complex was 43 msec. A Teflon patch was then sewn in dividing the single ventricle into two chambers. An outflow patch was also sewn from the

From the Department of Pharmacology and Pediatrics, College of Physicians & Surgeons of Columbia University, New York, NY and the Department of Cardiac Pulmonary and Armed Forces Institute of Pathology, Washington, DC.

Supported in part by NIH Grant HL 38 086 from the National Institutes of Health, United States Public Health Service.

Received for publication June 28, 1977.

Accepted for publication July 26, 1977.

Reprint requests to Ehud Krongrad MD, Babes Hospital (BHA1 1071 35th Broadway, New York, NY 10032).

Current address: Department of Medicine, National Medical Center, Salinas, California 95001.




Fig 1 Pre- and postoperative electrocardiogram of the patient L.S. Note normal sinus rhythm and normal A-V conduction prior to and following operation. In addition the postoperative electrocardiogram shows evidence of anteroseptal myocardial infarction with Q waves in Leads V₁ to V₅ and ST segment elevation in Leads V₁ to V₆.

reconstructed right ventricle to widen its outflow tract well into the area of the previous pulmonary artery band. Following completion of surgery the patient was in normal sinus rhythm with 1:1 A-V conduction. The right ventricular systolic pressure at end of surgery was 35 mm Hg and the left ventricular systolic pressure 75 mm Hg. Electrocardiogram done one day postoperatively showed a normal sinus rhythm with a P-R interval of 0.18 sec, frontal QRS axis of -120 degrees and a QRS duration of 0.12 sec, compatible with intraventricular conduction delay. Q waves were present in Leads V₁ to V₅ with ST elevation in Leads V₁ to V₆ compatible with acute myocardial infarction (Fig 1). Postoperatively the patient progressively developed a low cardiac output syndrome and died despite intensive therapeutic efforts.

At autopsy the heart was enlarged (373 g). The aorta was anterior and to the left of the pulmonary artery (L-transposition of the great arteries). Two A-V valves opened into a single ventricle. The intraventricular patch and the pulmonary artery outflow patch were intact. A bulboventricular foramen led from the single ventricle to a small subaortic outflow chamber. A false tendon like structure extended across the subaortic chamber (Fig 3) from the area where the specialized conduction system was identified by our mapping technique. Foci of subendocardial hemorrhage were present over the anterior ventricular wall and anterior papillary muscle.

The region of the heart in which the His bundle was identified during surgery was excised in toto and serially blocked. The blocks were oriented in the frontal plane relative to the atrial septum, embedded in paraffin and step sectioned, collecting every twelfth section. Sections were stained with hematoxylin and eosin and the Movat pentachrome stain. In

addition the atrial septum was excised in toto and serially blocked. The blocks were step sectioned, collecting every fifth section, and the sections were stained as above. An atrioventricular node in the normal position in the posterior interatrial septum was identified. This node was small and had no contact with the ventricular myocardium (Fig 4). In the area of the junction of the atrial septum and the right atrial appendage adjacent to the transposed pulmonary artery a second nodal structure (accessory or anterior atrioventricular node) was identified (Fig 5A). This collection of specialized atrial cells coalesced to form a bundle of fibers which coursed through the fibrous annulus to become the atrioventricular bundle.

The atrioventricular bundle penetrated the fibrous annulus (Fig 5B) adjacent to the pulmonary valve ring and superior to the bulboventricular foramen between the main ventricular chamber and the subaortic outlet chamber. In the ventricle the His bundle (Fig 5C) coarsened downward on the right rim of the bulboventricular foramen and expanded into a broad sheet of fibers consistent with the normal morphology of the left bundle branch. This left bundle branch then continued into the main ventricular chamber and expanded into a subendocardial network (Fig 6A). A smaller cylindrical bundle of specialized cells arising from the main bundle was identified (Fig 6B). A portion of this bundle arose above the bifurcation of the left bundle branch and traversed the upper aspect of the bulboventricular foramen in a cord like structure reminiscent of a false tendon across the outlet chamber (Fig 3). Here the specialized fibers formed subendocardial ramifications typical of the normal right bundle branch.

Case 2. M.K. was a 13 year old girl who was known to have L-transposition of the great arteries and a single ventricle type A, documented by cardiac catheterization and angiography in early infancy. Pulmonary artery banding was performed at 5 months of age. At 8 years of age the patient developed spontaneous complete heart block (Fig 7) and at age 12 years she developed repeated bouts of staphylococcal endocarditis sensitive to oxacillin therapy. She was referred for surgical repair because of increased and progressive fatigue and decreased exercise tolerance.

During open heart surgery a ventriculotomy was performed with the patient on total cardiopulmonary bypass. Following incision of the intraventricular anatomy the specialized conduction system was electrophysiologically identified by observing and recording specialized conduction system electrograms preceding the QRS complex. The locations where SCS electrograms were recorded were similar to the location of SCS electrograms described in Case 1—that is superior and anterior to the bulboventricular foramen.

Although complete atrioventricular block was present in this patient SCS electrograms were consistently recorded and were related to ventricular electrograms at an H-V interval of up to 103 msec (Fig 8). A Teflon patch was then sewn between the atrioventricular valves to divide the single ventricular cavity and care was taken not to interrupt the existing SCS. An additional patch was used to widen the constriction of the pulmonary artery band and to enlarge the "right ventricular" outflow tract. Postoperative electrocardiograms showed (Fig 7) complete atrioventricular conduction delay identical to the previous tracing. Postoperatively the




Fig. 2 Specialized conduction system electrograms obtained in the patient L. III during open heart surgery. The upper three tracings show the intracardiac electrograms obtained with the electrode probe. The middle tracing (HRA) is a high right atrial electrogram showing the pacing artifact (P). The bottom three tracings are scalar electrocardiograms Leads I, II, and III. Note His bundle electrograms (SCS) seen between the pacing artifacts and the ventricular electrograms in each of the three cardiac cycles.

patient developed progressive low cardiac output and despite good anatomic repair and vigorous inotropic therapy she died several days postoperatively.

At autopsy the heart was markedly enlarged (428 g). The aorta was anterior and to the left of the pulmonary artery. Two atrioventricular valves entered the single ventricle and were separated by the Teflon patch. The newly created septum and pulmonary patch were intact. A bulboventricular foramen lead from the newly created left sided chamber to a small subaortic outflow chamber. The conduction system was sectioned and stained in the same manner as previously described. Two atrioventricular nodes were present—a hypoplastic posterior A-V node in the usual position and an anterior node at the junction of the right atrial appendage adjacent to the pulmonary artery (Fig. 9A). There was no communication of the posterior A-V node with the ventricular specialized conduction system.

A rudimentary atrioventricular bundle rose from the anterior node (Fig. 9A). Fibers of this bundle reached the fibrous annulus but could not be traced through the fibrous ring adjacent to the pulmonary valve ring. On the ventricular aspect of the fibrous ring adjacent to the pulmonary valve ring a discrete His bundle (Fig. 9B) lacking any continuity with the atrioventricular bundle was identified. The His bundle coursed down the right superior aspect of the bulboventricular foramen giving rise to a broad sheet of fibers which

continued into the subendocardium of the main chamber and a cord like bundle of fibers (so called false tendon) that traveled from the superior anterior aspect of the bulboventricular foramen across the outlet chamber. These bundles of specialized conduction tissue are the left and right bundle branches respectively and were identical to those described in Case 1.

Discussion

Using the electrophysiological technique for delineation of the specialized conduction system we were able to record typical intraventricular specialized conduction system electrograms superior and anterior to the bulboventricular foramen in both cases. The location of the specialized conduction system electrograms in these two patients were similar to the location of intraventricular specialized conduction system electrograms obtained by us and others in patients with corrected transposition of the great arteries, two well developed ventricles and a ventricular septal defect.^{1,2} Further it is of interest to note that in one patient the course of the specialized conduc-



Fig 3 Gross anatomical view of the heart in first patient RAV = right A V valve LAV = left A V valve P = pulmonary valve D = part of patch used for closure of defect The dashed area indicates the sites where specialized conduction system electrograms were obtained The arrow points to the false tendon extending from the bulboventricular foramen into the subaortic infundibulum Histologic examination of this structure identified it as the right bundle branch



Fig 4 Posterior atrioventricular node (arrow) in the normal position in the atrial septum There was no contact with the ventricular myocardium from this node (Hematoxylin and eosin stain original magnification $\times 8$)

tion system could be traced electrophysiologically even in the presence of complete heart block.

Our histologic observations demonstrate that the His bundle and the bundle branches were indeed located immediately underneath the

recording sites Even prior to histologic verification the electrophysiological studies indicated that the His bundle in these two patients was located in an unusual location superior and anterior to the bulboventricular foramen rather than in the posteroinferior aspect of the defect. Because of this unusual location in which the specialized conduction system electrograms were recorded in our cases and because our histological studies indeed demonstrated the presence of specialized conduction system tissue at this site our findings verify the relationship between the location of the specialized conduction system and specialized conduction system electrograms obtained in the human patient

This correlation shows that specialized conduction system electrograms were indeed recorded at the location in which the specialized conduction system was found with histologic studies and clearly identifies for the surgeon the area of the specialized conduction system at risk

The current data are in accord with a recent electrophysiologic study from our group which showed that the amplitude of the specialized conduction system electrograms fell off sharply with distance and disappear within 2 to 3 mm




Fig 5 A through C A Anterior atrioventricular node (arrows) situated between atrial septum at its anterior junction with the atrial appendage and the pulmonary artery B Fibers of the anterior A V node were continuous with the atrioventricular bundle (arrows) which penetrated the fibrous ring C Continuity between the atrioventricular bundle and the specialized conducting system of the ventricle was traced through the fibrous ring adjacent to the pulmonary valve ring The His bundle (arrows) ran down the right rim of the bulboventricular foramen between the two chambers (Hematoxylin and eosin stain original magnification $\times 8$)

from the recording probe. The current study which demonstrates the relation between the histologic location of the His bundle and the locations from which specialized conduction system electrograms are recorded in man and the study by Dick and colleagues which describes the spatial behavior of these electrograms in man therefore prove that the intracardiac electrograms recorded either during open heart surgery or during cardiac catheterization originate in the specialized conduction system of the heart.

Histologic studies describing the course of the specialized conduction system in patients with single ventricle and atrioventricular discordance have been recently described by Anderson and



Fig 6 A and B A At the level of the ventricular septum the left bundle branch continued into the main chamber and expands into a subendocardial network (arrows) B A cord like structure arises from the main bundle and transverse the foramen to the outlet chamber as a separate bundle of fibers. In the outlet chamber (arrows) this bundle of fibers the right bundle branch rapidly expanded to form a subendocardial network (Hematoxylin and eosin stain original magnification $\times 11$)




Fig 7 Preoperative and postoperative scalar electrocardiograms of the second patient. Note complete A V block prior to and following surgery. The frontal orientation of the QRS complex is $+120$ degrees and the QRS duration is 0.10 sec.




Fig 2 Intracardiac electrograms (three upper panels) and scalar electrocardiograms (three lower panels) of the second patient. Note a His bundle electrogram preceding each QRS complex. Note also that the tracing was obtained in a patient with complete heart block.

colleagues⁹ and by Bharati and Lev¹⁰ and concur with our observations. In each patient the intraoperative delineation was quite helpful to preserve the preoperative cardiac rhythm. In one patient no injury to the specialized conduction system occurred during the division of the single chamber into two chambers and the patient maintained a normal sinus rhythm postoperatively. In the second patient with complete heart block and junctional rhythm, prior to surgery the same heart rate and the same QRS duration and morphology were present postoperatively indicating that no further damage occurred to the specialized conduction system during surgery.

In most patients in whom intraoperative delineation of the specialized conduction system is carried out the procedure is done during a supraventricular rhythm such as normal sinus rhythm or during atrial stimulation. Such a supraventricular rhythm facilitates recognition of specialized conduction system electrograms which occur between the P and QRS complexes of the scalar electrocardiogram. As shown however by our second case, in some instances the location of the intraventricular parts of the specialized conduction system can be identified during complete heart block. In addition to identifying

the intraventricular parts of the specialized conduction system in patients with complete heart block and junctional rhythm we were able in the past to identify the specialized conduction system in patients with atrial fibrillation which occurs often during open heart surgery and precludes atrial pacing.

Operative correction of Type A single ventricle has been previously reported for 23 patients^{1, 3, 8, 11, 12} (Table I). Prior to the availability of specialized conduction system mapping procedure six patients out of seven developed heart block following surgery (Table I), and one case¹¹ developed a transient heart block during surgery. In contrast most previously reported patients who had electrophysiological delineation of their specialized conduction system did not develop heart block (Table I).¹¹

Although the technique of placing sutures close to the specialized conduction system during normal sinus rhythm may be useful to prevent complete heart block transient injury and occasional complete damage can nevertheless occur. Since the location of the specialized conduction system can vary considerably¹ and many times the specialized conduction system can be visualized following electrophysiologic identification

Table 1 Reported cases of primitive ventricle and outlet chamber (Type A) submitted for total operative repair

Number of cases with normal sinus rhythm	Reference	Intra operative mapping	Number developing postoperative heart block
1	1	no	1
2	11	no	2
1	11	no	1
1	11	no	1
2	12	no	2
1	13	yes	0
1	15	yes	0
24	16	yes	5
5	16	no	5
21	Current report	yes	11

The primitive heart block which developed appeared upon removal of sutures. On one case had the right bundle prior to operation but no further injury occurred to the specialized conduction system during the operation.

We feel that this simple and brief technique should be employed in all centers in which congenital heart defects are being repaired.

Summary

The specialized cardiac conduction system was delineated by electrophysiologic mapping during open heart surgery in two patients with single ventricle and levotransposition of the great arteries. In both patients the conduction system was found to be superior and anterior to the bulboventricular foramen. The sites where specialized conduction system electrograms were obtained were subsequently shown to contain the His bundle and the right and left bundle branches. In one patient with congenital complete heart block the histologic studies demonstrated the site of block to be due to complete interruption of the His bundle. The electrophysiologic-histologic correlation carried out in this study demonstrates the relationship between specialized conduction system electrograms obtained under direct vision during open heart surgery and the anatomic location of the specialized conduction system. The study further supports the value of the electrophysiologic technique for intraoperative identification of the specialized conduction system and its reliability in cases where electrograms were obtained showing the specialized conduction system to be not in its anticipated location.



Fig 3 A and B The anterior atrioventricular node (large arrow) of the second patient with complete heart block was located between the atrial septum and the pulmonary artery. This node gives rise to a beginning of an atrioventricular bundle (small arrows) however the bundle is rudimentary and ends before penetrating the fibrous ring. No connection with the specialized conducting system of the ventricular septum could be traced either from the anterior or posterior atrioventricular nodes (Hematoxylin and eosin stain original magnification $\times 8$). B On the ventricular aspect of the fibrous ring beneath the anterior atrioventricular node a bundle of specialized conducting tissue (arrows) was identified. This bundle of fibers resembled the His bundle and branched into left and right bundle branches in similar fashion to the His bundle in Case 1 (Figs 5 and 6). However no connection to the anterior node was identified (Hematoxylin and eosin stain original magnification $\times 25$).

The authors wish to thank Ms Sharon Kutner for her technical assistance.

REFERENCES

1. Kaiser G A, Waldo A L, Beach P W, Bowman F O Jr, Hoffman B F and Malm J R. Specialized cardiac conduction system. Improved electrophysiologic identification at surgery. *Arch. Surg.* 101:673, 1970.
2. Krongrad H, Malm J R, Bowman F O Jr, Hoffman B F, Kaiser G A and Waldo A L. Electrophysiologic delineation of the specialized atrioventricular conduction system in patients with congenital heart disease. I. Delineation of the His bundle proximal to the




Fig 1 Intracardiac electrograms (three upper panels) and scalar electrocardiograms (three lower panels) of the second patient. Note a His bundle electrogram preceding each QRS complex. Note also that the tracing was obtained in a patient with complete heart block.

colleagues⁹ and by Bharati and Lev,¹⁰ and concur with our observations. In each patient the intraoperative delineation was quite helpful to preserve the preoperative cardiac rhythm. In one patient no injury to the specialized conduction system occurred during the division of the single chamber into two chambers and the patient maintained a normal sinus rhythm postoperatively. In the second patient with complete heart block and junctional rhythm, prior to surgery the same heart rate and the same QRS duration and morphology were present postoperatively, indicating that no further damage occurred to the specialized conduction system during surgery.

In most patients in whom intraoperative delineation of the specialized conduction system is carried out, the procedure is done during a supraventricular rhythm such as normal sinus rhythm or during atrial stimulation. Such a supraventricular rhythm facilitates recognition of specialized conduction system electrograms which occur between the P and QRS complexes of the scalar electrocardiogram. As shown however by our second case, in some instances the location of the intraventricular parts of the specialized conduction system can be identified during complete heart block. In addition to identifying

the intraventricular parts of the specialized conduction system in patients with complete heart block and junctional rhythm, we were able in the past to identify the specialized conduction system in patients with atrial fibrillation which occurs often during open heart surgery and precludes atrial pacing.

Operative correction of Type A single ventricle has been previously reported for 23 patients^{1, 2, 5, 11, 12} (Table I). Prior to the availability of specialized conduction system mapping procedure six patients out of seven developed heart block following surgery (Table I) and one case¹¹ developed a transient heart block during surgery. In contrast most previously reported patients who had electrophysiological delineation of their specialized conduction system did not develop heart block (Table I).

Although the technique of placing sutures close to the specialized conduction system during normal sinus rhythm may be useful to prevent complete heart block, transient injury and occasional complete damage can nevertheless occur. Since the location of the specialized conduction system can vary considerably¹ and many times the specialized conduction system can be visualized following electrophysiologic identification

Pleural effusion as a manifestation of Dressler's syndrome in the distant post infarction period

W Roger Domby M D
Michael E Whitcomb M D
Boston Mass

Dressler's syndrome is a well recognized clinical entity which occurs in 3 to 4 per cent of patients following myocardial infarction.¹ This syndrome usually develops within the first few weeks after infarction and is characterized by episodes of acute chest pain fever and pericarditis that tend to recur over many years. During the initial episode of Dressler's syndrome pleural effusions are present in a high percentage of cases. Although the development of a pleural effusion many months after infarction has been reported as the sole manifestation of this syndrome this clinical presentation is not well recognized. We have recently evaluated a patient who presented with a bloody pleural effusion 1 1/2 years after the initial onset of Dressler's syndrome. Because of the therapeutic implications involved we are reporting this case to emphasize that pleural manifestations of this syndrome may occur in the distant post infarction period.

Case report

A 65-year-old white woman presented in January 1974 with an acute anterior myocardial infarction. Forty-eight hours post infarction she complained of recurrent chest pain and a pericardial friction rub was noted. This resolved after 4 days without specific therapy.

In May 1974 she was readmitted complaining of left lateral pleuritic chest pain. She stated that the pain which was intermittent in nature would last for 2 to 3 days and

was associated with low grade fever. She noted the presence of a non productive cough but denied hemoptysis. There was no history of calf tenderness trauma or symptoms of other systemic diseases. Her medications were digoxin chlorothiazide and spironolactone. Positive physical findings included an oral temperature of 101 F., a pleural friction rub over the left lateral chest and a 3 component pericardial friction rub over the anterior chest. An electrocardiogram showed diffuse ST segment elevation consistent with pericarditis and residual changes of an old anterior myocardial infarction. A chest roentgenogram revealed blunting of both costophrenic angles. Pleural fluid was not demonstrated on decubitus films. A lung scan revealed no perfusion defects. Lupus erythematosus preparations and antinuclear antibody studies were negative. The patient's pain and fever responded to indomethacin and she was discharged after 6 days. However over the next 3 months she was admitted on five occasions for recurrence of the left sided chest pain. A pericardial friction rub was present on two of these admissions. On each occasion her symptoms resolved on indomethacin therapy.

In September 1976 she was admitted with complaints of dyspnea on exertion left pleuritic chest pain fever and a non productive cough. At this time her medications were digoxin chlorothiazide and alpha methyl dopa. Physical examination revealed a well nourished white female in no acute distress. She had an oral temperature of 101 F pulse of 90 beats per minute blood pressure of 150/90 mm Hg and a respiratory rate of 22/minute. Cardiac examination was normal. Examination of the lungs revealed decreased tactile fremitus flatness to percussion and decreased breath sounds over the lower one third of the left hemithorax. A coarse pleural friction rub was heard over this area. A chest roentgenogram revealed a large left pleural effusion blunting of the right costophrenic angle and borderline cardiomegaly (Fig 1). An electrocardiogram showed evidence of the old anterior infarction. Her routine laboratory studies were normal. Serum studies for rheumatoid factor and antinuclear antibodies were negative. Serum complement was within normal limits. A thoracentesis yielded grossly bloody fluid. Analysis of the fluid revealed 20,000 RBC/mm 1,800 WBC/mm (1 polymorphonuclear leukocyte 51 lymphocytes 3 monocytes, 37 large mononuclear cells) protein was 5.1 Gm per cent sugar was 139 mg

From the Pulmonary Disease Service University Hospital, Department of Medicine Boston University School of Medicine.

Received for publication July 19 1977.

Accepted for publication August 1 1977.

Reprint request: W Roger Domby M D Pulmonary Division N 35 Medical Hall, Ohio State University Hospital 466 West 10th Avenue Columbus, Ohio 43210.

- membranous septum J Thorac Cardiovasc Surg 67 875 1974
- 3 Krongrad E Malm J R Bowman F O Jr Hoffman B F and Waldo A L Electrophysiological delineation of the specialized A V conduction system in patients with congenital heart disease II Delineation of the distal His bundle and the right bundle branch Circulation 46 1232 1974
- 4 Dick M II Krongrad E Antar R E Ross S Bowman F O Jr Malm J R and Hoffman B F Intraoperative recording of the His bundle electrogram in man An assessment of its precision Circulation 53 224 1976
- 5 Van Praagh R Ongley P A and Swan H Anatomic types of single or common ventricles Am J Cardiol 13 367 1964
- 6 Kupersmith J Krongrad E Gersony W M and Bowman F O Jr Electrophysiologic identification of the specialized conduction system in corrected transposition of the great arteries Circulation 50 795 1974
- 7 Krongrad E Ellis K Steeg C N Bowman F O Jr Malm J R and Gersony W M Subpulmonary obstruction in congenitally corrected transposition of the great arteries due to ventricular membranous septal aneurysms Circulation 54 679 1976
- 8 Waldo A L Pacifico A D Barger L M James T N and Kirkin J W Electrophysiological delineation of the specialized A V conduction system in patients with corrected transposition of the great vessels and ventricular septal defect Circulation 52 435 1975
- 9 Anderson R H Arnold R Thapar M K Junos R S and Hamilton D I Cardiac specialized tissue in hearts with an apparently single ventricular chamber (Double inlet left ventricle) Am J Cardiol 33 95 1974
- 10 Bhurati S and Lev M The course of the conduction system in single ventricle with inverted (L) loops and inverted (L) transposition Circulation 51 793 1975
- 11 Edie R N Ellis K Gersony W M Krongrad E Bowman F O Jr and Malm J R Surgical repair of single ventricle J Thorac Cardiovasc Surg 66 300 1973
- 12 Ionescu M I Macartney F J and Wooler G H Intracardiac repair of single ventricle with pulmonary stenosis J Thorac Cardiovasc Surg 65 607 1973
- 13 Hallman G L Gill S S Bloodwell R D McNamara D G Latson J R Leachman R D and Cooley D A Surgical treatment of cardiac defects associated with corrected transposition of the great vessels, Circulation 35 (Suppl 1) 133 1967
- 14 Somerville J Becu L and Ross D Common ventricle with acquired subaortic obstruction Am J Cardiol 34 206 1974
- 15 Maloney J D Ritter D G McGoon D C and Danielson G K Identification of the conduction system in corrected transposition and common ventricle at operation Mayo Clin Proc 50 387 1975
- 16 McGoon D C Danielson G K Wallace R B Maloney J D and Marcelletti C The problem of correcting single and common ventricle J Thorac Cardiovasc Surg 74 218 1977
- 17 Maloney J D Personal communication Mayo Clinic Rochester Minnesota
- 18 Wilkinson J L Anderson R H Arnold R Hamilton D and Smith A The conduction tissues in primitive ventricular hearts without an outlet chamber Circulation 53 930 1976

Summary

A 65 year old woman developed a bloody pleural effusion 2 1/4 years after the onset of Dressler's syndrome. Since an extensive evaluation failed to reveal a specific etiology the effusion was presumed to be a manifestation of Dressler's syndrome. Because of the therapeutic implications involved we are reporting this case to emphasize that pleural effusions may occur as a manifestation of Dressler's Syndrome in the distant post infarction period.

REFERENCES

- 1 Dressler W. The post myocardial infarction syndrome. *Arch. Intern. Med.* 103:28, 1959.
- 2 Levin E. J. and Bryk D. Dressler's syndrome (post myocardial infarction syndrome). *Radiology* 87, 31, 1966.
- 3 Gelfand M. L., and Effros R. M. Hemorrhagic pleural effusion following acute myocardial infarction. *N. Y. State J. Med.* 65:1153, 1965.
- 4 Black L. F. The pleural space and pleural fluid. *Mayo Clin. Proc.* 47:493, 1972.



Fig 1 Chest roentgenogram obtained at the time of admission to the hospital in September 1976 revealing a left pleural effusion

per cent LDH was 705 IU amylase was 11 IU Pathologic examination of pleural biopsy specimens obtained on two different occasions showed changes of chronic inflammation Cell blocks and cultures of the pleural fluid were negative A tuberculin skin test (5 tu) was non reactive A perfusion lung scan revealed a non segmental defect in the area corresponding to the left sided pleural effusion A bronchoscopic examination was normal and washings yielded no abnormal cytologies A bone survey gallium scan and liver scan were all normal Methyldopa and hydrochlorothiazide were discontinued without effect

A tentative diagnosis of pleural effusion secondary to Dressler's syndrome was made The patient was treated with indomethacin with prompt resolution of her symptoms and a decrease in the amount of pleural fluid Because of gastrointestinal intolerance indomethacin was discontinued and the pain and pleural effusion recurred Institution of corticosteroid resulted in dramatic improvement in her symptoms and a decrease in the size of the effusion The patient has been followed for 9 months since the initial recognition of her bloody pleural effusion She has developed no evidence of an underlying malignancy connective tissue disorder or other systemic disease

Discussion

Although it is impossible to substantiate the diagnosis we feel that the bloody pleural effusion that developed in our patient was a manifestation of Dressler's syndrome The patient's history of recurrent chest pain and pericarditis over many months is characteristic of this syndrome Although the pleural effusion could have been caused by other diseases an extensive evaluation at the time of hospitalization and the subsequent period of follow up make it highly unlikely that the effusion was due to pulmonary infarction malignancy, infection drug reaction or systemic collagen vascular disease

Pleural effusions have been reported to occur in 68 to 88 per cent of the patients with Dressler's syndrome¹⁻² The effusions are generally small and are unilateral in approximately 50 per cent of the cases Bloody pleural effusions are distinctly uncommon Of the 35 effusions in Dressler's series only three were hemorrhagic and one of these appeared to be a direct complication of anticoagulant therapy Gelfand and Effros¹ reported an additional case of a bloody pleural effusion in Dressler's syndrome but the patient in this report was also receiving anticoagulants Although the majority of patients with this syndrome have pericarditis it is well recognized that clinical evidence of pericardial disease may not be present at the time pulmonary manifestations are apparent

In the absence of pericardial disease the development of a pleural effusion in a patient with Dressler's syndrome presents a difficult diagnostic problem since as in our case more common etiologies of pleural effusion must be considered⁴ Nevertheless it is important to be aware of the fact that isolated pleural effusions may occur in Dressler's syndrome since hemopericardium and cardiac tamponade have occurred in patients with this syndrome who were anticoagulated Thus in a patient who has had prior manifestations of Dressler's syndrome and who develops a pleural effusion the diagnosis of pulmonary infarction must be carefully documented prior to the institution of anticoagulant therapy The possibility that the effusion represents a manifestation of Dressler's syndrome should be considered In this event the majority of these patients will respond dramatically to corticosteroids although salicylates or indomethacin may also be effective




Fig 2 Chest radiograph taken 1 month before death showing marked cardiac enlargement



Fig 3 Frames from left ventricular angiogram in end systole (left) and diastole (right). The left ventricular wall is markedly thickened and the left ventricular cavity is not dilated

heart failure Shortly after admission cardiac catheterization was performed and showed the following pressures in mm of mercury in the right atrium (mean) 4 right ventricle 20/3 pulmonary artery 21/0 with a mean of 11 left atrium (mean) 11 left ventricle 65/7 No gradient was demonstrated across the left ventricular outflow tract Cardiac output was 0.8 liters/minute left ventricular stroke volume was 51 ml which was 30 per cent above the predicted value for height and weight Systemic and pulmonary vascular resistance were low Right and left

ventricular angiograms showed thickened ventricular walls and interventricular septum normally related ventricular cavities and great vessels and a left ventricular ejection fraction of 70 per cent (Fig 3) No coronary artery anomalies intracardiac shunts or valvular regurgitation or stenosis could be demonstrated Echocardiogram (Fig 4) demonstrated symmetrical left ventricular hypertrophy without ventricular cavity enlargement Thallium 201 myocardial perfusion imaging showed homogenous tracer uptake without focal defects a markedly thickened non

Pompe's disease presenting as hypertrophic myocardiopathy with Wolff-Parkinson-White syndrome

Bernadine H. Bullock, MD

Grover M. Hutchins, MD

Baltimore, Md

Clinical summary

A 5-month-old white female was the offspring of a consanguineous mating between her 17-year-old mentally retarded mother and the mother's 61-year-old maternal grandfather. After an uneventful pregnancy and delivery, the child exhibited unexplained irritability and poor feeding. Continued failure to thrive was noted after discharge home and by age 2 months a precordial murmur and cardiomegaly were noted and she was admitted to the hospital for evaluation.

On examination she was an alert, irritable, thin infant with circumoral cyanosis. Length, weight, and head circumference were at the 3rd percentile for age. Pulse rate was 140 per minute and regular respirations were 45 per minute and blood pressure was 95 mm. Hg by palpation. Pertinent physical findings included an enlarged tongue and clear lungs and a Grade 2/6 harsh systolic ejection type murmur over the aortic area. There were no heaves, thrills, or precordial bulges and the left ventricular impulse was displaced laterally. The liver extended 2 cm. below the right costal margin. Firm prominent musculature was noted in all extremities but muscle tone was diminished and strength poor.



Fig 1 Electrocardiogram taken at age 3 months showing short PP interval, left ventricular hypertrophy, and the suggestion of a delta wave in V_1 and V_2 . The heart rate was 140; the paper speed has been increased to 50 mm/sec. in V_1 , V_2 , and V_3 and in the precordial leads.

Laboratory studies showed a hematocrit of 37, white blood count 18,600, serum potassium of 6.0 mEq./ml., with other serum electrolytes normal, and serum glucose of 120 mEq./ml. Chest radiograph (Fig 1) showed cardiomegaly with a cardiothoracic ratio of 0.7, a left aortic arch and normal pulmonary vasculature. Electrocardiogram showed a short PR interval (0.08) and left ventricular hypertrophy and possible subendocardial ischemia (Fig 2). Arterial blood gases on 40 per cent inspired oxygen were as follows: P_{O_2} 61 mm. Hg, P_{CO_2} 43, pH 7.37. Serum creatinine phosphokinase was elevated to 17.0 with a positive MB fraction, raising the possibility of myocardial infarction as a cause of her obscure congestive

From the Cardiovascular Division of the Department of Medicine and the Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Md.

Supported in Grant F50-HL-17770-01 with The National Institutes of Health, Public Health Service, Department of Health, Education and Welfare and the Searles Research Fund for Women Physicians.

Received for publication May 6, 1977.

Reprint requests: Dr. Bernadine H. Bullock, Cardiovascular Division, The Johns Hopkins Hospital, Baltimore, Md. 21205.




Fig 2 Chest radiograph taken 1 month before death showing marked cardiac enlargement



Fig 3 Frames from left ventricular angiogram in end systole (left) and diastole (right) The left ventricular wall is markedly thickened and the left ventricular cavity is not dilated

heart failure Shortly after admission cardiac catheterization was performed and showed the following pressures in mm of mercury in the right atrium (mean) 4 right ventricle 20/3 pulmonary artery 21/5 with a mean of 11 left atrium (mean) 11 left ventricle 65/7 No gradient was demonstrated across the left ventricular outflow tract Cardiac output was 0.8 liters/minute left ventricular stroke volume was 5.1 ml which was 30 per cent above the predicted value for height and weight Systemic and pulmonary vascular resistance were low Right and left

ventricular angiograms showed thickened ventricular walls and interventricular septum normally related ventricular cavities and great vessels and a left ventricular ejection fraction of 70 per cent (Fig 3) No coronary artery anomalies intracardiac shunts or valvular regurgitation or stenosis could be demonstrated. Echocardiogram (Fig 4) demonstrated symmetrical left ventricular hypertrophy without ventricular cavity enlargement Thallium 201 myocardial perfusion imaging showed homogenous tracer uptake without focal defects a markedly thickened non




Fig. 4 Echocardiogram showing small left ventricular cavity and good wall motion. The decreased E to F slope of the mitral valve (MV) is compatible with diminished left ventricular compliance associated with severe left ventricular hypertrophy. LVF = left ventricular free wall.

dilated left ventricle without asymmetric septal hypertrophy, gated cardiac blood pool scan demonstrated an ejection fraction of in excess of 70 per cent and no segmental wall motion abnormalities.

Treatment with digitalis and diuretics failed to improve her heart failure. Because of the results of both invasive and noninvasive studies showing hyperdynamic hypercontractile heart digitalis was discontinued and propranolol instituted with demonstrated improvement. Because of tongue and skeletal muscle abnormalities, skeletal muscle biopsy was performed and revealed changes compatible with glycogen storage disease.

The child was discharged home but continued to do poorly failing to gain weight and continuing to have episodes of cyanosis and irritability. On frequent outpatient visits she remained relatively unchanged although by chest radiograph her heart continued to enlarge. Without warning at five months of age she died suddenly at home.

Discussion

DR. BERNADINE H. BULKLEY This 5 month old female was unwell from the time of birth. Initially she showed nonspecific signs of poor

feeding and irritability. The cause of her failure to thrive did not become apparent however until 2 months of age when she was noted to have a heart murmur and unexplained cardiomegaly. Echocardiogram suggested left ventricular hypertrophy without evidence of asymmetric septal hypertrophy and Thallium 201 myocardial perfusion imaging which may also be a useful noninvasive method for detection of asymmetric septal hypertrophy showed only concentric hypertrophy with a normal to small sized left ventricular cavity. Cardiac catheterization revealed essentially normal right and left ventricular pressure and no evidence of intracardiac shunting valve abnormalities or congenital malformation. She did have an increased stroke volume for size and an increased ejection fraction of 70 per cent suggesting a hypertrophic cardiomyopathy. Bi ventricular angiogram also showed ventricular hypertrophy and a small left ventricular cavity.

Thus, congenital aortic stenosis or atresia were ruled out by the catheterization studies, as was the possibility of an anomalous left coronary artery which might have been suggested by the elevated cardiac enzymes. The lack of ventricular dilatation and good ventricular function elimi-




Fig 5 A and B A Histological section of skeletal muscle biopsy showing marked vacuolization of muscle fibers by glycogen deposits. There is considerable variation in fiber size (hematoxylin and eosin stain original magnification $\times 300$) B Electron micrograph of skeletal muscle showing extensive granular glycogen deposits between the myofibrils (original magnification $\times 63,000$)

nated viral myocarditis or endocardial fibroelastosis from consideration. Her clinical findings were most compatible with a hypertrophic cardiomyopathy, a condition which infrequently presents this early in life. Features of her presentation that led to the precise diagnosis were largely extracardiac. By physical examination she had a noticeably enlarged tongue and her skeletal muscle in all four extremities was firm, prominent but also weak with poor tone. Also, her liver was enlarged. The best explanation for the large tongue, hepatomegaly, hypotonia, and cardiomegaly was glycogen storage disease. Other myopathies that may affect skeletal muscle such as Duchenne's muscular dystrophy, either do not present this early in life or do not have the degree of cardiac involvement.

Dr Hutchins: will you describe the findings on skeletal muscle biopsy?

Dr GROVER M. HUTCHINS: The skeletal muscle pathology was quite typical of Type II glycogen storage disease. The muscle fibers are all distended by sarcoplasmic accumulations of glycogen (Fig 5). By analysis the tissue had 93 Gm per cent glycogen compared to normal levels

of less than 15 Gm per cent. Furthermore, absence of the enzyme of $\alpha 1$ 4 glycosidase was shown by assay.

The accumulation of massive quantities of normal glycogen in certain tissues of patients with Type II glycogenosis or Pompe's disease appears to be explained by deficiency of the lysosomal enzyme capable of degrading the glycogen molecule. The normal metabolic pathways of glucose utilization are intact; however, so that energy productivity by the cell is unimpaired.

The lysosomal acid maltase is absent not only in cardiac and skeletal muscle but also in leukocytes, fibroblasts, and cells of the liver and central nervous system. Diagnosis can be made by demonstrating the enzyme deficiency in leukocytes, but the most definitive diagnostic technique is muscle biopsy with glycogen quantitation.

Dr BULKLEY: Type II glycogen storage disease carries a grave prognosis, with most infants dying of cardiac involvement within the first year of life. There have been unsuccessful attempts to treat these infants with enzyme infusions, and to date treatment is only symptomatic. This child




Fig 8 A through D Histology of tissues obtained from autopsy A Myocardium with marked vacuolization of cardiac muscle cells (Periodic acid Schiff stain original magnification $\times 150$) B Striated muscle of tongue with distortion and vacuolization of muscle cells by sarcoplasmic glycogen accumulation The media of arterioles (arrow) also shows vacuolization of smooth muscle cells by glycogen accumulation (Hematoxylin and eosin stain original magnification $\times 300$) C Liver with hepatocytes distended by glycogen deposits (Hematoxylin and eosin stain original magnification $\times 400$) D Spinal cord anterior horn with motor neurons containing glycogen (Hematoxylin and eosin stain original magnification $\times 300$)

deteriorated on digitals as is true of hypertrophic cardiomyopathy, and was improved with propranolol therapy. Over the last 3 months of her life however, she showed progressive cardiomegaly and finally died suddenly at home.

Dr Hutchins would you describe the autopsy findings?

DR HUTCHINS The body was small for a 5 month old infant weighing only 3 kilograms and being 55 cm in length. The musculature was




Fig 7 A through C Selected serial histological sections of the atrioventricular node and bundles. Sections are viewed with right side on right and interatrial septum at top A At level of atrioventricular (AV) node which is on the atrial side of the central fibrous body (CFB) B Slightly further along the conducting pathways the poorly defined His bundle establishes contact with the right ventricular septal muscle C The left bundle arises more distally in the conducting system TV = tricuspid valve (All periodic acid Schiff stain original magnification $\times 10$)

prominent especially in the tongue and diaphragm. The heart was markedly enlarged weighing 88 grams as compared to an expected weight of approximately 26 grams. Despite the overall increase in heart size the chambers were all of about normal volume and the valve diameters were appropriate for the overall body size. The myocardium was greatly thickened in all chambers as a result of the same glycogenic accumulation as seen in the skeletal muscles (Fig 6). Extensive glycogen accumulation was present in the working myocardium of all four cardiac chambers. There was no histologic evidence of myocardial necrosis or fibrosis and the coronary arteries were normal.

The other organs were grossly unremarkable. The lungs had severe congestion and edema. No other cause of death could be found. Glycogen demonstrated by comparison of periodic acid Schiff stains with and without diastase digestion was found especially in the liver, skeletal muscle, smooth muscle and in neurons of both the central and peripheral nervous system (Fig 6). It is possible that the skeletal muscle weakness in these patients relates to neuronal glycogenosis.

The autopsy findings in this patient are typical of Type II glycogen storage disease, the only one of the several disorders of glycogen accumulation associated with specific enzyme defects that significantly affects cardiac function.

DR. BULKLEY: Pompe's disease is a rare disorder that appears to have an autosomal recessive

pattern of inheritance. No more than 50 or 60 cases have been reported in the literature, most of them having limited clinical and pathologic evaluation. Comparing our patient with three previously reported¹⁻³ in whom cardiac catheterization had been performed during life, the clinical illnesses appear remarkably similar. Each of the infants presented with a general failure to thrive and had idiopathic left ventricular hypertrophy, short PR intervals on electrocardiogram, and at catheterization had hyperdynamic cardiac function. In one of these reported patients¹ outflow tract gradients could be provoked, suggesting an obstructive form of hypertrophic disease. The similarity of these patients to those with familial idiopathic hypertrophic subaortic stenosis associated with asymmetric septal hypertrophy⁴ points out the heterogeneous spectrum of disease which falls within the category of hypertrophic cardiomyopathy.⁵ These patients also point out the nonspecificity of most of the findings associated with hypertrophic states with or without gradients at catheterization: all hypertrophic cardiomyopathies are clearly not associated with asymmetric septal hypertrophy and abnormal myocardial fiber arrangement.

Another interesting aspect of the cardiac disorder of Pompe's disease is the occurrence of a pre-excitation syndrome. Wolff-Parkinson-White syndrome (WPW) has been associated with a variety of congenital disorders including Ebstein's

anomaly, atrial septal defect, ventricular septal defect and tetralogy of Fallot.¹⁴ In addition familial hypertrophic cardiomyopathy is not infrequently associated with Wolff Parkinson White syndrome.¹⁵ The abnormal ICG in this infant was compatible with a number of congenital lesions and with hypertrophic cardiomyopathy or Pompe's disease.

Pre excitation syndromes are generally believed to result from an accessory atrioventricular myocardial pathway which is separate from and bypasses, the AV node and bundle of His. Accessory pathways are generally believed to cross the posterior and lateral wall of the atrioventricular groove but some may be located more centrally near the atrioventricular node.¹⁶ Although a pre excitation syndrome has been described in Pompe's disease, there is little or no information about the morphology of the conduction system in this disease. Dr Hutchins did you study the conduction system in this infant?

DR HUTCHINS: The conduction system in this child was of great interest at autopsy, and serial histological sections of the sinoatrial node and atrioventricular (AV) node His bundle and bundle branches were performed. Glycogen accumulation was present in the specialized conduction tissues as in the working myocardium. In addition the anatomy of the atrioventricular node His bundle and bundle branches was unusual (Fig 7). The His bundle was remarkably ill defined. The AV node penetrated the central fibrous body at a more proximal level than usual and within a few hundred microns gave rise to a large right bundle connecting directly with the myocardium of the interventricular septum. The fascicles of the left bundle arose at a more distal level. Thus the pre excitation in this infant appears to be explained by a centrally located abnormality within the AV node and His bundle per se.

DR BULKLEY: In summary this unfortunate infant offspring of a consanguineous union was born with a recessively inherited metabolic disease which lead to her death by 5 months of age. Although she had increased and progressive glycogen deposition in most of the tissues of her body, it was the cardiac involvement that caused most of her clinical illness and death.

There are at least eight different forms of inherited diseases of glycogen metabolism that are now recognized which form a broad spectrum

of clinical illness. Type II glycogen storage disease, the only one to extensively involve the heart, carries one of the bleakest outlooks.

REFERENCES

- 1 Bulkeley B H, Rouleau J, Strauss H W, and Pitt B. Idiopathic hypertrophic subaortic stenosis. Detection by Thallium 201 myocardial perfusion imaging. *N Engl J Med* 293 1113 1975.
- 2 Huyghe F, van Creveld S, and Loeckert C. Diagnosis of generalized glycogen storage disease (Pompe's disease). *J Pediatr* 63 984 1963.
- 3 Brudhuim P, Hersh H C, and Loeb H. An electron microscopic and biochemical study of Type II glycogenosis. *Lab Invest* 13 1139 1964.
- 4 Smith J, Zellweger H, and Afifi A K. Muscular form of glycogenosis type II (Pompe). Report of a case with unusual features. *Neurology* 17 537 1967.
- 5 Huttenberg H D, Steidl R M, Carey L S, Edwards J E. Glycogen storage disease of the heart. Hemodynamic and angiographic features in 2 cases. *AM HEART J* 67 469 1964.
- 6 Flierer K H, and Engle M A. Glycogen storage disease of myocardium. *AM HEART J* 65 145 1963.
- 7 Hohn A R, Lowe C U, Sokal J E, and Lambert E C. Cardiac problems in the glycogenoses with specific reference to Pompe's disease. *Pediatrics* 35 313 1965.
- 8 Flierer K H, Hagstrom J W, C Lukas D S, Redo S F, Engle M A. Glycogen-storage disease of the myocardium with obstruction to left ventricular outflow. *Circulation* 25 96 1962.
- 9 Teare D. Asymmetrical hypertrophy of the heart in young adults. *Br Heart J* 20 1 1958.
- 10 Braunwald E, Morrow A G, Cornell W P, Aygen M M, and Hultberg T F. Idiopathic hypertrophic subaortic stenosis. Clinical, hemodynamic and angiographic manifestations. *Am J Med* 29 295 1960.
- 11 Bulkeley B H, and Fortuin N J. Systolic anterior motion of the mitral valve without asymmetric septal hypertrophy. *Chest* 69 694 1976.
- 12 Come P C, Bulkeley B H, Goodman Z P, Hutchins G M, Pitt B, and Fortuin N J. Hypercontractile cardiac states simulating hypertrophic cardiomyopathy. *Circulation* 55 901 1977.
- 13 Bulkeley B H, Weisfeldt M L, and Hutchins C M. Isometric cardiac contraction: A possible cause of the disorganized myocardial pattern of IHSS. *N Engl J Med* 295 135 1977.
- 14 Bulkeley B H, Weisfeldt M L, and Hutchins G M. Asymmetric septal hypertrophy and myocardial fiber disarray: features of normal developing and malformed hearts. *Circulation* 56 292 1977.
- 15 Schiebeler G L, Adams P Jr, and Anderson R C. The Wolff Parkinson White syndrome in infants and children: A review and a report of 28 cases. *Pediatrics* 24 587 1959.
- 16 Westlake R F, Cohen W, and Willis W H. Wolff Parkinson White syndrome and familial cardiomegaly. *AM HEART J* 64 314 1964.
- 17 James T N. The Wolff Parkinson White syndrome: Evolving concepts of its pathogenesis. *Progr Cardiovasc Dis* 13 159 1970.
- 18 Mann R B, Fisher R S, Scherlis S, and Hutchins G M. Accessory left atrioventricular connection in type A Wolff Parkinson White syndrome. *Johns Hopkins Med J* 132 242 1973.

Mitral valve repair for significant mitral insufficiency

Jerome Harold Kay MD
Pablo Zubiate MD
Michael A. Mendez MD
Neal Vanstrom MD
Taro Yokoyama MD
Los Angeles Calif

Prior to the article by Starr and Edwards in 1961¹ on mitral valve replacement it was necessary to repair the abnormally functioning mitral valve at the time of surgery since a prosthetic mitral valve was not available. With the introduction of prosthetic valves it has been technically easier for surgeons to replace the valve than attempt repair. Our first repair for pure mitral insufficiency was performed in 1959 and except for brief periods this has remained our method of choice for surgery for significant mitral insufficiency for the past 18 years. Repair has not been popular with surgeons however since repair is more difficult and takes greater thought than excising a valve and replacing it with a prosthesis. With 15 years clinical and experimental experience with various prosthetic devices it is our strong conviction that a mitral prosthesis of any variety or a porcine valve should be inserted only if repair cannot be accomplished.

With short and long term results of mitral valve replacement being published not only with the Starr-Edwards valve but also the Hancock porcine valve it would appear of interest to compare these results to the results with repair of the insufficient mitral valve. The following is a report of two groups of patients: 145 patients with

pure mitral insufficiency in whom mitral repair was performed from 1959 to 1977 and 55 patients with mitral insufficiency and coronary artery disease in whom repair was performed at the time of myocardial revascularization from 1970 to 1977.

Although the basic principle is the same for repair of the insufficient mitral valve for all patients the data from the two groups of patients is presented separately in this article.

Since 1970 myocardial revascularization has been performed in all but one patient with mitral insufficiency and coronary artery disease requiring mitral valve surgery when significant coronary artery disease was present. In this patient revascularization was not needed nor possible since the vessel obstructed led to an area of infarct and the other two vessels had only minimal disease. These patients comprise Group II. There were 14 patients operated upon prior to 1970 with mitral insufficiency and coronary artery disease but myocardial revascularization was not combined with repair or replacement by us until 1970. These patients are included in the first group of patients with pure mitral insufficiency. There may be other patients in Group I who had coronary artery disease and whose mitral insufficiency was due to or associated with the coronary artery disease and were operated upon for their mitral insufficiency during the years from 1959. If so the coronary artery disease was not proven even though suspected since coronary arteriography was not performed in these patients.

In order to better understand our approach to

From The Los Angeles Heart Institute at The St. Vincent Medical Center, Los Angeles, and The University of Southern California School of Medicine, Los Angeles.

Aided by a grant from The Los Angeles Theoretical and Clinical Research Foundation.

Received for publication Dec. 14, 1977.

Reprint requests: Jerome Harold Kay, MD, 123 South Alameda Street, Los Angeles, Calif. 90067.




Fig 1 The area of the leaflet involved with stretched or torn chordae tendineae or torn papillary muscle is repaired by placing interrupted figure of eight sutures of 2/0 Tevdek through the head of the nearer papillary muscle and then bringing this suture up through the leading edge of the involved area of the leaflet. Usually two separate sutures are used at each area. For ease of exposure all sutures are placed prior to tying



Fig 2 In order to obliterate the insufficiency the greatly dilated sagging mural annulus is decreased considerably in size. This must be accomplished by decreasing the length of the mural annulus to about 1/5 of its size and thereby bringing it up into apposition with the anterior leaflet. The annulus of the anterior leaflet cannot be encroached upon. The repair is accomplished with No. 2 silk sutures as illustrated.

the repair of the mitral valve it is important to be familiar with our thinking as to the development of mitral insufficiency. Whether the patient began with mitral valve prolapse without significant insufficiency and over the years developed wide open mitral insufficiency or whether the patient had myocarditis and developed mitral insufficiency secondary to this the progression is similar. With mitral valve prolapse the annulus is large and the leaflets meet only at their edges. With myocarditis the left ventricle enlarges thereby enlarging the annulus and the mitral leaflets do not coapt. Because the leaflets meet only at their edges or not at all there is

significant tension on the leaflets each time the heart contracts. This creates tension on the chordae tendineae as well. With time the leaflets stretch and enlarge as do the chordae tendineae. In many patients the chordae tendineae tear. The leaflets are usually thickened and reveal fibromyxoid degeneration. This fibromyxoid degeneration in the leaflets is secondary to the trauma produced by the pressure of the blood on the unsupported leaflets during systole.

With mitral insufficiency secondary to coronary artery disease the mitral insufficiency may be due to tearing of infarcted papillary muscle or




Fig 3 Actuarial curves Mitral repair results for Group I and Group II patients using Biomedical Computer Program BMD11S

chordae tendineae because of infarcted papillary muscle. With these patients there is always secondary annular dilatation due to enlargement of the left ventricle. In other patients with coronary artery disease the infarct may involve the muscle near the annulus with resultant dilatation of the annulus and failure of coaptation of the leaflets. In some patients with a massive infarct the annulus may be stretched due to enlargement of the left ventricle.

No matter what the etiology of the mitral insufficiency it is always necessary to decrease the size of the annulus and this part of the repair is almost always performed in the same manner. This consists of decreasing the length of the mural annulus and not the annulus of the anterior leaflet. The trigona fibrosa cordis prevents the annulus of the anterior leaflet of the mitral valve from stretching. The mural leaflet portion of the annulus does not have a similar support and therefore the mitral annulus dilates at the area of the mural annulus but not the area of the anterior annulus. It is important to remember that the mural annulus only is stretched in all patients with mitral insufficiency.

The majority of patients with mitral insufficiency not secondary to coronary artery disease will have torn chordae tendineae and/or stretched chordae tendineae. The patient with mitral insufficiency secondary to myocardial infarction may or may not have torn chordae

tendineae or torn papillary muscle but they will not have associated stretched chordae tendineae unless the insufficiency is of many years duration.

Technique

The technique of repair is as follows. After opening the left atrium a careful search is made to determine if there are torn or stretched chordae tendineae or torn papillary muscle. If there are significantly stretched chordae tendineae, torn chordae tendineae or torn papillary muscle this area of the valve is sutured down to the nearest papillary muscle head (Fig 1). New chordae are not constructed. The anterolateral posteromedial, midportion or all three areas of the mural leaflet may require suturing to the nearest papillary muscle. If there are torn or stretched chordae tendineae of the anterior leaflet this area is sutured to the head of the papillary muscle involved. If all of the chordae tendineae of the anterior leaflet are stretched then either the anterolateral or posteromedial portion of the anterior leaflet is sutured to the head of the nearest area involved (Fig 1). This allows the remaining portion of the anterior leaflet to billow and close against the mural leaflet. It is important for the anterior leaflet to billow in order to abut against the mural leaflet otherwise the insufficiency will not be corrected.

Except for minor variations in individual

Table 1 Mitral insufficiency without myocardial revascularization—repair failures

Patient No	Age at first surgery	Date of first surgery	Initial cause of mitral insufficiency	Cause of failure	Date of subsequent surgery	Procedure	Outcome
1	R F 36	8/11/59	Torn chordae tendineae of anterior leaflet	Torn chordae not repaired at initial operation	10/1/63	Replacement with No 3 Starr Edwards Ball valve 4 yrs later	Ball valve replaced 11 years later for valve thrombosis
				Thrombosis of Starr valve	9/27/74	Replacement with No 31 Hancock glutaraldehyde porcine valve 11 yrs later	Living and well on Coumadin 3 yrs
2	G P 37	9/2/60	Dilated annulus prolapsed anterior leaflet with stretched chordae tendineae	Stenosis with calcification of area of previous repair	7/11/74	Replacement with No 29 Hancock glutaraldehyde porcine valve 14 yrs later	CVA 3 yrs after insertion of porcine valve Living and well 3 yrs on Coumadin
3	M P 48	10/31/61	Cross dilatation due to stretched CT mural & anterior leaflet	Torn CT anterior leaflet greatly dilated tricuspid annulus with insufficiency	12/10/70	Second repair of mitral valve and primary repair of tricuspid valve 11 yrs later	Living and well 7 yrs no murmurs or medication
4	J P 37	5/19/64	Dilated annulus with calcification slightly stretched CT	Stenosis due to calcification of both leaflets	9/9/76	Replacement with No 31 Hancock glutaraldehyde porcine valve 12 yrs later	Living and well 1 year on Coumadin
5	P C 39	7/29/66	Torn CT mural leaflet	Recurrence of torn chordae tendineae	1/17/68	Replacement with No 4 Kay Shiley disc valve Tricuspid annuloplasty 2 yrs later	Living and well 9.5 years on Coumadin
6	T D A 47	9/8/67	Torn CT mural leaflet	Repair of mural leaflet intact Torn CT occurred at anterior leaflet	10/8/73	Replacement with No 7 Kay Shiley disc valve with muscle guard 11 yrs later	Hosp death Bronchial pneumonia probable myocardial infarction

patients the remaining part of the mitral valve repair is now the same for all patients and consists of decreasing the annulus of the mitral valve by doing away with approximately 65 per cent to 70 per cent of the annulus of the mural leaflet. The annulus is decreased mainly at the posteromedial commissural area where usually two interrupted figure of eight sutures of No 2 silk are placed and tied to do away with 40 per cent or 45 per cent of the annulus. The same

procedure is used to decrease the mural annulus of the anterolateral commissural area for another 20 per cent or 25 per cent. The sutures placed at the anterolateral commissural area should not be deep so that the circumflex coronary artery is encircled. When the annuloplasty is completed approximately 30 per cent or 35 per cent of the mural annulus remains and there is a snug two fingerbreadth opening (Fig 2). It is important not to encroach on the annulus of the anterior leaflet,

Table 1 continued

Patient No	Age at first surgery	Date of first surgery	Initial cause of mitral insufficiency	Cause of failure	Date of subsequent surgery	Procedure	Outcome
7	M T 61	10/1/68	Calcification mural leaflet Prolapse of both leaflets	Mitral insuff due to large anterior leaflet with stretched CT	5/10/76	Second mitral valve repair 8 yrs later	Living and well 1 year no medication no murmur
8	J G 66	11/26/68	Torn CT mural leaflet	Prolapse of anterior leaflet due to stretched CT	5/27/69	Replacement with No 6 Kay Shiley disc valve with muscle guard 1 yr later	Died 6 months after surgery Cause unknown
9	J G 59	1/9/69	Torn CT mural leaflet	Mitral insuff through center of repaired valve	2/20/63	Replacement with No 8 Kay Shiley disc valve with muscle guard 1 month later	Lost to follow up
10	G B 47	1/14/71	Torn CT mural leaflet	Mitral insuff due to tear of suture line	10/7/71	Replacement with No 7 Kay Shiley disc valve with muscle guard	Living and well 6 years on Coumadin
11	E L 51	6/24/74	Torn CT mural leaflet stretched CT anterior leaflet SBE 6 yrs prior to surgery	Torn CT anterior leaflet	6/16/75	Replacement with No 31 Hancock glutaraldehyde porcine valve 1 yr later	On Coumadin & aspirin Emboli causing temporary blindness after valve replaced living 2 years
12	D C 6	12/9/74	Dilated annulus with stretched CT coarctation & aortic aneurysmectomy 20 years previously	Mitral insuff due to prolapsed anterior leaflet	4/3/76	Replacement with No 31 Hancock glutaraldehyde porcine valve 4 months later	Living and well 2 years on Coumadin

otherwise mitral stenosis may be produced with out correcting the insufficiency This technique was first described in 1961 and in subsequent publications

Material

Group I—Mitral insufficiency without myocardial revascularization Between 1959 and 1977 216 patients were operated upon with significant pure mitral insufficiency The majority of these patients had mitral valve prolapse with severe insufficiency and without coronary artery disease Mitral valve repair was performed in 145 patients (67 per cent) and replacement was performed in 71 (33 per cent) Ages varied from 17 to 76 years in these patients There were 80 men

and 65 women followed from 6 months to 17 years after surgery Thirty eight were in New York Heart Association Class IV and 107 were in Class III Nine patients (6 per cent) had a myocardial infarct 15 days to 84 months (mean 18 months) before surgery Six of these nine patients had angina at the time of surgery Five more patients (3 per cent) had angina preoperatively but had not had an infarct In 68 patients (47 per cent) a history of rheumatic heart disease and in 10 patients (47 per cent) a history of subacute bacterial endocarditis had been noted The heart size as demonstrated by x ray ranged from Grade 2/6 to 5/6 enlarged with a mean of 3/6 Seventy three patients had torn chordae tendineae and 15 had a ruptured infarcted or necrotic head of a

papillary muscle. In 26 patients there were stretched chordae tendineae and in the remaining 31 patients the operative report mentioned only a dilated annulus. Prior to performing repair a portion of the valve was removed for biopsy in 29 patients. Fibromyxoid degeneration of the mitral leaflet was noted in 19 patients. Inactive rheumatic changes in seven patients and calcification of the valve with calcification in three patients. These pathological findings were essentially the same as in those patients in whom the excised valve was replaced.

Group II—Mitral insufficiency and myocardial revascularization. From 1970 to 1977 67 patients were operated upon with myocardial revascularization and mitral repair or replacement. In 57 patients mitral insufficiency occurred secondary to coronary artery disease and in 10 the patient's knowledge of mitral insufficiency antedated the history of coronary artery disease. Repair was feasible in 55 of these patients (82 per cent). Of these 55 patients undergoing repair 19 were women and 36 were men between 42 and 72 years of age (mean 59). Twenty-seven patients were in New York Heart Association Class III and 28 were in Class IV. The patients were classified on the basis of fatigue, dyspnea, and congestive heart failure. These symptoms were accompanied by angina in 46 patients, but severity of angina was not used for classification. Eleven patients had Grade II/VI, 26 had Grade III/VI, and 18 Grade IV/VI mitral insufficiency. The amount of insufficiency was determined as follows. The cardiac output was obtained by the Fick Principle. The stroke volume of the left ventricle was determined by radiographic means with injection of 76 per cent Renografin into the left ventricle. If the amount of blood ejected into the left atrium equaled that ejected into the aorta, then this was graded as II/VI. If the blood ejected into the left atrium was two times the amount ejected into the aorta, this was Grade IV/VI. If the amount ejected into the left atrium was three times the amount ejected into the aorta, this was graded as VI/VI.

The pulmonary artery pressure was measured prior to left ventriculography and coronary arteriography in 27 patients. These varied from a normal of 24/13 to a high of 119/61 with 16 patients (59 per cent) having a pulmonary artery systolic pressure of 50 mm Hg or more. The left

ventricular end diastolic pressure prior to radiopaque studies was measured in 35 patients and varied from 7 mm Hg to 38. Twenty-nine patients (83 per cent) had an end diastolic pressure of 10 mm Hg (mean 22.6) or greater. The ejection fraction was also measured prior to coronary arteriography and ranged from 0.15 to 0.7 in these 55 patients.

Thirty-three patients had a ruptured or infarcted papillary muscle or torn chordae tendineae with secondary annular dilatation. Twenty-two patients had a dilated annulus only. At operation 92 vein grafts and six left internal mammary arteries were employed for myocardial revascularization.

Results

Group I. There were 7 hospital deaths (5 per cent) in the 145 patients with mitral valve repair. Repair failed in 12 patients (8 per cent) from 1 month to 14 years (mean 4.6 years) after the initial operation. Table I. Two of these patients had a second repair 7½ and 8¼ years after the first operation and both are doing well without a murmur 1 and 7 years following the second operation. In one of these two patients tricuspid repair as described in 1965¹¹ was also successfully performed at the time of the second operation. Of the 10 patients with subsequent valve replacement seven patients are alive 9 months to 9½ years after mitral valve replacement.

There were 30 (20 per cent) late deaths from 3 months to 10 years (mean 5 years) after mitral valve repair. Table II. Two of the 30 late deaths were due to hepatitis, 12 were due to myocardial infarction, and six deaths were due to carcinoma or leukemia. Thromboembolic events occurred in four patients followed for a total of 922 years, 0.4 per cent per patient year. These four emboli resulted in the hospital death in one patient and late death in two patients. The fourth patient had a cerebral vascular accident 2½ years after mitral repair from which he recovered completely but died 6½ years later. The autopsy revealed a recent myocardial infarct with pulmonary emboli. Change in the New York Heart Association classification as judged by a physician is noted in Table III. The actuarial curve revealed a survival of 61.5% ($\pm 5.5\%$) at 17 years (Fig. 3). Of the 10 patients with subsequent valve replacement one is lost to follow up and seven patients are

Table II Mitral insufficiency without myocardial revascularization—late deaths

No. of patients	Cause of death	Time postoperative
1	Serum hepatitis	5 mos
1	Infectious hepatitis	7 yrs
1	Myocardial infarction	3 mos to 4 yrs
1	Stroke	5 yr
1	Lung carcinoma	1½ and 10 yrs
1	Stroke	1½ and 5 yrs
1	Breast carcinoma	8 and 1½ yrs
1	Intestinal cancer	3 yrs
1	Pulmonary embolus (1 myocardial inf.)	5½ and 6½ yrs
1	Ventricular fibrillation	1 yr
1	Leukemia	5 yrs
4	Unknown	4 yrs to 9 yrs

alive from 1 to 9½ years with a survivability of 73.6 per cent ($\pm 16\%$) at 9 years.

Group II: There were two (4 per cent) hospital deaths in these 50 patients. One patient with an ejection fraction of 0.2 died of bacterial endocarditis 37 days following surgery, and one patient with an ejection fraction of 0.4 died 8 days after surgery of a pulmonary embolus. Table IV reveals the hospital deaths and late deaths as related to the ejection fraction and Table V lists the cause of the six late deaths. Table VI reveals the postoperative change in New York Heart Association Classification of the 47 surviving patients. The survivability at 7 years is $80\% \pm 6\%$ (Fig. 3).

There was one peripheral embolic event resulting in hemiplegia in the 50 patients with repair followed for a total of 164 years, or 0.6 per cent per patient year. One patient with repair died from cerebral hemorrhage 7 months after surgery; however, this patient was continued on sodium warfarin by her family physician for 7 months at which time she had a cerebral hemorrhage with the prothrombin time at 10 per cent. Anticoagulant therapy was advised for only 3 months following mitral repair with the prothrombin time maintained at 20 per cent.

Discussion

Patients with mitral insufficiency should be operated upon if with adequate medical therapy their symptoms prevent them from performing their daily duties in a manner satisfactory to the

Table III Mitral insufficiency without myocardial revascularization—NYHA functional classification of 96 surviving patients

	Percent per class			
	I	II	III	IV
Preoperative class	1	11	17	1
III		2	4	
II				
I				

Table IV Preoperative ejection fraction as related to mortality in patients with mitral repair and myocardial revascularization

	Ejection fraction		
	0.15-0.29	0.25-0.41	0.41-0.7
Total patients	4	9	8
Hospital deaths	1	1	0
Late deaths	2	1	3
Total deaths	3 (75%)	2 (22%)	3 (38%)

patient. Because of the increased morbidity with mitral valve prostheses it is imperative that mitral valve repair be considered before replacement. Few surgeons, however, are presently prepared to attempt repair for mitral insufficiency. In 1976 Salomon, Stinson, Griepp and Shum way reported on 66 patients with pure mitral insufficiency without coronary artery disease. This group of patients is similar to our 145 patients with pure mitral insufficiency in whom repair was performed. The mitral valve was replaced in their 66 patients. Starr-Edwards Model 6120 valves were used in 38 patients, porcine aortic valve xenografts (Hancock) in 20 and stented aortic valve allografts in eight. The operative mortality rate was 6 per cent. The overall survival rate calculated by the actuarial method was 50 per cent ± 8 per cent at five years. Ten of their 38 operative patients with the Starr-Edwards valve inserted in the mitral area had systemic thromboembolic episodes with two deaths from the emboli. Two of their eight patients with an allograft in the mitral area had systemic thromboembolic episodes. None of the patients with the porcine valve had systemic thromboembolic episodes at the time of this

papillary muscle. In 26 patients there were stretched chordae tendineae and in the remaining 31 patients the operative report mentioned only a dilated annulus. Prior to performing repair, a portion of the valve was removed for biopsy in 29 patients. Fibromyxoid degeneration of the mitral leaflet was noted in 19 patients. Inactive rheumatic changes in seven patients and valvulitis of the valve with calcification in three patients. These pathological findings were essentially the same as in those patients in whom the excised valve was replaced.

Group II—Mitral insufficiency and myocardial revascularization. From 1970 to 1977 67 patients were operated upon with myocardial revascularization and mitral repair or replacement. In 57 patients mitral insufficiency occurred secondary to coronary artery disease and in 10 the patient's knowledge of mitral insufficiency antedated the history of coronary artery disease. Repair was feasible in 55 of these patients (82 per cent). Of these 55 patients undergoing repair, 19 were women and 36 were men between 42 and 72 years of age (mean 59). Twenty-seven patients were in New York Heart Association Class III and 28 were in Class IV. The patients were classified on the basis of fatigue, dyspnea and congestive heart failure. These symptoms were accompanied by angina in 46 patients, but severity of angina was not used for classification. Eleven patients had Grade II/VI, 26 had Grade III/VI and 18 Grade IV/VI mitral insufficiency. The amount of insufficiency was determined as follows. The cardiac output was obtained by the Fick Principle. The stroke volume of the left ventricle was determined by radiographic means with injection of 76 per cent Renografin into the left ventricle. If the amount of blood ejected into the left atrium equaled that ejected into the aorta, then this was graded as II/VI. If the blood ejected into the left atrium was two times the amount ejected into the aorta, this was Grade IV/VI. If the amount ejected into the left atrium was three times the amount ejected into the aorta, this was graded as VI/VI.

The pulmonary artery pressure was measured prior to left ventriculography and coronary arteriography in 27 patients. These varied from a normal of 24/13 to a high of 119/61 with 16 patients (59 per cent) having a pulmonary artery systolic pressure of 50 mm Hg or more. The left

ventricular end diastolic pressure prior to radiopaque studies was measured in 35 patients and varied from 7 mm Hg to 38. Twenty-nine patients (83 per cent) had an end diastolic pressure of 15 mm Hg (mean 22.6) or greater. The ejection fraction was also measured prior to coronary arteriography and ranged from 0.15 to 0.7 in these 55 patients.

Thirty-three patients had a ruptured or infarcted papillary muscle or torn chordae tendineae with secondary annular dilatation. Twenty-two patients had a dilated annulus only. At operation 92 vein grafts and six left internal mammary arteries were employed for myocardial revascularization.

Results

Group I. There were 7 hospital deaths (5 per cent) in the 145 patients with mitral valve repair. Repair failed in 12 patients (8 per cent) from 1 month to 14 years (mean 4.6 years) after the initial operation. Table I. Two of these patients had a second repair 7¹/₂ and 8¹/₂ years after the first operation and both are doing well without a murmur 1 and 7 years following the second operation. In one of these two patients tricuspid repair as described in 1965¹¹ was also successfully performed at the time of the second operation. Of the 10 patients with subsequent valve replacement seven patients are alive 9 months to 9¹/₂ years after mitral valve replacement.

There were 30 (20 per cent) late deaths from 3 months to 10 years (mean 5 years) after mitral valve repair. Table II. Two of the 30 late deaths were due to hepatitis, 12 were due to myocardial infarction and six deaths were due to carcinoma or leukemia. Thromboembolic events occurred in four patients followed for a total of 922 years. 0.4 per cent per patient year. These four emboli resulted in the hospital death in one patient and late death in two patients. The fourth patient had a cerebral vascular accident 2¹/₄ years after mitral repair from which he recovered completely but died 6¹/₂ years later. The autopsy revealed a recent myocardial infarct with pulmonary emboli. Change in the New York Heart Association classification as judged by a physician is noted in Table III. The actuarial curve revealed a survival of 61.5% ($\pm 5.5\%$) at 17 years (Fig. 3). Of the 10 patients with subsequent valve replacement one is lost to follow up and seven patients are

a Hancock porcine valve were free of emboli. They furthermore stated that there was a linearized thromboembolism rate of 5.2 per cent per patient year—a very high rate for the Hancock glutaraldehyde porcine valve at first thought to be emboli free.

There is a paucity of reports of the results for patients operated upon with mitral replacement with glutaraldehyde treated porcine valves with concomitant coronary artery disease or where the mitral insufficiency was secondary to coronary artery disease. The reports include very few patients and are as follows: Horowitz and co-workers reported one death among 23 patients who had isolated mitral valve replacement with the Hancock glutaraldehyde preserved porcine heterograft without revascularization and two operative deaths among the remaining nine patients who had additional valve surgery or coronary artery grafting.

In the report by Buch and associates noted previously they reported on 120 patients undergoing mitral valve replacement with the Hancock stabilized glutaraldehyde process porcine xenograft from March 1971 through April 1975. There was a group of 23 patients who had mitral valve disease with coronary artery disease. Twelve of these had rheumatic valvular disease and coronary artery disease and the other 11 had coronary artery disease and nonrheumatic mitral regurgitation. Six of these 23 patients (26 per cent) died within the first 30 days following replacement of the patient's mitral valve with a porcine valve. Three more patients died after discharge from the hospital so that there were nine deaths in this group of 23 patients with mitral replacement and coronary artery disease. Fourteen of these 23 patients had aorto coronary bypass grafts.

In the report of Stinson and colleagues quoted previously they reported in 1977 on 243 patients with isolated replacement of the mitral valve with the Hancock glutaraldehyde preserved porcine aortic valve xenografts. They stated that Mitral valve patients with associated coronary artery disease accounted for a substantial portion of both early and late deaths. For example in 54 patients the diagnosis of coronary artery disease was established by coronary angiography, electrocardiographic evidence of previous myocardial infarction or postmortem examination within one year after operation. Operative mortality rate

in this group was 18.5 per cent and the survival rate of 2 years was only 56 (± 7.8) per cent. Patients undergoing simultaneous coronary artery bypass grafting for angiographically defined coronary artery lesions fared similarly.

In our 55 patients with mitral valve repair for significant mitral insufficiency and myocardial revascularization there were two (4 per cent) operative deaths and six late deaths (11 per cent). The operative and long term results were fairly similar for the patients with an ejection fraction of 0.45 to 0.70 and for the patients with an ejection fraction of 0.25 to 0.40. For the former there were no operative deaths for 27 patients and three late deaths for a total of three deaths (11 per cent) and for the latter one operative death in 24 patients and one late death for a total of two deaths (8 per cent). For patients with an ejection fraction of 0.1 to 0.2 there was one operative death in four patients operated upon however only one long term survival. By actuarial methods the 7 year survival for the 55 patients with repair and revascularization including the operative mortality rate of 4 per cent was 80 per cent ± 6 per cent. Fig. 3 reveals the actuarial curve of our two groups of patients undergoing repair at 17 years for Group I and 7 years for Group II.

There was one peripheral thromboembolic episode in the 55 patients with repair followed for a total of 164 years for a 0.6 per cent rate per year. There is again a significant difference in the results of the patients with repair and revascularization compared to those series with replacement with a prosthesis or glutaraldehyde porcine valve and revascularization.

Although the use of the porcine valve for mitral valve replacement may have reduced the incidence of peripheral embolization compared to other prostheses the number of emboli with this valve is still unacceptably high. The uncertain long term durability of porcine valves also continues to be of great concern to most physicians and surgeons. If the experience of ours and others with homografts is a logical basis for this concern then the use of glutaraldehyde treated porcine valves as well as other prostheses must be restricted to the minority of patients with mitral insufficiency in whom valve repair is not feasible.

We would agree completely with Burch and Giles⁴ that the physician should not consider the patient cured once he has undergone cardiac

Table V Mitral insufficiency repair and myocardial revascularization—late deaths

Ejection fraction	Cause of death	Months postop
0.60	Cerebral hemorrhage (on sodium warfarin/prothrombin time 10 $\frac{1}{2}$)	7
0.18	Cardiac arrest	8
0.46	Pulmonary emboli	3
0.32	Mediastinitis	3
0.68	Unknown	18
0.15	Died in sleep	11

report however a subsequent article by Shumway revealed a significant incidence of cerebral emboli with the Hancock glutaraldehyde treated porcine valve.

In our 145 patients with pure mitral insufficiency who had a mitral annuloplasty performed from 1959 through 1976, there were seven hospital deaths and 30 late deaths. A peripheral embolus occurred in only four of these 145 patients with mitral valve repair followed for a total of 922 years or 0.4 per cent per patient year. The overall survival rate calculated by the actuarial method at 17 years is 61.5 per cent (± 5.5 per cent) for repair alone. This does not include the remaining seven of 10 patients still alive after subsequent valve replacement. Of the original 145 patients with repair there are 96 alive with mitral repair and seven more alive after subsequent replacement for a total of 103 living (71 per cent). Of the 30 late deaths two died of hepatitis, six died of cancer, and 12 patients died of myocardial infarction. Approximately $\frac{1}{3}$ of the deaths were unrelated to the mitral repair. Two patients with repair and one with subsequent replacement are lost to follow up and these are counted as dead. There would appear to be a significant difference in results with the group of patients reported by Silomon, Stinson, Gnepp and Shumway with replacement for pure mitral insufficiency. Our patient group included 14 patients with a history of angina and infarction, a subset with a poorer prognosis because revascularization was not performed for these patients prior to 1970. Our patient group also included a subset of 68 patients with pure mitral insufficiency with a history of rheumatic fever. However, neither at surgery by visualizing the valve or myocardium or in long term longevity could one detect any difference in

Table VI Mitral repair and myocardial revascularization NYHA functional classification of 47 surviving patients

	To postoperative class			
	IV	III	II	I
Preoperative class IV	—	2	14	5
III	—	1	11	14
II	—	—	—	—
I	—	—	—	—

this subset or the subset with mitral valve prolapse with pure mitral insufficiency without a prior history of rheumatic fever.

In 1976 Starr and colleagues¹⁴ reported on 290 patients who had isolated mitral valve replacement for single mitral valve disease with their currently used prostheses. These were the non cloth covered Model 6120 prosthesis and the cloth covered composite seat Model 6310/6320 prosthesis inserted between 1965 and 1975. There was a 6.6 per cent combined operative mortality rate. There was a 58 per cent observed survival at 10 years for operative survivors only, so that the observed survival is closer to 51 per cent at 10 years if one includes the operative mortality rate. They stated that for operative survivors, at 6 years the chance to be embolus free is 85 per cent with the cloth covered prosthesis and 66 per cent with the non cloth covered prosthesis. The chance to be embolus free at 10 years with the non cloth covered prosthesis is 51 per cent—obviously a high incidence of peripheral embolization compared to repair.

Buch and associates¹⁵ reported in 1975 on mitral valve replacement with the Hancock stabilized glutaraldehyde valve. The predicted survival of 87 patients without coronary artery disease or prior prosthetic valve replacements was 87.5 per cent at 2 years and 77.5 per cent at 4 years. There were four thromboembolic episodes, a rate of 2.4 per cent per patient year.

In 1977 Stinson and associates¹⁶ reported on the long term experience with the Hancock porcine valve in the mitral area. There were 243 patients with isolated replacement of the mitral valve. The operative mortality rate was 7.8 per cent. Actuarial analysis at 4.4 years revealed a survival rate of 78 per cent. At this same interval 92 per cent of the patients with mitral replacement with

**Even if your pacemaker
patient misses his regular
check up....**



Pacesetter's Reliability Takes away the worry

Although your patient may never be adrift in the Pacific, wouldn't it be reassuring to know that his pacemaker is the most reliable available? That the manufacturer has an outstanding reputation for reliability and innovation in the industry?

If you implant or recommend the use of one of our Pacesetter lithium powered pulse generators, you can rest assured that it will still be working years after we implant it. We guarantee it. Our reliability was engineered in from the very first, not inspected in afterward. We even offer the only lead warranty in the business. Years of trouble-free implants all over the world, in addition to stringent inspection and quality assurance procedures make these statements possible.



Your Pacesetter representative will be extremely helpful in evaluating the proper pulse generators and lead systems to meet your patient's needs. You'll find that all Pacesetter representatives are as reliable as our product — in offering outstanding service and technical support 24 hours a day.

To arrange for one of our people to show you the complete Pacesetter picture call (toll free, of course) 800 423 5611 and ask for Professional Service. Where Reliability is a Way of Life!

Pacesetter Systems Inc. —
12740 San Fernando Road Sylmar, California 91342 U.S.A.
1 (800) 423 5611 Telex 69815 Cable PACESETTER
In California call collect (213) 367 1911

valve replacement, but rather should consider him to be the subject of meticulous long term medical care. We would also go one step further to urge the surgeon to do his best to repair the mitral valve before considering replacement with any type of valve presently available.

Summary

There has been skepticism since the early days of open heart surgery that good long term or even short term results were possible with repair for pure mitral insufficiency. The authors report 145 patients in whom a markedly insufficient mitral valve was repaired 6 months to 17 years previously and another 55 patients in whom repair of the insufficient mitral valve was performed along with myocardial revascularization from 6 months to 7 years previously. Comparative data with other published work reveals superior results with repair than with replacement with Starr Edwards and Hancock glutaraldehyde treated porcine valves and with far less emboli. Conservatism is urged in operating upon patients with mitral insufficiency. Repair of the valve rather than replacement is stressed for those patients requiring surgery.

REFERENCES

- 1 Starr A and Edwards M J Mitral replacement: Clinical experience with a ball valve prosthesis. *Ann Surg* 154:726 1961
- 2 Kay J H, Magidson O, Mehaus J E, Lewis R, Egerton W S, Zubiate I and Lefevre T Mitral insufficiency and mitral stenosis: Surgical treatment using the heart lung machine. *Calif Med* 95:382 1961
- 3 Kay J H and Egerton W S The repair of mitral insufficiency associated with ruptured chordae tendineae. *Ann Surg* 157:310 1963
- 4 Kay J H, Maselli Campagna G and Tsuji H K Surgical treatment of mitral insufficiency. *West J Surg Obstet Gynecol* 72:149 1964
- 5 Kay J H, Tsuji H K and Redington J V The surgical treatment of mitral insufficiency associated with torn chordae tendineae. *Ann Thorac Surg* 1:99 1965
- 6 Kay J H, Tsuji H K, Redington J V and Yokoyama T Surgical treatment of mitral insufficiency. *Calif Med* 107:311 1967
- 7 Kay J H, Tsuji H K, Redington J V and Mendez A M The surgical treatment of mitral insufficiency associated with torn chordae tendineae. *Vasc Surg* 2:189 1968
- 8 Mori T, Zubiate P, Mendez A M and Kay J H Results of surgery for mitral insufficiency due to coronary artery disease. *Israel J Med Sci* 11:745 1975
- 9 Kay J H, Zubiate P, Mendez A M and Dunne E F Myocardial revascularization and mitral repair or replacement for mitral insufficiency due to coronary artery disease. *Circulation* 54(Suppl III):94 1976
- 10 Kay J H, Zubiate P, Mendez A M, Carpena C, Watanabe K and Magidson O Mitral valve repair for patients with pure mitral insufficiency: 1 to 15-year follow up. *JAMA* 236:1584 1976
- 11 Kay J H and Tsuji H K Surgical treatment of tricuspid insufficiency. *Ann Surg* 162:53 1965
- 12 Kay J H, Mendez A M and Zubiate P A further look at tricuspid annuloplasty. *Ann Thorac Surg* 22:498 1976
- 13 Salomon N W, Stinson E B, Gnepp R B and Shumway N E Surgical treatment of degenerative mitral regurgitation. *Am J Cardiol* 38:463 1976
- 14 Starr A, Grunkemeier G, Lambert L, Oles J E and Thomas D Mitral valve replacement: A 10 year follow up of non-cloth covered vs cloth covered caged ball prostheses. *Circulation* 54(Suppl III):47 1976
- 15 Buch W S, Pipkin R D, Hancock W D and Fogarty T J Mitral valve replacement with the Hancock stabilized glutaraldehyde valve: Clinical and laboratory evaluation. *Arch Surg* 110:1409 1975
- 16 Stinson E B, Gnepp R B, Over P E and Shumway R F Long term experience with porcine aortic valve xenografts. *J Thorac Cardiovasc Surg* 73:54 1977
- 17 Horowitz M S, Goodman D J, Fogarty T J and Harrison D C Mitral valve replacement with the glutaraldehyde preserved porcine heterograft: Clinical hemodynamic and pathological correlations. *J Thorac Cardiovasc Surg* 67:885 1974
- 18 Burch G E and Giles T D Clinical evaluation of aortic and mitral valve prostheses. *Am Heart J* 92:245 1976

Predict optimum lidocaine levels in just minutes.


udies in normal volunteers and myocardial infarct patients have demonstrated that lidocaine clearance in the blood is directly affected by alterations in hepatic blood flow as measured by Cardio Green® (CG®) sterile Indocyanine Green USP ampules. Since liver impairment is often coexistent with congestive heart failure, hepatic elimination of lidocaine can vary widely, creating blood lidocaine concentrations that are in

adequate or toxic depending on hepatic function.

To determine these levels quickly, a new application for Cardio Green has been developed. With this procedure, a dichromatic ear densitometer may be used to measure the rate of Cardio Green elimination, thereby allowing investigators to predict blood lidocaine concentrations. Dosage adjustment can be directed toward keeping,

plasma lidocaine within the accepted therapeutic range.

A suggested clinical protocol using Cardio Green for the determination of lidocaine dosage in preventing post myocardial infarction ventricular fibrillation is available on request. Write: Hynson Westcott & Dunning Inc., Chase and Charles Streets, Baltimore, MD 21201.



DESCRIPTION: Cardio-Green (CG) is a sterile, aqueous solution of Indocyanine Green (ICG) in water. It is used for the determination of lidocaine levels in the blood. The CG is a sterile, aqueous solution of Indocyanine Green (ICG) in water. It is used for the determination of lidocaine levels in the blood. The CG is a sterile, aqueous solution of Indocyanine Green (ICG) in water. It is used for the determination of lidocaine levels in the blood.

CG is a sterile, aqueous solution of Indocyanine Green (ICG) in water. It is used for the determination of lidocaine levels in the blood. The CG is a sterile, aqueous solution of Indocyanine Green (ICG) in water. It is used for the determination of lidocaine levels in the blood. The CG is a sterile, aqueous solution of Indocyanine Green (ICG) in water. It is used for the determination of lidocaine levels in the blood.

CG is a sterile, aqueous solution of Indocyanine Green (ICG) in water. It is used for the determination of lidocaine levels in the blood. The CG is a sterile, aqueous solution of Indocyanine Green (ICG) in water. It is used for the determination of lidocaine levels in the blood. The CG is a sterile, aqueous solution of Indocyanine Green (ICG) in water. It is used for the determination of lidocaine levels in the blood.

ECG/Phono/Pulse 3-Channel System



■ Features

- Model FD-31P is a 3-channel direct writing system for simultaneous recording of ECG/ECG/ECG, PCG/PCG/ECG, PCG/ECG/Pulse or Pulse/Pulse/ECG
- The system retains all standard features of a 3-channel ECG with the added provisions of simultaneous Heart Sound ECG and Pulse Wave recording thus providing valuable diagnosis
- The FD-31P employs a special envelope detection method and includes the most advanced galvanometer design providing optimum resolution of diagnostic information
- Electrical safety is attained by a specially designed floating input amplifier
- Other Products available

Single Channel ECG/2-Channel ECG/3-Channel ECG/Vector Cardioscope/ECG Cassette Recorder and Play-back System/Monitoring Oscilloscope/Patient Monitor

model

FD-31P



■ For Further Information

write to



FUKUDA DENSHI CO., LTD

3-39-4 Hongo Bunkyo-ku
Tokyo 113 Japan
Phone (03)815-2121
Telex 272-2217 FUKUDA J

In North America
Fukuda Denshi Co Ltd
c/o Medical Systems Corp
230 Middle Neck Road
Great Neck NY 11021
Phone (516)466-2000

lidocaine levels in just minutes.

[illegible]

Now, a full color atlas
that realistically depicts the normal
so you can better understand
the abnormal

Available soon:

COLOR ATLAS OF SECTIONAL ANATOMY:

Chest, Abdomen and Pelvis

This impressive atlas promises to become one of the most valuable clinical tools you'll use. Designed as a reference for normals, it features a complete set of sections (sagittal, transverse and coronal) 1 cm thick — *all in full color plates* — of the chest, abdomen and pelvis. It also offers oblique views of the heart. To aid you in interpretation, each plate is accompanied by a labelled line diagram. Throughout, the photography is far superior to that in any other atlas currently available on this subject — *and every organ is shown in its natural color* since the body was frozen without embalming. In addition, 60 unmounted slides (ten 35 mm strips each with six plates) are included at the back of the book.

This is an excellent opportunity to refine your skills in interpreting scans and recognizing abnormalities and to increase your understanding of important spatial relationships of internal structures.

But the only way to appreciate how this monumental atlas can help you in practice is to SEE IT YOURSELF! Be among the first to evaluate this landmark volume — order your copy TODAY!

By E. A. Lyons MD October 1978 Approx. 340 pages 12" x 9" 348 illustrations and 60 unmounted 35mm transparencies About \$130.00

For faster service or if coupon has been removed call us! Dial 1-800-325-4177 ext 10 in Missouri call collect 314 872 8370 ext 10 during our regular business hours

MOSBY
TIMES MIRROR

THE C. V. MOSBY COMPANY
11830 WESTLINE INDUSTRIAL DRIVE
ST. LOUIS, MISSOURI 63141

ORDER YOUR COPY TODAY!

Mail this coupon to reserve your copy today!

YES! I want to reserve an on approval copy of **COLOR ATLAS OF SECTIONAL ANATOMY (3052 5) \$130.00**

- ☐ Bill me
☐ Payment enclosed
☐ mastercharge # _____
☐ VISA # _____

MOSBY
TIMES MIRROR

THE C. V. MOSBY COMPANY
11830 WESTLINE INDUSTRIAL DRIVE
ST. LOUIS, MISSOURI 63141


Name _____
Address _____
City _____
State _____ Zip _____

Estimated price subject to revision prior to publication

Complete and mail to: The C. V. Mosby Company 11830 Westline

From Searle
NORPACE[®]
(disopyramide phosphate)

As effective as
quinidine sulfate
for specific
ventricular
arrhythmias...
but with a
lower incidence
of severe
side effects



Efficacy thoroughly proved and documented—no other antiarrhythmic agent subjected to such rigidly controlled study prior to introduction

Effective in specific ventricular arrhythmias—indicated in premature ventricular contractions (PVCs), unifocal, multifocal or paired PVCs or episodes of ventricular tachycardia (VT)

Excellent patient tolerance—lower incidence of severe side effects than quinidine and significantly better tolerated

Dose related plasma levels—plasma levels correlate closely with dosage

Norpace effect on hemodynamics—rarely alters blood pressure significantly at recommended oral doses and may reduce cardiac output by about 10%

Please see next page for a brief summary of prescribing information

In specific ventricular arrhythmias...

NORPACE


(disopyramide phosphate)

as effective as quinidine sulfate... with

Results of double-blind controlled studies

A double blind multicenter clinical study involving five investigators was conducted to compare the relative effectiveness and tolerance of Norpace and quinidine sulfate. Prior to qualifying for the study, each patient had antiarrhythmic medication discontinued for at least one week. Nine-hour Holter record-ings were then used to establish an admission

criterion of at least 60 ectopic beats per hour (PVCs, PACs or combination of the two). All other arrhythmias were excluded except paroxysmal ventricular or atrial tachycardias occurring in conjunction with the above. It was apparent that both drugs were capable of reducing ectopic activity and maintaining suppression throughout the course of therapy.



Includes patients with more than 60 total (atrial and ventricular) ectopic beats per hour but who had fewer than 60 ventricular ectopic beats per hour

There was no statistically significant difference in reduction of ectopy between the two drugs

Effective by extensive Holter monitoring

Lower incidence of severe side effects

Significantly fewer dropouts with Norpace


entire study population was analyzed for side effects. The side effects experienced by Norpace patients were usually mild and mainly anticholinergic including dry mouth, urinary hesitancy, constipation, blurred vision. The anticholinergic effects were generally transient. Severe reactions with quinidine were more serious and affected a greater number of patients. The most common symptoms were severe diarrhea, gastrointestinal symptoms including cramps, nausea and vomiting, dizziness, fever, and rash.

(disopyramide phosphate)

Quinidine dropouts in 82 patients



Norpace dropouts in 82 patients



Dosage and administration

applied as 100 mg and 150 mg capsules. Dosage should be individualized based on response and tolerance. Usual adult dosage is 400 to 800 mg per day given in divided doses four times daily. Initial Norpace dosage:

Patients 110 lb and over	150 mg q 6 h
Patients less than 110 lb	100 mg q 6 h
Patients with specific complications Patients with possible cardiac decompensation, cardiac myopathies, reduced left ventricular function or hypotension due to these or other causes	100 mg q 6 h
Patients with moderate renal ($Cl_{cr} > 40$ ml/min) or hepatic insufficiency	100 mg q 6 h (200 mg loading dose optional)
Patients with severe renal insufficiency ($Cl_{cr} < 40$ ml/min)	100 mg given approximately every half life ($T_{1/2}$) (200 mg loading dose optional)
$Cl_{cr} = 40-15$ ml/min $Cl_{cr} = 15-5$ ml/min $Cl_{cr} = 5-1$ ml/min	q 10 h q 20 h q 30 h
In patients without the complications specified above in whom rapid control of arrhythmias is essential, therapy may be initiated with a loading dose of 300 mg (200 mg for patients under 110 lb).	

For complete Norpace dosage recommendations, please see full prescribing information at which appears on the next page.

SEARLE

NorPace
(disopyramide phosphate)



as effective as quinidine sulfate for specific ventricular arrhythmias...with a lower incidence of severe side effects

Before prescribing Norpace (disopyramide phosphate) please consult current complete prescribing information a summary of which follows

Indications Norpace is indicated for suppression and prevention of recurrence of the following cardiac arrhythmias when they occur singly or in combination: unifocal premature (ectopic) ventricular contractions; premature (ectopic) ventricular contractions of multiform origin; paired premature ventricular contractions (couplets); and episodes of ventricular tachycardia (persistent ventricular tachycardia is ordinarily treated with D.C. cardioversion).

Norpace is equally effective in treating the above arrhythmias in both digitalized and nondigitalized patients. It is also equally effective in treating primary cardiac arrhythmias and those which occur in association with organic heart disease including coronary artery disease. Oral Norpace has not been adequately studied in patients with acute myocardial infarction or in patients with persistent ventricular tachycardia or atrial arrhythmias and is not indicated for arrhythmias due to digitalis intoxication. The value of antiarrhythmic drugs in preventing sudden death in patients with serious ventricular ectopic activity has not been established.

Contraindications Cardiogenic shock; preexisting second or third degree AV block (if no pacemaker is present) or known hypersensitivity to the drug.

Warnings Severe hypotension has been observed primarily in patients with primary cardiomyopathy or inadequately compensated congestive heart failure. If hypotension develops Norpace should be discontinued promptly unless hypotension is due to the arrhythmia.

Norpace should not be used in the presence of poorly compensated or uncompensated congestive heart failure unless it is exacerbated by or caused by an arrhythmia and proper treatment including optimal digitalization has been accomplished. In some patients with marginally compensated heart failure Norpace may worsen cardiac decompensation. In these patients progressing congestive heart failure should generally be treated with cardiac glycosides and diuretics and the course of treatment closely followed. Norpace dosage should be reduced or discontinued if adequate control of congestive failure is not attained.

If first-degree heart block develops the dosage of Norpace should be reduced. If the block persists continuation of Norpace must depend upon an assessment of the benefit versus the risk. Development of second or third degree AV block or uni- or trifascicular block requires discontinuation of Norpace unless the ventricular rate is adequately controlled by a pacemaker.

Because of its anticholinergic properties Norpace should not be used in patients with glaucoma, myasthenia gravis or urinary retention unless adequate overriding measures are taken.

Precautions If significant widening (greater than 25%) of the QRS complex occurs Norpace should be discontinued. If Q-T prolongation greater than 25% occurs and if ectopy continues monitor closely and consider discontinuing Norpace.

Patients with atrial flutter or fibrillation should be digitalized prior to Norpace administration to ensure that drug induced enhancement of AV conduction does not allow a ventricular rate beyond physiologically acceptable limits.

The effect of Norpace is presently uncertain in patients with sick sinus syndrome, Wolff-Parkinson-White syndrome or bundle branch block.

Patients with myocarditis or other cardiomyopathy may develop significant hypotension in response to the usual dosage of Norpace (disopyramide phosphate).

Norpace should be administered cautiously to patients who are taking or who have recently received other antiarrhythmic drugs. Exaggerated widening of the QRS complex and/or prolongation of the Q-T interval may occur in such instances.

Norpace dosage should be reduced in patients with impaired renal or hepatic function and the electrocardiogram carefully monitored for signs of overdosage.

Antiarrhythmic drugs may be ineffective in patients with hypokalemia. Therefore, any potassium deficit should be corrected before using Norpace therapy.

Use in Pregnancy and Lactation Safe use in pregnancy has not been established. Norpace has been reported to stimulate contractions of the pregnant uterus. The use of Norpace in pregnant women requires that the potential benefit be weighed against possible hazards to the fetus.

It is not known whether disopyramide is excreted in human milk. However, studies in rats have shown that the concentration of disopyramide and its metabolites is up to three times greater in milk than in plasma. Use of the drug is deemed essential; an alternate method of feeding should be instituted.

Labor and Delivery The effects of Norpace on the fetus during delivery or on the course of labor and delivery are unknown.

Pediatrics The safety and effectiveness of Norpace in children has not been established.

Adverse Reactions Anticholinergic: dry mouth, urinary hesitancy, staphosia, blurred vision, dry nose/eyes/throat, urinary retention. Gastrointestinal: anorexia, nausea, vomiting, epigastric pain/bloating/gas, anorexia, diarrhea, constipation. General: nervousness, dizziness, general fatigue/muscle weakness, headache, malaise, tinnitus, cardiovascular: hypotension, congestive heart failure, cardiac conduction disturbances, edema/weight gain, shortness of breath, syncope, chest pain. Dermatologic: generalized rash/dermatoses. The following have occurred but a causal relationship is uncertain: impotence, depression, insomnia, hypoglycemia, dysuria. Acute psychosis and cholestatic jaundice both reversible have been reported.

Dosage and Administration Dosage must be individualized for each patient on the basis of response and tolerance. The usual adult dose is 400 to 800 mg per day given in divided doses four times daily. The recommended dosage schedule for most adults is 150 mg every six hours. For patients weighing less than 110 pounds (50 kg) the recommended dosage is 100 mg every six hours.

If rapid control of arrhythmia is essential an initial loading dose of 100 mg of Norpace (200 mg for patients weighing less than 110 pounds) is recommended. For patients with cardiomyopathy or possible marked decompensation a loading dose should not be given and the initial dose limited to 100 mg every six hours with subsequent dosage adjustment made gradually under close monitoring.

See current complete prescribing information for dosage recommendations.



How Supplied Capsules containing 100 mg or 150 mg of disopyramide base. Available in bottles of 100 capsules.

SEARLE

Searle Laboratories
Division of G. D. Searle & Co.
Box 5110 Chicago, Illinois 60680

From Searle
NORPACE[®]
(disopyramide phosphate)

As effective as
quinidine sulfate
for specific
ventricular
arrhythmias...
but with a
lower incidence
of severe
side effects



Efficacy thoroughly proved and documented—no other antiarrhythmic agent subjected to such rigidly controlled study prior to introduction

Effective in specific ventricular arrhythmias—indicated in premature ventricular contractions (PVCs) unifocal multifocal or paired PVCs or episodes of ventricular tachycardia (VT)

Excellent patient tolerance—lower incidence of severe side effects than quinidine and significantly better tolerated

Dose related plasma levels—plasma levels correlate closely with dosage

Norpace effect on hemodynamics—rarely alters blood pressure significantly at recommended oral doses and may reduce cardiac output by about 10%

Please see next page for a brief summary of prescribing information

In specific ventricular arrhythmias...

NORPACE


(disopyramide phosphate)

as effective as quinidine sulfate... with

Results of double-blind controlled studies

A double blind multicenter clinical study involving five investigators was conducted to compare the relative effectiveness and tolerance of Norpace and quinidine sulfate. Prior to qualifying for the study, each patient had antiarrhythmic medication discontinued for at least one week. Nine hour Holter record ings were then used to establish an admission

criterion of at least 60 ectopic beats per hour (PVCs, PACs or combination of the two). All other arrhythmias were excluded except paroxysmal ventricular or atrial tachycardias occurring in conjunction with the above. It was apparent that both drugs were capable of reducing ectopic activity and maintaining suppression throughout the course of therapy.



Includes patients with more than 60 total (atrial and ventricular) ectopic beats per hour but who had fewer than 60 ventricular ectopic beats per hour

There was no statistically significant difference in reduction of ectopy between the two drugs

Effective by extensive Holter monitoring


Lower incidence of severe side effects

Significantly fewer dropouts with Norpace


(disopyramide phosphate)

entire study population was analyzed
side effects. The side effects experi-
ed by Norpace patients were usually
and mainly anticholinergic including
mouth urinary hesitancy constipa-
tion blurred vision. The anticholinergic
e effects were generally transient
verse reactions with quinidine were
re serious and affected a greater num-
r of patients. The most common symp-
ns were severe diarrhea gastrointes-
al symptoms including cramps nausea
d vomiting dizziness fever and rash.

Quinidine dropouts in 62 patients



Norpace dropouts in 62 patients



Dosage and administration

applied as 100-mg and 150-mg capsules. Dosage should be individualized based on response
and tolerance. Usual adult dosage is 400 to 800 mg per day given in divided doses four times daily.
Initial Norpace dosage

Patients 110 lb and over	150 mg q 6 h
Patients less than 110 lb	100 mg q 6 h
Patients with specific complications Patients with possible cardiac decompensation cardio- myopathies reduced left ventricular function or hypotension due to these or other causes	100 mg q 6 h
Patients with moderate renal ($C_{cr} > 40$ ml/min) or hepatic insufficiency	100 mg q 6 h (200 mg loading dose optional)
Patients with severe renal insufficiency ($C_{cr} < 40$ ml/min)	100 mg given approximately every half life ($T_{1/2}$) (200 mg loading dose optional)
$C_{cr} = 40-15$ ml/min	q 10 h
$C_{cr} = 15-5$ ml/min	q 20 h
$C_{cr} = 5-1$ ml/min	q 30 h
In patients without the complications specified above in whom rapid control of arrhythmias is essential therapy may be initiated with a loading dose of 300 mg (200 mg for patients under 110 lb)	

For complete Norpace dosage recommendations please see full prescribing
information a brief summary of which appears on the next page

SEARLE

NORPACE[®]
(disopyramide phosphate)



as effective as quinidine sulfate for specific ventricular arrhythmias... with a lower incidence of severe side effects

Before prescribing Norpace (disopyramide phosphate) please consult current complete prescribing information a summary of which follows

Indications Norpace is indicated for suppression and prevention of recurrence of the following cardiac arrhythmias when they occur singly or in combination: unifocal premature (ectopic) ventricular contractions; premature (ectopic) ventricular contractions of multifocal origin; paired premature ventricular contractions (couplets); and episodes of ventricular tachycardia (persistent ventricular tachycardia is ordinarily treated with D.C. cardioversion).

Norpace is equally effective in treating the above arrhythmias in both digitalized and nondigitalized patients. It is also equally effective in treating primary cardiac arrhythmias and those which occur in association with organic heart disease including coronary artery disease. Oral Norpace has not been adequately studied in patients with acute myocardial infarction or in patients with persistent ventricular tachycardia or atrial arrhythmias and is not indicated for arrhythmias due to digitalis intoxication. The value of antiarrhythmic drugs in preventing sudden death in patients with serious ventricular ectopic activity has not been established.

Contraindications Cardiac shock preexisting second or third degree AV block (if no pacemaker is present) or known hypersensitivity to the drug.

Warnings Severe hypotension has been observed primarily in patients with primary cardiomyopathy or inadequately compensated congestive heart failure. Hypotension develops Norpace should be discontinued promptly unless hypotension is due to the arrhythmia.

Norpace should not be used in the presence of poorly compensated or uncompensated congestive heart failure unless it is exacerbated by or caused by an arrhythmia and proper treatment including optimal digitalization has been accomplished. In some patients with marginally compensated heart failure Norpace may worsen cardiac decompensation. In these patients progressing congestive heart failure should generally be treated with cardiac glycosides and diuretics and the course of treatment closely followed. Norpace dosage should be reduced or discontinued if adequate control of congestive failure is not attained.

If first degree heart block develops the dosage of Norpace should be reduced. If the block persists continuation of Norpace must depend upon an assessment of the benefit versus the risk. Development of second or third degree AV block or bi- or trifascicular block requires discontinuation of Norpace unless the ventricular rate is adequately controlled by a pacemaker.

Because of its anticholinergic properties Norpace should not be used in patients with glaucoma, myasthenia gravis or urinary retention unless adequate overriding measures are taken.

Precautions If significant widening (greater than 25%) of the QRS complex occurs Norpace should be discontinued. If Q-T prolongation greater than 25% occurs and if ectopy continues monitor closely and consider discontinuing Norpace.

Patients with atrial flutter or fibrillation should be digitalized prior to Norpace administration to ensure that drug induced enhancement of AV conduction does not allow a ventricular rate beyond physiologically acceptable limits.

The effect of Norpace is presently uncertain in patients with sick sinus syndrome, Wolff Parkinson White syndrome or bundle branch block.

Patients with myocarditis or other cardiomyopathy may develop significant hypotension in response to the usual dosage of Norpace (disopyramide phosphate).

Norpace should be administered cautiously to patients who are not taking or who have recently received other antiarrhythmic drugs. Excess widening of the QRS complex and/or prolongation of the Q-T interval may occur in such instances.

Norpace dosage should be reduced in patients with impaired renal/hepatic function and the electrocardiogram carefully monitored for signs of overdosage.

Antiarrhythmic drugs may be ineffective in patients with hypokalemia. Therefore any potassium deficit should be corrected before starting Norpace therapy.

Use in Pregnancy and Lactation Safe use in pregnancy has not been established. Norpace has been reported to stimulate contractions of the pregnant uterus. The use of Norpace in pregnant women requires that the potential benefit be weighed against possible hazards to the fetus.

It is not known whether disopyramide is excreted in human milk. However studies in rats have shown that the concentration of disopyramide and its metabolites is up to three times greater in milk than in plasma. If use of the drug is deemed essential an alternate method of infant feeding should be instituted.

Labor and Delivery The effects of Norpace on the fetus during labor or on the course of labor and delivery are unknown.

Pediatrics The safety and effectiveness of Norpace in children have not been established.

Adverse Reactions Anticholinergic: dry mouth, urinary hesitancy, constipation, blurred vision, dry nose/eyes/throat, urinary retention. Genitourinary: urinary frequency and urgency. Gastrointestinal: nausea, pain/bloating/gas, anorexia, diarrhea, vomiting. General: nervousness, dizziness, general fatigue/muscle weakness, headache, malaise. Cardiovascular: hypotension, congestive heart failure, cardiac conduction disturbances, edema/weight gain, shortness of breath, syncope, chest pain. Dermatologic: generalized rash/dermatoses. The following have occurred but a causal relationship is uncertain: impotence, depression, insomnia, hypoglycemia, dysuria. Acute psychosis and cholestatic jaundice both reversible have been reported.

Dosage and Administration Dosage must be individualized for each patient on the basis of response and tolerance. The usual adult dosage: 400 to 800 mg per day given in divided doses four times daily. The recommended dosage schedule for most adults is 150 mg every six hours. For patients weighing less than 110 pounds (50 kg) the recommended dosage is 100 mg every six hours.

If rapid control of arrhythmia is essential an initial loading dose of 3 mg of Norpace (200 mg for patients weighing less than 110 pounds) is recommended. For patients with cardiomyopathy or possible cardiac decompensation a loading dose should not be given and the initial dose limited to 100 mg every six hours with subsequent dosage adjustments made gradually under close monitoring.

See current complete prescribing information for dosage recommendations.

How Supplied Capsules containing 100 mg or 150 mg of disopyramide base. Available in bottles of 100 capsules.

SEARLE

Searle Laboratories
Division of G. D. Searle & Co.
Box 5110 Chicago, Illinois 60680

Appraisal and reappraisal of cardiac therapy

Edited by Arthur E. DeGraff and Julian Frieden

Infective endocarditis Part II Current therapy

Joan I. Casey M.D.
Michael H. Miller M.D.
Bronx, N.Y.

Many clinical and experimental studies have been undertaken in the past few years to determine optimal therapy for infectious endocarditis which continues to be one of the most serious infectious diseases of man. The increased prominence of unusual organisms and the changes in sensitivity patterns of the more characteristic organisms is important therapeutically. Therapy often must be started prior to a knowledge of the causative organisms. It is useful to review briefly some of the predisposing conditions associated with this disease. A knowledge of the probable portal of entry enables one to make an educated guess as to the organisms and therefore the most useful antibiotic or combination of antibiotics.

In recent years there has been a decrease in rheumatic heart disease and an increase in the number of people surviving with prosthetic valves, congenital heart disease, and arteriosclerotic heart disease. These people are at an increased risk of bacterial endocarditis so that over all there has been no decrease in the number of patients with bacterial endocarditis.

There has also been a change in the types of organisms causing bacterial endocarditis. Documentation of bacteremias associated with dental procedures has reaffirmed the importance of the mouth flora as a primary source of organisms. These organisms usually viridans streptococci have an ability to adhere to heart valves not found in other organisms such as gram negative

rods. This may be the reason these streptococci remain the leading cause of infective endocarditis. The disease is usually subacute although fulminating infection can occur with these organisms. The increased use of intravenous infusions in the hospital and intravenous heroin in the community has increased the incidence of bacteremias which may lead to valvular infections. The organisms involved in these latter infections are usually *Staphylococcus aureus*, *Enterobacteriaceae* Sp. *Pseudomonas aeruginosa* or enterococci. Manipulation or infection of the genitourinary and gastrointestinal tracts may lead to transient bacteremias and valvular infections with Group D streptococci or rarely gram negative rods. Group D enterococcus endocarditis rarely seen prior to the introduction of antibiotics is now not uncommon in this setting. The disease may be acute or subacute. Group D non enterococcus includes *Streptococcus bovis* increasingly recognized as a cause of endocarditis¹ and *Streptococcus equinus* only rarely a cause of human disease.

Staphylococcus aureus is found on normal human skin and may enter the blood stream secondarily to intravenous lines, superficial skin infections or wound infections. *Staphylococcus aureus* endocarditis may be seen in children including those with hematogenous osteomyelitis and this association should be recognized. Blood cultures growing *Staphylococcus epidermidis* which is also found on normal skin may represent contamination or infection. Continuous bacteremia must be considered to represent intravascular infection and be treated as such although true infection with *Staphylococcus epidermidis* is unusual except in the patients with prosthetic valves.

From the Division of Infectious Diseases Department of Medicine, Montefiore Hospital and Medical Center and the Albert Einstein College of Medicine, Bronx, N.Y.

Received for publication April 6, 1978.

Reprint requests: Joan I. Casey M.D., Department of Medicine Division of Infectious Diseases, Montefiore Hospital and Medical Center, 333 Graham St., Philadelphia, Pa. 19104.

they may be very sensitive or relatively resistant to penicillin.¹⁵ They are treated in the same way as described for viridans streptococci.

Staphylococcus aureus

If the organism is known to be sensitive to penicillin, that antibiotic is the drug of choice. Few strains of *Staphylococcus aureus* are sensitive, however, and for this reason initial therapy of staphylococcal infections is with a penicillinase-resistant penicillin such as nafcillin or oxacillin. The dose of penicillin is similar to that for sensitive viridans streptococci, the dose of nafcillin is 1 gram intravenously every 2 hours or 2 grams intravenously every four hours. Patients occasionally complain of pain when these antibiotics are given intravenously and the infusion may be given more slowly in these situations. Recent data, both in vitro and in animals suggest that the combination of nafcillin and gentamicin results in more rapid killing of *Staphylococcus aureus* than nafcillin alone. The advantage of rapid killing is that destruction of the valve which may be seen with *Staphylococcus aureus* infections in particular may be prevented. Controlled clinical trials are currently underway to test this combination of drugs in large numbers of patients with *Staphylococcus aureus* endocarditis. In a small study by Watanakunakorn and Baird¹⁶ there appeared to be little difference between patients treated with the combination and those treated with nafcillin alone. For the penicillin-allergic patient in whom cephalosporins may be considered, we prefer cephalothin since all cephalosporins may not be equally effective in therapy of staphylococcal infections. If the risk of hypersensitivity reactions is considered prohibitive to the use of cephalosporins, vancomycin 500 mg intravenously every six hours, or one gram every twelve hours may be used. A recently recognized problem with the penicillinase-resistant penicillins, cephalosporins and vancomycin is the so-called tolerance of certain strains of *Staphylococcus aureus* to these antibiotics. In these strains the difference between the MIC and the MBC is thirty-two fold or higher. This contrasts with the usual two to fourfold differences seen in most strains. These tolerant strains are resistant to the action of these drugs although they are reported as sensitive by the Kirby-Bauer disc assay which correlates with the MIC only. The clinical significance of this phenomenon is not known. However,

if the patient is not responding well on the usual antibiotic regimen, and the spread in MIC/MBC is demonstrated, several antibiotic combinations such as nafcillin/gentamicin should be tested and the optimal one chosen. Intrinsic resistance to methicillin and other penicillinase-resistant penicillins which may be recognized by the Kirby-Bauer disc assay has not been a major problem in this country, although it may be seen occasionally. Disc sensitivities which suggest that an organism is resistant to methicillin and sensitive to cephalosporins are probably inaccurate. These latter strains of *Staphylococcus aureus* are resistant usually to cephalosporins also but unlike the tolerant organisms are frequently sensitive to vancomycin. At least six weeks of intravenous therapy is most commonly used for *Staphylococcus aureus* endocarditis.

There is some uncertainty about duration of therapy for patients who have one or possible two blood cultures positive for *Staphylococcus aureus* secondary to removable foci of infection. Commonly a four to six week course has been recommended, but therapy in these cases must be individualized. Iannini and Crossley¹⁷ suggest that a ten-day course of antistaphylococcal antibiotics is sufficient, but Watanakunakorn and Baird¹⁶ reiterate that in their experience endocarditis is commonly seen in such patients. It is essential in these situations that at least three to five blood cultures be obtained over several hours and if these are positive for *Staphylococcus aureus* the patient should be treated as if he or she has endocarditis.

Staphylococcus epidermidis

Staphylococcus epidermidis may be sensitive to penicillin or the penicillinase-resistant penicillins in which case therapy is similar to that of *Staphylococcus aureus*. Some strains of *Staphylococcus epidermidis* are resistant by tube dilution assays to these antibiotics even when disc tests indicate sensitivity to the cephalosporins. Recent animal data indicate that a combination of vancomycin and gentamicin may be the most active combination for nafcillin-resistant *Staphylococcus epidermidis*.¹⁸

Anaerobic organisms

Anaerobic organisms are rare causes of infective endocarditis. The gram-positive cocci such as peptostreptococcus and peptococcus are usually

sensitive to penicillin. These infections can be treated with high doses of penicillin such as 24 millions units per day. Patients who are allergic to penicillin or patients who have *Bacteroides fragilis* (an anaerobic gram negative rod) infections present problems. For the allergic patient desensitization and treatment with penicillin may be the therapeutic regimen of choice. For the patient with *Bacteroides fragilis* infective endocarditis the choice of drugs is limited as these organisms are commonly resistant to penicillin and sensitive only to drugs considered to be bacteriostatic and not bacteriocidal. Clindamycin has been reported to be bacteriocidal for some strains of *Bacteroides fragilis*⁷ and if this is demonstrated for a particular organism this drug could be used in doses of 300 mg intravenously every four to six hours. Serum bactericidal levels must be monitored and the patient carefully observed for evidence of toxic side effects. The most common side effect is diarrhea which can lead to pseudomembranous colitis. This serious effect is not common especially if the drug is stopped as soon as diarrhea begins. The process may be reversible with cholestyramine.⁸ Cardiac arrhythmias and liver function abnormalities are occasionally observed. The only bacteriocidal drug for treating *Bacteroides fragilis* endocarditis at the present time is metronidazole. Although this drug has recently been shown to be carcinogenic in mice in this serious situation it may be the best drug. Cephoxitin, a new cephalosporin may prove to be useful in treating infections with *Bacteroides fragilis*. Preliminary data indicates that cephoxitin has activity against these organisms and it is a relatively non-toxic drug. Currently it is available only for research purposes.

Aerobic gram negative rods

Aerobic gram negative rods rarely cause infective endocarditis except in unusual circumstances such as in post valvular replacement infections and in drug addicted persons.

Some of these organisms such as *Escherichia coli* and *Proteus mirabilis* may be sensitive to ampicillin and cephalothin. Other such as *Klebsiella pneumoniae* are resistant to ampicillin but may be sensitive to cephalothin and others such as *Pseudomonas aeruginosa* are resistant to ampicillin and cephalothin but are usually sensitive to gentamicin. Some hospitals are now

reporting gram negative rods which are resistant to gentamicin and sensitive only to amikacin. The least toxic bacteriocidal drug should be used and therapy should continue for four and possibly six weeks. Combination of drugs such as cephalothin and gentamicin may be synergistic against *Klebsiella* and are suggested in those infections with organisms sensitive to both drugs. If the organism is *Pseudomonas aeruginosa* and it is sensitive to both carbenicillin and tobramycin the combination should be used. Ticarcillin may be used in place of carbenicillin and gentamicin in place of tobramycin. The dose of tobramycin for pseudomonas infections is 1.5 mg/Kg intramuscularly every eight hours and carbenicillin is given in dose of 4 to 6 grams intravenously every four hours. Carbenicillin may cause hypokalemic alkalosis and/or a bleeding diathesis the latter especially in patients with impaired renal function.

Fungal Endocarditis

Fungal endocarditis is rare and occurs almost exclusively in patients who have prosthetic valves, prolonged intravenous infusions or heroin addiction. Several reports of candida bacteremia following gastrectomies suggest that the risk of this infection may be increased in these patients. Rubinstein and colleagues¹¹ found that the heroin addicted persons were likely to have unusual species of candida such as *parapsilosis* and *tropica* while the patients who had had cardiac surgery were infected with *candida albicans* or *aspergillus*.

It is difficult to differentiate transient fungemia from actual infection. Endocarditis has been documented in patients several months after so called transient fungemia.¹² Medoff and colleagues¹ suggests a short course of amphotericin for patients with transient fungemia. This might apply to those individuals who are at increased risk of fungal infections. However since most individuals who develop transient candida fungemia respond to simple maneuvers such as discontinuation of intravenous or bladder catheters we would recommend these procedures for the majority of patients. If blood cultures are positive following discontinuation of the catheters antifungal therapy should be instituted. In patients with *aspergillus* endocarditis blood cultures are rarely positive.

Once the decision is made that the patient has

they may be very sensitive or relatively resistant to penicillin.¹³ They are treated in the same way as described for viridans streptococci.

Staphylococcus aureus

If the organism is known to be sensitive to penicillin, that antibiotic is the drug of choice. Few strains of *Staphylococcus aureus* are sensitive, however, and for this reason initial therapy of staphylococcal infections is with a penicillinase-resistant penicillin such as nafcillin or oxacillin. The dose of penicillin is similar to that for sensitive viridans streptococci, the dose of nafcillin is 1 gram intravenously every 2 hours or 2 grams intravenously every four hours. Patients occasionally complain of pain when these antibiotics are given intravenously and the infusion may be given more slowly in these situations. Recent data, both in vitro and in animals suggest that the combination of nafcillin and gentamicin results in more rapid killing of *Staphylococcus aureus* than nafcillin alone. The advantage of rapid killing is that destruction of the valve which may be seen with *Staphylococcus aureus* infections in particular may be prevented. Controlled clinical trials are currently underway to test this combination of drugs in large numbers of patients with *Staphylococcus aureus* endocarditis. In a small study by Watanakunakorn and Baird¹⁴ there appeared to be little difference between patients treated with the combination and those treated with nafcillin alone. For the penicillin-allergic patient in whom cephalosporins may be considered, we prefer cephalothin since all cephalosporins may not be equally effective in therapy of staphylococcal infections. If the risk of hypersensitivity reactions is considered prohibitive to the use of cephalosporins, vancomycin 500 mg intravenously every six hours or one gram every twelve hours may be used. A recently recognized problem with the penicillinase-resistant penicillins, cephalosporins and vancomycin is the so-called tolerance of certain strains of *Staphylococcus aureus* to these antibiotics. In these strains the difference between the MIC and the MBC is thirty-two fold or higher. This contrasts with the usual two to fourfold differences seen in most strains. These tolerant strains are resistant to the action of these drugs although they are reported as sensitive by the Kirby-Bauer disc assay which correlates with the MIC only. The clinical significance of this phenomenon is not known. However,

if the patient is not responding well on the usual antibiotic regimen, and the spread in MIC/MBC is demonstrated, several antibiotic combinations, such as nafcillin/gentamicin should be tested and the optimal one chosen. Intrinsic resistance to methicillin and other penicillinase-resistant penicillins which may be recognized by the Kirby-Bauer disc assay has not been a major problem in this country, although it may be seen occasionally. Disc sensitivities which suggest that an organism is resistant to methicillin and sensitive to cephalosporins are probably inaccurate. These latter strains of *Staphylococcus aureus* are resistant usually to cephalosporins also, but unlike the tolerant organisms are frequently sensitive to vancomycin. At least six weeks of intravenous therapy is most commonly used for *Staphylococcus aureus* endocarditis.

There is some uncertainty about duration of therapy for patients who have one or possible two blood cultures positive for *Staphylococcus aureus* secondary to removable foci of infection. Commonly a four to six week course has been recommended, but therapy in these cases must be individualized. Iannini and Crossley¹⁵ suggest that a ten-day course of antistaphylococcal antibiotics is sufficient, but Watanakunakorn and Baird¹⁴ reiterate that in their experience endocarditis is commonly seen in such patients. It is essential in these situations that at least three to five blood cultures be obtained over several hours and if these are positive for *Staphylococcus aureus* the patient should be treated as if he or she has endocarditis.

Staphylococcus epidermidis

Staphylococcus epidermidis may be sensitive to penicillin or the penicillinase-resistant penicillins in which case therapy is similar to that of *Staphylococcus aureus*. Some strains of *Staphylococcus epidermidis* are resistant by tube dilution assays to these antibiotics even when disc tests indicate sensitivity to the cephalosporins. Recent animal data indicate that a combination of vancomycin and gentamicin may be the most active combination for nafcillin-resistant *Staphylococcus epidermidis*.¹⁶

Anaerobic organisms

Anaerobic organisms are rare causes of infective endocarditis. The gram-positive cocci such as peptostreptococcus and peptococcus are usually

- Watanakunakorn C., and Baur I M Prognostic factors in *Staphylococcus aureus* endocarditis and results of therapy with penicillin and gentamicin Am J Med Sci. 273 133 1977
- Iannini, P B and Crossley K Therapy of *Staphylococcus aureus* bacteremia associated with a removable focus of infection Ann Intern Med 84 558 1976
- Watanakunakorn C., and Baur I M Staphylococcus bacteremia and endocarditis associated with a removable infected intravenous device Am J Med 63 253 1977
- Lowy F Walsh J Mayers M and Steigbigel N Therapy of experimental methicillin resistant staphylococcus epidermidis infection Abstract No. 234 17th Interscience Conference on Antimicrobial Agents and Chemotherapy October 1977
- Nastro L J and Finegold S M Bactericidal activity of five antimicrobial agents against *Bacteroides fragilis* J Infect Dis 126 104 1972
- Barbige E and Milligan F Pseudomembranous colitis. Association with antibiotics and therapy with cholestyramine JA MA 231 1157 1975
- Rubinstein E Noriega E Simberloff M Holzman R and Rahal J J Fungal Endocarditis Analysis of 24 cases and review of the literature Medicine 54 331 1975
- Medoff G Oismukes W E Meade R H., and Moses J A new therapeutic approach to candida infections Arch Intern Med 130 741 1972
- Bennett J E Chemotherapy of systemic mycosis N Engl J Med. 290 30 1974
- Foss, R J and Pethena R L 5-Fluorocytosine in the treatment of cryptococcal and Candida mycosis Ann Intern Med 74 535 1971

in fact fungal infection, antifungal therapy is instituted. Amphotericin intravenously is started, usually at a dose of 1 mg of amphotericin B in 500 ml of 5 per cent dextrose in water. The infusion is given over a time period of three to four hours. The initial infusion may cause severe reactions such as fever, shaking chills, headaches, nausea and vomiting and even hypotension. Aspirin and benedryl by mouth and hydrocortisone given in doses of 25 to 50 mg in the infusion bottle may be useful if the reactions are poorly tolerated. The dose of amphotericin is increased in increments of 5 mg per day to a total dose of 0.5 to 0.6 mg per kilogram of body weight. It is usual for the BUN and creatinine to rise. Renal function should be closely monitored until these parameters stabilize. Bennett¹ prefers to keep the BUN below 50 mg per cent and the creatinine below 3.5 mg per cent. If these parameters do stabilize the dose may be gradually changed to 1.0 to 1.2 mg per kilogram given every other day. Hypokalemia may require potassium therapy. The hematocrit may fall secondary to decreased production of erythrocytes. The toxic side effects of the drug usually resolve after therapy is discontinued although subtle renal impairment may persist. Since fungal endocarditis rarely, if ever responds to medical therapy alone replacement of the infected valve is usually undertaken after a week or 10 days of therapy from the time the optimal dose is achieved. Chemotherapy is continued for at least 4 to 6 weeks after surgery.

Some species of fungi may be sensitive to 5-fluorocytosine. There is very little data regarding the effectiveness of this drug in endocarditis although the combination with amphotericin B may be additive or minimally synergistic.²¹ The dose of drug is 30 mg per kilogram by mouth, every six hours in patients with normal renal function. Because of the leukopenia and thrombocytopenia associated with this drug and because its use in endocarditis has been minimal we do not recommend it in patients with decreased renal function.

Abacteremic endocarditis

For patients in whom the clinical suspicion of endocarditis is very high but blood cultures are negative, penicillin one million units intravenously every two hours and streptomycin 500 mg intramuscularly every 12 hours is a rational regimen. This combination treats viridans strep-

tococci, enterococcus, and some of the unusual pathogens mentioned. Penicillin alone may result in a clinical response but not a microbiological cure. If the patient does not respond to this regimen nafcillin 1 gram every two hours may be added although *Staphylococcus aureus* is such an invasive organism it is unlikely that abacteremic endocarditis is seen in *Staphylococcus aureus* infections, unless the patient has had antibiotics prior to blood culturing.

REFERENCES

1. Juhlind M and Barnes M W. Changing etiology of bacterial endocarditis in the antibacterial era. Experience of the Boston City Hospital 1933-60. *Ann Intern Med* 77:341 1970.
2. Watanakunakorn C. Streptococcus bovis endocarditis. *Am J Med* 56:256 1974.
3. Fagle II, Fleishman R and Musselman A D. Effect of schedule of administration on therapeutic efficacy of penicillin: importance of aggregate time penicillin remains at effectively bactericidal levels. *Am J Med* 9:280 1970.
4. Schlichter J G and MacLean II A. A method of determining the effective therapeutic level in the treatment of subacute endocarditis with penicillin: a preliminary report. *Am Heart J* 34:209 1947.
5. Blount J G. Bacterial endocarditis. *Am J Med* 38:909 1965.
6. Wolfe J C and Johnson W D. Penicillin sensitive streptococcal endocarditis: In vitro and clinical observations on penicillin-streptomycin therapy. *Ann Intern Med* 81:178 1974.
7. Tan J S, Terhune C A, Kaplan II and Hamburger M. Successful two week treatment schedule for penicillin susceptible streptococcus viridans endocarditis. *Lancet* 2:1340 1971.
8. Cox F, Quinn E, Madhavan T and Fisher E. Oral treatment of bacterial endocarditis: Results in 100 cases. Abstract No. 208. 13th Interscience Conference on Antimicrobial Agents and Chemotherapy. September 1973.
9. Standford H D, DeMaime H B and Kirby W M M. Antibiotic synergism of enterococci. *Arch Intern Med* 126:255 1970.
10. Moellering II C, Wennersten C, Medrek T and Weinberg A. Prevalence of high level resistance to aminoglycosides in clinical isolates of enterococci. *Antimicrob Agents Chemother* 10:335 1970.
11. Watanakunakorn C. Penicillin combined with gentamicin or streptomycin synergism against enterococci. *J Infect Dis* 124:581 1971.
12. Fellner M, VanHecke E, Rozan M and Baer R. Mechanisms of clinical desensitization in urticarial hypersensitivity to penicillin. *J Allergy* 45:55 1970.
13. Gerace J E. Vancomycin. *Mayo Clin Proc* 52:631 1977.
14. Watanakunakorn C and Babie C. Synergism of vancomycin-gentamicin and vancomycin-streptomycin against enterococci. *Antimicrob Agents Chemother* 4:120 1973.
15. Thorneberry C, Baker C N and Facklam R R. Antibiotic susceptibility of *Streptococcus bovis* and other group D streptococci causing endocarditis. *Antimicrob Agents Chemother* 6:228 1974.

- 16 Watanakunakorn C and Baird I M Prognostic factors in *Staphylococcus aureus* endocarditis and results of therapy with penicillin and gentamicin Am J Med Sci. 273 133 1977
- 17 Iannini, P H and Crossley K Therapy of *Staphylococcus aureus* bacteremia associated with a removable focus of infection Ann Intern Med 84 5,8 19 6
- 18 Watanakunakorn C and Baird I M Staphylococcus bacteremia and endocarditis associated with a removable infected intravenous device Am J Med 63 2,3 1977
- 19 Lowy F Walsh J Mayers, M and Steigbigel N Therapy of experimental methicillin resistant staphylococcus epidermidis infection Abstract No 234 17th Interscience Conference on Antimicrobial Agents and Chemotherapy October 1977
- 20 Hastro L J and Finegold E M Bactericidal activity of five antimicrobial agents against *Bacteroides fragilis* J Infect Dis 126 104 1972
- 21 Burbige E and Milligan F D Pseudomembranous colitis. Association with antibiotics and therapy with cholestyramine J.A.M.A 231 1157 1973
- 22 Rubinstein E Noriega E Simberloff M Holzman R and Rahal, J J Fungal Endocarditis Analysis of 24 cases and review of the literature Medicine 54 331 1975
- 23 Medoff G Dismukes, W E Meade R H and Moses J A new therapeutic approach to candida infections Arch Intern Med. 130 241 1972
- 24 Bennett J E Chemotherapy of systemic mycosis, N Engl J Med 290 30 1974
- 25 Foss R J and Perhens R L 5 Fluorocytosine in the treatment of cryptococcal and Candida mycosis, Ann Intern Med 74 35 1971

Hypertension and the cerebral circulation—its relevance to the elderly

Jackson and colleagues described six patients aged between 64 and 81 years in whom antihypertensive therapy had been started and had resulted in marked reductions in blood pressure. Associated with the reductions in blood pressure were syncopal episodes. They concluded that in the elderly the decrease in elasticity in the cerebral vessels together with the probable presence of atheromatous change in these vessels might lead to a critical reduction in cerebral blood flow when a major reduction in blood pressure occurred. In recent years there have been several studies which provide evidence to support this viewpoint.

Cerebral blood flow in normotensive animals and in man is maintained constant despite variations in blood pressure in the course of everyday events. In other words autoregulation of cerebral blood flow occurs. When pressure rises acutely the cerebral vessels constrict and when pressure falls the cerebral vessels dilate. The net result is that cerebral blood flow remains unaltered over a fairly wide range of perfusion pressures.

The absolute values for cerebral blood flow are the same in both hypertensive and normotensive people. Similar values for cerebral blood flow have also been found in normotensive and hypertensive baboons. However the range of pressures over which the hypertensive individual can maintain a constant cerebral perfusion is different in hypertensive subjects when compared to normotensive subjects. Almost invariably the whole autoregulatory curve is shifted to higher levels of mean arterial blood pressure in hypertension. Furthermore the range of blood pressure over which the hypertensive individual can maintain a constant cerebral blood flow may be somewhat less than in the normotensive person. These differences may be explained on structural grounds. In hypertensive rats it has been shown that the vessels of the perfused hindquarters are less capable of dilating maximally when compared to vessels from paired normotensive rats. Therefore if the impairment of dilatation is also applicable to the cerebral vessels in hypertension and there does not seem to be any good reason why it should not be it is evident that the pattern of cerebral blood flow autoregulation would be different from that seen in the normotensive cerebral circulation. Specifically the diminished ability to dilate would impair the responses of the cerebral vessels when blood pressure is lowered markedly in an acute way. Thus the net result would be that cerebral blood flow would start to fall at higher levels of mean arterial blood pressure in hypertensive individuals and therefore there would be evidence of brain hypoperfusion at pressures that might well be regarded as normal and the ideal therapeutic end point.

Blood vessels tend to become less distensible as ageing progresses. It may therefore follow that elderly people *per se* are less tolerant to major reductions in cerebral perfusion

pressure than are those of a younger age group. Super added hypertension may compound the issue such that in the elderly hypertensive subject there is even less cerebral circulatory tolerance to lowering the blood pressure. Unfortunately there have so far been no detailed studies of the effect of ageing on the pattern of autoregulation of cerebral blood flow nor have younger hypertensive subjects been compared with elderly hypertensive subjects in this regard.

Strandgaard and colleagues showed that the lower limit of autoregulation of cerebral blood flow was not equal to the point at which syncopal symptoms occurred. Instead they found that further reductions in blood pressure were required before consciousness started to be impaired. No such studies have specifically been performed on the elderly although some of the patients studied by Strandgaard and co-workers were in the older age group.

The neuropathological sequelae of a precipitate reduction in cerebral blood flow consequent upon over vigorous antihypertensive therapy have been described in two patients. In both there was ischemic brain damage of cerebral perfusion type.

In view of the continuing controversy as to whether or not antihypertensive therapy is even of any benefit in the elderly it would seem that extremely cautious introduction of such therapy should be the approach if any treatment is contemplated at all. Certainly it seems unreasonable to impose vigorous therapy with possible side effects and potentially lethal cerebral complications upon patients in whom the benefit has not yet clearly been shown. However it has been found that the changes in the pattern of cerebral blood flow autoregulation in hypertension are to some extent reversible with long term therapy and that larger doses of antihypertensive drugs might be tolerated later in the treatment period as a result. It is possible that similar benefit may accrue in elderly hypertensive persons and that the initial extreme caution can be replaced at a later date by a somewhat more vigorous therapeutic approach.

John V Jones Ph.D. MRCP
David I Graham Ph.D. MRCP
Cardiac Department Radcliffe Infirmary
Oxford OX2 6HE England and
The University Department of Neuropathology
Southern General Hospital
Glasgow Scotland

REFERENCES

- 1 Jackson G, Pierscianowski T A, Mahon W and Condon J. Inappropriate antihypertensive therapy in the elderly. *Lancet* 2:1317 1976.
- 2 Lassen N A. Cerebral blood flow and oxygen consumption in man. *Physiol Rev* 39:183 1959.
- 3 Mackenzie E T, Strandgaard S, Graham D I, Jones

- J V Harper A M and Farrar K Effects of acutely induced hypertension in cats on pial arteriolar caliber local cerebral blood flow and the blood brain barrier *Circ Res* 39 33 1976
- 4 Kety S S Hafkenschel J H Jeffers W A Leopold I H and Shentum II A The blood flow vascular resistance and oxygen consumption of the brain in essential hypertension *J Clin Invest* 57 511 1976
- 5 Strandgaard S Mackenzie E T, Sengupta II Rowan J O Lassen N A and Harper A M Upper limit of autoregulation of cerebral blood flow in the baboon *Circ Res* 34 435 1974
- 6 Strandgaard S Jones J V, Mackenzie E T and Harper A M Upper limit of cerebral blood flow autoregulation in experimental renovascular hypertension in the baboon *Circ Res* 37 164 1975
- 7 Strandgaard S, Olesen J Skinhøj E and Lassen N A Autoregulation of brain circulation in severe arterial hypertension *Br Med J* 1 507 1973
- 8 Jones J V Fitch W Mackenzie E T, Strandgaard S and Harper A M Lower limit of cerebral blood flow autoregulation in experimental renovascular hypertension in the baboon *Circ Res* 39 555 1976
- 9 Folkow B Hallback M, Lundgren Y Sivertsson R and Weiss L Importance of adaptive changes in vascular design for establishment of primary hypertension studied in man and in spontaneously hypertensive rats *Circ Res* 32 and 33 (Suppl. 1) 1973
- 10 Graham II I Ischaemic brain damage of cerebral perfusion failure type after treatment of severe hypertension *Br Med J* iv 739 1975
- 11 Editorial Hypertension in the elderly *Lancet* 1 684 1977
- 12 Strandgaard S Autoregulation of cerebral blood flow in hypertensive patients The modifying influence of prolonged antihypertensive treatment on the tolerance to acute drug induced hypotension *Circulation* 53 720 1976

Intramural ramification of the left bundle branch

Attention has been focused recently upon location and distribution of the fascicles of the left bundle branch (LBB) in the human heart since these anatomical details may have an important bearing on pathophysiology of intraventricular conduction. It can be useful therefore to briefly illustrate an unusual variety in morphology of the LBB.

The different and largely unpredictable patterns of

subdivision of the LBB hitherto described only refer to the sagittal plane indeed the ramifications of the branch are well known to fan and flatten out in thin bands, over the left subendocardial surface of the ventricular septum. Occasional anastomoses of individual LBB fibers with the underlying myocardium are too short to be considered as true extensions of the branch on the frontal plane.




Fig 1 Left the root of the LBB (black arrow) gives off a medial fascicle (open arrow) penetrating the septal myocardium. Right further intramural course of the LBB ramification (Azan stain original magnification $\times 12$)

In turn the right bundle branch (RBB) which is a compact fascicle in its middle course normally exhibits a medial bent on the frontal plane entering the myocardial context of the septum (intramural or mimetic tract). Sometimes the entire RBB has been seen to travel inside the septal myocardium.

In a 51 year old man who died from heart failure without conduction blocks the conducting system was examined histologically with the technique of longitudinal serial sections and an intramural ramification of the LBB was observed. The atrioventricular (AV) node and His bundle were normal at the Hisian bifurcation the root of the LBB was subdivided on the frontal plane into two thin fascicles one lying in the ipsilateral subendocardium while the other penetrated medially the muscle of the upper ventricular septum (Fig. 1). This intramural ramification belonged to the posterior part of the LBB and took a straight intra-septal course among thick bundles of working myocardium surrounded by a sheath of loose interstitial tissue (Fig. 1). The specific fascicle could be followed downwards and anteriorly over a length of about 1.2 cm along the series of sections and eventually melted with the septal muscle.

The present evidence of a distinct proximal intramural division of the LBB in an otherwise normal AV system can be regarded as an apparently unique anatomical variety. In a previously described case the intramural root of the LBB belonged to an aberrant Hisian bifurcation completely embedded within the septal myocardium.

Besides the morphological interest the intramural location of tracts of the LBB is worthwhile our attention in discussing pathophysiology of LBB conduction disturbances from acute septal infarction particularly.

It has been pointed out that a lower oxygen uptake makes the conducting myocytes more resistant than the working

myocardium to ischemic damage.⁸ Moreover the LBB owing to its widespread subendocardial layout and closeness to the left ventricle cavity can be protected from anoxia by transendocardial oxygen diffusion. Intramural tracts of the LBB are not likely to share this latter oxygen source with the rest of the branch and thus are comparatively more vulnerable by impaired blood supply through the nutrient arteries.

L. Rossi: *LD Path Unit*

Via Annunziata 23/4

20121 Milan Italy

REFERENCES

- 1 Lev M, Unger P N, Rosen K M and Bharati S. The anatomic base of electrocardiographic abnormality. Left bundle branch block. Recent advances in ventricular conduction in *Advances in Cardiology* vol 14 Basel, 1975 S Karger p 16.
- 2 Massing G K., and James T N. Anatomical configuration of the His bundle and bundle branches in the human heart. *Circulation* 53: 609, 1976.
- 3 Truex R C and Smythe M Q. Recent observations on the human cardiac conduction system with special consideration of the atrioventricular node and bundle in *Electrophysiology of the heart* Taccardi B and Marchetti G eds Oxford 1965 Pergamon Press, p 177.
- 4 Rossi L. Histopathologic features of cardiac arrhythmias. Milan 1969 Casa Editrice Ambrosiana.
- 5 Rossi L. Histopathology of conducting system in left anterior hemiblock. *Br Heart J* 38: 1304, 1976.
- 6 Burch G E. Of the conduction system and myocardial function. *AM HEART J* 92: 809, 1976.
- 7 Hackel D B, Wagner G, Rathff N B, Cies A and Estes E H. Anatomic studies of the cardiac conducting system in acute myocardial infarction. *AM HEART J* 83: 77, 1972.

Of the myocardium and myotonia atrophica (dystrophica myotonia)

The striated cardiac muscle and the striated skeletal muscle are known to be different physiologically. Although both muscles are striated their differences are further reflected by the differences in their behavior in myotonia congenita and myotonia atrophica. For example it is obvious what would happen if the myocardium were to manifest myotonia as skeletal muscle does and the heart were to go into systole and remain contracted for a fairly long period of time as skeletal muscle does. Fortunately this state does not develop in heart muscle to any clinically measurable degree. If it did the patients would die of systolic arrest. It is also interesting that cardiomyopathy and related cardiac disturbances are reported not to exist in association with myotonia congenita but skeletal muscle does develop myotonia. It is of further interest that patients with myotonia atrophica have a high incidence of conduction tissue dysfunction¹ with impairment of conduction manifested by various degrees of heart block to complete A-V block and complete SA node block. Because of

this high incidence of pathophysiology of the conduction tissue one wonders if this is not additional evidence that although the disease tends to skip the myocardium itself it strikes the conduction tissue just as it strikes skeletal muscle and therefore cardiac muscle and conduction tissue in the heart are different.

The mechanism for the block of the excitation wave front in conduction tissues and within the SA node itself stimulates interesting speculative physiologic considerations. For example it is interesting to speculate that the excitation impulse attempts to flow through conduction tissue but a myotonic phenomenon occurs within the cells so that the wave front cannot progress and an additional one cannot even get started. This would be myotonia electrica. In the case of the SA node the impulse might even be considered to be generated but it is unable to spread through the SA node and escape the node (SA node exit block) to stimulate the atria.

Pathologic studies of the myocardium both by light and

electron microscopy reveal relatively little morphologic change in the myocardium in myotonia atrophica. The changes are not specific and may even be the result of previous disease other than the dystrophy itself. The histologic and ultrastructural changes in the conduction tissue and myocardium need further investigation as these rare cases become available for study. Surely detailed electrophysiologic investigations are needed to learn more about the electric events associated with myotonia atrophica. Thoughtful considerations of the cardiac aspects of this disease can be quite provocative.

George E Burch, M.D.

Tulane University School of Medicine and Charity Hospital
New Orleans, La.

REFERENCES

- 1 Orndahl G, Thulesius H, Enestrom S and Dehlin O. The heart in myotonic disease. *Acta Med Scand* 176:479, 1964.

Mutton's law

When an enterprising reporter asked Willie Sutton the notorious bank robber why he always robbed banks he reputedly replied, "Because that's where the money is." Willie's logic spurred Dock to coin the term "Sutton's Law" as a reminder for physicians to go where the diagnosis is.

Although many patients benefit from Sutton's Law, some profit from a different approach—careful, continued observation. John Milton gave us a way to remember this when he wrote what I call Milton's Law. They also serve who only stand and wait.

Thus Sutton's Law encourages specific, well-directed action while Milton's Law pleads for disciplined, thoughtful

- 2 Perloff J H. Cardiac involvement in hereditary familial neuromyopathic diseases. *Cardiovasc Clin* 4:334, 1972.
- 3 Cannon P J. The heart and lungs in myotonic muscular dystrophy. *Am J Med* 32:765, 1967.
- 4 Petkovich N J, Dunn M and Reed W. Myotonia dystrophica with A-V dissociation and Stokes-Adams attacks. A case report and review of the literature. *Am Heart J* 68:391, 1964.
- 5 Thomson A M P. Dystrophia cordis myotonica studied by serial histology of the pacemaker and conducting system. *J Pathol Bact* 96:283, 1968.
- 6 Kennel A J, Titus J L and Mendeth J. Pathologic findings in the sinoventricular conduction system in myotonic dystrophy. *Mayo Clin Proc* 49:838, 1974.
- 7 Gings R C, Davis R J, Anderson M C and Dove J T. Cardiac conduction in myotonic dystrophy. *Am J Med* 59:37, 1975.

inaction. Proper blending of the two is the art of medicine, knowing what to do and when to do it. That's "Mutton's Law."

Herbert L. Fred, M.D.
St. Joseph Hospital
1819 LaBranch
Houston, Texas 77002

REFERENCES

- 1 Dock, W. Quoted in *Where the Money Was: the Memoirs of a Bank Robber* Willie Sutton with Edward Linn. New York, 1976. The Viking Press, pp. 119, 121.
- 2 John Milton. *On His Blindness*. London, 1637.

Steroids in myocardial disease

To the Editor

I read with interest the article by Greenwood Nadas and Fyler (The clinical course of primary myocardial disease in infants and children AMERICAN HEART JOURNAL 92 549 560 1976)

There is one statement made by the authors which I think requires some clarification and explanation. The statement concerning the treatment of children with myocardial disease with steroids may be misleading. The authors do not state what dose or range of steroids was generally used in these patients. This information is I think of critical importance to the implied statement on the efficacy of steroids.

There is as the authors do mention controversy concerning the use of steroids in these conditions. Part of this controversy is dose. Some experts purport the use of pharmacologic or physiologic doses of steroids (equivalent to 150 mg/kg of hydrocortisone intravenously) for use in cardiovascular emergencies rather than usual doses of parenteral steroids to provide optimal effect with minimal problems.

I don't know whether or not during the times of data collection for this study the use of these physiologic doses of steroids was considered and carried out in these patients. This is pertinent information.

Salatore J. Giordanni Jr. Pharm.D.
Clinical Coordinator
Pharmacy Services
Lenox Hill Hospital
100 F 77th St
New York N.Y. 10021

REFERENCES

1. Melby J. C. Adrenocorticosteroids in medical emergencies. *Med Clin North Am* 45:875 1961
2. Shoemaker W. C. Hemodynamic and oxygen transport patterns of common shock syndromes. From the Proceedings of a symposium on recent research developments and current clinical practice in shock. The Upjohn Company 1975
3. Lillehei R. Steroids and shock controversy. *Med Opin* ion August 1971

Diagnosing magnesium deficiency

To the Editor

With the large number of patients who are now receiving diuretic therapy in clinical practice the incidence of occult magnesium deficiency may indeed be much more common than is generally appreciated. The comprehensive review by Burch and Giles brought out very effectively the possible role of magnesium deficiency in the genesis of alcoholic cardiomyopathy, ischemic heart disease, arrhythmias and electrocardiographic abnormalities. We feel that an equally important aspect is the diagnosis of magnesium deficiency and this aspect has received inadequate emphasis in this article.

The diagnosis of magnesium deficiency can be difficult. It is clear that serum magnesium levels do not always correlate with total body levels of magnesium. Hypomagnesemia is certainly consistent with a magnesium deficient state but a normal serum magnesium level does not rule it out. Measurement of urinary magnesium may also be helpful in the diagnosis. In addition to serum and urine measurements, Thoren¹ has described a test that utilizes the urinary excretion of magnesium following an intravenous load which may be a more sensitive index of magnesium deficiency. In this test 6 mg per kilogram body weight is infused intravenously over a 3 to 4 hour period and the ensuing 24 hour urine collected and analyzed for its magnesium content. Accordingly, if the stores of magnesium are adequate more than 80 per cent of an intravenous dose is excreted within the 24 hour period. Experience with this appears to be limited, however we feel that to more adequately document a magnesium deficient state serum and urine magnesium measurements, a magnesium infusion test and of course the response to magnesium therapy may be more revealing than a single serum magnesium measurement. We appreciate that in many instances these may not be particularly practicable.

Carlo Tommaso M.D.
Joseph R. Tucci M.D.

Dept. of Medicine
Roger Williams General Hospital
Brown University
Providence R.I.

REFERENCES

1. Burch G. E. and Giles T. D. The importance of magnesium deficiency in cardiovascular disease. *Am Heart J* 94:649 1977
2. Vendt E. R. Disorders of calcium, phosphorus, and magnesium metabolism. In Maxwell M. H. and Kleeman C. H. eds. *Clinical disorders of fluid and electrolyte metabolism*. New York 1972. McGraw Hill Book Company Inc. pp 460-503
3. (Editorial) Magnesium deficiency. *Lancet* 1:523 1976

Lymphatic drainage of the brain and catarrhea

To the Editor

Foldi states that the existence of brain-lymphatic connections has been well established for 100 years; however this had already been worked out by the Greeks 2500 years ago.

The brain was said to attract moisture from the stomach forming phlegm which then drained out into the eyes, nose, ears and throat into the cervical glands or down into the lungs and stomach. Lymphostatic encephalopathy was well recognized, lethargy and convulsions were attributed to damming up of phlegm in the brain. In goats with convulsions Hippocrates noted excess fluid in the subarachnoid spaces, significantly although the brains were also infected he placed no importance on this. The related condition of benign intracranial hypertension was also known and the dimness of

vision and headache were noted to be relieved by rhinorrhea likewise spontaneous decompression into the mastoid caused otitis media. The optic nerves were believed to be the route whereby phlegm drained into the eyes. Meningitis and encephalitis would then merely depend on retrograde passage of organisms up pre-existing widely patent lymph pathways. As Foldi notes, cherished dogmata—in this case the infectious theory of disease—can completely suppress such simple basic ideas. As well as explaining cerebral disorders, the concept of catarrhea (the downward defluxion of phlegm) has far more general applicability since phlegm by overloading the drainage vessels can easily cause such disorders as sinusitis, otitis media, the common cold, pneumonia and gastroenteritis depending on its local over accumulation.

Foldi mentions perivascular and perineural cranial prelymphatic routes. Hippocrates favors a third major route since he specifically remarks that the cranial bones are porous like a sponge and that moisture seeps through these thin bones. Such a route neatly explains why hydrocephalus fits optic atrophy, facial palsy and deafness as seen in numerous cranial dysostoses like osteopetrosis where osseous occlusion of lymph drainage routes is likely.

A G Gordon
32 Love Walk
London SE5 8AD
England

REFERENCES

- 1 Foldi M. Preliminary-lymphatic drainage of the brain. *AM HEART J* 93 121 1977
- 2 vander Linden J A. *Hippocratis Opera Omnia*. Gassae, Lugduni Batavorum 1665

Exaggerated impedance waveform—a noninvasive assist

To the Editor

The article by Dr Ramos on the abnormal early diastolic impedance waveform (*AM HEART J* 94 278 1977) describes in excellent fashion the impedance or volume counterpart of a left atrial pressure V wave. It is indeed Labadie's O point (labeled in Fig. 2) and is synchronous with echo mitral E point.

We have routinely simultaneously combined on the same strip chart recorder echo and impedance traces for almost three years (over 900 cases) and have repeatedly found an exaggerated impedance O (or V) whenever significant mitral regurgitation was present. This was true even when the left atrium was greatly enlarged. In our experience an exaggerated O (or V) has proved so reliable that we unhesitatingly diagnose mitral regurgitation in those cases of idiopathic and ischemic congestive cardiomyopathy in which we cannot hear a murmur.

Someday we hope the responsible medical profession will undertake a serious investigation of what we are convinced is an excellent practical noninvasive assist.

A Leschin M.D.
L E Schnitzler B.A. R.T. ARDMS
Echocardiography Department
Marshalltown Area Community Hospital
3 South 4th Avenue
Marshalltown Iowa 50158

Reply

To the Editor

It was most exciting to learn that Dr Leschin and his associates have been performing such comprehensive studies. As an author it is most rewarding to become cognizant that in their extensive experience with simultaneous recordings they have accumulated data which tend to support the notion that this abnormal impedance waveform described in my report may represent a functional ventricular inflow impairment.

I concur with their hopes for future investigations in this important area. "It is only through simultaneous invasive and non invasive studies that the etiology of this abnormal waveform will be clearly elucidated."

Marcos U Ramos M.D.
Assistant Chief
Department of Rehabilitation Medicine
University Hospital
70 East Newton St
Boston Mass 02114

REFERENCE

- 1 Ramos M U. An abnormal early diastolic impedance waveform. A predictor of poor prognosis in the cardiac patient? *AM HEART J* 94 278 1977

Sensing the cardiac electrogram

To the Editor

I would like to thank Drs Furman, Hartzler and De Caprio (Cardiac pacing and pacemakers III) Sensing the cardiac electrogram (*AM HEART J* 93 794 1977) for their excellent summary of sensing by cardiac electrodes. However I would like to point out a few printing errors.

In the discussion on time domain test signals, the terms low frequency cutoff and upper cutoff frequency appear to be interchanged. The slope of a test signal will be a measure of the upper cutoff frequency and the duration will be a measure of low frequency cutoff.

Also reference 6 seems to suffer from a printer's devil. The first author should be listed as Van Durre et al and the correct numbers are *J Electrocardiol* 6 97 1973. It would seem however that this reference was meant for some other portion of the paper since it does not provide any reference to the topic of electrode impedance. I would suggest that the following two references might be more appropriate for the subject of electrode impedance under sensing conditions.

- 1 Amundson D C. Sensing properties of pacemaker electrodes. *Proceedings of the 28th ACMB* p 83 (Abstr.) September 19 5
- Raber M B, Cuddy T E and Israel D A. Pacemaker electrodes act as high pass filters on the electrogram (Electrodes as high pass filters). Digest of the Fifth International Symposium on Cardiac Pacing Tokyo March, 1976

M B Raber P.Eng
Director
Biomedical Engineering Dept
Health Sciences Centre
700 William Ave
Winnipeg Manitoba R3E 0Z3
Canada

Reply

To the Editor

We appreciate Mr. Raber's comments and believe that our differences are substantially semantic. It is true that the slope of a test signal will be a measure of the (or should it be its) low frequency cutoff. We refer however on page 800 to the cutoff frequencies of the sensing circuit under test not to the test signal. Adjustment of the slope to a threshold value causes the upper cutoff frequency of the test signal to coincide with the lower cutoff frequency of the sensing circuit under test and conversely for the adjustment of the duration to a threshold value.

We thank Mr. Raber for pointing out an error in reference No. 6 but in addition reference No. 6 in the 1st line of the left hand column of page 798 should have been listed as No. 5. Reference No. 6 does discuss electrode impedance. We especially appreciate his listing of the two additional excellent references.

Seymour Furman MD
Philip Hurcler PhD
111 East 210th Street
Bronx N.Y. 10467

REFERENCE

1. Furman S, Hurcler P and De Caprio V. Cardiac pacing and pacemakers III. Sensing the cardiac electrogram. *Am Heart J* 93:791, 1977.

Ischemic myocardial disease and alterations in the ECG

To the Editor

The letter regarding subendocardial infarction by Doctors Genovesi, Salaki, Kennedy, and Grace in the *AMERICAN HEART JOURNAL* for October 1976 (92:542, 1976) provides helpful information. I would like to add further comments which could be helpful in diagnosis and treatment.

All aspects of recorded electrocardiograms are the result of chemical changes occurring rhythmically and nearly simultaneously in the living individual cells of the many myocardial cells. The myocardium is apparently the only bodily tissue with this rather precise rhythmicity. The effect from any other bodily function upon the electrocardiogram has to be mediated through myocardial cell metabolism and will vary with the state of health and chemical reactions within the individual myocardial cells. The slow electrical changes known as T waves occurring during the restorative phase of cardiac metabolism usually show changes with lesser metabolic alteration than is needed to change the explosive QRS complex. Sickened cells have abnormal metabolism and therefore altered electrical output. Dead cells have no rhythmic metabolism and therefore do not directly form the electrocardiogram. Dead cells may contribute indirectly to the ECG by the catabolic products diffusing to adjacent living cells and acting as foreign substances to alter their metabolism. Sickened and dead cells have cell walls altered so that diffusion of enzymes may occur into the pericellular spaces and thence into the general circulation.

Alteration of the ECG is dependent upon the degree of metabolic alteration of cells and also upon the mass of cells

with altered metabolism. A very few cells can be sickened to death surrounded by a small mass of moderately to slightly sickened cells, and these in turn surrounded by cells with normal or nearly normal metabolism yet little change in even the sensitive T waves will occur because the electrical current reaching the pick up electrode is a summation of all currents reaching the electrode. Furthermore cells may sicken to recover or die at varying rates in time. This can affect the development of the T wave changes and also affect the appearance of measurably increased enzymes in the blood stream.

Our measurements are made of the enzymes in the general circulation at the given moment of drawing blood. If a thousand cells die suddenly and are surrounded by a lot of living cells with walls damaged to permit rapid effusion of intracellular enzymes, high enzyme measurements can be recorded for many hours. If the death of a thousand cells is spread slowly in small increments over a two week period, there may at no time be a rise of enzymes sufficient to furnish what we now consider necessary for diagnosis of myocardial infarction. Yet a thousand cells have died in each of the two instances. Enzymes have been shown to disappear rapidly from the blood stream so a constant and continued high outpouring is necessary to give high measurements.

The above and the following have been illustrated and discussed. QRS waves do not necessarily occur as a signal of infarction as has been shown in my published and unpublished cases. Neither do T waves necessarily have to be inverted to be a signal of infarction. An infarction of narrow dimensions zigzagging at an angle may be transmural yet never cause a QRS wave in meticulous following over period of 10, 20, or 30 years or more as I have followed patients. It is true that the use of 12 chest leads instead of the usual 12 does give an increased chance of recording QRS waves and an increased accuracy of geographic localization of disease. Increased value is particularly the case if the electrodes are accurately positioned on the chest wall time after time for year after year and the electrode is held as closely as possible to the chest wall by a rubber strap and the electrode paste is carefully applied to a small area occupied by the chest electrode and the paste is carefully removed from each spot before moving on to the next.

Almost all disease can be more easily and better treated if it is recognized in the early stages. The Humpty Dumpty method of refusing to recognize as ischemic myocardial disease anything less than a massive transmural infarction has been all too common and pervasive. It should have and could have been abandoned long ago.

David Halbersleben MD
42 Goodnough Road
Chestnut Hill, Mass. 02167

REFERENCES

1. Halbersleben D. Value of T wave abnormalities in the diagnosis, prognosis and treatment of coronary arterio-sclerotic heart disease. *Med Ann District of Columbia* 28:477, 1959.
2. Halbersleben D. Myocardial ischemia. T wave changes and control of ischemia. *Med Ann District of Columbia* 33:316, 1964.
3. Halbersleben D. The clinical value of more than six chest leads in electrocardiography. *JAMA* 175:504, 1961.

the O point and diastolic impedance waveform

the Editor

In a recent clinical communication in the AMERICAN HEART JOURNAL, Ramos discussed the prognostic value of the diastolic waveform of the first derivative of the impedance cardiogram in patients with myocardial infarcts. Kubicek and associates have developed the electrical impedance

cardiograph referred to as the Minnesota Impedance Cardiograph to assess stroke volume by means of the changes in the transthoracic electrical impedance (Fig 1) which occur during the cardiac cycle. In 1971 my associates and I and more recently Naggar and colleagues, demonstrated the strong correlation between the stroke volume measured by the Fick and dye dilution techniques and the stroke volume measured from the primary waveform of the first derivative of




Fig 1 The position of the electrodes used to record the first derivative thoracic impedance cardiogram




Fig 2 Diagram of the cardiac cycle showing the different waves of the impedance cardiogram as they relate to carotid pressure, apex cardiogram, jugular impulse, phonocardiogram, and electrocardiogram




Fig 3 Tracing from a 60 year old man with mitral stenosis. Notice the prominent impedance diastolic wave with the O point corresponding to the opening snap.




Fig 4 Continuous tracing of impedance cardiogram on a child six years old with held inspiration. Notice the very prominent O wave and how it regresses during held inspiration.

the impedance cardiogram In 1970 we had also reported a detailed description of the impedance waveform related to the heart sounds and events in the cardiac cycle¹ Dr Ramos mentioned in his article that we had only ten patients with mitral stenosis that showed an O point This may need some clarification in fact the O point was present in *all* patients and normal controls Since our patients were children in whom mitral stenosis is rare we had to borrow those ten patients with mitral stenosis from the adult cardiology service On the other hand I would like to support the observations of Dr Ramos that patients with myocardial disease have a taller diastolic impedance wave and thus higher and more prominent O point

We have observed as shown in Fig 2 that the diastolic

wave which starts after the second heart sound has a notch (Z point) corresponding to S and ending with the A point corresponding to the fourth heart sound. The peak of this diastolic wave is the O point which correlates well with the O point of the apexcardiogram and the opening snap of patients with mitral stenosis (Fig 3). We have also noticed that the O point of the impedance cardiogram is more prominent in patients with a large left atrium secondary to left ventricular failure, mitral stenosis or large left to right shunts. It is also more prominent after exercise during high output states and after deep inspiration. Fig 4 demonstrates the waveform of the first deviation impedance cardiogram after a deeply held inspiration. Notice the very prominent O point and the height of the diastolic wave immediately after the inspiration and

that it becomes less prominent as the inspiration is held for a long time. The initial prominence is probably secondary to the initial increase in venous return.

In conclusion, I believe that the height of the diastolic waveform of the first deviation of the impedance cardiogram is a representative of the left atrial size which is often seen in patients with left ventricular failure and can thus be a prognostic sign as was demonstrated by Dr Ramos.

Zuhdi Lababidi, M.D.
Associate Professor and
Director of Pediatric Cardiology
School of Medicine
Department of Child Health
University of Missouri Columbia
Columbia Mo 65201

REFERENCES

1. Ramos M U. An abnormal early diastolic impedance waveform: A predictor of poor prognosis in the cardiac patient? *Am HEART J* 94:274, 1977.
2. Kubicek W G, Patterson R P, Lillehei A H, Castaneda, A and Eserk H. Impedance cardiography as a non invasive means to monitor cardiac function. *J Am Assoc. Adv Med Instrumentation* 4:79, 1970.
3. Lababidi, Z, Ehmke D A, Durnin H E, Leaverton P E and Lauer R M. Evaluation of impedance cardiac output in children. *Pediatrics* 47:870, 1971.
4. Naggar C Z, Dobnik, D E, Flessas A P, Kripke B J and Ryan T J. Accuracy of the stroke index as determined by the transthoracic electrical impedance method. *Anesthesiology* 42:201, 1975.
5. Lababidi, Z, Ehmke D A, Durnin R E, Leaverton P E and Lauer R M. The first derivative thoracic impedance cardiogram. *Circulation* 41:651, 1970.

Reply

To the Editor

I wish to thank Dr Lababidi for his most kind remarks about my article. I also wish to thank him for the publication of these figures. Once again these tracings offer a very accurate relationship of the different cardiac events and the way they are reflected in the impedance tracing.

His remarks regarding the presence of the O point in all patients and normals are noted. Upon reviewing his 1970 article, this concept did not become clear since the O point is only mentioned in the 10 patients with mitral stenosis. This led me to make the statement which Dr Lababidi feels needs some clarification. His remarks are well taken and very much appreciated. Despite this, the prognostic implication of the abnormal early diastolic impedance waveform I described in my article still applies.

Dr Lababidi's observation of the abnormal waveform in patients with large left atrium, mitral stenosis, and large left to-right shunts tends to support my theory that this waveform may possibly represent the inability of the ventricles to handle the venous return presented to them during early diastole.

Marcos U Ramos, M.D.
Assistant Chief
Department of Rehabilitation
Medicine

Boston University School of Medicine
University Hospital
75 East Newton St
Boston, Mass 02118

Book reviews

Cardiac Arrhythmias in the Neonate Infant and Child Edited by Nigel K. Roberts and Henry Gelband New York 1977 Appleton Century Crofts Inc 533 pages Price \$32.50

This book edited by Roberts and Gelband is devoted to an important and neglected field of cardiology. The book is well organized being divided essentially into chapters on embryology of conduction tissues anatomy of the conduction system physiology of the conduction tissues mechanisms of arrhythmias clinical manifestations of arrhythmias and management. Disturbances in cardiac mechanism in infants and neonates deserve special consideration and are problems for the pediatric cardiologists and not of adult cardiologists. However adult cardiologists were responsible for establishing the fundamental clinical principles of practically all aspects of disturbances in the heart beat in man. Their interest had been primarily limited to adults and not the newborn. Thus this book provides a good source of information on arrhythmias in early life. The need for such a book is evident. This reviewer would suggest that all pediatricians and all cardiologists including adult cardiologists own a copy. This is a valuable well written and well organized book.

Current Cardiovascular Topics vol III Angina Pectoris Edited by Ephraim Donoso M.D. and Richard Gorlin M.D. New York 1977 Stratton Intercontinental Medical Book Corporation

This issue of *Current Cardiovascular Topics* on angina pectoris consists of an orderly review of angina pectoris as viewed by several selected contributors. The book includes discussions of metabolism of ischemic myocardium collateral circulation electrocardiography radiographic studies ventricular function coronary angiography and medical and surgical management. The concluding remarks by Gorlin summarize the symposium well. The respective subjects are short summaries of many publications reflecting the intensive rate of publications on coronary heart disease. The practicing internist and general physician who treat many if not most of the patients with ischemic heart disease will find a great deal of this book difficult to read critically because of their lack of experience with laboratory methods and the special complex methods used in diagnosis and management today. Nevertheless this is a good review of most of the present more

aggressive approaches to diagnosis and management of ischemic heart disease. Ischemic heart disease is one of the most common causes of disease in man.

Practical Electrocardiography sixth edition By Henry J. L. Marriott M.D., Baltimore 1977 The Williams & Wilkins Company 333 pages Price \$14.50

Marriott's book has been a very popular and useful source for training in electrocardiography. He has in the various succeeding editions kept this book up to date. The presentations are good and intended for clinicians who have had an interest in cardiology and the interpretation of electrocardiograms for others. The emphasis has been on cardiac arrhythmias. The approach to teaching the electrocardiographic manifestations of heart disease differs from that of others. There is a tendency for the author to teach pattern rather than the mechanisms responsible for them. This is exemplified for example in the chapter on bundle branch block. Again on page 84 the criteria for the diagnosis of left anterior hemiblock would confuse one with the changes due to left ventricular hypertrophy with dilatation. Regardless of differences of opinion that might exist among cardiologists concerning aspects of this book it is a good book which would be of greater value to those who already know the fundamental principles of electrocardiography. This sixth edition would continue the interest in Marriott's book on practical clinical electrocardiography.

Echocardiology Edited by N. Bom The Hague 1978 Martinus Nijhoff Medical Division 360 pages

Monographs on echocardiography (ECHO) have been appearing in rapid succession. This new one is an excellent addition to the series. The editors have selected a large number of contributors whose discussions are practical reliable and based on fundamental principles of ECHO. The papers are grouped into those concerned with clinical echocardiography Doppler instrumentation and application and two dimensional imaging. The respective subjects are clearly and thoroughly discussed. The illustrations and bibliography are well selected. This is a very good book which is highly recommended to all physicians cardiologists and especially to trainees in cardiology.

Books received

Clinical Application of Intra aortic Balloon Pump By Hoo-chang Bolooki, M.D. Mount Kisco N.Y. 1977 Futura Publishing Co. 500 pages Price \$34.50

Rheology of Blood in Diagnostic and Preventive Medicine An Introduction to Clinical Haemorheology By Leopold Dintenfass Ph.D. London Boston 1978 Butterworth & Co Ltd. 412 pages Price \$ 9.00

Computer Electrocardiography Present Status and Criteria By Leon Fordy M.D. New York 1977 Futura Publishing Co., 374 pages Price \$39.50

Diagnostic Electrocardiography second edition By Michael C. Rutishauser M.D. Philadelphia 1977 J.B. Lippincott Company 210 pages Price \$22.50

Announcements

Sixteenth Annual Seminar in Cardiology

The Sixteenth Annual Seminar in Cardiology under the sponsorship of the Rogers Heart Foundation will be held at the Loews Hotel Monte Carlo on October 4 through 11 1978. Fee for the course is \$200 US funds. Three travel programs will be available. "A Basic" will depart from the US on October 3 and will return on October 11 at a cost of approximately \$699. "B France-Extended" will depart from the US on September 27 and will return on October 11 and will include 7 day Wine Tour via motorcoach beginning in Paris and ending in Monaco at a cost of approximately \$990. "C Italy-Extended" will depart from the US on October 3 and will return on October 11 and will include a classical tour of Florence Venice and Rome by motorcoach with a return flight from Rome at a cost of approximately \$1060. All programs include seven nights in Monte Carlo at the Loews Hotel for the Seminar plus round trip air transportation by Air France from New York to Nice. Also included are a daily continental breakfast and airport transfers plus tax and service charges. For further information contact Program Chairman Rogers Heart Foundation St Anthony's Hospital St Petersburg Fla 33705 Telephone (813) 894 0790.

"B France-Extended" will depart from the US on October 3 and will return on October 11 and will include a classical tour of Florence Venice and Rome by motorcoach with a return flight from Rome at a cost of approximately \$1060. All programs include seven nights in Monte Carlo at the Loews Hotel for the Seminar plus round trip air transportation by Air France from New York to Nice. Also included are a daily continental breakfast and airport transfers plus tax and service charges. For further information contact Program Chairman Rogers Heart Foundation St Anthony's Hospital St Petersburg Fla 33705 Telephone (813) 894 0790.

Nineteenth Workshop in Electrocardiography

The Rogers Heart Foundation will present the Nineteenth Workshop in Electrocardiography for Nurses and Physicians to be held at the Tides Hotel and Bath Club Redington Beach St Petersburg Fla on October 26 through 30 1978. Workshop director will be Henry J L Marriott MD. Fee for the workshop is \$100 US funds. 24 CEU credit hours will be given to nurses and the workshop is acceptable for 24 prescribed hours by AAFP and for credit toward Category I of the AMA Physicians Recognition Award. For further information contact Program Chairman Rogers Heart Foundation St Anthony's Hospital St Petersburg Fla 33705 Telephone (813) 894 0790.

Approach to Cardiology 1978

A program entitled "An Approach to Cardiology 1978 for the Physician in Practice" will be held in White Sulphur Springs W Va., on October 25 through 27 1978 under the sponsorship of the Council on Clinical Cardiology of the American Heart Association. For further information contact Administrator Postgraduate Programs American Heart Association 7320 Greenville Ave Dallas Texas 75231 Telephone (214) 750 5441.

International Conference on Cerebrovascular Disease and Cerebral Circulation

The Stroke Council of the American Heart Association announces the Fourth International Conference on Cerebrovascular Disease and Cerebral Circulation to be held at the

Hyatt Regency Hotel Phoenix Arizona on February 8 through 10 1979. The meeting will be held in conjunction with the Cerebrovascular Surgery Section American Association of Neurological Surgeons Canadian Stroke Society Canadian Heart Association and the Society for Vascular Surgery. Those interested are encouraged to submit abstracts to the Program Committee for consideration. Abstracts accepted will be published in the January 1979 issue of *Stroke*. Deadline for receipt of abstracts is Sept. 1 1978. Further information can be obtained from Administrator Postgraduate Programs American Heart Association 7320 Greenville Ave Dallas Texas 75231 Telephone (214) 750-5441.

Symposium on Hypoxia

A Symposium on Hypoxia sponsored by the Arctic Institute will be held in Banff Alberta Canada on February 21 through 23 1979. The purpose of the symposium is to bring together those engaged in hypoxia research and clinicians who diagnose and treat illnesses in which hypoxia is an important element. Internationally known specialists will lead each session. Abstracts are invited and ample time for open discussion will be available. Enrollment will be limited to 250 persons at a registration fee of \$100 with a special rate for health science students. A package rate including rooms and meals will be available. For further information contact Charles S Houston MD Chairman Hypoxia Symposium Arctic Institute of North America University Library Tower 2920-24th Ave NW Calgary Alberta Canada T2N 1N4.

Teaching Conference in Cardiac Arrhythmias

The Inaugural International Teaching Conference in Cardiac Arrhythmias will be held in Tel Aviv Israel on October 22 through November 1 1978. Travel arrangements are being handled by Leisure Time Tours 1428 Brickell Ave Miami Fla 33131. For information regarding the conference please contact Benjamin Befeler MD Program Director School of Medicine VA Hospital Cardiovascular Laboratory 1201 NW 16th St Miami Fla 33125.

Cardiopulmonary radiology seminar

The Cardiopulmonary Section of The Department of Radiology of Southwestern Medical School The University of Texas Health Science Center at Dallas is offering a continuing medical education seminar entitled "Cardiopulmonary Radiology Update 78". The seminar will be held October 13 through 15 1978 at The Fairmont Hotel in Dallas Texas. For further information and program brochure requests contact Mary J Ryals Administrative Coordinator Department of Radiology Southwestern Medical School 5323 Harry Hines Blvd Dallas Texas 75235 Telephone (214) 638 1800 ext 2613.

Editorial

Venous thromboembolism after stroke

Charles Warlow MD MRCP

Oxford, England

Much is known of the morphological hemodynamic electrical and biochemical changes which occur in the brain after stroke due to either atherothrombotic infarction or intracranial hemorrhage. These changes particularly the development of cerebral edema are largely responsible for death occurring within a few days of stroke and presumably determine the extent of the neurological disabilities of those who survive this early period. Unfortunately therapeutic attempts to reverse or confine these changes have met with little definite success. Later deaths are more often due to non neurological complications which even if not fatal can delay functional recovery and which may be preventable treatable or both these include pneumonia urinary tract infection peptic ulceration and in particular venous thromboembolism arising in the legs.¹

The clinical signs of deep venous thrombosis (DVT) in the veins of a leg paralyzed as a result of a stroke were described as long ago as 1810 by Fernar in a patient previously affected by a paralytic stroke and subsequently in 1833 Lobstein clearly described the pathological appearances: "Les parois des veines du côté paralytique étaient toutes plus ou moins obstruées par

des polypes tandis que celles du côté sain renfermaient un sang dissous et fluide." It is therefore surprising that this complication of stroke is not mentioned in many recent general medical and neurological textbooks. The necropsy frequency of DVT has not been recorded although its occurrence in hemiplegic legs has been commented on.² Using the ¹²⁵I fibrinogen test the frequency during life has been reported in 40 to 53 per cent of patients,³ and the onset is within the first few days after the stroke. The DVT occurs almost exclusively in the paralyzed rather than in the normal leg and this has also been found in 42 chronic hemiplegics where the frequency was 41 per cent and 8 per cent respectively using venography to make the diagnosis.⁴

At necropsy Kucera⁵ reported the presence of pulmonary embolism in 37 per cent of patients dying from apoplexy and it was the main cause of death in 10 per cent. In another necropsy series embolism was found in only 1 per cent of patients dying within seven days of stroke but in the longer survivors it was present in 25 per cent. The frequency of embolism during life is notoriously difficult to determine and particularly so in stroke patients who may be elderly unconscious or aphasic liable to other cardiopulmonary complications and usually not extensively investigated. In a series in which the necropsy rate was only 21 per cent the over all frequency of pulmonary embolism was 16 per cent but this must have been an underestimate since over half the patients who came to necropsy were shown to have emboli. Therefore approximately half the

From the Department of Clinical Neurology, Churchill Hospital, Oxford, England.

Received for publication Aug. 31, 1977.

Reprint requests: Charles Warlow, MD, Dept. of Clinical Neurology, Churchill Hospital, Oxford OX3 7JN, England.

© 1978 by Mosby, a Division of C.V. Mosby Co., St. Louis, MO.

Announcements

Sixteenth Annual Seminar in Cardiology

The Sixteenth Annual Seminar in Cardiology under the sponsorship of the Rogers Heart Foundation will be held at the Loews Hotel Monte Carlo on October 4 through 11 1978. Fee for the course is \$200 U.S. funds. Three travel programs will be available: "A Basic" will depart from the U.S. on October 4 and will return on October 11 at a cost of approximately \$699. "B France-Extended" will depart from the U.S. on September 27 and will return on October 11 and will include 7 day Wine Tour via motorcoach beginning in Paris and ending in Monaco at a cost of approximately \$990.

"B Italy-Extended" will depart from the U.S. on October 3 and will return on October 18 and will include a classical tour of Florence Venice and Rome by motorcoach with a return flight from Rome at a cost of approximately \$1060. All programs include seven nights in Monte Carlo at the Loews Hotel for the Seminar plus round trip air transportation by Air France from New York to Nice. Also included are a daily continental breakfast and airport transfers plus tax and service charges. For further information contact Program Chairman Rogers Heart Foundation St. Anthony's Hospital St. Petersburg Fla. 33705 Telephone (813) 894-0790.

Nineteenth Workshop in Electrocardiography

The Rogers Heart Foundation will present the Nineteenth Workshop in Electrocardiography for Nurses and Physicians to be held at the Tides Hotel and Bath Club Redington Beach St. Petersburg Fla. on October 26 through 30 1978. Workshop director will be Henry J. L. Marriott M.D. Fee for the workshop is \$100 U.S. funds. 24 CEU credit hours will be given to nurses and the workshop is acceptable for 24 prescribed hours by AAFP and for credit toward Category 1 of the AMA Physicians Recognition Award. For further information contact Program Chairman Rogers Heart Foundation St. Anthony's Hospital St. Petersburg Fla. 33705 Telephone (813) 894-0790.

Approach to Cardiology 1978

A program entitled "An Approach to Cardiology 1978 for the Physician in Practice" will be held in White Sulphur Springs W. Va. on October 25 through 27 1978 under the sponsorship of the Council on Clinical Cardiology of the American Heart Association. For further information contact Administrator Postgraduate Programs American Heart Association 7320 Greenville Ave. Dallas Texas 75231 Telephone (214) 750-5441.

International Conference on Cerebrovascular Disease and Cerebral Circulation

The Stroke Council of the American Heart Association announces the Fourth International Conference on Cerebrovascular Disease and Cerebral Circulation to be held at the

Hyatt Regency Hotel Phoenix Arizona on February 1 through 10 1979. The meeting will be held in conjunction with the Cerebrovascular Surgery Section American Association of Neurological Surgeons Canadian Stroke Society Canadian Heart Association and the Society for Vascular Surgery. Those interested are encouraged to submit abstracts to the Program Committee for consideration. Abstracts accepted will be published in the January 1979 issue of Stroke. Deadline for receipt of abstracts is Sept. 1 1978. Further information can be obtained from Administrator Postgraduate Programs American Heart Association 7320 Greenville Ave. Dallas Texas 75231 Telephone (214) 750-5441.

Symposium on Hypoxia

A Symposium on Hypoxia sponsored by the Arctic Institute will be held in Banff Alberta Canada on February 21 through 23 1979. The purpose of the symposium is to bring together those engaged in hypoxia research and clinicians who diagnose and treat illnesses in which hypoxia is an important element. Internationally known specialists will lead each session. Abstracts are invited and ample time for open discussion will be available. Enrollment will be limited to 250 persons at a registration fee of \$100 with a special rate for health science students. A package rate including rooms and meals will be available. For further information contact Charles S. Houston M.D. Chairman Hypoxia Symposium Arctic Institute of North America University Library Tower 2920-24th Ave. N.W. Calgary Alberta Canada T2N 1N4.

Teaching Conference in Cardiac Arrhythmias

The Inaugural International Teaching Conference in Cardiac Arrhythmias will be held in Tel Aviv Israel on October 22 through November 1 1978. Travel arrangements are being handled by Leisure Time Tours 1428 Brickell Ave. Miami Fla. 33131. For information regarding the conference please contact Benjamin Befejer M.D. Program Director School of Medicine V.A. Hospital Cardiovascular Laboratory 1201 N.W. 16th St. Miami Fla. 33125.

Cardiopulmonary radiology seminar

The Cardiopulmonary Section of The Department of Radiology of Southwestern Medical School The University of Texas Health Science Center at Dallas is offering a continuing medical education seminar entitled "Cardiopulmonary Radiology Update 78". The seminar will be held October 13 through 15 1978 at The Fairmont Hotel in Dallas Texas. For further information and program brochure requests contact Mary J. Ryals Administrative Coordinator Department of Radiology Southwestern Medical School 5323 Harry Hines Blvd. Dallas Texas 75235 Telephone (214) 638-1800 ext. 2613.

- E and Zaritz S H Stroke intensive care—an appraisal
AM HEART J 80 188 19 0
- 1 Brown M and Glassenberg M Mortality factors in
patients with acute stroke J A M A 224 1493 1973
- 2 Ferrar J An affection of the lymphatic vessels hitherto
misunderstood in Medical histories and reflections vol
3 London 1810 Cadell and Davies
- 3 Lobstein J F De l'obstruction et de l'oblitération des
veines in Traité d'Anatomie pathologique vol 2
L'Anatomie pathologique spéciale Paris 1833 Le-
vrault
- 4 Byrne J J and O'Neil E E Fatal pulmonary emboli
a study of 130 autopsy proven fatal emboli Am J Surg
83 47 1957
- 5 Gibbs N M Venous thrombosis of the lower limbs with
particular reference to bedrest Br J Surg 45 209
195
- 6 Denham M J Farran H and James G The value of
fibrinogen in the diagnosis of deep venous thrombosis
in hemiplegia Age and Ageing 2 207 1973
- 7 Warlow C P Ogston D and Douglas A S Deep
venous thrombosis of the legs after strokes I Incidence
and predisposing factors Br Med J 1 1118 19 6
- 8 Gliber F B Gould S R and Marks P Incidence of
deep vein thrombosis and leg oedema in patients with
strokes J Neurol Neurosurg Psychiatry 39 1222
19 6
- 9 Cope C Rye T M and Skersky N J Phil bo
graphic analysis of the incidence of thrombosis in hemi-
paresis Diagnostic Radiology 109 591 1973
- 10 Kucera M Some problems of venous thromboembolism
in patients with heart disease Pev Czech led 14 50
1968
- 11 Warlow C P Ogston D and Douglas A S Deep
venous thrombosis of the legs after strokes II Natural
history Br Med J 1 1181 1976
- 12 Kinkel W R and Jacobs L Computerized axial trans-
verse tomography in cerebrovascular disease Neurology
28 974 19 6
- 13 Hume R The relationship to age and cerebral vascular
accidents of fibrin and fibrinolytic activity J Clin
Pathol 14 167 1961
- 14 Datta G Platelet adhesiveness in cerebrovascular
disease Atherosclerosis 11 223 19 0
- 15 Todd D McDevitt E and McDowell F Stroke and
blood coagulation Stroke 4 400 1973
- 16 Fletcher A P Alkjaerung N Davies A Lewis M
Brooks J Hardin W Landau W and Raichle M E
Blood coagulation and plasma fibrinolytic enzyme
system pathophysiology in stroke Stroke 7 337 1976
- 17 Sano T Boxer M G J Boxer L A and Yokoyama
M Platelet sensitivity to aggregation in normal and
diseased groups Thromb Diath. Haemorrh 35 574
1971
- 18 Dougherty J H Levy H E and Weksler B B
Platelet activation in acute cerebral ischemia Lancet
1 871 1977
- 19 Warlow C P Rennie J A N Ogston D and Douglas
A S Platelet adhesiveness and fibrinolysis after recent
cerebrovascular accidents and their relationship with
subsequent deep venous thrombosis of the legs Thromb
Haemostasis 36 177 19 6
- 20 Ogston D and Fullerton H W Plasma fibrinolytic
activity following recent myocardial and cerebral infarc-
tion Lancet 2 99 1965
- 21 Ellis L H and Weiss S Vasomotor disturbance and
edema associated with cerebral hemiplegia Arch Neurol.
Psychiatr 36 36 1936
- 22 Redisch W Tangco F I Wertheimer L Lewis A J
and Steele J M Vasomotor responses in the extremities
of subjects with various neurologic lesions Circulation
15 518 1957
- 23 Warlow C P Deep venous thrombosis of the legs and
its prevention M D Thesis, University of Cambridge
England 19 4
- 24 Laban M M and Johnson E W Velocity of blood
flow in the saphenous vein of hemiplegic patients Arch.
Phys Med Rehab 46 245 1965
- 25 Wright H P Osborn S B and Hayden M Venous
velocity in bedridden medical patients Lancet 2 699
1967
- 26 Hewson W An enquiry into the properties of the blood
(18 0) in The Works of William Hewson Guliver ed
Sydenham Society London 1846
- 27 Warlow C P Low-dose heparin deep venous throm-
bosis and myocardial infarction in Heparin chemistry
and clinical usage Hakkar V V and Thomas D P, eds
London New York and San Francisco 19 6 Academic
Press

patients admitted to hospital with an acute stroke resulting in a hemiplegia or hemiparesis will develop a DVT, and up to half of those who die will have pulmonary embolism. The excess mortality due to embolism is unknown, but presumably is not negligible and the morbidity due to both embolism and DVT will, of course, delay rehabilitation.

Why venous thromboembolism occurs so frequently after stroke is uncertain and whether the mechanism or indeed the frequency depends on whether the stroke is due to atherothrombosis or hemorrhage is unknown. Most investigators have not attempted to distinguish between these two main causes of stroke and even those who have may have been mistaken since only with the recent availability of computerized axial tomography has the high frequency of error in their clinical differentiation become glaringly apparent.¹¹ Acute changes in some hemostatic parameters occur after stroke and these include a rise in plasma fibrinogen, an increase in fibrinogen/fibrin formation, an increase in the platelet count but not adhesion, an increase in circulating platelet aggregates and sensitivity to ADP and adrenaline and a slight shortening of the whole blood clotting time.¹²⁻¹⁴ There is not unlike many other tissue injury situations, any change in plasminogen activator although those developing DVT tend to have lower levels than those not doing so.¹⁵⁻¹⁷ None of these changes can by themselves, account for DVT since they are not confined to individuals developing this complication; there are few if any substantial differences in the parameters between those with and without DVT and when DVT does occur it is almost always confined to the paralyzed leg. Paralysis, but not its degree, must determine the appearance of DVT in susceptible individuals after stroke. This susceptibility cannot be defined by changes in any hemostatic or other parameter which has so far been studied and indeed the relationship between such changes and hypercoagulability is very uncertain.

The way in which paralysis causes DVT in 'susceptible' individuals is not known although there are a number of possibilities. Prolonged immobility, whether due to lack of power or sensory loss may perhaps by pressure on the calf cause vein wall trauma and so initiate thrombosis. It cannot, however, be mere rest in bed since the non paralyzed leg is normally unaffected by

DVT and the duration of bed rest is not related to the frequency of DVT.¹⁸ Furthermore there is no very adequate explanation for the occurrence of DVT in the leg and not in the equally immobile arm, perhaps the differing anatomical arrangement of the veins or the larger quantity of vein wall plasminogen activator in the arm play a part here. There are presumably local changes in venous blood flow due to impairment of the calf muscle pump but total limb flow is either normal or even increased in hemiplegic legs.¹⁹ Venous blood flow may be low compared with the unaffected side.²⁰ When precautions were taken to study patients before the development of DVT, no such difference was found. In any case venous stasis alone does not cause thromboembolism experimentally.²¹

There have been no trials of the prevention of venous thromboembolism after stroke. One cannot assume that preventive methods shown to be successful in postoperative patients are necessarily useful in stroke or other medical patients when prophylaxis can only be started after the stressful event which presumably initiates the DVT. Both conventional anticoagulation and low-dose heparin may prevent venous thromboembolism after myocardial infarction²² but such methods may be dangerous in acute stroke patients due to the difficulty of diagnosing intracranial hemorrhage without computerized axial tomography. However with this diagnostic facility to exclude patients with hemorrhage it would be both reasonable and justifiable to mount a trial of anticoagulation after stroke. Physical preventive methods, such as calf compression may be helpful if tolerated by the patients but no evidence is available. How long prophylaxis should be continued is another unknown factor. At the moment although one recognizes the high frequency of venous thromboembolism in stroke patients there is nothing of proven value which will prevent this potentially lethal and commonly troublesome complication.

REFERENCES

- 1 Hutchinson E C Management of acute cerebral infarction in Cerebral arterial disease ed Ross Russell R W ed Edinburgh London New York 1976 Churchill Livingstone
- 2 Richardson A Spontaneous intracerebral and cerebellar haemorrhage in Cerebral arterial disease Ross Russell R W ed Edinburgh London New York 1976 Churchill Livingstone
- 3 Kennedy F B Fozen T J Gabelman E H Tutthill J




Fig 1 Diagram of a flutter wave as seen in Lead 2 of the electrocardiogram S represents the absolute amplitude A (in mm) of a flutter wave (from the highest to the lowest voltage point) a is the point where the rate of descent changes producing the left atrial wave. The left atrial depolarization is considered to last from m to N . Its duration is represented (in msec) by the mN interval and its amplitude (in mm) by nN segment (a)




Fig 2 66-year old patient with RHD mitral regurgitation. The echocardiogram shows a normal sized left atrium $LADs = 3.3$ cm LA/AO ratio = 0.92.

matic adjustable beam blanking device which permitted us to record a very clear vector f loop. The cut off frequency response was 100 Hz. The vectorcardiographic loops were interrupted at a rate of 500 times per second. In all tracing, the inscription was interrupted by the large end of the time dash.

To study the f loop a high degree of magnification is required. In our study magnification averaged 3 cm for 10 mV. To avoid distortion by a preceding T wave a complete f wave cycle occurring just prior to a QRS complex was recorded and analyzed. The vectorcardiograms were analyzed for shape, sense of direction and speed of inscription (even or uneven).

The echocardiogram was recorded in the supine position with an Ekoline 20 Echograph SKI utilizing a 0.5 inch diameter 2.25 MHz transducer focused at 10 cm with a repetition rate of 1000 impulses/second. The ultrasound transducer was placed in the fourth or fifth left intercostal space close to the sternum. The signal from the echograph was displayed and recorded on an Electronics for Medicine VR6 stripchart multichannel oscilloscopic recorder.

Ultrasonic scans were recorded from apex to base and echocardiograms were recorded with rigid adherence to the technique and criteria previously established to evaluate left atrial size and the size of the aortic root.¹¹ Left atrial

Atrial flutter Electrocardiographic, vectorcardiographic and echocardiographic correlation

Olga Zoneruch MD FACC
Samuel Zoneruch MD FACC
Jai J Rhce MD
David Jordan PhD
Stony Brook and Jamaica, N.Y.

Little is known about the clinical significance of flutter wave contour and amplitude. While many studies have analyzed the amplitude of the fibrillatory waves of atrial fibrillation in various types of heart disease, the atrial flutter wave eludes the investigators.

The renewed interest in the study of atrial flutter results from the data provided by echocardiography in noninvasively assessing atrial size.

In a previous report we have proven by ultrasound techniques that there is a direct correlation between mechanical events at the level of the left atrium and electrical activation in atrial flutter.

The present prospective study was undertaken to evaluate (1) the amplitude and duration of flutter wave (f) in relation to the size of the left atrium, (2) the vectorcardiographic pattern of flutter loops (fLF) in relation to left atrial size and (3) the relation between post conversion sinus P wave (duration, shape) f (duration, shape) and left atrial dimension.

Material and method

The study group was comprised of 32 patients, nine females and 23 males. They ranged in age from 33 to 94 years with a mean age of 68 years. The diagnosis was coronary atherosclerosis.

From the Division of Cardiology, Department of Medicine, State University of New York at Stony Brook Clinical Campus at Queens Hospital Center, the Long Island Jewish Medical Center, Jamaica, N.Y.

Received for publication July 12, 1977

Accepted for publication October 2, 1977

Reprint requests: Olga Zoneruch MD, Cardiology Service, Queens Hospital Center, 47-18 114th Street, Jamaica, N.Y. 11435

(ASHD) in 15 patients (four had associated diabetes mellitus), rheumatic heart disease (RHD) in seven, primary cardiomyopathy (PMD) in five patients and miscellaneous (five patients). The electrocardiogram revealed atrial flutter in all (30 of the common type and two of the uncommon type).

Electrocardiograms, vectorcardiograms and echocardiograms were recorded during the same morning for each patient.

Twelve lead electrocardiograms were recorded and the flutter waves (f) were measured with a magnifying glass by two independent observers.

The following parameters were measured and compared between the group with normal left atrium and the group with enlarged left atrium: (1) the amplitude (in mm) of left atrial wave (Fig. 1) in Lead 2 ($n = a$), (2) the duration (in msec) of the left atrial wave, (3) the surface area of the left atrial wave, i.e. the product of n and $n \cdot N$, (4) the maximum amplitude (A) of the f in Lead 2 (S_s in mm) and (5) the maximum amplitude of the f (S_{f_1}) in V_1 .

Differences between the means were calculated for all measures and tested for significance using t ratios for uncorrelated groups. After spontaneous or electrical conversion to sinus rhythm, the P wave was analyzed for criteria of left atrial enlargement and intra atrial conduction disturbances. The vectorcardiograms were recorded with Hart Electronics PV 5 vectorcardiograph using the Frank lead system. Frontal (F) horizontal (H) and right sagittal (S) vectorcardiograms of the f were obtained by using an auto




Fig 5 Electrocardiogram and vectorcardiogram of the same patient described in Fig 4 A = 3 mm n n = 2 mm n N = 80 msec (Large left atrium and increased n N interval) The duration of the atrial wave is very well seen in panel B of Fig 6 The VCG shows pattern I




Fig 6 Same patient as in Fig 4 While the left atrial size remained unchanged the flutter wave contour changed considerably (for details see text)

atrium (NLA) in Group 1 and 18 patients with an enlarged left atrium (ELA) in Group 2

Results

The duration of the left atrial wave in L (n N) varied between 40 and 60 msec in Group 1 with

NLA and between 40 to 120 msec in Group 2 with ELA (Figs 3 4 and 5) Seventy five per cent of patients with ELA have a duration of more than 40 msec of n N interval In the group with NLA only four patients (28 per cent) have a duration of the n N interval above 40 msec The amplitude of




Fig 3 Electrocardiogram and vectorcardiogram (VCG) of the same patient described in Fig 2. The A in Lead II is 2 mm and 1.5 mm in Lead V. The n-N interval is 50 msec and the amplitude of the left atrial wave is 1 mm (normal size left atrium and short n-N). The VCG shows pattern I (a).




Fig 4 63 year old male patient with ASHD. The echocardiogram shows an enlarged left atrium. $LADs = 4.7$ cm. LA/AO ratio = 1.02.

measurements were taken at the maximum upward motion of the aortic wall which represents end systole (from the anterior edge of the posterior aorta to the interior edge of the posterior left atrial wall).

The left atrium-aortic root ratio was also used to standardize the left atrial dimension. This ratio is obtained by dividing the end systolic left atrial dimension by the end diastolic aortic dimension

as measured from the outer edge of the anterior aortic wall echo to the inner edge of the posterior wall echo (Fig 2).

The echocardiographic diagnosis of left atrial enlargement was based on (1) transverse left atrial diameter greater than 4.0 cm and (2) ratio of transverse left atrial to aortic root dimension greater than 1.17. Using these criteria 14 patients were classified as having a normal sized left




Fig 8 60-year-old patient with mitral regurgitation. Left atrium was enlarged. LADs = 4.0 cm. The duration of the left atrial wave is 60 msec. The VCG shows a distorted triangular pattern in F and S planes with dense conduction delay pattern II (a).

P wave abnormalities. After conversion to sinus rhythm 10 patients (62 per cent) in the group with ELA presented a P wave with a duration of 0.12 sec or more (two patients from this group failed to convert to regular sinus rhythm). In the group with NLA six patients (43 per cent) had a P wave with a duration of 0.12 sec or more (Table II). The P wave had an enlarged duration and bifid contour in 10 patients (six in Group 1 and four in Group 2).

It is worthwhile to mention that in the group with ELA eight patients who had an abnormal duration of P wave had also an nN interval of 60 msec or more while in Group 1 only three had an abnormal duration of P wave and prolonged nN interval.

Discussion

The clinical classification of flutter based on the form of the f in Leads 2, 3, aV_r, and aV₆ of the electrocardiogram recognizes two types of flutter: the common and the uncommon type.

In the common type the atrial f waves are inverted in Leads 2 and 3 and aV_r, and are upright in aV₆ (Fig 3), and in the uncommon type the f waves are upright in Leads 2 and 3 and aV_r, and aV₆ and inverted in Lead aV₆.

Neither the theory of focal impulse formation nor that of circus movement can explain all observations in humans or animals.

In the common type the depolarization of the left atrium is considered to proceed in a caudo-cranial direction.

Table II Duration and contour of sinus P wave as related to left atrial size

Enlarged left atrium (18 patients)				Normal size left atrium (14 patients)			
P ≥ 0.12 sec		P < 0.10 sec		P ≥ 0.10 sec		P < 0.12 sec	
10 patients		6 patients		6 patients		8 patients	
Bifid Dome		Bifid Normal		Bifid Dome		Bifid Normal	
6		3		4		1	

The depolarization process first involves the interatrial septum and reaches the inferolateral wall about the same time as the roof of the left atrium. In the uncommon type the impulse is considered to originate high in the right atrium and the activation of the right atrium precedes that of the left. Alderman and colleagues showed by echocardiographic recordings in three cases of common atrial flutter that the onset of forward motion of the mitral valve coincided with notch to nadir interval in Lead 2 of the electrocardiogram. This suggests that left atrial activation occurs at this time producing the left atrial wave (nN in Fig 1). We showed the duration of this wave is influenced by atrial size and/or atrial conduction disturbances.

The amplitude of fibrillatory waves in atrial fibrillation has been studied, but no attempt has been made to correlate the amplitude, contour and conduction disturbances of the flutter wave with the size of the left atrium.

Our study demonstrated a good relationship




Fig 7 56 year old patient with aortic stenosis. Left atrial size was normal. The atrial wave has a duration of 40 msec and the amplitude (A) in Lead 2 = 3 mm. The VCC (pattern 1b) shows dense conduction delay.

Table 1 Difference between the means of groups with normal and enlarged left atrium for selected electrocardiographic measures

Variable	Normal \bar{x} (SD)	Enlarged \bar{x} (SD)	t	p
n n (a) in mm	1.19 (42)	1.26 (47)	41	NS
n N duration (in msec)	43.8 (63)	72.91 (31)	37.90	< 01
Area (a x n N)	53.7 (24.4)	89.2 (45.9)	2.72	< 01
S ₁ (A) in L (in mm)	2.15 (72)	2.06 (73)	34	NS
S ₁ (A) in V (in mm)	1.51 (56)	1.81 (100)	1.11	NS

The value is expressed in arbitrary units (mm x msec)

left atrial wave (a) in L varied between 0.5 to 2.2 mm in the group with ELA and between 0.5 and 3 mm in the group with NLA. The amplitude of f in L (A) was between 1 and 2.8 mm in the group with ELA and between 1 mm and 3.5 mm in the group with NLA. In V, the A varied between 1 and 3 mm in the ELA group and between 1 and 2.5 mm in the NLA group. The surface area for the group with NLA varied between 40 to 100 arbitrary units and in the group with ELA it varied between 30 and 156 units (mm x msec).

The results of the comparison of the mean differences between the two groups for the five electrocardiographic measures are presented in Table 1. The means of the group with ELA were significantly greater for the duration of the left atrial wave ($t = 37.9$, $p < 01$) and the area under the curve ($t = 2.72$, $p < 01$). In other words

those individuals with ELA as determined by echocardiography had a significantly longer depolarization time of the left atrium as seen in the electrocardiograms.

No significant difference was found for the A of the f as measured by E_s, segment between the two groups in Leads 2 and V₁.

Atrial rate in relation of left atrial size In the group with NLA the mean rate was 284 and in group with ELA the mean atrial rate of f was 264.

The vectorcardiogram Two vectorcardiographic patterns were present in both groups.

1 Pattern I with an elongated elliptical continuously recorded fsE loop in F and S planes (Fig 3). This pattern was subdivided into two subgroups a and b a having smooth conductive delays mostly in the left side of the loop (Fig 3) and b having scattered patches of conduction delays throughout the entire fsE loop (Figs 4, 5, 6 and 7).

2 Pattern II exhibited a distorted irregular fsE loop contour. This pattern also presented features which allowed us to subdivide it into two subgroups a those with triangular shaped f loops in F and S planes with dense conduction delay (Fig 8) b Those with very distorted fsE loops with scattered conduction delays (Fig 9). The sense of direction was predominantly counter clockwise (CCW) in the frontal plane CCW or figure of eight in the horizontal plane and clockwise (CW) in the right sagittal plane in both groups. In the group with ELA two VCGs had a CW direction in the frontal plane.




Fig 11 60 year old patient with PMD Left atrium was enlarged (LADs 53 cm) The ECG shows the uncommon type flutter with rounded upright f wave in Lead 2 and aV The VCG shows a triangular distorted contour in frontal and sagittal planes and in the horizontal plane a very narrow f loop is oriented anteriorly and to the right

flutter contour Fig 5 shows important changes in the contour and direction of the f wave while the size of the left atrium remains unchanged Such changes may be due to a shift in the origin of the ectopic focus or to conduction disturbances *

The vectorcardiographic study of the f wave has been neglected mostly due to difficulties in recording and interpretation Although the continuous f wave makes it difficult to decide the location of the zero point Sano and associates entertained the possibility of identifying the beginning of fsE loop in two patients

Alderman and colleagues¹¹ reported three patients studied by computer processed vector cardiograph who showed a typical type of flutter activity The vector loops of left atrial depolarization in all three patients were oriented superiorly (corresponding to the notch to nadir interval of Lead 2) This preliminary observation seems to be useful in evaluation of the vectorial atrial forces in common flutter It is extremely difficult to determine in the vectorcardiogram the zero point (origin) of the fsE loop The fsE loop recorded by our system offers a distinct advantage One can easily determine the distortions and the conduction delays of the fsE loop Such changes when present might reflect underlying morphological myocardial changes and/or conduction disturbances in both atria Our study based on the fsE pattern obtained in 30 patients with flutter of the common type revealed two patterns of atrial

depolarization Type I pattern was found most frequently (63 per cent in patients with NLA while Type II with distorted pattern and dense conduction delays was seen in 67 per cent of patients with ELA The conduction delays and the even speed of depolarization and repolarization seen in many fsE loops could be due to structural changes (fibrotic processes etc) or to blockage in the specific pathways¹² of the newly discovered bridges in the atria After conversion of flutter to RSR the PsE loop also shows the presence of intra atrial conduction delays (Fig 10)

In a previous paper¹³ we presented evidence that the duration of the P wave is not related to the left atrial size alone Other factors possibly intra atrial conduction disturbances in the specific pathways play an important role in the prolongation of the duration of the P wave and distort the PsE loop

Sixty two per cent of the patients with ELA showed (post conversion) an abnormal sinus P wave and 43 per cent of the patients with NLA who developed flutter showed an abnormal P wave (duration and contour) The bifid type of P wave was predominant in both groups In patients with NLA the abnormal P wave was probably due to conduction disturbances

In two cases we recorded the uncommon type of flutter with upright rounded f in Leads 2 and 3 and aV_r (Fig 11) The VCG showed a distorted




Fig 9 6-year old patient with ASHD Left atrium was enlarged (LADs = 4.2 cm) The flutter waves are very small The VCG shows a very distorted QRS loop with dense conduction delays (pattern IIb)




Fig 10 ECG and VCG of the patient described in Fig 9 recorded after conversion to sinus rhythm The P wave has a duration of 0.14 msec and the PSE shows dense conduction delays (intra atrial conduction disturbances)

between the duration of left atrial depolarization as seen in the f of the electrocardiogram in Lead 2 and the size of the left atrium calculated echocardiographically. In 75 per cent of the patients with ELA, the duration of the P-N interval (left atrial wave) was more than 40 msec while four patients (28 per cent) in the group with NLA had a P-N duration above 40 msec ($p < 0.01$). The surface area of left atrial wave ($a \times n$) was smaller in

patients with NLA (mean 53.7 ± 24.4) as compared to the group of patients with ELA (89.2 ± 45.9 , $p < 0.01$) (Table I). The A of the f wave in Leads 2 and V_1 of the ECG failed to correlate with the size of the left atrium.

In atrial flutter the pathway of atrial depolarization is not fully elucidated.¹⁰ Structural and functional changes in the atrial myocardium and of the specific pathways¹ probably change the

Hemorrhagic myocardial infarction associated with aortocoronary bypass revascularization

J T Lie MD

Gerald M Lawrie MD

George C Morris Jr MD

William L Winters MD

Houston Tex

A decade of experience with aortocoronary bypass surgery has accumulated since its clinical application initially for the relief of angina pectoris in patients with obstructive coronary artery disease. Bringing blood to the blighted ischemic heart muscle is a therapeutic approach of such appealing logic that beginning in 1970 there have been a growing number of reports on the use of aortocoronary bypass for patients with impending or evolving myocardial infarction.¹ It was reasoned that aortocoronary bypass performed during the early phase of myocardial infarction might salvage the jeopardized myocardium and reduce the ultimate size of the infarct.²

Since 1974 the enthusiasm for aortocoronary bypass as an emergency procedure has been dampened by reports from several independent workers of deleterious effects of myocardial reperfusion. In closed chest experiments in dogs described by Lang and associates,³ Bre nahan and co workers,⁴ and Mathur and associates,⁵ reperfusion after 3 to 11 hours of coronary artery occlusion not only failed to reduce the size of the infarct but had in fact extended the area of myocardial necrosis in 44 to 70 per cent of the

animals and the infarction was characteristically hemorrhagic.

Our autopsy study of patients with myocardial infarction immediately preceding or following aortocoronary bypass confirms the hazard of hemorrhagic infarction in myocardial revascularization and suggests that this complication may account for the high mortality of evolving and perioperative myocardial infarctions within the first 14 days of aortocoronary bypass as reported by Dawson and associates⁶ and by Pifarre and co workers.

Material and methods

Between 1968 and 1975 aortocoronary bypass with autogenous saphenous vein grafts was performed on 1837 patients by an operative technique reported previously.⁷ The overall graft patency was 84 per cent in 281 patients with 492 vein grafts at a mean follow up of 19 months (range 0 to 75 months). Only those patients who died with histologically documented acute myocardial infarction and were autopsied in one of the affiliated hospitals a total of 44 patients were included in the present study.

The method of postmortem examination of the heart has been described in detail elsewhere.⁸ The infarcts were dated according to the histologic criteria of Mallory and associates.⁹ Special attention was directed to the identification of myofibrillar degeneration eosinophilia and wavy distortion of fibers all of these being sensitive markers of acute myocardial ischemia. Evidence of adequate healing of infarcts was determined by the identification of (1) in the second week

From the Department of Thoracic Surgery and Medicine, Baylor College of Medicine, Houston, Texas.

Supported in part by Grant HL-17455 from the National Heart, Lung, and Blood Institute, National Institutes of Health, United States Public Health Service.

Received for publication July 26, 1977.

Accepted for publication August 25, 1977.

Reprint requests: J T Lie MD, May Clinic, 200 First Street Southwest, Rochester, Minnesota 55901.

contour in frontal and right sagittal planes with dense even conduction delay. As long as the electrocardiographic recordings are obtained by conventional leads, it is natural to doubt if this rounded pattern is due to severe conduction disturbances at the atrial level or to a different origin of the ectopic mechanism.²¹

Summary

The duration, contour and amplitude of atrial flutter wave (f) was studied by electrocardiogram (ECG) and vectorcardiogram (VCG) in 32 patients and was related to the size of the left atrium (LA) measured by the echocardiogram (E). The following ECG parameters were analyzed: (1) the duration of left atrial depolarization (LAD), (2) the amplitude of LA wave (LAw), (3) the surface area of LA wave (LAwA), (4) the maximum amplitude (A) of f in Leads 2 and V₁. There was good correlation between LA size and the duration of depolarization and surface area ($p < 0.01$) but the maximum amplitude of the f wave in Leads 2 and V₁ failed to predict LA size.

The post conversion sinus P wave showed abnormal LA depolarization time ($P > 0.12$ sec) in 62 per cent of patients with enlarged left atrium (ELA) and in 43 per cent of patients with normal size LA (NLA).

The VCG of the flutter wave revealed two patterns: (1) an elliptical smooth f-w loop in 63 per cent of patients with NLA and (2) distorted f-w loop in 67 per cent of patients with ELA.

Both VCG patterns were subdivided in two subgroups according to the number and location of conduction delays. The VCG of post conversion P wave confirmed conduction delays in both groups.

We conclude that both the size of the left atrium and conduction delays play a basic role in the duration and contour of left atrial wave.

The authors wish to thank Mrs. Ada Kamars for her technical assistance and to acknowledge the secretarial assistance of Mrs. Karen Franklin.

REFERENCES

1. Skoulas A and Horlick L. The atrial F wave in various types of heart disease and its response to treatment. *Am J Cardiol* 14:174 1964.

2. Bailey J W, Branniff B A, Hancock E W and Cohen F. Relation of left atrial pathology to atrial fibrillation in mitral valvular disease. *Ann Intern Med* 69:11 1968.
3. Probst P, Goldschlager N and Selzer A. Left atrial size and atrial fibrillation in mitral stenosis. Factors influencing their relationship. *Circulation* 48:122 1973.
4. Waggoner A D, Adyanthaya A V, Quinones M A and Alexander J K. Left atrial enlargement. Echocardiographic assessment of electrocardiographic criteria. *Circulation* 54:553 1976.
5. Zonerach S, Zonerach O and Rhee J J. Echocardiographic findings in atrial flutter. *Circulation* 52:4 1975.
6. Morris J J, Estes L H, Whalen R E, Thompson H K and McIntosh H D. P wave analysis in valvular heart disease. *Circulation* 29:242 1964.
7. Feigenbaum H. *Echocardiography*. Philadelphia 1968. Lea & Febiger Publishers. pp 235, 246.
8. Hurata T, Wolfe S H, Popp H L, Helman C R and Feigenbaum H. Estimation of left atrial size using ultrasound. *Am Heart J* 78:43 1969.
9. Brown O R, Harrison D C and Popp P L. An improved method for echographic detection of left atrial enlargement. *Circulation* 50:58 1974.
10. Scherf D and Cohen J. The atrio-ventricular node and selected cardiac arrhythmias. *Flutter and fibrillation*. New York 1974. Grune & Stratton. pp 194-23.
11. Scherf D and Schott A. *Extrasystoles and other arrhythmias*. Chicago 1973. Year Book Medical Publishers Inc. pp 416-420.
12. Ciraud G, Latour H and Puech P. Le flutter humain. Etude de l'activation auriculaire par les dérives oesophagiennes et endocavitaires. *Arch Mal Coeur* 48:817 1955.
13. Puech P, Latour H and Grolleau R. Le flutter et ses limites. *Arch Mal Coeur* 63:116 1970.
14. Rosen K M and Damato A N. Stimulation of atrial flutter by rapid coronary sinus pacing. *Am Heart J* 78:635 1969.
15. Lewis T, Drury A N and Ilievu C C. A demonstration of circus movement in clinical flutter of the human heart. *Heart* 8:341 1921.
16. Rydand D A. The circus movement (Entrapped circuit wave). Hypothesis and atrial flutter. *Ann Intern Med* 65:125 1966.
17. Alderman E L, Rydand D A, Crow R B, Finegan R E and Harrison D C. Normal and prosthetic atrioventricular valve motion in atrial flutter. Correlation of ultrasound, vectorcardiographic and phonocardiographic findings. *Circulation* 45:1206 1972.
18. James T N and Sherf L. Specialized tissues and preferential conduction in the atria of the heart. *Am J Cardiol* 28:414 1971.
19. Sano T, Hiroki T, Hazama H and Henton T. I vector loop in atrial flutter. *Bull Tokyo Med Dent Univ* 15:59 1968.
20. Zonerach O and Zonerach S. Intra atrial conduction disturbances. Vectorcardiographic patterns. *Am J Cardiol* 37:736 1976.
21. Mironovski M and Alkan W J. Left atrial impulse formation—atrial flutter. *Br Heart J* 29:299 1967.

Table 1 Preoperative and operative variables in 44 patients with myocardial infarction (MI) associated with aortocoronary bypass (ACB) surgery

Variables	Group I (14 patients)	Group II (13 patients)	Group III (17 patients)
Mean age (yr)	54.2	51.2	57.3
Sex	13M 1F	11M 2F	13M 4F
Hypertension (no. of patients)	2	2	2
Left ventricular hypertrophy (no. of patients)	8	7	9
Autopsy-confirmed old MI (no. of patients)	6	6	8
Mean ACB pump time (hr)	2.2	2.0	2.4
Mean number of ACB grafts	2.4	2.5	2.3

Tx = more recordings of systolic pressure greater than 140 mm Hg and diastolic pressure greater than 90 mm Hg

Table 2 Distribution and number of coronary arteries with significant occlusive disease in 44 patients with myocardial infarction associated with aortocoronary bypass surgery

Significant occlusive disease of major coronary arteries	Number of patients		
	Group I (14 patients)	Group II (13 patients)	Group III (17 patients)
Distribution			
Left main coronary artery	1	0	1
Left anterior descending artery	11	11	13
Left circumflex artery	8	7	12
Right coronary artery	9	7	10
Number of vessels involved			
One	0	0	0
Two	4	5	4
Three	9	6	11
Four	1	2	2

Vessels with luminal narrowing of 5 per cent or more

myocardial infarction after aortocoronary bypass as determined by symptoms, new Q waves and serum enzyme changes.

Hemorrhagic infarcts were evident in 57 per cent of patients (eight of 14) in Group I and 38 per cent (five of 13) in Group II whereas only 6 per cent of patients (one of 17) in Group III had hemorrhagic infarcts (Fig 2). The differences were significant between Groups I and III ($P < 0.005$) and between Groups II and III ($P < 0.05$) but not between Groups I and II. In all cases a vein graft had been inserted to the artery supplying the area of infarction and it remained patent. Poor runoff due to atherosclerosis of the distal coronary arteries as determined at autopsy was the presumed anatomic basis of myocardial infarction in patients of Groups II and III.

In Group I patients with hemorrhagic infarcts there was no discernible difference in amount of

hemorrhage between those having a 1 day old infarct and those having a 1 week old infarct. On the other hand hemorrhagic infarcts when present were more severe in patients in Group I than in those in Group II.

There were no significant differences among the three groups of patients in regard to the following variables: mean age, sex ratio, clinical evidence of hypertension, left ventricular hypertrophy, autopsy confirmed old myocardial infarcts, aortocoronary bypass pump time and the number of aortocoronary bypass grafts (Table I). The distribution and the number of coronary arteries with significant occlusive disease also were similar (Table II). The number of patients with two-vessel or three-vessel disease was slightly higher proportionately in Group I (13 of 14 or 93 per cent) than in Group II (11 of 13 or 85 per cent) or Group III (15 of 17 or 88 per cent) but the differences were not significant. None



Fig 1 Left Heart cut sagittally to show hemorrhagic myocardial infarct of posterior wall of left ventricle (dark blotchy area) Right Low power magnification photomicrograph of hemorrhagic myocardial infarct. Infarct is in upper left corner of picture. Note that interstitial hemorrhage (dark linear streaks) extends well beyond infarct (Hematoxylin and eosin original magnification $\times 40$)

HEMORRHAGIC MI ASSOCIATED WITH ACB




Fig 2 Percentage of hemorrhagic myocardial infarcts (MI) in each group of patients who underwent aortocoronary bypass. Group I had infarction predating aortocoronary bypass by 1 to 7 days. Group II had infarction 1 to 14 days after aortocoronary bypass, and group III had infarction 1 to 90 days postoperatively.

laryorrhexis of polymorphonuclear leukocytes and ingrowth of blood vessels and fibroblasts (2) in the third week, removal of the necrotic muscle by phagocytic leukocytes and influx of lymphocytes and plasma cells, and (3) in the fourth and subsequent weeks, condensation of collagen and hyalinization of the fibrous scar tissue.

Hemorrhagic myocardial infarct was defined as an infarct with grossly discernible interstitial

hemorrhage or microscopically evident extension of the hemorrhage beyond the infarcted zone (Fig 1). The size of the infarct was determined morphologically by the method of Hackel and Ratliff. The results were evaluated statistically by means of Fisher's exact method for 2×2 tables.

Results

Although the indication for aortocoronary bypass was angina pectoris, 14 patients (Group I) of the total of 44 had unsuspected evolving myocardial infarction histologically either predating aortocoronary bypass from 1 to 7 days or occurring within 12 hours after the operation. None of these 14 patients had diagnostic electrocardiographic or serum enzymatic evidence of acute myocardial infarction. Thirteen other patients (Group II) were found histologically to have experienced myocardial infarction between the first and fourteenth postoperative days. The remaining 17 patients (Group III) had myocardial infarction in the more remote postoperative period of 2 weeks to 3 months after aortocoronary bypass. All patients in Groups II and III died with acute myocardial infarction defined as ischemic necrosis of the myocardium 1 day to 4 weeks old. The histologic age of the infarct corresponded closely to the clinical onset of



Fig 3 Upper Photomicrograph of border zone of a hemorrhagic myocardial infarct shows focal ischemic necrosis surrounded by interstitial edema and hemorrhage. Necrotic fibers appear darker (more eosinophilic) and show contraction bands in midst of some normal looking fibers. Note that infiltration by polymorphonuclear cells has begun (Hematoxylin and eosin original magnification $\times 240$). Lower High power magnification photomicrograph showing individual cell necrosis (myofibrillar degeneration with contraction bands) surrounded by numerous extravasated red blood cells (Hematoxylin and eosin original magnification $\times 1,900$).

of the second week. In contrast islands of necrotic muscle in hemorrhagic infarcts appeared to lie dormant in a sea of red blood cells even as late as the fourth week (Fig 4). Another unfavorable histologic feature of hemorrhagic infarcts was the extension of ischemic injury. Patchy foci of myocardial necrosis often appeared outside the infarcted areas but well within the zone of edema and hemorrhage. The necrosis was characterized

by eosinophilia and waviness and myofibrillar degeneration of individual fibers with or without infiltration by polymorphonuclear leukocytes (Fig 5).

Pathologically hemorrhagic infarcts also differed from nonhemorrhagic infarcts in regard to infarct size expressed as the percentage of left ventricle involved. The infarct was 50 per cent or larger in nine of 14 patients (64 per cent) with




Fig 3 Photomicrographs of hemorrhagic myocardial infarction showing two varieties of interstitial hemorrhage unidirectional (*left*) and multidirectional (*right*). Note that extravasated blood has created false tissue planes that split myocardium. Individual acutely ischemic fibers appear darker because of eosinophilia (Hematoxylin and eosin original magnification $\times 120$).




Fig 4 Photomicrographs of acute myocardial infarction. *Left*: In 2 week old nonhemorrhagic myocardial infarct note removal of necrotic tissue (*left upper quadrant* of picture) by phagocytic macrophages at edge of infarct. *Right*: In 4 week old hemorrhagic infarct note group of smudgy anuclear necrotic muscle fibers (*in center of picture*) in a sea of red blood cells as yet to be removed (Hematoxylin and eosin original magnification $\times 200$).

of the patients had only single vessel disease.

Hemorrhagic myocardial infarction occurred in both transmural and subendocardial infarction. Although free perforation had not taken place in any of the infarcts, hemorrhage often extended beyond the infarcted zones. The extravasated blood formed irregular unidirectional or multidirectional

dissecting tracts and created false tissue planes that split the myocardium (Fig 3). Most hemorrhagic infarcts showed an impaired healing process histologically. For non hemorrhagic infarcts, removal of necrotic muscle by phagocytic leukocytes and the formation of vascular granulation tissue were well under way toward the end

the brain and kidney; restoration of blood flow after an anoxic period often results in non-uniform hypoperfusion of ischemic regions. Anoxia induced cellular and interstitial edema is responsible for this phenomenon of no-reflow in the microcirculation of the jeopardized tissue—much of course compounds the deleterious effects of ischemia.

The pathogenesis of hemorrhagic myocardial infarction in the patients in Group II is unclear. Since aortocoronary bypass predated the ischemic injury, hemorrhage cannot be attributed to the direct effect of reperfusion. It is possible that the hemorrhage occurs as a complication of cardiopulmonary bypass coincidental to the myocardial infarction that has developed. Presumably perioperative hemorrhage if present would have resolved by 10 to 90 days after aortocoronary bypass in the patients in Group III.

In conclusion, immediate revascularization for evolving myocardial infarction, although a theoretically attractive concept and surgically feasible, must be approached with caution because of the prevalence of hemorrhagic myocardial infarction and its attendant high mortality rate. The two possible exceptions are for patients in whom acute myocardial infarction develops during cardiac catheterization² and for those in cardiogenic shock after acute infarction.³ In these desperate situations, prompt surgical intervention may indeed be life saving and may represent the treatment of choice. The question of optimal management for patients with persistent pain after documented myocardial infarction remains to be answered.

Summary

Experimentally hemorrhage and extension of myocardial infarction occur commonly when there is reperfusion after coronary artery occlusion. To investigate this hazard in a clinical setting, we compared the histopathologic picture of myocardial infarction in 44 patients who had undergone aortocoronary bypass. 14 (Group I) had myocardial infarction that predated aortocoronary bypass by 1 to 7 days, 13 (Group II) had infarction 1 to 14 days after the surgery, and 17 (Group III) had infarction 15 to 90 days postoperatively. All 44 patients had two or more coronary arteries with luminal narrowing of more than 75

per cent and patent vein grafts to arteries supplying areas of infarction. Hemorrhagic infarcts were present in 57 per cent of patients (eight of 14) in Group I and 38 per cent of patients (five of 13) in Group II, contrasting with 6 per cent of patients (one of 17) in Group III ($P < 0.005$ and $P < 0.05$ respectively). In hemorrhagic infarcts the extravasated blood formed irregular intramural dissecting tracts beyond the area of infarction and foci of myocardial necrosis were present in the border zones. Infarcts affected more than 50 per cent of the left ventricular muscle in 64 per cent of cases of hemorrhagic infarction and in 13 per cent of cases of nonhemorrhagic infarction ($P < 0.05$). The prevalence of hemorrhagic infarction after revascularization may account for the high mortality of evolving and perioperative myocardial infarction associated with aortocoronary bypass, and this finding militates against wholesale immediate revascularization in patients who have uncomplicated myocardial infarction.

REFERENCES

1. Sheldon R C and Loop F D. Direct myocardial revascularization—1976. Progress report on the Cleveland Clinic experience. *Cleveland Clin Q* 43: 101-106.
2. Adam M, Altich J B F and Lambert C J. Immediate revascularization of the heart. *Circulation* 41 and 42 (Suppl II): II-3, 1970.
3. Hall J D, Kerth W J, Kelly J J, Selzer A, Armstrong W, Pepper R W, Langston W F and Cohn A E. Emergency aortocoronary bypass for impending or extending myocardial infarction. *Circulation* 43 and 44 (Suppl 2): I-105, 1971.
4. Mundt E D, Buckley M J, Leimbach R C, DeSanto H W, Sanders C A, Kantrowitz A and Austen W G. Myocardial revascularization for the treatment of cardiogenic shock complicating acute myocardial infarction. *Surgery* 76: 18, 1973.
5. Dunkman W B, Leimbach R C, Buckley M J, Mundt E D, Kantrowitz A R, Austen W G and Sanders C A. Clinical and hemodynamic results of intra-aortic balloon pumping and surgery for cardiogenic shock. *Circulation* 46: 465, 1972.
6. Sawtelle H, Chatterjee H, Malloff J M, Marty A T, Swan H J C and Fields J. Emergency bypass surgery in impending and complicated myocardial infarction. *Arch Surg* 105: 30, 1972.
7. Smulders S N, Wiener L, Karpman H, Brest A N, Bacharach D, Noble P H and Templeton I V. Evaluation and surgical management of acute evolving myocardial infarction. *J Thorac Cardiovasc Surg* 64: 495, 1972.
8. Cohn L R, Gorlin R, Herman M V and Collins J J Jr. Aortocoronary bypass for acute coronary occlusion. *J Thorac Cardiovasc Surg* 64: 503, 1972.
9. Chatterjee H, Effler D B, Loop F D, Groves L A, Sheldon W C, Razavi M and Sones F M Jr.

hemorrhagic infarcts contrasting with only four of 30 patients (13 per cent) with nonhemorrhagic infarcts ($P < 0.05$). That all patients with an infarct size of 50 per cent or larger had died in pump failure was evident by the finding of severe pulmonary edema at autopsy.

Discussion

After a decade of clinical experience, there is now little or no contradiction to the general belief that aortocoronary bypass surgery usually relieves angina and the 30 day surgical mortality rate in uncomplicated cases is 5 per cent or lower. The late attrition of aortocoronary bypass ranges from 1.5 to 5 per cent per year and this compares favorably with the expected yearly mortality rate of 6 to 18 per cent in a similar group of patients treated medically.¹

Encouraged by these results a number of centers have included impending and evolving myocardial infarction as indications for aortocoronary bypass.²⁻¹⁰ The rationale for immediate revascularization in the early phase of myocardial infarction is to minimize the size of the infarct by increasing perfusion to the ischemic myocardium around the infarct. Experimental studies in dogs killed at varying intervals after coronary artery occlusion have demonstrated a twilight zone of ischemic tissue separating the area of necrosis from the surrounding uncompromised myocardium.¹¹

However, reperfusion during evolving myocardial infarction is not a panacea. To be effective, reperfusion must commence within 1 or 2 hours of coronary occlusion,¹²⁻¹⁵ a deadline that can seldom be met in most clinical situations. Recent experimental findings suggest that indeed revascularization may exacerbate rather than limit myocardial injury.¹⁶⁻¹⁸ When conscious dogs were subjected to coronary occlusion by constriction of an exteriorized snare for 5 hours myocardial hemorrhage occurred in 44 per cent of the animals when reperfusion was implemented by releasing the occlusive snare. This was accompanied by massive extension of the infarction as reflected by serial changes in serum creatine phosphokinase.¹⁹ In addition the hemodynamic status of the reperfused animals was significantly worse 2 to 3 hours after reperfusion than that of the control group at corresponding times and pathologic Q waves indicating transmural infarction developed

sooner in the animals undergoing reperfusion.²⁰⁻²²

The results of our study indicate that a parallel situation exists in the clinical setting. The risk of developing hemorrhagic myocardial infarction in patients who had infarction 14 days or longer after aortocoronary bypass (6 per cent in Group III) was probably no greater than that in patients without aortocoronary bypass. However hemorrhagic myocardial infarction was almost ten times more common in patients who had evolving myocardial infarction and aortocoronary bypass (57 per cent in Group I) and more than six times common in patients who had aortocoronary bypass and perioperative myocardial infarction (38 per cent in Group II). Pathologically, hemorrhagic infarcts showed several features that are prognostically unfavorable for survival namely delayed healing, extension of ischemic injury to the myocardium and pump failure.

The prevalence of hemorrhagic infarcts may account for the high mortality of patients who have had evolving and perioperative myocardial infarction associated with aortocoronary bypass.¹⁶⁻¹⁸ Analyzing the data on 1700 patients who had undergone aortocoronary bypass without additional cardiovascular procedures Dawson and associates¹⁶ found that the early mortality in patients who had undergone aortocoronary bypass within the first 7 days after acute myocardial infarction (38.1 per cent) was more than six times greater than the mortality in patients who had been operated on 31 to 60 days after acute infarction (5.8 per cent). The results reported by Pifarre and associates¹⁷ were equally alarming; the mortality rate of patients who had undergone aortocoronary bypass at 2 to 12 hours, 13 to 48 hours, 2 to 13 days, 14 to 30 days and 31 to 60 days was 33 per cent, 100 per cent, 50 per cent, 17 per cent and 0 per cent respectively.

Hemorrhagic infarction is a reperfusion injury following prolonged myocardial ischemic anoxia. It has been observed before aortocoronary bypass was in vogue in surgical procedures requiring cardiopulmonary bypass. Experimentally, the extent of hemorrhagic necrosis is directly proportional to the duration of the preceding period of ischemic anoxia and the hemorrhage is attributable to anoxic injury to the capillary endothelium.²³⁻²⁵ In the heart, "as in

the brain and kidney'.¹ restoration of blood flow after an anoxic period often results in non-uniform hypoperfusion of ischemic regions. Anoxia induced cellular and interstitial edema is responsible for this phenomenon of no reflow in the microcirculation of the jeopardized tissue—which of course compounds the deleterious effects of ischemia.

The pathogenesis of hemorrhagic myocardial infarction in the patients in Group II is unclear. Since aortocoronary bypass predated the ischemic injury, hemorrhage cannot be attributed to the direct effect of reperfusion. It is possible that the hemorrhage occurs as a complication of cardiopulmonary bypass coincidental to the myocardial infarction that has developed. Presumably perioperative hemorrhage if present would have resolved by 15 to 90 days after aortocoronary bypass in the patients in Group III.

In conclusion, immediate revascularization for evolving myocardial infarction, although a theoretically attractive concept and surgically feasible, must be approached with caution because of the prevalence of hemorrhagic myocardial infarction and its attendant high mortality rate. The two possible exceptions are for patients in whom acute myocardial infarction develops during cardiac catheterization² and for those in cardiogenic shock after acute infarction. In these desperate situations, prompt surgical intervention may indeed be life saving and may represent the treatment of choice. The question of optimal management for patients with persistent pain after documented myocardial infarction remains to be answered.

Summary

Experimentally, hemorrhage and extension of myocardial infarction occur commonly when there is reperfusion after coronary artery occlusion. To investigate this hazard in a clinical setting, we compared the histopathologic picture of myocardial infarction in 44 patients who had undergone aortocoronary bypass. 14 (Group I) had myocardial infarction that predated aortocoronary bypass by 1 to 7 days; 13 (Group II) had infarction 1 to 14 days after the surgery; and 17 (Group III) had infarction 15 to 90 days postoperatively. All 44 patients had two or more coronary arteries with luminal narrowing of more than 75

per cent and patent vein grafts to arteries supplying areas of infarction. Hemorrhagic infarcts were present in 57 per cent of patients (eight of 14) in Group I and 38 per cent of patients (five of 13) in Group II, contrasting with 6 per cent of patients (one of 17) in Group III ($P < 0.005$ and $P < 0.05$ respectively). In hemorrhagic infarcts, the extravasated blood formed irregular intramural dissecting tracts beyond the area of infarction, and foci of myocardial necrosis were present in the border zones. Infarcts affected more than 50 per cent of the left ventricular muscle in 64 per cent of cases of hemorrhagic infarction and in 13 per cent of cases of nonhemorrhagic infarction ($P < 0.05$). The prevalence of hemorrhagic infarction after revascularization may account for the high mortality of evolving and perioperative myocardial infarction associated with aortocoronary bypass, and this finding militates against wholesale immediate revascularization in patients who have uncomplicated myocardial infarction.

REFERENCES

- Sheldon W C and Loop F D: Direct myocardial revascularization—1966 Progress report on the Cleveland Clinic experience. *Cleveland Clin Q* 43:97, 1976.
- Adam M, Mitchell B F and Lambert C J: Immediate revascularization of the heart. *Circulation* 41 and 42 (Suppl II) II:73, 1970.
- Hill J D, Kerth W J, Kelly J J, Selzer A, Armstrong W, Popper R W, Langston W F and Cohn K E: Emergency aortocoronary bypass for impending or extending myocardial infarction. *Circulation* 43 and 44 (Suppl I) I:107, 1971.
- Mundth, E D, Buckley M J, Leimbach II C, DeSantis R W, Sanders C A, Kantrowitz A and Austen W G: Myocardial revascularization for the treatment of cardiogenic shock complicating acute myocardial infarction. *Surgery* 70:78, 1971.
- Dunkman W B, Leimbach R C, Buckley M J, Mundth, E D, Kantrowitz A II, Austen W G and Sanders C A: Clinical and hemodynamic results of intra-aortic balloon pumping and surgery for cardiogenic shock. *Circulation* 45:465, 1972.
- Sustanta H, Chatterjee K, Matloff J M, Marty A T, Swan H J C and Fields J F: Emergency bypass surgery in impending and complicated myocardial infarction. *Arch Surg* 105:30, 1972.
- Smulders S N, Wæner L, Hasparian H, Brest A N, Bacharach B, Noble P H and Templeton J Y: Evaluation and surgical management of acute evolving myocardial infarction. *J Thorac Cardiovasc Surg* 64:495, 1972.
- Cohn L H, Gorlin R, Herman M V and Collins I J Jr: Aortocoronary bypass for acute coronary occlusion. *J Thorac Cardiovasc Surg* 64:404, 1972.
- Cheavens C, Effler D B, Loop F D, Groves L H, Sheldon, W C, Razavi M and Sones, F M Jr:

Long term follow up of aneurysmectomy for recurrent ventricular tachycardia or fibrillation

Magdi Sami MD
Bernard R Chaitman MD
Martial G Bourassa MD
Denis Charpin MD
Michel Chabot MD
Montreal Quebec Canada

The association of life threatening recurrent ventricular tachyarrhythmias and left ventricular aneurysm has been recognized for several years. Since Couche first described a case of recurrent ventricular tachycardia abolished by aneurysmectomy, there have been numerous reports of such treatment. However, most studies involved small series or isolated case reports with relatively short follow up periods using end points such as symptoms and the standard resting electrocardiogram. The present study describes ten patients whose primary indication for aneurysmectomy was the presence of recurrent ventricular tachyarrhythmias. Their long term follow up included a graded exercise test and 24 hour Holter monitoring in order to further evaluate the role of aneurysmectomy in the treatment of recurrent ventricular arrhythmias.

Material and methods

Patient material From January 1972 through January 1976, 106 patients underwent surgical resection of a saccular aneurysm at the Montreal Heart Institute. Of these 10 patients whose

primary indication for aneurysmectomy was the presence of recurrent ventricular arrhythmias were selected for study. Table 1 lists the clinical and angiographic features of these patients. There were nine men and one woman; their mean age was 53 years (Range 26 to 69 years). The aneurysm was caused by myocardial infarction in nine patients and was post-traumatic in one patient. All patients had symptoms of recurrent ventricular arrhythmias in the preoperative period resistant to standard antiarrhythmic therapy. Each arrhythmia was documented on rhythm strips during observation in hospital.

The preoperative diagnosis of left ventricular aneurysm was based on biplane left ventricular angiography. The angiographic criteria for left ventricular aneurysm included a saccular deformation of the left ventricular cavity which persisted both in systole and diastole. The contraction pattern of the remaining myocardium was classified as good when there were no contraction abnormalities in non-aneurysmal segments; fair when moderate hypokinesis, akinesis, or dyskinesis was observed in one segment; and poor when one of these abnormalities was observed in more than one segment. At operation, a true saccular aneurysm as defined by Loop¹ was resected in all patients. Survivors were reevaluated an average of 22 (4 to 42) months after surgery. All had a history and physical examination, a resting electrocardiogram, a multistage bicycle exercise test, and ambulatory 24 hour Holter monitoring. The multistage bicycle ergometric test was performed using initial workload of three metabolic equiv-

From the Montreal Heart Institute and the Department of Medicine (University of Montreal Medical School), Montreal, Quebec, Canada. Work supported in part by the J. L. Lévesque Foundation.

Received for publication July 18, 1977.

A reprinted publication, Sept. 19, 1977.

Reprint requests: Martial G. Bourassa, MD, Montreal Heart Institute, 5000 Belanger Street East, Montreal, Quebec H3T 1C8, Canada.

Present address: Magdi Sami, MD, Cardiology Division, Stanford University School of Medicine, Stanford, Calif. 94305.

Table 1 Preoperative clinical and hemodynamic status

Age at operation	Type of arrhythmia	Clinical status		Hemodynamic status					
		Symptoms during arrhythmia	Symptoms between episodes	Ventriculographic findings			Coronary angiography		
				Aneurysm site	Aneurysm size	Remaining myocardium	No of vessels with stenosis $\geq 50\%$	Rest LVEF (%)	
1 51 M	Ventricular fibrillation	Cardiac arrest	Dyspnea Class II*	Anterolateral	Large	Good	1	13	
2 50 F	Ventricular tachycardia	Dizziness and palpitation	Dyspnea Class I	Anterolateral diaphragmatic	Large	Fair	2	12	
3 60 M	Ventricular tachycardia	Dizziness and palpitation	Asymptomatic	Anterolateral diaphragmatic	Large	Good	1	41	
4 56 M	Ventricular tachycardia	Palpitation dyspnea angina hypotension	Asymptomatic	Anterolateral	Large	Fair	3	26	
5 58 M	Supraventricular and ventricular tachycardia	Angina	Angina Class II	Posteroanterior	Moderate	Good	3	9	
6 69 M	Ventricular fibrillation Ventricular tachycardia	Cardiac arrest Syncope	CHD embolism	Anterolateral Distal septal	Large	Poor	1	31	
7 36 M	Ventricular tachycardia	Palpitation angina	Asymptomatic	Anterolateral	Moderate	Good	0	6	
8 46 M	Ventricular tachycardia	Dizziness palpitation	Asymptomatic	Anterolateral	Large	Good	3	48	
9 58 M	Ventricular tachycardia	Palpitation angina	Angina Class II	Anterolateral	Moderate	Good	2	10	
10 64 M	Ventricular tachycardia	Dizziness angina	Dyspnea Class II	Anterolateral Distal-septal	Large	Poor	2	30	

New York Heart Association functional classification

Abbreviations: LVF/DL left ventricular and diastolic pressure; F, female; M, male

alents (mets) increasing by one met increments every 2 minutes. During exercise and for 5 to 10 minutes thereafter Leads CM and CM₁ were continuously monitored on an oscilloscope and recorded each minute or more often if an arrhythmia was noted. The indications for stopping the test are shown in Table II.

Ambulatory electrocardiographic monitoring was done with a portable Avionic Electrocardio recorder model 425 with standard disposable silver-silver chloride electrodes employing a modified Lead V₁ and V₅ configuration. Each patient kept a diary to record events. Analysis of the recordings were done using an Avionic Dynamic Electrocardioscanner model 660 A in a semiauto-

mated manner as described by Lown and associates.¹ The electrocardioscanner has a high speed playback analyzer running at 60 or 120 times real time and a low speed paper recorder. Audiovisual techniques using an R wave triggered oscilloscopic display and an electrocardiographic coupled sound system enabled detection of ventricular events. At the same time normal heart beats and ventricular extrasystoles were automatically counted on a digital computer and were charted hourly. Focality of the ventricular extrasystoles were noted as well as the presence of couplets or runs of ventricular tachycardia. All ventricular events were re-run at real time speed to verify their nature and number. All tapes were

interpreted by two experienced cardiologists and consensus opinion was reached on the number and type of ventricular arrhythmias

Results

There was no operative mortality. Of six patients with multivessel disease three had associated aortocoronary bypass procedures (cases 1, 2, 4, 5). Two patients (cases No 6 and 8) died suddenly at 7 and 15 months respectively following operation. Neither patient had an associated revascularization procedure and patient No 6 had poor left ventricular contraction in the non aneurysmal myocardium preoperatively. The signs and symptoms of the eight survivors are shown in Table II. Although seven out of eight patients had persistent palpitations all but one considered themselves symptomatically improved. No patient had radiologic evidence of congestive heart failure. The resting electrocardiogram showed ventricular extrasystoles in only three out of eight cases whereas the Holter monitor demonstrated multifocal ventricular extrasystoles in all patients and short runs of ventricular tachycardia which were asymptomatic in three patients. Exercise increased the number of premature ventricular contractions in three patients. Antiarrhythmic medication had been stopped in all but one patient following aneurysmectomy because of symptomatic improvement. Table II shows that there was no correlation between recurrence of ventricular arrhythmias and aneurysm size or contraction pattern of non aneurysmal segments or the extent of coronary disease.

Discussion

Our results suggest that aneurysmectomy may be beneficial in the treatment of recurrent ventricular tachyarrhythmias. However long term follow up using ambulatory Holter monitoring revealed a surprisingly high incidence of persistent serious ventricular arrhythmias which call for a careful patient selection for surgery as well as close follow up of these patients.

The overall incidence of arrhythmias in patients with left ventricular aneurysm is not known. In our hospital aneurysmectomy was performed in 106 patients during a 3 year period. Ten of our patients (9 per cent) had persistent serious and/or recurrent ventricular tachyarrhythmias preoperatively and a similar incidence can be found in most other large series. However it is possible that a much larger percentage of patients with left ventricular aneurysm experience short runs of ventricular tachycardia which are not symptomatic and are undetected.

Several investigators have observed that tachyarrhythmias are more frequent in patients with large aneurysms and virtually absent in patients with small aneurysms. Roche, Maure and colleagues have also related prognosis to aneurysmal size noting that arrhythmias accounted for seven of eight deaths in their group with large size aneurysms. The function of other left ventricular segments as well as the extent of coronary artery disease in the genesis of ventricular tachyarrhythmias is not clear. Four patients in our series had important ventricular arrhythmias with single vessel disease and good contraction of non aneurysmal segments. Furthermore there are many reported cases of ventricular tachyarrhythmias in patients with a left ventricular aneurysm and normal coronary arteries. For these reasons it is difficult to evaluate the coincident role of multiple vessel disease and non aneurysmal segments in the initiation and maintenance of ventricular arrhythmias. However multivessel disease may have a bearing on the patient's ability to cope with his arrhythmia as well as on the prognosis of aneurysmectomy if complete revascularization cannot be obtained. Of the two patients in our series who died during the follow up period one had poor contraction in left ventricular segments other than the aneurysm and the other had triple vessel disease not suitable for aortocoronary bypass surgery.

Role of surgery

Many authors have reported on the beneficial role of aneurysmectomy in the control of ventricular tachyarrhythmias. Sixty per cent of our patients were less symptomatic after surgery. By removing the saccular aneurysm myocardial efficiency is improved thereby increasing cardiac reserve and reducing symptomatic episodes of tachyarrhythmias. However our study has shown that aneurysmectomy does not totally abolish serious ventricular tachyarrhythmias. Ricks and colleagues have also shown frequent

Table 1 Preoperative clinical and hemodynamic status

Age at operation	Clinical status			Hemodynamic status				
	Type of arrhythmia	Symptoms during arrhythmia	Symptoms between episodes	Ventriculographic findings			Coronary artery	
				Aneurysm site	Aneurysm size	Remaining myocardium	No of vessels with stenosis $\geq 50\%$	Rest LVF ¹ (mm Hg)
1 41 M	Ventricular fibrillation	Cardiac arrest	Dyspnea Class II	Anterolateral	Large	Good	1	11
2 53 F	Ventricular tachycardia	Dizziness and palpitation	Dyspnea Class I	Anterolateral diaphragmatic	Large	Fair	1	12
3 60 M	Ventricular tachycardia	Dizziness and palpitation	Asymptomatic	Anterolateral diaphragmatic	Large	Good	1	9
4 56 M	Ventricular tachycardia	Palpitation dyspnea angina hypotension	Asymptomatic	Anterolateral	Large	Fair	3	20
5 58 M	Supraventricular and ventricular tachycardia	Angina	Angina Class II	Posterobasal	Moderate	Good	3	8
6 69 M	Ventricular fibrillation	Cardiac arrest	CH ₂ embolism	Anterolateral	Large	Poor	1	31
	Ventricular tachycardia	Syncope		Distal-septal				
7 26 M	Ventricular tachycardia	Palpitation angina	Asymptomatic	Anterolateral	Moderate	Good	0	6
8 46 M	Ventricular tachycardia	Dizziness palpitation	Asymptomatic	Anterolateral	Large	Good	3	78
9 58 M	Ventricular tachycardia	Palpitation angina	Angina Class II	Anterolateral	Moderate	Good	2	10
10 64 M	Ventricular tachycardia	Dizziness angina	Dyspnea Class II	Anterolateral	Large	Poor	2	30
				Distal-septal				

New York Heart Association functional classification

Abbreviations: LVF₁ left ventricular end diastolic pressure; F female; M male

alents (mets) increasing by one met increments every 2 minutes. During exercise and for 5 to 10 minutes thereafter Leads CM and CM₄ were continuously monitored on an oscilloscope and recorded each minute or more often if an arrhythmia was noted. The indications for stopping the test are shown in Table II.

Ambulatory electrocardiographic monitoring was done with a portable Avionic Electrocardio recorder model 425 with standard disposable silver-silver chloride electrodes employing a modified Lead V₁ and V configuration. Each patient kept a diary to record events. Analysis of the recordings were done using an Avionic Dynamic Electrocardioscanner model 660 A in a semiauto-

mated manner as described by Lown and associates.¹ The electrocardioscanner has a high speed playback analyzer running at 60 or 120 times real time and a low speed paper recorder. Audiovisual techniques using an R wave triggered oscilloscopic display and an electrocardiographic coupled sound system enabled detection of ventricular events. At the same time normal heart beats and ventricular extrasystoles were automatically counted on a digital computer and were charted hourly. Focality of the ventricular extrasystoles were noted as well as the presence of couplets or runs of ventricular tachycardia. All ventricular events were rerun at real time speed to verify their nature and number. All tapes were

excessive stretch and mechanical trauma to the His Purkinje system. The marginal zone of most aneurysms is a mixture of healthy tissue and scar and is not totally resected using current surgical techniques. If the unstable site was located in the marginal zone of the aneurysm it would explain the persistence of ventricular arrhythmias postoperatively. Epicardial mapping and preoperative electrophysiologic studies may become useful techniques in localizing the arrhythmogenic segment(s).

Since complex arrhythmias persist following aneurysm resection the presence of these arrhythmias preoperatively in an asymptomatic or mildly symptomatic patient should not be an indication for surgery. The operative mortality rate for aneurysmectomy in several series is reported to be 10 to 20 per cent and there are no data presently available which show that aneurysm resection prolongs life in asymptomatic or mildly symptomatic patients. For these reasons aneurysmectomy to control ventricular arrhythmias should be reserved for patients whose symptoms cannot be controlled by antiarrhythmic medication. Our results show that all patients who have a ventricular aneurysm resection for ventricular ectopy should have dynamic monitoring postoperatively. The presence of complex arrhythmias following aneurysmectomy is an indication for vigorous antiarrhythmic therapy.

Summary

The success of aneurysmectomy in abolishing recurrent ventricular tachycardia or ventricular fibrillation has not been clearly defined. Ten patients who underwent aneurysm resection to control ventricular arrhythmias were studied before and an average of 19 (4 to 42) months following operation. All patients had moderate to large aneurysms and four had atherosclerosis in adjacent segments. Of four patients with significant stenosis in vessels not supplying the aneurysm three had aortocoronary bypass grafts in addition to their resection. Ambulatory Holter monitoring and 12 graded exercise tests were performed in all patients postoperatively.

There was no operative mortality. Two patients who did not have associated revascularization procedures died suddenly 15 and 7 months postoperatively. Of the eight survivors despite clinical improvement the Holter ECG revealed runs of ventricular tachycardia in three

patients and frequent multifocal ventricular extrasystoles in the other five patients. No correlation was found between recurrence of the ventricular arrhythmias and aneurysm size, contraction pattern of other myocardial segments, extent of coronary disease or the presence of congestive heart failure.

In conclusion aneurysmectomy does not abolish ventricular tachyarrhythmias and probably should be reserved for patients who remain symptomatic despite an adequate medical trial. The persistence of complex arrhythmias following operation warrants a close follow up in these patients.

REFERENCES

- 1 Wasserman F and Jules J. Cardiac aneurysm with ventricular tachycardia. Case report and brief review of the literature. *Ann Intern Med* 39:448 1953.
- 2 Couch O A Jr. Cardiac aneurysm with ventricular tachycardia and subsequent excision of aneurysm. Case report. *Circulation* 20:91 1959.
- 3 Dubnow M H, Burchell H B and Titus J L. Post-infarction ventricular aneurysm. A clinicomorphologic and electrocardiographic study of 80 cases. *Am Heart J* 70:153 1965.
- 4 Rochemaurio J, Humbert J and Lenègre J. Evolution des anévrysmes ventriculaires après infarctus du myocarde. *Arch Mal Coeur* 59:1849 1966.
- 5 Mouriquand A, Olsen E, Raphael M J et al. Clinical diagnosis and prognosis of ventricular aneurysm. *Br Heart J* 30:44 1968.
- 6 Bouvain J, Slama R, Motte G et al. Les tachycardies ventriculaires. Etologie et évolution. *Arch Mal Coeur* 61:909 1968.
- 7 Favaloro R C, Filler D B, Cronin L K et al. Ventricular aneurysm: clinical experience. *Ann Thorac Surg* 8:277 1963.
- 8 Hunt D, Sloman C and Westlake C. Ventricular aneurysmectomy for recurrent tachycardia. *Br Heart J* 31:764 1969.
- 9 Kremer H, Chafant C, Ponlok R et al. Tachycardie ventriculaire récurrente guérie par résection d'un anévrysme pariétal du ventricule gauche. *Acta Cardiol* 24:233 1969.
- 10 Rutter F R. Intractable ventricular tachycardia due to ventricular aneurysm with surgical cure. *Ann Intern Med* 71:115 1969.
- 11 Froment R and Champaur G. Dix sept ans d'évolution d'un anévrysme traumatique du ventricule gauche. *Arch Mal Coeur* 64:180 1971.
- 12 Schlesinger Z, Lieberman Y and Neufeld H N. Ventricular aneurysmectomy for severe rhythm disturbances. *J Thorac Cardiovasc Surg* 61:607 1971.
- 13 Thind C S, Blakemore W S and Zinscr H F. Ventricular aneurysmectomy for the treatment of recurrent ventricular tachyarrhythmias. *Am J Cardiol* 27:690 1971.
- 14 Jull R J, Dunn B E, Gregoratos G et al. Ventricular aneurysm due to card resection with surgical cure of refractory ventricular tachycardia. *Am J Cardiol* 30:282 1972.
- 15 Bista L, Takeshita A, Thelen H O et al. Aneurysmectomy in the treatment of ventricular and supraventricular tachyarrhythmias in patients with post-infarction

Table II Follow up of surviving patients

Pt no	Clinical aspects				Holter monitoring		Multistage bicycle ergometric test			
	Time of post op follow up	Symptoms	Medication at time of follow up	Resting ECG	Total no of HB	Ventricular arrhythmias	Indication for stopping	Peak HR	ST depression ≥ 1 mm	Ventricular arrhythmias
1	42 mos	Palpitations	Quinidine bisulfate 400 mg/d	No arrhythmias	99394	168 multifocal PVBs 1 couplet in 21 h	Dyspnea	130 (78% of MPHR)	Absent	Multifocal PVBs > 1/10 HB with effort
2	40 mos	Palpitations and orthopnea	Digoxin 0.25 mg/d Furosemide 40 mg/d	No arrhythmias	99367	112 multifocal PVBs 1 ventricular tachycardia in 23 h	Angina	130 (80% of MPHR)	Present	None
7	28 mos	Palpitations	None	Unifocal PVBs < 1/10 HB	133353	2000 multifocal PVBs > 10 couplets in 23 h	End point	142 (90% of MPHR)	Absent	Unifocal PVBs < 1/10 HB no effort with effort
4	24 mos	Dizziness, dyspnea Class II orthopnea	Digoxin 0.25 mg/d Furosemide 40 mg/d	Multifocal PVBs > 1/10 HB	101488	4700 multifocal PVBs in 22 h	Exhaustion	140 (80% of MPHR)	Absent	Multifocal PVBs < 1/10 HB no effort with effort
5	21 mos	Palpitations and angina Class II dizziness	Digoxin 0.25 mg/d Furosemide 60 mg/d Propranolol 60 mg/d	Multifocal PVBs < 1/10 HB	103982	4800 multifocal PVBs > 10 couplets 1 ventricular tachycardia in 23 h	Angina	120 (70% of MPHR)	Present	Multifocal PVBs > 1/10 HB couplets with effort
7	12 mos	Palpitations	None	No arrhythmias	129417	153 multifocal PVBs in 24 h	End point	190 (90% of MPHR)	Absent	None
9	15 mos	Angina at rest syncope palpitations orthopnea	None	No arrhythmias	129792	69 multifocal PVBs 1 ventricular tachycardia in 23 h	End point	148 (90% of MPHR)	Absent	None
10	4 mos	Asymptomatic	None	No arrhythmias	127421	300 multifocal PVBs in 24 h	End point	142 (90% of MPHR)	Absent	None

NYHA functional classification

HB = heart beats; MPHR = maximal predicted heart rate; PVBs = premature ventricular beats

ventricular irritability in eight of 12 patients following aneurysm resection performed to abolish ventricular arrhythmias. The focus of irritability following aneurysm formation could be caused by reentrant arrhythmias arising from

decreased velocity of conduction through scar tissue; variable refractory periods of ischemic and non ischemic tissue; non uniform repolarization of tissue bordering the aneurysm; and/or enhanced automaticity caused by ischemia

Coronary ectasia Incidence and results of coronary bypass surgery

Agop Aintablian MD
Robert I Hamby MD
Irwin Hoffman MD
Robert J Kramer MD
New York Park and Stony Brook N Y

Localized or diffuse coronary artery dilatation with or without coronary artery stenosis has been called aneurysm by some authors¹ and ectasia by others.² Most of these coronary abnormalities have been considered atherosclerotic and/or congenital³ in origin. Others have been attributed to bacterial infection,⁴ syphilis,⁵ septic embolism,⁶ trauma,⁷ dissection,⁸ or have been described in association with polyarteritis nodosa,⁹ scleroderma,¹⁰ Ehlers Danlos syndrome,¹¹ Takayasu's arteriopathy,¹² Marfan's syndrome,¹³ and metastatic tumor.¹⁴ After the first autopsy reports of coronary dilatation by Morgagni in 1761¹⁵ and by Gougon in 1812,¹⁶ approximately 164 more cases of coronary aneurysm have appeared in the literature. The antemortem diagnosis of coronary aneurysm has been reported in only 9¹⁷ patients, and of those 36 have undergone resection of the aneurysm or saphenous vein bypass surgery.¹⁸ In one reported series,¹⁹ the short term prognosis of coronary ectasia was observed to be poor with a yearly mortality rate of 15 per cent.

In order to evaluate the significance of coronary ectasia and the result of saphenous vein bypass graft in this group we reviewed our experience

in 42 patients with coronary ectasia of whom 30 underwent bypass grafting.

Material and methods

Between January 1974 and December 1976 1 660 patients underwent coronary angiography for chest pain or shortness of breath at the Long Island Jewish Hillside Medical Center. In all patients right and left cardiac catheterization and selective coronary angiography was performed either by the Judkins or Sones techniques using the General Electric image intensification system recorded on 35 mm film at 60 frames/sec. In quantitating left ventricular dysfunction and the pattern of left ventricular contraction the same techniques and principles were used as previously reported,²⁰ utilizing the descriptive terminology suggested by Herman and associates.²¹ Coronary arteries with at least 50 per cent reduction in diameter were considered significantly stenosed and were bypassed whenever feasible in patients with exertional or resting angina pectoris. No patients with coronary ectasia underwent coronary bypass surgery unless one or more of their coronary arteries demonstrated at least 50 per cent reduction in diameter. The severity and extent of coronary disease were graded according to the criteria of Bruschke and associates.²² Post bypass recatheterization and angiography were done 10 to 15 days after surgery in order to assess the patency of the grafts and any change in left ventricular function. The electrocardiographic criteria for the diagnosis of myocardial infarction were those of Class 1 and 2 of the Minnesota code reported by Blackburn and associates.²³ All

From the Department of Medicine, Division of Cardiology, Long Island Jewish Hillside Medical Center, New York 11414, N.Y. and Department of Medicine, School of Medicine, H. Lehman College, State University of New York, 64-100 Queens Blvd., Flushing, N.Y.

Received for publication Aug 16, 1977

Revised for publication Oct 20, 1977

Reprint requests: Agop Aintablian, MD, Division of Cardiology, Long Island Jewish Hillside Medical Center, New York Park and Stony Brook, N.Y.

- and traumatic aneurysm *Am J Cardiol* 32:693 1973
- 16 Loop F D Aneurysm of the left ventricle Survival and results of a ten year surgical experience *Ann Surg* 178:389 1973
- 17 Heitz A Campeau L and Saltiel J Anévrisme et asynnergie ventriculaire opérés Aspect clinique Electro cardiographique et radiologique *Coeur Med Interne* 14:487 1976
- 18 Lown B Calvert A F Armstrong R et al Monitoring for serious arrhythmias and high risk of sudden death *Circulation* 51 and 52(Suppl III):III 149 1975
- 19 Chessler F Dubb A and Oulim L Ventricular tachycardia due to subvalvular left ventricular aneurysm *S Afr Med J* 41:518 1967
- 20 Heitz A Campeau L and Grondin P Anévrismes et asynnergies ventriculaires opérés Aspect évolutif *Coeur Med Interne* 15:13 1976
- 21 Ricks W B Winkle R A Shumway N F, et al Surgical management of life threatening ventricular arrhythmias in patients with coronary artery disease *Circulation* 56:38 1977
- 22 Durrer D Van Lier A A W and Buller J Epicardial and intramural excitation in chronic myocardial infarction *Am Heart J* 70:765 1964
- 23 Mandell W J Burgess M J Nevill J et al Analysis of T wave abnormalities associated with myocardial infarction using a theoretic model *Circulation* 38:5 1968
- 24 Moe A K on the multiple wavelet hypothesis of atrial fibrillation *Arch Intern Pharmacodyn* 140:183 1967
- 25 De Sanctis R W Block P and Hutter A M Jr Tachyarrhythmias in myocardial infarction *Circulation* 45:681 1972
- 26 Humbert J Rochemaure J and Lenègre J Les lésions anatomiques dans 100 anévrismes ventriculaires après infarctus du myocarde *Arch Mal Coeur* 8:170 1966

Information for authors

Most of the provisions of the Copyright Act of 1976 became effective on January 1 1978. Therefore all manuscripts must be accompanied by the following statement signed by each author: The undersigned author(s) transfers all copyright ownership of the manuscript entitled (title of article) to The C V Mosby Company in the event the work is published. The author(s) warrants that the article is original is not under consideration by another journal, and has not been previously published. Authors will be consulted when possible regarding republication of their material.

Among the 1 660 patients 42 (2.5 per cent) had coronary ectasia. Twenty-five patients were over age 50 and 17 under 50. This study did not include patients with coronary aneurysmal dilatation secondary to coronary arteriovenous fistulae or fistulae between coronary arteries and cardiac chambers. The 42 patients with coronary ectasia were matched for age and sex with a control group also referred for symptomatic coronary artery disease. Thirty patients with coronary ectasia and 27 patients in the control group underwent aortocoronary bypass surgery. Postoperatively angiograms were performed in 19 patients in the ectasia group and in 17 controls.

Results

Of 42 patients with coronary ectasia 25 had resting angina, 16 exertional angina and two young patients were asymptomatic and had coronary angiography because of strongly positive stress tests after recent myocardial infarction. There was no significant difference (Table I) between the clinical profile when ectasia and control groups were compared. Comparison between the groups for the number of vessels involved, the frequency of left main coronary artery disease and segmental abnormal wall motion revealed no differences (Table I). The mean serum cholesterol level was 240 ± 75 and 250 ± 45 mg/100 ml in the ectasia and control groups respectively, while the triglyceride level was 224 ± 106 in the ectasia and 170 ± 68 mg/100 ml in the control group ($p < 0.025$). Three patients with ectasia had significant aortic valvular disease (two aortic insufficiency and one aortic stenosis). Coronary calcification was equally distributed in patients with (70 per cent) or without (80 per cent) ectasia.

Of 64 ectatic vessels in 42 patients 34 (53 per cent) occurred in the right coronary, 16 (25 per cent) in the left anterior descending artery and 14 (22 per cent) in the circumflex artery (Table II). Only 39 of 64 (61 per cent) ectatic coronary arteries had luminal narrowing exceeding 50 per cent. In affected vessels diffuse ectasia was noted in 35 per cent of right, 71 per cent of circumflex and 50 per cent of left anterior descending arteries. Type III ectasia was noted mostly in the right coronary artery (Table II).

Coronary bypass surgery and post surgical follow up. Saphenous vein bypass surgery was performed in 30 patients with coronary ectasia and in 27 controls. Two weeks post bypass angio-

TYPE III



Fig 3 Type III ectasia. In a patient with severe triple vessel coronary disease only right coronary artery was diffusely ectatic and had significant stenosis of the vessel at the level of the crux (arrow).

grams were performed in 19 of 30 (63 per cent) patients with ectasia and in 17 of 27 (63 per cent) control patients. Of the 46 bypass grafts studied postoperatively in the ectasia group two (4 per cent) were closed while five of 41 (12 per cent) were closed in the non ectasia control group. There were no deaths in any surgical patients with or without ectasia. In two patients of each group new Q waves developed postoperatively, and three patients of the ectasia group and two controls had recurrent angina pectoris after bypass. Of 12 patients with ectasia who did not have surgery three had coronary stenosis less than 50 per cent, five were not considered candidates for surgery because of diffuse double or triple vessel involvement while the remaining four had single vessel disease. In the non operated controls four patients had coronary stenosis less than 50 per cent, four had isolated single vessel disease and of the remaining seven patients two refused surgery while five had diffuse coronary disease judged not amenable to bypass surgery. One of the patients with a 60 to 90 per cent stenosis of an ectatic right coronary artery (Fig 3) developed inferior wall infarction one year after his initial angiogram but subsequently underwent double vessel bypass surgery for progressive angina.

In a mean follow up period of 18 months no deaths occurred in the ectasia group while one

TYPE I




Fig 1 Type I ectasia coronary angiogram of a patient with diffuse ectasia of right (A) and circumflex artery (B) with localized ectasia and significant proximal stenosis of the left anterior descending artery (B)

TYPE II




Fig 2 Type II ectasia coronary angiogram of 32 year old male performed in 1974 showing diffuse ectasia and significant narrowing (arrow) of the right coronary artery (A) with localized ectasia of circumflex artery (arrow in B) A year after this study he sustained a transmural inferior wall infarction Two years later repeat coronary angiogram showed progression of disease not only on the right coronary (arrow in D) but also on main left (white arrow in E) and left anterior descending arteries (upper black arrows in E)

the angiograms were reviewed by two cardiologists (A A and R I H) and coronary ectasia was diagnosed In this study localized or diffuse dilatation of a coronary artery is designated as ectasia rather than aneurysm since most of our patients had associated coronary stenosis while none had a past history suggestive of polyarteritis nodosa trauma or penetrating chest wounds Coronary ectasia was defined as a localized or

diffuse coronary dilatation at least one and one half times the diameter of the patient's largest vessel Ectasia was classified according to the criteria of Marks and colleagues ' Type I (Fig 1) consisted of diffuse ectasia of two or three vessels Type II (Fig 2) diffuse ectasia of one and localized ectasia of another Type III (Fig 3) diffuse ectasia of only one vessel Type IV (Fig 4) localized or segmental ectasia of one vessel

Table I Clinical profile and extent of coronary disease

	Coronary ectasia	Control group
Patients (No)	4 ^a	4 ^a
Hypertension	10	1 ^a
Abnormal glucose tolerance	18	20
Family history		
Coronary artery disease	26	29
Hypertension	14	20
Diabetes	13	8
Electrocardiogram		
Normal	19	21
Inferior infarction	13	13
Anterior infarction	8	7
Left ventricular hypertrophy	4	1
Number of vessels involved		
Single	11	10
Double	11	12
Triple	16	18
Main left	3	4
< 50% Stenosis	4	2
Left ventricular wall motion		
Normal	13	10
Abnormal		
One wall	21	22
Two walls	8	10

and colleagues¹³ both considered hypertension to be an important factor in the pathogenesis of this entity but could not explain why other patients with hypertension did not develop ectatic coronaries. Microscopic examination of the ectatic vessels revealed massive destruction of the muscular elements of the media at times with inflammatory reaction and focal calcium deposits as well as subintimal fibrosis with deposition of lipid material. It is conceivable that the primary abnormality in these patients is a congenital abnormality of the arterial wall with superimposed metabolic derangement. The higher serum triglyceride levels noted in these patients may play a role in the genesis of the lesions. In our series the presence of transmural myocardial infarction in the electrocardiogram was just as frequent in patients with (50 per cent) or without (48 per cent) ectasia whereas in the Marks and colleagues series (14) patients with ectasia had a higher incidence of electrocardiographic evidence of transmural infarction (80 per cent) than did controls (46 per cent). Unlike Marks and colleagues we found no difference in the family history of coronary artery disease in

Table II Type and extent of coronary ectasia

	Total	Type I	Type II	Type III	Type IV
Number	42	9	8	14	11
Ectasia { RCA	34	■	7	13	5
LAD	16	7	6	■	3
CX	14	7	3	1	3
Valve surgery	3	■	0	0	3
Bypass surgery (pts)	30	7	4	■	10
Grafts placed	67	16	7	18	16
Grafts studied	47	14	■	15	12
Closed grafts	2	1	0	1	0
Deaths	0	0	0	0	0
Postop new Q waves	2	1	0	1	0

Abbreviations: RCA = right coronary artery; LAD = left anterior descending artery; CX = left circumflex artery.

patients with or without ectasia (Table I). In the ectasia group four patients met electrocardiographic criteria for left ventricular hypertrophy compared to only one in the control group. However in three of these four patients the electrocardiographic changes were due to severe aortic valvular disease requiring surgery (one rheumatic and the other two tricuspid calcific valves). The only difference between the patients with or without coronary ectasia was a higher mean serum triglyceride level in the ectasia group.

The causes of death in previously reported patients with coronary ectasia has been rupture of an abdominal aneurysm⁴ or thrombosis or rupture of a coronary aneurysm.^{10,11} Myocardial infarction was attributed to thrombosis in the aneurysm or embolization of thrombus from the aneurysmal sac to the distal coronary artery.^{1,2}

Since the first report of bypass surgery in a patient with coronary aneurysm or ectasia 34 more cases have been reported in the literature with four deaths.^{12,20,21,22} None of our 42 patients with coronary ectasia who did or did not undergo coronary bypass surgery died in a mean follow up period of 18 months. One patient in the control group died while waiting at home for triple bypass surgery. These results are different from those of Marks and colleagues¹ who reported a 15 per cent yearly mortality rate in a mean follow up period of 24 months in 20 patients with coronary ectasia treated medically. In the surgically treated group with coronary ectasia the incidence of postoperative new Q waves early

TYPE IV




Fig 4 Type IV ectasia. Here are shown left coronary angiograms of three different patients with localized ectasia of proximal portion of left anterior descending artery (white arrow in A and black arrows in B and D) with significant narrowings distal to the ectasia (white arrows in B and D). In the fourth patient (C) the localized ectasia is located at the level of the crux (lower arrow) with slight narrowing of the proximal right coronary artery (upper arrow).

control patient died while waiting at home for elective bypass surgery.

Discussion

In 1929 Packard and Wechsler¹ reviewed the literature on 22 autopsy cases of fusiform or saccular coronary aneurysm and added their own case of ruptured left coronary aneurysm. According to them, most of these aneurysms were of mycotic embolic or arteriosclerotic origin. Scott reviewed 46 reported cases and added one of his own. Of those, only 34 per cent of coronary ectasias occurred in the right coronary artery, whereas 64 per cent involved the left coronary system. Most of these coronary aneurysms were considered of congenital or mycotic embolic origin. Davoud and colleagues⁴ in 1963 compiled 79 cases of coronary ectasia and added 10 cases collected from 694 (1.5 per cent) autopsies over a

2½ year period. In their 10 cases, 66 per cent of ectasias were noted in the right coronary and 34 per cent in the left coronary system. In our series, the overall incidence of coronary ectasia was 2.5 per cent and occurred twice as often in the right coronary artery (53 per cent) than in the left anterior descending (25 per cent) or circumflex arteries (22 per cent).

In the series of Davoud and colleagues, six of 10 patients had a history of hypertension and eight died as a result of abdominal aneurysms. Markis and associates¹⁴ as well as Befeler and co-workers¹⁵ also noted a high incidence of a history of hypertension in patients with coronary ectasia. In our series, the incidence of hypertension was the same in patients with or without ectasia (Table I) and those with ectasia did not have obvious clinical signs or symptoms of abdominal aneurysm. Markis and associates¹⁴ and Duran¹⁶

- 25 Morgagni, J B De sedibus et causis morborum per anatomen indagatus Tomus primus Liber II Epist 27 Article 78 Venetis 1761
- 6 Bougon M *Biblioth Med* 37 183 1819
- 27 Schneider K W Jesse R and Deeg F Arteriosclerotic coronary arterial aneurysms in a 49 year old man with crescendo angina Family History natural course and prevalence *Angiology* 28 52 1977
- 28 Berkoff H A and Rowe G G Atherosclerotic ulcerative disease and associated aneurysms of the coronary arteries *Am HEART J* 90 153 1975
- 29 Wilson C S Weaver W F and Forker A D Bilateral arteriosclerotic coronary artery aneurysms successfully treated with saphenous vein bypass grafting *Am J Cardiol* 35 315 1975
- 30 Falsetti H L and Carroll H J Coronary artery aneurysms A review of the literature with a report of 11 new cases *Chest* 51 630 19 6
- 31 Befeler H Arende J A Embi A Mullin F L El Sherif N and Lazzare R Coronary artery aneurysms—study of their etiology—clinical course and effect of left ventricular function and prognosis *Am J Med* 62 587 1977
- 32 Matten A L Baker M P McHale J J and Lee D E Congenital coronary aneurysms with angina pectoris and myocardial infarction treated with saphenous vein bypass graft *Am J Cardiol* 30 906 1972
- 33 McMartin D E Stone A J and Franch R H Multiple coronary artery aneurysms in a child with angina pectoris *N Engl J Med* 290 669 19 4
- 34 Bjork V O and Bjork L Intramural coronary artery aneurysm a coronary artery steal syndrome *J Thorac Cardiovasc Surg* 54 50 1967
- 35 Ebert P A Peter R H Gunnells J C et al Resection and grafting of coronary artery aneurysm *Circulation* 43 593 1971
- 36 Grahramani A Iyenger R Cunha D et al Myocardial infarction due to congenital coronary arterial aneurysm (with successful saphenous vein bypass graft) *Am J Cardiol* 29 863 1972
- 37 Hamby R I Tabrah F Amtablian A Hartstein M L and Wisoff H G Left ventricular hemodynamics and contractile pattern after coronary bypass surgery Factors affecting reversibility of abnormal left ventricular function *Am HEART J* 88 149 19 4
- 38 Herman M V Heinle R A Klein M D and Gorlin R Localized disorders in myocardial contraction Asynergy and its role in congestive heart failure *N Engl J Med* 277 22 1967
- 39 Bruschke A V G The diagnostic significance of the coronary arteriogram A study of its value in relation to other diagnostic methods Utrecht and New York 19 0 Kreminsk en Zoon
- 40 Blackburn H Keys A Sumson E et al The electrocardiogram in population studies classification system *Circulation* 21 1160 1960
- 41 Flachta A and Speer F D Aneurysm of the left coronary artery Review of the literature and report of three cases *Arch Pathol (Chicago)* 66 210 1958

closure of bypass grafts and recurrence of angina pectoris was not different from controls

In conclusion coronary ectasia is more common in the right coronary artery, and is mostly of the diffuse type. The presence of coronary ectasia does not indicate unusually severe or widespread coronary disease and that short term follow up of patients with coronary ectasia with or without bypass surgery, does not differ from control patients

Summary

Coronary angiograms were performed in 1,660 patients between the ages of 27 and 84 years. Coronary ectasia was noted in 42 (2.5 per cent) patients. These 42 patients were compared with an equal number of patients with coronary artery disease matched for age and sex. There were no significant differences in numbers of vessels involved with significant disease, coronary score, main left or left anterior descending artery disease, coronary calcification, hypertension or abnormal glucose tolerance test in patients with or without ectasia. A family history of coronary artery disease, diabetes mellitus, and hypertension did not separate the groups; neither did serum cholesterol level. The serum level of triglyceride was higher in the coronary ectasia group ($p < 0.025$). The location of infarction by electrocardiogram or abnormal left ventricular contractility was similar in both groups. Of 64 ectatic vessels, 34 (53 per cent) occurred in the right coronary, 16 (25 per cent) in the left anterior descending and 14 (22 per cent) in the left circumflex artery. Thirty patients with ectasia and 26 in the control group underwent bypass surgery. Nineteen of the ectasia group and 17 of the control group had post bypass graft angiograms. In the ectasia group, two out of 47 and in the control group five out of 41 grafts were closed. The postoperative course was similar in both groups. An 18 month (mean) follow up of the 42 patients with coronary ectasia revealed no late deaths whereas one death occurred in a control patient who did not have surgery. In conclusion, coronary ectasia is more common in the right coronary artery. The presence of coronary ectasia does not indicate more severe or widespread coronary disease than in controls. Short term follow up of patients with ectasia with or without bypass surgery does not differ from control patients.

REFERENCES

1. Packard M and Wechsler H F. Aneurysm of the coronary arteries. *Arch Intern Med* 43:1 1979
2. Scott D H. Aneurysm of the coronary arteries. *Am Heart J* 36:403 1948
3. Crocker H W, Sobin S and Thomas W C. Aneurysms of coronary arteries: report of three cases in infants and review of the literature. *Am J Pathol* 37:819 1957
4. Davoud A S, Pankin D, Tulgan H and Florentz R. A. Aneurysms of the coronary artery: report of ten cases and review of literature. *Am J Cardiol* 11:228 1963
5. Sherkat A, Kavanagh Gray D and Edworthy J. Localized aneurysms of the coronary arteries. *Radiology* 89:24 1967
6. Ellis R and Hurth R J. Calcified coronary artery aneurysm. *JAMA* 203:51 1968
7. Chaitrathaphan S, Goldberg E, O'Reilly M and Joux P. Multiple aneurysms of coronary artery in scleroderma heart disease. *Angiology* 24:86 1973
8. Saygeh S, Adad W and McLeod C A. Multiple aneurysms of the coronary arteries. *Am Heart J* 76:266 1968
9. Kalke B and Edwards J E. Localized aneurysms of the coronary arteries. *Angiology* 19:460 1968
10. Konecke L L, Spitzer S, Mason D, Kasparian H and James P M. Traumatic aneurysm of the left coronary artery. *Am J Cardiol* 27:221 1971
11. Dawson J E Jr and Ellison R H. Isolated aneurysm of the anterior descending coronary artery: surgical treatment. *Am J Cardiol* 29:868 1972
12. Crook B R M, Rafferty E B and Oram S M. Multiple aneurysms of coronary arteries. *Br Heart J* 35:10 1973
13. Björk L. Fectasia of coronary arteries. *Radiology* 87:J 1966
14. Markus J E, Joffe D C, Cohn P F, Feen D J, Herman M V and Gorlin R. Clinical significance of coronary ectasia. *Am J Cardiol* 37:217 1976
15. Durairaj S K, Edmiston W A, Fink E, Gutman M and Haywood L J. Significance of coronary artery ectasia in ischemic heart disease. (Abstr.) *Clin Res* 25:88A 1977
16. Frithz G, Cullhed I and Björk L. Congenital localized coronary artery aneurysm without fistula. Report of a preoperatively diagnosed case. *Am Heart J* 78:64 1968
17. Wenger M H. Rare causes of coronary artery disease. In Hurst J W and Logue R B. *editors The heart*. New York, 1970. McGraw Hill Book Company, Inc. p 1041
18. McKoeown F. Dissecting aneurysm of the coronary artery in arachnodactyly. *Br Heart J* 22:434 1960
19. Sinclair M Jr and Nitsch E. Polyarteritis nodosa of the coronary arteries—report of a case in an infant with rupture of an aneurysm and intrapericardial hemorrhage. *Am Heart J* 38:893 1949
20. Roberts F B and Fetterman G H. Polyarteritis nodosa in infancy. *J Pediatr* 63:519 1963
21. Benjo N B, Perrin E V. Periarthritis nodosa in infancy. *Am J Dis Child* 116:539 1968
22. Tang P H I and Segal A J. Polyarteritis nodosa of infancy. Fatal late complication. *JAMA* 217:1666 1970
23. Chamberlain J L and Ferry L W. Infantile periarthritis nodosa with coronary and brachial aneurysms. A case diagnosed during life. *J Pediatr* 78:1039 1971
24. Shiro Imahori, Bannerman R M, Graf C J and Brennan J C. Ehlers Danlos syndrome with multiple arterial lesions. *Am J Med* 47:967 1969

Table II Antegrade refractory period data

Pt no	CL	ERP of Atrium		ERP of A V node		FRP of A V node		RRP Ab of HPS		RRP HV of HPS		ERP of HPS		FRP of HPS		Gap in A V conduction	
		Con	30 min	Con	30 min	Con	30 min	Con	30 min	Con	30 min	Con	30 min	Con	30 min	Con	30 min
1	800	270	III	—	—	350	310	425	425	445	445	410	390	450	440	—	—
	700	2 0	2 0	—	—	355	345	400	410	440	415	385	395	415	470	—	—
	600	280	260	—	—	340	345	375	375	500	500	490	490	505	500	—	—
2	900	350	320	—	—	460	425	—	—	500	500	490	490	505	500	—	—
	800	330	320	—	—	4 5	470	—	—	490	490	485	485	490	490	—	—
3	100	240	250	—	—	355	340	420	415	4 0	415	365	365	425	410	Types I & II	Type I
	650	250	230	—	—	340	340	400	395	400	395	355	350	395	400	Type I	—
4	800	280	210	—	—	395	380	510	510	4 0	4 0	430	440	475	480	—	—
	700	280	< 310	—	—	365	355	420	415	390	370	380	360	390	390	—	—
6	800	260	260	—	—	335	3 0	430	445	430	445	380	415	435	450	—	—
	700	2 0	250	—	—	360	360	410	410	410	410	380	380	415	4 0	—	—
7	1000	2 0	290	—	—	380	3 0	440	440	445	445	420	420	465	475	—	—
	800	240	300	—	—	370	360	415	415	420	415	400	400	430	430	—	—
8	700	250	310	—	—	3 0	350	—	—	400	410	380	380	405	410	Types I & II	Types I & II
	700	230	240	—	—	375	355	—	—	440	—	435	440	445	445	Type II	Type II
9	600	230	250	—	—	345	340	—	—	410	395	405	390	405	405	—	—
	870	290	< 350	—	—	390	< 395	480	4 0	480	470	415	400	450	430	—	—
10	870	300	290	—	—	390	380	435	430	435	430	395	395	430	430	—	—
	800	230	250	—	—	405	405	445	445	430	430	405	470	430	430	Type I	Type I
11	100	290	280	—	—	380	370	460	460	460	460	435	440	455	475	Type I & II	Type II
	900	270	210	—	—	390	395	—	—	460	450	410	425	460	460	Type I	Type I
13	800	240	250	280	300	385	390	—	—	440	440	395	400	435	450	Type I	Type I
	III	240	270	340	320	405	390	440	440	440	440	430	430	445	450	None	Type I
14	5 0	220	220	—	—	305	310	355	355	355	355	31	315	340	335	Type II	Type II

All measurements in milliseconds

Abbreviations: CL = cycle length; HPS = His Purkinje system; AVN = atrioventricular node; ERP = effective refractory period; FRP = functional refractory period; RRP Ab = relative refractory period of HPS determined by QRS aberration; RRP HV = relative refractory period of HPS determined by HV prolongation

rogram, as well as electrocardiographic Leads I II III V and time lines generated at 10 and 100 msec were simultaneously displayed on a multi channel oscilloscope and relayed to a magnetic tape recorder. Records were later reproduced at a paper speed of 150 mm/sec. Careful attention was paid to the grounding of all equipment. Measurements of A V nodal and His Purkinje conduction times were made during sinus rhythm and at atrial paced rates up to a maximum of 200 beats/minute.

Using the atrial extrastimulus method² refractory periods of the atrium, A V node, and HPS were determined at one or more paced cycle lengths in each patient.

Effective refractory period of HPS could be determined in 22 out of 24 consecutive patients in whom antegrade refractory periods were performed. In 14 out of 22 patients repeat studies

were performed at comparable cycle lengths after a period of 30 minutes.

In no patient were the characteristics of the delivered stimuli changed during the course of the study. An intravenous line was started with 5 per cent dextrose in all patients at the beginning of the study to stimulate drug studies. Blood pressure determinations were made at the beginning of the study and at the completion of the 30 minute studies. Statistical analyses were performed using the Student's paired t test.

Definition of terms

A H interval was measured from the onset of low atrial electrogram to the onset of His bundle deflection and was taken as an approximation of A V nodal conduction time (normal values for our lab are 60 to 140 msec).

H V interval representing His Purkinje con

Study of the temporal effects on conduction and refractoriness of the His-Purkinje system in man

C Pratap Reddy MD*
 Anthony N Damato, MD
 Masood Akhtar, MD
 Malkiat S Dhatt MD
 Joseph A Gomes, MD
 James R Foster, MD
 Staten Island NY

The effect of time on refractoriness of the atrium and atrioventricular node have been previously described.¹ However, insufficient data are available concerning temporal effects on refractoriness within the His Purkinje System (HPS). Such data are essential in evaluating those antiarrhythmic agents whose primary effect is on the HPS. The present report concerns observations made in a prospective study on temporal effects on the relative refractory period (RRP), effective refractory period (ERP), and functional refractory period (FRP) in a group of 14 patients over a 30 minute period.

Methods

Electrophysiological studies were performed in the postabsorptive nonsedated state. The nature of the study was explained and a signed consent was obtained. No patient was receiving cardioactive drugs at the time of study. Bundle of His electrograms were recorded as previously described using a tri- or quadripolar electrode catheter introduced percutaneously into the right femoral vein and fluoroscopically positioned in the region of the tricuspid valve.² A No. 7 quadripolar catheter was introduced into the antecubital vein and advanced to the high right atrium near its junction with the superior vena cava. The distal pair of electrodes were used to stimulate the atrium and the proximal pair to record high right atrial electrogram. In addition, in some patients, a No. 6 quadripolar electrode catheter was positioned at the right ventricular apex for ventricular stimulation and recording of local ventricular activity. Atrial stimulation was performed using a programmed digital stimulator which delivered rectangular impulses of 1.5 msec duration at a minimum milliamperage which allowed reliable atrial capture. Intra-cardiac elec-

Table 1 Clinical data

Pt no	Age	Sex	Clinical diagnosis	ECG diagnosis
1	40	M	NHD	Normal
2	68	M	ASHD	RBBB LAD
3	29	M	NHD	VPBs LAD
4	28	M	NHD	Incomplete RBBB
5	62	M	NHD	APBs
6	41	M	NHD	Normal
7	58	M	ASHD	Sinus bradycardia
8	62	M	ASHD	RBBB LAD
9	62	M	ASHD	RBBB LAD APB
10	55	M	NHD	RBB LAD APBs
11	45	M	ASHD	LAD
12	60	M	ASHD	VPBs
13	49	M	NHD	VPBs
14	51	M	NHD	VPBs

Abbreviations: NHD no heart disease; ASHD atherosclerotic heart disease; RBBB right bundle branch block; LAD left axis deviation; VPBs ventricular premature beats; APBs atrial premature beats.

tronic stimulation was performed using a programmed digital stimulator which delivered rectangular impulses of 1.5 msec duration at a minimum milliamperage which allowed reliable atrial capture. Intra-cardiac elec-

From the Cardiopulmonary Laboratory, U.S. Public Health Service Hospital, Staten Island, NY.

This work was supported in part by the Bureau of Medical Services, National Heart, Lung, and Blood Institute, Project HL 12436-06.

Received for publication Aug. 29, 1977.

Accepted for publication Oct. 25, 1977.

Reprint requests: Anthony N. Damato, MD, United States Public Health Service Hospital, Staten Island, NY 10304.

Present address: Department of Medicine, University of Kentucky College of Medicine, Lexington, KY.

Table II Antegrade refractory period data

Patient	CL	ERP of Atrium		ERP of A V node		FRP of A V node		RRP Ab of HPS		RRP HV of HPS		ERP of HPS		FRP of HPS		Gap in A V conduction	
		Control	30 min	Control	30 min	Control	30 min	Control	30 min	Control	30 min	Control	30 min	Control	30 min	Control	30 min
1	800	240	280	—	—	350	340	425	475	445	445	410	390	450	440	—	—
	100	240	240	—	—	355	445	400	410	405	415	385	395	415	470	—	—
	600	280	260	—	—	340	445	375	315	385	390	365	360	380	395	—	—
2	900	350	320	—	—	465	425	—	—	500	500	490	490	505	500	—	—
	850	330	370	—	—	445	470	—	—	490	490	485	485	490	490	—	—
3	750	240	250	—	—	355	340	420	415	440	415	365	365	475	410	Types I & II	Type I
	650	250	230	—	—	310	340	400	395	400	395	355	350	395	400	Type I	—
4	800	280	270	—	—	395	380	510	510	470	470	430	440	470	480	—	—
5	100	280	< 310	—	—	365	355	470	415	490	340	380	360	390	390	—	—
6	800	260	260	—	—	335	370	430	445	430	445	390	415	435	450	—	—
	700	240	250	—	—	360	360	410	410	410	410	380	380	415	470	—	—
7	1000	240	290	—	—	380	370	440	440	445	445	420	470	465	475	—	—
	800	240	300	—	—	370	360	415	415	470	415	400	400	430	430	—	—
	700	250	310	—	—	370	360	—	—	400	410	380	380	405	410	—	—
8	700	230	240	—	—	375	345	—	—	440	—	435	440	445	445	Types I & II	Types I & II
	600	230	250	—	—	345	340	—	—	410	395	405	390	405	405	Type II	Type II
9	970	290	< 350	—	—	390	< 395	480	470	480	470	415	400	470	430	—	—
	870	300	290	—	—	390	380	435	430	435	430	395	390	470	430	—	—
10	600	240	250	—	—	405	405	445	445	430	430	405	470	430	430	Type I	Type I
11	50	290	260	—	—	380	370	460	460	460	460	415	440	455	475	Type I & II	Type II
12	900	270	240	—	—	380	395	—	—	450	450	410	425	460	460	Type I	Type I
	800	250	250	280	300	385	390	—	—	440	440	395	400	430	450	Type I	Type I
13	740	240	270	340	320	405	390	440	440	440	440	430	430	445	450	None	Type I
14	540	270	220	—	—	305	310	355	355	355	355	315	315	340	335	Type II	Type II

All measurements in msec.

Abbreviations: CL = cycle length; HPS = His-Purkinje system; AVN = atrioventricular node; ERP = effective refractory period; FRP = functional refractory period; RRP Ab = late refractory period of His bundle determined by QRS aberration; RRP HV = relative refractory period of HPS determined by HV prolongation.

trigrams as well as electrocardiographic Leads I II III V and time lines generated at 10 and 100 msec were simultaneously displayed on a multi channel oscilloscope and relayed to a magnetic tape recorder. Records were later reproduced at a paper speed of 150 mm/sec. Careful attention was paid to the grounding of all equipment. Measurements of A V nodal and His Purkinje conduction times were made during sinus rhythm and at atrial paced rates up to a maximum of 200 beats/minute.

Using the atrial extrastimulus method, refractory periods of the atrium, A V node, and HPS were determined at one or more paced cycle lengths in each patient.

Effective refractory period of HPS could be determined in 22 out of 254 consecutive patients in whom antegrade refractory periods were performed. In 14 out of 22 patients repeat studies

were performed at comparable cycle lengths after a period of 30 minutes.

In no patient were the characteristics of the delivered stimuli changed during the course of the study. An intravenous line was started with 5 per cent dextrose in all patients at the beginning of the study to stimulate drug studies. Blood pressure determinations were made at the beginning of the study and at the completion of the 30 minute studies. Statistical analyses were performed using the Student's paired t test.

Definition of terms

A H interval was measured from the onset of low atrial electrogram to the onset of His bundle deflection and was taken as an approximation of A V nodal conduction time (normal values for our lab are 60 to 140 msec).

H V interval representing His Purkinje con

Table III Cumulative data

Parameter	Control mean \pm SD	30 min later mean \pm SD	Change	P	Mean absolute change \pm SD
Sinus rate	71 \pm 11	72 \pm 11.5	\uparrow 1.2	NS	3.4 \pm 9.2
A H interval sinus	77 \pm 14	76 \pm 14	\uparrow 1.0	NS	1.4 \pm 9.3
H V interval sinus	48.5 \pm 6.5	48.5 \pm 6.5	—	—	—
AVN Wenckebach block (beats/min)	175 \pm 18	181 \pm 12	\uparrow 6.0	NS	9.2 \pm 11.3
FRP of atrium	264 \pm 32	265 \pm 30	\uparrow 1.0	NS	18.6 \pm 16.4
FRP of A V node	374 \pm 36	366 \pm 28	\downarrow 8.0	<0.05	19.6 \pm 11
RRI Ab of HPS	427 \pm 37	426 \pm 36	\uparrow 1.0	NS	3.7 \pm 4.6
RRP HV of HPS	431 \pm 35	430 \pm 36	\uparrow 1.0	NS	4.5 \pm 6
FRP of HPS	403 \pm 38	401 \pm 40	\downarrow 2.0	NS	7.9 \pm 9.1
FRP of HPS	432 \pm 36	434 \pm 37	\uparrow 2.0	NS	6.4 \pm 6.5

The measurements of conduction time intervals and refractory period measurements are in milliseconds

Abbreviations: A H interval = an approximation of A V nodal conduction time; H V interval = His Purkinje conduction time; ER = effective refractory period; FRP = functional refractory period; RRI Ab = relative refractory period determined by QRS aberration; RRP HV = relative refractory period determined by H V prolongation; NS = not significant at 0.05 level of confidence

\uparrow = increase

\downarrow = decrease

— represents average value of change irrespective of its direction

Table IV Conduction studies

Pt no	Sinus rhythm Control			Sinus rhythm 30 min later			Onset of AVN Wenckebach block (beats/min)	
	HR	AH	HV	HR	AH	HV	Control	30 min later
1	67	100	45	71	95	45	190	190
2	69	80	50	62	75	55	130	150
3	64	80	45	68	80	45	190	200
4	75	80	45	77	80	40	190	180
5	80	60	40	92	60	40	175	180
6	71	90	50	69	90	50	185	185
7	68	50	40	55	50	40	175	185
8	71	60	60	77	60	60	180	180
9	55	70	50	67	70	50	175	180
10	60	70	50	63	75	50	None done	
11	69	90	60	69	90	60	170	170
12	67	80	45	63	90	45	190	175
13	80	70	50	82	70	50	150	190
14	100	80	40	96	80	45	1:1 conduction up to 200	1:1 conduction up to 200

Abbreviations: HR = heart rate; AH interval = an approximation of A V nodal conduction time; HV interval = His Purkinje conduction time; AVN = atrioventricular node

duction time was measured from the onset of the His bundle deflection to the earliest point of ventricular activation as observed on the ECG tracing or the local ventricular electrogram (normal values for our lab are 30 to 55 msec)

S_1 , A_1 , H_1 and V_1 represent the stimulus artifact atrial, His bundle and ventricular electrogram of the basic atrial drive beats respectively

S_2 , A_2 , H and V represent the stimulus artifact atrial, His bundle and ventricular electro-

grams of the atrial premature beats respectively. A_1 , A_2 represents basic paced atrial cycle length

Effective refractory period (ERP) of the atrium is the longest S_2 interval at which S_2 does not evoke an atrial response

ERP of the A V node is the longest A_2 interval at which A_2 fails to depolarize the bundle of His

ERP of the HPS is the longest H_2 interval at which H_2 does not propagate to the ventricle

Functional Refractory Period (FRP) of the A




Fig 1 Patient No 3 Relative Refractory Period (RRP HV and RRP Ab) of HPS. Each panel shows from top to bottom standard electrocardiographic Lead I 11 V high right atrial electrogram (HRA) His bundle electrogram (HBE) and time lines (T) recorded at 10 and 100 msec. S = stimulus artifact. Similar abbreviations will be used in subsequent figures. The basic cycle length measures 650 msec and is constant in all panels. In the control period (panel A) at a coupling interval (A-A) of 380 msec A conducts to the ventricles with an H-H interval of 405 msec with minor aberration of QRS morphology but an unchanged H-V interval compared to basic drive beats. At a closer A-A intervals of 370 msec (panel B) A conducts with an H-H interval of 400 msec and results in incomplete left bundle branch block aberration and prolonged H-V interval. The H-H interval of 400 msec defines RRP Ab and RRP HV of HPS. During the repeat study after 30 minutes at an A-A interval of 380 msec (panel C) A conducts with an H-H interval of 400 msec. No H-V prolongation or QRS aberration are seen. At a closer coupling interval (panel D) the resulting H-H interval measures 395 msec and A conducts with a long H-V interval and minor aberration. Note the decrease of 5 msec in RRP of HPS.

node is the shortest H-H₁ interval in response to any A-A₁. The FRP of the A-V node can only be determined when it is not limited by atrial refractoriness.

FRP of the HPS is the shortest V-V₁ interval in response to any range of H-H₁ intervals. The FRP of the HPS can only be determined when it exceeds the FRP of the A-V node. Therefore at a certain range of H-H₁ intervals H must be asso-

ciated with longer H₁V₁ intervals than those of the basic drive beats (H₁V₁).

Relative refractory period (RRP) of HPS is generally defined as the longest H₁H₁ interval at which H₁ conducts to the ventricles with a longer H-V interval than the basic drive beat or results in an aberrant QRS complex. The detection of minor degrees of aberrant ventricular conduction was more difficult and was subject to greater




Fig 2 Patient No 3 H-H intervals vs H-V intervals during control study. The basic cycle length is constant at 650 msec in both panels. In panel A at an A₁ interval of 320 msec the resulting H₁-H₂ interval is 360 msec and A₁ conducts with an H₁-V₁ interval of 80 msec and complete left bundle branch block aberration. In panel B at comparable A₁A₂ and H₁H₂ intervals the resulting H₁V₁ measures 125 msec and aberration is more pronounced. In this patient similar changes in H-V intervals at comparable H-H intervals were present during repeat studies. RVE = right ventricular electrogram.

observer error. Therefore for the purpose of this study the longest H₁H₂ interval resulting in definite bundle branch block (BBB) pattern or QRS axis of more than 15 degrees in frontal plane (RRP Ab) or H-V prolongation (RRP HV) was taken as the RRP of the HPS.

The foregoing definitions of refractory periods apply to conduction along the normal pathways at a given basic cycle length in the absence of antegrade functional bypass tracts.

Results

Table I lists the essential clinical data for the 14 patients. All patients were in sinus rhythm and had constant P-R interval. Eight of 14 patients had a normal QRS complex and six out of 14 patients had an abnormal QRS on standard electrocardiogram. The mean age of the patients was 51 years.

Data on refractory periods for individual patients are listed in Table II and mean values are listed in Table III. Table IV lists conduction data for all patients. Statistical significance was determined using refractory period data at all cycle lengths. Cumulative data were similar to

those obtained by comparing refractory period data at the longest cycle length alone.

The results on heart rate, A-V nodal conduction time and refractoriness of atrium and A-V node (Table III) were similar to our previously published data.¹ No significant change occurred in the effective refractory periods of the atrium and A-V node over a 30 minute period. Only the FRP of the A-V node was significantly decreased ($p < 0.05$). For the purpose of this report only the data on refractory periods and conduction times (H-V interval) of the HPS will be presented in detail.

His Purkinje conduction. His Purkinje conduction time (H-V interval) was within the range of normal values in all but two patients (Nos 8 and 11) during control studies. H-V intervals remained constant during incremental pacing in all patients. After 30 minutes H-V intervals during sinus rhythm and atrial pacing were identical to those of control in all patients.

Relative refractory period of HPS

Control data. The RRP Ab could be determined in 11 patients and RRP HV in 14 patients.




Fig 3 Patient No 10 Effective Refractory Period of HPS The basic paced atrial cycle length = 800 msec in all panels During control at an AA interval of 310 msec (panel A) A conducts to the ventricles with an HH interval of 410 msec and an HV interval of 85 msec On decreasing the AA interval to 300 msec (panel B) A blocks within the HPS at an HH interval of 405 msec Note that H is not followed by ventricular electrogram (V) Thus HH interval of 405 msec defines the ERP of HPS for the control period During the repeat study at an AA interval of 340 msec (panel C) the A conducts to the ventricles with an HH interval of 425 msec and a longer HV interval compared to basic drive beats As the AA interval is decreased to 320 msec (panel D) A blocks within the HPS at an HH interval of 40 msec (ERP of HPS) Note an increase of 15 msec in ERP of HPS

during control studies In two patients the RRP HV was encountered before the RRP Ab In three patients RRP Ab was reached before RRP HV while in six others RRP Ab and RRP HV occurred at the same HH intervals In three patients (Nos 2 8 and 12) only the RRP HV could be determined The RRP of HPS decreased as the paced atrial cycle length was decreased

30 minute data The above mentioned rela-

tionships between onset of RRP Ab and RRP HV and cycle length dependent changes in refractoriness persisted during repeat studies Average changes in RRP Ab and RRP HV were insignificant ($p > 0.1$) after 30 minutes (Table III Fig 1) Compared to control the RRP HV increased in two patients (Nos 1 and 6) decreased in four patients (Nos 3 5 8 and 9) and was variably altered in one (No 7) depending on the basic




Fig 4 Patient No 1 Effective Refractory Period of HPS The basic atrial cycle length is 800 msec in all panels During the control period at an A-A interval of 385 msec (panel B) A blocks within the HPS at an H-H interval of 410 msec (ERP of HPS) After 30 minutes at a coupling interval of 370 msec (panel D) A blocks within the HPS at an H-H interval of 390 msec (ERP of HPS) Note a decrease of 20 msec in ERP of HPS

cycle length In seven patients no change from control values occurred in RRP HV Changes in RRP Ab were similar to changes in RRP HV During both control and repeated studies, three out of 14 patients (Nos 3, 11 and 14) repeatedly demonstrated varying H_2V_2 intervals within a narrow range of comparable H_1H_2 intervals (Fig 2) In the remaining patients for any given H_1H_2 interval the resulting H-V intervals were generally the same as in control (i.e. within 5 msec)

Effective refractory period of HPS

Control data The ERP of HPS decreased as the paced atrial cycle length was decreased The

Mean ERP of HPS for control was 403 ± 38 msec

30 minute data The relationship between cycle length and ERP persisted during repeat studies The mean value for the ERP of HPS after 30 minutes was 401 ± 30 msec which represented a statistically insignificant change ($p > 0.5$) However a maximum increase of 25 msec and a maximum decrease of 20 msec from control values were seen in individual patients (Figs 3 and 4) Compared to control the ERP of HPS increased in four patients decreased in two patients and was variably altered in four patients depending upon the atrial cycle length at which




Fig 5 Patient No 11 Type II gap in A-V conduction—30 minute study The basic cycle length is constant and measures 50 msec in all panels At an A-A interval of 410 msec (panel A) A conducts with an H-H interval of 445 msec and an H-V interval of 70 msec On decreasing the A-A interval to 400 msec (panel B) A blocks within the HPS at an H-H interval of 440 msec In panel C at a shorter H-H interval of 435 msec A-V conduction is resumed with a longer H-V interval (Type II gap) A-V conduction continues to occur on further decreasing of the A-A intervals to 30 msec A blocks within the HPS again at an H-H interval of 415 msec (panel D) The zones of no A-V conduction are 5 and 20 msec in duration

testing was done In four other patients the ERP was identical to control values at all paced cycle lengths Changes in ERP of HPS occurred in patients with or without gap phenomena in A-V conduction (see below)

Functional refractory period data

Control data The FRP of HPS exceeded the FRP of A-V node in all patients and at all cycle lengths tested A direct relationship existed

between cycle length and FRP of HPS The mean FRP of HPS during control was 432 ± 36 msec

30 minute data During repeat studies cycle length dependent changes in the FRP of HPS persisted A statistically insignificant ($p > 0.5$) increase occurred in FRP of HPS after 30 minutes (432 ± 32 vs 434 ± 37 msec) (Table III) Compared to control the FRP increased in six patients decreased in three patients and was variably altered in two patients depending on the

paced cycle length. In three other patients, the FRP remained unchanged from control values.

Gap phenomena in A V conduction

Control data. A Type I gap in A V conduction was seen in five patients (Nos 3, 8, 10, 11, and 12) and a Type II gap in four patients (Nos 3, 8, 11, and 14). Three of five patients exhibited both a Type I and Type II gap in A V conduction (Nos 3, 8, and 11).

30 minute data. In two patients (Nos 3 and 11) a Type I gap could not be demonstrated during repeat studies. However, in patient No 3 absence of a Type I gap occurred only at the shorter cycle length. In patient No 12 a Type I gap was only demonstrated during the 30 minute study. Patient No 3 also failed to demonstrate a Type II gap during repeat studies. During both control and repeat studies, Type II gaps were generally of short duration (range 5 to 50 msec) and often multiple (Fig 5), while Type I gap zones were single and of long duration. No consistent relation was present between the changes in ERP of HPS and the presence or absence of a Type II gap in A V conduction.

Blood pressure. The blood pressure was not significantly altered in any patient. The mean systolic blood pressure was 128 mm Hg for control period and 131 mm Hg after 30 minutes.

Discussion

The results of this study confirm previous observations regarding stability of heart rate A V nodal conduction time and refractoriness of the atrium and A V node over a 30 minute period. Additionally, the results of the present study suggest that on the average and over a similar time period the ERP of the HPS remains unchanged. However, changes of the magnitude of 5 to 25 msec in either direction from control values commonly occur. Knowledge concerning behavior of the HPS over time is important in assessing cardiovascular drugs which act primarily on the distal part of the A V conduction system (e.g., procainamide, quinidine, etc.). Since refractory periods were measured at comparable cycle lengths and identical H₁H₂ intervals, the frequently observed but insignificant changes may represent physiological variations in the refractoriness of HPS itself. Alternative possi-

ties include changes in autonomic balance and gap phenomena in A V conduction.

There are conflicting reports regarding the vagal effects on electrophysiological properties of ventricular specialized conducting system.¹¹ There is some evidence which suggests that the vagus nerve may influence the electrophysiological properties of HPS.¹² Adrenergic stimulation and administration of catecholamines tend to shorten refractoriness within the HPS.¹³ The net result of interplay between the parasympathetic and sympathetic systems could cause an increase or decrease in refractoriness of HPS. Since control heart rates and A H intervals were not significantly altered over time (Table IV), it can be surmised that small changes in refractoriness were not due to any detectable alterations in autonomic balance.

The small changes observed in ERP of HPS were not limited to patients with gap phenomena in A V conduction. Since Type II gap zones tend to be multiple and zones of no A V conduction short in duration, the possibility cannot be entirely ruled out that some changes in ERP were due to gap phenomena. Interestingly, in three out of four patients in whom the ERP did not change at all, a Type II gap phenomenon was not present. As previously noted, the presence of a Type II gap in A V conduction places limitations on the conventional definition of the ERP of HPS.¹

When normal conduction merges into delayed conduction and when the RRP merges into the ERP, refractoriness of the HPS may not behave predictably and result in small changes in refractoriness. Delayed conduction and nonhomogeneous refractoriness are probably responsible for the conduction of premature beats of identical coupling intervals with varying degrees of aberration and different H V intervals.

The incidence of block within the HPS during premature atrial stimulation was approximately 10 per cent (22 out of 254 patients) in the present study. It is recognized that this incidence could have been higher had refractory period determinations been performed at longer sinus cycle lengths. Interestingly, greater than 50 per cent of patients demonstrating block within the HPS had normal QRS complexes.

The results of the present study as well as our previous publication on time dependent changes

provide baseline data for future investigations of cardiovascular drugs

Summary

Temporal effects on refractoriness within the His Purkinje system (HPS) were studied in 14 patients in whom effective refractory period (ERP) of HPS could be determined using His bundle electrograms incremental atrial pacing and atrial extrastimulus method. His Purkinje conduction times (H V interval) and relative (R) effective (E) and functional (F) refractory periods (RP) of HPS were measured during the control period and repeat measurements were made after a 30 minute interval. H V intervals were unchanged from control in all patients. Although changes of the magnitude of 5 to 25 msec in either direction from control values commonly occurred on the average no statistically significant changes were seen in RRP, ERP or FRP of HPS. The results of the present study confirm the stability of refractoriness of HPS over a 30 minute period and provide baseline data for future investigations of cardiovascular drugs which act primarily on the distal part of the A V conduction system.

REFERENCES

1. Reddy C P, Damato A N, Akhtar M, Ogunkelu J B, Caracta A R, Ruskin J N and Lau S H. Time dependent changes in the functional properties of the atrioventricular conduction system in man. *Circulation* 51: 1012 1975.
2. Scherlag B J, Lau S H, Helfant R H, Berokowitz W D, Stein E and Damato A N. Catheter technique for recording His bundle activity in man. *Circulation* 39: 13 1969.
3. Krayer O, Mandok J J and Mendez C. Studies on veratramine alkaloids. XVI. The action of epinephrine and veratramine on the functional refractory period of the atrioventricular transmission in the heart-lung preparation of the dog. *J Pharmacol Exp Ther* 103: 412 1951.
4. Varghese P J, Damato A N, Lau S H, Akhtar M, Bobb G A. The effect of heart rate, acetylcholine and vagal stimulation on antegrade and retrograde His-Purkinje conduction in the intact heart. *Am HEART J* 86: 203 1973.
5. Mendez C, Han J and Moe G K. Comparison of the effects of epinephrine and vagal stimulation upon the refractory periods of the A V node and the bundle of His. *Naunyn-Schmiedeberg's Arch. Exp. Pathol.* 248: 99 1964.
6. Akhtar M, Damato A N, Caracta A H, Batsford W P, Josephson M E and Lau S H. Electrophysiologic effects of atropine on atrioventricular conduction studied by His bundle electrogram. *Am J Cardiol* 33: 333 1974.
7. Bailey J, Greenspan K, Elizari, M V., Anderson G J and Fisch C. The effects of acetylcholine on automaticity and conduction within the proximal His Purkinje specialized conduction system. *Circ Res* 20: 210 1972.
8. Spear J F and Moore E W. Influence of brief vagal and stellate nerve stimulation and pacemaker activity and conduction within the atrioventricular conduction system of the dog. *Circ Res* 32: 27 1973.
9. Joo F and Csulik H. Cholinesterase activity of intercalated discs in mammalian heart muscle. *Nature (London)* 193: 1197 1962.
10. Jacobowitz D, Cooper T., and Barner W B. Histochemical and chemical studies of the localization of adrenergic and cholinergic nerves in normal and denervated cat hearts. *Circ Res* 20: 789 1967.
11. Kent K M, Epstein S E, Cooper T and Jacobowitz D M. Cholinergic innervation of the canine and human ventricular conducting system. *Circulation* 50: 948 1974.
12. Wallace A G and Sarnoff R J. Effects of cardiac sympathetic nerve stimulation on conduction of the heart. *Circ Res* 14: 86 1964.
13. Dhingra R C, Winslow E, Pouget J, Rahimtoola S and Rosen K M. The effect of isoproterenol on atrioventricular and intra-ventricular conduction. *Am J Cardiol* 32: 829 1973.
14. Vargas G, Akhtar M and Damato A N. Electrophysiologic effects of isoproterenol on cardiac conduction system in man. *Am HEART J* 90: 25 1975.
15. Rushmer R F. Autonomic balance in cardiac control. *Am J Physiol* 192: 631 1958.
16. Akhtar M, Damato A N, Batsford W P, Caracta A R, Vargas G and Lau S H. Unmasking and conversion of gap phenomenon in the human heart. *Circulation* 49: 674 1974.

Hypertrophic cardiomyopathy in the aged

Norman Krasnow, M D

Richard A Stein M D

Brooklyn N Y

Hypertrophic cardiomyopathy is a not uncommon disease which has been well characterized since the early reports presenting a composite picture of the disease by Brachfeld and Gorlin,¹ Braunwald and associates, and others.² The obstructive variant, also called idiopathic hypertrophic subaortic stenosis, is associated with characteristic clinical findings,³ including a systolic ejection murmur, unusually brisk carotid pulses, bifid apical impulses, increase in the intensity of the murmur with Valsalva maneuver, and often associated mitral insufficiency. Symptoms and signs include syncope, heart failure, arrhythmias, and angina. Left ventricular hypertrophy is often present on the electrocardiogram and chest x ray. When any one or more of these abnormalities occurs in a young healthy adult, detailed investigation is likely to be carried out and a diagnosis established. The echocardiogram has contributed enormously to the noninvasive diagnosis of this condition, especially in its nonobstructive variety (asymmetric septal hypertrophy).

Previous studies have indicated that the disease predominates in the young or middle aged population, although instances of hypertrophic cardiomyopathy in older patients have been noted in these studies.⁴⁻¹⁰ In the past 28 months, 23 new cases of hypertrophic cardiomyopathy have been detected at the Cardiac Graphics Laboratory of the Downstate Medical Center. Twenty of the patients were over the age of 50 years and form the subject of this report. Fifteen of these patients

were over the age of 60 years. In the majority, the correct diagnosis was not made clinically, either because it was not considered in these elderly patients or because some of the usual characteristic features were masked or attributed to other conditions more common in this age group. Cardiac catheterization is often avoided in the elderly if a clear therapeutic decision is not apparent.

The twofold purpose of this paper is (1) to emphasize the occurrence of hypertrophic cardiomyopathy in the older patient in whom the diagnosis is more likely to be missed and (2) to emphasize the apparent compatibility of this disease with long life, which, in part, conflicts with current thinking on the natural history of the disease.

Materials and methods

Clinical echocardiograms were performed on a Smith Kline Echocardiograph Model 20A using a Honeywell 1856 ultraviolet recorder and a 2.25 MHz, 1/2 inch diameter transducer. Phonocardiograms and carotid pulse recordings were performed on a Honeywell recorder using two microphones simultaneously, each recording in 50 to 120 Hz and 100 to 500 Hz bands, or on a Schwarzer six channel direct writing polygraph.

Echocardiograms from many of these elderly patients were difficult technically because of overlying lung tissue damping the high frequency sound. Nevertheless, great care was taken to delineate as well as possible both right and left margins of the interventricular septum in order to define thickness carefully at the level of the mitral valve and posterior wall. Echoes from the septal leaflet of the tricuspid valve were carefully differentiated from the right (anterior) margin of the septum.

From the Department of Medicine, Cardiology Division, Downstate Medical Center, Brooklyn, N Y.

Received for publication Sept. 7, 1977.

Accepted for publication Nov. 7, 1977.

Reprint requests: Norman Krasnow, M.D., Dept. of Medicine, Cardiology Division, Downstate Medical Center, 450 Clarkson Ave., Brooklyn, N Y 11203.




Fig 1 Hypertrophic obstructive cardiomyopathy in a 61 year old woman (H M) with a history of rheumatic fever in childhood and a clinical diagnosis of mitral insufficiency. The right side of the septum in this portion of the recording is obscured. There is a SAM, narrow transverse LV diameter, notched aortic valve and spike and dome carotid pulse.

Patient selection. Of about 2 000 subjects studied, 17 patients over the age of 50 had hypertrophic cardiomyopathy. Seventeen of these met the criteria for hypertrophic obstructive cardiomyopathy (e.g. Fig 1). These required criteria included (a) septal hypertrophy (greater than 1.2 cm thickness) out of proportion to posterior wall thickness (septum/posterior wall thickness ratio 1.4 or greater); (b) systolic anterior motion (SAM) of the anterior mitral leaflet present either at rest or after amyl nitrate inhalation. The SAM in all cases was discrete and abrupt. It did not appear to be related to underlying papillary muscle motion. Additional criteria not sufficient in themselves for diagnosis were (c) anterior displacement and slowing of the early diastolic closing motion of the anterior mitral leaflet in diastole; (d) decrease in transverse left ventricular diameter at the level of the mitral valve (usually producing a characteristic "bushy" appearance of the recording); and (e) notching of the aortic valves. In each case there was no stenosis of the aortic valve.

Characteristic pulse abnormalities (Fig 1) were a rapid rate of carotid upstroke with spike and

dome configuration. Prolonged ejection time index and decreased systolic time intervals were taken as indices of outflow tract obstruction, but not differential for valvular vs subvalvular location. The presence of pulse abnormalities was considered confirmatory but not diagnostic and the absence of pulse abnormalities did not exclude the diagnosis.

In three cases the diagnosis of hypertrophic cardiomyopathy without outflow tract obstruction was based on disproportionate septal hypertrophy (criterion a as above) in the absence of other clinical or echocardiographic explanations for a thickened septum.

Results

Patient profile. (Tables I and II). The oldest patient in this series was 76. Fifteen of the 20 in the group were 60 years of age or older. Fifteen were women. The most common presenting complaints (Table I) were syncope or dizziness in nine, signs of heart failure in five, and chest pain in four. In two cases the cardiac lesion was discovered and diagnosed incidental to other unrelated events.

Table I Hypertrophic cardiomyopathy in the aged Clinical characteristics

Patient	Age	Sex	Duration of presenting		Associated findings					Positive family history	Referring diagnoses
			Symptoms	Complaint	CHF	Pain	Mur mur	HBP	Arrhythmia		
D A	65	M	4 yr	HBP	+	-	+	+	-	-	HBP CAD ^a
E B	68	F	10+yr	dyspnea Syncope	++	-	-	+	-	-	valve disease HBP CAD ^a
S B	65	F	6 yr	Syncope	++	+	+	++	-	-	valve disease MI AS ? HOCM
A H	50	F	3 days	Dyspnea	+	-	+	++	-	-	MI AS
N B	57	F	7 yr	Syncope	+	+	-	-	+	+	Angina ? HOCM
F C	73	F	0	Syncope	-	-	-	-	-	-	AS ? HOCM
E G	58	F	8 yr	Dyspnea	+	+	+	-	+	+	CAD
B J	75	F	4 yr	Pain	-	+++	-	+	-	-	CAD
G L	67	F	60 days	Syncope	+	-	-	-	+	-	AS MI
H M	82	F	4 yr	Dyspnea	+	-	-	+	+	+	MI
A M	63	M	7 days	Pain	-	+	+	+	-	-	AS CAD
M M	76	M	1 yr	Syncope	-	-	-	-	-	-	CAD ? HOCM
J P	75	F	2 yr	Dizziness	+	-	-	+	±	-	AS ? MI ?HOCM
P P	64	M	1 yr	Dizziness	-	-	-	-	-	-	HOCM
E S	73	F	5+yr	Pain	±	+	-	-	-	-	AS MI
R W	68	F	9 yr	Pain	+	+	+	-	-	-	AS CAD
A Wl	61	F	0	None	-	-	+	+	-	-	MI
A Wn	58	F	6 yr	None	+	±	-	+	-	-	CAD
R F	67	F	05 yr	CVA	-	-	-	-	-	-	CAD
K M	65	F	41 yr	Dyspnea	+	+	+	+	+	+	AS

Abbreviations: HBP = hypertension CHF = congestive heart failure CVA = cerebrovascular accident CAD = coronary artery disease MI = myocardial infarction AS = aortic stenosis HOCM = hypertrophic obstructive cardiomyopathy Symptoms graded on scale + to +++

The correct diagnosis was suspected in only four cases but was not made definitively by the referring or consulting physician (usually a cardiologist Attending or Fellow) Valvular heart disease, either aortic stenosis or mitral insufficiency, or both was considered in 11 hypertensive and/or atherosclerotic heart disease in nine, in one patient both valvular and atherosclerotic heart disease were the prime diagnostic considerations

The duration of symptoms prior to diagnosis averaged 5 years, excluding two patients who had no symptoms, and three who had symptoms for less than 1 week before admission Seven patients were aware of a heart murmur for at least several years previously, but had not undergone diagnostic study

Palpable carotid pulse abnormalities were present in only five cases all of whom had evidence of outflow tract obstruction on echocardiogram

Carotid pulse tracings (Table III) A spike and dome configuration was recorded in 10 of 13 subjects, and the corrected ejection time index¹¹ was increased by more than 2 standard deviations from the normal in nine of 17 subjects The systolic time interval (ratio of pre ejection period to ejection time PEP/ET)¹² was less than 0.25 in six of 15 subjects

Echocardiogram (Table III) The average septal thickness was 22 mm with a septum/posterior wall ratio of 2.2 in 17 cases A systolic anterior motion (SAM) was recorded at rest, or with amyl nitrate inhalation in 17 cases although in most cases it was qualitatively not severe Six patients had increased right ventricular anterior wall thickness, ranging from 4 to 11 mm An incidental finding was a small echo free space posteriorly in eight patients

Cardiac catheterization was performed in seven cases (Table III) Care was taken to avoid catheter entrapment during pressure recordings and

Table II Hypertrophic cardiomyopathy in the aged Objective clinical data

Patient	Physical findings					Laboratory findings				
	Quick pulse	Ejection murmur	Pan systolic murmur	S ₁ -S ₂	Blood pressure	Congestive heart failure	Cardio megal	ECG	Chest x ray	Cardiac catheterization
D A	+	+	-	+	160/90		+	LVH		
E B		+	+	+	160/80		+	LVH	LVH	
S B		+	-	-	130/80		+	LVH	Dilated Ao	LV 155/22 CI 31 OTG 0 0 with exercise septal bulge in systole
A B		+	+	-	140/90	+	+	LVH	LVH dilated Ao	LV 270/20 CI 29 OTG 90 2+ aortic insufficiency
N B		-	-	-	130/86		-	RBBB	N1	LV 130/8 CI 42 OTG 26 40 with isoproterenol
F C	±	+	-	-	200/110		+	LVH	Ca mitral annulus Ca cor artery	
E G		+	-	-	130/90		+	LVH LAH	N1	
B J		-	-	-	150/110		-	RBBB	N1	LV 160/8 normal EDV obliterated cavity at end systole moderate CAD
G L		+	+	-	140/70		+	LVH	EH	
H M		+	+	+	120/0		+	LVH	EH	LV 165/7 CI 26 OTG 35 3+ mitral insufficiency
A M	+	+	-	-	190/90		+	LVH	EH	LV 165/16 CI 33 OTG 35 70 with amyl nitrate
M M	+	+	-	+	130/90		+	LVH ASMI PVC	LVH dilated Ao	
J P	+	+	-	+	170/90		+	LVH	LVH	
P P		+	-	-	120/80		+	LVH	LVH	
E S		+	+	-	130/80	+	+	LVH	LVH pleural effusion	
R W		-	+	+	140/80	+	+	ASMI	N1	
A W		+	+	-	125/80		-	ST T change	LVH dilated Ao	
A Wn		+	-	-	200/90		+	Vent Ta chv cardia	N1	
R F		-	+	-	130/80		-	LVH	N1	
K M		+	-	+	165/55		+	LVH RBBB	EH	LV 200/32 CI 26 OTG 0 normal EDV 2+ aortic insufficiency calcified coronary artery

Abbreviations: LVH = left ventricular hypertrophy; LAH = left atrial hypertrophy; ASMI = antero-septal myocardial infarction; RBBB = right bundle branch block; Ao = aorta; EH = cardiac enlargement; LV = left ventricular; end-diastolic pressures (mm. Hg); CI = cardiac index (L./min./M²); OTG = left ventricular end-diastolic pressure (mm. Hg); N1 = normal.

Table III Hypertrophic cardiomyopathy in the aged Graphic data

Patient	Carotid pulse			Phonocardiogram			Echocardiogram									
	Spike and dome	Corrected ejection time (sec)	PEP	Systolic ejection murmur	Pansystolic murmur	S ₁ or S	Septum (cm)	Post u all (cm)	S/PW	EDD (cm)	ESD (cm)	SAM	Septal motion	Aml nitrate effect		
			ET													
D A	-	41	32	+	-	+	20	09	22	39	25	1+	1+	+		
E B	+	43	26	+	+	-	24	13	19	36	19	2+	2+	ND		
S B	-	42	19	+	±	+	18	8	21	39	33	0	1+	+		
A B	+	44	33	+	-	+	20	10	20	42	32	4+	1+	ND		
N B	+	46	21	-	+	-	21	11	19	46	28	1+	0	+		
F C	-	39		++	±	-	23	-	-	17	15	2+	0	+		
E G	-	39	37	++	-	-	16	09	18	40	23	2+	1+	+		
B J	-			-	-	-	18	10	18	35	19	0	2+	ND		
G L	+	48	19	++	++	+	24	-	-	-	-	2+	3+	+		
H M	+	47	34	++	-	+	33	11	30	29	-	3+	2+	ND		
A M							19	09	22	39	-	3+	0	+		
M M	+	44	28	++	+	+	33	08	41	44	-	2+	0	ND		
J P	+	34	29	++	-	-	24	09	27	46	-	2+	1+	0		
P P	+	48	28	++	-	+	20	10	20	47	27	2+	3+	0		
E S	+	49	13	++	-	+	21	-	-	19	-	3+	0	0		
R W	+	45	14	++	-	+	22	12	18	30	-	3+	0	0		
A Wl	-	46	15	+	-	+	24	11	22	31	18	2+	+	0		
A Wn	-	41	27	+	-	+	19	10	19	50	35	0	2+	0		
R F							21	09	22	45	33	4+	0	0		
K M	-	40		+	++	+	20	09	21	39	20	0	4+	ND		

pullback recording An intraventricular gradient was found at rest in four cases all of whom had evidence of obstruction on the resting echocardiogram In one case there was marked obliteration of the left ventricular cavity at end systole without distortion of the chamber configuration In one case the end systole appearance of the left ventricular cavity had a "bent banana" shape related to septal hypertrophy

Illustrative cases

Case 1 (B J Fig 2) A 75 year old female had severe classical angina pectoris and hypertension for several years without evidence of infarction Physical examination was entirely normal except for a blood pressure of 160/110 before treatment ECG showed right bundle branch block, and heart size and shape were normal on chest x ray At cardiac catheterization there was mild diffuse narrowing of the coronary arteries with no obstruction greater than 50 per cent of the arterial diameter Left ventriculography demonstrated a normal chamber in end diastole and a marked obliteration of the left ventricular cavity at end systole (Fig 1) No outflow tract gradient

was present at rest, and in this case isoproterenol stimulation was not performed

Echocardiogram showed marked asymmetrical hypertrophy of the interventricular septum a small left ventricular cavity, and increased thickness of the anterior right ventricular free wall were seen No SAM was demonstrable at rest or after amyl nitrate and the anterior mitral leaflet morphology was normal The patient improved after more intensive treatment with propranolol

Comment This patient had no clinical stigmata of hypertrophic cardiomyopathy except for severe angina The correct diagnosis was made at ventriculography and confirmed by subsequent echocardiography

Case 2 (F C) A 73 year old female was admitted for trauma associated with her first episode of syncope She was otherwise well except for rheumatoid arthritis Carotid pulses were somewhat brisk The apex impulse was tapping, 2 cm left of mid clavicular line and a Grade III+ systolic ejection murmur was heard in the third intercostal space 3 cm to the left of the sternum Electrocardiogram showed mild left

ventricular hypertrophy with small q waves in Leads I and aV₁. Echocardiogram showed a thick septum SAM small left ventricular cavity abnormal anterior mitral leaflet in diastole and a calcified mitral annulus Fluoroscopy confirmed the calcification of the mitral annulus and showed extensive calcification of the coronary arteries as well Treatment with propranolol 160 mg /day reduced the intensity of the murmur and diminished the SAM on echocardiogram

Comment In the absence of echocardiography the murmur might well have been attributed exclusively to the calcified mitral annulus or to valvular aortic stenosis

Case 3 (N B) A 57 year old female complained of chest pain syncope and palpitation for seven years Her mother was said to have had an enlarged heart for at least 30 years Her first two syncopal episodes were associated with seizures and pulmonary congestion was diagnosed clinically 2 years previously Physical examination showed slightly distended neck veins without right ventricular heave A right bundle branch block was present on electrocardiogram X ray of the chest was normal Carotid pulse studies showed a spike dome configuration the PEP/ET was 0.21 and the ejection time index was increased A regurgitant systolic murmur was recorded at apex and lower left sternal border Echocardiogram showed a thickened septum (2.1 cm) with a septum/posterior wall ratio of 1.9 A small SAM was present which was increased by amyl nitrate The mitral EF slope was 45 At cardiac catheterization a 25 mm Hg subvalvular outflow tract gradient was found The ventriculogram showed a markedly reduced end systolic volume the coronary arteries were normal

Comment In this case the symptoms were sufficiently vague and atypical that cardiac neurosis was suspected initially

Case 4 (R W) A 68 year old female was told of a murmur many years previously She had angina for 9 years and signs of congestive heart failure for 3 years She was thought to be hypothyroid She was admitted for acute chest pain and found to have an apex impulse in fifth interspace near the anterior axillary line There was a Grade III pansystolic murmur at apex an S gallop and basilar râles Electrocardiogram suggested an anterior subendocardial infarction without left ventricular hypertrophy X ray



Fig 2 Hypertrophic non-obstructive cardiomyopathy in a 6-year-old woman with mild hypertension and severe angina pectoris Angiogram shows marked reduction of end systolic cavity similar to the echocardiogram which showed a septum 1.8 cm thick

showed the heart to be at normal size Pulse and heart sound recording showed a spike and dome configuration with prolonged ejection time PEP/ET was 0.14 and a regurgitant murmur was seen Echocardiography showed a thickened septum (2.2 cm) and a septum/posterior wall ratio of 1.8 with prominent SAM narrowing the outflow tract diameter in systole to 3 mm

Comment In this patient there was electrocardiographic evidence of associated coronary heart disease The murmur and heart failure would have been attributed to papillary muscle dysfunction and myocardial infarction exclusively whereas the hypertrophic obstruction may have played a significant role

Case 5 (E B) A 68-year old female had a long history of heart disease and dyspnea with




Fig 3 Hypertrophic cardiomyopathy in a 65 year old man being followed for hypertension and mild dyspnea. The septum is thick but obstruction is not present at rest. With Valsalva maneuver and amyl nitrate inhalation a murmur, carotid pulse abnormality, and SAM appear.

cardiomegaly known for 6 years. She was being treated for mild hypertension when she was limited for syncope associated with a respiratory infection. BP was 160/80. An S₄ gallop was present. A regurgitant murmur was present at the apex and a systolic ejection type murmur was heard along the sternal border which radiated to the neck. ECG and x ray indicated left ventricular hypertrophy. Carotid pulse showed a spike dome pattern with normal ejection time index and PEP/ET and 0.26. Phonocardiogram confirmed the ejection and regurgitant murmurs. The echocardiogram revealed a thickened septum (2.4 cm) with septum/posterior wall ratio of 1.9. 2+ SAM with 4 mm systolic outflow tract diameter and the mitral leaflet was displaced anteriorly. The aortic valve was noted to be notched late in systole. Propranolol 2 mg administered intravenously during the study decreased the SAM within five minutes.

Case III (D A Fig 3) This 65 year old man was told of a leaky valve at age 17 but knew no more of heart disease till 5 years prior to study (age 60) when he noted dyspnea on walking rapidly. Cardiomegaly was noted and he was being treated for hypertension. His mother died in her thirties during the 1918 influenza epidemic; a son died suddenly during a soccer match without known prior heart disease. Blood pressure was 160/90. There was an apical systolic ejection murmur increasing during Valsalva maneuver and an S₄ was present. The pulses were normal and the ECG showed LVH. Echocardiogram and phonocardiogram showed development of a murmur and SAM during amyl nitrate inhalation. There was moderate asymmetric septal hypertrophy.

Comment This patient has apparently mild disease clinically. The findings could have been dismissed as compatible with hypertension. The son who died during exertion was presumably severely affected.

Discussion

Hypertrophic cardiomyopathy is easily diagnosed in young or middle aged patients when there are characteristic clinical findings: consisting of dyspnea or signs of congestive heart failure, chest pain, syncope or palpitations in association with the findings of a brisk carotid upstroke and a systolic murmur heard best along the left sternal

border which is poorly transmitted to the neck. The picture is complete with an ECG meeting the criteria of left ventricular hypertrophy and a chest x ray revealing a small ascending aorta and left ventricular predominance. Mitral insufficiency is frequently present, occasionally dominating the clinical picture.

In the aged, our clinical study of hypertrophic obstructive cardiomyopathy shows that the diagnosis was frequently missed, similar to the experience of Hamby and Antablian¹¹ and Whiting and colleagues.¹² The symptoms and signs are frequently misinterpreted as manifestations of more common diseases such as coronary artery disease or hypertensive heart disease. Mild hypertension common in this age group is frequently considered the basis of the cardiomegaly. Syncope or dizziness, a common presenting sign in this series as in that of Whiting and associates,⁹ may be ascribed to cerebrovascular insufficiency or heart block. The brisk carotid pulse may be ascribed to rigidity of the arterial walls or conversely it may be sluggish due to associated intrinsic atherosclerotic and thrombotic disease (one patient in this series had total obstruction of a carotid artery and underwent endarterectomy). The ascending aorta may be dilated rather than small, leading one to ascribe the systolic murmur to aortic stenosis. The associated mitral insufficiency was often explained as papillary muscle dysfunction or as in one patient in our series to a calcified mitral annulus.

Carotid pulse tracings and heart sound recordings offer important clues to the proper diagnosis but the echocardiogram provides the most accurate specific diagnostic support short of cardiac catheterization. The characteristic echocardiographic features include a thickened septum out of proportion to the thickness of the posterior left ventricular wall, an anterior mitral valve leaflet echo showing anterior posterior an anterior systolic motion often abutting the septum and a slow early diastolic closing motion. Septal motion is often diminished but may be normal. The left ventricular valve cavity is small and the record appears busy. The aortic valve leaflets appear thin and open widely but may show a notch at midsystolic closure.

The extensive use of the echocardiogram in a large medical teaching service contributed to the increasing frequency of diagnosis in a group of




Fig 3 Hypertrophic cardiomyopathy in a 65 year old man being followed for hypertension and mild dyspnea. The septum is thick, but obstruction is not present at rest. With Valsalva maneuver and amyl nitrate inhalation a murmur, carotid pulse abnormality and SAM appear.

not the result not the cause of prolonged obstruction¹⁹ and could possibly be progressive in character. The mechanism of progressive obstruction may become clearer now that longitudinal studies by echocardiography are possible.

A corollary of the thesis of progressive development of the lesion is that the clinical course is slow. In several recent studies a gradual progression of symptoms is described for many patients regardless of the clinical classification of the patients when first studied. Hardarson and colleagues¹ postulates a long phase of asymptomatic disease until about age 30 after which symptoms may supervene with progressive clinical deterioration. Sudden death can occur at any time in this course however even in asymptomatic subjects responding well to medical or surgical therapy. In the 49 patients followed for an average of 7.5 years by Hanania and associates¹⁸ 65 per cent survived 20 years from the onset of the first symptoms. These data support the concept of Hardarson and co workers¹ on the prolonged course of the disease.

To confound the description of the natural history and prognosis further Hanania and colleagues¹⁸ found that more cases improved with time than deteriorated treatment with propranolol did not account for this result. Adelman and co workers² and Powell and colleagues²⁰ also noted significant improvement in many patients of their respective series attributing the change to medical therapy with beta adrenergic blocking drugs but without a true control series for comparison. The present series thus extends the potential survival curve even further than that suggested by Hardarson, Hanania and their associates.

Summary

Although usually considered a disease of young or middle aged adults hypertrophic cardiomyopathy is not infrequently seen in older patients as well. Twenty of 23 cases of hypertrophic cardiomyopathy seen in the past 2½ years at our institution have been in patients whose average age was 65 years and who ranged up to 76 years. Sixteen of these had evidence of an obstructive component at cardiac catheterization or echocardiography. Symptoms and signs were similar to those described for the younger patients in the literature but were often attributed to other

causes including valvular aortic stenosis atherosclerotic or hypertensive heart disease or cerebrovascular disease. Left ventricular hypertrophy was more consistently present on ECG than on x ray.

The not infrequent occurrence of hypertrophic cardiomyopathy in older patients predominantly females indicates that the natural history of this disease includes a group who suffer few or no symptoms until late in life. Clinical management of younger patients with this diagnosis should be considered in light of this more favorable possible course.

The excellent technical assistance of Mrs. Henrietta Stokes and Miss Shirley Staiano and secretarial assistance of Mrs. Yetta Israelite is gratefully acknowledged.

REFERENCES

- 1 Brachfeld N and Gorlin R. Subaortic stenosis. A revised concept of the disease. *Medicine* 38:415, 1959.
- 2 Braunwald E, Morrow A G, Cornell W P, Aygen M M and Kibish T. Idiopathic hypertrophic subaortic stenosis. Clinical hemodynamic and angiographic manifestations. *Am J Med* 111:924, 1960.
- 3 Wigle E D, Heimbecker R O, and Gunton and R W. Idiopathic ventricular septal hypertrophy causing muscular subaortic stenosis. *Circulation* 26:375, 1962.
- 4 Cohen J, Effat H, Goodwin J F, Oakley C M and Steiner R E. Hypertrophic obstructive cardiomyopathy. *Br Heart J* 26:16, 1964.
- 5 Menges H, Jr, Brandenburger R O and Brown A L, Jr. The clinical hemodynamic and pathologic diagnosis of muscular subvalvular aortic stenosis. *Circulation* 24:1126, 1961.
- 6 Goodwin J F. Congestive and hypertrophic cardiomyopathies. *Lancet* 1:731, 1970.
- 7 Hardarson T, Cuneo R, DeLaCruz C and Goodwin J F. Prognosis and mortality of hypertrophic obstructive cardiomyopathy. *Lancet* 2:1467, 1973.
- 8 Adelman A G, Wigle E D, Ranganathan N, Webb J J, Kidd S S S, Bellow W G and Silver M D. The clinical course in muscular subaortic stenosis. *Ann Intern Med* 77:15, 1972.
- 9 Parker B M. The course in idiopathic hypertrophic muscular subaortic stenosis. *Ann Intern Med* 70:903, 1969.
- 10 Whiting R E, Powell W J, Jr, Dinsmore R E, and Sanders C A. Idiopathic hypertrophic subaortic stenosis in the elderly. *N Engl J Med* 285:196, 1971.
- 11 Popp R L. Echocardiographic assessment of cardiac disease. *Circulation* 54:538, 1976.
- 12 Wessler A M. Non-invasive cardiology. New York 1974. Grune & Stratton Inc.
- 13 Frank S and Braunwald E. Idiopathic hypertrophic subaortic stenosis. *Circulation* 37:759, 1968.
- 14 Hamby R I and Antablian A. Idiopathic hypertrophic subaortic stenosis in the septuagenarian. *Clin Res* 24:720A, 1976.
- 15 Henry W L, Clark C E, Glancy L and Epstein S E. Echocardiographic measurement of the left ventricular outflow gradient in idiopathic hypertrophic subaortic stenosis. *N Engl J Med* 288:989, 1973.

patients who otherwise would have remained misdiagnosed had cardiac catheterization been required. It is to be expected that the increasing utilization of the echocardiogram will be associated with fewer missed diagnoses of hypertrophic cardiomyopathy in the elderly.

Hypertrophic cardiomyopathy is more common in older people than was previously thought. In earlier series of hypertrophic cardiomyopathy, aged patients were rare and most patients were young or middle aged adults or children. In the series of 119 patients followed by Hardarson and colleagues,⁷ only one was over 60 years of age and Adelman and associates⁸ reported on 60 patients the oldest of whom was 55. In the large early series of 126 patients analyzed by Frank and Braunwald,¹¹ only two were over 60. None of the 18 patients reported by Parker⁹ was over 45. Recently however Whiting and colleagues¹⁰ reported 14 cases over the age of 60, and Hamby and Aintablian¹² found nine cases of hypertrophic cardiomyopathy in patients over 70. In our present series of 23 cases of hypertrophic cardiomyopathy of all ages seen in the past 3 years, 20 were over the age of 50 years.

The recognition of hypertrophic cardiomyopathy in patients in the seventh and eighth decades of life, some of whom who are even then minimally symptomatic, extends our understanding of the natural history of the disease from that portrayed in previous studies. The patients in this series suggest that the lesion of hypertrophic cardiomyopathy is compatible with a long life and that selected patients may remain asymptomatic to a late age. The explanation for this more benign prognosis in selected patients is not clear. Two possible explanations suggest themselves: one is that this group of patients had a relatively mild degree of obstruction and thus survived to old age; the other is that the obstructive process is not present in early years but develops and progresses in the course of aging.

The possibility of our series representing a milder form of the obstructive lesion is suggested by the small resting gradients at cardiac catheterization and normal cardiac indices among the seven subjects who underwent cardiac catheterization. Also the echocardiogram did not suggest high grade obstruction¹³⁻¹⁵; the outflow tract was not completely obliterated for long periods of systole in most patients. Previous studies do not

however, suggest a milder obstructive lesion in the elderly. Whiting and associates¹⁶ found no severe gradients at catheterization among the older patients, as compared to the younger group. Pomerance and Davies¹⁶ found severe hypertrophy at necropsy in the older patients with average heart weight of 560 grams even though in some cases of their series the lesion was an incidental finding and was not symptomatic or diagnosed during life.

There is, however, difficulty in defining clearly the severity of this disease especially when sudden death may occur at any stage of disease unheralded by any symptoms. There is disagreement among investigators as to the prognostic usefulness of clinical or hemodynamic parameters. Hanania and colleagues¹⁷ found that clinical prognosis related only to the age of onset of symptoms. One agreed upon datum is the poorer prognosis of the familial form of the disease compared to the sporadic form.¹⁸ Only few subjects in the present series had a history suggestive of familial disease but this datum is not reliable since in a number of our cases the family history was not well known to the patient.

The present study, with its predominance (90 per cent) of female patients suggests also that males may have a severer form of the disease. In the series of Frank and Braunwald¹¹ there was an equal sex incidence in younger patients but in the older patients, females predominated. Hamby and Aintablian¹² also found seven females out of nine aged patients with hypertrophic cardiomyopathy. In the series of necropsy cases studied by Pomerance and Davies¹⁶ the sex incidence was equal, but females averaged 76 years of age compared to 66 for males. Whiting and co-workers¹⁰ found 10 of 14 elderly patients to be females. One could thus infer that women have a better chance of living longer with the disease.

The second possible explanation for the prolonged survival is that in this disease albeit often a familial one the obstructive process is not present in early years but develops and progresses with age. This contention is supported by the work of Williams and colleagues,¹⁹ who documented the development of the obstructive component over 4 years in a 15 year old girl. Even the disordered myocardial architecture previously thought to be a feature of the congenital myopathic character of the disease may repre-

Effects of rapid digitalization on total and regional myocardial performance in patients with coronary artery disease*

Jack Ferlinz M D
Michael DelVicario M D
Wilbert S Aronow M D
Long Beach and Irvine Calif

The hemodynamic effects of acute digitalization have been studied extensively in experimental animals¹ in normal human subjects² and in patients with congestive heart failure.³ Similar studies were also carried out in patients with coronary artery disease (CAD) who were not in overt left ventricular (LV) failure.⁴ In contrast little is known about the influence of rapid digitalization on LV volumes and ejection fraction in man. Furthermore although many patients with CAD develop LV wall motion abnormalities there is very little pertinent information concerning the possible effects of digitalis therapy on these areas of disordered contractility.

Since it has been shown that digitalis increases myocardial oxygen consumption when given to experimental animals with nonfailing hearts it has been postulated that the increased myocardial oxygen demand could lead to greater myocardial ischemia in CAD patients without heart failure.⁵ Furthermore it has been demonstrated that positive inotropic stimulation of surviving myocardium in the experimental animals may accentuate the extent of paradoxical systolic motion. The area of paradoxical motion may act

as a slack elastic element in series with the contractile portions of the remaining left ventricle.⁶ Because of this slack area increased velocity of contraction would be required to generate tension during isovolumic systole thereby increasing cardiac work—an effect which could further increase myocardial oxygen consumption.^{7,8}

It is therefore apparent that subjects with CAD and LV asynergy but no heart failure may represent a category of patients who would not benefit from digitalis therapy and could actually be harmed. This study was undertaken to determine hemodynamic volumetric and regional wall motion changes that occur in patients with chronic CAD after rapid digitalization and to establish whether digitalis could exert a salutary effect on areas of disordered LV contractility.

Materials and methods

Twenty one consecutive patients with suspected CAD were selected for this study. All gave informed consent and underwent routine diagnostic cardiac catheterization studies which in our laboratory include complete left and right heart hemodynamic evaluation, cardiac output determination with the green dye indicator dilution technique, selective left ventriculography, and coronary arteriography. All patients were in normal sinus rhythm. None had systemic hypertension, congestive heart failure, or significant valvular or congenital lesions.

Some of the patients received various cardiovascular medications in the past but in each

From the Cardiology Section, Medical Service, Veterans Administration Hospital, Long Beach, Calif (main address) and the University of California School of Medicine, Irvine, Calif (residence).

Received for publication Aug 8, 1977.

Accepted for publication Sept. 30, 1977.

Reprint requests: Jack Ferlinz, M D, Chief Cardiac Catheterization Laboratory, Veterans Administration Hospital, 5901 East Seventh St, Long Beach, Calif 90822.

Presented in part at the 26th Annual Scientific Session of the American College of Cardiology, Las Vegas, Nev., March 1977.

- 16 Pomerance A and Davies M J Pathological features of hypertrophic obstructive cardiomyopathy (HOCM) in the elderly *Br Heart J* 37 305 1975
- 17 Hanania G Marino J P Magnier S Baragan J Guillemaut P, Fernandez F, and Gerbaux A Evolution Spontanee des Myocardiopathies Obstructives *Arch Mal Coeur* 69 1023 1976
- 18 Williams R G Ellison C and Nadas A S Development of left ventricular outflow obstruction in idiopathic hypertrophic subaortic stenosis *N Engl J Med* 288 868 1973
- 19 Bulkley B H Weisfeldt M L and Hutchins G V Isometric cardiac contraction: A possible cause of the disorganized myocardial pattern of idiopathic hypertrophic subaortic stenosis *N Engl J Med* 296 1977
- 20 Powell W J Jr Whiting R B Dymally R E and Sanders C A Symptomatic prognosis in patients with idiopathic hypertrophic subaortic stenosis (IHSS) *Am J Med* 55 15 1973
- 21 Claser J Mid systolic A2 Closure in IHSS *Circulation* 51 1172 1975

Copyright information

The appearance of a code at the bottom of the first page of an original article in this journal indicates the copyright owner's consent that copies of the article may be made for personal or internal use or for the personal or internal use of specific clients. This consent is given on the condition, however, that the copier pay the stated per copy fee through the Copyright Clearance Center, Inc., P.O. Box 765, Schenectady, N.Y. 12301, 518-374-4430 for copying beyond that permitted by Sections 107 or 108 of the U.S. Copyright Law. This consent does not extend to other kinds of copying, such as copying for general distribution for advertising or promotional purposes, for creating new collective works, or for resale.

skinesis were encountered. An asynergic segment was considered to have improved following administration of ouabain when it showed a 10 per cent increase²¹ and became worse when exhibited a ≥ 10 per cent decrease in per cent shortening.

Cardiac output (CO), arterial-venous difference and pressure data were collected prior to each ventriculogram. Cardiac output was determined by the Lyons green dye indicator dilution computer. Aortic (AP) and pulmonary artery (PAP) systolic, diastolic and mean, right and left intracardiac systolic and end diastolic, mean right atrial (RAP) and mean pulmonary capillary wedge (PCWP) pressures were measured in each case with Statham model P23Db strain gauges and recorded with an Electronics for Medicine DR 12 Simultaneous recorder. The maximum rate of rise of LV pressure (dP/dt) was obtained with a fluid filled system and a Model RC 1 differential circuit which has a time constant of 0.5 msec and an output that is linearly proportional to the input frequency within ± 5 per cent. Heart rate was monitored throughout the study. In addition, systemic vascular resistance (SVR = $[\text{mean AP} - \text{mean RAP}] / \text{CO}$), pulmonary vascular resistance (PVR = $[\text{mean PAP} - \text{mean PCWP}] / \text{CO}$), LV stroke work index (LVSWI = $\text{SVI} \times [\text{LV systolic mean} - \text{LV}_{\text{ED}}] \times 0.0136$)²² and mean velocity of circumferential fiber shortening ($V_{\text{cf}} = d_{\text{ED}} - d_{\text{ES}} / d_{\text{ED}} \times \text{ejection time}$ where d_{ED} and d_{ES} are left ventricular minor axes in end diastole and end systole)²³ were calculated for each patient. The normal range for V_{cf} in our laboratory is 1.07 ± 0.24 circ/sec.

All coronary cineangiograms were of high technical quality. Significant CAD was considered to be present only when there was at least a 75 per cent occlusion of at least one of the three coronary arteries and when this observation was confirmed by two independent observers. Whenever coronary collaterals were present, the origin and the extent of these collaterals were recorded in detail.

Data were analyzed with Student's *t* test. The *t* test for non paired variables was used when comparing intergroup differences while data comparing pre and post ouabain values within a single group were analyzed with the *t* test for paired variables. All statistical calculations were performed on the Sigma 7 computer at the University of California, Irvine.




Fig. 1 Normal left ventricular silhouette in end systole and end-diastole. End systolic and end-diastolic images were fitted with a longitudinal axis which was quadrisectioned by six hemiaxes (solid hemiaxes: end-diastole; dashed hemiaxes: end-systole).

Results

Of the 21 patients studied (20 males and one female) all had the chest pain syndrome. Seven patients had no CAD detected on coronary angiograms and served as normal (control) subjects (Group I). Fourteen patients had extensive coronary disease (Group II). The mean age of patients in Group I was 46 ± 5 years and in Group II 53 ± 7 years (*P* not significant). Age related changes in ouabain pharmacology²⁴ therefore had minimal (if any) effect on the results of this study.

The complete hemodynamic and volumetric data for Groups I and II before and after ouabain administration are given in Tables I and II. All pre ouabain parameters in both groups were within the normal limits. After ouabain administration, both groups exhibited virtually identical directional responses in all measured parameters. Specifically, the LV end diastolic pressure remained essentially unchanged in both groups. Similarly, ouabain failed to appreciably alter the LV filling pressure, systemic and pulmonary vascular resistance or the heart rate. Cardiac index and LV stroke work index increased slightly after ouabain administration in normals and in patients with CAD, but this increase was not statistically significant. In contrast, the systolic and mean aortic pressure and the indices of contractility (V_{cf} and dP/dt) rose significantly after ouabain infusion in both groups.

Volumetric analysis revealed that LV end diastolic volume does not change significantly after ouabain administration. There was a significant decrease in the end systolic volume following ouabain in both groups, however, with

instance all drugs were discontinued at least 5 days prior to the study without any clinical evidence of deterioration of cardiac function, or increase in chest pain. Only one patient was on a prior chronic digitalis therapy, but this drug was considered to be unnecessary, and was stopped one month before the study without any adverse effects. The only drug continued up to the day of the study was sublingual nitroglycerin. None of the patients had to take nitroglycerin for at least 12 hours prior to cardiac catheterization.

After the completion of the first ventriculogram 0.007 mg/Kg of ouabain was infused intravenously over a five minute period. The infusion mode of administration was deliberately selected in order to produce less variability in the pharmacokinetic constants,⁹ and to minimize the effects of ouabain on systemic and coronary vascular resistance which have been shown to increase significantly if this drug is given as a bolus.¹ The total amount of administered ouabain (based on the 0.007 mg/Kg dosage) ranged from 0.50 to 0.75 mg which is commonly accepted to represent the total digitalizing dose for an average adult.⁴

Following the first ventriculogram (and after the infusion of ouabain) coronary arteriography was performed. Sixty minutes after the first ventriculography (and 20 minutes after coronary angiography) the second left ventriculogram was done. The time span of 60 minutes was selected to assure the peak effect of ouabain¹⁰ and to eliminate the pharmacological effects of the contrast medium on myocardial contractility.^{2,24} Furthermore 20 minutes were allowed to elapse after the coronary cineangiography in order to avoid the possible effects of transient reactive hyperemia on myocardial contractility.²⁵

The reproducibility of the angiographically determined volumes and ejection fraction derived from the two left ventriculograms done during the same catheterization and at a comparable hemodynamic state have been examined previously in our laboratory. In consensus with the data reported by other investigators,² no significant difference was found between volumes and ejection fraction determined from the two sequential studies. Furthermore McAnulty and associates²⁶ have shown that sequential ventriculograms without any pharmacological interventions reproduce areas of LV asynergy that are constant in site and magnitude, and can therefore

be used to study the effects of medical and surgical treatment on left ventricular wall motion abnormalities.

Both selective left ventriculograms were obtained with a No. 8 Cordis pigtail catheter which was positioned in the left ventricle. From five to 50 ml of 76 per cent meglumine sodium diatrizoate (Renografin 76) were injected over a 3 second interval. Left ventriculograms in 30 degree right anterior oblique position were recorded at 64 frames per second on 35 mm Kodak Cinegram F film with Philips 9 inch image intensifier. Only the first four beats after complete opacification were analyzed by two independent observers. If an infrequent premature ventricular contraction was encountered, at least two successive normal sinus beats (following the premature beat) had to occur before a frame was selected for analysis.

A modification²⁷ of the area-length method of Dodge²⁸ was used in the analysis of all LV volumes. End diastolic volume index (EDVI), end systolic volume index (ESVI), stroke volume index (SVI) and ejection fraction ($EF = SVI/EDVI$) were calculated for each patient.

Each ventriculogram was also interpreted qualitatively for vigor and uniformity of contraction at all points along the ventricular outline. A quantitative analysis was performed by combining previously described approaches:^{21,22,29} using internal thoracic structures (spine, no margins or a diaphragm) as fixed reference systems. End systolic (ES) and end diastolic (ED) images were fitted with a longitudinal axis (obtained by dividing the images with a connecting line between the bisected aortic valve and the ventricular apex) and six hemiaxes (perpendicular to the longitudinal axis which was divided into four equal segments) (Fig. 1). The longitudinal axis and each hemiaxis were then measured and normalized as per cent decrease (or increase) in length from the end diastolic dimension.

$$\% \text{ shortening} = \frac{ED \text{ axis} - ES \text{ axis}}{ED \text{ axis}} \times 100$$

A hypokinetic zone was defined to occur when < 25 per cent hemiaxis shortening was observed in the initial ventriculogram.³⁰ According to the classification of Herman and associates³¹ hypokinesis represented the mildest form of asynergy, followed by increasingly more pronounced LV wall motion abnormalities when akinesis and

kinesis were encountered. An asynergic segment was considered to have improved following administration of ouabain when it showed a 10 per cent increase and became worse when exhibited ≥ 10 per cent decrease in per cent shortening.

Cardiac output (CO), arterial-venous difference and pressure data were collected prior to echocardiogram. Cardiac output was determined by the Lyons green dye indicator-dilution computer. Aortic (AP) and pulmonary artery (PAP) systolic, diastolic and mean, right and left ventricular systolic and end diastolic, mean right atrial (RAP) and mean pulmonary capillary wedge (PCWP) pressures were measured in each case with Statham model P23Db strain gauges and recorded with an Electronics for Medicine R 12 Simultaneous recorder. The maximum rate of rise of LV pressure (dP/dt) was obtained with a fluid-filled system and a Model RC 1 differentiating circuit which has a time constant of 0.5 sec and an output that is linearly proportional to the input frequency within ± 5 per cent. Heart rate was monitored throughout the study. In addition, systemic vascular resistance ($SVR = \text{mean AP} - \text{mean RAP} / \text{CO}$), pulmonary vascular resistance ($PVR = [\text{mean PAP} - \text{mean PCWP}] / \text{CO}$), LV stroke work index ($LVSWI = VI \times [LV \text{ systolic mean} - LV_{ED}] \times 0.0136$), and mean velocity of circumferential fiber shortening ($V_{CF} = d_{ED} - d_{ES} / d_{ED} \times \text{ejection time}$, where d_{ED} and d_{ES} are left ventricular minor axes at end diastole and end systole) were calculated for each patient. The normal range for V_{CF} in our laboratory is 1.07 ± 0.24 circ/sec.

All coronary cineangiograms were of high technical quality. Significant CAD was considered to be present only when there was at least a 75 per cent occlusion of at least one of the three coronary arteries and when this observation was confirmed by two independent observers. When no coronary collaterals were present, the origin and the extent of these collaterals were recorded in detail.

Data were analyzed with Student's *t* test. The *t* test for non paired variables was used when comparing intergroup differences while data comparing pre and post ouabain values within a single group were analyzed with the *t* test for paired variables. All statistical calculations were performed on the Sigma 7 computer at the University of California, Irvine.




Fig 1 Normal left ventricular silhouette in end-systole and end-diastole. End systolic and end-diastolic images were fitted with a longitudinal axis which was quadrisectioned by six hemiaxes (solid hemiaxes end-diastole, dashed hemiaxes end-systole).

Results

Of the 21 patients studied (20 males and one female) all had the chest pain syndrome. Seven patients had no CAD detected on coronary angiograms and served as normal (control) subjects (Group I). Fourteen patients had extensive coronary disease (Group II). The mean age of patients in Group I was 46 ± 5 years and in Group II 53 ± 7 years (*P* not significant). Age related changes in ouabain pharmacology therefore had minimal (if any) effect on the results of this study.

The complete hemodynamic and volumetric data for Groups I and II before and after ouabain administration are given in Tables I and II. All pre ouabain parameters in both groups were within the normal limits. After ouabain administration both groups exhibited virtually identical directional responses in all measured parameters. Specifically, the LV end diastolic pressure remained essentially unchanged in both groups. Similarly, ouabain failed to appreciably alter the LV filling pressure, systemic and pulmonary vascular resistance, or the heart rate. Cardiac index and LV stroke work index increased slightly after ouabain administration in normals and in patients with CAD, but this increase was not statistically significant. In contrast, the systolic and mean aortic pressure and the indices of contractility (V_{CF} and dP/dt) rose significantly after ouabain infusion in both groups.

Volumetric analysis revealed that LV end diastolic volume does not change significantly after ouabain administration. There was a significant decrease in the end systolic volume following ouabain in both groups, however, with

Table 1 Hemodynamic and volumetric data before and after ouabain administration—Group I (normals)

Parameter	Before ouabain (mean \pm 1 SD)	After ouabain (mean \pm 1 SD)	P
LVEDP (mm Hg)	8 \pm 3	9 \pm 2	N S
RVEDP (mm Hg)	3 \pm 1	4 \pm 1	N S
Syst AP (mm Hg)	113 \pm 15	130 \pm 26	<0.05
Diast AP (mm Hg)	70 \pm 6	74 \pm 9	N S
Mean AP (mm Hg)	91 \pm 11	99 \pm 13	<0.05
Mean PAP (mm Hg)	12 \pm 3	14 \pm 3	<0.05
Mean RAP (mm Hg)	3 \pm 1	4 \pm 1	N S
Mean PCWP (mm Hg)	5 \pm 2	6 \pm 2	N S
SVR (dynes sec-cm ⁻⁵)	1220 \pm 238	1129 \pm 213	N S
PVR (dynes sec-cm ⁻⁵)	105 \pm 24	94 \pm 37	N S
dP/dt (mm Hg/sec)	1283 \pm 391	1487 \pm 466	<0.05
(A V)O ₂ (vol %)	40 \pm 13	35 \pm 13	N S
CI (L/min/M ²)	31 \pm 0.6	36 \pm 0.4	N S
LVS WI (Gm m/M ² /beat)	47 \pm 11	60 \pm 16	N S
V _{cr} (circ/sec)	0.99 \pm 0.19	1.19 \pm 0.15	<0.001
HR at ventriculogram (beats/min)	76 \pm 9	73 \pm 12	N S
EDVI (ml/M ²)	72 \pm 23	74 \pm 23	N S
FSVI (ml/M ²)	21 \pm 8	15 \pm 5	<0.01
SVI (ml/M ²)	50 \pm 13	58 \pm 20	N S
EF (%)	70 \pm 6	79 \pm 4	<0.01

Abbreviations AP = arterial pressure (A V)O₂ = arterial venous difference CI = cardiac index dP/dt = rate of rise of ventricular pressure EF = ejection fraction EDVI = end-diastolic volume index ESVI = end-systolic volume index HR = heart rate LVEDP = left ventricular end-diastolic pressure LVS WI = left ventricular stroke work index NS = not significant PAP = pulmonary arterial pressure PCWP = pulmonary capillary wedge pressure PVR = pulmonary vascular resistance RAP = right atrial pressure RVEDP = right ventricular end-diastolic pressure SD = standard deviation SVI = stroke volume index SVR = systemic vascular resistance V_{cr} = mean velocity of circumferential fiber shortening

resulting marked increase in the LV ejection fraction ($P < 0.01$)

In order to determine if Group I (normals) and Group II (patients with coronary disease) represented markedly different patient populations, the pre and post ouabain intergroup values were compared. No statistically significant differences were found to exist between Groups I and II for either hemodynamic or volumetric parameters.

None of the patients in Group I but eight patients in Group II had regional disorders of LV contractility, delineated by 23 abnormal hexaxial axes of shortening. In each case, the area of asynergy was supplied by a critically narrowed coronary artery. After ouabain administration 15

Table II Hemodynamic and volumetric data before and after ouabain administration—Group II (patients with coronary artery disease)

Parameter	Before ouabain (mean \pm 1 SD)	After ouabain (mean \pm 1 SD)	P
LVEDP* (mm Hg)	9 \pm 5	9 \pm 4	N S
RVEDP (mm Hg)	4 \pm 2	4 \pm 2	N S
Syst AP (mm Hg)	129 \pm 21	137 \pm 27	<0.01
Diast AP (mm Hg)	72 \pm 9	73 \pm 17	N S
Mean AP (mm Hg)	95 \pm 13	100 \pm 17	<0.05
Mean PAP (mm Hg)	13 \pm 3	13 \pm 3	N S
Mean RAP (mm Hg)	3 \pm 2	4 \pm 2	N S
Mean PCWP (mm Hg)	6 \pm 4	6 \pm 3	N S
SVR (dynes sec-cm ⁻⁵)	1149 \pm 276	1146 \pm 234	N S
PVR (dynes sec-cm ⁻⁵)	91 \pm 30	92 \pm 33	N S
dP/dt (mm Hg/sec)	1677 \pm 576	2078 \pm 571	<0.05
(A V)O ₂ (vol %)	43 \pm 12	44 \pm 11	N S
CI (L/min/M ²)	34 \pm 0.8	36 \pm 0.7	N S
LVS WI (Gm m/M ² /beat)	46 \pm 14	50 \pm 18	N S
V _{cr} (circ/sec)	0.85 \pm 0.24	0.98 \pm 0.30	<0.05
HR at ventriculogram (beats/min)	78 \pm 12	74 \pm 10	N S
EDVI (ml/M ²)	72 \pm 14	70 \pm 14	N S
ESVI (ml/M ²)	25 \pm 7	22 \pm 7	<0.01
SVI (ml/M ²)	46 \pm 13	49 \pm 13	N S
EF (%)	64 \pm 10	70 \pm 9	<0.01

See Table I for abbreviations

out of 23 asynergic segments (65 per cent) improved; seven remained unchanged, and one worsened (Fig 2). In general, only hypokinetic segments managed to return to normal contractility, while akinetic and dyskinetic segments remained in the asynergy zone despite the improvement in their contraction. A typical study is illustrated in Fig 3.

Ten patients out of 14 in Group II were found to have angiographically demonstrable collateral circulation. Among them, three patients with extensive collaterals had no LV asynergy. Alternately, collaterals were present in all but one patient with the LV asynergy. The single patient with the abnormal LV wall motion and no collateral circulation showed the least improvement in the regional LV contractility upon ouabain administration. The other three patients, however, not only had no collaterals but also had no LV asynergy.

At the completion of each ventriculographic or coronary angiographic analysis, the interobserver differences were examined. There was only a




Fig 2 Response to ouabain by 23 abnormal hemiaxes of shortening. Fifteen asynergic left ventricular segments improved, seven remained unchanged and one became worse.

negligible variance in the values obtained by the two observers.

Discussion

The hemodynamic data for Group I (normal) patients in the present study confirm earlier observations that digitals enhances the contractile force (characterized by dP/dt , V_{cr} , etc.) of the normal heart. Various investigators¹ have described significant increases in LV dP/dt after intravenous administration of cardiac glycosides to human subjects with normal or nonfailing hearts. Peak active force and the maximal rate of force development were increased by an average of 21 per cent when digitals was given to normal experimental animals. Sonnenblick and associates found marked increases in the velocity of myocardial shortening after infusion of ouabain to six patients with normal cardiac status.




Fig 3 A representative ventriculographic study in a patient with left ventricular asynergy. The pre-ouabain ventriculogram shows hypokinesis of the inferior wall (segments 4, 5 and 6). Marked improvement in the contraction of the inferior wall is noted after ouabain administration.

In contrast, cardiac output exhibited only an insignificant rise in Group I patients. This finding is consistent with the accumulated evidence that cardiac output and the contractile state of the normal myocardium cannot be related to one another in a simple manner and that augmentation of the latter does not necessarily elevate cardiac output.⁴

The slight increase in the LV stroke work index in the normal subjects is apparently due to the systemic vasoconstriction after ouabain administration and the accompanying rise in the LV systolic pressure. The presence of vasoconstriction and rise in the systolic pressure is also reflected by the significant increase in the mean aortic pressure—a phenomenon that has been previously observed after acute digitalization.³¹ The concomitant increase in the systemic vascular resistance was not observed, however, probably because it was maintained at the pre-ouabain levels by the simultaneous increase in the cardiac output.

LV end diastolic volume and pressure remained unchanged in Group I after ouabain administration. The effects of digitals on LV volumes and ejection fraction in a normal man have not been previously studied. Some investigators have postulated that normal LV end diastolic volume decreases after acute digitalization, presumably because LV end diastolic pressure fell in their experiments while the aortic pressure was held constant. Yet the LV end diastolic pressure more accurately reflects the status of LV compliance rather than end diastolic volume, so that in some patients with chronic heart disease, volumes three to four times normal may occur with diastolic pressures that are normal.³² Covell and co-workers³ found only a slight decrease of LV end

diastolic volume and pressure in normal experimental animals after digitalis administration if the aortic pressure was maintained at a constant level. In an ultrasound study, Mahler and associates²² demonstrated no appreciable change in the LV end diastolic diameter after daily intramuscular injections of digoxin, even though the LV systolic pressure increased by 10 mm Hg from the average control value.

LV end systolic volume decreased, and LV ejection fraction significantly increased in Group I patients after ouabain administration. While no other angiographic studies are available for comparison, two ultrasound investigations^{23, 24} have yielded comparable data. Both studies^{23, 24} have shown that in normal subjects the mean end systolic dimension decreased, and ejection fraction increased²³ after digitalis was administered.

The baseline hemodynamic and volumetric values for patients with CAD (Group II) corresponded closely to their normal (Group I) counterparts and exhibited almost identical changes after ouabain administration. It is, therefore, clear that digitalis produces fundamentally similar responses when given to normal patients or to patients with chronic CAD and nonfailing hearts. There was a uniform and significant increase in all measured indices of LV contractility (dP/dt velocity of circumferential fiber shortening, and LV ejection fraction) after ouabain administration to Group II patients. Similar enhancement of the LV inotropic state had been observed by other investigators^{25, 26} after digitalization of patients with chronic CAD. In contrast, Cohn and associates²⁷ have reported acute deterioration of cardiac function in a small number of patients with CAD after rapid digitalization. All of their patients were also in congestive heart failure; however, and therefore probably represent a different spectrum of subjects than do the patients in this study.

In a recent report De Mols and co-workers² have noted a decrease in the LV end diastolic pressure and volume after ouabain administration to patients with chronic CAD who were thought not to be in congestive heart failure. These observations are contrary to the findings of our study in which LV end diastolic volume and pressure remained essentially unchanged after ouabain infusion. Two possibilities could account for this discrepancy: (1) Patients in the study of

De Mols and colleagues had borderline elevation of LV end diastolic pressure (11.5 ± 1.4 mm Hg) and marked elevation of LV end diastolic volume (100 ± 17 ml/M²) in comparison to the normal LV end diastolic value of 70 ± 20 ml/M² established by Dodge and Baxley.²⁸ It is therefore possible that these patients were in the incipient congestive heart failure which was not clinically apparent, and responded to ouabain with a decrease in the LV end diastolic volume and pressure. (2) In our study, the mean arterial blood pressure rose after ouabain administration while the LV end diastolic pressure remained unchanged. In contrast, De Mols and colleagues describe not only a decrease in the LV end diastolic pressure but also a drop in the mean arterial pressure after ouabain administration. Since it has been demonstrated that decreases in preload and afterload diminish LV end diastolic dimensions,²⁹ the lower post ouabain LV end diastolic volumes in the study of De Mols and colleagues may be secondary to these hemodynamic alterations.

While the results of this study clearly demonstrate that the total LV performance improves when cardiac glycosides are administered to patients with chronic CAD, it was of critical importance to determine if the regional disorders of ventricular contractility also benefit by digitalis therapy. In eight patients from Group II who had LV asynergy, 15 out of 23 abnormally contracting segments improved (65 per cent); seven remained unchanged and only one deteriorated after digitalization. This marked decrease in the regional abnormalities of LV contraction could be considered a relatively unexpected finding. Namely, all of the patients with LV asynergy had normal LV volumes and were not in congestive heart failure. Therefore, their myocardial oxygen consumption should increase after ouabain administration^{30, 31} resulting in an additional metabolic burden to the already ischemic asynergic zones, hence accentuating the abnormal LV wall motion even further. Similar deleterious effects following acute digitalization have been demonstrated in the experimental animals with ischemic myocardial injury, but no ventricular enlargement, the epicardial mapping technique registered augmentation of myocardial damage after infusion of ouabain.^{32, 33} Unfortunately, recent reports^{34, 35} question the relevance of epicardial ST segment mapping in p

the severity of myocardial ischemia and the previous conclusions⁴⁻⁶ may no longer be valid or directly applicable to the findings of this study.

Three recent studies have investigated the contractile performance of infarcted intermediate ischemic and non ischemic ventricular zones in experimental animals after acute myocardial injury.⁴⁻⁶ Digitalis augmented contractility of the intermediate (border) zones indicating that ischemic myocardium retains the capacity to respond to the positive inotropic stimuli of cardiac glycosides. Similar conclusions were reached in a noninvasive study which employed videotracking technique to determine the effect of digitalization on the LV wall motion in patients with a prior myocardial infarction.⁷ While our report represents the first combined hemodynamic-angiographic investigative effort to determine the response of abnormally contracting LV myocardium to digitalis administration in human subjects it is in agreement with the noninvasive and experimental animal studies which have indicated that LV asynergy improves after digitalization.

Numerous mechanisms may be responsible for the improvement of LV asynergy in patients with CAD when treatment with cardiac glycosides is instituted. It has been shown that ouabain increases glucose transport to myocardial tissues⁸ and that the enhanced sugar uptake may be associated with the increased positive inotropic effect of the drug.⁹ Yet it is very doubtful that this mechanism is of major importance in improving contraction of ischemic myocardium in order to provide the required adenosine triphosphate for normal muscular contraction from carbohydrate anaerobically at the same rate as during aerobic metabolism; the glucose utilization rate must increase approximately nineteen fold.

Many investigators have examined the role of endogenous catecholamine release which normally follows the administration of digitalis and how this release modifies the inotropic action of the drug. Some¹⁰⁻¹² conclude that catecholamine stores are not essential for the positive inotropic effect of cardiac glycosides while others¹³⁻¹⁵ claim that the enhanced inotropic action of digitalis is closely linked to the increase in catecholamine concentration in the circulating blood. It has been shown that administration of catecholamines (l-epinephrine) can improve LV motion

abnormalities in patients with CAD.¹⁶ This improvement presumably takes place due to the increased blood flow to marginally ischemic myocardium possibly through collateral channels or through interdigitation of primary vessels originating from the unoccluded coronary artery.¹⁷⁻¹⁹ It is conceivable that a similar mechanism contributed to the improvement of the LV wall motion abnormalities after ouabain administration in our patients with LV asynergy.

A great deal of controversy still exists about the effect of collateral circulation on LV asynergy.²⁰⁻²² It has been shown that digitalis directly augments the coronary collateral blood flow and decreases the myocardial oxygen consumption whenever it reduces the LV diastolic pressure or increases the mean coronary perfusion gradient.²³⁻²⁵ Seven of our eight patients with LV asynergy had extensive coronary collaterals and while there was no change in the LV diastolic pressure after the administration of ouabain the diastolic aortic pressure displayed a modest rise therefore causing a slight increase in the coronary perfusion pressure. It is unresolved if this phenomenon caused an improvement in LV asynergy—not only because of the minimal rise of the coronary perfusion gradient but also because the angiographic visualization of a collateral vessel gives no information about the blood flow that this vessel can actually carry.

Despite the fact that some—or even all of these mechanisms may alter the contractile properties of ischemic myocardium after the administration of cardiac glycosides the primary positive inotropic effect of digitalis on the normal heart is produced by its binding to a site on the cell membrane which in turn results in a series of changes involving the Na⁺/K⁺-ATPase and ultimately provides additional calcium to the contractile proteins.²⁶⁻²⁸ While considerably attenuated,²⁹ the uptake of digitalis continues into the ischemic border zones of the heart.³⁰ It is very likely that it is this fundamental property of cardiac glycosides which is primarily responsible for the increase in contractility of the ischemic myocardium after digitalization.

Summary

In order to evaluate the effects of rapid digitalization on LV volumes, ejection fraction and asynergy 21 patients without heart failure were studied with a combination of hemodynamic and

angiographic techniques before and after administration of intravenous ouabain (0.007 mg/kg). Seven patients had no CAD and served as normal (control) subjects (Group I), while 14 patients had extensive coronary disease (Group II). All pre ouabain parameters were within the normal limits in Group I. After ouabain infusion, all indices of LV contractility dP/dt , V_{CF} , and ejection fraction rose significantly in the normal group, while LV filling pressure and end diastolic volume remained unchanged.

The baseline hemodynamic and volumetric values for Group II patients corresponded closely to their normal (Group I) counterparts and exhibited similar changes after ouabain administration. Eight patients in Group II also had regional disorders of LV contractility, delineated by 23 abnormal hemiaxes of shortening. After ouabain, 15 out of 23 asynergic segments (65 per cent) improved; seven remained unchanged and one worsened. It is therefore concluded that rapid digitalization not only enhances LV performance in normal subjects and in patients with CAD, but can also markedly reduce the extent of LV asynergy.

The authors wish to thank Clifford Risk, Ph.D., for statistical analysis of all the data, and Mrs. Wilma Mottin for her extensive secretarial help in the preparation of this manuscript.

REFERENCES

1. Kumar R, Hood W B Jr, Joison J, Gilmur D P, Norman J C and Abelman W H. Experimental myocardial infarction. VI. Efficacy and toxicity of digitalis in acute and healing phase in intact conscious dogs. *J Clin Invest* 49:358, 1970.
2. Hood W B Jr, Covelli V H and Norman J C. Acute coronary occlusion in pigs. Effects of acetyl strophanthidin. *Cardiovasc Res* 3:441, 1969.
3. Watanabe T, Covelli J W, Maroko P R, Braunwald E and Rose J Jr. Effects of increased arterial pressure and positive inotropic agents on the severity of myocardial ischemia in the acutely depressed heart. *Am J Cardiol* 30:371, 1972.
4. Vatner S F, Higgins C B, Patrick T, Franklin D and Braunwald E. Effects of cardiac depression and of anesthesia on the myocardial action of a cardiac glycoside. *J Clin Invest* 50:2585, 1971.
5. Vatner S F and Braunwald E. Effects of chronic heart failure on the inotropic response of the right ventricle of the conscious dog to a cardiac glycoside and to tachycardia. *Circulation* 50:728, 1974.
6. Williams M H Jr, Zohman L R and Ratner A C. Hemodynamic effects of cardiac glycosides on normal human subjects during rest and exercise. *J Appl Physiol* 13:417, 1955.
7. Rodman T, Gorczyca C A and Pastor B H. The effects of digitalis on the cardiac output of the normal heart at rest and during exercise. *Ann Intern Med* 55:620, 1961.

8. Yankopoulos N A, Kawai, C, Federici, E E, Adler L N and Abelman W H. The hemodynamic effects of ouabain upon the diseased left ventricle. *AM HEART J* 76:466, 1968.
9. Balcon R, Hoy J and Sowton E. Hemodynamic effects of rapid digitalization following acute myocardial infarction. *Br Heart J* 30:373, 1968.
10. Cohn J N, Tristani F E and Akhtar, I M. Cardiac and peripheral vascular effects of digitalis in clinical cardiogenic shock. *AM HEART J* 78:318, 1969.
11. Hodges, M, Friesinger G C, Riggins, R C K and Dagenais G R. Effects of intravenously administered digoxin on mild left ventricular failure in acute myocardial infarction in man. *Am J Cardiol* 29:49, 1972.
12. Rahumtoola S H, DiGirolamo M, Sinno M Z, Loeb H S, Rosen K M and Gunnar R M. Effects of ouabain on impaired left ventricular function during congestive heart failure after acute myocardial infarction. *Circulation* 44:66, 1971.
13. Rahumtoola S H, Sinno M Z, Chuquima R, Loeb H S, Rosen K M and Gunnar R M. Effects of ouabain on impaired left ventricular function in acute myocardial infarction. *N Engl J Med* 287:5, 1973.
14. Lipp H, Denes P, Gambetta M and Resnekov L. Hemodynamic response to acute intravenous digoxin in patients with recent myocardial infarction and coronary insufficiency with and without heart failure. *Chest* 63:862, 1973.
15. Covelli J W, Braunwald E, Ross J Jr and Sonnenblick E H. Studies on digitalis and its effects on myocardial oxygen consumption. *J Clin Invest* 45:1835, 1966.
16. Puri P S and Bing R J. Effect of drugs on myocardial contractility in the intact dog and in experimental myocardial infarction. Basis for their use in cardiogenic shock. *Am J Cardiol* 21:886, 1968.
17. Herman M V and Gorlin R. Implications of left ventricular asynergy. *Am J Cardiol* 23:538, 1969.
18. Britman N A and Levine H J. Contractile element work: A major determinant of myocardial oxygen consumption. *J Clin Invest* 43:1397, 1964.
19. Ross J Jr, Covelli J W and Sonnenblick E H. The mechanics of left ventricular contraction in acute experimental cardiac failure. *J Clin Invest* 46:299, 1967.
20. Koup J R, Greenblatt D J, Jusko W J, Smith T W and Koch-Weser J. Pharmacokinetics of digoxin in normal subjects after intravenous bolus and infusion doses. *J Pharm Biopharm* 3:181, 1975.
21. DeMots H, McNulty J, Porter G and Rahumtoola S. Effects of rapid and slow infusion of ouabain on systemic and coronary vascular resistance in patients without heart failure (Abstr.). *Circulation* 52(Suppl. II):77, 1975.
22. Moe C K and Farah A E. Digitalis and allied cardiac glycosides chap 31 in The pharmacological basis of therapeutics Goodman L S and Gilman A eds. New York 1975. Macmillan Publishing Co. Inc. p. 613.
23. Mullins C B, Leshin S J, Mierzwak D S, Alsbrook H D and Mitchell J H. Changes in left ventricular function produced by the injection of contrast media. *AM HEART J* 83:373, 1972.
24. Hamby R I, Aintablian A, Wisoff B G and Hartstein M L. Effects of contrast medium on left ventricular pressure and volume with emphasis on coronary artery disease. *AM HEART J* 93:9, 1977.
25. Kloster F E, Friesen W G, Green G S and Judkins M P. Effects of coronary arteriography on myocardial blood flow. *Circulation* 46:438, 1972.
26. Gould K L, Lipscomb K and Hamilton G W. Physiologic basis for assessing critical coronary stenosis.

- Instantaneous flow response and regional distribution during coronary hyperemia as measures of coronary flow reserve *Am J Cardiol* 33 87 1974
- Cohn F F Levine J A Bergeron G A and Gorlin R Reproducibility of the angiographic left ventricular ejection fraction in patients with coronary artery disease *AM HEART J* 88 713 1974
- McAnulty J H Kermack E L Rosch J Hatten hauer M T and Rahimtoola S H Spontaneous changes in left ventricular function between sequential studies *Am J Cardiol* 34 23 1974
- Ferlinz J Herman M V, Cohn P F and Gorlin R Comparison of selective left ventriculograms with levo phase ("forward") ventriculograms in patients with coronary artery disease *AM HEART J* 81 721 1976
- Dodge H T Determination of left ventricular volume and mass, *Radiol Clin North Am* 9 443 1971
- Sunderman A D Marpole D and Fallen E L Regional contraction patterns in the normal and ischemic left ventricle in man *Am J Cardiol* 31 484 1973
- Leighton R F Wilt S M and Lewis R P Detection of hypokinesia by a quantitative analysis of left ventricular cineangiograms, *Circulation* 50 121 1974
- Berka V S Bodenheimer M M Shah R and Helfant R H Intervention ventriculography Comparative value of nitroglycerin post-extrasystolic potentiation and nitroglycerin plus post-extrasystolic potentiation, *Circulation* 53 63 1976
- Herman M V, Heine R A, Klein M D and Gorlin R Localized disorders in myocardial contraction Asynergy and its role in congestive heart failure *N Engl J Med* 227 221 1967
- Yang S S Bentivoglio L G Maranhão V and Goldberg H From cardiac catheterization data to hemodynamic parameters Philadelphia 1974 P A Davis Company p 164
- Karlner J S Gault J H Eckberg D, Mullins C B and Ross J Jr Mean velocity of fiber shortening A simplified measure of left ventricular myocardial contractility *Circulation* 44 373 1971
- Colton T Statistics in medicine Boston 1974, Little Brown & Co p 127
- Glantz S A, Kernoff R and Goldman R H Age related changes in ouabain pharmacology *Circ Res* 39 407 1976
- Mason D T and Braunwald E Studies on digitalis IX. Effects of ouabain on the nonfailing human heart *J Clin Invest* 42 1105 1963
- Murphy H W Schreiner B F Bleakley E L and Yu P N Left ventricular performance following digitalization in patients with and without heart failure *Circulation* 30 358 1964
- Williams J F Jr and Potter H D The effect of chronic digoxin administration on the contractile state of normal and nonfailing hypertrophied myocardium *J Clin Invest* 56 71 1975
- Sonnenblick E H Williams J F Jr, Glick G Mason D T and Braunwald E Studies on digitalis XV Effects of cardiac glycosides on myocardial force-velocity relations in the nonfailing human heart *Circulation* 34 537 1966
- Mason, D T Spann J F Jr and Zelis R New developments in the understanding of the actions of the digitalis glycosides *Progr Cardiovasc Dis* 11 443 1969
- Braunwald E On the difference between the heart's output and its contractile state *Circulation* 43 171 1971
- Smith T W, and Haber E Digitalis, *N Engl J Med* 289 1010 1973
- Ross, J. Jr Waldhausen J A and Braunwald E Studies on digitalis I Direct effects on peripheral vascular resistance *J Clin Invest* 39 930 1960
- Ross, J Jr Braunwald E, and Waldhausen J A Studies on digitalis II Extracardiac effects on venous return and on the capacity of the peripheral vascular bed *J Clin Invest* 39 937 1960
- Braunwald, E Bloodwell, R D Goldberg L I and Morrow A G Studies on digitalis IV Observations in man on the effects of digitalis preparations on the contractility of the non failing heart and on total vascular resistance *J Clin Invest* 40 59 1961
- Mason D T, and Braunwald E. Studies on digitalis, V Effects of ouabain on forearm vascular resistance and venous tone in normal subjects and in patients with heart failure *J Clin Invest* 43 532, 1964
- Glover W E, Hanna M J D and Speden R N Actions of cardiac glycosides on the vessels of the forearm and hand *Cardiovasc Res* 1 241 1967
- Somlyo A P and Somlyo A V Vascular smooth muscle II Pharmacology of normal and hypertensive vessels *Pharmacol Rev* 22 249 1970
- Sarnoff S J Gilmore J P Wallace A G Skinner N S Jr, Mitchell, J H and Daggett W M Effect of acetyl strophanthidin therapy on cardiac dynamics oxygen consumption and efficiency in the isolated heart with and without hypoxia *Am J Med* 37 3 1964
- Dodge H T Sandler H Baxley W A, and Hawley R R. Usefulness and limitations of radiographic methods for determining left ventricular volume *Am J Cardiol* 18 10 1966
- Mahler F Karlner J S and O'Rourke R A Effects of chronic digoxin administration on left ventricular performance in the normal conscious dog *Circulation* 50 720 1974
- Crawford M H Karlner J S and O'Rourke R A Favorable effects of oral maintenance digoxin therapy on left ventricular performance in normal subjects Echo cardiographic study *Am J Cardiol* 38 843 1976
- Karlner N H Gilbert C A Pruitt A W and Goldberg L I Effects of maintenance digoxin therapy on systolic time intervals and serum digoxin concentrations, *Circulation* 50 94 1974
- De Mols H Rahimtoola S H Kremkau, E L Bennett W and Mahler D Effects of ouabain on myocardial oxygen supply and demand in patients with chronic coronary artery disease *J Clin Invest* 58 312, 1976
- Cohn K Selzer A. Kersh E S Karpman, L S and Goldschlager H Variability of hemodynamic responses to acute digitalization in chronic cardiac failure due to cardiomyopathy and coronary artery disease *Am J Cardiol* 35 461 1975
- Dodge H T, and Baxley W A Hemodynamic aspects of heart failure *Am J Cardiol* 22 24 1963
- Isedike A J Pasternack A, Sonnenblick, E H and Gorlin R Changes in canine ventricular dimensions with acute changes in preload and afterload *Am J Physiol* 223 820 1972
- Karlner J S and Braunwald, E Present status of digitalis treatment of acute myocardial infarction *Circulation* 45 891, 1972
- Maroko P R Kjekshus J K, Sobel B E Watanabe T Covell J W Ross J Jr and Braunwald E Factors influencing infarct size following experimental coronary artery occlusions *Circulation* 43 67 1971
- Maroko P R and Braunwald E Effects of metabolic

and pharmacologic interventions on myocardial infarct size following coronary occlusion *Circulation* 53(Suppl 1) 11-12 1976

64 Bodenheimer M, Banka V S, Shah R and Helfant R H Dissociation of epicardial ST changes and local contractile ability following experimental coronary revascularization (Abstr) *Circulation* 50(Suppl 111) 111-163 1974

65 Heng M K, Singh B N, Norris R M, John M H and Elliot R H Relationship between epicardial ST segment elevation and myocardial ischemic damage after experimental coronary artery occlusion in dogs *J Clin Invest* 58 1317 1976

66 Puri P S Modification of experimental myocardial infarct size by cardiac drugs *Am J Cardiol* 33 521 1974

67 Kerber R F, Ahhoud F M, Marcus M L and Eckberg D L Effect of inotropic agents on the localized dyskinesia of acutely ischemic myocardium. An experimental ultrasound study *Circulation* 49 1038 1974

68 Banka V S, Chadda K D, Bodenheimer M M and Helfant R H Digitalis in experimental myocardial infarction. Differential effects on contractile performance of ischemic border and nonischemic ventricular zones in the dog *Am J Cardiol* 35 801 1975

69 O'Rourke R, Henning H, Theroux P, Crawford M H and Co J Jr Favorable effects of orally administered digoxin on left heart size and ventricular wall motion in patients with previous myocardial infarction *Am J Cardiol* 37 708 1976

70 Cooper F G, Booker W M and Johnson J H Pharmacological interventions in experimental myocardial infarction. Recent Adv Stud Cardiac Struct Metab 3 831 1973

71 Bihler I and Sawh P C A comparison of the effects of ouabain on sugar and sodium transport and on contractile activity of isolated atria *Proc West Pharmacol Soc* 18 106 1975

72 Wasserman K and Whipp B J Exercise physiology in health and disease *Am Rev Resp Dis* 112 219 1975

73 Braunwald E, Mason D T, Ross J Jr Studies on the cardiocirculatory actions of digitalis *Medicine (Baltimore)* 44 233 1965

74 Brann J F Jr, Sonnenblick E H, Cooper T, Chidsey C A, Wilman V L and Braunwald E Studies on digitalis. XIV Influence of cardiac norepinephrine stores on the response of isolated heart muscle to digitalis *Circ Res* 19 326 1966

75 Lee K S and Klaus W The subcellular basis for the mechanism of inotropic action of cardiac glycosides *Pharmacol Rev* 23 193 1971

76 Seifen F Evidence for participation of catecholamines in cardiac action of ouabain. Release of catecholamines *Eur J Pharmacol* 26 115 1974

77 Tanabe T, Shudo I and Saito H Adrenergic contribution to digitalis action *Proc West Pharmacol Soc* 18 20 1975

78 Horn H H, Teichholz L E, Cohn P F, Herman M V and Gorlin R Augmentation of left ventricular contraction pattern in coronary disease by an inotropic catecholamine. The epinephrine ventriculogram *Circulation* 49 1063 1974

79 Vatner S F, Millard R W, Patrick, T A and Hendrickx G R Effects of isoproterenol on regional myocardial function, electrogram and blood flow in conscious dogs with myocardial ischemia *J Clin Invest* 57 1261 1976

80 Lambert P R, Hess D S and Bache R J Effect of exercise on perfusion of collateral dependent myocardium in dogs with chronic artery occlusion *J Clin Invest* 59 1 1977

81 Carroll R J, Verani M S and Falsetti H L The effect of collateral circulation on segmental left ventricular contraction *Circulation* 50 709 1974

82 Banka V S, Bodenheimer M M and Helfant R H Determinants of reversible asynergy. Effect of pathologic Q waves, coronary collaterals and anatomic location *Circulation* 50 714 1974

83 See J R, Cohn P F, Holman M L, Roberts B H and Adams D F Angiographic abnormalities associated with alterations in regional myocardial blood flow in coronary artery disease *Br Heart J* 38 12, 8 19 6

84 Kirk E S, Nelson G R and Sonnenblick E H Digitalis. Mechanism of action in ischemic heart failure (Abstr) *Circulation* 52(Suppl 1) 11 24 1975

85 Nelson G R and Kirk E S The relative influence of supply vs demand on the level of collateral coronary blood flow (Abstr) *Circulation* 54(Suppl. 1) 11 64 1976

86 Akera T, Blushkin S I, Robin T and Brody T M Cardiac glycosides. Temporal relationship between the inotropic action and binding to and dissociation from Na⁺ K⁺ activated ATPase in vitro *Recent Adv St d Cardiac Struct Metab* 4 149 1974

87 Schwartz A Is the cell membrane Na⁺ K⁺ ATPase enzyme system the pharmacological receptor for digitalis? *Circ Res* 39 2 1976

88 Beller G A, Conroy J and Smith T W Ischemia induced alterations in myocardial (Na⁺ + K⁺) ATPase and cardiac glycoside binding *J Clin Invest* 57 341 1976

89 Beller G A, Smith T W and Hood W B Jr Altered distribution of tritiated digoxin in the infarcted canine left ventricle *Circulation* 46 572 1972

90 Thompson A J, Hargis J, Murphy M L and Doherty J E Tritiated digoxin. XV Tissue distribution in experimental myocardial infarction *Am Heart J* 88 319 1974

Non invasive assessment of left internal mammary-coronary bypass patency using the external Doppler probe

Alberto Benchimol MD
Philippe Reyns MD
Sergio Alvarez MD
Kenneth B Desser MD
Karen McCullough

Phoenix Ariz

The purpose of this paper is to report a new method for the non invasive assessment of left internal mammary-coronary artery bypass patency

Material and method

The study group was comprised of 14 consecutive subjects who underwent left anterior descending coronary artery bypass utilizing the left internal mammary artery. All patients had angina pectoris considered refractory to therapy with nitrates propranolol and other medication. Twelve of 14 subjects also had saphenous vein bypass procedures for obstructive disease in the balance of the coronary artery system. All patients underwent cardiac catheterization 1 to 8 months ($\bar{x} = 4.2$) into the postoperative period. The latter study included native coronary arteriography, left ventriculography and opacification of saphenous vein and internal mammary artery bypass grafts.

Non invasive assessment of internal mammary arterial graft patency was performed within 48 hours of catheterization by means of a commercially available non directional Doppler ultra-




Fig 1 Simultaneously recorded Lead II (LII) of the electrocardiogram, mitral area (MA) phonocardiogram, external carotid artery pulse tracing (CT) and blood velocity signals recorded at the second intercostal spaces (ICS). Right (RIMA) and left (LIMA) internal mammary artery blood velocities are characterized by a large systolic wave succeeded by a smaller diastolic fraction.

sonic probe (Model No 803 Parks Electronics Laboratory Beaverton Oreg). The principles of this technique and its application for the study of phasic instantaneous blood flow velocity have been previously described in detail.¹ With subjects in the supine position the Doppler probe tip was placed at the second intercostal space at the left and right sternal borders. At these respective sites the internal mammary artery

From the Institute for Cardiovascular Diseases, Good Samaritan Hospital, 1033 East McDowell Road, Phoenix, Arizona 85006.
Supported in part by the E. Nicholas and Kim S. Gwirth Memorial Fund, and the Institute for Cardiovascular Diseases.
Received for publication Sept 1, 1977.
Accepted for publication Sept 21, 1977.
Reprint requests: Alberto Benchimol, MD, Good Samaritan Hospital, 1033 East McDowell Road, Phoenix, Arizona 85006.




Fig 2 Lead II (LII) of electrocardiogram, mitral area (MA) phonocardiogram, external carotid artery pulse tracing (CT) and non invasive Doppler blood velocity signals from the right and left internal mammary arteries of a 52 year old woman with a patent left internal mammary artery graft to the left anterior descending coronary artery. Note the high amplitude phasic left internal mammary blood velocity recorded at the second left intercostal space. The internal mammary artery graft was angiographically patent.




Fig 3 Lead II (LII) of electrocardiogram, mitral area (MA) phonocardiogram, external carotid artery pulse tracing (CT) and internal mammary artery blood velocity in a 61 year old man with an occluded left internal mammary artery bypass to the left anterior descending coronary artery. Note the marked reduction of left internal mammary artery (LIMA) blood velocity at the second intercostal space.

blood velocity profile was detected such ultrasonic signals were characterized by a large systolic wave followed by a smaller diastolic fraction. Movement of the probe tip inferiorly along the parasternal border defined the internal mammary artery and its audible blood velocity signals. These latter blood velocity waveforms were easily distinguished from those of the intercostal arteries which require angulation of the Doppler probe tip toward the inferior border of the overlying rib for detection.

In two cases external Doppler blood velocity was performed in the catheterization laboratory during internal mammary graft angiography. Fluoroscopic image intensification demonstrated that the Doppler probe tip was directly over the site of internal mammary graft flow.

Blood velocity signals. Lead II of the electrocardiogram, phonocardiograms and external carotid pulse tracings were simultaneously recorded in an Electronics for Medicine DR II oscilloscope-photographic recorder and stored on tape. Fig 1 demonstrates characteristic internal mammary artery blood velocity signals from a normal subject.

Results

Of 14 patients studied 13 had patent left internal mammary artery grafts demonstrated at cardiac catheterization. Twelve of these 13 subjects had normal left internal mammary arterial Doppler blood velocity waveforms (Fig 2). A 61 year old man with aortic-right coronary artery saphenous vein and internal mammary artery-left anterior descending coronary artery bypass grafts was referred for angiography because of recurrent angina pectoris. Both grafts were shown to be proximally occluded at the time of cardiac catheterization. External Doppler ultrasonic examination indicated a marked attenuation of phasic left internal mammary artery blood velocity signals (Fig 3). A single patient with a patent left internal mammary artery graft was found to have a reduction of peak external Doppler blood velocity. Flow in this particular graft was qualitatively designated as sluggish at angiography.

Discussion

External Doppler ultrasonography has been applied for the determination of saphenous vein

coronary bypass patency.* Owing to its relatively superficial anatomic location the left internal mammary artery is amenable for study with the ungated non directional Doppler ultrasonic probe. Significantly no subject with an angiographically patent internal mammary graft had absent blood velocity signals on non invasive study with this technic.

Advantages of the method include (1) ease of application (2) non invasive audible features and (3) potential for widespread ambulatory follow up of such patients. A larger series of subjects with occlusion of left internal mammary artery grafts at different sites must be systematically studied in order to determine the frequency of false positive and false negative results. The unidirectional non invasive Doppler probe applied in this study does not estimate the magnitude of blood flow actually delivered to the myocardium by the internal mammary graft. Despite this drawback the method does provide information regarding some characteristics of blood transport within these structures.

Summary

Non directional blood velocity of left internal mammary bypass grafts was non invasively studied with the Doppler ultrasonic probe. Thirteen of 14 subjects had angiographic evidence of bypass graft patency and their Doppler signals demonstrated high amplitude phasic blood velocities. A single patient with proximal left internal mammary arterial graft occlusion manifested marked attenuation of Doppler blood velocity signals. It is concluded that this technic offers a potential for ambulatory and in office screening of internal mammary artery bypass graft function.

We would like to acknowledge the technical assistance of Carole Crevier, Sydney Peebles and Kathleen Tustison.

REFERENCES

1. Benchamol, A. and Desser, K. B. Clinical application of the Doppler ultrasonic flowmeter. *Am J Cardiol* 29:540 1972.
2. Gould, K. L., Mozerky, D. J., Hokanson, D. E. et al. A non invasive technic for determining patency of saphenous vein coronary bypass grafts. *Circulation* 66:595 1972.




Fig 2 Lead II (LII) of electrocardiogram mitral area (MA) phonocardiogram external carotid artery pulse tracing (CT) and non-invasive Doppler blood velocity signals from the right and left internal mammary arteries of a 52 year old woman with a patent left internal mammary artery graft to the left anterior descending coronary artery. Note the high amplitude phasic left internal mammary blood velocity recorded at the second left intercostal space. The internal mammary artery graft was angiographically patent.

blood velocity profile was detected such ultrasonic signals were characterized by a large systolic wave followed by a smaller diastolic fraction. Movement of the probe tip inferiorly along the parasternal border defined the internal mammary artery and its audible blood velocity signals. These latter blood velocity waveforms were easily distinguished from those of the intercostal arteries which require angulation of the Doppler probe tip toward the inferior border of the overlying rib for detection.

In two cases external Doppler blood velocity was performed in the catheterization laboratory during internal mammary graft angiography. Fluoroscopic image intensification demonstrated that the Doppler probe tip was directly over the site of internal mammary graft flow.

Blood velocity signals, Lead II of the electrocardiogram, phonocardiograms and external carotid pulse tracings were simultaneously recorded in an Electronics for Medicine DR 8 oscilloscopic-photographic recorder and stored on tape. Fig 1 demonstrates characteristic internal mammary artery blood velocity signals from a normal subject.




Fig 3 Lead II (LII) of electrocardiogram mitral area (MA) phonocardiogram external carotid artery pulse tracing (CT) and internal mammary artery blood velocity in a 61 year old man with an occluded left internal mammary artery bypass to the left anterior descending coronary artery. Note the marked reduction of left internal mammary artery (LIMA) blood velocity at the second intercostal space.

Results

Of 14 patients studied 13 had patent left internal mammary artery grafts demonstrated at cardiac catheterization. Twelve of these 13 subjects had normal left internal mammary arterial Doppler blood velocity waveforms (Fig 2). A 61 year old man with aortic-right coronary artery saphenous vein and internal mammary artery-left anterior descending coronary artery bypass grafts was referred for angiography because of recurrent angina pectoris. Both grafts were shown to be proximally occluded at the time of cardiac catheterization. External Doppler ultrasonic examination indicated a marked attenuation of phasic left internal mammary artery blood velocity signals (Fig 3). A single patient with a patent left internal mammary artery graft was found to have a reduction of peak external Doppler blood velocity. Flow in this particular graft was qualitatively designated as sluggish at angiography.

Discussion

External Doppler ultrasonography has been applied for the determination of saphenous vein

Table 1 Clinical details and trial data in 20 patients with intractable angina

Patient number	Age & sex	Previous therapy	Coronary artery disease (% block)	Trial data					
				Placebo			Perhexiline		
				Weekly GTN	Social home & job activities	Total work (hpm)	Weekly GTN	Social home & job activities	Total work (hpm)
1	46 M	Propranolol	RCA100 LAD 50 C75	13	No change	1823	7	Improved	2430
2	57 M	Propranolol	RCA100 LAD90 C25	20	No change	1343	18	No change	1400
3	57 M	Propranolol	RCA100 LAD90 C25	15	Decreased	2564	15	Improved	3816
4	55 F	Propranolol	RCA50 LAD50	114	No change	610	66	Improved	DNA
5	46 M	Oxprenolol	RCA50 LAD30	35	Decreased	3135	25	No change	1596
6	44 M	Propranolol	RCA75 LAD50 C15	DNT	No change	1230	DNT	Improved	4010
7	53 F	Oxprenolol	RCA50 C95	5	Improved	1 09	12	Decreased	630
8	45 M	Atenolol	RCA75 LAD75 C50	45	Decreased	734	13	Improved	1566
9	49 M	propranolol	RCA100 C50	6	Improved	1836	15	Decreased	612
10	60 M	Oxprenolol, metoprolol	RCA75 LAD75 C50 LMS95	DNT	No change	2676	DNT	No change	3040
11	53 F	Propranolol	C50 LAD25	5	Decreased	454	1	Improved	1188
12	53 M	Propranolol	RCA100 C100	8	Decreased	3197	11	Improved	8840
13	53 M	Oxprenolol	RCA50	DNT	No change	1453	DNT	No change	6240
14	48 M	Oxprenolol	LAD75 C100	8	Decreased	1813	2	Improved	4584
15	46 F	Propranolol oxprenolol	RCA25 LAD50 C25	15	No change	1188	16	Slightly improved	1166
16	1 M	Oxprenolol metoprolol	RCA100 C25	37	Decreased	2377	15	Improved	6120
17	38 M	Propranolol	RCA100 LAD75 C25	7	Decreased	4158	2	Improved	5676
18	47 F	Oxprenolol	RCA100 LAD50	DNT	No change	300	DNT	Improved	1217
19	1 M	Oxprenolol	C75 LAD50	DNT	Decreased	1730	DNT	Improved	3696
20	49 M	Propranolol	RCA75 LAD50 C50	6	No change	4453	2	Improved	6170

Abbreviations: GTN = glyceryl trinitrate; LMS = left main stem; C = circumflex artery; DNA = did not attend; RCA = right coronary artery; LAD = left anterior descending; DNT = did not tolerate.

completion of the trial. A decision was made if there was a definite increase in exercise tolerance and a clear improvement in one of the three following parameters: reduction in GTN consumption, reduction in anginal crises and improvement in home social or job activities. Improvement in any of the three activities was accepted when a patient was able to do more without angina, i.e. dancing, brisk walking, gardening, etc. On the other hand, deterioration meant that such activities had to be abandoned or curtailed because of angina. Each improvement was awarded +1 and each deterioration -1. Student's paired *t* test was used to assess the statistical significance between placebo and perhexiline data.

Results

Eight patients could not complete the trial; three had aortocoronary bypass graft surgery

two withdrew during the first period (one perhexiline and one placebo) because of an increase in angina; one left the area and the two others stopped because of dizziness, tremor, aches and pains. When the code was opened, one of these two patients was found to have been taking placebo. These eight patients did not differ from the other 20 patients as regards their coronary angiographic findings and GTN consumption. Their mean weekly GTN consumption during the two week pre-trial period was 25 tablets as compared with a mean of 27 tablets used by those who completed the study. Of the remaining 20 patients, 14 preferred perhexiline to placebo, three (patient numbers 5, 7 and 9) preferred placebo and in the three others (patient numbers 2, 10 and 15) no decision could be made (Table 1). Of the 14 patients who benefited from perhexiline, 12 improved within the first two weeks of treatment. Patient numbers 18 and 19 noticed a marked

Assessment of perhexiline maleate in angiographically proven intractable angina

A double-blind trial

M Afzal Mir, MB, MRCP, DCH
EM Kafetzakis, MD
Manchester England

The long term treatment of angina has remained unsatisfactory in spite of various therapeutic advances. Numerous reports show that between 20 and 50 per cent of patients with angina do not respond to beta blocking drugs.¹⁻⁴ Aortocoronary bypass graft surgery is ineffective in about 20 per cent patients^{5,6} and the number of patients with intractable angina tends to increase as the time passes after surgery.^{7,8}

Perhexiline maleate (Pexid) a new anti anginal drug has been found to be effective in over 70 per cent of patients with angina.⁹⁻¹¹ These investigators have suggested that perhexiline is effective in many patients with beta blocker resistant angina.¹²⁻¹⁴ The purpose of this study was to assess the efficacy of perhexiline in intractable angina.

Patients and methods

Twenty eight patients with intractable angina who had not responded to 480 mg or more of propranolol or oxprenolol were invited to participate in this study. Coronary angiography showed significant disease (i.e. at least 50 per cent block in one or more vessels) in all. Fourteen patients had three vessel disease, 13 had two vessel blocks and one patient had single vessel disease. Their mean age was 51 years (range 38 to 62 years) (Table I).

This was a randomized double blind placebo controlled study and consisted of a two week control period during which beta blocking agents were withdrawn followed by two six week treatment periods. In each period patients took one tablet (perhexiline 100 mg or placebo) twice a day. Of the first seven patients two had to be withdrawn because of an increased frequency of angina (one on placebo and one on perhexiline) and two others experienced no benefit in either period. The single dose policy was therefore changed to a fixed two dose level as the eighth patient was entered in the trial so that all patients thereafter had one tablet twice a day for the first two weeks of each period and two tablets twice a day for the remaining four weeks of either period.

Each patient attended for an exercise test on a bicycle ergometer (Monark, Sweden) on three occasions before starting the trial at six weeks (the cross over point) and at the completion of the trial at 12 weeks. The patients were instructed not to take glyceryl trinitrate (GTN) on the test day. These patients were severely disabled and we started with low work loads and increased stepwise until angina occurred. Heart rate was monitored and recorded through Lead V₅.

Patients were seen and examined at two weekly intervals. They kept a record of anginal crises (prolonged angina unresponsive to GTN), GTN consumption and of any other symptoms. Blood was collected for transaminases and a Vickers analysis at each visit.

The patient preference for either period was decided by us before the code was broken at the

From the University Department of Cardiology, Manchester Royal Infirmary, Manchester, England.

Received for publication Oct 10 1977

Accepted for publication Oct 25 1977

Reprint requests: M.A. Mir, Department of Medicine, University Hospital of Wales, Heath Park, Cardiff CF4 4XN, United Kingdom.

myocardial oxygen extraction¹. Animal experiments have suggested that perhexiline dilates coronary vessels¹ but Pepine and co workers² were unable to confirm this in humans. Perhexiline like beta blocking drugs but not through beta blockade reduces exercise induced tachycardia and delays angina by a reduction in the rate of rise of heart rate during exercise¹. Our results confirm that perhexiline reduces exercise induced tachycardia (Table II) but this is unlikely to be the sole explanation for its beneficial effects in angina. One of our patients (case 17) improved on perhexiline (Table I) but his heart rate was 70 beats per minute faster than on placebo at the points of angina.

Eight patients (29 per cent) had to be withdrawn from this trial. Three of these had surgery and only two patients taking perhexiline withdrew because of an increase in angina or side effects. The incidence of side effects in this study was higher (50%) than reported by other workers¹ but these did not seriously interfere with patients' daily activities. The rise in serum transaminases was transient as observed in other trials.

We conclude that perhexiline is a valuable drug for treating intractable angina when beta blockers are contraindicated or have failed. It has a special place in those patients in whom there are no graftable vessels beyond a blocked coronary artery and in whom angina has recurred after surgery. Perhexiline is also worth considering when surgical risks are expected to be high.

Summary

We report a randomized double blind placebo controlled trial on perhexiline. Twenty eight patients with beta blocker resistant intractable angina were included but only 20 of these completed the 12 week period of the trial. Perhexiline was effective in 14 patients (70 per cent) as shown by a significant ($P < 0.01$) decrease in glyceryl trinitrate consumption and in anginal crises. Exercise tests on a bicycle ergometer showed a significant ($P < 0.01$) increase in exercise tolerance and a reduction in exercise induced tachycardia. Three patients experienced profound relief from angina and declined to have aortocoronary bypass surgery. The main side effects were tremor, dizziness and nausea but these did not seriously incapacitate the patients.

We conclude that perhexiline is a valuable drug for treating intractable angina especially when surgery is not feasible.

We thank Drs. E. G. Wade, G. Howitt and D. J. Rowlands for allowing us to study the patients under their care. Our thanks are due to Dr. H. C. Masheter of Richardson Merrell Ltd. for advice and for the supplies of perhexiline and placebo used in this study.

REFERENCES

1. Nestel P. J. Evaluation of propranolol (Inderal) in the treatment of angina pectoris, *Med J Aust* 2: 1974 1966.
2. Grant R. H. E., Keelan P., Kernohan R. J., Leonard, J. C., Nancekivell, L. and Sinclair K. Multicenter trial of propranolol in angina pectoris. *Am J Cardiol* 18: 361 1966.
3. Hebb A. R., Godwin T. F. and Gunn H. W. A new beta adrenergic blocking agent, propranolol in the treatment of angina pectoris. *Can Med Assoc J* 98: 246 1968.
4. Sandler G. and Clayton C. A. Clinical evaluation of practolol, a new cardioselective beta blocking agent in angina pectoris. *Brit Med J* 2: 399 1970.
5. Shumway N. E., Fogarty T. J., Daily P. D., Hu M., Brown B. and Harrison D. C. The long term follow up of patients undergoing saphenous vein bypass surgery. *Circulation* 49: 77 1974.
6. Bartel, A. M., Behar V. S., Peter R. H., Orgain E. S. and Hong, Y. Exercise stress testing in evaluation of aortic coronary bypass surgery. Report of 123 patients. *Circulation* 48: 141 1973.
7. Reul G. J., Morris G. C., Howell J. F., Crawford L. S. and Selzer V. J. Current concepts in coronary artery surgery. A critical analysis of 1,387 patients. *Ann Thorac Surg* 14: 243 1972.
8. Segal, B. L., Lakoff W., Najmi M. and Linhart J. W. Editorial. Saphenous vein bypass surgery for coronary artery disease. *Am J Cardiol* 32: 1010 1973.
9. Anderson R. P., Shahbuddin H. R., Bonchek L. J. and Starr A. The prognosis of patients with coronary artery disease after coronary bypass operations. Time related progress of 137 patients with disabling angina pectoris. *Circulation* 50: 274 1974.
10. McNeer J. F., Starman C. F., Bartel A. G., Behar V. S., Kong Y., Peter R. H. and Rosati R. A. The nature of treatment selection in coronary artery disease. Experience with medical and surgical treatment of a chronic disease. *Circulation* 49: 606 1974.
11. Burns-Cox C. J., Chandrasekhar K. P., Ikram H., Ierace T. H., Elcher J., Quinlan C. D. M. and Russell Rees J. Clinical evaluation of perhexiline maleate in patients with angina pectoris. *Br Med J* 4: 586 1971.
12. Dacey A. K., Bagni A. K., Kelkar P. N., Varma S. R., Bhootra R. K. and Amin M. M. Proceedings. Perhexiline maleate: a new anti-anginal drug. *Postgrad Med J* 49 (Suppl. 3): 75 1973.
13. Lockhart J. D. F. and Masheter H. C. Letter. Perhexiline maleate in angina pectoris. *Br Med J* 1: 153a 1976.
14. Morgans C. M. and Russell Rees J. The action of perhexiline maleate on patients with angina. *AM HEART J* 1: 86 329 1973.
15. Pepine C. J., Schang S. J. and Weiner L. Effect of perhexiline on hemodynamic and myocardial metabolic responses in angina pectoris (abstract). *Clin Res* 20: 390 1972.

Table II Clinical and exercise response to perhexiline compared with placebo

	Placebo	Per hexiline	Difference between per hexiline and placebo
Mean resting heart rate	79	80	± 1 $P = NS$
Change in heart rate at comparable loads (mean)	44	27	-17 $P < 0.01$
Work performance (mean KPM)	1975	3356	+1381 $P < 0.01$
Weekly GTN consumption (mean)	23	14	-9 $P < 0.005^*$
Weekly anginal crises (mean number)	13	6	-7 $P < 0.01$

*Student's paired *t* test

reduction in anginal attacks in the third week when the dose of perhexiline had been doubled

GTN consumption and anginal crises Five patients did not tolerate GTN. The remaining 15 patients consumed a mean of 23 GTN tablets a week during placebo and 14 tablets ($P < 0.005$) during the perhexiline period (Table II). The mean number of anginal crises (duration 10 to 12 minutes, unresponsive to GTN) was 13 per week during the placebo period and it dropped significantly ($P < 0.01$) to 6 per week during the perhexiline period.

Exercise performance Exercise data were obtained in 19 patients; one patient (Case 4) went on holiday and did not attend for the test. Fifteen patients improved their exercise performance (work load \times speed \times time) during the perhexiline period and they were able to exercise longer and against higher loads until the point of angina. The increase in the total work varied from 8 per cent (patient 2) to 329 per cent (patient 13) with a mean of 70 per cent ($P < 0.01$) (Tables I and II). Four patients (cases 5, 7, 9 and 15) performed better during the placebo period. The resting heart rate was not different during the two periods but the increase in the heart rate at the comparable work load was significantly ($P < 0.01$) less on perhexiline (27 beats per minute) than on placebo (44 bpm).

Home social and job activities Ten patients showed improvement and two showed deterioration

in all the three activities during perhexiline period. A paired *t* test showed a significant ($P < 0.05$) over all benefit from perhexiline as compared with placebo.

Side effects Fourteen patients (50 per cent) had side effects, two during the placebo period. Dizziness, tremor, aches and pains and nausea occurred frequently but were troublesome in only two patients who withdrew from the trial. One of these was on placebo.

Eleven patients showed a slight rise in serum transaminases (SGOT in all and SGPT in 9) none of these were on perhexiline 400 mg a day while two patients were on placebo. These last two patients had also a slightly elevated creatine kinase (CPK) level, and the rise in transaminases in these two was probably caused by a myocardial ischemic episode. The rise in transaminases was transient and reverted to normal within two weeks in all but two patients. There was no rise in serum bilirubin or alkaline phosphatase levels.

Discussion

Perhexiline was beneficial in 14 patients with intractable angina as shown by a significant reduction in GTN consumption and in anginal crises, an improvement in social or home activities and an increase in exercise tolerance. Six of these (patients 1, 2, 5, 7, 14 and 17) had triple vessel disease and seven (patients 3, 9, 10, 12, 13, 15, and 16) had two vessel disease. Their angina had not responded to an adequate trial with beta blocking therapy and aortocoronary bypass surgery was the only treatment with some chance of relieving their symptoms. However surgery is not without risk, the mortality rate is higher in patients with multiple vessel disease than in single vessel disease. A distinct minority derive no benefit from surgery and have late complications. It must be pointed out that while surgery relieved angina completely in nine out of 29 patients with intractable angina operated upon in our Unit (unpublished data), perhexiline improved only three patients (20 per cent) (cases 3, 4 and 16) to an extent which led to their declining bypass graft surgery. In the remaining 11 responding patients the anginal episodes were significantly reduced but not completely relieved.

The mode of action of perhexiline is not clear though there is some evidence that it increases

Comparative influence of ouabain norepinephrine and heart rate on myocardial oxygen consumption and inotropic state in dogs

Robert C Boerth M.D. Ph.D.
Karl E Hammermeister M.D.
J Richard Warbasse M.D.
Baltimore Md and Nashville Tenn

It is well recognized that tension development in the heart is an important determinant of myocardial oxygen consumption. Another major determinant of myocardial oxygen consumption (MVO) is the velocity of myocardial contraction which is an index of the inotropic state of the heart. A positive linear relationship between MVO and the maximum contractile element velocity has been demonstrated in the intact canine heart when inotropic state is augmented by norepinephrine or by increasing heart rate. However it is not known whether the magnitude of this relationship is the same or different when inotropic state is increased to the same extent by various positive inotropic interventions.

Whereas cardiac glycosides and aglycones have been shown to increase the inotropic state of both normal and failing myocardium it has been reported that these agents either decrease increase or produce no change in MVO. However in many of these studies myocardial tension development was uncontrolled and since tension development is an important determinant

of MVO, changes of this factor might have obscured a positive relationship between inotropic state and MVO.

Coleman¹ demonstrated that when peak developed tension was maintained constant in isometrically contracting cat papillary muscles acetylcholinesterase inhibitors increased both the rate of force development and MVO. Covell and associates² reported similar results for the intact canine heart when there was little change in developed tension. Although these studies indicate there is a positive relationship between inotropic state and MVO when inotropic state is augmented by acetylcholinesterase inhibitors they do not show whether the magnitude of this relationship is the same as that which exists when inotropic state is augmented by other positive inotropic interventions. It was the purpose of the present investigation to directly compare the effects of ouabain and norepinephrine on the relationship between maximum contractile element velocity (ie inotropic state) and myocardial oxygen consumption and further to compare the results produced by these pharmacologic agents with results obtained previously where inotropic state and myocardial oxygen consumption were increased by increasing heart rate. In order to avoid problems related to changes in tension development an isovolumic left ventricular preparation in dogs was employed in which peak left ventricular wall stress (stress = tension per unit cross sectional area) was maintained constant in each experimental animal.

From the Cardiac Service and Laboratories, United States Public Health Service Hospital, L.B. Moore, Md. and the Departments of Pediatrics and Pharmacology, Vanderbilt University School of Medicine, Nashville, Tenn.

This work was supported in part by Grant A-69-5 from the Federal Programs Service-USPHS and by FHS Grant HL 1629.

Received for publication July 1, 1977.
Accepted for publication Feb 13, 1978.

Reprint requests: Robert C. Boerth, M.D., Division of Pediatric Clinical Pharmacology, Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee 37232.

- 16 Hudak W J, Lewis R E and Kuhn W L Cardiovascular pharmacology of perhexiline J Pharmacol Exp Ther 173 371 1970
- 17 Pepine C J, Schang S J and Bemiller C R Effects of perhexiline on coronary hemodynamic and myocardial metabolic responses to tachycardia Circulation 49 887 1974
- 18 Martins de Oliveira J, Lovola S F and Chaves J L D Perhexilene maleate: eighteen months of continuous administration in patients with angina pectoris Postgrad Med J 49 (Suppl) 78 1973
- 19 Newberne J W Proceedings Assessment of safety data from patients on short and long term perhexiline therapy Postgrad Med J 49 (Suppl 3) 190 1973

Information for authors

Most of the provisions of the Copyright Act of 1976 became effective on January 1 1978. Therefore, all manuscripts must be accompanied by the following statement signed by each author: 'The undersigned author(s) transfers all copyright ownership of the manuscript entitled (title of article) to The C V Mosby Company in the event the work is published. The author(s) warrants that the article is original, is not under consideration by another journal, and has not been previously published.' Authors will be consulted, when possible, regarding republication of their material.

Table 1 Effects of norepinephrine and ouabain on left ventricular dynamics and myocardial oxygen consumption

	Norepinephrine		Ouabain	
	Control	Drug effect	Control	Drug effect
HR (beats/min)	156 ± 8	156 ± 8 (NS)	136 ± 5	136 ± 5 (NS)
Lv vol (ml)	15.1 ± 1.5	13.8 ± 1.6 (p < 0.01)	18.5 ± 1.8	17.0 ± 1.7 (p < 0.01)
LVP (mm Hg)	69 ± 5	76 ± 5 (p < 0.01)	75 ± 3	78 ± 3 (p < 0.01)
Lv dP/dt (mm H/sec)	9.4 ± 4.3	10.9 ± 1.1 (p < 0.001)	8.9 ± 3.6	9.6 ± 4.0 (p < 0.05)
P (Gm/cm)	7.9 ± 4.0	28.2 ± 4.1 (NS)	36.0 ± 3.8	30.8 ± 3.7 (NS)
MAX V (muscle lengths/sec)	1.48 ± 0.13	1.81 ± 0.17 (p < 0.01)	1.16 ± 0.09	1.26 ± 0.08 (p < 0.001)
TTP (msec)	139 ± 7	131 ± 7 (p < 0.05)	155 ± 3	151 ± 4 (NS)
Dur (msec)	33° ± 18	318 ± 19 (p < 0.01)	3.7 ± 1.0	3.4 ± 1.9 (NS)
AP (mm Hg)	89 ± 5	97 ± 6 (p < 0.05)	93 ± 6	100 ± 6 (p < 0.01)
CBF (ml/min)	107 ± 12	122 ± 14 (p < 0.01)	83 ± 10	85 ± 10 (NS)
A VO (ml/100 ml)	83 ± 0.7	9.0 ± 0.7 (NS)	9.6 ± 1.0	10.2 ± 1.0 (p < 0.001)
MVO (μl/beat/100 Gm)	43.8 ± 3.7	54.5 ± 4.2 (p < 0.01)	45.4 ± 3.4	49.8 ± 3.4 (p < 0.01)

HR = heart rate; LV = left ventricular volume; LVP = peak left ventricular pressure; LV dP/dt = maximum rate of rise of left ventricular pressure; P = peak left ventricular wall stress; MAX V = maximum observed contractile element velocity at lowest common level of wall stress; TTP = time from onset of left ventricular contraction to peak wall stress; Dur = duration of contraction; AP = mean systolic arterial perfusion pressure; CBF = coronary blood flow; AVO = coronary artery oxygen difference; MVO = myocardial oxygen consumption; numbers in parentheses are p values for statistical comparison before and after drug effects (NS) = no significant difference between control and drug effect; all values are mean ± SEM.

Norepinephrine (2×10^{-6} moles/Kg/minute) was infused intraarterially via a cannula inserted into a carotid artery and advanced so that the tip was in the ascending aorta just above the aortic valve. Ouabain (4×10^{-6} moles/Kg) was injected intravenously over 30 to 60 seconds. As the effects of norepinephrine or ouabain were observed the volume of saline in the left ventricular balloon usually had to be reduced in order to maintain peak calculated LVS constant within each experimental animal. Oscillographic tracings and blood samples were then obtained during steady state conditions of drug effects (5 to 10 minutes after beginning norepinephrine infusion or 15 to 20 minutes after ouabain administration).

At the end of each experiment the weight of the left ventricle including the septum was obtained after removal of the atria and the free wall of the right ventricle. Assuming a specific

gravity of 1 this weight was used as the actual muscle volume of the left ventricle. Values of LVP and Lv dP/dt were determined at 10 msec intervals from two successive beats during each control and drug induced period and were utilized for digital calculation of left ventricular wall stress and contractile element velocity (V_{ce}). In an isovolumic contraction V_{ce} is equal to the rate of lengthening of the series elastic component (V_e) and V_e is directly proportional to the rate of stress development (dS/dt) and inversely related to the stiffness of the series elastic component (dS/dl). Thus V_{ce} in muscle lengths (or circumferences) per second was calculated as $V_{ce} = V_e = (dS/dt)/(dS/dl)$ where $dS/dl = 28S^{0.7}$. Calculated values of simultaneous left ventricular wall stress and V_{ce} were plotted to obtain stress-velocity curves and the maximum observed V_{ce} at the lowest common level of left ventricular wall stress in each animal (MAX V).




Fig 1 Representative stress-velocity relations in a dog before and after norepinephrine. $V_{FLOCITY}$ = contractile element velocity. $STRESS$ = left ventricular wall stress. $LV VOL$ = left ventricular volume. MVO_2 = myocardial oxygen consumption values of MVO_2 (1.32 and 1.62 muscle lengths/sec control and norepinephrine respectively) were obtained at common left ventricular wall stress of 6.2 g/cm².

Methods

Fourteen mongrel dogs of either sex weighing from 16.3 to 32.2 kilograms were anesthetized with intravenous pentobarbital sodium (30 mg/Kg). Respiration was maintained with a positive pressure respirator and the heart and great vessels were exposed through a midline sternotomy. The experimental preparation has been described previously.¹¹ Following the administration of heparin sodium (750 U/kg) the experimental animal was placed on total cardiopulmonary bypass. Venous blood from the superior and inferior venae cavae and from the right ventricle was drained to a reservoir oxygenated, passed through a heat exchanger and pumped retrogradely into a femoral artery. The hilum of each lung was securely ligated and the lungs were removed distal to the ligatures. A thin latex balloon attached to a wide bore metal cannula was placed in the left ventricle through the left atrium, the metal cannula emerged from the left ventricle through a small stab wound in the left ventricular apex. A plastic disc was wedged in the left ventricular outflow tract and a second plastic disc was sutured into the mitral annulus to keep the balloon within the left ventricular cavity. Left ventricular isovolumic contractions were produced by placing known amounts of saline

into the balloon through one arm of a three-way stopcock connected to the metal cannula. Left ventricular pressure (LVP) was measured through the metal cannula by a Statham P23DB pressure transducer attached to the other arm of the three way stopcock. Systemic arterial pressure was measured from the left subclavian artery. The sinoatrial node was crushed and heart rate was maintained constant in each experimental animal by electrical pacing of the right atrium. To eliminate reflex autonomic effects on the heart both vagus nerves were sectioned in the neck and the stellate ganglia were removed bilaterally.

The first derivative of left ventricular pressure with respect to time ($LV dp/dt$) was determined using an active differentiator (Electronic Gas Inc., Model UD 20B). Left ventricular wall stress (LVS) expressed as the tangential tension per unit cross sectional area of the left ventricular wall, was continuously calculated by an analog computer (Electronic Associates Inc., Model TP 20). Assuming a thick walled spherical model, LVS in Gm/cm² was calculated as $P r_i / (r_o^2 - r_i^2)$ where P = left ventricular pressure in Gm/cm², r_i = internal radius of the left ventricular cavity in cm and r_o = internal radius of the left ventricular cavity plus left ventricular wall thickness in cm.¹² Systemic arterial pressure (LVP, $LV dp/dt$, LVS and the electrocardiogram were recorded on a direct writing oscillograph at a paper speed of 100 mm/sec.

Coronary blood flow was determined by timed collection of the venous effluence from the drainage tube in the right ventricle. Coronary venous blood samples were also obtained from this drainage tube. Duplicate determinations of oxygen content of each arterial and coronary venous blood sample were obtained manometrically by the method of Van Slyke and Neill.¹³ MVO_2 (expressed as µl/beat/100 Gm left ventricular weight) was calculated as the product of coronary blood flow times the coronary arteriovenous oxygen content difference divided by heart rate.

In each experimental animal control oscillographic tracings and control arterial and coronary venous blood samples were obtained simultaneously during steady state conditions. Following the control period norepinephrine or ouabain was administered. Six dogs received only ouabain six dogs received only norepinephrine and two animals received ouabain after norepinephrine.

Table II Slopes of linear regression of myocardial oxygen consumption (MVO) versus maximum observed contractile element velocity at lowest common wall stress (MAX V)

Intervention	Slope
Quabain (8)	45.4 ± 12.5
Norepinephrine (8)	34.5 ± 5.6
Increasing heart rate (8)	10.0 ± 1.5†

Numbers in parentheses indicate number of dogs

U is if slopes are (μl/beat/100 gm)/(muscle le gths/sec) values are mean ± SEM

† Values for increasing heart rate were obtained from a previous study. The slope was calculated after subtracting basal MVO consumption from total O₂ consumption on an e basal O₂ consumption per beat decrease with increasing heart rate (see Boerth et al.). Basal O₂ consumption was subtracted from total O₂ consumption of quabain or norepinephrine since heart rate did not change, and thus subtraction of basal O₂ consumption would not change the slope of the regression of these factors on MVO.

‡ Significant difference from slope of quabain at $p < 0.05$ and significant difference from slope of norepinephrine at $p < 0.001$.

MAX V for ouabain and norepinephrine were each statistically compared by t test to that slope obtained by altering heart rate. The results in Table II show that the mean slope produced by increasing heart rate was significantly less than the slope for either norepinephrine or ouabain.

Discussion

Whereas it is well known that catecholamines increase myocardial oxygen consumption confusion has existed in the past as to the oxygen cost of cardiac glycosides and aglycones. In 1932 Rohde and Ogawa¹ reported that in isovolumically contracting cat hearts strophanthidin produced an increase in MVO which was closely proportional to the increase in cardiac work produced by that drug. Other early workers using dog heart-lung preparations reported either a decrease^{2,3} no change⁴ or an increase⁵ in MVO after administration of cardiac glycosides. More recent studies have shown that these agents either increase^{6,7} or produce no change in MVO.

The results of the current study certainly agree with previous investigations showing increased MVO associated with the positive inotropic effect of norepinephrine. In addition our results indicate that the positive inotropic effect of cardiac glycosides is also accompanied by increased myocardial oxygen demands (Table I Figs 2 and 3). These latter results might seem to




Fig 3 Calculated mean regression lines of myocardial oxygen consumption versus inotropic state for ouabain and norepinephrine. See text for derivation of mean regression lines. MVO = myocardial oxygen consumption; MAX V = maximum observed contractile element velocity at lowest common level of left ventricular wall stress. N = number of dogs; p value indicates significance level for a positive slope greater than zero.

be at variance with other reports which showed cardiac glycosides or aglycones to either decrease or not change MVO. However in most of the previous studies involving whole heart preparations there was no control over the amount of stress or tension generated within the left ventricle and it has been shown that cardiac glycosides and aglycones decrease left ventricular end diastolic volume in the intact heart under conditions of constant aortic pressure and heart rate^{8,9} thus decreasing peak left ventricular stress. Since stress development is a major determinant of MVO a fall of peak left ventricular stress in the previous studies would have tended to decrease MVO, and this could easily have obscured a change in MVO associated with increased velocity of contraction. Coleman has shown that when developed stress is maintained constant in cat papillary muscle preparations (either by changing initial length in isometrically contracting muscles or at constant afterload in isotonic contracting muscles) acetylstrophanthidin increases both MVO and velocity of contraction. Thus if one considers the important influence of stress development upon MVO there is good correlation between the present results and the findings of previous investigations and all this information together strongly indicates that the cardiac glycosides and aglycones increase MVO in association with increased velocity of myocardial contraction.




Fig 2 Effects of norepinephrine and ouabain on myocardial oxygen consumption and inotropic state in individual dogs. MVO = myocardial oxygen consumption. MAX V = maximum observed contractile element velocity at lowest common level of left ventricular wall stress.

was used to characterize the inotropic state of the heart.

For each animal the slope and Y intercept of the linear regression of MVO (in $\mu\text{l}/\text{beat}/100\text{ Gm}$ left ventricular weight) versus MAX V were calculated using the method of least squares. The slopes and Y intercepts of individual experiments were averaged for each drug to obtain a mean regression of MVO versus MAX V for norepinephrine and a separate mean regression for ouabain. All statistical comparisons were made using t tests with a criterion of significance of $P < 0.05$.

Results

The effects of norepinephrine and of ouabain on the dynamics of left ventricular isovolumic contraction are shown in Table I. Each of these drugs produced an increase in peak LVP so that to maintain peak calculated wall stress constant in each animal, left ventricular volume usually had to be reduced. Despite the reduction of left ventricular volume, maximum LV dP/dt was increased by both norepinephrine and ouabain, but norepinephrine had the greater effect upon this parameter.

The increased LV dP/dt indicated that each of these drugs augmented the velocity of myocardial contraction. Fig 1 shows representative stress-velocity curves obtained from a dog before and after norepinephrine administration and similar curves were seen in the dogs receiving

ouabain. Each of these agents produced an increase in MAX V together with a simultaneous increase in MVO and these increases occurred at a time when peak left ventricular wall stress (P/λ intercept) was not significantly different than during the control period (Table I).

Fig 2 shows the simultaneous changes in MVO and MAX V for all the dogs receiving either norepinephrine or ouabain. In every case MVO and MAX V were increased by norepinephrine or ouabain but in two of the dogs receiving ouabain the changes were very small. Although the enhanced MVO was greater with norepinephrine than it was with ouabain, norepinephrine also produced a larger augmentation of inotropic state as characterized by increased values of MAX V (Table I, Fig 2). Therefore, it was necessary to determine whether there was a difference between norepinephrine and ouabain in the increase in MVO for an equal increase in inotropic state.

Linear regression of MVO on MAX V was calculated for each of the 16 individual observations using steady state values during the control and drug induced periods as the experimental points. The values of the slopes and Y intercepts for these regressions were then averaged to obtain separate calculated mean regression lines for norepinephrine and for ouabain as shown in Fig 3. The positive slope of this relationship for norepinephrine was $34.5 \pm 5.6 \mu\text{l}/\text{beat}/100\text{ Gm}/\text{muscle lengths/sec}$ (mean \pm SEM) and that for ouabain was $45.4 \pm 12.5 \mu\text{l}/\text{beat}/100\text{ Gm}/\text{muscle lengths/sec}$ (mean \pm SEM). Each of these slopes was highly significant ($p < 0.001$ for norepinephrine and $p < 0.01$ for ouabain) indicating that the augmented inotropic state (i.e. increased MAX V) produced by each of these agents was associated with a significant increase in MVO. However, there was no significant difference between the slopes of these mean regressions for ouabain and norepinephrine. Thus, for an equal increase in inotropic state at constant peak wall stress, ouabain increased MVO, to the same extent as did norepinephrine.

The second purpose of this investigation was to determine whether there was a difference in the myocardial oxygen cost of increased inotropic state produced by pharmacologic agents (ouabain and norepinephrine) as compared to that produced by increasing heart rate. In order to make this comparison the slopes of MVO versus

Summary

The purpose of this study was to compare the myocardial oxygen cost of augmented inotropic state produced by ouabain norepinephrine or increased heart rate. This problem was examined in dogs using an isovolumically contracting left ventricular preparation. Inotropic state was measured as the maximum observed contractile element velocity at the lowest common level of wall stress (MAX V). Peak left ventricular wall stress was maintained constant in each dog so that it would not influence changes in myocardial oxygen consumption (MVO). Ouabain (4×10^{-5} μ mole/Kg) and norepinephrine (2×10^{-5} μ mole/Kg/minute) always augmented inotropic state (MAX V) and increased MVO. The positive slopes of the regression of MVO on MAX V for ouabain (45.4 ± 12.5 μ l/beat/100 Gm/muscle length/sec mean \pm SEM) and norepinephrine (34.5 ± 5.6 μ l/beat/100 Gm/muscle length/sec mean \pm SEM) were not significantly different indicating that for an equal augmentation of inotropic state ouabain increases myocardial oxygen demands to the same extent as does norepinephrine. When the results with ouabain or norepinephrine were compared to results obtained by altering heart rate it was found that increasing inotropic state by these pharmacologic agents is more costly in terms of myocardial energy demands than when inotropic state is enhanced by increasing heart rate.

The authors wish to express their sincere appreciation to Mr. Richard Evans, Mr. Thomas Vondersmith and Mr. Robert Hester for their excellent technical assistance and to Mrs. Kathleen Goralski for her typing of the manuscript.

REFERENCES

1. Sarnoff R B, Braunwald E, Welch G H Jr, Case R B, Stansby W M and Macruz R. Hemodynamic determinants of oxygen consumption of the heart with special reference to the tension time index. *Am J Physiol* 192: 148, 1958.
2. Monroe R G and French G N. Left ventricular pressure-volume relationships and myocardial oxygen consumption in the isolated heart. *Circ Res* 9: 367, 1961.
3. Monroe R G. Myocardial oxygen consumption during ventricular contraction and relaxation. *Circ Res* 14: 294, 1964.
4. Rodbard S, Williams C B, Rodbard D and Berglund E. Myocardial tension and oxygen uptake. *Circ Res* 14: 139, 1964.
5. McDonald R H Jr, Taylor R H and Cingolani, H E. Measurement of myocardial developed tension and its relation to oxygen consumption. *Am J Physiol* 211: 677, 1966.

support to the concept that inotropic state is an important determinant of myocardial oxygen consumption. It has become apparent that in heart muscle neither V_{max} (extrapolated velocity of contraction at zero stress) nor the maximum observed velocity of contraction is an index of inotropic state entirely independent of initial muscle length or preload. However the results of Parnley and co-workers show that in the two element or Voigt three element model of isometric contraction in cat papillary muscles changes in initial heart muscle length (on the ascending limb of the length-stress curve) produce no distinct differences in calculated velocity of contraction at common low levels of stress. In the current study contractile element velocity was calculated using total stress rather than developed stress (see Methods section) so that our results are indicative of a two-element or Voigt three element model of heart muscle. In addition the index of inotropic state was not an extrapolated V_{max} but rather it was the contractile element velocity at the lowest common level of wall stress in each animal (MAX V). Furthermore even if the values of MAX V were influenced more by changes in initial muscle length in the Maxwell three element model of heart muscle this influence would be to decrease MAX V since left ventricular volume was reduced during the drug effects. Thus in that case the observed increases in MAX V would actually have underestimated the augmentation of inotropic state by norepinephrine and ouabain but this would not alter the basic conclusions of the study.

It is concluded that augmented inotropic state produced by either norepinephrine or ouabain is associated with increased myocardial oxygen consumption. Furthermore there is no significant difference between the effects of norepinephrine and ouabain on this relationship so that for an equal increase in inotropic state ouabain increases myocardial oxygen demands to the same extent as does norepinephrine. However when the results produced by these pharmacologic agents are compared with results obtained by altering heart rate it appears that the enhanced inotropic state produced by increasing heart rate is associated with a smaller increase in myocardial oxygen consumption than occurs with either norepinephrine or ouabain.

Since the positive inotropic effects (i.e. increased velocity of contraction) produced by catecholamines and by cardiac glycosides and aglycones are both accompanied by increased MVO it is of basic importance to know whether the increased oxygen demands produced by these two groups of agents are the same or different for an equal increase in inotropic state. The current study shows that in the isovolumically contracting canine left ventricle norepinephrine and ouabain each produce a significant positive linear relationship between MVO, and inotropic state as defined by MAX V (Fig. 3). Furthermore this study shows that there is no significant difference in the slope of this relationship for ouabain compared to that for norepinephrine indicating that ouabain (and presumably other cardiac glycosides and aglycones) increases MVO to the same extent as does norepinephrine for an equal increase in inotropic state.

It was suggested in an earlier study¹¹ using the same experimental preparation, that the increased MVO associated with increased inotropic state might be less when inotropic state is augmented by increasing heart rate as compared to norepinephrine. In order to examine this possibility more closely the slopes of the regression of MVO versus MAX V for ouabain and norepinephrine were each statistically compared to that slope obtained previously by increasing heart rate.¹¹ As shown in Table II the slope produced by increasing heart rate was significantly less than the slope for either norepinephrine or ouabain. Thus, there appears to be a basic difference between the positive inotropic effect of increasing heart rate and the positive inotropic effect of norepinephrine and ouabain such that the augmented inotropic state produced by increasing heart rate is less costly in terms of myocardial energy demands. The reason for such a difference is unknown at present. The difference is probably not due to a metabolic effect of the drugs which is independent of contraction such as direct stimulation of intermediary metabolism or uncoupling of oxidative phosphorylation since pharmacologic concentrations of either catecholamines^{12,13} or cardiac aglycones¹⁴ do not alter resting energy utilization of myocardium. It is possible that basal oxygen consumption per unit time might decrease at higher heart rates and this would significantly increase the slope of

contraction dependent oxygen consumption versus MAX V for increasing heart rate thus eliminating the differences in the slopes for increasing heart rate and the positive inotropic drugs. Although this possibility intuitively seems wrong it can be neither proven nor disproven experimentally. However, a more likely explanation is that increasing heart rate and these positive inotropic drugs may have different effects upon mechanical-chemical coupling in heart muscle.

In order to be sure that the changes in myocardial oxygen consumption observed in the present study were associated only with changes in velocity of contraction it is important to determine whether other factors might have influenced the results. The observed increases in MVO were due to changes in peak left ventricular wall stress because left ventricular volume was reduced in order to maintain peak calculated wall stress constant between the control and drug induced periods in each dog (Table I). Neither can the increased MVO be explained by increased integrated stress since time to peak wall stress and the duration of contraction were not altered by ouabain and were actually decreased slightly by norepinephrine. The observed drug effects were not due to changes in heart rate because heart rate was held constant within each animal. Myocardial fiber shortening against a load to produce external work has also been shown to influence myocardial energy utilization.¹⁵ In the isovolumic left ventricular preparation of the present study no external work was produced although there probably was a small amount of fiber shortening associated with a change in shape of the ventricle during contraction.¹⁶ However, the small amount of fiber shortening would have been similar during the control and drug induced periods in each dog and therefore would not have influenced the results. In addition Pool and colleagues¹⁷ have suggested that fiber shortening *per se* is not a determinant of myocardial energy utilization. Finally, it is unlikely that the observed increases in MVO were due to changes in basal or resting oxygen consumption since catecholamines^{12,13} and cardiac aglycones¹⁴ have been shown to not alter resting energy utilization in isolated myocardial preparations. Thus the positive relationship between MVO and velocity of contraction (inotropic state) in the present study appears to be valid and lends additional

cardiac dose response relationship for intravenously infused glucagon in normal intact dogs and men*

Thomas C Smitherman M D

Roger C Osborn Jr M D *

James M Atkins M D

Dallas Texas

The pancreatic hormone glucagon has been known to have cardiac effects since 1960 when Farah and Tuttle reported that the inotropic and chronotropic effects on the heart that had been attributed to insulin were due to contamination with glucagon. Since that finding there have been numerous studies of glucagon's cardiovascular effects in a number of experimental animal models and in men in various states of health and glucagon has been used clinically as a cardio tonic agent with disparate results. The mechanism of its action on the heart remains unclear. There is substantial suggestive evidence that its action is mediated by cyclic AMP although recent studies in rabbits, guinea pigs and fetal mice have reported an apparent dissociation between the inotropic effects of glucagon and the adeny cyclase system. In some patients with

From the Medical Service of the Dallas Veterans Administration Hospital and the Department of Internal Medicine, Southwestern Medical School University of Texas Health Science Center at Dallas, Dallas, Texas.

This work was supported in part by the Medical Research Service of the Veterans Administration and the American Heart Association. Texas Affiliate M. Osborn was supported by the Moss Heart Fund, Dallas, Texas.

Received for publication November 1, 1977.

Accepted for publication March 6, 1978.

Reprint requests: Dr. Thomas C. Smitherman, Veterans Administration Hospital (11A-6), 4500 South Lancaster Road, Dallas, Texas 75216.

Presented in part at the meeting of the Southern Section of the American Federation for Clinical Research, New Orleans, Louisiana, January 1978.

Present address: Department of Internal Medicine, University of Alabama Medical Center, Birmingham, Alabama 35294.




Fig 1 Mean plasma glucagon levels at varying doses in normal men and dogs

chronic congestive heart failure and cats with chronic right sided failure due to pulmonary artery banding failure of glucagon to exert a cardiac effect has been demonstrated. Consequently a clearer understanding of glucagon's mechanism(s) of action on the heart may prove useful by providing clues to cellular abnormalities important in cardiac decompensation.

Surprisingly the cardiac dose response to glucagon in normal intact unanesthetized animals or men has not been elucidated previously. Since this is relevant to both its clinical use and its mechanism of action we have studied this

- 6 Graham T P Jr, Covell J W, Sonnenblick E H, Ross J Jr and Braunwald E Control of myocardial oxygen consumption. Relative influence of contractile state and tension development. *J Clin Invest* 47: 375 1968
- 7 Ross J Jr, Sonnenblick E H, Kasser C A, Frommer P L and Braunwald E Electroaugmentation of ventricular performance and oxygen consumption by repetitive application of pulsed electrical stimuli. *Circ Res* 16: 332 1965
- 8 Sonnenblick E H, Ross J Jr, Covell J W, Kasser G A and Braunwald E Velocity of contraction as a determinant of myocardial oxygen consumption. *Am J Physiol* 209: 919 1965
- 9 Coleman H N Role of acetylcholinesterase in augmenting myocardial oxygen consumption. Relation of increased O₂ consumption to changes in velocity of contraction. *Circ Res* 21: 487 1967
- 10 Graham T P Jr, Ross J Jr, Covell J W, Sonnenblick E H and Clancy R I Myocardial oxygen consumption in acute experimental cardiac depression. *Circ Res* 21: 123 1967
- 11 Boerth R C, Covell J W, Pool P E and Ross J Jr Increased myocardial oxygen consumption and contractile state associated with increased heart rate in dogs. *Circ Res* 24: 720 1969
- 12 Gremels H Zur Physiologie und Pharmakologie der Energetik des Säugetierherzens. *Naunyn-Schmiedeberg's Arch Pharmacol* 169: 689 1933
- 13 Gremels H Über den Einfluss von Digitalisglykosiden auf die energetischen Vorgänge am Säugetierherzen. *Naunyn-Schmiedeberg's Arch Pharmacol* 186: 625 1937
- 14 Gollwitzer Meier H and Kruger E Herzenergetik und Strophanthinwirkung bei verschiedenen Formen der experimentellen Herzinsuffizienz. *Pflügers Arch* 238: 251 1956
- 15 Rohde E and Ogawa S Gaswechsel und Tätigkeit des Herzens unter dem Einfluss von Giften und Nervenreizung. *Naunyn-Schmiedeberg's Arch Pharmacol* 69: 200 1912
- 16 Peters H C and Visscher M B The energy metabolism of the heart in failure and the influence of drugs upon it. *AM HEART J* 11: 273 1936
- 17 Lee K S, Yu D H and Burstein R The effect of ouabain on the oxygen consumption, the high energy phosphates and the contractility of the cat papillary muscle. *J Pharmacol Exp Ther* 129: 115 1960
- 18 Covell J W, Braunwald E, Ross J Jr and Sonnenblick E H Studies on digitalis. XVI Effects on myocardial oxygen consumption. *J Clin Invest* 45: 1535 1966
- 19 Clancy R L, Graham T P Jr, Powell W J Jr and Gilmore J P Inotropic augmentation of myocardial oxygen consumption. *Am J Physiol* 212: 1055 1967
- 20 Gousios A G, Felts J M and Havel R J Effects of ouabain on force of contraction, oxygen consumption and metabolism of free fatty acids in the perfused rabbit heart. *Circ Res* 21: 445 1967
- 21 Klaus W and Krebs R Über den Einfluss von Digitalis und Strophanthin auf mechanische Aktivität, Sauerstoffverbrauch isolierter Herzmuskelpreparat. *Naunyn-Schmiedeberg's Arch Pharmacol* 261: 18 1968
- 22 Klaus W and Krebs R Über die Abhängigkeit des Strophanthinwirkung auf mechanische Sauerstoffverbrauch vom Funktionszustand des Herzens. *Naunyn-Schmiedeberg's Arch Pharmacol* 264: 33 1968
- 23 Bing R J, Marast F M, Dammann J F Jr, Dwyer A Jr, Heimbecker R, Daley R, Gerard R and Calazel P Effect of strophanthin on coronary blood flow and cardiac oxygen consumption of normal and failing human hearts. *Circulation* 2: 513 1950
- 24 Sarnoff S J, Gilmore J P, Wallace A G, Skorton D S Jr, Mitchell J H and Daggett W M Effect of acetylcholinesterase therapy on cardiac dynamics, oxygen consumption and efficiency in the isolated heart with and without hypoxia. *Am J Med* 37: 3 1964
- 25 Covell J W, Führer J S, Boerth R C and Ross J Jr Production of isotonic contractions in the intact canine left ventricle. *J Appl Physiol* 27: 511 1969
- 26 Van Slyke D D and Neill J M Determination of gases in blood and other solutions by vacuum extraction and manometric measurement. *J Biol Chem* 61: 571 1924
- 27 Sonnenblick E H Series elastic and contractile elements in heart muscle. Changes in muscle length. *J Physiol* 207: 1330 1964
- 28 Steel R G D and Torrie J H Principles and procedures of statistics. New York 1960 McGraw Hill Book Company Inc
- 29 Coleman H N, Sonnenblick E H and Braunwald E Mechanism of norepinephrine induced stimulation of myocardial oxygen consumption. *Am J Physiol* 221: 778 1971
- 30 Lee K S and Yu D H Effects of epinephrine on metabolism and contraction of cat papillary muscle. *Am J Physiol* 206: 520 1964
- 31 Chandler B M, Sonnenblick E H and Pool P E Mechanicochemistry of cardiac muscle. III Effects of norepinephrine on the utilization of high energy phosphates. *Circ Res* 22: 729 1968
- 32 Pool P E, Chandler B M, Seagren S C and Sonnenblick E H Mechanicochemistry of cardiac muscle. II. The isotonic contraction. *Circ Res* 22: 465 1968
- 33 Coleman H N Effect of alterations in shortening and external work on oxygen consumption of cat papillary muscle. *Am J Physiol* 214: 100 1968
- 34 Hawthorne E W Instantaneous dimensional changes of the left ventricle in dogs. *Circ Res* 9: 110 1961
- 35 Pollack G H Maximum velocity as an index of contractility in cardiac muscle. A critical evaluation. *Circ Res* 26: 111 1970
- 36 Farnley W W, Chuck L and Sonnenblick E H Relation of v_{max} to different models of cardiac muscle. *Circ Res* 30: 34 1972

System (Smith Kline Ekoline 20A Electronics for Medicine VR 6 Echocardiographic Processor Electronics for Medicine Simultaneous VR 6 record) Systolic time intervals including LV ejection time index (LVETI) pre ejection period index (PEPI) onset of electrocardiographic Q wave to onset of the second heart sound index (Q S₁) and PEP/LVET were measured according to the methods of Weissler and associates¹⁰ using external transducers (Electronics for Medicine PS 2) or carotid pulse (1 to 30 Hz) and heart sound (30 to 1000 Hz) analysis Blood pressure was obtained by sphygmomanometry and the pressure-rate (double) product was calculated Basal cardiac indices and plasma glucagon levels (PGL) were obtained after administration of normal saline intravenously for 30 to 45 minutes Three infusions of glucagon at rates of 10^{-10} and 10^{-8} moles/minute (Glucagon for injection USP/Lilly in normal saline) were delivered continuously by infusion pump (Harvard Apparatus Inc) for thirty minutes each followed by a single glucagon bolus of 0.5 mg (five men) or 1.0 mg (five men) Cardiac and plasma glucagon determinations were made at the end of each infusion and 2 to 7 minutes following the bolus delivery a time previously shown to be associated with maximal cardiac effect

Experiments with intact unanesthetized dogs In five normal dogs weighing 15 to 38 kilograms an electromagnetic aortic flow probe (Zepeda EDP 2 square wave calibrated as previously described¹¹) a solid state left ventricular pressure transducer (Kongsberg P 21) and indwelling left atrial and pulmonary artery catheters were surgically implanted The dogs recuperated a minimum of one month They were studied while fasting after reaching the basal state 0.5 to 1 hr after transfer to the laboratory Glucagon was infused intravenously at a rate of 2.7×10^{-13} , 2.7×10^{-12} , 1.35×10^{-11} and 2.7×10^{-10} moles/minute for 30 minutes per infusion rate followed by a single 2 mg intravenous bolus Heart rate stroke volume left ventricular pressure and the maximum rate of pressure development (dP/dt) were measured

In two of the dogs the 1.35×10^{-11} moles/minute infusion rate was maintained for 6 hours in order to ascertain if cardiac effects not present during short periods of exposure to pathophysiologic levels would be demonstrated during a more prolonged exposure Hourly hemodynamic and




Fig 2 Left ventricular ejection fraction end-diastolic volume end systolic volume and stroke volume at increasing glucagon infusion rates and mean plasma glucagon levels in normal men Bars represent one standard error of the mean Values that differ significantly from the values of the basal state are indicated by the p value

plasma glucagon measurements were obtained

Since it has been suggested that chronic hyperglucagonemia might occur with chronic congestive heart failure leading to occupation of all available glucagon receptors¹² and hence failure of its cardiac effects one dog received four times daily subcutaneous administration of 1 mg of glucagon for 7 days following the initial glucagon infusion followed by repeat physiologic evaluation following a 2 mg intravenous injection of glucagon

Plasma glucagon and insulin levels were measured by radioimmunoassay¹³ Plasma glucose levels were determined by the glucose oxidase method¹⁴

Table 1 Hemodynamic indices as a function of glucagon infusion rates in normal men—glucagon infusions rate (moles/minute)

	Basal	10 *	10	10 *	Bolus .5 mg	Bolus 1 mg
HR (Min)	55.9 ± 1.9(10)	56.8 ± 2.2(10)	58.4 ± 3.4(5)	69.9 ± 3.3(5)	67.2 ± 1.7(5)	9.5 ± 6.0(3)
BP(SYS) (mm Hg)	117 ± 3(10)	120 ± 4(10)	112 ± 4(5)	122 ± 5(5)	131 ± 6(5)	128 ± 9(3)
BP(DIA) (mm Hg)	74 ± 3(10)	70 ± 3(10)	72 ± 6(5)	75 ± 7(5)	77 ± 3(5)	70 ± 8(3)
PRP (Sys BPxHR/100)	65.6 ± 4.0(10)	68.5 ± 4.2(10)	65.6 ± 5.4(5)	93.4 ± 6.3(5)	87.0 ± 4.0(5)	173.4 ± 14.8(3)
CO (liters/min)	5.0 ± 0.3(10)	5.2 ± 0.3(10)	5.2 ± 0.3(5)	6.7 ± 0.8(5)	6.4 ± 0.6(5)	8.6 ± 0.4(4)
EDV (ml)	118 ± 7(10)	125 ± 8(10)	117 ± 13(5)	124 ± 9(5)	132 ± 16(5)	113 ± 11(4)
ESV (ml)	35 ± 4(10)	33 ± 3(10)	23 ± 4(5)	26 ± 3(5)	27 ± 4(5)	74 ± 9(4)
SV (ml)	88 ± 5(10)	92 ± 6(10)	90 ± 9(5)	96 ± 8(5)	103 ± 15(5)	91 ± 17(4)
EF (%)	73 ± 2(10)	74 ± 2(10)	77 ± 1(5)	77 ± 2(5)	79 ± 3(5)	79 ± 9(4)
PWD (mm)	10.8 ± 0.4(10)	11.0 ± 0.3(10)	11.5 ± 0.4(5)	13.0 ± 0.6(5)	14.0 ± 0.7(5)	17.3 ± 1.4(4)
PWV (mm /sec)	36.6 ± 1.4(10)	30.5 ± 1.6(10)	38.3 ± 2.4(5)	45.2 ± 2.6(5)	43.1 ± 3.1(5)	41.4 ± 3.1(4)
QSI (msec)	527 ± 3(10)	530 ± 4(10)	522 ± 10(5)	519 ± 3(5)	529 ± 9(5)	531 ± 9(5)
LVETI (msec)	421 ± 3(10)	424 ± 5(10)	423 ± 6(5)	426 ± 4(5)	443 ± 13(5)	438 ± 5(3)
PEPI (msec)	108 ± 3(10)	104 ± 13(10)	104 ± 13(5)	93 ± 3(5)	86 ± 7(5)	80 ± 6(5)
PEP/LVET	260 ± 009(10)	261 ± 016(10)	248 ± 019(5)	221 ± 012(5)	183 ± 026(5)	204 ± 019(3)
\bar{V}_{cr} (circumferential/sec)	1.03 ± 0.4(9)	1.15 ± 0.4(8)	1.20 ± 0.6(5)	1.32 ± 0.8(4)	1.48 ± 0.27(5)	1.47 ± 0.6(4)
D to E slope (mm /sec)	285 ± 29(10)	290 ± 36(9)	268 ± 45(5)	298 ± 28(5)	308 ± 70(5)	379 ± 34(4)
Plasma glucagon levels (pg /ml)	226 ± 65(10)	309 ± 109(9)	1930 ± 730(5)	27300 ± 700(5)	44000 ± 11800(5)	119000 ± 41000(3)
Plasma insulin levels (U /ml)	9 ± 3(9)	14 ± 4(10)	45 ± 13(4)	76 ± 14(5)	26 ± 8(5)	56 ± 23(5)
Plasma glucose levels (mg /dl)	65 ± 9(9)	86 ± 2(8)	127 ± 8(5)	98 ± 19(5)	69 ± 10(4)	100 ± 27(5)

All values are mean ± SEM

Values in parenthesis are number of subjects

cardiac dose response of glucagon in dogs and men

Materials and methods

Experiments in normal men Ten paid informed volunteers all young men, mean age 22 with normal cardiac history, physical exam and electrocardiogram were studied non invasively in the supine position and the post absorptive state. Measurements of the echocardiographic indices

of left ventricular function including end systolic (ESV) end diastolic (EDV) and stroke volume (SV) ejection fraction (EF) mean posterior wall velocity (PWV) and displacement (PWD) rate of mitral valve opening (D to E slope) were made by the methods of Feigenbaum¹ and mean circumferential fiber shortening rate (\bar{V}_{cr}) were made by the methods of Cooper and colleagues² using a 2.25 MHz transducer (Smith Kline C 14) and an M mode strip chart echocardiographic




Fig 3 Mean circumferential fiber shortening rate (\bar{V}) left ventricular posterior wall displacement and mean velocity in normal men at increasing infusion rates and mean plasma glucagon levels in normal men. Bars represent one standard error of the mean. Values that differ significantly from the values of the basal state are indicated by the p value.

diographic assessment of left ventricular performance demonstrated small yet significant evidence for an enhanced inotropic state at a mean plasma glucagon level of 2000 pg/ml, a level only slightly higher than those reported in a number of stressful pathologic states such as infections, ketoacidosis, burns, trauma, and myocardial infarction.³ The small (5 per cent) but significant increase in ejection fraction was due to a significant decrease in end systolic volume without a statistically significant change in diastolic volume (Fig 2). At this glucagon




Fig 4 Heart rate and cardiac output in normal men at increasing glucagon infusion rates and mean plasma glucagon levels. Bars represent one standard error of the mean. Values that differ significantly from the values of the basal state are indicated by the p value.

level there was also a significant increase in posterior wall displacement (Fig 3). The small increases in stroke volume, posterior wall velocity and V_{cr} at this infusion level were not significant. With the next infusion level associated with a mean plasma glucagon concentration of 27,300 pg/ml, the magnitude of the chronotropic and inotropic response were almost as great as those observed following the injection of a bolus of glucagon. There were significant changes in ejection fraction and posterior wall displacement and velocity at this level. Heart rate and cardiac output were modestly raised at mean glucagon levels of 27,300 pg/ml and above (Fig 4). The increase in cardiac output was almost exclusively secondary to the chronotropic effect, since stroke volume was only slightly raised. The D to E slope of the anterior leaflet of the mitral valve was not

Table II Hemodynamic measurements in dogs at various glucagon infusion rates (moles/minute)

	Basal	Infusion rate						
		2.7×10^{-10}	1.4×10^{-9}	2.7×10^{-9}	1.4×10^{-8}	2.7×10^{-8}	2.7×10^{-7}	2 mg bolus
HR (min)	92 ± 14 (5)	99 ± 18 (5)	101 ± 19 (4)	95 ± 10 (5)	104 ± 14 (4)	98 ± 11 (5)	138 ± 5 (5)	141 ± 16 (5)
SV (ml)	22.5 ± 4.3 (5)	22.7 ± 4.4 (5)	22.3 ± 4.0 (4)	22.3 ± 4.4 (5)	23.7 ± 5.1 (4)	22.3 ± 3.8 (5)	21.7 ± 3.0 (5)	23.1 ± 3.0 (5)
CO (L/min)	2.14 ± 0.60 (5)	2.31 ± 0.62 (5)	2.24 ± 0.89 (4)	2.03 ± 0.75 (5)	2.45 ± 1.15 (4)	2.12 ± 0.70 (5)	3.01 ± 1.07 (5)	3.42 ± 1.8 (5)
dP/dt (mm Hg/sec)	2739 ± 135 (5)	2991 ± 312 (5)	2899 ± 70 (4)	2672 ± 156 (5)	2333 ± 235 (4)	2860 ± 156 (5)	3710 ± 107 (5)	4192 ± 161 (5)
LAP (mm Hg)	6.5 ± 0.6 (5)	5.3 ± 0.5 (5)	6.2 ± 1.0 (4)	5.6 ± 1.0 (5)	2.9 ± 2.0 (4)	2.8 ± 1.0 (5)	1.3 ± 1.6 (5)	1.6 ± 1.1 (5)
Plasma glucagon level (pg/ml)	188 ± 40 (5)	201 ± 33 (4)	900 ± 10 (2)	37.0 ± 1390 (5)	14 580 ± 3870 (4)	31 500 ± 5840 (4)	261 000 ± 61 200 (5)	24 000 ± 80.00 (8)
Plasma glucose level (mg/dl)	98 ± 5 (4)	117 ± 11 (4)	100 ± 0 (4)	111 ± 12 (4)	101 ± 10 (4)	99 ± 6 (4)	109 ± 4 (4)	111 ± 9 (4)
Plasma insulin level (μv/ml)	22 ± 8 (4)	22 ± 4 (4)	34 ± 15 (4)	34 ± 19 (4)	29 ± 17 (4)	39 ± 31 (4)	42 ± 30 (4)	43 ± 95 (4)

All values ± S.E.M.

Value in parenthesis is number of values

Data were analyzed by Student's *t* test for paired observations

Results

Plasma glucagon levels Plasma glucagon levels increased in a linear fashion (Fig 1). The infusion levels were chosen to deliver approximately equivalent amounts to men and dogs relative to body weight. The maximum infusion rate in dogs was 10 times higher than that in man so that the levels achieved after the bolus injection were no greater than with the highest infusion level.

In men, somewhat higher plasma glucagon levels were achieved following the bolus than with any infusion level.

The infusion levels were chosen to achieve plasma glucagon levels equivalent to those seen physiologically (up to 350 mg/ml) and pathophysiology (400 to 1500 pg/ml) as well as those achieved following the intravenous injections (1 to 10 mg) and infusions (1 to 16 mg/hr)

that have usually been employed for cardiovascular effects.

In men and dogs infusion of approximately 10^{-10} moles/min/Kg (10^{-10} moles/minute for men and 2.7×10^{-10} moles/minute for dogs) hardly elevated the plasma levels above the basal level. A tenfold higher infusion rate led to levels near those seen pathophysiologically. At a rate of 10^{-9} moles/minute for men (2.2 mg/hr) and 2.7×10^{-9} moles/minute for dogs (0.8 mg/hr) the infusion rate was in the range utilized clinically. Levels approximately 10 times pathophysiology and 100 times basal were attained. At the final infusion rate in dogs, and following the bolus injection in both men and dogs also at doses frequently employed clinically the levels were tenfold higher again.

In both men and dogs there were predictable small increases in both plasma glucose and insulin following glucagon infusion (Tables I and II).

Experiments in normal men In men echocardiographic




Fig 5 Systolic time intervals in normal men at increasing glucagon infusion rates and mean plasma glucagon levels. Left ventricular ejection time index (LVETI) Pre ejection period index (PEPI) and the ratio PEP/LVET are shown. Bars represent one standard error of the mean. Values that differ significantly from the values of the basal state are indicated by the *p* value.

cant increase in the inotropic state of the heart. Although these disorders are associated with a hyperactive circulatory state it is unlikely that hyperglucagonemia plays a major role in the generation of the hyperkinetic state since the measured changes were so slight at this level and the much more efficacious catecholamines are also present in increased amounts in these states. At a mean glucagon level of 27 300 pg/ml which was achieved with 30 minutes of infusion with 10 moles/minute (22 mg/hr) the inotropic and chronotropic changes were nearly equal in magnitude to the maximal changes seen in this study following a bolus injection of 0.5 or 1 mg. While gastrointestinal symptoms in man prevent absolute confirmation of the minimal




Fig 6 Cardiac output stroke volume and heart rate for intact unanesthetized dogs at increasing glucagon infusion rates and mean plasma glucagon levels. Bars represent one standard error of the mean. Values that differ significantly from the values of the basal state are indicated by the *p* value.

dose necessary to achieve maximal cardiovascular responses the half maximal serum concentration appears to be approximately 10^{-8} M (35 000 pg/ml).

Nausea and vomiting are the chief problems limiting the use of glucagon as a cardiotonic agent. They were rare at an infusion rate of 10^{-8} moles/minute but common following a 1 mg bolus injection. Since it appears possible in normal men to achieve nearly maximal cardiac effects with infusion of 10^{-8} moles/minute (0.2 mg/minute) of glucagon with virtually no gastrointestinal side effects achieving higher levels may be unnecessary and undesirable. However the disparate responses to glucagon in a heterogeneous population makes it necessary to apply this conclusion to patients with cardiac disease with caution.

Whether the tenfold lower threshold for cardiac effect in men compared to dogs is a real

Table III

Threshold of cardiac effects of glucagon in normal men

Infusion level (moles/min)	1×10	1×10^{-6}	1 mg bolus
Mean plasma glucagon level (pg/ml)	1930	27300	11'000
Index of cardiac performance	ESV	HR	LVETI
	FF	CO	
	PWD	PEPI	
	V_{cr}	PEP/LVET	
		PRP	

Threshold of cardiac effects of glucagon in normal unanesthetized dogs

Infusion level (moles/min)	27×10	27×10^{-6}	
Mean plasma glucagon level (pg/ml)	31,500	161000	
Index of cardiac performance	LVEDP	HR	
		CO	
		LV dP/dt	

changed significantly at any glucagon level, although this measurement has been found to correlate with the cardiac output³

Systolic time intervals were less sensitive for detection of the cardiovascular effects of glucagon than the echocardiographic measurement of ejection fraction and posterior wall displacement. At a mean plasma glucagon level of 27,300, PEPI and PEP/LVET were significantly shortened (Fig 5). LVETI was not significantly increased until a mean plasma glucagon level of 112,000 pg/ml was reached following the bolus injection. Q S₁I was not significantly changed at any level of hyperglucagonemia.

Neither the systolic nor the diastolic blood pressure was significantly changed at any level (Table I). Due to the chronotropic effect the pressure-rate product was significantly raised at plasma glucagon levels of 27,300 pg/ml and above.

Experiments in intact unanesthetized dogs In dogs the threshold for cardiac stimulation was higher than in man. The earliest detectable significant change was a drop in left atrial mean pressure, which occurred at the 27×10^{-6} moles/minute infusion rate, corresponding to a glucagon level of 31,500 pg/ml (Table II). As in man there was no significant change in the stroke volume at any level. Heart rate and consequently cardiac output were significantly elevated at glucagon levels of 224,000 and 261,000 pg/ml (Fig 6). The rate of rise of left ventricular pressure also showed no change until a mean glucagon level of 224,000 pg/ml was reached (Fig 7).

Both dogs that received a 6 hour constant infusion of glucagon maintained a hyperglu-

gonemic state, one from 500 to 3300 pg/ml and the other from 3200 to 4,100 pg/ml. Neither demonstrated detectable inotropic or chronotropic effects.

The dog that was subjected to a chronic hyperglucagonemic state for one week had a cardiac response to a repeat injection of 2 mg of glucagon that was similar in magnitude to that of the earlier response (heart rate increased 11 per cent after one week compared to 18 per cent before and a 53 per cent increase in LV dP/dt after one week compared to 35 per cent before).

Discussion

This study defines for the first time the cardiac dose response to glucagon in normal unanesthetized men and dogs. The cardiovascular effects of glucagon reported here are generally in agreement with the results of previous studies with a modest but significant chronotropic and inotropic response. While there was a modest rise in blood pressure, it did not reach statistical significance whereas others using only higher doses of glucagon have found significant increases in systolic and diastolic pressure levels. The failure of the small increase in stroke volume to reach a statistically significant level is in agreement with some studies and in disagreement with others. As might be anticipated from the common clinical practice of administering very large doses of glucagon the threshold for any cardiac effect is high in both men and dogs (Table III). However in men at a plasma glucagon level of about 2000 pg/ml which is only slightly greater than that reported in a number of stressful pathological states there was evidence of a small but signifi-




Fig 5 Systolic time intervals in normal men at increasing glucagon infusion rates and mean plasma glucagon levels. Left is tricusular ejection time index (LVETI). Pre ejection period index (PEPI) and the ratio PEP/LVET are shown. Bars represent one standard error of the mean. Values that differ significantly from the values of the basal state are indicated by the *p* value.

cant increase in the inotropic state of the heart. Although these disorders are associated with a hyperactive circulatory state it is unlikely that hyperglucagonemia plays a major role in the generation of the hyperkinetic state since the measured changes were so slight at this level and the much more efficacious catecholamines are also present in increased amounts in these states. At a mean glucagon level of 27 300 pg/ml which was achieved with 30 minutes of infusion with 10 moles/minute (22 mg/hr) the inotropic and chronotropic changes were nearly equal in magnitude to the maximal changes seen in this study following a bolus injection of 0.5 or 1 mg. While gastrointestinal symptoms in man prevent absolute confirmation of the minimal




Fig 6 Cardiac output stroke volume and heart rate for intact, unanesthetized dogs at increasing glucagon infusion rates and mean plasma glucagon levels. Bars represent one standard error of the mean. Values that differ significantly from the values of the basal state are indicated by the *p* value.

dose necessary to achieve maximal cardiovascular responses the half maximal serum concentration appears to be approximately 10^{-7} M (35 000 pg/ml).

Nausea and vomiting are the chief problems limiting the use of glucagon as a cardiostimulant. They were rare at an infusion rate of 10^{-8} moles/minute but common following a 1 mg bolus injection. Since it appears possible in normal men to achieve nearly maximal cardiac effects with infusion of 10^{-8} moles/minute (0.2 mg/minute) of glucagon with virtually no gastrointestinal side effects achieving higher levels may be unnecessary and undesirable. However the disparate responses to glucagon in a heterogeneous population makes it necessary to apply this conclusion to patients with cardiac disease with caution.

Whether the tenfold lower threshold for cardiac effect in men compared to dogs is a real




Fig 7 Peak rate of left ventricular pressure rise in intact unanesthetized dogs at increasing glucagon infusion rates and mean plasma glucagon levels. Bars represent one standard error of the mean. Values that differ significantly from the values of the basal state are indicated by the p value.

difference or an apparent one due to the different techniques that were employed to assess the response cannot be stated with certainty. The magnitude of the difference favors a true difference.

Since normal men rarely come to diagnostic cardiac catheterization, the dose response relation was determined non invasively by means of systolic time intervals and echocardiography. This study provides evidence that non invasive assessment of cardiac performance is satisfactory for the determination of the effect of pharmacological interventions in normal subjects. Echocardiographic evaluation, especially of wall motion and ejection fraction, appears to be more sensitive than determination of systolic time intervals.

Summary

The mechanism of glucagon's cardiac effects is not well understood. As the cardiac dose response to glucagon in intact animals has not been elucidated, this was determined in normal men and dogs. In man, heart rate, blood pressure, systolic time intervals, and echocardiographic indices of ventricular wall motion were determined. Plasma glucagon levels (PGL) were measured by radioimmunoassay. Men received 3 glucagon infusions of 10^{-10} to 10^{-8} moles/minute, followed by a bolus of

0.5 mg or 10 mg. Small but significant changes were observed in ejection fraction and left ventricular posterior wall displacement at the 10^{-8} moles/minute infusion rate (mean PGL 19 ng/ml), a PGL close to that of some pathophysiologic states such as burns, ketoacidosis, and acute myocardial infarction, while cardiac output, heart rate, and other indices of cardiac performance were significantly changed only at the 10^{-8} moles/minute and bolus injections. Some indices, notably stroke volume, were unchanged.

In dogs, left ventricular (LV) pressure, LV pressure derivative (LV dP/dt), and aortic flow were measured with implanted LV solid state pressure transducers and electromagnetic flow probes. Dogs received six infusions from 2.7×10^{-11} to 2.7×10^{-8} moles/minute followed by a bolus of 2 mg. In dogs, significant changes occurred in LV dP/dt at 2.7×10^{-8} moles/minute (mean PGL 31.5 ng/ml) and in heart rate at 2.7×10^{-8} moles/minute only. It appears that substantial hemodynamic effects do not appear in man or dogs until PGL 10 to 100 times those seen in pathophysiologic states are achieved. Thus it seems unlikely that glucagon contributes substantially to the hyperdynamic circulatory conditions observed in these states. Significant hemodynamic response to glucagon was noted in normal men, however, at a PGL less than that achieved by usual pharmacologic doses of glucagon, and this lower PGL was not associated with the gastrointestinal symptoms commonly observed clinically.

We acknowledge with gratitude the technical assistance of Mrs. Arvella Peters and Mr. Paul Jordan and the secretarial assistance of Mrs. Betty Bibus. We are indebted to Dr. Roger Unger for the performance of glucagon, glucose, and insulin assays.

REFERENCES

- Farah A and Tuttle R. Studies on the pharmacology of glucagon. *J Pharmacol Exp Ther* 129:49, 1960.
- Kones R J and Phillips J H. Glucagon: Present status in cardiovascular disease. *Clin Pharmacol Ther* 12:427, 1971.
- Entman M L. The role of cyclic AMP in the modulation of cardiac contractility. In Greengard P and Robison G A, editors. *Advances in cyclic nucleotide research*, vol 4. New York: 1974. Raven Press, p 163.
- Smitherman T, Shapiro W, and Taubert K. Responsiveness of rabbit heart to glucagon: Dissociation of inotropic and adenyl cyclase activation (Abstr). *Clin Res* 24:6A, 1976.
- Henry P D, Dobson J G, and Sobel B E. Dissociation between changes in myocardial cyclic adenosine monophosphate and contractility. *Circ Res* 36:392, 1975.

6. Wendthall K, Allen D O, Karlsson J, Wakeland J R, and Clark C M. Species variability and apparent disparities between changes in beating adenylate cyclase activation and cyclic AMP concentration. *J Clin Invest* 52:551 1966
7. Gold H K, Prindle K H, Levey G S, and Epstein S E. Effects of experimental heart failure on the capacity of glucagon to augment myocardial contractility and activate adenyl cyclase. *J Clin Invest* 48:999 1970
8. Feigenbaum H. *Echocardiography*. Philadelphia 1976. Lea & Febiger pp 89-309-323
9. Cooper R H, O'Rourke D A, Karlner J S, Peterson K L, and Leopold W H. Comparison of ultrasound and cineangiographic measurements of the mean rate of circumferential fiber shortening in man. *Circulation* 46:914 1972
10. Weissler A M, Harris W S., and Schoenfeld C D. Bedside technique for the evaluation of ventricular function in man. *Am J Cardiol* 23:571 1969
11. Byrne M J, Pigott V, and Spodick D H. Cardiovascular responses to glucagon. Physiologic measurement by external recordings. *Am Heart J* 83:635 1972
12. Horwitz L D, Atkins J M, and Leshem J. Role of the Frank-Starling mechanism in exercise. *Circ Res* 31:868 1972
13. Glick G. Glucagon: A perspective (Editorial). *Circulation* 45:513 1972
14. Faloona G R, and Unger R H. *Methods of Hormone Immunoassay*. Jaffe B M, and Behrman H R, editors. New York 1974. Academic Press p 317
15. Herbert V, Lau K S, Gotlib C W, and Bleicher S J. Coated charcoal immunoassay of insulin. *Clin Endocrinol* 25:1375 1965
16. Warner W H, Ruy G, and Weisinger H. Properties of a new chromagen for the blood sugar determination according to the GOD/POD method. *E Anal Chem* 252:274 1970
17. Rocha D M, Santeusanio F, Faloona G R, and Unger R H. Abnormal alpha cell function in bacterial infection. *N Engl J Med* 14: 00 1973
18. Muller W A, Faloona G R, and Unger R H. Hyperglucagonemia in diabetic ketoacidosis: its prevalence and significance. *Am J Med* 54:52 1973
19. Wilmore D W, Moylan J A, Pruitt H A, Lindsey C A, Faloona G R, and Unger R H. Hyperglucagonemia after burns. *Lancet* 1:73 1974
20. Lindsey C A, Santeusanio F., Braaten J., Faloona G R, and Unger R H. Pancreatic alpha cell function in trauma. *Trans Assoc Am Physicians* 227:757 1974
21. Willerson J T, Hutchison D R, Lechin S J, Faloona G R, and Unger R H. Serum glucagon and insulin levels and their relationship to blood glucose values in patients with acute myocardial infarction and acute coronary insufficiency. *Am J Med* 57: 47 1974
22. Laniado S, Segal P, and Esrig B. The role of glucagon hypersecretion in the pathogenesis of hyperglycemia following acute myocardial infarction. *Circulation* 48:797 1973
23. Pennock H, Kingsley B, Kawai N, Kimbiris D., and Segal B L. Stroke volume and cardiac output measured by echocardiography (Abstract). *Am J Cardiol* 26:121 1970

Table I Comparison of paired myocardial O_2 consumption index values* obtained in five preparations with constant heart rate of 120/minute at regular and bigeminal rhythm before and after coronary artery occlusion (CAO)

	Regular rhythm	Bigeminal R R 300 msec	Mean difference	p
Control	8.81 \pm 0.54	10.89 \pm 0.95	2.07 \pm 0.40	NS
CAO	9.70 \pm 0.75	10.38 \pm 0.70	0.68 \pm 0.44	NS
Mean difference	0.89 \pm 0.60	-0.50 \pm 0.70		
p	NS	NS		

MVO I in ml/minute 100 Gm LV

†Abbreviations NS = non significant R R = coupling interval

Table II Comparison of paired myocardial O_2 consumption index values* obtained in six preparations at constant heart rate of 120/minute and bigeminal rhythm with coupling intervals of 300, 400 and 500 msec (regular rhythm) before and after coronary artery occlusion (CAO)

Coupling interval (msec)	300	400	500	p†
Control	10.67 \pm 0.80	10.00 \pm 0.57	8.69 \pm 0.44	NS
CAO	10.49 \pm 0.51	9.54 \pm 0.50	9.44 \pm 0.67	NS
Mean difference	-0.18 \pm 0.56	-0.47 \pm 0.42	0.75 \pm 0.17	
p†	NS	NS	NS	

MVO I in ml/minute 100 Gm LV

†p obtained by t test for paired observations

‡p obtained by analysis of variance

§Abbreviations NS = non significant

pCO of blood samples were determined using the Astrup apparatus. The hematocrit (HCT) of the arterial samples was also determined. Myocardial oxygen consumption (MVO) was derived as the product of the CBF and the corresponding arteriovenous oxygen difference (Ca-cvO) and was then indexed to 100 Gm of wet left ventricular myocardium (MVO I) (vide infra).

Mean pressure ($\bar{A}P$) at the aortic root was set and maintained throughout the experiment at 70 mm Hg by adjusting the resistance of the extra corporeal arterial circuit while adjustment of the capacitance was used to maintain an appropriate wave form. Cardiac output (i.e. venous return pump rate) was set and kept at 120 ml/minute per kilogram of body weight (Kg BW) in all instances except during the studies of the HR effect at constant stroke volume, where the cardiac output was set as the product of stroke volume equal to 1 ml/Kg BW and the HR. Data were recorded on an oscillographic recorder (Honeywell 1612 Denver, Colo).

Twenty seven mongrel dogs were studied. In seven of these animals the previously prepared

anterior interventricular branch of the left coronary artery was ligated and additional data were obtained after coronary artery occlusion (CAO). The experimental protocols followed were:

A Effect of the number of PVDs on MVO I In seven preparations with heart rate fixed at 120/minute data were obtained in random order of sequence at regular rhythm and while PVDs with fixed coupling (R R) interval of 300 msec and compensatory pause of 700 msec were introduced at regular pentatetral, tri and bigeminal patterns. Thus five data points were obtained in each preparation for constant heart rate of 120/minute and 0 (regular rhythm), 24, 30, 40 and 60 PVDs per minute. Individual regression lines of MVO I versus number of PVDs per minute were derived and the mean weighted slope for the group was then calculated by multiplying the slope of each line (b_i) by the reciprocal square of its standard error ($w_i = 1/sb_i^2$) and dividing the sum of products (Σwb_i) by the sum of the weights (Σw).

In five of the seven preparations with CAO data were obtained before and after CAO at a rate

of 120/minute with both regular and bigeminal rhythm (60 PVDs/minute with 300 msec R R interval). Statistical evaluation of these data was performed by the *t* test for paired observations.

Effect of coupling interval of PVDs on MVOI. In nine preparations with heart rate of 170/minute half of the depolarizations were induced prematurely in bigeminal pattern. Then the coupling interval (R R) of these PVDs was changed in steps multiple of 50 msec at random order from 500 msec (regular rate of 120/minute) to 190 to 230 msec (paired pulse stimulation) while adjustments for proper full compensatory pause were made. Four to eight data points were obtained within this range of R R intervals from each preparation and individual regression lines of MVOI versus R R were computed by regression analysis. Then the mean weighted slope for the group was calculated as described.

In six of the seven preparations with CAO data were obtained before and after CAO at heart rate of 120/minute and bigeminal rhythm at R R intervals of 300, 400 and 500 msec. These data were evaluated by analysis of variance for the coupling interval effect and by the *t* test for paired observations for the CAO effect.

Effect of heart rate. The effect of heart rate on MVOI was first studied in a control group of three preparations by changing HR in random sequence among the rates of 90, 120, 150 and 180/minute. Initially CO was kept constant at 120 ml/minute Kg BW. Then at each HR the CO was adjusted in order to maintain a constant SV of 1 ml Kg BW. During the constant SV runs the resistance of the systemic circuit was adjusted to maintain a constant mean aortic root pressure of 70 mm Hg. Regression lines of MVOI versus HR were obtained at constant SV as well as at constant CO. The lower magnitude of HR effect on MVOI obtained during the constant CO runs could be attributed to the reciprocal decrease of SV with increase in HR but other factors could not be excluded. It was therefore hypothesized that if the HR to SV relationship were the sole factor responsible then data obtained at constant SV could be derived from data obtained at constant CO and vice versa through correction for this factor. In order to test this hypothesis MVOI data obtained at each HR step for constant CO of 120 ml/minute Kg BW were normalized for constant SV of 1 ml Kg BW




Fig. 3 Effect of heart rate on MVOI in three preparations studied both at constant cardiac output (CO) (dots) and constant stroke volume (SV) (solid triangles). Solid lines are regression slopes of the mean values. Corresponding regression slopes of calculated values are indicated with broken lines. Values calculated from actual constant SV data normalized for constant CO (open circles) and vice versa (open triangles) are shown. Actual and calculated data did not differ significantly. Error terms have been omitted (see Table III). MVOI = myocardial oxygen consumption index.

and vice versa. The normalization was done as follows. Because CO per minute was fixed at 120 ml/minute Kg BW, SV at HR of 120/minute was 1 ml Kg BW. At different HR SV changed with the reciprocal 120/HR. Therefore MVOI data obtained at constant CO were divided by this reciprocal. For the opposite correction i.e. of data obtained at constant SV for constant CO the data were multiplied by the same reciprocal. The derived data and their regression slopes were then compared with those of actual data.

The HR effect was further studied in 14 animals at constant CO by changing HR at two to four of the above heart rates and/or 200/minute. In a subgroup of six of these animals MVOI was also determined after CAO at the same heart rates except 180/minute. The mean MVOI values were calculated for the available control and post CAO data at each HR step and the regression lines of mean MVOI values versus HR were obtained. Post CAO data at each HR step were also compared with their corresponding control data using the *t* test for paired observa-

Table III Comparison of effect of heart rate (HR) on myocardial O₂ consumption and left ventricular dynamics at constant cardiac output (CO) and constant stroke volume (SV)

	HR	90	120	150	180			
	no	3	3	3	3	$y = b \text{ HR} + a$	r	p
MVOI <	Constant CO	10.09 ± 0.90		11.51 ± 1.06	12.43 ± 1.61	0.027 HR + 4.48	0.98	< 0.01
	Constant SV	8.27 ± 0.98	10.45 ± 1.09	13.63 ± 1.31	18.57 ± 2.83	0.114 HR - 2.60	0.94	< 0.01
	Constant CO	8.2 ± 0.04		6.4 ± 0.50	6.1 ± 0.50	-0.023 HR + 10.68	0.94	< 0.01
LVdp <			8.0 ± 0.50					
	Constant SV	6.4 ± 0.60		8.0 ± 0.50	9.5 ± 0.70	0.030 HR + 3.83	0.95	< 0.01
	Constant CO	14.70 ± 88		12.60 ± 70	14.20 ± 76	-0.90 HR + 1504		
LVdp/dt <			13.80 ± 48					
	Constant SV	11.50 ± 72		16.30 ± 60	21.50 ± 96	10.83 HR + 115	0.99	< 0.01

Values were obtained at constant CO of 120 ml/minute Kg BW and at constant SV of 1 ml Kg BW At HR of 120/minute all values are identical Abbreviations: b = intercept b = slope LV dp/dt = first derivative of LV pressure (mm Hg/sec) LVdp = LV end-diastolic pressure mm Hg MVOI = myocardial O₂ consumption index (ml O₂/minute 100 Gm⁻¹ LV) r = correlation coefficient

trons Subsequently, MVO₂I per beat was calculated for each heart rate for both control and post CAO periods and regression lines of mean values were derived Then because CO per minute was fixed at 120 ml/minute Kg⁻¹ BW MVOI values per beat were normalized as described to a SV of 1 ml Kg⁻¹ BW per beat for all heart rates by multiplying each value by the 120/HR factor Regression lines were then obtained on these normalized data

At the end of the experiment the heart was excised and the left ventricle was weighed in order to index CBF and MVO to 100 Gm to LV myocardium In the animals with ligated coronary artery Evans blue dye was injected distal to the ligature and the stained myocardium was excised and weighed for gross estimation of the ischemic area

Error terms in the data reported are standard error of mean (± SE)

Results

1 MVO effect

A Number of PVDs The effect of number of PVDs with fixed coupling interval on MVO₂I is shown in Fig 1 Individual regression lines obtained from seven preparations had SE less than 0.024 and did not show significant correlation of MVOI with the number of PVDs The weighted mean slope at 95 per cent confidence limits (CL) was 0.003 ± 0.002 ml O₂/minute 100 Gm⁻¹ LV per PVD, and not significantly different from zero

In the group of five preparations where MVOI was measured at regular and bigeminal rhythm before and after CAO no significant difference was found by t test comparison of data paired either for rhythm or for control versus post CAO conditions (Table I) However the difference between regular and bigeminal rhythm at control approached statistical significance ($p < 0.05$)

B Coupling interval The effect of varying coupling interval of a fixed number of PVDs on MVOI is shown in Fig 2 In the nine preparations with heart rate of 120/minute in bigeminal pattern and varying coupling (RR) interval linear regression analysis of MVOI data versus RR' showed significant correlation of these variables in only two out of nine preparations ($r = 0.92$ and 0.97 $p < 0.05$) with only one of the two slopes being significantly different from horizontal (-0.013 ± 0.003) The SE of the regression lines was less than 0.008 and the mean weighted slope was -0.001 ± 0.005 ml O₂/minute 100 Gm⁻¹ LV per ms of RR interval lengthening at 95 per cent confidence limits

In the group of six preparations with constant heart rate of 120/minute and bigeminal rhythm MVOI at RR intervals of 300, 400 and 500 msec (regular rhythm) was not found to differ significantly by analysis of variance either before or after CAO Also no statistically significant difference was found between paired pre and post CAO data at any coupling interval (Table II)

C Heart rate effect The effect of HR changes

Table IV Effect of heart rate on coronary and left ventricular dynamics before (C) and after coronary artery occlusion (CAO)

	HR	90	120	150	180	200	$Y = b \text{ HR} \pm \text{SE}$	r	p
	no	8	14	12	6	3			
Control									
MVO I	8.15 ± 0.41	8.99 ± 0.24	10.22 ± 0.37	11.01 ± 0.62	11.27 ± 0.25	0.93 HR + 6.30	.98	< 0.05	
LVEDp	8.1 ± 0.9	7.9 ± 0.7	6.5 ± 0.6	6.3 ± 0.6	6.0 ± 1.0	-0.21 HR + 10.05	.96	< 0.05	
LV dp/dt	1415 ± 98	1303 ± 64	1277 ± 68	1336 ± 94	1435 ± 73	17 HR + 1327	-	NS	
	no	3	6	4	-	3	$Y = b \text{ HR} \pm b$	r	p
CAO									
MVO I	9.57 ± 1.10	9.58 ± 0.64	10.47 ± 0.80		11.20 ± 0.53	0.17 HR + 7.88	.97	< 0.05	
LVEDp	9.7 ± 1.9	7.3 ± 1.3	6.8 ± 1.4		5.7 ± 1.9	-0.33 + 12.06	.93	NS	
LV dp/dt	1500 ± 161	1330 ± 99	1337 ± 44		1435 ± 73	-4.1 + 1441	-	NS	

Abbreviations: MVO I = myocardial O₂ uptake (ml O₂/100 gm LV); LVEDp = LV end diastolic pressure (mm Hg); LV dp/dt = first derivative of LV pressure (mm Hg/sec).

(90 to 180/minute) on MVO I in the three preparations studied both at constant CO and constant SV conditions is shown in Table III. At all HR steps values obtained at constant CO of 120 ml/minute Kg BW and normalized for constant SV of 1 ml Kg BW did not differ significantly by paired t test from values actually obtained at this constant SV (Fig 3). Also values obtained at constant SV of 1 ml Kg BW and normalized for constant CO of 120 ml/minute Kg BW did not differ from actual values obtained at this constant CO. The slopes of regression lines obtained from these actual and calculated data did not differ significantly in the individual preparations and for the group however slopes obtained at constant SV were significantly steeper (Fig 3).

The effect of HR changes at constant CO on MVO I and left ventricular dynamics before and after CAO is shown in Table IV. Regression lines of the mean MVO I values obtained at each HR were $0.025 \pm 0.003 \text{ ml O}_2/\text{minute } 100 \text{ Gm LV}$ per beat of HR increase ($r = 0.98$, $p < 0.005$) for the pre CAO data and 0.017 ± 0.003 ($r = 0.97$, $p < 0.05$) for the post CAO data (Fig 4). Slopes of these lines were not found to differ significantly. T-test comparison of paired MVO I data obtained before and after CAO showed no significant difference at any HR.

The relationship between these MVO I data expressed per beat and the heart rate is shown in Fig 5a. Parallel regression lines with negative slopes -0.35 ± 0.06 and $-0.38 \pm 0.09 \text{ } \mu\text{l O}_2/100$

Gm LV per beat of HR increase ($r = 0.96$ and 0.92 , $p < 0.001$) were derived for the control and post CAO data respectively. The apparent curvature was not found statistically significant. Lines of same per beat data normalized for constant SV of 1 ml Kg BW as described (Fig 5b) were also parallel but slopes were positive (0.20 ± 0.02 and 0.17 ± 0.05 , $r = 0.98$ and 0.90 , $p < 0.001$ respectively).

2 LVED pressure effect LVED pressure remained below 12 mm Hg in all experiments. During PVD introduction variation of LVED pressure on a beat to beat basis resulted from changing duration of the filling period according to the RR interval and the compensatory period but the average values did not change.

The small LVED pressure decrease associated with increasing HR at constant CO (Table III) was significant ($r = 0.94$, $p < 0.05$). Regression lines with similar slopes ($r = 0.96$ and $r = 0.93$) were also derived from the control and post CAO mean data of Table IV. In contrast at constant SV the LVED pressure increased with increasing HR ($r = 0.95$, $p < 0.05$) (Table III).

3 LV dp/dt effect During PVD introduction LV dp/dt varied on a beat to beat basis as result of RR interval and SV variations associated with the duration of filling period. However LV dp/dt values obtained with regular rate immediately after discontinuation of PVDs did not differ significantly from control.

Heart rate changes at constant CO resulted in highest LV dp/dt values at HR of 90 and 180/

Table III Comparison of effect of heart rate (HR) on myocardial O₂ consumption and left ventricular dynamics at constant cardiac output (CO) and constant stroke volume (SV)

	HR	90	120	150	180	$y = b \text{ HR} + a$	r	p
	no	3	3	3	3			
MVO I	Constant CO	10.09 \pm 0.90*		11.51 \pm 1.06	12.43 \pm 1.61	0.027 HR + 7.48	0.98	< .01
	Constant SV	8.27 \pm 0.98		13.63 \pm 1.31	18.57 \pm 2.83	0.114 HR - 2.60	0.99	< .01
	Constant CO	8.2 \pm 0.04		6.4 \pm 0.00	6.1 \pm 0.50	-0.023 HR + 10.68	0.94	< .01
LVdp			8.0 \pm 0.50					
	Constant SV	6.4 \pm 0.60		8.0 \pm 0.50	9.5 \pm 0.70	0.030 HR + 3.83	0.99	< .01
	Constant CO	14.70 \pm .88		12.60 \pm .70	14.20 \pm .76	-0.90 HR + 15.04		
LVdp/dt			13.80 \pm .88					
	Constant SV	11.50 \pm .72		16.30 \pm .60	21.50 \pm .96	10.83 HR + 11.5	0.99	< .01

Values were obtained at constant CO of 100 ml/minute Kg⁻¹ BW and at constant SV of 1 ml Kg⁻¹ BW. At HR of 100/minute all values are identical. Abbreviations: a = intercept; b = slope; LV dp/dt = first derivative of LV pressure (mm Hg/sec); LVdp = LV end-diastolic pressure (mm Hg); MVO I = myocardial O₂ consumption index (ml O₂/minute 100 Gm⁻¹ LV); r = correlation coefficient.

tions. Subsequently MVO I per beat was calculated for each heart rate for both control and post CAO periods and regression lines of mean values were derived. Then because CO per minute was fixed at 120 ml/minute Kg⁻¹ BW, MVO I values per beat were normalized as described to a SV of 1 ml Kg⁻¹ BW per beat for all heart rates by multiplying each value by the 120/HR factor. Regression lines were then obtained on these normalized data.

At the end of the experiment the heart was excised and the left ventricle was weighed in order to index CBF and MVO to 100 Gm to LV myocardium. In the animals with ligated coronary artery Evans blue dye was injected distal to the ligature and the stained myocardium was excised and weighed for gross estimation of the ischemic area.

Error terms in the data reported are standard error of mean (\pm SE).

Results

1 MVO effect

A Number of PVDs. The effect of number of PVDs with fixed coupling interval on MVO₂I is shown in Fig 1. Individual regression lines obtained from seven preparations had SE less than 0.024 and did not show significant correlation of MVO I with the number of PVDs. The weighted mean slope at 95 per cent confidence limits (CL) was 0.003 ± 0.002 ml O₂/minute 100 Gm⁻¹ LV per PVD and not significantly different from zero.

In the group of five preparations where MVO I was measured at regular and bigeminal rhythm before and after CAO, no significant difference was found by t test comparison of data paired either for rhythm or for control versus post CAO conditions (Table I). However, the difference between regular and bigeminal rhythm at control approached statistical significance ($p < 0.2$).

B Coupling interval. The effect of varying coupling interval of a fixed number of PVD or MVO I is shown in Fig 2. In the nine preparations with heart rate of 120/minute in bigeminal pattern and varying coupling (R R') interval linear regression analysis of MVO I data versus R R' showed significant correlation of these variables in only two out of nine preparations ($r = 0.92$ and 0.97 , $p < 0.05$) with only one of the two slopes being significantly different from horizontal (-0.013 ± 0.003). The SE of the regression lines was less than 0.008 and the mean weighted slope was -0.001 ± 0.005 ml O₂/minute 100 Gm⁻¹ LV per ms of R R' interval lengthening at 95 per cent confidence limits.

In the group of six preparations with constant heart rate of 120/minute and bigeminal rhythm MVO I at R R' intervals of 300, 400, and 500 msec (regular rhythm) was not found to differ significantly by analysis of variance either before or after CAO. Also no statistically significant difference was found between paired pre and post CAO data at any coupling interval (Table II).

C Heart rate effect. The effect of HR changes




Fig 5 Effect of heart rate on MVO I per beat during control (circles and broken lines) and after coronary artery occlusion (dots and solid lines) a Actual data obtained at constant CO of 170 ml/minute Kg BW b Same data normalized for constant SV of 1 ml/kg BW Data did not differ significantly CAO = coronary artery occlusion MVO I = myocardial O₂ consumption index

appeared as result of the force-frequency relationship for heart rates above 150 minute while at lower heart rates associated with larger stroke volumes appeared as result of the force-length relationship. Since LV dp/dt is affected by preload changes the contractility effect may have been underestimated at higher heart rates where preload is decreasing. On the contrary at lower heart rates where preload is higher contractility was probably overestimated by LV dp/dt.

According to these data no significant MVO I effect is expected as result of PVDs with full compensatory pause. However increase of HR by 1 beat per minute when minute work is constant is expected to increase MVO by a statistically significant 0.025 ml O₂/minute 100 Gm LV and up to 0.114 ml O₂/minute 100 Gm LV when stroke work is maintained constant. Thus while rhythm change occurring from PVDs at rest when minute work is constant will not affect MVO, in either direction the effect of changing HR may be substantial. At constant stroke work the effect of similar HR change becomes approximately five times more pronounced.

The above findings were not modified by loss of functioning myocardium resulting from coronary artery occlusion. Constancy of MVO at each heart rate step after loss of up to 27 per cent of functional myocardium resulting from coronary occlusion confirms for this range of heart rates the previously reported independence of MVO I from the mass of functioning myocardium. It

also suggests constancy of efficiency of the intact myocardium for the 14 to 27 per cent range of relative workload increases corresponding to the size of the functionally lost ischemic myocardium for the range of heart rates tested.

In conclusion and of possible clinical importance it appears that (1) no significant effect on either MVO or contractility should be expected as the result of rhythm changes devoid of changes in heart rate (2) the effect of heart rate depends to a great extent on the stroke volume. Thus changes occurring at constant cardiac output simulating rest are significant but approximately only one fifth of the effect expected at same heart rate and constant stroke volume as may happen during exercise (3) reduction of functioning myocardium by coronary artery ligation does not modify significantly the magnitude, direction and quantitative relationship of rate and rhythm effects on MVO.

REFERENCES

- Boerth R C, Covell J W, Pool P E and Ross J Jr. Increased myocardial O₂ consumption and contractile state associated with increased heart rate in dogs. *Circ Res* 24: 725 1969.
- Laurent D, Bolene Williams C, Williams F L and Katz L N. Effects of heart rate on coronary flow and cardiac oxygen consumption. *Am J Physiol* 185: 350 1956.
- Tsaganis T J, McDonnell M A, Sutton R B and Kuda H. Effect of ventricular pacing (paired and single) on coronary hemodynamics and myocardial contractility. *Cardiology* 50: 57 1974.
- Klocke F, Braunwald E and Ross J Jr. Oxygen cost




Fig. 4 Effect of heart rate on MVOI during control and after coronary artery occlusion (CAO). Mean values and their standard error are indicated. Control and the post CAO data did not differ significantly. MVOI = myocardial O₂ consumption index. n = number of observations.

minute and lowest at HR of 150/minute but no significant slope (Table III). Similarly in both control and post CAO data (Table IV), no significant slope or difference between slopes was demonstrated. For constant stroke volume the regression line of LV dp/dt values showed positive slope 10.83 ± 13 , $r = .99$, $p < 0.05$ (Table III). Similar positive slopes of 11.8 ± 12 and 11.5 ± 15 mm Hg/sec per beat of HR increase respectively ($r = 0.99$, $p < 0.01$ and $r = 0.98$, $p < 0.05$) were derived in the control and post CAO data of Table IV after normalization for constant SV.

CaO₂, pH, pO₂ and HCT were kept within normal range and did not vary as a result of rate and rhythm changes. The grossly estimated size of ischemic myocardium in the preparations with coronary artery occlusion ranged between 14 and 27 per cent of the wet left ventricular weight.

Discussion

In this study with controlled heart rate arterial pressure and cardiac output the effect of number of PVDs on MVOI appeared to be insignificant. The mean effect of changing coupling interval of a fixed number of PVDs on MVO₂ appears also to be insignificant although in two out of nine experiments a significant correlation of these variables was found. The

force-length effect of the post extrasystolic beat shown to increase isometric time tension index by Takida and colleagues⁸ is apparently counterbalanced by the equal decrease of this index associated with the PVD. On this basis results of this study concur with previous studies^{3, 11} suggesting that the effect of rhythm changes on contractility if any is negligible.

In contrast the significant positive correlation of HR changes with substantial MVO changes was reconfirmed. Slopes were approximately five times steeper when in gross simulation of exertion stroke volume was kept constant at all HR steps as compared to those obtained at fixed cardiac output and minute work where in simulation of paroxysmal tachycardias stroke volume and work changed with the reciprocal of heart rate. The similarity of corresponding actual and calculated MVO data at fixed SV or CO (Fig. 3) suggests that the reciprocal HR to SV relationship is the only factor responsible for the substantial slope difference. The findings obtained at constant SV in this study are basically in agreement with previous work in isovolumic left ventricular preparations attributing the effect of heart rate on MVO to changes of contractile state related to the force-frequency relationship.¹ In this study at constant CO changes in LV dp/dt (Tables III and IV)

echocardiographic diagnosis of left ventricular mural thrombi occurring in cardiomyopathy

Neil E Kramer MD FACC*
 Ramesh Rathod MD**
 Kamal K Chawla MD FACC FRCP(C)***
 Ramesh Patel MD****
 William D Towne MD FACP FACC*****
 Chicago, Ill

The diagnosis of left ventricular clots in patients with cardiac disease is often suspected subsequent to an episode of systemic embolization discovered incidentally at the time of left ventriculography or determined at autopsy. It has been estimated that emboli originate from within the heart in approximately 80 to 90 per cent of cases.^{1,2} Since the natural course of these structures is unpredictable, earlier diagnosis by simple means may be beneficial in the clinical management of these patients. Recently a documented left ventricular thrombus was detected by Echocardiography in a patient with multiple myocardial infarcts. This report presents the echocardiographic features of multiple left ventricular thrombi occurring in a patient with congestive cardiomyopathy.

Case Report

A 49 year-old black man with a history of chronic alcoholic consumption was admitted to Cook County Hospital on June

From the Division of Adult Cardiology, Cook County Hospital, Chicago, Ill.

Received for publication Aug 16, 1977.

Accepted for publication Sept. 11, 1977.

Reprint requests: Neil E Kramer MD, Attending Physician, Division of Adult Cardiology, Cook County Hospital, 1825 W. Harrison St., Chicago, Ill. 60612.

Attending Physician, Division of Adult Cardiology, Director, Noninvasive Laboratory, Cook County Hospital.

Flow Division of Adult Cardiology, Cook County Hospital.

Attending Physician, Division of Adult Cardiology, Assistant Director, Electrocardiography and Human Performance Laboratory, Cook County Hospital.

Attending Physician, Division of Adult Cardiology, Cook County Hospital.

Chairman, Division of Adult Cardiology, Cook County Hospital, and Clinical Associate Professor, Loyola University Medical Center, Maywood, Ill.

20, 1976, with progressive exertional dyspnea and vague right-sided chest pain of three weeks duration. There was no cough, fever, hemoptysis, paroxysmal nocturnal dyspnea, peripheral edema, or calf pain.

Physical examination revealed a chronically ill man. The blood pressure was 98/80, pulse 120 beats/minute and respiratory rate 26 breaths/minute. The cervical veins were distended at 45 degrees. Bibasilar rales were heard. The cardiac impulse was diffuse at the sixth left intercostal space just outside the midclavicular line. The first and second heart sounds were normal. A third heart sound was noted at the apex. No murmurs or rubs were appreciated. The liver was enlarged. The pulses were normal. There was no peripheral edema. An initial clinical diagnosis of alcoholic cardiomyopathy was made.

The routine admitting laboratory data were normal as was the liver and coagulation studies. An electrocardiogram revealed a sinus tachycardia with left anterior hemiblock, poor R wave progressions across the right precordial leads and nonspecific ST wave abnormalities. The chest x-ray showed moderate cardiomegaly with increased vascular markings.

After two weeks of hospitalization the patient dramatically improved on digoxin, diuretics, and bed rest. Over the next three months his initial symptoms recurred despite alcohol abstinence and conventional medical management. On September 27, 1976, he was rehospitalized markedly dyspneic with hemoptysis, bilateral pedal edema, and leg pain.

Physical examination revealed the patient to be in moderate respiratory distress with a respiratory rate of 20 breaths/minute. Blood pressure was 90/70, pulse was 120 beats/minute and temperature was 99°F. There was percussion dullness and rales at the right base. The cardiovascular examination was unchanged. The liver was enlarged and tender. Moderate pedal edema was noted.

The pertinent laboratory data showed a prerenal azotemia with marked hepatic and coagulation abnormalities. The electrocardiogram was unchanged. A chest x-ray again revealed moderate cardiomegaly with a new right lower lobe infiltrate. A lung scan suggested the possibility of pulmonary emboli to the right middle lobe.

Vigorous treatment for congestive heart failure was insti-

- of electrical activation of the heart *Circ Res* 18:357 1966
- 5 Ross J Jr Sonnenblick E H Kasser G A Frommer P L and Braunwald E Electroaugmentation of ventricular performance and oxygen consumption by repetitive application of paired electrical stimuli *Circ Res* 16:332 1965
- 6 Takada H Takeuchi S Ando K Kato A Yoshida S Hisada S and Mizuno Y Experimental studies on myocardial contractility and hemodynamics of extrasystoles *Jpn Circ J* 34:419 1970
- 7 Krahn A C Tsagaris T J and Kuida H Myocardial oxygen consumption after major coronary artery occlusion in anesthetized dogs with constant left ventricular workload *Cardiovasc Res* 10:642 1976
- 8 Walsh L F Mueller W J and Burgess M J A stimulator control unit for use in card research *J Electrocardiol* 4:231 1971
- 9 Krahn A C Tsagaris T J and Kuida H Myocardial oxygen consumption at constant left ventricular workload and varying arterial oxygenation *Cardiovasc Res* 9:811 1975
- 10 Van Slyke D D and Neil J M Determination of oxygen in blood and other solutions by vacuum extraction and manometric measurement *J Biol Chem* 61:511 1945
- 11 Tsagaris T J Lengyel J Thorpe J L and Luria F Hemodynamic effects of paired pulse stimulation - normal and bristlet calyx *Am J Physiol* 215:144 1969
- 12 Tsagaris T J Sutton R B and Kuida H Perovariability in hemodynamic response to paired pulse stimulation *Am J Physiol* 215:1409 1969

Copyright information

The appearance of a code at the bottom of the first page of an original article in this journal indicates the copyright owner's consent that copies of the article may be made for personal or internal use or for the personal or internal use of specific clients. This consent is given on the condition, however, that the copier pay the stated per copy fee through the Copyright Clearance Center Inc, P O Box 765 Schenectady, N Y 12301 518 374 4430 for copying beyond that permitted by Sections 107 or 108 of the U S Copyright Law. This consent does not extend to other kinds of copying, such as copying for general distribution for advertising or promotional purposes, for creating new collective works, or for resale.

result in widespread embolization. In this regard their earlier identification could be important both diagnostically and therapeutically.

Recently Horgan and associates described the echocardiographic features of a documented septal thrombus which occurred in a patient who had sustained several myocardial infarctions. The echocardiogram demonstrated a mass of dense echoes which were closely applied to the left septal surface. This pattern was similar in appearance to the septal densities described herein. The authors also emphasized the importance of manually scanning the left ventricle when thrombi are suspected. In our case this maneuver was extremely helpful and enabled us to visualize the leading edge of the thrombus (Fig 1 arrow); the pitfall of diagnosing a thickened septum was thus avoided. Additionally, inferior angulation of the transducer uncovered several smaller apical densities (Fig 2 2B) closely resembling the anatomical findings.

The ability to visualize intracavitary thrombi by echocardiography is of course dependent on their size, acoustical properties and location. In this case the clots were large, well organized and within the sound path of the transducer. The explanation for the paucity of previous data may therefore relate to the routine omission of the scanning technique, the presence of smaller or unorganized thrombi, or the appearance of thrombi in atypical locations. The inability to identify the smaller right ventricular thrombi and the apicolateral thrombus in this case probably represents a failure to identify these portions of the heart with the conventional single crystal technique. Perhaps with the newer wide angle real time imaging systems such areas may be better visualized.

We would conclude that recognition of the described echocardiographic patterns may be helpful when the etiology of a systemic embolus is sought or in those patients who are at high risk of developing intracavitary thrombi. The sensitivity and specificity of this technique, however, in detecting such structures is unknown and must await definitive investigation.



Fig 3 Pathological specimen of the heart visualizing the large septal thrombus (1), the posteromedial thrombus (2) with septal bridge (B) and apicolateral thrombus (3).

Summary

A patient with alcoholic cardiomyopathy presented with recurrent biventricular heart failure. Echocardiography supported the clinical diagnosis and suggested the presence of multiple left ventricular mural thrombi. At postmortem large left ventricular and small right ventricular thrombi were found in association with systemic and pulmonary emboli. Echocardiography may be of value in the earlier detection of intramural left ventricular thrombi.

REFERENCES

1. Billing D D, Hallman G L, and Cooley D A. Arterial embolism. *Arch Surg* 95:1, 1967.
2. Thompson J E, Sider L, Raub P S, et al. Arterial embolectomy: A 20 year experience with 163 cases. *Surgery* 67:217, 1970.
3. Levy J F and Butcher H B. Arterial emboli: An analysis of 125 patients. *Surgery* 68:968, 1970.
4. Horgan J H, Shiel F O M, and Goodman A C. Demonstration of left ventricular thrombus by conventional echocardiography. *J Clin Ultrasound* 4:287, 1976.




Fig 1 Echocardiogram demonstrating dilatation and hypokinesis of the left ventricle with a cluster of linear densities (1) applied to the left septal surface *ct* = chordae tendineae *mv* = mitral valve




Fig 2 Left ventricular condensed scan showing septal densities (1) and additional apical densities (2) *B* = apical intracavitary density bridging posterior wall and septum

tuted. Anticoagulation was withheld because of the derangement in hepatic and coagulation function studies. The patient gradually unproved with resolution of hemoptysis and a 30 pound weight loss. An echocardiogram (Fig 1) demonstrated dilatation of the left ventricle with hypokinesis and thinning of the posterior wall and septum. The left atrium, right ventricle and aortic root were of normal dimensions. A cluster of linear densities closely applied to the septum (Fig 1 1) was noted at the chordae tendineae level. These separated from the septum at the mitral valve level (arrow). There was delayed mitral valve closure and reduced leaflet amplitude indicative of an increased end diastolic pressure with diminished mitral valve flow respectively. Upon scanning the left ventricle with the transducer additional intracavitary densities (Fig 2 2) were visualized in the area of the apex. One such large density (Fig 2 B) appeared to bridge both the septum and posterior wall of the left ventricle. Four days thereafter the patient suddenly became apneic and died.

Postmortem examination demonstrated the heart to be markedly enlarged weighing 700 Gm. The valves were thin and pliable. The left ventricle was markedly dilated and lined almost entirely by organized mural thrombi. The largest

thrombus (Fig 3 1) measured $10 \times 7 \times 3$ cm and was attached to the anterosseptal portion of the chamber. A second thrombus (Fig 3 2) located at the posteromedial wall measured $4.5 \times 2.5 \times 0.4$ cm and extended toward the apex. At its most inferior portion it bridged the septal thrombus (Fig 3 B). At the apicolateral area another thrombus (Fig 3 3) was observed measuring $6.0 \times 3.5 \times 2.0$ cm. Subjacent to the thrombi there was extensive subendocardial fibrosis. The right ventricle contained two small mural thrombi in its midportion and one large apical thrombus. The coronary arteries were widely patent. Pulmonary emboli associated with infarction were noted in the left upper and right lower lobes. The right kidney contained an area of infarction. There was marked pulmonary congestion.

Discussion

Intracardiac mural thrombi are frequently associated with hypocontractile ventricular segments such as occur in myocardial infarction, ventricular aneurysm, and cardiomyopathy. Clinically thrombi may remain dormant or they may




Fig 1 A and B Serial echocardiograms showing A shaggy mitral (MV) densities highly suggestive of vegetations, pansystolic mitral valve prolapse (*) and exaggerated LV posterior wall left atrial junction motion (Y) submarginally AV = aortic valve LA = left atrium B further prolapse of the mitral valve leaflets into the left atrium () and the development of a LV echo free space (A) associated with systolic expansion (■)

An echocardiogram performed on Mar 6 1966 (Fig 1A) showed pansystolic prolapse of the mitral valve leaflets () associated with shaggy dense material highly suggestive of vegetations. The motion of the left atrial LV junction was exaggerated (Y) possibly because of mitral regurgitation. The LV and left atrial dimensions were normal.

On March 29 the patient had an intermittent pericardial friction rub. On March 31 a Grade 3/6 apical holosystolic murmur was noted for the first time. The patient continued to run a low grade fever but repeat blood cultures were negative. A gallium scan was compatible with multiple areas of mu. cie abscesses.

A repeat echocardiogram (Fig 1B) revealed a localized echo-free space posterior to the posterior left ventricular wall

This echo-free space showed systolic expansion (■). A localized pericardial effusion or a myocardial abscess was considered. The posterior mitral valve leaflets were now noted to move briskly anteriorly behind the anterior leaflets and to prolapse into the left atrium during systole (*) suggesting a flail posterior leaflet. The previously described shaggy densities were now more granular and localized on the mitral valve.

On April 8 1966 right and left cardiac catheterization was performed (see Table 1). Resting right heart and aortic pressures were normal. An aortogram showed no aortic valve or gross coronary artery pathology. A right atrial angiogram showed no pericardial effusion but in the levophase there was a poorly defined left ventricular aneurysm.

Infective aneurysm of the left ventricle angiographic and echocardiographic features

Franklin B Saksena, MD, FACP, FACC, FRCP (C)*

Neil E Kramer, MD, FACC**

William D Towne, MD, FACP, FACC***

Mushtaq Khan, MD****

Robert Gamble, MD*****

Jairo B Cruz, MD*****

Sukhjit Gill, MD*****

Chicago Ill

An infective (mycotic) saccular aneurysm of the left ventricle (LV) is a rare complication of bacterial endocarditis.¹

This paper describes the unique echocardiographic and angiographic features of an infective saccular aneurysm involving the posterior LV free wall subsequent to staphylococcal endocarditis of the mitral valve.

To our knowledge the echocardiographic features of such an aneurysm have not been reported.

Case report

A 17 year old black male with a known seizure disorder came to the Cook County Hospital emergency room on Feb 25 1976 complaining of generalized myalgias and fever. Five

From the Division of Adult Cardiology Cook County Hospital Chicago.

Received for publication Sept 20 1977.

Accepted for publication Oct 25 1977.

Reprint requests: F Saksena MD Division of Adult Cardiology Cook County Hospital 1825 W Harrison St Chicago Ill 60612.

Chief Cardiac Catheterization Laboratory Cook County Hospital and Assistant Professor of Medicine Northwestern University Chicago.

Director Noninvasive Laboratory Division of Adult Cardiology Cook County Hospital Chicago.

* Chairman Division of Adult Cardiology Cook County Hospital Chicago and Clinical Associate Professor Loyola University Maywood Ill.

Director Intensive Care Unit Cook County Hospital Chicago.

Deputy Chairman Cardiovascular Surgery Cook County Hospital Chicago.

Fellow Division of Adult Cardiology Cook County Hospital Chicago.

Table 1 Hemodynamic data

	4-8 76	4 10 76	4 2 76
Pressures (mm hg)			
RA	1		
RV s/d	37/1		
PA s/d	30/		
LV s/d	—	105/9	128/4
Ao s/d	130/100	90/5	122/0
Cardiac index	2.28 L/min/M ²	.9	
Ejection fraction		1+	++
Mitral regurgitation			

Abbreviations: Ao = Aorta; d = diastolic pressure; ed = end-diastolic pressure; LV = left ventricle; PA = pulmonary artery; RA = right atrial mean pressure; RV = right ventricle; s = systolic pressure. As seen on LV angiography 0 to 4+ scale.

days prior to admission he had sustained blunt trauma to the right thigh resulting in persistent pain and swelling. There was no history of prior cardiovascular disease, rheumatic fever, or drug abuse.

On admission the patient had a blood pressure of 110/0 pulse of 90/minute, temperature 102.8 F, height 76 inches, weight 155 pounds. He was lethargic with severe generalized muscle tenderness. Cardiac examination revealed a normal heart size and a Grade 2/6 pulmonary flow murmur. A chest x-ray was normal. The electrocardiogram showed non-specific ST-T changes. The white blood count was 8,600/mm³. Blood cultures grew *Staphylococcus aureus*. The CPH was 33.0 LU (Normal 0 to 50 IU).

He was diagnosed as having staphylococcal septicemia and treated with oxacillin and then nafcillin and gentamicin. Over the next month the patient showed evidence of septic emboli with Roth spots, sub-conjunctival hemorrhages, Janeway spots, and recurrent crops of cutaneous pustular lesions. A muscle biopsy showed acute myositis.




Fig 3 Saline injection into aneurysmal sac at time of cardiac catheterization showing filling of the echo free space (AN) Ao = aorta LA = left atrium PRE = prior to saline injection.

was no adhesive pericarditis. The mouth of the aneurysm was closed by a Dacron patch and the mitral valve was replaced by a stented porcine aortic valve. The postoperative course was unremarkable and the patient had an uneventful recovery.

The postoperative echocardiogram (Fig 1C) showed a considerable reduction in the exaggeration motion of the left atrial LV junction (X) and obliteration of the previously described echo free space. The mitral prosthesis (MVP) motion was normal.

In September 1976 a murmur of aortic insufficiency was noted for the first time. As in June 1978 the patient has remained asymptomatic.

Discussion

Mycotic aneurysms of the LV usually involve either the membranous septum or the mitral-aortic intervalvular fibrosa.⁸ Unique to our case was the involvement of the posterior free wall of the LV.

Posterior wall saccular aneurysms having a similar angiographic appearance to that seen in our patient have also been described in young African negroes with idiopathic mitral subannular left ventricular aneurysms⁹ but unlike our case they had no underlying infection and probably were of congenital origin.

We believe that our patient had a mitral valve ring abscess because he had mitral regurgitation of recent origin and an evanescent pericarditis occurring in the setting of acute staphylococcal

endocarditis.¹⁰ This mitral valve ring abscess then burrowed into the adjacent myocardium leading to the formation of a LV aneurysm.¹⁰

Sequential echocardiography was diagnostically helpful in this case in the early detection of mitral valve vegetations leading to the development of a flail posterior leaflet along with mitral regurgitation. The subsequent formation of a localized posterior echo free space while suggesting either pericardial fluid accumulation or abscess formation favored the latter in light of the patient's clinical course and prior demonstration of vegetations. We were able to demonstrate that this echo free space was due to an aneurysmal sac because it could be temporarily obliterated by injecting it with saline at catheterization and also because it could no longer be detected postoperatively. The discrepancy in size of the space noted by the angiographic and echocardiographic methods probably represents superior angulation by the single crystal transducer. It is anticipated that the development of the newer real time imaging systems will permit broader visualization of these types of structures.

Our patient's aneurysm was probably a pseudoaneurysm because (1) the neck of the sac was narrower than its fundus and (2) the surrounding myocardium appeared normal and sharply




Fig 1C Serial echocardiogram showing obliteration of the echo free space postoperatively and a normally functioning mitral valve prosthesis (MVP) LA = left atrium




Fig 2 LV angiogram during systole in 30 degree right anterior oblique view showing a saccular aneurysm of the posterior wall (outlined by black arrows) associated with prolapse of posterior mitral valve leaflet (*)

In order to better define the LV aneurysm left heart catheterization was performed. The LV pressures were normal (Table I). Left ventriculography performed in 30 degree right anterior oblique and 60 degree left anterior oblique views showed a postero basal aneurysm arising at the level of the mitral valve ring as well as mild mitral regurgitation with

mitral prolapse (Fig 2). There was no ventricular septal defect.

In May 1976 the patient developed progressive obstructive jaundice and hepatomegaly. Celiac angiography revealed multiple mycotic aneurysms of the hepatic artery compressing the common bile duct. Ligation and drainage of the pseudoaneurysm of the hepatic artery was accomplished without sequelae.

Further details concerning this patient's hepatic artery aneurysm have recently been published by Mojab and associates (Am J Roentgenol 128:143-144, 1977).

A follow up left ventriculogram in August 1976 showed progressive enlargement of LV aneurysm with an increased left ventricular end diastolic pressure (Table I). Saline injection of the aneurysm with simultaneous echocardiography obliterated the previously described posterior echo-free space (Fig 3) thus providing supportive evidence that the echo free space represented the aneurysmal sac.

On August 31 1976 the patient underwent cardiac surgery. At operation a saccular aneurysm of LV was found. The aneurysm was 2 cm wide 10 cm long and 0.2 cm thick with an approximate volume of 50 cc. It was located in the posterobasal aspect of free wall of LV just below the mitral valve and inferior to the circumflex artery. The aneurysm appeared to be endothelialized covered by epicardium and contained no blood clots. No microscopic sectioning of the wall of the aneurysm was carried out. There was no involvement of the membranous septum or the aorto mitral intervalvular fibrosa by the aneurysm. There was a perforation 1 cm in diameter of both mitral valve cusps at their posterior commissural junction. The aortic valve was not visualized however no aortic regurgitation was seen at operation. There

Spironolactone

Hermann H Ochs MD
David J Greenblatt MD
Gunther Bodem MD
Thomas W Smith MD

Boston, Mass and Bonn, West Germany

The isolation and identification of aldosterone was followed by attempts to synthesize spironolactone steroids capable of blocking its physiologic and pharmacologic effects. The most important and effective aldosterone antagonists are spironolactone, canrenone, canrenoate, and more recently prerenone. The spironolactones were the first potassium-sparing diuretics and have been increasingly used for the clinical treatment of congestive heart failure, hepatic ascites, primary aldosteronism, and essential hypertension.¹⁻³

Chemical properties and methods of quantitation

Spironolactones have a structure similar to that of other steroids, with a lactone ring as a substituent at C-17 (Fig. 1). Spironolactone and its metabolites are usually designated by Roman numerals in the chemical and pharmacologic literature. Spironolactone is the active constituent of Aldactone, whereas canrenoate is a water-soluble potassium salt used for intravenous injection (Fig. 1). When canrenoate is reconstituted from its lyophilized form prior to injection, the solution often becomes turbid after a short period

of standing at room temperature. The turbidity appears to be due to precipitation of canrenone (aldadiene SC 9376), a pharmacologically active derivative of canrenoate. Thus, canrenone can be formed from canrenoate both *in vitro* and *in vivo*. It is not established whether the turbid solutions are clinically effective when injected intravenously.

Several methods are available for quantitation of spironolactone and its metabolites in body fluids. These include radioactive tracer techniques, chromatography, fluorescence, mass spectrometry, and ultraviolet spectrometry.⁴⁻¹⁰ A radioimmunoassay will soon be available.¹⁰ One disadvantage of techniques based on quantitation of tritiated spironolactone is that relatively large amounts of tritiated water are formed by endogenous metabolism of the parent compound.¹¹

Using spectrophotofluorometric technique for quantitation of canrenone, Karim and colleagues¹² were able to assay this compound in a 1 ml plasma sample at levels as low as 15 ng/ml. The coefficient of variation for identical samples in the range of 75 to 1,200 ng/ml was 8 per cent or less. Sadee and associates¹³ modified the technique to allow separate quantitation of spironolactone, canrenoate, and the polar glucuronic ester conjugate of canrenoate. The method is sensitive and specific enough to allow reliable measurement of these compounds in plasma after therapeutic doses of spironolactone.

The presence of spironolactone and its metabolites in plasma appears to interfere with determination of plasma cortisol by fluorometric assay.^{14,15} It is also suggested that spironolactone metabolites interfere with estimation of serum digoxin by radioimmunoassay.¹⁶

From the Cardiac Vascular Division, Department of Medicine, Peter Bent Brigham Hospital, the Clinical Pharmacology Unit, Massachusetts General Hospital, the Department of Medicine, Harvard Medical School, and Medizinische Universitätsklinik, Bonn, West Germany.

Supported in part by Deutsche Forschungsgemeinschaft, Bonn, and by Grants MH 1279 and HL-18003 from the United States Public Health Service.

Received for publication Feb 10, 1977.

Reprint requests: David J. Greenblatt, MD, Clinical Pharmacology Unit, Department of Medicine, Massachusetts General Hospital, Boston, Mass. 02114.

Dr. Smith is an Established Investigator of the American Heart Association.

demarcated from the mouth of the sac. The absence of both an adhesive pericarditis and a thrombus within the sac may be because the pseudoaneurysm was not as longstanding as those reported in the literature.^{11, 18}

In conclusion, this case report emphasizes that an infective aneurysm of the LV should be suspected if echocardiography shows a localized echo free space in a patient with staphylococcal septicemia. An early diagnosis by LV angiography is essential since an infective aneurysm has a significant risk of rupture¹ and may be surgically treatable.

Summary

A 17 year old man with staphylococcal endocarditis of the mitral valve developed an infective aneurysm of the posterior left ventricular wall. Echocardiography revealed an echo free space posterior to the posterior left ventricular wall. This echo free space undoubtedly represented the aneurysmal sac, because it could be temporarily obliterated by injecting saline into it and was no longer detectable following surgical closure of the sac. Thus echocardiography may be helpful in the detection of an infective aneurysm of the left ventricle.

We gratefully acknowledge the secretarial assistance of Mrs Evelyn Hunt and the technical assistance of Mr H Fischer, Mrs Dorothy Gore, Mrs S Rochon and Miss M Smith.

REFERENCES

1. Prani C L. Erosive (Mycotic) aneurysm of the heart with rupture. *Arch Pathol* 36:579 1943
2. Layman T E and January L E. Mycotic left ventricular aneurysm involving the fibrous atrioventricular body. *Am J Cardiol* 20:423 1967
3. Chesler E, Korns M E, Porter G E and Edwards J E. False aneurysm of the left ventricle secondary to bacterial endocarditis with perforation of the mitral aortic intervalvular fibrosa. *Circulation* 27:518 1963
4. Wong Y, Chesler E, Korns M E and Edwards J. Mycotic aneurysms of the left ventricle and ascending aorta. *Minn Med* 51:395 1968
5. Symbas P N, Baldwin III J, Schlant II C and Hu J. J. W. Unusual complications of bacterial endocarditis. *Br Heart J* 33:664 1971
6. Chesler E. Aneurysms of the left ventricle. *Cardiovasc Clinics* 4:188 1972
7. Qizilbash A H and Schwartz C J. False aneurysm of the left ventricle due to perforation of mitral aortic intervalvular fibrosa with rupture and cardiac tamponade. *Am J Cardiol* 32:110 1973
8. Beck, W. and Schrire V. Idiopathic mitral subannular left ventricular aneurysm in the Bantu. *Am Heart J* 78:28 1969
9. Chesler E, Joffe N, Schamroth L, and Meers L. Annular subvalvular left ventricular aneurysms in the South African Bantu. *Circulation* 32:43 1965
10. Arnett E N and Roberts W C. Valve ring abscess in active infective endocarditis. *Circulation* 54:140 1956
11. Ersek R A, Chesler E, Korns M E and Edwards J. Spontaneous rupture of a false left ventricular aneurysm following myocardial infarction. *Am Heart J* 71:67 1969
12. Chesler E, Korns M E, Semba T and Edwards J. False aneurysms of the left ventricle following myocardial infarction. *Am J Cardiol* 23:78 1969
13. Gobel F L, Vaidh Arom H, and Edwards J. Pseudoaneurysm of the left ventricle leading to recurrent pericardial hemorrhage. *Chest* 59:23 1971
14. Roberts W C and Morrow A G. Pseudoaneurysm of the left ventricle. *Am J Med* 43:639 1967
15. Cone R B and Hawley R L. Pseudoaneurysm of the heart following infarction. *Arch Pathol* 77:80 1964
16. Swanson D A, Lau C M, Alexander C B, and Haffner S A. Posterior left ventricular aneurysm. *Radiology* 106:275 1973
17. Hurst C O, Fine G, and Keyes J W. Pseudoaneurysm of the heart. Report of a case and review of literature. *Circulation* 28:427 1963
18. Bjornsson L. Pseudoaneurysm of the left ventricle of the heart. A rare complication of myocardial rupture following infarction—report of a case. *Am J Clin Pathol* 41:302 1964

intravenous canrenoate in equimolar doses has been used as an absolute bioavailability standard

After oral administration of a solution of canrenoate the serum concentration curve was nearly superimposable upon that obtained after intravenous injection suggesting that canrenoate is rapidly and completely absorbed from an oral solution and that a clinically important first pass effect does not exist. Bioavailability of spironolactone tablets reached 96 per cent in comparison to an oral solution but only 60 per cent when compared with oral administration of canrenoate K in one patient. In a more extensive crossover study in 12 healthy volunteers, bioavailability of conventional 25 mg spironolactone tablets was compared to that of a new 100 mg tablet formulation and to an oral solution. The mean (\pm SD) bioavailability of the two tablets relative to the oral solution based upon the area under the 24 hour canrenone plasma concentration curve were 99.6 ± 18.2 per cent and 92.1 ± 22.9 per cent. Differences in the peak plasma concentrations of metabolites among two tablet preparations (25 and 100 mg) of spironolactone were unimportant. Spomer and colleagues¹ investigated the absolute and relative bioavailability of two oral spironolactone preparations in 20 volunteers. Absorption of 100 mg of spironolactone given either as two tablets or one capsule was complete. However when 400 mg were given orally as a single dose absorption of the drug was reduced.

Metabolic pathways As indicated previously the metabolic degradation of spironolactone in humans proceeds very rapidly by enzymatic cleavage of the C 7 acetylthio substituent to yield canrenone. Serum concentrations of spironolactone fall to undetectable limits within a few minutes of a dose. The two major metabolites canrenone and canrenoate exist in equilibrium.

Comparison of fluorescent compounds and metabolites in serum and urine with the findings from studies of radioactive labeled spironolactone and canrenoate clearly demonstrate the formation of a variety of nonfluorescent radioactive metabolites including tritiated water. After administration of tritiated canrenoate elimination of total radioactivity proceeds with a much slower half life (43 to 705 hours) than does

elimination of fluorescent substances due to the presence of nonspecific radioactivity. Karim and colleagues¹¹ suggest that the apparent elimination half life of total radioactivity extractable into ethyl acetate (about 37 hours) probably represents that attributable to spironolactones. In any case accumulation of these nonfluorescent and as yet unidentified metabolites may explain in part why maximal clinical effects of spironolactone are achieved only after several days of treatment and that efficacy of the drug can still be demonstrated 3 to 3 days after the last dose. Since the activity of single doses of spironolactone persist for up to 24 hours, once or twice daily dosage with spironolactone may be satisfactory.

Karim and co workers¹² described the disappearance of serum radioactivity following intravenous tritiated canrenoate by a triexponential function. The terminal elimination portion of the curve was reached after 5 hours. Forty seven per cent of radioactivity was excreted in the urine and 14 per cent in the feces within 5 days. Approximately 50 per cent of radioactive compounds were fluorescent metabolites. Only 1 per cent of the dose was excreted in the urine as unchanged drug. One of the major water soluble metabolites was a glucuronide ester. After oral administration of tritiated spironolactone in an alcoholic solution no unchanged spironolactone was recovered in the urine. In 5 days 32 per cent of radioactivity was excreted in urine and 23 per cent in feces. The major urinary metabolites were canrenone (5 per cent of the dose), the $\beta\beta$ hydroxy sulfoxide metabolite (5 per cent) and the glucuronide ester of canrenone (6 per cent). When potassium canrenoate was administered intravenously 34 per cent of the dose was excreted in the urine as unchanged canrenone. Further study of human metabolites of spironolactone is needed since metabolites other than canrenone and canrenoate may contribute to its clinical activity. Structure activity studies of spironolactone analogues suggest that beta unsaturation at the C6/C7 position, gamma lactone unsaturation and gamma lactone ring opening with formation of a water soluble salt all result in decreased activity.

Both spironolactone and canrenone are extensively bound to plasma proteins (89 per cent or more) at therapeutic concentrations. Blood to




Fig 1 Structural formula of spironolactone and its major metabolites canrenone (aldadiene) and canrenoate (shown as the potassium salt)

Pharmacokinetics

Animal studies Following intravenous administration of spironolactone to dogs or rats³⁷⁻⁴⁰ the apparent elimination half life of the parent drug is approximately 10 minutes. Excretion of radioactive labeled spironolactone and canrenoate occurs mostly via the biliary tract in the form of polar conjugated metabolites (80 to 95 per cent within 12 hours in the rat, 35 per cent during 6 hours in the dog). Renal excretion of radioactivity reaches only 3 per cent over 12 hours in the rat and 1 per cent within 6 hours in the dog. Bioavailability studies in the dog indicate that absorption of spironolactone is about 80 per cent complete. A suitable pharmacokinetic model for spironolactone in these species has not yet been developed.

Clinical Studies

Distribution, elimination and accumulation Spironolactone itself is very rapidly cleared by the human organism. The metabolites canrenone and/or canrenoate, having considerably longer half life values than the parent drug, are usually measured in body fluids after administration of spironolactone to humans. The apparent elimination half life of canrenoate plus canrenone was between 17 and 22 hours after a single intravenous injection of canrenoate to five patients.⁴¹ Karim and co workers⁴² in a study of five healthy male subjects similarly observed a mean elimination half life of 16.8 hours for these two compounds after single doses of spironolactone. After termination of chronic spironolactone therapy (200 mg once daily) the apparent elimination half life of canrenone averaged 19.7 hours, however, when the same total dose was divided into 50 mg taken 4 times daily the apparent elimination half life was 12.5 hours.⁴³ With both

dosage regimens steady state was achieved after about 4 days of therapy, although the amount of interdose fluctuation in plasma levels on the 'q.i.d.' regimen was less than on the once-daily schedule. The clinical significance of these fluctuations is not known.⁴⁴

In another multiple dose study, 100 mg of oral spironolactone was administered twice a day to six patients recovering from acute myocardial infarction.⁴⁵ Accumulation of canrenone and canrenoate was only 50 per cent complete after one to four days. The apparent elimination half life values observed after both single doses and 10 days of chronic administration were not significantly different being about 20 hours in both instances (range 17 to 22 hours). The amount of time necessary for achievement of steady state was longer than that predicted on the basis of single dose studies. Thus elimination and accumulation half lives are not consistent. The reasons for this are not established, although the authors suggest a change in macromolecular binding or tissue distribution due to cumulation of unknown metabolites.⁴⁶

During three weeks of spironolactone therapy in 44 patients steady state plasma levels of canrenone were no different in patients with unpaired renal or hepatic function than in individuals without such diseases.⁴⁷ Steady state plasma levels differed fifteenfold among individuals receiving the same daily dose. Higher maintenance doses led to approximately proportional increases in steady state plasma levels.

Biologic availability Problems with bioavailability of spironolactone preparations have been observed since as early as 1962.⁴⁸⁻⁵⁰ A parenteral preparation of spironolactone for use in absolute bioavailability studies is not available.⁵¹ Instead

avenous canrenoate in equimolar doses has been used as an absolute bioavailability standard.

After oral administration of a solution of canrenoate the serum concentration curve was nearly superimposable upon that obtained after intravenous injection suggesting that canrenoate is rapidly and completely absorbed from an oral solution and that a clinically important first pass effect does not exist.³ Bioavailability of spironolactone tablets reached 96 per cent in comparison to an oral solution but only 60 per cent when compared with oral administration of canrenoate K in one patient. In a more extensive crossover study in 12 healthy volunteers,⁴ bioavailability of conventional 25 mg spironolactone tablets was compared to that of a new 100 mg tablet formulation and to an oral solution. The mean (\pm SD) bioavailability of the two tablets relative to the oral solution based upon the area under the 24 hour canrenone plasma concentration curve were 99.6 ± 18.2 per cent and 92.1 ± 22.9 per cent. Differences in the peak plasma concentrations of metabolites among two tablet preparations (25 and 100 mg) of spironolactone were unimportant. Sporer and colleagues investigated the absolute and relative bioavailability of two oral spironolactone preparations in 20 volunteers. Absorption of 100 mg of spironolactone given either as two tablets or one capsule was complete. However when 400 mg were given orally as a single dose absorption of the drug was reduced.

Metabolic pathways As indicated previously the metabolic degradation of spironolactone in humans proceeds very rapidly by enzymatic cleavage of the C 7 acetylthio substituent to yield canrenone. Serum concentrations of spironolactone fall to undetectable limits within a few minutes of a dose. The two major metabolites canrenone and canrenoate exist in equilibrium.^{5, 6}

Comparison of fluorescent compounds and metabolites in serum and urine with the findings from studies of radioactive labeled spironolactone and canrenoate clearly demonstrate the formation of a variety of nonfluorescent radioactive metabolites including tritiated water. After administration of tritiated canrenoate elimination of total radioactivity proceeds with a much slower half life (43 to 70.5 hours) than does

elimination of fluorescent substances due to the presence of nonspecific radioactivity. Karim and colleagues⁷ suggest that the apparent elimination half life of total radioactivity extractable into ethyl acetate (about 37 hours) probably represents that attributable to spironolactone. In any case accumulation of these nonfluorescent and as yet unidentified metabolites may explain in part why maximal clinical effects of spironolactone are achieved only after several days of treatment and that efficacy of the drug can still be demonstrated 2 to 3 days after the last dose. Since the activity of single doses of spironolactone persist for up to 24 hours⁶ once or twice daily dosage with spironolactone may be satisfactory.

Karim and co workers³⁵ described the disappearance of serum radioactivity following intravenous tritiated canrenoate by a triexponential function. The terminal elimination portion of the curve was reached after 5 hours. Forty seven per cent of radioactivity was excreted in the urine and 14 per cent in the feces within 5 days. Approximately 50 per cent of radioactive compounds were fluorescent metabolites. Only 1 per cent of the dose was excreted in the urine as unchanged drug. One of the major water soluble metabolites was a glucuronide ester.³⁶ After oral administration of tritiated spironolactone in an alcoholic solution no unchanged spironolactone was recovered in the urine. In 5 days 32 per cent of radioactivity was excreted in urine and 23 per cent in feces. The major urinary metabolites were canrenone (5 per cent of the dose), the 6 β hydroxy sulfoxide metabolite (5 per cent) and the glucuronide ester of canrenone (6 per cent). When potassium canrenoate was administered intravenously 34 per cent of the dose was excreted in the urine as unchanged canrenone. Further study of human metabolites of spironolactone is needed since metabolites other than canrenone and canrenoate may contribute to its clinical activity.³⁷ Structure activity studies of spironolactone analogues suggest that beta unsaturation at the C6/C7 position, gamma lactone unsaturation and gamma lactone ring opening with formation of a water soluble salt all result in decreased activity.³⁸

Both spironolactone and canrenone are extensively bound to plasma proteins (89 per cent or more) at therapeutic concentrations.³⁹ Blood to

plasma concentration ratios are about 0.5, suggesting no selective uptake of the compounds by red cells

Drug distribution and pharmacologic effects
In rats the maximal reduction of aldosterone induced sodium retention occurs when renal elimination of spironolactone is maximal.⁶⁸ Thus the extent of the tubular effects of the anti-aldosterones appears to depend on their concentration in the renal tubules. Clearance studies⁶ indicate that spironolactone is secreted by the tubules. This secretion can be blocked with bromocresol green, with a parallel decline in renal effects. *In vitro*, 11 hydroxy spironolactone inhibits the synthesis of aldosterone in rat adrenals.⁶ *In vivo* the drug stimulates the renin-angiotensin-aldosterone system to a great extent with hyperplasia of the zona glomerulosa of the adrenals.³⁰ Spironolactone induces hyperreninemia, hyponatremia, and hyperkalemia which again stimulates the secretion of aldosterone.⁶ This effect of increased aldosterone secretion after high doses of 800 to 2000 mg per day of spironolactone has been applied clinically for treatment of the post-traumatic edema of the brain.¹

Mechanisms of action

Spironolactone is a competitive antagonist of aldosterone and modifies electrolyte metabolism only in the presence of aldosterone like compounds.¹¹ It reverses all electrolyte regulating effects of aldosterone regardless of the tissue studied. The effects of spironolactone are surmountable by raising the level of aldosterone like compounds.¹¹ Spironolactone inhibits the formation of the aldosterone complex in the nuclei of kidney epithelial cells of adrenalectomized rats. This occurs at concentration ratios that inhibit the action of aldosterone in the rat *in vivo*.¹⁰ Recent studies in humans suggest a direct inhibitory effect of canrenone on adrenal aldosterone production.¹

In vitro studies with kidney tissue slices from rats demonstrate displacement of aldosterone from its specific intracellular receptors by spironolactone.⁶

Influence on myocardial contractility

Positive inotropic effects of the spironolactones have been demonstrated *in vitro* and *in vivo* in humans during cardiac catheterization.¹¹ The

injection of 200 to 400 mg of canrenone in 41 patients resulted in a long lasting increase of stroke volume as well as an increase in the maximal slope of the pressure-time curve in both ventricles. These positive inotropic effects could also be demonstrated in digitalized patients, and therefore are additive to the effects of digitalis. Improvement in cardiac contractility has been observed during long term spironolactone therapy as well.³ The mechanism of this action is not well understood but spironolactone does inhibit sodium-potassium ATPase in human erythrocytes, similar to that produced by cardiac glycosides.⁶⁹

Effects on respiration

Respiratory improvement has been observed in patients with chronic respiratory insufficiency after administration of spironolactone.^{10,11} Although progesterone a structurally related steroid produces direct respiratory stimulation, this has not been shown with spironolactone.^{10,11} Canrenone does not change the response to a carbon dioxide challenge.¹⁰ Spironolactone lowers neither airway resistance nor pulmonary compliance.

Antiandrogenic effects

Erbler¹⁰⁰ demonstrated a clear decline in plasma testosterone levels over 9 hours after a single dose of 5 mg/Kg of canrenone to healthy males. Strupp and associates¹⁰¹ administered 400 mg of spironolactone daily to five healthy male volunteers for 5 days. Plasma progesterone and 17 α hydroxy progesterone increased significantly. Plasma follicle stimulating hormone and luteinizing hormone levels also increased but the effect was only transient and was not significant by the third and fifth days of the study. Plasma testosterone, 17 β -estradiol and prolactin did not change significantly. However, the first plasma sample was not taken until 12 hours after the initial dose at which time Erbler¹⁰⁰ found that testosterone levels were returning to normal.

Studies in rats suggest that spironolactone blocks testosterone receptors.^{10,101} Castro and co-workers¹⁰² attempted to use spironolactone therapeutically for hypertrophy of the prostate but obtained only temporary improvement of symptoms. Unwanted antiandrogenic effects

commonly accompany spironolactone therapy and are discussed in the section on side effects

Drug interactions

Antagonism by salicylates In 1962 Elliott¹⁰³ suggested a possible antagonism of spironolactone's natriuretic effect when it was given with aspirin. This was later documented in laboratory animals and in man.^{104, 105} Sodium excretion during long term treatment with spironolactone (100 mg per day) was reduced by one third when 600 mg aspirin was coadministered.¹⁰⁶ In another study,¹⁰⁷ aspirin coadministration reduced urinary excretion of canrenone between 4 and 6 hours after ingestion of spironolactone. Such findings suggest that aspirin and spironolactone should not be coadministered if possible. A similar interaction was demonstrated for sodium salicylate, indomethacin and mefenamic acid but not for the analgesic antipyretic drug acetaminophen. In rats however, indomethacin did not antagonize spironolactone's effect on the kidney.¹⁰⁸ Stein¹⁰⁹ demonstrated reduction in the renal tubular secretion and clearance of digoxin by spironolactone although the magnitude of the effect was small.

Enzyme induction and inhibition The influence of spironolactone on microsomal enzyme activity and the pharmacokinetics of coadministered drugs has been investigated extensively in various animal species and in man.¹¹⁰⁻¹¹⁶ (Table I) In humans, simultaneous administration of 400 mg of spironolactone shortens the half life of digoxin by 20 per cent. Urinary excretion of unchanged digoxin decreases from 80 to 66 per cent with an increase of water soluble metabolites from 12 to 26 per cent. The profound effects of spironolactone upon pharmacokinetics of methyl digoxin observed in rats are without any significance for human conditions. Antipyrine half life was shortened in nine volunteers from 12.4 to 7.6 hours after a 2 week period of spironolactone treatment. In animal studies the enhanced catabolism of many drugs by spironolactone has been successfully applied to prevent or reduce toxicity by these drugs (Table I). For other substances (such as mercury, furosemide and digitalis) the exact mechanism by which spironolactone prevents toxicity in animals is not known. Some studies demonstrate inhibition of enzyme activity by spironolac-

Table I Effects of spironolactone on hepatic function

Species	Effect	Reference
Rat	Increased bile flow	117, 115
	Increased liver weight	116
	Increased activity and/or quantity of liver enzymes	
	bilirubin UDP glucuronyl transferase	112, 114
	ethylmorphine N demethylase	117, 119
	aniline hydroxylase	118, 120
	cytochrome C reductase	116, 117
	3,4 benzpyrene hydroxylase (in females)	117
	Accelerated biotransformation or elimination of	
	aniline	121
	bilirubin	114
	benzo (a)pyrene	116
	pentobarbital	102, 123
	hexobarbital	117, 121
	bromsulphthalein	113
	phenol 3,6-dibromophthalein disulfonate	113
	dimethylbenzanthracene	124
	7-hydroxy coumarin	125
	3,4 benzpyrene	116
	diazepam	115
	spironolactone	117, 126
	digitalis glycosides	119, 127, 137
Mouse	Increased liver weight	119, 127
	Increased activity of liver enzymes	
	ethylmorphine N demethylase	119
	NADPH oxidase	119
	cytochrome P 450	119
	NADPH cytochrome C reductase	117
	NADPH-cytochrome P-450 reductase	119
	Accelerated hexobarbital metabolism	138
Man	Accelerated biotransformation of digoxin	139
	Accelerated biotransformation of antipyrine	140-142

Biotransformation stimulated in females, impaired in males

tone.^{110, 112, 103, 114} Microsomal cytochrome P 450 activity in the guinea pig and the dog was reduced 50 to 80 per cent by spironolactone administration with a simultaneous increase in 17 α hydroxylase activity. Spironolactone inhibits corticosterone production in quartered rat adrenals.

although the effect of canrenone is considerably greater.¹⁶¹

Antihypertensive effects

Spironolactone produces very little fall in blood pressure in normotensive subjects. Until the early 1960s the blood pressure lowering effect of spironolactone in hypertensive patients was not considered to be attributable to a decrease of circulatory volume.¹⁰ Recently, however, it has been shown that even in patients with primary hyperaldosteronism the antihypertensive action of spironolactone is nonspecific and largely dependent on depletion of salt and water.¹⁷³ Furthermore, maintenance of reduced plasma volume or extracellular fluid volume is essential for continued antihypertensive activity of spironolactone. This contrasts with earlier findings demonstrating that blood pressure is reduced either by spironolactone or thiazide diuretics in essential hypertensives, whereas patients with primary aldosteronism respond only to spironolactone.¹¹ It now appears questionable whether high dose spironolactone is the treatment of choice in primary aldosteronism. Brown and associates¹⁷⁴ compared the results of spironolactone therapy and ablative surgery in 67 patients with elevated aldosterone serum levels. They confirmed and extended earlier reports of the predictive value of spironolactone on the subsequent hypotensive effect of adrenal surgery in patients with adrenocortical adenoma.¹⁶ On the other hand, occasional failure to respond to spironolactone and subsequently successful surgery have been reported.^{175,176} The situation however might be different in cases with carcinoma or micronodular hyperplasia of the adrenal glands.¹⁶⁷ For the latter it has been stated that no fall in blood pressure can be expected after surgical intervention if a 4 week therapeutic trial with spironolactone is unsuccessful.¹⁶⁸ Thus spironolactone may be a reasonable therapeutic alternative for patients with adrenocortical adenoma who are not candidates for surgery.

Patients with essential hypertension can be divided into those with low, low normal, normal and high plasma renin activity (PRA).^{2,10,177} Whereas spironolactone does not appear to be very effective in hypertensive patients with normal or elevated PRA, the drug reduces the blood pressure in about 75 per cent of patients with hyporesponsive PRA.^{2,3,178} A better blood

pressure response in this group of patients has also been demonstrated for hydrochlorothiazide, however, despite comparable diuretic response, the hypotensive response observed with spironolactone was significantly greater, suggesting that mineralocorticoid excess may be responsible for the hypertension and low PRA.¹ On the other hand, two reports suggest a similar antihypertensive effect for spironolactone and chlorthalidone with both drugs having similar effects on PRA and plasma volume.^{172,179} A third study demonstrated that chlorthalidone, spironolactone and propranolol had similarly effective antihypertensive properties in patients with essential hypertension and normal PRA.¹⁷⁴

The value of classification of patients with essential hypertension according to PRA is not established. Spironolactone interferes with the PRA even up to 9 months after discontinuation of the drug.¹⁷³ Although aldosterone secretion rate is higher in secondary rather than in primary aldosteronism, spironolactone has little or no effect on the arterial pressure in secondary aldosteronism.

Clinical use as a diuretic

Spironolactone is an effective diuretic agent in patients with edema or ascites from heart failure, cirrhosis or renal impairment and does not directly influence renal blood flow or glomerular filtration rate.^{15,16} Whereas hepatic coma can be precipitated by treatment with thiazide diuretics, perhaps as a result of potassium depletion, this risk is lessened when spironolactone is used. Since aldosterone secretion is not raised in untreated congestive heart failure, the success of spironolactone treatment will be more evident when aldosterone secretion has been provoked by sodium depletion resulting from long term therapy with other diuretics. Spironolactone is often useful as a diuretic in patients with edema due to the nephrotic syndrome who have not responded to thiazide treatment and bed rest alone.¹

Electrolyte balance

Aldosterone antagonists block sodium reabsorption in the distal nephron, whereas most of the other diuretics prevent sodium reabsorption proximally. Thus additional blockade of sodium reabsorption might be obtained by combining other diuretics with spironolactone. Ammonium and hydrogen ion excretion is decreased by

spironolactone. Since the drug decreases sodium absorption in the distal tubule the ability to excrete dilute urine is impaired and hyponatremia can be a consequence of therapy.

Spironolactone blocks aldosterone dependent potassium excretion. This is therapeutically useful since most patients with edema treated with other diuretics experience potassium depletion. It has been suggested that greater sodium diuresis will occur if potassium supplements are given during combined therapy with spironolactone and thiazide diuretics.¹⁰⁰ However coadministration of potassium supplements and spironolactone should be undertaken only with great caution due to the risk of hyperkalemia. Spironolactone likewise impairs magnesium excretion. The clearance of magnesium is reduced by spironolactone while the magnesium to potassium clearance ratio is unchanged.¹⁰¹

Wills and associates¹⁰² have shown that spironolactone in a dose as low as 200 mg daily increases urinary calcium excretion. However Prati and colleagues¹⁰³ demonstrated that hypercalcemia after spironolactone administration is an artifact due to the calcium content (approximately 37 mg) of commercially available spironolactone tablets.

Unwanted effects

A report from the Boston Collaborative Drug Surveillance Program indicated that 788 (5.9 per cent) of 13,349 hospitalized medical patients received spironolactone during their hospital stay. Unwanted side effects were attributed to spironolactone in 164 (20.8 per cent) of these patients. These adverse effects included hyperkalemia (41.5 per cent of adverse reactions), dehydration (16.5 per cent), hyponatremia (11.5 per cent), gastrointestinal symptoms (11 per cent), neurologic complaints (9.8 per cent), exanthema (2.4 per cent), and gynecomastia (1.2 per cent). Some of the unwanted effects i.e. hyperkalemia, hyponatremia, hypovolemia might have been avoided if the drug were administered more cautiously. Hyperkalemia clearly is the most important and serious potential complication of spironolactone therapy. The risk is greater in patients with renal insufficiency and those who receive potassium supplements. In rare cases hyperkalemia might contribute or lead to intermittent paralysis.

Because of its steroid configuration spironolac-

tone has endocrine effects which are not easily explained by a single mechanism.^{99, 102, 103, 104} In male patients gynecomastia, impotence and diminished libido have been reported with doses as low as 100 mg per day. In women reversible oligomenorrhea, amenorrhea and breast soreness have been noticed. Loubet and Quirk¹⁰⁵ observed five women in whom breast carcinoma developed during or after the prolonged administration of spironolactone. The number of cases however is too small to draw any conclusions and the findings may well be purely coincidental.

New spironolactones

Prorenoate is a water soluble salt of a steroid acid structurally related to spironolactone.^{106, 107} The potency of prorenoate in man with respect to spironolactone as measured by retention of potassium (38 l) is significantly higher than its relative potency in promoting natriuresis (16 l).¹⁰⁸ In a single dose study the responses to prorenoate potassium 40 mg were not different from those to spironolactone 100 mg.¹⁰⁹ The possible clinical role of prorenoate is now under evaluation.

We are grateful for the editorial assistance of Ms Ann Werner.

REFERENCES

1. Kagawa C M, Cella J A., and Van Arman E G. Action of new steroids in blocking effects of aldosterone and desoxy corticosterone on salt. *Science* 126:1015, 1957.
2. Adlin V E, Marks H A, and Channock B J. Spironolactone and hydrochlorothiazide in essential hypertension. *Arch Intern Med* 130:855, 1972.
3. Crane M G, and Harris J J. Effects of spironolactone in hypertensive patients. *Am J Med Sci* 260:311, 1970.
4. Greenblatt D J, and Koch Weser J. Adverse reactions to spironolactone: a report from the Boston Collaborative Drug Surveillance Program. *J A M A* 225:40, 1973.
5. Gwinup G., and Steinberg T. Differential response to thiazides and spironolactone in primary aldosteronism. *Arch Intern Med* 120:436, 1967.
6. Vaughan E D, Laragh J H., Gavras, I, Buhler F R, Gavras, H., Brunner H R, and Bear L. Volume factor in low and normal renin essential hypertension. *Am J Cardiol* 32:573, 1973.
7. Werning C. *Kurzes Lehrbuch der Hochdruckkrankheiten*, Stuttgart 1975. Ferdinand Enke Verlag.
8. Hollander W, and Chobanian A V. Antihypertensive effect of spironolactone (SC-9420) steroidal antagonist. *Circulation* 20:713, 1959.
9. Hollander W, Chobanian A V, and Wilkins R W. The antihypertensive actions of mercurial thiazide and spironolactone diuretics. In *Diuretics and diuretics* an International Symposium, edited by E Buchhorn and K. D Bock, Berlin 1959. Springer Verlag pp 297-312.

- 10 Ross E J Aldosterone and its antagonists Clin Pharmacol Ther 11 65 1965
- 11 Spark R F, and Melby J C Aldosteronism in hypertension the spironolactone response test Ann Intern Med 69 685 1968
- 12 Spark R F, O'Hare C M and Regan R M Low renin hypertension: restoration of normotension and renin responsiveness Arch Intern Med 133 205 1974
- 13 Brown J J, Davies D L, Ferriss J B, Fraser R, Haywood E, Lever A F and Robertson J I S Comparison of surgery and prolonged spironolactone therapy in patients with hypertension aldosterone excess and low plasma renin Br Med J 2 729 1972
- 14 Winer B M, Lubbe W F and Colton T Antihypertensive actions of diuretics: comparative study of an aldosterone antagonist and a thiazide alone and together J A M A 204 775 1968
- 15 Papadopoulos N, Darsinos J, Alexandrou K and Karl J High doses of spironolactone in the treatment of liver cirrhosis with ascites Br J Clin Pract 26 27 1972
- 16 Sellar R H, Swartz, C D, Ramirez Muxo O, Brest A H and Moyer J H Aldosterone antagonists in diuretic therapy Arch Intern Med 113 350 1964
- 17 Gold H, Golfinos A F, Mehta D, Messeloff C H and Zahm W Spironolactone in diuretic regimens with meralluride or thiazides for pseudocontractile ascites of cirrhosis J Clin Pharmacol 12 35 1972
- 18 Gold H, Mehta D, Golfinos A, Messeloff C H, Wit N and Zahm W Spironolactone in regimens for pseudocontractile edema of heart failure J Clin Pharmacol 11 125 1971
- 19 Howard M M and Leevy C M Management of ascites Arch Intern Med 112 702 1963
- 20 Manning R T and Behrle F C Use of spironolactone in renal edema J A M A 176 769 1961
- 21 McNay J L, MacCannell K L and Oran E Potassium retaining diuretics electrolyte changes induced in hypertensive patients Pharmacologia Clinica 2 94 1970
- 22 McKenna T J, Donohoe J F, Brien T G, Healy J J, Canning H St J and Muldowney F P Potassium sparing agents during diuretic therapy in hypertension Br Med J 2 739 1971
- 23 Farrelly R O, Howie R N and North J D K Use of spironolactone and hydrochlorothiazide in treatment of oedema Br Med J 2 339 1960
- 24 Genest J and Pigeon G Use of diuretics in treatment of kidney disease Ann N Y Acad Sci 88 890 1960
- 25 Reubi F C The action and use of diuretics in renal disease Progr Cardiovasc Dis 3 563 1961
- 26 Ross E J and Wintermuth W W The effect of an aldosterone antagonist on the renal response to sodium restriction Clin Sci 20 143 1961
- 27 Slater J D H, Moxham A, Hurter R and Nabarro J D N Clinical and metabolic effects of aldosterone antagonists Lancet 2 931 1959
- 28 Stewart W K and Constable L W The diuretic response to hygroton, mersalyl and Aldactone Lancet 1 523 1961
- 29 Kert M J, Tarr L W, Franklin S, Gold H, Okun H and Maxwell M Experience with the use of an aldosterone antagonist in selected hypertensive patients Angiology 23 617 1972
- 30 Werning C Das Renin-Angiotensin-Aldosteron-System Stuttgart 1972 Georg Thieme Verlag
- 31 Ehrlich U and Klepzig H Langzeittherapie bis über neun Jahre mit Spironolactone bei der hypertensiven Herzinsuffizienz Med Klin 71 1346 1976
- 32 Hoffbrand I I, Edmonds C J and Smith T Spironolactone in essential hypertension: evidence against its effect through mineralocorticoid antagonism Br Med J 1 682 1976
- 33 Gerhards H and Engelhardt R Zum Stoffwechsel von 3 (3-oxo-17a-acetylthio-17 β -hydroxy-4-androst-17a-yl) propionsäure γ -lacton Arzneim Forsch 13 377 1963
- 34 Gochmann N and Gantt C L A fluorometric method for the determination of the major spironolactone (Aldactone) metabolite in human plasma J Pharmacol Exp Ther 135 312 1962
- 35 Karim A, Ranney R E and Maibach H I Pharmacokinetic and metabolic fate of potassium canrenoate (SC 14266) in man J Pharm Sci 50 708 1971
- 36 Sadée W, Dagioglu M and Riegelman S Fluorometric microassay for spironolactone and its metabolites in biological fluids J Pharm Sci 61 1196 1972
- 37 Sadée W, Abshagen U, Finn C and Rietbrock A Conversion of spironolactone to canrenone and disposition kinetics of spironolactone and canrenone-potassium in rats Naunyn-Schmiedeberg Arch Pharmacol 283 303 1974
- 38 Karim A, Hnbar J, Alsamir W, Doherty M and Chinn L J Spironolactone metabolism in man studied by gas chromatograph mass spectrometry Drug Metab Disp 3 467 1975
- 39 Radó J P, Szende L, Takó J, Nagy O and Kósa C Application of a simple fluorometric method on absorption of canrenone Int J Clin Pharmacol 13 123 1976
- 40 Hofmann L M A radioimmunoassay for aldosterone (canrenone) Chicago: Seale Laboratories (personal communication 1975)
- 41 Karim A, Zagarella J, Hnbar J and Dooley W Spironolactone I Disposition and metabolism Clin Pharmacol Ther 19 158 1976
- 42 Karim A, Zagarella J, Hnbar J, Hnbar T C, Chao A and Baltes H J Spironolactone II Bioavailability Clin Pharmacol Ther 19 170 1976
- 43 Dumlao J S, Kannon C, Krauss T, and Brooks M H Spironolactone and plasma cortisol Arch Pharmacol Ther 14 992 1973
- 44 Lurie A O Spironolactone and steroid assay Br Med J 2 326 1969
- 45 Metcalf M G Spironolactone and plasma cortisol Br Med J 2 1201 1964
- 46 Simon N M Coagulation nondisease N Engl J Med 282 1214 1970
- 47 Wood L C, Richards R and Ingbar S H Interference in the measurement of plasma 11-hydroxycorticosteroids caused by spironolactone administration N Engl J Med 282 650 1970
- 48 Jambroes G, Kruyswijk H H, Boink H B T J, Maas A H J and Willebrand A F Clinical experiences with the determination of the plasma digoxin level Ned Tydschr Geneesk 117 1807 1973
- 49 Huffman D H The effect of spironolactone and canrenone on the digoxin radioimmunoassay Res Commun Chem Pathol Pharmacol 8 787 1970
- 50 Phillips A P The improvement of specificity in radioimmunoassays Clin Chim Acta 44 333 1973
- 51 Ravel R Negligible interference by spironolactone and prednisone in digoxin radioimmunoassay Clin Chem 21 1801 1975
- 52 Sadée W, Riegelman S and Jones S C Disposition

- of tritium labeled spironolactones in the dog *J Pharm Sci* 61 113 197
- 53 Sadee W Riegelman S and Jones M C Plasma levels of spironolactone in the dog *J Pharm Sci* 61 1129 1972
- 54 Sadee W Dagcioglu M and Schroder R Pharmacokinetics of spironolactone canrenone and canrenoate K in humans *J Pharmacol Exp Ther* 185 686 1973
- 55 Karim A Zagarella J Hutsell T C and Dooley M Spironolactone III Canrenone—maximum and minimum steady state plasma levels *Clin Pharmacol Ther* 10 177 1976
- 56 Sadee W Schroder R Leitner V E and Dagcioglu M Multiple dose kinetics of spironolactone and canrenoate potassium in cardiac and hepatic failure *Eur J Clin Pharmacol* 7 195 1974
- 57 Levy G Availability of spironolactone given by mouth *Lancet* 2 723 1967
- 58 Gantt C L Gochmann N and Dyniewicz J M Gastrointestinal absorption of spironolactone *Lancet* 1 1130 1967
- 59 Todd M J Collins W T and Chamberlain J A comparison of the dissolution and bioavailability characteristics of three spironolactone tablet formulations including preliminary data on two spironolactone me tablets *J Int Med Res* 4 86 1976
- 60 Hofmann L M Dutt J E Dayach L G Lencin H and Tao L Comparison of spironolactone tablet dosage forms in healthy humans *J Pharm Sci* 61 1248 1974
- 61 Spöner G et al *Pharmakokinetik von Aldosteron Antagonisten Der Krankenhausarzt (In press)*
- 62 Edmonds C J and Wilson C M The action of hydroflumethiazide in relation to adrenal steroids and potassium loss *Lancet* 1 505 1960
- 63 Hofmann L M Polk R C and Maibach H I Renal clearance of canrenoate in normal man *Clin Pharmacol Ther* 18 748 1975
- 64 Ramsay L E Shelton J R Walkinson D and Todd M J Canrenone—the principal active metabolite of spironolactone? *Br J Clin Pharmacol* 3 607 1976
- 65 Ramsay L Shelton J Harrison I Todd M and Asbury M Spironolactone and potassium canrenoate in normal man *Clin Pharmacol Ther* 20 167 1976
- 66 Funder J W Feldman P Highland E and Edelman I S Molecular modifications of antialdosterone compounds effects on affinity of spironolactones for renal aldosterone receptors *Biochem Pharmacol* 23 1493 1974
- 67 Chen Y W Hofmann L M Lambert H J and Tao L C Binding of spironolactones to human plasma proteins *J Pharm Sci* 65 1337 1976
- 68 Hoffmann G Senft G and Werner C Tubuläre Wirkungen und renale Elimination von Spironolactonen Naunyn-Schmiedeberg Arch Exp Pathol Pharmacol 247 419 1964
- 69 Erbler H C Selective inhibition of aldosterone synthesis by 11 hydroxylated spironolactone in rat adrenals Naunyn-Schmiedeberg Arch Pharmacol 280 331 1973
- 70 Maebuchi M and Yoshinaga K Changes in plasma renin activity after administration of spironolactone *Jap Circ J* 31 435 1977
- 71 Schmidt K Baethmann A Schneider E Brendel W Enzenbach R and Marguth F Use of spironolactone in the treatment of cerebral edema in neurosurgical patients, in *Extrarenal activity of aldosterone and its metabolites* edited by W Brendel et al Amsterdam 1979 Excerpta Medica pp 234-237
- 72 Kautzsch G Beeinflussung der Schwensenkolyte durch Spironolactone beim sekundären Hyperaldosteronismus, Dissertation Erfurt 1964
- 73 Liddle G W Aldosterone antagonists *Arch Intern Med* 102 998 1958
- 74 Crabbe J Decreased effectiveness of aldosterone on active sodium transport by the isolated toad bladder in the presence of other steroids *Acta Endocrinol* 47 419 1964
- 75 Salassa R M Mattox V R and Power M H Effect of an aldosterone antagonist on sodium and potassium excretion in primary hyperaldosteronism *J Clin Endocrinol Metab* 18 787 1958
- 76 Vete T and Vennig E H The effect of cortisone and spironolactone on potassium excreting action of aldosterone and desoxycorticosterone *Proc Soc Exp Biol Med* 109 60 1962
- 77 Koczorek K R Jahrmarker H Hofmann H Vogt W Schmieder P Simon M and Balde E Kombinierte Anwendung antihypertensiver Substanzen mit konventionellen Diuretika in Renaler Transport und Diuretika Internationales Symposium Feldafing 1968 edited by K Thürau and H Jahrmarker Berlin 1969 Springer Verlag pp 769-771
- 78 Kagawa C M Sturtevant F M and Van Arman C G Pharmacology of a new steroid that blocks salt activity of aldosterone and desoxycorticosterone *J Pharmacol Exp Ther* 126 193 1959
- 79 Liddle G W Specific and nonspecific inhibition of mineralocorticoid activity *Metabolism* 10 1071 1961
- 80 Herman T S Fumagalli G M and Edelman I S Studies on renal aldosterone binding proteins *J Biol Chem* 243 3849 1968
- 81 Erbler H C Wernze H and Hilfenhaus M Effect of the aldosterone antagonist canrenone on plasma aldosterone concentration and plasma renin activity and on the excretion of aldosterone and electrolytes by man *Eur J Clin Pharmacol* 9 253 1976
- 82 Grohmann H W Theisen K Halbritter R Koczorek K and Jahrmarker H Zum Verhalten der Refraktanz des menschlichen Herzens unter Aldosteron und Kalcium in Extrarenal activity of aldosterone and its metabolites edited by W Brendel et al Amsterdam 1979 Excerpta Medica pp 119-121
- 83 Strauer B E Avenhaus H and Nose M Evidence for a positive inotropic effect of aldosterone on the isolated ventricular myocardium *Klin Wochenschr* 50 387 1972
- 84 Tamm R D Studies on the inotropic action of aldosterone on isolated cardiac tissue preparations including the effects of pH ouabain and SC 8109 *J Pharmacol Exp Ther* 135 71 1962
- 85 Schroder R Ramdohr B Huttermann U and Schuren K P Direkte positive inotrope Herzwirkung von Aldosteron (Spironolactone Canrenoate Kalcium) *Dtsch Med Wochenschr* 97 1535 1972
- 86 Schroder R Schuren K P Bannino G Meyer V and Sadee W Positive inotrope Herzwirkung von Aldosteron Kalcium (Aldosterone pro injectione) *Klin Wochenschr* 49 1093 1971
- 87 Strauer B H The influence of the aldosterone antagonist spironolactone on myocardial contractility *Arch Int Pharmacodyn Ther* 201 59 1973
- 88 Coraboeuf E and Derobaux E Effect of a spironolactone derivative sodium canrenoate on mechanical and

- electrical activities of isolated rat myocardium *J Pharmacol Exp Ther* 191 128 1974
- 89 Kleeberg U R and Belz G G Die Hemmung der Na K Membran ATPase und der Rubidium Aufnahme menschlicher Erythrozyten durch Spironolacton und seine Metaboliten *Verh Dtsch Ges Inn Med* 80 1521 1974
 - 90 Ferlinz R E Schroers K and Stadeler H J Ergebnisse der Behandlung der chronischen generellen alveolaren Hypoventilation mit Aldactone Kalium *Med Welt* 20 1751 1969
 - 91 Hanel J Aldactone Wirkung auf die fortgeschrittene respiratorische Insuffizienz (respiratorische Azidose) des chronischen Cor pulmonale München *Med Wochenschr* 105 2179 1963
 - 92 Huttemann U and Schüren K P Zur Behandlung des chronischen Cor Pulmonale mit Aldactone (Spironolacton Canrenoat Kalium) *Dtsch Med Wochenschr* 97 1533 1972
 - 93 Huttemann U and Schüren K P Die Wirkung von Aldactone auf Atmung und Lungenkreislauf beim chronischen Cor pulmonale *Klin Wochenschr* 50 953 1972
 - 94 Noble M I M Trenchard D and Guz A The value of diuretics in respiratory failure *Lancet* 2 257 1966
 - 95 Picodalo J J and Weber J J Aldactone chez les insuffisants respiratoires chroniques avec coeur pulmonaire chronique In Colloque sur la Spironolactone edited by R Cattani Paris 1962 Balhère pp 255 259
 - 96 Nolte D and Lueder Luehr J Untersuchungen an Gesunden zur Frage der atemstimulierenden Wirkung von Spironolactone *Klin Wochenschr* 51 200 1973
 - 97 Landau R L Bergenstal D M Lugibihl K and Kascht M E The metabolic effects of progesterone in man *J Clin Endocrinol Metab* 15 1194 1955
 - 98 Schafer J H Huttemann U and Schüren K P Untersuchungen zur zentralen Atemwirksamkeit von Canrenoat Kalium *Klin Wochenschr* 51 674 1973
 - 99 Cochrane G M and Clark T J H Ventilatory response to spironolactone in respiratory failure *Br J Dis Chest* 66 67 1972
 - 100 Erbiler H C Suppression by the spironolactone metabolite canrenone of plasma testosterone in man *Naunyn Schmiedeberg Arch Pharmacol* 285 403 1974
 - 101 Strupp B Taylor A A Bartter P C Gillette J R Lonaux D L Easley R and Menard R H Effect of spironolactone on sex hormones in man *J Clin Endocrinol Metab* 41 777 1975
 - 102 Basinger G T and Gittes R F Antiandrogenic effects of spironolactone in rats *J Urol* 111 77 1974
 - 103 Steelman S L Brooks J R Morgan E R and Patanelli D J Antiandrogenic activity of spironolactone Steroids 14 449 1969
 - 104 Castro J E Griffiths H J and Edwards E D A double blind controlled clinical trial of spironolactone for benign prostatic hypertrophy *Br J Surg* 58 485 1971
 - 105 Elliot H C Reduced adrenocortical steroid excretion rates in man following a-purin administration *Metabolism* 11 1015 1962
 - 106 Hofmann L M Krupnick M I and Garcia H A Interactions of spironolactone and hydrochlorothiazide with aspirin in the rat and dog *J Pharmacol Exp Ther* 180 1 1972
 - 107 Tweeddale M G and Ogilvie R I Antagonism of spironolactone induced natriuresis by aspirin in man *N Engl J Med* 289 198 1973
 - 108 Tweeddale M G Antagonism between antipyretic analgesic drugs and spironolactone in man *Clin Res* 22 727A 1974
 - 109 Ramsay L E Harrison I R Shelton J R and Lee C W Influence of acetylsalicylic acid on the renal handling of a spironolactone metabolite in healthy subjects *Eur J Clin Pharmacol* 10 43 1966
 - 110 Hofmann L M and Garcia H A Interactions of spironolactone and indomethacin at the renal level *Proc Soc Exp Biol Med* 141 353 1973
 - 111 Steiness E Renal tubular secretion of diuretics *Circulation* 50 103 1974
 - 112 Radzawlowski F M Effect of spironolactone and pregnenolone-16 α carbonitrile on bilirubin metabolism and plasma levels in male and female rats *Biochem Pharmacol* 22 1607 1973
 - 113 Zsigmond G and Solymossy B Effect of spironolactone, pregnenolone 16 α carbonitrile and cortisol on the metabolism and biliary excretion of sulfobromophthalen and phenol 3 6 dibromophthalen disulfonates in rats *J Pharmacol Exp Ther* 183 499 1973
 - 114 Solymossy B and Zsigmond G Effect of various steroids on the hepatic glucuronidation and biliary excretion of bilirubin *Can J Physiol Pharmacol* 51 319 1972
 - 115 Haataja M Nieminen L Kangas L Mottonen M and Bjondahl K Effect of spironolactone on pentobarbital anaesthesia diazepam metabolism and toxicity of spironolactone and furosemide *Ann Med Exp Biol Fenn* 50 57 1972
 - 116 Solymossy B Toth S Varga S Werringer J and Zsigmond G Effect of spironolactone and ethylethrelon on benz(a)pyrene hydroxylase (EC 1.14.11.1) and other chemical constituents of hepatic microsomes *Can J Physiol Pharmacol* 49 841 1971
 - 117 Stipp B Hamrick M M Zampagnone N G and Gillette J R The effect of spironolactone on drug metabolism by hepatic microsomes *J Pharmacol Exp Ther* 176 766 1971
 - 118 Gerald M C and Feller D R Evidence for spironolactone as a possible inducer of liver microsomal enzymes in mice *Biochem Pharmacol* 19 959 1970
 - 119 Feller D R and Gerald M C Interactions of spironolactone with hepatic microsomal drug metabolism n-5 enzyme systems *Biochem Pharmacol* 20 1991 1971
 - 120 Talcott R E and Stohs J J Metabolism of androstenedione and hexobarbital by liver homogenates of spironolactone pretreated male rats *J Pharm Sci* 61 296 1972
 - 121 Talcott R E and Stohs J J The effect of cytochrome acetate pretreatment on the *in vitro* metabolism of aniline hexobarbital and H digitoxigenin *J Pharmacol Exp Ther* 184 419 1973
 - 122 Solymossy B Classen H G and Varga S Increased hepatic microsomal activity induced by spironolactone and other steroids *Proc Soc Exp Biol Med* 132 940 1969
 - 123 Solymossy B Krajny M Varga S and Werringer J Suppression by nuclear acid and protein synthesis inhibitors of drug detoxication induced by spironolactone or ethylethrelon *J Pharmacol Exp Ther* 174 473 1970
 - 124 Solymossy B Somogyi Á and Kovács K Effect of spironolactone and proadifen on 7 12 dimethylbenz(a)anthracene induced haematologic changes *Haematologia* 5 87 1971
 - 125 Solymossy B Varga S Krajny M and Werringer J Influence of spironolactone and other steroids on the enzymatic decay and anticoagulant activity of bushy dioxycoumarin *Thromb Diath Haemorrh* 23 5C 1970
 - 126 Solymossy B Tóth S, Varga S and Krajny M The influence of spironolactone on its own biotransformation *Steroids* 16 263 1970

- Feller D R and Gerald M C Stimulation of liver microsomal drug metabolism in male and female mice by spironolactone and aldadiene *Proc Soc Exp Biol Med* 136 1447 1971
- Vohnrager H F Weller L and Ruetbrock N Influence of spironolactone pretreatment on pharmacokinetics and metabolism of digitoxin in rats *Naunyn Schmiedeberg Arch Pharmacol* 287 129 1975
- Klaassen C D Stimulation of the development of the hepatic excretory mechanism for ouabain in newborn rats with microsomal enzyme inducers *J Pharmacol Exp Ther* 191 212 1974
- Wurth K E and Frolich J C Effect of spironolactone on excretion of H-digoxin and its metabolites in rats *Eur J Pharmacol* 29 43 1974
- Klaassen C D Effect of microsomal enzyme inducers on the biliary excretion of cardiac glycosides *J Pharmacol Exp Ther* 191 201 1974
- Buck S H and Lage G L Possible mechanism of the prevention of digitoxin toxicity by spironolactone in the mouse *Arch Int Pharmacodyn Ther* 183 192 1971
- Castle M C and Lage G L Effect of pretreatment with spironolactone phenobarbital or β -diethylaminoethyl diph enylpropylacetate (SKF 525 A) on tritium levels in blood heart and liver of rats at various times after administration of [3 H] digitoxin *Bio hem Pharmacol* 21 1449 19 2
- Solymoss B Toth S Varga S and Krajny M Influence of spironolactone and other steroids on the plasma level of digitoxin in Recent advances in studies on cardiac structure and metabolism vol 1 edited by E Bajusz and Rona Baltimore 1979 University Park Press pp 605 611
- Castle M C and Lage G L Enhanced biliary excretion of digitoxin following spironolactone as it relates to the prevention of digitoxin toxicity *Res Commun Chem Pathol Pharmacol* 5 99 1973
- Abhagen U Effects of pretreatment with spironolactone on pharmacokinetics of 4-methylidigoxin in rats *Naunyn Schmiedeberg Arch Pharmacol* 278 91 1973
- Wurth K E and Frolich J C The influence of spironolactone on the excretion and metabolism of H-digoxin in the rat *Naunyn Schmiedeberg Arch Pharmacol* 282(suppl) R107 1974
- Gerald M C and Feller D R Stimulation of barbiturate metabolism by spironolactone in mice *Arch Int Pharmacodyn Ther* 187 10 19 0
- Wurth K E Frolich C J Holtsfeld J W Falkner F C Sweetman B S and Oates J A Metabolism of digitoxin in man and its modification by spironolactone *Eur J Clin Pharmacol* 9 345 1975
- Taylor S A Rawlins M D and Smith S E Spironolactone—a weak enzyme inducer in man *J Pharm Pharmacol* 24 318 1974
- Huffman D H Shoeman D W Pentikainen P and Azarnoff B L The effect of spironolactone on antipyrine metabolism in man *Pharmacology* 10 338 1973
- Huffman D H Pentikainen P Shoeman D W and Azarnoff B L The effect of spironolactone on antipyrine metabolism in man *Clin Res* 21 469 1973
- von Bergmann K Schwarz H P and Baumgartner C Effect of phenobarbital spironolactone and pregnenolone-16 α -carbonitrile on bile formation in the rat *Naunyn Schmiedeberg Arch Pharmacol* 287 19 5
- Leber H W Rauer P and Schütterle G Beeinflussung mikrosomaler Enzyme der Rattenleber durch Spironolactone Ethacrynsäure und Furosemid *Klin Wochenschr* 49 116 19 1
- Horvath E Somogyi A and Kovács K Einfluss von Spironolacton auf das Regenerationsvermögen der Leber bei Ratten *Klin Wochenschr* 48 385 1970
- Selye H Mees J and Savore L Inhibition of anesthetic and sedative actions by spironolactone *Anesthesiology* 31 261 1969
- Abhagen U Rennekamp H and Kuhlmann J Effects of pretreatment with spironolactone on pharmacokinetics of 4-methylidigoxin in man *Naunyn Schmiedeberg Arch Pharmacol* 292 87 1976
- Selye H Mercury poisoning prevention by spironolactone *Science* 169 75 1970
- deGuzman N T. and Yeh B K Potassium carbonate in the treatment of long term digoxin induced arrhythmias in conscious dogs *Am J Cardiol* 35 413 1975
- Selye H Krajny M and Savore L Digitoxin poisoning prevention by spironolactone *Science* 164 842 1969
- Talcott R F and Stohs E J Effect of phenobarbital and spironolactone pretreatment on digitoxin induced mortality in male and female rats *Arch Int Pharmacodyn Ther* 204 86 1973
- Selye H Mécs I and Tamura T Effect of spironolactone and norbolethone on the toxicity of digitalis compounds in the rat *Br J Pharmacol* 37 485 1969
- Solymoss B Toth S Varga S and Selye H Protection by spironolactone and oxandrolone against chronic digitoxin or indomethacin intoxication *Toxicol Appl Pharmacol* 18 586 1971
- Savore L Krajny M and Selye H Prophylactic action of spironolactone in digitoxin poisoning *Proc Can Fed Biol Soc* 12 38 1969
- Carlson G P Fuller G C and Fausto N Effects of spironolactone on carbon tetrachloride hepatotoxicity *Proc Soc Exp Biol Med* 145 187 1974
- Selye H and Solymoss B Protection by catatoxic steroids against meprobamate *Neuropharmacology* 9 39 1970
- Selye H Prevention of mephenequin intoxication by catatoxic steroids *Acta Pharmacol Toxicol* 28 145 19 0
- Selye H Prevention of indomethacin induced intestinal ulcers by various catatoxic steroids *Exp Med Sur* 28 169 19 0
- Selye H Prevention of indomethacin induced intestinal ulcers by spironolactone and norbolethone *Can J Physiol Pharmacol* 47 981 1969
- Selye H Role of the liver in the prevention of indomethacin induced intestinal ulcers by spironolactone *Acta Hepatosplenol* 17 393 1970
- Selye H Mandeville R and Yeghayan E On the catatoxic effect of antimineralocorticoids *Naunyn Schmiedeberg Arch Pharmacol* 266 34 1970
- Selye H Protection against methypyrone overdosage by catatoxic steroids *Can Anaesth Soc J* 17 107 19 0
- Memard R H Martin H F Strupp B Gillette J R and Barter F C Spironolactone and cytochrome P 450: impairment of steroid hydroxylation in the adrenal cortex *Life Sci* 15 1639 1974
- Erbiler H C On the mechanism of the inhibitory action of the spironolactone SC 93 G (aldadiene) on the production of corticosteroids in rat adrenals *in vitro* *Naunyn Schmiedeberg Arch Pharmacol* 277 139 1973
- Bravo E L, Dusan H P., and Tarazi R C Spironolactone as a nonspecific treatment for primary aldosteronism *Circulation* 48 491 1973
- Beckers D G Brown J J Ferras J B Fraser R

- Lever A F and Robertson J I S The use of spironolactone in the diagnosis and the treatment of hypertension associated with mineralocorticoid excess *Am Heart J* 86 404 1973
- 167 Mantero F Armanini E and Urbani S Antihypertensive effect of spironolactone in essential renal and mineralocorticoid hypertension *Clin Sci Mol Med* 45 219s 1973
- 168 Peart W S Renin-angiotensin system *N Engl J Med* 292 302 1975
- 169 Distler A Keim H J Philipp T et al Austauschbares Natrium Gesamtkörperkalium Plasmaplasma- und blutdrucksenkende Wirkung verschiedener Diuretika bei Patienten mit essentieller Hypertonie und niedrigem Plasmaprenin *Dtsch Med Wochenschr* 99 864 1974
- 170 Klumpff F Braun B Klaus D Lemke R Zehner J und Zöfel P Spironolacton und Thiazidazid bei der Behandlung der essentiellen Hypertonie *Dtsch Med Wochenschr* 100 577 1975
- 171 Carey R M Douglas J G Schweikert J R and Liddle G W The syndrome of essential hypertension and suppressed plasma renin activity *Arch Intern Med* 130 849 1972
- 172 Hunyor S N Zweiffer A J Hansson L Schork M A and Ellis C Effect of high dose spironolactone and chlorthalidone in essential hypertension relation to plasma renin activity and plasma volume *Aust N Z J Med* 5 17 1975
- 173 Acciardo S Dustan H P and Tarazi R C Similar effects of hydrochlorothiazide and spironolactone on plasma renin activity in essential hypertension *Cleve Clin Q* 39 153 1972
- 174 Driver J I M Kloppenborg P W C Festen J van t Laar A and Benraad T J Inpatient comparison of treatment with chlorthalidone spironolactone and propranolol in normoreninemic essential hypertension *Am J Cardiol* 38 716 1975
- 175 Lowder E C and Liddle G W Prolonged alteration of renin responsiveness after spironolactone therapy *N Engl J Med* 291 1243 1974
- 176 Faloon W W The effects of changing sodium and potassium intakes on the action of spironolactones in The clinical use of aldosterone antagonists edited by F C Bartter Springfield Ill 1960 Charles C Thomas Publisher pp 115 120
- 177 Ross E J Importance of potassium supplements during the use of spironolactone and thiazide diuretics *Br Med J* 1 1508 1961
- 178 Taylor F F and Faloon W W The role of potassium in the natriuretic response to a steroid lactone (SC 9420) *J Clin Endocrinol Metab* 19 1683 1959
- 179 Hood W G Jr Hill S R Jr Pittman J A Jr and Farmer T A Jr Studies on the metabolic effects of spironolactone in man *Ann N Y Acad Sci* 88 864 1960
- 180 Holten C and Peterson V P Malignant hypertension with increased secretion of aldosterone and depletion of potassium *Lancet* 2 918 1956
- 181 Mountokalakis T Merikas G Skopelitis P Vardakis M Sevastos N and Alivizatos J Changes of fractional renal clearance of magnesium after spironolactone administration in normal subjects *Klin Wochenschr* 53 633 1975
- 182 Wills M R Gill J R Jr and Bartter F C The interrelationships of calcium and sodium excretion *Clin Sci* 37 621 1969
- 183 Prati R C Alfrey A C and Hull A R Spironolactone induced hypercalcemia *J Lab Clin Med* 80 241 1972
- 184 Greenblatt D J and Koch Weser J Adverse reactions to spironolactone *J A M A* 225 138 1973
- 185 Winter I C Adverse reactions to spironolactone *J A M A* 225 1387 1973
- 186 Pongpaew C Songkhla R N., and Koram R L Hyperkalemic cardiac arrhythmia secondary to spironolactone *Chest* 63 1023 1973
- 187 Sjöberg W E Jr and Kreisler J E Hyperkalemia and sudden death during spironolactone (Aldactone) therapy *Texas State J Med* 58 1027 1967
- 188 Herman E and Rado J Fatal hyperkalemic paralysis associated with spironolactone *Arch Neurol* 15 4 1966
- 189 Radó J P Marosi J Takó J Dévényi I Hritík Z et al Intermittent paralysis associated with spironolactone in a patient with cardiac cirrhosis *Am Heart J* 76 393 1968
- 190 Greenblatt D J and Koch Weser J Gynecomastia and impotence complications of spironolactone therapy *J A M A* 223 82 1973
- 191 Clark E Spironolactone therapy and gynecomastia *J A M A* 193 163 1965
- 192 Mann N M Gynecomastia during therapy with spironolactone *J A M A* 184 78 1963
- 193 Pentikainen P J Pentikainen L A Huffman D H and Azarnoff D L The effect of spironolactone on sexual hormones in males *Clin Res* 21 417 1973
- 194 Levitt J I Spironolactone therapy and amenorrhea *J A M A* 211 2014 1970
- 195 Mroczek W J Davidov M E Horoschak A A Finnerty F A Jr Canrenoate in normal man *Clin Pharmacol Exp Ther* 16 336 1974
- 196 Erbler H C The effect of saluretics and spironolactone on aldosterone production and electrolyte excretion in man *Naunyn-Schmiedeberg Arch Pharmacol* 286 145 1974
- 197 Loube S D and Quirk R A Breast cancer associated with administration of spironolactone *Lancet* 1 143 1975
- 198 Ramsay L Harrison I Shelton J and Tidd M Relative potency of prerenal and spironolactone in normal man *Clin Pharmacol Ther* 18 391 1975
- 199 Ramsay L E Hessup P and Tidd M J Bioassay of aldosterone antagonists in normal human subjects: a relationship between the level of plasma uric acid before treatment and apparent drug responses *Br J Clin Pharmacol* 2 271 1975
- 200 Ramsay L E Shelton J R and Tidd M J The pharmacodynamics of single doses of prerenal potassium and spironolactone in hydrocortisone treated normal subjects *Br J Clin Pharmacol* 3 475 1976

ECG/Phono/Pulse 3-Channel System



model

FD-31P

■ Features

- Model FD-31P is a 3-channel direct writing system for simultaneous recording of ECG/ECG/ECG PCG/PCG/ECG PCG/ECG/Pulse or Pulse/Pulse/ECG
- The system retains all standard features of a 3-channel ECG with the added provisions of simultaneous Heart Sound ECG and Pulse Wave recording thus providing valuable diagnosis
- The FD-31P employs a special envelope detection method and includes the most advanced galvanometer design providing optimum resolution of diagnostic information
- Electrical safety is attained by a specially designed floating input amplifier
- Other Products available

Single Channel ECG/2-Channel ECG/3-Channel ECG/Vector Cardioscope/ECG Cassette Recorder and Play-back System/Monitoring Oscilloscope/Patient Monitor



Example 30 ye III male WPW Syndrome (Ebstein's anomaly)

■ For Further Information

write to



FUKUDA DENZHI CO., LTD

3 39 4 Hongo Bunkyo ku,
Tokyo 113, Japan
Phone (03)815 2121
Telex 272 2217 FUKUDA J

In North America
Fukuda Denzhi Co. Ltd.
c/o Medical Systems Corp
230 Middle Neck Road
Great Neck NY 11021
Phone (516)466 2000

When reactions must be instantaneous and exact...

**A popular Mosby book can help you prepare
to effectively meet cardiac emergencies:**

New 2nd Edition!

TREATMENT OF CARDIAC EMERGENCIES

Comprehensive yet easy to follow, the new edition of this widely used book presents pertinent data on every aspect of cardiac emergencies: diagnosis, treatment, equipment, and pharmacology.

Its convenient three part format is ideal for on the spot reference in emergency situations. Part I describes cardiac emergency syndromes including causes, pathophysiology, diagnosis, differential diagnosis, emergency and definitive treatment for each condition. You'll find new information on Swan Ganz monitoring and vasodilator drugs in the treatment of cardiogenic shock, revised criteria for the use of IV sodium bicarbonate for cardiac arrest, and timely material on the use of HIS bundle electrograms and digitalis toxicity in patients with atrial fibrillation.

The second section examines all the apparatus used for cardiac emergencies. Part III focuses on commonly used drugs for cardiac emergencies and includes new information on diazoxide, digoxin dosage, lidocaine, procainamide, propranolol, and sodium nitroprusside.

Inside the back cover ■ handy table of emergency treatments guides you to the appropriate discussion in the text—quickly and conveniently.

Why not see for yourself how this book can help you practice? Order your copy today!

By Emanuel Goldberger, M.D., F.A.C.P., with 1 contributor

October 1977 402 pages 243 illustrations Price \$17.50

ORDER BY PHONE NOW! Call (800) 325-4177 ext. 10 or
Missouri, call collect (314) 872-8370 ext. 10 9 a.m. to 5 p.m. (CST)
Monday through Friday A80594

MOSBY
TIMES MIRROR

THE C. V. MOSBY COMPANY
11830 WESTLINE INDUSTRIAL DRIVE
ST. LOUIS, MISSOURI 63141

Act now...
use this coupon:

yes!

I want to inspect an on approval copy of

TREATMENT OF CARDIAC EMERGENCIES (1854 1) \$17.50

☐ Bill me ☐ mastercharge _____

☐ Payment enclosed ☐ VISA _____

Name _____

Address _____

City _____ State _____ Zip Code _____

30 day approval good in U.S. and Canada A80594 10 05

Mail this coupon today and you'll have 30 days to evaluate your selection

Telephone calls!

Via telephone ECG system
by **O.T.E. BIOMEDICA**


EQUIPMENT AND INSTALLATION FOR

- Cardiophysiology ● Neurophysiology
- Patient monitoring ● Intensive care

P O BOX 400 50127 FIRENZE



MONTEDISON GROUP
CARLO ERBA



®

Sublingual Tablets

nitroglycerin tablets, USP)

PARKE DAVIS & COMPANY
Detroit, MI 48232

PD-JA 2357 1C-P(2 78)



PERSONALIZED LIBRARY CASES

Keep your personal copies of AMERICAN HEART JOURNAL in these specially designed library file cases. Each file holds an entire year's issues. Designed to keep your journal copies near at hand in your office, library, or home.

Your case is heavy bookbinder's board in a rich red Kivar cover. Files are scuff resistant and washable.

Lettering is stamped in gold leaf and the cases make a fit companion for the most costly binding.

Files are reasonably priced—only \$4.95 each postpaid (3 for \$14 ■ for \$24). Add \$1.00 postage per case for orders outside U.S. Satisfaction unconditionally guaranteed or your money back! Use the coupon for prompt shipment.

Jesse Jones Box Corporation (est. 1843)
P. O. Box 5170
Philadelphia, Pa. 19141

Please send me postpaid _____ library cases for
AMERICAN HEART JOURNAL at \$4.95 each
(3/\$14 6/\$41)

Name _____

Address _____

City _____ State _____ Zip _____

Refine your diagnostic expertise and learn more about echocardiography with this new book: **Clinical Echocardiography**

Use this eminently practical guide to make echocardiography an even more valuable part of your practice. Well written and generously illustrated it thoroughly explores — and visually demonstrates — all aspects of the dynamic technique. The authors first provide a succinct review of clinical cardiology pertinent ultrasound principles and examination techniques. Subsequent chapters organized according to anatomical structure analyze technical considerations, normal tracings, disease manifestations and functional observations. Throughout more than 650 superb anatomical drawings and sample echocardiograms offer you both an excellent opportunity to compare normal and abnormal findings and a challenging review. But why not see for yourself? Look through the table of contents for a fuller understanding of this book's outstanding coverage. Then order your copy today!

By Navin C. Nanda, M.D. and Raymond Gramiak, M.D. July 1978. Approx. 400 pages. 666 illustrations. About \$37.50.

CONTENTS: FUNDAMENTALS OF ECHOCARDIOGRAPHY. Clinical cardiology. Basic principles of ultrasound. Echocardiographic examination technique. CLINICAL ECHOCARDIOGRAPHY. Mitral valve. Aortic valve. Tricuspid valve. Pulmonary valve. Left ventricle. Pericardial effusion. Prosthetic valves. Complex malformations. Two dimensional echocardiography. APPENDIX. REVIEWS.

For even faster service or if coupon has been removed, call us! Dial toll free (800) 325-4177 ext. 10, in Missouri, call collect (314) 872-8370 ext. 10 from 9 am to 5 pm (CDT) Monday through Friday. AS0728

Return this coupon today!

Mail this coupon today and you'll have 30 days to evaluate your selection.

Yes! I want to inspect an on approval copy of CLINICAL ECHOCARDIOGRAPHY (3622 1) \$37.50.

Est. mailed price, subject to review on print or to publication.

☐ Bill me ☐ Payment enclosed

☐ mastercharge

☐ BankAmericard/VISA

Name _____

Address _____

City _____

State _____

Zip Code _____

30-day approval good in U.S. and Canada.

AS0726 02 05

Complete and mail to: The C. V. Mosby Company, 11830 Westline Industrial Drive, St. Louis, Mo 63141.

MOSBY

TIMES MIRROR

THE C. V. MOSBY COMPANY
11830 WESTLINE INDUSTRIAL DRIVE
ST. LOUIS, MISSOURI 63141

Even if your pacemaker patient misses his regular check up....



Pacesetter's Reliability Takes away the worry

Although your patient may never be adrift in the Pacific wouldn't it be reassuring to know that his pacemaker is the most reliable available? That the manufacturer has an outstanding reputation for reliability and innovation in the industry?

If you implant or recommend the use of one of the Pacesetter lithium powered pulse generators you can rest assured that it will still be working year after year. We guarantee it. Our reliability was engineered in from the very first not inspected in afterward. We even offer the only lead warranty in the business. Years of trouble free implants all over the world, in addition to stringent inspection and quality assurance procedures make these statements possible.



Your Pacesetter representative will be extra helpful in evaluating the proper pulse generator lead systems to meet your patients needs. You that all Pacesetter representatives are as reliable as our product — in offering outstanding service and technical support 24 hours a day.

To arrange for one of our people to show you a complete Pacesetter picture, call (toll free of course) 800 423 5611 and ask for Professional Service. Where Reliability is a Way of Life!

Pacesetter Systems, Inc. —
12740 San Fernando Road Sylmar, Calif. 91342 US
1 (800) 423 5611 Telex 69815
In Califor

PACESSETT

Diabetic angiopathy—its lessons in vascular physiology

Donald E. McMillan MD

Santa Barbara, Calif

Many of the diabetic's cardiovascular problems differ from those of the non-diabetic only by occurring more often. What has been learned by the cardiologist is equally applicable to the problems of these diabetics. There are, however, some conditions and complications unique to the diabetic which are not regularly seen by the cardiologist. Many of these sequelae are due to vascular alterations specific to diabetes. The endocrinologist's improving understanding of this diabetic angiopathy has produced some points of interest for cardiologists which are discussed here.

The concept of diabetic angiopathy

In the 19th century ketosis-prone diabetics usually survived for only a brief period. Changes observed at autopsy were almost all caused by marked hyperglycemia. Only diabetics with onset in middle and later life survived long enough to have cardiovascular, neurologic, and ophthalmologic difficulties.¹ The only cardiovascular complication regularly linked to chronic diabetes was gangrene of the lower extremities.² The use of insulin for treating young diabetics has demonstrated that diabetics of all ages are subject to specific changes in these three systems.

Systematic analysis of diabetics surviving for more than 15 years demonstrated that many specific long-term complications of diabetes were mediated by a disturbance of the circulation. Diabetic retinopathy, neuropathy, and nephropathy

are now often merged under the collective term diabetic angiopathy. Because most of the vessels affected are small, we often add the prefix "micro" to angiopathy. The local pathology is different in the eye, kidney, and nervous system. But in all three areas it develops as duration increases. In each area changes develop in parallel with those elsewhere.

The term "diabetic angiopathy" should be used only for conditions specific to the diabetic state, not for changes secondary to atherosclerosis occurring in the diabetic. Calcific changes in the arterial media illustrate this distinction quite well. Their occurrence is more closely related to duration of diabetes than to age,³ but symptoms are more likely to be age-related. The arterial media changes interact with arterial intima changes to produce a rather profound disturbance of the peripheral circulation in older diabetics. It may be impossible in an individual patient with peripheral vascular insufficiency to say how much is due to diabetic angiopathy and how much to atherosclerosis.⁴ Calcium in the arterial media favors a role for diabetic angiopathy, since calcification is associated with changes in elastin⁵ and with PAS positivity in the media. Similar histologic changes without calcification are found in a wide variety of vessels in the diabetic—arteries, arterioles, capillaries, venules, and veins.⁶ The pathology in the arterial system shares features with changes found in hypertension.⁷ The slow development of widespread vascular changes is the most substantial evidence for the concept of diabetic angiopathy.

Angiopathy and atherosclerosis

Some writers consider that diabetic (small) vessel changes develop in parallel with atherosclerosis in

From the Sannum Medical Research Foundation, Santa Barbara, Calif.

Supported in part by the Donald F. Palm Trust and the Kroenke Foundation.

Received for publication April 11, 1978.

Reprint requests: Donald E. McMillan MD, in Medical Research Foundation, P.O. Drawer 11, Santa Barbara, CA 93102.

larger arteries. This concept should not be accepted since it is contradicted by a number of studies. The Pima Indians of Arizona are regularly obese. Half of them develop diabetes in maturity. They have much less ischemic heart and peripheral artery disease than in the general US population, but the diabetic Pimas have just as much retinopathy and nephropathy.¹⁰ In parts of the world where diabetes and malnutrition coincide, there is also as much retinopathy but much less atherosclerosis.¹¹ The association we make between atherosclerosis and diabetes is probably attributable to two factors. First, the majority of diabetes is probably attributable to two factors. First, the majority of diabetics in western society have maturity onset non ketosis prone diabetes, a condition provoked by overweight. Since these diabetics are usually obese they would be expected to have more atherosclerosis.¹² Second, the development of hyperglycemia is accompanied by elevation of the plasma triglyceride level. Triglyceride's role in the generation of atherosclerosis in the non diabetic is only marginal but its elevation is linked quite distinctly to atherosclerosis in diabetics.¹³

Angiopathy and hypertension

Diabetics are more likely to be hypertensive than non diabetics.¹⁴ Even at diagnosis there is often a mild increase in blood pressure. This may be attributable to a tendency of the blood volume to be expanded, a process which may be associated with low aldosterone levels.¹⁵ The combination of diabetes and hypertension is worse than either disorder alone. Diabetic microangiopathy and hypertension share pathologic features in the arterioles, even though diabetic arteriolar changes are patchier than those in hypertension. Diabetes involves mainly arterioles small enough to lack an internal elastic lamina, while hypertension affects somewhat larger arterioles just as strikingly.¹⁶ The hyaline arteriosclerosis in the eye and kidney in benign hypertension and in diabetic retinopathy and nephropathy are therefore rather similar.¹⁶ Hypertension accompanying diabetic nephropathy accelerates the progression of uremia.¹⁷ The overlapping anatomic changes in hypertension and diabetes appear to be additive.

Angiopathy and basement membrane changes

The ability to look at smaller and smaller structures with the electron microscope has

changed our concept of diabetic angiopathy. The smallest microcirculatory structure, the capillary, has been found to have a thickened basement membrane in diabetes. Controversy about the role of capillary basement membrane thickening in causing diabetes has provoked much interest. During the basement membrane controversies we have often forgotten much that we knew before about how angiopathy develops as diabetes progresses. Capillary basement membrane thickening in diabetes is widespread in the body.¹⁸ Most studies have concentrated on three body tissues—skeletal muscle, the kidney, and the eye. Skin was found to have too erratic an anatomy to be used.

Studies of skeletal muscle capillary basement membrane are the most widely known source of major controversy. Zacks and associates¹⁹ first established that it is thickened in diabetes. Siperstein and colleagues²⁰ used this observation as a means for investigating large numbers of diabetics. Their studies were started when interest in a 'pre diabetic' state was widespread. Diabetes was assumed to be inherited as a recessive trait with incomplete penetrance. Studies on individuals who had close family members with diabetes showed basement membrane thickening in the presence of a normal glucose tolerance. Although the thickening was not as substantial as that seen in diabetes, evidence that an inherited microcirculation defect was present before the onset of diabetes led to the hypothesis that such an anatomic change could somehow trigger the development of diabetes.²⁰ Attention shifted away from the relation of capillary changes to diabetic complications and toward their role in causing diabetes. Current analyses show that basement membrane measurements are diagnostic neither of diabetes nor pre diabetes. Children with ketosis prone diabetes have no basement membrane thickening. In adolescent identical twins one of whom had diabetes, only the diabetic twin had basement membrane thickening.²¹ Basement membrane thickens both with advancing age and increasing duration of diabetes.²² Among the Pima Indians individuals who are predisposed to diabetes on a recognizable genetic basis are reported to have basement membrane thickening but their glucose tolerance, though normal, differs from the Pimas not hereditarily predisposed to diabetes.²³

The two studies supporting a linkage between skeletal muscle basement membrane thickening

and diabetic retinopathy should be noted with are Kilo and co workers²⁹ and Yodaiken and collaborators³⁰ found both a progression in basement membrane thickening with duration of diabetes and greater basement membrane thickening in diabetics with retinopathy. In neither study was it possible to match individuals with and without retinopathy for duration of diabetes so that it cannot be firmly concluded that retinopathy rather than duration of diabetes was responsible for the observed increase. Skeletal muscle biopsy has little or no use in determining the likelihood of future development of diabetic retinopathy.

In addition to the absence of a close relationship between basement membrane thickening in muscle and evidence of diabetic angiopathy in other body areas, no observations yet link thickening of the basement membrane in the muscle to an impairment of muscle function. In skeletal muscle with its low blood flow at rest, capillaries remain empty much of the time, opening to blood flow mainly on demand. Maximal exercise ability is often impaired in diabetics, but no one has yet been able to show that basement membrane contributes to the problem even though the basement membrane is the structure across which all oxygen molecules have to pass to enter muscle. It is not illogical to believe that the thickening could impair oxygenation during exercise. Changes in diabetic red blood cells also favor disruption of oxygen delivery.³¹ A careful study showing whether diabetic exercise intolerance is more closely related to red cell or basement membrane factors would be very useful to our understanding of both diabetes and exercise.

Diabetic retinopathy

The eyes may become severely disrupted in long term diabetes by progressive changes in their vasculature. Capillary basement membrane thickening which occurs in parallel with ciliary process basement membrane thickening is not an early or major element in the pathology. Hyaline changes in the precapillary arterioles are more important. Ashton considers them probably to be analogous to capillary basement membrane thickening. The development of small areas of non perfused acellular capillaries beyond these hyaline precapillary arterioles is a major event in diabetic retinopathy. The affected capillaries normally supply the metabolically active areas deep in the retina. The acellular capillary

areas regularly become surrounded by microaneurysms. Only late in their life do these microaneurysms develop thickening of the basement membrane in their walls.

Not yet rigorously proven but important to understanding retinopathy is the proposal that oxygen deprived retinal neurons produce a substance which influences blood vessel formation generating microaneurysms, venous alterations and even proliferative new vessel growth. The substance or substances controlling vascular development would be a major force in causing vitreous hemorrhage and rubeosis iridis as well as producing background retinopathy in response to local hypoxia.^{32,33} Evidence in favor of an angiogenesis factor is the fact that similar retinal pathology—microaneurysms, exudates and proliferative vascular changes—occurs in other types of retinal ischemia. Laser treatment may be effective in retinopathy by restoring the balance between blood supply and metabolic need through reduction of the total amount of retinal tissue.

There is evidence that occlusive atherosclerotic changes in one ophthalmic artery are associated with increased retinopathy in the eye supplied with less blood.³⁴ In apparent contrast is the report that retinopathy is worse in the eye with the higher intraocular arterial pressure.³⁵ This conflict may be explained if two separate mechanisms are involved. Reduction in blood flow would be expected to aggravate anoxia mediated retinopathy. Hypertension may combine with diabetes to increase the rate of development of arteriosclerosis causing new ischemic areas. Either too much pressure or too little flow may well produce the same retinal pathology.

Diabetic nephropathy

Rather than being a steady oxygen consumer like the retina, the kidney is a filtering system subject to sudden changes in its blood supply. While the glomerulus is the structure most strikingly affected in diabetes, the interlobular afferent and efferent arterioles are altered as well. The afferent arteriole is the first structure affected, a change said to be a necessary predecessor to glomerular disease.³⁶ The glomerular basement membrane is more an epithelial than a vascular structure. It is in contact with glomerular epithelial cells even in areas away from the capillary lumen. Silver staining studies have demonstrated that new basement membrane is

formed principally by the epithelial cells³⁴ Progressive thickening of the glomerular basement membrane follows the onset of diabetes accompanied by an enlargement of the entire glomerulus³⁵ The glomerular basement membrane thickening is symmetric, involving the afferent and efferent glomerular areas equally³¹ Both glomerular enlargement and basement membrane thickening may be mediated by high growth hormone levels³⁶ There is no associated diminution in function, glomerular filtration rate is higher than normal in early diabetes, particularly when growth hormone is markedly elevated

Another kind of glomerular change brings about the disruption of glomerular filtration in long standing diabetes An avilly placed intercellular substance accumulates in continuity with the hyaline in the afferent arteriole The mesangial cells that inhabit the avial area come to be surrounded by islands of amorphous material which appear to be similar to basement membrane but are usually physically separate from it The amorphous avial material is mainly at the afferent end of the glomerulus³⁷ This extramembranous accumulation is the basis for both diffuse and nodular glomerulosclerosis It causes a progressive distortion of the glomerulus and interacts with basement membrane changes to increase the resistance to blood flow Renal function declines at a point signalled by the development of proteinuria³⁸

Diabetics may die from renal insufficiency with kidneys which are larger than normal in size³⁴ While there is a mild over all loss of glomeruli, many more glomeruli remain at death than are found in terminal glomerulonephritis or pyelonephritis The remaining glomeruli are receiving a sufficient blood supply—the renal cortex is not atrophied Yet almost no filtration is occurring Glomerular deformation and arteriolosclerosis probably combine to lower the glomerular pressure head to below the oncotic pressure of the plasma, blocking filtration and urine formation³⁹

Arterial blood pressure affects diabetic nephropathy Kimmelstiel Wilson disease was found only in the kidney receiving full arterial pressure in a hypertensive diabetic who had unilateral occlusive renal arterial disease⁴⁰ The kidney exposed to a lower arterial pressure was unaffected A prospective study has shown that when

diabetics who develop proteinuria are treated vigorously for associated hypertension there is a slowing of the rate of decline of creatinine clearance⁴¹ If reduced filtration pressure is the most critical issue in the progression of diabetic nephropathy, why should lowering the blood pressure help the situation? Timing may be important When renal insufficiency is well established hypotension reduces urine formation Before renal insufficiency is advanced it is likely that hyaline arteriolar changes induced by hypertension add to the diabetic pathology, further reducing the arterial pressure at the level of the glomerulus

Angiopathy and blood flow

The abnormalities found in diabetic retinopathy and nephropathy demonstrate that not only must blood be pumped from the heart through the arteries to the tissues it must be distributed at an appropriate pressure and oxygen tension to satisfy local metabolic needs Disruptions even at a microscopic level, are sufficient to impair function In diabetes these disruptions are brought about by changes in the walls of blood vessels While the capillary may be easiest to study, it is probably not the area of greatest importance The precapillary arteriole appears to be the structure whose compromise is most disruptive

Local microcirculatory compromise may interact with large vessel disease Circulation to the skin has been studied in diabetes It has been found that maximum blood flow is impaired when diabetic retinopathy is present Diabetics often have severe coronary disease Their intracardiac microcirculatory changes appear to enhance the ischemia produced by atherosclerosis, making cell death more likely once insult has occurred⁴² In other chronic disorders microcirculatory changes less pronounced and less destructive than those in diabetes might also interact to contribute to cardiac pathology

Properties of blood altered by diabetes affect the delivery of oxygen Hemoglobin A1c formation and its level in erythrocytes are increased in diabetes⁴³ Glucose becomes attached to hemoglobin during the erythrocyte's lifetime in the circulation The attachment of glucose to hemoglobin increases its affinity for oxygen so that unless blood flow is increased tissue oxygen tension is lowered Diabetic erythrocytes in addition to hoarding oxygen do not deform as easily

normal erythrocytes when passing through structures smaller than their own diameter." Since in many areas of the body the oxygen supplying capillaries are smaller than 8 microns either a larger pressure gradient must be developed or less local flow will occur. Both erythrocyte abnormalities contribute to a reduction in the effectiveness of the microcirculation in diabetes even when sclerotic changes are not present. Their role in the development of diabetic angiopathy and in enhancing its circulatory disruption is not yet established.

A number of studies attempting to reduce the rate of development of complications in diabetes have been carried out. Diabetics are subject to both microvascular—neuropathy, retinopathy and nephropathy—and atherosclerotic complications—ischemic heart disease and peripheral arterial insufficiency. The diabetic of youthful onset has a different morbidity and mortality pattern than the older diabetic. He is more subject to microvascular complications and less subject to atherosclerosis. In the older diabetic a high proportion of major recognizable sequelae are related to atherosclerotic changes. Efforts to modify diabetic complications should take this more fully into account. Studies mixing younger and older diabetics may miss the benefit of treatment on the progress of microvascular disease. Weight loss is being emphasized in management of the older diabetic. While probably beneficial in atherosclerosis, weight loss is not known to have any effect on microvascular changes. Hypertension in the younger diabetic is quite often a sign of developing diabetic nephropathy while in the older diabetic hypertension may have antedated diabetes and may therefore not aggravate microangiopathy as much. The differences in outlook for younger and older diabetics should be taken into better account in selecting subjects in future studies.

Improved control of diabetes by multiple doses of insulin reduces progression of diabetic retinopathy. Diabetics treated with more insulin have a tendency to gain weight. High insulin levels also cause a short term decline in blood volume. The stage may now be set for an increased frequency of ischemic heart disease. By attacking only diabetic microvascular complications with vigor we may quite conceivably increase the frequency of ischemic vascular disease. To avoid such a possibility we are going to have to manage

diabetics in such a way that we will prevent atherosclerotic as well as microvascular problems.

Summary

Progress in our understanding of diabetic angiopathy has been slow but we are now learning a number of lessons of interest to the cardiologist. Diabetic angiopathy is a collective term for conditions specific to the diabetic state and related to its duration more than to patient age. The angiopathy produces calcification of the media of larger arteries but its major effects are in the microcirculation. Intense interest in one feature, skeletal muscle capillary basement membrane thickening, has dominated the last decade. Capillary basement membrane thickening while characteristic of diabetes is associated with little direct impairment of the microcirculation. It appears to play no role in the pathogenesis of diabetes itself. The pathology of diabetic retinopathy and diabetic nephropathy suggests that arteriolar changes may be the major mediator of diabetic angiopathy. This concept is supported by the interactions between hypertension and diabetes in the eye and kidney. The course of diabetes of youthful onset differs from that of maturity onset. The relative frequency of diabetic angiopathy is higher and of atherosclerotic complications is lower. This has made it difficult to demonstrate the potential value of preventive measures. Benefit to one type of problem may become hidden by worsening of the other. If the diabetic benefits from what is learned about how ischemic heart disease risk can be reduced, he will require even more effective management to prevent or control diabetic angiopathy.

REFERENCES

1. Nannyn B. *Der Diabetes Melitus*. Vienna 1898. Alfred Holder pp 173-733.
2. Marchal de Calvi. *Recherches Sur Les Accidents Diabetiques*. Paris 1864. P. Asselin pp 1-110.
3. Lundbaek K. *Long term diabetes*. Copenhagen 1953. Ejnar Munksgaard.
4. Ditzel J and Rooth G. The micro angiopathy in diabetes mellitus. *Diabetes* 4:474 1955.
5. Ferner T M. Radiologically demonstrable arterial calcification in diabetes mellitus. *Australas Ann Med* 13:2-2 1964.
6. Strandberg D E, Priest W E and Gibbons G E. Combined clinical and pathologic study of diabetic and nondiabetic peripheral arterial disease. *Diabetes* 13:366 1964.
7. Urry D W. On the molecular basis for vascular calcification. *Perspect Biol Med* 18:68 1974.

formed principally by the epithelial cells³⁴ Progressive thickening of the glomerular basement membrane follows the onset of diabetes accompanied by an enlargement of the entire glomerulus³⁵ The glomerular basement membrane thickening is symmetric, involving the afferent and efferent glomerular areas equally³⁵ Both glomerular enlargement and basement membrane thickening may be mediated by high growth hormone levels³⁶ There is no associated diminution in function glomerular filtration rate is higher than normal in early diabetes, particularly when growth hormone is markedly elevated

Another kind of glomerular change brings about the disruption of glomerular filtration in long standing diabetes An axially placed intercellular substance accumulates in continuity with the hyaline in the afferent arteriole The mesangial cells that inhabit the axial area come to be surrounded by islands of amorphous material which appear to be similar to basement membrane but are usually physically separate from it The amorphous axial material is mainly at the afferent end of the glomerulus³⁷ This extramembranous accumulation is the basis for both diffuse and nodular glomerulosclerosis It causes a progressive distortion of the glomerulus and interacts with basement membrane changes to increase the resistance to blood flow Renal function declines at a point signalled by the development of proteinuria¹⁸

Diabetics may die from renal insufficiency with kidneys which are larger than normal in size¹⁴ While there is a mild over all loss of glomeruli many more glomeruli remain at death than are found in terminal glomerulonephritis or pyelonephritis The remaining glomeruli are receiving a sufficient blood supply—the renal cortex is not atrophied Yet almost no filtration is occurring Glomerular deformation and arteriosclerosis probably combine to lower the glomerular pressure head to below the oncotic pressure of the plasma, blocking filtration and urine formation³⁸

Arterial blood pressure affects diabetic nephropathy Kimmelstiel Wilson disease was found only in the kidney receiving full arterial pressure in a hypertensive diabetic who had unilateral occlusive renal arterial disease³⁹ The kidney exposed to a lower arterial pressure was unaffected A prospective study has shown that when

diabetics who develop proteinuria are treated vigorously for associated hypertension there is a slowing of the rate of decline of creatinine clearance¹⁸ If reduced filtration pressure is the most critical issue in the progression of diabetic nephropathy, why should lowering the blood pressure help the situation? Timing may be important When renal insufficiency is well established hypotension reduces urine formation Before renal insufficiency is advanced it is likely that hyaline arteriolar changes induced by hypertension add to the diabetic pathology, further reducing the arterial pressure at the level of the glomerulus

Angiopathy and blood flow

The abnormalities found in diabetic retinopathy and nephropathy demonstrate that not only must blood be pumped from the heart through the arteries to the tissues, it must be distributed at an appropriate pressure and oxygen tension to satisfy local metabolic needs Disruptions even at a microscopic level are sufficient to impair function In diabetes these disruptions are brought about by changes in the walls of blood vessels While the capillary may be easiest to study, it is probably not the area of greatest importance The precapillary arteriole appears to be the structure whose compromise is most disruptive

Local microcirculatory compromise may interact with large vessel disease Circulation to the skin has been studied in diabetes It has been found that maximum blood flow is impaired when diabetic retinopathy is present Diabetics often have severe coronary disease Their intracardiac microcirculatory changes appear to enhance the ischemia produced by atherosclerosis making cell death more likely once insult has occurred⁴⁰ In other chronic disorders microcirculatory changes less pronounced and less destructive than those in diabetes might also interact to contribute to cardiac pathology

Properties of blood altered by diabetes affect the delivery of oxygen Hemoglobin A_{1c} formation and its level in erythrocytes are increased in diabetes⁴¹ Glucose becomes attached to hemoglobin during the erythrocyte's lifetime in the circulation The attachment of glucose to hemoglobin increases its affinity for oxygen, so that unless blood flow is increased tissue oxygen tension is lowered Diabetic erythrocytes in addition to hoarding oxygen do not deform as easily⁴²

Complications due to cloth wear in cloth covered Starr-Edwards aortic and mitral valve prostheses—and their management

Anilkumar Shah M D

Martin Dolgin M D

David A. Tice M D

Naresh Trehan M D

New York N Y

Since the introduction of the ball in cage heart valve prostheses by Harken and colleagues in 1960 and by Starr and Edwards in 1961 the natural history of valvular heart disease has been favorably altered. Complications related to prosthetic valve material and design however remain a substantial source of morbidity and mortality.¹ The potentially life threatening complications such as ball variance, infective endocarditis, persistent severe hemolytic anemia, systemic arterial embolization, thrombotic obstruction of the prosthesis and paraprosthetic regurgitation require prompt detection and aggressive treatment. Continued improvement in prosthetic valve material and design has reduced some of these complications. For example, the problem of ball variance has been virtually eliminated by the use of the hollow metal ball (Stellite 21).² The introduction of cloth covered aortic and mitral valve prostheses has substantially reduced the incidence of thromboemboli in patients receiving anticoagulant therapy.

Although successful in reducing thromboembolic complications, cloth covered valves suffer from a greater degree of hemolysis and problems of cloth wear.³ A varying degree of strut cloth wear is an incidental finding in a majority of

patients with cloth covered Starr-Edwards aortic valve prosthesis who come for reoperation for infection or periprosthetic leak. However, clinically significant hemolytic anemia and systemic arterial embolization due to extensive cloth wear have also been described.^{4,5} The consequences of cloth wear, their clinical significance and recognition and their management have not received sufficient attention in the long term management of cloth covered prosthetic valves. The following case reports illustrate the clinically significant complications resulting from cloth wear and their correction by replacement of the cloth covered prostheses.

Case reports

Case 1 This 52 year old man was admitted to the New York Veterans Administration Hospital for recurrent strokes. Seven years prior to admission he had received a No. 11 Model 2300 Starr-Edwards cloth covered aortic valve prosthesis for aortic stenosis and insufficiency. Six years after valve replacement he suffered sudden onset of left hemiparesis, expressive aphasia and left homonymous hemianopsia with nearly full recovery in 2 weeks. One year later he suffered sudden onset of right hemiparesis. He had no symptoms of diminished cardiac reserve. The anticoagulant therapy throughout his postoperative course had been erratic and inadequate. Physical examination revealed an afebrile patient with expressive aphasia and mild residual right hemiparesis. He was in normal sinus rhythm. His blood pressure was 140/90 mm Hg. Both carotid pulses were normal and without bruits. Prosthetic aortic

From the Cardiology Section and Cardiac Surgery Section, Veterans Administration Hospital, New York, N.Y., and Department of Medicine and Surgery, New York University School of Medicine, New York, N.Y.

Received for publication May 8, 1978

Reprint request: Anilkumar Shah, M.D., Cardiology Section, Veterans Administration Hospital, First Avenue, 24th Street, New York, N.Y. 10010

- 8 Optiz V M and von Dorsche H H Histotopochemical investigations on elastic membranes of blood vessels with special regard to diabetes mellitus *Acta Histochem* 54 193 1975
- 9 Goldenberg S Alex M Joshi R and Blumenthal H Nonatheromatous peripheral vascular disease of the lower extremity in diabetes mellitus *Diabetes* 8 261 1959
- 10 Ingelfinger J A Bennett P H Liebow I M and Miller M Coronary heart disease in the Pima Indians *Diabetes* 25 561 1976
- 11 Moses S G P and Kannan V The clinical profile of undernourished diabetics aged 30 or less with associated complications in Madras India *Diabetes mellitus in Asia* S Baba Y Goto and I Fukui eds Amsterdam 1976 Excerpta Medica pp 259 262
- 12 Stamler J Beard R Connor W E deWolfe V G Stokes J Willis P W Lilienfeld A M Dawber T R Doyle J T Epstein F H Kuller L H and Winkelstein W Primary prevention of the atherosclerotic diseases *Circulation* 42 A 55 1970
- 13 Stout R W Bierman E L and Brunzell J D Atherosclerosis and disorders of lipid metabolism in diabetes *Diabetes Its physiological and biochemical basis* J Vallance Owen ed Baltimore 1975 University Park Press pp 125 169
- 14 Bell E T Renal vascular disease in diabetes mellitus *Diabetes* 2 376 1953
- 15 Christlieb A R Renin-angiotensin-aldosterone system in diabetes mellitus *Diabetes* 25 820 1976
- 16 McGee W G and Ashworth C T Fine structure of chronic hypertensive arteriopathy in the human kidney *Br J Ophthalmol* 43 273 1963
- 17 Ashton N Vascular basement membrane changes in diabetic retinopathy *Br J Ophthalmol* 58 344 1974
- 18 Mogensen C E Renal function changes in diabetes *Diabetes* 25 872 1976
- 19 Siperstein M D Norton W Unger R H and Madison L L Muscle capillary basement membrane width in normal diabetic and prediabetic patients *Trans Assoc Am Physicians* 79 330 1966
- 20 Zacks S I Peques J J and Elliott F A Interstitial muscle capillaries in patients with diabetes mellitus A light and electron microscope study *Metabolism* 11 381 1962
- 21 Siperstein M D Unger R H and Madison L L Studies of muscle capillary basement membranes in normal subjects diabetic and pre diabetic patients *J Clin Invest* 47 1973 1968
- 22 Raskin P Marks J Burns H Jr Plumer M and Siperstein M D Capillary basement membrane width in diabetic children *Am J Med* 58 365 1975
- 23 Karam J H Rosenthal M O'Donnell J J Thalikian E Lorenzi M Gench J E Siperstein M D and Forsham P H Discordance of diabetic microangiopathy in identical twins *Diabetes* 25 24 1976
- 24 Aronoff S L Bennett P H Williamson J R Siperstein M D Plumer M E and Miller M Muscle capillary basement membrane (MCBM) measurements in prediabetic diabetic and normal Pima Indians and normal Caucasians *Clin Res* 24 455A 1976
- 25 Kilo C Vogler N and Williamson J Muscle capillary basement membrane changes related to aging and to diabetes mellitus *Diabetes* 21 831 1972
- 26 Yodaiken R Menefee M Seftel H C Kew M C and McClaren M J Capillaries of South African diabetics. IV Relation to retinopathy *Diabetes* 24 286 1975
- 27 Ditzel J Oxygen transport impairment in diabetes *Diabetes* 25 832 1976
- 28 Yamashita T and Becker H The basement membrane in the human diabetic eye *Diabetes* 10 167 1961
- 29 Wise G N Retinal neovascularization *Trans Am Soc. Ophthalmol* 54 729 1956
- 30 Brem S Preis I Langer R Brem H Folkman J and Patz A Inhibition of neovascularization by an extract derived from vitreous *Am J Ophthalmol* 84 323 1977
- 31 Garner A and Ashton N Ophthalmic artery stenosis and diabetic retinopathy *Trans Ophthalmol Soc U K* 92 101 1972
- 32 Gay A and Rosenbaum A Retinal artery pressure in asymmetric diabetic retinopathy *Arch Ophthalmol* 75 758 1966
- 33 Fisher E R Perez Stable E Amidi M Sarver M E and Danowski T III Ultrastructural changes in juvenile diabetes *JAMA* 202 143 1967
- 34 Walker F The origin turnover and removal of glomerular basement-membrane *J Pathol* 110 233 1973
- 35 Osterby R Early phases in the development of diabetic glomerulopathy *Acta Med Scand Suppl* 574 13 1975
- 36 Lundbaek K Growth hormones role in diabetic microangiopathy *Diabetes* 25 845 1976
- 37 Farquhar M Hopper J and Moon H Diabetic glomerulosclerosis Electron and light microscopic studies *Am J Pathol* 23 721 1959
- 38 Brenner H M and Humes H Mechanics of glomerular ultrafiltration *N Engl J Med* 297 148 1977
- 39 Berman J and Rifkin H Unilateral nodular diabetic glomerulosclerosis (Kimmelstiel Wilson) Report of a case *Metabolism* 22 715 1973
- 40 Yodaiken R E The relationship between diabetic capillaropathy and myocardial infarction A hypothesis *Diabetes* 25 928 1976
- 41 McMillan D E Utterback N G and La Puma J Reduced erythrocyte deformability in diabetes *Diabetes* 26 369 1977 and in press
- 42 Job D Eschaege E Guyot Argenton C Aubry J P and Tchobroutsky G Effect of multiple daily insulin injections on the course of diabetic retinopathy *Diabetes* 25 463 1976
- 43 Gundersen H J G and Christensen N J Intravenous insulin causing loss of intravascular water and albumin and increased adrenergic nervous activity in diabetes *Diabetes* 26 551 1977




Fig 2 Photograph of a single cine frame from cinefluorographic study of Starr Edwards model 2320 aortic valve in patient No 4 left anterior oblique view. Note incomplete seating of the poppet on valve closure with a radiolucent space between the poppet and the adjacent strut and orifice. This radiolucent space was present on posteroanterior and right anterior oblique views also.

prior to admission for severe mitral stenosis. He had been on 10 to 12.5 mg of coumadin daily and his prothrombin time had been one and one half to two times the control during most of his clinic visits. Physical examination revealed an afebrile patient. He was normotensive and in normal sinus rhythm. Both carotid pulses were normal and without bruits. The heart size was normal. The mitral prosthetic valve closing and opening clicks were normal. There was a Grade 2/6 ejection systolic murmur over the aortic area. The spleen was not palpable. The optic fundi were normal. The neurologic examination was within normal limits. Blood cultures were negative. There was no evidence of mitral prosthetic valve malfunction on fluoroscopy, phonocardiography or echocardiography. The electroencephalogram and the brain scan were normal. Ophthalmodynamometric studies were normal bilaterally. Selective right and left common carotid angiograms were normal. Cardiac catheterization revealed a resting mean diastolic pressure gradient of 10 mm Hg across the prosthetic mitral valve and mild aortic

regurgitation. A diagnosis of transient cerebral ischemic attacks (TIAs) due to thromboemboli from the mitral prosthetic valve was made. At reoperation the sewing ring of the mitral prosthesis was bare of its cloth covering. There was approximately 50 to 60 per cent loss of cloth from the struts. Loose threads of cloth were found on the sewing ring. No clot was found on the mitral prosthesis or in the left atrial cavity. The Starr Edwards mitral valve prosthesis was replaced by a No 29 Hancock porcine xenograft bioprosthesis. He has been symptom free postoperatively except for one episode of atrial fibrillation. He is not on anticoagulants.

Case 4 This 40 year old man was admitted for increasing fatigue, weakness and dyspnea on exertion. Eighteen months prior to admission he had received a No 10 model 2320 Starr Edwards aortic valve prosthesis for severe aortic valve stenosis. His hematocrit was 43 per cent before valve replacement. Three weeks after surgery the hematocrit was 28 per cent. The reticulocyte count was 27.2 per cent. The peripheral blood



Fig 1 Starr Edwards model 2300 aortic valve prosthesis removed from patient No 1. The cloth is completely loose except at the base of one of the struts. Note the fragmentation of the cloth along its edges.

valve sounds were normal with a Grade 2/6 early systolic murmur. There was no diastolic murmur. The spleen was not palpable. Six blood cultures were negative. There was no evidence of aortic prosthetic valve malfunction on fluoroscopy, phonocardiography or echocardiography. The perfusion scan of the brain showed defects in both posterior parietal lobes. Computerized axial tomography showed evidence of multiple bilateral cerebral infarcts. Selective right and left common carotid artery angiograms showed normal cerebral vessels. He was reoperated on the presumption that he had had recurrent cerebral thromboemboli from the aortic valve prosthesis. At surgery the cloth covering on the struts of the Starr Edwards valve was barely attached at one point on the ring of the prosthesis. The rest of the cloth was floating free in the blood stream in the aortic root. There was also some loss of cloth fibers from the free edges of the cloth (Fig 1). There was no thrombus on the prosthesis. The model 2300 Starr Edwards valve was removed and replaced by a No 23 Carpentier Edwards porcine xenograft bioprosthesis. Postoperatively he has required permanent pacemaker implantation due to syncope from sinus arrest. Sixteen months after reoperation he has not had any episode of systemic emboli.

Case 2 This 61 year old man received a No 11 model 2320 Starr Edwards aortic valve prosthesis on Oct 25, 1973 for severe aortic regurgitation. Eighteen months after valve replacement while not anticoagulated, he suffered right upper extremity paresis from which he fully recovered. He was adequately anticoagulated with coumadin after this episode. Four years and 2 months after valve replacement he began to have episodes of "feeling ill at ease," glare in the left eye, and transient loss of memory. This was followed by sudden onset of weakness of the right hand that lasted for 15 minutes. His prothrombin time was 27.3 seconds to a control of 12.4 seconds when he suffered this episode. Physical examination revealed an afebrile patient. He was in chronic atrial fibrillation. Both carotid pulses were normal and without bruits. The neurologic examination was within normal limits. Cardiac auscultation revealed a high pitched metallic quality of the prosthetic valve opening and closing clicks. When asked the patient admitted to having noticed a change in quality and loudness of the valve sounds. A Grade 2/6 ejection systolic murmur was present. There was no diastolic murmur. The spleen was not palpable. Blood cultures were negative. The electroencephalogram and the brain scan were normal. There was no evidence of prosthetic aortic valve malfunction on fluoroscopy, phonocardiography or echocardiography. He was reoperated because of recurrent cerebral thromboemboli presumably arising from the aortic valve prosthesis. At surgery the aortic valve prosthesis showed extensive cloth wear along the struts with exposure of the metal. A small 3 mm deposit of a white thrombus was present on one of the struts. The left atrium was examined and no clot was found in the left atrial cavity. The Starr Edwards aortic valve prosthesis was replaced by a porcine xenograft bioprosthesis. Postoperative recovery was poor in this patient due to pulmonary infection in the early postoperative period and serum hepatitis 4 months after surgery. He was taken off anticoagulants 2 months after surgery. He has not had any episode suggestive of systemic embolization since reoperation.

Case 3 This 40 year old man was admitted to the New York Veterans Administration Hospital for two episodes of transient blindness in the left eye in one month. He had received a model 6320 Starr Edwards mitral valve prosthesis 7 years

thus leaving an intravalvular open space through which mild aortic regurgitation was noted. Thus the radiolucent space seen on fluoroscopy between the poppet and the valve ring and the adjacent strut probably represented loss of cloth in this area leading to incomplete seating of the poppet. There was no thrombus on the valve. The Starr Edwards aortic valve prosthesis was replaced by a porcine aortic xenograft bioprosthesis. His hematocrit has increased to 41 per cent postoperatively and he is asymptomatic. He is not on anticoagulants.

Case 5. This 21 year old man had received a No 10 model 2320 Starr Edwards aortic valve prosthesis for severe aortic regurgitation. His preoperative hematocrit was 47 per cent. One month after valve replacement his hematocrit had decreased to 36 per cent and the serum LDH level was 740 units per ml. He was on coumadin and his prothrombin time was 29.5 seconds to a control of 11.6 seconds. Ten months after valve replacement he was admitted for severe fatigue and exertional dyspnea. Physical examination revealed an afebrile patient. The prosthetic aortic valve opening and closing clicks were normal. There was a Grade 3/6 harsh ejection systolic murmur all over the precordium. A Grade 2/6 high pitched decrescendo early diastolic murmur was also heard along the left sternal border. The spleen was not palpable. The hematocrit was 16.5 per cent and the serum LDH was 2,400 units per ml. The peripheral blood smear showed many fragmented red blood cells and poikilocytes. The serum iron and iron binding capacity were 64 mg per cent and 414 mg per cent. Stool examination was negative for occult blood. Urine hemosiderin was 4+. Direct and indirect Coombs tests were negative. Severe hemolytic anemia due to traumatization of red cells over the aortic valve prosthesis was diagnosed. Phonocardiogram revealed normal prosthetic aortic valve opening and closing clicks along with the systolic and diastolic murmurs described on auscultation. The echocardiogram revealed a slightly enlarged left ventricle with normal ejection fraction and fine diastolic fluttering of the anterior mitral leaflet consistent with aortic regurgitation. Fluoroscopy revealed incomplete seating of the poppet on the ring during valve closure and marked transverse rocking motion of the poppet during valve opening. His hematocrit increased to 36 per cent after multiple blood transfusions and he was reoper-

ated 11 months after valve replacement. At surgery the Starr Edwards aortic valve prosthesis showed extensive cloth wear on all struts and one of the struts was completely denuded of its cloth covering. There were several small cloth fibers attached loosely to the valve ring. There was no thrombus. The Starr Edwards prosthesis was replaced with a No 21 Hancock porcine xenograft bioprosthesis. He has been asymptomatic 12 months after reoperation. His hematocrit is 50 per cent. He is free of cardiovascular symptoms and does not take anticoagulants.

Discussion

Incidence of cloth wear. Braunwald and Bonchek⁸ first demonstrated that covering of rigid prosthetic heart valves with porous cloth encourages autogenous tissue growth to cover the valve prosthesis. Such coverage by autologous tissue prevents the blood and tissue-metal interface and makes thrombus formation unlikely. Long term postoperative follow up of patients with cloth covered Starr Edwards aortic and mitral valve prostheses has shown significant reduction in the incidence of thromboembolism in the presence of anticoagulant therapy when compared with patients with non cloth covered valves.⁹ However wear of cloth in the areas struck by the metal poppet has been an inherent problem. The true incidence of cloth wear in general and that of clinically significant cloth wear is not definitely known. Starr and co-workers³ reported that 12 out of 18 patients with cloth covered aortic valves (models 2310-2320) who were reoperated for perivalvular leak, hemolytic anemia, infection or thrombotic obstruction of the prosthesis showed evidence of strut or orifice cloth wear. More importantly four of these 12 patients were reoperated for hemolytic anemia and all four patients had strut cloth wear. Isom and associates¹⁰ have reported that the incidence of clinically significant cloth wear is probably less than one per cent in their experience. At the New York Veterans Administration Hospital four of 121 (3.3 per cent) survivors with cloth covered Starr Edwards aortic valve prostheses and one of 83 (1.2 per cent) survivors with cloth covered Starr Edwards mitral valve prostheses have been reoperated for consequences of cloth wear. An overall incidence of 2.5 per cent. Although the incidence of clinically significant cloth wear is small its early recognition and

Table I Clinical and operative findings

Case No	Model and size of Starr Edwards valve prosthesis	Duration since valve replacement	Chief complaint	Operative finding
<i>Systemic emboli</i>				
1	2300 No 11	7 years	2 CVA's	Cloth covering barely attached to the orifice at one point rest of the cloth floating in blood stream loss of fibers at edges of the cloth
2	2320 No 10	4 years and 4 months	Transient loss of memory monoparesis	Extensive cloth wear on all struts small 3 mm white thrombus on one strut
3	6320	7 years and 8 months	Amaurosis fugax	50% to 60% loss of cloth from the struts cloth covering the orifice almost completely shredded
<i>Hemolytic anemia</i>				
4	2320 No 10	6 months	Fatigue exertional dyspnea	Extensive cloth wear on all struts one strut completely bare of its cloth covering
5	2320 No 10	18 months	Fatigue dark urine after exercise	Extensive cloth wear on the inner surface of all struts

CVA = cerebrovascular accident

Table II Findings that should arouse suspicion of cloth wear

- 1 Recurrent transient cerebral ischemic attacks or other systemic emboli despite adequate anticoagulation
- 2 Systemic arterial embolization more than 4 years after valve replacement with cloth covered prosthesis
- 3 Increase in loudness of the prosthetic valve clicks on auscultation particularly with a metallic pith
- 4 Persistent severe hemolytic anemia with or without regurgitation across the prosthesis
- 5 Incomplete seating of the poppet on the valve orifice seen on cinefluorography or intravalvular regurgitation seen on angiography

smear showed many fragmented red blood cells Serum SGOT was 117 units per ml Serum LDH was 2,550 units per ml Free serum hemoglobin was 122 mg per cent There was 4+ hemosiderinuria Stool examination was negative for occult blood Direct and indirect Coombs tests were negative Diagnosis of hemolytic anemia due to excessive trauma to the red cells was made He was placed on Ferrous sulfate 325 mg three times a day and advised to refrain from vigorous physical activities Folic acid 2 mg daily was added to the therapy later on Nine months after valve replacement his hematocrit was 27 per cent Bone marrow examination revealed no stamable iron stores Eighteen months after valve replacement, he was admitted to the New York Veterans

Administration Hospital for reoperation because of persistent hemolytic anemia despite restricted physical activity iron and folic acid therapy Physical examination revealed an afebrile patient He was normotensive and in normal sinus rhythm Prosthetic aortic valve sounds were normal A Grade 2/6 ejection systolic murmur was heard all over the precordium There was no diastolic murmur The spleen was not palpable Blood cultures were negative Prothrombin time was 23.8 seconds to a control of 12.6 seconds There was no evidence of prosthetic aortic valve malfunction on phonocardiography and echocardiography The left ventricular ejection time index was normal Cardiac fluoroscopy revealed a well anchored prosthesis ring and a smooth poppet The poppet motion showed marked lateral oscillations during opening and closing movement The seating of the poppet at the time of valve closure revealed a persistent radiolucent space between the poppet and the valve ring and between the poppet and the adjacent strut (Fig 2) A gated cardiac blood pool scan showed the left ventricle to be of normal size with an ejection fraction of 84 per cent At surgery the Starr Edwards aortic valve prosthesis showed severe cloth wear along the inner surface of all the struts The seating of the poppet on the ring at the time of valve closure showed loss of cloth on the strut and the corresponding area of the ring

ics such as obstruction or regurgitation across the prosthesis but these techniques do not detect presence of clot or cloth wear on the prosthesis. However incomplete seating of the poppet caused by cloth wear may permit intravalvular regurgitation. The demonstration of intravalvular regurgitation by angiography in patients with cloth covered metal ball valvular prostheses should arouse suspicion of cloth wear.

The clinical findings which should arouse suspicion of clinically significant cloth wear are summarized in Table II. The incidence of thromboembolism is highest in the first two years after valve replacement, decreases during third and fourth year and is uncommon after four years. Thus recurrent systemic arterial embolization despite adequate anticoagulation more than four years after valve replacement may favor cloth fiber emboli rather than thromboemboli as was the case in our patients (No. 1, 2 and 3).

Management of suspected cloth wear. Asymptomatic patients with suspected cloth wear should be observed carefully for development of serious complications. When medically untreatable complications develop aggressive treatment with reoperation becomes necessary. Recurrent systemic emboli despite adequate anticoagulation and severe hemolytic anemia are the clinically significant consequences of cloth wear that can be corrected by reoperation. At reoperation the valve may be replaced by the newer model composite strut Starr Edwards valve (2400 aortic and 6400 mitral) or by porcine xenograft bioprosthesis. The composite strut Starr Edwards valves are reported to be noisy and require long term anticoagulation.¹ However they produce a lesser degree of hemolysis and strut cloth wear does not occur.² At the New York Veterans Administration Hospital all five patients reoperated for cloth wear have received porcine xenograft bioprostheses. Actually determined over all survival rates of patients receiving xenograft valves in both the aortic and mitral positions are comparable to the survival rates reported by Bonchek and Starr³ with cloth covered composite seat prostheses.² The incidence of thromboembolic events is less with xenograft valves and the majority of thromboemboli have occurred in the early 0 to 12 week postoperative period. Thus anticoagulant therapy is recommended during the 0 to 12 weeks after insertion of xenograft

valves in the aortic or mitral position after which period anticoagulation is not necessary except in the presence of large left atrium and chronic atrial fibrillation.

Summary

Five cases of complications due to cloth wear in cloth covered composite seat Starr Edwards aortic and mitral valvular prostheses are described. The complications of cloth wear were recurrent systemic emboli in three patients, two with aortic and one with mitral prosthesis and severe hemolytic anemia in two patients with aortic prosthesis. The overall incidence of clinically significant complications due to cloth wear in aortic and mitral valve prosthesis was 25 per cent. The diagnosis of cloth wear is impossible before reoperation and it was made by exclusion of other causes of recurrent transient cerebral ischemic attacks or systemic emboli and by exclusion of other causes of hemolytic anemia. Clinical and laboratory findings suggestive of cloth wear are described. Aggressive management of complications of cloth wear by reoperation is likely to prevent disabling or lethal consequences. Porcine xenograft aortic and mitral bioprostheses were used in these patients to replace the cloth covered valvular prostheses. The symptoms due to cloth wear were abolished in all patients by reoperation and all patients are off anticoagulants postoperatively. The operative mortality rate for reoperation in this small group of patients was zero.

REFERENCES

1. Harken D E, Sroff H S, Taylor W J et al. Partial and complete prostheses in aortic insufficiency. *J Thorac Cardiovasc Surg* 40:744 1960.
2. Starr A and Edwards M L. Mitral replacement. Clinical experience with a ball valve prosthesis. *Ann Surg* 154:726 1961.
3. Bonchek L I and Starr A. Ball valve prostheses. Current appraisal of late results. *Am J Cardiol* 35:843 1975.
4. Kloster F E. Diagnosis and management of complications of prosthetic heart valves. *Am J Cardiol* 35:872 1975.
5. Starr A, Bonchek L I, Anderson R P, Wood J A and Chapman R D. Late complications of aortic valve replacement with cloth-covered composite seat prostheses. *Ann Thorac Surg* 19:289 1975.
6. Thomas C E, Kilen D A, Alford W C, Burrus G R and Stoney W S. Cloth disruption in the Starr Edwards composite seat mitral valve prosthesis. *Ann Thorac Surg* 15:434 1973.
7. Baruchow I B, Ramsey H W and Wheat M W, Jr.

aggressive treatment can prevent disabling or lethal consequences

Consequences of cloth wear The two major complications due to cloth wear are cloth fiber emboli to the systemic circulation and hemolytic anemia with or without regurgitation across the prosthesis, as illustrated by the above described case reports. The clinical and operative findings in these patients are summarized in Table I. Starr¹ has stated that three out of four patients who are reoperated following aortic valve replacement with cloth covered aortic valves show evidence of cloth wear, perhaps asymptomatic. The consequences of cloth wear may vary from minor events such as transient cerebral ischemic attacks without residua to serious ones such as recurrent cerebral embolism,^{1, 8} paravalvular leak,⁹ severe hemolytic anemia,⁷ and even sudden death.¹³ Although absolute confirmation of cloth fiber systemic embolism is impossible in the absence of examination of the involved organs, postmortem studies have demonstrated Teflon emboli in multiple peripheral organs.⁸ Cloth fiber emboli can occur with either aortic or mitral valve prosthesis while clinically significant hemolysis is associated only with the aortic prosthesis. Clinically significant hemolysis has not been a problem with the mitral prosthesis.¹⁴

Diagnosis of cloth wear The diagnosis of clinically significant cloth wear should be suspected in any patient with cloth covered valvular prosthesis who has recurrent systemic emboli despite adequate anticoagulation or who has hemolytic anemia with or without regurgitation across the prosthesis. The absolute confirmation of cloth wear being responsible for emboli or hemolytic anemia can only be made at reoperation. Hence, all other causes of systemic emboli or hemolytic anemia should be first excluded. Since a vast majority of systemic emboli present as recurrent transient cerebral ischemic attacks, it is important to exclude extracranial carotid artery disease as well as intracranial space occupying lesions which may produce similar symptoms. This may be accomplished by electroencephalography, perfusion scan of the brain, computerized axial tomography, and common carotid arteriography as in patients No. 1, 2 and 3. Carotid angiography may not be necessary if ophthalmodynamometry is normal bilaterally. Infective endocarditis of the prosthesis is another important

cause of systemic emboli that should be ruled out. Absence of fever and splenomegaly, absence of new murmur, and negative blood cultures usually exclude infection of the prosthesis. In patients with anemia, complete hematologic work up is necessary to confirm that it is caused by red cell traumatization around the prosthesis. Presence of schistocytes on peripheral blood smear and elevated serum LDH level with negative Coombs test usually confirm that the hemolytic anemia is related to the valvular prosthesis.

Cinefluorography of the prosthetic valve showed marked lateral oscillations of the poppet on valve opening and incomplete seating of the poppet on valve closure in both patients with hemolytic anemia (Cases No. 4 and 5). These may be important clues suggesting cloth wear. As the cloth on the inner surface of the struts is worn out, the internal diameter of the cage would increase, permitting excessive play on the poppet leading to lateral oscillations as it moves from the seat to the apex of the cage on valve opening. Loss of cloth from the strut and the adjacent orifice may be responsible for the incomplete seating of the poppet, thus producing a radiolucent space between the poppet and the strut as shown in Fig. 2.

Phonocardiography is helpful in detecting changes in amplitude and timing of prosthetic valve opening and closing clicks and in detecting new murmurs.^{15, 16} Since cloth wear most commonly occurs along the inner aspect of the struts, development of louder valve clicks particularly with a metallic pitch on auscultation (as metal poppet strikes against metal struts) as observed in case No. 2, should arouse suspicion of cloth wear.

Echocardiography alone or combined phonocardiography of the valvular prosthesis further assists in the evaluation of its mechanical function. This technique is particularly valuable in evaluation of the mitral valve prosthesis.¹⁷ Evaluation of the aortic valve prosthesis is much more limited due to technical difficulties in recording satisfactory echocardiograms.¹⁸ Echocardiograms of the valvular prostheses in all five of our patients were unremarkable. Thus there are no specific echocardiographic features that suggest presence of cloth wear.

Cardiac catheterization and angiocardiography provide information regarding the hemodynamic

Spontaneous changes in the severity of angina pectoris*

Angina is known to be affected by many extra cardiac factors such as changes in the weather, changes in body weight, the development of anaemia, cervical spondylosis, duodenal ulceration and disease of the biliary tract. But sometimes angina becomes steadily worse in the absence of any recognizable extra-cardiac factor and sometimes it gradually subsides and disappears. How common are these spontaneous changes in the severity of angina and what is their outcome?

Three hundred and seventeen patients with angina associated with ischemic heart disease were followed until death or until an average of six and a half years had elapsed from the onset of their symptoms. (Cases in which the angina was due to valvular heart disease or non coronary cardiomyopathy were excluded.) The male/female ratio was 1.3:1 and the median age for the onset of angina was in the sixth decade for men and in the seventh decade for women.

Crescendo angina. In 64 patients (a little over a quarter of the total) the angina became progressively more easily induced in the absence of any detectable extra cardiac factor and without change in treatment. In half these patients (41) the crescendo phase culminated in myocardial infarction or sudden death; in the remainder it gradually subsided to its previous level of intensity. In a few instances the crescendo phase was associated with evidence of heart failure or deterioration in the electrocardiogram suggesting a small myocardial infarct or coronary thrombosis, but in the majority there was no objective clinical evidence of deterioration in the cardiovascular system.

The crescendo phase was found to develop at any time from the first week to as long as 33 years after the onset of the angina. The interval between the onset of the crescendo phase and the development of incapacity ranged from two days to almost a year; in half the incapacity developed within a month, and in three-quarters within three months.

It is difficult to compare our findings with those of previous workers, because cases of crescendo effort angina have usually been included with cases of recent onset effort angina and cases of spontaneous angina at rest in a group now commonly referred to as unstable angina. The valuable reports of Levy and Duncan and associates illustrate this problem. Levy reviewed the course of 158 patients with what he called changing patterns of angina and found that nearly 40 per cent proceeded to myocardial infarction or sudden death. Duncan and colleagues studied the natural history of 251 patients with what they termed new or worsening angina and found that only 16 per cent developed myocardial infarction

or died suddenly. An important difference between the two series lies in the relative proportion of cases of recent onset angina and crescendo angina. Cases of crescendo angina formed 67 per cent of Levy's series whereas they accounted for only 41 per cent of the Edinburgh series. Both reports are consistent with our finding that approximately half the patients developing spontaneous crescendo angina proceed to myocardial infarction or sudden death.

Spontaneous subsidence of angina. In 55 patients (one sixth of the total) angina ceased spontaneously for at least some months (without the development of myocardial infarction) and in half (28) of these it had not returned by the end of the period of observation. In two thirds of the cases the subsidence occurred within a year of the onset but three patients lost their angina after it had been present for three years and one after ten years. Those whose angina subsided did not differ from other patients with angina in respect of sex or associated hypertensive heart disease. Rather more than average had a normal previous electrocardiogram, yet almost half had evidence of previous myocardial infarction or a major electrocardiographic abnormality.

In the Framingham Study angina was noted as ceasing spontaneously in 30 per cent of subjects. This is almost double the proportion in our series but the Framingham Study probably included patients with angina which was too mild to necessitate referral for cardiological advice. In any case it is clear that a considerable proportion of patients with angina do lose their symptoms even after the angina has been present for several years. It is possible that this natural tendency is counteracted by recalling patients for frequent follow up examination with the consequent focusing of their attention on their hearts.

David Short Ph.D. FRCP
Consultant Physician
Mary Stowers M.B. B.S.
Research Assistant
Aberdeen Royal Infirmary
Foresterhill
Aberdeen AB9 2ZB
Scotland

REFERENCES

1. Levy H. Natural history of changing patterns of angina pectoris. *Ann Intern Med* 44:123, 1956.
2. Duncan B, Fulton M, Morrison S L, et al. Prognosis of new and worsening angina pectoris. *Br Med J* 1:981, 1966.
3. Kannel W B and Feinleib M. Natural history of angina pectoris in the Framingham Study: Prognosis and survival. *Am J Cardiol* 29:154, 1972.

*We are indebted to the British Heart Foundation for a generous grant in support of this study.

- Complications following destruction of the cloth covering of a Starr Edwards aortic valve prosthesis *J Thorac Cardiovasc Surg* 62 290 1971
- 8 Crawford F A Sethi G K Scott S M and Takaro T Systemic emboli due to cloth wear in a Starr Edwards model 2320 aortic prosthesis *Ann Thorac Surg* 16 614 1973
- 9 Niles N R Teflon embolism from Starr Edwards valves *J Thorac Cardiovasc Surg* 59 794 1970
- 10 Braunwald N S and Bonchek L I Prevention of thrombus formation on rigid prosthetic heart valves by the ingrowth of autogenous tissue *J Thorac Cardiovasc Surg* 54 630 1967
- 11 Isom O W Spencer F C Glassman E Teiko P Boyd A D Cunningham J N and Reed G E Long term results in 1375 patients undergoing valve replacement with the Starr Edwards cloth covered steel ball prosthesis *Ann Surg* 186 310 1977
- 12 Starr A In discussion of Oyer et al' *Ann Surg* 186 307 1977
- 13 Rubin J W Moore H V Hillson R F and Ellison R G Thirteen year experience with aortic valve replacement *Am J Cardiol* 40 345 1977
- 14 Allen W B Karp R II and Kouchoukos N T Mitral valve replacement—Starr Edwards cloth-covered composite seat prosthesis *Arch Surg* 109 649 1974
- 15 Craige E Hutchin P and Sutton R Impaired function of cloth covered Starr Edwards mitral valve prosthesis Detection by phonocardiography *Circulation* 41 141 1970
- 16 Hylen J C Mechanical malfunction and thrombosis of prosthetic heart valves *Am J Cardiol* 30 396 1972
- 17 Brodie B R Grossman W McLaurin L P Starek P J K and Craige E Diagnosis of prosthetic mitral valve malfunction with combined echo phonocardiography *Circulation* 53 93 1976
- 18 Segal B L Konecke L L Kawai N et al Echocardiography Current concepts and clinical application *Am J Med* 57 267 1974
- 19 Friedli B Aenichde N Grondin P and Campeau L Thromboembolic complications of heart valve prostheses *AM HEART J* 81 702 1971
- 20 Oyer P E Stinson E B Griep R II and Shumway N E Valve replacement with the Starr Edwards and Hancock prostheses Comparative analysis of late morbidity and mortality *Ann Surg* 186 301 1977

Spontaneous changes in the severity of angina pectoris*

Angina is known to be affected by many extra cardiac factors such as changes in the weather, changes in body weight, the development of anaemia, cervical spondylosis, duodenal ulceration and disease of the biliary tract. But sometimes angina becomes steadily worse in the absence of any recognizable extra-cardiac factor and sometimes it gradually subsides and disappears. How common are these spontaneous changes in the severity of angina and what is their outcome?

Three hundred and seventeen patients with angina associated with ischaemic heart disease were followed until death or until an average of six and a half years had elapsed from the onset of their symptoms (Cases in which the angina was due to valvular heart disease or non-coronary cardiomyopathy were excluded). The male/female ratio was 13/1 and the median age for the onset of angina was in the sixth decade for men and in the seventh decade for women.

Crescendo angina. In 114 patients (a little over a quarter of the total) the angina became progressively more easily induced in the absence of any detectable extra-cardiac factor and without change in treatment. In half these patients (41) the crescendo phase culminated in myocardial infarction or sudden death, in the remainder it gradually subsided to its previous level of intensity. In a few instances the crescendo phase was associated with evidence of heart failure or deterioration in the electrocardiogram suggesting a small myocardial infarct or coronary thrombosis, but in the majority there was no objective clinical evidence of deterioration in the cardiovascular system.

The crescendo phase was found to develop at any time from the first week to as long as 22 years after the onset of the angina. The interval between the onset of the crescendo phase and the development of incapacity ranged from two days to almost a year; in half the incapacity developed within a month, and in three-quarters within three months.

It is difficult to compare our findings with those of previous workers, because cases of crescendo effort angina have usually been included with cases of recent onset effort angina and cases of spontaneous angina at rest in a group now commonly referred to as unstable angina. The valuable reports of Levy and Duncan and associates illustrate this problem. Levy reviewed the course of 158 patients with what he called changing patterns of angina, and found that nearly 40 per cent proceeded to myocardial infarction or sudden death. Duncan and colleagues studied the natural history of 251 patients with what they termed "new or worsening angina" and found that only 16 per cent developed myocardial infarction or died suddenly.

An important difference between the two series lies in the relative proportion of cases of recent onset angina and crescendo angina. Cases of crescendo angina formed 67 per cent of Levy's series whereas they accounted for only 41 per cent of the Edinburgh series. Both reports are consistent with our finding that approximately half the patients developing spontaneous crescendo angina proceed to myocardial infarction or sudden death.

Spontaneous subsidence of angina. In 55 patients (one sixth of the total) angina ceased spontaneously for at least some months (without the development of myocardial infarction) and in half (28) of these it had not returned by the end of the period of observation. In two thirds of the cases the subsidence occurred within a year of the onset, but three patients lost their angina after it had been present for three years and one after ten years. Those whose angina subsided did not differ from other patients with angina in respect of sex or associated hypertensive heart disease. Rather more than average had a normal previous electrocardiogram, yet almost half had evidence of previous myocardial infarction or a major electrocardiographic abnormality.

In the Framingham Study angina was noted as ceasing spontaneously in 30 per cent of subjects. This is almost double the proportion in our series, but the Framingham Study probably included patients with angina which was too mild to necessitate referral for cardiological advice. In any case it is clear that a considerable proportion of patients with angina do lose their symptoms even after the angina has been present for several years. It is possible that this natural tendency is counteracted by recalling patients for frequent follow up examination with the consequent focusing of their attention on their hearts.

David Short Ph.D. F.R.C.P.
Consultant Physician
Mary Stowers M.B. B.Sc.
Research Assistant
Aberdeen Royal Infirmary
Foreskerhill
Aberdeen AB9 2ZB
Scotland

REFERENCES

1. Levy H. Natural history of changing patterns of angina pectoris. *Ann Intern Med* 44:1123-19,6.
2. Duncan E, Fulton M, Morrison S L, et al. Prognosis of new and worsening angina pectoris. *Br Med J* 1981; 29:6.
3. Kannel W H and Feinleib M. Natural history of angina pectoris in the Framingham study. Prognosis and survival. *Am J Cardiol* 29:154-19,0.

* We are indebted to the British Heart Foundation for a generous grant in support of this study.

Of discoveries

The great advancements in science and knowledge are not planned and are rarely if ever the product of previously outlined plans of large research programs. The great discoveries are unexpected and no one can control them or has had a monopoly on them. To realize this one merely has to reflect upon the great scientific discoveries and advancements in science and knowledge of the past: e.g. polarized light by Nicol, x-ray by Roentgen, natural radiation by Henri Becquerel and Curie and the vacuum tube by DeForest to list a few.

An article in *Science* of August 1, 1975¹ describes an interesting situation that led to an important and unplanned discovery in astronomy which culminated in the Nobel Prize Award for Physics. To quote the article in *Science*: perhaps the most dramatic scientific event of the decade was the discovery in 1967 of the celestial objects known as pulsating radio stars or pulsars.² These objects were determined to be neutron stars, embers of stellar activity, and barely detectable on earth. This was a serendipitous discovery by Jocelyn Bell (now Mrs. Burnell), a 19-year-old graduate student training under Anthony Hewish at the University of Cambridge in England. The 1974 Nobel Prize in Physics was awarded to Anthony Hewish, supervisor of Jocelyn Bell for the discovery of pulsars, and to Martin Ryle, founder of the Cavendish Laboratory radioastronomy team at Cambridge for his research in radio astrophysics.

The events and details of research in the laboratory leading to the discovery of pulsars are interesting. They summarize the influence of scientific bureaucracy in the world today. The events that led to this most important discovery are presented in the *Science* article, and in the lecture delivered by Anthony Hewish when he received the Nobel Award. Apparently the first observation of a pulsar occurred in August 1967, and the discovery was first reported during February 1968. The five authors of that report included Hewish and Bell and four others were acknowledged for their assistance with the report including Sir Martin Ryle. However, of extreme interest is the fact that this important discovery was made by Miss Bell, an unknown, inexperienced graduate student and research trainee.

Miss Bell first noted and recognized the significance of the signals which emanated from certain stars. After Professor Hewish became convinced of the genuine nature and importance of her observations, he supervised the follow-through of the discovery. Despite some controversy concerning the Nobel Prize Award, Mrs. Jocelyn Bell Burnell remains satisfied that the award was given to Professor Hewish, who had to take all the risks and who readily acknowledges that the pulsars were first found by Mrs. Burnell.

The manner in which this award-winning discovery was made by a novice in research presents an interesting tale which is briefly summarized here. As a graduate student, Miss Bell helped construct the 4½-acre radiotelescope used in her discovery. She operated the new telescope and had to study and analyze her Ph.D. thesis strip chart data which poured out at a rate of 96 feet per day, or 400 feet of triple-track trace per one complete coverage of the sky. After beginning the recordings in July, 1967, Miss Bell had a backlog of 1,000 feet of chart to be analyzed by October and by December she had

a backlog of ¼ mile. She scanned the tracings by eye and happened to note a "bit of scruff," ¼ inch long on a length 400-foot chart, which she could not classify as artifacts from man-made sources. This observation was different and new to her, and she tried diligently to follow up on the scruff. Professor Hewish was first of the opinion that the pulsations represented a flare star that had been missed. He insisted on several occasions that it was an artifact and unimportant. But Miss Bell reported further recording of the scruff to Professor Hewish, consisting of a series of pulses 1 ¼ seconds apart. Because of this extremely fast rate, it was difficult to believe that the source was not man-made. Hewish later confirmed, after review of the recordings following the perseverance of Miss Bell, that the pulses followed sidereal time. By contacting other observatories, Hewish ruled out the possibility that the "scruff" was due to other astronomical equipment generating electrical interference at a fixed sidereal time. Even the idea of a civilization from another planet signaling the earth was considered and was ruled out when the only Doppler shift noted was that due to motion of the earth alone. In his logbook, Miss Bell referred to the source as "Belisha beacon," the nickname for pedestrian traffic signals in London.

A second and different source of pulsations with a period of 1 ¼ seconds was discovered by Miss Bell in December 1967. Hewish confirmed this second source in January, and it became obvious to Miss Bell and Professor Hewish that the pulses represented recordings from very rapidly rotating stars. Before their paper describing the discovery was submitted for publication in February, they had recorded two more similar sources. These observations remained a closely guarded secret until announced by Hewish at a seminar at Cambridge and published in *Nature*. Miss Bell was forced to discontinue these studies to write her Ph.D. thesis, and the discovery appeared only as an appendix in her thesis.

In retrospect, Mrs. Burnell (nee Jocelyn Bell) notes that the most difficult aspect of this momentous discovery of x-radiation in astronomy was the detection of the "scruff" on the 400 feet of triple-track chart paper, and except for her perseverance, the pulses would have been dismissed as man-made artifacts.

Should Mrs. Burnell have shared the Nobel Prize award with Hewish and Ryle? The Franklin Institute of Philadelphia awarded its Albert A. Michelson medal to Hewish and Burnell jointly in 1973. Mrs. Burnell obviously understood what she was doing in her research and she was not told in advance to look for "pulsars," nor was this a part of the experimental protocol. This was a discovery, not even sought after.

So what about awards, honors, and appointments to select groups or societies in science? And what about scientific bureaucracy?

The opinion of astrophysicists throughout the world concerning Jocelyn Bell Burnell's discovery of September 1967 was clearly made evident at the Texas Conference held in Boston in December 1976. The organizing group of the Texas Symposium on Relativistic Astrophysics invited her to be the featured after-dinner speaker at their banquet. Tom Gold of Cornell University introduced her as having made "perhaps the greatest single discovery in astronomy in this century." After her speech, she was extended a standing

ovation for her discovery by the 400 astrophysicists in the audience. She had not visited the US previously and would have not been able to attend the symposium except for the invitation extended to her. She was not envious of the Nobel decision and even expressed her opinion that the supervisor should receive both credit and blame for a graduate student's results. Besides, she said at the banquet, 'it's no skin off my nose to look at the company I'm in.'

Such is the reward of research and of awards.

George E Burch MD
Tulane University School of Medicine
and Charity Hospital of Louisiana
New Orleans, La

REFERENCES

- 1 Wade N. Discovery of pulsars: a graduate student's story. *Science* 189:358, 1975.
- 2 Hewish A, Bell S J, Pilkington J D H, Scott P F and Collins R A. Observation of a rapidly pulsating radio source. *Nature* 217:709, 1968.
- 3 Findlay J W. The 1974 Nobel Prize in Physics. *Science* 186:620, 1974.
- 4 Hewish A. Pulsars and high density physics. *Science* 188:1079, 1975.
- 5 Metz W D. Astrophysics: Discovery and the ubiquity of black holes. *Science* 195:216, 1977.

The carbon copy pain of myocardial infarction*

It is a matter of considerable practical importance to decide whether an episode of spontaneous chest pain in a patient with a history of angina is cardiac or not. Patients with angina tend to be abnormally aware of sensations in the chest which others would ignore, so that this is a problem which not uncommonly presents itself to doctors.

Most authorities state or imply that the site of the pain in myocardial infarction is identical with that of angina, though it has long been recognized that the pain of infarction may be felt in the epigastrium.

Three hundred and thirty patients with angina pectoris were followed until death or until an average of six and a half years had elapsed from the onset of their symptoms. The site of the anginal pain, though differing from patient to patient, was constant for each individual except that it tended to spread to other parts of the torso if the attacks were severe. Among the 330 patients studied, there were 145 in whom the site of the anginal pain had been precisely recorded and who subsequently developed myocardial infarction. In 136 (94 per cent) the epicenter of the pain of infarction was similar to that of the preceding angina (though the pain often extended more widely). This was true even when the site of angina had been unusual, e.g. in the right side of the chest or the back. In nine (6 per cent) of the patients, however, the pain of

infarction had a different epicenter from that of the preceding angina. In each of these nine cases, the pain of infarction was lower than (caudal to) that of the angina. Thus, if the pain of angina had been felt in the upper chest, that of infarction was felt in the mid chest; if the pain of angina had been felt at the lower end of the sternum, that of infarction was felt in the epigastrium. Many of our patients developed pains which were lateral to or at a higher site than that of their angina, but in such cases there was never any evidence of acute cardiac ischemia or infarction; however severe the pain might be.

Thus the pain of infarction may be thought of as a carbon copy of the angina, the copy being usually more intense than the original and occasionally slipping to a lower level. Pain which does not have the same epicenter as the angina, or is not immediately below it, is unlikely to be cardiac in origin.

David Short Ph.D. FRCP
Consultant Physician
Mary Stowers M.B. B.S.
Research Assistant
Cardiac Department
Aberdeen Royal Infirmary
Foresterhill
Aberdeen AB9 2ZB
Scotland

REFERENCE

- 1 Fredberg C K. Diseases of the heart. 3rd ed. Philadelphia 1966. W B Saunders Company, p. 798.

We are indebted to the British Heart Foundation for a grant in support of this study.

The effect of a new beta blocking agent, levo-bunolol, on exercise induced or augmented ventricular arrhythmias*

The control of ventricular ectopic arrhythmias continues to be a significant clinical problem. Recent studies have stressed

*This work was supported in part by a grant from the Veterans Administration.

the efficacy of conventional drugs and the high incidence of their deleterious side effects. In addition, these reports have stressed the need to demonstrate efficacy through exercise stress and/or long term monitoring rather than with brief routine electrocardiograms.

Annotations

We carried out an open pilot placebo controlled study to determine the effect of a 2 mg single oral dose of a new beta adreno blocking agent levo bunolol* on exercise stress induced or augmented ventricular ectopic activity (EIAVEA) Levo bunolol is 40 times as potent as propranolol by weight and appears to have a longer duration of action on exercise capacity in angina pectoris. Patients studied were seven male volunteers aged 43 to 60 years known to develop ventricular ectopic activity during or within 5 minutes after exercise. The developed arrhythmias were either premature ventricular contractions greater than 10 per minute couplets runs (three or more sequentially) bigeminy or multifocal beats. On each of two study days at least 3 days apart each patient took the prescribed medication placebo or drug and was exercised exactly 2 and 4 hours after dosing. The criteria for effectiveness was reduction (> 50 per cent) or elimination of the EIAVEA by the active drug. There were no adverse effects observed. Five of seven patients had gross improvement in their EIAVEA. One patient had insignificant suppression of EIAVEA. Another patient who after placebo had frequent premature ventricular contractions at rest with little augmentation by exercise had < 50 per cent suppression at rest and during exercise.

These results were comparable to similar studies carried out with propranolol*. It appears advantageous to utilize this class of drugs initially in suitable patients instead of quinidine and procainamide which under similar circumstances have been less effective and were associated with frequent side effects. The potential advantage of levo bunolol consists of its greater potency both by weight and in duration of action.

The relationship between high grade ventricular ectopic

activity and sudden cardiac death remains to be absolutely proved. Circumstantial data pointing to such a causal relationship has been reasonably impressive. In addition many of these patients report disturbing symptoms with activity which would justify suppressive therapy. In our experience propranolol and probably levo bunolol are effective agents for the suppression of EIAVEA in selected patients and were not complicated by serious adverse effects thus far.

William Shapiro MD

Janet Park

Cardiovascular Section

VA Hospital

4500 S Lancaster Rd

Dallas Texas 75216

and Department of Internal Medicine

University of Texas Health Science Center at Dallas

Southwestern Medical School

REFERENCES

- 1 Gey G O, Levy R H, Fisher L, Pettet G and Bruce R A. Plasma concentrations of procaine amide and prevalence of exertional arrhythmias. *Ann Intern Med* 80:718 1974
- 2 Jelinek M V, Lohrbauer L and Lown B. Anti arrhythmic drug therapy for sporadic ventricular ectopic arrhythmias. *Circulation* 49:659 1974
- 3 Gey G O, Levy R H, Pettet L P N and Fisher I. Quinidine plasma concentration and exertional arrhythmia. *AM HEART J* 90:19 1975
- 4 Shapiro W and Park J. Unpublished observations
- 5 Pennington W, Ritter W S, Nixon J V and Shapiro W. Suppression of stress induced ventricular arrhythmias by propranolol. *Circulation* 54 (Suppl II) 17 1976

Kindly supplied by Warner Lambert Inc

Truncus arteriosus in a family

To the Editor

We wish to report a family in which three out of four siblings were born with persistent truncus arteriosus. This lesion is a very rare cardiovascular anomaly representing only 0.4 to 2.0 per cent of all congenital heart defects. A brief discussion of possible etiologic factors is presented.

Case 1

The first patient (IV 1, Fig 1) was a full term 4170 Gm male born to a 17 year old P O O O O mother. The pregnancy was complicated by excessive maternal weight gain and pedal edema. She was treated daily with an unspecified diuretic from the fifth month until term.

The neonatal period was marked by poor feeding, dyspnea, sweating, and cyanosis with crying. Cardiac catheterization data were compatible with truncus arteriosus Type II. Medical management with digitals and diuretics was unsuccessful and pulmonary artery banding was performed at nine weeks of age. Despite the banding, the infant continued to deteriorate and died on the second postoperative day. At autopsy a Type II truncus arteriosus was found. No other anomalies were present.

Case 2

The second patient (IV 2, Fig 1) was a female born following a normal 37 week pregnancy. The mother was now 18 years old. Birth weight was 2475 Gms. On the first day of life, mild cyanosis was appreciated but vital signs were normal. Over the following days, mild congestive heart failure developed and the infant was treated with digitals and Lasix. Cardiac catheterization and angiography were performed on the sixth day of life. The findings were compatible with truncus arteriosus Type II. The baby was managed medically but congestive heart failure persisted. She was scheduled for

surgery but sustained a cardiac arrest and died on the 23rd day of life. Autopsy examination revealed truncus arteriosus Type II. Non-cardiac anomalies included a hydronephrotic left kidney with double ureters, an absent gall bladder, fibrosis and hemosiderosis of the liver.

Case 3

Patient 3 (IV 4, Fig 1) was a female born after an uncomplicated 42 week pregnancy. Birth weight was 3360 Gms. The mother was now 21 years old and gravida 4. At age 20 she had given birth to a 3900 Gm male who is normal.

The baby became cyanotic at six hours of age and a holosystolic murmur was heard. She subsequently developed evidence of congestive heart failure. Cardiac catheterization and angiography were compatible with a truncus arteriosus Type III. The infant did not respond to vigorous anticongestive therapy and underwent left pulmonary artery banding on the 13th day of life. Several hours later she had a cardiorespiratory arrest and could not be resuscitated. Autopsy findings revealed a truncus arteriosus Type III.

The family history (Fig 1) was significant in that the father (III 7, Fig 1) had a patent ductus arteriosus which was ligated at 5 years of age. He also has diabetes mellitus treated with insulin. A maternal uncle (II 5, Fig 1) died at the age of 9 months due to an unspecified congenital heart defect. An autopsy was not performed.

Discussion

The etiology of most congenital heart defects is believed to be multifactorial, i.e., genetic predisposition plus an environmental insult during a critical period of cardiac development. Some cases, for example, idiopathic hypertrophic subaortic




Fig 1 Diagram representing family tree. CHA = congenital heart anomaly. CUA = congenital urinary tract anomaly. Oblique line (IV-4) = consanguineous relationship.

stenosis' and Marfan's syndrome' are transmitted as autosomal dominants. Familial occurrence of congenital cardiovascular defects suggestive of a polygenic inheritance include hypoplastic left ventricle⁴, tetralogy of Fallot and atrial septal defect⁵. In some children the nature of the cardiovascular anomaly is predictable as part of a chromosomal abnormality or a constellation of defects representing a specific syndrome⁶ and in others environmental factors are implicated the most documented being thalidomide⁷ and rubella virus.

The etiology or mode of transmission of truncus arteriosus is not known. The presence of the same defect in three of four siblings whose parents do not have the defect suggests a recessive mode of inheritance. It is of interest that both parents have a grandmother born in Ireland but no further evidence to support consanguinity is present.

The father had a patent ductus arteriosus which is a very common anomaly and is unlikely to be related to the occurrence of truncus arteriosus in his offspring. The mother did not take any medications during the first trimester of any pregnancy. The father is a warehouse worker and no contact of either parent with any chemicals or other teratogenic agents could be established. A seasonal association⁸ is unlikely since two of the affected infants were born in April, a healthy sibling in March and another infant with truncus arteriosus was born in August.

Maternal diabetes mellitus has been associated with congenital anomalies of the great vessels in offspring but no such relationship in infants born to diabetic fathers has been shown. In this family the data strongly suggest that a recessive inheritance though a multifactorial cause cannot be completely excluded.

Addendum

Since this letter was submitted a fifth infant was delivered who died on the second day of life following repair of a diaphragmatic hernia. At autopsy left pulmonary hypoplasia and a small ventricular septal defect were found. Chromosome studies of this infant and of Case 3 were normal.

Sandra C Brunson MD
Dov B Nudl MD

Norman Gootman MD
Belinde Aftab MD

Divisions of Pediatric Cardiology and Pathology
Department of Pediatrics

Long Island Jewish Hillside Medical Center
Neu Hyde Park N Y 11040
and School of Medicine Health Sciences Center
State University of New York at Stony Brook
Stony Brook N Y 11794

REFERENCES

- 1 Keith J K, Rowe R D and Vlad P. Heart disease in infancy and childhood. 2nd ed. New York 1967 Macmillan Publishing Co. Inc.
- 2 Braunwald E, Lambrew C T, Ross J J and Morrow A G. Idiopathic hypertrophic subaortic stenosis. Circulation 30(Suppl 4) 3 213 1964.
- 3 Nora J J, Wolfe R R and Miles V N. Etiologic aspects of cardiovascular disease and predisposition detectable in the infant and child. Progress in cardiovascular

disease. Neonatal heart disease. New York 19 1. Grune & Stratton Inc.

- 4 Kojima H, Ohgami Y, Mizutani K and Nishimura Y. I. Hypoplastic left heart syndrome in siblings. Lancet 2 701 1969.
- 5 Nora J J, McNamara D C and Fraser F C. Hereditary factors in atrial septal defect. Circulation 35 44 1967.
- 6 Berg J M, Crome L and France N. Congenital cardiac malformations in mongolism. Br Heart J 22 331 1960.
- 7 McKusick V A. Introduction to birth defects. Original Article Series Vol VII No 5 August 1972 The National Foundation.
- 8 McBride W G. Thalidomide and congenital abnormalities. Lancet 2 1358 1961.
- 9 Freire Maia N and Arce Gomez B. Epidemiology of Congenital cardiovascular malformations. Hum Hered. 21 209 1971.
- 10 Rothman K and Fyler D. Association of congenital heart defects with season and population density. Teratology 13 29 1976.

Serum myoglobin tests by RIA

To the Editor

The article in your highly esteemed AMERICAN HEART JOURNAL on Serum myoglobin determinations by radioimmunoassay from the group in Dallas (Vol. 95 page 0 January 1978) deserves comment from a practicing Pathologist.

Throughout the paper the statements are made within four hours the four hour radioimmunoassay a four hour test the four hour shortened method. These numbers are just not true.

The numbers do not account for the numerous steps prior to the incubation (THE FOUR HOUR INCUBATION) such as the Emergency Room doctor requesting of the Emergency Room clerk the notification of the Laboratory the Laboratory person getting to the Emergency Room identifying the patient and obtaining the blood the clotting of the blood which can vary remarkably if the patient is on anticoagulants the obtaining of the serum and the preparation of the RIA tubes. Subsequent to the FOUR HOUR INCUBATION there is precipitation with centrifugation and radiation counting (which may vary according to the intensity of the label). All these steps are based on the immediate availability of people, veins, equipment (centrifuges especially) and telephone.

The true time from notification to the Laboratory to reporting the results of the test to the doctor will range from over 5 to over 11 hours.

The expenses of performing this RIA test on the serum of one patient at a time are also very high.

James C Roberts Jr MD
15 Portuguese Bend Road
Rolling Hills Calif 90744

REFERENCE

- 1 Gilkeson G, Stone M J, Waterman M, Ting R, Gomez Sanchez C E, Hull A and Willerson J T. Detection of myoglobin by radioimmunoassay in human sera. Its usefulness and limitations as an emergency room screening test for acute myocardial infarction. AM HEART J 95 70 1978.

Nocturnal angina

To the Editor

Despite its potential interest the article on nocturnal angina by Lachstein and associates (AM HEART J 93 723 1977) contributes little to our understanding of the topic First the method used namely retrospective query of past anginal records conducted at time of admission for acute myocardial infarction is grossly subjective and of questionable scientific value The authors fail to furnish a patient age range in their data When dealing with subjects over the average age of 58 years one questions the reliability of recall vs age especially when reviewing 174 unselected and consecutive cases Thus one also is reluctant to accept interpretation based on a potentially unreliable group of 43 study patients in a field of 174 Again the authors furnish no information regarding treatment of selected patients during nocturnal anginal episodes Perhaps inadequate or even excessive therapy was responsible for the angina irrespective of the type of the ultimate infarct Finally in the discussion the comparisons of infant types have no relation to the topic and the authors' explanations for nocturnal angina apply as well to any type of angina

Richard M. Luceri, M.D.
Dept. of Medicine
Booth Memorial Medical Center
Main Street
Flushing, New York 11355

REFERENCE

1. Lichstein H, Alonso C, Chadda K, D and Gupta P
K. Significance and treatment of nocturnal angina
preceding myocardial infarction. AM HEART J 93 /23
1977

Quality of early ECG tracings

To the Editor

In the early twenties the electrocardiogram became a valuable aid to cardiologists all over the world. In that period I worked in the Leiden University Hospital with an original Einthoven string galvanometer. What strikes me now is the poor quality of many of the electrocardiograms made with rod-in machines. Only few are comparable in quality with those obtained by Einthoven. Improvement of the frequency characteristics of the whole system, mainly due to less inertia in the recorder (possibly direct recording from a cathode ray tube on film) might bring us back to the good standard. A challenge to industry to the benefit of cardiac patients!

J H Aloys MD†
126 Al de Sully
1814 La Tour de Peil
Suiszerland

1 Dr & Wyn passed away on March 26 1988 while this letter was at the printers.

Hypertension control: an alternate view from Gimbel's

To The Editor

We share the concern of Professor Sackett and associates about the risks that confront those students of hypertension who emerge from the laboratory or ward and venture out into the community. Since the Gumbel program was specifically mentioned its sponsors were presumably among those feared

to be abandoning scientific method for, (a) collection of hopes, homies, and unconfirmed conventional wisdom." While pleading guilty to harboring in our innermost thoughts a glimmer of hope we are unwilling to concede that our papers contain a single homely nor did we ever lay claim to wisdom conventional or otherwise.

But Professor Sackett and his colleagues have raised more important issues. They cited studies conducted among Canadian storeworkers to support the conclusion that neither provision of care at the work site nor augmented educational effort enhance patient compliance or long term blood pressure control. In the Canadian experiment a small fraction of an available male hypertensive population perhaps characterized by an aversion to medical care was randomly assigned to treatment by either an industrial physician or by each individual's family doctor. Six months later compliance and blood pressure control in both settings were found to be appalling.

We believe that these results may best be understood as reflecting the similarity of the fundamental therapeutic process. Since no evidence was presented here to indicate that either community or industrial physicians were effective providers of antihypertensive care and in view of experience repeatedly reported in other conventional settings, the dismal outcomes observed might have been expected. Thus, the impact of the physician-patient interaction and not the alteration of the site of care remains the principal determinant of outcome.

Promoting education (mastery learning sessions) in isolation from the fundamental therapeutic setting also failed to improve long term outcome. The lack of success associated with these artificial and separate encounters should not however be offered as evidence that an educational process integrated within the structure of medical care would not be valuable.

We contend that superior rates of compliance and blood pressure control achieved in our studies are the result of integrated patient education and facilitated access to treatment in a socially supportive environment (in this case the union). These factors are indeed the major components of the Gumbel's program which also involves the use of a protocol and reliance on a health team. Dissection and isolated evaluation of individual parts destroy the meaning of the whole and render assessment of the resulting segments irrelevant to the holistic scheme.

The appropriate next step is to translate encouraging clinical results into a working hypothesis to be rigorously validated. We question whether a research design in which individual patients are randomly allocated to alternate interventions is the appropriate model through which to evaluate the Gumbels project. Indeed, assignment of individual members of the whole group to alternate treatment approaches would inevitably mask the impact of peer support, a factor deemed important to compliance. Instead, the methodology we are employing involves the allocation of comparable whole groups to alternate intervention strategies (e.g. Gumbels vs. Conventional Care). Two such studies are currently underway. In one, in order to determine the impact of physical accessibility on compliance, our systematic treatment program is provided in on or off site locations. A second experiment involves screening at a number of sites and then allocating all hypotensive subjects at some locations to the on-site treatment program and at other locations referring

stenosis² and Marfan's syndrome³ are transmitted as autosomal dominants. Familial occurrence of congenital cardiovascular defects suggestive of a polygenic inheritance include hypoplastic left ventricle, tetralogy of Fallot, and atrial septal defect.⁴ In some children the nature of the cardiovascular anomaly is predictable as part of a chromosomal abnormality or a constellation of defects representing a specific syndrome¹ and in others environmental factors are implicated the most documented being thalidomide and rubella virus.

The etiology or mode of transmission of truncus arteriosus is not known. The presence of the same defect in three of four siblings whose parents do not have the defect suggests a recessive mode of inheritance. It is of interest that both parents have a grandmother born in Ireland but no further evidence to support consanguinity is present.

The father had a patent ductus arteriosus which is a very common anomaly and is unlikely to be related to the occurrence of truncus arteriosus in his offspring. The mother did not take any medications during the first trimester of any pregnancy. The father is a warehouse worker and no contact of either parent with any chemicals or other teratogenic agents could be established. A seasonal association is unlikely since two of the affected infants were born in April, a healthy sibling in March and another infant with truncus arteriosus was born in August.

Maternal diabetes mellitus has been associated with congenital anomalies of the great vessels in offspring but no such relationship in infants born to diabetic fathers has been shown. In this family the data strongly suggest that a recessive inheritance though a multifactorial cause cannot be completely excluded.

Addendum

Since this letter was submitted a fifth infant was delivered who died on the second day of life following repair of a diaphragmatic hernia. At autopsy left pulmonary hypoplasia and a small ventricular septal defect were found. Chromosome studies of this infant and of Case 3 were normal.

Sandra C Brunson MD

Dov B Nudel MD

Norman Gootman MD

Beline Aflaton MD

Divisions of Pediatric Cardiology and Pathology

Department of Pediatrics

Long Island Jewish Hillside Medical Center

Neu Hyde Park N Y 11040

and School of Medicine Health Sciences Center

State University of New York at Stony Brook

Stony Brook N Y 11794

REFERENCES

- 1 Keith J H, Rowe R D and Vlad P. Heart disease in infancy and childhood. 2nd ed. New York 1967 Macmillan Publishing Co. Inc.
- 2 Braunwald E, Lambrew C T, Ross J J and Morrow A G. Idiopathic hypertrophic subaortic stenosis. Circulation 30(Suppl 4) 213 1964.
- 3 Nora J J, Wolfe R R and Miles V N. Etiologic aspects of cardiovascular disease and predisposition detectable in the infant and child. Progress in cardiovas-

cular disease. Neonatal heart disease. New York 1972 Grune & Stratton Inc.

- 4 Kojima H, Ohgami Y, Mizutani K and Nishimura Y I. Hypoplastic left heart syndrome in siblings. Lancet 2 701 1969.
- 5 Nora J J, McNamara D G and Fraser F C. Hereditary factors in atrial septal defect. Circulation 35 418 1967.
- 6 Berg J M, Crome L and France N. Congenital cardiac malformations in mongolism. Br Heart J 22 331 1960.
- 7 McKusick V A. Introduction to birth defects. Original Article Series Vol VII No 5 August 1970 The National Foundation.
- 8 McBride W G. Thalidomide and congenital abnormalities. Lancet 2 1358 1961.
- 9 Freire Maia N and Arce Gomez M. Epidemiology of Congenital cardiovascular malformations. Hum Hered 21 209 1971.
- 10 Rothman K and Fyler D. Association of congenital heart defects with season and population density. Teratology 13 29 1976.

Serum myoglobin tests by RIA

To the Editor

The article in your highly esteemed AMERICAN HEART JOURNAL on Serum myoglobin determinations by radioimmunoassay from the group in Dallas (Vol 95 page 6 January 1978) deserves comment from a practicing Pathologist.

Throughout the paper the statements are made within four hours the four hour radioimmunoassay a four hour test the four hour shortened method. These numbers are just not true.

The numbers do not account for the numerous steps prior to the incubation (THE FOUR HOUR INCUBATION) such as the Emergency Room doctor requesting of the Emergency Room clerk the notification of the Laboratory the Laboratory person getting to the Emergency Room identifying the patient and obtaining the blood the clotting of the blood which can vary remarkably if the patient is on anticoagulant, the obtaining of the serum and the preparation of the RIA tubes. Subsequent to the FOUR HOUR INCUBATION there is precipitation with centrifugation and radiation counting (which may vary according to the intensity of the label). All these steps are based on the immediate availability of people, vials, equipment (centrifuges especially) and telephone.

The true time from notification to the Laboratory to reporting the results of the test to the doctor will range from over 5 to over 6 hours.

The expenses of performing this RIA test on the serum of one patient at a time are also very high.

James C Roberts Jr MD
15 Portuguese Bend Road
Rolling Hills Calif 90744

REFERENCE

- 1 Gilkeson G, Stone M J, Waterman M, Ting R, Gomez Sanchez C E, Hull A and Willerson J T. Detection of myoglobin by radioimmunoassay in human sera. Its usefulness and limitations as an emergency room screening test for acute myocardial infarction. AM HEART J 95 70 1978.

REFERENCES

- 1 Alderman M H and Schoenbaum E E Detection and treatment of hypertension at the work site *N Engl J Med* 293 65 1975
- 2 Sackett D L, Haynes B B, Gibson E S, Hackett B C, Taylor D W, Roberts R S and John A L Randomised clinical trial of strategies for improving medication compliance in primary hypertension *Lancet* 11 905 1975
- 3 Brett G Z The value of lung cancer detection by six monthly chest radiographs *Thorax* 23 414 1968

Smoking and the cause of CHD

To the Editor

In regard to the Annotation of Dr P R J Burch (*AM HEART J* 93 805 1977) the findings of our epidemiological studies on the islands of Crete and Corfu should not distract from the great significance of smoking to CHD. This could be disastrous during a period when such effort is being exercised against smoking.

In our studies for the past almost 18 years among the farmers on the islands of Crete and Corfu the relationship between smoking and CHD was positive although not strong as in other studies. But one should not forget the fact that these populations are practically free of all other risk factors known today. One can only assume with caution that smoking alone and in the amount and with the type of tobacco used in Crete and Corfu can be of less significance as a predisposing factor. But as an additive factor to all other known risk factors it is much more destructive to the cardiovascular system.

Christ Aravanis MD
Professor and Director
Evangelamos Hospital Medical Center
First Department of Cardiology
Athens
Greece

REFERENCE

- 1 Burch P R J Coronary heart disease Tests of etiological hypotheses *AM HEART J* 93 805 1977

Reply

To the Editor

The purpose of my Annotation was to consider how we might test etiological hypotheses of CHD bearing in mind that Correlation does not necessarily imply causation. In passing I mentioned in connection with smoking, a complication that arises at the outset because an earlier study had failed to demonstrate a significant correlation between smoking and CHD in several countries including Crete and Corfu. Dr Aravanis is now able to tell us that among farmers on the islands of Crete and Corfu a positive but relatively weak association between smoking and CHD has been found after some 18 years of investigation. Unfortunately his finding does not answer the question: Does the association imply causation? It merely adds to the list of countries in which such associations are found.

In my Annotation I pointed out that critical evidence capable in principle of answering the above question is furnished by studies of twins (especially MZ twins) that are discordant for smoking habits. Although the numbers avail-

able so far are too small for definitive conclusions they tend to support a constitutional (genetic) rather than a causal interpretation of the association. More recently I have analyzed the secular trends in sex specific and age-specific death rates from CHD in England and Wales, 1921 to 1973 and I find that the constitutional hypothesis is strongly supported. Any causal action of smoking appears to be small or negligible.

I can appreciate the concern of Dr Aravanis and others for the possibly destructive effects of smoking on the cardiovascular system. It is of the utmost importance that medical scientists should establish, as objectively as possible whether or not such concern has a secure scientific foundation.

In my view the critical evidence now available to us indicates that cigarette smoking can be largely or wholly exonerated as a causal factor in CHD.

Philip R J Burch PhD
The University of Leeds
Department of Medical Physics
The General Infirmary
Leeds LS1 3EX
England

REFERENCES

- 1 Burch P R J Coronary heart disease Tests of etiological hypotheses *AM HEART J* 93 805 1977
- 2 Keys A (Editor) Coronary heart disease in seven countries, Circulation 41 (suppl. 1) 1 1970
- 3 Burch P R J Coronary heart disease Risk factors and ageing *Gerontology* 24 123 1978

More on BP measurement and cuff size

To the Editor

The review article on hypertension in children by Dr McLain makes many significant points calling attention to the necessity for more frequent determinations of blood pressure in children. So many of his points are correct and well stated that I dislike to suggest a correction. However since it is the American Heart Association Committee that made the error relative to blood pressure cuff size perhaps he will accept this suggestion.

The Committee on Blood Pressure Determination of the American Heart Association recommended in 1967 that a cuff for adults should be 20 per cent wider than the diameter of the limb. This took into account the problems of obesity in adults and the erroneously high pressures that could be obtained if one used a cuff that was too small for an obese arm. Studies in adults have indicated very large errors using a standard 12 cm. adult cuff for seriously obese subjects. In a normal non-obese adult population, Geddes and Whistler reported in a recent issue of *AMERICAN HEART JOURNAL* the effects of cuff width: they found that a cuff that is too narrow overestimates and a cuff that is too wide underestimates blood pressure.

For some unexplained reason the Committee on Blood Pressure Determination recommended in 1967 that the size of the cuff for a child should be based on the length of the limb. Obviously since there is no fixed relationship of the diameter of a limb to its length, this recommendation does not allow for a larger cuff size for an obese child nor as Dr McLain correctly pointed out will it allow for an appropriate width for the very large, muscular teen-ager. It is not surprising then that an increasing number of reports are demonstrating an apparent relationship between obesity and hypertension.

all hypertensive employees to care through conventional channels

In sum then while agreeing that the Hamilton experience substantiates the fact that neither augmented education nor facilitated access to care improve compliance or outcome when employed in isolated additions to conventional systems of care we contend that the value of these same elements as integral components of a comprehensive program remains to be demonstrated. Hopefully experiments currently underway will establish the proper role of occupationally based systematic programs for the control of hypertension within the community.

Michael H Alderman M.D.

Arthur H Seligmann M.D.

Toni K Davis M.S.

Department of Public Health

and

The Cardiovascular Center

Cornell University Medical College

New York, N.Y.

REFERENCES

- 1 Sackett D L, Haynes R B, Gibson E S, Taylor D W, Roberts R S and Johnson A L. Hypertension control compliance and science. *AM HEART J* 94:606 1977
- 2 Sackett D L, Haynes R C, Gibson E S, Hackett B C, Taylor D W, Roberts R B and Johnson A L. Randomized clinical trials of strategies for improving medication compliance in primary hypertension. *Lancet* 1:1205 1975
- 3 Alderman M H and Schoenbaum E. Treatment of primary hypertension (Letter). *Lancet* 2:31 1975
- 4 Langfeld J B. Hypertension: Deficient care of the medically served. *Ann Intern Med* 78:19 1973
- 5 Wilber J A. Hypertension as a community problem. *Prev Med* 3:353 1974
- 6 Alderman M H and Schoenbaum E. Detection and Treatment of hypertension at the work site. *N Engl J Med* 293:65 1975
- 7 Alderman M H and Engelland A L. A research paradigm for preventive cardiology. *Cardiovasc Med* 2:621 1977

Reply

To the Editor

Michael Alderman and his colleagues have carried out important pilot projects in hypertension control and we applaud their stand on toughening the scientific methods they will use to study their contention that strategies which have failed to improve compliance or blood pressure control in existing systems of care will do so when they are integral components of comprehensive care. Indeed we suggest that the adoption of tougher science in the assessment of evidence would have prevented many of their disagreements with our work.

For example they have characterized the rate of blood pressure control observed in our trials as appalling and dismal and that obtained in their own programs as "superior". The application of the tougher science we were advocating in our Annotation reveals that the results in Hamilton and New York are the same! The two studies simply defined satisfactory blood pressure control by different criteria: we required that patients (who started treatment with fifth phase diastolic pressures consistently ≥ 90 mm Hg)

achieve a more rigorous blood pressure goal (< 90 mm Hg), whereas Dr Alderman's subjects (who started treatment with systolic values of ≥ 160 and/or fifth phase diastolic pressures ≥ 90 mm Hg and/or were already on hypotensive medication) were considered controlled if their blood pressure fell ≥ 10 per cent or below a less strict goal of 160/95. When compared by more compatible criteria (< 95 in Hamilton and $< 160/95$ in New York) the rates of control are 67 per cent and 60 per cent! Thus greater attention to the need for common criteria when comparing programs would have prevented their misinterpretation of the relative impacts of the two approaches.

A second example of the need for tougher science is seen in the failure to assess ancillary evidence concerning an intervention. Dr Alderman and his colleagues inferred that the hypertensives in our trial are perhaps characterized by an aversion to medical care. Yet the reference they cited also documented that 94 per cent of these same patients agreed not only to accept treatment but to enter a randomized trial of compliance improving strategies! Furthermore a review of other ancillary evidence reveals that the value of instructing patients about their illnesses and treatments has now been tested in ten controlled trials and the maneuver improved compliance in only one (two of these ten trials were randomized trials and both were negative). Finally an assessment of other more behaviorally oriented strategies will show that, even when applied in isolation or in the current health care system (several (but not all) have been found successful in the randomized trials in which they have been tested).

Vigorous debate over the validity, transferability and generalizability of strategies for controlling blood pressure can make us better scientists and clinicians and should therefore be welcomed by investigators and fostered by journals as should methodologic discussions of issues such as the appropriate unit to be randomized in a clinical trial (for example in order to answer different questions we have randomized by individual patients, families and whole practices) and others have been randomized by entire factories!)

The key issue and the cardinal assertion in our Annotation is that strategies for achieving blood pressure control should no more be placed in general use without prior validation than should unproven drugs or untested surgery. The criterion for accepting or rejecting new evidence must be the scientific merit of the methods which produced it, not the extent to which it concurs with the beholder's private or published views on the issue. For this reason we were keenly disappointed to learn that Dr Alderman and his colleagues will not randomize the firms or groups of patients to the alternative programs described in his letter but will decide which companies receive which interventions on other grounds. As a result support for his important hypothesis will continue to rest on an uncertain foundation of sub-experimental evidence.

David L. Sackett

R Brian Haynes

Eduard S Gibson

D Wayne Taylor

Robin S Roberts

Arnold L Johnson

Kilgore S Trout

Department of Clinical Epidemiology and Biostatistics

McMaster University Health Sciences Centre

and Dominion Foundries and Steel Limited

Hamilton, Ontario, Canada

Book reviews

Clinical Vectorcardiography and Electrocardiography second edition By Jon D Cooksey M III Marvin Dunn MD and Edward Masse MD Chicago 1977 Year Book Medical Publishers, Inc 759 pages.

This second edition brings up to date the first edition published in 1960 17 years ago. The authors have added new developments in the fields of electrocardiography and vectorcardiography. This is a textbook type publication. The many chapters include anatomic considerations, the dipole concept, lead systems, vector analysis, vectorcardiographic reference frames, the normal electrocardiogram, ventricular gradient, vectorcardiography, and of course the electrocardiogram and vectorcardiogram in almost all the abnormal cardiac states. The diagrams are ample and clearly reflect the authors' approach and concepts of electrocardiography and vectorcardiography. This is a good book that is not easy to read or study, but it is well worth the effort. However, the great surge in interest in cardiology and in electrocardiographic monitoring requires a fundamental knowledge of electrocardiography and vectorcardiography to interpret properly the recordings. Readers will find this to be a valuable source of material for study. The book continues the high standards of the first edition.

Cardiovascular Disease Continuing Education Review Joseph W Linhart M.D., and Onkar S Narula M.D. Flushing, NY 1977 Medical Examination Publishing Co Inc 135 pages. Price \$12.00

Briefly, this book contains 541 questions and referenced answers. Those preparing for their specialty board examinations in general internal medicine and cardiology will find this to be a good test of their knowledge of cardiology. This book readily reveals the superiority of the essay type of examination over the current multiple choice questions in order to test the knowledge of a physician. The questions and the narrative answers are well selected and practical in nature. It is unfortunate that in order to keep the book small, the answers to posed questions are brief, but the reader will readily find the answers and can determine for himself how to extend the answers in greater detail. This book in itself is good training. Physicians will profit considerably by studying the book.

Myocardial Failure Edited by G Ruecker A. Weber and J Goodwin Co Edited by H D Bolte B Ludertiz B E Strauer and E Erdmann, New York 1977 Springer Verlag 374 pages. Price \$22.10

This publication contains the papers presented at an international symposium held in Germany from June 17 through 19, 1976. The three sessions were concerned with the molecular basis of myocardial function, clinical aspects of myocardial failure, and clinical pharmacology. The many papers briefly review the problems of myocardial failure in an attempt to relate structural disturbances to functional impairment. The action of drugs used in the treatment of congestive heart failure is discussed. Those who have followed the literature closely will find little new in this publication, whereas those who have not followed publications closely will find this paperback book to be an interesting review of the complex problems of congestive heart failure. The presentations reflect very well the interest and opinions of many observers who have been concerned with congestive heart failure. This is an interesting publication on a very important subject, congestive heart failure. The approach has been concerned precisely with the myocardium itself. The role of the peripheral circulation, kidneys, endocrine system, and nervous system has been essentially ignored in the many brief papers. Regardless, it is the heart itself which was selected for discussion at this symposium.

Treatment of Cardiac Emergencies second edition By Emanuel Goldberger MD F.A.C.P. St Louis 1977 The C V Mosby Company 391 pages. Price \$16.50

This is the second edition of a useful book. It should be placed in all emergency rooms and coronary care and intensive care units. It is intended for the physician in practice. The author describes the cardiac emergencies and presents their management in detail. Dosage levels of potent drugs for example are carefully indicated. The common and important cardiac emergencies are discussed all in such a manner that nurses will find the book comprehensible. It is a well written, useful up-to-date book on an important subject in cardiology. Goldberger is an experienced clinical cardiologist.

As a pediatrician I am aware that we frequently demand special standards for children since they are not little adults. However it is unreasonable to think that physical laws do not apply to children and the hard evidence is that the physical considerations that led to the adult recommendation of cuff width based on arm diameter should apply to children as well.¹ It may be very well to frighten children and adults into weight reduction by labeling them as hypertensives but we should not confuse ourselves as to the real meaning of an elevated blood pressure in an obese patient when the cuff is too small.

Warren G. Guntheroth MD

Professor of Pediatrics

Head Division of Pediatric Cardiology

School of Medicine

University of Washington

Seattle Wash 98195

REFERENCES

1. McLain L G. Hypertension in childhood. A review. *AM HEART J* 92:634 1976
2. Kirkendall W M, Burton A C, Epstein F H and Fries E D. Recommendations for human blood pressure determinations by sphygmomanometers. *Circulation* 36:980 1967
3. Trout K W, Bertrand C A and Williams M H. Measurement of blood pressure in the obese person. *JAMA* 162:970 1956
4. Geddes L A and Whistler E J. The error in indirect blood pressure measurement with the incorrect size of cuff. *AM HEART J* 96:4 1978
5. Park M K and Guntheroth W G. Direct blood pressure measurements in brachial and femoral arteries in children. *Circulation* 41:231 1970
6. Park M K, Kawabara I and Guntheroth W G. Need for an improved standard for blood pressure cuff size. *Clin Pediatr* 15:784 1976

Oral ISDN—long acting nitrite

To the Editor

In your issues of February and March 1977 Dr Prediman K. Shah reviewed the role of vasodilators in acute and chronic cardiac conditions requiring ventricular unloading.

I should like to comment on one point in these excellent papers referring to the use of oral isosorbide dinitrate (page

405).¹ The author mentions the lack of evidence for pharmacological activity of ISDN metabolites found in large amounts in the blood of dogs after oral administration of the compound.

This is rather at variance with the clinically ascertained lasting hemodynamic improvement after oral ISDN intake despite rapid disappearance of the unaltered drug from the blood stream.^{2,3}

The main ISDN metabolites (2 IS mononitrate and 5 IS mononitrate) have been isolated and used for clinical trials in humans by two independent research groups in Germany.⁴

Both groups reported marked hemodynamic responses after adequate intravenous doses of the two mononitrates. The pharmacological activity evidently accounts for the prolonged effect of orally taken ISDN and justifies its qualification as a long acting nitrite.

Noemi Pascal MD

Cardiovascular Research Division

Pharma-Schwarz GmbH

Mittelstrasse 11 13

Monheim 4013

W. Germany

REFERENCES

1. Chasseaud L F, Down W H and Grundy R A. Concentrations of the vasodilator isosorbide dinitrate and its metabolites in the blood of human subjects. *Europ J Clin Pharmacol* 8:157 1975
2. Assinder D F, Chasseaud L F and Taylor T. Plasma isosorbide dinitrate concentrations in human subjects after administration of standard and sustained release formulations. *J Pharm Sci* 65:770 1976
3. Stauch M, Grewe N and Nissen H. Die Wirkung von 2 und 5 Isosorbidmononitrat auf das Belastungs EKG von Patienten mit koronarer Insuffizienz. *Verh Dtsch Ges Kreislauff* 41:182 1975
4. Michel D. Der Einfluss von Metaboliten des Isosorbid dinitrats auf das Belastungs EKG bei koronarer Insuffizienz. *Herz/Kreisl* 8/8:444 1976
5. Shah P K. Ventricular unloading in the management of heart disease. Role of vasodilators. Part I. *AM HEART J* 93:256 1977
6. Shah P K. Ventricular unloading in the management of heart disease. Role of vasodilators. Part II. *AM HEART J* 93:403 1977

Clinical Vectorcardiography and Electrocardiography second edition By Jon D Cooksey M.D. Marvin Dunn M.D. and Edward Masse M.D. Chicago 1977 Year Book Medical Publishers Inc 759 pages.

This second edition brings up to date the first edition published in 1960 18 years ago. The authors have added new developments in the fields of electrocardiography and vectorcardiography. This is a textbook type publication. The many chapters include anatomic considerations, the dipole concept, lead systems, vector analysis, vectorcardiographic reference frames, the normal electrocardiogram, ventricular gradient vectorcardiography and, of course, the electrocardiogram and vectorcardiogram in almost all the abnormal cardiac states. The diagrams are simple and clearly reflect the authors' approach and concepts of electrocardiography and vectorcardiography. This is a good book that is not easy to read or study but it is well worth the effort. However, the great surge in interest in cardiology and in electrocardiographic monitoring requires a fundamental knowledge of electrocardiography and vectorcardiography to interpret properly the recordings. Readers will find this to be a valuable source of material for study. The book continues the high standards of the first edition.

Cardiovascular Disease: Continuing Education Review Joseph W Linhart M.D. and Onkar S Narula M.D. Flushing N.Y. 1977 Medical Examination Publishing Co Inc 135 pages. Price \$12.00

Briefly, this book contains 541 questions and referenced answers. Those preparing for their specialty board examinations in general internal medicine and cardiology will find this to be a good test of their knowledge of cardiology. This book readily reveals the superiority of the essay type of examination over the current multiple choice questions in order to test the knowledge of a physician. The questions and the narrative answers are well selected and practical in nature. It is unfortunate that in order to keep the book small the answers to posed questions are brief but the reader will readily find the answers and can determine for himself how to extend the answers in greater detail. This book in itself is good training. Physicians will profit considerably by studying the book.

Myocardial Failure Edited by G Riecker, A Weber and J Goodwin. Co-Edited by H D Bolte, B Ludentz, B E Strauer and E Erdmann. New York 1977 Springer Verlag 374 pages. Price \$22.10

This publication contains the papers presented at an international symposium held in Germany from June 17 through 19, 1976. The three sessions were concerned with the molecular basis of myocardial function, clinical aspects of myocardial failure, and clinical pharmacology. The many papers briefly review the problems of myocardial failure in an attempt to relate structural disturbances to functional impairment. The action of drugs used in the treatment of congestive heart failure is discussed. Those who have followed the literature closely will find little new in this publication, whereas those who have not followed publications closely will find this paperback book to be an interesting review of the complex problems of congestive heart failure. The presentations reflect very well the interest and opinions of many observers who have been concerned with congestive heart failure. This is an interesting publication on a very important subject: congestive heart failure. The approach has been concerned precisely with the myocardium itself. The role of the peripheral circulation, kidneys, endocrine system, and nervous system has been essentially ignored in the many brief papers. *Regardless, it is the heart itself which was selected for discussion at this symposium.*

Treatment of Cardiac Emergencies second edition By Emanuel Goldberger M.D. F.A.C.P. St. Louis 1977 The C.V. Mosby Company 391 pages. Price \$16.50

This is the second edition of a useful book. It should be placed in all emergency rooms and coronary care and intensive care units. It is intended for the physician in practice. The author describes the cardiac emergencies and presents their management in detail. Dosage levels of potent drugs, for example, are carefully indicated. The common and important cardiac emergencies are discussed in such a manner that nurses will find the book comprehensible. It is a well written, useful up-to-date book on an important subject in cardiology. Goldberger is an experienced clinical cardiologist.

Diabetes and the Heart By Samuel Zoneraich M D, Springfield, Ill. 1977 Charles C Thomas Publisher 275 pages Price \$27.50

Clinical Electrocardiography A Simplified Approach By Ary Lous Goldberger and Emanuel Goldberger St Louis 1977 The C V Mosby Company 256 pages Price \$9.95

Diabetes Mellitus B Edited by K Oberdisse Berlin 1977 Springer Verlag 1198 pages Price \$215.60

Unit 1 Congestive Heart Failure By Rose Pinneo RN MS New York 1977 Appleton Century Crofts Inc 62 pages Price \$4.50

Actualités Cardio Vasculaires Médico-Chirurgicales By R. Froment P. David A. Gonin A. Perrin P. Michaud, and J. Descotes Paris 1977, Editions Masson 176 pages

Progress in Lymphology Edited by R. C. Mayall and Marjorie H. Witte New York 1977 Plenum Publishing Corp 389 pages Price \$39.50

Lipid Metabolism in Mammals vol 2 Edited by Fred Snyder New York 1977 Plenum Publishing Corp 376 pages Price \$42.50

Announcements

Workshop on Thyroid Disease

A Workshop on Thyroid Disease sponsored by the American Thyroid Association will be held at the Copley Plaza Hotel Boston from November 5 through 7 1978. This two day program is designed for practicing physicians in internal medicine family practice and for surgeons and obstetricians who do not have subspecialty training in the field of thyroidology. The workshop will emphasize practical approaches to clinical problems through a syllabus lectures small group discussions and self administered quizzes. For program and registration information please write: WT Registration Center for Continuing Education 1307 East 60th St Chicago Ill 60637. For additional information please contact the program chairman Dr P. Reed Larsen, Peter Bent Brigham Hospital 721 Huntington Ave Boston Mass. 02116.

Workshop in Echocardiography

A Workshop in Echocardiography will be presented at the Don Cesar Beach Resort Hotel St Petersburg Beach Fla on January 25 through 28 1979. The workshop will be directed by Dr Lous Evan Teichholz, Associate Chief of Cardiology Mt Sinai Medical Center and Associate Professor of Medicine Mt Sinai School of Medicine New York. For further information regarding this workshop please contact Ms Bulle N. Chules Tampa Trainings P O Box 1245 Tarpon Springs FL 33589.

Editorial

Population screening for myocardial ischemia

Geoffrey Rose DM FRCP FFCM

London England

The clinician does not usually become involved in the care of coronary heart disease (CHD) until myocardial injury is advanced and irreversible when angina or heart attack finally brings the patient to him. By then the possibilities of salvage though real and important are not large—secondary prevention comes too late for most patients. Clearly the long term goal is primary prevention but pending the desired mass changes in eating and smoking habits etc attempts to change the risk factors of individuals are effortful and not outstandingly effective. Interest thus turns to a third preventive strategy intermediate between on the one hand primary prevention (instituted before recognizable myocardial injury) and on the other hand secondary prevention (usually following myocardial infarction). This intermediate strategy would start with population screening for signs of early myocardial ischemia. What potential has such screening and can it lead to action that will effectively improve the prognosis? A recent report from England answers some of the questions whilst others remain frustratingly open.

The Whitehall Study¹ started with a simple screening examination of 11403 male civil servants in London aged 40 to 64 years. Early myocardial ischemia was defined on the basis of

either (1) a positive response to a standardized and validated questionnaire on chest pain (the London School of Hygiene questionnaire in its self administered form²) or (2) a positive resting ECG (Q/QS ST segment or T wave items or left bundle branch block according to Minnesota Code criteria). The ECG comprised limb leads only and it was coded by specially trained and supervised technicians. The whole examination therefore was speedy and cheap if it were adjudged useful. Acceptability and expense would be a small barrier to its widespread use.

The first surprise from this study was that a self administered questionnaire was almost as effective as the ECG in predicting risk of CHD death. Each technique identified a group with about a fivefold increase in five year CHD mortality. Either result carried a much greater predictive power than the familiar primary risk factors from which it was essentially independent. Predictive power declined only slowly and for men with suspect ischemia the relative risk was still significantly elevated even in the fifth year of follow up. The two indicators of ischemia (symptoms and ECG findings) showed rather little overlap and the most unimpressive prediction of risk came therefore from a combination of the two. The men who by either criterion or both, had suspect ischemia (14 per cent of the whole examined population) included no less than half of all those who were to die from CHD in the ensuing five years.

Clearly the traditional view is mistaken that heart attack commonly comes out of the blue

From the Epidemiology Department, St. Mary Hospital, Medical School, London W2, England.

Received for publication Oct. 11 1977

Reprint requests: Dr. Geoffrey Rose, London School of Hygiene and Tropical Medicine, Dept. of Medical Statistics & Epidemiology, Keppel St., London WC1, England.

To patient and doctor this may appear to be so, since earlier ECG changes and episodes of chest pain are usually transient, and either pass unnoticed or are soon forgotten. But when one simple and crude examination can give advance warning of half the fatal attacks which will occur in the next five years, then clearly annual and perhaps more refined examinations could give warning of considerably more. With annual checkups for myocardial ischemia, probably few major attacks would come unheralded—but would this lead to more effective preventive action, and how many false alarms would occur?

The most dangerous mistake for would be screeners is to believe that their activity is justified by the number of diagnoses they make. In the Whitehall Study, despite the high relative risk and high proportion of deaths predicted, the absolute risk facing the man with suspect ischemia was nevertheless small. Only about 1 per cent per year developed a fatal attack. (London civil servants are a favored group in their low over all risk of CHD, and in an average American group of workers this risk might be somewhat higher.) Here lies the first problem of screening for ischemia—if the criteria for a case are set wide enough to give warning of a high proportion of future heart attacks then only a small minority of the positive cases will actually encounter serious trouble in the next few years. Stricter criteria can reduce false alarms but at the price of reducing also the amount of potential benefit to the community as a whole. In the Whitehall Study a definition of ischemia requiring positive symptoms and ECG identified 0.6 per cent of men, whose five year CHD mortality rate was 15 per cent but it predicted only 8 per cent of the CHD deaths.

On present evidence the chance of averting some of those 50 per cent of potentially predictable heart attacks is limited by our judgment on what treatment we feel would be acceptable to a man whose chances of surviving five years without our help are better than 90 per cent. If we were in that position ourselves, would we wish to take long term antiarrhythmic therapy? Supposing that controlled trials in such a group were to have demonstrated some benefit, how large would that benefit need to be in order to justify instituting the treatment? Would five years of beta blockade have to save the lives of 1 in 100—or 5 in 100—or 10 in 100? My own instinctive feeling (I

should not care to try and rationalize it) is that the first figure at least would be too low. But even the second figure is out of range for a group whose five year mortality rate without treatment was only about 5 per cent. The results of a trial of the prophylactic value of long term antiarrhythmic therapy in early myocardial ischemia would be intensely interesting, but one suspects that the entry criteria would need to ensure a risk without treatment somewhat higher than the 1 per cent per year of the Whitehall Study, and that would be a pity, because stricter entry criteria would exclude many men who are going to die of a heart attack.

The Whitehall Study also produced challenging findings on the relation between myocardial ischemia and the main primary risk factors. It might be expected that the importance of those factors well established in the stages preceding myocardial injury, would be much diminished once disease had got to this more advanced stage just as it is generally much diminished following myocardial infarction. In fact, for blood pressure and plasma cholesterol concentration the predictive significance was as great in men with ischemia as in those without. For overweight subjects there was a clear risk gradient in the ischemic group which was not evident in the remainder. In the ischemic group mortality was higher among smokers than among non smokers, but the difference was less than in the remainder of the study group. The results for leisure time activity were equivocal.

In summary, it seems that the predictive force of the main modifiable risk factors remains unabated even at the relatively late stage of disease when there is already incipient ischemic injury. Of course this does not mean that reduction of blood pressure, cholesterol, or weight at this stage would necessarily be beneficial. That issue can only be tested by controlled trials. But there need be less anxiety about intervention based simply on risk factor reduction than about long term use of drugs acting on the myocardium.

It is a grievous thing to contemplate the possibility of mass screening for ischemia. It involves telling men who thought they were well that their electrocardiogram shows abnormality or that minor symptoms may betoken heart disease rather than indigestion. Such wifful trauma could only be justified if adequate trials had demon-

strated a commensurate benefit from some treatment whether advice or drugs which could not otherwise have been instituted. Such trials are much needed because they might lead to a strategy with considerable benefit to the community.

All preventive trials are alarmingly large, tedious and costly but trials of intermediate prevention because they would be conducted in relatively high risk groups would at least not need to be nearly so large as those of primary

prevention. Meanwhile screening for myocardial ischemia is certainly traumatic; its benefits have not been demonstrated and its general use is not to be recommended except in research studies.

REFERENCES

1. Rose G, Reid D D, Hamilton P J S, McCartney P., Keen H and Jarrett R J. Myocardial ischaemia risk factors and death from coronary heart-disease. *Lancet* 1:105 1977.
2. Rose G, McCartney P., and Reid D H. Self administration of a questionnaire on chest pain and intermittent claudication. *Br J Prev Soc Med* 31:47 1977.

Information for authors

Most of the provisions of the Copyright Act of 1976 became effective on January 1 1978. Therefore all manuscripts must be accompanied by the following statement signed by each author: The undersigned author(s) transfers all copyright ownership of the manuscript entitled (title of article) to The C V Mosby Company in the event the work is published. The author(s) warrants that the article is original, is not under consideration by another journal and has not been previously published. Authors will be consulted when possible regarding republication of their material.

Reproducibility of a consensus panel in the interpretation of coronary angiograms

Miguel E Sanmarco, MD*
Samuel H Brooks, D Sc**
David H Blankenhorn, MD***
Los Angeles and Downey Calif

Coronary cineangiography is now generally accepted as the definitive procedure for the diagnosis of coronary artery disease. Adequate assessment of coronary artery abnormality requires high quality angiograms and correct interpretation of films. Angiographic interpretation should include an assessment of the severity and distribution of lesions coupled with judgement as to adequacy of the distal vascular bed.

The most common method to evaluate distribution and severity of coronary lesions is joint review by angiographer and surgeon with both examining the films simultaneously. Other methods are independent reading by two or more observers and a joint meeting to resolve disagreement¹ and review by a panel of experts.² Lesion assessment by any method can be judged in the light of two interrelated criteria: accuracy and consistency. The criterion accuracy asks: 'How truly does the evaluation reflect actual coronary morphology?' Accuracy is influenced by all factors involved in production and interpretation of films; it is the most inclusive and valid single

standard. Accuracy of coronary angiography has been evaluated by comparing it to postmortem findings in several reports.^{3,4}

The second criterion, consistency, evaluates a subset among the factors which contribute to accuracy and asks the question: 'How reproducible is the interpretation of a single angiogram?' This paper describes an evaluation of consistency of film reading by an expert panel. There are two general ways by which films can be evaluated by a panel. Panel members can render either group opinion⁵ or 'consensus opinion'. For group opinion, panel members read films independently and render separate estimates which are later averaged. Zir and co-workers⁶ have evaluated the group opinion method as carried out by expert angiographers and report that interobserver variability is a significant limitation. One cause of interobserver variability reported by Zir and colleagues was lack of uniformity in designation of the location of lesions. For example, when films were read independently, one reader might assign a lesion to mid LAD and another assign the same lesion to proximal LAD. This problem is minimized when all panelists review films simultaneously to render consensus opinion.

For consensus opinion, panelists review films simultaneously and arrive at a common judgement. A consensus panel comprised of a senior radiologist and cardiologist plus a second year cardiac fellow was used to provide a standard to judge the performance of independent film readers by DeRouen and co-workers.⁷ It was found that the number of angiograms interpreted by individual readers in the preceding year was significantly and positively associated with agree-

From the University of Southern California School of Medicine, Los Angeles and the Rancho Los Amigos Hospital, Downey, Calif.

Supported by NHLBI Specialized Center of Research in Atherosclerosis, Grant No. HL 14138.

Received for publication Sept. 1, 1977.

Accepted for publication Nov. 7, 1977.

Reprint requests: David H. Blankenhorn, MD, Director, Cardiology, University of Southern California School of Medicine, 2025 Zonal Ave., Los Angeles, Calif. 90033.

Assistant Professor of Medicine, University of Southern California School of Medicine, Los Angeles.

Associate Professor of Medicine (Biostatistics), University of Southern California School of Medicine, Los Angeles.

Professor of Medicine, University of Southern California School of Medicine, Los Angeles.

EN

EN




Fig 1 Blank sketch of the coronary tree in LAO (top) and RAO (bottom) views. Patient's initials are shown in upper right.

ment with the panel. The length of experience in practice and whether or not they were certified in cardiology did not influence the degree to which individual readers agreed with the panel. DeRouen and co-workers did not evaluate the consistency of performance of their reference panel but accepted a single consensus opinion as a standard.

We recently convened a consensus panel of four expert angiographers to assess change in coronary angiograms for a pilot study of medical therapy in patients with premature atherosclerosis. We randomly selected fourteen films for duplicate reading to determine the consistency of consensus panel opinion.




Fig 2 Record of panel consensus in patient E N

Materials and methods

Coronary angiography was performed by the Judkins technique by one angiographer (MES). Angiograms were recorded at 60 frames per second on 35 mm Shellburst film utilizing a General Electric 6 inch cesium iodide image intensifier with overframing. In all patients the left coronary artery was recorded in at least five views and the right coronary artery in at least three. Films were projected on a Tage Arno projector and were viewed simultaneously by the panel.

In all the panel evaluated films of 38 men ages 40 to 51 years with premature atherosclerosis manifest by myocardial infarction. These patients participated in a clinical trial to evaluate the effect of risk factors on the natural history of coronary artery disease. During the clinical study, each patient had had two coronary angio-

Table 1 Panel assessment of coronary obstruction Maximum per cent stenosis within each vessel segment

Patient	Panel session	LM*	LAD ₁	LAD ₂	LAD ₃	D ₁	D ₂	CX ₁	CX ₂	OM	PL	R ₁	R ₂	P ₁	PD	IWB
R B	1	90	60	85	75	75	0	75	0	0	0	100	DTO†	DTO	DTO	DTO
	2	27	50	85	75	80	0	75	40	0	0	100	DTO	DTO	DTO	DTO
R B	1	0	0	50	20	0	0	60	50	30	0	75	0	50	0	0
	2	0	0	40	0	0	0	65	65	50	0	70	0	50	0	0
G B	1	0	50	100	DTO	100	0	0	0	75	0	100	DTO	DTO	0	0
	2	0	60	100	DTO	100	0	0	0	80	0	100	DTO	DTO	50	0
V G	1	40	30	60	50	50	0	60	90	0	50	80	100	00	DTO	DTO
	2	30	50	70	0	0	0	30	90	35	0	80	100	90	DTO	DTO
A L	1	0	75	0	40	0	0	0	75	0	100	20	0	0	75	60
	2	0	70	0	0	0	0	0	85	30	100	25	0	0	15	50
S M	1	0	30	100	DTO	60	0	50	90	60	50	75	50	75	50	0
	2	0	20	100	DTO	70	0	50	90	70	70	75	50	75	60	0
H N	1	0	50	70	0	0	0	40	40	30	50	80	100	DTO	DTO	DTO
	2	0	60	75	0	0	0	40	50	60	30	90	100	DTO	DTO	DTO
R P	1	20	90	0	40	0	0	70	40	80	0	100	DTO	DTO	DTO	DTO
	2	30	90	0	50	0	0	75	50	50	0	100	DTO	DTO	DTO	DTO
D R	1	0	75	0	0	0	0	40	0	60	0	0	20	0	0	0
	2	0	80	0	0	100	0	50	0	60	0	0	20	0	0	0
G S	1	0	40	80	30	50	0	50	0	50	0	50	100	DTO	DTO	85
	2	0	50	80	30	0	0	70	0	60	0	55	100	DTO	DTO	00
S S	1	0	0	40	30	0	0	50	0	0	0	70	70	95	0	0
	2	0	0	40	0	0	0	40	0	0	0	75	75	95	0	0
I S	1	0	75	60	0	70	0	0	0	70	0	100	DTO	DTO	DTO	DTO
	2	75	75	75	0	75	0	0	0	75	0	100	DTO	DTO	DTO	DTO
H W	1	30	00	50	0	0	0	0	75	70	0	50	50	70	0	100
	2	0	95	55	0	0	0	0	75	75	0	55	55	60	0	100
C W	1	40	50	50	0	60	70	40	0	0	0	70	100	DTO	80	00
	2	30	30	40	0	35	75	50	0	0	0	75	100	DTO	90	0

Segment abbreviations are LM = left main LAD = left anterior descending D = diagonals CX = circumflex OM = obtuse marginal PL = posterolateral R = right coronary artery PD = posterior descending IWB = inferior wall branches (See Ref 8 for further detail) †Distal to occlusion segment not evaluated

grams and as part of the panel review process serial films were evaluated for change, but findings regarding this change will not be reported here. This report deals only with the consistency of an expert panel and presents a comparison of stenosis estimates derived from the same films on two occasions.

The panel was convened for two sessions each lasting two consecutive days. In August 1975 the panel evaluated 25 films. In March, 1976, the panel evaluated 13 new films and 14 films selected at random from those of the preceding August. At the March session the panel was informed that an undesignated number of August films would be intermixed at random with new films. Seven months had elapsed between sessions and we feel that duplicate panel assessments can be considered independent of each other. The panel members were

J Michael Criley, M.D., Professor of Medicine and Radiology, UCLA School of Medicine,
Melvin P Judkins M.D. Professor and Chairman Department of Radiology, Loma Linda University School of Medicine,
George G Rowe M.D., Professor of Medicine University of Wisconsin School of Medicine,
Ronald H Selvester M.D., Professor of Medicine University of Southern California School of Medicine

The procedure for film reading was as follows. While the film was being mounted for projection each panel member was provided an identical outline of the coronary tree to be reviewed. These coronary sketches displayed a blank outline of the RAO and LAO views of each individual patient's coronary arteries (Fig 1). Panel members had no clinical data regarding patients except knowledge that all were men with proven

myocardial infarction at an early age. All angiograms had been exposed to show coronary artery views in the same sequence: LCA injection 60° LAO 30° LAO 15° RAO 30° RAO and 5° RAO. RCA injection 60° LAO 30° LAO and 30° RAO. A technician advanced the film past all identifying data to the first coronary sequence before panel members viewed a film. Panel members sat around the projector and one panelist in rotation operated the projector. Each panelist working independently sketched and reported stenosis estimates on the diagrams without revealing these to other panel members. Films were next replayed and discussed openly by the panel to arrive at a consensus estimate of the degree and location of all stenotic lesions. During the open discussion individual graders could change their previously recorded diagram and frequently did so as a result their readings were no longer independent precluding group opinion analysis. Consensus estimates were dictated by the panel to a physician (M.E.S.) who diagrammed them on a separate record (Fig. 2). When a panel consensus had been recorded, panel members turned in their individual diagrams and adjourned to another location while the technician mounted a new film. The average time required by the panel to review a single film by this method was approximately 30 minutes.

To provide common units of information for data analysis, each consensus diagram was divided into segments according to the reporting system suggested by the American Heart Association Ad Hoc Committee for Grading Coronary Artery Disease. This was modified to include inferior and left branches of the right coronary artery distal to the crux.

Consensus estimates of stenosis ranged from zero (no luminal narrowing) to 100 per cent (complete obstruction) and were based on the maximum narrowing seen in any projection. Data analysis was done by vessel site and quantified the difference between first and second grading sessions. There were 15 possible sites in each of the 14 patients. Among the 210 possible sites, 186 were evaluated. Vessel sites which were not graded were those distal to complete obstruction. A significant lesion was defined as stenosis equal to or greater than 70 per cent stenosis (reduction in cross sectional area).

Panel consistency was analyzed three ways. First, for consistency in designating the presence

Table II Measures of dispersion between the first and second panel readings for per cent of stenosis

Coronary artery segment	Number observed	Per cent agreement presence of $\geq 70\%$ stenosis	Per cent having readings differ by 20% or more	Standard deviation of differences
LM	14	86	21.4	24.8
LAD	14	100	14.3	7.0
LAD	11	86	0.0	5.9
LAD	12	100	33.3	18.1
D	14	100	28.6	29.7
D	14	100	0.0	1.3
CX	14	93	14.3	9.1
CX	14	100	7.1	11.1
OM	14	93	35.7	13.3
PL	14	93	21.4	14.6
R	14	100	0.0	3.2
R	10	100	0.0	2.1
R	7	86	0.0	3.8
PD	8	100	12.5	17.3
IWB	9	100	0.0	6.5
Weighted Averages		94.6	13.44	14.14

Segment abbreviations are as given in Table I

or absence of a significant lesion in each segment. Next, the degree of disagreement was computed by the number of sites with duplicate readings which differed by 20 per cent or more. Third, the standard deviation of the difference between readings was obtained for each site.

Results

Table I shows the per cent stenosis assessed by the panel for each lesion site for each patient for the two grading sessions. Sites which could not be graded (distal to complete occlusions) are designated DTO. Pairwise *t* tests were done for the session differences for each lesion site and none were significantly different from zero. This indicates that the panel did not exhibit a measurable tendency to increase or decrease stenosis estimates between the two sessions. Over all, average stenosis estimates on the second session was less than 0.6 per cent higher than at the first session.

There was good agreement between the sessions regarding the presence or absence of a significant lesion with only ten discrepant readings. Agreement therefore for all 186 lesion sites was 94.6 per cent as shown in Table II as a

weighted average. Somewhat less consistency was observed in small vessels, for example mid LAD first diagonal and distal right, which showed 86 per cent agreement. It should be noted that the difference between significant and not significant might represent a difference between 60 per cent and 70 per cent stenosis and, indeed, that was the case in four out of ten discrepant readings. An important exception was the magnitude of the discrepancies in the left main segment in two of the 14 patients. These are discussed individually later.

Table II shows two additional measures of dispersion between the first and second panel readings. The next measure is the per cent of patients for whom a given vessel site had stenosis readings which deviated by 20 per cent or more between the two grading sessions. Among major coronary vessels the right coronary artery in all three segments showed the greatest consistency by this measure and all grades from the first session were within 20 per cent of grades from the second sessions. The proximal LAD and circumflex also showed excellent agreement. In minor vessels the disagreement ranged from 0 (D) to 36 per cent (OM). In the case of the second diagonal branch the excellent agreement may be explained in part by the high proportion of 0 per cent and 100 per cent stenosis because these extremes conceptually invite consistent readings. However the first diagonal branch of patient D R which filled faintly through collaterals was graded 0 per cent stenosis at the first session and 100 per cent at the second session.

The vessels showing most grading inconsistencies by this method were the obtuse marginal branch, the distal segment of the left anterior descending and the first diagonal branch. Considering all 186 vessel segments, 25 (13.44 per cent) were discrepant by 20 per cent or more at the two panel sessions (see Table II). Every patient in the series had at least one vessel site with a discrepant reading of 20 per cent or more. One patient V G, had six such discrepancies. Of the 25 discrepancies, 16 (64 per cent) may be considered hemodynamically insignificant since they deal with non-critical lesions by conventional standards according to both panel readings.

The third measure of dispersion in Table II is the standard deviation of the difference of the two readings for each vessel site. The standard deviation may be regarded as the better measure of

consistency since it utilizes all discrepancies and gives considerable weight to the larger ones. A weighted average* of the standard deviations for all sites yields an over all variability of 14.1 per cent. The greatest standard deviations were observed for the first diagonal branch (30 per cent) and the left main segment (25 per cent).

Discussion

It appears from this study that a panel of expert angiographers has a consistency of 95 per cent when rendering consensus opinion with respect to the presence or absence of a significant lesion (≥ 70 per cent stenosis). Significant stenosis has been variously defined in previous reports of angiographic precision as 70 per cent lumen reduction or 50 per cent "diameter" reduction. Since these two measurements are equivalent we adopt the 70 per cent convention. However, it is important to point out that this degree of agreement may be overstated since it compresses all possible degrees of coronary abnormality into two classes: significant and non-significant. Compression to this extent severely limits the use of coronary angiography for description of the natural history of ischemic heart disease or stratification of patients for clinical therapy trials.

This is the only report in which a panel had been asked to provide duplicate readings of the same coronary angiogram at two different sessions. Therefore the estimate of panel consistency is not directly comparable to previous reports.¹⁻⁴ Our results, however, do seem somewhat better than the agreement between panel members rendering "group opinion" reported by Zar and co-workers.⁵

To study the natural history of coronary disease or stratify patients for clinical trial a more useful estimate of panel performance can be derived from the raw data and standard deviations presented in Table II. These standard deviations indicate that a consensus panel appears adequate for evaluation of the right coronary artery, proximal and mid left anterior descending coronary artery, and circumflex where standard deviation of duplicate stenosis estimates do not exceed 10 per cent. In the left main coronary segment and diagonal and marginal branches the

$$\text{Weighted average} = \left(\frac{\sum (N-1) SD^2}{\sum (N-1)} \right)^{1/2}$$




Fig. 3 A and B Two examples of left main segments with major discrepancies in panel consistency A patient R II B patient I ■ See text for discussion

standard deviation of duplicate stenosis estimates ranged from 15 to 30 per cent. In these vessels panel reading could usefully be augmented by one of several additional reading procedures described later.

It has been suggested that one factor which may influence observer variability is the number of positive findings. There will be better agreement in those vessels with no lesion or complete stenosis. In our study this appears to be the case in the second diagonal branch which was free of disease in all but one patient. On the other hand it is to be noted that the proximal and mid left anterior descending and right coronary artery show good reproducibility with 36.43 and 57 per cent positive findings. Good agreement in these

segments is in keeping with the previous reports of Zir and co-workers⁴ and Detre and colleagues.⁵

Despite the over all encouraging results reported here we must emphasize the problem we have encountered in stenosis estimates of left main coronary segment. In two of the 14 cases the left main segment was considered without significant disease at one time and severely stenotic at another time. Since significant left main lesions pose a very special problem because of their prognosis^{6,7} discussion of these two patients is pertinent. Fig. 3A shows a frame of proximal left coronary artery on patient R II. During the first review it was agreed by the members of the panel that he had a 90 per cent

narrowing of the left main. On the second review, the panel members spent approximately 45 minutes trying to decide on whether there was a left main lesion or if there were two separate ostia for the LAD and circumflex. According to the second view the finding could be explained by a jet from the tip of the catheter filling both ostia and appearing to be a stenotic lesion. After considerable discussion they did not reach an agreement, readings varied from 0 to 80 per cent stenosis (average 27 per cent). The second patient with a discrepant left main lesion was I S Fig 3B illustrates a frame of the coronary angiogram. On the second review the panel decided there was 75 per cent ostial stenosis, in their first review the left main was read as normal.

We are not the first to encounter difficulty in evaluating left main lesions. In the left main coronary artery, Zur and co-workers* found disagreement among the four observers in three of the 20 angiograms (15 per cent). While our methods are not directly comparable, our results are very similar since the disagreement of our panel with itself was two out of 14 or 14 per cent. Improved stenosis estimation is clearly desirable because of the importance of this segment in the genesis of massive myocardial infarction and sudden cardiac death. We feel that the problem presented by the left main coronary segment has two elements. First, there is a need for different or improved imaging procedures to provide multiple views, and second, there is need for improved reading procedures. The case illustrated in Fig 3A appears to require an improved or different imaging procedure with multiple views, and will not be remedied by improved reading techniques alone. The problem illustrated in Fig 3B could be alleviated by improved film reading procedures. With human readers, either individual or panel members, it seems important to employ film reading schedules which reduce reader fatigue while requiring the systematic examination of all segments. Systematic reading is particularly important when multiple segments are involved and there are some lesions present which tend to attract the reader's attention to the exclusion of others. An alternative approach could be to augment human reading with automated stenosis estimates of all coronary segments. The quantitative procedure described by Brown and associates¹³ which requires that a reader trace the coronary arteries has been shown feasible. An

instrumental procedure with less potential for human error since it provides for automatic vessel edge finding, has been described by Selzer and co-workers.¹⁴ Routine acquisition of quantitative data on all segments could extend the scope of coronary angiographic interpretation and assist in quality control.

Summary

This report describes the consistency of coronary angiogram evaluation by a four man panel of experts rendering "consensus opinion." The panel evaluated films from 38 patients at two grading sessions separated by an interval of several months. Fourteen patients' films were selected at random for duplicate evaluation. These contained 186 lesion sites. The panel was 95 per cent consistent in designating significant stenosis (≥ 70 per cent). Consensus' panel reading appears more consistent than group opinion panel reading. The over all standard deviation of the difference in panel reading was 14 per cent. The panel was most consistent in evaluating the right coronary artery, proximal LAD, and proximal circumflex. In the left main segment two of fourteen duplicate evaluations showed major discrepancy.

REFERENCES

1. Henderson R R and Rowe G G. The progression of coronary atherosclerotic disease as assessed by coronary arteriography. *AM HEART J* 85:163 1973.
2. DeRouen T A, Murray J A and Owen W. Variability in the analysis of coronary arteriograms. *Circulation* 55:324 1977.
3. Grondin C M, Dyrdal I, Pasternak A, Campeau L, Bourassa M G and Lesperance J. Discrepancies between cineangiographic and postmortem findings in patients with coronary artery disease and recent myocardial revascularization. *Circulation* 49:703 1974.
4. Schwartz J N, Kong Y, Hackel D B and Bartel A G. Comparison of angiographic and postmortem findings in patients with coronary artery disease. *Am J Cardiol* 36:174 1975.
5. Vlodaver M, Frech R, Van Tassel R A and Edwards J E. Correlation of the antemortem coronary arteriogram and the postmortem specimen. *Circulation* 47:162 1973.
6. Zur L M, Miller S W, Dinsmore R F, Gilbert J P and Harthorne J W. Interobserver variability in coronary angiography. *Circulation* 53:627 1976.
7. McGoon D C (Chairman). A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease. Council on Cardiovascular Surgery. *American Heart Association Circulation* 51:7 1975.
8. Detre K M, Wright E, Murphy M L and Takaro T. Observer agreement in evaluating coronary angiograms. *Circulation* 52:975 1975.

- 9 Cohen, M V and Gorlin R J Main left coronary artery disease Clinical experience from 1964-1974 *Circulation* 52 275 1975
- 10 Lim J S Proudfit W L and Sones F M Jr Left main coronary arterial obstruction Long term follow up of 141 non surgical cases *Am J Cardiol* 36 131 1975
- 11 De Mota H Bonchek L I Rosch J Anderson R P Starr A and Rahimtoola S H Left main coronary artery disease Risks of angiography importance of coexisting disease of other coronary arteries and effects of revascularization *Am J Cardiol* 36 136 1975
- 12 Talano J V, Scanlon P J Meadows W R Khan M Pifarre R and Gunnar R M Influence of surgery on survival in 145 patients with left main coronary artery disease *Circulation* 52 (Suppl 1) 1 105 1975
- 13 Brown H G Bolsow E Frimer M and Dodge H T Quantitative coronary arteriography Estimation of dimensions, hemodynamic resistance and atheroma mass of coronary artery lesions using the arteriogram and digital computation *Circulation* 55 379 1977
- 14 Selzer N H Blankenhorn D H Crawford N W Brooks S H, and Barndt H Jr Computer analysis of cardiovascular imagery in Proceedings of the CalTech/JPL Conference on Image Processing Technology Data Sources, and Software for Commercial and Scientific Applications California Institute of Technology Pasadena 1976

Coronary artery fistulas emptying into left heart chambers

Djavad T Arani, MD FACC*
David G Greene, MD FACC**
Francis J Klocke, MD, FACC***
Buffalo N Y

A coronary artery fistula is an uncommon congenital anomaly. The majority of these fistulas empty into the right heart chambers. In a review of two hundred cases of coronary fistulas, only 17 entered the left heart. In 2,300 patients studied with selective coronary arteriography in our laboratory, three patients had coronary artery fistulas which emptied into the left side of the heart.

Case 1

B P was a 27 year old white female school teacher who was admitted to the Buffalo General Hospital for evaluation of heart murmur and recurrent atrial fibrillation. She had a febrile illness diagnosed as 'acute rheumatic fever' at age 7 for which she was hospitalized for 3 months. Subsequently she was well until 3 years before admission when she began to have recurrent episodes of palpitation. On April 17 1972 she had a severe episode of palpitation for which she went to the emergency room of another hospital and was noted to have atrial fibrillation with rapid

ventricular response. The rhythm was converted to sinus electrically and she was started on digoxin and quinidine. One week before admission she had another episode of atrial fibrillation which ceased spontaneously. She denied symptoms of congestive heart failure.

Physical examination disclosed a well developed obese white female. The pulse was 80 per minute and regular, and the blood pressure was 150/40 mm Hg. Carotid pulses were bounding. The first heart sound was normal. A Grade 3/6 continuous murmur with a predominant diastolic component was heard over the entire precordium with maximal intensity over the third left intercostal space. A third heart sound was audible at the apex. Examination otherwise was within normal limits. The electrocardiogram showed notched P waves in Leads I and II suggestive of left atrial enlargement. The chest x ray showed cardiomegaly with evidence of left atrial and left ventricular enlargement.

Catheterization of the right and left heart was performed. Pressures in the right side of the heart were normal. The left atrial pressure measured by the transseptal technique was also normal. Simultaneous pressures in the left atrium and left ventricle showed a small (2 mm Hg) pressure difference between the left atrium and left ventricle during the rapid filling period of the left ventricle and again at the end of ventricular diastole during the left atrial contraction. The left ventricular pressure was normal and the aortic pressure showed a wide pulse pressure (130/60 mm Hg).

Coronangiograms following injection of contrast into the left atrium showed enlargement of the left atrium and a normal appearance of the mitral

From the Department of Medicine, State University of New York at Buffalo and the Buffalo General Hospital, Buffalo, N Y.

Supported in part by Program Project Grant HL 15194 from the National Heart, Lung, and Blood Institute and in part by contributions to the Buffalo General Hospital in memory of Cecil Kessel.

Received for publication Sept. 9, 1977.

Accepted for publication Jan. 13, 1978.

Reprint requests: Djavad T. Arani, MD, Buffalo General Hospital, 100 High Street, Buffalo, N Y 14203.

Clinical Assistant Professor of Medicine, State University of New York at Buffalo; Clinical Associate in Medicine, Buffalo General Hospital.

Professor of Medicine, State University of New York at Buffalo; Attending Physician, Buffalo General Hospital.

Professor of Medicine and Head, Division of Cardiology, State University of New York at Buffalo.

valve Left ventriculograms showed enlargement of the left ventricle with an end diastolic volume of 343 ml and an ejection fraction of 62 per cent There was neither evidence of aortic regurgitation nor evidence of left to right shunt

Aortic root cineangiograms showed aneurysmal dilatation of the left sinus of Valsalva The main left coronary artery was markedly dilated (about 1 cm in diameter) A large fistula was derived from the left coronary artery and was directed superiorly and medially before it connected with the left atrium

Fig 1 shows frontal projections of the left coronary arteriogram made with 32 ml of Renografin and serial cut films at a rate of 4/second for 2 seconds In Fig 1A the main left coronary artery is markedly dilated and appears aneurysmal in its distal portion There is light opacification of the left atrium Fig 1B is the next frame of the arteriogram shown in Fig 1A The fistula now is visualized and the left atrium shows dense opacification

Open heart surgery was performed on July 9 1973 at the Texas Heart Institute by Dr Denton Cooley Exploration revealed that she had an anomalous branch of the left circumflex coronary artery which had a fistulous communication with the left atrium The left coronary artery was greatly dilated and almost aneurysmal at its nearest termination at the fistula site The left atrium was opened and the ostium of the fistula was found above the mitral valve and adjacent to the base of the auricular appendage The fistula was oversewn at that point The coronary artery was dissected out carefully preserving the circumflex and left anterior descending branches The coronary artery was ligated at the appropriate point and the anomalous artery was then obliterated with sutures Her postoperative course was uneventful except for the development of atrial fibrillation on the fifth postoperative day which was converted to sinus rhythm with quinidine Disappearance of the murmur and atrial fibrillation and decreased heart size were noted following surgery

Case 2

J Q was a 65 year old white man with a history of acute rheumatic fever at the age of 20 Involvement of the mitral valve was noted at age 25 He had been seen periodically by one of us (D G G) since 1958 with the diagnosis of mitral



Fig 1 A and B A frontal projection of the left coronary arteriogram during power injection of 32 ml of Renografin into the left coronary artery The left main coronary artery is markedly dilated and its distal portion appears aneurysmal There is light opacification of the left atrium MLC = main left coronary artery LA = left atrium B Next frame of the arteriogram shown in 1A The fistula is now opacified and directed superiorly and medially connecting with the left atrium Note dense opacification of a large left atrium through the fistula Abbreviations as in 1A F = fistula

stenosis and regurgitation He had had intermittent episodes of atrial fibrillation for which he was treated with digitalis and quinidine He had good exercise tolerance until October 1972 when he developed increasing fatigue dyspnea and orthopnea Physical examination revealed a blood pressure of 170/90 mm Hg a regular pulse of 70 per minute normal jugular venous pressure and a loud first heart sound An opening snap a Grade 3/6 diastolic rumble and a Grade 2/6 pansystolic murmur were heard at the apex The chest x ray showed left atrial enlargement slight left ventricular enlargement and pulmonary



Fig 2 A and B A Left anterior oblique view of the left coronary arteriogram using cut film demonstrates a round angiomatous plexus. The origin of the fistula from the proximal left circumflex artery and its connection with the left atrium were clearly seen by cineangiography. Abbreviations as Fig 1 LAD = left anterior descending artery MAR = marginal branch of left circumflex artery TC = terminal circumflex artery D = diagonal branch of the left anterior descending artery B Right anterior oblique projection of the left coronary arteriogram shows the fistula and contrast in the left atrium. Abbreviations as in Figs 1 and 2A

venous congestion. The electrocardiogram showed first degree atrioventricular block, left anterior hemiblock, and digitalis effect.

On April 20, 1973 right and left heart catheterizations and angiography were performed. The pulmonary wedge pressure was 25 mm Hg, the pulmonary artery pressure was 40/12 mm Hg, and there was an 18 mm Hg gradient across the mitral valve. The left ventricular pressure was normal. Left ventriculography showed minimal mitral regurgitation. Visualization of the left heart following injection of the contrast into the pulmonary artery showed left atrial enlargement. The mitral valve appeared thickened and bulged down during diastole in a manner typical of mitral stenosis.

The right coronary arteriogram showed mild stenosis of this artery shortly before the origin of the posterior descending branch. The left coronary arteriogram showed a main left coronary artery and left anterior descending which appeared normal. The left circumflex artery showed no evidence of an occlusive lesion. However, about a centimeter from its origin it gave rise to a branch which was the arterial supply of a hemangioma about 2.5 cm in diameter which emptied into the left atrium (see Fig 2).

Cardiac output and estimation of flow through fistula. Cardiac output was done by dissolved hydrogen technique using left ventricular infusion and aortic sampling, and measured 5.8 l/min. For the estimation of shunt flow isotonic

saline containing a known amount of dissolved hydrogen was infused directly into the left coronary artery at a rate of 72 ml per minute. Left ventricular samples were drawn between two to four minutes of the infusion and analyzed for hydrogen. The amount of infused hydrogen recovered in the left ventricle was calculated as the product of average left ventricular hydrogen concentration and cardiac output. This product was then expressed as a fraction of hydrogen input (hydrogen concentration in infusate \times 72 ml/minute). Since hydrogen traversing the normal coronary circulation is eliminated essentially completely in the lungs, the fraction of infused hydrogen recovered in the left ventricle represents the fraction of the left coronary inflow passing through the fistula. Flow through the fistula calculated in this manner was 69 per cent of the left coronary inflow.

Exploration during mitral commissurotomy by Dr Thomas Z. Lajos revealed three small orifices in the left atrium. The fistulas were oversewn at these points.

Case 3

J B a 44 year old black female school teacher was hospitalized for evaluation of chest pain and dyspnea of 9 months duration. These symptoms usually occurred with exertion and were relieved after about 5 minutes of rest. Chest x ray shortly after the onset of symptoms showed an enlarged heart. The patient was placed on digoxin 0.25 mgm daily without improvement. Physical examination revealed a blood pressure of 150/80 mm Hg. The pulse was 72 per minute and regular. The heart sounds were normal. A Grade 2/6 systolic ejection murmur was heard along the left sternal border. The chest x ray showed left ventricular enlargement. The electrocardiogram showed left anterior hemiblock and voltage criteria for left ventricular hypertrophy.

On April 25, 1973, left heart catheterization and coronary arteriograms were done. Left ventricular and aortic pressures were normal and there was no gradient across the aortic valve. The right coronary artery and circumflex branch of the left coronary artery were small and appeared normal. The left anterior descending branch of the left coronary artery was markedly enlarged. A small anomalous branch derived from the anterior descending in its distal portion connected directly with the ventricle.




Fig 3 A and B A Right anterior oblique view of the left coronary arteriogram shows enlargement of the left anterior descending artery and a fistula of small caliber (arrow) joining the left anterior descending artery with the left ventricle. Note contrast bursting into the left ventricle. Abbreviations as in Figs 1 and 2. L1 = left ventricle. B Later frame of the arteriogram seen in 3A. The fistula now shows smaller caliber and the contrast filled left ventricular cavity is outlined. Abbreviations as in 3A.

Fig 3A is a right anterior oblique projection of the left coronary arteriogram using cut film showing a small fistula emptying into the left ventricle.

Fig 3B is a later frame of the same large film sequence showing opacification of the entire left ventricular cavity through the fistulous communication.

By using hydrogen as a tracer as described in Case 2, cardiac output measured 4.72 L/minute and shunt flow through the fistula was 38 per

cent of the left coronary inflow *† This patient was not operated on and her symptoms have remained unchanged

Discussion

With advances in selective coronary arteriography and coronary surgery, diagnosis and correction of coronary fistulas are done more frequently. Coronary arteriography is especially helpful in diagnosing fistulas without clinical manifestation or those involving multiple vessels or recipient chambers. The fistula originates most frequently from the right coronary artery. The most common recipient chambers in order of frequency are the right ventricle, the right atrium, and the pulmonary artery.⁴ Oldham and colleagues reported 12 cases of coronary fistulas, and reviewed 188 published cases.¹⁻³ The fistula emptied into the left atrium in only 12 of their 200 cases. Two other cases have been published.^{11,12} Reddy and colleagues¹⁰ reported a case of coronary fistula to the left ventricle and reviewed nine previous cases. We have found eight additional reported cases.¹⁻¹² Therefore to our knowledge 32 cases of fistula emptying into the left heart have been published. Symptoms of congestive heart failure, angina pectoris, bacterial endocarditis, and frequent upper respiratory tract infections are usually seen in these patients. Atrial fibrillation is commonly found in older patients and may precipitate congestive heart failure.⁴

In our first patient recurrent atrial fibrillation was the presenting symptom although she was only 27 years old. Findings of a continuous murmur, a wide arterial pulse pressure and enlargement of the left atrium and left ventricle were similar to those with patent ductus arteriosus. The loud diastolic component of the murmur and the absence of increased pulmonary vascularity, however, were not compatible with this lesion.⁴ Dilatation and overload of the left atrium by a large shunt through the fistula appeared to be responsible for the arrhythmia and this mechanism

was confirmed by cessation of the atrial fibrillation and decreased heart size after surgery. In the second patient the symptoms could be explained by mitral valve disease. However, since he was 65 years old and the left ventriculogram showed impairment of contractility, coronary arteriography was done prior to mitral commissurotomy and to our surprise a fistula from the left coronary artery to the left atrium was discovered. The flow through this fistula was found to be about two thirds of the left coronary inflow. Whether there is any relation between the fistula and left ventricular dysfunction is not clear. Our third patient had dyspnea and atypical angina pectoris and had no signs related to the fistula except a non specific systolic murmur.

Coronary fistulas to the left ventricle are usually associated with a continuous* or only a diastolic murmur. Closure of the fistulous communication during ventricular systole accounts for the absence of a systolic component in some patients. Cases without a heart murmur have also been reported.¹⁴⁻¹⁶ Coronary arteriography in our patient revealed enlargement of the left anterior descending artery, presumably due to increased flow through this artery and 'run off' to the left ventricle. Left ventriculography showed hypokinesis of the anterior wall. Calculation of the shunt through the fistula by the method described earlier showed that about one third of the left coronary inflow entered the left ventricle through the fistula. Myocardial ischemia is an uncommon manifestation of coronary artery fistula. It is postulated that blood is shunted away from the coronary circulation causing a decreased pressure gradient across the myocardial capillaries. This hypothesis could explain both chest pain and hypokinesis of the anterior wall of the left ventricle in this patient with left coronary-left ventricular fistula. Using hydrogen dissolved in saline as tracer we were able to estimate the shunt flow in the second and third patients. In the first patient this method of shunt flow measurement did not seem applicable. Since the fistula had a short conduit and a large flow, a large amount of hydrogen which had entered the left heart through the fistula would recirculate into the left coronary artery.

Summary

We present three cases of coronary artery fistulas entering into the left heart chambers. Coronary arteriography in one showed aneurysm

*Because of the left to-left shunt a small amount of hydrogen entered the left ventricle from shunt outflow in addition to the large amount of hydrogen infused, thus the value of cardiac output probably underestimates actual cardiac output by 5 to 15 per cent.

†Reflux of the solution containing hydrogen from the left main coronary into the aorta appeared unlikely because of the following reasons: (1) Left main coronary arteries were not short in these patients and the catheter tips were in satisfactory positions in the main left coronary arteries. (2) Hydrogen dissolved in saline was injected at a low rate of 7.2 ml/min. Any reflux which occurred would cause the calculation of coronary blood flow to be too low.

mal dilatation of the main left coronary artery and a fistulous communication with a large left atrium. Exploration during repair revealed an anomalous branch of the left circumflex emptying into the left atrium. In the second case the proximal left circumflex gave rise to a branch supplying a hemangioma which emptied into the left atrium. Coronary arteriograms of the third patient showed an enlarged left anterior descending artery with an anomalous branch emptying into the left ventricle. Shunt flow was estimated with hydrogen as a tracer in the last two cases and was two thirds and one third of the left coronary inflow respectively. Review of the literature shows 32 previously reported cases of a fistula draining into the left side of the heart.

REFERENCES

1. Effler D B, Sheldon W C, Turner J J and Groves L K. Coronary arteriovenous fistula. Diagnosis and surgical management. Report of 15 cases. *Surgery* 61:41 1968.
2. Oldham H N Jr, Ebert P A, Young W G and Sabiston D C Jr. Surgical management of congenital coronary artery fistula. *Ann Thorac Surg* 12:503 1971.
3. Klocke F J, Greene D G and Koberstein R E. Indicator-dilution measurement of cardiac output with dissolved hydrogen. *Circ Res* 22:841 1968.
4. McNamara J J and Gross R E. Congenital coronary artery fistula. *Surgery* 66:59 1969.
5. Abbott O A, Rivaola C H and Logue R B. Surgical correction of coronary arteriovenous fistula. *J Thorac Cardiovasc. Surg* 42:660 1961.
6. Agusti, R, Liebman, J, Ankeny J, Macleod C A, Linton D S and Whitte R. Congenital right coronary artery to left atrium fistula. *Am J Cardiol* 18:478 1967.
7. Floy W L, Young W G and Johnsrude I S. Coronary arterial left atrial fistula. Case with obstruction of the inferior vena cava by a giant left atrium. *Am J Cardiol* 25:716 1970.
8. Reed W A and Little F. Congenital coronary artery fistula. *Arch Surg* 93:772, 1966.
9. Sloman G, Macphie A and Farley K. An unusual coronary arteriovenous fistula. *Am J Cardiol* 15:856 1965.
10. Mozen H E. Congenital cirsoid aneurysm of a coronary artery with associated arterio atrial fistula treated by operation. A case report. *Ann Surg* 144:215 1956.
11. Gasul, H M, Arcilla R A, Fell E H, Lynfield J, Bcoff J P and Luan L L. Congenital coronary arteriovenous fistula. *Pediatrics* 25:531 1960.
12. Manabe H, Fujimoto J, Oku N, Nishizaki H, Fujino T, Nakata K and Kato N. Coronary arteriovenous fistula. *J Jap Assoc Thorac Surg* 10:519 1967.
13. Char F and Hara M. Congenital coronary artery fistula. Communication of the left coronary artery with the left atrium. *Lancet* 86:111 1966.
14. Montella S, Schiavetti E, Calza G and Barbieri, L. Congenital coronary fistula draining in the left atrium. *J Ital Cardiol* 4:493 1974.
15. Kung S B and Schoonmaker F W. Coronary artery to left atrial fistula in association with severe atherosclerosis and mitral stenosis. Report of surgical repair. *Chest* 67:361 1975.
16. Reddy H, Gupta M and Hambro R I. Multiple coronary arteriovenous fistulas. *Am J Cardiol* 33:304 1974.
17. Haravon A, Franklin M and Krauthamer M J. Congenital coronary artery to left ventricle fistula with angina pectoris. *N Y State J Med* 72:2196 1972.
18. Eie, H and Hillestad L. Arteriovenous fistulas of the coronary arteries. A report of six cases. *Scand J Thorac Cardiovasc Surg* 5:34 1971.
19. Suzuki T, Hoshino M, Nagamine G, Hamada S, Iwatsuki, F., Motomura, K, Fujii S, Kikuchi M and Honda K. One case of fistula of the left coronary artery opening into the left ventricle. Successful treatment and review of literature. *J Jap Assoc Thorac Surg* 21:893 1973.
20. Okuda, Y, Tsuneda T, Morishima A, Matsumoto S, Ito Y and Tazuka, M. Right coronary artery to left ventricle fistula. The sixth case in the literature and discussion. *Jap Heart J* 14:184 1973.
21. Binaghi, G, Mortarino G, Caresano A, Favero C, Di Repetto S and Roella C. A case of fistula between left coronary artery and left ventricle. *J Ital Cardiol* 1:168 1971.
22. Miyahara M, Kikuni T, Agata K, Hamagami Y and Togashi, M. A case of right coronary artery fistula into left ventricle. *Jap Circ J* 35:1411 1971.
23. Gahoto F M, Reitman M J, Slorus A J and Sarot I A. Right coronary artery to left ventricle fistula. *Am Heart J* 82:93 1971.
24. Agata K, Hamagami V, Nakagawa K, Takabashi N and Kikuni, T. *Jap Circ J* 34:568 1970. Cited by Okuda Y et al. in reference 20.
25. Lovitt W V Jr and Lutz M Jr. Embryological aneurysm of the myocardial vessels. *Arch Pathol* 57:163 1954.

Arterial hypoxemia following the administration of sublingual nitroglycerin

Ercument A Kopman, MD *
Glenn R Weygandt, MD **
Spomenko Bauer, MD ***
Thomas B Ferguson, MD ****
St Louis Mo

It is our policy to administer sublingual nitroglycerin 10 to 15 minutes before induction of anesthesia in patients about to undergo coronary artery bypass surgery. Routine blood gas determinations, after the administration of nitroglycerin and before the induction of anesthesia, revealed that some patients had surprisingly low arterial PO_2 (PaO_2) values. We, therefore, decided to study the effect of nitroglycerin on arterial blood gases and hemodynamics in a group of these patients. Our results demonstrate that PaO_2 falls significantly following the administration of sublingual nitroglycerin to patients with coronary artery disease breathing room air. The possible mechanisms and clinical implications are discussed.

Materials and methods

Seventeen men and four women 38 to 61 years of age, were studied. Each had experienced typical stable exertional angina for at least six months. Coronary angiography revealed that each had one or more high grade obstructive lesions. There was no evidence of congestive heart

failure or valvular disease in any of these patients. All medications except nitroglycerin had been discontinued 48 hours prior to coronary artery bypass surgery.

Blood gas determinations were done before and after nitroglycerin in a total of 21 patients. They were divided into two groups. Group I consisted of 13 patients who had received morphine (10 to 15 mgm) scopolamine (0.4 to 0.5 mgm) premedication intramuscularly, approximately 60 minutes before the studies. Both blood gas and hemodynamic studies were done in this group. Group II in eight unpremedicated patients only blood gas determinations were done before and after nitroglycerin to evaluate a possible combined effect of nitroglycerin and morphine-scopolamine premedication on blood gases. A No. 20 gauge plastic cannula was inserted into the right radial artery for blood sampling and for monitoring arterial blood pressures in both groups. pH , pCO_2 , and PO_2 were measured with an Instrumentation Laboratory analyzer No. 213. In Group I a No. 7 Swan Ganz thermodilution catheter was inserted percutaneously under local anesthesia into the pulmonary artery via the right internal jugular vein for measurement of pulmonary artery pressure, pulmonary arterial wedge pressure, central venous pressure, and cardiac output. All pressures were monitored continuously with No. 500 Sanborn transducers and recorded on a multichannel recorder (Brush Mark 220). ECG Lead II was also recorded. Cardiac output was determined by thermodilution with an Edwards CAB Model 4510 A cardiac output computer. In both groups studies were performed before the induction of anesthesia.

From the Departments of Anesthesiology and Surgery, Washington University School of Medicine, St. Louis, Mo.
Received for publication Sept. 12, 1977.
Accepted for publication Nov. 18, 1977.

Reprint requests: Ercument A. Kopman, MD, Dept. of Anesthesiology, Washington University School of Medicine, 660 S. Euclid Ave., St. Louis, Mo. 63110.

Assistant Professor of Anesthesiology

Associate Professor of Anesthesiology

Instructor in Anesthesiology

* Professor of Cardiothoracic Surgery, Division of Cardiothoracic Surgery

with the patient in the supine position breathing room air. Arterial blood gases and hemodynamic parameters were determined before and 10 minutes after the taking of sublingual nitroglycerin 0.6 mg dissolved in 0.5 ml saline. Student's *t* values were used for statistical analysis.

Results

PaO₂ fell after nitroglycerin in all but one of the 21 patients studied. In the 13 premedicated patients (Group I Table I) PaO₂ decreased from a mean of 65 SD \pm 13 to 55 SD \pm 11 ($p < 0.001$) following the administration of nitroglycerin. pH and pCO₂ did not change significantly.

After nitroglycerin (Table II) mean arterial pressure decreased from a control value of 91 SD \pm 8 to 74 SD \pm 3 mm Hg ($p < 0.001$). central venous pressure fell from 59 SD \pm 26 to 26 SD \pm 26 mm Hg ($p < 0.001$). pulmonary artery pressure fell from 16 SD \pm 4 to 10 SD \pm 4 mm Hg ($p < 0.001$). pulmonary arterial wedge pressure dropped from 86 SD \pm 32 to 33 SD \pm 25 mm Hg ($p < 0.001$). cardiac index decreased from 2.68 SD \pm 0.5 to 2.31 SD \pm 0.4 L/min/M ($p < 0.001$). the calculated values for systemic and pulmonary vascular resistance were not significantly altered and heart rate was not significantly changed. In the eight unpremedicated patients (Table III) PaO₂ also fell after nitroglycerin from a mean value of 78 SD \pm 10 to 64 SD \pm 8 mm Hg ($p < 0.001$). pH and pCO₂ did not change significantly. Initial PaO₂ values were higher in the unpremedicated group 78 SD \pm 10 vs 65 SD \pm 13 mm Hg in the premedicated patients. This difference was significant ($p < 0.05$). The fall in PaO₂ after nitroglycerin was also slightly greater in the unpremedicated group 14 SD \pm 5 vs 10 SD \pm 8 mm Hg in the premedicated group. This difference however was not statistically significant. From this small sampling it would appear that morphine-scopolamine premedication lowered initial PaO₂ values but had no effect on the magnitude of the change in PaO₂ after nitroglycerin.

Discussion

This study gives conclusive evidence that sublingual nitroglycerin adversely affects arterial PaO₂, levels in most patients with coronary artery disease breathing room air. The cause however remains obscure. Arterial PCO₂ did not change



Fig 1 ECG of a patient A Before angina pectoris B after onset of chest pain C ten minutes after NTG (0.6 mg) D five minutes after breathing 100 per cent oxygen

Table I Premedicated patients

Case No	Control data			Data 10 minutes after NTG		
	pH	PCO ₂	PO ₂	pH	PCO ₂	PO ₂
1	7.37	44	59	7.43	39	48
2	7.38	44	88	7.44	40	58
3	7.35	45	69	7.36	45	51
4	7.42	41	69	7.45	34	52
5	7.49	40	66	7.43	35	57
6	7.38	38	62	7.42	37	50
7	7.44	37	55	7.41	40	55
8	7.41	38	55	7.44	35	49
9	7.44	34	55	7.44	32	57
10	7.41	38	57	7.40	38	48
11	7.40	44	87	7.40	47	88
12	7.40	44	87	7.40	47	73
13	7.41	38	50	7.42	38	43
Mean	7.38	40.3	64.9	7.42	38.6	55.1
SD \pm	0.07	3.5	13.6	0.02	5.1	11.4

Change not significant from control value.

Change significantly different from control values ($p < 0.01$).

after nitroglycerin thus alveolar ventilation was not decreased. Nitroglycerin is reported to relax bronchial musculature so an increase in the evenness of ventilation is unlikely. As mentioned previously morphine-scopolamine premedication appeared to lower initial PaO₂ values but the fall in PaO₂ after nitroglycerin was about the same with or without premedication. The reduction of PaO₂ after nitroglycerin then would seem to be related to hemodynamic changes that occur after its administration. Several possibilities exist: (1) vasodilation in poorly or non ventilated areas of the lungs (2) opening of arteriovenous anastomoses which bypass alveoli (the fact that calculated pulmonary vascular resistance did not change after nitroglycerin does not rule out these two possibilities because calculated pulmonary vascular resistance may remain unchanged even though pulmonary vasomotor tone has been altered considerably) (3) the fall in pulmonary artery pressure might favor perfusion to dependent less well ventilated regions of the lungs (4)

Table II Hemodynamic data before and 10 minutes after nitroglycerin

Case No	Control data								Data 10 minutes after NTG							
	HR†	MAP	CVP	PA	PAW	CI	SVR	PVR	HR*	MAP*	CVP*	PA*	PAW	CI*	SVR	PVR
1	72	103	5	18	12	2.59	1504	93	75	70	1	10	5	2.13	1.04	94
2	60	89	4	14	6	3.27	1066	100	63	80	0	6	1	2.88	1.73	10
3	58	90	4	14	5	2.76	1081	138	65	70	0	9	1	2.62	9.8	106
4	75	98	■	15	10	2.85	1226	54	80	80	1	6	3	2.51	1194	40
5	58	94	6	12	7	1.85	1660	94	60	81	1	6	2	1.79	1564	8
6	72	102	4	16	8	3.04	1354	221	78	72	2	12	3	2.67	1100	141
7	69	91	6	16	8	2.36	1510	142	60	76	4	11	2	1.91	1641	90
8	68	78	6	16	8	1.87	1264	171	60	88	4	11	2	1.12	1500	95
■	68	92	2	12	6	2.02	1935	143	68	90	0	10	2	1.80	216*	19*
10	86	83	9	19	9	2.28	1617	218	88	78	8	16	5	1.55	2258	322
11	68	100	10	21	11	2.64	1555	172	70	83	4	9	5	2.67	1389	0
12	65	75	4	10	6	2.92	1054	98.2	88	76	2	6	2	2.56	101*	13*
13	74	88	11	26	17	3.94	1635	177	55	88	7	21	10	3.03	1134	145
Mean	68.6	91	5.9	16	8.6	2.68	1419	138	68.4	74.3	2.6	10.2	3.3	2.31	1457	13*
SD ±	7.6	8.6	2.4	4.2	3.2	0.58	260	61.6	9.5	6.2	2.6	4.3	2.5	0.6*	416	58.9

* = Change not significant from control values

* = Change significantly different from control values ($p < .001$)†HR = heart rate (beats/min) MAP = mean arterial pressure in mm Hg CVP = central venous pressure PA = mean pulmonary artery pressure PAW = pulmonary arterial wedge pressure CI = cardiac index SVR = systemic vascular resistance PVR = pulmonary vascular resistance (dynes/cm²)

Table III Unpremedicated patients

Case No	Control data			Data 10 minutes after nitroglycerin		
	pH	PCO ₂	PO ₂	pH	PCO ₂ *	PO ₂ *
1	7.44	36	90	7.40	44.5	69
2	7.40	42.5	80	7.40	41	64
3	7.40	30	91	7.40	31	70
4	7.43	34	77	7.45	35	67
■	7.39	39	70	7.44	36	64
■	7.45	30	86	7.42	35	74
7	7.48	37.1	69	7.46	35.5	58
8	7.43	35	62	7.44	36	49
Mean	7.43	35.4	78.1	7.43	37	64
SD ±	0.3	4.3	10	0.2	4.1	8.0

Change not significant from control values

Change significantly different from control values ($p < .001$)

several theoretical studies^{2,3} suggest that the observed decrease in cardiac output could account for the fall in PaO₂. However, to the best of our knowledge there is no experimental evidence to support these theories. Further studies will obviously be necessary.

Several clinical implications can be derived from these findings.

1 A fall in PaO₂ could conceivably explain

inadequate pain relief experienced by some patients after taking nitroglycerin, i.e. despite the decrease in wall tension produced by nitroglycerin, myocardial hypoxia may still result from a decrease in available oxygen. A trial with high inspired oxygen concentrations along with nitroglycerin would seem indicated in such patients. Pertinent to this, two patients experienced anginal pain before induction of anesthesia that was still present 10 minutes after 0.6 mgm sublingual nitroglycerin. One hundred per cent oxygen was then started and complete relief occurred within five minutes. ST segment depression occurred in one of these patients and remained so after nitroglycerin but returned to base line after five minutes of 100 per cent oxygen (Fig 1). Although this strongly suggests that 100 per cent oxygen was helpful to these patients it is also possible that spontaneous resolution of the process could have occurred during the time oxygen was being administered.

2 This study lends support to the use of high inspired oxygen concentrations when narcotics and nitroglycerin are used in combination for the treatment of anginal pain.

3 When preoperative narcotic medications are given to patients with severe coronary artery

disease some form of oxygen therapy should probably be started shortly after their administration

4 Rarely patients with coronary artery disease appear to have a paradoxical response to nitroglycerin: the nitrate causes ST segment changes and an increase in anginal pain. It has been postulated but not demonstrated angiographically that the vasodilators may further diminish blood flow to ischemic myocardium (coronary steal syndrome)*. In attempting to define the mechanisms of myocardial ischemia attributed to coronary steal syndrome we suggest that a decreased availability of oxygen initiated by nitroglycerin should also be considered. It would be of interest to measure PaO_2 before and after nitroglycerin in these patients and to see if 100 per cent oxygen is beneficial.

Summary

The effect of nitroglycerin on arterial blood gases and cardiovascular hemodynamics were studied in patients with coronary artery disease.

In 13 premedicated patients blood gases and cardiovascular hemodynamics were studied before and 10 minutes after sublingual nitroglycerin (0.6 mg). In eight unpremedicated patients only blood gases were determined before and 10 minutes after sublingual nitroglycerin 0.6 mg. All studies were performed before induction of anesthesia with the patients in the supine position breathing room air.

In both groups arterial PO_2 decreased significantly ($p < 0.001$). pH and pCO_2 did not change. In the 13 patients on which hemodynamic studies were performed the mean arterial pressure

($p < 0.001$) cardiac index ($p < 0.001$) central venous pressure ($p < 0.001$) pulmonary artery ($p < 0.001$) and pulmonary artery wedge pressure ($p < 0.001$) decreased. Calculated values for systemic and pulmonary vascular resistance were not significantly altered ($p > 0.4$). This study gives conclusive evidence that nitroglycerin reduces arterial PO_2 in most patients with coronary artery disease breathing room air in the supine position. The possible mechanisms and clinical implications are discussed.

We thank Miss Dorothy Hollander for technical assistance and Mrs. Mary Rogers for preparation of the manuscript.

REFERENCES

1. Dickerson M. Vasodilator drugs. In: The pharmacological basis of therapeutics, edited by Goodman L. S. and Gilman A. H. New York, 1967. The Macmillan Company, p. 740.
2. Burton A. C. The relation between pressure and flow in the pulmonary bed. In: Pulmonary circulation, edited by Adams W. and Veith J. New York, 1959. Grune & Stratton Inc., p. 26.
3. West, J. B. Ventilation-perfusion inequality and overall gas exchange in computer models of the lung. *Respir. Physiol.* 7: 64, 1969.
4. Marshall B. E. and Wyche M. Q. Hypoxemia during and after anesthesia. *Anesthesiology* 37: 178, 1977.
5. Keinan G. R., Nunn J. F., Prys Roberts C. and Greenbaum R. The influence of cardiac output on arterial oxygenation: a theoretical study. *Br J Anaesth.* 39: 450, 1967.
6. Katush A. A. and Gregg D. E. Some determinants of coronary collateral blood flow in the open-chest dog. *Circ. Res.* 7: 6-8, 1959.
7. Rowe G. Inequalities of myocardial perfusion in coronary artery disease (coronary steal). *Circulation* 42: 193, 1970.
8. Forman R. Kirk J. M., Downey J. M. et al. Nitroglycerin and heterogeneity of myocardial blood flow: reduced subendocardial blood flow and ventricular contractile force. *J. Clin. Invest.* 52: 905, 1973.

Table II Hemodynamic data before and 10 minutes after nitroglycerin

Case No	Control data								Data 10 minutes after NTG							
	HR†	MAP	CVP	PA	PAW	CI	SVR	PVR	HR*	MAP	CVP*	PA*	PAW	CI**	SVR	PVR
1	72	103	5	18	12	2.59	1504	93	75	70	1	10	5	2.13	1.04	94
2	60	89	4	14	6	3.27	1066	100	63	80	0	8	1	2.88	1.73	77
3	58	90	4	14	5	2.76	1081	138	65	70	0	9	1	2.6*	9.8	106
4	75	98	6	15	10	2.85	1226	54	80	80	1	6	3	2.51	1194	46
5	58	94	6	12	7	1.85	1660	94	60	81	1	8	2	1.79	1584	8
6	72	102	4	16	8	3.04	1354	221	78	72	2	12	3	2.67	1100	141
7	69	91	6	16	8	2.36	1510	142	60	76	4	11	2	1.91	1641	20
8	68	78	6	16	8	1.87	1264	171	60	88	4	11	2	1.1*	1500	96
9	68	92	2	12	6	2.02	1935	143	68	90	0	10	1	1.80	116*	199
10	86	83	9	19	9	2.28	1617	218	88	78	8	16	6	1.55	2258	322
11	68	100	10	21	11	2.64	1555	172	70	83	4	9	5	2.6*	1389	0
12	65	75	4	10	6	2.92	1054	98.2	68	76	2	6	2	2.56	101*	13*
13	74	88	11	26	17	3.94	1635	177	55	88	7	21	10	3.03	1134	145
Mean	68.6	91	5.9	16	8.6	2.68	1419	138	68.4	74.3	2.6	10.2	3.3	2.31	145*	13*
SD ±	7.6	8.6	2.4	4.2	3.2	0.58	260	51.6	9.5	6.2	2.6	4.3	2.5	0.62	416	69.9

* = Change not significant from control values

* = Change significantly different from control values ($p < .001$)

†HR = heart rate (beats/min) MAP = mean arterial pressure in mm Hg CVP = central venous pressure PA = mean pulmonary artery pressure PAW = pulmonary arterial wedge pressure CI = cardiac index SVR = systemic vascular resistance PVR = pulmonary vascular resistance (dynes/cm²)

Table III Unpremedicated patients

Case No	Control data			Data 10 minutes after nitroglycerin		
	pH	PCO	PO	pH*	PCO*	PO**
1	7.44	36	90	7.40	44.5	69
2	7.40	42.5	80	7.40	41	64
3	7.40	30	91	7.40	31	70
4	7.43	34	77	7.45	35	67
5	7.39	39	70	7.44	36	64
6	7.45	30	86	7.42	35	74
7	7.48	37.1	69	7.46	35.5	58
8	7.43	35	88	7.44	36	49
Mean	7.43	35.4	78.1	7.43	37	64
SD ±	0.3	4.3	10	0.2	4.1	8.0

* Change not significant from control values

* Change significantly different from control values ($p < .001$)

several theoretical studies^{3,4} suggest that the observed decrease in cardiac output could account for the fall in PaO₂. However, to the best of our knowledge there is no experimental evidence to support these theories. Further studies will obviously be necessary.

Several clinical implications can be derived from these findings.

1 A fall in PaO₂ could conceivably explain

inadequate pain relief experienced by some patients after taking nitroglycerin, i.e. despite the decrease in wall tension produced by nitroglycerin myocardial hypoxia may still result from a decrease in available oxygen. A trial with high inspired oxygen concentrations along with nitroglycerin, would seem indicated in such patients. Pertinent to this two patients experienced anginal pain before induction of anesthesia that was still present 10 minutes after 0.6 mgm sublingual nitroglycerin. One hundred per cent oxygen was then started and complete relief occurred within five minutes. ST segment depression occurred in one of these patients and remained so after nitroglycerin, but returned to base line after five minutes of 100 per cent oxygen (Fig 1). Although this strongly suggests that 100 per cent oxygen was helpful to these patients, it is also possible that spontaneous resolution of the process could have occurred during the time oxygen was being administered.

2 This study lends support to the use of high inspired oxygen concentrations when narcotics and nitroglycerin are used in combination for the treatment of anginal pain.

3 When preoperative narcotic medications are given to patients with severe coronary artery




Fig 1 Echocardiogram (A) and line drawing (B) showing a porcine heterograft valve in the mitral position. Note the faint echoes from the valve leaflets within the heavier stent echoes. ED = external stent diameter. ID = internal stent diameter. EX = total leaflet excursion. AL = anterior leaflet. PL = posterior leaflet. RV wall = right ventricular wall. IVS = echoes from the area of the interventricular septum. P wall = posterior left ventricular wall.

fourth intercostal space at the left sternal border superomedial angulation recorded the left atrium and the aorta and the porcine heterograft valve stent and leaflets in the aortic position. The inferolateral angulation normally used to record the mitral valve produced echoes from the porcine heterograft stent and leaflets in the mitral position with the interventricular septum anteriorly and posterior left ventricular wall or left atrium posterior to the prosthetic valve. High gain and low reject settings were often needed to bring out the faint echoes of the valve leaflets. In some cases placement of the transducer farther from the left sternal border was helpful in recording leaflet echoes.

Measurements for porcine heterograft valve in mitral position. The external stent diameter (ED) was measured as the distance between the outer echoes of the anterior and posterior stent (Fig. 1). The internal stent diameter (ID) was measured from the posterior echoes of the anterior stent to the anterior echoes of the posterior stent. These diameters were recorded at their maximum valve. The ratio of the internal to external stent diameter was then calculated. The DE excursion of the anterior leaflet was measured in all cases. In

cases where a posterior leaflet could be recorded the posterior leaflet excursion and total leaflet opening were measured.

The initial posterior diastolic slope of the anterior valve stent was measured in all cases (Fig. 2). The diastolic (EF) slope of the valve leaflets was in most cases identical to that of the stent (Fig. 1) but occasionally was faster (Fig. 2) and was recorded in all cases. When the EF slope varied due to atrial fibrillation or due to transducer angle the fastest slope was measured. The left ventricular outflow tract was measured at end systole just prior to posterior motion of the valve stent.

Measurements of the heterograft in the aortic position. The external and internal stent diameters were measured and the ratio was determined in the same manner as heterografts in the mitral position (Fig. 3). The maximal excursion of the anterior and posterior leaflets was measured in all patients.

Results

Heterograft valves in the mitral position. Auscultatory findings did not correlate with postoperative class time post surgery or valve

Echocardiographic evaluation of porcine heterograft valves in the mitral and aortic positions

William E Harston Jr MD

Rose M Robertson, MD

Gotthieb C Friesinger MD

Nashville Tenn

Porcine aortic valves, mounted on a flexible stent¹ and preserved with glutaraldehyde, are being used in increasing numbers for valve replacement in both the mitral and aortic position, with good results over a follow up period that now extends to seven years.² The low incidence of emboli even without anticoagulation, has been the major advantage over conventional replacements. However prosthetic stenosis due to thrombus formation has been reported,³⁻¹⁰ and significant gradients have been found at postoperative catheterization.⁷⁻⁸ A small percentage of earlier models of the porcine heterograft valves have shown tissue degeneration with cusp perforation⁴ and early, though minor pathologic changes have been seen in the presently available device.¹⁰ For this reason, non invasive assessment of this prosthesis is important and echocardiographic studies of 31 patients have previously been described¹¹⁻¹³ all with valves in the mitral position. No correlative catheterization and echocardiographic study is available. We have studied the echocardiograms in 15 additional patients as well as in seven patients with valves in the aortic position and present our results combined with those previously reported, in an attempt to provide criteria for the range of movement of normally functioning valves. In addition postoperative catheterization

studies in three of these patients are presented and their implications are discussed

Materials and methods

Of 36 patients who underwent valve replacement with porcine heterograft valves at the Vanderbilt University Hospital or Nashville Veterans Administration Hospital from Jan 29 1975 to Jan 28 1976 21 were available for echocardiographic study and clinical examination one to 19 months after surgery and comprise the study population. Additional patients were contacted by telephone to determine if our study population was similar to the total group. Fifteen patients had mitral valve replacement and seven had aortic valve replacement one having both. The average age of patients with mitral replacement was 45 years (range 19 to 67 years) and the patients with aortic valve replacement had an average age of 43 years (range 19 to 67 years). Clinical data are presented in Tables I and II. These patients are not representative of the total operated group because of three in whom the clinical status prompted re catheterization. However those not catheterized were representative of the total group as far as could be determined by telephone conversation with the patients and their physicians. Clinical data on the entire group are available on request.

Echocardiograms were performed with an Ekoline 20 ultrasonoscope using a 2.25 mega Hertz 13 mm nonfocused transducer with a repetition rate of 1 000 cycles per second. Recordings were made on a Cambridge strip chart recorder. With the transducer in the third or

From the Division of Cardiology Department of Medicine Vanderbilt Medical School and the Nashville Veterans Hospital, Nashville Tenn

Received for publication Sept. 20 1977

Accepted for publication Nov 11 1977

Reprint requests: William E Harston Jr MD Nashville Veterans Hospital 1310 24th Ave South Nashville Tenn 37203




Fig 3 Echocardiogram (A) and line drawing (B) of a porcine heterograft valve in the aortic position. Note the excess echoes within the valve stent emanating from the muscular leaflet of the heterograft and giving the appearance of valve deformity. Abbreviations as in Figs 1 and 2

Table 1 Patients with mitral valve replacement

Pt	Age Sex	Length of follow up (months)	Diagnosis	Status preop†	Status postop†	Anti coagulation	Comments
JL	56F	19	MS‡	III	II		
AP	52M	11	MS	III	I	+	1 month after study died of paratracheal bleed secondary to over anticoagulation
CW	41M	12	MR 2 paravalvular leak	IV	II		Bjork Shiley mitral valve replaced for mitral regurgitation
RD	32M	16	MR/AR	IV	II		Both aortic valve and mitral valve replaced with porcine valves
EC	57F	12	MS/AS	IV	II	+	Bjork Shiley put in aortic position
CJ	49M	5	MS/MR/AS	IV	I	+	Bjork-Shiley put in aortic position
NG	27F	13	Wada mitral valve	II	II		Wada valve replaced prophylactically
CR	65M	1	MS	IV	II	+	S/P aortic valve replacement with Starr Edwards valve
PD	67M	12	MR 2 IHD	IV	II		
RB	19F	7	MR	III	I		
IH	50F	5	MS	III	I		
KG	45M	9	MR	IV	II	+	Left atrial thrombus at operation
ML	45F	13	MR 2 IHD	IV	I	+	S/P ASD repair persistent atrial arrhythmias
JL	37M	14	MR	III	I		Coronary artery bypass to LAD and RCA
RR	45M	3	MR	III	I	+	Starr Edwards mitral valve replaced because of mitral regurgitation
							Ruptured chordae

— patient undergoing post operative catheterization

† — by NYHA Classification

‡ Abbreviations: MR = mitral regurgitation MS = mitral stenosis AR = aortic regurgitation AS = aortic stenosis IHD = ischemic heart disease
 AVR = aortic valve replacement MVR = mitral valve replacement ASD = atrial septal defect




Fig 2 Echocardiogram (A) and drawing with labels (B) of a porcine heterograft valve in the mitral position Note excessive echoes in vicinity of valve leaflets in second and fourth cardiac cycles Phono = phonocardiogram ECG = electrocardiogram RV wall = right ventricular wall Apex CG = apexcardiogram IVS = interventricular septum AL = anterior leaflet

size A diastolic rumble was frequently heard, occasionally after a soft opening sound Strong echoes from the valve stents were easily recorded in all patients The anterior and posterior stent move in parallel with anterior movement during systole and posterior movement during diastole The external stent diameter agreed with the known valve size within 2 mm in all patients As shown in Figs 1 and 2 the weaker echoes of the valve leaflets are seen between the stent echoes There is abrupt opening of the leaflets at the beginning of diastole with a very rapid opening slope (DE Fig 2) The valve leaflets (leaflet EF Fig 2) and stent (stent EF Fig 2) move posteriorly early in diastole as does the native mitral valve, with the leaflets usually remaining open throughout diastole and closing abruptly at the onset of systole (AC, Fig 2) The diastolic posterior movement (EF slope) of the anterior valve leaflet is parallel to the stent movement (Fig 1) and is within the range of EF slopes seen in mitral stenosis Leaflet opening is asymmetrical with the anterior leaflet having a greater excursion This is consistent with the surgical practice of placing the valve so that the larger leaflet is

parallel to the interventricular septum Anterior leaflet opening was recorded in all patients but the posterior leaflet could be recorded in only 19 of 15 patients Total leaflet opening could thus be measured only in these 12 An 'a' wave or the fluttering motion seen in native valves in the presence of atrial flutter or fibrillation was inconsistently seen (See last complex in Fig 1) Excessive echoes from the vicinity of the valve leaflets were often recorded with higher gain settings and varying transducer position (compare second and third complexes in Fig 2) Paradoxical septal motion was noted in six of 16 patients recorded below the mitral valve prosthesis Table III details these results and compares them with those in the literature

Heterograft valves in aortic position Measured external stent diameter, (ED Fig 3) agreed within 2 mm to the manufacturer's valve size Internal stent diameter (ID Fig 3) averaged 19.8 mm and the mean calculated ratio of internal to external stent diameter was 0.75 with a range of 0.71 to 0.80 The valve leaflets open abruptly in systole, remain open during systole with a gradual anterior movement in parallel with the

Table IV Echocardiographic measurements of porcine heterograft valves in the aortic position

Patient	Valve Size	Stent diameter by echo (mm)			Septal motion	Leaflet excursion (mm)		
		External	Internal	Int/Ext		Anterior	Posterior	Total
JF	25	27	20	0.74	N	9	9	18
ID	25	25	20	0.80	N	8	8	16
JJ	27	26	20	0.77	N	8	6	14
RB	27	27	20	0.74	P	8	9	17
BT	27	28	0	0.71	P	8	8	16
AS	27	27	19	0.76	P	10	8	16
Mean of normals			19.8	0.75		8.2	8	16
Range	25-27	25-28		0.71-0.80		8-10	6-9	14-18
RD	23	23	16	0.70	N	7	7	14

= patient evaluated by postoperative catheterization

Abbreviations: Int/Ext = ratio of internal diameter to external diameter; N = normal septal motion; P = paradoxical septal motion.

valve stent and abruptly close at the end of systole. Anterior and posterior leaflet (AL and PL, Fig 3) opening was usually symmetrical and in some patients a central nonmoving leaflet was recorded. In those patients in whom valve opening was asymmetrical either the anterior or posterior leaflet might open to a greater degree consistent with the surgical practice of varying alignment of the prosthesis. The total valve excursion (EX, Fig 3) averaged 16 mm with a range of 14 to 18 mm, slightly less than normal native aortic valve opening. Excess echoes were seen within the stent in all patients but were variably placed anteriorly or posteriorly. Values for individual patients and the mean values and range for the group are shown in Table IV.

Hemodynamic correlation. Three patients underwent postoperative cardiac catheterization and the results are presented in Table V.

Patient N G presented in 1970 with severe mitral regurgitation and heart failure. She underwent mitral valve replacement with a Wada prosthesis and improved to Class I status. Because of reports of occluder embolization with the Wada valve, it was elected to prophylactically replace this with a porcine heterograft because of her excellent clinical status. No preoperative catheterization was performed. After surgery she developed dyspnea on moderate exertion and fatigue and was catheterized twelve months after surgery, one month prior to her echocardiographic study. Her cardiac index was depressed at 2.4 and there was mild to moderate prosthetic stenosis with a left atrial-left ventricular diastolic gradient of 8 and a calculated valve area of 1.4

square centimeters. The gradient rose to 15 with exercise with no rise in the LVDP. Echocardiographically her valve measurements were all within the previously and presently reported range of normal. She did, however, have the slowest stent and anterior leaflet slope that we have seen although no slower than one clinically normal patient seen by Bloch and colleagues.¹²

Patient C W had mitral valve replacement in 1972 for mixed mitral disease but tissue overgrowth caused prosthetic stenosis and he had a second mitral valve replacement in 1973. Although he was improved for several years, increasing congestive failure developed in 1975 and a paravalvular leak with severe mitral regurgitation was found. After porcine valve replacement he continued to have dyspnea on strenuous exertion. Restudy showed only mild prosthetic stenosis. The mean gradient was 9, the end-diastolic gradient was only 3, the valve area 1.8 square centimeters, and the cardiac index is slightly depressed at 2.6 but doubling with moderate exercise. On echocardiographic study all parameters were well within the range of normal. Pulmonary function tests showed a moderately severe restrictive defect and his symptoms were thought to be primarily due to pulmonary disease.

Patient R D had both mitral and aortic valves replaced for severe aortic regurgitation with coexisting mitral regurgitation thought due to massive left ventricular dilatation. He did very well postoperatively with dyspnea only on extreme exertion but because of a loud persistent systolic murmur was recatheterized. His

Table II Patients with aortic valve replacement

Pt	Age Sex	Length of follow up (Months)	Diagnosis	Status preop†	Status postop†	Anti coagulation	Comments
RD*	32M	19	AR/MR†	IV	II	°	MVR as well with porcine valve
JJ	40M	15	AR	III	I	°	
JF	25F	11	AR	III	I	°	
RB	53M	11	AR	II	I	°	
PD	19M	2	Bjork Shiley AV with AR	IV	I	°	
BT	66M	9	AR	IV	I	°	
AS	67F	17	AS	II	I	°	

* ~ patients undergoing postoperation catheterizations

† Abbreviations AR = aortic regurgitation MR = mitral regurgitation MVR = mitral valve replacement AS = aortic stenosis

Table III Echocardiographic measurements of porcine heterograft valves in the mitral position Present study and review of the literature

Patient	Valve size (mm)	Stent diameter by echo (mm)			Septal motion	LVOT (cm)	Diastolic slope (mm/sec)		Leaflet excursion (mm)		
		External	Internal	Int/Ext†			Stent	Anterior leaflet	Anterior	Posterior	Total
JI	27	28	21	0.75	N	1.5	24	46	11	8	19
AP	27	26	17	0.65	N	2.0	24	24	13	2	15
CW*	27	28	19	0.68	N	1.2	39	39	10	2	11
RD*	27	25	17	0.68	N	0.9	40	40	8	—	—
EC	29	28	17	0.61	P	1.8	13	13	11	4	15
CJ	29	27	17	0.63	P	2.5	20	20	10	—	—
NG*	29	29	18	0.62	N	0.8	11	11	12	4	16
CR	29	28	18	0.64	N	2.0	22	22	10	—	—
PD	31	31	20	0.65	N	2.3	24	32	10	5	15
RB	31	29	19	0.66	N	1.2	20	20	11	4	15
IH	31	30	18	0.60	P	0.7	23	23	12	3	15
KG	31	32	24	0.75	P	1.0	20	30	12	4	16
ML	31	30	17	0.57	P	2.1	24	44	13	3	16
JL	33	33	22	0.67	P	1.2	20	27	14	2	16
RR	33	32	20	0.73	N	1.6	25	25	9	4	13
Mean of present study (range)	(27-33)	(25-33)	19	0.66		1.5	23.3	27.9	11	4	15
No of pts = 15			(17-24)	(0.57-0.75)		(0.7-2.6)	(11-40)	(11-46)	(8-14)	(2-8)	(11-19)
Horowitz et al.	(27-35)	(28-36)	20	0.66	P = 7	1.2	24				15
No of pts = 20			(17-24)	(0.56-0.74)	N = 3	(0.5-2.2)	(19-33)				(10-21)
					A = 6						
					T = 4						
Bloch et al.	(27-31)	(19-30)	20	0.77			21.5	19			11
No of pts = 10			(16-24)	(0.60-0.84)			(11-59)	(9-38)			(10-14)
								N = 9			N = 6
Bloch 1 pt with thrombus	36	indefinite	21				26				
Mean of normals (range)	(27-33)	(19-36)	20	0.69		1.4	23.4	24.5			14.5
			(17-24)	(0.50-0.84)		(0.5-2.5)	(11-59)	(9-46)			(10-21)

patients evaluated by postoperative catheterization

† Abbreviations Int/Ext = ratio of internal diameter to external diameter N = normal septal motion P = paradoxical septal motion A = abnormal septal motion T = technically inadequate LVOT = left ventricular outflow tract at end-systole

with tissue mitral prostheses has not been found to correlate with calculated valve areas or diastolic gradients and we concur in this finding. A tapping sound is also heard in some of these patients again seemingly without hemodynamic significance.

Reports of structural changes even in clinically satisfactory valves with inflammatory cells lining the leaflets, fibrin thrombus, giant cell invasion with focal disruption of collagen¹ and calcium deposition as well as sporadic cases of thrombus causing prosthetic stenosis² make noninvasive evaluation of these valves desirable. Also postoperative hemodynamic evaluation has shown mitral valve gradients ranging from 0 to 32 mm Hg with calculated valve areas from 0.64 to 3.4 cm²^{3,4} and mean aortic valve gradients from 0 to 53 mm Hg with valve areas from 0.49 to 1.9 square centimeters.^{5,6} However, these cases have not been evaluated noninvasively.

Echocardiography has proven useful in the diagnosis of some instances of mechanical prosthetic valve dysfunction⁷ but has generally been considered only an adjunct to auscultation and phonocardiography in detecting ball variance or thrombus formation. However, since auscultatory phenomena have been less helpful with the tissue valves, echocardiographic visualization of the valve leaflets themselves might have a more important role, especially if it can detect early stiffening or calcification. If those hemodynamic factors that alter native valve motion affect prosthetic tissue leaflets in the same manner, function as well as anatomy could be evaluated. Demonstrated abnormalities in fascia lata prostheses,⁸ homografts,⁹ and in one porcine heterograft support the role of echocardiography. However, only small series of normally functioning heterografts evaluated by echocardiography have been reported, making it difficult to be certain if a particular valve's motion is normal. The present series confirms the studies of normal valves by Bloch and associates¹⁰ and Horowitz and colleagues,¹¹ adding sufficient numbers to present a meaningful range of normal values for stent and leaflet motion in the mitral prosthesis and preliminary data for valves in the aortic position. We have also added three cases in which catheterization data can be compared to echocardiographic parameters.

Heterograft prostheses in the mitral position

It is not difficult to record echoes from the stent of the heterograft prostheses. The external diameter of the ring is quite accurately estimated despite the potential for being misled by reverberations from this echodense structure. The ratio of internal to external diameter has been suggested as a guide to detecting thrombosis or fibrosis compromising the valve orifice, and our values for this agree with those of other investigators. However, the internal diameter per se is more direct estimate of orifice size, varies considerably, and does not correspond well to valve size as can be seen from the wide range of measurements we and others have found. This suggests that this value and the ratio may be of use only if a change from a previous study is demonstrated.

We found that an anterior valve leaflet could be visualized in all patients, although multiple attempts were required in several patients early in the study. With practice, the last patients could be echoed in no more time than required for a usual clinical echocardiogram. We would agree with Bloch and associates¹⁰ that a valve whose anterior leaflet cannot be recorded should be suspected of dysfunction if other cardiac structures can be recorded clearly. However, an anterior leaflet that can be recorded does not exclude moderate obstruction to flow, as our correlations with catheterization data revealed. Also, as the porcine aortic valve has some muscular tissue in one of its leaflets, the presence of excess echoes in the mitral valve area are less suggestive of a thickened valve or valvular vegetations than they would be in the native valve (see Fig. 2).

Prosthetic leaflet excursion is less than that of the native mitral valve since the leaflets are shorter. Usually the total leaflet excursion falls within the range of normal aortic valve opening with conditions of low flow *in vitro*, sequential and incomplete valve opening may be seen¹² and this may contribute to the decreased excursion in some. If discrete leaflets are seen, values for total excursion that fall below the range presented here suggest a diminished cardiac output. As the DE and AC slopes of native valves may vary with alterations in left ventricular diastolic pressures, these were of interest, but we found them difficult to measure reproducibly because of the short excursion and excess echoes between the stents. The EF slope was not difficult to determine since this slope is slowed in rheumatic mitral

Table V Postoperative hemodynamic data in three patients with porcine heterograft valves

Patient	Time of cath	Catheterization data				CO/CI	MG (mean)	AG (mean & peak)	MVA (cm ²)	AVA (cm ²)	Comments
		PA†	LA or PCW	LV	Ao						
N G	1970	Left ventricular angiography only showing severe mitral regurgitation in critically ill patient									
	12 mos post op	42/18	v = 22 mean = 16	150/0 12	150/95	3.7/2.4	8	11	1.4		Wada mitral valve replacement in 1971. Class I pre-op in 1975, had elective valve replacement and not re-catheterized.
C W	pre op	60/22	v = 50 mean = 30	90/0 12	90/50	1.9/1.0	16		≥ 5		Severe mitral regurgitation.
	8 mos post op	33/12	a = 15 mean = 13 v = 17 mean = 30	125/0 10	125/70	4.9/2.6	11		1.8		No mitral regurgitation. Cardiac output rose to 8.4 l/min with exercise.
R D	pre op	85/48	v = 36 mean = 15	170/0 28	120/67	2.2/1.2	0	25	52	0.35	Severe aortic regurgitation and moderate mitral regurgitation.
	9 mos post op	33/14	v = 17 mean = 10	145/0 10	95/70	7.2/3.9	0	42	50	1.2	No mitral or aortic regurgitation.

All pressures are expressed in mm Hg

†Abbreviations PA = pulmonary artery LA or PCW = left atrium or pulmonary capillary wedge LV = left ventricle Ao = aorta CO = cardiac output/cardiac index MG = mitral gradient AG = aortic gradient MVA = mitral valve area AVA = aortic valve area

mitral prosthesis was functioning well, with no diastolic gradient but the aortic valve a size 23 (the smallest in this series), had a gradient and reduced valve area. The cardiac output and index were normal despite this. The aortic valve leaflets opened rapidly by echocardiographic study but were at the low end of the range of our normal valves. This valve had the smallest internal diameter and internal to external diameter ratio we have seen. His mitral prosthesis had a diastolic slope in the normal range but the lowest anterior leaflet excursion.

Due to the small number of patients no definite conclusions can be reached but the data suggest a relationship between the calculated mitral valve area and the diastolic slope of the stent. Diastolic E/F slopes were faster in the two patients with either no gradient or a large valve area and slowest in the patient with the smallest valve area. None of these patients was sufficiently symptomatic to require reoperation so we have

no pathological data regarding the status of these valves.

Discussion

Porcine heterograft valves have several advantages over mechanical prosthetic valves. The reported rate of thromboembolism without anticoagulation over long term follow up of 11 to 14 years has generally ranged from 0.2 to 0.4 per cent per patient year, with most emboli occurring in the first 3 months usually in patients with atrial fibrillation. Most institutions at present anticoagulate only patients with atrial fibrillation and even then for a limited period usually 3 months. Significant hemolysis has not been reported. No externally audible valve sounds make this prosthesis highly acceptable to patients and physicians but the lack of mechanical opening and closing clicks has made clinical evaluation more difficult.

The presence of a diastolic rumble in patients

h tissue mitral prostheses has not been found to correlate with calculated valve areas or diastolic gradients⁸ and we concur in this finding. An opening sound is also heard in some of these patients again seemingly without hemodynamic significance.

Reports of structural changes even in clinically satisfactory valves with inflammatory cells lining the leaflets, fibrin thrombus, giant cell invasion with focal disruption of collagen¹⁰ and calcium deposition as well as sporadic cases of thrombus causing prosthetic stenosis¹¹ make noninvasive evaluation of these valves desirable. Also postoperative hemodynamic evaluation has shown mitral valve gradients ranging from 0 to 32 mm Hg with calculated valve areas from 0.64 to 1.4 cm²^{12,13} and mean aortic valve gradients from 0 to 83 mm Hg with valve areas from 0.49 to 1.1 square centimeters.¹² However, these cases have not been evaluated noninvasively.

Echocardiography has proven useful in the diagnosis of some instances of mechanical prosthetic valve dysfunction¹⁴ but has generally been considered only an adjunct to auscultation and phonocardiography in detecting ball variance or thrombus formation. However, since auscultatory phenomena have been less helpful with the tissue valves, echocardiographic visualization of the valve leaflets themselves might have a more important role, especially if it can detect early stiffening or calcification. If those hemodynamic factors that alter native valve motion affect prosthetic tissue leaflets in the same manner, function as well as anatomy could be evaluated. Demonstrated abnormalities in fascia lata prostheses, homografts, and in one porcine heterograft support the role of echocardiography. However, only small series of normally functioning heterografts evaluated by echocardiography have been reported, making it difficult to be certain if a particular valve's motion is normal. The present series confirms the studies of normal values by Bloch and associates¹ and Horowitz and colleagues², adding sufficient numbers to present a meaningful range of normal values for stent and leaflet motion in the mitral prosthesis and preliminary data for valves in the aortic position. We have also added three cases in which catheterization data can be compared to echocardiographic parameters.

Heterograft prostheses in the mitral position

It is not difficult to record echoes from the stent of the heterograft prostheses. The external diameter of the ring is quite accurately estimated despite the potential for being misled by reverberations from this echodense structure. The ratio of internal to external diameter has been suggested as a guide to detecting thrombosis or fibrosis compromising the valve orifice, and our values for this agree with those of other investigators. However, the internal diameter per se is a more direct estimate of orifice size, varies considerably, and does not correspond well to valve size as can be seen from the wide range of measurements we and others have found. This suggests that this value and the ratio may be of use only if a change from a previous study is demonstrated.

We found that an anterior valve leaflet could be visualized in all patients, although multiple attempts were required in several patients early in the study. With practice, the last patients could be echoed in no more time than required for a usual clinical echocardiogram. We would agree with Bloch and associates¹ that a valve whose anterior leaflet cannot be recorded should be suspected of dysfunction if other cardiac structures can be recorded clearly. However, an anterior leaflet that can be recorded does not exclude moderate obstruction to flow, as our correlations with catheterization data revealed. Also, as the porcine aortic valve has some muscular tissue in one of its leaflets, the presence of excess echoes in the mitral valve area are less suggestive of a thickened valve or valvular vegetations than they would be in the native valve (see Fig. 2).

Prosthetic leaflet excursion is less than that of the native mitral valve, since the leaflets are shorter. Usually, the total leaflet excursion falls within the range of normal aortic valve opening with conditions of low flow *in vitro*; sequential and incomplete valve opening may be seen¹⁵ and this may contribute to the decreased excursion in some. If discrete leaflets are seen, values for total excursion that fall below the range presented here suggest a diminished cardiac output. As the D/E and A/C slopes of native valves may vary with alterations in left ventricular diastolic pressures, these were of interest, but we found them difficult to measure reproducibly because of the short excursion and excess echoes between the stents.

The E/F slope was not difficult to determine, since this slope is slowed in rheumatic mitral

stenosis one would expect that the heterograft leaflet also would remain open in diastole if there was obstruction to flow. This should be true whether the obstruction resulted from leaflet thickening, fusion and/or calcification, or an orifice compromised by fibrosis or thrombus. It has been demonstrated that anterior leaflet motion closely approximates annulus motion in mitral stenosis,¹¹ and the posterior leaflet in diastole follows the same course. Since the prosthetic stent is attached to the annulus, stent motion is equal to annular motion. Therefore stenotic heterografts might be more likely to have a leaflet E F slope equal to that of the stent, while non stenotic valves would be expected to have a faster E F slope than that of the stent. In one case of surgically documented prosthetic stenosis due to thrombus,¹² the echocardiographic appearance of the valve suggested material within the stent as well as an increased stent excursion, a normal stent E F slope, but no distinguishable anterior leaflet E F slope. With only three catheterized patients, we cannot test this hypothesis with certainty but since all three patients had equal leaflet and stent slopes and two of these three had mild or no obstruction the absence of a faster leaflet E F slope does not necessarily denote stenosis. We found steeper slopes in two patients with mild or no stenosis than in the single case with moderate obstruction. Certainly in native valves the E F slope may be reduced by pathology other than mitral stenosis. The most common causes are conditions that alter left ventricular filling characteristics such as wall hypertrophy secondary to hypertension or aortic stenosis. Further correlations are needed to determine if decreases in slope will parallel the degree of mitral valve obstruction in the absence of left ventricular abnormalities.

Heterograft prostheses in the aortic position

Opening sounds were not heard with the prosthesis in the aortic position but most patients had a systolic ejection murmur of variable intensity. With persistence recording of the prosthetic stent and both anterior and posterior valve leaflets was possible in all patients. This did require 30 to 40 minutes in some patients and this prolonged effort often resulted in only a few measurable complexes.

The muscular leaflet produced excess echos in most patients, if discovered later in a patient's

course, these might be mistaken for vegetations or thickened leaflets, especially if a baseline postoperative echo was not available for comparison.

The total valve opening falls at the lower end of the normal range for native aortic valves with two patients having valve opening less than the lower limit of normal. One of these patients was catheterized and had a significant gradient. As with the mitral valve, a diminished cardiac output will open the valve less, and it may be difficult to differentiate valvular obstruction due to stiffening or calcification of the leaflets from a low output state. The left ventricular echogram may aid in this differentiation, particularly after the early (six months) postoperative period during which paradoxical septal motion will be seen in most patients. In small prostheses, where the obstruction to flow is likely to be at the annular level, demonstration of normally moving leaflets will not establish the absence of a hemodynamically significant gradient as shown in our patient, R D. In the larger valves, where obstruction may be due to tissue ingrowth or leaflet dysfunction, echocardiography should be more helpful, especially if sequential studies are obtained.

Further correlative catheterization-echocardiographic studies should be performed to clarify the hemodynamics of heterograft valve motion and add to our understanding of echocardiographic patterns of stent and leaflet movement. These early studies provide a base for further work and help determine whether baseline and sequential echocardiograms will be of significant assistance in the follow up of patients undergoing valve replacement with porcine heterografts.

Summary

We evaluated 15 porcine heterograft valves in the mitral position and seven in the aortic position by echocardiography. Combining our quantitative description of valve stent and leaflet motion with 31 previously reported cases we suggest echocardiographic criteria for the range of normal porcine heterograft valve motion in the mitral position. Quantitative evaluation of valve leaflet and stent motion for valves in the aortic position is described for the first time. Correlative hemodynamic and echocardiographic data is provided for three patients who underwent po-

operative catheterization. The use of echocardiography in following the function of porcine heterograft valves is discussed.

We gratefully acknowledge the technical assistance of Mr Dan Wheeler in recording the echocardiograms and the secretarial assistance of Ms Thelma Barrett and Ms Billie Rich. We wish to thank Dr Taylor Wray for critical review of the manuscript and illustrations.

REFERENCES

1. Reis R L, Hancock W D, Yarbrough J W, Glancy D L and Morrow A G. The flexible stent. *J Thorac Cardiovasc Surg* 62:683 1971.
2. Zuhdi, N, Hawley W, Voehl, V, Hancock W, Carey J and Greer A. Porcine aortic valves as replacements for human heart valves. *Ann Thorac Surg* 17:479 1974.
3. Horowitz M S, Goodman D J, Fogarty T J and Harrison D C. Mitral valve replacement with the glutaraldehyde preserved porcine heterograft. *J Thorac Cardiovasc Surg* 67:885 1974.
4. Carpenter A, Deloche A, Reiland J, Fabiani, J N, Forman J, Camilleri J P, Soyler R and Dubost C. Six year follow up of glutaraldehyde preserved heterografts. *J Thorac Cardiovasc Surg* 68:771 1974.
5. Johnson A D, Daily P O, Peterson K L, LeWinter M, DiDonna G J, Blair G and Niwayama G. Functional evaluation of the porcine heterograft in the mitral position. *Circulation* 50 and 51 (Suppl. I) 1-40 1977.
6. McIntosh L L, Michaels L L, Morrow A G, Itskovitz S B, Redwood D R and Epstein E E. Atrioventricular valve replacement with the Hancock porcine xenograft. A five year clinical experience. *Surgery* 78:68 1975.
7. Johnson A, Thompson S, Vieweg W V R, Daily P O, Orry J, Tsui, J and Peterson K. *In vivo* function of the stent mounted porcine heterograft in the aortic position (Abstr.) *Circulation* 53 and 54 (Suppl. II) 148 1976.
8. Lurie J, Müller R, Maxwell K, Vismara L A, Hurley E J and Mason D T. Postoperative hemodynamic assessment of the glutaraldehyde preserved porcine heterograft in the aortic and mitral positions (Abstr.) *Circulation* 53 and 54 (Suppl. II) 148 1976.
9. Gallucci V, Ceresa P G, Morel F., Volta F D and Casarotto D. Hancock bioprosthesis: analysis of long term results (6 years) (Abstr.) *Circulation* 53 and 54 (Suppl. II) 149 1976.
10. Spray T L, Arnett E N, Morrow A G and Roberts W C. Structural changes in porcine xenograft cardiac valve bioprostheses (Abstr.) *Circulation* 53 and 54 (Suppl. II) 149 1976.
11. Horowitz M S, Tecklenberg I L, Goodman D J, Harrison D C and Popp R L. Echocardiographic evaluation of the stent mounted aortic bioprosthesis valve in the mitral position. *Circulation* 54:91 1976.
12. Bloch, W N Jr, Felner J M, Wickliffe C, Symbas P N and Schlant R C. Echocardiogram of the porcine aortic bioprosthesis in the mitral position. *Am J Cardiol* 38:293 1976.
13. Brown J W, Myerowitz P D, Cann M S, Colvan S H, McIntosh C L and Morrow A G. Clinical and hemodynamic comparisons of *May Shiley Starr Edwards #690* and Hancock porcine xenograft mitral valves. Presented at the International Cardiovascular and Vascular Surgery Society Meetings, Chicago, Ill. 1974.
14. Horowitz M S, Goodman D J and Popp R L. Echocardiographic diagnosis of calcific stenosis of a stented aortic homograft in the mitral position. *J Clin Ultrasound* 2:179 1974.
15. Mary D A S, Pakrashi B C et al. Echocardiographic studies of stented fascia lata grafts in the mitral position. *Circulation* 49:237 1974.
16. Long J W, Reis R L, Bolton M E, Freeman J A, Polombo R A, Fugh D M, Dunn M I, McIntosh C L and Morrow A G. Clinical and hemodynamic assessments of porcine heterograft prostheses mounted in flexible stents (Abstr.) *Circulation* (Suppl. IV) 75 1973.
17. Feigenbaum H. *Prosthetic valves in Echocardiography*. Philadelphia 1976. Lea and Febiger Publishers.
18. Chalson S A, Siggers D C, Wharton C F P and Deuchar D C. Study of normal and abnormal movements of mitral valve ring using reflected ultrasound. *Br Heart J* 34:490 1972.

stenosis, one would expect that the heterograft leaflet also would remain open in diastole if there was obstruction to flow. This should be true whether the obstruction resulted from leaflet thickening, fusion and/or calcification or an orifice compromised by fibrosis or thrombus. It has been demonstrated that anterior leaflet motion closely approximates annulus motion in mitral stenosis,¹⁸ and the posterior leaflet in diastole follows the same course. Since the prosthetic stent is attached to the annulus, stent motion is equal to annular motion. Therefore, stenotic heterografts might be more likely to have a leaflet E F slope equal to that of the stent, while non stenotic valves would be expected to have a faster E F slope than that of the stent. In one case of surgically documented prosthetic stenosis due to thrombus,¹ the echocardiographic appearance of the valve suggested material within the stent as well as an increased stent excursion, a normal stent E F slope, but no distinguishable anterior leaflet E F slope. With only three catheterized patients, we cannot test this hypothesis with certainty, but since all three patients had equal leaflet and stent slopes and two of these three had mild or no obstruction, the absence of a faster leaflet E F slope does not necessarily denote stenosis. We found steeper slopes in two patients with mild or no stenosis than in the single case with moderate obstruction. Certainly in native valves the E F slope may be reduced by pathology other than mitral stenosis. The most common causes are conditions that alter left ventricular filling characteristics, such as wall hypertrophy secondary to hypertension or aortic stenosis. Further correlations are needed to determine if decreases in slope will parallel the degree of mitral valve obstruction in the absence of left ventricular abnormalities.

Heterograft prostheses in the aortic position
Opening sounds were not heard with the prosthesis in the aortic position but most patients had a systolic ejection murmur of variable intensity. With persistence, recording of the prosthetic stent and both anterior and posterior valve leaflets was possible in all patients. This did require 30 to 40 minutes in some patients and this prolonged effort often resulted in only a few measurable complexes.

The muscular leaflet produced excess echoes in most patients, if discovered later in a patient's

course, these might be mistaken for vegetations, or thickened leaflets, especially if a baseline postoperative echo was not available for comparison.

The total valve opening falls at the lower end of the normal range for native aortic valves with two patients having valve opening less than the lower limit of normal. One of these patients was catheterized and had a significant gradient. As with the mitral valve, a diminished cardiac output will open the valve less and it may be difficult to differentiate valvular obstruction due to stiffening or calcification of the leaflets from a low output state. The left ventricular echogram may aid in this differentiation, particularly after the early (six months) postoperative period during which paradoxical septal motion will be seen in most patients. In small prostheses, where the obstruction to flow is likely to be at the annular level, demonstration of normally moving leaflets will not establish the absence of a hemodynamically significant gradient, as shown in our patient, R D. In the larger valves, where obstruction may be due to tissue ingrowth or leaflet dysfunction, echocardiography should be more helpful, especially if sequential studies are obtained.

Further correlative catheterization-echocardiographic studies should be performed to clarify the hemodynamics of heterograft valve motion and add to our understanding of echocardiographic patterns of stent and leaflet movement. These early studies provide a base for further work and help determine whether baseline and sequential echocardiograms will be of significant assistance in the follow up of patients undergoing valve replacement with porcine heterografts.

Summary

We evaluated 15 porcine heterograft valves in the mitral position and seven in the aortic position by echocardiography. Combining our quantitative description of valve stent and leaflet motion with 31 previously reported cases, we suggest echocardiographic criteria for the range of normal porcine heterograft valve motion in the mitral position. Quantitative evaluation of valve leaflet and stent motion for valves in the aortic position is described for the first time. Correlative hemodynamic and echocardiographic data is provided for three patients who underwent post




Fig 1 Prevalence of coronary disease ($n = 193$) in each patient group ($n = 302$)

downsloping ST segment depression or elevation was required

The following groups of patients were eliminated from the study. Those with valvular heart disease, those on digitalis, and those whose resting ECG showed LBBB or LVH. Patients without exercise-induced chest pain or ischemic ECG abnormalities who did not achieve 85 per cent sub-maximal heart rate during exercise were also excluded.

Coronary cineangiography was performed in all patients usually the day following the stress test but in no instance were the two studies more than two months apart. In each case the decision to do angiography was made prior to the exercise test which was performed as a part of the routine evaluation of these patients. The cineangiograms of each major vessel were reviewed in multiple projections. For the purposes of analysis, coronary artery disease was defined as significant if two or more observers estimated luminal narrowing of a vessel to be greater than 70 per cent.

Exercise test sensitivity was defined as the percentage of patients with documented coronary disease having a positive ECG or chest pain response and specificity was defined as the percentage of patients without coronary disease having a negative ECG or chest pain response. Predictive value was defined as the percentage of patients with a positive ECG or chest pain response who also had coronary disease.

All analyses of data was carried out using the Chi square test.




Fig 2 Prevalence of multivessel coronary disease ($n = 12$) in each patient group with coronary disease ($n = 193$)

Results

Patient groups—general characteristics The patients were divided into four groups. Group I consisted of 85 patients who during exercise testing developed both chest pain and a positive ECG response. Group II consisted of 87 patients who had a negative chest pain response but a positive ECG response. Group III consisted of 25 patients with a positive chest pain response but a negative ECG response. Group IV consisted of 105 patients who were negative for both chest pain and ECG response.

Angiographic correlations The prevalence of coronary disease in each group is shown in Fig 1. Coronary disease was present in 81 of 85 patients (95 per cent) in Group I, 65 of 87 patients (75 per cent) in Group II, 18 of 25 patients (72 per cent) in Group III, and 29 of 105 patients (28 per cent) in Group IV. Thus chest pain alone (i.e. Group III) is as good as ECG changes alone (i.e. Group II) in predicting the presence of coronary disease. Moreover, the concordance of chest pain and ECG response, either positive as in Group I or negative as in Group IV, is more highly predictive of the presence or the absence of coronary disease respectively than either response alone.

To test whether our data would correlate with the extent of coronary disease, the patient groups were also analyzed according to the prevalence of multivessel disease, which was defined as significant luminal narrowing (≥ 70 per cent) in two or more major vessels (Fig 2). Group I was again more highly predictive than either Groups II or III. Groups II and III did not differ significantly.

The predictive value of anginal chest pain as an indicator of coronary disease during exercise testing*

Am Heart J 1978, 96 (4), 458-462

Donald A. Weiner, M.D.
Carolyn McCabe, B.S.
David C. Hueter, M.D.
Thomas J. Ryan, M.D.
William B. Hood, Jr., M.D.
Boston, Mass.

Exercise testing is the traditional non invasive method of evaluating patients with chest pain for the presence of coronary artery disease. The classical response has been measured in terms of ST segment depression alone. Using only that criterion the prevalence of false negative responses varies from 20 to 65 per cent.

It is the purpose of this report to present our experience using anginal chest pain induced by exercise as an additional and independent criterion for a positive exercise response. The goal was to determine if such chest pain would increase the yield of true positive responses and correlate with the extent of coronary disease. To accomplish this objective, exercise test data were reviewed on a group of patients referred for cardiac catheterization who had exercise tests just prior to the catheterization.

Methods

The patient population, who were studied retrospectively consisted of 302 patients who underwent both an exercise test and coronary

angiography at University Hospital in the last four years. The patients were studied because of possible or definite ischemic heart disease. All patients underwent graded exercise on a bicycle ergometer or treadmill the latter using the Bruce protocol. A 12 lead ECG was recorded at rest, at 3 minute intervals during the exercise test and during 10 minutes of recovery. All patients were exercised to an end point consisting of fatigue or chest pain, repetitive ventricular arrhythmias or greater than 4 mm ST segment depression on the electrocardiogram. Patients who developed characteristic anginal chest pain (i.e. substernal pressure-sensation with or without radiation which increased with continuing exercise) during the exercise test were asked to grade it on a scale from 1 to 4, 1 being mild and 4 being severe. The exercise test was stopped if the patient developed either 3+ anginal chest pain alone or 2+ anginal chest pain associated with other clinical evidence of significant ischemia. For the purposes of analysis, a positive chest pain response was defined as anginal chest pain of grade 2 or more severity. Pain which was judged by the exercise physiologist and the physician supervising the test to be musculoskeletal in origin or related to respiratory efforts or which was atypical in character was considered a negative chest pain response. A positive ECG response was defined as the appearance of 1 mm of horizontal or downsloping ST segment depression, or 1 mm of ST segment elevation. If the resting ECG had abnormal ST segments an additional 1 mm of horizontal or

From the Cardiology Departments and the Division of Medicine of the University Hospital and Boston City Hospital, Boston University School of Medicine, Boston, Mass.

Supported by United States Public Health Service Grants HL 14646, NO1 HV 53001, RR 533 and HL-18318.

Received for publication Oct 3, 1977.

Accepted for publication Nov 18, 1977.

Reprint requests: Donald A. Weiner, M.D., Cardiology Dept., Boston City Hospital, 818 Harrison Ave., Boston, Mass. 02118.

Presented in part at the 49th Scientific Sessions of The American Heart Association, November 1976.

and 33 per cent and 65 per cent of patients with neither response. Thus it appears that exercise induced chest pain not only adds to the predictive value of an ischemic ECG response but also by itself predicts coronary disease as accurately as an ischemic ECG response alone.

Conversely the presence of a totally negative response (Group IV) predicted the absence of significant coronary disease in 72 per cent of patients studied. We recognize that due to the selection bias of our sample population consisting of patients referred for cardiac catheterization we have probably overestimated the predictive value of chest pain and an ischemic ECG response as they would apply to the general population.¹³ By the same token we may have underestimated the ability of a doubly negative exercise test to predict the probability of the absence of significant coronary disease.

The sensitivity of the exercise test varies with the type of stress test employed and the criterion used for an ischemic ST segment response ranging between 35 and 80 per cent.¹ By using computers to measure an ST segment index¹ and by including the criterion of a slowly upsloping ST segment depression¹⁴ it is possible to increase the sensitivity of the stress test although the specificity may concurrently be decreased. Our data suggest that the sensitivity of the exercise test could be increased to 85 per cent by including the criterion of exercise induced chest pain with or without ischemic ECG changes at the expense of a slightly decreased specificity (Table I). These results are in agreement with other studies in the literature which considered the chest pain response to exercise.² (Table I). If the value of exercise induced chest pain response alone¹⁵ analyzed the specificity is very high (90 per cent) but the sensitivity is much lower (51 per cent).

Certain other clinical signs or ECG changes during an exercise test have recently been shown to predict increasing severity of coronary disease. These have included myocardial ischemia occurring early on in the exercise period¹⁶ or extending late into recovery,¹⁷ the presence of hypotension during exercise,¹⁸ extreme ST segment depression,¹⁹ inadequate heart rate response to exercise²⁰ and serious ventricular arrhythmias²¹ during exercise. The data presented here indicate that exercise induced chest pain associated with ischemic ECG changes predicts multivessel coro-

nary disease more accurately than either response separately. Although an ischemic ECG response alone was more predictive of multivessel coronary disease than a totally negative exercise test which agrees with other studies,²²⁻²⁴ the combination of chest pain and ischemic ECG response was even more predictive. Although Lindsey and Cohn²⁵ could not find any difference between 74 patients with chest pain and ischemic ECG changes compared to 39 patients with only ischemic ECG changes alone in terms of extent of coronary disease, our findings are in agreement with the studies of Jelinek and colleagues²⁶ and Tonkon and co workers²⁷ both of whom found that patients with exercise induced ischemic ECG changes and chest pain were more likely to have multivessel disease. A recent study by Cole and Ellestad²⁸ analyzed 950 patients in terms of coronary events and mortality after five years of follow up and found that patients with exercise induced anginal pain plus ischemic ST changes had a worse prognosis than patients with only ischemic ST changes. Thus it appears that the concordance of exercise induced anginal chest pain and ischemic ECG changes correlates with the severity of coronary disease by both angiographic and long term follow up studies.

Summary

To determine the significance of anginal chest pain during exercise testing a series of 302 patients undergoing coronary arteriography with exercise testing was reviewed. Of the 302 patients 85 had ischemic ECG changes and chest pain (Group I), 87 patients had ischemic ECG changes but no chest pain (Group II), 25 patients had chest pain but no ischemic ECG changes (Group III), 105 patients had neither chest pain nor ischemic ECG changes (Group IV). Coronary artery disease was present in 95 per cent of Group I, 75 per cent of Group II, 72 per cent of Group III and 28 per cent of Group IV. Of those patients with coronary disease multiple vessels were involved in 94 per cent of Group I, 51 per cent of Group II, 67 per cent of Group III and 21 per cent of Group IV. The predictive value for presence and extent of coronary disease showed Group I > Groups II and III > Group IV ($p < 0.025$). We conclude that (1) anginal chest pain during exercise testing predicts the presence and extent of coronary disease more accurately than its absence, (2) the presence of chest pain even

Table 1 Comparison of results in seven studies

	Sensitivity			Specificity			Predictive value	
	Positive chest pain alone	Positive ECG alone	Positive ECG and/or chest pain	Positive chest pain alone	Positive ECG alone	Positive ECG and/or chest pain	Positive chest pain	Positive ECG
This study (n = 302)	51%	76%	85%	90%	76%	70%	90%	83%
Kelerman et al. ¹ (n = 74)	85%	54%		100%	96%		100%	96%
Bartel et al. (n = 650)	45%	65%	*		92%	*	86%	
Pressens et al. [†] (n = 40)	70%	65%	83%	90%	83%	77%	90%	84%
Eriksen et al. ¹ (n = 105)	25%	84%		83%			74%	69%
Rios and Hurwitz ¹¹ (n = 50)	41%	83%	83%	*	90%	*	*	90%
Jelinek et al. [‡] (n = 153)	62%	57%	78%	67%	82%	54%	90%	93%

Results could not be obtained because of insufficient data

[†]Includes 15 mm upslowing ST segment depression as positive ECG criterion

[‡]Master's test. Includes 0.5 mm of horizontal or downslowing ST segment depression as a positive test

from each other, and Groups II and III were more highly predictive than Group IV

Clinical correlations Among the 302 patients, 172 (57 per cent) had an ischemic ECG response on the exercise test and 146 of these patients (81 per cent) had significant coronary disease. Of interest is the fact that only 85 of 146 patients (56 per cent) with ischemic ECG changes and documented coronary disease had anginal chest pain precipitated by exercise testing.

On the other hand, 110 of 302 patients (36 per cent) developed anginal chest pain during the exercise test and of these 99 (90 per cent) had coronary disease. Of these latter 99 patients with exercise induced chest pain and coronary disease 81 (82 per cent) had an ischemic ECG response.

Discussion

Classical angina pectoris by history has been found to be highly predictive of coronary disease ranging between 85 and 92 per cent.¹⁻⁶ However when patients with atypical chest pain were analyzed by subsequent coronary angiography only 29 to 66 per cent were found to have coronary disease.^{3,4} In our series we found that the predictive value of exercise induced anginal chest pain (independent of ECG changes) was 90 per cent, which was comparable to the 85 per cent

predictive value of exercise induced ischemic ECG changes (Table 1). Other authors¹⁻¹¹ have also found that chest pain precipitated by exercise testing correlates to a high degree with the presence of coronary disease ranging from 74 to 100 per cent (Table 1). Thus chest pain during the exercise test may be a more reliable method of evaluating a patient's symptoms than the clinical history of chest pain (which may contain many atypical features), and is as good or better in predicting the presence of coronary disease.

Our data indicate that exercise induced chest pain combined with ischemic ECG changes predict the presence of coronary disease more reliably than either response alone. Both the occurrence of exercise induced chest pain alone and ischemic ECG changes alone were better in predicting coronary disease than the total absence of these responses. These results are in agreement with two smaller series reported by Pressens and associates⁹ and by Jelinek and colleagues¹² who found that the combination of chest pain and ischemic ECG changes predicted coronary disease in 96 per cent and 98 per cent of their patients, respectively compared to 78 per cent and 86 per cent of patients with just exercise induced chest pain, 56 per cent and 80 per cent of patients with just ischemic ECG changes alone.

Peroperative myocardial infarction related to coronary bypass surgery

Juan S. Lim MD
William L. Proudfoot MD
William C. Sheldon MD FACC
Carlos Alosilla MD
Daniel F. Phillips MD
Floyd D. Loop MD FACC
Cleveland Ohio

The incidence of postoperative transmural myocardial infarction after coronary bypass surgery has been reported as ranging from 10 per cent to 33 per cent. This study was made to determine the incidence of transmural myocardial infarction within the first 10 days after aortocoronary artery bypass surgery to correlate the serum enzyme values with the diagnosis of transmural myocardial infarction occurring in the early postoperative period to compare graft patency and left ventriculographic findings in groups with and without infarction and to determine the clinical course of patients with peroperative infarction.

Materials and methods

Preoperative and serial postoperative electrocardiograms of 1582 patients who underwent coronary bypass grafting in 1973 were analyzed and stored in an automated cardiovascular information registry. Only development of new Q waves was accepted as evidence of acute infarction. ST-T wave changes regardless of characteristics were not accepted as evidence of infarction in the absence of Q waves. The electrocardiograms of the group with postoperative infarction and those without infarction but with serum

From the Department of Cardiology, the Department of Cardiovascular Surgery, The Cleveland Clinic Foundation and The Cleveland Clinic Educational Foundation, Cleveland, Ohio.

Received for publication Oct. 3, 1977.

Accepted for publication Dec. 1, 1977.

Reprint requests: Juan S. Lim, MD, Department of Cardiology, The Cleveland Clinic Foundation, 9500 Euclid Ave., Cleveland, Ohio 44106.

glutamic oxaloacetic transaminase (SGOT) levels of 100 or more units on any of the first three postoperative days were retrieved and reviewed by two cardiologists. If both agreed on the diagnosis, the patient was considered to have infarction.

In all patients blood was drawn for serial postoperative determinations of SGOT and creatine phosphokinase (CPK) values in the first, second, and third days after operation. Since different methods were used in the determination of the CPK level, this enzyme was not used for correlative study.

Preoperative coronary arteriography was performed by the Sones and Shurey technique. In 45 of the 94 patients with early postoperative transmural myocardial infarction and in 141 consecutive patients in the group without infarction postoperative angiography of the bypass grafts was performed with selected coronary arteriography 1 to 20 months (mean 11.5 months) and 0 to 28 months (mean 15 months) respectively from the date of operation.

The left ventriculograms were examined in the right anterior projection for localized areas with diminished or absent contractions. Preoperative and postoperative angiograms were compared for possible changes in segmental wall motion. The postoperative ventriculograms with new areas of diminished or absent contractions were interpreted as worse and those with disappearance of previously abnormal contraction areas were considered improved.

without an ischemic ECG response during exercise testing appears to be as predictive of coronary disease as an ischemic ECG response alone, and (3) the combination of anginal chest pain during exercise testing and an ischemic ECG response is highly predictive of multivessel coronary artery disease.

The authors would like to acknowledge the secretarial assistance of Ms Marie Gardner.

REFERENCES

- 1 Redwood D R and Epstein S E Uses and limitations of stress testing in the evaluation of ischemic heart disease *Circulation* 46 1115 1972
- 2 Bruce R A and Hornsten T R Exercise stress testing in evaluation of patients with ischemic heart disease *Progr Cardiovasc Dis* 11 371 1969
- 3 Proudfoot W L Shurey E K and Sones F M Jr Selective cine coronary angiography: Correlation with clinical findings in 1000 patients *Circulation* 33 901 1966
- 4 Paulin S Coronary angiography: A technical and tomographic and clinical study *Acta Radiol (Suppl)* 233 Part 1 1964
- 5 Campeau L Bourassa M G Bois M A Saltiel J Lesperance J Rico O Delcan J L and Tellena M Clinical significance of selective coronary cinearteriography *Can Med Assoc J* 99 1063 1968
- 6 Ascoop C A Simoons M L, Egmond W G and Bruschke A V G Exercise test history and serum lipid levels in patients with chest pain and normal electrocardiogram at rest: Comparison to findings at coronary arteriography *AM HEART J* 82 609 1971
- 7 Keleman M H Gillilan R E Bouchard R J Heppner R L and Warbasse J Diagnosis of obstructive coronary disease by maximal exercise and atrial pacing *Circulation* 48 1227 1973
- 8 Bartel A G Behar V S Peter R H Orgain E S and Kong Y Graded exercise stress tests in angiographically documented coronary artery disease *Circulation* 49 348 1974
- 9 Plessens J VanMiegheem W Kesteloot H and DeGeest H Diagnostic value of clinical history, exercise testing and atrial pacing in patients with chest pain *Am J Cardiol* 33 351 1974
- 10 Erikssen J Enge I Forfang K and Storstein O False positive diagnostic tests and coronary angiographic findings in 105 presumably healthy males *Circulation* 54 371 1976
- 11 Rios J C and Hurwitz L E Electrocardiographic responses to atrial pacing and multistage treadmill exercise testing: Correlation with coronary arteriography *Am J Cardiol* 34 661 1974
- 12 Jelinek V M Herman M V Schwartz P and Gorlin R The significance of chest pain occurring with the Master Two Step test *Aust N Z J Med* 6 22 1976
- 13 Redwood D R Borer J S and Epstein S E Whether the ST segment during exercise? *Circulation* 54 65 1976
- 14 McHenry P L Phillips J F and Knoebel S H Correlation of computer quantitated treadmill exercise electrocardiogram with arteriographic location of coronary artery disease *Am J Cardiol* 30 74 19 2
- 15 Stuart R J Jr and Ellestad M H Uploading ST segments in exercise stress testing *Am J Cardiol* 37 19 1976
- 16 Ellestad M H Allen W Wan M K C and Kemp G Maximal treadmill stress testing for cardiovascular evaluation *Circulation* 39 517 1969
- 17 Goldschlager N Selzer A and Cohn A Treadmill stress tests as indicators of presence and severity of coronary artery disease *Ann Intern Med* 85 77 1976
- 18 Thomson P D and Kelemen M H Hypertension accompanying the onset of exertional angina *Circulation* 52 28 1975
- 19 Chetlin M D Davis J E deCastro C M Barrow E A and Anderson W T Correlation of critical left coronary artery lesions with positive submaximal exercise tests in patients with chest pain *AM HEART J* 89 305 1975
- 20 Ellestad M H and Wan M K C Predictive implications of stress testing *Circulation* 51 363 1975
- 21 Goldschlager N Calkins D and Cohn A Exercise induced ventricular arrhythmias in patients with coronary artery disease: Their relation to angiographic findings *Am J Cardiol* 31 434 1973
- 22 McHenry P L Morris S N Kavalier M and Jordan J W Comparative study of exercise induced ventricular arrhythmias in normal subjects and patients with documented coronary artery disease *Am J Cardiol* 37 609 1976
- 23 Kaplan M A Harris C N Aronow W S Parker D P and Ellestad M H Inability of the submaximal treadmill stress test to predict the location of coronary artery disease *Circulation* 47 250 1973
- 24 Martin C M and McConahary D R Maximal treadmill exercise electrocardiography *Circulation* 46 936 1972
- 25 Lindsey H E Jr and Cohn P F Silent ischemia during and after exercise testing in patients with coronary artery disease *Circulation* 52 (Suppl 11) 11 46 1975
- 26 Tonkon M J Miller R R DeMara A N, Vismara L A Amsterdam E A and Mason D T Multifactor evaluation of the determinants of ischemic electrocardiographic response to maximal treadmill testing in coronary disease *Am J Med* 62 339 1977
- 27 Cole J P and Ellestad M H Correlation of chest pain during treadmill exercise electrocardiography and coronary events *Circulation* 54 (Suppl 11) 11 206 19 6

Improvement in contractility was noted in some patients in the group without infarction but not in the group with infarction

Clinical course in group with infarction
Follow up information (Table V) was obtained in all patients with infarction after they were discharged from the hospital. The minimum follow up period was 12 months (mean 26.9 months) with two deaths occurring at 2 and 8 months of follow up. Almost half the patients continued to have chest pain. Post hospital infarction occurred in one patient 4 months after operation. Congestive heart failure was noted in four patients followed 36 to 39 months. Reoperation was done in two symptomatic patients with graft failure. One patient required a permanent pacemaker at 34 months for sick sinus node syndrome and lastly one patient was confined to a long term care institution for dementia.

Discussion

The mechanism of transmural myocardial infarction during coronary bypass surgery is unknown. Early graft occlusion is probably not the only cause of infarction. The incidence of this complication may be related to a combination of factors which may include the selection of the vessels to be grafted, cardiopulmonary perfusion time and mean arterial pressure, period of anoxic arrest and ventricular fibrillation and bypass graft patency rate. In our study there was a significant difference in the status of the bypass graft in the groups with and without transmural infarction ($p < 0.001$) and early graft closure was found in 49 per cent of the infarction. However, evidence of myocardial infarction is not a reliable indication of graft status supplying the zone of infarction since 51 per cent of these patients had patent grafts. Postmortem examination in the small group with postoperative mortality confirmed the occurrence of myocardial infarction in areas supplied by patent grafts. Similar observations have been made by others.³

The accuracy of the serum enzyme in diagnosing transmural myocardial infarction was low with only 49 per cent of patients with SGOT of 100 or more units having myocardial infarction. However, except for one patient all patients with transmural myocardial infarction had this enzyme level. It would appear that perioperative transmural myocardial infarction is unlikely if

Table IV Postoperative angiographic findings in groups with and without infarction

	Group with infarction (45 patients)	Group without infarction† (141 patients)
Patients with at least one graft occluded	22 (49%)‡	24 (17%)
Postoperative left ventriculogram		
Unchanged	17	106
Worse	28 (62%)	20 (14%)
Improved	0	15

Includes only patients who had postoperative angiography

†First consecutive patients who returned for postoperative angiography

‡Includes only patients with occlusion of graft to vessel supplying area of infarction

Table V Post hospital course of patients with infarction

	No. of patients
No chest pain	39
Pain suggesting angina	40
Subsequent infarction	1
Congestive failure	4
Reoperation	2
Pacemaker implant	1
Dementia	1
Deaths	2
Total	83

the SGOT level in the first three postoperative days is less than 100 units.

Intraoperative infarction is associated with an increase in mortality and morbidity. The five postoperative hospital deaths in the group with infarction indicate a 5.3 per cent operative mortality rate. Two subsequent deaths a few months after surgery and the development of congestive failure in four other patients could well be related to the occurrence of perioperative infarction. Because almost half the patients in the infarction group has occluded grafts to vessels supplying areas of infarction, graft occlusion and the attendant infarction may be a factor in the less satisfactory symptomatic improvement.¹⁴

REFERENCES

- Rose M R, Glassman H, Isom H W and Spencer F C: Electrocardiographic and serum enzyme changes of myocardial infarction after coronary artery bypass surgery. *Am J Cardiol* 33:215, 1974.

Table I Operative mortality and incidence of transmural myocardial infarction

	No of patients
Operations	1 582
Operative mortality	15 (0.9%)
Peroperative infarction	94 (6.2%)

Table II Enzyme values on postoperative days 1 through 3

SGOT (Units/liter)*	Group with infarction (94 patients)	Group without infarction (1 374 patients)
<100	1	1 279 (93%)
≥100	93 (99%)	95 (7%)
≥170	66 (70%)	43 (3%)

Normal values 8 to 33 U/liter

Table III Postoperative mean peak SGOT values in groups with and without infarction*

Postoperative days	SGOT (units/liter)	
	Group without infarction (95 patients)	Group with infarction (93 patients)
1	124	233
2	107	189
3	88	90

Includes only patients with elevated enzyme (≥SGOT 100 U/liter)
Curve is flatter for those without infarction

The surgical techniques for saphenous vein and left internal mammary artery bypass grafting have been described by Favalaro and colleagues⁴ and Loop and associates⁵

A correlative study was made of the site of transmural infarction in relation to the zone of myocardium supplied by the grafted vessels based on the expected arterial supply to the various areas of the left ventricular myocardium.¹⁰

Autopsy data on 11 of 15 patients who died in the hospital after operation were reviewed to determine the presence of acute myocardial infarction and the status of the bypass grafts.

Follow up information was obtained by sending questionnaires to referring physicians or to patients and by reviewing the medical records of patients who returned for postoperative angiography.

Results

The operative mortality and incidence of transmural myocardial infarction related to pure coronary bypass surgery are shown in Table I. The 6.2 per cent incidence of transmural infarction included five patients who died with evidence of acute myocardial infarction confirmed by post mortem examination. In two of these patients the bypass grafts to the zones of infarction were closed. In the other three patients the grafts were patent and one of these three had emergency operation for severe left main trunk obstruction. Another six patients had no evidence of acute infarction at postmortem examination. Autopsies were not performed on the remaining four patients: two died of stroke and two had severe left main trunk lesions.

Serum enzyme and transmural myocardial infarction. Of the 94 patients with postoperative transmural myocardial infarction, 93 had SGOT values of 100 or more units on one of the first three days after operation (Table II). Although these enzyme levels were highly sensitive in confirming transmural infarction, the accuracy rate was only 49 per cent (93 of 188 patients), with a substantial incidence of false positive results. Even using SGOT levels of ≥170 units (the mean peak SGOT values in the group with infarction) the accuracy rate rose to only 60.5 per cent (66 of 109 patients) with a concomitant fall in sensitivity.

Table III shows the mean peak SGOT values on the first, second, and third postoperative days in the groups with and without myocardial infarction. In the latter group only patients with elevated enzyme (≥100 SGOT U/liter) were included for comparison.

Postoperative angiographic findings. Table IV shows the status of the bypass grafts and postoperative left ventricular function as determined by segmental wall motion. The frequency of graft occlusions was greater in the group with transmural infarction. However, 51 per cent of the infarction areas were supplied by patent grafts. Analysis of segmental wall motion by left ventriculography performed in the right anterior oblique projection showed localized impairment of contractility in a substantial number of patients with transmural myocardial infarction. In the group without infarction postoperative impairment of contractility was related to graft occlusion and progression of disease in ungrafted arteries.

Improvement in contractility was noted in some patients in the group without infarction but not in the group with infarction

Clinical course in group with infarction
Follow up information (Table V) was obtained in all patients with infarction after they were discharged from the hospital. The minimum follow up period was 12 months (mean 26.9 months) with two deaths occurring at 2 and 8 months of follow up. Almost half the patients continued to have chest pain. Post hospital infarction occurred in one patient 4 months after operation. Congestive heart failure was noted in four patients followed 36 to 39 months. Reoperation was done in two symptomatic patients with graft failure. One patient required a permanent pacemaker at 34 months for sick sinus node syndrome and lastly, one patient was confined to a long term care institution for dementia.

Discussion

The mechanism of transmural myocardial infarction during coronary bypass surgery is unknown. Early graft occlusion is probably not the only cause of infarction. The incidence of this complication may be related to a combination of factors which may include the selection of the vessels to be grafted, cardiopulmonary perfusion time and mean arterial pressure, period of anoxic arrest and ventricular fibrillation and bypass graft patency rate. In our study there was a significant difference in the status of the bypass graft in the groups with and without transmural infarction ($p < 0.001$) and early graft closure was found in 49 per cent of the infarction. However, evidence of myocardial infarction is not a reliable indication of graft status supplying the zone of infarction since 51 per cent of these patients had patent grafts. Postmortem examination in the small group with postoperative mortality confirmed the occurrence of myocardial infarction in areas supplied by patent grafts. Similar observations have been made by others.¹

The accuracy of the serum enzyme in diagnosing transmural myocardial infarction was low with only 49 per cent of patients with SGOT of 100 or more units having myocardial infarction. However, except for one patient all patients with transmural myocardial infarction had this enzyme level. It would appear that peroperative transmural myocardial infarction is unlikely if

Table IV Postoperative angiographic findings in groups with and without infarction

	Group with infarction (45 patients)	Group without infarction† (141 patients)
Patients with at least one graft occluded	22 (49%)‡	24 (17%)
Postoperative left ventriculogram		
Unchanged	17	106
Worse	28 (62%)	20 (14%)
Improved	0	15

† Includes only patients who had postoperative angiography.
‡ First consecutive patients who returned for postoperative angiography.
§ Includes only patients with occlusion of graft to vessel supplying area of infarction.

Table V Post hospital course of patients with infarction

	No. of patients
No chest pain	37
Pain suggesting angina	40
Subsequent infarction	1
Congestive failure	4
Reoperation	2
Pacemaker implant	1
Dementia	1
Deaths	2
Total	83

the SGOT level in the first three postoperative days is less than 100 units.

Intraoperative infarction is associated with an increase in mortality and morbidity. The five postoperative hospital deaths in the group with infarction indicate a 5.3 per cent operative mortality rate. Two subsequent deaths a few months after surgery and the development of congestive failure in four other patients could well be related to the occurrence of peroperative infarction. Because almost half the patients in the infarction group has occluded grafts to vessels supplying areas of infarction, graft occlusion and the attendant infarction may be a factor in the less satisfactory symptomatic improvement.¹

REFERENCES

1. Rose M R, Glasman E, Isom O W and Spencer F C. Electrocardiographic and serum enzyme changes of myocardial infarction after coronary artery bypass surgery. *Am. J. Cardiol.* 33:215, 1974.

- 2 Brewer D L Bilbro R H and Bartel A G Myocardial infarction as a complication of coronary bypass surgery *Circulation* 47 58 1973
- 3 Assad Morell J L Frye R L Connolly D C Gau G T Pluth J R, Barnhorst D A Wallace R B Davis G D Elveback L R and Danielson G K Relation of intraoperative or early postoperative transmural myocardial infarction to patency of aortocoronary bypass grafts and to diseased ungrafted coronary arteries *Am J Cardiol* 35 767 1975
- 4 Fruehan C T Johnson L W Potts J L Smulyan H Parker F B Jr and Eich R H Follow up catheterization of patients with myocardial infarction during coronary artery bypass surgery *Am HEART J* 91 186 1976
- 5 Espinoza J Lipski J Litwak H Donoso E and Dack S New Q waves after coronary artery bypass surgery for angina pectoris *Am J Cardiol* 33 221, 1974
- 6 Anderson W T Brundage H H and Chentim M D Vectorcardiographic changes following saphenous vein bypass graft (Abstr) *Am J Cardiol* 31 116 1973
- 7 Sones F M Jr and Shurey E h Cine coronary arteriography *Mod Concepts Cardiovasc Dis* 31 735 1962
- 8 Favaloro R G Effler D M Groves L K Sheldon W C and Sones F M Jr Direct myocardial revascularization by saphenous vein graft Present operative technique and indications *Ann Thorac Surg* 10 97 19 0
- 9 Loop F D Effler D B Spampinato N Groves L K and Cheanvechai C Myocardial revascularization by internal mammary artery grafts A technique without optical assistance *J Thorac Cardiovasc Surg* 63 6 1972
- 10 James T N The coronary circulation and conduction system in acute myocardial infarction *Progr Cardiovasc Dis* 10 410 1968
- 11 Shurey E K Proudfit W L and Sones F M Jr Serum enzyme and electrocardiographic changes after coronary artery surgery correlation with selective cine coronary arteriography and left ventriculography *Chest* 57 122 1970
- 12 Alderman E L Matloff H J Shumway N E and Harrison D C Evaluation of enzyme testing for the detection of myocardial infarction following direct coronary surgery *Circulation* 48 135 1973
- 13 Greenberg H H McCallister B D Frye R L and Wallace R H Serum glutamic oxalacetic transaminase and electrocardiographic changes after myocardial revascularization procedures in patients with coronary artery disease *Am J Cardiol* 26 135 1970
- 14 Siegel W Lim J S Proudfit W L Sheldon W C and Loop F D The spectrum of exercise test and angiographic correlations in myocardial revascularization surgery *Circulation* 51 and 52(Suppl 1) 156 1975

An evaluation of range gated pulsed Doppler echocardiography for detecting pulmonary outflow tract obstruction in d transposition of the great vessels

José C Areias MD

Stanley J Goldberg MD

Silja E C Spitaels MD

Volkert H de Villeneuve MD

Rotterdam, The Netherlands and Tucson, Arizona

Pulmonary stenosis associated with d transposition of the great vessels (d TGV) represents an important diagnostic problem. Knowledge of the presence of pulmonary stenosis complicating d TGV is important because of operative and mortality considerations.^{1,2} The problem is further complicated by the fact that pulmonary stenosis may develop or increase in severity at any time in the course of the disease.^{3,4} In many children the level and severity of the outflow obstruction can be determined by cardiac catheterization but this investigation is difficult⁵ and can not be repeated as often as desired. Accordingly a noninvasive test which could serially track the course of the disease would be valuable. Unfortunately M mode echocardiography is not well suited to evaluation of diaphragms or rings of muscular stenosis in the left ventricular outflow tract. M mode verification of noncalcified semilunar stenosis also represents a formidable problem. Two dimensional echocardiographic study of the pulmonary outflow tract in d TGV offers better spatial orientation for anatomic study than M mode but the subject of its applicability for detecting obstruction of the pulmo-

nary outflow tract in d TGV remains relatively unexplored.

Recently, a range gated pulsed Doppler (RGPD) has been combined with M mode echocardiography to provide red cell velocity information in a known area of the heart.¹⁰ Additionally spectral analysis of the Doppler velocity signal is possible and should allow differentiation between laminar and turbulent flow.

The purpose of the following investigation was to evaluate the accuracy of RGPD for determining the presence and site of obstruction in patients with d TGV.

Methods

Our study population consisted of a random selection from the available patients with d TGV followed at Sophia Children's Hospital in Rotterdam. Diagnosis of d TGV and status of the pulmonary outflow tract for this group were established previously by cardiac catheterization and angiography and in most instances were confirmed by operative visualization of the area. For purposes of this study pulmonary outflow tract will refer to the area from the left ventricular outflow tract through the pulmonary artery and its right branch.

The examiners were unfamiliar with the children. Each child was assigned a number and all information was collected and analyzed in a blind manner according to that number. Children were studied without sedation. An electrocardiograph

From Sophia Children's Hospital, Erasmus University, Rotterdam, The Netherlands, and the University of Arizona Health Sciences Center, Tucson, Arizona.

Received for publication Oct 10 1977.

Accepted for publication Dec 19 1977.

Reprint requests: J Goldberg MD, 1501 N Campbell, Dept. of Pediatrics, University of Arizona HSC, Tucson, AZ 85724.

- 2 Brewer D L Balbro R H and Bartel A G Myocardial infarction as a complication of coronary bypass surgery *Circulation* 47 58 1973
- 3 Assad Morell J L Frye R L Connolly D C Gau G T Pluth J R Barnhorst D A Wallace R H Davis G D Elveback L R and Danielson G K Relation of intraoperative or early postoperative transmural myocardial infarction to patency of aortocoronary bypass grafts and to diseased ungrafted coronary arteries *Am J Cardiol* 35 767 1975
- 4 Fruehan C T Johnson L W Potts J L Smulyan H Parker F H Jr and Eich R H Follow up catheterization of patients with myocardial infarction during coronary artery bypass surgery *Am Heart J* 91 186 1976
- 5 Espinoza J Lipski J Litwak N Donoso E and Dack S New Q waves after coronary artery bypass surgery for angina pectoris *Am J Cardiol* 33 221 1974
- 6 Anderson W T Brundage M H and Cheitlin M D Vectorcardiographic changes following saphenous vein bypass graft (Abstr) *Am J Cardiol* 31 116 1973
- 7 Sones F M Jr and Shurey E K Cine coronary arteriography *Mod Concepts Cardiovasc Dis* 31 735 1962
- 8 Favaloro R G Effler D B Groves L K Sheldon W C and Sones F M Jr Direct myocardial revascularization by saphenous vein graft Present operative technique and indications *Ann Thorac Surg* 10 9: 1970
- 9 Loop F D Effler D B Spampinato N Groves L K and Cheanvechai C Myocardial revascularization by internal mammary artery grafts A technique without optical assistance *J Thorac Cardiovasc Surg* 63 64 1972
- 10 James T N The coronary circulation and conduction system in acute myocardial infarction *Progr Cardiovasc Dis* 10 410 1968
- 11 Shurey F K Proudfit W L and Sones F M Jr Serum enzyme and electrocardiographic changes after coronary artery surgery correlation with selective cine coronary arteriography and left ventriculography *Chest* 57 122 1970
- 12 Alderman E L Matloff H J Shumway N E and Harrison D C Evaluation of enzyme testing for the detection of myocardial infarction following direct coronary surgery, *Circulation* 48 135 1973
- 13 Greenberg H H McCallister B D Frye R L and Wallace R H Serum glutamic oxalacetic transaminase and electrocardiographic changes after myocardial revascularization procedures in patients with coronary artery disease *Am J Cardiol* 26 135 1970
- 14 Siegel W Lam J S Proudfit W L Sheldon W C and Loop F D The spectrum of exercise test and angiographic correlations in myocardial revascularization surgery *Circulation* 51 and 52(Suppl 1) 156 1975




Fig 2 The sample volume (SV) is in the right pulmonary artery. Mild systolic TIH dispersion is evident and the dispersion is greater than 1 cm in amplitude. The general pattern of the TIH is still recognizable. This was classified as disorganized (D) with pattern. This child No 7 had measured pressure difference of 40 mm across the subvalvular area. For abbreviations see legend of Fig 1. This sample was selected because it showed the least dispersion that was recognized by our criterion.

then recorded in the pulmonary artery. Finally the right pulmonary artery was located from the suprasternal notch and the Doppler information within it was recorded. In each location the recording consisted of an M mode echocardiogram which indicated the site of the sample volume, an electrocardiogram and a TIH. During the RCPD examination an audible signal was present which represented the Doppler frequency shift. This audible signal was used only to find a position in the area under investigation that was free of valve wall or septum but was usually left on during the examination.

Analysis of the numbered tracings was accomplished by classifying the TIH as coherent, disorganized but with pattern, or noncoherent. A one cm bandwidth was required to classify a pattern as disorganized or noncoherent. This criterion resulted from pilot studies of normal flow

patterns which showed no bandwidths greater than 7.5 mm. Examples of each pattern are shown in Figs 1 to 3. Each patient's record was judged independently by two observers. Results of each observer were then coded with the examination number. The code was then broken by matching the TIH results to the previously established diagnosis.

Results

Twenty one children comprised the original group. One was excluded because of lack of cooperation. Another was excluded because the status of the outflow tract was uncertain at time of catheterization. A third child was excluded because of a Potts anastomosis. Reason for this exclusion will be later discussed. An adequate examination was possible in each of the remaining 18 children. Average examination time was 15




Fig. 1 This suprasternal notch study sample was from patient No. 15 who had no obstruction of the pulmonary outflow tract. The example shows time interval histogram (TIH) during a sweep from the right pulmonary artery (RPA) to the transverse aortic arch (TAA). Each dot represents the average frequency of reflections during 1/4 000 of a second. In this instance the dots are relatively coherent. No dispersion consistently exceeds 1 cm. The beats before, under, and to the right of the label TIH show increased dispersion during deceleration as compared to acceleration. Transient RPA disturbance in beat 1 is artifact and not repeated in beat 2. SV = sample volume. YLA = left atrium viewed in the Y axis.

ic lead was recorded for time reference. Instrumentation consisted of an ATL 500A* and a Honeywell 1856 recorder. This instrument package includes a second generation time interval histogram (TIH) output, the theory of which is covered elsewhere.¹¹ The second generation TIH differs from the first in improved precision of the output. A 3 Mhz transducer provided both Doppler and M mode signal. The echo Doppler examination of the pulmonary outflow tract was conducted in a manner similar to the standard pediatric M mode examination except as noted. The pediatric examination from the suprasternal notch was performed after the method of Allen and co-workers.¹² The Doppler signal could be sampled from any site along the echo beam by the range gating feature and the sampling site was depicted by a marker on the standard M mode tracing. This sampling site, an area of about 2 x 4

mm, is called the sample volume. The threshold was set to low noise setting, line level was set to demonstrate positive peaks on the line level indicator, and baseline was set in the noncompressed state. The sample volume was placed between the septum and anterior mitral valve leaflet to record Doppler information in the left ventricular outflow tract. In each instance the recording objective was to find a normal TIH. If an abnormal TIH remained after considerable effort to find a normal one, the abnormal TIH was accepted as a representative of that area. The search, in effect, was seeking to find a place in which a valve wall or septum did not pass into the sample volume for such passage causes a signal which would create confusion in later analysis. After recording the left ventricular outflow tract signal, the transducer position was changed so that the area at the tips of the pulmonary leaflets or the area just above them was sighted by M mode. The Doppler signal was

Table 1 Comparison of echo Doppler and actual diagnosis

Patient	Age	Doppler		True diagnosis of Pulm outflow tract	Most recent evaluation procedure	Doppler assessment	
		LVOT	Pulm Art			Right	Wrong
1	1	N	N	No obstruction	Operation	x	
2	13	N	+	51 mm pulm valv stenosis	Catheterization	x	
3	13	N	N	No obstruction	Operation	x	
4	9	+	+	Subvalv stenosis and pulm banding	Operation	x	
5	9	N	N	No obstruction	Operation	x	
6	7	+	+	40 mm subvalv stenosis	Catheterization	x	
7	3	+	+	40 mm subvalv stenosis	Operation	x	
8	9	N	+	64 mm valv stenosis	Operation	x	
9	5	N	N	No obstruction	Operation	x	
10	6	N	N	No obstruction	Operation	x	
11	4	N	+	Hypoplastic pulm with obstr post valvotomy	Operation	x	
12	7	N	N	No obstruction	Catheterization	x	
13	11	N	N	No obstruction	Catheterization	x	
14	15	N	N	No obstruction	Catheterization	x	
15	9	N	N	No obstruction	Operation	x	
16	2	N	N	No obstruction	Operation	x	
17	6	+	+	130 mm gradient subvalv stenosis not resected	Operation	x	
18	8	N	+	No obstruction	Catheterization		x

N = no detectable turbulence + = turbulence detected.

N obstruction means no pressure difference across any portion of the outflow tract measure 1 that exceeded 10 mm Hg. Catheterization or no detectable narrowing of the outflow tract at direct operative examination.

efficacy in detecting obstructions to pulmonary outflow in d TGV. This is not surprising for these obstructions frequently occur in a portion of the heart that has considerable superior-inferior motion and they are difficult to track by single crystal M mode echo. In nontransposition subaortic diaphragms the only direct finding may be an unidentified line in the outflow tract that is difficult to separate from artifact. In others findings may be absent. Indirect findings have also been reported.¹ Moreover semilunar stenosis in children has remained a difficult diagnostic problem from M mode echo. However one common factor for each type of obstruction is production of nonlaminar flow. A flow disturbance can be identified by spectral analysis of the Doppler signal² and thus formed the rationale for this study.

Detailed echo Doppler theory is covered else

where.^{3,4} Briefly the ultrasound is scattered when it strikes red cells moving within the blood stream. The frequency shift can be sensed and velocity information can be recovered.

The magnitude and direction of this frequency shift depend upon the direction of motion of the scattering particles and the angle between the sound beam axis and the vector direction of motion. Accurate calibration of velocity requires knowledge of this angle but this information is not usually available. Thus quantitation is not usually possible but qualitative assessment is possible.

Although the best echocardiographic signal is obtained when the structure is at right angles to the ultrasound beam the reverse is true for the Doppler signal. It is maximized when it is least perpendicular to the motion of the scattering particles. Thus the optimal echo and optimal




Fig 3 The sample volume is in the left ventricular outflow tract in the left panel (RV = right ventricular cavity SEPT = septum MV = anterior mitral valve leaflet LVPW = left ventricular posterior wall) A systolic flow disturbance exceeding 1 cm amplitude is apparent and marked (T) The pattern although not smooth in diastole has coherence (C) and frequency dispersion in diastole does not exceed 1 cm The right panel shows marked frequency dispersion in systole with coherent in diastole This patient No 6 has subvalvular pulmonary stenosis For abbreviations see legend for Fig 1 Calibration is similar in both panels

minutes Subjects ranged in age from 12 months to 13 years The two observers classified the selected patterns identically However no finer gradation than the three described patterns was attempted

Eleven of the children had normal pulmonary outflow tracts (Table I) Ten of these were correctly classified by RGPD technique and criteria that were applied One child with a normal valve at pre and postoperative catheterization at operation was misclassified The reason for misclassification was not apparent

Seven of the children had pulmonary stenosis (four valvular, three subvalvular) (Table I) In each instance the presence and site of the first obstruction was correctly identified One child (No 4) had more than one level of obstruction The second level, at the pulmonary artery could not be differentiated from the first which occurred at the subvalvular level

Although two patterns of disturbance were

present (noncoherent and disorganized) both were classified merely as abnormal since no data exist to prove that they indicate a different origin

Discussion

Obstruction to the pulmonary outflow occurs in approximately 20 per cent of children with d TGV¹² Although the different types of obstruction are numerous, they can be generally classified as subvalvular, valvular, or supra-valvular This classification is functional for purposes of Doppler evaluation, for the individual lesions are recognized only by their location Nevertheless the presence of these malformations is of critical importance due to their increased risk¹⁴ Many can be corrected at operation and others can be palliated if their presence is known

Although a few cases of pulmonary outflow obstruction have been observed by echocardiography¹⁵ conventional M mode echo has no proven

exclude this child from the results. The child had evidence of an abnormal pulmonary artery TIH but the origin could not be determined by the Doppler examination. However the area under the valve could be studied in this instance. This problem presents an important limiting factor for the Doppler examination.

Echo-Doppler appears to be a promising technique which has the capability of providing information in many areas other than the one described in this report.²¹ However the present technical and inherent problems create important limitations but should not detract from further investigations of its utility.

Summary

The aim of this study was to determine the accuracy of range gated pulsed Doppler (RGPD) echocardiography for detecting obstruction to the pulmonary outflow tract in children with d transposition of the great vessels (d TGV). Twenty one children were randomly selected for those available with d TGV and were studied by precordial and suprasternal RGPD echocardiography. Three were excluded leaving a population of 18 subjects. The exclusive criterion used to judge the RGPD results was the output of the time interval histogram (TIH). Coherence of the TIH was considered to represent laminar flow. Dispersion of the TIH was considered evidence of flow disturbance and obstruction to the outflow tract. With the range gating feature the first site of disturbance could be localized. Information was handled by a technique that decreased bias. RGPD results were then compared to diagnoses of the outflow tract established at cardiac catheterization or operation. Comparison of these results indicated that all seven children with obstruction were correctly identified by RGPD study and the level of the first obstruction was correctly identified. With one exception all children without pulmonary obstruction were correctly identified by the examination.

REFERENCES

- Shrivatsava S, Tadavarthy M, Fukuda T and Edwards J E. Anatomic causes of pulmonary stenosis in complete transposition. *Circulation* 54:154 1976.
- Shaher H M, Puddu G C, Khoury G, Moen C A F, and Mustard W. Complete transposition of the great vessels with anatomic obstruction of the outflow tract of the left ventricle. Surgical implications of anatomic findings. *Am J Cardiol* 19:658 1967.
- Moss, A J and Adams F H. Heart disease in infants, children and adolescents, Baltimore 1968 The Williams & Wilkins Co.
- Clarkson P M, Neutze J M, Barrat-Bove, E G., and Brandt P W T. Late postoperative hemodynamic results and cineangiographic findings after Mustard atrial baffle repair for transposition of the great arteries. *Circulation* 53:525 1976.
- Godman H J, Friedl B, Pasternak A, Kidd B S L, Trusler O A and Mustard W T. Hemodynamic studies in children four to ten years after the Mustard operation for transposition of the great arteries. *Circulation* 53:532 1976.
- Shaher H M, Moen, C A F and Khoury G. Radiologic and angiographic findings in complete transposition of the great vessels with left ventricular outflow tract obstruction. *Radiology* 111:1092 1967.
- Barta A, Kincaid O W, Davis G H, Kuyken J W., and Ongley P A. Transposition of the great arteries: an angiographic study. *Am. J. Roentgenol* 100:249 1967.
- Popp R L, Silverman N J, French J W, Stinson E M and Harrison D C. Echocardiographic findings in discrete subvalvular aortic stenosis. *Circulation* 49:226 1974.
- Goldberg S J, Allen H D and Sahni D J. Pediatric and adolescent echocardiography. A Handbook. Chicago 1975 Year Book Medical Publishers Inc.
- Reneman R S and Hoeks A. Continuous wave and pulsed Doppler flowmeters: a general introduction. In: *Echocardiography* N Bom editor. The Hague 1977. Martinus Nijhoff.
- Baker D W. Pulsed ultrasonic Doppler blood flow sensing. *IEEE Transactions on Sonics and Ultrasonics* SU 17:1,0 1970.
- Allen H D, Goldberg S J, Sahni D, Oviatt T W., and Goldberg B B. Suprasternal notch echocardiography. *Circulation* 55:605 1977.
- Morgan J R, Miller B L, Dancoff G R and Andrews E J. Hemodynamic and angiographic evaluation after Mustard procedure for transposition of the great arteries. *J Thorac Cardiovasc Surg* 64:8 8 1979.
- Rudolph A M. Congenital diseases of the heart. Chicago 1974. Year Book Medical Publishers Inc.
- Nanda N C, Gramiak, R, Hannung J A, and Lipchik E. Echocardiographic features of subpulmonic obstruction in dextro transposition of the great vessels. *Circulation* 51:515 1975.
- Dillon J C. Echocardiographic manifestation of discrete subaortic stenosis. *Am J Cardiol* 33:977 1974.
- Baker D W. EE ultrasonic instruments. *Semin Roentgenol* X:265 1975.
- Johnson, S L. Pulsed Doppler echocardiography. Seatle 1975. Celson Press.
- Baker D W, Rubenstein S A., and Lorch, G S. Pulsed Doppler echocardiography: Principles and applications. *Am J Med* 63:69 1977.
- Baker D W, Lorch, G and Rubenstein S E. *Echocardiography with Doppler application and real time imaging*. Edited by N Bom. The Hague 1977. Martinus Nijhoff Medical Divisions.
- Johnson S L, Baker D W, Lute P A and Dodge H T. Doppler echocardiography. *Circulation* 48:810 1973.
- Kalmanson D., Veyrat C, Boochareine F., and Degroote A. Noninvasive recording of mitral valve flow velocity patterns using pulsed Doppler echocardiography. *Br Heart J* 39:517 1977.
- Johnson S L, Baker D W., Lute R A and Murray J

Doppler signal cannot usually coexist, and a tradeoff must take place. The usual tradeoff is a degraded but recognizable M mode signal.

In laminar flow with a relatively flat velocity profile, blood cells passing through the Doppler sampling volume will have nearly the same velocity and direction. The output signal at any instant in time will have a narrow bandwidth frequency shift and this can be appreciated by spectral analysis or, to a less precise extent, by listening to the nearly pure tone produced by passing the Doppler shifted frequency into an audio amplifier and speaker. In the case of disturbed flow, the scattering particles simultaneously have multiple velocities and directions. The disturbed flow may be turbulent but no way exists with the Doppler to prove actual turbulence, so the term 'disturbed flow' will be used instead. Disturbed flow causes the Doppler frequency shift to have a greater bandwidth and produces a more randomly composed sound. The audible characteristics may be learned but are difficult to evaluate in a standardized objective manner. Rapid spectral analysis and fast Fourier transforms are possible but not yet available for real time use with this instrumentation. However, a TIH output, which closely approximates the result of other types of analyses, is available and translates the Doppler output into a form which can be graphically recorded.²⁰

No technique has been developed to measure the dispersion of the TIH, thus it must be evaluated in a manner that is not entirely quantitative. We chose to classify tracings as coherent, noncoherent, and disorganized. The first two are simple to separate but the third is more qualitative. It was defined as a pattern which was more disorganized than usual and had an amplitude of 1 cm or more but not random. An electronic dispersion measuring technique would be an improvement over this classification.

The population had been previously studied and their diagnoses were established by pressure recording across the area of interest at cardiac catheterization, angiography, and in most cases, results were confirmed by direct observation and examination of the pulmonary outflow tract at operation. The objective of this investigation was to separate those children with pulmonary outflow obstruction from those without obstruction. Results indicate that this was usually possible with the described techniques and criteria.

One misclassification occurred and the reason for this is not obvious, as the examination and record were both acceptable.

The method used to establish the true diagnosis is not ideal. Perhaps the best confirmation would be passage of a transducer catheter through the area of interest just prior to RGPD examination but this was neither practical nor justifiable. The surgeon's evaluation at operation by direct visualization and examination or a postoperative catheterization with pressure measurement with a hydraulic catheter system across the area of interest or both were accepted as valid. If a child had neither evaluation, or if one was in question that individual's results were excluded.

The close agreement between examiners for spectral patterns is not unexpected. The areas studied produce strong Doppler signals and are among the simplest to classify. Other areas of heart may prove more difficult.

Although the results are encouraging, the technique requires further study and development. The examination is not simple. The sample volume (2×4 mm) at 3 Mhz is relatively large for small children. The sample size can be decreased by increasing the echo-Doppler frequency, but this change decreased penetration. Additionally, the sample volume must be set at a selected depth but the cardiac structures are in motion and tend to intercept the stationary sample volume. This causes artifactual dispersion of TIH. Much time was expended in finding a place in a chamber in which the sample volume was free within the cavity during the entire cardiac cycle. Finally, the echo signal used as a locator for the sample volume is necessarily degraded in order to obtain a useful Doppler signal. These are principally technical problems which may have solutions. A more difficult non-technical problem relates to the accurate classification of the situations in which two levels of obstruction are in close physical proximity to one another. Once a flow disturbance is created in a system as small as the heart or great vessels it does not quickly dissipate. Thus a disturbance produced by a distal obstruction could be masked by one produced at a proximal location. In a similar manner a disturbance produced by a systemic-pulmonary artery shunt could mask one produced by a nearby obstruction. This problem was encountered in the investigation with a child who had a Pott's anastomosis and led us to

Blood pressure levels in acute myocardial infarction

Thomas C Gibson MB FRCP

Burlington Vt

The concept of salvaging ischemic myocardium in patients with acute myocardial infarction by reducing left ventricular afterload has become an applied reality with the development of indications for intervention and the use of many agents including antihypertensives.¹ The level of systemic blood pressure has been used as a monitor of afterload primarily because it is easy to measure either directly or indirectly and may be serially recorded as a marker for assessing the efficacy of therapeutic intervention. It is important if such a measurement is to be used to know more of the apparent natural history of blood pressure levels in the hospital setting especially in the early stages of admission for cardiac pain suspected to be due to acute MI, such is the purpose of this study. It is certainly correct that no patient in these circumstances is allowed a truly natural course since there are many variables iatrogenic and otherwise which alter the hemodynamic state. Nevertheless a realistic definition of the trends to be expected should result from such an investigation.

Material and methods

Prospective data were obtained from a group of 1 000 patients admitted successively to a Coronary Care Unit of these 623 had chest pain which was diagnosed as cardiac in origin using previously established criteria. Those included in the study were aged 65 or less admitted to the

hospital within 4 hours of the onset of chest pain were not in cardiogenic shock and were not given specific antihypertensive or unloading therapy. They comprised 112 patients (95 male 17 female) with acute myocardial infarction (AMI) and 96 patients (79 male 17 female) ultimately diagnosed as having angina due to cardiac ischemia without clinical evidence of myocardial necrosis. Serial sphygmomanometric blood pressures were taken by specially trained nursing staff from the time of admission over a period of 72 hours. During the first 24 hours in hospital blood pressures were recorded at least hourly. The diastolic cut off point was the absence of sounds (Korotkoff phase 5). Initially the blood pressure in both arms was taken and the arm with the highest diastolic pressure was selected for serial measurement. Cuff width was 14 cm unless the arm diameter warranted a larger size. Blood pressures taken during the course of major arrhythmias were not included in the data. Ventricular standstill ventricular fibrillation ventricular tachycardia supraventricular tachycardia atrial flutter atrial fibrillation and second and third degree AV block were all considered major arrhythmias. Class II and Class III (Kilip) were used to define patients in cardiac failure.²

Patients with angina were included because it is not possible in the early stages of their clinical course to rule out the diagnosis of acute myocardial infarction conclusively accordingly they might be considered for antihypertensive treatment aimed at myocardial sparing. In addition since they did not have clinically determined myocardial injury they constitute a control group with an environmental and emotional commonality.

From the Division of Cardiology, University of Vermont College of Medicine, Burlington Vt.

Received for publication Oct 13, 1977

Accepted for publication Jan 13, 1978

Reprint requests: Dr Thomas C Gibson, Division of Cardiology, University of Vermont College of Medicine, Burlington Vt 05405.

- A Detection of mitral regurgitation by Doppler echocardiography *Am J Cardiol* 33 147 1974
- 24 Johnson S L Baker D W Lute R A and Kawabon I Detection of left to right shunts and right ventricular outflow tract obstruction by Doppler echocardiography *Circulation* 48 (Suppl 10) 82 1973
- 25 Johnson S L Rubenstein S Kawabon I Dooley T and Baker D W The detection of atrial septal defect by pulse Doppler flowmeter (Abstracts) *Circulation* 53 and 54 (suppl II) 1976
- 26 Ward J M Baker D W Rubenstein S A and Johnson M L Detection of aortic insufficiency by pulse Doppler echocardiography, *J Clin Res* 5 5 1977
- 27 Stevenson J G Kawabon I Guntheroth, W G Differentiation of ventricular septal defects from mitral regurgitation by pulsed Doppler echocardiography *Circulation* 56 14 1977

Copyright information

The appearance of a code at the bottom of the first page of an original article in this journal indicates the copyright owner's consent that copies of the article may be made for personal or internal use or for the personal or internal use of specific clients. This consent is given on the condition, however, that the copier pay the stated per copy fee through the Copyright Clearance Center, Inc., P O Box 765 Schenectady, N Y 12301, 518 374-4430 for copying beyond that permitted by Sections 107 or 108 of the U S Copyright Law. This consent does not extend to other kinds of copying, such as copying for general distribution for advertising or promotional purposes, for creating new collective works or for resale.

Blood pressure levels in acute myocardial infarction

Thomas C Gibson MB FRCP

Burlington Vt

The concept of salvaging ischemic myocardium in patients with acute myocardial infarction by reducing left ventricular afterload has become an applied reality with the development of indications for intervention and the use of many agents including antihypertensives.¹ The level of systemic blood pressure has been used as a monitor of afterload primarily because it is easy to measure either directly or indirectly and may be serially recorded as a marker for assessing the efficacy of therapeutic intervention. It is important if such a measurement is to be used to know more of the apparent natural history of blood pressure levels in the hospital setting especially in the early stages of admission for cardiac pain suspected to be due to acute MI such is the purpose of this study. It is certainly correct that no patient in these circumstances is allowed a truly natural course since there are many variables iatrogenic and otherwise which alter the hemodynamic state. Nevertheless a realistic definition of the trends to be expected should result from such an investigation.

Material and methods

Prospective data were obtained from a group of 1000 patients admitted successively to a Coronary Care Unit of these 623 had chest pain which was diagnosed as cardiac in origin using previously established criteria.² Those included in the study were aged 65 or less admitted to the

hospital within 6 hours of the onset of chest pain were not in cardiogenic shock and were not given specific antihypertensive or unloading therapy. They comprised 112 patients (95 male 17 female) with acute myocardial infarction (AMI) and 96 patients (79 male 17 female) ultimately diagnosed as having angina due to cardiac ischemia without clinical evidence of myocardial necrosis. Serial sphygmomanometric blood pressures were taken by specially trained nursing staff from the time of admission over a period of 72 hours. During the first 24 hours in hospital, blood pressures were recorded at least hourly. The diastolic cut off point was the absence of sounds (Korotkoff phase 5). Initially the blood pressure in both arms was taken and the arm with the highest diastolic pressure was selected for serial measurement. Cuff width was 14 cm unless the arm diameter warranted a larger size. Blood pressures taken during the course of major arrhythmias were not included in the data. Ventricular standstill, ventricular fibrillation, ventricular tachycardia, supraventricular tachycardia, atrial flutter, atrial fibrillation and second and third degree AV block were all considered major arrhythmias. Class II and Class III (Kilip) were used to define patients in cardiac failure.³

Patients with angina were included because it is not possible in the early stages of their clinical course to rule out the diagnosis of acute myocardial infarction conclusively; accordingly they might be considered for antihypertensive treatment aimed at myocardial sparing. In addition since they did not have clinically determined myocardial injury they constitute a control group with an environmental and emotional commonality.

From the Division of Cardiology, University of Vermont College of Medicine, Burlington Vt.

Received for publication Oct. 13, 1977.

Accepted for publication Jan. 13, 1978.

Reprint requests: Dr. Thomas C. Gibson, Division of Cardiology, University of Vermont College of Medicine, Burlington Vt 05401.




Fig 1 Maximal systolic and diastolic blood pressure levels (mm Hg) recorded in the study population during first hour of hospital admission

Results

First hour blood pressure During the first hour of hospitalization mean systolic blood pressure (SBP) for the whole cohort was $150.2 (\pm 30.7)$ mm Hg. A SBP ≥ 160 mm Hg was present in 81 patients (38.9 per cent). Mean diastolic blood pressure (DBP) was $92.1 (\pm 18.7)$ mm Hg and a DBP ≥ 100 was present in 88 patients (42.3 per cent). The range of maximal blood pressure (BP) readings is shown in Fig 1. These data show that in acute myocardial infarction (AMI) SBP appears unimodal with a shift to the left and that in cardiac ischemia SBP demonstrates bimodality due to the number of patients with SBP $180+$. The DBP levels tend to parallel each other for cardiac ischemia and AMI with a shift to the right.

Table I shows mean BP levels by diagnosis and sex. Men and women with angina have a significantly higher mean SBP than those with AMI. This also applies to DBP in women. Women have higher mean SBP than men for both cardiac ischemia and AMI but this is not a statistically significant difference. This also applies to DBP in women with cardiac ischemia.

If the criterion for unloading therapy was set at

Table I Initial (mean and SD) blood pressure levels (mm Hg) in acute myocardial infarction and cardiac ischemia

	Total	Men	Women
AMI (n = 112)		(n = 95)	(n = 17)
Systolic	143.2 \pm 28.7	140.9 \pm 26.7	156.5 \pm 36.3
Diastolic	90.2 \pm 18.9	90.4 \pm 19.5	88.9 \pm 15.9
Ischemia (n = 96)		(n = 79)	(n = 17)
Systolic	158.3 \pm 31.1	154.7 \pm 31.3	174.9 \pm 74.6
Diastolic	94.3 \pm 18.3	93.5 \pm 16.4	103.3 \pm 17.0

a BP 140/90 then 93 (44.7 per cent) of the total group would qualify during the first hour of admission. If it were set at 160/100 or greater then this number would be 66 (31.7 per cent).

Changes in blood pressure during first 6 hour period BP changes during the first six hours were evaluated since it is during this time that BP lowering may be considered or, if in effect monitored. By the sixth hour SBP mean for the group had fallen from 150.2 to 130.1 (± 24.0) mm Hg and DBP from 92.1 to 81.3 (± 15.5) mm Hg. The 93 patients with an initial first hour BP of 140/90 were evaluated and the data are shown in Fig 2. Only 23 patients (24.7 per cent) were still in this range by the sixth hour with the major fall occurring within 3 hours. This is 11.1 per cent of the total cohort. Separation of the data by diagnosis showed no statistically significant difference in BP behavior between AMI and cardiac ischemia. The 66 patients with an initial 1 hour BP of 160/100 or more demonstrated similar striking falls in BP by 6 hours. At that time only 13 (19.7 per cent) remained with such a BP elevation. This is 6.3 per cent of the total cohort. Again there was no significant difference in behavior between AMI and cardiac ischemia. It was also not possible to separate out this group with persistent hypertension by any clinically predictive means.

Changes in blood pressure during the first 72 hour period During the 18 hours following the first 6 hours 21 patients (10.5 per cent) had at least one blood pressure reading of 160/100 or more. Only eight developed this de novo and in five this was associated with return of chest pain.

Fig 3 shows the percentage of patients with certain defined levels of BP fluctuation for systole and diastole during the first 24 hour period. The degree of change can be seen to be




Fig 2 Percentage of study population with blood pressure levels greater than 140/90 mm Hg and 160/100 mm Hg or more recorded during the first six hours and from 7 to 24 hours of hospital admission

considerable in the majority of patients and such fluctuations were with very few exceptions due to a sequential fall rather than a rise in level. A mean fall in SBP in the region of 50 mm Hg (cardiac ischemia 52.2 AMI 49.0) and a mean fall of approximately 30 mm Hg in DBP (cardiac ischemia 32.4 AMI 34.0) took place (Table II). A sex difference in mean SBP was apparent since women with AMI or cardiac ischemia had a greater fall.

Fig 4 shows the fall in the number of patients with certain BP levels during a 3 day period. There is a consistent pattern for both SBP and DBP fall in patients with cardiac ischemia and AMI. By the third day those patients who had the higher BP readings of 160 systolic or more and 100 diastolic or more were few. This group did not consist of only those patients who had persistent hypertension but also included those who had any isolated reading which was above the levels set. Only two patients with AMI had persistent hypertension (BP 160/100 or more) during the first 72 hours.

Clinical course of patients with acute myocardial infarction. A number of clinical variables were examined in order to determine differences between hypertensive patients (BP 160/100 or more) and non hypertensive patients during hospitalization (Table III). The only statistically significant difference was in the incidence of supraventricular tachyarrhythmias in non hypertensive patients. Trends were present suggesting that heart failure, higher degrees of AV block and sinus bradycardia were more common in the non hypertensive group. The last two features might




Fig 3 Maximal systolic and diastolic blood pressure fluctuations over first 24 hours of hospital admission grouped by degree

be explained by a higher incidence of inferior myocardial infarct (48.1 per cent) in this group when compared to the hypertensive group (22.6 per cent).

Discussion

This study was done to quantify what has been for decades a common clinical observation to wit that elevated blood pressure is often found in patients admitted to hospital with acute myocardial infarction. Data are available on long term follow up of such hypertensive patients⁴ and prognostic indices related to initial blood pressure recorded in hospital⁵ have been developed. Hypotension is established as an index of poor prognosis but there is controversy concerning the role of hypertension. The short term data mostly indicate that the presence of an elevated blood pressure has no significance prognostically. However, Fox and colleagues⁶ found that the mortality rate, incidence of cardiac failure, major arrhythmias and mean peak SGOT were significantly greater in a group of patients with a




Fig 4 Percentage of patients with acute myocardial infarction and cardiac ischemia at specified levels of systolic and diastolic blood pressure by hospital days 1 to 3 (24 hour periods). Terminal digit preference is apparent for diastolic blood pressure levels of 90 mm Hg or more (90+) compared to greater than 90 mm Hg (>90). It is present but less apparent for systolic blood pressures of 140+ mm Hg compared to >140 mm Hg.

Table II Fluctuation (mean and SD) over 24 hours of blood pressure (mm Hg) in acute myocardial infarction and cardiac ischemia

	Total	Men	Women
AMI (n = 112)		(n = 95)	(n = 17)
Systolic	49.0 ± 20.2	47.1 ± 19.3	60.3 ± 21.4
Diastolic	34.0 ± 15.1	34.4 ± 15.4	31.8 ± 13.2
Ischemia (n = 96)		(n = 79)	(n = 17)
Systolic	62.2 ± 24.3	49.4 ± 24.0	65.1 ± 22.4
Diastolic	32.4 ± 14.1	30.9 ± 12.8	39.2 ± 17.9

Table III Comparison of selected variables between hypertensive and non hypertensive patients with AMI

	Total (n = 112)	Hypertensive (n = 31)	Non hypertensive (n = 81)
Mortality	10 (8.9)	3 (9.7)	7 (8.6)
Heart failure	42 (37.5)	8 (25.8)	34 (42.0)
VF VT	23 (20.5)	5 (16.0)	18 (22.2)
2° 3° AV block	17 (15.2)	2 (6.5)	15 (18.5)
SV tachycardia	20 (17.9)	2 (6.5)	18 (22.2)
Ventricular ectopics	82 (73.2)	24 (77.4)	58 (71.6)
Sinus bradycardia	45 (40.2)	8 (25.8)	37 (45.7)
Sinus tachycardia	65 (49.1)	14 (45.2)	41 (50.6)

Percentages in brackets.

11 (9.8) primary in CCU

†P < 0.05

VF = ventricular fibrillation VT = ventricular tachycardia SV = supraventricular

systolic blood pressure of at least 170 mm Hg on admission to hospital

Since blood pressure elevation is a possible marker for unloading therapy in the early stages of acute myocardial infarction, it was appropriate to measure this serially in a defined population. By this means the usefulness of such measurements in the management of acute myocardial infarction might be established. This could be especially important if hemodynamic data were lacking and simple clinical findings were all that might be available to make decisions on unloading therapy.

The results indicate that initial blood pressure

elevation is common and, depending on the criteria used, is present in 30 to 40 per cent of patients with acute myocardial infarction not in cardiogenic shock. The more dramatic finding was the lability of this hypertension, since a considerable fall in blood pressure occurred very early on in the clinical course, so that by six hours after hospital

admission the number of hypertensive patients has fallen to 11 to 10 per cent. The number of patients with persistently elevated blood pressure over 24 hours is very small. Women with acute myocardial infarction and cardiac ischemia are more likely to have higher initial blood pressure readings than men and to be equally labile.

The etiology of hypertension in acute myocardial infarction is speculative. It is easy to attribute it to anxiety and stress with increased catechol release. This has been studied in the past and catechol levels do roughly correlate with blood pressure.⁸ We found a remarkably similar blood pressure course in patients with acute myocardial infarction or cardiac ischemia, suggesting that a psychic response to environment or chest pain may be the common denominator. In addition, a homeostatic hemodynamic response to a decreased cardiac output might be considered with possibly an overshoot phenomenon. Little is known concerning the initial somatic reaction to myocardial injury, although evidence for enhanced autonomic activity is frequently present in the early stages.⁹ Furthermore, a previously hypertensive or hyperreactive patient might respond differently to stress. The identification of such patients admitted to a Coronary Care Unit is difficult since many have not had blood pressure recordings taken in the past and it is unrealistic to attempt to separate out such a group. There are experimental and clinical data suggesting that an initial hypertensive or pressor response in the early stages of acute myocardial infarction may be protective against ventricular fibrillation and sudden death.¹⁰

The rapid fall in blood pressure must also be considered. Heart failure is common in the early stages of acute myocardial infarction and cardiac output may fall without much change in other factors determining blood pressure. Inappropriate use of diuretics at this stage could lead to hypovolemia with diminution of effective circulating volume. In the Coronary Care Unit, sedatives and narcotics are often used to allay patient fear and pain. This therapy could contribute to such a fall. It could be that the simplest unloading therapy in early uncomplicated AMI is reassurance, meticulous attention to relief of pain, and adequate sedation.

This study has demonstrated in a more objective fashion the type of changes that are to be expected in blood pressure in a group of patients

with acute myocardial infarction. It is important to understand the constraints that apply to any investigation requiring indirect blood pressure measurement, and these have been well reviewed by Rose, Holland, and Crowley.¹¹ Although methodology was standardized and sphygmomanometers were carefully maintained, blood pressures were taken by several individuals, thus leading to the possibility of well-defined areas of inaccuracy. Without an automatic blood pressure monitoring system, it is very difficult to eliminate both observer prejudice and terminal digit preference. Terminal digit preference did occur in this study, as seen by a disproportionate number of zero readings.

It was also difficult to control the number of variables that could exist in such a clinical situation. All patients were at bed rest during the observed period and standard protocols were used for treatment. However, in a Coronary Care Unit, most drugs used have effects on blood pressure levels, and even sleep¹² or the administration of oxygen¹³ may alter blood pressure levels. It was not possible to account for or eliminate all the variables that may exist under these circumstances, and this has to be taken into consideration when evaluating our data.

We would conclude that blood pressure levels, although easily obtained, are too labile a measurement in acute myocardial infarction for use in the first few hours as a marker for unloading manipulation, whether for initiation or maintenance. Furthermore, hypertension on admission to hospital did not worsen prognosis in our patients.

Summary

Serial blood pressure recordings were taken for 72 hours in 112 patients with acute myocardial infarction and in 96 patients with cardiac ischemia admitted to hospital no more than 6 hours after the onset of chest pain. During the first hour of admission, 66 (31.7 per cent) had a blood pressure recorded 160/100 or greater. By the sixth hour, without specific antihypertensive therapy, this number had fallen to 13 (6.3 per cent). This fall was subsequently maintained with very similar trends for both acute myocardial infarction and cardiac ischemia. Such an early blood pressure fall in acute myocardial infarction may indicate that this is too labile a measurement to determine the need for or efficacy of antihyper-

tensive therapy aimed at the preservation of myocardium. The hospital course and mortality rate of patients with acute myocardial infarction and early hypertension, as defined, did not differ significantly from the non hypertensive group.

REFERENCES

- 1 Maroko P R and Braunwald E. Modification of myocardial infarction size after coronary occlusion. *Ann Intern Med* 79:720 1973
- 2 Cohn J H. Vasodilator therapy of myocardial infarction (Editorial). *N Engl J Med* 290:1433 1974
- 3 Shell W E and Sobel B E. Protection of jeopardized ischemic myocardium by reduction of ventricular after load. *N Engl J Med* 291:481 1974
- 4 Gibson T C. The significance of fever in acute myocardial infarction: a reappraisal. *Am Heart J* 87:439 1974
- 5 Wolk M J, Scheidt S and Killip T. Heart failure complicating acute myocardial infarction. *Circulation* 45:1125 1972
- 6 Master A M, Jaffe H L, Dack S and Silver N. The course of the blood pressure before, during and after coronary occlusion. *Am Heart J* 26:92 1943
- 7 Peel A A, Semple T, Wang I, Lancaster W M and Dall J L G. A coronary prognostic index for grading the severity of infarction. *Br Heart J* 24:745 1962
- 8 Hughes W L, Kalbeneleisch J M, Brandt E N and Costiloe J P. Myocardial infarction prognosis by discriminant analysis. *Arch Intern Med* 113:338 1963
- 9 Norris R M, Brandt P W T and Lee A J. Mortality in a coronary care unit analyzed by a new coronary prognostic index. *Lancet* 1:278 1969
- 10 Norris R M, Caughey D E, Deeming L W, Mercer C J and Scott P J. Coronary prognostic index for predicting survival after recovery from acute myocardial infarction. *Lancet* 2:485 1970
- 11 Marx H J and Yu P N. Prognostic factors in acute myocardial infarction. In *Myocardial Infarction* edited by Corday E and Swan H J C. Baltimore 1973. The Williams & Wilkins Company pp 195-204
- 12 Moss A J, DeCamilla J, Engstrom F, Hoffman W, Odoroff C and Davi H. The post hospital phase of myocardial infarction. Identification of patients with increased mortality risk. *Circulation* 49:460 1974
- 13 Helmers C. Short and long term prognostic indices in acute myocardial infarction. *Acta Med Scand (Suppl 555)* 286 1973
- 14 Fox K M, Tomlinson I W, Portal R W and Aber C P. Prognostic significance of acute systolic hypertension after myocardial infarction. *Br Med J* 3:178 1975
- 15 Luna M H, Knoke J D, Margolis R M, Hendrix F H and Kupiec J B. Acute myocardial infarction. Prognosis after recovery. *Ann Intern Med* 85:661 1976
- 16 Siggers D C, Salter C and Fluck D C. Serial plasma adrenaline and noradrenaline levels in myocardial infarction using a new double isotope technique. *Br Heart J* 33:878 1971
- 17 Oliver M F. Acute systolic hypertension during myocardial infarction. *Br Med J* 3:437 1975
- 18 Rose G A, Holland W W and Crowley E A A. Sphygmomanometer for epidemiologists. *Lancet* 1:936 1964
- 19 Littler W A, Honour A J, Carter R D and Sleight P. Sleep and blood pressure. *Br Med J* 3:346 1973
- 20 Sukumalchandra Y, Levy S, Danzig R, Rubin S, Alpern H and Swan H J C. Correcting arterial hypoxemia by O_2 therapy in patients with acute myocardial infarction. Effect on ventilation and hemodynamics. *Am J Cardiol* 24:838 1969
- 21 Webb S W, Adgey A A J and Pantridge J F. Autonomic disturbance at onset of acute myocardial infarction. *Br Med J* 3:89 1972
- 22 Blatt C M, Verrier R L and Lown B. Acute blood pressure elevation and ventricular fibrillation threshold during coronary occlusion and reperfusion in the dog. *Am J Cardiol* 39:523 1977
- 23 Irving J H, Bruce R A, Chinn N and De Rouen T. Significance of exertional hypertension in men with ischemic heart disease (Abstract). *Am J Cardiol* 37:144 1976

The effect of aging on ventricular contractile performance

F Urthaler MD
A A Walker BS
T N James MD
Birmingham Ala

Recent studies using canine ventricular trabeculae have shown that maturation is associated with a significant improvement in contractile performance.¹⁻³ Few studies, most of them carried out in rats, have attempted to assess the changes in contractility that occur later in life with the aging process.⁴⁻⁶ Since the reported results are not only conflicting but the conclusions sometimes diametrically opposed,⁴⁻⁶ we decided to study the contractile performance of canine right ventricular trabeculae at ages comparable to human adulthood and senescence.

Method

Sixteen mongrel dogs weighing 16 to 18 kilograms and of either sex were anesthetized with sodium pentobarbital (30 mg/Kg) administered intravenously. Two age groups were studied. The first group was composed of nine dogs 36 ± 4 weeks of age or about 9 months. The second group included seven old dogs free from parasitic disease that a veterinarian estimated to be at least eight years of age. Each dog had poor teeth and cataracts but its nutritional state showed no obvious deterioration. None had evidence of cardiac disease or congestive heart failure. The entire heart was rapidly removed and placed in a beaker of Krebs Ringer bicarbonate solution

that was continuously bubbled at 37° C with a 95 per cent O₂, 5 per cent CO₂ gas mixture. The bathing solution contained (mmoles/liter): Na 145, K 4.2, Ca²⁺ 1.25, Mg²⁺ 1.2, Cl 125, SO₄²⁻ 12, H₂PO₄ 2.4, HCO₃⁻ 25, and glucose 5.6. The same continuously oxygenated and stirred solution was subsequently utilized for isolated muscle superfusion. After equilibration the solution had an oxygen tension (PO₂) of 550 mm Hg or greater and a pH of 7.40 ± 0.02 .

Ventricular trabeculae were isolated from the same regions of the right ventricle as previously described.¹ Each muscle was then mounted in a myograph⁸ with one end of the muscle attached to a fixed force gauge that has no measurable nonlinearity in the tension signal over applied forces up to 10 mN. The other end of the muscle was attached to a light aluminum pendulum for measurement of length changes. Positional changes of the length lever were sensed by a linear differential transformer whose small iron core was firmly attached to the lever. The equivalent mass of the lever was 0.3 g, which has negligible effect on muscle characteristics. Displacements of up to 10 mm showed no measurable nonlinearity in the length signal. The frequency responses for both systems was determined and was found accurate up to 100 Hz. The compliance of the tension transducers and the lever system combined was less than 0.5 μ per gram. An adjustable micrometer which restrained the lever movement was used to set the muscle lengths. Along the lever a small wire carrying electrical current in a magnetic field generated the desired forces (load on muscle) to hold the lever against the micrometer.

Outputs from the force and length gauges along

From the Department of Medicine, University of Alabama Medical Center, Birmingham, Alabama 35294.

This work was supported by the National Heart, Lung, and Blood Institute (Program Project Grant HL 11310 and SCOR on Ischemic Heart Disease No. 1 P17 HL 17567) and by the National Fund for Medical Research.

Received for publication Dec. 11, 1977.

Accepted for publication Jan. 25, 1978.

Reprint requests: F. Urthaler, MD, Department of Medicine, University of Alabama Medical Center, Birmingham, Ala. 35294.




Fig 1 Record illustrating the difference in contractile performance in a 9 month old and a > 1 year old ventricular trabeculae. Tension is inscribed from bottom to top whereas shortening is inscribed from top to bottom.

Table I Values from the length-tension curves obtained in 16 canine right ventricular trabeculae at L_{max}

Age	Weight (mg)	Length (mm)	Cross sectional area (mm ²)	Resting tension (G/mm ²)	DVLP (G/mm ²)	MRTR (G/sec/mm ²)	TLAT (msec)	TMRT (msec)	TMAT (msec)	DRTN (msec)	TRLA (msec)
9 Months (n = 9)	6.27 ± 3.16	5.85 ± 1.28	1.01 ± 0.35	0.375 ± 0.079	4.503 ± 0.545	1513 ± 2.86	81.9 ± 19.5	239.7 ± 46.7	574.0 ± 73.8	1284.2 ± 136.6	710.9 ± 122.6
> 8 years (n = 7)	5.98 ± 3.24	6.50 ± 0.75	0.87 ± 0.46	0.488 ± 0.202	4.566 ± 0.385	12.31 ± 1.89	98.1 ± 23.6	283.8 ± 55.4	689.6 ± 149.6	1768.8 ± 617.6	1077.4 ± 499.7
t	0.17	1.12	0.65	1.31	0.24	2.11	1.41	1.24	1.89	2.14	1.00
P	NS	NS	NS	NS	NS	p < 0.05	p < 0.10	NS	p < 0.05	p < 0.025	p < 0.05

DVLP = maximum developed tension. MRTR = maximum rate of tension rise. TLAT = latency time. TMRT = time to maximum rate of tension rise. TMAT = time to maximum tension. DRTN = duration of contraction and TRLA = relaxation time calculated by subtracting time to maximum tension from duration of contraction. NS = not significant ($P < 0.05$).

with the stimulus signal were sent through an A/D converter to a PDP 7 computer. The computer then signaled through a D/A converter back to the apparatus to control loading of the muscle. Prior to each isometric tension series the computer recalibrated the tension transducer if necessary. The contractions were then registered and the following data were routinely calculated

and recorded on digital tape: the length and tension signals at 1000 samples per second; resting tension; developed tension (peak developed isometric tension at L_{max}); maximum rate of tension rise; maximum change in length; maximum velocity of shortening; latency time (defined and measured as the interval between the onset of the stimulus and the point at which the developed

tension reached 2 per cent of its maximum value) time to maximum tension time to maximum rate of tension rise time to maximum shortening time to maximum velocity of shortening and relaxation time The cross sectional area was estimated at L_m (the length of the muscle at which developed tension was maximum) by dividing the weight of the muscle by its length This value was then utilized as the normalizing factor for the tensions

After being mounted the muscles were first allowed to shorten with a preload equivalent to approximately 50 per cent of the resting tension subsequently observed at L_m After about 2 to 3 hours length-tension curves were then obtained for the next 24 hour period during which each experiment was performed there was no significant further increase or decrease in peak isometric tension In every experiment after each incremental change of initial muscle length 5 minutes were allowed to elapse before the data were recorded This procedure was adopted to minimize the effect of stress relaxation Temperature was kept constant ($25.0 \pm 0.1^\circ \text{C}$) through a feedback controlled Peltier junction

All preparations used were quiescent unless stimulated Unless otherwise indicated each muscle was stimulated 12 times per minute by square wave pulses delivered to plate electrodes from a Grass stimulator Stimulus duration was 5 msec and the voltages used were 10 per cent above threshold All results are expressed as means ± 1 SD The significance of differences was assessed by Student's *t* test the comparison of regression lines was done by a standard technique

Results

Contractile performance of normally mature and of old right ventricular trabeculae

Isometric variables Table I summarizes all the data obtained at L_m in 16 muscles isolated from the same region of the right ventricle of dogs 9 months ($n = 9$) and more than 8 years ($n = 7$) of age Weight length cross sectional area resting tension and developed tension were the same Old age however was associated with a definite decrease in maximum rate of tension rise (-18 per cent) and a significant increase in total twitch duration ($+33$ per cent) There was no concomitant change in the latency time Relaxation time increased proportionally far more ($+52$ per cent) than the time to maximum tension ($+20$ per




Fig 2 Two length-tension curves of right ventricular trabeculae at 9 ($n = 9$) months of age and > 8 years ($n = 7$) old (shaded area) The two diagrams represent the linear regressions of all data points collected The equations for DVLP (developed tension) and REST (resting tension) in the shaded area are those of the older muscle group There is no significant difference between tensions developed in the normally mature and old muscles (upper set of regression lines) In contrast passive stiffness up to L_m ($= 1.00$) is significantly greater in the older muscle

cent) indicating that slowing of individual twitches was mostly due to a profound prolongation of the relaxation phase (Fig 1) Fig 2 illustrates the linear regressions of the two length tension diagrams plotted from all the data collected in those 16 ventricular trabeculae Whereas the developed tensions remained virtually unchanged between the period of normal maturation (9 months) and old age (over 8 years) the resting tensions underwent a remarkable transformation Both the slope and the x intercept changed significantly with aging Whereas the L_m in the adult muscles averaged $0.901 \pm 0.014 \text{ mm}/L_m$ that of the old muscles increased to as much as $0.940 \pm 0.024 \text{ mm}/L_m$ This difference was significant at a $p < 0.001$ level Although the resting tensions at L_m were virtually identical in the younger and older

Table II Values from the force-muscle shortening relationships obtained in 16 canine right ventricular trabeculae at L_{max} and constant afterload (1 g)

Age	Weight	Length	Cross sectional area	Resting tension (G/mm^2)	DLTL (mm/L_m)	MAXV ($mm/sec/L_m$)	TLAT (msec)	TMAXV (msec)	TVAS (msec)	DRTV (msec)
9 Months (n = 9)	6.27 ± 3.16	5.85 ± 1.28	1.01 ± 0.35	0.405 ± 0.103	0.085 ± 0.014	0.264 ± 0.061	85.0 ± 19.4	263.3 ± 42.0	718.2 ± 85.1	1068.7 ± 13.7
>8 years (n = 7)	5.98 ± 3.24	6.50 ± 0.75	0.87 ± 0.46	0.476 ± 0.178	0.077 ± 0.014	0.204 ± 0.051	104.6 ± 24.5	290.0 ± 76.2	930.1 ± 23.5	1388.4 ± 401.0
t	0.17	1.12	0.65	0.94	1.68	2.00	1.67	1.11	2.37	2.09
p	NS	NS	NS	NS	$p < 0.10$	$p < 0.05$	$p < 0.10$	NS	$p < 0.05$	$p < 0.05$

DLTL = maximum muscle shortening MAXV = maximum velocity of shortening TLAT = time to maximum velocity of shortening and TMAXV = time to maximum shortening

muscles an analysis of the respective slope of those passive tensions indicated that the difference was statistically significant at the $p < 0.05$ level.

Isotonic variables Table II is a summary of all the data collected. When studied and compared at the same initial muscle length and constant afterload of 1 g the extent of shortening in young and old muscles (Fig. 1) was quite comparable. However there was a significant difference in their respective v intercepts ($p < 0.05$). Fig. 3 depicts the force extent of shortening relationships, further illustrating that the amount of shortening did indeed decrease with aging. Fig. 4 and Table II demonstrate that the maximum velocity of shortening was significantly reduced in the older muscles (-23 per cent). In addition, time to maximum shortening as well as time to maximum velocity of shortening were also prolonged (+30 per cent and +14 per cent respectively). Total twitch duration was prolonged by as much as 30 per cent.

Discussion

There is little question that the efficiency of cardiac performance tends to decrease with age. Both heart rate⁹ and cardiac output¹⁰ are significantly decreased in the elderly. In our study the strength of myocardial contraction was little affected by aging but the extent of shortening tended to decrease. However the rate of rise of tension and the velocity of shortening were both definitely diminished in the older muscles. Compared to 3 and 9 months old ventricular trabeculae,¹¹ the duration of each individual twitch in older muscles was distinctly prolonged. On closer analysis the depression of the time dependent parameters was far from uniform. At

one extreme the latency time remained unchanged, whereas at the other extreme relaxation time underwent the most profound prolongation. Taken collectively all these observations indicate that canine right ventricular muscles lose speed but keep their strength with aging. Furthermore it appears that increased duration in relaxation time might represent an early and sensitive indication of the aging process.

Equally intriguing were the age associated changes of resting tension. With increasing age L_m was significantly shifted to the right and there was a significant increase in passive stiffness equivalent changes in muscle length brought about twice as much increase in resting tension in the older muscle as in the normal mature muscle. It is apparent that the resistance to stretch changes during aging. From the length at which resting tension was first detected normally mature muscles could be stretched by as much as 10 per cent before reaching L_m , while the old muscles would only allow a 6 per cent stretch before reaching the same optimal length.

Summary

The effects of aging on mechanical performance of isolated canine right ventricular trabeculae were studied in two age groups. The first group was comprised of nine dogs about 9 months of age. The second group was composed of seven dogs over 8 years of age. Aging had no significant effect on developed force. Extent of shortening tended to decrease. There was a significant decrease in both the rate of rise of tension and the velocity of shortening (20 per cent). This reduction was primarily due to an increased duration of contraction. Twitch duration increased by as much as 40 per cent during aging but most of this




Fig 3 The extent of shortening at a load of 1 g was not significantly different at a $p < 0.05$ level between the young adult and the older muscles (see Table II). The y intercepts however were significantly different. The two curves represent the linear regressions of all data points collected.

prolongation was due to a profound slowing of relaxation. Aging caused a significant increase in passive stiffness since equivalent changes in muscle length brought about twice as much increase in resting tension in the aged muscle as in the young muscle. On the other hand aging caused a significant shift of L_0 to the right. Taken collectively these results indicate that aging is associated with increased passive stiffness and decreased speed of contraction without changes in strength.




Fig 4 The velocity of shortening was significantly diminished in the old muscles.

REFERENCES

1. Urthaler F, Walker A A, Hefner L L and James T N. Comparison of contractile performance of canine atrial and ventricular muscles. *Circ Res* 37:762, 1975.
2. Urthaler F, Walker A A, Kawamura K, Hefner L L and James T N. Atrial and ventricular muscle mechanics studied as a function of age. *Circ Res* (in press).
3. Albert N R, Cale H H., and Taylor N. The effect of age on contractile protein ATPase activity and the velocity of shortening in Factors influencing myocardial contractility. Tanz R E et al. eds. New York 1967 Academic Press.
4. Grodner A S, Pool P E and Braunwald E. Influence of age on the mechanics of rat cardiac muscle (Abstr.) *Circulation* 42(Suppl III):115, 1970.
5. Heller L J and Whitehorn W N. Age associated alterations in myocardial contractile properties. *Am J Physiol* 222:1613, 1972.
6. Donald T C, Ungnoppetchara K, Peterson D and Hefner L L. Effect of initial muscle length on V_{max} in isometric contraction of cardiac muscle. *Am J Physiol* 223:167, 1972.
7. Brownlee V A. Statistical theory and methodology in science and engineering. 2nd edition. New York 1960 John Wiley & Sons Inc.
8. Cavato F V, Velhber J and Roberts J. Electrophysiological changes in the rat atrium with age. *Am J Physiol* 226:1793, 1974.
9. Brandfonbrener M, Landowne M and Shock N W. Changes in cardiac output with age. *Circulation* 12:537, 1955.
10. Eddleman H E. The effect of age on the normal kinetocardiogram. *Ala J Med Sci* 6:22, 1960.

The prevention and reversal of digoxin intoxication with specific antibodies

T Hess

G Scholtysik

W Riesen

Berne Switzerland

Signs of intoxication may be expected to occur in 10 to 20 per cent of all digitalized patients^{1, 7, 11}. Glycoside poisoning proves fatal in 5 to 10 per cent of all cases, the figure rising to 20 to 25 per cent when a massive overdose is taken notably with suicidal intent^{1, 8}. At the present time treatment is limited to symptomatic measures which are not always satisfactory. No effective antidote is as yet available.

Animal experiments with digoxin specific antibodies^{9, 12, 14, 15} and the first successful use of Fab fragments with anti digoxin specificity in a case of attempted suicide¹⁷ offer the prospect of a new form of causal therapy.

The present paper is a report on the production of digoxin specific antibodies and the efficacy of various antibody fractions for the prevention and treatment of digoxin induced arrhythmias in cats.

Methods

1 Production of antibodies Digoxin was oxidized with periodate and bound to human albumin¹⁶. Yearling sheep were immunized with the digoxin-albumin conjugate in Freund's complete adjuvant and were given booster doses at intervals of 14 days. On each occasion 3 mg of antigen was administered. One month after the start of immunization, blood was sampled every

14 days. The concentration of digoxin antibodies in the serum was determined spectrophotometrically after isolation with an immunoabsorbent prepared as previously described⁶; it varied between 4 and 10 mg/ml.

Digoxin specific sheep gammaglobulin was precipitated from anti digoxin antiserum by 40 per cent saturation with ammonium sulphate.

The specific antibodies were isolated with the aid of an immunoabsorbent consisting of ouabain-ribonuclease conjugate cross reacting with digoxin specific antibodies and coupled to Sepharose 4B¹⁸. The antibodies were separated into two fractions on Sephadex G 200 (100 x 25 cm). One was a macroglobulin fraction (60 per cent) and the other was a fraction corresponding to 7 S gammaglobulin (40 per cent) (Fig 1). It was shown by immunoelectrophoresis using specific sera against sheep proteins (anti whole sheep anti sheep IgG and anti sheep IgM) that both fractions consisted of IgG. The macroglobulin fraction was thus aggregated IgG.

F(ab')₂ was prepared by splitting the gamma globulin fraction with pepsin¹⁹. Isolation of F(ab')₂ and intact IgG by immunoadsorption and separating off the intact IgG by fractionation on Sephadex G 200 (Fig 2).

2 Animal experiments Experiments were performed in spontaneously breathing adult cats of either sex with a body weight between 2.1 and 2.9 kilograms. The cats were anesthetized with intramuscular doses of 43 mg/Kg chloralose and 430 mg/Kg urethane. The trachea and a jugular vein were cannulated. Heart rate and mean blood pressure were recorded continuously by means of a catheter in a femoral artery using a Statham P23Db transducer and a polygraph (Texas In-

From the Medical Department, Anna Seiler Haus, Inselspital, Berne; the Pharmaceutical Department, Medical and Biological Research, Sandoz, Ltd., Basle; and the Institute for Clinical and Experimental Cancer Research, University of Berne.

Received for publication Dec 12 1977.

Accepted for publication Jan 26 1978.

Reprint requests: Dr T Hess, Medical Department, Anna Seiler Haus, Inselspital, CH 3000 Berne, Switzerland.




Fig 1 Filtration of isolated anti digoxin antibodies through Sephadex G 90. The first peak corresponds to the elution volume of macroglobulins and consists of aggregated IgG. The second peak corresponds to the elution volume of 7 S (monomeric) IgG.




Fig 2 Filtration of pepsin treated anti digoxin antibodies through Sephadex G 90. The first and second peak consist of undigested IgG (Fig 1); the third peak consists of F(ab)₂ fragments.

struments) The ECG (Leads I, II and III 50 mm/sec) was taken with subcutaneous needle electrodes monitored on an oscilloscope and recorded on a 3 channel Mingograph at intervals of 5 minutes and additionally whenever arrhythmias occurred.

A Prophylactic administration of digoxin specific antibodies. After the animals had been anesthetized digoxin was administered by infusion into a jugular vein at a rate of 10 µg/Kg/min. The concentration of the infusion solution was matched to the individual body weight of each animal while the infusion volume was kept constant at 0.2 ml/min. At the onset of ventricular tachycardia or when ventricular extrasystoles exceeded 50 per cent the infusion of digoxin was stopped and the survival time was measured.

The effectiveness of three antibody preparations (gamma globulin, IgG and F(ab)₂) was investigated by comparing the three groups of

treated animals with an untreated control group.

CONTROLS (Group 1 animals 1 to 5) The animals did not receive prophylactic treatment with digoxin specific antibodies.

PROPHYLAXIS WITH DIGOXIN SPECIFIC ANTIBODIES (Groups 2, 3 and 4) Immediately before administration of digoxin the animals received an intravenous infusion (10 to 20 ml, 1 ml/min) of gamma globulin (precipitated from anti digoxin antiserum with ammonium sulphate at 40 per cent saturation).

(Group 2 animals 6 to 10) The antibody doses varied between 42 and 129 mg/Kg.

IgG anti digoxin antibodies

(Group 3 animals 11 to 15) The antibody doses varied between 62 and 88 mg/Kg. Two animals (Nos 11 and 12) received the macroglobulin and the 7S fraction and 3 animals (Nos 13, 14, 15) only the 7S fraction.

F(ab)₂ fragment of digoxin specific antibody




Fig 3 Effects of prophylactic administration of digoxin specific antibodies in anesthetized cats. Antibodies were injected intravenously before infusion of digoxin $10 \mu\text{g/kg/min}$




Fig 4 The influence of digoxin specific antibodies on digoxin induced arrhythmias in anesthetized cats. Subsequent treatment with antibodies was performed in animals from which results are also presented in Fig 3. The time at the end of each column represents death of the cats.

Table 1 Serum electrolytes before and after administration of the antibody preparations to 4 animals by infusion (p = not significant for all electrolytes)

Animal no	Sodium (mmol/L)		Potassium (mmol/L)		Calcium (mg/100 ml)		Inorganic phosphorus (mg/100 ml)	
	Before	After	Before	After	Before	After	Before	After
13	147	148	3.77	3.67	9.4	8.2	4.35	4.16
17	150	150	4.0	3.70	9.0	8.8	4.87	4.47
18	148	147	3.4	3.40	10.1	9.45	5.00	4.76
19	149	145	3.41	3.24	9.5	8.5	4.46	4.08

(Group 4 animals 16 to 19) The antibody doses varied between 52 and 75 mg/kg.

In four animals (Group 5 animals No 12, 14, 19) treatment with digoxin-specific antibodies after onset of the ventricular dysrhythmia was performed. The antibody doses varied between 111 and 73 mg/kg.

The serum levels of sodium, potassium, calcium and inorganic phosphorus were determined before and after infusion of the antibodies in four animals (Nos 13, 17, 18, 19).

B Therapeutic administration of digoxin

specific antibodies The animals were digitalized with daily intramuscular doses of 30 µg/kg digoxin administered on 3 consecutive days and were observed for any side effects. On day 4 the animals were anaesthetized and prepared as described above. Digoxin was then administered via a catheter in the jugular vein at intervals of 15 minutes in a dose of 20 µg/kg for the first two injections and in a dose of 10 µg/kg for the third and subsequent injections until ventricular tachycardia developed. If a normal sinus rhythm was not re-established within 120 minutes the




Fig 3 Effects of prophylactic administration of digoxin specific antibodies in anesthetized cats. Antibodies were injected intravenously before infusion of digoxin $10 \mu\text{g/Kg/min}$




Fig 4 The influence of digoxin specific antibodies on digoxin induced arrhythmias in anesthetized cats subsequent treatment with antibodies was performed in animals from which results are also presented in Fig 3 The time at the end of each column represents death of the cats

Table 1 Serum electrolytes before and after administration of the antibody preparations to 4 animals by infusion (p = not significant for all electrolytes)

Animal no	Sodium (mmol/L)		Potassium (mmol/L)		Calcium (mg/100 mL)		Inorganic phosphorus (mg/100 mL)	
	Before	After	Before	After	Before	After	Before	After
13	147	142	3.7	3.67	9.4	8.9	4.35	4.16
17	150	150	4.05	3.0	9.0	8.8	4.87	4.47
18	148	147	3.45	3.40	10.1	9.45	5.00	4.76
19	149	145	3.43	3.24	9.5	8.5	4.46	4.09

(Group 4 animals 16 to 19) The antibody doses varied between 52 and 75 mg/Kg

In four animals (Group 5 animals No 6 12 14 19) a treatment with digoxin specific antibodies after onset of the ventricular dysrhythmia was performed. The antibody doses varied between 19 and 73 mg/kg

The serum levels of sodium potassium calcium and inorganic phosphorus were determined before and after infusion of the antibodies in four animals (Nos 13 17 18 19)

II Therapeutic administration of digoxin

specific antibodies The animals were digitalized with daily intramuscular doses of 30 µg/kg digoxin administered on 3 consecutive days and were observed for any side effects. On day 4 the animals were anaesthetized and prepared as described above. Digoxin was then administered via a catheter in the jugular vein at intervals of 15 minutes in a dose of 20 µg/Kg for the first two injections and in a dose of 10 µg/Kg for the third and subsequent injections until ventricular tachycardia developed. If a normal sinus rhythm was not re-established within 120 minutes the




Fig ■ ECG (Lead II 50 mm/sec) of animal No. 14 Prophylactic treatment with IgG (76 mg/Kg) Forty four minutes after the start of the digoxin infusion sinus bradycardia and ST changes after 44.5 minutes (= 445 µg/Kg digoxin) onset of ventricular tachycardia. Intravenous treatment with gammaglobulin (19 mg/Kg) Ten minutes later nodal rhythm occurred after 50 minutes stable sinus rhythm resumed. On renewed infusion of digoxin arrhythmia again induced after 12.5 minutes (= 125 µg/Kg digoxin) with the resulting death of the animal.




Fig 8 ECG (Lead II 50 mm/sec) of animal No 26. Daily intramuscular doses of digoxin (30 μ g/Kg) on day 1 to 3. On day 4 after injection of total 100 μ g/kg digoxin ventricular tachycardia appeared. Intravenous treatment with F(ab')₂ 28 mg/kg was initiated. 25 minutes later stable sinus rhythm resumed. To induce renewed ventricular dysrhythmia, total injections of 340 μ g/kg digoxin were needed.

Table II Therapeutic administration of digoxin specific antibodies

Digitalization with digoxin 30 µg/kg daily for 3 consecutive days	Side effects	Rhythm at the start of experiment	Dose of digoxin (µg/kg) needed to trigger ventricular tachycardia	F(ab) ₂ (mg/kg) i.v.
Controls (Group 6)				
Animal 20	None	Sinus	90	-
Animal 21	None	Sinus	70	-
Animal 22	None	Sinus	80	-
Animal 23	Loss of weight	Sinus	70	-
Animal 24	Loss of weight vomiting	Sinus	80	-
			$\bar{x} = 78$ $SD = 8.4$ $p < 0.3$	
Treatment F(ab)₂ (Group 7)				
Animal 25	Loss of weight vomiting	Sinus	50	24
Animal 26	None	Sinus	100	28
Animal 27	None	Sinus	70	28
Animal 28	Vomiting	Sinus	60	31
Animal 29	Loss of weight	Sinus	60	30
Animal 30	Loss of weight	Sinus	60	64
Day 1 3				Day 4

animals were killed. When the ventricular tachycardia converted within this time to a stable sinus rhythm which was uninterrupted for at least 10 minutes by signs of arrhythmia, the dose of digoxin required to induce renewed ventricular tachycardia was determined. Digoxin was administered intravenously at intervals of 5 minutes in a dose of 20 µg/Kg for the first 7 injections and in a dose of 40 µg/Kg for the eighth and subsequent injections.

Two groups of animals were investigated: (1) **Controls** (Group 6, animals 20 to 24). These animals did not receive any treatment after induction of ventricular tachycardia. (2) **F(ab)₂ treatment** (Group 7, animals 25 to 30). After onset of ventricular tachycardia F(ab)₂ fragment of digoxin specific antibodies was administered intravenously in a dose of 28 to 64 mg/Kg.

The results were tested for significance by Student's *t* test.

Results

A Prophylactic administration of digoxin specific antibodies (Fig. 3)

Controls (Group 1, animals 1 to 5). 270 to 370 ($\bar{x} = 331$, $SD = 47$) µg/Kg digoxin were needed

to induce ventricular dysrhythmia. The survival time after discontinuing the digoxin infusion was 6.5 to 18 (mean 11.2) minutes.

Prophylaxis with digoxin specific antibodies (Group 2, 3 and 4). The dose of digoxin required to induce dysrhythmia was significantly ($p < 0.001$) greater for all prophylactically treated groups than for the control group. The digoxin doses were as follows: (1) gammaglobulin from anti digoxin antiserum (Group 2, animals 6 to 10) 520 to 1085 ($\bar{x} = 729$, $SD = 235$) µg/Kg digoxin, (2) IgG anti digoxin antibodies (Group 3, animals 11 to 15) 445 to 725 ($\bar{x} = 591$, $SD = 105$) µg/Kg digoxin, (3) F(ab)₂ fragment of the digoxin specific antibodies (Group 4, animals 16 to 19) 600 to 795 ($\bar{x} = 591$, $SD = 80$) µg/Kg digoxin.

The mean survival time for the animals in group 2 (34.3 minutes) and Group 4 (31.7 minutes) was significantly ($p < 0.02$) longer than for the control animals, whereas the survival time for Group 3 (mean 8.3 minutes) did not differ from that for the control group.

Serum levels of sodium, potassium, calcium and inorganic phosphorus measured in four animals were not significantly affected by infusion of the antibody preparation (Table I).

Course	Dose of digoxin ($\mu\text{g}/\text{kg}$) required to re induce ventricular tachycardia
Died 45 min after onset of ventricular tachycardia	—
Died 56 min after onset of ventricular tachycardia	—
Died 89 min after onset of ventricular tachycardia	—
Ventricular tachycardia still persisted after 120 min (killed)	—
Ventricular tachycardia still persisted after 170 min (killed)	—
Stable sinus rhythm after 95 min	280
Stable sinus rhythm after 20 min	340
Stable sinus rhythm after 31 min	300
Stable sinus rhythm after 30 min	270
Stable sinus rhythm after 27 min	470
Stable sinus rhythm after 37 min	600

Of the four prophylactically treated animals which again received digoxin specific antibodies (gamma globulin or IgG) after onset of the ventricular dysrhythmia three survived and were in stable sinus rhythm 50 to 100 (on average 75) minutes later (Figs 4 and 5). Between 125 and 220 (on average 168) $\mu\text{g}/\text{kg}$ digoxin was required to re induce ventricular dysrhythmia in these animals and they survived the second arrhythmia for an average period of 19 minutes. One animal died after 48 minutes despite the subsequent treatment and without conversion to sinus rhythm.

B Therapeutic administration of digoxin specific antibodies (Table II). No difference was observed between the control animals (Group 6 animals 20 to 24) and the animals treated with F(ab)₂ (Group 7 animals 25 to 30) after digitalization over 3 days with digoxin: a few animals in both groups suffered from vomiting and loss of weight. After anaesthetization and preparation all were in sinus rhythm. There was no significant difference between the doses of digoxin required to induce ventricular tachycardia in the two groups.

Conversion to stable sinus rhythm did not

occur in any of the controls. Three animals died 45, 56 and 89 minutes after onset of ventricular tachycardia; two animals were still dysrhythmic after 120 minutes and were killed.

Stable sinus rhythm was reinstated in all the animals treated with F(ab)₂ fragment of digoxin specific antibodies. Conversion to sinus rhythm occurred after a minimum time of 20 minutes and a maximum time of 95 minutes (mean time 43 minutes). Prior to conversion moreover short periods of sinus rhythm were observed which again passed into phases of ventricular tachycardia or ventricular extrasystoles (Fig. 6).

Digoxin doses of 220 to 600 (mean 360) $\mu\text{g}/\text{kg}$ were needed in order to induce ventricular tachycardia again after reinstatement of stable sinus rhythm in the animals treated with antibodies and a relation between digoxin dose and dose of antibody administered was discernible.

Discussion

In 1966 Butler and Chen¹ described the preparation of heterologous digoxin specific antibodies. Butler and co workers subsequently demonstrated the effectiveness of the antibodies for prevention and reversal of the effect of the glycoside *in vitro*²⁻⁴ and in animal experiments especially in digoxin intoxication.⁵⁻¹¹ The Fab fragment of sheep digoxin specific antibodies was first successfully employed in a human subject with potentially lethal digoxin poisoning in 1976.¹² As far as we are aware no other patients have so far been treated.

The frequency of glycoside intoxication and the considerable mortality rate prompted these present investigations with digoxin specific antibodies with a view to their clinical use.

Used prophylactically the digoxin specific antibodies in the form of preparations of gamma globulin IgG or F(ab)₂ had a statistically significant protective effect in our experiments on anaesthetized cats. Depending upon the dose of antibody administered the dose of digoxin required to induce ventricular dysrhythmia was up to three times greater than in untreated control animals. The arrhythmia induced by the glycoside led to the death of all the animals from ventricular fibrillation and asystole. For this reason four animals were given additional digoxin specific antibodies in the form of gamma globulin or IgG after onset of the digitals induced arrhythmia.

One of these subsequently treated animals died despite a high dose of antibodies and did not revert to sinus rhythm. However, this particular animal had shown transient ventricular fibrillation shortly after onset of the digoxin induced ventricular tachycardia. The remaining three animals were again in stable sinus rhythm 50 to 100 minutes later, and sinus rhythm was frequently restored for short periods even earlier than this.

Digoxin specific antibodies were found to be highly effective in the treatment of digoxin induced arrhythmia. Five untreated controls were digitalized over 3 days and on the fourth day ventricular tachycardia was induced with injections of digoxin. Of these five animals, three died early and the other two were still in ventricular tachycardia after 120 minutes. By contrast stable sinus rhythm was re established in all six animals treated with F(ab)₂ after an average time of 43 minutes. In similar experiments in dogs with the Fab fragment of digoxin specific antibodies conversion to sinus rhythm was achieved as early as 20 minutes after administration. The different times taken may be due to the different experimental procedure or to the fact that F(ab)₂ is distributed more slowly through the compartments than Fab.

It proved possible in all the animals treated with specific antibodies to induce renewed toxic arrhythmias with digoxin. This is evidence that the cardiac glycoside receptors of the myocardium are not blocked by pharmacologically inactive antibody hapten complexes. Investigations on the isolated papillary muscle of the cat lend support to such a view.

Pharmacokinetic studies in the dog suggest that the Fab fragment of digoxin specific antibodies probably has considerable advantages over the intact antibodies: the smaller size of the molecule permits more rapid distribution and diffusion in the extravascular compartment and more rapid renal excretion of the digoxin-Fab-complex by glomerular filtration. Fab and F(ab)₂ have a shorter half life in the organism than the intact immunoglobulin molecules and since they lack the Fc component they probably have a lower immunogenicity than the intact molecules. Our antibody preparations were in general well tolerated in these acute experiments as judged from the heart rate, blood

pressure, respiration, and ECG. The risk of sensitization to foreign protein is at present an obstacle to the wider clinical use of digoxin specific antibodies. At the present time such treatment should be reserved for cases in which conventional treatment is without avail and which are likely to prove fatal.

Summary

The formation of digoxin specific antibodies was induced in sheep by immunization with a digoxin-albumin conjugate. The efficacy of the antibodies was investigated in anesthetized cats.

When the digoxin specific antibodies were administered prophylactically as a gammaglobulin IgG or F(ab)₂ preparation the dose of digoxin needed to induce ventricular dysrhythmia was significantly greater ($p < 0.001$) for the pretreated animals than for the controls.

To investigate therapeutic efficacy the animals were digitalized with digoxin over a period of three days and were given digoxin injections on the fourth day to provoke ventricular tachycardia. Of the control animals three died before two hours had elapsed and the arrhythmia persisted in the two remaining animals. By contrast a stable sinus rhythm was restored in all animals which were treated with F(ab)₂ fragment of the digoxin specific antibodies after onset of ventricular tachycardia. The doses of digoxin required to trigger renewed ventricular dysrhythmia in these animals were greater than those required at the start of the experiment.

The potential clinical use of digoxin specific antibodies is discussed in the light of these results and reports in the literature.

We are grateful to Miss Ischi and Miss Dosogne for their technical assistance and to Mr J. E. Smith for his English translation of the manuscript.

REFERENCES

1. Beller G. A., Smith T. W., Abelmann W. H., Haber E. and Hood W. B. Digitalis intoxication. *N. Engl. J. Med.* 284: 989, 1971.
2. Bismuth C., Gaultier M., Conso F. and Eftymiou M. L. Hyperkalemia in acute digitalis poisoning. Prognostic significance and therapeutic implications. *Clin. Toxicol.* 6: 153, 1973.
3. Butler V. P. and Chen J. P. Digoxin specific antibodies. *Proc. Natl. Acad. Sci. USA* 57: 71, 1967.
4. Butler V. P., Watson J. F., Schmidt D. H., Gardner J. D., Mandel W. J. and Skelton C. L. Reversal of the pharmacological and toxic effects of cardiac glycosides by specific antibodies. *Pharmacol. Rev.* 25: 239, 1973.

- 5 Butler V P, Schmidt D H, Smith T W, Haber E, Raynor B II and Demartini P. Effects of sheep digoxin specific antibodies and their Fab fragments on digoxin pharmacokinetics in dogs. *J Clin Invest* 59:345 1977
- 6 Curd J, Smith T W, Jaton, J C and Haber E. The isolation of digoxin-specific antibody and its use in reversing the effects of digoxin. *Proc Natl Acad Sci USA* 68:2401 1971
- 7 Evered, D C and Chapman C. Plasma digoxin concentrations and digoxin toxicity in hospital patients. *Br Heart J* 33:540 1971
- 8 Gaultier M, Fournier H, Efthymiou M L, Frejaville J P, Jouannot P and Dentan M. Intoxication digitale aiguë. *Soc Med Hôp Paris* 119:47 1968
- 9 Mandel W J, Bigger T and Butler V P. The electrophysiologic effects of low and high digoxin concentrations on isolated mammalian cardiac tissue. Reversal by digoxin specific antibody. *J Clin Invest* 51:1348 1972
- 10 Masonoff A, Wussler F C, Lipman L N and Woernly D L. Separation of univalent fragments from the bivalent rabbit antibody molecule by reduction of disulfide bonds. *Arch Biochem Biophys* 89:930 1960
- 11 Ogilvie H J and Raedy J. An educational program in digitalis therapy. *J A M A* 222:50 1972.
- 12 Rodensky P L and Wasserman F. Observations on digitalis intoxication. *Arch Intern Med* 108:171 1961
- 13 Schmidt D H and Butler V P. Immunological protection against digoxin toxicity. *J Clin Invest* 50:866 1971
- 14 Schmidt D H and Butler V P. Reversal of digoxin toxicity with specific antibodies. *J Clin Invest* 50:1738 1971
- 15 Schölmmerich P, Pabst K, Jahrreis O and Lange K P. Nebenwirkungen der Therapie mit Herzglykosiden. *Dtsch. Med Wschr* 89:12 1964
- 16 Smith T W, Butler V P and Haber E. Characterization of antibodies of high affinity and specificity for the digitalis glycoside digoxin. *Biochemistry* 9:331 1970
- 17 Smith T W, Haber E, Yeatman L and Butler V P. Reversal of advanced digoxin intoxication with Fab fragments of digoxin-specific antibodies. *N Engl J Med* 294:797 1976
- 18 Watson J F and Butler V P. Biologic activity of digoxin specific antisera. *J Clin Invest* 51:638 1972

Transmural gradients of experimental myocardial ischemia Limited correlation of ultrastructure with epicardial S-T segment elevation

John J Lamberti, M D
Helayne Silver, B S
Joel Howell, B S
Kenneth Kampman, M D
Seymour Glagov, M D
Chicago Ill

Relatively short periods of experimentally induced ischemia produce functional, electrocardiographic, and morphologic changes in the working canine heart.¹ Maroko and associates² have presented evidence that the height of epicardial S-T segment elevation in the ischemic canine heart may be a useful indicator of both the extent and the severity of underlying myocardial injury, and that epicardial S-T segment elevations recorded after 15 minutes of permanent coronary occlusion correlate well with changes in myocardial morphology at 24 hours³ with myocardial creatine phosphokinase depletion,^{2,3} and with regional myocardial blood flow.³ The practical value of such observations has been challenged^{4,5} for definite inconsistencies have been observed. For example, other investigators have not found close correlation between the extent of myocardial injury and the height of S-T segment elevation⁶ and functional changes in the myocardium have been shown to persist long after S-T segments have reverted to normal.⁷

In view of these conflicting data, we undertook a series of experiments designed to explore the

transmural ultrastructural state of the myocardium immediately underlying sites of epicardial S-T segment recording in the canine heart. Several investigators have asserted that ischemic injury resulting from coronary occlusion of twenty minutes or less is completely reversible.⁸⁻¹⁰ In two of these reports,^{11,12} morphologic alterations were observed after temporary circumflex coronary artery occlusion. They describe the pathologic findings in the posterior papillary muscle of the dog. The commonly used technique of epicardial S-T segment mapping describes changes in the myocardium of the anterior apical left ventricle of the dog.¹ By means of standardized fixation and sampling techniques, we were able to characterize reproducible gradients of ischemic morphologic change across the anterior apical ventricular wall and to correlate these with simultaneously recorded epicardial electrocardiograms. In this report, we present data dealing with the effects of 20 minutes of ischemia.

Materials and methods

Our objective was to obtain epicardial electrocardiographic recordings over ischemic and non-ischemic zones of myocardium and to study the ultrastructure of transmural samples of myocardium immediately beneath any selected recording point. To this end, we utilized a technique for rapid perfusion fixation of the entire heart immediately after recording the electrophysiologic changes. This procedure provided a rigid and

From the Departments of Surgery and Pathology, The University of Chicago, The Pritzker School of Medicine, Chicago, Illinois.

Supported by the Louis L. Block Fund of The University of Chicago Grant HL17648 awarded by The National Heart, Lung, and Blood Institute, DHEW, and American Heart Association Grant 76-632.

Received for publication Jan. 16, 1978.

Accepted for publication Feb. 13, 1978.

Reprint requests to John J. Lamberti, M.D., Department of Surgery, The University of Chicago, 950 E. 59th St., Chicago, Ill. 60637.




Fig 1 Schematic diagram of experimental preparation for immediate perfusion-fixation of the heart *in situ*

uniformly fixed specimen suitable for precise sampling. Ventricle was in a nearly diastolic configuration³ and anatomic landmarks were well preserved permitting points of recording and zones of grossly observed ischemia to be marked accurately on the epicardial surface.

Operative procedures Mongrel dogs weighing between 15 and 40 kilograms were anesthetized with sodium pentobarbital intubated and ventilated with a Harvard respirator.⁴ Arterial blood gases were determined and supplemental oxygen was utilized as necessary to maintain the arterial PO₂ at normal levels. In each instance the heart was exposed through a left thoracotomy incision and suspended in a pericardial cradle. An electromagnetic flow probe⁵ was placed around the left anterior descending coronary artery (LAD) at its origin and pressure monitoring catheters were placed in the ascending aorta and in the right and left atria. Arterial and atrial pressures were measured with Statham pressure transducers.⁶ The right brachiocephalic trunk was ligated and cannulated proximal to the ligature with a large bore tube for subsequent perfusion fixation. The descending aorta distal to the ligamentum arteriosum was encircled with a snare. The mid portion of the left anterior descending coronary artery (LAD) or one of its major branches was selected for occlusion, dissected free of epicardial

adipose tissue and encircled with an atraumatic silicone rubber tape. Occlusion sites were selected after evaluation of coronary artery distribution with the aim of producing a zone of ischemia involving the distal antero lateral or antero apical portion of the left ventricle. After recording baseline hemodynamic data and determining hematocrit and serum osmolality, the coronary artery was occluded for a period of 20 minutes.

A saline soaked wick connected to the V lead of an ECG amplifier was used to record the epicardial electrocardiogram from selected epicardial sites.⁷ All variables including epicardial and limb electrocardiograms were monitored and recorded on an Electronics for Medicine recorder.⁸ At five minute intervals epicardial electrocardiograms were recorded at eight to 12 sites along the distribution of the LAD.⁹ After 20 minutes the heart was fibrillated by means of low voltage direct current. The coronary ligature was released and perfusion fixation began immediately.

Perfusion-Fixation Coronary perfusion was achieved by closing the snares around the brachiocephalic trunk and the descending aorta opening the left and right atria to vent the heart and starting a calibrated roller pump which propelled fluid into the brachiocephalic cannula (Fig 1). Fibrillation prior to snare occlusion prevented acute left ventricular afterload in

¹ *Rever Apparatus*, Cambridge, Mass. Inset.

² *Carolina Medical Electronics*, Raleigh, N. C. *Carolina*

³ *Cham Instruments*, 111 E. Bay Pkwy. R. C.

⁴ *Electronics for Medicine*, Des Plaines, Illinois

crease and allowed immediate coronary perfusion. The coronary arteries were first perfused with balanced electrolyte solution, until the coronary sinus effluent was grossly clear of blood, this usually was achieved in one to two minutes. The perfusate was then changed to 2 per cent glutaraldehyde solution, and perfusion continued. The fixative solution was prepared by diluting concentrated glutaraldehyde solution (50 per cent) with distilled water, adjusting the pH to 7.4 with sodium hydroxide, and adding sodium chloride to adjust the osmolality to the appropriate level for the animal under study. Serum osmolality of the animals studied ranged from 297 to 316 mosm. The osmolalities of the balanced electrolyte and 2 per cent glutaraldehyde solutions used for perfusion were corrected to within 2 per cent of the serum osmolality of each dog studied prior to perfusion. Both the flushing and fixation solutions were maintained at 37° C in a water bath. Pressure in the ascending aorta was monitored throughout perfusion, and pump speed was adjusted to maintain perfusion pressure at a mean level of 90 mm Hg. Overflow of fixative from the atrial vents accumulated in the pericardial well and prevented drying of the epicardial surface during the fixation period. Hearts were completely fixed, with excellent preservation of ultrastructural detail after 30 minutes of controlled pressure perfusion at 37° C.

Specimen sampling and preparation At the conclusion of the perfusion-fixation period, the heart was removed from the thorax by transection of the major vessels and immersed in a container of fixative. The sites of S-T segment mapping were marked on the epicardium with indelible ink, according to maps drawn at the time of recording, and the specimen was photographed. Ischemic zone sampling sites were selected on the basis of anatomic location, appearance during coronary occlusion, and S-T segment elevation. Regions distant from zones of presumed ischemia and with isoelectric S-T segments were sampled as non ischemic, normal controls for each heart. Large transmural tissue blocks were removed from ischemic and non ischemic zones by means of a sharp flat sectioning knife. Each tissue block measured approximately 10 × 10 cm at the endocardial and epicardial surfaces. Final sampling was accomplished by subdividing each block under a dissect

ing microscope. Cuts were made perpendicular to the epicardial surface to produce a column of tissue approximately 1.5 mm on each edge and of a length determined by the thickness of the ventricle. Thus, each column had the ink dot marked epicardium at one end and the corresponding endocardium at the other. One of the trimmings facing the final column sample was processed for study by light microscopy. The column was then divided into 10 to 20 mm cubes, each of which was placed in a separate vial and numbered consecutively from epicardium to endocardium. Eight to 15 transventricular samples were therefore available at each site, depending upon ventricular thickness. Each transmural cube was post fixed in 1 per cent osmium tetroxide for one hour, dehydrated in graded alcohol solutions and propylene oxide, and embedded in epon.

Subepicardial, subendocardial, and midventricular specimens were sectioned from each sampling location. Selected specimens at other levels were viewed in some instances to confirm the presence of transmural gradients. Thick sections were stained with toluidine blue. For thin sectioning specimens were reoriented when necessary to provide longitudinal sections of myocardial fibers. Thin sections were treated with lead hydroxide and uranyl acetate to enhance electron density and were viewed in an RCA EMU 3D electron microscope. In each heart a section from the non ischemic zone was compared to at least one sample from the ischemic zone. In some hearts two sites in the ischemic zone were analyzed to allow comparison of ischemic sites with differing degrees of S-T segment elevation. Sections were examined and photographed systematically at a standard series of magnifications in order to obtain comparable data with regard to nuclear morphology, abundance of glycogen, mitochondrial preservation, and the state of sarcomeres, filaments, membranes, and intercalated discs. Perfusion fixed specimens tended to show larger intra and extra cellular spaces than are normally seen after immersion fixation, but comparison of samples from ischemic and non ischemic zones permitted evaluation of swelling due to ischemia. Care was taken to observe and to photograph capillary endothelial cells and tissue histiocytes as often as possible in order to reveal non specific changes.




Fig 2 Range of mitochondrial change associated with increasing severity of ischemic injury after 20 minutes of coronary occlusion. A In control zones with normal ST segments mitochondria are intact cristae are closely packed and uniformly oriented B In zones of moderate ischemic damage (++) mitochondria show focal intracristal widening (arrows) C In zones of severe ischemia (++++), swollen mitochondria with focal total cristal disruption are frequent (All magnifications originally $\times 44,000$)

and to assess changes peculiar to myofiber ischemia. Photographs were reviewed and compared as unknowns by each of the authors. Analysis of the photographs revealed that ultrastructural changes could be graded in five steps (0 to 4+). When no ischemic alterations were found in any photographs of an individual myocardial sample the tissue was graded zero (0). Samples which revealed minimal clumping of nuclear chromatin patchy but definite decrease in glycogen stores and early alterations in mitochondrial structure were graded +. Samples with mitochondrial disruption marked edema marked nuclear clumping and/or derangement of nuclear structure and severe depletion or absence of glycogen stores were graded +++. Intermediate degrees of change were graded ++ or ++.

Experiments The findings which form the basis of this report are drawn from 12 experiments. In six, fixation was carried out immediately after 20 minutes of coronary occlusion with epicardial mapping at five minute intervals. In a second group of six animals, the coronary artery snare was released after 20 minutes and additional epicardial electrocardiograms recorded five, 15, 30 and 60 minutes after reperfusion. These exper-

iments were then terminated by fibrillation and immediate perfusion-fixation.

Results

Morphologic changes related to ischemic injury were similar to those reported by others¹¹. Clumping and margination of nuclear chromatin were a striking and consistent finding when present; this change was usually uniform in degree throughout the section and involved practically every myofiber nucleus. Glycogen granule depletion was also a consistent finding but was much less uniform in any given block than was the nuclear change. Mitochondrial change after 20 minutes of ischemia ranged from focal widening of intercrystal spaces to over all mitochondrial swelling and focal disruption of cristal architecture. For any given section, mitochondrial changes were more uniform in extent and degree than glycogen depletion changes and less uniform than the nuclear changes. Thus, although mitochondrial changes paralleled nuclear changes, these alterations could not always be shown side by side on photographs of the same magnification. The sequence of severity of mitochondrial change is shown in Fig 2. The corresponding effects of ischemia on nuclear configura-

Table 1 Transmural ultrastructure after 20 minutes of coronary occlusion

Dog	Epicardial electrocardiogram at 15 min		Sampling sites	Height of ST at 15 min (mm)	Myocardial thickness (mm)	Ultrastructural evidence of myocardial ischemia		
	N ST > 2	Σ ST				Subendocardial	Midmyocardial	Subepicardial
A	0	0	NI	00	11	II	0	0
			I	00	11	+++	II	0
B	0	5	NI	00	20	+	0	0
			I ₁	10	15	++	++	0
			I ₂	20	15	++++	+++	+
C	4	26	NI	20	20	0	II	0
			I ₁	20	16	++	+++	0
			I ₂	60	12	+++	++	+
D	6	35	NI	15	12	0	0	0
			I	50	10	++	+	0
E	5	41	NI	00	20	II	0	0
			I	70	18	+++	++	+
F	7	80	NI	10	14	0	II	0
			I	40	12	++++	++	+
			I ₂	130	11	+++	++	0

+ = no ischemic change + to +++ = increasing ultrastructural evidence of ischemia (See text) NI = non ischemic zone by anatomic criteria and gross appearance before fixation I = ischemic zone by anatomic criteria and gross appearance before fixation

tion and glycogen granules are better seen at the lower magnifications used in subsequent illustrations. Except for Fig 2 all illustrations are presented at the same magnifications to permit ready comparison; fields have been chosen to represent typical composite findings.

In no instances were the ischemic changes so consistently evident in myocardial fibers, seen in capillary endothelial cells, tissue histiocytes, or fibroblasts even when these interstitial cells were immediately adjacent to abnormal myofibers. We interpreted this finding to be a reflection of the differential effects of ischemia on these cells and as further evidence that the changes we noted were not attributable to inadequate penetration of fixative. Specimens from control areas i.e. away from presumed ischemic zones and without ST segment elevation showed good preservation of myocardium at all depths.

Correlations Between ST segment elevation and ultrastructural change after 20 minutes of ischemia. The results for the six dogs studied immediately after 20 minutes of LAD occlusion are presented in Table 1 in order of increasing ST segment change. The number of sites of ST segment elevation greater than 2 mm (N ST) and the sum of ST elevation (Σ ST) at 15 minutes of ischemia are presented in a manner similar to

that used by others describing comparable experiments.¹ Thickness of myocardium, height of epicardial ST segments at sampling sites and the state of the myocardium at typical depths of sampling are given for each site. The number of sites of ST (N ST) segment elevation greater than 2 mm ranged from 0 to 7 (4). The sum of ST segment elevation (Σ ST) in the ischemic areas ranged from 0 to 85 mm (32). Except for the animal with no ST segment elevation (Dog A) abnormal areas of myocardium were grossly visible after occlusion of the coronary branch. In most instances, there was cyanosis of the myocardium distal to the ligature with paradoxical bulging during systole. A gradient of increasing ischemic ultrastructural change from epicardium to endocardium was seen in all the ischemic zone samples. Samples from non ischemic zones appeared normal in all cases except the subendocardial sample in Dog B, where minimal alterations in nuclear chromatin and mitochondria were noted. The ischemic zone sample sites in animal B, however, followed the consistent pattern of transmural gradient of change seen in the other five animals studied at 20 minutes.

ST segment elevations in ischemic zones were always associated with underlying morphologic evidence of injury but there was not a consistent




Fig 3 Typical fields from myocardial samples after twenty minutes of coronary occlusion in a single animal (Dog F). A transmural gradient of injury from epicardium to endocardium underlies the abnormal S-T segment elevation of 4 mm. **A** Subendocardial zone from control area (ie away from zone of ischemia and underlying a normal S-T segment). Nucleus (N) and mitochondria (m) are intact and glycogen (g) is abundant. **B** Subepicardial sample (Site 1) underlying abnormal S-T segment. Nuclear chromatin clumping and margination is moderate, glycogen is depleted, and mitochondria show focal intercrystal swelling and blebbing. **C** Midmyocardial sample (Site 1) (0.8 cm. from epicardial surface). Nuclear chromatin clumping and margination are marked, glycogen is absent, and mitochondria show increased swelling and deformation. **D** Subendocardial sample (Site 1) (1.2 cm. from epicardial surface). Nucleus is practically translucent, glycogen is markedly depleted and mitochondria are frequently disrupted. In addition, myofibers are thinned and attenuated with focal filament disruption. (All original magnifications $\times 800$.)




Fig 4 Specimen taken from an ischemic zone (Dog C) with minimal S T segment elevation (2 mm). In contrast to the findings in Fig 3 this zone showed no ischemic injury in the subepicardial sample. Ischemic damage was however evident in the midmyocardium and in the subendocardial sample. **A** Subendocardial zone of control area. Nucleus, mitochondria, and glycogen stores are normal. **B** Subepicardial sample from the ischemic zone showed no abnormalities. **C** Mid-myocardial sample in the ischemic zone (0.8 cm from epicardial surface). Nuclear chromatin is clumped, mitochondria are swollen, glycogen is absent, myofibers are attenuated. **D** Subendocardial sample from ischemic zone (1.6 cm below epicardial surface). Mitochondrial damage is more severe, edema is more pronounced, nuclear chromatin is distinctly clumped and margined, glycogen is depleted. (All original magnifications $\times 7800$)



Fig 5 Samples underlying a point in the ischemic zone with no elevation of ST segment (Dog A). Severe ischemic changes were present in the subendocardial sample (B) 17 cm below the epicardial surface. There were only minimal ischemic changes in the midmyocardial sample (A) 0.9 cm below the surface. There were no abnormalities in the subepicardial sample. (All original magnifications $\times 7800$)

relationship between the extent of change and the height of ST segment elevation. In addition, zero or minimal elevation of ST segments could be associated with marked ischemic change. Comparison of animals D and E for example would suggest a relationship between ST segment elevation and transmural extent of ischemic change. In animal D, an ST segment elevation of 5 mm was observed at the ischemic sampling site; at this point the subepicardial myocardium was normal and identical to the non-ischemic site while the subendocardial site 0.8 cm beneath the surface of the heart showed moderately advanced ischemic changes ($++$) and the mid-myocardial sample revealed minimal change. In animal E, with a slightly higher ST segment elevation (i.e., 7 mm) over the ischemic zone sample site, morphologic abnormalities were present at all depths with a gradient of severity from epicardium to endocardium. Other comparisons among ischemic zones, even in blocks from different sites in the ischemic zone of the same animal, failed to show a quantitative relationship between morphologic change and ST segment

elevation. Dog F for example showed the usual gradient of change from epicardium to endocardium in both of the samples. Ischemic zones: one site (I_1) had more damage in the subendocardial layer than did the other site (I_2), but the latter had a higher ST segment elevation. Typical fields from the non-ischemic zone and from the subepicardial, mid-myocardial and subendocardial myocardium in ischemic zone I_1 of dog F are shown in Fig 3.

In contrast, minimal ST segment elevations could be associated with severe ischemic changes (Fig 4). In dog C, two sites were studied in the ischemic zone. One site showed a 2 mm ST segment elevation, an elevation generally considered to be insignificant. In this area, the subepicardial myocardium was intact but both the mid and the subendocardial samples showed marked ischemic changes. Similarly, the heart of Dog A showed no ST segment elevations at a point expected to be ischemic on the basis of the anatomic site of vessel occlusion and the gross appearance of the myocardium during occlusion. At this site, moderate ischemic changes were seen

in the mid myocardium and marked abnormalities were seen in the subendocardial myocardium (Fig 5). The non ischemic, control zone in this animal was entirely normal. Finally, dog B had minimal ST segment elevation at the sampled sites in the ischemic zone, although the myocardium appeared to be abnormal during coronary artery occlusion. Significant ultrastructural abnormalities were prominent in both sample sites with the typical transmural gradient of severity.

Reperfusion after 20 minutes of ischemia The six animals allowed to recover for 60 minutes after the ischemic interval had N ST ranging from 3 to 7 (5), and Σ ST ranging from 27.5 to 62 mm (44) 15 minutes after occlusion. After release to the occlusion, the epicardial electrocardiogram returned to the control state in all animals before they were killed. Myocardium in non ischemic zones appeared entirely normal. Only slight and focal clumping of nuclear chromatin could be discerned in some subendocardial sites in the ischemic zone. These nuclear changes were in marked contrast to the nearly universal changes observed after 20 minutes of ischemia in the other six dogs.

Correlations with hemodynamic data Pre ligation heart rates ranged from 120 to 150 beats per minute while post ligation heart rates ranged from 120 to 180 beats per minute. Tachycardia induced by myocardial ischemia did not correlate with either the extent or the degree of ultrastructural change in the samples examined. Left atrial pressures ranged from 6 to 8 mm Hg and remained constant or rose slightly (1 to 2 mm Hg) after coronary ligation. Hematocrit values ranged from 31 to 42 per cent and did not correlate with the extent or degree of ischemic damage. Proximal LAD blood flow was reduced from 25 to 60 per cent during ligation of the distal LAD or its diagonal branch. Animal F had the greatest decrease in LAD flow and correspondingly exhibited the most severe ischemic changes; other animals showed no consistent relationship between the extent of proximal LAD flow decrease and the extent of morphologic alteration. Mean arterial pressure ranged from 80 to 120 mm Hg in the six animals (A-F) studied immediately after 20 minutes of ischemia and the extent of ischemic alteration did not correlate with the level of arterial pressure. The six animals which underwent reperfusion and recovery after 20

minutes of ischemia had heart rates ranging from 120 to 180 beats per minute, mean arterial pressure ranging from 100 to 130 mm Hg and decreased coronary flow ranging from 30 per cent to 40 per cent.

Discussion

In the present study our goal was to determine the transmural myocardial ultrastructural alterations which correspond to various degrees of ST segment elevation under conditions of reversible injury. Controlled pressure perfusion-fixation of the arrested heart produced a uniformly fixed rigid specimen in which the myocardium could be sampled from epicardium to endocardium in precise relationship to ST segment recording sites. Non ischemic zones were consistently normal in appearance from epicardium to endocardium, but, 20 minutes of coronary occlusion provided a distinct gradient of unequivocal injury in the ischemic zones. Changes typical of ischemia were greatest as expected in the subendocardial region. The most severe changes, graded + + + +, appeared to be somewhat more severe in the samples examined than those reported by others at 20 minutes of papillary muscle ischemia.¹ Since animals which were allowed to recover before fixation exhibited no ultrastructural alterations in the previously ischemic zones we may presume that the observed ischemic changes were reversible.

Despite care exercised in mapping fixation, and sampling in these experiments we were unable to demonstrate a consistent relationship between ST segment elevation and transmural morphologic changes. We were thus unable to establish any quantitative or predictive value of epicardial ST segment mapping for determining the severity of the transmural, ultrastructural myocardial injury. Although ST segment elevation in the anatomically ischemic zones always indicated the presence of ultrastructural changes marked changes in myocardial ultrastructure were also seen in ischemic zones when ST segment elevations were minimal. In this model ST segment changes tend to underestimate the extent of early ischemic damage. Heng and colleagues² also found that myocardial injury could be present at sites where ST segments were not elevated during early ischemia confirming our findings.

There is other evidence to suggest that changes

in the epicardial electrocardiogram do not always predict changes in underlying myocardium. Cohen and Kirk⁷ found that apparent improvement in S-T segment elevation could be associated with increasing ischemia. In another study comparing the effects of various methods of hemodilution on the acutely ischemic working heart, significant reduction in S-T segment elevation was observed after dextran hemodilution, but analysis of regional myocardial blood flow showed no change in ischemic zone blood flow when improvement in the epicardial electrocardiogram was recorded. Since there was no demonstrated increase in blood flow and since oxygen delivery was decreased by hemodilution, this is presumably another example of a paradoxical change in S-T segment elevation. Additional confusion has been generated by reports in which functional alterations in the myocardium have been shown to persist long after reversion of the epicardial electrocardiogram to normal.⁸ Holland and Brooks found that interpretation of the epicardial surface potential was complex and difficult and they suggested that conclusions based only upon epicardial E-T segment mapping may not be accurate. Muller and associates⁹ suggest that apparent paradoxical results obtained with the use of epicardial E-T segment mapping can be ascribed to misinterpretation of changes in the overall QRS pattern. They suggest that sites where severe ischemia results in QRS conduction delay cannot be interpreted in the same manner as ischemic sites without conduction delay. In our experiments for example, dog F exhibited a widened QRS at site I (S-T = 13 mm) indicating severe ischemia, but the ultrastructural morphology was not worse than that of site I, (S-T = 4 mm). Since regional myocardial blood flow is known to be quite variable in ischemic canine myocardium, the finding that early ultrastructural changes do not correspond precisely to simultaneous epicardial maps should not be unexpected.

Our study does not thus far address itself to the role of epicardial S-T segment measurements in predicting the overall extent of myocardial injury, for we have not examined the relationship between the sum of S-T segment elevations and the overall ischemic changes in the myocardium. The electrocardiogram recorded at a single point on the epicardium is likely to represent the

influence of a much larger mass of muscle than that immediately underlying the mapping electrode. If the entire ischemic zone were to be divided into columns of myocardium, a three-dimensional map of the ischemic portion of the ventricle could be constructed. It is conceivable that such an anatomic map would then correlate closely with an overall epicardial S-T segment map. The preparation described in the present study of reversible ischemia should prove useful for further exploration of the relationships between the epicardial electrocardiogram and the underlying myocardium and for evaluating the effectiveness of interventions thought to be useful in the prevention and treatment of myocardial ischemic injury.

Summary

A standardized preparation was developed to investigate the precise relationship between epicardial S-T segment elevation and myocardial ultrastructure. The distal left anterior descending coronary artery was occluded for 20 minutes and epicardial S-T segments were recorded at five minute intervals. Immediate perfusion-fixation with glutaraldehyde preserved pre-mortem anatomic relationships and allowed precise sampling of the myocardium immediately underlying sites of S-T segment recording. Ischemic and non ischemic zones were defined both anatomically and by S-T segment mapping. Transmural samples at 0.2 cm intervals were compared at sites in ischemic and non ischemic zones. In non ischemic zones S-T segment elevations ranged from 0 to 2 mm and myocardial ultrastructure was normal. In ischemic zones S-T segment elevations ranged from 0 to 14 mm and samples showed a gradient of ischemic injury with greatest change in subendocardial blocks. The extent of ultrastructural change at any point was not consistently proportional to the height of S-T segment elevation. E-T segment elevations greater than 11 mm were always associated with a marked transmural gradient of change, but S-T segment elevations less than 2 mm in ischemic zones could also be associated with severe subendocardial and mid myocardial change. In a second group of dogs the coronary artery snare was released after 20 minutes of occlusion and recovery was allowed for 60 minutes before killing and subjecting to perfusion-fixation. These

hearts exhibited no abnormality in myocardial ultrastructure when sampled in the same fashion as the first group

In this model a reproducible gradient of transmural myocardial ultrastructural change was demonstrated under conditions of reversible injury. Prominent ST segment elevation in ischemic zones always indicated the presence of underlying ultrastructural change, but marked changes were also present when ST segment elevations were minimal, indicating that the ST segment maps tended to underestimate the extent of early ischemic change. We were unable to establish a quantitative relationship between the extent of ST segment elevation and the extent of transmural ultrastructural change.

REFERENCES

- 1 Sobel B F Biochemical and morphologic changes in infarcting myocardium. In: *The Myocardium: Failure and Infarction*, edited by Braunwald E. New York: 1974. H P Publishing Company, chapter 22, pp 247-260.
- 2 Maroko P R, Kjekshus J K, Sobel B E, Watanabe T, Covell J W, Ross J Jr and Braunwald E Factors influencing infarct size following experimental coronary artery occlusions. *Circulation* 43:67, 1971.
- 3 Maroko P R and Braunwald E Modification of myocardial infarction size after coronary occlusion. *Ann Intern Med* 79:720, 1973.
- 4 Sybers H D, Maroko P R, Ashraf M, Libby P, Braunwald B A and Braunwald E The effect of glucose-insulin-potassium on cardiac ultrastructure following acute experimental coronary occlusion. *Am J Pathol* 70:401, 1973.
- 5 Kjekshus J K, Maroko P R and Sobel B F Distribution of myocardial injury and its relation to epicardial ST segment changes after coronary occlusion in the dog. *Cardiovasc Res* 6:490, 1972.
- 6 Holland R P and Brooks H Precordial and epicardial surface potentials during myocardial ischemia in the pig. *Circ Res* 37:471, 1975.
- 7 Cohen M V and Kirk E S Reduction of epicardial ST segment elevation following increased myocardial ischemia: experimental and theoretical considerations. *Clin Res* 22:169A, 1974.
- 8 Lekven J, Heibek A, Fonstelen E and Kul F Relationship between ST segment elevation and local tissue flow during myocardial ischemia in dogs. *Cardiovasc Res* 9:627, 1975.
- 9 Heng M K, Singh B N, Norris R M, John M B and Elliot R Relationship between epicardial ST segment elevation and myocardial ischemic damage after experimental coronary artery occlusion in dogs. *J Clin Invest* 58:1317, 1976.
- 10 Weimer J M, Apstein C S, Arthur J H, Puzada F A and Hood W E Persistence of myocardial injury following brief periods of coronary occlusion. *Cardiovasc Res* 10:678, 1976.
- 11 Jennings R B, Sommers H M, Smith E A, Flack H A and Linns H Myocardial necrosis induced by temporary occlusion of a coronary artery in the dog. *Arch Pathol* 70:82, 1960.
- 12 Jennings R B and Ganote C E Structural changes in myocardium during acute ischemia. *Circ Res* (Suppl III) 34 and 35:156, 1974.
- 13 Cerna F B, Lajos T Z, Montes M and Siegel J H Quantitative assessment of late fibrosis after reversible myocardial anoxia. *J Surg Res* 18:185, 1975.
- 14 Glagov S, Eckner F A O and Lev M Controlled pressure fixation apparatus for hearts. *Arch. Pathol* 76:62, 1963.
- 15 Eckner F A O, Brown B W, Davidson D L and Glagov S Dimensions of normal human hearts. *Arch. Pathol* 88:497, 1969.
- 16 Cohn L H, Lamberti J J, Florian A, Moses R, Vandervanter E, Kirk E and Collins J J Effects of hemodilution on acute myocardial ischemia. *J Surg Res* 18:523, 1975.
- 17 Heyndrickx G R, Millard R W, Maroko P R, McRitchie R J and Vatner S F Effects of acute ischemia on regional myocardial function and electrocardiogram in conscious dogs. *Am J Cardiol* 35:144, 1975.
- 18 Muller J E, Maroko P R and Braunwald E Evaluation of precordial electrocardiographic mapping as a means of assessing changes in myocardial ischemic injury. *Circulation* 52:16, July 1975.
- 19 Marcus M L, Kerber R E, Ehrhardt J and Abboud F M Three dimensional geometry of acutely ischemic myocardium. *Circulation* 52:254, 1975.

Dose independent pharmacokinetics of digoxin in humans

Hermann R Ochs MD
David J Greenblatt MD
Günther Bodem MD
Jerold S Harnatz

Bonn University, Bonn, Germany and Boston, Mass

The pharmacokinetics of digoxin in humans has been the subject of numerous investigations. Most have focused on differences between individuals in digoxin disposition and on the effects of such factors as age, weight, sex, renal function, and disease states upon pharmacokinetics. Few studies, however, have assessed the effect of digoxin dosage variations upon its pharmacokinetic properties within the same individual.² The present study systematically investigated the pharmacokinetics of digoxin in healthy human subjects, each of whom received the drug intravenously over a threefold range of doses.

Methods

Subjects and procedure Nine healthy male volunteers participated in the study (Table 1). All were free of identifiable medical disease, were taking no medications on a chronic basis, and had normal values of creatinine clearance.

Each received three intravenous doses of digoxin (0.5, 1.0, and 1.5 mg) in random sequence in a single dose, three-way crossover study, with at least four weeks elapsing between drug exposures. For each trial, the appropriate dose was diluted to

Table 1 Subject characteristics

Subject number	Age (years)	Weight (kg)	Creatinine clearance (ml/min/kg)
1	33	69	181
2	33	90	147
3	37	80	144
4	25	72	174
5	35	72	106
6	37	76	126
7	30	83	150
8	23	76	147
9	34	82	181
Mean (±SE)	31.3 (±1.5)	77.7 (±2.2)	150 (±0.09)

30 ml with physiologic saline and infused intravenously into an antecubital vein over a period of one hour by a constant rate infusion pump. Venous blood samples were drawn from the contralateral arm from an indwelling Butterfly cannula or by separate venipuncture prior to the infusion at the end of the infusion and the following times after the termination of the infusion: 0.5, 1.0, 1.5, 2.5, 3.4, 5.7, 11, 23, and 35 hours. All urine was collected for a period of six days after the start of the infusion in 24 hour intervals. Serum samples and aliquots of urine were frozen until the time of assay.

Analysis of serum and urine Digoxin concentrations in all serum and urine samples were determined by radioimmunoassay.³

Analysis of data Post infusion serum digoxin concentration values were analyzed by weighted iterative nonlinear least squares regression tech-

From the Medizinische Universitätsklinik Bonn, Bonn University, West Germany and the Clinical Pharmacology Department, Massachusetts General Hospital, Boston, Mass.

Supported in part by Deutsche Forschungsgemeinschaft Bonn-BF 4, Bonn, West Germany (Dr. Ochs and Bodem). Grant MH 15000 from the United States Public Health Service (Dr. Greenblatt) and the National Institutes of Health (Dr. Harnatz).

Received for publication July 31, 1978.
Accepted for publication November 16, 1978.

Reprint requests: Dr. David J. Greenblatt, MD, Clinical Pharmacology Unit, Massachusetts General Hospital, Boston, MA 02114.

Dr. Hermann R. Ochs, MD, Medizinische Universitätsklinik Bonn, West Germany.

0003-6892/79/0000-0000\$01.50/0 © 1979 American Heart Journal




Fig 1 Serum digoxin concentrations following 0.5, 1.0 and 1.5 mg intravenous doses. Each point is the mean for all subjects receiving the indicated dose at corresponding points in time. Also shown are pharmacokinetic functions determined by nonlinear least squares regression analysis (Standard errors for individual data points were omitted for clarity and are available upon request from the authors).

niques.¹⁰ Each set of data were fitted to the following two functions

$$C = Ae^{-\alpha t} + Be^{-\beta t} \quad (1)$$

$$C = Ae^{-\alpha t} + Pe^{-\beta t} + Be^{-\gamma t} \quad (2)$$

where C is the serum concentration at time t after the end of the infusion. The coefficients A , P , and B are hybrid intercept terms and were appropriately corrected for the infusion period¹⁰, α , β , and γ are hybrid exponents. For each set of data the choice between Equations 1 and 2 as functions of best fit was determined by comparison of the sum of squares of weighted residual errors for the two solutions and by assessment of the randomness of scatter of actual data points about the fitted function.¹¹ The fitted functions were used to calculate the following pharmacokinetic variables:^{12,13} distribution half life ($t_{1/2\alpha}$), elimination half life ($t_{1/2\beta}$), total apparent volume of distribution by the area method (V_d) and total clearance.

The apparent urinary excretion half life of digoxin was calculated from logarithmic plots of average excretion rate versus midpoint of the

collection interval. Cumulative excretion projected to 'infinite' time was determined using the apparent excretion half life and the excretion rate at the end of the 6 day collection period.^{13,14} The renal clearance of digoxin was calculated as the product of total clearance and the fraction of the dose recovered in the urine projected to infinite time.

The effect of dose upon pharmacokinetic variables was assessed by two way analysis of variance.

Results

No subjective effects or untoward clinical experiences were reported by any of the volunteers during or after digoxin infusion.

Disappearance of digoxin from serum was best described by Equation 1 in 20 of the 27 subject trials and by Equation 2 in the other seven. Equation 2 best described disappearance of digoxin for the composite data points formed by across subject mean serum concentration values at corresponding points in time (Fig 1 shows




Fig 2 Urinary excretion of immunoassayable digoxin following 0.5, 1.0 and 1.5 mg intravenous doses. Each point is the mean for all subjects receiving the indicated dose at corresponding points in time. (Standard errors for individual data points were omitted for clarity and are available upon request from the authors.)

composite data points and functions of best fit. Fig 2 shows mean values for urinary excretion of digoxin following the three doses.

Table II shows pharmacokinetic variables at each of the three dose levels. Two-way analysis of variance indicated that dose had no significant effect upon any of these variables. Mean renal clearance of digoxin did not differ significantly from creatinine clearance (paired t test = 0.98) and the two were not correlated ($r = -0.06$).

Discussion

Surveys of serum digoxin concentrations in patients receiving maintenance therapy generally suggest that steady state serum levels become higher with increasing doses.^{1,2} However, the relation of digoxin dosage to digoxin clearance and/or steady state serum levels within the same individual has received relatively little attention and is not precisely established.³ The present study systematically assessed the disposition of intravenous digoxin in healthy subjects following 0.5, 1.0 and 1.5 mg doses. None of the identifiable pharmacokinetic variables changed significantly

with dose, suggesting that digoxin pharmacokinetics in healthy humans are dose independent over a relatively wide range of doses. Further systematic studies of this type are needed in patients with cardiac disease.

In the majority of our subjects, disappearance of digoxin from serum was biexponential, consistent with a two-compartment open pharmacokinetic model. In some cases, the data were best described by a triexponential function, consistent with a three-compartment open pharmacokinetic model. The triexponential pattern occurred randomly, unassociated with a particular dose or a particular subject. Both patterns are reported previously.^{2,11}

Kinetic variables for digoxin in our study are similar to those described previously.^{11,12} Digoxin distribution is extensive, with apparent volumes of distribution averaging five to six times total body weight. Our values of $t_{1/2\beta}$ at all three doses averaged 27 to 28 hours and thus are slightly shorter than the usually quoted value of 36 hours. However, the estimate of $t_{1/2\beta}$ can be influenced both by the duration of sampling

Table II Relation of digoxin pharmacokinetics to size of intravenous dose

Kinetic variable	Mean (\pm SE) values			Value of F (df = 2/16) from 2 way ANOVA*
	Dose			
	0.5 mg	1.0 mg	1.5 mg	
Distribution half life (hours)	0.45 (± 0.08)	0.27 (± 0.04)	0.32 (± 0.09)	1.69
Elimination half life (hours)	28.0 (± 5.2)	28.3 (± 5.1)	27.4 (± 3.7)	0.01
Volume of distribution (liters/Kg)	4.88 (± 0.66)	5.98 (± 0.96)	5.52 (± 0.57)	0.50
Total clearance (ml/min/Kg)	2.38 (± 0.48)	2.65 (± 0.36)	2.50 (± 0.21)	0.16
6 Day urinary excretion (per cent of dose)	61.4 (± 6.7)	71.0 (± 4.8)	63.5 (± 4.2)	2.63
Urinary excretion half life (hours)	54.6 (± 10.1)	37.9 (± 5.1)	35.4 (± 2.8)	2.67
Projected cumulative urinary excretion (per cent of dose)	67.7 (± 6.8)	75.7 (± 5.2)	66.8 (± 4.4)	2.30
Renal clearance (ml/min/Kg)	1.50 (± 0.24)	2.02 (± 0.31)	1.62 (± 0.12)	1.72

For all values of F $p > 0.1$

following a single dose¹ as well as by the choice of pharmacokinetic model.¹ We measured serum digoxin concentrations for only 36 hours after a dose which could have biased toward slightly shorter values of $t_{1/2}$. This could also explain why urinary excretion half life values, based upon 6 days of sampling were longer than serum elimination half lives.

Projected cumulative urinary excretion of digoxin by our subjects averaged no more than 76 per cent of the dose. Similar findings are reported by others.^{1,2} Thus contrary to traditional teaching a substantial fraction of a dose of digoxin is eliminated by extrarenal mechanisms. Renal clearance of digoxin in our study averaged 1.5 to 2.0 ml/min/Kg and did not differ significantly from creatinine clearance. The exact mechanism of renal excretion of digoxin is controversial,³ but most studies indicate that values of renal clearance for digoxin and creatinine are similar or identical.^{3,4}

Summary

Nine healthy male volunteers received single 0.5, 1.0 and 1.5 mg doses of intravenous digoxin in a randomized three way crossover study. Multiple venous blood samples were drawn during 35 hours after each dose and all urine was collected for 6 consecutive days. Concentrations of digoxin in serum and urine were determined by

radioimmunoassay. Over all mean values for kinetic variables were: distribution half life 0.35 hours, elimination half life 27.9 hours, volume of distribution 5.46 liters/Kg, total clearance 2.51 ml/min/Kg. The mean projected cumulative urinary excretion of digoxin was 70.1 per cent of the dose, mean renal clearance of digoxin was 1.71 ml/min/Kg, not significantly different from creatinine clearance (1.50 ml/min/Kg). None of the identifiable pharmacokinetic variables was significantly influenced by dose suggesting that digoxin disposition is dose independent in healthy individuals.

We are grateful for the assistance of Ann Werner and Dr Dean S. MacLaughlin. Dr MacLaughlin is supported in part by Grant GM 24330 from the United States Public Health Service to the Boston Collaborative Drug Utilization Program.

REFERENCES

- Greenblatt D J, Smith T W and Koch-Weser J. Bioavailability of drugs: the digoxin dilemma. *Clin Pharmacokin* 1:36 1976.
- Lalo E. Clinical pharmacokinetics of digoxin. *Clin Pharmacokin* 2:1 1977.
- Huffman D H, Manion C V and Azarnoff D L. Absorption of digoxin from different oral preparations in normal subjects during steady state. *Clin Pharmacol Ther* 16:310 1974.
- Dobbs S M, Parkes J and Rodgers M. Digoxin linearity between dose and serum concentration. *Br J Clin Pharmacol* 3:940 1976.
- Okada R D, Hager W D, Marcus M I, Graves P, Pernier D and Majersohn M. Digoxin dose-plasma

- concentration relationship in man *Clin Res* 11:101A 1978
- Smith, T W, Butler V P, and Haber E. Determination of therapeutic and toxic serum digoxin concentrations by radioimmunoassay *N Engl J Med* 281:1212 1969
- Greenblatt D J, Duhamel D W, Koch Weser J and Smith T W. Evaluation of digoxin bioavailability in single-dose studies *N Engl J Med* 289:651 1973
- Usanis, R. A. *NLM-N*-Nonlinear least squares estimation of parameters (Library Services Series Document No LSR-089 1) Research Triangle Park, N C. 1972 Triangle Universities Computation Center
- Marquardt D W. An algorithm for least squares estimation of nonlinear parameters *J Soc Ind Appl Math* 11:431 1963
- Loo J C K. and Riegelman S. Assessment of pharmacokinetic constants from postinfusion blood curves obtained after IV infusion *J Pharm Sci* 59:3 1970
- Boxenbaum H G, Riegelman S and Elashoff R M. Statistical estimations in pharmacokinetics *J Pharmacokin Biopharm* 2:123 1974
- Greenblatt D J and Koch Weser J. Clinical pharmacokinetics *N Engl J Med* 293:707 964 1975
- Wagner J G. *Fundamentals of Clinical Pharmacokinetics*. Hamilton Illinois 1975 Drug Intelligence Publications.
- Gibaldi M, Perrier D. *Pharmacokinetics*. New York 1975 Marcel Dekker Inc.
- Greenblatt D J, Pfeiffer H J, Ochs H H, Franke K, MacLaughlin H H, Smith, T W, and Koch Weser J. Pharmacokinetics of quinidine in humans after intravenous intramuscular and oral administration *J Pharmacol Exp Ther* 202:365 1977
- Chamberlain D A, White R J., Howard, M R and Smith T W. Plasma digoxin concentrations in patients with atrial fibrillation *Br Med J* 3:429 1970
- Evered D C and Chapman C. Plasma digoxin concentrations and digoxin toxicity in hospital patients *Br Heart J* 33:40 1971
- McCreddie R M, Chua B L and Knight P W. Infant versus adult plasma digoxin levels *Aust N Z J Med* 4:221 1974
- 19 Isalo E, Dahl M and Sundqvist H. Serum digoxin in adults and children *Int J Clin Pharmacol* 7:219 1971
- 20 Holt H W., Williamson J D and Volans G N. Digoxin measurements in general practice *Br J Clin Pharmacol* 4:371 1977
- 21 Kramer W G, Lewis R P, Cobb F C, Forester W F, Jr, Visconti J A, Wanke L A., Boxenbaum H G and Reuning H H. Pharmacokinetics of digoxin: comparison of a two- and a three-compartment model in man *J Pharmacokin Biopharm* 2:299 1974
- 22 Koup J R, Greenblatt D J, Jusko W J, Smith, T W and Koch Weser J. Pharmacokinetics of digoxin in normal subjects after intravenous bolus and infusion doses *J Pharmacokin Biopharm* 3:181 1975
- 23 Sumner D J, Russell, A J and Whiting H. Digoxin pharmacokinetics: multicompartmental analysis and its clinical implications. *Br J Clin Pharmacol* 3:221 1976
- 24 Gibaldi, M and Weintraub H. Some considerations as to the determination and significance of biologic half life *J Pharm Sci* 60:674 1971
- 25 Kramer P. Digitalis pharmacokinetics and therapy with respect to impaired renal function *Klin Wochenschr* 55:1 1977
- 26 Bloom I M and Nelp W B. Relationship of the excretion of tritiated digoxin to renal function *Am J Med Sci* 251:133 1966
- 27 Fwy G A, Kapadia G G, Yao I, Lullin M and Marcus F I. Digoxin metabolism in the elderly *Circulation* 59:443 1969
- 28 Doherty J E, Flanagan W J and Dalrymple G V. Tritiated digoxin *Am J Cardiol* 29:470 1972
- 29 Steiness E. Renal tubular secretion of digoxin *Circulation* 50:101 1974
- 30 Wettrell G and Aronson K E, Bertler A and Lundstrom N R. Concentrations of digoxin in plasma and urine in neonates, infants and children with heart disease *Acta Paediatr Scand* 63:705 1974
- 31 Halkin H, Shemer L B, Peck, C C and Melmon L. Determinants of the renal clearance of digoxin *Clin Pharmacol Ther* 17:385 1975

Origin of the basal systolic murmurs in mitral stenosis A study with intracardiac phonocardiography

Tadashi Kambe, MD
Shohachi Suzuki, MD
Tadayuki Kato, MD
Norio Hibi, MD
Yochi Fukui, MD
Takemi Arakawa, MD
Kinya Nishimura, MD
Arata Miwa, MD
Nobuo Sakamoto, MD
Nagoya Japan

Intracardiac phonocardiography, introduced by Yamakawa and colleagues¹ in 1953, was a break through in the realm of clinical phonocardiography. Conventional external phonocardiography may not always reflect the acoustic events occurring in the cardiac chambers or great vessels. In contrast, intracardiac phonocardiography is able to obtain the vibratory events at the site of generation of murmurs.

Functional or innocent murmurs are generally thought to originate in the pulmonary artery. However, the earlier studies^{2,3} were mostly confined to the right side of the heart. A few intracardiac studies on the left side of the heart in normal subjects have demonstrated systolic murmurs within the aorta.^{4,5} Also, a specific type of innocent murmur has been thought to originate in the aorta near the aortic valve.⁶

The basal systolic murmurs occasionally recorded in mitral stenosis have been so far regarded as occurring in the pulmonary artery just above the pulmonic valve.⁷ The purpose of

the present study is to describe the origins of the basal systolic murmurs in mitral stenosis without other valvular diseases.

Material and method

Left and right heart catheterization was carried out on 18 cases of mitral stenosis with basal systolic murmurs using a catheter tip micromanometer of Millar or a double lumen phonocatheter of American Electric Laboratory. The age of subjects ranged from 20 to 48 years, and the cardiac diagnosis, as shown in Table I, was confirmed by heart catheterization and angiocardiology. Both mitral and aortic regurgitations were excluded from the examined patients. Of the 18 patients, the diagnosis of 14 was eventually verified by surgical intervention.

The hemodynamic data are shown in Table I in which there is no significant systolic pressure gradient across the aortic valve nor across the pulmonic valve.

All procedures of heart catheterization were performed in the sedated and postabsorptive state after informed consent was obtained. In the majority of cases, a simultaneous recording of intracardiac and external phonocardiograms was made in conjunction with intracardiac pressure tracing with the aid of a Polygraph (Fukuda denshi MCM 8000) and a photographic recorder.

From the Third Department of Internal Medicine, Nagoya University School of Medicine, Nagoya, Japan.

Received for publication Oct. 13, 1977.

Accepted for publication Dec. 1, 1977.

Reprint requests: Tadashi Kambe, MD, The Third Department of Internal Medicine, Nagoya University School of Medicine, Tsurumai-cho 65, Showa-ku, Nagoya 466, Japan.

Table I Findings at catheterization

Case No	Name	Sex	Age	Diagnosis	PA cap press S/D (mean) mm Hg	Mean PA press S/D (mean) mm Hg	Rt press S/D (mean) mm Hg	Aorta press S/D (mean) mm Hg	Lt press S/D (mean) mm Hg
1	K.N	m	24	MS	12/2 (7)	24/8 (1 ^o)	26/0 (8)	120/60 (80)	118/6 (44)
2	Y.G	f	38	MS	3/12 (7 ^o)	55/17 (30)	57/7 (18)	120/80 (95)	125/18 (80)
3	Y.H	f	21	MS	28/16 (19)	34/18 (18)	47/2 (20)	90/60 (70)	90/5 (40)
4	H.N	m	31	MS	28/14 (19)	47/23 (22)	46/2 (15)	98/67 (82)	104/8 (42)
5	M.h.	m	42	MS	21/10 (15)	33/13 (20)	41/4 (15)	129/0 (90)	134/8 (38)
6	Y.A	f	20	MS	27/20 (24)	46/21 (33)	46/4 (21)	100/65 (77)	100/6 (40)
7	K.T	m	32	MS	33/20 (24)	44/20 (30)	50/4 (20)	118/5 (90)	125/4 (45)
8	K.A.	m	28	MS	30/20 (26)	55/22 (24)	56/6 (22)	125/60 (90)	126/5 (40)
9	H.T	f	45	MS	30/10 (18)	54/25 (33)	54/2 (20)	120/67 (82)	118/11 (43)
10	S.I	f	38	MS	37/17 (18)	60/35 (34)	60/5 (28)	135/78 (100)	135/8 (40)
11	M.I	f	40	MS	29/10 (12)	30/13 (20)	37/2 (10)	110/60 (70)	110/4 (40)
12	S.Y	f	39	MS	17/10 (13)	37/10 (17)	38/0 (19)	114/87 (90)	118/6 (68)
13	S.K.	m	48	MS	30/16 (20)	42/20 (30)	40/2 (20)	151/102 (130)	184/10 (85)
14	Y.S	f	44	MS	18/14 (16)	40/15 (23)	40/3 (14)	110/55 (65)	110/4 (35)
15	T.G	f	44	MS	27/10 (15)	33/15 (23)	34/3 (17)	120/65 (90)	120/7 (40)
16	H.I	f	34	MS	27/16 (20)	42/19 (26)	40/0 (16)	162/100 (120)	158/12 (75)
17	T.S	m	33	MS	14/9 (11)	30/13 (15)	32/4 (12)	130/75 (100)	135/10 (62)
18	M.A	m	34	MS	25/13 (18)	29/10 (22)	35/3 (13)	105/70 (82)	105/7 (44)

Abbreviations MS = mitral stenosis m = male f = female PA = pulmonary artery CAP = capillary Rt = right ventricle Lt = left ventricle S = systolic D = diastolic

(Sanei sokki 100A) Paper speed was 100 mm/sec in the majority of cases

Intracardiac murmurs were explored in the pulmonary artery and the right ventricle and atrium on the right side of the heart and in the aorta just above the aortic valve and the left ventricle on the left side

Results

In this study we obtained ejection systolic murmurs in the aorta near the aortic valve the pulmonary artery and the outflow tract of the right ventricle using intracardiac phonocardiography of the left and right sides of the heart

I Aortic origin As shown in Table II an intra aortic systolic murmur was maximally recorded in 14 out of the 18 subjects having mitral stenosis with no clinical evidence of other valvular diseases. In these cases the ejection systolic murmur was definitely louder in the aorta than in the pulmonary artery. On insertion of the phonocatheter into the outflow tract of the left ventricle it disappeared or diminished in intensity. The timing of this murmur ranged from early to mid systole and it was crescendo-decrescendo in configuration.

Fig 1 shows intracardiac tracings obtained

from a 44 year old patient with mitral stenosis (Y.S.). A loud ejection systolic murmur is recorded in the aorta near the aortic valve on the intracardiac phonocardiogram (I PCG) in panel A whereas there is no significant murmur in the main pulmonary artery in panel B. Thus the basal systolic murmur in this case is thought to originate in the aorta near the aortic valve but not in the pulmonary artery.

Fig 2 indicates another example of the ejection systolic murmur in the aorta in a 34 year old patient with mitral stenosis (H.I.). The intracardiac phonocardiogram shows an early systolic murmur in the aorta just above the valve. However there was no loud systolic murmur in the main pulmonary artery. Although the ascending branch of the aortic pressure tracing is slow and distorted there was no significant pressure gradient across the aortic valve in systole.

II Pulmonic origin Two mitral stenosis patients showed the maximal ejection systolic murmur in the pulmonary artery whereas in the aorta only a slight systolic murmur was recorded.

Fig 3 shows an ejection systolic murmur in the pulmonary artery in a 48 year old patient (S.K.). This case showed an ejection systolic murmur




Fig 1 Intracardiac phonocardiograms obtained from a 44 year old patient with mitral stenosis (Y S). A loud ejection systolic murmur is noted in the aorta near the aortic valve (panel A) whereas there is no significant systolic murmur in the main pulmonary artery (panel B). Thus the basal systolic murmur probably originates in the aorta near the aortic valve. I-PCG = intracardiac phonocardiogram PCG = external phonocardiogram PA = pulmonary artery SM = systolic murmur DM = diastolic murmur I = first heart sound II = second heart sound OS = mitral opening snap Press = pressure

(Grade 2/6) at the second left intercostal space on the chest wall. In the intracardiac phonocardiogram, an ejection systolic murmur is shown in the pulmonary artery, accompanied by a small, early diastolic murmur. However the systolic murmur was less loud in the aorta. Thus the main pulmonary artery is thought to be the origin of this murmur.

III Right ventricular origin In two cases a late systolic murmur was obtained from the outflow tract of the right ventricle and it diminished in the pulmonary artery and the aorta. As a result, we postulate here that the outflow tract of the right ventricle is another origin of the basal systolic murmur in mitral stenosis although it was not so loud on the chest wall. Fig 4 shows a loud systolic murmur in the outflow tract of the right ventricle in a 45 year old female with mitral stenosis (H T). A late systolic murmur is noted on the intracardiac phonocardiogram of the right ventricular outflow tract.

Table II Intracardiac location of the basal systolic murmurs in mitral stenosis

Case No	Name	Sex	Age	Diagnosis	Location of systolic murmur		
					Aorta	PA	RV outflow
1	h N	m	24	MS†	++	-	-
2	Y O	f	30	MS	++	-	-
3	Y H	f	21	MS	++	+	-
4	H N	m	31	MS	++	+	-
5	M K	m	42	MS	+	-	-
6	Y A	f	20	MS	+	+	++
7	h T	m	32	MS	+	-	-
8	K A	m	28	MS	+	-	-
9	H T	f	45	MS	+	+	++
10	S I	f	38	MS	-	++	-
11	M I	f	40	MS	++	-	-
12	S Y	f	39	MS	++	-	-
13	S K	m	48	MS	+	++	-
14	Y S	f	44	MS	++	+	-
15	T O	f	44	MS	++	+	-
16	H I	f	34	MS	++	+	-
17	T S	m	33	MS	+	-	-
18	M A	m	34	MS	+	-	-

Of the 18 patients with mitral stenosis, 14 showed the maximum systolic murmur in the aorta near the aortic valve whereas in two cases the loud ejection systolic murmur was recorded in the main pulmonary artery. In the other two cases a late systolic murmur was maximally recorded in the outflow tract of the right ventricle.

†Abbreviations and symbols MS = mitral stenosis PA = pulmonary artery RV = right ventricle ++ = loud systolic murmur + = slight systolic murmur m = male f = female

Discussion

Our observations showed that the basal systolic murmur in mitral stenosis without associated valvular diseases originated mostly in the aorta and in a few cases in the pulmonary artery and the outflow tract of the right ventricle.

According to the study by Kunos and associates¹ the basal systolic murmur in mitral stenosis was derived from the acoustic events in the pulmonary artery, and was elucidated by relative pulmonic stenosis. On the other hand, Stuckey⁶ has reported that the majority of the innocent murmurs may have an aortic origin. The etiology of this systolic murmur is suggested by its timing which corresponds to that of the maximum ejection of blood from the ventricles. This was not proved however, by the intracardiac sound analysis.

In earlier studies^{2,3} with intracardiac phonocardiography, the ejection systolic murmur in




Fig 2 In ra arterial so and p essure tracing simultan ously r corded with external phonocardiogram in a 34 year old subject with mitral stenosis (II I) An early systolic murmur is recognized in the aorta just above the aortic valve However on loud systolic murmur is noted in the main pulmonary artery The ascending branch of the aortic pressure tracing is slow and distorted although there was no significant pressure gradient across the aortic valve in systole It may be due to a technical artifact I PCG = intracardiac phonocardiogram PCG = external phonocardiogram SM = systolic murmur DM = diastolic murmur I = first heart sound II = second heart sound OS = mitral opening snap Pre s = pressure




Fig 3 An ejection systolic murmur in the pulmonary artery This tracing was obtained from a 48 year old patient with mitral stenosis (S h) The loudest ejection systolic murmur is recorded on the phonocardiogram of the main pulmonary artery accompanied by a small early diastolic murmur The systolic murmur is thought to originate in the pulmonary artery since it was less loud in the aorta I PCG = intracardiac phonocardiogram PCG = external phonocardiogram PA = pulmonary artery SM = systolic murmur DM = diastolic murmur I = first heart sound II = second heart sound OS = opening snap AL = the fourth left intercostal space Press. = pressure

normal subjects was regarded to occur in the pulmonary artery. However these studies were mainly confined to the intracardiac events of the right side of the heart. In contrast a few intracardiac studies, in the left side of the heart in normal subjects have demonstrated systolic murmurs within the aorta and the innocent vibratory murmur has been thought to originate near the aortic valve.

Recently Stein and Sabbah showed that disturbed blood flow with a turbulent energy density about one third of that of patients with aortic insufficiency is found in the ascending aorta of patients with a normal aortic valve. Subsequently studies of turbulent blood flow and ejection systolic murmurs have shown a linear relation between the intensity of the intraarterially recorded murmurs and turbulent power




Fig 4 A late systolic murmur in the outflow tract of the right ventricle. The intracardiac sound was obtained from a 45 year old patient with mitral stenosis (H T). A late systolic murmur is clearly noted in the outflow tract of the right ventricle whereas there was no loud murmur in the pulmonary artery and the aorta. A functional infundibular stenosis may be closely related to the turbulence of blood flow in the right ventricular outflow tract which is responsible for the genesis of the late systolic murmur. RV = right ventricle. Other abbreviations are the same as in Fig 1.

production, thus demonstrating a clear association between the magnitude of turbulent flow and ejection systolic murmurs. Moreover, their preliminary studies¹⁰ have shown that turbulence in patients without valve disease occurs with greater intensity in the aorta than in the pulmonary artery. The reason that turbulence is greater within the aorta may be related to the more compliant walls of the pulmonary artery which may have a damping effect upon turbulence.

More recently, Stein and Sabbah¹¹ reported that the intensity of the intraarterial sound was greater above the aortic than above the pulmonary valve. These findings suggest that innocent murmurs may be of aortic origin, which led us to undertake this study on the origin of the basal systolic murmurs in mitral stenosis.

The majority of our patients showed systolic murmurs in the aorta rather than in the pulmonary artery, in spite of no significant systolic pressure gradients across the aortic valve. Similar to the mechanism of production of innocent murmur the turbulence in the aorta is probably greater than in the pulmonary artery. These systolic murmurs are thought to occur due to the turbulence within the aorta and may be functional or organo functional since the aortic valve in mitral stenosis occasionally shows a rheumatic

change which may not produce pressure gradients.

With regard to the second origin of the basal systolic murmur, we noted a loud ejection systolic murmur in the main pulmonary artery of two mitral stenosis patients, whereas there was less loud bruit in the aorta near the aortic valve. No significant pressure gradients across the pulmonary valve were noted in systole. The ejection systolic murmur is thought to occur due to the turbulence of blood flow produced by the dilated pulmonary artery.

Next the outflow tract of the right ventricle is also regarded as another origin of the basal systolic murmur. We encountered a late systolic murmur during exploration of the right ventricle with phonocatheter. Till now a study using intracardiac phonocardiography in which the late systolic murmur emanates from the right ventricular outflow tract in mitral stenosis has never been reported.

Aunger and associates¹² reported that the expiratory compression of the right ventricular outflow tract by the thoracic wall was responsible for the production of the basal systolic murmur in mitral stenosis. Moreover, Leatham¹³ mentioned that the physiological ejection systolic murmur found in normal children probably originates

from the right ventricular outflow tract because of its adjacency to the stethoscope though vibrations can be recorded in both right and left outflow tracts by intracardiac phonocardiography. In moderate to severe valvular pulmonic stenosis Kambe and associates¹ pointed out that a late systolic murmur occurred in the right ventricular outflow tract due to functional infundibular stenosis.

It is our opinion that the late systolic murmur in mitral stenosis is most likely to occur due to functional or relative stenosis of the right ventricular outflow tract. The term functional murmur³ may be applied to those basal systolic murmurs originating from the cardiovascular system mentioned above.

In general intracardiac phonocardiography is most useful to localize cardiac murmurs and sounds. A major advantage of this method is that it may detect even a small eddy not audible as a murmur on the chest wall. However it may produce an artificial turbulence in the heart in addition to already existing murmurs. Moreover a positional gap may occur between the turbulence of blood flow and the axis of the sensitive element. However intracardiac phonocardiography though invasive is thought to be most useful to localize the basal systolic murmurs in mitral stenosis.

Summary

In order to study the origin of the basal systolic murmurs in mitral stenosis left and right heart catheterization was performed in 18 patients with mitral stenosis using intracardiac phonocardiography. Our data revealed that the basal systolic murmurs originated in the aorta, the pulmonary artery, and the outflow tract of the right ventricle.

In 14 cases we noted the maximal ejection systolic murmur in the aorta near the aortic valve. However in two cases there was a loud systolic murmur in the pulmonary artery. These murmurs occurred in early to mid systole and were crescendo-decrescendo in configuration. The pitch of the murmur ranged from low to medium frequency in the majority of cases. They are produced by the turbulence of blood flow in the aorta and the pulmonary artery.

A late systolic murmur was also recorded in the outflow tract of the right ventricle in two patients. This is thought to occur due to functional or relative infundibular stenosis of the right ventricle. It differs in location and timing from those in the aorta and the pulmonary artery. The outflow tract of the right ventricle is regarded as the third origin of the basal systolic murmur in mitral stenosis.

We thank Mr. Yoshinobu Kitamura for his technical assistance.

REFERENCES

1. Yamakawa K, Shiono Y, Nagai T, Kitamura K, Ohta S and Yamamoto T. An attempt on the intracardiac phonocardiography. *Tohoku J Exp Med* 58:311, 1953.
2. Lewis D H, Ertugrul A, Deitz E W, Wallace J D, Brown J R Jr and Moghadam A N. Intracardiac phonocardiography in the diagnosis of congenital heart disease. *Pediatrics* 23:837, 1959.
3. Segal B L, Novak K and Kasparian H. Intracardiac phonocardiography. *Am J Cardiol* 13:188, 1964.
4. Lieberman J and Good S. Diastolic murmurs in apparently normal children. *Circulation* 38:755, 1968.
5. Lucsada A A, Liu C K and Szatkowski J. Intracardiac phonocardiography in 172 cases studied by left and right heart catheterization or both. *Acta Cardiol* 18:533, 1963.
6. Vernevoeld A. The origin of the innocent "vibratory" murmur studied with intracardiac phonocardiography. *Acta Med Scand* 181:1, 1967.
7. Kuno I, Gardin V and Rohisek F. Die Bewertung der Schallerscheinungen über der Pulmonalarterie bei Mitralklappenstenose. *Z Kreislaufforsch* 46:39, 1957.
8. Stuckey D. Innocent systolic murmurs of aortic origin. *Med J Aust* 1:38, 1955.
9. Stein P D and Sabbah H N. Turbulent blood flow in the ascending aorta of humans with normal and diseased aortic valves. *Circ Res* 38:68, 1976.
10. Stein P D and Sabbah H N. Physiological implications of turbulent blood flow in the pulmonary vasculature (In preparation).
11. Stein P D and Sabbah H N. Aortic origin of innocent murmurs. *Am J Cardiol* 39:665, 1977.
12. Aunger W, Hartl O, Kaundl W and Kuhn P. Systolische Bausgeräusche bei Mitralklappenstenosen. *Z Kreislaufforsch* 53:465, 1964.
13. Leatham A. Right ventricular outflow obstruction. In: *American Heart Association Monograph 46. Physiological principles of heart murmurs*. Leon D F, Shaver J A, ed. New York: 1955. American Heart Association, p. 119.
14. Kambe T, Kato T, Hibi Y, Fukui Y, Arakawa T, Nishimura K, Tatematsu H, Miwa A, Tada H and Sakamoto N. Differential diagnosis of pulmonic stenosis by means of intracardiac phonocardiography. *Jap Heart J* 17:693, 1976.
15. Tavel M E. The systolic murmur—innocent or guilty? *Am J Cardiol* 39:757, 1977.

The noninterference of aluminum hydroxide gel with quinidine sulfate absorption An approach to control quinidine-induced diarrhea

John A. Romankiewicz, Pharm D
Marcus Reidenberg, MD
Dennis Drayer, PhD
John E. Franklin, Jr, MD
New York, NY

Quinidine has been used in the successful treatment of cardiac arrhythmias for over two decades. However, its toxicity, including nausea, vomiting, diarrhea, and more serious problems of arrhythmias and sudden death has limited its usefulness in certain situations. Of particular note is the gastrointestinal intolerance that many patients experience. It is estimated that nausea, vomiting, and diarrhea occur in 30 per cent of patients ingesting quinidine, requiring discontinuation of therapy in as many as 10 per cent.¹ These side effects are not related to dose or to blood levels. They are believed to be due to a direct stimulant action on the smooth muscle of the small intestine.²

We have encountered patients who have required quinidine for the successful control of their arrhythmias, but who could not tolerate the resulting gastrointestinal symptoms, particularly diarrhea. Concomitant administration of aluminum hydroxide gel with their quinidine dose resulted in reduction of diarrhea with apparently continued control of their arrhythmias.

Previous reports of interference with drug absorption by antacids prompted a study to determine the effects of aluminum hydroxide gel on quinidine absorption.

From the Departments of Pharmacy, Pharmacology and Medicine, The New York Hospital—Cornell Medical Center.

Received for publication Oct. 13, 1977.

Accepted for publication Nov. 21, 1977.

Reprint requests: John A. Romankiewicz, Pharm D, Assistant Apothecary in Chief, Pharmacy Dept., The New York Hospital, 5, E. 68th St., New York, NY 10021.




Fig. 1. Comparison of concentration versus time curves of quinidine sulfate administered with aluminum hydroxide gel or water in four normal volunteers. Brackets indicate \pm SEM.

Methodology

Four healthy volunteers ranging in age from 28 to 42 years ingested 200 mg of quinidine sulfate and 30 milliliters of aluminum hydroxide gel (Amphogel antacid trial) or water (placebo trial) after an overnight fast. The aluminum hydroxide gel was ingested concomitantly with and a second 30 ml dose one hour after quinidine sulfate. Blood sampling for quinidine was obtained at 2, 4, 6, 8, 24, and 26 hours after drug ingestion. Twenty-four hour urine collections for quinidine and pH determinations were obtained.

After a two week washout period the experiment was repeated. Volunteers receiving antacid were given placebo and those receiving placebo were given antacid using a randomized cross over design.

Assay

Quinidine was quantitated by the Kessler and associates' modification of the method of Cramer and Isaksson. Briefly to a 12 ml centrifuge tube 0.5 ml serum, 0.5 ml 0.1N NaOH and 1 ml benzene are added. The contents of the tube are mixed with a vortex type mixer and centrifuged. The organic phase is transferred after the addition of 0.2 ml isoamyl alcohol to a new centrifuge tube containing 3 ml of 0.1N H₂SO₄. After mixing and subsequent centrifugation the fluorescence of the acid phase is read in an Aminco Bowman spectrophotofluorometer at an excitation wavelength of 340 nm and an emission wavelength of 450 nm.

Results

The results of this study are presented in Fig 1 and Table I. No significant differences in quinidine levels were seen in the concentration versus time plots; the two curves appearing almost superimposable. This is confirmed by the lack of significant difference in the area under curve determinations (Table I). This indicates no impairment of absorption of quinidine by aluminum hydroxide gel. The urine pH during the antacid trial ranged from 5.0 to 6.2 with a mean of 5.7. During the placebo trial the urine pH ranged from 5.0 to 6.0 with a mean of 5.5. The average cumulative excretion of quinidine over 24 hours after the antacid trial was 19 per cent of the dose and after the placebo trial was 18 per cent.

Discussion

The effects of antacids on the absorption of drugs has been studied to a limited extent.¹⁻⁴ Antacids may alter the absorption of medications administered concomitantly. Our study shows that aluminum hydroxide gel does not interfere with the absorption of quinidine sulfate.

Aluminum hydroxide gel has been given to treat the diarrhea associated with quinidine administration. We have thus far encountered four patients whose arrhythmias were controlled by quinidine but who developed diarrhea second

Table I. Areas under curve expressed as mcg/ml/hr calculated by the trapezoidal rule.

Subject	Placebo	Amphogel
1	308	376
2	266	236
3	429	472
4	497	393
Mean	375	357
SD	107	100

Not significantly different ($P > 0.1$)

ary to quinidine ingestion. In three, aluminum hydroxide gel was successful in controlling this effect; in the fourth, reduction in stool frequency to tolerable levels was achieved. In all cases control of the arrhythmia was maintained without altering the dose of quinidine.

The mechanism for diarrhea induced by quinidine is unknown at present but may be due to local stimulant effect on intestinal motility. Studies in canines have demonstrated that quinidine increases the frequency of fast or spike potentials in the small intestine and colon.⁵ These potentials correlate with increases in intestinal contraction. Thus quinidine may exert its diarrheogenic effect by increasing intestinal tone and motility.

Aluminum hydroxide is known to delay gastric emptying time both in animals and man.⁶ This action is mediated by the action of aluminum ion. It has been demonstrated that intraluminal applied aluminum solution inhibits contractions elicited by serosally administered acetylcholine both in rat and human gastric smooth muscle.⁷ It is therefore possible that the effect of quinidine on increasing intestinal motility is blocked by the smooth muscle relaxing effect of the aluminum ion resulting in control of diarrhea.

REFERENCES

1. Rokseth R. and Storstein O. Quinidine therapy of chronic supraventricular fibrillation. *Arch. Intern. Med.* 117:184-193.
2. Hall J. I. and Wood D. H. Factors affecting cardiovascular and atrial arrhythmias with special reference to quinidine. *Br. Heart J.* 30:84, 1968.
3. Selzer A. When quinidine is the right drug. *Drug Therapy* 115 Sept. 1975.
4. Garrett J. M., Schlegel J. F., and Code C. F. Effect of quinidine on electrical and motor activity of canine small bowel. *Gut* 7:565, 1966.
5. Romanekewicz J. A. Effects of antacids on gastrointestinal absorption of drugs. *Primary Care* 3:53-1976.
6. Kessler R. M., Lowenthal, D. T., Warner H., et al.

- Quinidine elimination in patients with congestive heart failure or poor renal function, *N Engl J Med* **290** 706 1974
- 7 Cramer G and Isaksson B Quantitative determination of quinidine in plasma *Scand J Clin Lab Invest* **15** 553 1963
- 8 Hurwitz A Robinson R G Vats T S et al Effects of antacids on gastric emptying *Gastroenterology* **71** 268 1976
- 9 Hava M and Hurwitz A The relaxing effect of aluminum and lanthanum on rat and human gastric smooth muscle in vitro *Europ J Pharmacol* **72** 100 1973
- 10 Hurwitz A Antacid therapy and drug kinetics *Clin Pharmacokinetics* **2** 269 1977

Information for authors

Most of the provisions of the Copyright Act of 1976 became effective on January 1 1978. Therefore all manuscripts must be accompanied by the following statement signed by each author: 'The undersigned author(s) transfers all copyright ownership of the manuscript entitled (title of article) to The C V Mosby Company in the event the work is published. The author(s) warrants that the article is original is not under consideration by another journal, and has not been previously published. Authors will be consulted, when possible, regarding republication of their material.'

Noninvasive diagnosis of ischemic cardiomyopathy by fluoroscopic detection of coronary artery calcification

Allen D Johnson MD
Stuart L Laiken MD
Ralph Shabetai, MD
La Jolla and San Diego Calif

Severe coronary artery disease may give rise to progressive cardiomegaly and congestive heart failure. In the absence of a clear history of myocardial infarction the resulting ischemic cardiomyopathy may be difficult to distinguish from nonischemic cardiomyopathy. Since the clinical course and management of ischemic and nonischemic cardiomyopathy may differ it is important to identify accurately these two clinical entities. While coronary arteriography has been used to make this differential diagnosis it would be desirable to have a reliable noninvasive method. Both echocardiography^{1,2} and thallium 201 perfusion imaging recently have been employed to separate patients with severe left ventricular dysfunction and a history of myocardial infarction from those with nonischemic cardiomyopathy. However this distinction can be made readily from the clinical history and it remains to be seen whether either technique can ascertain the diagnosis in the patient with cardiomyopathy in whom the presence or absence of significant coronary artery disease cannot be determined by routine clinical evaluation. In this report the clinical, hemodynamic and angiographic data in 24 patients presenting with severe congestive heart failure and cardiomegaly of

unknown etiology are reviewed and it is shown that identification of coronary arterial calcification by fluoroscopy provides a reliable means of distinguishing those with ischemic from those with nonischemic cardiomyopathy.

Methods

The study group was derived from those patients presenting to the San Diego Veterans Administration Hospital with severe congestive heart failure and cardiomegaly who underwent diagnostic cardiac catheterization and coronary arteriography between July 1974 and July 1977. Patients with a history of myocardial infarction were excluded prior to catheterization and patients found to have significant valvular lesions were excluded following catheterization. The 24 remaining patients, none of whom had a history of excessive alcohol intake, constituted the study group. Prior to left ventriculography and coronary arteriography all patients underwent cardiac fluoroscopy with cesium iodide image intensification in the anteroposterior, left anterior oblique and right anterior oblique projections. All studies were performed by one fluoroscopist (A.D.J.) with observation and verification by a second physician who was in attendance. The findings on fluoroscopy were then compared with the results of coronary arteriography performed by either the Sones or Judkins techniques. A 75 per cent or greater reduction in cross-sectional area of at least one major coronary vessel was required for a diagnosis of significant coronary disease.

Biplane left ventriculograms were obtained

From the Cardiology Division, Department of Medicine, University of California, San Diego School of Medicine, La Jolla and the San Diego Veterans Administration Hospital.

Received for publication Oct 24, 1977

Accepted for publication Dec 1, 1977

Reprint requests: Allen D Johnson, MD, Veterans Administration Hospital, Cardiology Section-111A, 3340 La Jolla Village Dr, San Diego, Calif 92161.

Table I Clinical, hemodynamic angiographic and fluoroscopic data from 24 patients

Patient*	Age	Risk factors	Chest pain		Electrocardiogram				LV function		Coronary arteriography			Coronary calcification		
			Typ†	Atyp	Q	LBBB	RBBB	LVH	LVEDI	EF	RT	LAD	CIRC	RT	LAD	CIRC
Ischemic Cardiomyopathy																
1	GC	63	+						198	29	+	+		+	+	
2	HR	42	+	+		+			102	21		+		+	+	+
3	AC	46	+		+				117	22	+	+		+	+	+
4	MW	54	+	+		+			110	18		+			+	+
5	CF	50					+		122	28	+	+			+	+
■	GB	39	+		+	+			125	26	+	+		+	+	
7	AC	53	+		+				177	13	+	+		+	+	+
■	HM	51							136	35	+	+		+	+	+
9	RW	68	+						147	25	+	+	+	+	+	+
10	RC	58	+						100	32	+	+	+	+	+	+
Non ischemic Cardiomyopathy																
11	KK	26	+		+	+			150	16		Normal				Absent
12	DA	42	+	+		+			124	19		Normal				Absent
13	HS	57			+	+			160	22		Normal				Absent
14	DP	34	+						101	32		Normal				Absent
15	SN	54	+			+			158	29		Normal				Absent
16	WK	46					+		156	20		Normal				Absent
17	BB	27				+			166	10		Normal				Absent
18	DT	31						+	150	15		Normal				Absent
19	PO	42							122	19		Normal				Absent
20	RD	26	+						150	15		Normal				Absent
21	EW	50	+				+		171	26		Normal				Absent
■	CL	60					+		189	24		Normal				Absent
23	WR	56	+					+	116	32		Normal				Absent
24	MC	62	+		+				251	34		Normal				Absent

Patients 1-10 abnormal coronary arteriograms patients 11-24 normal coronary arteriograms

†Abbreviations Typ = typical ischemic chest pain Atyp = atypical ischemic chest pain LVEDI = end-diastolic volume index EF = ejection fraction

using standard techniques Ejection fraction and left ventricular end diastolic volume index (LVEDI) were calculated using volumes determined by the area-length method⁸

All patients were then characterized with respect to their clinical electrocardiographic and hemodynamic findings as summarized in Table I Those patients with abnormal coronary arteriograms were considered to have ischemic cardiomyopathy, while those with normal coronary arteriograms were considered to have a form of nonischemic cardiomyopathy

Student's t test was used for comparison of clinical hemodynamic and angiographic data between the two groups of patients

Results

Coronary arteriography Ten patients were found to have abnormal coronary arteriograms

Six had triple vessel disease three had double vessel disease and all had significant lesions of the left anterior descending coronary artery These ten patients were considered to have ischemic myocardial disease The remaining 14 patients had unequivocally normal coronary arteriograms and were given the diagnosis of nonischemic cardiomyopathy

Hemodynamic findings All 24 patients showed evidence of significant hemodynamic compromise No patient had a left ventricular end diastolic volume index less than 100 cc/M, and no patient had an ejection fraction greater than 35 As shown in Table II the mean left ventricular end diastolic volume index was somewhat greater in the nonischemic group and the mean ejection fraction somewhat lower However, the differences between the two groups were not statistically significant The left ventriculograms of all

Table II Comparison of clinical and hemodynamic characteristics

	No	Mean age (yrs)	Mean LVEDP (ml / M)	Mean EF	Risk Factors	Chest pain	ECG Q waves
Ischemic cardiomyopathy	10	52	133	25	80%	50%	30%
Nonischemic cardiomyopathy	14	44	154	20	57%	30%	43%

A given patient was included in this category if the clinical history revealed smoking, hypertension, diabetes, or past family history for myocardial infarction. No patient in either group was diabetic.

24 patients showed diffuse hypokinesia with no evidence of a discrete left ventricular aneurysm.

Clinical history The mean ages of the patients in the two groups did not differ significantly, although no patient with ischemic cardiomyopathy was less than 39 years of age. Chest pain typical or atypical for angina pectoris and the presence of at least one coronary risk factor (see Table II) were more common in those patients with ischemic cardiomyopathy. However, these features were not unique to the patients with ischemic cardiomyopathy, as they were present in a significant fraction of the patients with normal coronary arteriograms.

Electrocardiogram The presence of significant Q waves (≥ 0.4 seconds duration) on the ECG was not a distinguishing characteristic of the patients with ischemic cardiomyopathy. Indeed, they were more common in the group with nonischemic cardiomyopathy.

Fluoroscopy All ten patients with significant coronary disease had coronary artery calcification identified on fluoroscopy. Each had calcification in the region of the left anterior descending coronary artery; three had calcium present in the region of two major coronary arteries and six patients had calcification in each of the three major coronary vessels. None of the 14 patients with normal coronary angiograms (nonischemic cardiomyopathy) had coronary calcification identified by fluoroscopy.

Discussion

Burch and co-workers¹ have used the term "ischemic cardiomyopathy" to describe a class of patients with severe myocardial dysfunction and coronary artery disease. With a carefully obtained clinical history, many patients with ischemic cardiomyopathy may be distinguished by the occurrence of a previous myocardial infarction or angina pectoris. Nevertheless, there remains a group of patients with ischemic heart

disease such as the one presented in this study which cannot be clearly distinguished from patients with idiopathic cardiomyopathy on the basis of the clinical history or electrocardiogram. No patient gave a history of myocardial infarction. While coronary risk factors and chest pain were more frequent in the ten patients with ischemic cardiomyopathy, they were also found in the patients with nonischemic cardiomyopathy. The presence of Q waves on the electrocardiogram was neither a sensitive nor a specific indicator of ischemic disease. Other studies have shown that patients with nonischemic cardiomyopathy commonly demonstrate Q waves.² Furthermore, the frequent occurrence of left bundle branch block or left ventricular hypertrophy can obscure the electrocardiographic diagnosis of prior myocardial infarction in this setting.

Fluoroscopic examination of the coronary arteries for calcification offers an appealing method for differentiating ischemic from nonischemic cardiomyopathy without coronary arteriography. The work of Bartel and associates³ has demonstrated that this technique, when carefully performed, can detect coronary artery calcification in the majority of patients with two or three vessel coronary disease giving few false positives. All of the patients with ischemic cardiomyopathy in our study had coronary artery calcification easily detected by fluoroscopy. The remarkable sensitivity of cardiac fluoroscopy in these hemodynamically compromised patients may be related to the severity of their underlying coronary disease. None of our patients with cardiomyopathy and normal coronary arteriograms had coronary artery calcification, which indicates that fluoroscopic detection of coronary calcification was a highly specific marker for ischemic cardiomyopathy in the population of patients studied.

In conclusion, we recommend that cardiac

Table I Clinical, hemodynamic, angiographic, and fluoroscopic data from 24 patients

Patient	Age	Risk factors	Chest pain		Electrocardiogram				LV function		Coronary arteriography			Coronary calcification		
			Typ†	Atyp	Q	LBBB	RBBB	LVB	LVEDI	EF	RT	LAD	CIRC	RT	LAD	CIRC
Ischemic Cardiomyopathy																
1	GC	63	+					+	198	29	+	+		+	+	
2	HR	42	+	+		+			102	21		+		+	+	+
3	AC	46	+		+				117	22	+	+		+	+	+
4	MW	54	+	+		+			110	18		+			+	+
5	CF	50					+		122	28	+	+			+	+
6	GB	39	+		+	+			125	25	+	+			+	+
7	AC	53	+		+				177	13	+	+		+	+	+
8	HM	51							136	35	+	+		+	+	+
9	RW	68	+						147	25	+	+		+	+	+
10	RC	58	+						100	32	+	+		+	+	+
Non ischemic Cardiomyopathy																
11	KK	26	+		+	+			150	16		Normal			Absent	
12	DA	42	+	+		+			124	19		Normal			Absent	
13	HS	57			+	+			160	22		Normal			Absent	
14	DP	34	+						101	32		Normal			Absent	
15	SN	54	+			+			158	29		Normal			Absent	
16	WK	46					+		156	20		Normal			Absent	
17	BB	27				+			166	10		Normal			Absent	
18	DT	31						+	150	15		Normal			Absent	
19	PO	42							122	19		Normal			Absent	
20	RD	26	+						150	15		Normal			Absent	
21	EW	50	+				+		171	26		Normal			Absent	
22	CL	50					+		189	24		Normal			Absent	
23	WR	56	+					+	116	32		Normal			Absent	
24	MC	62	+		+				251	34		Normal			Absent	

Patients 1-10 abnormal coronary arteriograms patients 11-24 normal coronary arteriograms

†Abbreviations: Typ = typical ischemic chest pain Atyp = atypical ischemic chest pain LVEDI = end-diastolic volume index EF = ejection fraction

using standard techniques Ejection fraction and left ventricular end diastolic volume index (LVEDI) were calculated using volumes determined by the area-length method⁶

All patients were then characterized with respect to their clinical, electrocardiographic, and hemodynamic findings, as summarized in Table I Those patients with abnormal coronary arteriograms were considered to have ischemic cardiomyopathy while those with normal coronary arteriograms were considered to have a form of nonischemic cardiomyopathy

Student's t test was used for comparison of clinical, hemodynamic and angiographic data between the two groups of patients

Results

Coronary arteriography Ten patients were found to have abnormal coronary arteriograms

Six had triple vessel disease three had double vessel disease, and all had significant lesions of the left anterior descending coronary artery These ten patients were considered to have ischemic myocardial disease The remaining 14 patients had unequivocally normal coronary arteriograms and were given the diagnosis of nonischemic cardiomyopathy

Hemodynamic findings All 24 patients showed evidence of significant hemodynamic compromise No patient had a left ventricular end diastolic volume index less than 100 cc/M and no patient had an ejection fraction greater than 35 As shown in Table II the mean left ventricular end diastolic volume index was somewhat greater in the nonischemic group and the mean ejection fraction somewhat lower However the differences between the two groups were not statistically significant The left ventriculograms of all

Echocardiographic detection of a subannular aortic aneurysm*

Barry R Alter Maj MC
Robert L Treasure Col MC
Hal A Martin Lt Col MC
Stephen H Humphrey Capt MC
Joseph P Murgo Lt Col MC
George M McGowan Jr Col MC
Fort Sam Houston Texas

Subannular aortic aneurysms have been reported in a number of clinical and autopsy studies.¹⁻³ In most cases the diagnosis was made incidentally either at surgery or at postmortem examination.³ On occasion the diagnosis has been made by angiography.⁴ Echocardiograms on a patient with aortic and mitral insufficiency suggested the possibility of such an aneurysm. The aneurysm was subsequently demonstrated by angiography and confirmed at surgery.

Case report

A 44-year-old white female was admitted to the hospital with complaints of nonspecific precordial chest discomfort, low grade fever, nonproductive cough, and malaise. There was no history of rheumatic fever or intravenous drug use. Evaluation including multiple blood cultures yielded no specific diagnosis. The patient's symptoms improved without therapy. However, during follow-up examination four weeks later previously undetected murmurs of aortic and mitral insufficiency were heard, and signs of mild congestive heart failure were noted. Multiple blood cultures, serological tests, and skin tests were negative. A presumptive diagnosis of bacterial endocarditis was made and a four-week course of penicillin and streptomycin was administered. Nonetheless, the patient developed worsening congestive heart failure associated with clinically severe aortic and mitral regurgitation and was

scheduled for cardiac catheterization. An echocardiogram was performed from the standard fourth left intercostal space using a 2.25 mHz transducer, a Smith Kline Industries Ekoline 20A scanner, and a Honeywell 1858 fiberoptic strip chart recorder. Abnormal dense echoes were recorded behind the posterior aortic wall. The line of echoes moved abruptly posterior at the onset of systole and then moved anteriorly parallel to the posterior aortic wall (Fig 1). The motion of the echoes suggested a chamber posterior to the aorta, expanding in systole and emptying in diastole. Transesophageal echocardiography was performed with an Aerotech 3.6 mHz transesophageal transducer using the same scanner and strip chart recorder. The transesophageal echocardiogram revealed identical abnormal echoes behind the posterior aortic wall (Fig 2).

Angiography performed at cardiac catheterization revealed an enlarged left ventricle and severe mitral and aortic insufficiency. There was a large aneurysm posterior to the aorta with its orifice beneath the left aortic cusp. The aneurysm filled during ventricular systole and emptied during diastole. The motion of the posterior wall of the aneurysm was consistent with the motion of the abnormal echoes noted on the echocardiograms. In addition to the large posterior aneurysm, there were two smaller aneurysms: one in the left sinus of Valsalva below the origin of the left coronary artery and a second adjacent to the mitral annulus (Fig 3).

At operation, the mitral valve was exposed through the left atrium and the aortic valve through the aorta. The anterior leaflet of the mitral valve was completely flail secondary to extensive chordal rupture. The mitral valve was replaced with a Bjork-Sliley prosthesis. The aortic valve leaflets were normal. A 3 mm opening was found in the left coronary sinus of Valsalva which led to an aneurysmal pocket posteriorly. A similar but larger orifice (6 mm) was identified under the aortic annulus just below the commissure between the noncoronary and left coronary leaflets. This orifice communicated with a second aneurysm which was larger and inseparable from the left atrium (Fig 4). Repair of these lesions was impossible without significant distortion of the aortic valve. Therefore, the aortic valve was excised and the orifices were

From Cardiology Service, Department of Medicine, Brooke Army Medical Center, Fort Sam Houston, Texas.

Received for publication Sept. 7, 1977.

Accepted for publication Oct. 31, 1977.

Reprint requests: Barry R. Alter, M.D., Director, Cardiovascular Laboratories, Veterans Administration Hospital, 1401 N. 15th Street, Sixth St., Miami, Fla. 33125.

*The opinions or assertions contained herein are the private views of the authors and are not to be construed as reflecting the views of the Department of the Army or the Department of Defense.

fluoroscopy, with image intensification to detect the presence or absence of coronary calcification be performed in all patients presenting with congestive heart failure of unknown etiology. This technique provides a simple, noninvasive, reliable, and economical means of differentiating patients with ischemic cardiomyopathy from those with idiopathic myocardial disease.

Summary

Twenty four patients with severe congestive heart failure and cardiomegaly in whom the presence or absence of significant coronary disease could not be ascertained clinically, underwent fluoroscopy for coronary artery calcification prior to cardiac catheterization. Ten of the patients were found to have significant coronary artery disease, and 14 had normal coronary arteriograms. Coronary artery calcification was found in all ten patients with significant coronary disease and was absent in all of those patients with normal coronary arteriograms. We conclude that fluoroscopy for coronary artery calcification provides a reliable noninvasive method for differentiating ischemic from nonischemic cardiomyopathy.

REFERENCES

- 1 Burch G E, Giles T D and Colcolough H L. Ischemic cardiomyopathy. *AM HEART J* 79:991 1970.
- 2 Burch G E, Tsui G Y and Harb J M. Ischemic cardiomyopathy. *AM HEART J* 83:340 1972.
- 3 Burch, G E and Giles, T D. Ischemic cardiomyopathy. *Diagnostic pathophysiologic and therapeutic considerations*. *Cardiovasc Clin* 4:204 1972.
- 4 Yatteau R F, Peter R J, Behar V S, Bartel A G, Rosati R A and Kong Y. Ischemic cardiomyopathy. The myopathy of coronary artery disease. *Am J Cardiol* 34:520 1974.
- 5 Corya H C, Feigenbaum H, Rasmussen S and Black M F. Echocardiographic features of congestive cardiomyopathy compared with normal subjects and patients with coronary artery disease. *Circulation* 49:1153 1974.
- 6 Shors C M, Kozul V J and Henderson F. The differential diagnosis of congestive cardiomyopathy and ischemic cardiomyopathy by echocardiography. *Angiology* 26:723 1975.
- 7 Bulkley B H, Hutchins W M, Bailey I, Strauss W H and Pitt M. Thallium 201 imaging and gated blood pool scans in patients with ischemic and idiopathic congestive cardiomyopathy. *Circulation* 55:53 1977.
- 8 Dodge H T, Sandler H, Ballew D W and Lord J D. The use of biplane angiocardiography for the measurement of left ventricular volume in man. *AM HEART J* 60:762 1960.
- 9 Marriott H J. Electrocardiographic abnormalities: conduction disorders and arrhythmias in primary myocardial disease. *Progr Cardiovasc Dis* 7:99 1964.
- 10 Bartel A G, Chen J T, Peter R H, Behar V S, Kong Y and Lester R G. The significance of coronary calcification detected by fluoroscopy. *Circulation* 49:1247 1974.




Fig 3 Aortic root a-gram, lateral projection. A large aneurysm with a subannular origin is noted. A small supra-annular aneurysm can also be seen. The small aneurysm adjacent to the mitral valve is not seen in this view. Ao = aorta, LV = left ventricle.

of the aneurysm was noted to be subvalvular. In the current case both the transthoracic and transeophageal echocardiograms clearly demonstrated a posterior chamber between the aorta and left atrium which increased in size in early systole and decreased in diastole strongly suggesting the presence of an aneurysm. The angiogram confirmed its presence and delineated its subannular origin.

This case confirms the usefulness of echocardiography in detection of subannular aortic aneurysms and its indication for evaluating the aortic outflow area in patients with aortic valve disease especially when endocarditis is either proved or suspected. In addition transeophageal echocardiography was demonstrated to be useful in evaluating the aortic outflow tract for this particular abnormality and may be indicated in the assessment of patients in whom external echocardiography is technically suboptimal. Angiography remains the ultimate technique for confirming the presence and exact location of such aneurysm.

Summary

A subannular aortic aneurysm was detected on standard and transeophageal echocardiograms obtained from a patient with severe aortic and mitral regurgitation. The presumed etiology was bacterial endocarditis. A brief discussion of




Fig 4 Illustration of the two aneurysms as seen at surgery. The origin of the large subannular aneurysm is below the valve at the junction of the noncoronary and left coronary cusps. The origin of the supra-annular aneurysm is in the left coronary cusp. LCA = left coronary artery, RCA = right coronary artery.

subannular aneurysms is presented along with pertinent material from this case.

The authors wish to thank Gregory Snyder for his technical expertise, George Thomas for his illustration, and Bettye Johnston for her editorial assistance.

REFERENCES

1. Abrahams D G, Barton C J, Cockshott W P, Edington M M, and Weaver E J M. Annular subval-




Fig 1 Standard echocardiogram demonstrating a sweep from mitral valve to aorta. A dense line of echoes representing the aneurysm wall (AnW) is noted posterior to the aorta (Ao). AAW = anterior aortic wall; AML = anterior mitral leaflet; An = aneurysm; LA = left atrium; PAW = posterior aortic wall; PML = posterior mitral leaflet.




Fig 2 Transesophageal echocardiogram demonstrating a sweep from anterior mitral leaflet (AML) to aorta. The top of the figure is posterior. The aneurysm (An) is clearly defined posterior to the aorta. AAW = anterior aortic wall; AnW = aneurysm wall; AV = aortic valve; ECG = electrocardiogram; PAW = posterior aortic wall.

closed with buttressed sutures which were incorporated into the sewing ring of a Bjork Shiley aortic valve. The aneurysm adjacent to the mitral annulus visualized on angiography was not found. The patient was removed from cardiopulmonary bypass without difficulty and her postoperative course was uncomplicated.

Discussion

Subannular aortic aneurysms arise in the fibrous connective tissue supporting the aortic and mitral valves. The exact etiology of these aneurysms is unknown. There is strong support for the concept of congenital weakness of the fibrous skeleton of the valve rings with subsequent aneurysm formation.¹⁻³ In addition, cases of aneurysms have been reported following episodes of bacterial and fungal endocarditis^{2,5} and following trauma.⁶ Endocarditis may or may not play a primary role in the formation of these aneurysms. In the case presented, there was no

histological evidence of endocarditis on either the aortic or mitral valve leaflets. Aortic insufficiency was secondary to distortion of the valve created by the aneurysms, and the mitral insufficiency was secondary to rupture of the chordae tendineae. Endocarditis is the presumed etiology in this case but it is by no means certain.

Abnormalities of the aortic outflow tract and valve, including hypertrophic cardiomyopathy, valvular subvalvular and supra-valvular aortic stenosis, sinus of Valsalva aneurysms, and aortic valve vegetations have well defined echocardiographic patterns. A recent paper described dense interrupted echoes adjacent to the posterior wall of the aorta in a patient with endocarditis and aortic insufficiency. An aneurysm was noted on angiography.¹¹ Preoperatively, this was thought to represent an aneurysm of the noncoronary sinus of Valsalva; however, at surgery the ostium




Fig 3 Aortic root angiogram, lateral projection. A large aneurysm with a subannular origin is noted. A small supra-annular aneurysm can also be seen. The small aneurysm adjacent to the mitral valve is not seen in this view. Ao = aorta, LV = left ventricle.

of the aneurysm was noted to be subvalvular. In the current case, both the transthoracic and transesophageal echocardiograms clearly demonstrated a posterior chamber between the aorta and left atrium which increased in size in early systole and decreased in diastole, strongly suggesting the presence of an aneurysm. The angiogram confirmed its presence and delineated its subannular origin.

This case confirms the usefulness of echocardiography in detection of subannular aortic aneurysms and its indication for evaluating the aortic outflow area in patients with aortic valve disease, especially when endocarditis is either proved or suspected. In addition, transesophageal echocardiography was demonstrated to be useful in evaluating the aortic outflow tract for this particular abnormality and may be indicated in the assessment of patients in whom external echocardiography is technically suboptimal. Angiography remains the ultimate technique for confirming the presence and exact location of such aneurysms.

Summary

A subannular aortic aneurysm was detected on standard and transesophageal echocardiograms obtained from a patient with severe aortic and mitral regurgitation. The presumed etiology was bacterial endocarditis. A brief discussion of




Fig 4 Illustration of the two aneurysms as seen at surgery. The orifice of the large subannular aneurysm is below the valve at the junction of the noncoronary and left coronary cusps. The origin of the supra-annular aneurysm is in the left coronary cusp. LCA = left coronary artery, PCA = right coronary artery.

subannular aneurysms is presented along with pertinent material from this case.

The authors wish to thank Gregory Snyder for his technical expertise, George Thomas for his illustration, and Betty Jo Houston for her editorial assistance.

REFERENCES

1. Abrahams D G, Barton C J, Cockshott W P, Edington G M, and Weaver E J M. Annular subval




Fig 1 Standard echocardiogram demonstrating a sweep from mitral valve to aorta. A dense line of echoes representing the aneurysm wall (AnW) is noted posterior to the aorta (Ao). AAW = anterior aortic wall, AML = anterior mitral leaflet, An = aneurysm, LA = left atrium, PAW = posterior aortic wall, PML = posterior mitral leaflet.




Fig 2 Transesophageal echocardiogram demonstrating a sweep from anterior mitral leaflet (AML) to aorta. The top of the figure is posterior. The aneurysm (An) is clearly defined posterior to the aorta. AAW = anterior aortic wall, AnW = aneurysm wall, AV = aortic valve, ECG = electrocardiogram, PAW = posterior aortic wall.

closed with buttressed sutures which were incorporated into the sewing ring of a Bjork Shiley aortic valve. The aneurysm adjacent to the mitral annulus visualized on angiography was not found. The patient was removed from cardiopulmonary bypass without difficulty and her postoperative course was uncomplicated.

Discussion

Subannular aortic aneurysms arise in the fibrous connective tissue supporting the aortic and mitral valves. The exact etiology of these aneurysms is unknown. There is strong support for the concept of congenital weakness of the fibrous skeleton of the valve rings with subsequent aneurysm formation.¹⁻³ In addition, cases of aneurysms have been reported following episodes of bacterial and fungal endocarditis^{3,4} and following trauma.⁵ Endocarditis may or may not play a primary role in the formation of these aneurysms. In the case presented, there was no

histological evidence of endocarditis on either the aortic or mitral valve leaflets. Aortic insufficiency was secondary to distortion of the valve created by the aneurysms, and the mitral insufficiency was secondary to rupture of the chordae tendineae. Endocarditis is the presumed etiology in this case, but it is by no means certain.

Abnormalities of the aortic outflow tract and valve, including hypertrophic cardiomyopathy, valvular, subvalvular and supravalvular aortic stenosis, sinus of Valsalva aneurysms and aortic valve vegetations have well defined echocardiographic patterns. A recent paper described dense interrupted echoes adjacent to the posterior wall of the aorta in a patient with endocarditis and aortic insufficiency. An aneurysm was noted on angiography.⁶ Preoperatively this was thought to represent an aneurysm of the noncoronary sinus of Valsalva; however, at surgery the ostium

Ventricular pre excitation and prolonged Q-T interval syndromes in a patient with mitral valve prolapse

David M Mirvis, MD
Stanley W Erwin MD
Memphis Tenn

Mitral valve prolapse has become a commonly recognized clinical syndrome¹ characterized by typical auscultatory echocardiographic and ventriculographic abnormalities. Clinical manifestations are varied ranging from the asymptomatic state to premature and sudden death.

The occurrence of supraventricular and ventricular dysrhythmias has received wide attention because of their frequency being recorded in as many as 75 per cent of subjects during exercise² and because of their presumed relationship to the lethal potential of the syndrome³. Little however is known of their pathogenesis. In the case to be described mitral valve prolapse was associated with two other clinical syndromes known to predispose to cardiac dysrhythmias.

Case report

A 34 year old black woman was referred for evaluation of palpitations and chest pain. The pain was anginal in quality and always followed the onset of rapid regular palpitations lasting one to five minutes. She denied dizziness or syncope. Past history revealed no risk factors for ischemic heart disease and no history of rheumatic fever. She was taking no medications. The patient had two sisters one with and one without palpitations and a heart murmur.

From the Section of Medical Physics Division of Circulatory Disease and University of Tennessee Center for Health Sciences, Memphis, Tenn.

This investigation was supported in part by a DeBorah Hospital Foundation Research Grant and by United States Public Health Service Grant HL-20560 from the National Heart, Lung, and Blood Institute National Institutes of Health.

Received for publication Sept. 21, 1977.

Accepted for publication Oct. 10, 1977.

Reprint requests: David M. Mirvis, MD, Section of Medical Physics, University of Tennessee Center for the Health Sciences, 383 Court Ave., Room 339M, Memphis, Tenn. 38163.

Physical examination revealed normal vital signs. She had a straight back and a pectus excavatum. A mid systolic click followed by a Grade III/VI high frequency murmur was heard at the cardiac apex. A straight back and narrow A-P chest diameter were observed on x-ray. An echocardiogram was typical of mid-late systolic prolapse of the posterior mitral valve leaflet.

Electrocardiographic findings (Fig. 1) included a sinus rhythm (77 beats per minute), a PR interval of 120 msec., a normal QRS complex without a delta wave, diffuse ST-T abnormalities and a prolonged Q-T interval (570 msec, Q-T = 0.58). Mean QRS axis was 10 degrees. Preordial voltage exceeded criteria for left ventricular hypertrophy. A 24 hour ECG tape recording revealed frequent episodes of ventricular bigeminy and three runs of unsustained ventricular tachycardia 8 to 10 beats in duration. Serial electrocardiograms demonstrated lability of the Q-T interval measuring 0.42 to 0.60 msec. during the study period.

Serum electrolyte concentrations (Na, K, Cl, HCO, Ca, Mg) blood cell counts and renal and hepatic function tests were normal. An audiogram was likewise normal.

Electrophysiologic studies were performed in an unpremedicated postabsorptive state after obtaining voluntary informed consent. Two bipolar electrode catheters were advanced to the high right atrium and His bundle areas from the right femoral vein. Intracardiac electrocardiograms were recorded during sinus rhythm and during atrial pacing after bandpass (30 to 400 Hz) filtering. His bundle recording was validated by His bundle pacing.

During sinus rhythm (cycle length = 1060 msec, Fig. 2A) values for P-A, A-H and H-V intervals were 30, 30 and 40 msec. respectively. The Q-T interval was normal at the time of study. Body surface and His bundle electrocardiograms and interval measurements during incremental atrial pacing are presented in Figs. 2B through 2F. Reducing the cycle length from 960 msec. to 560 msec. resulted in a minimal (< 10 msec.) increase in A-H intervals. Further decrements in pacing cycle length to 450 msec. produced no further changes in A-V nodal conduction time. At this heart rate the patient experienced chest discomfort similar to that causing referral. Tachycardias were not induced during the procedure.

Left ventriculography in the right anterior oblique projec-

- vular left ventricular aneurysms *Q J Med New Series* 31 345 1962
- 2 Chesler E Joffe N Schamroth L and Meyers A Annular subvalvular left ventricular aneurysms in the South African Bantu *Circulation* 32 43 1965
- 3 Chesler E Korns M Porter G E Reyes C N and Edwards J E False aneurysm of the left ventricle secondary to bacterial endocarditis with perforation of the mitral aortic intervalvular fibrosa *Circulation* 37 518 1968
- 4 Mershon J C Samuelson D R and Layman T E Left ventricular (fibrous body) aneurysm caused by *Aspergillus* and Endocarditis *Am J Cardiol* 22 281 1968
- 5 Martin Rodriguez E and Blesovsky A Subvalvular aortic aneurysm *J Cardiovasc Surg* 14 439 1973
- 6 Waldhausen J A Petry E L and Kurlander G J Successful repair of subvalvular annular aneurysm of the left ventricle *N Engl J Med* 275 984 1966
- 7 Puig Massana M Murtra M Castells E and Revuel ta J M Repair and long term followup of a subaortic annular aneurysm *J Thorac Cardiovasc Surg* 61 39 1971
- 8 Thoms M W Wilson R F Pure T and Arbulu A Circular calcification in the mediastinum *Chest* 63 42 1973
- 9 Arbulu A and Thoms N W Subannular aneurysms associated with acute massive aortic insufficiency *J Thorac Cardiovasc Surg* 66 380 1974
- 10 Cowley M J Wells J L Hood W P and Hukla J W Pulmonary arterial compression syndrome caused by false aneurysm of left ventricular outflow tract *Am J Cardiol* 38 959 1976
- 11 Gaasch W H and Cleveland R J Echocardiographic examination in aortic regurgitation *Chest* 70 771 19 6
- 12 Edwards J E and Burchell H H The pathological anatomy of deficiencies between the aortic root and the heart including aortic sinus aneurysms *Thorax* 12 126 1957




Fig 2 Electrocardiograms recorded from precordial Lead V and bipolar intracardiac lead at the His bundle recording area (HBE) during sinus rhythm (panel A) and during atrial pacing (panels B through F). P, A, H and V refer to deflections generated by high right atrial tissue (panel A) or by the artificial pacemaker (panels B through F) the low right atrium, the His bundle and the ventricular muscle respectively. Identified in each panel are cardiac cycle length (CL) and PA and AH intervals in msec.

Chandra and co workers¹¹, Chandraratna and collaborators¹² and by Bjerregaard and associates¹³. In contrast to the number of reports of classical Wolff Parkinson White patterns, A V nodal bypass of the type described here has been described in but three patients referred to by Devereux and colleagues¹⁴ and by Kastor and Josephson¹⁵. Finally Krikler and co workers¹⁶ reported one case of mitral prolapse with the Mahaim fiber type of pre excitation.

Overlap syndromes such as described here and in the reports previously referred to may be considered as coincidental concurrences of abnormalities without special significance. This approach is particularly justified when one disorder is common, as in mitral valve prolapse. An alternative approach is that the overlaps signify that one lesion predisposes to the others in some undefined manner. The overall clinical spectrum of the commonest disorder, i.e. mitral valve prolapse, depends then upon the frequency of concurrence with other lesions. For example, the incidence of clinically significant dysrhythmias in subjects with prolapse may relate to the incidence of anomalous atrioventricular pathways of prolonged Q T intervals or of other definable electrophysiologic aberrations in these patients. This was suggested by Shappell and associates¹⁷ with regard to Q T intervals. Kastor and Josephson¹⁵ provided support for this concept by demon-

strating bypass tracts in all studied patients with prolapse suffering with supraventricular tachycardias. It may therefore be possible to subdivide all patients into subgroups with different risks of morbidity and mortality.

Summary

A 34 year old woman with mitral valve prolapse, frequent ventricular dysrhythmias and chest pain was studied. Surface electrocardiograms demonstrated short PR and prolonged Q T intervals. A V nodal conduction times during atrial pacing were characteristic of A V nodal bypass tract function. The case is thus interpreted to be one of overlap between three syndromes known to predispose to cardiac dysrhythmias, i.e. mitral valve prolapse, Lown-Ganong-Levine syndrome and prolonged Q T interval syndrome.

REFERENCES

1. Barlow J B and Pocock W A. The problem of nonejection systolic clicks and associated mitral systolic murmurs. *Am Heart J* 90:636, 1975.
2. Devereux R B, Perloff J A, Reichek N, and Josephson M E. Mitral valve prolapse. *Circulation* 54:3, 1976.
3. Gouch A S, Vicente F, Maranhao V, and Goldberg H. Arrhythmias and left ventricular asynergy in the prolapsing mitral leaflet syndrome. *Am J Cardiol* 29:611, 1972.
4. Jernstam R M. Sudden death in the mitral valve prolapse-click syndrome. *Am J Cardiol* 37:317, 1976.




Fig 1 Electrocardiographic records demonstrating a short P-R interval (0.12 sec), diffuse ST-T abnormalities and a prolonged Q-T interval

tion confirmed the presence of posterior mitral leaflet prolapse. Coronary angiograms were normal.

Both sisters were subsequently examined. One with a history of palpitations had a mid systolic click. Electrocardiogram demonstrated a P-R interval of 100 msec and a Q-T interval of 0.54 msec. The second sister was asymptomatic with normal physical findings and electrocardiogram. Other family members were not available for evaluation; none had cardiac symptoms.

Discussion

Three distinct diagnoses are apparent in this patient. First she had the typical histological, physical, auscultatory, echocardiographic and ventriculographic features of mitral valve prolapse.^{1,2,3} Of particular relevance here is this patient's history of palpitations, correlating with episodic ventricular bigeminy and tachycardia on dynamic electrocardiography. Such rhythm disturbances may be observed in up to three fourths of afflicted persons and may be pathogenically related to abnormal stretching of papillary muscles⁴ or of pacemaker-like fibers in the mitral leaflets.⁵

Secondly, ventricular pre-excitation of the form described by Lown, Ganong and Levine⁶ is documented by the short P-R and A-H intervals at rest, the failure of A-V nodal conduction to slow at increased heart rates, the normal H-V time and the absence of a delta wave.⁷⁻¹⁰ This electrophysiologic anomaly is correlated with the presence of a path extending from the atrium to the His-Purkinje system, bypassing the slowly

conducting A-V node. The relationship between this syndrome and cardiac dysrhythmias is well known.¹¹

Lastly, the prolonged Q-T interval conforms to another electrophysiologic anomaly clearly associated with cardiac dysrhythmias.¹¹⁻¹³ This syndrome which may be familial with or without deafness or related to drug therapy¹² has been associated with autonomic dysfunction. Sudden death and syncope are caused by ventricular fibrillation or asystole.

Thus this patient represents an overlap of three conditions—one common and two uncommon—predisposing to cardiac dysrhythmias. Similar cases of two concurrent abnormalities are well known. Prolonged Q-T intervals in patients with mitral valve prolapse not related to drug therapy have been noted in five of 24 patients reported by Gooch and colleagues,¹ but in only one of 144 subjects reviewed by Barlow and Pocock.¹ The possible critical role of this finding in causing sudden death in patients with prolapse has been considered by Shappell and associates.¹⁴

Likewise various forms of ventricular pre-excitation have been occasionally noted with mitral leaflet prolapse. Gallagher and co-workers¹⁵ reported seven patients with prolapse and typical Wolff-Parkinson-White syndrome, suggesting a greater incidence than expected by chance alone. Other similar cases have been described by Fujino and associates¹⁶ by Devereux and colleagues.²

Fatigue dyspnea and abdominal swelling in a 13 year-old boy

Noble Fowler M.D.*

Kevin E. Bove M.D.**

Scott Dunbar M.D.***

Richard Meyer M.D.**

Cincinnati, Ohio

B C CHMC No 228488 was a healthy active 13 year old boy prior to insidious appearance of fatigue and listlessness poor appetite failure to gain weight and eventually dyspnea on exertion over an 8 month period. Most recently mild abdominal swelling had been noted and his parents had observed mild peroral cyanosis following moderate exercise. Two older brothers and a sister were in good health. There was no history of fever chest pain peripheral edema gastrointestinal disturbance arthralgia or of exposure to tuberculosis.

Physical examination on admission revealed a somewhat edematous boy with moderate abdominal distention and pitting ankle edema who was cyanotic at rest and in no acute distress. Weight was 97 pounds temperature 98.6° F, respirations 34/minute pulse 100/minute and blood pressure 90/70 mm Hg without pulsus paradoxus. Femoral artery pulsations were felt but intensity was not recorded. The jugular veins were distended to 10 cm above the clavicle while he

was seated there was no Kussmaul sign. Rales were present over both posterior lung fields. Heart size was within normal limits by palpation and no thrill was evident. S was normal. S was loud and closely split with an increased pulmonic component. A Grade II/VI pansystolic murmur was heard at the apex. An abdominal fluid wave was demonstrated and the liver edge was palpated 8 cm below the right costal margin. No neurological or musculo-skeletal abnormalities were observed.

Laboratory data disclosed a hemoglobin of 14.8 Gm/dl. The white blood count was 5400/mm³ with 74 per cent polymorphonuclear cells, 13 per cent lymphocytes, 11 per cent monocytes and 2 per cent eosinophils. Platelets were normal in number and appearance. Urinalysis was normal. The blood urea nitrogen was 18 mg/dl and serum concentration of Na, K, Cl and bicarbonate were normal.

The electrocardiogram showed sinus rhythm with broad notched P waves. The ST segments were depressed and the T waves flat in Leads I, 2, 3, aV_F, V₁, and V₂. Voltage was high normal and criteria for ventricular enlargement were absent.

He was treated with digoxin and chlorothiazide and his weight fell 15 pounds over a three day period. Hepatomegaly and neck vein distention regressed but did not disappear.

Cardiac catheterization performed 2 weeks after admission revealed the findings shown in Table I.

Cineangiography showed no intracardiac shunts, both ventricles were normal sized and contracted well. Prominent left atrial dilatation

From the Departments of Pediatrics, Medicine and Pathology, University of Cincinnati College of Medicine and Children's Hospital Medical Center, Cincinnati, Ohio.

Received for publication November 1, 1977.

Reprint requests: Kevin E. Bove, M.D., Children's Hospital Medical Center, Elland and Belmont Aves., Cincinnati, Ohio 45229.

*Professor of Medicine, University of Cincinnati College of Medicine.

Professor of Pediatrics and Pathology, University of Cincinnati College of Medicine.

Professor of Radiology, University of Cincinnati College of Medicine.

Associate Professor of Pediatrics, University of Cincinnati College of Medicine.

- 5 Criteria Committee of the New York Heart Association Nomenclature and criteria for diagnosis of diseases of the heart and great vessels seventh edition Boston 1973 Little Brown & Company
- 6 Bon Tempo C P Ronan J A Jr de Leon A C Jr and Twigg H L Radiographic appearance of the thorax in systolic click late systolic murmur syndrome Am J Cardiol 36 27 1975
- 7 Wit A L Fenoglio J J Wagner R M and Bassett A L Electrophysiological properties of cardiac muscle in the anterior mitral valve leaflet and the adjacent atrium in the dog Circ Res 32 731 1973
- 8 Lown H Ganong W F and Levine S A The syndrome of short P R interval normal QRS complex and paroxysmal rapid heart action Circulation 5 693 1952
- 9 Castellanos A Castillo C A Agha A S and Tessler M His bundle electrograms in patients with short P R intervals narrow QRS complexes and paroxysmal tachycardia Circulation 43 667 1971
- 10 Narula O S Electrophysiologic evaluation of accessory conduction pathways in His bundle electrocardiography and clinical electrophysiology O S Narula ed Philadelphia 1975 F A Davis chapter 15 pp 313 342
- 11 Jervell A Thungstad H and Endsjø T O The surdo cardiac syndrome AM HEART J 72 582 1966
- 12 Ward O C A new familial syndrome in children J Ir Med Assoc 54 103 1964
- 13 Koster R W and Wellens H J J Quinidine induced ventricular flutter and fibrillation without digitalis therapy Am J Cardiol 38 519 1976
- 14 Shappell S D Marshall C E Brown H E and Bruce T A Sudden death and the familial occurrence of mid systolic click late systolic murmur Circulation 48 1123 1973
- 15 Gallagher J J Gilbert M Svenson R H Sealy W C Kasell J and Wallace A G Wolff Parkinson White syndrome The problem evaluation and surgical correction Circulation 51 767 1975
- 16 Fujino T Ito M Kanaya S Arita M Fujino M and Mashiba H Detection of the pre excitation states in Wolff Parkinson White syndrome by echocardiography Proc Japan Acad 51 680 1975
- 17 Chandra M S Kerber R E Brown D H and Falk D C Echocardiography in Wolff Parkinson White syndrome Circulation 55 943 1976
- 18 Chandraratna P A N Ribas Menecher C Littman B H and Samet P Conduction disturbances in patients with mitral valve prolapse J Electrocardiol 10 233 1977
- 19 Bjerregaard P and Peterson H C Type A WPW and mitral valve prolapse Circulation 56 136 1977
- 20 Kastor J A and Josephson M Mechanisms of supra ventricular tachycardia in mitral valve prolapse Circulation 53(Suppl II) 48 1976
- 21 Krnkler D Curry P and Kafetz H Pre excitation and mitral valve prolapse Br Med J 1 1257 1976

history of heart disease. The patient when first seen at age 13½ had symptoms of heart failure namely tachycardia, tachypnea and low blood pressure even for this age. No evidence of paradoxical pulse was described. His venous pressure was quite high. There were rales over both lung fields but his heart was not thought to be enlarged. There was a systolic murmur at the apex that sounded as if it might be indicative of mitral incompetence. No diastolic murmur was heard. A gallop rhythm was not heard at this time. We do not know whether or not there was a sharp Y descent of the cervical venous pulse.

The original suspicion of constrictive pericarditis was raised. I am sure because of his persistent circulatory difficulty and his relatively normal heart size on roentgenogram and perhaps inconspicuous pulmonary congestion. The patient was treated for heart failure and had a response with diuresis. It would be interesting to know what happened to the venous pressure at that time. If he had constrictive pericarditis one would not expect any great improvement. If he had congestive heart failure secondary to valvular or myocardial disease one might have expected a fall in venous pressure with clinical improvement.

The patient then underwent cardiac catheterization that showed a number of things of interest including a rather low content of oxygen in his vena cava and right atrium suggesting that he may have had a subtle decrease in his cardiac output despite the low normal cardiac index. His left ventricular end diastolic pressure was 25 which is quite elevated and was about the same in the pulmonary artery and only slightly greater than that in the right atrium. Atrial pressures were almost equal. The pressures measured are of the kind seen in constrictive pericarditis or cardiac tamponade but may also be seen occasionally in cardiomyopathy.

A cineangiogram showed a large left atrium and no intracardiac shunt. Lack of both a diastolic murmur and of a diastolic pressure gradient between the left atrium and left ventricle indicates that mitral stenosis was not the cause of left atrial enlargement. We are uncertain as to whether there was or was not mitral incompetence. LV contractility was normal, an important finding in a patient with this degree of circulatory difficulty because it indicates that the site of the




Fig 1 Electrocardiogram from 15-year old male patient obtained 2½ months after onset and 4 weeks prior to death.

impedement was proximal to the body of the left ventricle.

Thus we have a young lad with circulatory failure and certain features suggesting that he had constrictive pericarditis namely a relatively small heart, elevated venous pressure, elevation of diastolic ventricular pressures and atrial pressure equalization. The relatively normal cardiac output is more in keeping with pericarditis than cardiomyopathy or some other cardiac disorder.

There has been considerable interest especially in recent years in the problem of restrictive cardiomyopathy, a rare disorder of the myocardium in which the heart is not greatly dilated in which the venous pressure may remain elevated and which has certain features in common with constrictive pericarditis. I would like now to concentrate on the differential diagnosis between these two disorders. Distinction between them is very important because constrictive pericarditis is a potentially curable illness whereas restrictive cardiomyopathy may be helped by digitalis and diuretics but a cure is unlikely to be achieved.

The failure of systemic venous pressure to decrease following treatment is an important characteristic of constrictive pericarditis but may also be seen in restrictive cardiomyopathy. The venous pressure must have been high after clinical improvement in this case because at cardiac catheterization right atrial pressure was elevated. Patients with restrictive cardiomyopathy may also have pulsus paradoxus limiting its

Table 1 Catheterization data

Position	% O ₂ saturation	Pressure (mm Hg)	Mean
SVC	64		
RA high	60		
RA mid	65	A = 18 V = 17	16
RA low	67		
LA	96	A = 22 V = 20	18
LA		A = 20 C = 18	18
LPV	94	A = 26 V = 20	19
RV	72	45/20	
MPA	73	50/25	39
LPA	73	48/24	
LPA MPA RV RA		48/24 45/22	
RA mid	66		
LV	95	88/25	
LV		95/25	
LA			
LV AO		95/25 95/70	80
Ejection fraction = 53%			
Cardiac index = 3.3/min/M ²			

was demonstrated. Mitral insufficiency was not demonstrated but the study was not adequate for this purpose.

One week later exploratory mediastinotomy was performed through a median sternotomy incision. The parietal pericardium was described as slightly thick and hypervascularized. The pericardial sac was the seat of filmy fibrous adhesions that were easily broken by blunt dissection. The surgeon's finger easily probed the entire sac and no evidence for constriction was found. The epicardial surface of the myocardium was an abnormal pale yellow color.

Examination of the 2 cm. square piece of parietal pericardium that was removed showed mild diffuse collagenous thickening without evidence of active inflammation or repair. No granulomas or mineral deposits were identified. The lesion was interpreted as consistent with a remote pericarditis of unknown type.

Lacking evidence for constrictive pericarditis the patient was thought to have a restrictive cardiomyopathy. He was discharged following an uneventful postoperative recovery on digoxin, 0.125 mgm twice a day, furosemide 40 mg three times a day, spironolactone 12.5 mg three times a day and supplemental KCl.

His subsequent activity was limited by increasing dyspnea and orthopnea. On second admission to the hospital 14 months later he was unable to

walk more than 20 yards without resting. Pitting peripheral edema, jugular venous distention and hepatomegaly were again prominent. Tachycardia, cyanosis of the lips and acrocyanosis were present at rest. Peripheral pulses were weak. Clinical signs of cardiomegaly were still absent. S₁ was split. An S₁ gallop rhythm became audible and a holosystolic murmur persisted at the apex. Phonocardiography demonstrated a prominent mid-systolic click suggesting mitral valve prolapse. The scalar electrocardiogram (Fig 1) was unchanged except for right axis deviation. The vectorcardiogram in comparison to the initial tracing, showed a change from counterclockwise to clockwise inscription in the horizontal plane indicating right ventricular hypertrophy. He responded to intravenous administration of ethacrynic acid with a 5 pound weight loss to 78 pounds but fluid rapidly reaccumulated. After a brief final admission several weeks later, he died suddenly during a similar therapeutic endeavor.

Discussion

DR FOWLER: This patient represents a problem of the differential diagnosis of heart disease with systemic and probably pulmonary congestion occurring over a period of 2½ years beginning at the age of 13½ and terminating in death apparently from circulatory failure 1½ years later. Of importance is the fact that there was no family




Fig. 4 Hyalinized mineralized epicardium lacks cellular infiltrate (Hematoxylin and eosin, original magnification $\times 135$)

myocardial disease over pericardial disease. An other point we might make about the plain roentgenogram is that if the patient has a combination of thickening due to scar plus fluid between the pericardial layers the pericardial silhouette may be quite sizeable. Calcification of the pericardium is not diagnostic of constriction and it is found in only 50 per cent of patients with constrictive pericarditis. So with signs of constriction the size of the cardiac silhouette may be normal or it may be considerably enlarged by scar alone or scar in combination with fluid. Pericardial fluid predominates in the effusive-constrictive pericarditis that may simulate congestive heart failure in adults. May we see the x rays?

DR. DUNBAR: The heart at the time of the first admission was minimally enlarged but was interpreted as showing striking enlargement of the left atrium (Fig. 2). The lungs show some congestion with multiple Kerley lines which are rather non-specific. Bilateral pleural fluid and thickening is present at least to a moderate degree. Despite its near normal size there is a striking abnormality of cardiac contour with straightening of the left heart border. I do not recognize any pericardial calcification although in fairness I should add that at least one staff radiologist suspected its presence.

The films obtained late in the course of his disease show little change.

DR. FOWLER: I am very struck by the very large left atrium although it did not look so striking on the barium esophagogram. The pronounced isolated chamber enlargement would be unusual to say the least in a patient with constrictive pericarditis as the constrictive process is usually rather uniformly applied although there may be some sparing of the pericardium of the posterior left atrial wall. The second thing I would emphasize is that Dr. Dunbar has mentioned the presence of Kerley lines. These are usually equated with elevation of pulmonary lymphatic and venous pressure and although occasionally seen with constrictive pericarditis are much more common in congestive heart failure. Therefore we have two radiograph features which are against constrictive pericarditis and favor primary myocardial disease and two points relatively normal cardiac size and equivocal evidence of pericardial calcification which are in keeping with constrictive pericarditis.

In the electrocardiogram we find several points of interest. In the initial tracing the P waves are very prominent and late peaks suggest that this is due to left rather than right atrial involvement. The ST segments are abnormal and may reflect digitalis therapy or may indicate some other diffuse myocardial problem. The voltage is a bit high but at this age this is difficult to judge. It might reflect some left ventricular involvement. The delay in the left precordial R wave might



Fig 2 Chest roentgenogram and barium esophagogram performed at the time of the first admission



Fig 3 Left anterolateral surface of parchment heart. Unusual quality of epicardium is highlighted by unusual wrinkles and folds that have been augmented by development of a tissue plane between the outer hyalinized zone and less altered epicardium adjacent to the myocardium. Path of most heavy mineral deposit traverses field above line of arrows and corresponds roughly to the plane of the mitral valve ring (dashed line)

usefulness as a discriminating feature. The patient had a negative Kussmaul sign that is, absence of inspiratory collapse of neck veins. We haven't found that to be helpful, for it may be present in patients with heart failure of any cause and absent in constrictive pericarditis.

Precordial phonocardiography is helpful if it shows the 'knock sound' which is a sharp sound that usually occurs 0.6 to 1.2 sec after the second heart sound in patients with constrictive pericarditis. It sounds very much like a mitral opening snap but is not followed by a diastolic murmur. It is a bit earlier than the gallop rhythm which usually occurs about 1.4 sec after the second heart sound. The phonocardiogram obtained on the first admission in this patient showed neither a knock nor a gallop. The absence of the knock in this boy does not at all rule out pericardial disease, but the subsequent development of a late sound consistent with a gallop would be a point against pericardial disease.

I shouldn't omit the fact that precordial palpation is also important. If one feels a good active precordium and can feel the gallop impulse, it is unlikely that one is dealing with significant pericardial disease.

A few words about the chest roentgenogram. In patients with constrictive pericarditis the heart size may be almost normal and the lungs are usually clear. Typically there is no congestion in the lungs and rales are not heard. The presence of rales in a patient such as this one would favor




Fig 7 A Atrophic basilar myocardium adjacent to the mitral valve consists of shrunken fibers separated by myxoid ground substance (Hematoxylin and eosin, original magnification $\times 300$) B Small muscular pulmonary artery exhibiting intimal and medial infiltrate of polymorphonuclear and mononuclear cells including stimulated lymphoid cells (Hematoxylin and eosin, original magnification $\times 500$)

constrictive pericarditis. The echocardiogram may also be helpful in terms of what it tells us about ventricular size and function and mitral valve performance. Dr Meyer, would you please interpret the echocardiogram for us?

DR MEYER: This tracing was made in September 1973. The posterior leaflet of the mitral valve instead of a normal gradual movement toward the anterior chest wall during systole moves somewhat posteriorly and there is evidence of pan prolapse of this valve into the left atrium. I would also point out the marked increase of his left atrial dimension. The left ventricular cavity dimensions are normal. The septal and free wall motions are normal and the calculated ejection fraction is in the low normal range. The pericardium is difficult to assess but there is no fluid in the pericardial space. The later echocardiograms show all of these features to be persistent. Right ventricular enlargement was not detected.

DR FOWLER: Do you think the echocardiogram can be used to exclude the necessity for surgical exploration for constrictive pericarditis?

DR MEYER: No. The echocardiogram may be

useful in identifying an effusion but it is not useful for the determination of constriction. In a negative sense the absence of any demonstrable sign of cardiomyopathy would make exploration of this patient mandatory.

DR FOWLER: Do you think that he had mitral insufficiency due to his prolapse?

DR MEYER: Yes. However, the failure of the left ventricle to dilate commensurately with the left atrium is puzzling.

DR FOWLER: We are left without a definitive angiogram and thus are not certain about mitral insufficiency. Clearly, however, this patient's heart had more trouble filling than emptying. He had both auscultatory and echocardiographic evidence favoring a diagnosis of mitral insufficiency and this must have contributed to the left atrial enlargement. From the surgical exploration we are told that he did not have significant pericardial disease although he did have some evidence of pre-existent inflammation.

I believe that the pattern of abnormality in this patient fits more with restrictive cardiomyopathy than with constrictive pericarditis. This is much



Fig 5 Basilar left ventricle. Mineralized epicardial scar in A-V groove extends into the myocardium. Pale myocardium (arrows) exhibits severe atrophy. Mitral valve, part of posterior papillary muscle, and remainder of myocardium are unaltered (Hematoxylin and eosin, original magnification $\times 4$).

suggest a delay in left ventricular activation. His later electrocardiogram is more striking on two of these points (Fig 1). He had developed an impressive degree of right axis deviation of about 120 degrees. His P waves are larger yet with the same late peak and in V_1 he has a prominent secondary negative component of the P wave which is usually equated with left atrial activation and is in keeping with the left atrial enlargement seen on the roentgenogram. In addition, he now has a very prominent R wave suggestive of right ventricular enlargement or conduction delay. His S waves have become more prominent over the left precordium which would also be in keeping with right ventricular enlargement. In an



Fig 6 Focal prolapse (arrows) and mild diffuse thickening of mitral valve leaflets are inconspicuous. Papillary muscles are normal. The large left atrial chamber dwarfs the normal sized left ventricle.

adult with this kind of electrocardiogram one would think strongly about the possibility of mitral valve disease, particularly obstruction at the mitral valve orifice.

In a typical case of pericarditis one would expect to see sinus rhythm, low voltage of QRS complexes in the limb leads, and normal P waves. A left atrial enlargement pattern may sometimes be seen but one would not expect the ventricular abnormalities suggested by the electrocardiogram in this patient. About 25 per cent of the patients show atrial fibrillation. The demonstration of a pattern of bundle branch block or of ventricular hypertrophy is a strong point against constrictive pericarditis. Of course a patient may always have two diseases.

What does one do with such a patient whose hemodynamic studies show pressures consistent with constrictive pericarditis but in whom there are many data that are inconsistent with this diagnosis? A left ventricular angiogram may be helpful in defining the thickness of the wall of the ventricle and of the overlying pericardial tissue. However, the angiogram is not always helpful in defining wall thickness, as has been our experience in two of seven cases with other evidence of

of the viscera included early congestive cirrhosis

In the absence of infiltrative or reparative lesions of the endocardium or subendocardial myocardium I believe a diagnosis of restrictive cardiomyopathy is untenable. The absence of histopathological changes in the papillary muscles makes it unlikely that dysfunction of these structures was responsible for the auscultatory signs of mitral insufficiency. Although the left atrium was markedly dilated, dilatation of the mitral valve ring was not a feature and moreover has been recently discredited as a major cause of regurgitation. The functional consequences of restriction of movement of the mitral valve apparatus by epicardial scar and basilar myocardial atrophy are not simple to predict but mild diffuse thickening of the leaflets and focal prolapse help to substantiate the clinical evidence that mitral valve dysfunction existed.

Constrictive pericarditis due primarily to epicardial scarring as occurred in this case is extremely unusual and appears not to have been previously well documented. Annular constriction has been described at the base of the heart in the region of the A V groove or in relation to the great arteries or veins.¹ It may calcify and has been reported to cause discrete intra- or extracardiac obstruction by producing rigidity of the valve or vessel which it encircles. Annular constriction has not been reported in pericarditis due to tuberculosis or collagen-vascular disease and thus one may speculate that epicarditis due to virus or bacteria is the precursor in our patient.

ANATOMIC DIAGNOSIS. Constrictive epicarditis, idiopathic-calcification, left A V groove-focal myocardial atrophy adjacent to mitral valve ring-minor prolapse of mitral valve. Left atrial dilatation. Right ventricular hypertrophy. Fresh and organized pulmonary emboli. Necrotizing vasculitis, lungs acute. Chronic passive congestion all viscera. Congestive cirrhosis early. Fibrosing pleuritis, peritonitis, perisplenitis.

DR FOWLER: I have several comments. I have read in the older literature of patients with constricting bands in the AV groove and even sometimes with diastolic murmur presumably due to mitral stenosis. Only one such case was reported in 53 patients with constrictive pericarditis but a separate report described three patients with features in common with this case. These features were primarily constriction of the

left ventricle, a constricting band in the A V groove producing mitral stenosis and left atrial and right ventricular enlargement. There seems to be no doubt that he did have significant epicardial scar. Having been in a situation before where the surgeon has not recognized constrictive pericarditis, I am a little dismayed that the biopsy sample included only parietal pericardium and I wonder why there wasn't an epicardial and myocardial biopsy obtained. It probably would have been very helpful.

Do you think that his epicardium looked like this when he was operated upon? It seems to me that since the surgeon was unimpressed by it that this may have been a later development. Was the epicarditis diffuse and do you think that the epicardial scar could have been removed and the process of constriction relieved?

Despite the surprising amount of pericardial disease I wonder still if there wasn't some myocardial factor in this boy's progressive disease.

DR BOYE: There may have been progressive epicardial scarring during the 16 month interval between exploration and death but I believe that the basic process was established prior to biopsy. The surgeon reported an abnormal yellowish appearance of the epicardial surface but did not appreciate its significance. Its appearance remained deceptively benign 1½ years later at autopsy. The only myocardial lesion was a very limited one at the base of the heart adjacent to the mitral A V groove. Of course one cannot absolutely eliminate a coexistent functional myocardial disorder solely on the basis of histologically normal myocardium.

The diffuse epicardial scar in my opinion might have been stripped without doing serious damage to the myocardium but I think that some difficulty might have been encountered in removing the scar in the left A V groove where it was heavily calcified and penetrated the basilar myocardium. Annular constrictive pericarditis has been reported to be amenable to surgical correction if it is recognized.

REFERENCES

1. Hancock, E. W. Subacute effusive constrictive pericarditis. *Circulation* 43: 182, 1971.
2. Goodwin, J. F., Gordan, H., Hollman, A., and Bishop, M. B. Clinical aspects of cardiomyopathy. *Br Med J* i 69, 1961.
3. Schlant, R. C. *Physiology of Idiopathic Cardiomyopathy*.

the rarest of the forms of primary cardiomyopathy, the two more common forms being the congestive and obstructive types. What is the nature and etiology of this condition? Restrictive cardiomyopathy is defined as a state "resembling constrictive pericarditis with diastolic filling difficulty due to myocardial rigidity, infiltration and often with endocardial involvement." The more commonly encountered variants are due to amyloidosis, localized endomyocardial fibrosis (East Africa), scleroderma, neoplasm, and hemochromatosis.³ Many cases are idiopathic. Because this patient lacks stigmata of any of these associated conditions and is so young, I must place his disease in the idiopathic category.

Patients who have a viral infection may have mild pericarditis and myocarditis and then go on to develop a picture of cardiomyopathy though usually of the congestive type. Conceivably there could be post-inflammatory endomyocardial sclerosis restricting left ventricular expansion and causing dysfunction of papillary muscles leading to mitral prolapse. Thus I would speculate that in this case a restrictive cardiomyopathy may have begun with a viral illness.

CLINICAL DIAGNOSIS Restrictive cardiomyopathy, idiopathic—secondary mitral prolapse and left atrial dilatation.

DR BOVE The outstanding feature at autopsy was a florid fibrous tissue proliferation that involved much of the surface of both pleural cavities, the peritoneum and to a lesser extent the parietal pericardium. We considered that this might be the result of infection or systemic collagen-vascular disease but could find evidence for neither. Therefore we interpreted the fibrosis of serosal surfaces as a concomitant of chronic effusion in a boy with systemic venous hypertension.

The nature of the cardiac disorder at first eluded us as it had eluded the surgeon and the cardiologist. The prosector easily had separated the parietal pericardium from the heart and it was only moderately increased in thickness. Doubting that either parietal pericardial constriction or cardiomyopathy was the basic problem, we turned our attention to the epicardium which was diffusely opacified, wrinkled and parchment-like in texture (Fig 3). Microscopically the superficial epicardium of both ventricles was replaced by a peculiar almost acellular focally

mineralized hyaline scar of uniform thickness (Fig 4) that had partially separated from the underlying left ventricular myocardium. Atrial epicardium was minimally altered. The tough non-elastic, hyalinized epicardium though it was deceptively thin, appeared capable of restricting left ventricular motion, particularly its expansion during diastole. Further examination revealed additional foci of dense calcified partially ossified scar in the left and posterior atrioventricular groove that appeared to have immobilized the mitral valve ring and focally extended into the subjacent basal myocardium causing local atrophy (Fig 5). We concluded that rigid epicardial scar constituted the basis for markedly impaired filling of the left ventricle.

Cardiac weight of 220 Gm was not abnormal for a 14-year-old boy 67 inches tall. Both atria were dilated, the left atrium markedly so and there was mild dilatation and hypertrophy of the right ventricle. The configuration of the left ventricular chamber was slightly more spherical than normal but the wall did not appear hypertrophied. The pulmonary valve circumference was normal but the aortic valve circumference was smaller than expected, 4.8 cm/5.9 cm, perhaps reflecting reduced flow. The only other valvular change consisted of mild gelatinous thickening of the mitral leaflets with minimal prolapse at the junction of the anterior and posterior leaflets (Fig 6). Endocardial fibrosis or mural thrombi were not a feature. The mitral papillary muscles exhibited normal bulk, were not malpositioned and were composed of unaltered fibers.

Histological evidence for myocardial hypertrophy was present in sections from the right ventricle, but absent in the left ventricle. Neither inflammation nor fibrosis were detected in six samples of the LV myocardium.

The lungs showed severe chronic passive congestion, several fresh pulmonary thromboemboli and microscopical evidence of fibroocclusive vascular disease consistent with previous episodes of embolization. There were multiple small hemorrhagic infarcts, several of which were the result, not of thromboemboli but of acute necrotizing arteritis (Fig 7). The latter is a recognized but uncommon complication of sustained pulmonary hypertension and has been noted to occur with particular frequency in patients with severe mitral stenosis. Severe chronic passive congestion

Echocardiography in ischemic heart disease Present status and future perspectives

Barry Massie MD
Jack J Kleid MD
Nelson Schiller MD
San Francisco Calif

The utility of ultrasound in a wide variety of pericardial myocardial valvular and congenital heart diseases has been repeatedly demonstrated but its role in the evaluation of patients with coronary artery disease remains unsettled. With the growing popularity of surgical therapy for coronary disease and the recent interest in the modification of infarct size there is an increasing need for a noninvasive method of evaluating candidates for these interventions and assessing their results.

Echocardiography also appears to be at an important juncture in its evolution. M mode echocardiography has progressed from an investigational technique to a routine clinical study. However, rapid advances in instrumentation have made systems capable of two dimensional real time visualization of the heart increasingly available. Consequently much of the current research in cardiac ultrasound involves cross sectional echocardiography and preliminary findings suggest that this technique will result in a wider range of applications particularly in patients with coronary artery disease.

It therefore seems appropriate at this time to critically assess the literature relating to the use of ultrasound in the setting of ischemic heart disease and to comment upon present approaches and future potential applications.

Measurements of left ventricular volume and function

The application of ultrasound to the measurement of left ventricular volume and contractile performance gained considerable attention in the period between 1970 and 1973. Initially the movement of the mitral valve ring and the left ventricular posterior wall were examined and utilized as indices of stroke volume and contractile function.¹⁻³ Subsequently a number of investigators found good correlations between echographic and angiographic volume and ejection fraction determinations. Two methods have been employed to calculate these parameters. Most workers have assumed that the left ventricle can be geometrically approximated by a prolate ellipse model with two equal short axes (d_1 and d_2) and a long axis (l) which is twice the length of the short axis.⁴⁻⁶ The volume (V) of such an ellipse is given by the formula:

$$V = \frac{\pi}{6} d_1 d_2 l$$

Using this model and further assuming that the echographic left ventricular internal dimension (LVID) approximates the short axis, left ventricular volume can be determined from the formula:

$$V = \frac{\pi}{3} LVID^3$$

or simply approximated as

$$V = LVID^3$$

Other investigators have determined left ventricular volume from linear regression relationships between angiographic volume and echographic left ventricular internal dimension.⁷⁻⁹ Echographic measurements of the mean velocity of circumferential fiber shortening¹⁰ and systolic

From the Department of Medicine, Cardiovascular Division and the Cardiovascular Research Institute, University of California III, San Francisco, CA 94143; Division of Cardiology, Montefiore Hospital and Medical Center, Bronx, NY.

This work was supported in part by NHLBI Program Project Grant HL 00285.

Received for publication January 24, 1978.

Reprint requests: Barry Massie MD, Cardiovascular Division, Hill Hospital, Room 1186, University of California San Francisco, CA 94143.

- thies in *Cardiomyopathy* edited by G E Burch Cardiovascular Clinics vol 4 No 1 pp 65 66 Philadelphia 1972 F A Davis Company
- 4 Bulkley H H and Roberts W C Dilatation of the mitral annulus A rare cause of mitral regurgitation *Am J Med* 59 457 1975
- 5 Paul O Castleman E and White P D Chronic constrictive pericarditis A study of 53 cases *Am J Med Sci* 216 361, 1948
- 6 Eliasch H Lagerlof J and Werko L Diagnosis of adhesive pericarditis with special consideration of heart catheterization *Nord Med* 44 1128 1950
- 7 Mounsey P Tricuspid incompetence following successful mitral valvotomy *Br Heart J* 21 123 1959
- 8 Seymour J Emanuel R and Pattinson N Acquired pulmonary stenosis *Br Heart J* 30 776 1968
- 9 White P D Alexander F Churchill J D and Sweet R H Chronic constrictive pericarditis over the left heart chambers and its surgical relief *Am J Med Sci* 216 378 1948

Copyright information

The appearance of a code at the bottom of the first page of an original article in this journal indicates the copyright owner's consent that copies of the article may be made for personal or internal use or for the personal or internal use of specific clients. This consent is given on the condition however that the copier pay the stated per copy fee through the Copyright Clearance Center Inc P O Box 765, Schenectady, N Y 12301 518 374 4430 for copying beyond that permitted by Sections 107 or 108 of the U S Copyright Law. This consent does not extend to other kinds of copying such as copying for general distribution for advertising or promotional purposes for creating new collective works or for resale.

Echocardiography in ischemic heart disease Present status and future prospectives

Barry Massie M D
Jack J Kleid M D
Nelson Schuller M D
San Francisco Calif

The utility of ultrasound in a wide variety of pericardial myocardial valvular and congenital heart diseases has been repeatedly demonstrated but its role in the evaluation of patients with coronary artery disease remains unsettled. With the growing popularity of surgical therapy for coronary disease and the recent interest in the modification of infarct size there is an increasing need for a noninvasive method of evaluating candidates for these interventions and assessing their results.

Echocardiography also appears to be at an important juncture in its evolution. M mode echocardiography has progressed from an investigational technique to a routine clinical study. However, rapid advances in instrumentation have made systems capable of two dimensional real time visualization of the heart increasingly available. Consequently much of the current research in cardiac ultrasound involves cross sectional echocardiography and preliminary findings suggest that this technique will result in a wider range of applications particularly in patients with coronary artery disease.

It therefore seems appropriate at this time to critically assess the literature relating to the use of ultrasound in the setting of ischemic heart disease and to comment upon present approaches and future potential applications.

Measurements of left ventricular volume and function

The application of ultrasound to the measurement of left ventricular volume and contractile performance gained considerable attention in the period between 1970 and 1973. Initially the movement of the mitral valve ring and the left ventricular posterior wall were examined and utilized as indices of stroke volume and contractile function.¹ Subsequently a number of investigators found good correlations between echographic and angiographic volume and ejection fraction determinations. Two methods have been employed to calculate these parameters. Most workers have assumed that the left ventricle can be geometrically approximated by a prolate ellipse model with two equal short axes (d and d) and a long axis (l) which is twice the length of the short axis.² The volume (V) of such an ellipse is given by the formula

$$V = \frac{\pi}{6} d d l$$

Using this model and further assuming that the echographic left ventricular internal dimension (LVID) approximates the short axis, left ventricular volume can be determined from the formula

$$V = \frac{\pi}{3} LVID$$

or simply approximated as

$$V \approx LVID^3$$

Other investigators have determined left ventricular volume from linear regression relationships between angiographic volume and echographic left ventricular internal dimension.³ Echographic measurements of the mean velocity of circumferential fiber shortening^{4,5} and systolic

From the Department of Medicine, Cardiovascular Division and the Cardiovascular Research Institute, University of California, San Francisco, Calif. and the Division of Cardiology, Montefiore Hospital and Medical Center, Bronx, N.Y.

This work was supported in part by NHLBI Program Project Grant HL 06265.

Received for publication June 24, 1978.

Reprint request: Barry Massie, M.D., Cardiovascular Division, Mount Zion Hospital, Room 1186, University of California, San Francisco, Calif. 94143.

time intervals¹⁻¹³ have also been found to correlate well with those from ventriculograms and carotid pulse tracings, respectively.

However, these studies utilized few, if any, patients with coronary artery disease. In fact, obvious exceptions to the overall correlations were found in patients with asynergy.^{8, 10, 11} Early experimental studies documented focal changes in the echographic pattern of wall motion with induced segmental ischemia,¹⁴⁻¹⁶ raising doubts about the reliability of ultrasonic determinations of volume and ejection fraction based upon measurements derived from a single plane through the heart. In addition, serious questions were raised about the validity of the prolate ellipse model and the assumed 2:1 ratio of the major to minor axes in patients with enlarged and asymmetric ventricles. Clinical studies soon appeared which clearly confirmed these suspicions,¹⁷⁻¹⁹ demonstrating poor correlation between ultrasonic and angiographic measurements in patients with asynergy.

Thus, the initial enthusiasm for quantitative echographic measurements of ventricular volume and function has yielded to skepticism. Nonetheless, several authors have at least partially dissociated themselves from this consensus. Ratskin and associates¹ suggested that the end diastolic dimension and end diastolic volume determinations remain accurate even in the presence of asynergy, although systolic parameters and therefore ejection fraction do not. Ludbrook and colleagues² found that echographic and angiographic measurements of the mean velocity of circumferential fiber shortening also continued to correlate well, but this finding has been disputed.²³

Recently Massie and co-workers²⁴ reported a new index of ventricular function based upon a simple measurement of the minimum separation between the mitral valve at its E point and the most posterior excursion of the interventricular septum. Normal subjects and those with preserved ventricular function have little (< 5 mm) or no mitral-septal separation, while those with reduced ejection fraction have increased separation. Their results indicate that E point-septal separation is also a reliable index of ventricular function in patients with coronary artery disease, correlating well with biplane angiographic ejection fraction ($r = -0.86$, $p < .001$) and remaining significantly more accu-

rate than other echographic indices in these patients.

Currently, it appears that echographic measurements of left ventricular size and function in patients with coronary artery disease may provide helpful qualitative information, but are not accurate enough for quantitative investigation. In particular, most studies indicate that patients with depressed left ventricular function by echocardiography will also have abnormalities in invasive indices, but that patients may appear to have normal function by ultrasound and still have significant dysfunction by angiographic measurements.

Evaluation of wall motion

Segmental wall motion disturbances are the hallmark of both acute and chronic ischemic heart disease.²⁵⁻²⁸ Several animal studies have shown that the echocardiogram will demonstrate decreased amplitude and velocity of wall motion and diminished wall thickening in regions of experimentally produced infarction or ischemia.^{15, 18, 27} Compensatory increases in wall motion may be detected in uninvolved regions.²⁹

Jacobs and associates³⁰ have actively investigated the clinical use of echocardiography to detect segmental wall motion disturbances. Initially utilizing the standard left parasternal echographic window from which the anterior interventricular septum and the true posterior wall can be visualized, they were able to detect abnormalities in 75 per cent of patients with angiographically demonstrated asynergy. Subsequently, they advocated expanding the usual window to the subxiphoid area and laterally along one or more intercostal spaces.³⁰⁻³² Addition of these approaches increased their number of successful examinations and allowed visualization of more extensive areas of the left ventricle, including the mid third of the interventricular septum and the posterolateral and anterior walls.³¹ Even though the involved area might be missed, compensatory hyperactivity of another region could frequently be detected.

Such techniques have made it possible for two groups to detect decreased wall motion corresponding to the location of electrocardiographic Q waves in 100 per cent and 84 per cent, respectively, of patients with acute transmural myocardial infarction³²⁻³³ and often to detect other areas of compensatory hypercontractility.³³⁻³⁴ Recent

ly investigators have evaluated the degree of segmental wall thickening during systole in addition to wall motion. Experimental studies have indicated that thickening is reduced by infarction and ischemia.²⁷ In patients with acute myocardial infarction actual systolic wall thinning can be seen.²⁸ Measurement of wall thickening allows assessment of regional function particularly of the interventricular septum in the presence of conditions which nonspecifically affect its motion such as right ventricular volume overload and electrical conduction disturbances.

Echographically visualized segmental abnormalities have also been found in areas of old infarction and in the distribution of critically narrowed coronary arteries.²⁹⁻³⁰ In particular disorders of septal motion have been found in some but not all patients with severe proximal left anterior descending coronary artery lesions.³¹⁻³³ A more quantitative estimation of the overall amount of asynergy has also been developed using a regression formula from which the per cent of abnormally contracting segments can be computed from the difference between echographic and Fick stroke volumes.³⁴

All laboratories which routinely perform echocardiograms in patients with ischemic heart disease do not have the extensive experience, quality of equipment and technical expertise of the groups who have published the results of their investigations in this area. Thus the high degree of success in detecting segmental asynergy which has been reported in the literature may not be duplicated in some clinical laboratories.

Nonetheless the echographic study of the left ventricle remains a useful adjunct in the evaluation of patients with ischemic heart disease. The many potential applications of this noninvasive technique of assessing segmental wall motion are readily apparent. The possibility of predicting the presence and anatomical location of ischemia even though echoes from the coronary arteries cannot be identified requires further investigation but remains exciting. Perhaps the ultrasonic evaluation of the left ventricle during or immediately after exercise or pharmacological stress would provide such information. Abnormal echocardiographic segmental wall motion prior to myocardial infarction could have important implications in patients with unstable or crescendo angina. Another possible role for echocardiography would be monitoring the course and

outcome of medical and surgical therapy for ischemic heart disease. In fact changes in the echographic parameters of ventricular size, function and wall motion after nitroglycerin administration and coronary artery revascularization have been reported.³⁵⁻³⁶

Echocardiography in acute myocardial infarction

In addition to its previously described use for the detection of segmental asynergy ultrasound has been utilized to monitor day to day changes in cardiac function to predict outcome and to diagnose complications in patients with acute infarction. Each of these applications however must be considered unproven until further prospective clinical studies are reported.

Serial echographic determinations of ventricular size and stroke volume index in patients with acute infarction have been found to correspond with clinical assessments of their studies.³⁷ Nieminen and Heikkilä³⁸ extensively evaluated left ventricular wall motion and function in patients with acute infarction. They found abnormalities in all subjects but commonly used indices of overall left ventricular function did not correlate well with clinical status or eventual outcome. However an index of the summed amplitudes of wall motion from seven different regions reflecting the degree of compensation of noninfarcted myocardium correlated closely with clinical parameters.³⁹

Corya and associates⁴⁰ serially studied a large group of infarction patients and found modest correlations between increased ventricular dimensions and clinical heart failure and between decreased PR-AC interval and the presence of a third heart sound. More impressive however was the ability of a ratio of ventricular dimension to mitral valve closure time which was felt to be analogous to a volume/pressure index to predict eventual mortality of these patients. DeMaria and co-workers⁴¹ developed a similar echographic prognostic index which was very reliable in their hands. These indices are based upon preliminary data and have not yet been demonstrated to be clinically useful. If validated they may have a role in the assessment of therapeutic interventions when measured serially.

Ultrasound has been used to study patients with several acute and chronic complications of myocardial infarction. Right ventricular infarction

tion or interventricular septal rupture should be considered when disproportionate right ventricular enlargement is seen on the echocardiogram in the course of an acute infarction, especially in patients without pre existing pulmonary hypertension " " Day to day increases in mitral valve EF slope and CE opening amplitude were found to correspond with the appearance of a murmur of papillary muscle dysfunction by one group," but these findings have not been confirmed by others " "

A number of reports have described the echographic findings in patients with ventricular aneurysms " " The most useful findings appear to be a sudden displacement of endocardial echoes as the ventricle is scanned, reduced or paradoxical wall motion, and disproportionately large left ventricular dimensions at the level of the apex Wall motion evaluation in uninvolved areas may be especially helpful in predicting the outcome of surgery in these patients " In addition, there has been one elegant report of a pseudoaneurysm of the left ventricle visualized echocardiographically " "

Two dimensional echocardiography In recent years, several systems capable of two dimensional ultrasonic visualization of the heart have been developed These have overcome some of the shortcomings of single crystal unidimensional echocardiography in the evaluation of patients with coronary artery disease Much of the early work in this area was done by electrocardiographically synchronized stop motion B mode scanning utilizing a single element transducer " Several groups have calculated left ventricular volumes and ejection fractions from analysis of these B mode scans and demonstrated good correlations with ventriculographic data " " Teichholz and associates" studied 14 patients with coronary disease and asynergy by both traditional M mode echocardiography and B mode ultrasonography They were able to detect areas of asynergy in all 14 by the latter technique but in only seven of the 14 by the former In addition, the two dimensional methodology considerably improved the accuracy of their ejection fraction calculations

B mode scanning is both time consuming and technically demanding and it is therefore not well suited for clinical use Subsequently, a number of prototype instruments capable of real time display of two dimensional echocardiograms

have been developed " " Several production models are now commercially available and forthcoming improvements in instrumentation promise to further improve resolution and ease of operation Early experience with two dimensional real time echocardiographic systems suggested a wide range of potential clinical applications including the evaluation of patients with ischemic heart disease " " Subsequent investigations have confirmed some of these expectations

Schiller and associates" " have gained extensive experience imaging the heart from the apex with an 80 degree sector scanner The views obtained with this transducer position, as well as from the precordium have significantly increased the portion of the ventricle which can be visualized and have allowed noninvasive biplane quantitation of left ventricular volumes and ejection fraction These investigators found good correlation between two dimensional echographic and biplane angiographic determinations of these parameters in 30 patients most of whom had coronary artery disease, suggesting that this technique may provide accurate data in this group of patients in whom M mode echocardiography is unreliable

Two groups have now published favorable reports evaluating the ability of two dimensional echocardiography to assess left ventricular wall motion Weyman and colleagues" were able to detect and localize ventricular aneurysms in 31 consecutive patients including 16 in whom M mode echocardiography failed to make the correct diagnosis Kisslo and associates" prospectively analyzed the correlation between two dimensional echographic and angiographic analyses of wall motion in 525 regions from 105 patients Only 18 per cent of these regions could not be visualized and 87 per cent of those imaged were correctly classified

Weyman and associates" recently reported their ability to visualize the left main coronary artery by cross sectional echocardiography They confirmed their identification of this structure by the intracoronary injection of cardiogreen dye while simultaneously recording the echocardiogram Clearly, more experience will have to be acquired before echocardiography can be used clinically to define such a critical aspect of coronary anatomy

If two dimensional echocardiography continues to live up to its early promise it would have

considerable advantage over both M mode echocardiography and other invasive and noninvasive techniques of wall motion analysis in patients with ischemic heart disease. It allows patients to be studied repetitively without risk while in a basal state and it permits beat to beat analysis of contractions in real time. As a result the effect of acute interventions such as exercise or changes in preload, afterload or heart rate or the result of spontaneous events such as extrasystoles or the onset of angina can be analyzed. Thus two dimensional echocardiography appears to be well suited for both the investigational and clinical study of patients with coronary artery disease.

Most present two dimensional echocardiographic systems suffer from two major limitations which prevent the quantitative evaluation of the left ventricle in some patients. The sector visualized from any single transducer position while significantly larger on more recent models is not always adequate to visualize the entire left ventricle. In addition resolution of the endocardium remains a difficult technical problem. Perhaps more important in limiting the availability and clinical use of this new technique is the high cost of the present equipment which approaches or exceeds \$100,000 for some models.

Summary

The initial general enthusiasm for echocardiography as a relatively simple and inexpensive noninvasive technique led to uncritical acceptance of some of its proposed applications. Patients with ischemic heart disease have proven to be difficult to evaluate echographically by usual techniques because the areas of the left ventricle which are visualized may not be representative. Thus, volume determinations and most indices of contractile performance while frequently providing helpful qualitative information have not been reliable in these patients. Useful information about segmental wall motion abnormalities can be obtained from the echocardiogram when the involved areas can be visualized but much of the ventricle is not routinely examined. The role of ultrasound in patients with uncomplicated acute infarction remains predominantly investigational but ultrasound may be helpful in the evaluation of patients with complications of infarction or those who may concomitantly have other forms of cardiac disease.

Although much work continues with M mode

echocardiography the development of two dimensional real time ultrasonic equipment has added new impetus to the use of echocardiography in patients with coronary artery disease. These instruments can visualize most if not all of the left ventricle and therefore are not subject to the inaccuracies inherent in evaluating M mode echocardiograms in patients affected by a segmental disease. Several production models are currently available and many improvements in instrumentation can be anticipated. Initial experience with two-dimensional echocardiography suggests that it is a valuable clinical and investigational tool but the relatively high cost of the present equipment may retard wide dissemination of this promising technique.

REFERENCES

- Feigenbaum H, Zaky A and Nasser W K. Use of ultrasound to measure left ventricular stroke volume. *Circulation* 35:1092, 1967.
- Krausz R F and Kennedy J W. Ultrasonic determination of left ventricular wall motion in normal man. *Am Heart J* 79:38, 1970.
- Pombo J F, Troy B L and Russell R D. Left ventricular volumes and ejection fraction by echocardiography. *Circulation* 43:480, 1971.
- Feigenbaum H, Popp R L, Wolfe S H, Troy B L, Pombo J F, Haine C L and Dodge H T. Ultrasonic measurements of the left ventricle. *Arch. Intern. Med.* 129:461, 1972.
- Murray J A, Johnston W and Reid J M. Echocardiographic determination of left ventricular dimensions, volumes and performance. *Am J Cardiol* 30:257, 1972.
- Gibson D G. Estimation of left ventricular size by echocardiography. *Br Heart J* 35:128, 1973.
- Belenkie I, Nutter D O, Clark D W, McGraw D B and Rauner A E. Assessment of left ventricular dimensions and function by echocardiography. *Am J Cardiol* 31:755, 1973.
- Fortuin N J, Hood W P, Sherman M E and Craige E. Determination of left ventricular volumes by ultrasound. *Circulation* 44:575, 1971.
- Fortuin N J, Hood W P and Craige E. Evaluation of left ventricular function by echocardiography. *Circulation* 46:26, 1972.
- Paraskos J A, Grossman W, Saltz M, Dalen J E and Dexter L. A noninvasive technique for the determination of velocity of circumferential fiber shortening in man. *Circ Res* 29:610, 1971.
- Cooper R H, Rourke J A, Karlner J S, Peterson K L and Leopold R R. Comparison of ultrasound and cineangiographic measurements of the mean rate of circumferential fiber shortening in man. *Circulation* 46:914, 1972.
- Vredovce L A, Creekmore S P and Schiller N B. The measurement of systolic time intervals by echocardiography. *J Clin Ultrasound* 2:99, 1974.
- Stefadouras M A and Witham A C. Systolic time intervals by echocardiography. *Circulation* 47:114, 1973.
- Stefan G and Bing R J. Echocardiographic findings in

- experimental myocardial infarction of the posterior left ventricular wall *Am J Cardiol* 30 629 1972
- 15 Kerber R E and Abboud F M Echocardiographic detection of regional myocardial infarction *Circulation* 47 997 1973
- 16 Kerber R E Marcus M L Ehrhardt J Wilson II and Abboud F M Correlation between echocardiographically demonstrated segmental dyskinesia and regional myocardial perfusion *Circulation* 52 1097 1975
- 17 Popp R L Alderman M L Brown O R and Harrison D C Sources of error in calculation of left ventricular volumes by echocardiography (Abstr) *Am J Cardiol* 31 152 1973
- 18 Teichholz L E Kreulen T H Herman M V and Gorlin R Problems in echocardiographic volume determinations Echocardiographic-angiographic correlations in the presence or absence of asynergy *Am J Cardiol* 37 7 1976
- 19 Linhart J W Mintz G S Segal B L Kawai N and Kotler M N Left ventricular volume measurements by echocardiography Fact or fiction? *Am J Cardiol* 36 114 1975
- 20 Henning H Schelbert H Crawford M H Karliner J S Ashburn W and O'Rourke D A Left ventricular performance assessed by radionuclide angiography and echocardiography in patients with previous myocardial infarction *Circulation* 52 1069 1975
- 21 Ratshin R A Boyd C N Rackley C E Moraski R E and Russell R O Quantitative echocardiography Correlations with ventricular volumes by angiocardiography in patients with coronary artery disease with and without wall motion abnormalities (Abstr) *Circulation* 47 and 48 (Suppl IV) 1V-48 1973
- 22 Ludbrook J Karliner J Peterson K Leopold G R and O'Rourke R A Comparison of ultrasound and cineangiographic measurements of left ventricular performance in patients with and without wall motion abnormalities *Br Heart J* 35 1026 1973
- 23 Quinones M A Gassch W H and Alexander J K Echocardiographic assessment of left ventricular function *Circulation* 50 42 1974
- 24 Massie B M Schiller N B Ratshin R A and Farnley W W Mitral septal separation A new echocardiographic index of left ventricular function *Am J Cardiol* 39 1008 1977
- 25 Herman M V and Gorlin R Implications of left ventricular asynergy *Am J Cardiol* 23 538 1969
- 26 Baxley W A and Reeves T J Abnormal region of myocardial performance in coronary artery disease *Progr Cardiovasc Dis* 13 405 1971
- 27 Kerber R E Marcus M L Wilson R Ehrhardt J and Abboud F M Effects of acute coronary occlusion on the motion and perfusion of the normal and ischemic interventricular septum *Circulation* 54 928 1976
- 28 Jacobs J J Feigenbaum H Corya B C and Phillips J F Detection of left ventricular asynergy by echocardiography *Circulation* 48 263 1973
- 29 Chang S and Feigenbaum H Subxiphoid echocardiography *J Clin Ultrasound* 1 14 1973
- 30 Corya B C Feigenbaum H Rasmussen S and Black M J Anterior left ventricular wall echoes in coronary artery disease *Am J Cardiol* 34 652 1974
- 31 Feigenbaum H Corya B C Dillon J C Weyman A E Rasmussen S Black M J and Chang S Role of echocardiography in patients with coronary artery disease *Am J Cardiol* 37 775 1976
- 32 Heikkilä J and Nieminen M Echoventriculographic detection localization and quantitation of left ventricular asynergy in acute myocardial infarction *Br Heart J* 37 46 1975
- 33 Corya B C Rasmussen S Knoebel S B and Feigenbaum H Echocardiography in acute myocardial infarction *Am J Cardiol* 36 1 1975
- 34 Nieminen M and Heikkilä J Echoventriculography in acute myocardial infarction III Clinical correlations and implications of the noninfarcted myocardium *Am J Cardiol* 38 1 1976
- 35 Corya B C Rasmussen S Feigenbaum H Knoebel S B and Black M J Systolic thickening and thinning of the septum and posterior wall in patients with coronary artery disease congestive cardiomyopathy and atrial septal defect *Am J Cardiol* 39 109 1977
- 36 Joffe C D Brink H Teichholz L Herman M and Gorlin R Echocardiographic diagnosis of left anterior descending coronary artery disease *Am J Cardiol* 40 11 1977
- 37 Gordon M J and Kerber R E Interventricular septal motion in patients with proximal and distal left anterior descending coronary artery lesions *Circulation* 55 348 1977
- 38 Sweet R L Moraski R E Russell N O and Rackley C E Relationship between echocardiography cardiac output and abnormally contracting segments in patient with ischemic heart disease *Circulation* 52 634 1975
- 39 Kisslo J, Wolfson S Ross A Pasternak H Hammond G and Cohen L S Ultrasonic assessment of left ventricular function following aortocoronary saphenous vein bypass grafting *Circulation* 47 and 48 (Suppl III) III 156 1973
- 40 Redwood D R Henry W L and Epstein S E Evaluation of the ability of echocardiography to measure acute alterations in left ventricular volume *Circulation* 50 901 1974
- 41 Ratshin R A Rackley E C and Russell R O Serial evaluation of left ventricular volumes and posterior wall movement in the acute phase of myocardial infarction using diagnostic ultrasound (Abstr) *Am J Cardiol* 29 286 1972
- 42 DeMans A N Angel J Amsterdam E A and Mason D T Accurate assessment of extent and prognosis of acute myocardial infarction by echographic index of ejection fraction and ventricular volume (Abstr) *Am J Cardiol* 37 131 1976
- 43 Sharpe D N Botvinick E H Shames D M Schiller N B Massie B M Chatterjee K and Farnley W W The noninvasive diagnosis of right ventricular infarction *Circulation* 57 483 1978
- 44 Chandraratna P A N Balachandran P K Shah P M and Hodges M Echocardiographic observations of ventricular septal rupture complicating acute myocardial infarction *Circulation* 51 506 1975
- 45 Tallury V K DePasquale N P and Burch G E The echocardiogram in papillary muscle dysfunction *Am Heart J* 83 12 1972
- 46 Bergeron G A Cohen M V Teichholz L E and Gorlin R Echocardiographic analysis of mitral valve motion after acute myocardial infarction *Circulation* 51 82 1975
- 47 Petersen J L Johnston W Hessel E A and Murray J A Echocardiographic recognition of left ventricular aneurysm *Am Heart J* 83 24 1972
- 48 Kreamer R Kerber R E and Abboud F M Ventricular aneurysm Use of echocardiography *J Clin Ultrasound* 1 60 1973
- 49 Dillon J C Feigenbaum H Weyman A E Corya B C Peskoe S and Chang S M mode echocardiography

- in the evaluation of patients for aneurysmectomy *Circulation* 53 657 1976
- 50 Roelandt J VanDenBrand M Vletter W B Nauta J and Huggenholtz P G Echocardiographic diagnosis of pseudoaneurysm of the left ventricle *Circulation* 53 466 1975
- 51 King D L Cardiac ultrasonography Cross sectional ultrasonic imaging of the heart *Circulation* 47 843 1973
- 52 King D L Jaffee C C Schmidt D H and Ellis W Left ventricular volume determination by cross sectional cardiac ultrasonography *Radiology* 104 201 1979
- 53 Teichholz L E Cohen M V Sonnenblick E H and Gorlin R Study of left ventricular geometry and function by H scan ultrasonography in patients with and without asynergy *N Engl J Med* 291 1990 1974
- 54 Gehrke J Leeman S Raphael M and Pryde R B Noninvasive left ventricular volume determination by two-dimensional echocardiography *Br Heart J* 37 911 1975
- 55 Bom N Lances C T vanZwieten G Kloster F E and Roelandt J Multiscan echocardiography I Technical description *Circulation* 48 1056 1973
- 56 Gramiak R Wan R C and Simon W Cine ultrasound cardiography *Radiology* 107 175 1973
- 57 Griffith J M and Henry W L A sector scanner for real time two-dimensional echocardiography *Circulation* 49 1147 1974
- 58 vonRamm O T and Thurstone F L Cardiac imaging using a phased array ultrasound system I System design *Circulation* 53 258 1976
- 59 Kloster F E Roelandt J tenCate F J Bom N and Huggenholtz P G Multiscan echocardiography II Technique and initial clinical results *Circulation* 48 1015 1973
- 60 Roelandt J Kloster F E tenCate F J vanDorp W E Honkoop J Bom N and Huggenholtz P G Multidimensional echocardiography An appraisal of its clinical usefulness *Br Heart J* 36 29 1974
- 61 Kusslo J vonRamm O T and Thurstone F L Cardiac imaging using a phased array ultrasound system II Clinical technique and application *Circulation* 53 287 1976
- 62 Schiller N H and Silverman N H Apex echocardiography A new method of imaging the adult heart using the phased array real time two dimensional 80° sector scanner (Abstr) *Am J Cardiol* 79 279 1977
- 63 Schiller N Drew D Acquatella H Boswell R Botvinick E Greenberg B and Carlsson E Noninvasive biplane quantitation of left ventricular volume and ejection fraction with a real time two-dimensional echocardiography system (Abstr) *Circulation* 53 and 54 (Suppl II) 234 1976
- 64 Weyman A E Peskoe S M Williams E S Dillon J C and Feigenbaum H Detection of left ventricular aneurysms by cross sectional echocardiography *Circulation* 54 936 1976
- 65 Kusslo J A Robertson D Gilbert B W vonRamm O and Behar V E A comparison of real time two dimensional echocardiography and cineangiography in detecting left ventricular asynergy *Circulation* 55 134 1977
- 66 Weyman A E Feigenbaum H Dillon J C Johnston K W and Eggleston R C Noninvasive visualization of the left main coronary artery by cross-sectional echocardiography *Circulation* 54 169 1976

- experimental myocardial infarction of the posterior left ventricular wall *Am J Cardiol* 30:629 1972
- 15 Kerber R E and Abboud F M Echocardiographic detection of regional myocardial infarction *Circulation* 47:997 1973
- 16 Kerber R E Marcus M L Ehrhardt J Wilson H and Abboud F M Correlation between echocardiographically demonstrated segmental dyskinesia and regional myocardial perfusion *Circulation* 52:1097 1975
- 17 Popp R L Alderman E L Brown O R and Harrison D C Sources of error in calculation of left ventricular volumes by echocardiography (Abstr.) *Am J Cardiol* 31:152 1973
- 18 Teichholz L E Kreulen T H Herman M V and Gorlin R Problems in echocardiographic volume determinations: Echocardiographic-angiographic correlations in the presence or absence of asynergy *Am J Cardiol* 37:7 1976
- 19 Linhart J W Mintz G S Segal B L Kawan N and Kotler M N Left ventricular volume measurements by echocardiography: Fact or fiction? *Am J Cardiol* 36:114 1975
- 20 Henning H Schelbert H Crawford M H Karlner J E Ashburn W and O'Rourke R A Left ventricular performance assessed by radionuclide angiography and echocardiography in patients with previous myocardial infarction *Circulation* 52:1069 1975
- 21 Ratshin R A Boyd C N Rackley C E Moraski R E and Russell R O Quantitative echocardiography: Correlations with ventricular volumes by angiocardiography in patients with coronary artery disease with and without wall motion abnormalities (Abstr.) *Circulation* 47 and 48 (Suppl. IV) 4V-48 1973
- 22 Ludbrook P Karlner J S Peterson K Leopold G R and O'Rourke R A Comparison of ultrasound and cineangiographic measurements of left ventricular performance in patients with and without wall motion abnormalities *Br Heart J* 35:1026 1973
- 23 Quinones M A Gassch W H and Alexander J K Echocardiographic assessment of left ventricular function *Circulation* 50:42 1974
- 24 Massie B M Schiller N B Ratshin R A and Parmley W W Mitral septal separation: A new echocardiographic index of left ventricular function *Am J Cardiol* 39:1008 1977
- 25 Herman M V and Gorlin R Implications of left ventricular asynergy *Am J Cardiol* 23:538 1969
- 26 Baxley W A and Reeves T J Abnormal region of myocardial performance in coronary artery disease *Progr Cardiovasc Dis* 13:405 1971
- 27 Kerber R E Marcus M L Wilson R Ehrhardt J and Abboud F M Effects of acute coronary occlusion on the motion and perfusion of the normal and ischemic interventricular septum *Circulation* 54:928 1976
- 28 Jacobs J J Feigenbaum H Corya B C and Phillips J F Detection of left ventricular asynergy by echocardiography *Circulation* 48:263 1973
- 29 Chang S and Feigenbaum H Subxiphoid echocardiography *J Clin Ultrasound* 1:14 1973
- 30 Corya B C Feigenbaum H Rasmussen S and Black M J Anterior left ventricular wall echoes in coronary artery disease *Am J Cardiol* 34:652 1974
- 31 Feigenbaum H Corya B C Dillon J C Weyman A E Rasmussen S Black M J and Chang S Role of echocardiography in patients with coronary artery disease *Am J Cardiol* 37:775 1976
- 32 Heikkila J and Nieminen M Echocardiographic detection, localization, and quantitation of left ventricular asynergy in acute myocardial infarction *Br Heart J* 37:46 1975
- 33 Corya B C Rasmussen S Knoebel S B and Feigenbaum H Echocardiography in acute myocardial infarction *Am J Cardiol* 36:1 1975
- 34 Nieminen M and Heikkila J Echocardiographic detection of acute myocardial infarction III: Clinical correlation and implications of the noninfarcted myocardium *Am J Cardiol* 38:1 1976
- 35 Corya B C Rasmussen S Feigenbaum H Knoebel S B and Black M J Systolic thickening and thinning of the septum and posterior wall in patients with coronary artery disease: congestive cardiomyopathy and strain septal defect *Am J Cardiol* 39:109 1977
- 36 Joffe C D Brink H Teichholz L Herman M and Gorlin R Echocardiographic diagnosis of left anterior descending coronary artery disease *Am J Cardiol* 40:11 1977
- 37 Gordon M J and Kerber R E Interventricular septal motion in patients with proximal and distal left anterior descending coronary artery lesions *Circulation* 55:123 1977
- 38 Sweet R L Moraski R E Russell R O and Rackley C E Relationship between echocardiography, cardiac output, and abnormally contracting segments in patients with ischemic heart disease *Circulation* 52:634 1975
- 39 Kussio J Wolfson S Ross A Pasternak R, Hammond G and Cohen L S Ultrasonic assessment of left ventricular function following aortocoronary saphenous vein bypass grafting *Circulation* 47 and 48 (Suppl. III) III:156 1973
- 40 Redwood D R Henry W L and Epstein S E Evaluation of the ability of echocardiography to measure acute alterations in left ventricular volume *Circulation* 50:901 1974
- 41 Ratshin R A Rackley E C and Russell R O Serial evaluation of left ventricular volumes and posterior wall movement in the acute phase of myocardial infarction using diagnostic ultrasound (Abstr.) *Am J Cardiol* 29:286 1972
- 42 DeMaria A N Angel J Amsterdam E A and Mason, D T Accurate assessment of extent and prognosis in acute myocardial infarction by echographic index of ejection fraction and ventricular volume (Abstr.) *Am J Cardiol* 37:131 1976
- 43 Sharpe D N Botwinick E H Shames D M Schiller N B Massie B M Chatterjee K and Parmley W W The noninvasive diagnosis of right ventricular infarction *Circulation* 57:483 1978
- 44 Chandraratna P A N Belachandran P K Shah P M and Hodges M Echocardiographic observations in ventricular septal rupture complicating acute myocardial infarction *Circulation* 51:506 1975
- 45 Tallury V K DePasquale N P and Burch G E The echocardiogram in papillary muscle dysfunction *Am Heart J* 83:12 1972
- 46 Bergeron G A Cohen M V Teichholz L E and Gorlin R Echocardiographic analysis of mitral valve motion after acute myocardial infarction *Circulation* 51:82 1975
- 47 Petersen J L Johnston W Hessel E A and Murray J A Echocardiographic recognition of left ventricular aneurysm *Am Heart J* 83:24 1972
- 48 Kreamer R Kerber R E and Abboud F M Ventricular aneurysm: Use of echocardiography *J Clin Ultrasound* 1:60 1973
- 49 Dillon J C Feigenbaum H Weyman A F Corya B C Peskoe S and Chang S M mode echocardiography

oxygen consumption and improves left ventricular contractility. Ejection fraction increases after nitroglycerin when asynergic segments are present in viable but ischemic myocardium. Blood flow redistribution from the epicardium to the endocardium has been shown with microspheres. Rubidium 86 and oxygen tension measurements at various myocardial layers.

Valvular disease

In severe aortic regurgitation, nitroglycerin infusion reduces afterload and improves hemodynamics by reducing regurgitant volume and improving left ventricular pump function. Lower total stroke work, reduced ventricular size and improved forward cardiac index delays left ventricular failure and progressive ventricular dysfunction.

Reduction of systemic vascular resistance during nitroglycerin infusion in patients with mitral regurgitation augments forward ejection flow, reduces regurgitant volume and relieves pulmonary vascular engorgement.

Intraoperative hypertension

Prevention of intraoperative myocardial infarction is a primary anesthesia concern in the presence of coronary artery disease or with previous infarction. Myocardial oxygen demand must be controlled. Factors which increase myocardial oxygen demand include increased wall tension, increased contractility or increased heart rate. Kaplan and associates treating intraoperative hypertension with nitroglycerin showed significant reduction in mean arterial pressure, central venous pressure and systemic vascular resistance without changes in heart rate, cardiac or stroke index. Improvements of ST segment depression occurred in 50 per cent of cases.

Controlled hypotension

Nitroglycerin has been used to intentionally decrease blood pressure in order to minimize surgical blood loss. Nitroglycerin has a short plasma half life, no toxic metabolic products at pharmacologic doses and a low incidence of severe hypotension.

History and physical characteristics

Nitroglycerin (glyceryl trinitrate, $C_3H_5(NO_2)_3$) was synthesized in 1846 by Sobrero.

Hering (1849) published the first paper on its effects in students and an 1853 monograph suggested the usefulness of this compound for treating angina pectoris, cardiac edema, epilepsy and headache. On percussion, nitroglycerin explodes violently and has been used as solid rocket fuel. It is soluble in water to the extent of 1.25 mg/ml, is extremely stable in neutral solution and has a low vapor pressure (0.00025 torr at 20° C). Saturated vapor in air is 0.33 ppm and can represent a commercial air pollution problem because it is readily absorbed through lipoidal surfaces of the skin and lungs.

Metabolism and mechanisms of action

Nitroglycerin is rapidly metabolized in the liver by partial denitration catalyzed by glutathione (GSH) organic nitrate reductase to 1,3 and 1,2 glyceryl denitrate (GDN), glyceryl mononitrate (GMN) and inorganic nitrate. Most metabolites can be recovered in the urine within 24 hours. Plasma half life of nitroglycerin appears to be 2 minutes in rats and man because of redistribution and rapid hepatic metabolism.

Nitroglycerin reacts with vascular smooth muscle sulfhydryl groups leading to relaxation by the formation of disulfide linkage and release of inorganic nitrite. Tolerance to chronic nitroglycerin exposure in man is associated with decreased tissue sulfhydryl concentration in vascular smooth muscle. This can be quickly reversed by disulfide reducing agents such as dithiothreitol. Tolerance develops because chronic nitroglycerin exposure produces disulfide linkage which cannot react further with organic nitrates. Nitroglycerin tolerant individuals respond to other common vasodilator compounds (papaverine, nitroprusside, etc.) suggesting that organic nitrates react at specific receptor sites distinct from other relaxant receptor sites.

Preparation and administration

Despite its advantages, intravenous nitroglycerin is not presently approved by the Food and Drug Administration for routine clinical use. After obtaining an investigational new drug number (IND No.) approval from Human Research Review Committees and informed consent, nitroglycerin (0.015 per cent) may be obtained from Eli Lilly & Company. Several methods for preparing therapeutic solutions of nitroglycerin have been described. Nitroglycerin

Intravenous nitroglycerin

James E. Cottrell, MD *
Herman Turndorf, MD **
New York N Y

Sublingual nitroglycerin has been administered for the relief of angina pectoris since 1853. Orally administered nitrates are rapidly metabolized and continuous intravenous nitroglycerin is presently used in carefully titrated amounts in critical care areas. Indications for the use of nitroglycerin have been expanded to include reduction of infarct size in acute infarction, reduction of acute and chronic left ventricular decompensation by afterload reduction, reduction of pulmonary artery hypertension during coronary artery bypass, and induction of surgical hypotension. The hypotension that results from venodilating properties of nitroglycerin may be physiologically better than hypotension from arterial dilators since cardiac output, stroke volume, heart rate, and peripheral vascular resistance tend to remain stable while left ventricular end diastolic volume is reduced. Incidentally since nitroglycerin does not produce arteriolar dilation, intracranial pressure increase is not seen in neurosurgical patients after nitroglycerin.

Acute myocardial infarction

Experimental and clinical studies have shown that acute myocardial infarction is a dynamic process unfolding over many hours. Reduction of oxygen consumption and/or work in the early phases of infarction may preserve ischemic myocardium and prevent necrosis. Armstrong

and colleagues have shown that nitroglycerin decreased left ventricular end diastolic and pulmonary capillary wedge pressure while maintaining cardiac index, heart rate and stroke volume in acute infarction with left ventricular failure. Nitroglycerin dilates venous capacitance vessels more than arteriolar resistance vessels, significantly reducing preload. Coronary artery perfusion pressures are maintained after nitroglycerin.

Nitroglycerin decreases coronary collateral flow resistance, increases collateral flow, and in dogs improves the endocardial/epicardial flow ratio in ischemic zones for up to four hours after nitroglycerin administration.

Although precordial ST segment mapping has not yet been validated as a means of assessing myocardial ischemia in man, animal work suggests that ST segment changes measured by epicardial or precordial electrodes correlate with histologic evidence of ischemic damage as well as myocardial creatine phosphokinase depletion. Nitroglycerin reverses precordial ST segment changes and restores creatine phosphokinase in acute myocardial infarction.

Ventricular fibrillation threshold increases in animals and post infarction extrastokes decrease in man after nitroglycerin.

Tachycardia and systemic arterial hypotension with decreased coronary artery perfusion may occur during nitroglycerin infusion in uncomplicated myocardial infarction (pulmonary capillary wedge pressure < 12 torr). Controlled use of alpha adrenergic agonists may permit the use of nitroglycerin in this situation.

Left ventricular failure

Nitroglycerin reduces afterload, decreases left ventricular end diastolic pressure and myocardial

From the Department of Anesthesiology, New York University School of Medicine, New York, N Y.

Received for publication May 15, 1978.

Reprint requests: Dr. James E. Cottrell, Dept. of Anesthesiology, New York University School of Medicine, 550 First Ave., New York, N Y 10016.

Assistant Professor, Dept. of Anesthesiology, New York University School of Medicine.

Professor and Chairman, Dept. of Anesthesiology, New York University School of Medicine.

- J Intracranial pressure changes induced by sodium nitroprusside in patients with intracranial mass lesions *J Neurosurg* 48 379 1978
- Cottrell, J E, Patel, K, Casthely P et al Nitroprus side tachyphylaxis without acidosis *Anesthesiology* (In press)
- Dashkoff N, Roland J M, Varghese P J et al Effect of nitroglycerin on ventricular fibrillation threshold of nonischemic Myocardium *Am J Cardiol* 38 184 1976
- DiCarlo F J Nitroglycerin revisited Chemistry biochemistry interactions, *Drug Metab Rev* 4 1 1975
- Epstein, E E, Kent K M, Borer J S et al Reduction of ischemic injury by nitroglycerin during acute myocardial infarction *N Engl J Med* 292 111 1975
- Figueras, J., and Forrester J S Nitroglycerin and myocardial ischemia *Chest* 73 1 1975
- Flaherty J T, Come P C, Baurd M G et al Effects of intravenous nitroglycerin on left ventricular function and ST segment changes in acute myocardial infarction *Br Heart J* 38 612 1976
- Flaherty J T, Reid P R, Kelly D T et al Intravenous nitroglycerin in acute myocardial infarction *Circulation* 51 137 1975
- Fung H L., and Rhodes C T Preparation of intravenous nitroglycerin solutions *Am J Hosp Pharm* 32 139 1975
- Greenberg H and Dwyer E M Effects of nitroglycerin on the major determinants of myocardial oxygen consumption, *Am J Cardiol* 36 426 1975
- Hempelmann G, Pipenbrock S et al Changes in hemodynamic parameters, inotropic state and myocardial oxygen consumption owing to intravenous application of nitroglycerin *J Thorac Cardiovasc Surg* 73 836 1977
- Hood W B Dynamite pills in the coronary care unit? *N Engl J Med* 293 1040 1975
- Kaplan J A, Dunbar R W and Jones E L Nitroglycerin infusion during coronary artery surgery *Anesthesiology* 45 14 1976
- Lang T W, Meerbaum S, Corday F et al Regional and global myocardial effects of intravenous and sublingual nitroglycerin treatment after experimental acute coronary occlusion *Am J Cardiol* 37 523 1976
- Lappas, D G, Lowenstein M, Hallowell P et al Hemodynamic effects of nitroglycerin in patients undergoing coronary artery surgery Abstracts of the American Society of Anesthesiologists 235 236 1975
- Needleman P, Blehm D J, Harkley A B et al The metabolic pathway in the degradation of glyceryl trinitrate *J Pharmacol Exp Ther* 179 347 1971
- Needleman P., Jakschik B and Johnson E M Sulfhydryl requirement for relaxation of vascular smooth muscle *J Pharmacol Exp Ther* 167 374 1973
- Needleman P and Johnson E M Mechanism of tolerance to organic nitrates *J Pharmacol Exp Ther* 164 709 1973
- Reid P R, Taylor D R., Kelley D T et al Myocardial infarct extension detected by precordial ST segment mapping *N Engl J Med* 290 123 1974
- Shah, R, Bodenheimer M M, Banks V S and Helfant H H Nitroglycerin and ventricular performance Differential effect in the presence of reversible and irreversible asynergy *Chest* 70 473 1976
- Strasser H F and Scherpe A Ventricular function and hemodynamics after intravenous nitroglycerin in coronary artery disease *AM HEART J* 95 210 1978
- Winburg M M, Howe B H and Weiss H R Effect of nitroglycerin and dipyridamole on epicardial and endocardial oxygen tension Further evidence for redistribution of myocardial blood flow *J Pharmacol Exp Ther* 176 184 1971

solution can be made by mixing crushed 0.6 mg tablets in sterile water to a concentration of 1 mg/ml filtering the solution through a millipore filter and storing in 30 ml vials. This solution is stable for 21 days when refrigerated. One vial (30 mg) is mixed in 250 ml of 5 per cent dextrose in water (120 µg/ml). Infusion should be started at 0.5 to 1.0 µg/Kg/minute to treat myocardial ischemia detected by electrocardiography, left ventricular decompensation (pulmonary capillary wedge greater than 20 torr), or systemic blood pressure greater than 150 torr. Induced hypotension requires larger doses to obtain significant decrease in mean arterial pressure.

Monitoring

Hemodynamic measurements are extremely important when administering intravenous nitroglycerin. Other than a precordial electrocardiogram, a balloon tip flotation catheter should be placed to measure cardiac output, left ventricular end diastolic pressure, and systemic pulmonary capillary wedge pressure. Indices of myocardial function including right and left ventricular stroke work, cardiac index, and pulmonary vascular resistance will be derived.

Hazards

Decrease in coronary artery perfusion pressure leading to greater myocardial ischemia is possible if significant arterial pressure fall occurs. Tachycardia can occur in patients who have no evidence of left ventricular failure increasing myocardial oxygen demand. Intramyocardial steal syndromes have been reported but further investigation is needed for substantiation.

A metabolic hazard may also exist. For each mole of nitroglycerin metabolized, one mole of nitrite (NO_2^-) is formed. Hemoglobin oxidation to methemoglobin may occur in significant quantities especially in the presence of methemoglobin reductase deficiencies or in congenital M hemoglobin variants.

Drug interactions

Nitroglycerin prolongs pentobarbital sleep time because of microsomal oxidase inhibition and it may be an inhibitor of narcotic biotransformation. Nitroglycerin potentiates the hypotensive and anticholinergic effects of tricyclic antidepressants. Synergism with other hypotensive agents has been reported.

Summary and conclusions

Experimental and clinical evidence indicate that nitroglycerin can improve performance of the ischemic myocardium. Simultaneously, regional myocardial oxygen supply may be increased by the vasodilating effects of nitroprusside on the coronary collateral vessels supplying the ischemic area. Oxygen demand is decreased by reduction in left ventricular wall tension from afterload reduction. Oxygen supply is increased in the ischemic myocardium, possibly reducing the severity of ischemia and actual infarct size.

These effects strongly suggest that intravenous nitroglycerin is a valuable tool for the patient with myocardial infarction, left ventricular failure, intraoperative hemodynamic changes (hypertension), valvular disease, systemic or pulmonary hypertension, and for induced surgical hypotension (especially neurosurgery).

REFERENCES

1. Armstrong P W, Waeker D C, Burton J R et al. Vasodilator therapy in acute myocardial infarction: A comparison of sodium nitroprusside and nitroglycerin. *Circulation* 52: 1118, 1975.
2. Aronow W S. The medical treatment of angina pectoris. Intravenous nitroglycerin as an antianginal drug. *AM HEART J* 84: 415, 1972.
3. Aronow W S. Management of stable angina. *N Engl J Med* 289: 516, 1973.
4. Becker L C, Fortuin N J and Pitt B. Effect of ischemia and antianginal drugs on the distribution of radioactive microspheres in the canine left ventricle. *Circ Res* 28: 263, 1971.
5. Borer J S, Redwood D R, Levitt B et al. Reduction in myocardial ischemia with nitroglycerin or nitroglycerin plus phenylephrine administered during acute myocardial infarction. *N Engl J Med* 293: 1008, 1975.
6. Bussman W D. Intravenous infusion of nitroglycerin and oral isosorbide dinitrate in left ventricular failure. *Circulation* 52(Suppl 2): 166, 1975.
7. Capurro N, Kent K M, Smith H S et al. Effects of intravenous nitroglycerin on coronary collateral function. *Pharmacologist* 17: 244, 1975.
8. Chestnut J S, Albin M S, Newfield P et al. Clinical evaluation of intravenous nitroglycerin for neurosurgery. *Neurosurgery* 48: 410, 1978.
9. Chianello M, Gold H K, Leimbach A C et al. Comparison between the effects of nitroglycerin and nitroprusside for induction of hypotension during anesthesia. *Can Anaesth Soc J* 22: 547, 1975.
10. Christenson H, Nordenfiet I, Westling H et al. Intravenous nitroglycerin in normal subjects. *Scand J Clin Lab Invest* 23: 49, 1969.
11. Come P C, Flaherty J T, Band M G et al. Reversal by phenylephrine of the beneficial effect of intravenous nitroglycerin in patients with acute myocardial infarction. *N Engl J Med* 293: 1003, 1975.
12. Cottrell J E, Casthely P, Brodie J D et al. Prevention of nitroprusside induced cyanide toxicity with hydroxocobalamin. *N Engl J Med* 298: 800, 1978.
13. Cottrell J E, Patel A, Turndorf H J and Stanshoff

- angina pathogenetic mechanisms and therapeutic implications. Proceedings of the Satellite Symposium of the Seventh European Congress of Cardiology, Pisa June 15-17 1976, New York 1978 Grune & Stratton Inc
- 7 Mudge G M Grossman W Mills H Lesh M and Braunwald H Reflex increase in coronary vascular resistance in patients with ischemic heart disease *N Engl J Med* 295 1333 1976
- 8 Maseri A L'Abbate A Pesola A Michelassi C

Marzilli M and De Nes D M Regional myocardial perfusion in patients with atherosclerotic coronary artery disease at rest and during angina pectoris induced by tachycardia *Circulation* 55 423 1977

- 9 Clark D A Quint R A Mitchell R L and Angell W W Coronary artery spasm: Medical management, surgical denervation and autotransplantation *J Thorac Cardiovasc Surg* 73 337 1977

Effect of transducer placement on echocardiographic mitral valve motion

Mitral valve prolapse is a common condition which often is readily diagnosed by clinical examination disclosing the typical non-ejection click and/or mid to late systolic murmur. However such patients may present with unusual or labile auscultatory findings and left ventricular angiography has been required to establish the diagnosis in some cases. The discovery that mitral valve prolapse can be accurately diagnosed in many patients using M mode echocardiography has been a great impetus to the study of this syndrome. In patients with angiographically proven mitral valve prolapse various echocardiographic patterns have been described and are used to establish the diagnosis in patients with or without typical auscultatory features of the prolapse syndrome.

In a group of 100 presumably healthy subjects, we performed echocardiograms to study the waveform of the mitral valve relative to other signs of prolapse and to tabulate the systolic mitral waveform specifically. In the design of this study we attempted to assess the effect of transducer position on the mitral waveform by trying to record the anterior and posterior mitral leaflets and left atrium (or atrioventricular junction) with the ultrasound transducer located at the second, third, fourth and fifth intercostal spaces.

During systole a single echo usually could be identified as continuously recorded from the point of leaflet apposition (C point) to the point of leaflet separation at end systole (D point). This echo was interpreted as representing the mitral valve leaflets in the area of coaptation and was analyzed for absolute anterior or posterior systolic motion. A straight line was drawn from the C point to the D point (C-D line) and deviation of the common continuous mitral echo from this line was noted.

We found the echocardiographic patterns previously associated with mitral valve prolapse i.e. a hammock-like smooth posterior motion beginning early in systole or a late systolic posterior motion could be obtained from some intercostal space in over 50 per cent of the subjects. We noticed that such patterns were more frequent when the transducer was located in the higher intercostal spaces, but less common in the same patients with the transducer located in the lower intercostal spaces. Further analysis showed the angulation of the transducer on the chest wall was a major determinant of the mitral valve systolic pattern while the absolute intercostal space in which the transducer was placed was less important. Extensive statistical work demonstrated an excellent correlation

between the phonocardiographic findings and the echocardiographic patterns when the ultrasound transducer was in a position perpendicular to the chest wall when recording the mitral leaflets and left atrium. This was considered the "perpendicular" position. Regardless of the intercostal space if the transducer was pointed caudally patterns suggesting mitral valve prolapse were observed in many subjects without phonocardiographic evidence for this syndrome. Conversely many patients with phonocardiographic evidence of prolapse did not have the echocardiographic features associated with this condition if the echocardiogram was recorded with the transducer located low on the chest wall and pointing markedly cephalad. In the latter situation the echocardiographic patterns associated with mitral valve prolapse usually were seen when repeating the study with the transducer located one intercostal space higher and being perpendicular to the chest wall.

The sequence of recorded echocardiographic patterns with various transducer angulations was consistent with previous studies describing the motion of the base of the heart during the cardiac cycle. During systole the base of the heart moves towards the apex as the annulus fibrosus moves caudally and anteriorly. During systole the normal mitral leaflets close and passively follow the motion of the mitral annulus. With the transducer located high on the chest the mitral annulus and leaflets move away from the transducer during systole as they descend toward the cardiac apex. In this situation the D point will be posterior to the C point and a hammock shaped posterior motion may be recorded without regard to the presence of actual mitral valve prolapse. Conversely when the transducer is located low on the chest pointing cephalad the mitral annulus and closed leaflets will move directly toward the transducer. In this situation the D point will be markedly anterior to the C point. The path of valve and annulus creates the smooth curvilinear anteriorly convex C-D segment commonly recorded from such a low intercostal space. With such transducer position and angulation, bulging of mitral valve leaflets as they prolapse toward the left atrium may not be apparent.

This study has shown the importance of transducer angulation and position in standardizing the echocardiogram for assessment of the mitral valve systolic waveform using M mode echocardiography. Recording both mitral leaflets and left atrium with the transducer perpendicular to the chest

Coronary artery spasm—diagnostic and therapeutic implications

The hypothesis of coronary vasospasm as a cause of angina suggested by accurate clinical observations long ago began to be reconsidered recently on the basis of some isolated occasional angiographic observations made more by chance than by design during attacks of variant angina.

The role of coronary vasospasm in angina pectoris at rest was confirmed in our institution by three series of studies.

1 Continuous hemodynamic monitoring demonstrated that anginal attacks at rest characterized by S T segment elevation or depression were never preceded by an increase of the hemodynamic variables that control myocardial oxygen consumption. Indeed the hemodynamic pattern observed consistently during these attacks was remarkably similar to that observed during experimental transient coronary occlusion.

2 Regional myocardial perfusion studies by Thallium 201 scintigraphy during anginal attacks showed massive transmural deficit of perfusion in patients with S T segment elevation and in more recent studies severe diffuse or subendocardial flow reduction in patients with S T segment depression.

3 Coronary angiography during attacks demonstrated a severe spasm of one or two major coronary vessels in patients with S T segment elevation and a spasm of a small branch or presence of collaterals or diffuse lumen reduction of several branches in patients with S T segment depression.

The degree of atherosclerotic involvement of the patients with vasospastic angina was extremely variable from normal coronary angiograms to severe triple vessel disease. The spasm appears to involve the vessel over a long segment and in the presence of organic stenosis extends proximally and/or distally to the lesion. Our studies indicate that the electrocardiogram may show S T segment elevation or depression depending on the predominantly transmural or subendocardial distribution of myocardial ischemia. Both patterns may be sometimes observed in the same patient during angina at rest depending on the severity of the vasospasm.

The objective demonstration of the possible role of coronary vasomotority reducing myocardial perfusion suggests a revision of the traditional notion that angina ensues only when myocardial metabolic demand increases beyond the possibility of coronary reserve (set by the degree of coronary stenosis and of collateral development). Indeed the concept that the only variable capable of determining an acute imbalance between demand and supply is an excessive increase of myocardial demand has so far conditioned medical and surgical approach to angina. Yet the demonstration that angina at rest is not preceded by a rise of the determinants of oxygen consumption indicates that it is not secondary to this mechanism.

In our experience the borders between primary vasospastic angina and traditional secondary angina are very ill defined because on the one hand some patients with vari-

ant angina (usually a reasonable landmark of vasospastic angina as suggested by Prinzmetal) may also have often induced angina with fixed reduced exercise tolerance and on the other some others may develop occasionally vasospastic angina on exertion. Finally alpha tone appears under some circumstances capable of reducing coronary reserve¹ and a severe reduction of myocardial perfusion was demonstrated in patients during angina induced by pacing.

The diagnostic evaluation of patients with angina at rest should aim to demonstrate whether or not onset of S T segment changes (not of chest pain which is always a late phenomenon) is preceded by increased metabolic demand beyond the possibilities of supply. In most cases the determination of the double or triple product at the onset of the attack and at the onset of ischemia during a graduated effort or a pacing test may serve the purpose.

The therapeutic approach of these patients is substantially different from that of the patients with angina secondary to excessive increase of demands for whom beta blockers and coronary surgery represent a rational approach. Since cardiac denervation does not prevent coronary vasospasm medical treatment with high doses of nitrates and calcium antagonists such as verapamil represents in our experience so far the most effective form of treatment for patients with vasospastic angina.

Attilio Maseri
Laboratorio di Fisiologia Clinica C.R.R.
Via Sallustiana 8
06100 P.A.
1006
A. L. Abbate
S. Chierchia
O. Parodi

REFERENCES

- 1 Maseri A, Pesola A, Mimmo R, Chierchia S and L. Abbate A. Pathogenetic mechanisms of angina at rest (Abstr.) *Circulation* 51 AND 52 (Suppl.) II 89 1975.
- 2 Maseri A, Mimmo R, Chierchia S, Marchesi C, Pesola A and L. Abbate A. Coronary artery spasm as a cause of acute myocardial ischemia in man. *Chest* 68 625 1975.
- 3 Maseri A, Parodi O, Severi S and Pesola A. Transient transmural reduction of myocardial blood flow demonstrated by Thallium 201 scintigraphy as a cause of variant angina. *Circulation* 54 280 1976.
- 4 Maseri A, L. Abbate A, Pesola A, Ballestra A, M. Marzilli M, Maltini G, Severi S, De Nesi D, M. Parodi O and Biagini A. Coronary vasospasm in angina pectoris. *Lancet* i 713 1977.
- 5 Friedberg L. K. Diseases of the heart 3rd ed. Philadelphia 1966 W. B. Saunders Company.
- 6 Maseri A., Klassen S. A. and Lesh M. eds. *Primary*

angina pathogenetic mechanisms and therapeutic implications. Proceedings of the Satellite Symposium of the Seventh European Congress of Cardiology Pisa June 15-17 1976 New York 1978 Grune & Stratton Inc

7 Mudge G H Grossman W Mills R Lesch M and Braunwald E. Reflex increase in coronary vascular resistance in patients with ischemic heart disease. *N Engl J Med* 295 1333 1976

8 Maeri A Labbate A Pesola A Michelassi C

Marzilli M and De Nes E Regional myocardial perfusion in patients with atherosclerotic coronary artery disease at rest and during angina pectoris induced by tachycardia. *Circulation* 55 423 1977

9 Clark D A Quint R A Mitchell R L and Angell W W. Coronary artery spasm. Medical management surgical denervation and autotransplantation. *J Thorac Cardiovasc Surg* 73 33- 1977

Effect of transducer placement on echocardiographic mitral valve motion

Mitral valve prolapse is a common condition which often is readily diagnosed by clinical examination disclosing the typical non-ejection click and/or mid to late systolic murmur. However such patients may present with unusual or labile auscultatory findings and left ventricular angiography has been required to establish the diagnosis in some cases. The discovery that mitral valve prolapse can be accurately diagnosed in many patients using M mode echocardiography has been a great impetus to the study of this syndrome. In patients with angiographically proven mitral valve prolapse various echocardiographic patterns have been described and are used to establish the diagnosis in patients with or without typical auscultatory features of the prolapse syndrome.

In a group of 100 presumably healthy subjects we performed echocardiograms to study the waveform of the mitral valve relative to other signs of prolapse and to tabulate the systolic mitral waveform specifically. In the design of this study we attempted to assess the effect of transducer position on the mitral waveform by trying to record the anterior and posterior mitral leaflets and left atrium (or atrioventricular junction) with the ultrasound transducer located at the second, third, fourth, and fifth intercostal spaces.

During systole a single echo usually could be identified as continuously recorded from the point of leaflet apposition (C point) to the point of leaflet separation at end systole (D point). This echo was interpreted as representing the mitral valve leaflets in the area of coaptation and was analyzed for absolute anterior or posterior systolic motion. A straight line was drawn from the C point to the D point (CD line) and deviation of the common continuous mitral echo from this line was noted.

We found the echocardiographic patterns previously associated with mitral valve prolapse i.e. a hammock like smooth posterior motion beginning early in systole or a late systolic posterior motion could be obtained from some intercostal space in over 50 per cent of the subjects. We noticed that such patterns were more frequent when the transducer was located in the higher intercostal spaces but less common in the same patients with the transducer located in the lower intercostal spaces. Further analysis showed the angulation of the transducer on the chest wall as a major determinant of the mitral valve systolic pattern while the absolute intercostal space in which the transducer was placed was less important. Extensive statistical work demonstrated an excellent correlation

between the phonocardiographic findings and the echocardiographic patterns when the ultrasound transducer was in a position perpendicular to the chest wall when recording the mitral leaflets and left atrium. This was considered the perpendicular position. Regardless of the intercostal space if the transducer was pointed caudally patterns suggesting mitral valve prolapse were observed in many subjects without phonocardiographic evidence for this syndrome. Conversely many patients with phonocardiographic evidence of prolapse did not have the echocardiographic features associated with this condition if the echocardiogram was recorded with the transducer located low on the chest wall and pointing marked by cephalad. In the latter situation the echocardiographic patterns associated with mitral valve prolapse usually were seen when repeating the study with the transducer located one intercostal space higher and being perpendicular to the chest wall.

The sequence of recorded echocardiographic patterns with various transducer angulations was consistent with previous studies describing the motion of the base of the heart during the cardiac cycle. During systole the base of the heart moves toward the apex as the annulus fibrosus moves caudally and anteriorly. During systole the normal mitral leaflets close and passively follow the motion of the mitral annulus. With the transducer located high on the chest the mitral annulus and leaflets move away from the transducer during systole as they descend toward the cardiac apex. In this situation the D point will be posterior to the C point and a hammock shaped posterior motion may be recorded without regard to the presence of actual mitral valve prolapse. Conversely when the transducer is located low on the chest pointing cephalad the mitral annulus and closed leaflets will move directly toward the transducer. In this situation the D point will be markedly anterior to the C point. The path of valve and annulus creates the smooth curvilinear anterior convex CD segment commonly recorded from such a low intercostal space. With such transducer position and angulation bulging of mitral valve leaflets as they prolapse toward the left atrium may not be apparent.

This study has shown the importance of transducer angulation and position in standardizing the echocardiogram for assessment of the mitral valve systolic waveform using M mode echocardiography. Recording both mitral leaflets and left atrium with the transducer perpendicular to the chest

wall or pointing very slightly cephalad is the optimal way to obtain records for analysis of possible mitral valve prolapse by echocardiography

Published echocardiograms should include a description of the location and angulation of the transducer on the chest wall especially when dealing with the mitral valve pattern associated with anatomic prolapse

W Markiewicz MD
Rambam University Hospital
Haifa Israel
E London
R L Popp MD
Cardiology Division
Stanford University School of Medicine
Stanford Calif 94305

REFERENCES

- 1 Kerber R E Isseff D M and Hancock E W
Echocardiographic patterns in patients with the

syndrome of systolic click and late systolic murmur *N Engl J Med* 284 691 1971

- 2 Dillon J C Haine C L Chang S and Ferencik H
Use of echocardiography in patients with prolapsed mitral valve *Circulation* 43 503 1971
- 3 Popp R L Brown O R Silverman J F and Harris D C
Echocardiographic abnormalities in the mitral valve prolapse syndrome *Circulation* 49 479 1974
- 4 DeMaria A N King J F Bogren H G Liss J E Mason D T
The variable spectrum of echocardiographic manifestations of the mitral valve prolapse syndrome *Circulation* 50 33 1974
- 5 Markiewicz W Stoner J London E Hunt S A Popp H L
Effect of transducer placement on echocardiographic mitral valve systolic motion *Europ J Cardiol* 4/3 359 1976
- 6 Zak A Grabhorn L and Feigenbaum H
Movements of mitral ring: A study in ultrasound cardiography *Cardiovasc Res* 1 212 1967
- 7 Dayem M K A Oakley C M Preger L and Steiner R E
Movements of the mitral valve annulus *Cardiovasc Res* 1 116 1967

Hazards of cardiac catheterization in children with primary pulmonary vascular obstruction

Primary pulmonary vascular obstruction (PPVO) in children is rare and affects both sexes equally. It is generally rapidly progressive and is usually fatal often suddenly with a few years of onset of symptoms. The cause is unknown and no effective form of therapy is available. PPVO can usually be diagnosed non-invasively and obstructive lesions resulting in pulmonary artery hypertension such as mitral valve stenosis, supraventricular mitral ring, cor triatriatum and pulmonary venous occlusive disease can usually be excluded by physical examination, electrocardiography, chest x-ray and echocardiography. However, cardiac catheterization is often hazardous in these very hemodynamically unstable patients. It is still undertaken to confirm the diagnosis of PPVO and assess response to medical forms of therapy such as oxygen, tolazoline and isoproterenol.

The following data represent our experiences with cardiac catheterization and the complications encountered in these patients during the past 25 years. Thirty-two catheterizations were performed in 24 patients: 13 females and 11 males ranging in age from 1 month to 19 years (median 11 years and 4 months). Pulmonary artery (PA) saturation ranged from 20 to 77 per cent (median 65 per cent), less than 60 per cent in over one-third; systemic artery (SA) saturation 75 to 98 per cent (median 94 per cent); pulmonary blood flow 0.7 to 5.2 L/min/M² (median 2.9) and PA systolic pressure was equal to or greater than the SA value in 80 per cent. There was no significant difference in these parameters between children who did and did not develop complications during the procedure. Among three patients recatheterized at a median interval of five years following the initial procedure, the PA systolic pressure had increased by 31 to 122 per cent. Oxygen

administered to 11 patients resulted in a PA systolic pressure reduction (by 25 per cent) in only one and tolazoline PA infusion in the same number resulted in a PA pressure increase in five without significant change in the other six. Isoproterenol PA infusion utilized in only one patient did not decrease PA pressure. The incidence of complications did not appear related to these maneuvers.

Major complications occurred in six patients and minor episodes in a similar number (Table I). The major complications consisted of episodes of sinus bradycardia with hypotension of sudden onset with the venous catheter in the pulmonary artery in three patients (Nos 1, 2 and 3) with a fatal outcome in one child (No 2, 1977). In this latter patient the episode commenced during percutaneous placement of an arterial line. Another patient died (No 4, 1953) immediately following completion of the procedure with sudden onset of nausea and gasping respirations initially without electrocardiographic change followed in minutes by ventricular fibrillation. The PA saturation had decreased from 47 to 20 per cent toward the end of the study. A third fatality (No 5, 1960) occurred immediately after general anesthesia administered before direct left atrial puncture attempted to exclude left atrial outflow obstruction. The sixth major episode consisted of transient ventricular fibrillation after simultaneous injection of contrast material into the main pulmonary artery and left atrium (1966) normal sinus rhythm being restored by cardioversion. The six transient minor complications consisted of nausea and vomiting (four), agitation with anoxia (one) and with chills (one).

In addition two patients died suddenly on the day after catheterization and yet another four within three weeks

Table I Catheterization data of 12 patients in whom complications occurred

Patient No	Age (yrs)	O saturations		Pressures (mm Hg)			Complications
		PA	SA	RA a"	PA	SA	
1	3 5/12	49	90	9	154/91	97/57	Transient sinus bradycardia and hypotension with catheter in PA died suddenly three days later
2	10 11/12	47	?	1°	118/65	?	Sinus bradycardia with catheter in PA then ventricular fibrillation and death
3	13 8/12	63	94	1°	150/110	110/70	Transient sinus bradycardia and hypotension with catheter in PA
4	19	90	75	?	130/100	88/65	Decrease in PA sat 47→90% then nausea gasping ventricular fibrillation and death
5	10 11/1°	54	93	13	120/70	110/70	Died immediately following general anesthesia
6	3 7/1°	57	90	12	105/55	100/80	Following simultaneous MPA and LA angiography developed ventricular fibrillation which was cardioverted
7	8 1/°	50	88	9	112/52	87/49	Transient nausea and vomiting died suddenly next day
8	12 11/1°	59	88	12	109/72	97/50	Transient nausea and vomiting
9	13 10/12	77	96	6	150/80	116/66	Transient nausea and vomiting
10	14 9/12	66	91	14	118/87	118/87	Transient nausea and vomiting
11	11 9/12	56	97	14	111/71	108/72	Transient agitation and anoxia
12	17 9/12	75	95	9	135/45	135/67	Transient agitation and chills

Abbreviations: PA = pulmonary artery SA = systemic artery RA = right atrium LA = left atrium

following the study emphasizing the extremely brittle status of these patients

Fatalities associated with cardiac catheterization among patients mostly adults with PPVO have previously been reported. At least four deaths occurred during the study and at least a similar number died immediately following completion of the procedure. While a variety of arrhythmias have been recorded among all deaths it is noteworthy that a very slow ventricular rate due either to sinus bradycardia or atrioventricular block has occurred frequently. Histologically abnormalities of the arterial vessels supplying both the sinoatrial and atrioventricular nodes in patients with PPVO have been described. While direct trauma by the catheter to these areas does not seem to have induced the bradycardia in most as the catheter was usually in the PA at the time it is conceivable that any further reduction of an already reduced pulmonary blood flow could lead to further node impairment. Angiography in the main PA was followed by death in one patient and by ventricular fibrillation successfully cardioverted in one of our own. Shunt angiography be deemed necessary in a patient whose mean PA pressure exceeds 40 mm Hg selective right and left pulmonary arteriography are considered less hazardous. Among our patients we observed no significant PA pressure reduction in response to either oxygen, tolazoline or isoproterenol, in contrast to other investigators.

In view of our own experience as well as a review of the English language literature we may state that cardiac catheterization in patients with PPVO is an unusually hazardous, often fatal, undertaking. One sympathizes fully with attempts to exclude by means of definitive physiologic studies and angiography the presence of remediable left sided obstructive lesions in clinical situations suggesting PPVO. Still one has to balance the urge to save no stone unturned against the

high risk of the procedure. Possibly the recently introduced sophisticated techniques particularly echocardiography may shift prudent cardiologists toward the non invasive route in these desperate situations.

John F. Feane MD
Donald C. Fyler MD
Alexander S. Nadas MD
Dept. of Cardiology
The Children's Hospital Medical Center
and Dept. of Pediatrics
Harvard Medical School
Boston, Mass.

REFERENCES

- Wood P. Disease of the heart and circulation. Philadelphia 1956 J. B. Lippincott Company, p 18
- Cutler J G, Nadas A S, Goodale W T, Hickler B R and Rudolph A M. Pulmonary arterial hypertension with markedly increased pulmonary resistance. *Am J Med* 17:485 1954
- Thilenius O G, Nadas A S and Jackin H. Primary pulmonary vascular obstruction in children. *Pediatrics* 36:5 1965
- Keane J F and Fyler D C. Letter To The Editor. *Lancet* 1:863 197
- Rudolph A M. Pediatric cardiology edited by H. Watson. Saint Louis 1968 The C V Mosby Company, p 68
- Nadas A S and Fyler D C. Pediatric cardiology. Philadelphia 1972 W. B. Saunders Company, p 537
- Sasahara A. Case records of the Massachusetts General Hospital. *Engl J Med* 294:433 1976
- Caldin P, Gensini G G and Hoffman M S. Primary pulmonary hypertension with death during right heart catheterization. *Am J Cardiol* 4:519 1959
- Schafer H., Blum J M, Ceballos R and Bing R J..

wall or pointing very slightly cephalad is the optimal way to obtain records for analysis of possible mitral valve prolapse by echocardiography.

Published echocardiograms should include a description of the location and angulation of the transducer on the chest wall especially when dealing with the mitral valve pattern associated with anatomic prolapse.

W Markiewicz MD

Rambam University Hospital

Haifa Israel

E London

R L Popp MD

Cardiology Division

Stanford University School of Medicine

Stanford Calif 94305

REFERENCES

- 1 Kerber R E Isaacs D M and Hancock E W
Echocardiographic patterns in patients with the

syndrome of systolic click and late systolic murmur
Engl J Med 284 691 1971

- 2 Dillon J C Hayne C L Chang M and Feinba
H Use of echocardiography in patients with prolapsed
mitral valve Circulation 43 503 1971
- 3 Popp R L Brown O R Silverman J F and Harr
D C Echocardiographic abnormalities in the mitral
valve prolapse syndrome Circulation 49 478 1974
- 4 DeMaria A N King J F Bogren H G Liss J E L
Mason D T The variable spectrum of echocardiographic
manifestations of the mitral valve prolapse
syndrome Circulation 50 33 1974
- 5 Markiewicz W Stoner J London E Hunt S
Popp R L Effect of transducer placement on echocardiographic
mitral valve systolic motion Europ J Cardiol 4/3 369 1976
- 6 Zaky A Grabhorn L and Feigenbaum H Movement
of mitral ring A study in ultrasound cardiography
Cardiovasc Res 1 212 1967
- 7 Dayem M K A Oakley C M Preger L and Sten
R E Movements of the mitral valve annulus, Card
vasc Res 1 116 1967

Hazards of cardiac catheterization in children with primary pulmonary vascular obstruction

Primary pulmonary vascular obstruction (PPVO) in children is rare and affects both sexes equally. It is generally rapidly progressive and is usually fatal often suddenly with a few years of onset of symptoms. The cause is unknown and no effective form of therapy is available. PPVO can usually be diagnosed non-invasively and obstructive lesions resulting in pulmonary artery hypertension such as mitral valve stenosis, supraventricular mitral ring contraction and pulmonary venous occlusive disease can usually be excluded by physical examination, electrocardiography, chest x-ray and echocardiography. However, cardiac catheterization often hazardous in these very hemodynamically unstable patients is still undertaken to confirm the diagnosis of PPVO and assess response to medical forms of therapy such as oxygen, tolazoline and isoproterenol.

The following data represent our experiences with cardiac catheterization and the complications encountered in these patients during the past 25 years. Thirty-two catheterizations were performed in 24 patients (13 females and 11 males) ranging in age from 1 month to 19 years (median 11 years and 4 months). Pulmonary artery (PA) saturation ranged from 20 to 77 per cent (median 65 per cent), less than 60 per cent in over one third; systemic artery (SA) saturation 75 to 98 per cent (median 94 per cent); pulmonary blood flow 0.7 to 5.2 L/min/M² (median 2.9); and PA systolic pressure was equal to or greater than the SA value in 80 per cent. There was no significant difference in these parameters between children who did and did not develop complications during the procedure. Among three patients recatheterized at a median interval of five years following the initial procedure, the PA systolic pressure had increased by 31 to 122 per cent. Oxygen

administered to 11 patients resulted in a PA systolic pressure reduction (by 20 per cent) in only one and tolazoline PA infusion in the same number resulted in a PA pressure increase in five without significant change in the other six. Isoproterenol PA infusion utilized in only one patient did not decrease PA pressure. The incidence of complications did not appear related to these maneuvers.

Major complications occurred in six patients and minor episodes in a similar number (Table 1). The major complications consisted of episodes of sinus bradycardia with hypotension of sudden onset with the venous catheter in the pulmonary artery in three patients (Nos. 12 and 3) with a fatal outcome in one child (No. 2 1977). In this latter patient the episode commenced during percutaneous placement of an arterial line. Another patient died (No. 4 1963) immediately following completion of the procedure with sudden onset of nausea and gasping respirations initially without electrocardiographic change followed in minutes by ventricular fibrillation. The PA saturation had decreased from 47 to 20 per cent toward the end of the study. A third fatality (No. 5 1960) occurred immediately after general anesthesia administered before direct left atrial puncture attempted to exclude left atrial outflow obstruction. The sixth major episode consisted of transient ventricular fibrillation after simultaneous injection of contrast material into the main pulmonary artery and left atrium (1966) normal sinus rhythm being restored by cardioversion. The six transient minor complications consisted of nausea and vomiting (four), agitation with anoxia (one) and with chills (one).

In addition two patients died suddenly on the day after catheterization and yet another four within three weeks.

4. Mitchell E C ed Symposium on prevention of atherosclerosis at the pediatric level Including identification of potential risks and prophylaxis *Am J Cardiol* 31:539 1973
5. Zeek P Juvenile arteriosclerosis *Arch Pathol* 10:417 1930
6. Klotz O and Manning M F Fatty streaks in the intima of arteries *J Path Bact* 16:211 1912
7. Lober P H Pathogenesis of coronary sclerosis *Arch Pathol* 55:357 1953
8. Holman R L McGill H C Jr Sironi J P and Geer J C The natural history of atherosclerosis The early aortic lesions as seen in New Orleans in the middle of the 20th century *Am J Pathol* 34:209 1958
9. Glueck C J Fallat R W and Tsang W Hypercholesterolemia and hypertriglyceridemia in children A pediatric approach to primary atherosclerosis prevention *Am J Dis Child* 128:569 1974
10. Sobel H S Burch G E Chu K C Lenderman E and Cokolou H L Ultrastructural changes in cardiac capillaries of Coxsackie virus B infected mice *Lab Invest* 19:399 1968
11. Burch G E Tsui C Y and Harb J M Pathologic changes of aorta and coronary arteries of mice infected with Coxsackie B virus *Proc Soc Exp Biol Med* 137:65 1971
12. Burch G E The etiology of arteriosclerosis—A thought *AM HEART J* 83:434 1972
13. Burch G E Harb J M Hiramoto Y and Shewey L Viral infection of the aorta of man associated with early atherosclerotic changes *AM HEART J* 86:523 1973
14. Burch G E and Harb J M Encephalomyocarditis (EMC) virus infection of the mouse aorta An ultrastructural study *AM HEART J* 86:669 1973
15. Burch G E Harb J M and Hiramoto Y Coxsackie viral infection of the aorta of man *South Med J* 67:166 1974
16. Burch G E Viruses and arteriosclerosis *AM HEART J* 87:407 1974
17. Burch G E and Harb J M Encephalomyocarditis (EMC) virus infection of the femoral artery of newborn mice *Proc Soc Exp Biol Med* 147:11 1974
18. Saltykow S Atherosklerose bei Kaninchen nach wiederholten Staphylokokkeninjektionen *Beitr Path Anat Allg Path* 43:147 1908
19. Frothingham C Jr The relation between acute infectious diseases and arterial lesions *Arch Intern Med* 8:153 1911
20. Lubarsch Zur pathogenese der atherosklerose der artienen *Munchen Med Wchnschr* 56:1819 1909

- Essential pulmonary hypertension A report of clinical physiological studies in patients with death following catheterization of the heart *Ann Intern Med* 44 505 1956
- 10 Berthrong M and Cochran T H Pathological findings in nine children with primary pulmonary hypertension *Bull Johns Hopkins Hosp* 97 69 1955
- 11 Walcott G Burchell H B and Brown A I Primary pulmonary hypertension *Am J Med* 49 70 1970
- 12 Snider G L Ferris E Gaensler E A Messer J V Hayes J A Gersten M M and Couto R E Primary pulmonary hypertension A fatality during pulmonary angiography *Chest* 64 628 1973
- 13 Yu P N Primary pulmonary hypertension Report of six cases and review of literature *Ann Intern Med* 49 1138 1958
- 14 James T N On the cause of syncope and sudden death in primary pulmonary hypertension *Ann Intern Med* 56 252 1962
- 15 Dresdale D T Michton R J and Schultz M Recent studies in primary pulmonary hypertension including pharmacodynamic observations on pulmonary vascular resistance *Bull N Y Acad Med* 30 195 1954
- 16 Aviado D M Jr and Schmidt C F Effects of sympathomimetic drugs on pulmonary circulation with special reference to a new pulmonary vasodilator *J Pharmacol Exp Ther* 120 512 1957
- 17 Daoud F S and Reeves J T Temporary relief of primary pulmonary hypertension with isoproterenol *Clin Res* 22 628A 1974
- 18 Shettigar U R Hultgren H N Specter M Martin R and Davies D H Primary pulmonary hypertension Favorable effects of isoproterenol *N Engl J Med* 295 1414 1976
- 19 Rudolph A M Paul M H Sommer L S and Hadas A S Effects of tolazoline hydrochloride (Priscoline) on circulatory dynamics of patients with pulmonary hypertension *AM HEART J* 55 424 1958

Of atherosclerosis in infants and children and viral infections

That atherosclerosis is common in infants and children is well known. What is not known is why. Why should infants and children have atherosclerosis if the risk factors for atherosclerosis are hypercholesterolemia, hyperlipidemia, hypertension, smoking, caffeine intake, tension, and anxiety states, wear, and tear, the aging process, etc.? These factors would not have existed very long if they existed at all in infants and young children. Perhaps these factors are not the etiologic agents at all but are only aggravating or contributing factors which require many years of existence and therefore can manifest their influence only in adults if the individuals live long enough. Surely the calcific lesions of arteriosclerosis of adults are not found in infants and young children. Calcification of arterial plaque requires a long time, just as calcification of lesions in other tissues of the body requires a long time.

But viral infections do occur regularly in infants and children, and infections produced by viruses are well known to be highly infectious and even highly lethal in infants and children. Furthermore, the picornaviruses such as the Coxsackie B group of viruses, which commonly infect the upper respiratory tract of infants and children, can severely damage the blood vessels of suckling mammals, including man.¹ These arterial lesions could be the initial lesions of the atherosclerotic plaques found in very early life of man. The atherosclerotic plaques would be the "healed" or healing lesions of the locally infected arteries and infected and damaged vasa vasorum. These plaques are of course found in the arteries and not in the veins, even though the risk factors and the viral infections apply to the veins as much as they do to the arteries. But the intravascular pressure is much higher in arteries than in veins, and arteries and veins are certainly morphologically different. Thus the healing or reparative processes of sites of viral infection and damage in the arteries of man especially of infants and children could result in atherosclerosis. Therefore smoking, caffeine intake, hyperten-

sion, hypercholesterolemia, hyperlipidemia, and the other commonly listed risk factors would really not be necessary for atherosclerotic plaques to develop but would only cause the plaques to develop more rapidly, more extensively, and more frequently and seriously and to differ morphologically, biochemically, and functionally. The only initiating factor then would be the viral infection by the proper viruses, whether they be known or unknown.

These concepts not only have merit as thoughts but also have factual support. The role of viruses in the production of atherosclerosis and arteriosclerosis needs thorough investigation as limited studies already indicate. Furthermore, if certain viruses are prone to initiate arteriosclerosis, then the potential for prevention of arteriosclerosis by vaccines is considerable. The possible role of even bacterial infection (tuberculosis, pneumococcus, staphylococcus, typhoid, etc.) as the initiating cause of arteriosclerosis was suggested at the beginning of this century. The role of viruses in infectious diseases was poorly known then and not even considered by the early investigators. Viral infection as an important disease of blood vessels needs serious and extensive investigation and research support.

G E Burch M D
Tulane University School of Medicine
and Charity Hospital
New Orleans La

REFERENCES

- 1 Moon H D Coronary arteries in fetuses, infants, and juveniles. *Circulation* 16 263 1957
- 2 Strong J P and McGill H C Jr The pediatric aspects of atherosclerosis. *J Atheroscler Res* 11 251 1969
- 3 Zinsverling W D Untersuchungen über atherosklerose I Über die aortaverfärbung bei kindern. *Archiv Path Anat Klin Med* 255 678 1975

report I repeat my concluding sentence that only a formal prospective epidemiological study can be expected to provide valid conclusions. "Incidentally the New York marathon 1977 attracted 4823 official starters of whom 3701 finished. 38% officially finished the Boston marathon 1978. That I am an experienced marathoner (as is Bassler¹) is quite irrelevant to the issue at hand.

As far as the medical justification for moderate exercise among post infarct men (as well as marathoning for those able to achieve this level of activity) I would agree with Bassler. Terry Kavanagh and others have clearly documented the validity of this approach although only about 2 to 3 per cent of Kavanagh's rehab patients can achieve the full marathon goal.

The unfounded hyperbole in which Bassler engages when he endlessly repeats his anecdotal stories about absolute CHD immunity among 42 km men is scientifically unjustified and misleading. It is potentially dangerous to the medically unsophisticated average runner.

Paul Milvy Ph.D.
Environmental Sciences Laboratory
Mount Sinai School of Medicine
100th St and Fifth Ave
New York N.Y. 10029

REFERENCES

1. Noakes T, Opie L and Beck W. Coronary heart disease in marathon runners. *Ann N Y Acad Sci* 301: 593, 1977.
2. Bassler T J. Letter to Editor. *Lancet* 11: 711, 1972.
3. Milvy P. ed. The Marathon. Physiological, medical, epidemiological and psychological studies. *Ann N Y Acad Sci* 301: 103, 1977.
4. Brown L. S. and Milvy P. A critique of several epidemiological studies of physical activity and its relationship to aging, health and mortality. *Ann N Y Acad Sci* 301: 103, 1977.
5. Vital Statistics U.S. (1973) Section II Mortality Part A, United States Public Health Service. Washington D.C. 1977.
6. Young K. Personal communication, 1978.

Acid gas induced MI

To the Editor

In the textbooks of cardiology we were not able to find any report of acute coronary events following exposures to gases or vapors. In one of our patients, the symptoms of acute myocardial infarction appeared immediately after the inhalation of a mixture of ammoniacal and acetic acid gases. The patient, a man of 46, a mild smoker (15 cigarettes a day) with neither previous symptoms of coronary heart disease nor disorders of lipid or glycidic metabolism, experienced subdermal pain when he inhaled gases produced by a photographic developing set (sodium hydroxide, sodium sulphite, ethylenediamine plus ammonium tyocanate, acetic acid and 11% zinc tartrate salt). The pain recurred twice in the night and in the following day he was admitted to our coronary care unit, where an inferior wall infarction was diagnosed (electrocardiographic and enzymatic confirmation).

After recovery from acute myocardial infarction effort angina persisted for some months indicating in our opinion anatomic coronary damage (no angiography could be

performed) however the strict relationship between gas inhalation and onset of symptoms suggests a possible triggering effect of the former.

We would greatly appreciate your opinion and the views of any of your readers about this possibility.

M Puletti M.D.
F Jacobellis M.D.
V Greco M.D.
F Pozzar M.D.
Coronary Care Unit
2 Clinica Medica
University of Rome
Rome 00100 Italy

Pathogenesis of myocardial infarction

To the Editor

The recent correspondence by Drs Penhler and Baroldi highlights yet again the controversy about the pathogenesis of myocardial infarction. Because our published work is discussed by both correspondents we are grateful to the Editor for allowing us to comment further. We submit that the problem is one of definitions. We agree with Dr Baroldi that one must not confuse the different types of myocardial necrosis frequently associated with this disease "which is the nub of the whole controversy. If the view is taken that all myocardial necroses from large macroscopic areas to microscopic foci, are to be regarded as myocardial infarction then it is scarcely surprising that there is wide divergence in the reported results of surveys of the relation of coronary thrombosis to myocardial infarction.

In our survey we chose a somewhat arbitrary macroscopic definition of a regional transmural infarct deliberately to exclude other forms of ischemic myocardial necrosis encountered in coronary heart disease. The myocardial necrosis was confirmed in all our cases by microscopy and no case had been subjected to cardiac surgery. Regional myocardial infarction as we defined it is common in patients dying of ischemic (coronary) heart disease and in the majority of cases is associated with a classical history of chest pain and the area of necrosis can be localized by ECG as anterior, inferior or lateral. We find the incidence of occlusive coronary thrombosis in such cases to be over 90 per cent. We are well aware that regional infarction is not the only form of myocardial necrosis seen in ischemic heart disease. In patients with longstanding coronary heart disease associated with multiple zones of coronary artery stenosis often of the triple vessel pattern multiple foci of myocardial necrosis varying from about 1 cm in diameter to microscopic lesions may be detected. The subendocardial region and the centers of the papillary muscles are particularly affected and in extreme cases the whole subendocardial zone may be necrotic in which case the term diffuse subendocardial, or laminar infarction would seem appropriate. The extreme degree is uncommon but lesser degrees of focal necrosis are frequent and identification of the latter may be possible only on microscopy of several blocks of myocardium. Such cases were excluded from our study.

The pathophysiology of diffuse subendocardial necrosis has been beautifully elucidated by Hoffman and Buckberg as a failure of intramyocardial perfusion from a variety of conditions, some of which do not involve any abnormality of the

Statistics marathoning and CHD

To the Editor

Milvy suggests that the absence of fatal CHD among marathon runners is not statistically significant (Am Heart J 95:538-539, 1978). He argues that a cohort of 958 male marathoners would generate only one or two CHD deaths per year because they are all lean young nonsmokers. This number of deaths is too small to measure any protection marathoning might offer. However, the number of marathoners at risk is closer to one million than to the 958 suggested by Milvy.

Our report, edited by Milvy, clearly states that all marathoners past and present are under our world wide surveillance. Cases from four continents covering five decades are included. The marathon distance has been popular since the turn of the century. Race results and autopsy slides are permanent; since marathons have been timed in excess of eight hours, anyone who even walks the distance is covered. A million runners could generate one CHD death per day if the life style offered no protection at all!

And all runners are certainly not lean young nonsmokers. I have personally covered the 42 km distance with more than a hundred graduates from Cardiac Rehabilitation Programs including 33 with myocardial infarction, 16 with bypass grafts and others with double vessel and triple vessel disease. This cohort of cardiac marathoners could generate one or two CHD deaths per year if the life style offered no protection at all!

Milvy is an experienced marathoner. He has participated in the New York and Boston races, popular courses which attract nearly 10,000 runners each year. Larger races have been seen in Europe, Africa and Asia. With 10,000 runners participating in a single race, I doubt that Milvy believes there are only 958 male marathoners. I can only conclude that his statements in the journal were delayed by several years and are now out of date.

Thomas J Bassler MD
Centinela Hospital
Inglewood Calif 90307

REFERENCE

1. Bassler T J. Marathon running and immunity to atherosclerosis. Ann N Y Acad Sci 301:579-1977.

Reply

To the Editor

Between 1972 and 1976 Bassler sent at least 27 letters to medical and scientific journals asserting that marathon running absolutely protects the marathoner from death from ischemic heart disease or alternatively from atherosclerosis or coronary heart disease. More of his letters have recently appeared indicating that it is the marathoner's life style that confers this remarkable immunity to CHD. In 1972 he said in an early prototype of these letters that a search of the literature failed to document a single death due to

coronary arteriosclerosis among marathon finishers. The only extensive paper by Bassler that seeks to document these unsupported claims has appeared rather ex post facto in the New York Academy of Sciences Marathon Conference Annals¹ to which Bassler makes reference in his most current letter. In his Methods section of this paper he writes that

An excess of 200 reports (of deaths among marathoners) have been received during the past 10 years. Many are duplicates. Most were below the 42 km threshold. Brown and Milvy in a critique of this paper comment that it would have been more impressive had the total case load relevant to the hypothesis been provided (22 cases including the legendary Pheidippides are reviewed in the paper). Their ages a critical factor in determining risk of CHD are mentioned in only nine of these 22 cases.

In his most recent letter commenting upon my annotation Bassler informs us that he knows of no deaths from CHD among one million marathoners past and present, yet fails to inform us of the validity of his data base. How many of these one million men and women have died? How many death certificates did he examine? Bassler insists that CHD not only be clinically proven but confirmed by autopsy and histologically proven. How many autopsy reports did he obtain? How many sets of histological slides did he review? We look in vain for such essential data!

In his Methods section¹ he further indicates that deaths among marathoners are reviewed worldwide. Since great differences in the incidence of CHD exist in the underdeveloped, developing and industrialized countries it would be helpful if Bassler sometime somewhere to provide a careful breakdown of where this marathon cohort of one million comes from and how he can keep abreast of deaths from such a large disparate group. Bassler correctly asserts that if his hypothesis is sound these one million marathoners will generate about 4 to 1 CHD deaths per day (if they average about 30 years of age, the age of the average US marathoner). In the age group 25 to 34 years in which 8 per cent of US deaths are from major cardiovascular diseases, the death rate from all causes is 2.14 per million per year. For the world at large the WHO estimates it to be only slightly higher. Ninety per cent of all scientists who ever lived are alive today. I do not know if an equal per cent of these million marathoners are currently alive but unless Bassler is inspecting about 2,000 permanent sets of pathology slides of dead marathoners per year his world wide surveillance is not thorough. That's 20,000 sets of marathoners slides per decade that should be available for his study! Yet in spite of his worldwide surveillance he comes up with only 200 cases, mostly duplicates, mostly less than full marathon distance and reports upon only 22 cases in any scientific and non anecdotal way. Where have the other 1998 dead marathoners gone? Or perhaps there aren't a million marathoners in the first place!

Finally I used 1975 figures for my analysis. The latest reasonably accurate figures we have available as of March 1978 are that about 23,000 US men completed a marathon in 1977. By multiplying my data by 24 we may update my

report I repeat my concluding sentence that only a formal prospective epidemiological study can be expected to provide valid conclusions. "Incidentally the New York marathon 1977 attracted 4873 official starters of whom 3.01 finished. 3.8% officially finished the Boston marathon 1978. That I am an experienced marathoner (as is Bassler!) is quite irrelevant to the issue at hand.

As far as the medical justification for moderate exercise among post-infarct men (as well as marathoning for those able to achieve this level of activity) I would agree with Bassler. Terry Kavanagh and others have clearly documented the validity of this approach, although only about 2 to 3 per cent of Kavanagh's rehab patients can achieve the full marathon goal.

The unfounded hyperbole in which Bassler engages when he endlessly repeats his anecdotal stories about absolute CHD immunity among 42 km men is scientifically unjustified and misleading. It is potentially dangerous to the medically unsophisticated average runner.

Paul Mitty Ph.D.
Environmental Sciences Laboratory
Mount Sinai School of Medicine
100th St and Fifth Ave
New York N.Y. 10029

REFERENCES

1. Noakes T, Opie L, and Beck W. Coronary heart disease in marathon runners. *Ann N Y Acad Sci.* 301:593 1977.
2. Bassler T J. Letter to Editor. *Lancet* 11 711 1972.
3. Mitty P. ed. The Marathon. Physiological, medical, epidemiological and psychological studies. *Ann N Y Acad Sci.* 301:19 7.
4. Brown R. S. and Mitty P. A critique of several epidemiological studies of physical activity and its relationship to aging, health and mortality. *Ann N Y Acad Sci.* 301:703 1977.
5. *Vital Statistics U.S. (1973) Section II Mortality Part A, United States Public Health Service Washington D.C. 1977.*
6. Young K. Personal communication 1978.

Acid gas induced MI

To the Editor

In the textbooks of cardiology we were not able to find any report of acute coronary events following exposure to gases or vapors. In one of our patients the symptoms of acute myocardial infarction appeared immediately after the inhalation of a mixture of ammoniacal and acetic acid gases. The patient, a man of 46, a mild smoker (15 cigarettes a day) with neither previous symptoms of coronary heart disease nor disorders of lipidic or glycidic metabolism, experienced subterminal pain when he inhaled gases produced by a photographic developing set (sodium hydroxide, sodium sulphite, ethylenediamine plus ammonium thiocyanate, acetic acid and H₂P₂O₇ (zincium salt)). The pain recurred twice in the night and in the following day he was admitted to our coronary care unit where an inferior wall infarction was diagnosed (electrocardiographic and enzymatic confirmation).

After recovery from acute myocardial infarction effort angina persisted for some months, indicating in our opinion anatomic coronary damage (no angiography could be

performed) however the strict relationship between gas inhalation and onset of symptoms suggests a possible triggering effect of the former.

We would greatly appreciate your opinion and the views of any of your readers about this possibility.

M. Puella M.D.
G.F. Jacobellis M.D.
V. Greco M.D.
F. Pozzi M.D.
Coronary Care Unit
2 Clinica Medica
University of Rome
Rome 00100 Italy

Pathogenesis of myocardial infarction

To the Editor

The recent correspondence by Drs Penhler and Baroldi highlights yet again the controversy about the pathogenesis of myocardial infarction. Because our published work is discussed by both correspondents, we are grateful to the Editor for allowing us to comment further. We submit that the problem is one of definitions. We agree with Dr Baroldi that one must not confuse the different types of myocardial necrosis frequently associated with this disease, which is the nub of the whole controversy. If the view is taken that all myocardial necroses from large macroscopic areas to microscopic foci are to be regarded as myocardial infarction, then it is scarcely surprising that there is wide divergence in the reported results of surveys of the relation of coronary thrombosis to myocardial infarction.

In our survey we chose a somewhat arbitrary macroscopic definition of a regional transmural infarct deliberately to exclude other forms of ischemic myocardial necrosis encountered in coronary heart disease. The myocardial necrosis was confirmed in all our cases by microscopy and no case had been subjected to cardiac surgery. Regional myocardial infarction as we defined it is common in patients dying of ischemic (coronary) heart disease and in the majority of cases is associated with a classical history of chest pain and the area of necrosis can be localized by ECG as anterior, inferior or lateral. We find the incidence of occlusive coronary thrombosis in such cases to be over 90 per cent. We are well aware that regional infarction is not the only form of myocardial necrosis seen in ischemic heart disease. In patients with longstanding coronary heart disease associated with multiple zones of coronary artery stenosis often of the triple vessel pattern multiple foci of myocardial necrosis varying from about 1 cm in diameter to microscopic lesions may be detected. The subendocardial region and the centers of the papillary muscles are particularly affected and in extreme cases the whole subendocardial zone may be necrotic in which case the term diffuse subendocardial or laminar infarction would seem appropriate. The extreme degree is uncommon but lesser degrees of focal necrosis are frequent and identification of the latter may be possible only on microscopy of several blocks of myocardium. Such cases were excluded from our study.

The pathophysiology of diffuse subendocardial necrosis has been beautifully elucidated by Hoffman and Buckberg as a failure of intramyocardial perfusion from a variety of conditions some of which do not involve any abnormality of the

major epicardial coronary arteries. This type of lesion may be seen for example following cardiac bypass operation where coronary artery perfusion has been inadequate. Severe stenosing coronary atherosclerosis may have the same effect and no recent occlusion is required to precipitate muscle necrosis although it can obviously do so.

We are currently conducting a prospective study of ischemic myocardial necrosis in which the necrosis is assessed and categorized by histochemical techniques and the coronary arteries dissected from the hearts are examined independently by histological techniques. Our preliminary findings indicate that single regional infarcts in cases without previous myocardial damage are always associated with recent thrombotic occlusion of the supplying coronary artery whereas in cases of advanced coronary atherosclerosis with triple vessel disease and myocardial scarring focal and subendocardial necroses are common findings but the incidence of recent coronary thrombosis is lower. We believe that this study will emphasize the important role played by case selection in determining the incidence of recent coronary thrombosis related to the various forms of myocardial necrosis.

The question as to which form of myocardial necrosis is the most important in terms of morbidity and mortality is another matter. Certainly the circumscribed regional infarct is the most easily recognized by pathologists perhaps giving a spurious view of its frequency. In current hospital practice with intensive and coronary care units widely available more cases of long term severe coronary atherosclerosis are dealt with. Necropsies from this group provide a higher proportion of examples of complex myocardial damage.

The question of whether coronary thrombosis causes or is secondary to myocardial infarction is probably best answered by *in vivo* studies using radioactive fibrinogen. It seems to us that the meticulous studies of Fulton and Sumner showing that coronary thrombi have a radionegative head provide the best evidence that coronary thrombosis antedates myocardial damage. If the opposite view is taken then an explanation is required for the finding of recent coronary thrombosis in a not inconsiderable proportion of cases of sudden cardiac death due to coronary atherosclerosis without evidence of myocardial necrosis.

Finally we would make a plea for a more precise and agreed set of definitions for the various forms of ischemic myocardial necrosis so that those interested in the subject can compare like with like. Pathologists owe it to their clinical colleagues to sort out the confusion that currently prevails a situation that can only bring morphologic studies and morphologists into disrepute.

Professor M J Davies

Professor W B Robertson

Professor N Woolf

Dr A Popple

St George's Hospital Medical School
Cranmer Terrace London SW 17 0RE
England

REFERENCES

- 1 Penhler P. Coronary thrombosis and acute myocardial infarction: cause or consequence? *AM HEART J* 94:392 1977
- 2 Davies M J, Woolf N and Robertson W B. Pathology of acute myocardial infarction with particular refer

ence to occlusive coronary thrombi. *Br Heart J* 38:6, 1976

- 3 Hoffman J I E and Buckberg G D. Pathophysiology of subendocardial ischemia. *Br Med J* 1:6 1975
- 4 Fulton W F M and Sumner D J. Causal role of coronary thrombotic occlusion and myocardial infarction. Evidence of stereo autoradiography serial sections and 125 I fibrinogen autoradiography. *Am J Cardiol* 39:322 1977

Reply

To the Editor

Dr Davies and associates explain the wide divergence of the frequency of the occlusive thrombus by the lack of distinction between subendocardial or laminar infarctions (from 1 cm in diameter to microfoci detectable only histopathologically) in general without a thrombus and regional infarcts most of which are associated with an occlusive thrombus. About the same opinion is shared by other authors.

In classifying the different diseases an entity is generally profiled according to the pathognomonic clinical and pathologic parameters independently from the size of a lesion. In order to investigate the natural history of the acute myocardial infarction in our study only patients who died in hospital because of a classical acute pattern of this disease (chest pain ECG typical changes etc.) without any other disorder and with postmortem documented myocardial coagulation necrosis were selected. The distribution of both the size of the pathognomonic necrosis (in per cent of the left ventricular mass) and the frequency of an occlusive thrombus as follows:

Table 1

Size (%)	Total cases	Cases + thrombus
< 10	29	4
11-20	20	7
21-30	25	10
31-40	11	5
41-50	12	9
> 50	3	3

In the group of 29 cases with a size inferior to 10 per cent only 12 cases were subendocardial i.e. the coagulation necrosis was not seen with the naked eye and detected histologically. In the other 88 cases this type of necrosis was unifocal very often transmural and with a diameter much greater than 1 cm. Following the distinction of Dr Davies I don't think that they can be called subendocardial or laminar. On the other hand if they are regional the over all frequency of the thrombus is 43 per cent. However if we compare the 73 cases with a size minor or equal to 40 per cent and the 15 cases with a size superior to 40 per cent the thrombus frequency is 35.6 and 73.3 respectively. This difference is statistically significant ($\chi^2 = 7.26$) and suggests that there is a trend of an increasing frequency of the thrombus in relation to the increasing size of the coagulation necrosis. Since Dr Davies mentions some preliminary results in cases

without previous myocardial damage ■ ■ ■ important to note that we were unable to see any relationship between thrombus frequency and the size of a scar (present in 6 of our cases 44 of which had a subendocardial scar) A first consideration seems appropriate namely that the distinction between small and large or regional infarcts ■ ■ ■ cloudy and perhaps it is better to size the extension of the coagulation necrosis as a per cent of the total left ventricular mass I suspect that a selection of the material on the basis of the major diameter only may include mainly very large infarcts If this is the case we agree on the very high frequency of the thrombus

However I have to repeat that the core of the controversy is not the frequency of the thrombus but its significance in further reducing the flow (see my reply to Dr Penther's letter) since it is generally located in a severe old stenosis preexisting for a long time prior to the onset of the infarct It sounds logical to presume that this long lasting silent period can be interpreted only by the presence of functioning collaterals Therefore the thrombus occurs in an already bypassed stenosis

I am very sensible to the plea of Dr Davies for a better understanding of the so called ischemic lesions One may agree or disagree on my definition of the different types of myocardial necrosis but nevertheless it is an attempt along this line keeping in mind that when I speak of different types of necrosis I mean their different nature—and likely with a different pathogenesis—as suggested by the clear cut distinction in terms of the structural changes So for instance the type of necrosis seen after cardiac bypass surgery—we are studying that—looks more like myocytolysis than coagulation necrosis and several facts support the view that myocytolysis may be a primary metabolic lesion and not an ischemic one Obviously the field becomes confused when we try to understand more but this confusion is welcome if we will be able to improve our knowledge Dispute will result only if we are investigating a problem without considering all the variants or if we speak of necroses without a distinction of their nature

Finally a last comment on the best evidence that coronary thrombosis antedates myocardial damage given by the demonstration that coronary thrombi have a radionegative head

Unfortunately the injection of radioactive fibrinogen is carried out hours after the appearance of the first clinical symptoms Therefore the radio negativity does not exclude that a thrombus is secondary It shows only that the thrombus was formed before injection not if it is primary or secondary On this subject in 106 witnessed cases of unexpected sudden coronary death 77 died within 10 minutes 29 in one hour and five in 5 hours The frequency of an occlusive thrombus was 13.9 and zero respectively This shows that a thrombus when present is a very early phenomenon

Finally the last question of Dr Davies is how to explain a recent thrombus without evidence of myocardial necrosis again in cases of sudden coronary death In my hypothesis on the secondary thrombus formation I always mentioned the possibility that an increased peripheral resistance may be the starting mechanism or at least one of the mechanisms as for instance in large infarcts (impairment of the intramural flow) In the past few years more and more evidence is given that a coronary spasm is a fact and not an artefact—I don't know if primary or secondary to angina or infarction However if it is a fact it may increase the peripheral resistance and

may become the cause of a thrombus as recently suggested even in the absence of myocardial infarction

Giorgio Baroldi M D
Fisiologia Clinica
Via Sassi 8
56100 Pisa Italy

REFERENCES

- Chandler A ■ Chapman I Erhardt L R Roberts W C Schwartz C J Sinapis D Spain D M Sherry S Ness P M, and Summ T L Coronary thrombosis in myocardial infarction *Am J Cardiol* 34 823 1974
- Baroldi G Radice F Schmid G, and Leone A Morphology of acute myocardial infarction in relation to coronary thrombosis *AM HEART J* 87 ■ 1974
- Penther P Coronary thrombosis and acute myocardial infarction cause or consequence? *AM HEART J* 94 392, 1977
- Baroldi G Different types of myocardial necrosis in coronary heart disease A pathophysiological review of their functional significance *AM HEART J* 89 42 1975
- Baroldi G Myocardial necrosis: the need for definition *J Molec Cell Cardiol* ■ 401 1974
- Baroldi G Falz ■ and Mariani F Significance of the morphologic changes in the sudden "coronary" death, Symposium Helsinki, in *Advances in Cardiology* Vol 35 Basel 1978 S Karger
- Oliva P B and Breckinridge J C Arteriographic evidence of coronary arterial spasm in acute myocardial infarction *Circulation* 56 366 1977

Orthostatic hypertension in normotensives and borderline hypertensive patients

To the Editor

The study of Hull and associates by means of a non invasive procedure confirms the high percentage of orthostatic diastolic hypertension previously observed in borderline hypertensive patients during 0-degree head up tilt However the distinction between normotensives and borderline hypertensive patients remains difficult and there is still an overlap which concerns 30 per cent of this latter group

In our study of 85 borderline hypertensive patients we measured the hemodynamic changes during tilt and the results provided an explanation for the differences in the orthostatic behavior of the borderline group It was obvious that orthostatic diastolic hypertension closely corresponded to the borderline hypertensive patients with elevated cardiac output neurogenic mechanisms were considered to play a predominant role in this group In contrast the orthostatic responses of the borderline hypertensive subjects with normal cardiac output were similar to those observed in normotensives It may be concluded that orthostatic diastolic hypertension is a useful but not decisive procedure in the assessment of the borderline status

Professeur Ag M Safar
Clinique Medicale Propedeutique
Hopital Broussais
96 Rue Didot 75674
Paris 14 France

REFERENCES

- Hull D H Wolthuis R A Cortese T Longo M R, Jr and Trebassier J H Borderline hypertension

versus normotension Differential response to orthostatic stress AM HEART J 94 414 1977

- 2 Safar M et al Hemodynamic study of 85 patients with borderline hypertension Am J Cardiol 31 315 1973

Chest thumping to terminate ventricular tachycardias

To the Editor

Chest or precordial thumping to terminate ventricular tachycardia can be fraught with risk and should be performed only when equipment for external defibrillation is immediately available Yakatis and Redding indicated that thumping can lead to ventricular fibrillation and have recommended its deletion in the treatment of cardiac arrest Pennington and colleagues study also revealed an incidence of conversion of ventricular tachycardia to ventricular fibrillation following chest thumping

With the possibility of provoking a more dangerous arrhythmia with a thump electrical cardioversion or drug therapy should be the treatment of choice

Donald Forester M D
Asst Professor of Medicine
New York Medical College
1249 Fifth Ave
New York N Y 10029

REFERENCES

- 1 Befeler B and Aranda J M Termination of ventricular tachycardia by a chest thump over the area of paradoxical pulsation AM HEART J 94 773 1977
- 2 Yakatis R W and Redding J S Precordial thumping during cardiac resuscitation Crit Care Med 1 22 1973
- 3 Pennington J E Taylor J and Lown B Chest thumping for reverting ventricular tachycardia N Engl J Med 283 1192 1970

Reply

To the Editor

Our present experience with the use of chest thump and other mechanical means for the conversion of ventricular and atrial arrhythmias extends to a group of close to 70 patients The whole of our experience is now in press under the title of

Mechanical stimulation of the heart Its therapeutic value in tachyarrhythmias to be published in the Journal Chest We have not encountered one single episode of precipitation of ventricular fibrillation after the application of a chest thump for the treatment of ventricular tachycardia It is important to know however that many patients if allowed to remain in ventricular tachycardia may degenerate into ventricular fibrillation No doubt these two arrhythmias are intimately related and of course one should always be prepared to treat ventricular tachyarrhythmias by electrical defibrillation

The article quoted by Dr Forester in his letter that of Yakatis and Redding² refers mostly to an experience in an experimental animal It does not refer to the actual use in patients The article by Pennington Taylor and Lown³ in fact advocates the use of thumping as a means of converting ventricular tachycardia In the one instance they mention of

the appearance of ventricular fibrillation is not clear whether it was precipitated by the thump or if it was the natural result of prolonged ventricular tachycardia

We feel that chest thump is not only a viable means of treatment but in fact advocate this modality as the first line of attack in the appearance of ventricular tachycardia particularly when the patient has physical evidence of ventricular aneurysm Of course we also feel that drug and electrical conversion should be available and may be necessary in some instances Furthermore we advocate the use of external as well as internal stimulation via a catheter as a safe easy to perform first line of treatment in patients with ventricular tachycardia as well as in patients with asystole in whom the induction of an ectopic ventricular beat may start an organized rhythm

As we gain more experience with the use of mechanical stimulation of the heart we will be better equipped to deliver the mechanical stimulus to the area which is either part of the reentrant mechanism or is closest to the point of origin of the ectopic rhythm The application of mechanical stimulation is presently being pursued both in patients in the Coronary Care Unit and in patients in whom intracardiac catheters have been introduced for either diagnostic or therapeutic reasons

A better understanding of the pathway of reentrant arrhythmias will allow a more rational use of low energy mechanical stimulation in the treatment of these tachyarrhythmias This has been under intensive study in several centers in the last few years

Benjamin Bufeler M D
School of Medicine
V A Hospital
Cardiovascular Laboratory
1201 N W 16th St
Miami Fla 33135

REFERENCES

- 1 Befeler B Mechanical stimulation of the heart is therapeutic value in tachyarrhythmias Chest (in press)
- 2 Yakatis R W and Redding J S Precordial thumping during cardiac resuscitation Crit Care Med 1 22 1973
- 3 Pennington J E Taylor J and Lown B Chest thumping for reverting ventricular tachycardia N Engl J Med 283 1192 1970

Observations on Q fever endocarditis

To the Editor

The report of a case of Q fever endocarditis by Dr Applefeld and colleagues (AM HEART J 93 669 1977) was welcome to those of us who have long wondered why this complication has been recorded so infrequently in the United States where in some areas at least both overt and subclinical Q fever infection in humans is far from rare It was of particular interest since indirectly it drew attention to the problem of diagnosis and the difficulties in management that might have ensued had the patient not died so soon after the date of the initial serological tests for *Coxiella burnetii* (C burnetii) As it is not clear from the case report I am assuming that the results of the initial tests were not available before the death of the patient

The diagnosis was far from proven. Although signs and symptoms of subacute infective endocarditis were present the titer of phase I complement fixing antibody of 1:32 was well below the lowest level (1:200) which the WHO Scientific Group on Rickettsial Diseases in Man considered suggestive of Q fever endocarditis. All 3rd asymptomatic patients described in two recent reports had phase I antibody titers of 1:128 or above. Particularly unusual and difficult to explain in the Baltimore case was the very low initial titer of phase II complement fixing antibody when the titer for phase I antibody was already 1:32. In none of the patients studied by Powell and Stallman where the phase II titer was negative or 1:8 was phase I antibody detected. Evidence of the fourfold rise in phase II antibody, itself an indication of acute infection or re-infection rather than chronic infection, was available only after death. Taken alone, elevated titers of phase I antibody usually indicate prolonged infection in the past, especially in a patient with a complication such as rheumatic mitral valvular disease but do not necessarily indicate present persisting infection. Elevated phase I titers, some as high as 1:128 have been found in completely asymptomatic patients with and without valvular heart disease. However, since the antibody to phase I antigen is probably a neutralizing antibody it is possible that during the period prior to the development of phase I antibody lack of neutralization allows seeding of the organism to occur. Patients with low or absent titers of phase I antibody may have chronic Q fever in evolution. A proven case with elevated titers of only phase II antibody has already been cited by Dr. Applefeld and colleagues in that patient the organism was eventually isolated at autopsy four months later not from the alve but from the spleen. In another case where the titer of phase I antibody was only 1:64 the organism was isolated not only from the blood during life but also from aortic and mitral valves postmortem. Previous treatment with tetracycline may also explain lower titers in some patients.

With this evidence and knowing what an insidious and destructive disease Q fever endocarditis can become the physician faced with a patient with infective endocarditis and only slightly elevated titers of phase I antibody cannot afford not to initiate appropriate antibiotic therapy immediately, even if, as in the Baltimore patient, the titer of phase II antibody is very low too. It would also be wise to start such treatment in those patients where the combination of valvular heart disease and only slightly elevated titers of phase I antibody occurs in the absence of signs of infective endocarditis, as the fatal case reported by McIVER demonstrated that it may take months after the attack of acute Q fever for those signs to develop. Traditionally tetracycline is considered to be the drug of choice but lincomycin used in combination with tetracycline may be even more effective in controlling the disease. The patient in whom this regime was originally employed received these antibiotics alone for just over five years. Four years and nine months after stopping antibiotic therapy she is alive and in good health, the longest survival so far reported.

Finally it is not correct to state that clinical evidence of hepatitis is rare in Q fever endocarditis. All of the 111 patients reported from Manchester and Edinburgh had evidence of liver involvement and in one this led to death from cirrhosis. In fact, two patients presented primarily with liver disease. All

but one of the patients had hepatomegaly and in many there was hepatic tenderness. Abnormal tests of liver function particularly hyperglobulinemia, raised alkaline phosphatase and abnormal bromsulphthalein retention were found in all patients. Hepatic histology was abnormal in all eight patients in whom it was studied. Other workers have recorded isolation of *C. burnetii* from hepatic tissue. These findings coupled with thrombocytopenia which also occurs frequently may help to differentiate Q fever endocarditis from bacterial endocarditis.

W.P.G. TURK, M.B.C.B. F.R.C.P.E.

Department of Medicine

Allice Ho Yiu Ling Nethersole Hospital

Bonham Road

Hong Kong

REFERENCES

1. World Health Organisation. Report to Director General, Meeting of Scientific Group on Rickettsial Diseases in Man, Geneva, July 1963, p. 21.
2. Wilson H M, Neilson G H, Galea E G, Stafford G and O'Brien M F. Q fever endocarditis in Queensland. *Am J Cardiol*, 53: 680, 1976.
3. Turk W P G, Howitt G, Turnberg L A, Fox H, Longson M, Matthews M H and Das Gupta R. Chronic Q fever. *Q J Med*, 45: 193, 1976.
4. Powell O W and Stallman N D. The incidence and significance of phase I complement fixing antibody in Q fever. *J Hyg*, 60: 359, 1970.
5. Schonell M E, Brotherton J G, Burnett R C S, Campbell J, Coghill J D, Moffatt M A J, Norval J and Sutherland J A W. Occupational infections in the Edinburgh abattoir. *Br Med J*, 2: 148, 1966.
6. Henderson R J. Q fever and leptospirosis in the dairy farming community and allied workers of Worcestershire. *J Clin Pathol*, 22: 511, 1969.
7. Henderson R J. Personal communication, 1970.
8. Marmion H P. Latency and rickettsial infections. *Proceedings of the sixth International Congress of Medicine and Maladies*, Lisbon, 5-7, 11, 1958.
9. Evans A D, Powell D E H and Burrell C D. Fatal endocarditis associated with Q fever. *Lancet*, 1: 864, 1959.
10. Grise N R. Complications cardio-vasculaires dues à la fièvre Q et autres rickettsioses. *Bull Soc Path. Exot*, 56: 648, 1963.
11. Powell O W, Kennedy K P, McIVER M and Silver stone H. Tetracycline in the treatment of Q fever. *Aust Ann Med*, 11: 184, 1962.
12. Clinico-pathological Conference. Four cases of rickettsial endocarditis. *Br Med J*, 4: 40, 1963.
13. McIVER M. A case of Q fever endocarditis. *Med J Aust*, 2: 3/9, 1967.
14. Turk W P G and Matthews M H. Rickettsial endocarditis. *Br Med J*, 1: 185, 1969.
15. Matthews M H. Personal communication, 1977.
16. Ferguson I C, Craik J E and Grise N R. Clinical virological and pathological findings in fatal case of Q fever endocarditis. *J Clin Pathol*, 15: 230, 1967.
17. Giroud P. Complications cardiovasculaires dues à la fièvre Q et autres rickettsioses (résumé et discussion). *Bull Soc Path. Exot*, 56: 689, 1963.
18. Mitchell R, Grise N R, Bazzaz C and Kenmuir A C F. Pathological, rickettsiological and immunofluorescence studies of a case of Q fever endocarditis. *J Pathol Bacteriol*, 91: 317, 1966.

Reply

To the Editor

We thank Dr Turck for his astute comments concerning our case report of Q fever endocarditis. It has been of interest to us as to why this complication has been infrequently documented to occur in the United States. In answer to Dr Turck's questions, the initial serologic studies were not available before the patient died. We agree that all of Koch's postulates were not fulfilled in this case. However, we believe the serologic studies as recorded strongly suggest *C. burnetii* as the etiology of the infective endocarditis in our patient. While it is true that phase I antibody in our patient was 1:32 as Dr Turck notes, Ferguson and associates have reported the patient with Q fever endocarditis in whom the organism was isolated from the blood as well as the heart valves at autopsy in which this antibody titer was 1:64. Additionally, the rise in phase II antibody in our patient suggests an active infective process. In the absence of any pathologic evidence of hepatitis in our case, we believe this serologic rise is even more indicative of active endocarditis due to *C. burnetii*. We agree with Dr Turck's recommendation that in the setting of a

patient who has clinical signs and symptoms of infective endocarditis but whose blood cultures are persistently sterile that appropriate serologic studies be drawn, including those for *C. burnetii*, and that treatment with tetracycline be seriously considered in addition to antibiotic therapy for more conventional organisms (i.e., *S. faecalis* and anaerobes). We are in the process of surveying our geographic area to detect other unrecognized cases of endocarditis due to this organism.

Mark M. Applefeld MD
Assistant Professor of Medicine
Division of Cardiology
University of Maryland
School of Medicine
Baltimore, Maryland 21201

REFERENCE

1. Ferguson I C, Crank J E, and Grist N R. Cardiac, virological and pathological findings in a fatal case of Q fever endocarditis. *J Clin Pathol* 15:335, 1962.

Book reviews

Progress in Brain Research volume 47 Hypertension and Brain Mechanisms Edited by W. DeJong, A. P. Provoost and A. P. Shapiro. Amsterdam, 1977. Elsevier Scientific Publishing Company. 437 pages. Price \$57.95.

This book represents many papers presented at a workshop held in Utrecht during June 28 to 30, 1975. The papers are grouped in accordance with the subjects discussed which included neuroanatomy and neurophysiological mechanisms of cardiovascular control, neurotransmissions in relation to cardiovascular control, brain damage and hypertension and pharmacological aspects of antihypertensive agents. The many papers as a whole are excellent. Furthermore, this workshop emphasizes the brain and nervous system in pathophysiology and pharmacology as related to hypertension. The contributors are from many parts of the world, all actively engaged in studying hypertension. Physiologists and pharmacologists especially should find this to be a useful book. Clinicians would profit greatly by studying the many contributions. This is a very good book and is highly recommended as a source of material on a subject of hypertension which is too often ignored.

Practical Atlas of Cardiac Scintigraphy St. Louis, Missouri, 1977. The C.V. Mosby Company. 110 plates plus 21 pages introduction. Price \$40.50.

This atlas on cardiac scintigraphy is timely. Interest in the use of nuclear medicine methods in cardiology is increasing rapidly. This reviewer however finds the methods to offer very little useful service to clinical cardiology, especially since the introduction of echocardiography. Nuclear diagnostic

procedures are expensive and increase further the already high cost of medicine. Nevertheless, the *Atlas* in French and English does describe very well methodology and recommended clinical applications of nuclear scintigrams of the heart to cardiology. The illustrations and legends are superb. The colored plates are clear. The practicing physician can determine for himself whether or not he would find these recordings useful in his practice. And this excellent atlas does provide the reader with an opportunity to learn the principles of the methods, applications and indications of the methods as well as the results. This is a fine atlas on a medical subject that is developing in popularity. But the reader must decide for himself just how these nuclear procedures apply along with the clinical and electrocardiographic data. Regardless, the methods are being used fairly extensively and it therefore behooves the physicians to know when and how to employ them. This book provides a good background for study.

Basic Electrocardiography Handbook By Leonard J. Lyon, MD. New York, 1977. Van Nostrand Reinhold Company. 175 pages. Price \$11.95.

This handbook of about 150 pages is intended for nurses, paramedical assistants in hospitals and clinics, and beginners in electrocardiography. The book summarizes the approach used by the author in his teaching exercises. The author has simplified many of the concepts in electrocardiography for nurses and paramedical personnel. The book is intended to train people to recognize acute cardiac problems, especially those related to arrhythmias. Nurses and technicians will find this to be a very useful book on an important subject.

Books received

ECG Diagnosis Self Assessment vol II By Edward K. Chung, MD. Hagerstown, Md. 1977. Harper & Row Publishers. 444 pages. Price \$17.95.

Mechanical Concepts in Cardiovascular and Pulmonary Physiology By Jerry Franklin Green, PhD. Philadelphia, 1977. Lea & Febiger Publishers. 166 pages. Price \$10.00.

Heart Disease in Infants, Children and Adolescents 2nd ed. Edited by Archibald J. Moss, Forrest H. Adams and George C. Emmanouilides. Baltimore, 1977. The Williams & Wilkins Company. 571 pages. Price \$27.00.

Recent Advances in Studies on Cardiac Structure and Metabolism Vol. 12 Cardiac Adaptation Edited by Tachio Kobayashi, Yoichi Ito and Georg Rona. Baltimore, London, Tokyo, 1978. University Park Press. 751 pages. Price \$57.50.

Recent Advances in Studies on Cardiac Structure and Metabolism Vol. 11 Heart Function and Metabolism Edited by Tachio Kobayashi, Toyomi Sano and Narayan S. Dhalla. Baltimore, London, Tokyo, 1978. University Park Press. 638 pages. Price \$49.50.

Symposium on Patient Education

The University of California San Francisco presents the second annual Symposium on Patient Education to be held in San Francisco on October 20 through 22 1978 Patient education is a process that involves a partnership between patients and members of the health care team This partnership has led to the development of this symposium in which persons who have had experience with disease and trauma will join with health professionals to learn about what is happening to their bodies and how to control the effects that their illness may have on their future lives This symposium has been designed to bring together key persons involved in these processes as a way to sustain the progress that has been achieved and to stimulate ideas and inquiries concerning patient education in the near future Fees for the symposium are Physicians—\$90 (includes credit) General—\$80 (includes credit) General—\$70 (does not include credit) Full time students—\$35 (letter of verification must accompany registration form) For registration information contact University of California San Francisco Continuing Education Health Sciences 1308 Third Ave San Francisco Ca 94143 Telephone (415) 666 2894

Advancement of Tension Control meeting

The fifth meeting of the American Association for the Advancement of Tension Control will be held on October 28 and 29 1978 at the Bismarck Hotel in Chicago Preceding the meeting will be a two day workshop conducted by Dr F J

McGuigan on October 26 and 27 For information about the workshop and meeting please contact Dr F J McGuigan, Executive Director AAATC P O Box 8005 Louisville Ky 40208

Pediatric and adolescent echocardiography course

The fourth annual Pediatric and Adolescent Echocardiography Course will be held on November 10 through 12 1978 in Las Vegas, Nevada The course is sponsored by the American Society of Echocardiography American Institute of Ultrasound in Medicine and by HEI P For further information, please contact Pediatric Echocardiography Course 4341 Placita Panuco Tucson Ariz 85718 Telephone (602) 686 6508

Lucien Dautrebande prize

The Foundation de Physiopathologie Professeur Lucien Dautrebande will award its next prize of approximately 900 000 Belgian francs during the year 1979 The award will be given to a study on human or animal clinical physiopathology such work preferably having therapeutic implications All applications for candidacy must be received by December 15 1978 For further information regarding the award and applications please write Office of the Foundation de Physiopathologie Professeur Lucien Dautrebande Chaussée de Liège 35 5200 Huy Belgium

Editorial

Coronary heart disease—the doctor's dilemma

George V Mann ScD MD*

Nashville Tenn

For 25 years the treatment dogma for coronary heart disease (CHD) has been a low cholesterol low fat polyunsaturated diet. This treatment grew out of a reasonable hypothesis raised in 1950 by Gofman and others but soon a clot of aggressive industrialists self interested foundations and selfish scientists turned this hypothesis into nutritional dogma which was widely impressed upon physicians and the general public. A nadir was reached when zealous doctors and salesmen arranged such 'prudent meals for national meetings of cardiologists' rather like Tupperware teas. There grew up in the interface between science and the government funding agencies a club of devoted supporters of the dogma which controlled the funding of research a group known by the cynics among us as the heart Mafia. Critics or disbelievers of the diet/heart dogma were seen as pariahs and they went unfunded while such extravaganzas as the Diet/Heart trial the MRFIT trial and a dozen or more lavish Lipid Research Centers divided up the booty. For a generation research on heart disease has been more political than scientific. All this resulted from the abuse of scientific method. A valid hypothesis was raised tested and found untenable. But for selfish reasons it has not been abandoned. T C Chamberlain the American

geologist and philosopher described the situation succinctly in 1897¹

The moment one has offered an original explanation for a phenomenon which seems satisfactory that moment affection for his intellectual child springs into existence and as the explanation grows into a definite theory his parental affections cluster about his offspring and it grows more and more dear to him. There springs up also unwittingly a pressing of the theory to make it fit the facts and a pressing of the facts to make them fit the theory.

Since 1955 many examinations of the diet/heart hypothesis have shown that neither the level of serum lipids²⁻⁴ nor the experience with CHD⁵ can be related to dietary practice. Clinical trials of prevention by diet both primary⁶ and secondary⁷⁻⁹ have shown that diet has no more than a trivial effect on cholesterolemia and has no real effect on morbidity and mortality. Two drugs niacin and atomid have larger effects than diet in lowering cholesterolemia but they gave no health advantage¹⁰⁻¹².

Three drug treatments were abandoned because they caused an excess of disease in treated men. These were estrogens at two levels¹³ and dextrothyroxine. The clinical trials do clearly show a doubling of the rate of cholelithiasis¹⁴ and a questionable increase of cancer in subjects treated.¹⁵ It is not reasonable to say that while diets and drugs may not help they do no harm, they may indeed cause harm.

This impasse creates two problems. How is the public to be reeducated? As a German journalist said 'I cannot tell my readers that the informa-

From the Department of Biochemistry Vanderbilt University School of Medicine Nashville.

Received for publication November 2, 1977.

Reprint requests: Dr George V Mann, Dept. of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tenn 37232.

Current mailing to (4-K06-HL-08288-16) from The National Heart Lung and Blood Institute.




Fig 1 The factor derived from *Penicillium* cultures has recently been characterized by Endo and associates¹¹ This material is active both in vitro on the enzyme system which synthesizes cholesterol and in vivo The acid form (*right*) is more active than the lactone form Both contain the glutarate skeleton

tion I have been giving them about diet and heart disease over the past ten years is wrong that would destroy my credibility." Physicians have a similar problem with their patients. But all of you, journalists and scientists, alike, had better recognize that the limb you are on is being sawed off.

The doctor's dilemma would be eased if he had an effective substitute for the dietary dogma. Partly because the diet/heart hypothesis has so usurped the research funds there is no established alternative—only some scattered unfunded ideas. Physicians may be interested in some of these

There are two classes of causes of hypercholesteremia. These are relevant because there is general agreement that cholesteremia is causally related in a curvilinear way to atherosclerotic disease. The rare form affecting about one in 500 persons, is a genetic lesion of cell receptors.¹⁴ This lesion prevents the cholesterol in the low density lipoproteins from entering the cells and regulating the synthesis of cholesterol. This is inherited as an autosomal recessive trait.¹⁵ Hypercholesteremia is present at birth in such persons and cardiovascular disease often but not always occurs prematurely. There is no available treatment but there are three in the offspring. One is hydroxy methyl glutarate,¹⁶ another is a material derived from *Penicillium* cultures¹⁷ (Fig 1), and a third is a material called 'milk factor' because it is found in milk.¹⁸ These materials offer promise of being of value in the control of synthesis of

cholesterol and the prevention of premature vascular disease in this rare genetic disorder. No presently available drugs or diets have been shown to do that.

The common cause of cholesteremia appears to be an environmental agent which interferes with the catabolism of cholesterol to bile acid for excretion.¹⁹ The identity of this agent is not known, but there are several suspects. These include the 'trans' fatty acids produced by the hydrogenation of polyunsaturated oils, as in the manufacture of soft margarine.⁹ Human feeding trials show that trans fatty acids have a remarkable hypercholesteremic effect.²¹ Another suspect is carbon monoxide, which is known to interfere with the hydroxylating enzymes responsible for converting cholesterol to bile acid.²² Still another suspect is vitamin D, which since about 1940 has been added to many human foods and often in excessive amounts.²³ Vitamin D in excess is an atherogenic agent in experimental animals.

The role of high density lipoproteins in serum¹¹ of the cations in hard water and of fiber in food as protective agents against CHD is incompletely understood. The fiber issue is clouded by bad epidemiological groundwork. Burkitt should have read Bishop Berkeley more carefully before using untended African populations as paragons of health. To be is to be perceived.

Physicians need to know, for their patients and for themselves what course to follow to minimize the risk of CHD. A most impressive collection of evidence suggests that exercise and fitness protect from CHD.³ The disease is rare in physically active cultures.²⁸ Men with exertional jobs²⁹ or men with sedentary jobs and exertional hobbies³⁰ have less trouble with CHD. Maasai men who are exceptionally active, do have extensive atherosclerosis but with enlarged, ectatic vessels as they grow old so that the plaques are inconsequential.³¹ A clinical trial is needed to examine the role of exercise in the primary prevention of CHD. Such a trial would be feasible because fitness measurements are available to measure compliance with the treatment. Unhappily, and perhaps cynically, there is more money in soft margarine than in sneakers and athletic support

There was a saying in the Old West that you can't sell from an empty wagon.' Diet/heart has been a demonstration of that truism. We need some solid evidence of the efficacy of exercise.

before we mount a public health campaign. In the meantime too many Americans are wearing the diet/heart hair shirt. To borrow a phrase from Martin Luther King: Let my people go.

REFERENCES

- 1 Chamberlin T C. The method of multiple working hypotheses. *Science* 148:754, 1965 (Reprinted).
- 2 Kannel W B and Gordon T. The Framingham Diet Study. Diet and the regulation of serum cholesterol. Section 24. Washington D C 1970. Department of Health, Education and Welfare.
- 3 Nichols A B, Ravenscroft C, Lamphier D E, et al. Daily nutritional intake and serum lipid levels: the Tecumseh Study. *Am J Clin Nutr* 29:1381, 1976.
- 4 Vital Statistics Reports No 95. February 11, 1977. U.S. Govt.
- 5 Dayton S and Pearce M L. Prevention of coronary heart disease and other complications of atherosclerosis by modified diet. *Am J Med* 48:751, 1964.
- 6 Leren P. The effect of plasma cholesterol lowering diet in male survivors of myocardial infarction. *Acta Med Scand (Suppl)* 466:539, 1966.
- 7 Miettinen M, Turpeinen O, Karvonen M J, et al. Effect of cholesterol lowering diet on mortality from coronary heart disease and other causes: a twelve year clinical trial in men and women. *Lancet* 2:835, 1972.
- 8 Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. *JAMA* 231:300, 1974.
- 9 Dietz K M and Shaw L. Long term changes of serum cholesterol with cholesterol altering drugs in patients with coronary heart disease. *Circulation* 50:998, 1974.
- 10 The Coronary Drug Project Research Group. Findings leading to discontinuation of the 2.5 mg/day estrogen group. *JAMA* 226:652, 1975.
- 11 The Coronary Drug Project Research Group. Findings leading to further modifications of its protocol with respect to dextrothyroxine. *JAMA* 220:896, 1972.
- 12 Coronary Drug Project Research Group. Gallbladder disease as a side effect of drugs influencing lipid metabolism. *Am J Med* 296:1185, 1977.
- 13 Ederer F, Leren P, Turpeinen O, et al. Cancer among men on cholesterol lowering diets: experience from five clinical trials. *Lancet* 2:900, 1971.
- 14 Brown M S and Goldstein J L. Familial hypercholesterolemia—a genetic defect in the low density lipoprotein receptor. *N Engl J Med* 294:1386, 1976.
- 15 Khachadurian A K. The inheritance of essential familial hypercholesterolemia. *Am J Med* 37:402, 1964.
- 16 Lapsien P J, et al. Effectiveness of 3-Hydroxy 3-Methylglutamic acid in familial hypercholesterolemia. *Lancet* 1:1256, 1973.
- 17 Fudo A M, Kusada K, and Tanzawa K. Inhibition of cholesterol synthesis in vitro and in vivo by MI 236A and MI 236B. *Eur J Biochem* 77:31, 1977.
- 18 Mann G V. Hypocholesterolemic effect of milk. *Lancet* 1:56, 1977.
- 19 Mann G V. Diet/Heart—End of an era. *N Engl J Med* 297:644, 1977.
- 20 Ottenstein M M, et al. Trans fatty acid content of commercial margarine samples determined by gas liquid chromatography of OV 275. *J Am Oil Chem Soc* 54:707, 1977.
- 21 Vergosen A J, ed. The role of fats in human nutrition. An introduction. New York, 1975. Academic Press. Inc. pp 1-36.
- 22 Wada F, Hwata K, Nakano K, et al. Participation of P 450 in 7 α hydroxylation of cholesterol. *J Biochem (Tokyo)* 64:415, 1968.
- 23 Seelig M. Vitamin D and cardiovascular renal and brain damage in infancy and childhood. *Ann N Y Acad Sci* 147:539, 1969.
- 24 Miller N E, Forde O H, Thelle D S, et al. The Tromsø Heart Study: high density lipoprotein and coronary heart disease. A prospective case-control study. *Lancet* 1:965, 1977.
- 25 Keys A. Coronary heart disease in seven countries. *Circulation* 41 (Suppl 1):11, 1970.
- 26 Passenberger R S, Hale W E, Brand R J, et al. Work energy level, personal characteristics and fatal heart attack: a birth cohort effect. *Am J Epidemiol* 105:200, 1977.
- 27 Morris J N, Chave S P W, Adam C, et al. Vigorous exercise in leisure time and the incidence of coronary heart disease. *Lancet* 1:333, 1973.
- 28 Karvonen M J, Rautaharju P M, Orma E, et al. Cardiovascular studies on lumberjacks. *J Occup Med* 3:49, 1961.
- 29 Mann G V, Sperry A, Gray M, et al. Atherosclerosis in the Maasai. *Am J Epidemiol* 95:26, 1972.

Adverse reactions to methyldopa with particular reference to hypotension

D H Lawson, MD, FRCP (Ed)*

D Gloss, MS, MPH

H Jick, MD

Waltham Mass

Methyldopa is widely used in the treatment of all forms of hypertension. After an initial period in which it was thought to act by inhibiting dopa decarboxylase in sympathetic nerves it is now generally accepted to mediate its effect by a direct action on the brain.¹

Side effects from this drug are often trouble some. Johnson and colleagues² reported their occurrence in 72 per cent of recipients, the major problems being weight gain and drowsiness occur

ring during long term therapy. Subsequently Pritchard and associates³ reported that 20 per cent of patients receiving this drug had to discontinue treatment because of side effects. The majority of reported side effects appear to be dose related,⁴ leading to the suggestion that an upper limit of 3 grams should be placed on the daily dose of methyldopa.⁵

The present report provides details of the adverse effects of methyldopa as seen in a large comprehensive drug surveillance program which monitors consecutive admissions to medical wards in university teaching hospitals. In particular the information available on the occurrence of hypotension during methyldopa therapy is analyzed in depth.

Patients and methods

The Boston Collaborative Drug Surveillance Program uses nurse monitors to collect information on consecutive admissions to medical wards in teaching hospitals in participating centers in seven countries. The information obtained includes routine demographic details, a history of past medication use, together with precise details of all medications prescribed during the patient's stay in hospital. Data collected include dose, route, frequency, starting and stopping indications for the drug. Where a patient develops any undesired or unintended effects attributed to the drug, a detailed evaluation of the effect is undertaken by the attending physician and a clinical pharmacologist. For the present report only those adverse effects deemed to be 'definitely' or 'probably' due to methyldopa are included. A record is kept of the results of certain routine laboratory tests taken on admission and up to four discharge diagnoses. Greater details of the

From the Boston Collaborative Drug Surveillance Program, Boston University Medical Center and the Department of Clinical Pharmacology, Royal Infirmary Glasgow, Scotland.

Received for publication Nov 9 1977

Accepted for publication Jan 11 1978

Reprint requests: Dr H Jick, Boston Collaborative Drug Surveillance Program, 400 Totten Pond Rd, Waltham, Mass 02154.

Present address: Royal Infirmary Glasgow, Scotland.

The Boston Collaborative Drug Surveillance Program has been supported by the National Institute of General Medical Sciences (Grant No. 1 R01 GM23490-01) and in part by grants from the United States Food and Drug Administration (Grant No. 1 R01 FD00920-01), the Canadian Health Protection Branch, the Israeli Ministry of Health, the Hadassah Medical Organisation, the Kupat Holim, Auckland Hospital, Auckland, New Zealand, Roger Williams General Hospital (Brown University NIGMS Grant No. GM 165 39-02) and the Scottish Home and Health Department. The hospitals which have participated in the ongoing part of the Boston Collaborative Drug Surveillance Program are: Boston, Massachusetts—Lemuel Shattuck Hospital, Peter Bent Brigham Hospital, Boston City Hospital, Veterans Administration Hospital, Massachusetts General Hospital and University Hospital, Providence, Rhode Island—Roger Williams General Hospital, Syracuse, New York—State University Hospital of the Upstate Medical Center, Tucson, Arizona—Arizona Medical Center, Richmond, Virginia—Virginia Commonwealth University Hospital, Canada—St Joseph's Hospital, London, Ontario—Israel—Hadassah Hebrew University Hospital, Jerusalem—Belinson Medical Center, Petah Tikva, Asaf Harari Hospital, Zerim, and Rambam University Hospital, Haifa, New Zealand—Auckland Hospital, Auckland, and Hutt Hospital, Wellington, Scotland—Western Infirmary and Stobhill General Hospital, Glasgow, Italy—Desso Hospital, Milan, West Germany—Klinikum Steglitz der Frei Universität Berlin.

exact methodology employed have been published elsewhere^{4,7}

This report is based on information collected between 1966 and 1975 on 26 294 consecutive hospitalized patients in 21 hospitals in the US Canada Israel New Zealand Scotland Italy and Germany of whom 1 067 (4 per cent) received methylidopa during their first monitored admission to the study

Results

The mean age of the 1 067 methylidopa recipients was 57 years 52 per cent were males and 3.5 per cent died during the monitored admission. The primary discharge diagnosis was of cardiovascular disease in 616 patients (58 per cent) renal disease in 99 (9 per cent) respiratory disease in 75 (7 per cent) endocrine disease in 66 (6 per cent). A variety of other conditions made up the remaining 20 per cent of diagnoses. A history of previous drug treatment was available for 952 (89 per cent) patients. Of these 275 (29 per cent) had not previously received hypotensive therapy. The sole indication for methylidopa treatment was hypertension. The mean diastolic blood pressure of the 275 newly diagnosed hypertensive patients was 116 (SEM 1.3) mm Hg on admission as compared to 100 (SEM 0.9) mm Hg for those who had received previous hypotensive therapy.

Adverse effects were attributed to methylidopa in 149 patients (14 per cent). The most frequent reaction was excessive hypotension which was reported in 110 patients (10.3 per cent) and was often noted to be postural. In the majority of patients where the actual pressure was recorded the systolic value was below 100 mm Hg or the diastolic below 70 mm Hg (see Discussion section). Other reactions included drowsiness, hematological upsets, cutaneous manifestations and upset in libido. Details of the reported frequency of these events is given in Table I.

Extrapyramidal signs and hemolytic anemia were reported in six patients who had a history of methylidopa use prior to hospitalization and responded gradually to withdrawal of the drug. Rise in blood urea nitrogen levels occurred in two patients, both of whom also suffered from significant hypotension. Bradycardias of 36 beats/minute and 42 beats/minute respectively were recorded in two patients shortly after commencing methylidopa. In one of these patients 250 mg was given orally and in the other 500 mg was

Table I Adverse effects attributed to methylidopa

	Number of patients	Per cent
Hypotension	110	10.3
Drowsiness	26	2.4
Depression	5	0.6
Extrapyramidal signs	4	0.4
Gastrointestinal upsets	4	0.4
Headaches	2	0.2
Cutaneous manifestations	2	0.2
Hemolytic anemia	2	0.2
Drug related fever	2	0.2
Bradycardia	2	0.2
Rise in blood urea nitrogen levels	2	0.2
Alteration in liver function	1	0.1
Disturbance in libido	1	0.1

A patient may have more than one ill effect attributed to methylidopa.

given intravenously. Bradycardia responded to reduction in the frequency of administration of the drug in both instances. Methylidopa related pyrexia was reported in two patients and again responded completely to withdrawal of the drug.

Adverse effects of methylidopa were judged by the attending physicians to have been life threatening in nine instances. Details of these patients are given in Table II. Six of these nine patients suffered from cerebral or cardiac ischemic episodes while receiving methylidopa. None died as a result of the adverse reaction.

For the purpose of further analyses designed to explore the relationships between toxicity and various patient and drug related factors, patients were classified into three categories according to the presence of hypotension related to methylidopa, other adverse effects of the drug, or no adverse effects. Patients suffering from more than one adverse effect were preferentially assigned to the hypotension category if this was one of the reported effects.

Hypotension related to methylidopa usually occurred early during treatment, over two thirds of the reported episodes occurring within four days of starting treatment, although some were reported as late as the 36th day of treatment (Fig. 1). The most common time for methylidopa related hypotension to be observed was between 24 and 72 hours after commencing treatment.

The frequency of all adverse effects (both

Adverse reactions to methyldopa with particular reference to hypotension

D H Lawson, MD, FRCP (Ed)*

D Gloss, MS, MPH

H Jick MD

Waltham Mass

Methyldopa is widely used in the treatment of all forms of hypertension. After an initial period in which it was thought to act by inhibiting dopa decarboxylase in sympathetic nerves it is now generally accepted to mediate its effect by a direct action on the brain.¹

Side effects from this drug are often troublesome. Johnson and colleagues² reported their occurrence in 72 per cent of recipients, the major problems being weight gain and drowsiness occurring

during long term therapy. Subsequently Pritchard and associates³ reported that 20 per cent of patients receiving this drug had to discontinue treatment because of side effects. The majority of reported side effects appear to be dose related,⁴ leading to the suggestion that an upper limit of 3 grams should be placed on the daily dose of methyldopa.⁵

The present report provides details of the adverse effects of methyldopa as seen in a large comprehensive drug surveillance program which monitors consecutive admissions to medical wards in university teaching hospitals. In particular the information available on the occurrence of hypotension during methyldopa therapy is analyzed in depth.

Patients and methods

The Boston Collaborative Drug Surveillance Program uses nurse monitors to collect information on consecutive admissions to medical wards in teaching hospitals in participating centers in seven countries. The information obtained includes routine demographic details, a history of past medication use, together with precise details of all medications prescribed during the patient's stay in hospital. Data collected include, dose, route, frequency, starting and stopping indications for the drug. Where a patient develops any undesired or unintended effects attributed to the drug, a detailed evaluation of the effect is undertaken by the attending physician and a clinical pharmacologist. For the present report only those adverse effects deemed to be definitely or probably due to methyldopa are included. A record is kept of the results of certain routine laboratory tests taken on admission and up to four discharge diagnoses. Greater details of the

From the Boston Collaborative Drug Surveillance Program, Boston University Medical Center and the Department of Clinical Pharmacology, Royal Infirmary Glasgow, Scotland.

Received for publication Nov 9 1977.

Accepted for publication Jan 16 1978.

Reprint requests: Dr H Jick, Boston Collaborative Drug Surveillance Program, 400 Totten Pond Rd, Waltham, Mass 02154.

Present address: Royal Infirmary Glasgow, Scotland.

The Boston Collaborative Drug Surveillance Program has been supported by the National Institute of General Medical Sciences (Grant No 1 R01 GM23430 01) and in part by grants from the United States Food and Drug Administration (Grant No 1 R01 FD00920 01), the Canadian Health Protection Branch, the Israeli Ministry of Health, the Hadassah Medical Organisation, the Kupat Holim Auckland Hospital, Auckland, New Zealand, Roger Williams General Hospital (Brown University, NIGMS Grant No GM 165 39 02) and the Scottish Home and Health Department. The hospitals which have participated in the ongoing part of the Boston Collaborative Drug Surveillance Program are: Boston, Massachusetts—Lemuel Shattuck Hospital, Peter Bent Brigham Hospital, Boston City Hospital, Veterans Administration Hospital, Massachusetts General Hospital and University Hospital, Providence; Rhode Island—Roger Williams General Hospital; Syracuse, New York—State University Hospital of the Upstate Medical Center; Tucson, Arizona—Arizona Medical Center; Richmond, Virginia—Virginia Commonwealth University Hospital; Canada—St Joseph's Hospital, London, Ontario; Israel—Hadassah Hebrew University Hospital, Jerusalem; Beilinson Medical Center, Petah Tikva; Asaf Harofeh Hospital, Zerlin; and Rambam University Hospital, Haifa. New Zealand—Auckland Hospital, Auckland; and Hutt Hospital, Wellington. Scotland—Western Infirmary and Stobhill General Hospital, Glasgow. Italy—Desio Hospital, Milan. West Germany—Klinikum Steglitz der Freie Universität Berlin.




Fig 1 Duration of methyldopa treatment in relation to occurrence of hypotension

hypotension was real or due to confounding by age and/or dose. The results showed that the frequency of methyldopa attributed hypotension was indeed related to diastolic blood pressure independently of both age and daily dose (Table VII).

Adverse reactions were not significantly related to sex, survival, admission serum albumin levels, a past history of methyldopa or of diuretic therapy, or concurrent treatment with diuretics. No attempts were made to consider the effects of prior hypotensive therapy with agents other than diuretics or methyldopa, since the available information indicated that this was an extremely complex matter likely to be evaluated satisfactorily only in a clinical trial situation or if greater number of patients were available for study by the present methods.

There was an apparent relationship between admission hematocrit levels and methyldopa toxicity. The mean hematocrit of patients with hypotension attributed to methyldopa was 37.9 (SEM 0.8) per cent as compared to 40 (SEM 0.3) per cent for those with no adverse reactions. However, there was an extremely strong relationship between admission blood urea nitrogen levels and hematocrit. Thus, whereas 74 per cent of patients with hematocrits greater than 40 per cent had admission BUN levels below 25 mg per cent, only 19 per cent of those with hematocrits below 34 per cent were in this group. Similarly, whereas only 4 per cent of those with hematocrits greater than 40 per cent had admission BUN levels above 50 mg per 100 ml, 57 per cent of those with hematocrits below 34 per cent were in this group.

When this confounding relationship between hematocrit and BUN was taken into account, the relationship between hematocrit and methyldopa toxicity disappeared.

Discussion

In this study, an adverse reaction is defined as any undesired or unintended effect attributed to a drug by an attending physician. No strict definitions of events such as drug attributed hypotension were given to the contributing centers. Nevertheless, in practice, where an accurate record of the patient's blood pressure was given, it was usually lower than a systolic of 100 mm Hg or diastolic of 70 mm Hg unless the patient complained of symptoms referable to a sudden drop in pressure, when even a recording of 120/80 mm Hg may have been deemed undesirable. By contrast, some patients may have experienced unrecognized episodes of hypotension. If these were not associated with symptoms which led the staff to actually record their blood pressure, such patients would go unrecorded in this program. In practice, the group of patients studied is one in which a clinically significant fall in blood pressure was recorded and attributed to methyldopa treatment.

The frequency of hypotension was positively related to admission blood urea nitrogen levels and to daily dose of methyldopa, and was negatively related to age and to weight. When the combined effects of these variables was taken into account by multiple stratification, all were found to be significant factors in predicting hypotension. Thus, for example, the risk of hypotension was 3 per cent in patients over the age of 55 years.

Table II Life threatening reactions attributed to methyldopa

Patient	Age/ sex	Diagnosis	Methyldopa daily dose (mg)	Total dose (mg)	Route	Time → AR(d)	Comment	Physician's assessment ¹
1	76/F	Hypertensive heart disease renal failure diabetes mellitus	750	1500	PO	2	Developed severe sinus bradycardia and hypotension (70/40) after two days treatment recovered in 3 days	P
2	46/M	Acute myocardial infarction	750	750	PO	1	Developed severe chest pain and became hypotensive after three 250 mg tabs methyldopa Recovered	P
3	59/M	Chronic glomerulonephritis	500	2500	PO	5	Hypotension (80/40) and marked drowsiness Responded to withdrawal of methyldopa	
4	61/M	Hypertension arteriosclerosis	1000	1000	PO	1	Transient left sided weakness and dysarthria Recovered completely in few days	P
5	43/M	Hypertension nephrosclerosis	1000	6000	PO	■	Developed postural hypotension (100/ 60) accompanied by severe chest pain Recovered without permanent cardiac damage	D
6	33/M	Subarachnoid hemorrhage hypertension	3000	3000	PO	1	After methyldopa and pethidine 75 mg IV became shocked (65/50) drowsy confused and dysarthric for three days Recovered without sequelae	D
7	42/M	Hypertension diabetes mellitus	2000	2000	PO	1	Became hypotensive (70/40) vomited and developed right hemiparesis which failed to respond to treatment	D
8	45/F	Essential hypertension gastric ulcer	2000	2000	IV	1	Found disoriented with hypotension (80/60) and extrapyramidal symptoms Recovered after receiving metaraminol IV infusion	D
9	48/M	Chronic pyelonephritis hypertension	500	500	PO	1	After receiving second dose of methyldopa developed transient left hemiparesis BP not recorded	D

P = drug probably caused reaction D = drug definitely caused reaction

hypotension and others) was related to duration of hospitalization some 11.6 per cent of 880 patients hospitalized for up to 19 days having a reported adverse effect as compared to 2.5 per cent of 187 patients hospitalized for more than 20 days ($X_1 = 25$, $p < 0.01$). The mean duration of hospitalization among reactors was 17.3 (SEM 1.5) days and among non reactors 12.5 (SEM 0.4) days.

The frequency of hypotension, but not of the other adverse effects was significantly related to age, blood urea nitrogen concentration (BUN) on admission to hospital, weight, daily dose of methyldopa, and admission diastolic blood pressure (Table III). There was a strong correlation between age and admission diastolic blood pressure both for the 677 patients who gave a history of taking hypotensive therapy before admission and for the 275 patients who did not take such therapy.

Detailed analysis undertaken to elucidate interactive effects between age, BUN levels and dose in the generation of hypotension showed that the effects of age and of daily dose were present within various strata of BUN levels both separately (Table IV) and together (Table V). Similar analyses to seek interactive effects between weight, BUN and (separately) age and daily dose of methyldopa showed the effects of age and of daily dose to be present both in light and in heavy subjects and to be most marked in those with admission BUN levels below 25 mg/100 ml. By contrast, in patients with elevated admission BUN levels the effect of weight on the frequency of hypotension was largely obscured by those of age and daily dose of methyldopa (Table VI).

Similarly detailed analyses were undertaken to determine whether the apparent effect of admission diastolic blood pressure on the frequency of

Table IV Frequency of hypotension in relation to admission blood urea nitrogen levels * age and daily dose (separately)

	Blood urea nitrogen (mg /100 ml)							
	0-24		25-49		50+		Total	
	No	%	No	%	No	%	No	%
Age (years)								
<49	19/18 = 10.4		14/45 = 31.1		20/83 = 24.1		53/310 = 17.1	
50-69	21/310 = 6.8		9/118 = 7.6		12/19 = 15.2		42/507 = 8.3	
70+	5/115 = 4.4		6/69 = 8.7		2/14 = 14.3		13/198 = 6.6	
Daily dose (G)								
<1	19/396 = 4.8		11/139 = 7.9		13/101 = 12.9		43/636 = 6.8	
1-1.9	17/154 = 11.0		6/59 = 10.2		14/57 = 24.6		37/270 = 13.7	
2+	9/57 = 15.8		12/34 = 35.3		7/18 = 38.9		28/109 = 25.7	

In 5 patients (4.8 per cent) the admission blood urea nitrogen level was not recorded

per cent of recipients in this series. This is less than has been reported by other workers¹ and is likely to be a substantial underestimate of the true frequency in part because drowsiness is less troublesome and indeed less noticeable in hospitalized patients as compared to ambulant subjects and in part because hospitalized patients may receive a wide variety of other drugs which can cause drowsiness and hence be incriminated in preference to methyldopa. Likewise depression which has been reported during methyldopa therapy³ could be under recorded in the present study.

Extrapyramidal signs following treatment with methyldopa have been recorded by some workers⁴ and are presumably due to inhibition of the dopa decarboxylase in the brain. In the present series only four patients (0.4 per cent) manifested clinically significant Parkinsonism.

Gastrointestinal upsets were rare following methyldopa therapy as were rashes. Moreover a detailed analysis of the entire Boston Collaborative Drug Surveillance Program data base failed to reveal any allergic reactions which could have been due to methyldopa which went unrecognized by the attending physicians.

Hemolytic anemia consequent upon methyldopa use has been well documented⁵ and occurred in two patients in the present series both of whom had received the drug prior to hospitalization. No information is available on the prevalence of positive Coombs tests in the current series of patients although the expected frequency appears to be between 5 and 30 per cent of long term users.

Table V Frequency of hypotension in relation to admission blood urea levels, age and daily dose of methyldopa

Daily dose (G)	Age (years)	Admission Blood Urea Nitrogen levels (mg /100 ml)					
		0-25		26+		Total	
		No	%	No	%	No	%
≤1	≤55	11/145	7.6	13/95	13.7	24/240	10.0
	55+	8/251	3.2	11/145	7.6	19/396	4.8
1+	≤55	15/113	13.3	25/9	31.6	40/192	20.8
	55+	11/98	11.2	14/89	15.7	25/187	13.4

Methyldopa related fever has been reported previously⁶ and was observed in two patients in this study. In one further patient mild pyrexia associated with alteration in liver function test results was attributed to methyldopa. This drug has been suspected of causing liver damage for some time^{2,7} and although it appears to be a rare complication drug induced hepatitis should be kept in mind as a possible cause of upset liver function in such patients.

Clinically significant bradycardia is rare after therapy with methyldopa and was reported in only two patients in the present series.

Disturbance in libido is a common complication of hypotensive therapy more so with the ganglion blocking drugs guanethidine and hexamethidine than with methyldopa. Nevertheless it is rarely reported voluntarily to medical attendants¹ and is likely to be least troublesome in a group of hospitalized patients. The fact that one patient in this study who had received the drug

Table III Factors predicting methyldopa toxicity

	Frequency of hypotension (%)	Frequency of other reactions (%)
Age		
Less than 50 years	54/321 = 16.8	12/321 = 3.7
50-59 years	23/272 = 8.5	9/272 = 3.3
60-69 years	19/261 = 7.3	10/261 = 3.8
70+ years	14/213 = 6.6	8/213 = 3.8
Blood urea nitrogen*		
Less than 25 mg/100 ml	45/607 = 7.4	20/607 = 3.3
25-49 mg/100 ml	29/232 = 12.5	10/232 = 4.3
50+ mg/100 ml	34/176 = 19.3	8/176 = 4.5
Weight†		
Less than 150 lb	44/321 = 13.7	18/321 = 5.6
150-174 lb	22/229 = 9.6	8/229 = 3.5
175+ lb	26/302 = 8.6	8/302 = 2.6
Daily dose		
Less than 1 G	44/660 = 6.7	16/660 = 2.4
1-1.9 G	38/280 = 13.6	18/280 = 6.4
2-2.9 G	18/70 = 25.7	3/70 = 4.3
3+ G	10/57 = 17.5	2/57 = 3.5
Admission diastolic blood pressure‡		
Less than 105 mm Hg	36/494 = 7.3	16/494 = 3.3
106-115 mm Hg	16/188 = 8.5	7/188 = 3.7
116+ mm Hg	58/380 = 15.3	16/380 = 4.2

*Value not recorded in 52 patients (4.8%)

†Value not recorded in 215 patients (20%)

‡Value not recorded in 5 patients (0.5%)

who had admission blood urea nitrogen levels below 25 mg per 100 ml and were given up to one gram of methyldopa daily. By contrast the risk was increased tenfold (to 32 per cent) among patients aged 55 years or less whose admission BUN level was greater than 25 mg per 100 ml and who received more than one gram of methyldopa daily.

Similarly, the risk of hypotension was 3 per cent in heavy subjects over the age of 55 years who had normal BUN levels on admission as compared to 24 per cent in lighter, younger subjects with elevated admission BUN levels. In heavy subjects with normal BUN levels receiving up to 1 gram methyldopa daily, the frequency of hypotension was 11 per cent, whereas in light subjects with elevated BUN levels receiving more than 1 gram daily, the comparable frequency was 24 per cent.

The relationship between dose and hypotension is readily explicable and has previously been noted by other workers including Smirk* who observed a large inter individual variation in the

dose necessary to produce hypotension. Methyldopa is known to be excreted in part in the urine and to be retained in the body in patients with renal failure,⁸ thus the relationship between increasing effect and increasing impairment of renal function as manifest by elevated admission BUN levels is also readily explicable. Similarly, the effect of patient weight can be explained on a pharmacological basis. The effect of age which was observed independently of dose weight diastolic blood pressure, and BUN concentration is less readily explicable on a pharmacological basis. It is unlikely to be due to observational differences between young and old patients since there was a gradual increase in the frequency of hypotension with decreasing age at all dose levels examined and this was present in both light and heavy patients in those with mild and those with severe hypertension, and in those with normal and elevated BUN levels. The most likely explanation of this finding is that hypertension occurring in younger patients is more labile than in the elderly, and hence more prone to fall after a given stimulus than in elderly subjects. Whatever the explanation, the finding is impressive since there was a threefold difference in the frequency of reported hypotension at all dose levels in the young relative to the elderly patients.

An initial association between hematocrit and hypotension appeared impressive insofar as patients with an admission hematocrit of less than 30 per cent had a twofold greater prevalence of methyldopa related hypotension than did those with hematocrits above 45 per cent. Nevertheless this difference was almost entirely a reflection of severity of renal impairment rather than any effect of anemia on the kinetics of methyldopa per se—a possibility which deserved careful consideration in a drug which may produce hemolytic anemia⁹ particularly since anemia has been shown to significantly alter the pharmacokinetic handling of other drugs such as gentamicin.¹⁰ Neither hypotension nor the other adverse effects of methyldopa were related to sex, admission serum albumin levels, previous exposure to methyldopa or diuretic drugs, or current exposure to diuretics. Moreover, the other adverse effects (predominantly drowsiness) were unrelated to age, weight, daily dose of methyldopa and only marginally related to admission BUN levels.

Drowsiness was reported in only two and a half

REFERENCES

- 1 Goodman L S and Gilman A The pharmacological basis of therapeutics 5th edition New York London 1970 MacMillan & Co
- 2 Johnson P Kitchin A H Lowther C P and Turner R W II Treatment of hypertension with methyldopa Br Med J 1 133 1966
- 3 Pritchard B N C., Johnston A W Hill A D and Rosenheim M L Bethandine guanethidine and methyldopa in the treatment of hypertension a within patient comparison Br Med J 1 135 1968
- 4 Smirk H Hypotensive action of methyldopa Br Med J 1 146 1963
- 5 Bulpitt C J and Dollery C T The drug treatment of hypertension Practitioner 207 43 1971
- 6 Jick H Miettinen O E Shapiro S Lewis C P Sukind V and Stone D Comprehensive drug surveillance JAMA 213 1455 1970
- 7 Miller R R and Greenblatt D J Drug effects in hospitalized patients New York 1976 John Wiley & Sons Inc
- 8 Myhre E Brodwall F K Stenbæk U and Hansen T Plasma turnover of methyldopa in advanced renal failure Acta Med Scand 191 343 1972
- 9 Worlitz S M Carstairs K C., and Dacie J V Autoimmune hemolytic anemia associated with methyldopa therapy Lancet 2 135 1966
- 10 Ruff L J and Jackson C G Pharmacology of gentamicin in man J Infect Dis 124 (Suppl 124) 98 1971
- 11 Bulpitt D J and Dollery C T Side effects of hypotensive agents evaluated by a self administered questionnaire Br Med J 3 430 1973
- 12 Oates J A Seligman A W and Clark M A R Latent efficacy of guanethidine methyldopa and pargline as antihypertensive agents N Engl J Med 273 729 1965
- 13 Pariente D Methyldopa and depression Br Med J 4 110 1973
- 14 Fleming H A Methyldopa and depression Br Med J 4 232 1973
- 15 Groden H M Parkinsonism occurring with methyldopa treatment Br Med J 1 1001 1973
- 16 Peaston M J T Parkinsonism associated with alpha methyldopa therapy Br Med J 2 168 1964
- 17 Arndt K A and Lick H Rates of cutaneous reactions to drugs JAMA 135 918 1976
- 18 Nes A S Adverse reactions and interactions limiting the use of antihypertensive drugs Am J Med 58 493 1975
- 19 Tester Dalderup C H M. Hypotensive drugs in side Effects of Drugs Annual 1 1977 ed Dukas M N G Amsterdam 1977 Excerpta Medica
- 20 Clontz G E and Saslaw S Methyldopa fever Arch Intern Med 122 445 1968
- 21 Maddrey W L and Boitnott J K Severe hepatitis from methyldopa Gastroenterology 68 301 1975
- 22 Hoyumpa A M and Connell A M Methyldopa hepatitis Am J Dig Dis 18 13 1973
- 23 Safatine L and Lowell D Methyldopa toxicity Gastroenterology 70 149 1976

Information for authors

Most of the provisions of the Copyright Act of 1976 became effective on January 1 1978. Therefore all manuscripts must be accompanied by the following statement signed by each author: The undersigned author(s) transfers all copyright ownership of the manuscript entitled (title of article) to The C V Mosby Company in the event the work is published. The author(s) warrants that the article is original is not under consideration by another journal and has not been previously published. Authors will be consulted when possible regarding republication of their material.

Table VI Frequency of hypotension in relation to admission blood urea levels, age, weight, and daily dose of methyldopa

	Weight*	Admission blood urea nitrogen levels (mg/100 ml)					
		0-25		25+		Total	
		No	%	No	%	No	%
Age (years)							
≤55	≤150	10/56 = 17.6		15/62 = 24.2		25/118 = 21.2	
55+		9/107 = 8.4		9/84 = 10.7		18/191 = 9.4	
≤55	150+	14/161 = 8.7		18/86 = 20.9		32/247 = 13.0	
55+		5/160 = 3.1		10/93 = 10.8		15/253 = 5.9	
Daily dose (G)							
≤1	≤150	10/113 = 8.8		8/80 = 10		18/193 = 9.3	
1+		9/50 = 18.0		16/66 = 24.2		25/116 = 21.6	
≤1	150+	6/204 = 2.9		11/106 = 10.4		17/310 = 5.5	
1+		13/117 = 11.1		17/73 = 23.3		30/190 = 15.8	

Value not recorded in 215 patients (20 per cent)

Table VII Frequency of hypotension in relation to age, admission diastolic blood pressure and daily dose of methyldopa

Admission diastolic BP (mm Hg)	Daily dose (G)	Age (years)					
		≤55		55+		Total	
		No	%	No	%	No	%
≤110	≤1	8/112 = 7.1		8/228 = 3.5		16/340 = 4.7	
	1+	10/63 = 15.9		12/99 = 12.1		22/162 = 13.6	
110+	≤1	16/137 = 11.7		12/180 = 6.7		28/317 = 8.8	
	1+	31/138 = 22.5		13/105 = 12.4		44/243 = 18.1	

Value not recorded in 5 patients (0.5 per cent)

prior to hospitalization was reported to suffer from this side effect dose not give an accurate picture of its prevalence in the outpatient setting

The present survey of over 1 000 consecutive recipients of methyldopa indicates that to minimize the risk of hypotension, therapy with this drug should be initiated cautiously especially in younger patients in the non obese in those presenting with severe hypertension, and in those with impairment of renal function as manifest by raised BUN levels on admission

Summary

Of 26 294 consecutive patients monitored in a comprehensive drug surveillance program, 1067 (4 per cent) received methyldopa for treatment of hypertension. Adverse reactions attributed to methyldopa were reported in 149 patients (14 per cent), the most frequent being hypotension. Life

threatening adverse effects were reported in nine patients (6 per cent of reactors)—the major problems being hypotension associated in several patients with signs of cardiac or cerebral ischemia. Hypotension attributed to methyldopa was more frequent in younger patients in those with uremia in lighter subjects and in those receiving a high daily dose. Marked interaction between these factors was demonstrated and eightfold differences in the frequency of hypotension were observed in different sub groups of methyldopa recipients. Adverse effects other than hypotension were reported infrequently and did not correlate well with the previously mentioned factors.

The findings suggest that methyldopa therapy should be commenced cautiously in younger patients in the non obese, and in those with impairment of renal function as manifest by elevated blood urea nitrogen levels.

range of normal venous oxygen saturations were depressed and there was a step up in oxygen saturation in the right atrium. During the latter part of the procedure the oxygen saturations became increased and were similar in both ventricles, in the pulmonary artery and in the ascending aorta. Pulmonary arterial systolic pressure was 30 mm Hg higher than aortic systolic pressure. Cineangiograms revealed bidirectional shunting at the atrial level shunting from the pulmonary artery to the aorta via a large ductus arteriosus and persistent filling of pulmonary veins for 15 seconds after the pulmonary artery injection. Neither the left atrium nor other channels of venous drainage opacified. The diagnosis was pulmonary venous obstruction probably due to common pulmonary vein atresia. The infant was maintained on a respirator with 100 per cent oxygen but he developed severe bradycardia and died nine hours later.

Autopsy findings

GROSS The lungs were normally located and well aerated. The pericardial sac contained a small amount of clear yellow fluid. The heart examined with the lungs intact was slightly enlarged but the external configuration was not otherwise remarkable. The right atrium and right ventricle were normal. A patent ductus arteriosus measuring 3 mm in diameter arose from the pulmonary artery of the same size and communicated with the distal segment of the aortic arch. Two pulmonary veins drained each lung and formed a common thin walled channel of 2 mm internal diameter which ended blindly near the right atrial wall. No accessory pulmonary veins were identified. Radiographic examination with contrast injection confirmed that the small channel formed a cul de sac and did not connect with either the right or left atrium and that there was no other connection of pulmonary veins. The left atrium was abnormally small and the mitral valve the left ventricle and the aorta were normal.

MICROSCOPIC Significant microscopic findings were found only in the lungs. Pulmonary tissue was mature but with the alveolar spaces incompletely expanded and some areas revealed atelectasis and capillary congestion. There were no areas of inflammation or hyaline membrane. The lymphatic vessels were dilated but apparently only to the extent as is usually seen in the lungs of stillborn infants.



Fig. 1a. Chest radiograph, Case 1. See text for description.

CASE 2 A 3.4 kilogram boy was delivered normally after a 44 week uncomplicated pregnancy to a quadrigravida quadruparous 33 year old woman. A first cousin had died with complete transposition of the great arteries. A nuchal cord was present. Apgar scores on the infant were 7 at one minute and 10 at three minutes. No resuscitative measures were necessary, however at eight minutes the infant quickly became cyanotic and cyanosis persisted despite oxygen therapy. At age two days he was admitted to the intensive care nursery by transfer from another hospital. Despite oxygen and bicarbonate therapy arterial blood gases on admission were pH 7.14, PO_2 38 mm Hg and base excess -16.

The baby appeared moribund with flaccidity, nasal flaring and grunting respirations at a rate of 84 per minute. There was diffuse cyanosis, however the head and face were purple secondary to the nuchal cord. The precordium was overactive; the first and second sounds were single and a murmur was not audible. All peripheral pulses were bounding in type and the liver edge was 3 cm below the right costal margin.

The chest roentgenogram revealed a bell configuration, pulmonary vascular congestion with mild hyperaeration and a normal heart size (Fig. 1b). The electrocardiogram was abnormal; signs of right ventricular hypertrophy included a QRS axis of 165 degrees, a high voltage QR pattern in Lead V_1 , and an rS ratio in Lead V_6 of 0.4.

The infant was digitalized, intravenous infusions of dextrose water and sodium bicarbonate were continued. An abbreviated cardiac catheterization was performed (Table I); he was resusci-

Common pulmonary vein atresia

Marion K Ledbetter MD *

David H Wells, MD **

Dean M Connors, MD ***

Madison Wisconsin

Atresia of the common pulmonary vein (CPVA) occurs rarely, to our knowledge this condition has been previously reported in only eleven infants.¹⁻⁶ The number of cases is larger if one includes those having a minor accessory pulmonary vein which drains into the systemic circulation.⁷⁻⁹ Two additional babies with a premortem diagnosis of isolated CPVA, and a third example of CPVA associated with the asplenia syndrome and other cardiac anomalies form the basis of this report. One baby had histological evidence of acute pericarditis, probably a fortuitous perinatal event unrelated to pathogenesis of the cardiac anomaly. These three infants had been admitted to the Intensive Care Nursery of St Marys Hospital Medical Center, Madison Wisconsin where they underwent cardiac catheterization, and subsequently postmortem examination.

This report emphasizes (1) the developmental relationship of the pulmonary and bronchial venous circulations together with the manner in which the collateral circulation may help to sustain life for a brief period (2) clinical and laboratory features upon which the diagnosis of atresia of the common pulmonary vein may be based, and (3) clinical implications of pathophysiology which must be considered so that diagnostic, medical, and surgical measures may be

pursued. Despite the fact that our patients and all other reported infants with atresia of the common pulmonary vein have not survived, a successful result of medical and surgical treatment is considered feasible.

Case reports

Case 1 A 24 hour term son of a 19 year old primigravida mother weighed 3.2 kilograms when admitted to the intensive care nursery from a nearby hospital. The gestational history had been uneventful. The one minute Apgar score of 9 had declined to 5 at the five minute evaluation. Cyanosis and distressed breathing had persisted since shortly after birth. Aspiration of a profuse amount of mucus from the airways and ventilation with 100 per cent oxygen did not diminish the cyanosis. The chest had a wide anterior-posterior diameter. Respirations were shallow at a rate of 88 per minute. The heart rate was 165 per minute, both heart sounds were loud and single without murmurs. The peripheral pulses were normal and the liver was not palpable.

Initial arterial blood gases with the infant breathing 100 per cent oxygen on the respirator were pH 7.19, PO_2 13 mm, and PCO_2 62 mm Hg. Dextrose water and bicarbonate were administered intravenously. The electrocardiogram was abnormal for age 24 hours with evidence of right ventricular hypertrophy, the QRS axis was deviated far rightward to 180 degrees, a high voltage QR pattern occurred in Lead V_1 , and the rS ratio in V_4 was 0.7. The chest roentgenogram revealed diffuse pulmonary congestion with an indistinct cardiac border (Fig 1a).

Cardiac catheterization was performed while the infant breathed 100 per cent oxygen in a vinyl hood (Table I). Venous pressure was at the upper

from the Departments of Pediatric Cardiology and Pathology St Marys Hospital Medical Center and the Department of Neonatology University of Wisconsin Madison Wisconsin.

Received for publication Nov 11 1977

Accepted for publication Jan 16 1978

Reprint requests Marion K Ledbetter MD Dept of Pediatric Cardiology Nicolet Clinic 411 Lincoln St Neenah Wisconsin 54956

Dept of Pediatric Cardiology St Marys Hospital Medical Center

Fellow Neonatology University of Wisconsin Madison present address Greenville Hospital System Greenville South Carolina

Dept of Pathology St Marys Hospital Medical Center




Fig 1b Chest radiograph Case 2 See text for description

ry pulmonary veins were present. Bronchial vessels were identified but were not abnormally prominent and communicated normally.

MICROSCOPIC Evidence of an active pericarditis was a conspicuous feature. The pericardium was thickened, edematous and infiltrated with numerous polymorphonuclear leukocytes and lesser numbers of eosinophils and lymphocytes. Some of the sections revealed a small amount of granular lipid material associated with this inflammatory lesion. The infiltrate was confined to the outer aspects of the myocardium and did not involve the endocardium at any point. Special stains for lipid infiltration of the heart and for fungi and bacteria were negative. The blebs noted over the external surfaces of the lungs were dilated lymphatic vessels.

Case 3 A 39 kilogram girl was delivered uneventfully to a primigravid 19 year old mother after an uncomplicated 40 week gestation. The one minute Apgar score was 8 and the five minute score was 9. At three hours the baby became cyanotic. The heart sounds were most prominent in the right hemithorax; the first and second sounds were single and a murmur was not audible. Roentgenograms (Fig 1c) revealed dextrocardia and indistinct cardiac borders but not severe pulmonary congestion. Many Howell-Jolly bodies were seen in the peripheral blood smear. The electrocardiogram was compatible with




Fig 1c Chest radiograph Case 3 See text for description

mirror image inversion of the atria and sinus rhythm. High voltage RS complexes in right precordial leads and a QR configuration from Leads V through V indicated right ventricular hypertrophy. The findings were diagnostic for the asplenia syndrome.

Cardiac catheterization was performed while the baby breathed 100 per cent oxygen (Table I). The inferior vena cava joined the cardiac silhouette at the usual location in the right paravertebral area and there was a left superior vena cava. The right atrium in a mid heart location was arterialized. Right ventricular and aortic systolic pressures were equal. A dilated right ventricle on the right heart border gave origin to a large transposed aorta in the levoposition. Pulmonary arteries smaller than the aorta were filled only from a patent ductus arteriosus. Pulmonary venous drainage was not identified although cine filming was continued for 45 seconds after the pulmonary arteries opacified. At nine days a Blalock shunt was performed with anastomosis of the right subclavian artery to the right pulmonary artery but the baby was not improved and died the following day.

Autopsy findings

GROSS The spleen was absent. The cardiac atria were inverted with the limbus of the fossa ovalis identified in the left sided chamber. Anomalous consisted of a large atrial septal defect of the ostium secundum type, a dilated and heavily trabeculated single anatomic right ventricle

Table I Cardiac catheterization

Site	Case 1 (age 1 day)†				Case 2 (age 3 days)†				Case 3 (age 2 days)†			
	PH	Oxygen saturation %	Pressure (mm Hg)		PH	Oxygen saturation %	Pressure (mm Hg)		PH	Oxygen saturation %	Pressure (mm Hg)	
			S/D*	Mean			S/D*	Mean			S/D	Mean
SVC	7.30	53	6/1	3	—	—	—	—	7.44	59	3/0	1
IVC	—	55	6/4	5	—	—	—	—	—	—	4/2	3
RA	—	70	7/3	5	6.83	19	16/9	12	—	84	5/0	?
LA	7.32	60	8/0	4	6.95	27	21/12	16	—	—	—	—
RV	—	61.88‡	88/0	—	—	21	62/0	ed = 12	—	82	87/0	ed = 5
LV	7.33	89‡	6.2/0	—	7.12	32	—	—	—	—	—	—
PA	—	91‡	87/27	65	—	—	—	—	—	—	—	—
Ao	7.33	93‡	54/34	46	—	—	39/25	—	7.40	79	58/57	70

Abbreviations: S/D = Systolic diastolic; ed = end diastolic

†All infants breathed 100 per cent oxygen. Cases 1 and 3 by a vinyl hood and Case 2 by a respirator.

‡Saturations were obtained near the end of procedure.

All peak venous pulses were a waves.

Table II Clinical features of common pulmonary vein atresia

History & physical examination

- 1 Usually term infants
- 2 Immediate condition at birth may be good
- 3 Cyanosis and distressed breathing ensue quickly
- 4 No cardiac murmur
- 5 Severe acidosis
- 6 Congestive heart failure

Electrocardiogram

Right ventricular hypertrophy

Roentgenogram

- 1 Heart size normal; border may be indistinct
- 2 Severe pulmonary congestion

Cardiac Catheterization

- 1 Oxygen saturation low and similar in all chambers
- 2 Pulmonary artery pressure suprasystemic
- 3 Elevated venous pressure

Angiocardiogram

- 1 Right to left shunting via foramen ovale and ductus arteriosus
- 2 Pulmonary veins opacify but not other structures of venous drainage

the pulmonary artery via a large ductus arteriosus, a small left atrium, and a small left ventricle. Pulmonary veins opacified distinctly behind the heart, but continued filming for 65 seconds revealed no opacification of the left atrium or any anomalous venous channels. The diagnosis was common pulmonary vein atresia. Surgical correction was planned but he died three hours later.

Autopsy findings

GROSS Both lungs were moderately emphysematous and blebs were seen over the external surfaces. The left lung was partially collapsed. There was no excess of pleural fluid. The pericardial sac contained 5 ml of blood-tinged fluid. The epicardial surface was smooth and glistening without abnormal openings or hemorrhage. The heart chambers and arteries were normally oriented. A huge pulmonary artery arose from a dilated and hypertrophied right ventricle. The aortic arch was approximately one third the size of the pulmonary artery and the aortic isthmus was hypoplastic. The ductus arteriosus was approximately equal in size to the pulmonary artery and communicated with a large descending aorta. An oval atrial septal defect just above a normal foramen ovale measured 2 × 1 cm. The tricuspid valve was structurally normal but dilated. The left atrium and left ventricle were small. Small pulmonary veins drained all lobes of the lungs but did not join the left atrium at any point. They formed a closed tube-like blind venous chamber measuring 2 × 1 cm. No access

tated throughout breathing 100 per cent oxygen via an endotracheal tube on a respirator. Venous pressure was severely elevated and blood in all chambers was hypoxemic. He was hypotensive; right ventricular systolic pressure exceeded aortic pressure. Cineangiograms in the right and left atria and right ventricle revealed bidirectional shunting across the atrial septum, tricuspid regurgitation, filling of the descending aorta from

such as occurs in the tetralogy of Fallot. Conversely the pulmonary circulation is engorged and the arterial pressure is elevated to a suprasystemic level when obstruction occurs beyond the pulmonary capillary bed as in CPVA and TACPv with obstruction. Histologic evidence indicates that there can be retrograde flow of capillary blood into the pulmonary arteries when the pulmonary veins are totally occluded. Wagenvoort and colleagues¹⁴ described dilated bronchopulmonary arteries and bronchopulmonary venous anastomoses in cases of aortic atresia with prematurely closed foramen ovale, a condition hemodynamically similar to CPVA. Marchand and associates¹⁵ found that the bronchial arteries in the full term fetal lung and in the atelectatic lung of the stillborn infant have a calibre nearly equal to that of adult vessels. Since the direction of flow in bronchopulmonary arterial anastomoses will depend upon the pressure relationship in the pulmonary and bronchial arteries, pulmonary capillary blood may enter the systemic circulation via bronchial arteries as well as bronchial veins.

The basis for clinical and laboratory features of CPVA. Cardiorespiratory function is severely altered immediately after birth in infants with CPVA and causes their early death. Thus it is urgent to establish the diagnosis quickly. Clinical and laboratory findings are summarized in Table II. Obstructed pulmonary venous drainage may be suspected in infants who do not require resuscitation at birth but who quickly develop cyanosis and severe respiratory distress. They have electrocardiographic evidence of right ventricular hypertrophy. The roentgenographic appearance of severe pulmonary congestion is similar in CPVA, TACPv with obstruction and idiopathic pulmonary lymphangiectasis. The heart size is normal radiographically but the borders may be obscured. Dilated pulmonary lymphatics have been demonstrated in all previous cases of CPVA. They are more abundant in the connective tissue containing peribulbar tissues than in the lobules. The elevated pulmonary venous pressure causes this pulmonary lymphangiectasis and much edema fluid is conveyed by these channels into the systemic circulation. Rywlin and Fojaco¹⁶ postulated that the lymphangiectasis is a retained lymphatic pattern of the fetal lung. This massive dilation of pulmonary lymphatic

vessels was appreciated histologically only in our Case 2, the infant with severely elevated venous pressure.

Pulmonary artery pressure has been elevated to suprasystemic levels in all patients with CPVA upon whom cardiac catheterization was performed. However, in our case three systolic pressures in the right ventricle and aorta were equal. The oxygen saturation is severely depressed and usually is similar in all heart chambers. The fetal pattern of blood flow persists with right to left shunting through the foramen ovale and the ductus arteriosus. Angiocardiography reveals persistent filling of pulmonary veins after the pulmonary artery injection, but the left atrium and any other cardiac chamber or veins do not opacify.

The anomalies of pulmonary artery atresia and TACPv occur commonly in the congenital asplenia syndrome as described by Ruttenberg and colleagues.¹⁷ Our Case 3 had both pulmonary artery and pulmonary vein atresia so that blood flowed to and from the lungs via the ductus arteriosus and intrapulmonary collateral vessels. She could not have benefited from the Blalock shunt. Most reported cases of CPVA have not had other anomalies and the gestational age has been 40 or more weeks.

Clinical problems related to pathophysiology. The tenuous existence of infants with CPVA indicates that surgical anastomosis of the vertebral pulmonary vein to the left atrium should be performed immediately after diagnostic studies have been completed. A surgical procedure utilizing extracorporeal circulation may allow some correction of the severe acidosis and hypoxemia. Deep hypothermia and circulatory arrest may be necessary for the surgery to be accomplished. Despite postmortem evidence of an adequate anastomosis for pulmonary venous flow into the left atrium, no infants with this problem have survived either when the ductus arteriosus was ligated or when it was left patent.¹ Factors compromising pulmonary ventilation and perfusion would be expected to persist following surgery. Hypoperfusion of the lungs and severe acidosis will have suppressed formation of surfactant.¹⁸ Deficiency of this antiatelectatic factor in addition to residual pulmonary congestion and lymphangiectasis will limit ventilation. Hypoxemia and acidosis are stimuli for persistent

which gave rise to a large levotransposed aorta, pulmonary valve atresia, and a patent ductus arteriosus. The right lung with four lobes and a trilobed left lung drained into a verticle pulmonary vein which ended blindly, it did not communicate with the left atrium or any other chamber or vessel. The mid line liver was predominantly left sided. The inverted gastrointestinal tract revealed the stomach on the right and the cecum and appendix on the left. Stenosis of the ureters at the bladder junction had caused bilateral hydronephrosis and hydroureter.

MICROSCOPIC The lungs revealed foamy macrophages and inflammatory cells, the features being those of aspiration pneumonia. The lymphatic vessels were dilated and showed no significant morphologic alteration.

Comments

Developmental relationship of pulmonary and bronchial venous circulations Lucas and colleagues¹ described the common embryologic features of total anomalous connection of pulmonary veins (TACPV) and CPVA. Development of the pulmonary venous system is recounted briefly. The splanchnic plexus of the primordial lung buds drains into somatic veins (the cardinal system) and abdominal visceral veins (the umbilico-vitelline system). Pulmonary veins do not connect with the heart until the common pulmonary vein has formed as a diverticulum on the sinoatrial chamber of the heart. As the left atrium grows it incorporates the common pulmonary vein so the individual pulmonary veins connect separately with the left atrium.

TACPV or CPVA results if the common pulmonary vein either fails to develop, undergoes involution, or becomes atretic. If one of these processes occurs at a time when connections of cardinal veins or umbilico-vitelline veins to the splanchnic plexus have persisted, there is TACPV. If all of these primitive venous channels have already undergone the normal involution process prior to failure of the common pulmonary vein to develop and join with the pulmonary veins then the anomalous entity is CPVA. Developmental failure of the common pulmonary vein from whatever cause is a pathogenetic feature of both conditions.

Shaner² and Marchand and co-workers¹⁰ described the intimate developmental relation-

ship of the bronchial and pulmonary circulations. Bronchial veins also are formed from the splanchnic plexus and drain into cardinal veins. There are two groups of bronchial veins. The deep or true bronchial veins are intrapulmonary vessels related to the bronchi; they drain into the pulmonary veins or the left atrium. The other group is the pleurohilar veins which drain the subpleural and hilar structures of the lungs. They exist when the cardinal system breaks up and drain into the azygous vein on the right and into the accessory hemiazygous or innominate vein on the left. These pleurohilar veins communicate freely with the pulmonary veins and provide a decompression mechanism when pulmonary venous pressure is raised.

In the first report of CPVA, Lucas and collaborators¹ described the clinical and pathological features of three infants who survived for 28, 22, and three days. Their patient who died three days following surgery had a large bronchial vein originating in the right pulmonary hilus and entering the esophageal wall to connect with esophageal varices. However, their other two infants and most of the other cases reported did not have such grossly dilated bronchial venous channels.

Bronchial-pulmonary vascular anastomoses are known to be present in health and in congenital and acquired disease states at the arterial, venous, and capillary levels.¹¹ Von Hayek¹² estimated that under normal conditions the extensive anastomoses of bronchial and pulmonary arteries and veins are capable of conveying approximately one tenth of the postnatal pulmonary circulation. This figure compares with the fraction of the right ventricular stroke volume which normally perfuses the fetal lung.¹³ Therefore the prenatal pulmonary circulation in CPVA may not have been compromised and there may have been little stimulus for retention of large fetal bronchopulmonary channels for collateral flow. However, survival of infants with CPVA for longer than several minutes indicates that a significant amount of arterialized blood must flow to the systemic circulation.

The usual stimulus for growth and proliferation of bronchial arteries and dilation of bronchopulmonary anastomotic channels in congenital heart disease is pulmonary oligemia and hypotension, an effect of precapillary obstruction.

Prolonged benefit of nitroglycerin ointment on exercise tolerance in patients with angina pectoris

Dennis L. Karsh MD
Richard E. Umbach MD
Lawrence S. Cohen MD FACC
Rene A. Langou MD FACC
New Haven Conn

Sublingual nitroglycerin has long been a mainstay in the symptomatic treatment of angina pectoris due to occlusive coronary disease. In addition it has been shown to have salutary effects on myocardial metabolism and left ventricular function in stress states such as exercise and pacing induced tachycardia.^{1,2} The major drawback to its use as prophylaxis for exercise induced angina is its relatively short duration of action. In 1955 Davis and Wiesel demonstrated that cutaneously applied nitroglycerin ointment could produce clinically satisfactory results in patients with intractable angina pectoris. In the majority of patients regular use of 2 per cent nitroglycerin ointment brought about a significant decrease in the number of daily angina episodes. It was not until 1974 however that a more systematic study of the duration and effect of nitroglycerin ointment upon exercise performance was undertaken.

The present report will describe the effects of nitroglycerin ointment upon exercise capacity in 10 patients with chronic stable angina pectoris, documented coronary disease, and positive stress electrocardiography.

Materials and methods

Patients The patient population consisted of nine men and one woman, aged 43 to 69 years

From the Department of Internal Medicine, Cardiology Section, Yale University School of Medicine, New Haven, Conn.

Received for publication No. 15, 1977

Accepted for publication Jan. 19, 1978

Reprint requests to Rene A. Langou MD, Cardiology Section, Yale University School of Medicine, 333 Cedar Street, 87 LMP, New Haven, Conn. 06510

with a mean age of 53 years. Criteria for admission to the study included:

1. A history of typical, stable angina pectoris for at least 1 year.

2. Documentation of an unequivocally positive exercise test during at least two graded exercise stress tests—a response was considered to be positive only if it included both symptoms of angina pectoris and electrocardiographic manifestations of myocardial ischemia (a minimum of 1.0 mm horizontal or downsloping ST segment depression at peak exercise with a resting electrocardiogram showing normal ST segments).

3. Angiographically proven coronary artery disease or a well documented myocardial infarction.

Nine of the patients had a greater than 70 per cent reduction in the internal lumen of at least two of the major coronary arteries. The remaining patient had sustained a well documented anteroapical myocardial infarction two years prior to this study. All patients had Class II or III angina pectoris by the functional classification of the New York Heart Association. All cardiac medications except for propranolol were discontinued one week prior to the study. Four patients taking propranolol were kept on an unchanging dose during the entire study. None of the patients had previously received nitroglycerin ointment.

The preparations studied were 2 per cent nitroglycerin ointment (Nitro-Bid, Marion Laboratories) and an inert ointment as a placebo. The selection of the appropriate study dosage of nitroglycerin ointment was individually determined for each patient during a two week period prior to the exercise test studies. The amount of nitroglycerin

constriction of small pulmonary arteries. Physiologic involution of the muscle coat surrounding these vessels, as in those of normal infants, can occur only gradually after hypoxemia has been alleviated.

Despite these remarks of pessimism, early recognition of CPVA followed by aggressive medical and surgical treatment may result in a successful outcome. Presumably the pathophysiologic changes occur only postnatally.

REFERENCES

- Lucas R V Jr, Woolfrey B F, Anderson R C, Lester R G and Edwards J E. Atresia of the common pulmonary vein. *Pediatrics* 29:729 1962.
- Nakb A, Moller J H, Kanjuh V I, Edwards J E. Anomalies of the pulmonary veins. *Am J Cardiol* 20:77 1967.
- Levine M A, Moller J H, Amplatz K and Edwards J E. Atresia of the common pulmonary vein. Case report and differential diagnosis. *Am J Roentgenol* 100:322 1967.
- Rywin A M and Fojaco R M. Congenital pulmonary lymphangectasis associated with a blind common pulmonary vein. *Pediatrics* 41:931 1968.
- Hawker R E, Celefman J, Gengos D C, Cartmill T B and Bowdler M H. Common pulmonary vein atresia. Premortem diagnosis in two infants. *Circulation* 46:368 1972.
- Delisle G, Ando M, Calder A L, Zuberbuhler J R, Rothenmacher S, Alday L E, Mangini O, Van Praagh R and Van Praagh R. Total anomalous pulmonary venous connection. Report of 93 autopsied cases with emphasis on diagnostic and surgical considerations. *AM HEART J* 91:99 1976.
- Modv G T and Folger G M Jr. Atresia of the common pulmonary vein. Report of one case. *Pediatrics* 54:62 1974.
- Hastreiter A R, Paul M H, Molthan M E and Miller R A. Total anomalous pulmonary venous connection with severe pulmonary venous obstruction. *Circulation* 25:916 1962.
- Shaner R F. The development of the bronchial veins, with special reference to anomalies of the pulmonary veins. *Anatomical Record* 140:159 1961.
- Marchand P, Gilbroy J C and Wilson V H. An anatomical study of the bronchial vascular system and its variations in disease. *Thorax* 5:207 1950.
- Harris P and Heath D. *Human pulmonary circulation*. Baltimore 1962. The Williams & Wilkins Co.
- Von Hayek H. *The human lung*. N Y., 1960. Hafner Publishing Co.
- Rudolph, A. The changes in the circulation after birth: their importance in congenital heart disease. *Circulation* 41:343 1970.
- Wagenvoort C A, Wagenvoort N and Becker E A. The effect of obstructed pulmonary venous blood flow on the development of alternative pathways in the lung. *J Pathol* 107:21 1971.
- Ruttenberg H D, Neufeld H N, Cucus R V Jr, Carey L S, Adams P Jr, Anderson R C and Edwards J E. Syndrome of congenital cardiac disease with asplenia. *Am J Cardiol* 13:387 1964.
- Boncheck L II, Anderson R P, Wood J A, Chapman R D and Starr A. Intracardiac surgery with extracorporeal circulation in infants. *Ann Thorac. Surg* 17:280 1974.
- Chu J, Clements J A, Cotton E K, Kjaus M H, Sweet A Y and Tooley W H. Neonatal pulmonary ischemia. I. Clinical and physiological studies. *Pediatrics* 40:709 1967.
- Merritt T A and Farrell P M. Diminished pulmonary lecithin synthesis in acidosis. Experimental findings as related to the respiratory distress syndrome. *Pediatrics* 57:32 1976.
- France N E and Brown R J D. Congenital pulmonary lymphangectasis. Report of 11 examples with special reference to cardiovascular findings. *Arch Dis Child* 46:528 1971.
- Naeije R L. Arterial changes during the perinatal period. *Arch Pathol* 71:121 1961.




Fig 1 Changes in total duration of exercise (minutes) after administration of nitroglycerin ointment. Large solid dots indicate mean value, solid bars indicate standard errors.




Fig 2 Changes in total duration of exercise (minutes) after administration of placebo ointment. Large solid dots indicate mean values, solid bars indicate standard errors.

repeated at 1 and 3 hours after administration of the ointment. Five patients received the active preparation first followed by the placebo, the other five received the placebo first followed by the active preparation. The end point of the stress test was again both angina and > 1 mm ST depression. After 48 hours stress testing was repeated at 1 and 3 hours after application of the alternate preparation.

Because it was recognized that the nitroglycerin ointment and placebo might be distinguishable by the patient and the physician on the basis of hemodynamics and symptomatic effects, the preparations were applied by a physician other than the one administering the stress test. Patients were not told that one preparation was inert but merely that the two preparations were different from each other. All patients were fully informed concerning the nature and details of this study including possible unpleasant or adverse effects which they might experience. Written consent was obtained for all patients after approval of the protocol by the Human Investigation Committee of Yale University School of Medicine.

Data analysis. Effort tolerance (ET) was calculated in the following manner: work load (watts) was multiplied by the duration of exercise (minutes) for each stage of the exercise protocol.




Fig 3 Changes in total duration of exercise (minutes) after administration of nitroglycerin and placebo ointments. These changes are expressed as mean values \pm standard errors.

Effort tolerance was expressed as the sum of this product for all stages of the protocol completed by the patient. Duration of exercise (DE) was expressed in minutes and represented total duration of the stress test. Heart rate (HR) was calculated by computer determination and electrocardiographic printouts. Blood pressure (BP) was measured using the standard cuff technique.

Table I Clinical data of patient population

Patient no and initials	Age	Sex	Duration of angina	Clinical classification (NYHA)	Previous MI	Medication	ECG	Coronary arteriography	No of coronary vessels diseased
1 J A	68	M	3 yrs	II	No	None	T waves	yes	0
2 M M	51	M	2 yrs	II	No	Propranolol	T waves	yes	2
3 J M	59	M	15 yrs	III	No	Propranolol	WNL	yes	3
4 F R	65	M	10 yrs	II	1972	Propranolol	IWMI	yes	0
5 N A	47	M	5 yrs	II	1974	None	IWMI	yes	3
6 L V	51	M	4 yrs	II	No	None	WNL	yes	3
7 J A	43	F	8 yrs	II	1973	None	IWMI	yes	3
8 D S	46	M	27 yrs	II	No	None	WNL	yes	3
9 H F	50	M	3 yrs	II	1974	None	ASWMI	no	0
10 J Z	48	M	4 yrs	II	No	Propranolol	T waves	yes	3

Abbreviations ASWMI = anteroapical myocardial infarction ECG = electrocardiogram IWMI = inferior wall myocardial infarction T waves = non specific T wave changes WNL = within normal limits

Table II Summary of significance of changes (P values) during exercise at 1 hr and 3 hrs after the application of nitroglycerin versus placebo ointments

Measurements	Difference (NTG versus placebo)	
	1 hr	3 hrs
Duration of exercise	< 0.025†*	< 0.005†
Effort tolerance	< 0.025†	< 0.005†
Resting heart rate	< 0.01†	NS†
Exercise heart rate	< 0.025†	NS
Resting systolic blood pressure	< 0.01†	< 0.025†
Exercise systolic blood pressure	NS	NS
Exercise double product	NS	NS
Exercise ST segment depression	< 0.05†	< 0.05†

The analysis of variance between nitroglycerin and placebo treatment are provided. The arrows indicate the direction of change between nitroglycerin and placebo ointments at 1 hr and 3 hrs
†Abbreviations NS = not significant

ern ointment which produced either a 10 mm Hg fall in resting blood pressure taken in the sitting position or a 10 beat per minute increase in resting heart rate or both one hour after its application was used as the patient's study dosage. To accomplish dosage titration, a one half inch ribbon of nitroglycerin ointment was applied to the precordium after baselines for blood pressure and heart rate were established. Blood pressure and heart rate were then checked at 10, 20, 30, 45, and 60 minutes after the applica-

tion. If the minimum required changes in blood pressure, heart rate, or both were not observed at one hour then the ointment remaining on the chest was thoroughly washed off. This procedure was repeated the following day with one half inch ribbon increments until the study dosage for that patient was established. In this study the average nitroglycerin ointment dosage was 2.4 inches (range 2 to 3 inches). The ointment was applied to an area of approximately 3 × 6 inches on the anterior chest wall and covered with plastic wrap.

Protocol After admission to the study, all 10 patients underwent a control graded bicycle ergometer stress test to a level sufficient to produce both anginal pain and > 1 mm ST segment depression. Exercise was performed on an upright Schwinn bicycle ergometer. Each patient pedaled steadily at 50 to 60 rpm at all levels of work. Exercise was begun at 25 watts (125 Kpm) and then increased by 25 watts (125 Kpm) every 4 minutes. The Frank orthogonal lead system plus a CC₁ lead (bipolar chest lead right V₁ to left V₁) were used and monitored continuously on an Avionics Model 3000 recorder. The electrocardiogram, heart rate, and blood pressure were recorded every minute throughout the exercise, at peak exercise and at 1, 3, 5, and 10 minutes into the recovery period.

After the control stress test, nitroglycerin ointment or a placebo was applied in a random double blinded manner and stress testing was




Fig 6 Changes in effort tolerance (watt minutes) after administration of nitroglycerin and placebo ointments. These changes are expressed as mean values \pm standard errors.

application from 877 ± 129 watt minutes in the control study to 947 ± 129 watt minutes ($p < 0.05$). However at 3 hours no significant change was observed (Fig 5). Of note only one patient of 10 exercised to a higher work load with the placebo. However the total increase of effort tolerance produced by nitroglycerin ointment was significantly greater than with the placebo (Fig 6 and Table II).

Heart rate at both rest and peak exercise was unchanged from the control measurements with both preparations at 1 and 3 hours (Table III). Nitroglycerin ointment produced a consistent reduction in resting systolic blood pressure from 123 ± 6 mm Hg in the control state to 108 ± 4 mm Hg at 1 hour ($p < 0.05$) and 102 ± 5 mm Hg at 3 hours ($p < 0.005$) after its cutaneous application. No changes were noted with the placebo (Table III). Systolic blood pressure at peak exercise did not differ significantly from the control stress test with either nitroglycerin or the placebo at 1 hour and 3 hours (Tables III and IV). Nitroglycerin ointment also produced a significant reduction of resting diastolic blood pressure at 1 hour and 3 hours; no changes were observed after application of placebo ointment. The peak exercise diastolic blood pressure did not differ in the control stress test after nitroglycerin or after the placebo (Table III). Double product at peak exercise was the same during the control stress test after nitroglycerin or after placebo ointments (Tables III and IV).

Exercise induced ST segment depression provided an objective index of myocardial ischemia. Nitroglycerin ointment produced a statistically




Fig 7 Changes in exercise induced ST segment depression (millimeters) after the administration of nitroglycerin and placebo ointments. These changes are expressed in mean values \pm standard errors.

significant decrease in the magnitude of ST segment depression at peak exercise after 1 hour and 3 hours of its application. The control stress test revealed 2.2 ± 0.3 mm ST segment depression which diminished to 1.8 ± 0.3 mm at 1 hour and 1.8 ± 0.29 mm at 3 hours ($p < 0.05$) with nitroglycerin ointment. Placebo ointment did not produce any change in exercise induced ST segment depression (Fig 7 and Tables II and IV).

Discussion

The present study documents the ability of nitroglycerin ointment to produce an enhancement of exercise tolerance lasting up to 3 hours in patients with documented coronary artery disease and stable angina pectoris. This occurs at a higher heart rate and a lower blood pressure level than with the placebo. Because of the opposing direction of changes of its two components the double product was not significantly affected (Tables II and IV). The degree of myocardial ischemia estimated by the magnitude of exercise induced ST segment depression was also significantly reduced by nitroglycerin ointment for at least 3 hours (Tables II and IV).

The hemodynamic effects of nitroglycerin ointment at rest and during exercise are consistent with those reported by several earlier investigators.⁴ However, several aspects of this study deserve comment.

It can be noted that resting heart rate 1 hour and 3 hours after application of nitroglycerin ointment did not change which differs from the findings reported in other studies.^{4,5} Propranolol




Fig 4 Changes in effort tolerance (watt minutes) after administration of nitroglycerin ointment. Large solid dots indicate mean values, solid bars indicate standard errors.

ST segment deviation during exercise was considered abnormal if the ST segment depressed more than 1 mm in three consecutive beats measured at least 60 msec after the J point in at least one of the four leads recorded. The electrocardiographic baseline from which ST segment depression was measured was the preceding PR interval. All patients had a normal ST segment in the pre exercise electrocardiographic recordings.

Data were analyzed using the Student's *t* test for paired and unpaired observations and by crossover analysis of variance between the two treatments.

Results

The patient population and clinical data are summarized in Table I. Nitroglycerin ointment produced a statistically significant improvement in the total duration of exercise both at 1 and 3 hours after administration. Exercise duration (mean \pm SE) increased from 137 ± 14 minutes




Fig 5 Changes in effort tolerance (watt minutes) after administration of placebo ointment. Large solid dots indicate mean values, solid bars indicate standard errors.

in the control stress test to 168 ± 14 minutes at 1 hour after nitroglycerin ($p < 0.001$) and 163 ± 12 minutes at 3 hours ($p < 0.001$). The values for 1 and 3 hours did not differ significantly (Fig 1). The duration of exercise 1 and 3 hours after administration of placebo is shown in Fig 2. Duration of exercise did increase from a control of 137 ± 14 minutes to 152 ± 12 at 1 hour ($p < 0.05$), however at 3 hours there was no significant difference from the control. In comparing the total duration of exercise after nitroglycerin ointment to that after the placebo (Fig 3, Table II) there was a significant increase after nitroglycerin ointment at 1 and 3 hours.

In addition, eight of the 10 patients were able to exercise to a higher workload after application of nitroglycerin ointment. To quantify this, a score representing total effort tolerance was used in the manner described above. Effort tolerance increased significantly in response to nitroglycerin ointment from 877 ± 129 watt minutes in the control period to 1165 ± 173 watt minutes at 1 hour ($p < 0.001$). Effort tolerance was still significantly higher than control at 3 hours after nitroglycerin application 1040 ± 137 ($p < 0.001$) (Fig 4). The placebo produced a statistically significant increase in effort tolerance 1 hour after

in this study were typical angina pectoris and > 1 mm ST segment depression on the electrocardiogram. The peak exercise double product, an index of myocardial oxygen demand, remained unchanged at 1 hour and 3 hours after application of nitroglycerin ointment when it was compared to the control or to the placebo values. It must be noted however that patients performed higher levels of external work measured as duration of exercise and exercise tolerance (Tables II and IV) before they reached the established end points of our protocol. This dissociation between internal (oxygen demand) and external work (exercise tolerance) is due in part to the sustained hemodynamic effects of nitroglycerin upon peripheral circulation (Table III).

Over all myocardial ischemia was evaluated in our study by the magnitude of exercise induced ST segment depression. When compared to the control stress tests or to the placebo stress tests, exercise ST segment depression was significantly reduced 1 hour and 3 hours after nitroglycerin administration. If the index of myocardial oxygen demand in our study was unchanged and the magnitude of myocardial ischemia was reduced, we postulate that there was either an improvement in oxygen supply to the myocardium or a reduction in oxygen consumption. This is not apparent in the double product and therefore does not explain our clinical findings. It is well recognized that a major action of nitroglycerin is predominantly to decrease oxygen demands through its peripheral effect on venous capacitance and arteriolar resistance.¹ It is still controversial whether significant coronary vasodilatation occurs in patients with coronary artery disease and angina pectoris following the administration of nitroglycerin. Although it has been stated that nitrates cause coronary vasodilatation,² intracoronary arterial administration of nitroglycerin fails to alleviate angina induced by atrial pacing while sublingual nitroglycerin relieves angina presumably by its peripheral effects.³ Studies on total,⁴ regional,^{5,6} and subendocardial,⁷ coronary blood flow have yielded contradictory results. Some authors⁸ state that nitroglycerin while leaving total myocardial blood flow unchanged increases subendocardial blood flow in normal and ischemic regions of the ventricle thus minimizing the severity of myocardial ischemia. The reduction in exercise induced ST segment depression observed in our patients after the application of

nitroglycerin ointment could represent this phenomenon. However, the alternative explanation is that a major reduction in oxygen consumption has occurred in our patients after the administration of nitroglycerin ointment which is not reflected in the double product. Several studies have demonstrated a significant reduction of left ventricular filling and the consequent reduction in wall tension after the administration of nitroglycerin.

Clinical use of nitroglycerin ointment. There is no accepted value for maximal efficacy or maximal duration of action for a nitrate. Although the degree and duration of improvement in exercise tolerance after the administration of nitrates may increase when larger doses of the drug are administered, there are physiologic limits of nitrate dosage that should not be exceeded because of potentially adverse effects. For these reasons we examined the effects of a dose of nitroglycerin effectiveness by purely arbitrary criteria. For each individual patient the amount of nitroglycerin ointment which produced a 10 mm Hg fall in resting systolic blood pressure or a 10 beat per minute rise in resting heart rate or both one hour after the application of the active preparation was used as the test dosage. It was difficult to predict how much ointment would produce the desired hemodynamic effects. Our average dose was 24 inches (range 2 to 48 inches). The protocol for dose titration avoided potential side effects of nitroglycerin overdose and our patients did not experience dizziness or orthostatic symptoms. Nitroglycerin ointment was applied over a substantial area of skin on the chest wall (6 × 48 inches). Because there is some evidence that a given dose applied over a smaller surface area may result in smaller and less predictable hemodynamic changes,⁹ the total surface area of 36 square inches was used. Data concerning the time course of transcutaneous nitroglycerin absorption are lacking, presumably the duration of improvement in exercise tolerance produced by nitroglycerin ointment reflects the rate of entry of the drug into the circulation.

Clinical implications. Topical application of nitroglycerin as an ointment has been known for a long time but only recently has there been much interest in its use. Hemodynamic effects persisting for 3 to 6 hours have been reported.^{10,11} Thus and two previous studies^{12,13} convincingly demonstrate improved exercise tolerance from 1

Table III Summary of hemodynamic effects of exercise before and after nitroglycerin and placebo ointments (mean \pm Standard Error)

	HR	SBP	DBP	DP (HR \times SBP)
<i>Control</i>				
Resting	77.5 \pm 4.3	123 \pm 6	78 \pm 3	967.8 \pm 9.3
Peak exercise	123.4 \pm 6.5	162 \pm 13	69 \pm 6	2048.7 \pm 285.9
3 min post exercise	83.8 \pm 3.5	117 \pm 4	76 \pm 2	915.9 \pm 58.8
<i>NTG 1 hr</i>				
Resting	74.7 \pm 3.6	108 \pm 4	67 \pm 3	809.9 \pm 57.3
Peak exercise	134.0 \pm 7.0	152 \pm 7	71 \pm 4	2074.6 \pm 187.5
3 min post exercise	90.8 \pm 4.5	100 \pm 5	66 \pm 4	901.3 \pm 53.6
<i>NTG 3 hrs</i>				
Resting	80.7 \pm 4.2	102 \pm 5	69 \pm 3	831.5 \pm 7.0
Peak exercise	132.1 \pm 7.4	152 \pm 9	65 \pm 3	2050.0 \pm 208.3
3 min post exercise	91.1 \pm 5.6	105 \pm 6	65 \pm 4	973.7 \pm 88.5
<i>Placebo 1 hr</i>				
Resting	69.3 \pm 3.4	114 \pm 5	74 \pm 3	804.6 \pm 69.7
Peak exercise	121.8 \pm 7.7	153 \pm 13	70 \pm 4	1935.9 \pm 300.6
3 min post exercise	83.6 \pm 5.4	113 \pm 6	72 \pm 3	948.9 \pm 81.4
<i>Placebo 3 hrs</i>				
Resting	75.2 \pm 4.2	113 \pm 6	72 \pm 3	887.8 \pm 88.5
Peak exercise	126.6 \pm 7.3	155 \pm 12	71 \pm 3	2005.7 \pm 27.5
3 min post exercise	85.3 \pm 4.6	115 \pm 6	71 \pm 3	987.8 \pm 85.9

Abbreviations: DBP = diastolic blood pressure (mm Hg); DP = double product (mm Hg \times min⁻¹); HR = heart rate (beat per minute); NTG = nitroglycerin ointment; SBP = systolic blood pressure (mm Hg).

Table IV Summary of significance of changes (P values) at rest and during exercise between the control state and after nitroglycerin and placebo ointment

Measurements	NTG†		Placebo	
	1 hr	3 hrs	1 hr	3 hrs
Duration of exercise	< 0.01†	< 0.01†	< 0.05†	NS
Tolerance	< 0.01†	< 0.01†	< 0.05†	NS
Resting heart rate	NS	NS	NS	NS
Exercise heart rate	NS	NS	NS	NS
Resting systolic blood pressure	< 0.05†	< 0.05†	NS	NS
Exercise systolic blood pressure	NS	NS	NS	NS
Exercise double product	NS	NS	NS	NS
Exercise ST segment depression	< 0.05†	< 0.05†	NS	NS

Significant changes from control studies by the Student t test are identified by the appropriate p value. The arrows indicate the direction of change.

†Abbreviations: NTG = nitroglycerin; NS = not significant.

was not discontinued in four patients who were receiving it prior to the study (Patients No. 2, 3, 4, and 10). Their doses were maintained unchanged throughout the entire investigational period. It is very probable that the beta adrenergic blockade achieved in our patients prevented the expected

increase in heart rate. It is unclear why our patients were able to exercise longer and at a higher work load 1 hour after the application of the inert ointment (Fig. 2 and Table IV). It is possible that during the study a conditioning effect occurred but it is unlikely that this factor played an important role, because all patients had only two previous exercise tests which were terminated by the appearance of angina and ST segment depression prior to entering the study. Furthermore, these exercise tests were terminated at the same work load and double product. In addition, the application of nitroglycerin ointment was done in a randomized manner which would minimize any significant effect produced by early exercise conditioning. Perhaps the most plausible explanation for this phenomenon was a placebo effect due to patient belief that an active medication rather than an inert ointment was being used. In any case, the increase was significantly less than that seen with nitroglycerin ointment (Table II).

Mechanism of beneficial effects of nitroglycerin ointment. Analysis of the hemodynamic and electrocardiographic changes before and during exercise suggests that nitroglycerin ointment may produce its effects through changes both in myocardial oxygen demand and in myocardial oxygen supply. The exercise stress test end points

in this study were typical angina pectoris and > 1 mm ST segment depression on the electrocardiogram. The peak exercise double product, an index of myocardial oxygen demand, remained unchanged at 1 hour and 3 hours after application of nitroglycerin ointment when it was compared to the control or to the placebo values. It must be noted however that patients performed higher levels of external work measured as duration of exercise and exercise tolerance (Tables II and IV) before they reached the established end points of our protocol. This dissociation between internal (oxygen demand) and external work (exercise tolerance) is due in part to the sustained hemodynamic effects of nitroglycerin upon peripheral circulation (Table III).

Over all myocardial ischemia was evaluated in our study by the magnitude of exercise induced ST segment depression. When compared to the control stress tests or to the placebo stress tests, exercise ST segment depression was significantly reduced 1 hour and 3 hours after nitroglycerin administration. If the index of myocardial oxygen demand in our study was unchanged and the magnitude of myocardial ischemia was reduced, we postulate that there was either an improvement in oxygen supply to the myocardium or a reduction in oxygen consumption. This is not apparent in the double product and therefore does not explain our clinical findings. It is well recognized that a major action of nitroglycerin is predominantly to decrease oxygen demands through its peripheral effect on venous capacitance and arteriolar resistance.^{1,2} It is still controversial whether significant coronary vasodilatation occurs in patients with coronary artery disease and angina pectoris following the administration of nitroglycerin. Although it has been stated that nitrates cause coronary vasodilatation,^{3,4} intracoronary arterial administration of nitroglycerin fails to alleviate angina induced by atrial pacing,⁵ while sublingual nitroglycerin relieves angina presumably by its peripheral effects.^{6,7} Studies on total,^{8,9} regional,^{10,11} and subendocardial¹² coronary blood flow have yielded contradictory results. Some authors state that nitroglycerin while leaving total myocardial blood flow unchanged increases subendocardial blood flow in normal and ischemic regions of the ventricle thus minimizing the severity of myocardial ischemia. The reduction in exercise induced ST segment depression observed in our patients after the application of

nitroglycerin ointment could represent this phenomenon. However the alternative explanation is that a major reduction in oxygen consumption has occurred in our patients after the administration of nitroglycerin ointment which is not reflected in the double product. Several studies have demonstrated a significant reduction of left ventricular filling and the consequent reduction in wall tension after the administration of nitroglycerin.

Clinical use of nitroglycerin ointment. There is no accepted value for maximal efficacy or maximal duration of action for a nitrate. Although the degree and duration of improvement in exercise tolerance after the administration of nitrates may increase when larger doses of the drugs are administered, there are clear physiologic limits of nitrate dosage that should not be exceeded because of potentially adverse effects. For these reasons we examined the effects of a dose of nitroglycerin effectiveness by purely arbitrary criteria. For each individual patient the amount of nitroglycerin ointment which produced a 10 mm Hg fall in resting systolic blood pressure or a 10 beat per minute rise in resting heart rate or both one hour after the application of the active preparation was used as the test dosage. It was difficult to predict how much ointment would produce the desired hemodynamic effects. Our average dose was 2.4 inches (range 2 to 3 inches). The protocol for dose titration avoided potential side effects of nitroglycerin overdose and our patients did not experience dizziness or orthostatic symptoms. Nitroglycerin ointment was applied over a substantial area of skin on the chest wall (6×6 inches). Because there is some evidence that a given dose applied over a smaller surface area may result in smaller and less predictable hemodynamic changes,¹³ the total surface area of 36 square inches was used. Data concerning the time course of transcutaneous nitroglycerin absorption are lacking, presumably the duration of improvement in exercise tolerance produced by nitroglycerin ointment reflects the rate of entry of the drug into the circulation.

Clinical implications. Topical application of nitroglycerin as an ointment has been known for a long time but only recently has there been much interest in its use. Hemodynamic effects persisting for 3 to 6 hours have been reported.^{14,15} This and two previous studies^{1,2} convincingly demonstrate improved exercise tolerance from 1

to 3 hours after its administration. Thus, nitroglycerin ointment is one of the nitrate preparations proven to have long lasting effects on angina pectoris.²¹ Clinical settings where it may be of value could include patients with nocturnal angina pectoris, as prophylactic nitrate preparation in patients with chronic exertional angina pectoris, or in patients with unstable angina pectoris. It must be realized, however, that the cutaneous form of nitroglycerin is a potent and long acting agent, and there is always danger of delivering a large amount of active nitrate to the circulation over a relatively short period of time thereby producing significant symptoms of overdosage.

Summary

The effect on exercise tolerance of 2 per cent nitroglycerin ointment and placebo was studied on the bicycle ergometer in 10 patients with angina pectoris, a positive exercise test, and documented coronary artery disease. After a control stress test sufficient to produce angina pectoris and > 1 mm horizontal or downsloping ST segment depression, nitroglycerin ointment or placebo was administered in a random double blinded manner and stress tests were repeated at 1 hour and 3 hours. End points for the exercise stress test were angina and 1 mm ST segment depression. Forty eight hours later, stress tests were again performed at 1 hour and 3 hours after administration of the alternate preparation. Work load (watts) plus duration of exercise (minutes) were calculated for each stage of the bicycle ergometer protocol and exercise tolerance was expressed as the sum of this product for all stages completed.

Nitroglycerin ointment produced a significant increase in exercise tolerance from a control value of 877 ± 129 watt minutes to 1165 ± 173 watt minutes at 1 hour and 1040 ± 137 watt minutes at 3 hours. Duration of exercise also increased significantly after nitroglycerin ointment from 137 ± 14 minutes in the control stress test to 168 ± 14 minutes at 1 hour and 163 ± 12 minutes at 3 hours. Exercise induced ST segment depression decreased significantly at 1 hour and 3 hours after nitroglycerin ointment but not after the placebo.

The placebo produced a small, but statistically significant, increase in exercise tolerance and duration of exercise at 1 hour after its application. However, these increases were significantly small

er than the one observed after nitroglycerin ointment. No changes were observed 3 hours after application of the placebo. Double product at peak exercise was unchanged after nitroglycerin or placebo ointments at 1 hour and 3 hours.

These data indicate that nitroglycerin ointment is capable of producing an improvement in exercise tolerance and a reduction in the magnitude of exercise induced ST segment depression up to 3 hours in patients with coronary artery disease and angina pectoris.

REFERENCES

1. Parker J O, Ledwith J R, West R O et al. Reversible cardiac failure during angina pectoris. *Circulation* 39: 745, 1969.
2. Chuang M A, West R O, and Parker J O. Influence of nitroglycerin on myocardial metabolism and hemodynamics during angina induced by atrial pacing. *Circulation* 45: 1044, 1972.
3. Davis J A, and Wiesel B H. The treatment of angina pectoris with a nitroglycerin ointment. *Am J Med Sci* 230: 259, 1955.
4. Reichel N, Goldstein R E, Redwood D R et al. Sustained effects of nitroglycerin ointment in patients with angina pectoris. *Circulation* 50: 348, 1974.
5. Parker J O, Augustine R J, Burton J R et al. Effect of nitroglycerin ointment on the clinical and hemodynamic response to exercise. *Am J Cardiol* 38: 167, 1976.
6. Armstrong P W, Mathew M T, Boromand K et al. Nitroglycerin ointment in acute myocardial infarction. *Am J Cardiol* 38: 474, 1976.
7. Parratt J W. Pharmacological approaches to the therapy of angina. *Arch Drug Res* 9: 103, 1974.
8. Mason D T, and Braunwald E. The effects of nitroglycerin and amyl nitrate on arteriolar and venous tone in the human forearm. *Circulation* 32: 755, 1965.
9. Ginsini G G. Quantitative angiography: the measurement of coronary vasomobility in the intact animal and man. *Chest* 60: 522, 1971.
10. Sones M F, and Shirey E K. Cine coronary arteriography. *Mod Concepts Cardiovasc Dis* 31: 735, 1967.
11. Ganz W, and Marcus H S. Failure of intracoronary nitroglycerin to alleviate pacing induced angina. *Circulation* 46: 880, 1972.
12. Ganz W, and Marcus H S. Changes in myocardial oxygen consumption during relief of pacing induced angina by nitroglycerin (Abstr.). *Am J Cardiol* 31: 133, 1973.
13. Leubs E D, Cohen A, Zaleski E J et al. Effect of nitroglycerin, nitroglycerin isoptin and papaverine on coronary blood flow in man measured by coincidence counting technique and rubidium 84. *Am J Cardiol* 17: 535, 1966.
14. Gorlin R, Brachfeld N, MacLeod C et al. Effect of nitroglycerin on the coronary circulation in patients with coronary artery disease or increased left ventricular work. *Circulation* 19: 705, 1959.
15. Fam W M, and McGregor M. Effects of coronary vasodilator drugs on retrograde flow in areas of chronic myocardial ischemia. *Circ Res* 15: 355, 1964.
16. Horwitz L D, Gorlin R, Taylor W J et al. Effects of nitroglycerin on regional myocardial blood flow in coronary artery disease. *J Clin Invest* 50: 1578, 1971.

Becker L, D Fortuin N J and Pitt B Effects of
ischemia and antianginal drugs on the distribution of
radioactive microspheres in the canine left ventricle
Circ Res 33: 963 1971

Forman, R Kirk, E H Downey J M et al Nitroglyc-
erin and heterogeneity of myocardial blood flow *J Clin*
Invest 52 905 1973

Meister S G Furr C Feitosa G et al Sustained

hemodynamic effects of nitroglycerin ointment (Abstr)
Am J Cardiol 37 155 1976

20 Taylor W R Forrester J S Magnusson P et al The
hemodynamic effects of nitroglycerin ointment in
congestive heart failure *Am J Cardiol* 38 469 1976

21 Danahy D T and Aronow W H Hemodynamics and
antianginal effects of high dose oral isosorbide dinitrate
after chronic use *Circulation* 56 205 1977

Information for authors

Most of the provisions of the Copyright Act of 1976 became effective on January 1 1978
Therefore all manuscripts must be accompanied by the following statement signed by each
author The undersigned author(s) transfers all copyright ownership of the manuscript
entitled (title of article) to The C V Mosby Company in the event the work is published
The author(s) warrants that the article is original is not under consideration by another
journal and has not been previously published Authors will be consulted when possible
regarding republication of their material

An evaluation of the results of left ventricular aneurysmectomy Use of a simplified method for analysis of the left ventriculogram

Harold Smulyan, MD*
Robert H Eich, MD**
Lewis W Johnson, MD***
Frederick B Parker, MD****
James L Potts, MD*****
Gerald P Tracy, MD*****
Syracuse N Y

Resection of left ventricular aneurysms frequently relieves angina pectoris, systemic embolization, intractable congestive heart failure and arrhythmias.¹⁻³ In order to improve the operative results, attempts have been made to develop preoperative angiographic criteria which will permit better patient selection. This development is dependent on two factors—an improved understanding of the disordered circulatory physiology in patients with ventricular aneurysm, and some objective description of the surgical results. The latter is necessary to determine the validity of any developed preoperative criteria.

Present understanding of cardiac dysfunction due to left ventricular aneurysm depends largely on analyses of the right anterior oblique ventriculogram. This two dimensional figure has usually

been divided into aneurysmal and contractile portions, and measurements from each converted mathematically to volumes of a variety of solid geometrical figures.⁴⁻¹¹ Such conversions assume that the ventriculographic segments approximate the shape of a selected three dimensional figure whose volume is calculable. These assumptions have not been tested experimentally, and if inaccurate, would provide erroneous calculated volumes and functional data, less useful than the two dimensional measurements themselves. Methods have also been described using ventriculographic perimeters and their aneurysmal and contractile sub segments which avoid the need for assumptions of this type.¹⁻¹¹

The results of surgery have been described almost entirely in clinical terms. Most series include a large proportion of patients who have also had coronary artery bypass grafts. The uncertain effects of these grafts on ventricular function invalidate the use of such cases in the study of aneurysmectomy results.

The present study attempts to avoid these difficulties by presenting a series of 23 consecutive patients who have undergone left ventricular antero-apical aneurysmectomy alone. Patients treated with valve replacement or coronary artery bypass grafting were specifically excluded. Seventeen of the 19 surgical survivors underwent follow up cardiac catheterization. A simple method for the two dimensional analysis of both pre and postoperative left ventricular angiograms is described which avoids the assumption that any

From the Departments of Medicine and Surgery, Upstate Medical Center of the State University of New York, Syracuse.

Received for publication Nov. 19, 1977.

Accepted for publication Jan. 10, 1978.

Reprint requests: Harold Smulyan, MD, Dept. of Medicine, Upstate Medical Center, 750 East Adams St., Syracuse, N. Y. 13210.

Professor of Medicine, Dept. of Medicine, Upstate Medical Center of the State University of New York at Syracuse.

* Professor of Medicine, Dept. of Medicine, Upstate Medical Center of the State University of New York at Syracuse.

Associate Professor of Medicine, Dept. of Medicine, Upstate Medical Center of the State University of New York at Syracuse.

Associate Professor of Surgery, Dept. of Surgery, Upstate Medical Center of the State University of New York at Syracuse.

Associate Professor of Medicine, Dept. of Medicine, Upstate Medical Center of the State University of New York at Syracuse.

Fellow in Cardiology, Dept. of Medicine, Upstate Medical Center of the State University of New York at Syracuse.

PI RF 6/25/76
 PRE OPERATIVE
 Aor Root 44cm
 Distal c Area/Aor Root
 T 1 463
 Aneurysm 308
 Non Aneurysm 155
 By spec Area Reduction (%)
 T 102
 Aneurysm 10
 Non Aneurysm 3.3




Fig 1 Example of right anterior oblique ventriculographic outline with division into aneurysmal and nonaneurysmal segments. Preoperative

ventricular segment approximates the shape of a known geometric figure. By these means it was found that errors in preoperative case selection accounted for only some of the postoperative failures. The remainder were explained by intraoperative and postoperative developments which could not have been predicted preoperatively.

Materials and methods

Patients Between May 1970 and March 1976 57 left ventricular aneurysms were resected in this institution. In 23 of these cases the aneurysmectomy was the only surgical procedure; there being no associated coronary artery bypass grafts or valve replacements. These 23 cases form the basis of this report. There were 18 males and five females whose ages ranged between 29 and 71 years at the time of surgery. All patients had had previous anterior wall myocardial infarctions with residual typical electrocardiographic Q waves in the precordial leads.

Every patient had a preoperative cardiac catheterization with left ventriculography in the right anterior oblique projection which demonstrated an aneurysm of the anterior and apical walls. The diagnosis of left ventricular aneurysm depended on the demonstration of aknetic or dyskinetic wall segments, but in a few instances severely hypokinetic segments were also present. Coronary arteriograms were carried out in every instance using multiple views in both right and left anterior oblique projections, and all 23 patients had severe occlusive disease of the left anterior descending coronary artery. In 19 cases this vessel was completely occluded and in four the occlusion was judged to be 75 per cent or

PI RF 6/26/76
 POST OPERATIVE
 Aor c Root 40cm
 Distal c Area/Aor c Root
 Total 308
 Aneurysm 94
 Non Aneurysm 214
 Systolic Area Red c to (%)
 Total 248
 Aneurysm 53
 Non Aneurysm 334




Fig 2 Example of right anterior oblique ventriculographic outline with division into aneurysmal and nonaneurysmal segments. Postoperative

greater. In 17 of the 23 patients coronary artery disease (50 per cent occlusion or greater) was present in vessels other than the left anterior descending coronary artery. Bypass grafts were not utilized in these patients for a variety of reasons, such as insufficiently severe proximal stenosis or because of small distal arterial caliber.

The indications for aneurysmectomy were often multiple in the same patient and included peripheral embolization (3), incapacitating congestive heart failure (21), angina pectoris (8), and ventricular arrhythmias (3).

Left ventricular aneurysmectomy was carried out without coronary artery bypass or other surgical procedures from one month to three years following the myocardial infarction. The procedure was performed under cardiopulmonary bypass utilizing modified hypothermia at 32° C in all cases. The aneurysm was totally excised with the exception of a narrow fibrous rim at its base for suture placement.

There were four in-hospital deaths and 19 long-term survivors. Seven of the survivors underwent repeat follow-up cardiac catheterization on request of their referring physician because of persistent or recurrent symptoms. All of the others were invited to be restudied with the approval of their referring physician for a more precise determination of their postoperative status. Two patients who were symptomatically improved refused restudy, and there were therefore 17 follow-up catheterizations. These repeat cardiac catheterizations were performed between 5 and 44 months postoperatively with an average of 25.3 months.

An evaluation of the results of left ventricular aneurysmectomy Use of a simplified method for analysis of the left ventriculogram

Harold Smulyan, M D *
Robert H Eich, M D **
Lewis W Johnson, M D ***
Frederick B Parker, M D ****
James L Potts, M D *****
Gerald P Tracy, M D *****
Syracuse N Y

Resection of left ventricular aneurysms frequently relieves angina pectoris, systemic embolization, intractable congestive heart failure, and arrhythmias.¹⁻⁶ In order to improve the operative results, attempts have been made to develop preoperative angiographic criteria which will permit better patient selection. This development is dependent on two factors—an improved understanding of the disordered circulatory physiology in patients with ventricular aneurysm, and some objective description of the surgical results. The latter is necessary to determine the validity of any developed preoperative criteria.

Present understanding of cardiac dysfunction due to left ventricular aneurysm depends largely on analyses of the right anterior oblique ventriculogram. This two dimensional figure has usually

been divided into aneurysmal and contractile portions, and measurements from each converted mathematically to volumes of a variety of solid geometrical figures.⁷⁻¹¹ Such conversions assume that the ventriculographic segments approximate the shape of a selected three dimensional figure whose volume is calculable. These assumptions have not been tested experimentally, and if inaccurate, would provide erroneous calculated volumes and functional data less useful than the two dimensional measurements themselves. Methods have also been described using ventriculographic penimeters and their aneurysmal and contractile sub segments which avoid the need for assumptions of this type.¹⁻¹¹

The results of surgery have been described almost entirely in clinical terms. Most series include a large proportion of patients who have also had coronary artery bypass grafts. The uncertain effects of these grafts on ventricular function invalidate the use of such cases in the study of aneurysmectomy results.

The present study attempts to avoid these difficulties by presenting a series of 23 consecutive patients who have undergone left ventricular antero apical aneurysmectomy alone. Patients treated with valve replacement or coronary artery bypass grafting were specifically excluded. Seventeen of the 19 surgical survivors underwent follow up cardiac catheterization. A simple method for the two dimensional analysis of both pre and postoperative left ventricular angiograms is described which avoids the assumption that any

From the Departments of Medicine and Surgery, Upstate Medical Center of the State University of New York, Syracuse.

Received for publication Nov 19 1977.

Accepted for publication Jan 10 1978.

Reprint requests: Harold Smulyan, M D, Dept of Medicine, Upstate Medical Center, 750 East Adams St., Syracuse, N Y 13210.

Professor of Medicine, Dept of Medicine, Upstate Medical Center of the State University of New York at Syracuse.

Professor of Medicine, Dept of Medicine, Upstate Medical Center of the State University of New York at Syracuse.

Associate Professor of Medicine, Dept of Medicine, Upstate Medical Center of the State University of New York at Syracuse.

Associate Professor of Surgery, Dept of Surgery, Upstate Medical Center of the State University of New York at Syracuse.

Associate Professor of Medicine, Dept of Medicine, Upstate Medical Center of the State University of New York at Syracuse.

Fellow in Cardiology, Dept of Medicine, Upstate Medical Center of the State University of New York at Syracuse.

the analysis of pre and postoperative left ventriculograms was chosen so that angiograms from any institution could be used in this study. There was no constant tube to target distance, no calibration grid and therefore no calculable ventricular volumes.

The outline of the ventriculogram images were traced at end systole and at end diastole from sinus beats at least two cycles following the nearest preceding premature ventricular beat. Systolic and diastolic images were not aligned along a common mid aortic root to apex axis, since in the presence of antero-apical aneurysm no distinct apical point could be constantly found. Furthermore there was no evidence that the nonaneurysmal left ventricular segment contracts uniformly about such an axis. The figures were aligned however by superimposing the systolic and diastolic aortic root shadows and irregular portions of the left ventricular perimeter common to both systole and diastole.

In most instances it was possible to find a point on the inferior and anterior ventricular perimeter which clearly demarcated the contractile from the noncontractile segments. These two points were connected by a straight line in systole and diastole thus separating the aneurysmal from nonaneurysmal left ventricular areas (Figs 1 and 2). In a few instances the contractile and aneurysmal perimeters were connected by a relatively long hypokinetic segment. In these cases the mid point of this hypokinetic junction was chosen as the separation point between aneurysm and nonaneurysm sections.

The aneurysmal and nonaneurysmal areas thus defined were measured in both systole and diastole by planimetry and their respective perimeters were delineated using a map measurer. Aneurysm size is also presented as a percentage of the total ventricular area. The percentage reduction in total area, aneurysmal area, nonaneurysmal area and their respective perimeters during systole was also calculated. This calculation is analogous to that of the ejection fraction when ventricular volumes are used.

In order to compare pre and postoperative areas in these noncalibrated ventriculograms the aortic root diameter was considered a reference dimension and assumed not to change significantly between the two studies. All measured areas were converted to ratios using the aortic root




Fig 5 Comparison of preoperative right anterior oblique ventriculographic areas corrected for aortic root diameter and left ventricular end-diastolic pressures in Group 1 and Group 2.

Table 1 Results of ventricular aneurysmectomy Group 2—mean values

Measurement	Preoperative	Postoperative
Ventricular area/aortic root diameter (diastole) (cm)		
Total	39.2	42.3
Aneurysm	11.1	19.5
Non Aneurysm	28.1	22.8
% Systolic area reduction		
Total	19.5	5.4
Aneurysm	3.5	2.9
Non Aneurysm	22.7	6.2

diameter as the denominator and the pre and postoperative ratios were compared.

Statistical analyses were carried out using Student's *t* test for paired and unpaired data.

Results

Clinical results of aneurysmectomy. The patients were divided as described above into two groups. Group 1 included 14 patients who were improved by clinical and catheterization criteria. Only eleven patients in this group were greatly improved and included five who had returned to work, two who were asymptomatic and four others who had only mild residual angina. Two patients of the remaining three had persistent bothersome angina but were included in Group 1 because the congestive heart failure for which they underwent surgery had improved both symptomatically and hemodynamically.




Fig 3 Effects of left ventricular aneurysm resection on right anterior oblique ventriculographic areas corrected for aortic root diameter and on left ventricular end diastolic pressures




Fig 4 Effects of left ventricular aneurysm resection on the per cent reduction during a systole of the right anterior oblique ventriculographic areas and on the percentage of the total area which is aneurysmal

At the time of hospitalization for restudy each patient underwent a complete history physical examination and routine laboratory work which included a chest x ray and ECG. The two patients who refused recatheterization were interviewed by telephone and their referring physicians records were reviewed.

The 23 patients were divided into those who improved postoperatively (Group 1—14 patients) and those who did not (Group 2—nine patients).

In assigning patients to these groups, emphasis was placed on their history, especially relief of preoperative presenting complaints, return to work levels of activity achieved, and satisfaction with the quality of life. The laboratory evaluation used for confirmation of patient referral to the groups included heart size by chest x ray, changes in left ventricular end diastolic pressure and pulmonary artery pressure, but did not include variations in left ventriculographic parameters described below. The addition of laboratory data to symptomatic evaluation was especially valuable in four patients. Two had persistent but not disabling angina postoperatively yet were improved of their preoperative heart failure and a third had multiple symptoms probably noncardiac in origin. These three showed striking improvement in heart size and catheterization findings and were therefore assigned to Group 1. One other patient was symptomatically better but had changed to a life style requiring minimal exertion. Laboratory data in this patient showed no improvement in pulmonary artery pressure, slight increase in left ventricular end diastolic pressure and no improvement in heart size. She was assigned to Group 2.

Group 1, those 14 patients who by symptoms and laboratory evaluation had a good response to surgery were followed for a mean of 25.6 months (range 9 to 44 months). Group 2, those nine patients who had a poor response to surgery, included the four postoperative deaths and the five other patients followed for an average of 21.2 months (range 5 to 34 months).

Catheterization technique. Pre and postoperative catheterizations were carried out by the retrograde arterial technique using either the brachial or femoral approach. Intracardiac pressures were sensed by strain gauges whose outputs were amplified and then recorded on a strip chart recorder. All pressures were referred to mid chest as a zero level. Left ventriculograms were analyzed only in the right anterior oblique (30 degrees) projection although many had left anterior oblique views as well. The right heart and pulmonary artery were catheterized in the usual fashion and cardiac output was measured using the standard Fick or indocyanine green indicator dilution technique.

Analysis of the right anterior oblique left ventriculogram. The method to be described for

the analysis of pre and postoperative left ventricular volumes was chosen so that angiograms from any institution could be used in this study. There was no constant tube to target distance, no calibration grid, and therefore no calculable ventricular volumes.

The outline of the ventriculogram images were traced at end systole and at end diastole from sinus beats at least two cycles following the nearest preceding premature ventricular beat. Systolic and diastolic images were not aligned along a common mid aortic root to apex axis since in the presence of antero-apical aneurysm no distinct apical point could be constantly found. Furthermore, there is no evidence that the nonaneurysmal left ventricular segment contracts uniformly about such an axis. The figures were aligned however by superimposing the systolic and diastolic aortic root shadows and irregular portions of the left ventricular perimeter common to both systole and diastole.

In most instances it was possible to find a point on the inferior and anterior ventricular perimeter which clearly demarcated the contractile from the noncontractile segments. These two points were connected by a straight line in systole and diastole, thus separating the aneurysmal from nonaneurysmal left ventricular areas (Figs 1 and 2). In a few instances the contractile and aneurysmal perimeters were connected by a relatively long hypokinetic segment. In these cases the mid point of this hypokinetic junction was chosen as the separation point between aneurysm and nonaneurysm sections.

The aneurysmal and nonaneurysmal areas thus defined were measured in both systole and diastole by planimetry and their respective perimeters were delineated using a map measurer. Aneurysm size is also presented as a percentage of the total ventricular area. The percentage reduction in total area, aneurysmal area, nonaneurysmal area, and their respective perimeters during systole was also calculated. This calculation is analogous to that of the ejection fraction when ventricular volumes are used.

In order to compare pre and postoperative areas in these noncalibrated ventriculograms, the aortic root diameter was considered a reference dimension and assumed not to change significantly between the two studies. All measured areas were converted to ratios using the aortic root




Fig 5 Comparison of preoperative right anterior oblique ventriculographic areas corrected for aortic root diameter and left ventricular end diastolic pressures in Group 1 and Group 2.

Table 1 Results of ventricular aneurysmectomy Group 2—mean values

Measurement	Preoperative	Postoperative
Ventricular area/aortic root diameter (diastole) (cm)		
Total	39.2	47.3
Aneurysm	11.1	19.5
Non Aneurysm	28.1	22.8
% Systolic area reduction		
Total	19.5	5.4
Aneurysm	3.5	2.9
Non Aneurysm	27.7	6.2

diameter as the denominator and the pre and postoperative ratios were compared.

Statistical analyses were carried out using Student's *t* test for paired and unpaired data.

Results

Clinical results of aneurysmectomy The patients were divided as described above into two groups. Group 1 included 14 patients who were improved by clinical and catheterization criteria only. Eleven patients in this group were greatly improved and included five who had returned to work, two who were asymptomatic, and four others who had only mild residual angina. Two patients of the remaining three had persistent bothersome angina but were included in Group 1 because the congestive heart failure for which they underwent surgery had improved both symptomatically and hemodynamically.




Fig 5 Comparison of preoperative per cent reduction during systole of the right anterior oblique ventriculographic areas and the per cent of the total area which is aneurysmal in Group 1 and Group 2

The remaining patient had persistent symptoms but the chest x ray and catheterization findings were improved

The nine patients in Group 2 responded poorly to surgery. Four of these nine patients died in the immediate postoperative period and all four showed evidence of low cardiac output after surgery. The immediate causes of death in these cases included complications of the intra aortic balloon assist device in one patient, postoperative infections in two (lung abscess and sepsis), and intractable ventricular tachycardia and fibrillation in the last. Five surgical survivors in this group had recurrent symptoms of congestive heart failure. In addition, one patient sustained a recurrent myocardial infarction and another had ventricular ectopic arrhythmias which were difficult to control.

Angiographic results of aneurysmectomy

Group I Fourteen patients: 12 follow up cardiac catheterizations. Fig 3 shows the results of aneurysmectomy on the planimeterized ventricular areas corrected for aortic root diameter. There were significant systolic and diastolic reductions in the total and aneurysmal areas whereas the nonaneurysmal areas were not significantly changed. These findings would be expected since the only surgical attack was on the aneurysm itself.




Fig 7 Distribution of predictive indexes of surgical success calculated from a multiple regression equation using mitral regurgitation (MR), coronary artery disease outside the aneurysm distribution (CAD) and excessively large or small aneurysm size (An) as independent variables

The effect of surgery on the per cent systolic area reduction in the three ventricular segments is displayed in Fig 4. This value was significantly improved for the entire heart (+12 per cent) and for the nonaneurysmal segment (+6 per cent) but not in the aneurysm itself. Also shown in this figure is the significant postoperative reduction in percentage of the total systolic ventricular area occupied by the aneurysm.

Preoperatively, only five patients had aneurysmal areas which were larger in systole than diastole. Of these five the largest bulge was 5 per cent and the remaining four increased in area only by 1 per cent. Bulging of the aneurysm was therefore an uncommon finding in this series and the phenomenon was not significantly altered by aneurysmectomy.

Group II Nine patients: five follow up catheterizations. The number of follow up studies is small and the value of statistical analysis uncertain, but it is apparent from Table I that there was no change as a result of aneurysmectomy of the average total ventricular area, the aneurysmal or nonaneurysmal areas all corrected for aortic root diameter. In contrast with the data in Group I there was a marked decrease in the per cent systolic area reduction of both contractile and total ventricular area following surgery.

Comparison of Group I and Group II preoperative ventriculograms. Figs 5 and 6 show that

Table II Results of ventricular aneurysmectomy Group II—9 patients

Patients	Pre Op factors				Peri Op factors		Post Op factors
	CAD other than LAD	Small an[area < 25%	Large an area > 87%	MR 1 2 +	MR		Worse CAD (not LAD)
					1 2 +	3-4 +	
J C	X	X					
R. K.	X			X			
A. C.	X						
M. S.	X			X		X	X
E. M.	X	X		X			X
E. Sm.	X					X	
F. M.	X		X				
C. H.	X					X	
E. So.	X						
Group I	8	0	0	2	5	0	0
Good Results				both relieved			(2 in LAD)
14 patients				post op			

Post operative d. eth.

Abbreviat ns: An = aneurysm CAD = coronary artery disease (50% stenosis or great) LAD = left anterior descending coronary artery

MR = mitral regurgitation

none of the angiographic area measurements made preoperatively effectively separated those patients who did well from those who did poorly following surgery

Perimetry The entire analysis was carried out using perimeters of the ventriculographic images rather than areas. In general the results were not as clear as those using planimetric areas. There was a significant decrease in the perimeter of the aneurysmal segments (corrected for aortic root diameter) and in the per cent of the perimeter which was aneurysmal before and after surgery in Group I patients. Perimeter measurements as with area measurements provided no preoperative separation between the two groups. Systolic perimeter shortening of the contractile segment was less than expected because of invagination and folding of the ventricular margins. This limited the usefulness of perimeter measurements in the calculation of per cent systolic perimeter reduction.

Hemodynamics The reduced left ventricular end-diastolic pressure after surgery in Group I patients (Fig. 3) was expected because elevation of this value was one basis for referral of patients to each of the two groups. But the preoperative values alone did not separate Group I from Group 2 patients (Fig. 5).

Measurements of cardiac output by either the Fick or indicator dilution methods were carried out in 10 preoperative and 13 postoperative stud-

ies. Although these data were not consistently available, review of the results showed them to be of little use in predicting postoperative results.

Separate analysis of Group II patients As a group there were no preoperative hemodynamic or angiographic features which completely separated the patients who did poorly from those who did well. Review of each case separately, however, identified individual factors which could be used to improve selection of cases for surgery. This analysis is displayed in Table II and can be divided into pre intra and postoperative factors.

Two patients had preoperative angiograms which demonstrated the smallest aneurysms in the entire series (9 and 13 per cent). These two patients had surgery in 1971 and were among the earliest patients to undergo aneurysmectomy in this institution. It appears that the heart failure present in these patients was as much related to widespread coronary artery disease and/or mitral insufficiency as it was to the aneurysms. Their resection therefore offered less hope of improvement than in other patients. The patient whose aneurysm was next in percentage of total ventricular area (25 per cent) did well postoperatively. Another patient preoperatively had the largest per cent aneurysm (96 per cent) and the smallest non aneurysmal segment area of the series. In this instance there was insufficient remaining contractile myocardium to support the circula-

tion following surgery. The patient whose aneurysm was second largest (87 per cent) had, in contrast, striking benefit from surgery. Four of the nine patients in Group 2 showed mild degrees of mitral regurgitation on their preoperative angiogram, while only two of 14 patients in Group 1 had this lesion. All nine patients in Group 2 had significant narrowing of coronary arteries supplying non aneurysmal myocardium, but eight of 14 in Group 1 also displayed this finding.

The three preoperative factors most influential in predicting surgical results were coronary artery disease outside the aneurysm distribution, mitral regurgitation and excessively small or large aneurysms. Each patient was assigned a value of either 10 or zero for each factor, depending upon its presence or absence, respectively. Patients in Group 1 were designated as 10 and those in Group 2 were given zero. Using surgical outcome as the dependent variable and the three preoperative factors as independent variables, a multiple regression analysis was carried out using a standard computer program. The multiple correlation coefficient obtained was 0.67 ($F = 11.05$, $p < 0.01$), indicating a significant influence of these preoperative factors on the surgical results. Using the multiple regression equation a value for the dependent variable was calculated for each patient, and these values (predictive index) are shown in Fig 7. The overlap between Groups 1 and 2 obviates the use of the index to predict surgical results with accuracy. But the display does suggest the effects of the preoperative factors, alone or in combination on the risks of a poor surgical result. For example among those patients with coronary artery disease outside the aneurysm seven of 10 patients did well, but when mitral insufficiency was added only one of four had a good result.

Severe mitral regurgitation probably induced at surgery contributed to the poor results in three instances. In two of these milder mitral insufficiency was present preoperatively. Aneurysmectomy also relieved mild mitral regurgitation in one patient in Group 2 and two patients in Group 1.

Several of the poor surgical results could be explained by postoperative findings also not predictable from preoperative studies. Two patients developed advancing coronary artery disease in vessels supplying the remaining contractile myocardium. In Group 1 there were

also two patients with advancing coronary artery disease located in the anterior descending coronary artery, a vessel supplying previously infarcted myocardium.

Discussion

The purpose of the present study was to evaluate the results of left ventricular aneurysmectomy. To aid in the evaluation a simple angiographic method was utilized with the hope that it would improve the selection of patients for surgery. In order to determine the usefulness of any preoperative angiographic method, postoperative evaluation should include cardiac catheterization of good and poor results in addition to a symptomatic review. Furthermore, the surgical series must be uncontaminated by patients treated with procedures other than aneurysmectomy, such as coronary artery bypass grafts or valve replacement. Although postoperative recatheterization has been previously reported^{14,15} these series did not exclude patients with concomitant coronary artery surgery, did not include a significant proportion of survivors, or did not analyze the ventriculograms in detail.

The circulatory disability induced by left ventricular aneurysm secondary to coronary artery atherosclerosis, has a dual nature. The loss of contractile myocardium in the aneurysm, its size and whether or not it absorbs cardiac energy by bulging during systole represents one liability. The contractility of the remaining segment and the adequacy of its blood supply is the second. Both aspects of this disorder are amenable to study using the left ventricular angiogram and coronary arteriography. Many previous efforts have converted single plane two dimensional angiographic images of the aneurysmal and contractile ventricular areas to volumes using formulas for a variety of known geometrical shapes. Precedent for this approach has arisen from the established usefulness of volumes calculated from the normal ventricle using the prolate ellipsoid as a three dimensional shape approximation.¹⁶⁻¹⁸ The validity of this technique in the non aneurysmal ventricle has solid experimental support, but no such support has been described for any of the shapes chosen to represent the aneurysmal ventricle or its subdivisions. Therefore seems doubtful that the conversion of two dimensional measurements to volumes will improve the utility of the original right anterior

oblique angiographic figure. Yet several recent studies using clinical status only as an end point have suggested angiographic methods for the prediction of surgical results. Watson and colleagues found a rough relationship between postoperative clinical class and ejection fraction of the contractile segment assumed to be a hemispheroid. Lee and associates⁸ calculated the difference between the ejection fraction taken from the angiographic figure (assuming an ellipsoidal shape) and the ejection fraction of a theoretical spherical model, the akinetic fraction of which was determined by perimetry. This difference between ejection fractions was useful in predicting operative survival but did not relate to long term or over all survival. In future inclusion of measurements taken from the left anterior oblique angiographic figure might allow better three dimensional assessment of the antero-apical aneurysmal volume.

Absolute volume measurements necessitate that angiographic magnification factors be controlled. To insure that such calculated volumes applied to all patients referred to a medical center for left ventricular aneurysmectomy, patients studied in outlying institutions would need repeat preoperative catheterization. The ejection fractions described above and the present method are volume independent, require no special equipment and are applicable to satisfactory left ventriculograms obtained in any institution. These ventriculographic measurements appear of some use since they demonstrate the changes expected from the division of cases into good and poor surgical results. The value of these methods are limited however in predicting results. Our technique would improve case selection by rejecting patients with the largest or smallest aneurysms but by no other measurement. The other more complex ventriculographic techniques have been little more effective in this regard and have not been subjected to a similar analysis using postoperative catheterization study. It also seems possible that no area or volume method will be of great predictive value since surgical failures in large measure depended on factors apart from the ventriculogram.

Analysis of these factors showed them to be of heterogeneous origin, divisible into pre-, intra- and postoperative types. The non ventriculographic preoperative factors more frequent among surgical failures included the presence of

coronary disease in arteries supplying the contractile myocardium and mitral insufficiency. The former has been previously described as a negative factor in predicting surgical success.¹⁹ Preoperative mitral insufficiency has not been emphasized previously but should be a warning to the surgeon since some patients with this finding were relieved of mitral insufficiency by surgery but others made worse. The postoperative factor contributing to unsatisfactory surgical results was advancing coronary artery disease in vessels supplying the contractile ventricular segment, a development which is unpredictable from the preoperative evaluation.

Aneurysmal bulging has been indicted in the past as a cardiac liability in addition to aneurysm size,²¹ especially in those patients whose aneurysm develops within a few weeks of acute myocardial infarction. Review of our angiographic data however failed to reveal impressive aneurysmal bulging in any of the preoperative angiograms including those in patients whose aneurysms developed within weeks of myocardial infarction. The present angiographic methods however should be useful in this regard in future patients where aneurysmal bulging may be important.

This study indicates that ventricular aneurysmectomy in many patients is a valuable procedure as presently carried out, that the preoperative ventricular and coronary angiogram can be used to better select patients for the procedure but that some unsatisfactory results are inevitable from advancing coronary artery disease. It also raises questions but no answers for the cardiac surgeon in determining how much aneurysm to resect, how small or large to leave the ventricular cavity for provision of an optimum volume to prevent postoperative mitral regurgitation. Only routine postoperative recatheterization will permit the surgeon to relate operating room experience to surgical results.

Summary

Twenty three patients underwent left ventricular aneurysmectomy without coronary artery bypass or other surgical procedure. Fourteen patients (Group 1) benefited from surgery and nine fared poorly (Group 2), including the four postoperative deaths. Among the 19 survivors 17 had postoperative catheterizations. Pre and postoperative left ventriculograms in the right

anterior oblique projection were analyzed by planimetry of the aneurysmal and non aneurysmal areas. This method provided data favorably altered by surgery in the improved patients and unchanged in the others. None of the preoperative ventriculographic measurements effectively separated the postoperative patient groups. The poor results in the Group 2 patients were of heterogeneous origin arising from pre, peri and postoperative factors. The more important factors were the largest and smallest aneurysms, surgically induced mitral insufficiency, and progressive coronary artery disease. Thus the improvement in surgical results from better angiographic preoperative case selection is possible, but limited.

REFERENCES

1. Favalaro H G, Effler D H, Groves L K, Wescott R N, Suarez E and Lozada J. Ventricular aneurysm—clinical experience. *Ann Thorac Surg* 6:227 1968.
2. Graber J D, Oakley C M, Pickering B N, Goodwin J F, Raphael M J and Steiner R E. Ventricular aneurysm. An appraisal of diagnosis and surgical treatment. *Br Heart J* 34:830 1972.
3. Basta L L, Takeshita A, Theilen E O, and Ehrenhaft J L. Aneurysmectomy in treatment of ventricular and supraventricular tachyarrhythmias in patients with postinfarction and traumatic ventricular aneurysms. *Am J Cardiol* 32:693 1973.
4. Loop F D, Effler D B, Navia J A, Sheldon W C and Groves L K. Aneurysms of the left ventricle. Survival and results of a ten year surgical experience. *Ann Surg* 178:399 1973.
5. Gerbode F, Kerth W J, Hill J D, Banerjee S and Marcelletti C. Elective operations for left ventricular aneurysm. *Thorax* 29:282 1974.
6. Rao G, Zikria E A, Miller W H, Samadani S R and Ford W H. Experience with sixty consecutive ventricular aneurysm resections. *Circulation* 50 (Suppl II) 149 1974.
7. Klein M D, Herman M V and Gorlin R A. Hemodynamic study of left ventricular aneurysm. *Circulation* 35:614 1967.
8. Crawford D W, Barndt R, Harrison E C and Lau F Y K. A model for estimating some of the effects of aneurysm resection following myocardial infarction. Preliminary clinical confirmation. *Chest* 59:517 1971.
9. Hamilton G W, Murray J A and Kennedy J W. Quantitative angiocardiology in ischemic heart disease. The spectrum of abnormal left ventricular function and the role of abnormally contracting segments. *Circulation* 45:1065 1972.
10. Kitamura S, Kay J H, Krohn H G, Magidson O and Dunne E F. Geometric and functional abnormalities of the left ventricle with a chronic localized noncontractile area. *Am J Cardiol* 31:701 1973.
11. Watson L E, Dickhaus D W and Martin R H. Left ventricular aneurysm. Preoperative hemodynamics, chamber volume and results of aneurysmectomy. *Circulation* 52:868 1975.
12. Feld H J, Russell R O Jr, Dowling J T and Rackley C E. Regional left ventricular performance in the year following myocardial infarction. *Circulation* 46:679 1972.
13. Miller R R, Olson H G, Vismara L A, Bogren H G, Amsterdam E A and Mason D T. Pump dysfunction after myocardial infarction. Importance of location, extent and pattern of abnormal left ventricular segmental contraction. *Am J Cardiol* 37:340 1976.
14. Kitamura S, Echevarria M, Kay J H, Krohn B G, Redington J V, Mendez A, Zubiate P and Dunne E F. Left ventricular performance before and after removal of the noncontractile area of the left ventricle and revascularization of the myocardium. *Circulation* 45:1005 1972.
15. Hazan E, Bloch G, Rioux C, Louville Y, Crotteau Y and Mathey J. Surgical treatment of aneurysm and segmental dyskinesia of the left ventricular wall after myocardial infarction. *Am J Cardiol* 31:708 1973.
16. Shaw R C, Connors J P, Hieb B R, Ludbrook P A, Krone R, Kleiger H E, Ferguson T B and Weldon C S. Postoperative investigation of left ventricular aneurysm resection. *Circulation* 56 (Suppl II) 7:197.
17. Dodge H T, Sandler H, Ballew D W and Lord J D Jr. The use of biplane angiocardiology for the measurement of left ventricular volume in man. *Am Heart J* 60:762 1960.
18. Greene D G, Carlisle R, Grant C and Bunnell I L. Estimation of left ventricular volume by one plane cineangiography. *Circulation* 35:61 1967.
19. Lee D C S, Johnson R A, Boucher C A, Wexler L F and McEnany M T. Angiographic predictors of survival following left ventricular aneurysmectomy. *Circulation* 56 (Suppl II) 12:1977.
20. Brawley R K, Schaff H, Stevens R, Ducci H, Gott V L and Donahoo J S. Influence of coronary artery anatomy on survival following resection of left ventricular aneurysms and chronic infarcts. *J Thorac Cardiovasc Surg* 73:120 1977.
21. Parnley W W, Chuck L, Kivowitz C, Matloff J M and Swan H J C. In vitro length-tension relations of human ventricular aneurysms. Relation of stiffness to mechanical disadvantage. *Am J Cardiol* 32:889 1973.

Coronary artery to pulmonary artery fistulas

Abdulmassih S Iskandrian MD

Demetrios Kimbiris MD

Charles E Bemis MD

Bernard L Segal MD

Philadelphia 1a

Congenital coronary artery fistulas are rare but well known clinical entities. These fistulas may drain into the low pressure right heart chambers the coronary sinus the pulmonary artery the bronchial circulation and left atrium and very rarely the left ventricle. According to the site of drainage these fistulas may present with characteristic continuous murmurs and occasionally may be confused with patent ductus arteriosus. Recent reports postulate that small coronary fistulas may be the result of severe obstructive coronary artery disease with the fistulas originating proximal to a severe coronary obstruction. The purpose of this report is to discuss our experience with 12 patients having coronary artery to pulmonary artery fistulas discovered during routine coronary arteriography in the past ten years.

Material and results

The twelve patients were discovered during diagnostic coronary arteriography performed at our institution. The clinical data of these patients is presented in Table 1. Patient No 1 was studied because of the presence of continuous murmur thought to be patent ductus arteriosus. Patient No 7 was studied for evaluation of rheumatic heart disease. Ten patients were studied for the evaluation of chest pain suspected to be angina pectoris. There were three women and nine men

with an age range of 35 to 70 years and an average age of 61 years. The ECG was normal in five patients. showed left ventricular hypertrophy in two patients and in five patients there were ST segment and/or T wave abnormalities. The left ventricular end diastolic pressure was normal (less than 12 mm Hg) in eight patients. Indicator dilution curves with injection of Cardiodiagnostic into the pulmonary artery and sampling in the aorta were obtained in all patients and were normal. Hydrogen studies performed in two patients were negative. Six patients had severe coronary artery disease (one vessel disease in two patients two vessel disease in one patient and three vessel disease in three patients). One patient had insignificant coronary artery disease (less than 50 per cent narrowing). One patient had rheumatic heart disease (mitral stenosis and insufficiency and aortic insufficiency) and six patients had normal coronary angiograms.

There were 14 fistulas in the 12 patients. ten fistulas originated from the proximal left anterior descending artery three from the proximal right coronary artery and one from the proximal left circumflex artery. In only four of the six patients with severe coronary artery disease the donor vessel (i.e. the vessel from which the fistula originates) was involved with significant narrowing. In the remaining two patients the donor vessel was not involved and the atherosclerotic narrowing was limited to the other vessels. Angiographically the fistulas could be divided into two types.

1. The fistula consisted of one large channel (Fig 1) or one or more small (Fig 2) but discrete channels. In each case the contrast media was clearly seen spurting into the main pulmonary

From the Division of Cardiovascular Medicine, Hahnemann Medical College and Hospital, Philadelphia, Pa.
Received for publication Dec 27 1977
Accepted for publication March 13 1978
Reprint requests: Abdulmassih S Iskandrian MD, Cardiovascular Institute, Hahnemann Medical College and Hospital, 230 N. Broad Street, Philadelphia, Pa. 19107.

Table 1 Clinical hemodynamic and angiographic data in 12 patients with coronary artery to pulmonary artery fistulas

Patient no initials age & sex	Coronary arteriography % narrowing				Origin of fistula	Type of fistula	Contin- uous murmur	ECG	LV EDP (mm Hg)	Dye dilu- tion	H ₂ study	Reason for study
	LM	LAD	LCF	RCA								
1 I F 40 M	0	0	0	0	LAD	Many small channels	+	LVH	10	N	Not done	Continuous murmur
2 L W 46 M	0	0	0	0	LAD	Single large channel	-	LAH ST T	12	N	(-)	Angina
3 O W 57 M	0	0	40%	40%	LAD	Single small	-	N	10	N	Not done	Atypical angina
4 S C 47 F	0	70%	100%	100%	LAD	Single large	-	IRBBB ST T	20	N	Not done	Angina
5 J G 70 M	95%	0	80%	0	RCA	Single small	-	ST T	8	N	Not done	Angina
6 G K 45 F	0	0	0	0	LAD	Single large	-	N	10	N	Not done	Atypical angina
7 M B 59 F	0	0	0	0	LCF	Two small	-	LVH A F	11	N	Not done	RHD
8 J F 35 M	0	0	0	0	LAD	Single large	-	ST T	12	N	Not done	Angina
9 P W 53 M	0	0	0	0	LAD	Single small	-	N	20	N	Not done	Atypical angina
10 J M 54 M	0	99%	90%	100%	LAD	Single small	-	LAH ST T	9	N	Not done	Angina
11 F W 54 M	0	70%	80%	99%	LAD	Plexiform	+	N	25	N	(-)	Angina
12 F T 58 M	0	100%	0	0	LAD	Plexiform	-	N	17	N	Not done	Angina

Abbreviations: M male, F female; LM left main coronary artery; LAD left anterior descending artery; LCF left circumflex artery; RCA right coronary artery; LV EDP left ventricular end diastolic pressure; N normal; LVH left ventricular hypertrophy; LAH left anterior hemiblock; ST T ST segment and T wave abnormalities; IRBBB incomplete right bundle branch block; AF atrial fibrillation; RHD rheumatic heart disease.

artery. This type was seen in 12 fistulas in the presence or absence of obstructive coronary artery disease.

2. The fistula was composed of a plexiform arrangement of vessels (Fig. 3). This type was seen in two patients, both with significant coronary artery disease.

There was no proximal dilatation of the donor vessel in any case. Patient No. 1 underwent ligation of the fistula and the angina disappeared following surgery. Patient No. 11 underwent ligation of the fistula with triple saphenous vein bypass surgery for the associated coronary artery disease. In each patient the fistula was suture ligated near the anastomosis with the pulmonary artery and the thrill which was felt over the pulmonary artery before ligation disappeared following the ligation.

Discussion

Coronary artery fistulas are anomalies due to defective development of the coronary circulation

during fetal life.¹⁰ They originate from the major coronary vessels and drain in the low pressure right cardiac chambers commonly into the right ventricle and less frequently into the right atrium, coronary sinus, pulmonary artery, bronchial circulation and very rarely into the left atrium and left ventricle.¹¹ The coronary artery involved is usually tortuous and markedly dilated.² The basic pathophysiologic abnormality of this disorder is left to right shunt, the magnitude of which will be influenced by the functional size of the opening of the fistula at the point of distal communication and other factors, such as systemic and pulmonary artery pressures.¹ The fistulas may drain with the single opening or with multiple openings in the form of plexiform vessels. Most of the patients present with characteristic continuous murmur located in areas other than the usual location of the continuous murmur of the patent ductus arteriosus. The location of the murmur is dependent upon the site of drainage of the fistula. In several patients the




Fig 1 Selective right coronary arteriogram in the right anterior oblique projection showing a discrete and relatively large fistula arising proximal to total occlusion of the vessel and draining into the pulmonary artery

correct diagnosis was made during surgery for suspected patent ductus arteriosus. The majority of the patients are asymptomatic for many years and symptoms occur usually in the older age group as a result of the long standing shunt or the development of obstructive coronary artery disease or systemic hypertension. The complications may include congestive heart failure, angina pectoris due to coronary steal, and bacterial endocarditis.

Recent reports indicated that coronary fistulas may exist without clinical manifestations and are discovered during diagnostic coronary arteriography. The reported cases were associated with significant obstructive coronary artery disease⁶ and the authors considered them as being acquired secondary to the coronary obstructions. In two patients the fistulas were reported to originate from the right coronary artery and drained into the right atrium. In the third patient the fistula originated from the left anterior descending artery and drained into the great cardiac vein. In the fourth patient the fistula originated from the left anterior descending and drained into the left atrium.⁶ All these fistulas were small, silent, and originated proximal to a severe obstruction of the diseased vessel. All the fistulas were interrupted during aortocoronary bypass surgery for the obstructive coronary disease.

In our study we have chosen only those fistulas which drain into the pulmonary artery and because of the anatomic location such fistulas

should be easily detected during coronary arteriography.

We found 14 fistulas in 12 patients (two patients had two fistulas each). Ten fistulas originated from the left anterior descending artery, three from the right coronary artery and one from the left circumflex artery. Five fistulas were composed of one large channel in each (Fig 1); seven fistulas were composed of one or more small but discrete channels (Fig 2). Two fistulas were formed of plexiform arrangement of channels (Fig 3). In each case contrast material was clearly seen spurring into the pulmonary artery during selective coronary arteriography. In four out of six patients with coronary artery disease the donor vessel was involved with significant narrowing and in each case the fistula originated proximal to the lesion. There was no proximal dilatation of the coronary artery in any of the 12 patients. The plexiform arrangement of fistulas was only seen in the presence of coronary artery disease; however, the discrete variety was seen in both normal subjects and in patients with coronary artery disease.

Two of our patients had characteristic continuous murmurs; one patient had a normal coronary angiogram and the second had severe coronary artery disease.

Hydrogen study was performed in two patients and was normal in each. Dye dilution curves performed in all patients were normal. It has been suggested that fistulas are visualized only because of the pressure of injection during coronary



Fig 2 Selective left coronary arteriogram in the right anterior oblique projection showing small but discrete fistulas arising from the proximal left anterior descending artery and draining into the pulmonary artery. The left circumflex artery is totally occluded.




Fig 3 Selective left coronary arteriogram in the left lateral projection showing a plexiform arrangement of coronary artery to pulmonary artery fistulas arising from the left anterior descending artery just proximal to its total occlusion.

arteriography and may very well be functionally closed at other times. Although this tends to substantiate the negative hydrogen studies and normal dye dilution curves in our patients, it does not explain the finding of a thrill over the pulmonary artery in two patients who underwent ligation of the fistulas. We rather believe that the amount of shunt was small and that there is definite limitation of the above techniques in shunt detection. Recently, Blau and associates¹¹

have used ^{99m}Tc albumen particles for a semi-quantitative estimation of the shunt in a patient with coronary artery fistula.

The pathogenesis of these fistulas is unknown. Probably they represent a spectrum of a developmental defect during fetal life as are the more classic forms of congenital coronary fistulas. The fact that half of our patients did not have obstructive coronary artery disease suggests that the coronary obstruction is not responsible for the

development of the fistulas. The functional significance of this type of fistula is uncertain. The presence and magnitude of coronary steal in our patients could not be answered from this study. The recent interest in myocardial imaging with Thallium 201 both at rest and during exercise may be useful in helping to make decisions about management of these patients. A perfusion deficit in the region of distribution of the donor vessel may be an indirect indication of coronary steal particularly in patients with normal coronary arteries.

In summary we have described 12 patients with coronary artery to pulmonary artery fistulas both in the presence and absence of obstructive coronary artery disease. We have no evidence to substantiate that obstructive coronary artery disease may cause coronary fistulas. We found no different morphologic or functional characteristics of the coronary fistulas with or without coronary obstructions. Their etiology therefore must be assumed to be congenital. Although in the majority of patients with otherwise normal coronary arteries the functional significance of the fistulas is not important, the development of obstruction may aggravate the perfusion deficit because of the coronary steal.

Summary

Twelve patients with a total of 14 coronary artery to pulmonary artery fistulas were discovered at the time of diagnostic coronary angiography. Six patients had severe coronary artery disease, five patients had normal coronary arteriography, one patient had insignificant coronary artery disease, and one patient had rheumatic heart disease. Only two patients had characteristic continuous murmurs, one patient had a normal coronary angiogram, and the second patient had severe coronary artery disease. Ten fistulas originated from the left anterior descending artery, three from the right coronary artery

and one from the left circumflex artery. The fistulas were either composed of one large (five fistulas) or one or more small channels (seven fistulas) or poorly defined plexiform channels (two fistulas). Hydrogen studies performed in two patients were negative, and dye dilution curves performed in all patients were normal. In only four out of the six patients with severe coronary artery disease the fistulas originated from a diseased vessel, and in each case the origin was proximal to the narrowing. The pathogenesis and functional role of these fistulas is largely unknown.

REFERENCES

1. Blake H A, Mason W C, Mattingly T W and Barold G. Coronary artery anomalies. *Circulation* 30:927 1964.
2. McNamara J J and Gross R E. Congenital coronary artery fistula. *Surgery* 65:59 1969.
3. Effler D M, Sheldon W C, Turner J J and Groves L K. Coronary arteriovenous fistulas. Diagnosis and surgical management. Report of 15 cases. *Surgery* 61:41 1967.
4. Ogden J A. Congenital anomalies of the coronary arteries. *Am J Cardiol* 25:4/4 1970.
5. Bjork, V O and Bjork L. Coronary artery fistula. *J Thorac Cardiovasc Surg* 49:971 1965.
6. Kimbiris D, Kaspanian H, Knibbe P and Brest A. Coronary artery-coronary sinus fistula. *Am J Cardiol* 26:532 1970.
7. Searcy R A, Stein P D, Ganesan G and Bruce T A. Arterio-atrial shunting in coronary atherosclerosis. *Chest* 59:398 1971.
8. Phillips P A. and Libanoff A J. Arteriovenous communication associated with obstructive arteriosclerotic coronary artery disease and myocardial infarction. *Chest* 65:106 1974.
9. King S H III, Schoemaker F W. Coronary artery to left atrial fistula in association with severe atherosclerosis and mitral stenosis. Report of a surgical repair. *Chest* 67:361 1975.
10. Wearn J T, Mettler S R, Klump T G and Zachies cho L J. The nature of the vascular communication between the coronary arteries and the chambers of the heart. *Am Heart J* 9:143 1933.
11. Blau N, Adatepe M H and Begg F R. Coronary artery fistula. Estimation of shunt using 99m Tc Albumin particles. *Cathet Cardiovasc Diagn* 3:241 1977.

Migraine and the mitral valve prolapse syndrome

George I Litman, M D
Harvey M Friedman, M D
Akron Ohio

The mitral valve prolapse syndrome occurs in about 8 per cent of young women¹ Clinical reports of this syndrome have emphasized the cardiac manifestations of a mid systolic click with or without a mid to late systolic murmur and the usually associated symptoms of atypical chest pain, dyspnea, fatigue, and palpitations Observations regarding secondary neurological symptoms are generally limited to descriptions of light headedness, dizziness syncope, and frequently undescribed 'psychoneurotic complaints' During the course of our evaluation of patients with prolapse of the mitral valve, we discovered a remarkably high incidence of migraine syndrome in these patients This report comprises our evaluation of the association of migraine and the mitral valve prolapse syndrome

Material and methods

A retrospective study was conducted on 230 patients with mitral valve prolapse syndrome seen during the past four years for cardiac or neurological evaluation Complete history and physical examinations were carried out The diagnosis of mitral valve prolapse was made by the presence of the typical mid to late systolic click with or without a late systolic murmur In those few patients in whom no physical findings were present, classic echocardiographic criteria and/or angiographic findings of mitral valve prolapse were present Two hundred twenty two patients had echocardiographic studies Ten patients had

cardiac catheterization studies at Akron General Medical Center Two other patients had catheterization studies elsewhere, and these were reviewed personally Where deemed necessary because of severe neurological symptoms additional studies such as electroencephalogram skull x rays radio nuclide brain scans and computerized tomography were done

Sixty four of the 230 patients or 28 per cent were identified as having symptoms characteristic of migraine Included were symptoms such as throbbing, pulsating headache, teichopsia visual scotoma, and transient neurological deficits that were repetitive in young people, such as hemiparesis Individual migraine syndromes were classified according to the criteria of the Ad Hoc Committee on Headache of the National Institute of Neurological Diseases and Blindness²

Results

There was a marked preponderance of Caucasian females in our patient group (Table I) The majority of patients had the onset of migraine during the second and third decades of life (Table II) The most frequent types of migraine encountered were the common and classic varieties (Table III)

Most patients had both physical examination and echocardiograms positive for the prolapse mitral valve syndrome (Table IV) In ten patients however the physical examination was negative Of these, nine had classically positive echocardiographic findings of mitral valve prolapse, and one had angiographic demonstration at cardiac catheterization

Illustrative case report

V C a 33 year old white woman was referred for evaluation of episodic visual loss and head

From the Divisions of Cardiology and Neurology Department of Medicine Akron General Medical Center Akron Ohio

Received for publication Feb 27 1978

Accepted for publication Apr 28 1978

Reprint requests: George I Litman M D Dept of Medicine Akron General Center 400 Wabash Ave Akron Ohio 44307

Table I Sex and race of 64 patients with diagnosis of migraine and prolapsed mitral valve

Female	59	92%
Male	5	8%
White	61	95%
Black	3	5%

Table II Age of onset of migraine in 64 patients with diagnosis of migraine and prolapsed mitral valve

Age of onset (yrs)	Total patients—64
0-10	3
11-20	27
21-30	11
31-40	7
41-50	5

ache. These began at age 26 and started with large blotches of darkness in both eyes. Her left eye gradually became blind. Simultaneously she noted brief flashing lights described as an exploding firecracker in her right eye also followed by blindness. These episodes lasted about ten minutes and were followed by the onset of a severe throbbing headache usually beginning behind the left eye and in the left temporal area accompanied by return of vision. Nausea and vomiting were frequent. She often had a similar headache without premonitory symptoms.

For several years she had experienced intermittent left lateral chest discomfort. The pain was described as sharp and located just to the left of the sternum at the sixth and seventh ribs. The pain did not radiate and lasted ten minutes to two hours. Palpitations were frequent. A cardiac murmur was first heard at age six but had not been investigated.

She had "convulsions" until the age of 12. Her mother had severe migraine headaches and a younger brother had been thought to have rheumatic fever elsewhere on the basis of cardiac examination. Her older brother had at least one episode of similar visual loss.

Cardiac examination revealed a normal apex impulse. First and second sounds were normal with a classic midsystolic click and late systolic murmur heard best in the left lateral decubitus position. No diastolic murmur was present (Fig 1). Rare premature ventricular beats were heard

Table III Classification of migraine in 64 patients with diagnosis of migraine and prolapsed mitral valve

Type of migraine	No
Common	42
Classic	12
Common and classic	1
Common and paroxysmal	1
Cluster	2
Hemiplegic	5
Ophthalmoplegic	1

Table IV Physical and ECHO findings in 62 patients with diagnosis of migraine and prolapsed mitral valve

Click of click murmur noted	54	84%
No click or murmur	10	16%
Total positive ECHO	47	73%

Of these 10 patients, nine had positive echoes and one had positive cineangiogram of mitral valve prolapse.

Blood pressure was normal. Neurological examination was normal.

Resting ECG, chest x ray and routine laboratory studies were normal. A 24 hour Holter monitor showed only unifocal ventricular premature beats. Echocardiographic evaluation (Fig 2) demonstrated mitral valve prolapse.

Neurological studies including electroencephalogram, brain scan, and skull x rays were normal.

She was treated with gradually increasing doses of propranolol ultimately to 160 mg per day. Chest pain and palpitations were rare at this level. Visual symptoms and headache were completely eliminated.

Discussion

To our knowledge this is the first reported association of these two syndromes. Prevalence of migraine among the female population is said to be about 10 per cent.² In our study 28 per cent of patients with mitral valve prolapse also had migraine. Although these were unselected patients this was not a randomized study since all patients were referred for either a cardiac or neurological evaluation. Only a large population study completely randomized can ultimately confirm or deny our conclusions regarding the association of the two syndromes.




Fig 1 Phonocardiogram demonstrated mid-systolic click (MSC) recorded at the apex




Fig 2 Echocardiogram reveals classic mid-systolic prolapse of mitral valve (see arrow)

Certain clinical features in both groups suggest a relationship between migraine and the prolapse valve syndrome. Both are more common in women. Paroxysmal tachycardia, syncope, light-headedness, vertigo, and chest pain have been linked to migraine and are well known in the mitral valve prolapse syndrome. Propranolol, a beta blocking agent, has been an effective drug in

reducing the symptoms and arrhythmias of the mitral valve prolapse syndrome. This same agent has been uniformly and impressively utilized for the treatment and prevention of migraine in our patient group. This drug has been so effective that it has become our first choice in treatment of migraine.

Recently Barnett and associates from London

Ontario⁷ documented transient ischemic attacks and completed strokes in patients with the mitral valve prolapse syndrome. Several of these patients appear to have had emboli as a pathologic mechanism. In the past four years we have recognized four patients with neurological disorders that we consider to be secondary to emboli from a prolapsed valve.

The reasons for emboli forming on this valve are unclear particularly in the absence of an associated endocarditis. Pathological changes on the margin of the prolapsed valves as described by Pomerance⁸ and by Silver⁹ may initiate platelet adherence and aggregation and a platelet fibrin thrombus eventually may form become detached and may cause embolic infarction.

Multiple reports have also stressed an increased incidence of stroke in patients with migraine especially those with complicated migraine.¹⁰ Migraine patients are known to demonstrate platelet hyperaggregability. Although vaso-spasm is usually cited as the cause of strokes associated with migraine the role of hyperaggregability of platelets in those strokes has not yet been investigated. Indeed if as we suggest these two syndromes are related this abnormality of platelet function could play a basic role in the origin of emboli from the abnormal mitral valve. Some manifestations of the migraine syndrome may in fact be a result of repetitive emboli from the mitral valve. Kalendovsky and Austin¹¹ suggested the possibility of an association between platelet hyperaggregability and neurologic symptoms of migraine. Support for this concept comes from a recent report by Caplan and co-workers¹² of the new onset of migraine syndrome occurring after insertion of a prosthetic cardiac valve. More recently however Couch and Hassanen¹³ have denied that symptoms of migraine are related to platelet aggregation but did suggest that the increased incidence of thrombotic stroke in migraine subjects could be due in part to platelet hyperaggregability. Weksler and associates¹⁴ recently demonstrated that propranolol added to platelets in vitro inhibited platelet aggregation induced by ADP epinephrine collagen and thrombin.

We believe it is most important for the physician to recognize the association of these syndromes. All patients with migraine syndrome should be evaluated to determine the presence or

absence of mitral valve prolapse. If the latter is recognized then consideration should be given to providing subacute bacterial endocarditis prophylaxis. Endocarditis represents a well known complication of mitral valve prolapse syndrome. On the other hand in patients with mitral valve prolapse seeking out the symptoms of migraine may prevent the prescription of birth control pills which might precipitate severe migraine or even strokes in susceptible patients.

Summary

We believe there is a significant association between migraine and the prolapse mitral valve syndrome. Propranolol is the drug of choice in these patients for the treatment and prevention of migraine. Increased platelet aggregability may be the common pathophysiologic mechanism as relates to emboli from the valve and possibly in strokes related to migraine. Recognition of the association of the two syndromes will result in appropriate subacute bacterial endocarditis prophylaxis for patients at risk as well as prevention of improper medication to those patients with migraine who are at risk for stroke.

This paper was presented in part on September 23, 1977 at the Fifth Annual Combined Meeting of the Ohio Chapter of the American College of Physicians and the Ohio Society of Internal Medicine, Kings Island, Ohio.

REFERENCES

1. Procacci, P. M., Savrou, M. V., Schreier, S. L. and Bryson, A. L. Prevalence of clinical mitral valve prolapse in 1169 young women. *Engl J Med* 294:1086, 1976.
2. Hancock, E. W. and Cohn, K. The syndrome associated with mid-systolic click and late systolic murmur. *Am J Med* 41:183, 1966.
3. Dillon, J. C., Haime, C. L., Chang, S. and Feiginbaum, H. Use of echocardiography in patients with prolapsed mitral valve. *Circulation* 43:503, 1971.
4. Ad hoc committee. Classification of headache. *JAMA* 179:717, 1962.
5. Blumenthal, L. S. Introduction in *Handbook of Clinical Neurology* edited by Vinken, P. J. and Bruyn, G. W. Amsterdam, 1968. North Holland Publishing Co. vol 5, pp 6-7.
6. O'Rourke, R. A. and Crawford, M. H. The systolic click-murmur syndrome. Clinical recognition and management. *Curr Probl Cardiol* 1:9, 1976.
7. Barnett, H. J. M., Jones, M. W., Boughner, D. R. and Hostak, W. J. Cerebral ischemic events associated with prolapsed mitral valve. *Arch Neurol* 33:777, 1976.
8. Pomerance, A. Ballooning deformity (mucoid degeneration) of atrioventricular valves. *Br Heart J* 31:343, 1969.
9. Silver, M. Rheumatic carditis. Acute and chronic atrioventricular valve disease. In *The Heart* edited by

- Edwards J Lev M, and Abel M Baltimore 1974 The William & Wilkins Company pp 87 109
- 10 Pearce J M S and Foster J B An investigation of complicated migraine Neurology 15 333 1965
- 11 Guest M A and Woolf A L Fatal infarction of brain in migraine Br Med J 1 225 1964
- 12 Couch J R and Hassanein R S Platelet aggregability in migraine Neurology 27 843 1977
- 13 Kalendovsky Z and Austin J H Changes in blood clotting systems during migraine attacks Headache 16 293 1977
- 14 Caplan L R Weiner H Weintraub R M and Austen, W G Migrainous neurologic dysfunction in patients with prosthetic cardiac valves Headache 16 218 1976
- 15 Weksler E B Gillick M and Pink J Effect of propranolol on platelet function Blood 49 18, 1977

Information for authors

Most of the provisions of the Copyright Act of 1976 became effective on January 1 1978 Therefore, all manuscripts must be accompanied by the following statement, signed by each author The undersigned author(s) transfers all copyright ownership of the manuscript entitled (title of article) to The C V Mosby Company in the event the work is published The author(s) warrants that the article is original ■ not under consideration by another journal and has not been previously published ■ Authors will be consulted when possible regarding republication of their material

The ventricular A wave a new echocardiographic index of late diastolic filling of the left ventricle

John A. Ambrose MD
Jose Meller MD
Michael V. Herman MD
Louis E. Teichholz MD
New York NY

In the normal heart left ventricular filling takes place predominantly during early and late diastole with little filling occurring during mid diastole.^{1,2} In the hypertrophied ventricle however it has been demonstrated that early filling is impeded. This is reflected by a reduction in the "y" descent of the left atrial pressure trace and by a decrease in the EF slope of the anterior mitral valve leaflet seen on echocardiography.^{3,7} The precise cause of decreased early filling in left ventricular hypertrophy is not known but it may be related to decreased left ventricular compliance.⁸ To insure adequate left ventricular filling atrial contraction becomes more forceful and prolonged augmenting the amount of filling in late diastole.⁹

Echocardiography has been a useful tool in the evaluation of left ventricular function especially in the absence of asynergy. Although echocardiographic correlates of early diastolic filling⁴ have previously been described there has been little emphasis on abnormalities of late diastolic filling. Therefore in order to study the late diastolic filling period we have measured the changes in left ventricular internal diameter occurring at end-diastole in patients with and without left ventricular hypertrophy.

Methods

From the population of patients studied in our non invasive laboratory 30 normal volunteers (group A) 25 consecutive patients with left ventricular hypertrophy (secondary to aortic stenosis idiopathic hypertrophic subaortic stenosis or hypertension) and normal sinus rhythm (group B) and 15 patients with atrial fibrillation (group C) in whom the endocardial surfaces of the left ventricular posterior wall and interventricular septum could clearly and precisely be defined were studied by standard time-motion echocardiography. All patients with abnormal septal motion were excluded. Echocardiographic criteria for left ventricular hypertrophy consisted of a posterior wall and/or interventricular septum > 11 mm. In addition 23 of 25 patients of group B had some other evidence of left ventricular hypertrophy either on electrocardiogram¹⁰ or by angiography.⁶ No patient in group B had known rheumatic mitral valve disease or mitral valve prolapse. In group C (atrial fibrillation) three patients had mitral stenosis three had left ventricular hypertrophy two had atrial fibrillation alone six had mitral stenosis and left ventricular hypertrophy and one had a mitral valve prosthesis.

All patients were examined supine or in the left lateral decubitus position. A Unirad echocardiograph and either a 10 mm diameter 2.25 MHz 7.5 or 10 cm focused or unfocused transducer was used for all the echocardiograms which were recorded on Honeywell or Tektronix recorders. Each echocardiogram was evaluated indepen-

From the Division of Cardiology Department of Medicine Mount Sinai School of Medicine of the City University of New York, New York, NY.

Received for publication November 11, 1977.

Accepted for publication December 19, 1977.

Reprint requests: John A. Ambrose MD, The Mount Sinai Medical Center On Gustave L. Levy Place New York, NY 10029.




Fig 1 Echocardiogram of a normal individual (group A) At right schematic representation showing methods of measurement to calculate the VAW IVS = interventricular septum L = left side of IVS R = right side of IVS PW = posterior wall of left ventricle Endo = endocardium of PW Epi = epicardium of PW D_1 = initial internal diastolic dimension of the left ventricle D_E = end diastolic dimension of the left ventricle VAW = ventricular A wave

Table 1 Summary of echocardiographic data*

Group	A	p	B ₁	p	B
Number	30		19		6
PR AC interval (sec)	Normal (> 0.6 sec)		Normal (> 0.6 sec)		Abnormal (< 0.6 sec)
Age (years)	34.5 ± 2.0	<0.001	53.3 ± 3.8	NS	57.5 ± 4.0
Heart rate (per min)	68.5 ± 1.5	NS	69.0 ± 2.7	NS	68.4 ± 4.1
LA size (cm/M ²)†	1.7 ± 0.1	NS	1.9 ± 0.1	NS	2.5 ± 0.2
PW thickness (mm)	9.6 ± 0.2	<0.001	13.8 ± 0.6	NS	14.4 ± 1.2
IVS thickness (mm)	10.0 ± 0.7	<0.001	15.3 ± 0.7	NS	15.6 ± 0.9
E F slope (mm/sec)	103.0 ± 4.3	<0.001	50.5 ± 5.3	NS	55.0 ± 12.7
D ₁ (cm)	4.3 ± 0.2	NS	3.9 ± 0.1	NS	4.3 ± 0.4
Ejection fractions (%)	65.0 ± 1.9	NS	67.0 ± 2.6	NS	61.0 ± 4.8
PR interval (sec)	0.17 ± 0.01	NS	0.19 ± 0.04	NS	0.20 ± 0.02

The values are expressed as the mean ± the standard error of the mean

†Abbreviations LA = left atrial PW = posterior wall IVS = interventricular septum D_1 = initial internal diastolic LV dimension

dently by at least two observers with less than 10 per cent variation in these interpretations

Four patients from group B₁ (see below) had additional echocardiograms performed during right ventricular pacing at heart rates just above their own intrinsic rate. In addition 15 subjects from all groups had repeat echocardiograms for evaluation of reproducibility of measurements

The following parameters were measured on each echocardiogram. Left atrial size the E F slope of the anterior mitral valve leaflet (the E F slope was measured when present) the PR minus AC interval of the mitral valve the diastolic interventricular septal and left ventricular posterior wall thickness measured before atrial systole and diastolic and systolic internal dimensions of




Fig 2 Echocardiogram of a patient with idiopathic hypertrophic subaortic stenosis (group III) showing a large VAW (arrow). In addition note the presence of posterior wall hypertrophy

the left ventricle. Systolic and diastolic left ventricular volumes and ejection fractions were calculated. On the basis of the PR minus AC interval group B was subdivided into group B₁ (19 patients) who had a normal PR minus AC interval (> 0.06 sec) and group B₂ (six patients) with a large notch on the AC slope and a shortened PR minus AC interval (< 0.06 sec).

Diastolic dimensions of the left ventricle were measured just below the mitral valve or where the posterior leaflet of the mitral valve was seen. An initial left ventricular late diastolic internal dimension (D_e) was measured at the beginning of the P wave of the electrocardiogram and an end diastolic internal dimension (D_i) was measured at the peak of the R wave of the QRS complex at




Fig 3 Echocardiogram of a patient in group B with hypertensive heart disease demonstrating (A) significant asymmetric left ventricular hypertrophy and a small VAW (arrow) and (B) a marked notch on the AC slope of the anterior mitral valve leaflet (arrow).

a time when the interventricular septum dipped anteriorly and the posterior wall moved posteriorly (see Fig 1). At least three complexes were averaged to determine the diastolic diameters of the left ventricle. In patients in atrial fibrillation the D_i was arbitrarily measured 160 msec before the QRS complex.

The absolute difference between these two diastolic dimensions ($D_e - D_i$) was defined as the ventricular A wave (VAW) and the per cent ventricular A wave (per cent VAW) normalized for D_i was measured as $D_e - D_i / D_i \times 100$. Statistical analyses were performed using the Student's *t* test.

Results

The results of the echocardiographic measurements in groups A, B₁ and B₂ are given in Table I. Representative echocardiograms from each of the groups are shown in Figs 1, 2 and 3.

When compared to group A the patients in groups B₁ and B₂ were older, had increased posterior wall and interventricular thickness and decreased EF slopes (Table I). Even though the PR intervals were longer and their left atria larger the differences between these groups were not significant. The left ventricular diastolic dimensions and ejection fractions were also similar between the groups. The VAW and per cent




Fig 4 Echocardiogram of a patient with left ventricular hypertrophy and atrial fibrillation (group C) showing an absent VAW (arrow)




Fig 5 Per cent ventricular A wave in relation to the EF slope of anterior mitral valve leaflet in normal individuals (group A) patients with left ventricular hypertrophy and patients with asymmetric septal hypertrophy (Group B)

VAW for these groups are shown in Table II

The VAW and per cent VAW of group B, were statistically greater than in groups A and B. There were no statistical differences between groups A and B. Although the age of the controls was significantly less than in group B, eight

control patients over the age of 35 (mean age of 46) had a per cent VAW of 6.1 per cent which was not significantly different from the rest of the control group (group A). With atrial fibrillation (group C), the per cent VAW was markedly smaller than in the normals, even if left ventricular hypertrophy was present (Table II and Fig 4).

Comparison of VAW with other echocardiographic parameters In groups A and B, there was a weak inverse relationship between the EF slope of the anterior mitral valve leaflet (as an index of early diastolic filling) and the per cent VAW (r value = -0.63) (Fig 5). However, 18 of the 19 patients in group B, had a reduced EF slope of the anterior mitral valve leaflet (< 70 mm/sec). On the other hand a direct correlation between the degree of hypertrophy and the per cent VAW was present, slightly better with inter ventricular septal thickness ($r = 0.74$) than with posterior wall thickness ($r = 0.70$) (Fig 6). No correlation between these parameters was found in the other groups.

The VAW and right ventricular pacing To further evaluate the relation of the VAW to atrial contraction four patients in group B, had echocardiograms performed during right ventricular pacing. The VAW disappeared during pacing and




Fig 6 Per cent ventricular A wave in relation to (A) interventricular septal thickness and (B) left ventricular posterior wall thickness, in normal individuals (control), patients with left ventricular hypertrophy and patients with asymmetric septal hypertrophy (group B)

Table II Summary of VAW data

Group	A	p	B	p	B	C
VAW (cm.)	0.23 ± 0.03	< 0.001	0.51 ± 0.03	< 0.001	0.22 ± 0.07	0.06 ± 0.04
% VAW	4.9 ± 0.6	< 0.001	14.5 ± 0.5	< 0.001	4.9 ± 1.6	0.5 ± 0.3

Abbreviations: VAW = ventricular A wave

reappeared during normal conduction or when atrial contraction preceded pacemaker activation of the left ventricle (Figs 7 and 8)

Reproducibility In the 15 subjects of this study who had a repeat echocardiogram to evaluate the reproducibility of our measurements we found no significant differences in the magnitude of the VAW

Discussion

The echocardiogram of the normal left ventricle during end-diastole shows a posterior motion of the endocardial surface of the posterior wall and an anterior motion of the interventricular septum. The significance of these movements has not been well studied. In 1970 Kraunz and Kennedy¹⁰ divided the precontraction dip of the posterior left ventricular wall into a late diastolic and an early systolic component. The late diastolic posterior motion was attributed to atrial contraction while the systolic component was assumed related to isovolumetric contraction. This increase in the left ventricular diameter during isovolumetric contraction has also been seen by ventriculography.¹¹

The importance of atrial contraction in late diastolic filling of the left ventricle was first

recognized by Harvey.¹² Although subsequent investigators have differed on the actual contribution of atrial contraction to left ventricular filling in the normal heart, most studies have shown that on the average 20 to 35 per cent of filling occurs during this period.¹³⁻¹⁵ The major determinants governing the amount of late diastolic filling are the presence of a normal mitral valve, the force and timing of atrial contraction and the pressure-volume relationship of the left ventricle.¹⁶

The larger VAW and per cent VAW in patients with left ventricular hypertrophy and a normal PR minus AC interval (group B₁) than in normal individuals indicates enhanced late diastolic filling subsequent to atrial contraction in these patients. These differences were independent of PR interval, left atrial and left ventricular size (see Table I). The weak inverse relationship between the EF slope of the anterior mitral valve leaflet and the per cent VAW suggests that as early diastolic filling decreases, reflected in a decrease in the EF slope, late diastolic filling is augmented in order to maintain a normal stroke volume. This type of relationship has also been found in patients with hypertrophic cardiomyopathy and coronary artery disease¹⁷ by angio




Fig 7 Echocardiogram of a patient with left ventricular hypertrophy A During sinus rhythm a VAW is present (arrow) B Same position as in A The VAW is absent (arrow) during right ventricular pacing at a slightly faster rate than in A

graphic studies. In patients with aortic stenosis, Stott and colleagues¹⁰ observed an increase in the left ventricular circumference during atrial systole in addition to augmented left ventricular filling occurring during this period. This further ventricular enlargement in diastole observed after atrial contraction is consistent with the larger VAW we observed in our patients with left ventricular hypertrophy. With atrial fibrillation or during ventricular pacing the VAW significantly decreased or disappeared respectively, confirming its relation to atrial contraction.

The increased end diastolic pressure at a normal end diastolic volume seen in patients with left ventricular hypertrophy has been attributed to abnormal left ventricular compliance.^{28, 29} Grossman and associates,²⁰ using simultaneous left ventricular pressure and echocardiographic volume measurements, found an exaggerated increase in pressure relative to change in volume at end diastole in patients with left ventricular hypertrophy. Although simultaneous pressures were not measured in our study, we believe that the ability of the hypertrophied ventricle to expand in end diastole as demonstrated echocardiographically (group B₁) suggests that an increase in end diastolic filling may partially be

responsible for elevations of end diastolic pressure in left ventricular hypertrophy. In another study, Grossman and co workers²¹ have also shown a relationship between the degree of diastolic stiffness and left ventricular wall thickness. In our study we have shown a relationship between the VAW and posterior wall on interventricular septal thickness, suggesting that late diastolic filling depends to some extent on the degree of hypertrophy.

The significantly smaller VAW in group B₁ (left ventricular hypertrophy and delayed mitral valve closure) than in group B₂ (left ventricular hypertrophy and normal mitral valve closure) suggests less of an increase in left ventricular size with atrial contraction in the former group. Along with the decreased EF slope of the anterior mitral valve leaflet, it would indicate impaired left ventricular filling throughout diastole while in group B₂, left ventricular filling is decreased only in early diastole.

A delayed mitral valve closure as seen in group B₁ has been related to an exaggerated increase of left ventricular end diastolic pressure¹⁴ and/or an abnormal left ventricular dp/dt.²² These parameters probably reflect left ventricular dysfunction with greater chamber stiffness in group B₁.




Fig 8 Echocardiogram of a patient with left ventricular hypertrophy demonstrating (A) the presence of a VAW during sinus rhythm and (B) its disappearance during right ventricular pacing and its reappearance when a P wave precedes the ventricular activation (arrow)

It should be noted that there are several limitations to the assessment of any echocardiographic measurement of the left ventricle. We assume that the ice pick view of the left ventricle obtained with the echocardiographic beam is representative of the entire chamber provided there is no regional left ventricular asynergy. We presumed normal left ventricular contraction in all our normal volunteers. Thirteen of the 25 patients in group II had normal and uniform ventricular contraction on left ventriculography. In 10 of the other 12 patients there was no clinical suggestion of left ventricular asynergy (i.e. no

history of myocardial infarction and no abnormal Q waves in the electrocardiogram) although angiography was not performed.

Only patients with adequate echocardiograms for the identification of left ventricular wall layers were included implying other limitations of this type of assessment. Approximately 30 per cent of the echocardiograms evaluated for this study were rejected because of inadequate images. Even in the adequate echocardiograms utilized important errors can result from problems in ultrasonic resolution. Different beam widths or gain control settings may give an error

in echocardiographic measurements in the order of 1 to 2 mm. In addition, in some individuals it may be impossible to discern the endocardium from other echoes (e.g., chordal structures, papillary muscle). Furthermore, we arbitrarily chose the peak of the R wave of the electrocardiogram to define end diastole although it may actually precede or follow this point by 0.01 or 0.02 sec. The peak of the R wave did not always coincide with the largest left ventricular diastolic diameter. However, the magnitude of the VAW by inspection of each echocardiogram was obviously larger in group B, compared to the other groups and we feel that these measurements reflect real changes in end diastolic volumes. In spite of these limitations and the fact that our study is based on small differences in the VAW between the different groups, we were able to reproduce these measurements in the subjects with duplicate echocardiograms.

In conclusion, our findings suggest that echocardiography might provide a unique, non-invasive method to follow patients with left ventricular hypertrophy, especially secondary to hypertension, aortic stenosis, and idiopathic hypertrophic subaortic stenosis. Not only is it an accurate indicator of left ventricular wall thickness^{33,34} but it also is sensitive in demonstrating impaired left ventricular filling in early diastole (as measured by a decreased EF slope of the anterior mitral valve leaflet) as well as reflecting the increased filling in late diastole (a large VAW). In most patients with left ventricular hypertrophy, there is a decrease in the EF slope of the anterior mitral valve leaflet with a large VAW. With progression of the left ventricular hypertrophy, perhaps the ventricle becomes more stiff resulting in impaired late diastolic filling (decreasing VAW) with delayed mitral valve closure in addition to the decrease in early diastolic filling. This stage probably precedes significant dilatation of the left ventricle. Future studies evaluating the VAW in patients with left ventricular volume overload (in contrast to our patients with left ventricular pressure overload) and adding hemodynamic and clinical data will be required to support these conclusions.

Summary

Echocardiography was used to evaluate the late diastolic filling period of the left ventricle in 30 normal individuals, 25 patients with left

ventricular hypertrophy, normal sinus rhythm and either a normal or delayed mitral valve closure, and 15 patients with atrial fibrillation. The echocardiographic ventricular A wave (VAW) was defined as the difference between the end diastolic and an earlier late diastolic internal left ventricular dimension and it was felt to primarily reflect the atrial contribution to late diastolic filling of the left ventricle. It disappeared during ventricular pacing and was significantly smaller than normal in patients with atrial fibrillation. The VAW was significantly larger in patients with left ventricular hypertrophy and normal mitral valve closure reflecting the greater contribution by atrial contraction to late diastolic filling in these patients. In patients with left ventricular hypertrophy and delayed mitral valve closure the VAW was normal reflecting lesser ventricular enlargement with atrial contraction than in the other patients with left ventricular hypertrophy. This suggested a greater impairment to left ventricular filling in these patients. Therefore, the VAW appears to be an indicator of abnormalities of late diastolic filling caused by left ventricular hypertrophy.

We gratefully acknowledge the secretarial assistance of Ms. Fern S. Pobner and Ms. Mona Schacht.

REFERENCES

1. Noble M I M, Milne E N C, Goerke R J, Carlsson E, Domenech R J, Saunders K B, and Hoffman J I. Left ventricular filling and diastolic pressure-volume relations in the conscious dog. *Circ Res* 24:296, 1969.
2. Nolan S P, Dixon S H, Fisher R D, and Morrow A G. The influence of atrial contraction and mitral valve mechanics on ventricular filling. *Am Heart J* 77:84, 1969.
3. Laniado S, Yellin E, Kotler M, Levy L, Stadler J, and Terduman R. A study of the dynamic relations between the mitral valve echogram and phasic mitral flow. *Circulation* 51:104, 1975.
4. Stewart S, Mason D T, Ross J, and Braunwald E. Slowing of the left atrial y descent: Evidence of impaired rate of left ventricular filling in idiopathic hypertrophic subaortic stenosis (Abstr.). *Am J Cardiol* 19:153, 1967.
5. Layton C, Gent G, Priddy H, McDonald A, and Bridgen W. Diastolic closure rate of normal mitral valve. *Br Heart J* 35:1066, 1973.
6. Quinones M A, Gaasch W H, Waiser E, and Alexander J K. Reduction in the rate of diastolic descent of the mitral valve echogram in patients with altered left ventricular diastolic pressure-volume relations. *Circulation* 49:246, 1974.
7. DeMarra A N, Miller R R, Amsterdam E A, Markson W, and Mason D T. Mitral valve early diastolic closing velocity in the echocardiogram: Relation to sequential diastolic flow and ventricular compliance. *Am J Cardiol* 37:693, 1976.
8. Braunwald E, and Frahm C V. Studies on Starling's

- law of the heart IV Observations on the hemodynamic functions of the left atrium in man *Circulation* 24 633 1961
- 9 Shah P M Gramiak R Kramers D H and Yu P N Determinants of atrial (S) and ventricular (S) gallop sounds in primary myocardial disease *N Engl J Med* 278 53 1968
 - 10 Stott D K Marpole D F Binstow J D Kloster F and Granswold H E The role of left atrial transport in aortic and mitral stenosis *Circulation* 41 1031 1970
 - 11 Popp R L, Wolfe H H Hurata T and Feigenbaum H Estimation of right and left ventricular size by ultrasound. A study of the echoes from the interventricular septum, *Am J Cardiol* 24 523 1969
 - 12 Fortum W J Hood W P Jr Herman N and Craige H Determinations of left ventricular volumes by ultrasound, *Circulation* 46 26 1972
 - 13 Feigenbaum H Popp R L Wolfe S B Troy H L Pomo J F Haine C L and Dodge H T Ultrasound measurements of the left ventricle A correlative study with angiocardiography *Arch Intern Med* 129 461 19 2
 - 14 Jacobs J J Feigenbaum H Corys B C and Phillips J F Detection of left ventricular asynergy by echocardiography *Circulation* 48 963 1973
 - 15 Marmot H J L Practical electro arborography Baltimore 1972 The Williams & Wilkins Company Publishers
 - 16 Rackley C E Dodge H T Coble Y D and Hay R E A method for determining left ventricular mass in man, *Circulation* 29 666 1964
 - 17 Zaky A Nasser W K and Feigenbaum H Study of mitral valve action recorded by reflected ultrasound and its application in the diagnosis of mitral stenosis, *Circulation* 37 189 1968
 - 18 Konecke L L Feigenbaum H Chang S Corys B C and Fischer J C Abnormal mitral valve motion in patients with elevated left ventricular end diastolic pressures *Circulation* 47 989 1973
 - 19 Teichholz L E Kreulen T Herman M V and Gorlin R Problems in echocardiographic volume determinations echocardiographic angiographic correlations in the presence or absence of asynergy *Am J Cardiol* 37 7 1976
 - 20 Krasus R F and Kennedy J W Ultrasonic determination of left ventricular wall motion in normal man *Am HEART J* 79 38 1970
 - 21 Rushmer R F Initial phase of ventricular systole Asynchronous contraction *Am J Physiol* 184 188 1956
 - 22 Harvey W Movement of the heart and blood in animals An anatomical essay Translated by Franklin A. J p 34 Oxford 1957 Blackwell Scientific Publications
 - 23 Gribbe P Hervonen L Lind J and Wegelius C Cineangiographic recordings of the cyclic changes in volume of the left ventricle *Cardiologia* 34 348 1959
 - 24 Wiggers C J and Katz L N The contours of the ventricular volume curves under different conditions *Am J Physiol* 58 439 1929
 - 25 Mitchell J H Gilmore J P, and Sarnoff S J The transport function of the atrium Factors influencing the relation between mean left atrial pressure and left ventricular end-diastolic pressure *Am J Cardiol* 9 237 1967
 - 26 Linden R J and Mitchell J H Relation between left ventricular diastolic pressure and myocardial segment length and observations on the contribution of atrial systole *Circ Res* 8 109 1960
 - 27 Miller R H Vismara L A DeMaria A N Gifford W, and Mason D T Atrial transport in patients with ischemic heart disease and hypertrophic cardiomyopathy Increased contribution to pump function in reduced left ventricular compliance (Abstr) *Clin Res* 23 197A 1975
 - 28 Dodge H T Hay H E and Snadler H Pressure-volume characteristics of the diastolic left ventricle of man with heart disease *Am HEART J* 84 303 1962
 - 29 Goldblatt A Aygen M M and Braunwald E Hemodynamic-phonocardiographic correlations of the fourth heart sound in aortic stenosis, *Circulation* 26 1962
 - 30 Grossman W Stefadouras M A, McLaurin L P Rolett E L and Young D T Quantitative assessment of left ventricular diastolic stiffness in man *Circulation* 47 567 1973
 - 31 Grossman W McLaurin L P Moos S P Stefadouras M A and Young D T Wall thickness and diastolic properties of the left ventricle *Circulation* 49 179 1974
 - 32 Kantrowitz P Present and future trends Advances in non invasive diagnostic cardiology edited by Kingsley B Thorofore N J 19 6 Charles B Slack Publisher p 210
 - 33 Feigenbaum, H Popp R L Chup J N and Haine, C L Left ventricular wall thickness measured by ultrasound *Arch. Intern Med.* 121 391 1968
 - 34 Abbas, A S MacAlpin H N Eder L M and Pearce M L Left ventricular hypertrophy diagnosed by echocardiography *N Engl J Med* 289 118 1973

Leukocyte function after aortic valve replacement

Bernt Kvarstein, M D

Jon Dale, M D

Oslo Norway

Patients with aortic ball valve prostheses regularly develop intravascular hemolysis to a higher or lesser degree,¹ and their platelet reactivity is disturbed. The shortened survival of red cells² and platelets^{3,4} is most probably caused by direct mechanical trauma inflicted by the valve. The prosthetic valve may also damage leukocytes and their functional capacity may be reduced, although sepsis is a rather rare cause of death in the late course of aortic valve replacement.

The consumption of oxygen by leukocytes during phagocytosis reflects their functional capacity.^{5,6} The purpose of the present study was to evaluate leukocyte function with an oxygen consumption test in patients with aortic ball valve prostheses and compare the results with normal volunteers.

Materials and methods

Thirty eight patients with prosthetic heart valves were included, 24 men and 14 women. They had all Starr Edwards aortic ball valves implanted on average 4.5 years previously. Two modifications of the valve had been used¹⁰, 16 had the older type 1200 which inflicts less trauma upon red cells and platelets than does type 2300¹ which had been implanted in 22 of the patients. The mean age in the patient group was 54 years. The normal material consisted of 50 healthy blood donors, 42 men and eight women, their mean age being 46 years.

Blood was collected into siliconized glass tubes

containing heparin, final concentration 0.007 M.

Isolation of leukocytes was done according to Bøyum.¹¹ A suspension rich in white cells and platelets was obtained.

Leukocyte counting in the suspensions was done with an electronic particle counter (Cellocope 101, AB Lars Ljungberg & Co, Stockholm, Sweden).¹² Counting in citrated blood (nine parts of blood to one part of 3.1 per cent of sodium citrate) was done microscopically using a hemocytometer, and the numbers were corrected for dilution with citrate. Differential leukocyte counting was also done microscopically after conventional staining of blood films.

Oxygen consumption during phagocytosis was measured polarographically with a Clark oxygen electrode (Yellow Springs Instruments Co, Yellow Springs, Ohio, USA) at 37°C in 2.5 ml of leukocyte suspension during magnetic stirring.^{7,13} The electrode was connected to a Beckman 10 inch recorder (Beckman Instruments Inc, Fullerton, California, USA). When the endogenous oxygen consumption had reached a stable level, 100 µl of a 10 per cent polystyrene latex particle suspension (Dow Chemical Company, Midland, Michigan, USA) were added. The oxygen consumption was then measured in nanomoles per minute and calculated per 10⁶ leukocytes.⁷

Serum lactate dehydrogenase (LDH) was determined as described previously¹⁴ at 25°C and expressed in international units.¹⁵

Results

The elevated serum LDH levels in the ball valve patients reflect the degree of intravascular hemolysis (Table I) which differed considerably between them. The mean number of leukocytes

From the Institute for Thrombosis Research and Medical Department B, Rikshospitalet University Hospital, Oslo, Norway.

Received for publication Nov. 11, 1977.

Accepted for publication Jan. 11, 1978.

Reprint requests to Dr. J. Dale, Medical Department B, Rikshospitalet, Oslo 1, Norway.

Table 1 Serum lactate dehydrogenase levels, white cell counts and oxygen consumption during phagocytosis in patients with Starr Edwards aortic ball valve prostheses and in healthy subjects

	Patients with ball valves		Healthy individuals		Student's <i>t</i> test
	Mean	S.D.	Mean	S.D.	
Serum lactate dehydrogenase (U/L.)	442.7	191.2	122.2	21.7	$p < 0.001$
Leucocytes per ml. of blood	7.16	1.96	7.33	1.34	N.S.
Oxygen consumption (n atoms/min./10 ⁶ leucocytes)	3.95	1.25	4.16	1.31	N.S.

was not significantly higher in the healthy subjects. Differential counting did not reveal marked differences but slightly more younger neutrophilic granulocytes were found in the patients. The increase in oxygen consumption by leukocytes during phagocytosis was not significantly lower in the ball valve patients than in the healthy subjects. The consumption by leukocytes from one ml. of blood was calculated: the mean values being 28.3 nano atoms in the patients and 30.5 in the normal material. The difference was not statistically significant. The individual values for oxygen consumption was compared with the degree of intravascular hemolysis but no significant correlation was found.

Discussion

Phagocytosis is accompanied by an increase in oxygen consumption which can be quite accurately measured by the polarographic technique. The method allows examination of leukocytes that are not separated from plasma and it reflects the total phagocytic capacity of all leukocytes. Thus the procedure mimics the *in vivo* situation as far as possible.

The study did not disclose a significantly reduced oxygen consumption by leukocytes during phagocytosis in patients with prosthetic heart valves indicating that the functional capacity of the cells is rendered intact and their defense mechanisms against bacterial infections are not weakened. Theoretically the leukocyte function could be disturbed by the trauma from the prosthetic valves or their capacity for phagocytosis could be reduced because they had engulfed circulating particles derived from other damaged cells. Our results indicate however that leukocytes are not easily affected by mechanical trauma or that new cells are formed so rapidly that a normal total capacity for phagocytosis is

maintained. Possibly the polarographic method is not sensitive enough to disclose minor disturbances of leukocyte function.

The results suggest that the cells are able to maintain phagocytosis even under more unfavorable conditions which may occur during severe bacterial infections with endotoxemia. Thus leukocytosis has been found to develop in dogs shortly after endotoxin infusions in spite of intravascular coagulation and shock.¹⁵

In conclusion the results indicate that the part of the defense against infections that depends upon leukocyte function is not weakened in patients with prosthetic heart valves.

Summary

Leukocyte function was studied in patients with prosthetic heart valves by oxygen consumption measurements during phagocytosis of polystyrene latex particles. The consumption reflects the phagocytotic capacity of the cells. In 38 patients with Starr Edwards aortic ball valves the mean oxygen consumption was 3.95 nano atoms per minute per 10⁶ leukocytes as compared to 4.15 in 50 healthy subjects; the difference not being statistically significant. The number of leukocytes per ml. of blood and the distribution of cell types was quite similar in the two groups although slightly more younger cells were found in the patients. It is concluded that the capacity for phagocytosis is not significantly reduced after aortic ball valve implantation.

REFERENCES

1. Myhre E, Dale J and Rasmussen K. Erythrocyte destruction in different types of Starr Edwards aortic ball valves, *Circulation* 42:515-19, 1970.
2. Dale J and Myhre E. Platelet functions in patients with aortic ball valves, *AM HEART J* 94:339, 1977.
3. Myhre E, Rasmussen K and Andersen A. Serum lactic dehydrogenase activity in patients with prosthetic

- heart valves. A parameter of intravascular hemolysis. *AM HEART J* 80:463 1970
- 4 Harker L A and Shchter S J. *Studies on platelet and fibrinogen kinetics in patients with prosthetic heart valves*. *N Engl J Med* 287:155 1972
- 5 Steele P, Weily H, Davies H, Pappas G and Genton G. Platelet survival time following aortic valve replacement. *Circulation* 51:358 1975
- 6 Stuart R K, McDonald J W, Ahuja S P and Coles J C. Platelet survival in patients with prosthetic heart valves. *Am J Cardiol* 33:840 1974
- 7 Kvarstein B. Oxygen consumption during the initial stage of human leukocyte phagocytosis of polystyrene latex particles. *Scand J Clin Lab Invest* 25:337 1970
- 8 Kvarstein B and Halvorsen K S. Oxygen consumption during the initial stage of human leukocyte phagocytosis as a test for chronic granulomatous disease. *Scand J Clin Lab Invest* 26:175 1970
- 9 Kvarstein B and Stormorken H. The influence of acetylsalicylic acid, butazolidine, colchicine, hydrocortisone, chlorpromazine and imipramine on the phagocytosis of polystyrene latex particles by human leukocytes. *Biochem Pharmacol* 20:119 1971
- 10 Herr R H, Starr A, Piene W R, Wood J A and Bigelow J C. Aortic valve replacement. A review of six years' experience with the ball valve prosthesis. *Ann Thorac Surg* 6:199 1968
- 11 Bøyum A. Separation of leukocytes from blood and bone marrow. *Scand J Clin Lab Invest* 21(Suppl. 9):1968
- 12 Kvarstein B. The use of an electronic particle counter (Celloscope 101) for counting leukocytes. *Scand J Clin Lab Invest* 29:389 1972
- 13 Chappel J B. The oxidation of citrate, iso-citrate and cis-aconitate by isolated mitochondria. *Biochem J* 90:225 1964
- 14 Dale J, Myhre E and Rasmussen K. Elimination of hemoglobin and lactate dehydrogenase from plasma in normal subjects and patients with intravascular hemolysis. *Scand J Clin Lab Invest* 29:389 1972
- 15 Aasen A, Dale J, Olsson K and Gallimore M. Effects of slow intravenous administration of endotoxin on blood cells and coagulation in dogs. *Europ J Surg Res* (in press)

Quinidine pharmacokinetics in patients with cirrhosis or receiving propranolol

Kenneth M Kessler MD
William C Humphries Jr MD
Martin Black MD
James F Spann MD
Philadelphia Pa

Quinidine is the prototype Class I antiarrhythmic agent and continues to find wide clinical usage. It is metabolized by the liver to nonphenolic hydroxy derivatives and their conjugates which are more water soluble than quinidine. These metabolites are in turn excreted by the kidney.¹ An active quinidine metabolite, O-desmethylquinidine, has been identified but its clinical significance has not been delineated.²

Although the binding of quinidine to plasma proteins is decreased in patients with cirrhosis and one patient with cirrhosis and the hepatorenal syndrome had an abnormally prolonged quinidine half-life,³ a systematic investigation of quinidine pharmacokinetics in patients with hepatic dysfunction has not been available.

In the present study a single 200 mg oral dose of quinidine was administered to control patients with moderate to severe cirrhosis and patients receiving propranolol. Quinidine concentration-time curves were constructed and the data were analyzed to answer the following specific questions:

- 1 Does hepatic dysfunction or propranolol alter quinidine pharmacokinetics?
- 2 If there is an alteration, how are half-life and

calculated volume of distribution and clearance individually altered?

- 3 Is the binding of quinidine to plasma proteins changed?

- 4 What are the relevant therapeutic implications of these findings?

Methods

Patients were selected from the inpatient population of Temple University Health Sciences Center. The study was explained in detail to each patient and signed consent was obtained from each participant. The patients were divided into the following groups:

Control group Eight patients with no evidence of impaired hepatic function, hypoalbuminemia, congestive heart failure, or renal failure. Their diagnoses were coronary artery disease with angina pectoris—five, atypical chest pain with normal coronary arteries—two, and mild mitral stenosis—one.

Cirrhotic group Eight patients with a history of chronic alcohol abuse and physical evidence of cirrhosis (e.g., spider angiomas, wasting ascites, and/or hepatomegaly) and confirmatory laboratory tests were selected. In each case the diagnosis of Laennec cirrhosis had been proven by percutaneous liver biopsy, although in no case was the biopsy performed solely for the purposes of this study. Patients with coexisting renal failure or congestive heart failure were excluded from this group. Additional diagnoses included anemia—five, electrolyte imbalance—three, urinary tract infection—one, improving hepatic encephalopathy—two, duodenal ulcer—one, diabetes mellitus—one.

Cholestatic group Two patients were incidentally studied, one of whom had biliary cirrhosis.

From the Department of Medicine, Section of Cardiology, Temple University Health Sciences Center, Philadelphia, Pa.

Supported in part by Grant N01-R05417 from the Division of Research Resources, National Institutes of Health. This research was also assisted by a grant from the Honorable Louis C. Bechtle, Judge of the United States District Court for the Eastern District of Pennsylvania. We are pleased to acknowledge the acknowledgment and express our sincere gratitude for this aid.

Received for publication November 29, 1977.

Accepted for publication February 27, 1978.

Reprint requests: Kenneth M. Kessler, MD, Dept. of Medicine, Section of Cardiology, Temple University Health Sciences Center, 3401 N. Broad St., Philadelphia, Pa. 19140.

Table 1 Clinical profiles of patients studied

Patient group	Age	Sex	Total protein (Gm %)	Albumin (Gm %)	Bili rubin (mg %)	Alkaline phosphatase (IU)	SGOT (IU)	Blood urea nitrogen (mg %)	Creatinine (mg %)	Prothrombin time (SEC)	Urinary pH
Control group (8)											
Mean \pm SE	43 67	3F 5M	68 ± 2	42 ± 1	4 \pm 1	70 \pm 8	26 \pm 5	15 \pm 1	11 \pm 1	11 \pm 2	62 \pm 1
Cirrhotic group (8)											
1 TB	45	M	64	22	30	150	30	11	09	139	70
2 WH	51	M	81	23	145	238	122	5	08	136	70
3 LK	54	F	68	16	41	138	54	13	12	178	50
4 MP	49	M	57	25	56	139	116	■	09	120	70
■ RF	46	M	85	32	82	105	65	17	09	118	65
6 HN	53	F	78	25	80	185	116	12	09	150	60
7 AL	47	F	70	28	58	229	103	7	08	126	60
8 LS	44	M	77	26	19	105	243	9	06	131	60
Mean \pm SE	44 54	3F 5M	72 ± 3	25 $\pm 2\frac{1}{2}$	64 $\pm 14\frac{1}{2}$	161 $\pm 18\frac{1}{2}$	106 $\pm 23\frac{1}{2}$	10 $\pm 1^*$	9 ± 1	14 \pm 10 $\frac{1}{2}$	63 \pm 2
Cholestatic group (2)											
1 TS	29	M	62	31	105	500	127	■	10	110	60
2 CS	37	M	76	34	44	1170	123	7	03	101	75
Propranolol group (7)											
Mean \pm SE	47 56	3F 4M	65 ± 2	36 \pm 1	4 \pm 1	88 \pm 13	49 \pm 17	16 \pm 3	11 \pm 1	11 \pm 3	63 \pm 3

SGOT = serum glutamic oxalacetic transaminase

p < .05 *p < .01 †p < .005 §p < .001 level of significance as compared to control group by unpaired Student's t test

and the other alcoholic liver disease characterized by fatty infiltration and bile plugging without fibrosis. Neither patient had renal failure or congestive heart failure. Additional diagnoses included alcohol withdrawal seizures and anemia—one.

Propranolol group Seven patients receiving stable propranolol doses ranging from 40 to 400 mg per day were studied (40 mg per day—W M in Table II, 160 mg—R H, 240 mg—M C C G, S R, 320 mg—J C, 400 mg—E F). Patients with coexisting hypoalbuminemia, renal failure, congestive heart failure, or liver disease were excluded from this group. Their diagnoses were coronary artery disease—six, stable angina pectoris—three, unstable angina—one, hypertension—two, inferior myocardial infarction—one, subendocardial myocardial infarction—one, and idiopathic hypertrophic subaortic stenosis—one.

Each patient was fully evaluated including a complete history (with particular note to alcohol intake, both recent and remote), physical examination, and a medication history (with emphasis on prior use of quinidine and known sensitivity to it). In addition, a complete blood count and differential, electrocardiogram, serum glutamic

oxalacetic transaminase, alkaline phosphatase, lactate dehydrogenase, bilirubin, prothrombin time, urinary pH, total protein and albumin were obtained. Each patient was screened for glucose 6 phosphate dehydrogenase deficiency. No patient had evidence of malabsorption.

Drug administration protocol Each patient received a 200 mg oral dose of quinidine sulfate before breakfast. Patients were monitored for side effects throughout the day. Blood samples were obtained at hourly intervals for four hours and subsequently at two hour intervals until 12 hours after the oral dose.

Quinidine determinations Quinidine concentrations were determined by both a double extraction¹² and a protein precipitate method.¹³ The double extraction method is more specific¹² and has been shown to compare favorably with gas chromatographic and gas chromatographic/mass-spectrometric techniques.¹⁴ The protein precipitate method is less specific, measuring both quinidine and its water soluble metabolites. Quinidine binding to plasma proteins was determined by an ultrafiltration method¹⁵ using the double extraction assay method.

Data analysis Quinidine concentration time

Table II Quinidine pharmacokinetic data

Group	Half life (hours)	Volume of distribution (L/kg)	Clearance (ml/min/kg)	Peak level (µg/ml)	Time to peak level (hours)	Percent unbound
Control group (8)						
1 TH	4.5	2.25	5.8	70	2	24.5
2 TF	5.5	2.15	4.5	83	4	33.5
3 IC	6	2.48	4.8	86	6	20
4 JG	9	2.43	3.1	82	4	10.5
5 IG	5.5	3.07	6.3	69	3.5	39.5
6 WR	7	3.02	5.0	58	2.5	65
7 HT	4	2.33	6.8	94	1.5	15
8 RD	6	2.00	3.8	97	1	12
Mean ± SE	6 ± 5	2.5 ± 1	5.0 ± 4	80 ± 05		
Cirrhotic group (8)						
1 TB	8	3.44	5.0	70	2	26.5
2 WH	9	5.15	6.6	57	1	47
3 LH	9	3.66	4.7	83	1	50.5
4 MP	6.5	3.56	6.3	74	2	40.5
5 RF	9	1.93	2.4	113	1	14.7
6 HN	11	5.41	5.6	41	0	26
7 AL	12	3.76	3.6	94	3	31
8 LS	6	3.64	7.0	57	1	54.5
Mean ± SE	9 ± 17	3.8 ± 47	5.2 ± 6	74 ± 08		
Propranolol group (7)						
1 EF	4	—	—	—	—	—
2 JC	5	1.7	4.0	1.29	1	25
3 RH	7	2.4	3.9	.59	6	41
4 WM	5.5	1.6	3.4	1.63	1	36
5 MC	5	2.2	5.0	.77	1	19
6 CG	7	2.8	1.7	1.4	1	13
7 SR	7.5	1.4	.9	1.8	2.5	15
Mean ± SE	6 ± 5	2.0 ± .2	3.1 ± 6	1.25 ± 20		

SGOT = serum glutamic oxaloacetic transaminase

p < .05 *p < .01 **p < .005 ***p < .001 level of significance as compared to control group by unpaired Student's t test

curves were plotted on semilogarithmic paper and the best straight line was fitted to the exponential disappearance phase of the curve. Quinidine half life was thus determined. Volume of distribution and clearance were calculated by the following formulas:

$$\text{Volume of distribution} = \frac{0.693 AUC}{D} \cdot \frac{1}{T_{1/2}}$$

$$\text{Clearance} = \frac{D}{AUC}$$

where D represents milligrams of quinidine base available to the circulation (85 per cent of the 200 mg oral quinidine sulfate dose). $T_{1/2}$ is the half life in hours determined as above and AUC is the area under the concentration time curve in mg·h/ml (calculated to infinity). Clearance and volume of distribution were adjusted per kilogram of body weight.

Statistics: Mean and standard error were calculated for each of the parameters and the

unpaired Student's t test was used to calculate statistical significance.¹³

Results

Patient profiles (Table I) The age range male to female ratio and random urinary pH were not different between control cirrhotic and propranolol groups. All patients had creatinine concentrations which fell within the normal range. Routine laboratory data and liver function tests fell within the normal range for each patient within the control and propranolol groups. The cirrhotic group had significantly lower albumin and blood urea nitrogen concentrations and significantly higher bilirubin, serum glutamic oxalacetic transaminase activity, alkaline phosphatase and prothrombin time than the control group. The two patients with cholestatic liver disease were both males and were younger than the other patients studied. They had normal




Fig 1 Plasma quinidine concentrations measured by the double extraction method during the logarithmic disappearance phase of the concentration-time curve in eight control patients

prothrombin times albumin levels greater than 3 mg per cent and markedly elevated alkaline phosphatase values

Quinidine pharmacokinetics (Table II Figs 1 through 4) The half life of quinidine was significantly prolonged (9 ± 1 hr) in the cirrhotic group when compared to the control group (6 ± 0.5 hr, $p < 0.1$, Fig 4). Six of the eight patients in the cirrhotic group had quinidine half lives of 8 hours or greater (i.e., greater than the mean plus two standard errors), whereas only one of the control group had a half life that long. In contrast to the significantly prolonged half life of quinidine in patients with cirrhosis, the quinidine clearance value in the cirrhotic patients (5.2 ± 6 ml/min/Kg) was almost identical to that of the control group (5.0 ± 4 ml/min/Kg). The prolongation of half life was related to a significantly greater volume of distribution of quinidine in the cirrhotic group (38 ± 4 L/Kg) when compared to the control group (25 ± 1 L/Kg, $p < 0.1$). This increase in volume of distribution did not significantly correlate to serum albumin

($R = -0.39$) bilirubin ($R = 0.42$) or prothrombin time ($R = 0.37$)

The half life of quinidine in the propranolol group was normal (6 ± 5 hr), however, the clearance rate (3.1 ± 6 ml/min/Kg) was significantly reduced when compared to the control group ($p < 0.05$). Clearance rates did not correlate to propranolol dose ($r = 0.05$). A decreased volume of distribution was evident in some of the propranolol patients and was further implied by their higher peak levels (125 ± 2 µg/ml vs 80 ± 5 µg/ml in the control group, $p < 0.05$).

The two patients with cholestatic liver disease had short half lives (4 and 25 hr) normal volumes of distribution and clearance rates higher (73 and 107 ml/min/Kg) than any of the other patients studied.

Quinidine binding to plasma proteins was determined in each of the patients and a greater than 25 per cent unbound fraction was considered abnormal. Abnormal binding was identified in three of the eight control patients, two of the five propranolol patients, seven of the eight patients




Fig 2 Plasma quinidine concentrations measured by the double-extraction method during the logarithmic disappearance phase of the concentration-time curve in eight patients with cirrhosis

with cirrhosis and both of the patients with cholestatic liver disease. Although as a group the cirrhotic patients had unpaired quinidine binding and low serum albumen concentrations the per cent unbound quinidine did not significantly correlate with serum albumen, bilirubin or the prothrombin time.

The ratio of the quinidine concentration determined by the protein precipitate method to the quinidine concentration determined by the double extraction method may be used as an index of the relative concentration of circulating quinidine metabolites. This ratio was determined in our main three groups of patients at 1 hour after their peak quinidine concentration and at 10 hours after the dose was given. In the control group this ratio was 1.5 ± 1 at one hour after the peak and 1.5 ± 1 at 10 hours after the dose. In the propranolol group the ratio was very similar (1.5 ± 1 one hour after the peak and 1.6 ± 1 at 10 hours after the dose). In the cirrhotic group however the ratio one hour after the peak was significantly

lower (1.0 ± 1 , $p < 0.1$) than in the control group. By ten hours after the dose this ratio (1.2 ± 2) was still lower although the difference was not statistically significant.

Absorption. Peak levels were obtained within 2.5 hours after the dose of quinidine in 16 of 25 patients. Variability was noted: three patients (one of each of the major groups) showing delayed peaks at 8 hours after the dose.

Side effects and toxicity. No major side effects were noted. Two patients had gastrointestinal side effects—one had nausea and the other nausea and diarrhea.

Discussion

This study characterizes the pharmacokinetics of quinidine in patients with liver dysfunction and receiving propranolol. Despite the knowledge that quinidine is metabolized by first order kinetics in the liver, little information is available on the effect of liver dysfunction on quinidine pharmacokinetics. In a single patient with both alco-




Fig 1 Plasma quinidine concentrations measured by the double extraction method during the logarithmic disappearance phase of the concentration-time curve in eight control patients

prothrombin times, albumin levels greater than 3 mg per cent and markedly elevated alkaline phosphatase values

Quinidine pharmacokinetics (Table II Figs 1 through 4) The half life of quinidine was significantly prolonged (9 ± 1 hr) in the cirrhotic group when compared to the control group (6 ± 0.5 hr, $p < 0.1$, Fig 4). Six of the eight patients in the cirrhotic group had quinidine half lives of 8 hours or greater (i.e., greater than the mean plus two standard errors) whereas only one of the control group had a half life that long. In contrast to the significantly prolonged half life of quinidine in patients with cirrhosis, the quinidine clearance value in the cirrhotic patients (5.2 ± 6 ml/min/Kg) was almost identical to that of the control group (5.0 ± 4 ml/min/Kg). The prolongation of half life was related to a significantly greater volume of distribution of quinidine in the cirrhotic group (3.8 ± 4 L/Kg) when compared to the control group (2.5 ± 1 L/Kg, $p < 0.1$). This increase in volume of distribution did not significantly correlate to serum albumin

($R = -0.39$), bilirubin ($R = 0.42$) or prothrombin time ($R = 0.37$).

The half life of quinidine in the propranolol group was normal (6 ± 1 hr), however, the clearance rate (3.1 ± 6 ml/min/Kg) was significantly reduced when compared to the control group ($p < 0.05$). Clearance rates did not correlate to propranolol dose ($r = 0.05$). A decreased volume of distribution was evident in some of the propranolol patients and was further implied by their higher peak levels (1.25 ± 2 µg/ml vs 80 ± 5 µg/ml in the control group, $p < 0.05$).

The two patients with cholestatic liver disease had short half lives (4 and 2.5 hr) normal volumes of distribution, and clearance rates higher (73 and 107 ml/min/Kg) than any of the other patients studied.

Quinidine binding to plasma proteins was determined in each of the patients and a greater than 25 per cent unbound fraction was considered abnormal. Abnormal binding was identified in three of the eight control patients, two of the five propranolol patients, seven of the eight patients

binding of quinidine to plasma proteins of patients with renal insufficiency is normal.¹² Thus changes in renal function and urinary pH have little consequence on quinidine therapeutics in the usual patient.

In the present study the effects of hepatic dysfunction and propranolol on quinidine pharmacokinetics was studied in detail. Four major parameters play a role in hepatic biotransformation: first the hepatic blood flow representing that portion of the cardiac output which transpires the liver; second the effects of anatomic disarray of the hepatic circulation causing shunting; third the binding of drug to serum and hepatic sites; and last the activity of the enzymes metabolizing that drug.¹³ Cirrhosis may interfere with any or all of the latter three parameters. Propranolol is known to reduce hepatic blood flow¹⁴ and can interfere with the metabolism of highly cleared drugs such as lidocaine and propranolol.¹⁵ Since patients with arrhythmias may have hepatic dysfunction (and vice versa) and since patients with cardiac disease may receive both quinidine and propranolol simultaneously, these interrelationships have obvious clinical importance.

In our current study the pharmacokinetics of quinidine were assessed after an oral dose. Using this method serum half life can be directly determined; however both clearance and volume of distribution are calculated values and are dependent on knowing how much drug reaches the circulation. The amount of quinidine reaching the circulation is in turn dependent on completeness of absorption and the hepatic first pass effect. Data regarding these parameters is scant; however quinidine availability after the administration of quinidine sulfate to nine cardiac patients was 87 ± 7 per cent and to eleven healthy volunteers was 81.9 ± 3.4 per cent. Therefore in the sulfate form quinidine is about 85 per cent available to the circulation and had a tolerable interpatient variability. The gluconate form has 47 to 99 per cent (mean 73 per cent) and 69.1 ± 2.8 per cent availability of quinidine and was specifically avoided. Although pharmacokinetics could have been more precisely measured the intravenous use of quinidine was also specifically avoided because many of our patients were clinically ill and the increased risks of this route of administration were not justified.

Our control group had a mean quinidine half life (6 ± 5 hr) volume of distribution (2.5 ± 1

L/Kg) and clearance (50 ± 4 ml/min/Kg) comparable to those reported by other investigators.²² In contrast the cirrhotic group had a significantly prolonged quinidine half life (9 ± 1 hr). This prolonged half life was related not to an altered clearance rate of quinidine as might have been expected by their advanced degree of parenchymal liver destruction but rather to a significantly increased volume of distribution of quinidine. This increase in volume of distribution is at least in part related to the decreased quinidine plasma protein binding found in patients with cirrhosis. This pattern of prolonged half life and increased volume of distribution of a drug in cirrhosis was also found to be true for another antiarrhythmic base—lidocaine.^{23, 24} Furthermore the ratio of the quinidine level by the precipitate to the double extraction method gives an estimate of the amount of quinidine metabolites circulating at any given time.¹ This ratio was significantly lower in the cirrhotic group when compared to the control group signifying fewer circulating metabolites in the cirrhotic patients; this finding confirms the slowed production of metabolites in patients with cirrhosis.

The two patients with cholestatic liver disease had normal volume of distribution, accelerated clearances and shortened half lives. These patients were significantly younger than the patients in the other groups. Quinidine pharmacokinetics have been shown to be age related; however the half life (4 and 2.5 hr) and clearance values (73 and 107 ml/min/Kg) of our two patients with cholestatic liver disease appear abnormal even when compared to the 12 healthy volunteers ages 23 to 31 years (half life 7.1 ± 0.7 hr and clearance 4.03 ± 0.35 ml/min/Kg) studied by Ochs and associates.²⁵ Age did not vary significantly in the control, cirrhotic or propranolol groups and should not be considered a variable in the assessment of their data. The number of patients with cholestatic liver disease does not allow for generalization of these findings but does provide a basis for further investigation of such an effect and its as yet unknown mechanism.

In contrast to the patients with liver disease patients receiving propranolol had normal quinidine half lives (6 ± 5 hr) but a significantly decreased rate of quinidine clearance. Consistent with the normal quinidine half life accompanied by a decreased clearance rate was the tendency of these patients to have a decreased volume of




Fig 3 Plasma quinidine concentration measured by the double extraction method during the logarithmic disappearance phase of the concentration-time curves in seven patients receiving propranolol




Fig 4 Quinidine half lives in control cirrhotic and propranolol patient groups. The horizontal and vertical lines indicate mean and standard error of the mean respectively. The * indicates a significant ($p < 0.1$) prolongation of half life in the cirrhotic group when compared with that in the control group (Student's *t* test unpaired).

hol related liver disease and the hepato renal syndrome a prolonged quinidine half life and an increased volume of distribution were found.¹ However, this example is complicated by the obscure pathophysiology of the hepato renal syndrome. Quinidine binding to plasma proteins has been shown to be decreased in many patients with cirrhosis.⁴ However, such binding information must be combined with half life data and calculated clearance and volume of distribution values to allow fully meaningful therapeutic recommendations.

Although the liver serves as the major organ of quinidine biotransformation, quinidine elimination had been ascribed to renal excretion.¹⁴ In 1969, Gerhardt and associates¹⁷ found that quinidine excretion is enhanced in acidic urine; however, only 20 per cent of the total quinidine dose was excreted unchanged even in patients with aciduria. Normal quinidine half life has been confirmed in patients with poor renal function¹ and in three anephric patients.¹⁸ Furthermore, the

cantly reduced quinidine clearance (33 ± 7 ml/min/Kg vs. 53 ± 5 ml/min/Kg in controls $p < 0.05$) and higher peak concentrations (125 ± 20 µg/ml vs. 80 ± 5 µg/ml in controls $p < 0.05$)

Therefore in patients receiving propranolol quinidine levels may be higher than expected shortly after dosage and therefore a potential for transient toxicity exists in these patients. Maintenance quinidine dosage may have to be reduced in patients with moderate to severe hepatic cirrhosis but not in patients receiving propranolol. Total quinidine concentration measurement underestimates free quinidine concentrations in most cirrhotic patients.

We wish to thank Ms Robin Leech for her expert technical assistance and Marcus M. Reidenberg, M.D. for his continued encouragement and for his review of the final manuscript.

REFERENCES

1. Brodie H H, Baer J E and Craig L C Metabolic products of the cinchona alkaloids in human urine. *J Biol Chem* 188:567 1951
2. Ueda, T C, Williamson B S., and Dzandzio B S Absolute quinidines bioavailability. *Clin Pharmacol Ther* 20:260 1976
3. Drayer D F, Cook, C E and Reidenberg M M Active quinidine metabolites. *Clin Res* 24:623A 1976
4. Afrime, M and Reidenberg M M The protein binding of some drugs in plasma from patients with alcoholic liver disease. *Europ J Clin Pharmacol* 8:267 1975
5. Conrad, R A, Melik B L and Chidsey C A Pharmacokinetic studies of quinidine in patients with arrhythmias. *Circulation* 55:1 1977
6. Cramér G and Isaksson H Quantitative determination of quinidine in plasma. *Scand J Clin Lab Invest* 15:553 1963
7. Kessler K M, Lowenthal D T, Warner H, Gibson T, Briggs W and Reidenberg M M Quinidine elimination in patients with congestive heart failure or poor renal function. *N Engl J Med* 290:706 1974
8. Brodie B B and Udenfriend S The estimation of quinidine in human plasma with a note on the estimation of quinidine. *J Pharmacol Exp Ther* 78:154 1943
9. Hartel G and Korhonen A Thin layer chromatography for the quantitative separation of quinidine and quinidine metabolites from biological fluids and tissues. *J Chromatogr* 37:70 1968
10. Hartel, G and Harjanne A Comparison of two methods for quinidine determination and chromatographic analysis of the difference. *Clin Chim Acta* 23:289 1969
11. Hoffman H H and Hignite C E Serum quinidine concentrations: comparison of fluorescence, gas-chromatographic and gas-chromatographic/mass spectrometric methods. *Clin Chem* 22:810 1976
12. Reidenberg M M., and Afrime M Influence of disease on binding of drugs to plasma proteins. *Ann N Y Acad Sci* 226:110 1973
13. Wilkinson G R and Shand D G A physiologic approach to hepatic drug clearance. *Clin Pharmacol Ther* 18:377 1975
14. Greenblatt D J, Pfeiffer H R, Oaks K., Franke K., Smith T W and Koch Weser J Bioavailability of oral quinidine sulfate and gluconate. *Clin Pharmacol Ther* 21:104 1977
15. Snedecor G W., and Cochran W G Statistical methods sixth edition Ames 1971 The Iowa State University Press, p 59
16. Moe G K., and Abildskov J A Antiarrhythmic drugs in The Pharmacological Basis of Therapeutics fifth edition edited by L S Goodman and A Gilman New York 1975 Macmillan Publishing Co Inc., pp 683-684
17. Gerhardt R E, Knous R F, Thyrum P T., et al Quinidine excretion in aciduria and alkaluria. *Ann Intern Med* 71:977 1969
18. Levy R., Sellers A, Mandel W J and Orun H Quinidine pharmacokinetics in anephric and normal subjects. *Clin Res* 24:85A 1976
19. Branch R A and Shand D G Propranolol disposition in chronic liver disease: A physiologic approach. *Clin Pharmacokinetics* 1:264 1976
20. Nies A S, Evans G H and Shand D G Regional hemodynamic effects of beta adrenergic blockade with propranolol in the unanesthetized primate. *AM HEART J* 85:97 1973
21. Branch R A, Shand D G, Wilkinson G R and Nies A S The reduction of lidocaine clearance by di-propranolol: An example of hemodynamic drug interaction. *J Pharmacol Exp Ther* 184:515 1973
22. Ueda C T., Hirschfeld, D S, Scheinman M M, Rowland, M, Williamson B J and Dzandzio B S Disposition kinetics of quinidine. *Clin Pharmacol Ther* 19:30 1976
23. Stenson R E, Constantino R T and Harrison D C Interrelationships of hepatic blood flow, cardiac output, and blood levels of lidocaine in man. *Circulation* 43:205 1971
24. Thompson P D, Melmon K L, Richardson J A, Cohn K, Steinbrunn W, Cuddehe R and Rowland M Lidocaine pharmacokinetics in advanced heart failure, liver disease and renal failure in humans. *Ann Intern Med* 78:499 1973
25. Ochs H R, Greenblatt D J, Woo H, Franke K. and Smith T W Reduced clearance of quinidine in elderly humans. *Clin Res* 25:513A 1977
26. Nickerson M and Collier B Drugs inhibiting adrenergic nerves and structures innervated by them in The Pharmacological Basis of Therapeutics fifth edition edited by L S Goodman and A Gilman New York 1975 Macmillan Publishing Co Inc p 550
27. Gaughan C E, Low B, Lanigan J, Voukydy P and Besser H W Acute oral testing for determining antiarrhythmic drug efficacy I Quinidine. *Am J Cardiol* 38:677 1976

distribution and significantly higher peak concentrations of quinidine. Propranolol may cause this effect by a decrease in hepatic blood flow, changing intrinsic hepatic clearance, or altering absorption. Since quinidine is not a highly extracted drug, propranolol mediated alterations in hepatic flow should be insufficient, in and of itself, to cause the marked reduction in clearance we observed (control group 5.0 ± 4 ml/min/Kg vs propranolol group 3.1 ± 6 ml/min/Kg). Propranolol has metabolic effects, but to date these are best described only as they relate to its antiadrenergic properties.¹¹ There is no evidence for an effect of propranolol on quinidine absorption per se and thus the mechanism of this interaction remains unclear. Again, because clearance and volume of distribution data are derived numbers, more emphasis can be placed on the normal quinidine half life and higher peak levels immediately after dosage.

Abnormalities in the binding of quinidine to plasma proteins were found infrequently in the control and propranolol group but commonly in the cirrhotic (seven of eight patients) and obstructive (two of two patients) groups. This frequency of quinidine binding abnormalities is consistent with the previous findings of Affrime and Reidenberg.⁴

Therapeutically, quinidine is usually administered using a cautious test dose. In cirrhotic patients the increased volume of quinidine distribution which would in itself cause a lower than predicted quinidine concentration is opposed by the decrease in quinidine binding to plasma proteins. The overall effect is an unpredictable free (active) quinidine concentration. In patients receiving propranolol, the decrease in clearance and tendency to lower volumes of distribution can result in higher than predicted plasma quinidine concentrations, especially soon after a quinidine dose. Because of the small amount (100 to 200 mg) of quinidine usually used, the administration of a standard test dose should not be a problem in either patients with cirrhosis or those receiving propranolol. Initiating quinidine therapy with a larger loading dose (e.g., 600 mg) as has been recently advocated²⁷ should be done with extreme caution, if at all, in patients with hepatic dysfunction or receiving propranolol.

During maintenance quinidine therapy drug dosage may need to be reduced or administered at greater inter dose intervals because of an overall

50 per cent prolongation of quinidine half life in cirrhotic patients. Furthermore, quinidine concentration determinations may underestimate free drug concentrations in cirrhotic patients because of decreased binding to plasma proteins, thus in the face of cirrhosis the lower end of the therapeutic range of 2.3 to $5 \mu\text{g/ml}$ should be used.

Standard maintenance quinidine therapy should be acceptable for the majority of patients receiving propranolol. However, the tendency to higher peak plasma levels might lead to toxic manifestations shortly after a dose. Decreasing the dose size and increasing dose frequency while maintaining the same total daily dose might be helpful under such circumstances.

In conclusion, quinidine pharmacokinetics are altered in patients with hepatic cirrhosis and in patients receiving propranolol. Patients with moderate to severe cirrhosis had a moderately prolonged quinidine half life accompanied by evidence for normal absorption, an increased volume of distribution (coincident with impaired binding of quinidine to plasma proteins) and a normal clearance rate. In contrast, patients receiving propranolol had a normal quinidine half life accompanied by evidence for normal absorption, a decreased clearance rate and higher peak levels. Analysis of these alterations has led to the specific therapeutic recommendations enumerated above.

Summary

Quinidine pharmacokinetics (half life, volume of distribution and clearance) as well as protein binding were evaluated following a single 200 mg oral dose of quinidine sulfate in eight control patients, eight patients with moderate to severe cirrhosis and in seven patients receiving 40 to 400 mg/day of propranolol. Patients with cirrhosis had a significantly longer quinidine half life (9 ± 1 hr, $p < 0.01$) when compared to control patients (6 ± 0.5 hr). This was not related to a reduced quinidine clearance rate but rather to an increase in quinidine volume of distribution (41 ± 4 L/Kg in cirrhotic patients vs 26 ± 1 L/Kg in control patients, $p < 0.01$). Abnormal quinidine binding (greater than 25 per cent unbound fraction) was noted in seven of the eight cirrhotic patients. In contrast, patients receiving propranolol had a normal quinidine half life of 6 ± 0.5 hr. However, these patients had a signifi-

degree left anterior oblique position. The left ventricular (LV) and right ventricular (RV) dimensions were recorded with the echobeam in a standard plane to guard against foreshortening of the measured diameter of the LV (minor axis). The transducer was positioned in the third to fifth interspace along the left sternal border and directed posteriorly to define the endocardial surfaces of the interventricular septum (IVS) and LV posterior wall (LVPW) at the level of the tips of the mitral leaflets. The interspace selected was that in which the mitral valve could be recorded with the transducer perpendicular to the chest wall. The echo beam was then directed to record the other intracardiac structures and chambers.

The time intervals of the cardiac cycle¹⁰ were recorded with an Electronics for Medicine VR 6 photographic recorder using a piezoelectric crystal transducer. A simultaneous electrocardiogram (ECG) phonocardiogram (PCG) and apexcardiogram (ACG) or carotid pulse tracing were recorded and these were superimposed on the echocardiographic recording of the LV. The mean measurements over several respiratory cycles were used in the analysis of both the echocardiogram and the systolic time interval recordings.

Data analysis

Echocardiography The left ventricular dimension (minor diameter) was measured at end diastole (Dd) and at end systole (Ds) (Fig 1). The percentage shortening of the LV diameter during systole (% Δ S) was calculated where


$$\% \Delta S = \frac{Dd - Ds}{Dd} \times 100\%$$

For comparison with other measurements in the literature we also calculated stroke index (SI) and cardiac index (CI). LV volumes were calculated from the cube of the diameter measurements. echocardiographic SI was the difference between EDV and ESV (indexed for body surface area) and CI was calculated by multiplying SI by heart rate (HR).

The following measurements were made of the velocity of LV contraction

a. The mean velocity of circumferential fibre shortening (mean Vcf) was calculated¹¹ where

$$\text{mean Vcf} = \frac{\% \Delta S}{LVET} \times 100 \text{ (circ/sec)}$$



1 Electrocardiogram (ECG) phonocardiogram (PCG) and echocardiogram to show method for measuring left ventricular (LV) dimensions. The internal LV diameter is measured at end-diastole (Dd) and end systole (Ds). Maximum velocity of posterior LV wall motion (Max Vpwm) is measured as the steepest tangent to the movement of the posterior LV endocardial surface. The solid vertical time lines are 1 second markers. IVS = interventricular septum LVPW = left ventricular posterior wall.

LVET is the left ventricular ejection time measured from the carotid pulse tracing

b. Maximum velocity of posterior LV wall motion (max Vpwm) was the steepest tangent to the endocardial surface of the posterior LV wall during systole (Fig 1). The thickness of the posterior wall of the LV and the interventricular septum (IVS) were measured at end-diastole. LV wall mass was calculated from the LV posterior wall thickness measurement and from LV Dd.

The internal dimension of the right ventricle (RVID) was measured through the R wave of the QRS complex of the ECG. Aortic root diameter was measured at end ventricular diastole. The left atrial (LA) dimension was measured at end ventricular systole.

The diastolic closure rate (EF slope) of the anterior mitral leaflet (AML) was measured. The EF slope was essentially monophasic when recorded at a paper speed of 50 mm/sec so that there was no ambiguity in measurement. The mitral EF slope is related to early diastolic compliance of the LV in the absence of mitral valve disease.¹² The total amplitude of movement

Left ventricular function in β -thalassemia and the effect of multiple transfusions

Basil S Lewis, MD MRCP, FCP (SA)
Eliezer A Rachmilewitz, MD
Noga Amitai, BSc
David A Halon, MB, ChB
Mervyn S Gotsman, MD, FRCP, FACC
Jerusalem, Israel

Cardiac failure is a common and life threatening complication of the severe forms of the thalassemia syndrome.¹⁻⁴ The patients suffer from severe chronic anemia from infancy due to ineffective erythropoiesis and increased hemolysis and require repeated blood transfusions; they develop severe progressive iron overload which may lead to severe congestive cardiac failure, arrhythmias and death in the second decade. The clinical spectrum of thalassemia is well described but there are no detailed studies of cardiac or left ventricular (LV) function. This information is of importance in the evaluation of different therapeutic measures e.g., hypertransfusion as compared to moderate transfusion regimens and the effects of long term therapy with iron chelators.

We have studied a group of patients with β thalassemia major and intermedia by non invasive techniques—echocardiography and systolic time interval measurements—to examine the effects of chronic severe anemia and the effects of multiple transfusions on cardiac chamber size and on LV function.

Patients

A consecutive group of 23 patients with thalassemia was studied. All the patients were homozygous for β thalassemia. Their detailed hematological and hemoglobin analyses have been reported

in previous communications.^{3,4} Twenty of them were splenectomized. They were divided into three groups on the basis of their transfusion requirements (Table I).

Group 1 consisted of seven patients who did not require blood transfusion or who had received a total of less than 10 transfusions on the basis of their milder clinical course. They were classified as having thalassemia intermedia.⁵ Their ages ranged from 11 to 29 years (mean 19 ± 6 years).

Group 2 (five patients) had β thalassemia major with a moderate course. These patients had received 10 to 80 blood transfusions. Their ages ranged from 14 to 23 years.

Group 3 (11 patients) had β thalassemia major and were more ill. They were heavily transfused and had received a total of more than 80 blood transfusions; six patients received more than 100 transfusions and one more than 200 transfusions. Patients in this group were younger (age range 7 to 22 years) ($p = 0.05$) and had a smaller body surface area ($p < 0.001$).

Methods

Data acquisition. All patients were examined clinically and the detailed cardiac studies were made after the maximum time interval between transfusions. Echocardiograms were recorded with an Ekoline 20A echocardiograph (Smith Kline Instruments) coupled to a VR 6 Electronics for Medicine photographic strip chart recorder. A 2.25 MHz transducer was used and this was focused at 7.5 cm. Recordings were made with the patient in a semisupine anteroposterior or a 20°

From the Departments of Cardiology and Haematology, Hadassah Hospital and the Hebrew University, Jerusalem, Israel.

Received for publication Dec 2, 1977.

Accepted for publication Apr 25, 1978.

Reprint requests: Dr. B. S. Lewis, Department of Cardiology, Hadassah Hospital, P.O. Box 499, Jerusalem, Israel.

Table II Echocardiographic measurements

Patient	BSA (M ²)	Dd* (cm)	Dd/BSA (cm/M ²)	Ds (cm)	%ΔS	SI (ml/M ²)	CI (L/min./M ²)	LVPW (cm)	IVS (cm)	LV wall mass (g/M ²)	Max Vpwm (mm./sec)	Mean Vcf (circ./sec)
Group 1 <i>Thalassemia intermedia</i>												
1	11.5	5.1	4.4	3.2	37	84	7.6	0.8	0.9	154	60	1.32
2	1.60	6.0	3.8	4.0	35	95	7.6	0.8	1.9	146	61	1.11
3	1.0	4.5	2.6	2.5	44	46	3.8	1.2	1.1	146	58	1.47
4	1.20	4.3	3.6	2.9	49	57	5.7	0.5	0.6	61	81	1.81
5	1.72	5.3	3.1	3.7	30	58	3.9	0.6	0.9	76	80	0.94
6	1.80	6.0	3.3	3.8	36	90	5.5	0.8	1.3	130	88	1.10
7	1.69	5.9	3.5	3.3	44	99	7.9	0.8	0.8	136	63	1.48
Mean±1 SD	1.55±0.24	5.3±0.7	3.5±0.5	3.4±0.6	39±6	76±20	5.9±1.5	0.8±0.2	1.1±0.4	121±34	67±12	1.42±0.27
Group 2 <i>Thalassemia major (moderate course)</i>												
8	1.54	5.5	3.6	3.2	42	87	6.5	0.9	1.7	152	66	1.56
9	1.27	5.3	4.2	3.3	38	89	7.3	0.6	1.4	104	66	1.41
10	1.18	5.2	4.4	3.4	35	85	8.3	0.6	0.7	109	84	1.25
11	1.25	5.6	4.5	3.5	38	106	9.3	0.5	0.9	81	80	1.31
12	1.6	4.8	3.5	3.0	38	61	4.5	0.4	1.1	51	69	1.08
Mean±1 SD	1.39±0.12	5.3±0.3	4.0±0.4	3.3±0.2	38±2	86±10	7.3±1.8	0.6±0.2	1.2±0.4	102±37	66±13	1.32±0.16
Group 3 <i>Thalassemia major (severe course)</i>												
13	1.34	4.9	3.6	2.9	41	70	7.3	0.8	1.0	192	46	1.57
14	1.16	5.1	4.4	3.0	42	89	5.9	0.7	—	136	57	1.29
15	1.15	4.6	4.0	—	—	—	—	1.1	1.0	212	77	—
16	1.40	6.0	4.3	4.3	—	97	9.4	1.1	0.8	251	55	1.21
17	1.14	4.5	3.9	3.3	97	57	5.2	0.6	0.8	193	71	1.04
18	1.92	5.5	4.5	3.4	38	104	10.1	0.6	1.2	116	69	1.58
19	0.4	4.8	6.5	3.4	30	95	9.6	1.1	0.4	331	57	1.01
20	1.94	4.9	4.0	3.1	37	71	7.4	0.5	0.7	74	75	—
21	1.04	5.2	5.0	2.5	53	120	10.6	0.5	—	99	73	1.84
22	1.14	4.6	4.0	2.6	45	43	7.1	0.8	0.6	128	54	1.66
23	1.95	5.6	4.5	3.3	41	119	9.9	0.6	—	140	76	1.54
Mean±1 SD	1.17±0.16	5.1±0.5	4.4±0.7	3.2±0.5	38±8	88±20	8.2±1.8	0.8±0.2	0.8±0.2	167±72	65±10	1.42±0.26
Normal values* (1937)	4.4±0.3	2.6	2.8±0.3	3.6±4	3.6±7	2.5±0.6	0.9±0.1	0.9±0.1	92±17	53±9	1.29±0.13	

See text for details of abbreviations and methods

PEP and LVET Δ Q A is the rate corrected value *

Isotolumic relaxation period (IRP) was measured as the time interval from aortic valve closure (A₂ on the PCG) to the onset of mitral valve opening (D point on the echocardiogram of the anterior mitral leaflet)

Critique of methods Echocardiographic measurements of LV function are widely used but the data must be analysed critically. The single plane echocardiogram measures the minor diameter of the left ventricle. In normal patients the LV is symmetrical and the echo measurements represent over all LV size and function but this is not

necessarily so in patients with cardiac disease and ventricular dilatation. Nonetheless stroke volume and cardiac output were calculated for comparison with measurements in the literature

Statistical analysis Statistical analysis between the groups was made using Student's *t* test for unpaired data

Results

Clinical findings The present group of patients were not hypertransfused and their pretransfusion hemoglobin level was in the range of 7 to 10 g/100 ml. The hemoglobin level was not signifi-

Table 1 The patients

Patient	Age (years)	Sex	Approximate total no of transfusions	Hb (g / 100 ml)	Splenectomy	Increased jugular venous pressure (cm)	Additional heart sounds	
							S	S
Group 1 <i>Thalassemia intermedia</i>								
1	11	M	—	74	+	+2	+	—
2	23	F	7	79	+	+3	+	—
3	29	F	—	90	+	+2	+	—
4	12	F	—	86	+	+5	+	+
5	19	M	—	101	+	0	+	+
6	18	M	—	85	—	+5	—	+
7	20	M	—	95	—	0	+	—
Mean \pm 1SD	19 \pm 6			87 \pm 09				
Group 2 <i>Thalassemia major (moderate course)</i>								
8	18	M	40	82	+	+4	++	—
9	16	M	60	93	+	+3	+	—
10	14	M	70	80	+	+3	++	—
11	23	F	55	74	+	0	+	—
12	20	F	58	87	+	0	+	—
Mean \pm 1SD	18 \pm 3			83 \pm 06				
Group 3 <i>Thalassemia major (severe course)</i>								
13	17	F	137	73	+	+3	+	—
14	14	M	210	103	+	+2	+	—
15	17	M	155	72	+	+6	++	—
16	22	F	165	78	+	+4	+	—
17	16	M	180	94	+	+3	—	—
18	11	F	100	76	—	+4	+	—
19	7	M	85	94	+	+5	++	+
20	14	M	80	59	+	+2	+	+
21	12	M	90	86	+	+4	++	—
22	13	M	84	79	+	+3	+	+
23	14	F	110	78	+	+2	—	—
Mean \pm 1SD	14 \pm 4			81 \pm 12				

of the AML (CE amplitude) was also measured. The time from the peak of the A wave to closure (point C) was measured (AC time). Since the AC time is partly determined by the PR interval of the ECG, the time PR - AC was calculated. A short PR - AC (i.e. prolonged AC) time is present in some patients with a high LV end diastolic pressure.¹³

Time interval measurements

Pre ejection period (PEP) is the time interval from the onset of the QRS complex of the ECG till aortic valve opening, which corresponds to the upstroke of the carotid pulse tracing after correction for pulse transmission time delay. **Isovolumic contraction time (ICT)** was measured from the onset of the upstroke of the apex cardiogram (U_{ACO}) to the moment of aortic valve opening.¹⁴

$$ICT = PEP - (Q_{FCO} - U_{ACO}) \text{ msec}$$

PEP and **ICT** are related to velocity measurements of LV contractility but also depend on preload and afterload.¹⁵

Left ventricular ejection time (LVET) was measured from the upstroke of the carotid pulse tracing to the nadir of the incisura of the diastolic notch. LVET depends on stroke volume after load and myocardial contractility. Since both PEP and LVET are heart rate dependent, we calculated Δ PEP and Δ LVET according to the method of Weissler and associates¹⁶ where the Δ value is the difference between the measured time interval and the predicted normal time interval measurement at a given heart rate.

The ratio **PEP/LVET** was calculated. The measurement is less dependent on heart rate magnifies abnormalities of ventricular contractility, and is related to LV ejection fraction.¹⁷ Total electromechanical systole (Q_A) was the sum of




Fig 3 Left atrial diameter (LA) aortic root diameter and right ventricular internal diameter (RVID) in patients with thalassemia. The LA, aorta, and right ventricle are enlarged in all three groups of patients and more so in Group 3 (normal range shaded) (p values compare Groups 1 and 3).

(Fig 4) The PR-AC time was less than 60 msec in one patient in Group 2 and in two patients in Group 3. This abnormality probably reflects an increase in LV end diastolic pressure in these patients but there was not a significant difference in the mean PR-AC time between the three groups (Fig 4).

Time interval measurements The time interval measurements are summarized in Table III and Fig 5. These measurements were in keeping with echocardiographic data and indicated good or increased LV performance in systole. Δ PEP was decreased in all three groups of patients. Δ LVET was prolonged and the PEP/LVET ratio was normal or decreased. The changes were small. Δ ICT was normal or decreased. Δ Q_A was slightly increased. There was not a significant difference in the systolic time interval data between the three groups of patients.

IRP was decreased in all three groups of patients. The decreased IRP may indicate an increased left atrial pressure due to an alteration

in LV compliance. It may also be related to the short ICT or the low aortic closing pressure in patients with a hyperdynamic circulation and reduced diastolic blood pressure.

Discussion

In thalassemia major and intermedia the heart is affected in two ways: all the patients suffer from severe chronic anemia while those who require repeated blood transfusions develop additional iron overload. Cardiac failure is a common clinical problem and is the major cause of death in the second decade of life.²

Our study shows that all the cardiac chambers are enlarged in patients with chronic anemia due to thalassemia. The LV is dilated and hypertrophied. Systolic left ventricular function is apparently normal; there is an increase in the velocity measurements of LV contraction (mean Vcf and max Vpwm) and in fractional fiber shortening (per cent Δ S). Stroke volume and cardiac output are high. Systolic time interval measurements




Fig 2 LV end diastolic dimension (Dd) percentage shortening during systole (%ΔS) mean velocity of circumferential fiber shortening (Vcf) and maximum velocity of posterior wall motion (Vpwm) in patients with thalassemia. Dd is increased in all three groups of patients and is larger in Group 3 ($p < 0.05$). Per cent ΔS, mean Vcf and max Vpwm are normal or increased in all three groups. The shaded area shows the normal range of values.

cantly different in the three groups of patients (Table I). Five of the seven patients in Group 1 and three of the five in Group 2 had an increased jugular venous pressure and were in congestive heart failure at the time of study. The jugular venous pressure was increased in all patients in Group 3. Most of the patients had a loud additional third heart sound and in several patients a fourth heart sound was also present. These signs were more marked in patients in Group 3 even though these were younger patients. One patient (Case 15) died in congestive heart failure three months after the study; another patient (Case 20) developed bronze diabetes following repeated blood transfusions.

Echocardiographic studies. The left ventricle was enlarged. Dd was greatly increased and was larger in patients who had than in those who had not received blood transfusions ($p < 0.05$) (Table II, Fig 2). Per cent ΔS was normal or increased. Mean Vcf and max Vpwm were normal or

increased, there was no statistical difference between the three groups of patients (Fig 2, Table II). Calculated stroke index and cardiac index were high and the increase in cardiac index was greatest in patients in Group 3 ($p < 0.001$) partly due to a greater increase in heart rate in these patients ($p < 0.05$). LV posterior wall thickness (LVPW) and interventricular septal thickness (IVS) were normal or increased. LV wall mass tended to be greater in patients in Group 3 but the difference between Groups 1 and 3 was not significant statistically (Table II).

The right ventricle dimension (RVID), left atrial diameter, and aortic root diameter were increased and the increase in relation to the surface area was greater in patients in Group 3 (Fig 3).

The amplitude of motion of the anterior mitral leaflet (CE) was increased in Groups 1 and 2 but less so in Group 3 ($p < 0.05$). The mitral diastolic closure rate (EF slope) was normal or increased




Fig 5 Systolic time interval measurements in the three groups of patients (mean \pm 1 SD) expressed as the deviation from the normal rate-corrected value Δ PEP is decreased Δ LVET increased and Δ Q A increased. The changes are greater in Group 1 but the differences are not statistically significant.

cardiac decompensation only occurring when there is additional underlying primary cardiac disease.

Our results question the magnitude of the problem of multiple transfusions in the management of patients with thalassemia major. Although these patients are more ill clinically at a younger age than patients in Groups 1 and 2 and are in "congestive cardiac failure" with a high jugular venous pressure, the previous assumption that there is poor systolic LV function with the hemodynamic picture of severe congestive cardiomyopathy at this stage of the disease seems to be incorrect. Although patients who receive multiple transfusions have larger hearts and persistent tachycardia, stroke index is high and the cardiac index increased. LV systolic function was normal

in all patients in the group even in the patient who died in severe congestive heart failure within 3 months of the non-invasive study. We did not have the opportunity to perform echocardiography at the time of the terminal episode; it is possible that serial echocardiographic studies may reveal terminal deterioration of LV performance in thalassemic patients dying of cardiac failure. Nonetheless, systolic function of the LV is preserved until very late in the course of the disease despite the fact that histological studies show extensive iron deposition and myocardial damage in thalassemic patients who receive multiple transfusions. It could be argued that the presence of greater tachycardia and a larger heart without a further increase in systolic function (as compared to patients in Groups 1 and 2)




Fig 4 Diastolic closure rate (EF slope) amplitude of excursion (CE) and closure time (PR-AC) of the anterior mitral leaflet. EF slope and CE amplitude are normal or increased but less so in Group 3. The mean PR-AC time is normal in all three groups.

Table III Systolic time interval data

	ΔPEP (msec)	$\Delta LVET^*$ (msec)	PEP/LVET	$\Delta Q A$ (msec)	ICT (msec)	IRP (msec)	HR (beats/min.)
Group 1	-7 ± 11	$+19 \pm 16$	0.30 ± 0.03	$+15 \pm 16$	58 ± 19	32 ± 11	81 ± 1^9
Group 2	-6 ± 13	$+10 \pm 17$	0.32 ± 0.05	$+2 \pm 21$	60 ± 4	43 ± 27	$8^9 \pm 7$
Group 3	-3 ± 12	$+10 \pm 18$	0.34 ± 0.07	$+7 \pm 12$	53 ± 17	36 ± 7	84 ± 10
Normal values *	0 ± 13 (M) 0 ± 11 (F)	0 ± 10	0.35 ± 0.04	0 ± 14	71 ± 10	54 ± 9	

M = males F = females

Δ values represent the deviation of the measured values from normal
See text for details of abbreviations and indices

show a shortened ICT and ΔPEP an increased $\Delta LVET$ and a low PEP/LVET ratio.

These data are in keeping with previous hemodynamic studies of chronic anemia which show that peripheral resistance falls as a consequence of tissue hypoxia while venous return, stroke volume, and cardiac output increase and the A-V oxygen difference widens.^{19, 21} During exercise there may be a further increase in myocardial contractility and cardiac output increases with

out changes in LV end diastolic volume or pressure. Coronary blood flow increases in relation to the increased cardiac output and supplies the additional myocardial oxygen demand.²² Ventricular enlargement and hypertrophy are compensatory mechanisms for the volume overload and do not necessarily imply impaired myocardial contractility. On the contrary, studies made in sickle cell anemia have shown that the left ventricle may tolerate volume overload for many years.




Fig 5 Systolic time interval measurements in the three groups of patients (mean \pm 1 SD) expressed as the deviation from the normal rate corrected value Δ PEP is decreased Δ LVET increased and Δ Q A increased. The changes are greater in Group 1 but the differences are not statistically significant.

cardiac decompensation only occurring when there is additional underlying primary cardiac disease.¹⁴

Our results question the magnitude of the problem of multiple transfusions in the management of patients with thalassemia major. Although these patients are more ill clinically at a younger age than patients in Groups 1 and 2 and are in congestive cardiac failure with a high jugular venous pressure, the previous assumption that there is poor systolic LV function with the hemodynamic picture of severe congestive cardiomyopathy at this stage of the disease seems to be incorrect.⁵ Although patients who receive multiple transfusions have larger hearts and persistent tachycardia, stroke index is high and the cardiac index increased. LV systolic function was normal

in all patients in the group even in the patient who died in severe congestive heart failure within 3 months of the non-invasive study. We did not have the opportunity to perform echocardiography at the time of the terminal episode; it is possible that serial echocardiographic studies may reveal terminal deterioration of LV performance in thalassemic patients dying of cardiac failure.⁵ Nonetheless, systolic function of the LV is preserved until very late in the course of the disease despite the fact that histological studies show extensive iron deposition and myocardial damage in thalassemic patients who receive multiple transfusions. It could be argued that the presence of greater tachycardia and a larger heart without a further increase in systolic function (as compared to patients in Groups 1 and 2)

indicates an incipient abnormality of LV systolic performance in the multiply transfused group, but these changes are small and are certainly not those of a severe congestive cardiomyopathy.

Most patients in the study were in clinical 'congestive heart failure' with large hearts and a high jugular venous pressure. Diastolic function of the LV is difficult to quantitate by non-invasive technique but the smaller increase in EF slope and CE amplitude in patients who had received multiple transfusions may indicate an abnormality of compliance especially since these patients have the highest stroke and cardiac indices. A short PR - AC time is present in some patients indicating, in them, increased LV end diastolic pressures.¹³ We believe, then, that the high filling pressures and the clinical 'congestive heart failure' which occurs in patients with thalassemia is predominantly the result of ventricular volume overload¹⁴ with possible additional changes in ventricular distensibility due to hypertrophy,¹⁵ iron deposition, and myocardial fibrosis.

Summary

Left ventricular performance was studied in 23 young patients with severe chronic anemia due to β thalassemia major and intermedia. The patients were divided into three groups according to the number of blood transfusions they had received. The left ventricle (LV) was enlarged in patients who had not received blood and larger still in patients who had received multiple transfusions. Echocardiography and systolic time interval measurements showed that systolic function of the LV was good in all the patients and that there was no statistical difference in systolic function in patients who had and those who had not received multiple transfusions. Heart rate was increased in the latter group. Stroke index and cardiac index were high especially in patients in Group III. The diastolic closure rate (EF slope) of the anterior mitral leaflet and its amplitude of movement were increased but less so in Group 3; this may reflect an alteration in diastolic LV distensibility. The results indicate that despite the presence of cardiomegaly and severe clinical congestive heart failure, LV performance is well preserved in patients with β thalassemia, even in those who have received repeated blood transfusions. Clinical cardiac failure is the consequence

of volume overload and abnormal chamber compliance. There was no evidence in this study of a congestive cardiomyopathy.

REFERENCES

- 1 Engle M A. Cardiac involvement in Cooley's anemia. *Ann N Y Acad Sci* 119:694 1964
- 2 Engle M A, Erlanson M, and Smith C H. Late cardiac complications of chronic severe refractory anemia with hemochromatosis. *Circulation* 38:65, 1967
- 3 Englehard D, Cividali G, and Rachmilewitz E A. Splenectomy in homozygous β thalassemia: A retrospective study of 30 patients. *Br J Haematol* 31:391 1975
- 4 Rachmilewitz E A, Lubin J H, and Shohet S B. Lipid membrane peroxidation in β thalassemia major. *Blood* 47:495 1976
- 5 Popp R L, Filly K, Brown O R, and Harrison D C. Effect of transducer placement on echocardiographic measurement of left ventricular dimensions. *Am J Cardiol* 35:537 1975
- 6 Feigenbaum H. *Echocardiography*. Philadelphia 1973. Lea & Febiger Publishers
- 7 Weissler A M, and Garrard C L, Jr. Systolic time intervals in cardiac disease (I). *Mod Concepts Cardiovasc Dis* 40:1 1971
- 8 Weissler A M, and Garrard C L, Jr. Systolic time intervals in cardiac disease (II). *Mod Concepts Cardiovasc Dis* 40:5 1971
- 9 Lewis B S, Armstrong T G, Everson R C, and Gotsman M S. Predictive value of the systolic time intervals in primary myocardial disease. *Chest* 64:431 1973
- 10 Peterson K L, Skloven D, Ludbrook P, Uther J B, and Ross J Jr. Comparison of volumetric and ejection phase indices of myocardial performance in man. *Circulation* 49:1088 1974
- 11 Upton M T, Gibson D G, and Brown D J. Instantaneous mitral valve leaflet velocity and its relation to left ventricular wall movement in normal subjects. *Br Heart J* 38:51 1976
- 12 De Maria A N, Miller R B, Amsterdam F A, Markson W, and Mason D T. Mitral valve early diastolic closing velocity in the echocardiogram: relation to sequential diastolic flow and ventricular compliance. *Am J Cardiol* 37:693 1976
- 13 Konecke L L, Feigenbaum H, Chang S, Corya B, and Fischer J C. Abnormal mitral valve motion in patients with elevated left ventricular diastolic pressure. *Circulation* 47:989 1973
- 14 Kumar R, and Spodick D H. Study of the mechanical events of the left ventricle by atrumatic techniques: comparison of methods of measurement and their significance. *Am Heart J* 80:401 1970
- 15 Talley R C, Meyer J F, and McNay J L. Evaluation of the pre ejection period as an estimate of myocardial contractility in dogs. *Am J Cardiol* 27:384 1971
- 16 Weissler A M, Harris W S, and Schoenfeld C D. Systolic time intervals in heart failure in man. *Circulation* 37:149 1968
- 17 Garrard C L, Weissler A M, and Dodge H T. Relationship of alterations in systolic time intervals to ejection fraction in patients with cardiac disease. *Circulation* 42:455 1970

- 18 Linhart J W, Mintz G S, Segal B L, Kawai H and Kotler M N. Left ventricular volume measurement by echocardiography—fact or fiction? *Am J Cardiol* 36 114 19 5
- 19 Escobar E, Jones N L, Rapaport E and Murray J F. Ventricular performance in acute normovolemic anemia and effects of beta blockade. *Am J Physiol* 211 877 1966
- 20 Duke M and Abelman W J. The haemodynamic response to chronic anemia. *Circulation* 39 503 1969
- 21 Fowler N O and Holmes J C. Ventricular function in anemia. *J Appl Physiol* 31 260 1971
- 22 Rodriguez J A, Chamorro G A and Rapaport E. Effect of isovolemic anemia on ventricular performance at rest and during exercise. *J Appl Physiol* 36 28 1974
- 23 Bhattacharya M L, Manchanda B C and Roy S B. Coronary haemodynamic studies in chronic severe anemia. *Br Heart J* 31 365 1969
- 24 Gerry J L, Bard M G and Fortuin N J. Evaluation of left ventricular function in patients with sickle cell anemia. *Am J Med* 60 968 1976
- 25 Goodwin J F, Gordon H, Hollman A and Bishop MB. Clinical aspects of cardiomyopathy. *Brit Med J* 1 69 1961
- 26 Henry W L, Neuhaus A W, Wiener M, Miller D H, Canale V C and Piomelli S. Echocardiographic evaluation of the heart in patients with iron overload (In press)
- 27 Gaasch W H, Levine H J, Quinones M A and Alexander J K. Left ventricular compliance mechanisms and clinical implications. *Am J Cardiol* 38 645 1976
- 28 Groseman W, McLaurin L P, Moos S P, Stafadouras M and Young B T. Wall thickness and diastolic properties of the left ventricle. *Circulation* 49 129 1974
- 29 Popp R L, Wolfe B, Hara T and Feigenbaum H. Estimation of right and left ventricular size by ultrasound. *Am J Cardiol* 24 523 1969
- 30 McDonald I G, Feigenbaum H and Chang S. Analysis of left ventricular wall motion by reflected ultrasound. Application to assessment of myocardial function. *Circulation* 46 14 1972
- 31 Popp R L. Echocardiographic assessment of cardiac disease. *Circulation* 53 528 1976

Hemodynamics of essential hypertension in young subjects*

Fetnat M Fouad, M D
Robert C Tarazi, M D
Harriet P Dustan, M D
Emmanuel L Bravo, M D
Cleveland Ohio

Contrary to the widely held belief that essential hypertension is rare among the young,¹ there is now evidence that it may occur at an early age² and account for a sizable proportion of hypertension even in children. Estimates vary from 10 per cent to 93 per cent.³⁻⁶ The importance of these observations was recently stressed by the Report of the Task Force on Blood Pressure Control in Children.⁷ Since essential hypertension (EH) in children and adolescents may represent the early stage of the disease⁸⁻¹⁰ with no, or minimal, complicating factors, its study at this young age would help to delineate more clearly variations in the individual hemodynamic factors and their functional interrelationship. Thus, it would provide information to better understand the genesis of EH. The practical importance of such a study derives from the seriousness of a diagnosis which entails lifelong therapy and from the fact that understanding the factors involved will help select rational therapy to provide better arterial pressure control with minimal side effects.

This report describes hemodynamic and blood volume variations encountered among 42 young essential hypertensive subjects. Findings were

evaluated in relation to arterial pressure levels obtained both from intraarterial readings at the time of study and from weekly average of four daily determinations. The difference between the two pressure levels allowed an estimate of the effect of invasive techniques on hemodynamic indices.

Material and Methods

The investigation involved 42 young hypertensive patients (37 males and five females) ranging in age between 15 and 25 years. They were classified into the following groups (Table I). Group I included 13 patients younger than 20 years, they were all males. Group II was made up of the older 29 patients (20 to 25 years), Group IIa included 24 males and Group IIb was composed of five females. The diagnosis of hypertension was based on the readings recorded by their referring physician as well as the levels obtained on the hospital admission examination. A blood pressure level exceeding 140/90 was considered abnormal; this critical level corresponded approximately to the 95 percentile limits for adolescents' blood pressure shown in the nomogram presented in the Task Force Report in 1977.⁷ Some of these initial blood pressure readings were normal ($< 140/90$) in 17 patients whereas in the remaining 25 all the readings obtained by either their physicians or at the time of admission to the hospital were higher than 140/90 mm Hg. In the hospital, supine brachial arterial pressure was measured four times a day, using a sphygmomanometer cuff of proper size ($\frac{2}{3}$ arm length). The response of blood pressure levels to hospitalization was evaluated against the initial physician or admission reading.

From the Research Division, The Cleveland Clinic Foundation, Cleveland, Ohio.

This study was supported in part by grant HL6835 from the National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Md.

Received for publication Dec 21, 1977.

Accepted for publication Jan 27, 1978.

Reprint requests: Robert C Tarazi, M D, Research Division, Cleveland Clinic, 9500 Euclid Ave., Cleveland, Ohio 44106.

This study was presented at the Third Pediatric Nephrology Seminar, January 5-8, 1978, and the data detailed here were referred to in the Proceedings of that seminar.

Table I Patients investigated—42 essential hypertensive (15 to 25 years)

Group	Age group (years)	Number	Sex	Arterial pressure (mm Hg)
I	15-19	13	Male	126/81 167/104
IIa	20-25	24	Male	123/74 180/122
IIb	20-25	5	Female	115/83-185/121

In all subjects extensive investigations including renal arteriography failed to reveal one of the known causes of hypertension.

Hemodynamic studies All hemodynamic studies were done in the morning after an overnight fast and without sedation. The details of the procedure were explained to the patient the day before and consent was obtained from the patient or his or her parents. Cardiac output (CO) was determined in all 42 subjects but blood volume was obtained in only 34 five females and 29 males.

Blood volume was determined after at least 30 minutes of supine rest using ^{51}I HSA and a 10 minute equilibration period. Total blood volume (TBV) was calculated from plasma volume and simultaneously determined hematocrit with appropriate correction for the difference between total body and large vessel hematocrit. Values were expressed in relation to body surface area as well as to body height.

Cardiac output (indocyanine green dye) was determined in triplicate immediately following the plasma volume measurement. The details of the procedure have been previously described in detail.¹¹ Arterial blood pressure was recorded continuously from a catheter introduced percutaneously (modified Seldinger technique) through the brachial artery to the subclavian artery or to the root of the ascending aorta. The derived parameters were calculated by classical formulae.

Moreover an index of aortic resistance to stretch was calculated from the ratio of pulse pressure to stroke volume (PP/SV mm Hg/ml). This ratio which was found to be a clinically applicable index of aortic compliance is closely related to age level of diastolic pressure and heart rate values from previous investigation of 76 subjects allowed the development of a nomogram based on the following multiple regression analysis:

Table II Blood volume in 34 essential hypertensive patients (15 to 25 years)

	Male (29)		Female (5)
	15-19 yrs (9)	20-25 yrs (20)	20-25 yrs
PV			
ml/cm	164 ± 0.79	169 ± 0.58	139 ± 1.35
% N	88 ± 4.24	90 ± 3.11	90 ± 8.74
L/M	1.53 ± 0.69	1.48 ± 0.40	1.43 ± 0.14
% N	88 ± 3.96	85 ± 2.33	89 ± 9.01
TBV			
ml/cm	274 ± 1.44	291 ± 1.00	220 ± 1.87
% N	89 ± 4.62	94 ± 3.22	91 ± 7.69
L/M	2.55 ± 0.12	2.58 ± 0.73	2.26 ± 0.19
% N	93 ± 4.44	94 ± 2.65	91 ± 7.62

$$\text{PP/SV} = (0.0069 \text{ age} + 0.0048 \text{ DBP} + 0.009 \text{ HR} - 0.64) \pm 0.18$$

Since young people may often have undue elevations of systolic pressure the diagnosis of systolic hypertension was based on the following expected ratio of systolic to diastolic blood pressure:

$$\text{SBP} = (\text{DBP} - 15) \times 2$$

Standard statistical methods were used to calculate t test χ^2 and correlation coefficient and assess their statistical significance.

Results

The age, sex and blood pressure range for each group are shown in Table I. The pressures reported are the averages of four daily readings for a week in the hospital. These varied among subjects from as low as 115/83 to as high as 185/121.

Blood volume and plasma volume results were expressed in relation to both height (ml/cm) and body surface area (L/M²) to avoid the marked influence of body fat variations on the expression ml/Kg. Moreover values were also calculated in per cent of normal to allow comparison between sex groups.¹² Average values were significantly below normal (Table II). However a study of blood volume distribution showed that although 61 per cent of the patients 20 to 25 years of age were hypovolemic 20 per cent fell within the normal range (91 to 109 per cent N) and there was a definite hypervolemic group (20 per cent of the patients) the per cent distribution among the nine younger patients was 17 per cent 22 per cent




Fig 1 Blood volume distribution among 34 essential hypertensive patients aged 15 to 25 years. Blood volume expressed in per cent of normal for our laboratory to allow comparison between sex groups. In both the younger (15 to 19 years) and older (20 to 25 years) age groups the majority of patients were hypovolemic (< 90 per cent N) but there was also a small hypervolemic subtype (> 110 per cent).

and 11 per cent, respectively (Fig 1). This distribution was established on the basis of normal values derived from older subjects in our unit (20 to 60 years). However, blood volume values are reported in most references without distinction as to age: subjects are grouped together from age 10 to 70 without qualification.⁴¹ Chien and associates⁴² reported no change in blood volume expressed in milliliters per centimeter height over a 17 year follow up of the same subjects.

In contrast to blood volume, cardiac output was reported to be significantly lower with increasing age from 19 to 86 years.⁴³ Our patients were therefore subdivided into two groups: below 20 years and from 20 to 25 years. There was no statistically significant difference between levels of blood pressure, heart rate, cardiac index or total peripheral resistance in the two groups (Table III). Comparing these values to the normal adult values of our laboratory (CI 3.0 ± 0.5 L/min/M², TPR 29 ± 7 u M²) both groups had a higher CO but normal TPR. Contrariwise, compared to results obtained from

Table III Hemodynamic indices (42 essential hypertensive subjects)

Index	Age group	
	15-20 yrs (13)	20-25 yrs (9)
MAP (mm Hg)	102 ± 2.86 †	110 ± 2.43
HR (b/min)	76 ± 4.34	78 ± 2.77
CI (L/min/M ²)	3.31 ± 0.24	3.47 ± 0.19
SI (ml/M ²)	44 ± 2.79	45 ± 1.61
TPR (u M ²)	32 ± 1.86	33 ± 1.48

Values reported as mean \pm SE

†None of the differences was statistically significant

literature for patients of similar age group and younger,²²⁻²⁴ the cardiac output of these young hypertensive subjects was found lower and total peripheral resistance was higher. However, such comparisons are rather unsatisfactory because of differences in methods between various laboratories. To evaluate the significance of cardiac output findings, various approaches were used. First, a histogram was drawn of the spread of cardiac output in this young essential hypertensive population (Fig 2); it demonstrated a relatively normal distribution ranging from 2.2 to 5.2 L/min/M². Secondly, cardiac output was evaluated in relation to arterial blood pressure level, calculated in three different ways, namely the weekly pressure average (BP_w), the intra-arterial pressure records (BP_i) during the study, and lastly the difference between these two levels of arterial pressure. As regards weekly pressure averages, there was no correlation between either systolic or diastolic levels and cardiac index in either the younger group ($r = 0.331$ for SBP and 0.325 for DBP) or the older group ($r = 0.239$ for SBP and 0.113 for DBP). Similarly, no correlation was found between intra-arterial pressure and cardiac index in the 20 to 25 year old group ($r = 0.163$ for SBP and 0.048 for DBP) and only a weak correlation of borderline significance ($r = 0.594$ and 0.559 respectively, $p < 0.05$) in the younger patients (Fig 3).

The comparison of BP_w and BP_i revealed important contrasts. The group means for intra-arterial pressure (BP_i) and for the weekly average (BP_w) were not markedly different; diastolic blood pressure levels were practically identical (87.8 mm Hg and 87.3 mm Hg respectively) and systolic levels showed a slight difference (145.5




Fig 2 A histogram of cardiac output values corrected for body surface area in 42 essential hypertensive patients aged 15 to 25 years. The control value (3 to 4 L/min/M²) was chosen on the basis of studies in normal young subjects.¹⁴

Table IV Blood volume and cardiac output (34 young essential hypertensive subjects)

	Total blood volume (%N)		
	≤ 90%	91-109%	≥ 110%
Number	21	7	6
BP (mm. Hg)†	137/86 ± 215/135	133/86 ± 402/3	138/90 ± 631/5
BP (mm. Hg)‡	148/89 ± 474/328	139/84 ± 265/274	141/89 ± 720/270
HR (b/min)	80 ± 38*	10 ± 164	72 ± 5.84
CI (L/min/M)	3.27 ± 0.13	3.31 ± 0.17	2.95 ± 0.27
SI (ml/M)	49 ± 1.81	47 ± 3.08	42 ± 2.70
TPR (uM)	34 ± 1.58	31 ± 2.44	38 ± 3.74

Blood volumes expressed as percent of normal for our laboratory to include 11 of the 34

†Blood pressure reported in two ways: BP — the average of four daily readings during week in hospital; BP — the intra-arterial level obtained during the hemodynamic study.

N = the difference was statistically significant.

mm Hg ± vs 138 mm Hg ± $p < 0.05$). This closeness of the means, however, obscured wider individual variations so that there was no significant correlation between the BP, and BP for either systolic or diastolic level (Fig 4). The difference between the intra-arterial pressure and the week average (BP_i - BP_w) was considered an index of the effect of the invasive technique over the wide variation observed in this index (-30 to +40 mm Hg for SBP and -15 to +31 mm Hg for DBP). There was no correlation between cardiac index and the pressure effect of the test ($r = 0.2403$ and 0.1101 respectively) (Fig 5).

A comparison of the hemodynamic data classified according to the magnitude of blood volume showed that there was no significant difference among the three groups of normo, hypo, and

hypervolemic patients (Table IV). In fact the hypervolemic patients tended to have if anything a lower cardiac index (2.95 vs 3.27 L/min/M) and a higher total peripheral resistance (38 vs 34 uM) than the hypovolemic patients.

The index of aortic resistance to stretch was beyond one standard deviation in 10 patients, whereas it was less than one standard deviation in only five, suggesting that evidence for unpaired aortic distensibility can be found in young people (Table V). This observation was further substantiated by analysis of six patients with pronounced elevation of systolic blood pressure. Among these patients stroke volume varied from low normal to high normal; only in one was it above two standard deviations of the mean. On the other hand the aortic index was increased well above two standard deviations in three patients (Table




Fig 3 No correlation was found in the group aged 20 to 25 years ($r = 0.048$) between cardiac index and intra arterial pressure either systolic or diastolic. Only the diastolic levels are demonstrated in this graph. However a correlation of borderline significance ($r = 0.559$) was found in the younger group (15 to 19 years).

Table V Aortic distensibility in young hypertensive subjects (Index of aortic rigidity calculated as PP/SV mm Hg/ml *)

Patients (42)	Distribution of PP/SV Values		
	> 1 SD	within 1 SD	< 1 SD
Number	10	27	5
Per cent	24	64	12

Index of aortic resistance to stretch (PP/SV mm Hg/ml) compared with expected values obtained from a multiple regression equation developed from studies in 76 subjects

$$PP/SV = (0.0069 \text{ age} + 0.0048 \text{ DBP} + 0.009 \text{ HR} - 0.64) \pm 0.18$$

VI) Systolic hypertension in patients younger than 25 years is therefore not uniformly due to an elevated stroke index

Discussion

Although the relationship of flow and pressure has been widely studied in normal adults and adult patients with essential hypertension^{2,28} only a limited amount of information is available concerning normal children.^{23,24} This may be related to the obvious difficulties associated with hemodynamic studies in young subjects.

It is only recently that the problem of essential hypertension in children and adolescents has received great interest.^{2,4,5,7,29,31} However, ethical problems associated with invasive studies in young asymptomatic subjects have limited the

Table VI Systolic hypertension in six hypertensive patients aged less than 25 years

Patient	Aortic index mm Hg/ml		Stroke index ($N 45 \pm 7 \text{ mL/M}$)
	Expected (± 0.18)	Actual	
1	0.65	1.35†	38
2	0.47	0.50	30
3	0.71	1.12†	36
4	0.55	0.63	56
5	0.54	0.59	57
6	0.39	0.80†	41

For definition see Table V

†Result > 2 SD expected value

number of hemodynamic studies in this age group. Moreover, the diagnostic criteria as well as the expression of results present problems of their own. In fact, the diagnosis of hypertension in young people has been often uncertain because of the lack of a common standard and because of the fluctuation in blood pressure. Londe and colleagues³ pointed out that criteria for blood pressure elevation led to the practical conclusion that any outpatient blood pressure reading above 140/90 can be considered abnormal for children older than 15 years. This is in close agreement with the recent nomogram of blood pressure and age presented in the Task Force Report.³

In our study a patient was included in the

hypertensive group if three abnormal readings were obtained at different times. Although Page and associates³² suggested that the diastolic blood pressure is more stable than the systolic, other authors³³ pointed out that both levels may be equally responsive in children to emotional situations. As far as this tension factor is concerned, Loggie³⁴ has recommended that the blood pressure of children with high office readings be measured by their parents in more familiar conditions before the diagnosis of hypertension is established. Seventeen of our patients had normal blood pressure when calculated for the week from daily readings in the hospital. This normalization of blood pressure in the hospital has been previously recorded both in adults and in children.^{30, 33, 35} This did not alter our diagnosis in such patients because neither the full implications of a blood pressure fall during hospitalization nor the normal range of values for hospitalized patients are well established.³⁶

Expression of hemodynamic results is particularly difficult in children because of variations in body size. Weight alone does not take into consideration differences due to fatness or muscularity. Height alone has been favored by Chien and co-workers³⁷ and by Tarazi and colleagues³⁸ as regards expression of blood volume values because it avoids the effects of obesity and of sex differences. Moreover, Chien and colleagues found that this expression gives stable values independent of age. However, body height alone does not take into account the metabolic demands of fatty tissue.³⁹ Body surface area, which combines both height and weight, seemed more appropriate,⁴⁰ although far from ideal.⁴¹ For our patients, blood volume was calculated in relation to both height and body surface area, while cardiac output was referred to the traditionally accepted reference of body surface area.

Blood volume. There was a spectrum of variation in the blood volume values among our patients from hypo to hypervolemic with a tendency to hypovolemia. The occurrence of this variability in blood volume levels (as well as cardiac output levels) introduced a new aspect to the consideration of adolescent essential hypertension. On the assumption that hypertension in the young represents an early phase of the disease, it was expected that its study in the young might reveal a more homogeneous picture




Fig. 4. In these 42 young essential hypertensive patients, no correlation was found between intraarterial pressure levels obtained during the hemodynamic study (BP) and the pressure average (BP av) calculated for the week of that study. The diagonal lines represent the line of identity ± 10 mm Hg. Only systolic pressures are illustrated in the graph; the diastolic pressures gave similar results. The lack of correlation between BP and BP av contrasts with the closeness of the averages (138 vs 146 mm Hg) and their small difference of borderline significance.

than in adults because of the absence of complicating factors. However, the above results show that the classification of untreated essential hypertension in adults into *hypo normo* and *hypervolemic* subjects^{39, 42} seems to extend to the young. The volume-expanded group might represent diuretic responsive patients equivalent to the volume-dependent adult hypertensive patients. Only long-term studies will demonstrate whether the different types remain true to themselves or if a hypovolemic patient will turn into hypervolemic and vice versa.

Cardiac output. Not only blood volume levels, but also hemodynamic characteristics in these young essential hypertensive patients were found to be as varied as among adults. Cardiac index in young hypertensive subjects was not uniformly increased, contrary to what would be expected from published studies of the early stages of essential hypertension.^{43, 44} Its level varied from 2.2 to 5.2 L/min/m²; this wide range introduced




Fig 5 Blood pressure change associated with the hemodynamic study is expressed as the difference between the intra arterial pressure recorded during the study (BP) and the pressure average for that week (BP). Only systolic blood pressure is shown in the graph. Over the wide range of blood pressure variation (-30 to +40 mm Hg) there was no correlation between difference in pressure and cardiac index indicating that the alteration in blood pressure was not necessarily dependent on the level of cardiac output.

new elements for data evaluation. There are greater difficulties in interpreting cardiac output levels than blood volume values, not only because cardiac output could be influenced by the tension of invasive procedures,⁴⁸ but also because of its variability with age. For these reasons, analysis of cardiac output data was undertaken in relation to two other hemodynamic parameters: blood volume and arterial pressure.

1 As regards blood volume, the magnitude of volemia did not seem to be the major determinant of cardiac output among young hypertensives because output values in the three groups studied (hypo, normo and hypervolemic subjects) were not statistically different. If anything, the hypervolemic group tended to have a lower cardiac output compared to the hypovolemic group. It has been previously shown that cardiac index was not in direct relation to the degree of volemia.⁴⁹ It would be therefore difficult to explain volume dependent hypertension on the basis of increased flow alone.⁴⁹

2 As regards arterial pressure, an analysis of data in relation to one value alone is in our opinion incomplete because of the marked variability of pressure levels. Indeed, there was no correlation between blood pressure measured during the hemodynamic study and the hospital blood pressure average for the week of the hemo-

dynamic study (Fig 4). Both pressure levels as well as their difference were therefore used to evaluate cardiac output in our patients. None of the approaches revealed a significant correlation between pressure and output. The difference between intra arterial pressure during the hemodynamic study (BP_{ia}) and the weekly hospital average was taken to represent the pressure response to the situational factors of the test. This response showed no correlation with the level of output. The consistent failure of all three approaches to find a significant correlation between cardiac output and blood pressure indicates that essential hypertension in the young is not the homogeneous entity primarily related as was previously thought to a raised cardiac output.

Aortic distensibility was reduced (index of aortic resistance to stretch > one standard deviation of expected value corrected for age and blood pressure) in 10 (24 per cent) of 42 young hypertensive patients. These results suggest that impaired aortic compliance may develop at a young age. Analysis of six young patients with undue systolic blood pressure elevation confirmed this impression. Systolic hypertension in the young has usually been ascribed to increased stroke volume.⁵⁰⁻⁵¹ However, in our six young patients stroke volume was increased only in one while

aortic rigidity was markedly increased in three out of six. One is left only to speculate regarding the reason for this abnormality. Structural changes in the arterial wall with increased collagen tissue similar to those described in young spontaneously hypertensive rats may be thought of. On the other hand Tarazi and Dustan²³ have previously suggested that an increased sympathetic tone might diminish distensibility of the aorta and large arteries. Future studies will certainly be needed to clarify such findings in young people.

In conclusion the complexity of the hemodynamic pattern of essential hypertension in our patients suggests that the subdivision of essential hypertension into various groups applies even to youths. Of great importance would be the development of normal standards for children and adolescents. Noninvasive techniques would be undoubtedly of valuable help not only for the study of normals but also for the follow up of a long term illness usually characterized by a markedly fluctuant course.

Summary

Cardiac output was determined in 42 young essential hypertensives (15 to 25 yrs) values ranged from 3.86 to 10.30 L/minute. These differences were not related to magnitude of volemia. Correlation of output to weekly blood pressure average (BP) was not significant. Its relationship to intraarterial pressure (BP_i) was not significant in 21 patients aged 20 to 25 and of borderline significance in 13 aged 15 to 19. Blood pressure changes associated with the study (BP, -BP) were also not consistently related to cardiac output. Six patients had systolic hypertension only one had elevated stroke volume.

These results outline as complex a picture in young essential hypertensives as in older subjects.

REFERENCES

1. Platt R. Severe hypertension in young persons. A study of 50 cases. *Q J Med* 17: 83 1948
2. Takeuchi J. Etiology of juvenile hypertension. *Jap Circ J* 30: 178 1966
3. Singh B P and Page L B. Hypertension in early life. *Am J Med Sci* 253: 255 1967
4. Loggie J M H. Systemic hypertension in children and adolescents. Causes and treatment. *Pediatr Clin North Am* 18: 1273 1971
5. Londe S, Bourgoigne J J, Robson A M and Goldring D. Hypertension in apparently normal children. *J Pediatr* 78: 569 1971

6. Zinner S H, Levy P S and Kass E H. Familial aggregation of blood pressure in childhood. *N Engl J Med* 284: 461 1971
7. Report of the Task Force on Blood Pressure Control in Children. *Pediatrics* 58 (Suppl.) No. 5 Part 2, 1977
8. Chaplin H Jr, Mollison P L and Vetter H. The body/venous hematocrit ratio: its constancy over a wide hematocrit range. *J Clin Invest* 32: 1309 1953
9. Tarazi, R C, Dustan H P., and Frohlich E D. Relation of plasma to interstitial fluid volume in essential hypertension. *Circulation* 40: 357 1969
10. Frohlich, E D., Urych M, Tarazi R C, Dustan H P and Page I H. Hemodynamic comparison of essential and renovascular hypertension. Cardiac output and total peripheral resistance—supine and tilted patients. *Circulation* 35: 289 1967
11. Tarazi, R C, Ibrahim M M, Dustan H P and Ferraro C M. Cardiac factors in hypertension. *Circ Res* 34 and 35 (Suppl. I) 213 1974
12. Tarazi R C, Magrini F and Dustan H P. The role of aortic distensibility in hypertension. In Recent advance in hypertension. International Symposium. Monte Carlo Reims France 1975. Lab Boehringer Ingelheim pp 133 142
13. Burton A C. In Physiology and biophysics of the circulation. Chicago 1966. Year Book Medical Publishers Inc pp 152 158
14. Koch Waser J. Correlation of pathophysiology and pharmacology in primary hypertension. *Am J Cardiol* 32: 499 1973
15. Croxson F E and Cowden D J. Applied general statistics. New York 1944. Prentice Hall Inc
16. Rettori O, Mejia K H and Fernandez L A. Factors of variation in blood volume determinations in the rat. *Acta Physiol Lat Am* 14: 221 1964
17. Chen S, Usami S, Simmons R L, McAllister F., and Gregersen M I. Blood volume and age repeated measurements on normal men after 17 years. *J Appl Physiol* 21: 583 1966
18. Tarazi, R C, Frohlich E D and Dustan H P. Plasma volume in men with essential hypertension. *N Engl J Med* 278: 762 1968
19. Retzlaff J A, Tauxe W N, Kiely J M and Stroebe C F. Erythrocyte volume, plasma volume and lean body mass in adult men and women. *Blood* 33: 649 1969
20. Tarazi, R C, Dustan H P, Frohlich E D, Gifford, R W Jr and Hoffman G C. Plasma volume and chronic hypertension. Relationship of arterial pressure levels in different hypertensive diseases. *Arch. Intern Med* 125: 835 1970
21. Altman P L. and Dittmer D S eds. In Respiration and circulation. Bethesda Maryland, 1971. FASEB pp 377 378
22. Cayler G C, Rudolph, A. M and Nadas A S. Systemic blood flow in infancy and children with and without heart disease. *Pediatrics* 32: 186 1963
23. Jegor W., Sekely P, Auld M A M, Simpson R and McGregor M. The relation between cardiac output and body size. *Br Heart J* 25: 495 1963
24. Pongpanich B, Rutter D G and Ongley P A. Hemodynamic findings in children without significant heart disease. *Mayo Clin. Proc* 44: 13 1969
25. Sannerstedt R. Hemodynamic response to exercise in patients with arterial hypertension. *Acta Med Scand* 180 (Suppl. 458) 1966
26. Janus S and Conway J. Hemodynamic studies in patients with borderline blood pressure elevation. *Circulation* 38: 987 1968

- 27 Frohlich E D Tarazi R C and Dustan H P Re examination of the hemodynamics of hypertension *Am J Med Sci* 257 9 1969
- 28 Frohlich E D Kozul V J Tarazi R C and Dustan H P Physiological comparison of labile and essential hypertension *Circ Res* 26 and 27(Suppl 1) 55 1970
- 29 Londe S Blood pressure standards for normal children as determined under office conditions *Clin Pediatr* 7 400 1968
- 30 Londe S and Goldring D Hypertension in children *Am HEART J* 84 1 1972
- 31 Kilcoyne M M Richter R W and Alsop P A Adolescent hypertension I Detection and prevalence *Circulation* 50 758 1974
- 32 Page L B Crawford J D Truman J T and Connelly, J P Childhood hypertension Etiology investigation and treatment *Clin Pediatr* 5 39 1966
- 33 Clayton G W and Hughes J G Variations in blood pressure in hospitalized children *J Pediatr* 40 462 1952
- 34 Freis E D The pathogenesis of essential hypertension in Proceedings of the Prague Symposium Cort J H Fenel V Hejl Z and Jirka J eds Prague 1960 Prague State Medical Publishing House p 112
- 35 Hoobler S W The pathogenesis of essential hypertension in Proceedings of the Prague Symposium Cort J H Fenel V Hejl Z and Jirka J, eds Prague 1960 Prague State Medical Publishing House p 314
- 36 Katcher A L Hypertension in adolescent children *Med Clin North Am* 48 1467 1964
- 37 Ballard K W Functional characteristics of the micro circulation in white adipose tissue (Unpublished observations)
- 38 Tanner J M Fallacy of per weight and per surface area standards and their relation to spurious correlation *J Appl Physiol* 2 1 1949
- 39 Tanner J M The construction of normal standards for cardiac output in man *J Clin Invest* 28 567 1949
- 40 Krovetz L J and Goldbloom S Normal standards for cardiovascular data I Examination of the validity of cardiac index Johns Hopkins Med J 130 174 1972
- 41 Taylor H L and Tiede K A comparison of the estimation of the basal cardiac output from a linear formula and the cardiac index *J Clin Invest* 31 209 1952
- 42 Brotmacher L and Deuchorr D C The systemic blood flow in congenital heart disease with an examination of the validity of the cardiac index *Clin Sci* 15 441 1956
- 43 Cayler G G Rudolph A M and Nadas A S Systemic blood flow in infants and children with and without heart disease *Pediatrics* 32 186 1963
- 44 Tarazi R C Dustan H P and Bravo F L The importance of plasma volume in the treatment of hypertension in Beta blockers—Present status and future prospects Schweizer W ed Bern 1975 Hans Huber pp 102 119
- 45 Dustan H P Bravo F L and Tarazi R C Volume-dependent essential and steroid hypertension *Am J Cardiol* 31 606 1973
- 46 Eich R H Peters R J Cuddy H P Smulyan H and Lyons R H The hemodynamics in labile hypertension *Am HEART J* 63 188 1962
- 47 Frohlich E D Hemodynamics of hypertension in Hypertension Physiology and treatment Genest J Kiow E and Kuchel O eds New York 1977 McGraw Hill Book Company pp 15 48
- 48 Hickam J B Cargill W H and Golden A Cardiovascular reactions to emotional stimuli Effect on the cardiac output arteriovenous oxygen difference arterial pressure and peripheral resistance *J Clin Invest* 27 290 1948
- 49 Laragh J Vasoconstriction—volume analysis for understanding and treating hypertension The use of renin and aldosterone profiles *Am J Med* 55 261 1973
- 50 Pickering G High blood pressure New York Grune & Stratton Inc 1968 printed in Great Britain by Whitefrans Press Ltd 717 pgs
- 51 Adamopoulos P N Chrysanthakopoulos S G, and Frohlich E D Systolic hypertension nonhomogeneous diseases *Am J Cardiol* 36 697 1975
- 52 Hofflander W Colombo M Nagra S and Paddock J Correlative studies of blood pressure plasma renin activity and cardiovascular disease in the hypertensive rat in Spontaneous hypertension Its pathogenesis and complications Proceedings of the Second International Symposium on the Spontaneously Hypertensive Rat 6 DHEW Publ No (NIH) 77 1179
- 53 Tarazi R C and Dustan H P The hemodynamics of labile hypertension in adolescents in Pediatric nephrology vol 3 Strauss J ed New York 1976 Plenum Publishing Co pp 97 106
- 54 Chapman C B and Fraser R S Studies on the effect of exercise on cardiovascular function I Cardiac output and mean circulation time *Circulation* 9 57 1954
- 55 Hanson J S and Tabakin H S Comparison of the circulatory response to upright exercise in 25 normal men and nine distance runners *Br Heart J* 7 711 1965

Congenital tricuspid incompetence simulating pulmonary atresia with intact ventricular septum a report of two cases

William Berman Jr MD

Victor Whitman MD

Paul Stanger MD

Abraham M Rudolph MD

Hershey Pa and San Francisco Calif

Isolated severe tricuspid incompetence in the neonatal period is associated with cyanosis and massive cardiomegaly. Although most reports of severe tricuspid incompetence in neonates emphasize the poor prognosis and high surgical mortality rate of these patients¹ Boucek and associates recently described a favorable course in four infants who were managed conservatively. Since tricuspid incompetence may be associated with severe right ventricular outflow obstruction, it is essential to distinguish patients with isolated tricuspid incompetence from those with associated severe right ventricular outflow tract obstruction. As pulmonary blood flow may be markedly reduced in both groups, differentiation can be difficult even with catheterization and angiography.

We report two cases of congenital tricuspid incompetence in which severe right ventricular outflow tract obstruction was suspected incorrectly after cardiac catheterization in the first days after birth. The management course and outcome of these two patients differed markedly.

Case reports

Case No 1 Baby V D was the 3.3 kilogram product of an uncomplicated pregnancy and delivery. Cyanosis and cardio-

respiratory distress were noted immediately after birth. Chest roentgenograms showed massive cardiomegaly and an electrocardiogram showed right atrial and right ventricular hypertrophy. The infant was intubated and placed on a respirator. Digoxin and diuretic therapy were begun and she was transferred to the Intensive Care Nursery at The University of California Hospitals, San Francisco.

Physical examination showed a cyanotic infant with massive hepatomegaly. The precordial impulse was active and diffuse. Peripheral pulses and blood pressures were normal. The first heart sound was normal, the second heart sound was single. A to and fro Grade III/VI systolic and II/VI diastolic murmur was heard best at the lower left sternal border. A descending aortic blood sample obtained from an umbilical artery catheter showed a PH of 68, PCO₂ > 100 torr and PO₂ of 30 torr while the infant breathed 100 per cent oxygen. After adjustment in the respirator rate and cycling the PO₂ remained at 30 torr but the pH was 7.44 and the PCO₂ 36 torr in 40 per cent oxygen. An echocardiogram showed right ventricular dilatation but no pulmonary valve echo was identified.

Cardiac catheterization was performed and the pertinent physiologic data are listed in Table I. A venous catheter could not be passed into the pulmonary artery. The retrograde arterial catheter was passed into the left ventricle but did not pass through the ductus arteriosus into the pulmonary artery. Oxygen saturation data showed a bidirectional atrial shunt and an aortic blood oxygen saturation of 66 per cent with the patient breathing 40 per cent oxygen. Pulmonary venous desaturation could not be excluded as a cause of cyanosis as a pulmonary vein was not entered. Right atrial mean pressure was normal, but the *c* wave exceeded the *a* wave. The right and left ventricular systolic pressures were equal and no systolic pressure difference between the left ventricle and the aorta was recorded. An angiogram in the right ventricular apex showed marked tricuspid incompetence, right ventricular and right atrial enlargement, a deformity of the right ventricular outflow tract and no opacification of the pulmonary arteries (Fig 1). An angiogram in the right ventricular infundibulum again failed to show opacification of pulmonary arterial structures (Fig 2). A left ventricular angiogram was normal. An angiogram performed in the ascending aorta

From The Departments of Pediatrics and Cardiology, The Milton S. Eshelman Medical Center, The Pennsylvania State University College of Medicine, Hershey, Pa, and The Departments of Pediatrics and Cardiac Research, Institute of Child Health, Stanford University, San Francisco, Calif.

Received for publication Sept 27 1977

Accepted for publication Oct 31 1977

Reprint requests: William Berman Jr MD, Department of Pediatrics, Hershey Medical Center, Hershey, Pa 17033

Table I Catheterization data

Case	Age	Parameters measured	SVC	IVC	RA			RV	MPA	PV	LA			L1	40
					mean	a	t				mean	a	t		
1	2 days	Pressure (mm Hg)			4	5	8	50/3	—	—		7	5	50/3	50/3
		Oxygen saturation (%)	37	40		53		52	—	—	56			60	60
2	2 days	Pressure (mm Hg)			4	6	5	40/6	—	—		5	5	75/1	50
		Oxygen saturation (%)	57	60		60		59	—	91	76			79	79
	3 wks	Pressure (mm Hg)			2	5	4	35/4	20/5	2		5		90/4	
		Oxygen saturation (%)	50	68		64		67	67		94			94	

revealed a normal aortic root a normal coronary arterial tree no narrowing of the aortic isthmus and a moderate sized tortuous patent ductus arteriosus. The right ventricular infundibulum was visualized faintly because of pulmonary regurgitation (Fig 3).

The angiograms were interpreted as showing severe right ventricular outflow tract obstruction with secondary tricuspid incompetence. At surgery the pulmonary valve was not stenotic. The tricuspid valve was then explored and found to be dysplastic with short chordae and multiple small myxomatous nodules on the free margins of the leaflets. The atrial septal defect was closed and the aneurysmally dilated right ventricular outflow tract was resected. The child was weaned from cardiopulmonary bypass but had a cardiac arrest shortly thereafter and could not be resuscitated. Postmortem examination showed a dilated dysplastic tricuspid valve without evidence of Ebstein's malformation. The pulmonary valve was normal.

Case No 2 Baby F was the 3.36 kilogram product of an uncomplicated pregnancy and delivery. Cyanosis, tachypnea and tachycardia were noted within the first hours of life. She was begun on digoxin and transferred to The Milton S. Hershhey Medical Center on the second day after birth.

Physical examination showed a moderately cyanotic infant with normal pulses and peripheral blood pressures. There was a prominent right ventricular impulse. The first heart sound was normal; the second sound was single. There was a harsh Grade III/VI systolic murmur at the lower left sternal border. Chest roentgenograms showed massive cardiomegaly and an electrocardiogram showed right atrial and right ventricular hypertrophy. The echocardiogram showed right ventricular dilatation but a pulmonary valve could not be identified. An arterial blood specimen obtained while the patient breathed room air showed a pH of 7.37, PO₂ of 37 torr and PCO₂ of 23 torr. Cardiac catheterization was performed and the data are summarized in Table I. The retrograde arterial catheter could not be passed through the ductus arteriosus. Neither conventional nor balloon tipped catheters could be passed into the pulmonary artery from the right ventricular outflow tract. Oxygen saturation data showed a slight reduction of pulmonary venous blood saturation and a moderate right to left atrial shunt. The aortic blood oxygen saturation was 79 per cent while the infant breathed room air. Right ventricular systolic pressure was slightly more than half the systemic arterial level. Right atrial phasic and mean pressures were

normal. An angiogram in the right ventricular apex showed massive tricuspid incompetence, an enlarged right atrium, an enlarged right ventricle, a deformed right ventricular outflow tract and no anterograde filling of the pulmonary arteries (Fig 4). An angiogram in the right ventricular infundibulum again failed to show opacification of pulmonary arteries (Fig 5). A left ventricular angiogram was normal. An ascending aortogram showed filling of the pulmonary arterial system through a small tortuous patent ductus arteriosus. The aortic isthmus was not narrow. The coronary arterial tree appeared normal.

Pulmonary atresia or critical pulmonic stenosis with secondary tricuspid incompetence were considered as possible diagnoses; however, the relatively mild elevation of right ventricular systolic pressure, the relatively moderate decrease in aortic blood oxygen saturation and the similarity of the catheterization findings to that of patients with isolated congenital tricuspid incompetence prompted us to delay surgical intervention. The infant was placed in an atmosphere of 40 per cent oxygen and this was gradually decreased to room air over 5 days as cyanosis and signs of congestive heart failure diminished.

The infant was recatheterized at 3 weeks of age (Table I). No right to left atrial shunt was noted. The right ventricular systolic pressure was 40 per cent of systemic and there was a 15 mm Hg systolic pressure gradient across the pulmonary valve. A right ventricular angiogram showed a dilated chamber, decreased wall motion, mild tricuspid incompetence and normal opacification of the pulmonary arterial tree (Fig 6). The pulmonic valve leaflets appeared thickened but moved well. A left ventricular angiogram showed that the ductus arteriosus had closed.

Discussion

A variety of lesions may cause severe tricuspid incompetence in the neonate (Table II). Of neonates with these conditions only those with marked right ventricular outflow tract or left sided obstructive lesions are candidates for cardiac surgery. Most of the others require supportive care including correction of pulmonary and/or metabolic abnormalities but will show improvement with medical management.



Fig 1 Right ventricular angiogram in case No 1 showing massive tricuspid incompetence and no opacification of pulmonary arterial structures




Fig 2 Right ventricular infundibular angiogram in case No 1 showing apparent pulmonary valve atresia

This is not necessarily the case with right ventricular outflow tract obstruction. The patient with mild to moderate right ventricular outflow tract obstruction associated with a large patent ductus arteriosus may improve as the patent ductus arteriosus closes and the right ventricular after load falls. On the other hand a patient with severe right ventricular outflow tract obstruction will become worse as the patent ductus arteriosus closes.

Therefore identification of neonates with severe tricuspid incompetence associated with



Fig 3 Aortogram in case No 1 showing tortuous ductus arteriosus (—>) pulmonary valve sinuses (->) and faint pulmonary regurgitation (>)



Fig 4 Right ventricular angiogram in case No 2 showing massive tricuspid regurgitation, deformed right ventricular outflow tract and no opacification of pulmonary arterial structures

marked right ventricular outflow tract obstruction is essential especially since the right ventricular outflow tract obstruction can coexist with tricuspid valve dysplasia. Occasionally differentiation can be made clinically or with the assistance of echocardiography however cardiac catheterization is usually required. Even with cardiac catheterization and angiography exclusion of right ventricular outflow obstruction may be difficult. In fact angiography may be misleading and prompt unnecessary surgery. Of the two cases of congenital tricuspid incompetence



Fig 5 Lateral projection of right ventricular infundibular angiogram in case No 2 showing apparent pulmonary valve atresia



Fig 6 Right ventricular angiogram in case No 3 performed at age 3 weeks showing marked reduction in tricuspid incompetence and good opacification of pulmonary arterial structures

reported by Reisman and co workers⁴ one was operated on for relief of suspected right ventricular outflow tract obstruction. A normal pulmonary valve was found and the patient died during surgery. Barr and co workers reported five neonates with tricuspid incompetence two of

which were shown at surgery, to be unassociated with right ventricular outflow tract obstruction. In each of those two cases the pulmonary artery was not entered at catheterization and right ventricular angiography failed to demonstrate patency of the pulmonic valve. Both patients underwent surgery and died postoperatively. Similarly, our first case died after surgery for relief of suspected right ventricular outflow tract obstruction.

In contrast the correct diagnosis is readily established by catheterization and cineangiography in neonates with tricuspid incompetence secondary to left sided obstructive lesions, elevated pulmonary vascular resistance or myocardial depression. In each of these conditions usually the catheter can be passed into the pulmonary arteries and pulmonary arterial pressure can be recorded. Moreover each of these lesions is associated with tricuspid incompetence which is acquired postnatally. Therefore the aortic isthmus shows the narrowing which is normal for the newborn infant.¹¹ The main diagnostic problem is in differentiating those patients with tricuspid incompetence secondary to right ventricular outflow tract obstruction from those with the primary forms of tricuspid incompetence. In these two groups the clinical features including physical examination, electrocardiogram, roentgenograms, and arterial blood gases may be similar. Furthermore the limited pulmonary valve

Table II Classification of primary and secondary forms of tricuspid incompetence in the newborn infant

I. Tricuspid valve lesions (primary)	
A.	Ebstein's malformation (5)
B.	Unguarded tricuspid valve (6)
C.	Tricuspid valve dysplasia (7)
D.	Endocardial cushion abnormality (8)
II. Conditions which can cause tricuspid incompetence (secondary)	
A.	Severe right ventricular outflow tract obstruction (9)
B.	Transient tricuspid incompetence of the neonate (10)
C.	Marked elevation of pulmonary vascular resistance
	(1) persistence of fetal circulatory pattern (11)
	(2) severe pulmonary parenchymal disease (10)
	(3) upper airway obstruction (as choanal atresia) (12)
D.	Left sided obstructive cardiac lesions (10)
E.	Myocardial depression or dilatation from any cause (myocarditis myocardiopathy hypoglycemia hypocalcemia hypoxemia, acidemia etc.) (13)

motion or abnormal valve orientation in both groups may preclude identification of the pulmonary valve on echocardiogram. Cardiac catheterization findings also may be similar in the two groups. Since flow patterns may be similar in both groups oxygen saturations may not be helpful in distinguishing them. Usually pulmonary artery pressures cannot be obtained and conclusions drawn from right ventricular pressures may be erroneous. Although right ventricular systolic pressures that are higher than systemic arterial levels suggest the presence of severe right ventricular outflow obstruction, a patient with mild or moderate pulmonary valve obstruction and a large patent ductus arteriosus also may have right ventricular systolic pressures above systemic levels. However a patient with pulmonary atresia with intact ventricular septum, massive tricuspid incompetence and low pulmonary blood flow may have right ventricular systolic pressures that are well below systemic levels. Right ventricular pressures at systemic arterial levels are common in pulmonary atresia with intact ventricular septum and have been reported also in neonates with isolated tricuspid incompetence.

The right ventricular angiograms show massive tricuspid incompetence and both groups may show no forward flow into the pulmonary arteries. Aortograms also show similar findings in both groups. The aortic isthmus does not show the narrowing noted normally in the newborn period. This lack of narrowing is associated with a decreased right ventricular forward flow *in utero* from any cause.¹ Furthermore the angulation

and tortuosity of the ductus are similar in both groups.

Passage of semi rigid wire guided or balloon tipped catheters from the right ventricle to the pulmonary artery in these patients may be quite difficult furthermore if the right ventricular angiogram shows no forward flow attempting such a maneuver is hazardous. Both of our cases one of the cases reported by Reisman and associates² one of the cases reported by Kincaid and colleagues³ and two of the cases reported by Barr and collaborators⁴ had diverticulum like deformities of the right ventricular outflow tract that made manipulation of semi rigid catheters into the main pulmonary artery difficult. The passage of balloon tipped catheters into the pulmonary artery is usually not possible as the regurgitation carries the inflated balloon back into the right atrium. Passage of a retrograde aortic catheter through the patent ductus arteriosus into the pulmonary artery is difficult because of the tortuosity and angulation of the ductus. Additionally there is the hazard of the ductus constricting when stimulated by a catheter.

If the right ventricular angiogram shows marked tricuspid incompetence without pulmonary arterial opacification it is crucial to determine whether or not the pulmonary valve is patent. Pulmonary regurgitation demonstrated on aortography excludes pulmonary atresia and is strong evidence against the presence of severe pulmonary stenosis. In addition since a high pulmonary vascular resistance may retard pulmonary artery filling in some of the conditions under consideration one might administer 100

per cent oxygen¹⁶ or tolazoline¹⁷ in an attempt to reduce pulmonary vascular resistance and promote pulmonary artery opacification on a right ventricular infundibular angiogram. However, tolazoline is a potent systemic as well as pulmonary vasodilator, and its use is accompanied by some risk especially if the patent ductus arteriosus is the sole source of pulmonary blood flow. Though both of our cases underwent right ventricular infundibular angiography without pulmonary artery filling, neither was given tolazoline or 100 per cent oxygen prior to angiography.

As these cases illustrate, right ventricular outflow tract patency cannot be established at catheterization in some infants with severe isolated tricuspid incompetence. Management may therefore be a problem. Though surgical intervention often is mandatory when severe right ventricular outflow tract obstruction exists, it has been ineffective in infants with isolated tricuspid incompetence. These two cases and those reviewed in the literature suggest that a combination of findings is characteristic though not diagnostic, of infants with isolated tricuspid incompetence without right ventricular outflow tract obstruction. These findings include

- a large right ventricle,
- right ventricular systolic pressures less than or equal to systemic
- aortic blood oxygen saturations over 65 per cent levels higher than those found in most infants with pulmonary atresia or critical pulmonary stenosis and

- moderate sized diverticulum like deformity of the right ventricular outflow tract

Even when these factors are considered uncertainty may remain and diagnostic errors may occur. Because of the apparent advantage of delaying surgical intervention in those infants without right ventricular outflow tract obstruction, intensive supportive care and observation should be instituted. Oxygen therapy may reduce pulmonary vascular resistance and thereby promote antegrade pulmonary artery flow and improve aortic oxygen saturation. Moreover if antegrade pulmonary blood flow increases a pulmonary valve echo may become visible on repeat echocardiography. However, as long as the diagnosis remains unclear, prompt surgical treatment should be available for those infants whose clinical status deteriorates.

Summary

Two infants with isolated congenital tricuspid incompetence appeared to have associated right ventricular outflow tract obstruction at diagnostic evaluation, including catheterization and cineangiography. One infant died during surgery, the other improved rapidly and survived with medical therapy. We discuss the problem of establishing the presence of patency of the right ventricular outflow tract in infants with massive tricuspid incompetence and outline an approach to the management of infants whose diagnosis remains unclear even after careful evaluation.

REFERENCES

- 1 Boucek R J Jr, Graham T J Jr, Morgan J P, Atwood G F and Boerth R C. Spontaneous resolution of massive congenital tricuspid insufficiency. *Circulation* 54: 795, 1976.
- 2 Barr P A, Celemajer J M, Bowdler J D and Cartmill T B. Severe congenital tricuspid incompetence in the neonate. *Circulation* 49: 962, 1974.
- 3 Hincaid O W, Swan H J C, Ongley P A and Titus J L. Congenital tricuspid insufficiency. Report of two cases. *Proc Mayo Clin* 37: 640, 1967.
- 4 Reisman M, Hipona F A, Bloor C M and Tainer N S. Congenital tricuspid insufficiency. *J Pediatr* 65: 669, 1965.
- 5 Kumar A B, Fyler D C, Miettinen O S and Nadas A S. Ebstein's anomaly. *Am J Cardiol* 28: 84, 1971.
- 6 Kanjuh V I, Stevenson J E, Amplatz K and Edwards J E. Congenital unguarded tricuspid orifice with coexistent pulmonary atresia. *Circulation* 30: 911, 1964.
- 7 Davignon A L, Greenwald W F, DuShane J W and Edwards J E. Congenital pulmonary atresia with intact ventricular septum. Clinicopathologic correlation of two anatomic types. *Am Heart J* 62: 591, 1961.
- 8 Schiebler G L, van Mierop L H S and Krovetz L J. Diseases of the tricuspid valve. chapter 20 in *Heart Disease in Infants, Children and Adolescents*. Moss A J and Adams F, eds. Baltimore, 1968. The Williams & Wilkins Company, p 134.
- 9 Becker A E, Becker M J and Edwards J E. Pathologic spectrum of dysplasia of the tricuspid valve. *Arch Pathol* 91: 167, 1971.
- 10 Bucciarelli R L, Nelson R M, Egan F A II, Eitzman D V and Gessner I H. Transient tricuspid insufficiency of the newborn. A form of myocardial dysfunction in stressed newborns. *Pediatrics* 59: 330, 1977.
- 11 Levin D L, Heymann M A, Kitterman J A, Gregory G A, Phibbs R H and Rudolph A M. Persistent pulmonary hypertension of the infant. *J Pediatr* 89: 676, 1976.
- 12 Rowe H D and Mehrez A. The neonate with congenital heart disease. vol 5 in *Major Problems in Clinical Pediatrics*. Schaffer A J, ed. Philadelphia, 1968. W B Saunders Company, p 3.
- 13 Rowe D E and Hoffman T. Transient myocardial ischemia of the newborn infant. A form of severe cardiorespiratory distress in full term infants. *J Pediatr* 81: 243, 1972.

- 14 Rudolph A M Congenital Diseases of the Heart Chicago 1974 Year Book Medical Publishers Inc p 369
- 15 Talner N S and Campbell A G M Recognition and management of cardiologic problems in the newborn infant, in Neonatal Heart Disease Friedman W F Lesch, M and Sonnenblick E H eds New York 1972 Grune & Stratton Inc ■ 95
- 16 Vogel J H K Averill, K H Pool P E and Blount E ■ Experimental pulmonary arterial hypertension in the newborn calf Circ Res 13 557 1963
- 17 Rudolph A M Paul M H Sommer L S and Nadas A S Effects of tolazoline hydrochloride (Priscoline) on circulatory dynamics of patients with pulmonary hypertension, AM HEART J 55 424 1958

Information for authors

Most of the provisions of the Copyright Act of 1976 became effective on January 1 1978. Therefore all manuscripts must be accompanied by the following statement signed by each author "The undersigned author(s) transfers all copyright ownership of the manuscript entitled (title of article) to The C V Mosby Company in the event the work is published. The author(s) warrants that the article is original is not under consideration by another journal and has not been previously published. Authors will be consulted when possible regarding republication of their material.

Exposure of concealed right bundle branch block in Wolff-Parkinson-White type B by pacing from the vicinity of the A-V node

Otto L. Garcia, M D
Agustin Castellanos M D
Ruey J. Sung, M D
Henry Gelband, M D
Miami, Fla

Electrocardiographic concealment of right bundle branch block by the Wolff Parkinson White syndrome type B as well as the electrocardiographic patterns resulting from the coexistence of these two conduction abnormalities, have been attributed to the relationship between the location of the accessory pathway (septal or parietal) and the site of right bundle branch block (central or peripheral).¹ We recently have observed that pacing from the vicinity of the A-V node may help to clarify and elucidate these phenomena.

Material and methods

Two patients having exclusively Wolff Parkinson White type B conduction during sinus rhythm on the electrocardiogram and in whom the presence of right bundle branch block was not suspected form the basis of this report.

An informed consent was obtained from the parents prior to electrophysiological studies. In each patient the study was performed in a post absorptive basal state under Demerol and Phenergan sedation.² None of them had received cardio tonic or antiarrhythmic medication for at least 48 hours prior to the procedure. A tetrapolar 5F electrode catheter (Elecath Corporation, Rahway, New Jersey) was used to pace and record

from different intracardiac sites. The electrodes had a width of 2 mm. The corresponding inter electrode distances were between one and two = 1 mm and between three and four = 5 mm. Bipolar recording was performed through electrodes one and two and bipolar pacing through electrodes three and four.

The corresponding electrograms filtered with a setting of 40 to 400 or 400 to 500 Hz were displayed simultaneously with three surface electrocardiographic leads, usually I, II, and V, on a multichannel oscilloscopic recorder (Electronics for Medicine DR 8, White Plains, New York).

The electrode catheter was initially used to determine the site which, during atrial pacing, resulted in the shortest S₁-delta interval. Thereafter the catheter was placed over the septal leaflet of the tricuspid valve to record a His bundle electrogram through the distal electrode pair. Once His bundle activity was identified electrical stimulation was performed from the proximal electrode pair.

Definition and measurement of P-A-H and H-V intervals were as conventionally described.³ Normal values in our laboratory for pediatric patients are 0 to 35 msec, 50 to 115 msec and 30 to 45 msec respectively.

The P-delta (or S₁-delta) intervals represented the time elapsing between onset of the P wave (or deliverance of the stimulus to an ectopic atrial site) and onset of ventricular depolarization.

Case 1

A one year old female with an A-V canal had an electrocardiogram which demonstrated Wolff Parkinson White type B without evidence of right bundle branch block during sinus

From the Divisions of Pediatric and Adult Cardiology, Department of Pediatrics and Medicine, University of Miami School of Medicine, Miami, Fla.

Received for publication Oct. 10, 1977.

Accepted for publication Nov. 18, 1977.

Reprint requests: Henry Gelband, M.D., Pediatric Cardiology Dept. of Pediatrics, University of Miami, School of Medicine, P.O. Box 016870, Miami, Fla. 33101.




Fig 1 (Case 1) Wolff Parkinson White syndrome type B without evidence of right bundle branch block during sinus rhythm at a cycle length of 430 msec (rate of 139/minute) HBE = His bundle electrographic lead A = low septal right atrial electrogram




Fig 2 (Case 1) Atrial pacing from the posteroseptal right atrial (PSRA) site at a rate of 200 beats/minute resulted in conduction block in the accessory pathway with subsequent conduction over the normal pathway (left anterior hemiblock incomplete right bundle branch block pattern)

rhythm (Fig 1) The duration of the corresponding intervals measured at a sinus cycle length of 430 msec were as follows P-delta = 110 msec P-A = 30 msec A-delta = 80 msec P-J interval = 220 msec and QRS duration = 110 msec The H deflection was incorporated within the ventricular electrogram recorded by the His bundle electrographic lead

Pacing from a posterolateral right atrial site resulted in the shortest St-delta interval 90 msec The ventricular complex was 15 msec longer than during sinus rhythm Hence A-V conduction was now taking place exclusively through the

accessory pathway The P waves were positive in Leads I, II and III A 1:1 A-V conduction ratio persisted until the cycle length was reduced to 300 msec (rate of 200/minute) There after propagation through the accessory pathway failed and the impulse was conducted exclusively via the normal (A-V node-His Purkinje) pathway with a left anterior hemiblock incomplete right bundle branch block pattern (Fig 2) The St-V intervals and QRS complexes measured 230 msec and 80 msec respectively

Since atrial pacing was performed from the vicinity of the




Fig 3 (Case 1) Pacing from the vicinity of the A V node resulting in fusion beats with (pseudo) normal QRS complexes and short H V interval at shorter cycle lengths (310 msec) than those at which exclusive accessory pathway conduction had occurred when pacing from close to the atrial entrance of the accessory pathway (Fig 2) Exclusive A V normal pathway conduction occurred toward the end of the right sided panel




Fig 4 (Case 2) Wolff Parkinson White syndrome type B without evidence of right bundle branch block during sinus rhythm (left sided panel) and atrial stimulation from the site yielding the shortest St-delta interval (right sided panel)

atrial entrance of the accessory pathway the corresponding ventricular electrogram (recorded through the same catheter) presumably represented the electrical activity of the tissue in the area of the ventricular junction of the accessory pathway. This is supported by inscription of the corresponding ventricular electrogram 50 to 10 msec before the onset of the QRS in the surface leads during exclusive accessory pathway conduction and 40 msec after the beginning of the QRS during normal pathway conduction as indicated in Fig 2.

In contrast when pacing was performed from the vicinity of the A V node P waves were negative in Leads II, III and aV₁,

and slightly positive in Lead I (Fig 3 left panel). A progressive increase in the pacing rate revealed that the QRS complexes were apparently normal when the cycle length was decreased to 350 msec (rate of 182/minute). There was a QR morphology in Lead I with rS complexes in V. The St-V interval was normal for the rate (135 msec.) but the H-V interval was short (20 msec.)

A similar QRS morphology persisted until the cycle length was reduced to 310 msec (Fig 3 right panel). At this cycle length the left anterior hemiblock-incomplete right bundle branch block pattern appeared with St-V and H-V intervals of




Fig 7 (Case 2) Pacing from the vicinity of the A V node and perhaps from the A V node itself (second beat) resulting in the QRS pattern suggestive of exclusive normal pathway conduction. This occurred at cycle lengths which were both longer (690 msec) and shorter (535 and 335 msec) than those which during sinus rhythm (660 msec) or pacing from the atrial site resulted in the shortest S₁-delta interval producing a Wolff Parkinson White type B morphology without right bundle branch block (Fig 4)

Some (second beat in Fig 5) had a normal contour (qR pattern in Lead I and rS in V) with almost simultaneous inscription of H and V. Others showed different degrees of incomplete right bundle branch block with shorter than normal (in the range of 0 to 30 msec) H-V intervals (Fig 7). Absence of Wolff Parkinson White type B pattern during pacing from the vicinity of the A-V node occurred at cycle lengths which were similar shorter or longer than those which during sinus rhythm or pacing from the mid right lateral atrium had produced Wolff Parkinson White type B (Fig 4). This phenomenon was related to the (peri A-V nodal) site of stimulation and not to tachycardia or bradycardia dependent block in the accessory pathway.

To summarize in this patient Wolff Parkinson White syndrome type B concealed the incomplete right bundle branch block during sinus rhythm and when pacing close to the atrial end of the accessory pathway. The incomplete right bundle branch block pattern however was exposed by stimulation from the vicinity of the A-V node which in addition produced inaccurate interpretations of surface electrocardiographic patterns of rate dependent block in the accessory pathway as well as pseudo normal QRS complexes.

Discussion

Conventional electrocardiographic theory states that if Wolff Parkinson White type B is due to conduction through a right sided accessory pathway, the simultaneous features of Wolff Parkinson White type B and complete right bundle branch block should not occur since the right ventricular pre-excitation is expected to mask the delayed right ventricular activation produced by the right bundle branch block. Yet,

both processes are known to coexist.¹⁰ To explain their simultaneous occurrence it has been suggested that a central right bundle branch block should be concealed by a 'distal' accessory pathway whereas a 'peripheral' right bundle branch block would not be hidden by a proximal 'accessory pathway'.

The right bundle branch block pattern displayed by the two patients reported in this communication was probably of the 'peripheral type'.¹¹ It was also 'incomplete' in the sense that during normal pathway conduction some parts of the right ventricle could still be activated by a delayed wavefront emerging from the right bundle branch.

Figs 1 through 7 show that the effects of a right sided accessory pathway on a right bundle branch block pattern also depended on the differences between the moment of arrival of excitation at the ventricular sites from which the corresponding wavefronts emerged from the accessory pathway and from the normal pathway (via the right and left bundle branches) as well as on the conduction time from these sites to the others. These differences in turn were a function of several factors namely duration of the refractory periods and conduction times of the structures involved rate of supraventricular impulses and pacing sites.

Reports discussing the effects of pacing sites on




Fig 8 Diagrams depicting the various mechanisms whereby a Wolf Parkinson White syndrome type B can obscure a coexisting (peripheral) right bundle branch block. See text for discussion.

A V conduction and QRS pattern in Wolf Parkinson White syndrome have dealt mainly with the changes produced by stimulation from close to the atrial entrance of the accessory pathway that is the site which yields the shortest St-delta intervals for a given rate. These studies explain why right atrial pacing produces shorter St V intervals in Wolf Parkinson White type B than left atrial (or coronary sinus) stimulation and why the reverse occurs in Wolf Parkinson White type A. Decreasing the atrial contribution to the St V intervals is of particular importance in the presence of intra atrial conduction defects which can be considerably exaggerated by electrical stimulation.

For instance in the left side of the panel of Fig 2 recorded during pacing in the proximity of the atrial end of the accessory pathway a pure Wolf Parkinson White type B pattern (without any evidence of right bundle branch block) occurred. This was due to the fact that the wavefront traversing the accessory pathway was able to depolarize the corresponding right and left ventricular areas ahead of (thereby rendering them refractory to) the wavefront traversing the normal pathway (Fig 8 top left).

On the other hand fusion QRS complexes (with a delta wave but no evidence of right bundle

branch block) were observed during sinus rhythm (Figs 1 and 3) when the wavefront traversing the accessory pathway reached the right ventricle before the wave front traversing the normal pathway (thus producing the delta wave) provided that it did not activate some left ventricular areas which were depolarized by the wave front emerging from the fascicles of the left bundle branch (Fig 8 top right).

In contrast Figs 2 and 7 show that atrial pacing from the vicinity of the A V node as well as His bundle stimulation (Fig 6) and perhaps A V nodal stimulation itself (second beat in Fig 7) produced the QRS pattern characteristic of normal pathway conduction with subsequent exposure of the right bundle branch block (Fig 8 bottom left). Apparently the wavefronts emerging from the bundle branches reached the ventricular end of the accessory pathway ahead of the wave front traversing the accessory pathway. This could be due to either earlier arrival of excitation at the site of emergence from the bundle branches and/or to late arrival at the ventricular end of the accessory pathway. The latter presumably was due to the delay in impulse propagation from stimulated (per A V nodal) site to atrial entrance of the accessory pathway.

Occasionally pacing from the vicinity of the

A V node produced apparently normal ventricular complexes without a delta wave. This even occurred with pacing rates which were slower than those which resulted in block in the accessory pathway when stimulation had been performed close to the atrial end of the accessory pathway (Figs 3 and 5). The normally appearing ventricular complexes were in reality fusion beats (Fig 8 bottom right). Although the wavefronts emerging from the fascicles of the left bundle branch were the first to depolarize the ventricles (thus explaining the absence of a delta wave), they *did not* reach the right ventricular end of the accessory pathway ahead of the wavefront traversing structure. Thus the left ventricle was activated through the A V node His Purkinje pathway and right ventricle via the accessory pathway.

Fig 8 summarizes the mechanism whereby right bundle branch block can remain concealed in certain patients with right sided accessory pathways when the QRS pattern is that of a fusion complex with or without delta waves, or pure Wolff Parkinson White type B or when the ventricular complexes appear to be "normal."

On the other hand Figs 3, 5 and 7 show that pseudo tachycardia and pseudo bradycardia dependent block in the right sided accessory pathway (occurring during per A V nodal pacing) most probably reflected a faster arrival of excitation at the A V node and consecutively at the sites of emergence from the bundle branches rather than an abnormal delay through the atria in reaching the accessory pathway. However, both factors could have played a role.

Summary

In two infants with Wolff Parkinson White type B right bundle branch block was concealed during sinus rhythm and pacing from close to the atrial entrance of the right sided accessory pathway. However, pacing from the vicinity of the A V node, the A V node itself, and the His bundle exposed the right bundle branch block by producing exclusive ventricular activation through the normal A V nodal His Purkinje pathway.

In addition, pacing from close to the A V node also resulted in fusion beats characterized by absence of delta waves with (pseudo) normal QRS complexes and short H V intervals. False patterns of tachycardia dependent and bradycardia dependent block in the accessory pathway

also occurred. These dynamic phenomena were attributed to the (per A V nodal) pacing related, relatively early arrival of excitation at the ventricles through the normal pathways coexisting with delayed arrival of excitation via the accessory pathway. The latter in turn was due to the longer intra atrial conduction time from paced (per A V nodal) site to atrial entrance of the accessory pathway.

REFERENCES

1. Gersony W M and Ekery D D. Concealed right bundle branch block in the presence of Type B ventricular pre-excitation. *Am Heart J* 77:668 1969.
2. Sobrino J A, Mate I, Munoz J E et al. Disappearance of right bundle branch block with left anterior hemiblock when associated with a type B pre-excitation syndrome. *Am Heart J* 87:497 1974.
3. Sung R J, Tamer D M, Agha A S et al. Etiology of the electrocardiographic pattern of incomplete right bundle branch block in atrial septal defect. An electrophysiological study. *J Pediatr* 87:1182 1975.
4. Gamboa R, Pensalozza D, Sime F et al. The role of the right and left ventricles in the ventricular pre-excitation (WPW) syndrome. *Am J Cardiol* 10:650 1962.
5. Cabrera E, Feldman J and Olinto F C. Estudio electrocardiográfico de un caso de Wolff Parkinson White con bloqueo de rama derecha. *Arch Inst Cardiol Mex* 29:404 1959.
6. Pick A and Fisch C. Ventricular pre-excitation (WPW) in the presence of bundle branch block. *Am Heart J* 55:504 1958.
7. Castellanos A Jr, Mayer J W and Lemberg L. The electrocardiogram and vectorcardiogram in Wolff Parkinson White syndrome associated with bundle branch blocks. *Am J Cardiol* 10:657 1962.
8. Schamroth L and Kinkler D M. Location of the pre-excitation areas in Wolff Parkinson White syndrome. *Am J Cardiol* 19:889 1967.
9. Robertson P G C, Enslin Smith D, Lowe H G et al. The association of type B ventricular pre-excitation and right bundle branch block. *Br Heart J* 25:153 1963.
10. Zakopoulos K S, Tsatsas A and Liohis T E. Type B Wolff Parkinson White syndrome associated with right bundle branch block. *Dis Chest* 46:348 1964.
11. Castellanos A, Aranda J, Gutierrez R et al. Effects of pacing site on QRS morphology in Wolff Parkinson White syndrome. With special reference to "pseudo-tachycardia-dependent block in accessory pathway and atrial gap." *Br Heart J* 38:363 1976.
12. Denes P, Wyndham R C, Dhingra R et al. Prediction of anomalous pathway location in patients with WPW syndrome using atrial pacing at multiple sites. (Abstract) *Circulation* 50(III):222 1974.
13. Gallagher J J, Gilbert M, Svenson R H et al. Wolff Parkinson White syndrome. The problem evaluation and surgical correction. *Circulation* 51:167 19 5.
14. Touboul P, Clement C, Porte C et al. Etude comparative des effets de la stimulation auriculaire gauche et droite dans le syndrome de Wolff Parkinson White. *Arch Mal Coeur* 56:1027 1973.
15. Wellens H J J and Durrer D. The role of an accessory atrioventricular pathway in reciprocal tachycardia. Observations in patients with and without the Wolff Parkinson White syndrome. *Circulation* 52:58 1975.

Intraventricular conduction disturbances A review of prevalence etiology, and progression for ten years within a stable population of Israeli adult males

Yardena Siegman Igra MD
Joseph H Yahini MD FACC
Uri Goldbourt MA
Henry N Neufeld MD FACC
Tel Aviv and Tel Hashomer Israel

The prevalence of right or left bundle branch block (RBBB or LBBB) has been studied repeatedly both in symptomatic and asymptomatic subjects during the last decades. Little information is available however on the prevalence of other intraventricular conduction disturbances (IVCD) such as left anterior hemiblock (LAH) or RBBB + LAH. In addition while it is well established that most patients with chronic complete heart block (CHB) suffer from a degenerative process affecting both bundle branches, the importance of the latter in producing other IVCD has not been hitherto evaluated. Likewise the prevalence of a degenerative disease of the conduction system among the general population and its ECG evolution have received little attention so far. Finally while numerous papers describe the clinical implications of right or left BBB in the ECG very few deal with the long term evolution of these patterns. The only IVCD whose progression has been investigated and only for short follow up periods is RBBB + LAH while the progression of monofascicular blocks (RBBB or LAH) has been left completely unexplored.

This study has elucidated the prevalence of various types of IVCD in a defined segment of the male population in Israel. It has determined some of the associated conditions and has followed the progression of the various forms of conduction disturbance during a 10 year period.

All subjects were part of the population study of the Israeli Ischemic Heart Disease Project, the details of which have been described elsewhere.¹ Briefly a random sample of Israeli male civil service employees aged 40 years and over and working for the State or municipality in the Jerusalem Haifa and Tel Aviv areas were studied in 1963 (10 232 men). These patients were re-examined and had an ECG recorded in 1965 and 1968. In the present study the ECG tracings of 5 204 subjects (average age 49.8 years) representing participants from the Tel Aviv area only were reviewed and only those showing IVCD were retained. There were 123 subjects who were invited for a further examination in 1973 thus achieving a 10 year follow up period (1963 to 1973). The mortality rate and follow up data are shown in Table I. The average follow up period for the 104 survivors was 9.7 years.

ECG criteria

ECG criteria for RBBB and LBBB were those of the ischemic heart disease project¹ as follows. LBBB was diagnosed when QRS duration was 0.12 sec or more in any three leads and R duration 0.08 sec in Leads V₁ or V₂ and S duration 0.04 sec and T negative in Lead I or aV₁.

From the Department of Internal Medicine, P. Rikach Hospital, Monopoli General Hospital, and the Heart Institute, Chaim Sheba Medical Center, Tel Hashomer, and the Department of Family Medicine, S. S. H. School of Medicine, Tel Aviv University, Tel Aviv, Israel.

Received for publication Sept. 16, 1977.

Reprint request: Joseph H. Yahini, MD, Heart Institute, Chaim Sheba Medical Center, Tel Hashomer, Israel.

Table I Prevalence mortality rate, and follow up in 123 patients with intraventricular conduction disturbances (IVCD) among 5 204 working adult males

Type of IVCD	Prevalence and age			Deaths		Survivors		
	No of patients	Prevalence in population	Average age (years)	No of patients	Average follow up period till death (years)	No of patients		Average follow up period for survivors (years)
						Survived	Incomplete follow up	
LAH*	74 (60%)	1.42%	53.2	10	6.3	64	4 (5 years)	9.1
RBBB	34 (28%)	0.65%	53.5	4	6.5	30	2 (2.5 years)	9.6
RBBB + LAH	9 (7%)	0.17%	58.2	1	8	8		10
LBBB*	6 (5%)	0.12%	53.7	4	3.2	2		10
Total	123 (100%)	2.36%	53.5	19 (15%)	5.8	104	6	9.1

LAH left anterior hemiblock RBBB right bundle branch block LBBB left bundle branch block

Table II Prevalence of IVCD according to age

Age in years	40-44	45-49	50-54	55-59	60+	Total
No of subjects	1716	1090	1128	772	498	5204
No of patients with IVCD	16	16	34	36	21	123
Prevalence	0.93%	1.47%	3.01%	4.66%	4.22%	2.36%

and no Q in V₁ or V₂. RBBB was diagnosed when QRS was 0.12 sec or more in any two standard leads and S duration 0.04 sec or more in Lead I or aV₁ and R' or QR present in V₁ or V₂. ECG criteria for LAH were based on those of Rosenbaum and others¹¹ and included the following: mean frontal plane electrical axis of the QRS between -45 degrees and -90 degrees; small q wave in aV₁ with rS pattern in Leads II, III, aV₂ (or qRS pattern in case of diaphragmatic myocardial infarction) and QRS duration not exceeding 0.10 sec in any lead. Patients with cor pulmonale and low voltage (25 patients with R or S less than 5 mm in any lead) or with pectus excavatus (three patients) were excluded in order to avoid false positive diagnosis of LAH. The criteria for left posterior hemiblock (LPH) were^{12, 13, 16} mean frontal plane electrical axis +120 degrees; rS pattern in Leads I, aV₁, and QR pattern in Leads II, III, aV₂, provided that these were found in an obese stocky person over 45 years of age without evidence of right ventricular hypertrophy and when some form of left ventricular disease is present (this could not be diagnosed with certainty in any of our cases). The criteria for RBBB + LAH were: a mean QRS axis between -45 degrees and -120 degrees in the presence of

RBBB. Bilateral bundle branch block (BBBB) was diagnosed when both criteria for RBBB and LBBB were present in the same recording.¹⁷ The method for determining the mean frontal plane QRS axis was that of Laiken and colleagues¹⁸ taking the average of values obtained for each of three pairs of leads for each recording.

Progression of conduction disturbances was diagnosed by the appearance of either a PR prolongation (> 0.22) or an added fascicular block or complete heart block (CHB).

Other criteria

A diagnosis of ischemic heart disease (IHD) was made according to the criteria of the Ischemic Heart Disease Project¹¹ and included (1) all subjects with definite angina pectoris; (2) all subjects whose previous history of heart attack was verified; and (3) all subjects with an ECG diagnosis of probable infarct.

The diagnosis of hypertension (HT) was retained only when diastolic pressure measurements were 100 mm Hg or over on two occasions.

Prevalence

The prevalence of RBBB or LBBB in different populations has been the subject of numerous investigations. The frequency of RBBB was found to be the lowest among young healthy individuals, mostly aircraft personnel or applicants, being 0.15 per cent to 0.29 per cent.¹⁹ This figure increases sharply with age even in a healthy population, reaching 2.4 per cent in selectively old populations (retirement community).

Table III Natural history of IVCD (15 patients)—progression according to ECG

Initial IVCD	No of patients	No of patients showing progression			
		to BFB	to BFB and CHB	to CHB without BFB	Total
LAH	74	5	1	1	7 (9.5%)
RBBB	34	■	2	1	8 (22.5%)
Total	108	10	3	2	15 (14%)

BFB-bifascicular block CHB-complete heart block

ty) aged 52 years or more.² Among symptomatic subjects usually outpatient populations RBBB was seen as frequently as in 1.15 per cent to 3.19 per cent.¹ While our figure of 0.65 per cent (Table I) is much higher than among the above young selected asymptomatic patients series it is as expected much lower than among symptomatic subjects. The only comparable general population study is that of Ostrander about the Tecumseh community.⁴ In this the prevalence of RBBB was only 0.2 per cent that is markedly lower than ours. However about half the subjects of the latter study were under the age of 20 and only 27 per cent were above the age of 40.

LBBB seems to be extremely rare among young and healthy subjects. Thus among aircraft personnel and applicants its average prevalence was between 0.02 per cent and 0.05 per cent.^{2,3} In younger age groups of the same population it was practically absent.^{3,4} However among elderly or symptomatic subjects the frequency of LBBB was much higher 1.0 to 1.2 per cent. In the Tecumseh community it was equal to the frequency of RBBB (0.2 per cent) surprisingly high for this relatively young population for which we have no explanation. Our figure of 0.12 per cent is as expected somewhat higher than among aircraft personnel but far lower than among old or symptomatic subjects.

As for LAH review of the English literature discloses very little data on its prevalence. More information is available concerning left axis deviation (LAD) without definite criteria of LAH. Grant⁵ in a pioneer work on LAD examined the ECG tracing recorded during the last week of life of unselected patients coming to autopsy and found an axis of -15 degrees or to its left in 20 per cent. This very high frequency can be ascribed to the strong bias introduced by the selection of fatal cases. Among young healthy aircraft personnel (aged 18 to 32 years) LAD of

Table IV Natural history of IVCD (15 patients)—progression according to etiology

Etiology	Total no of patients	Patients showing progression	
		No of patients	Average age (years)
IHD	35	5 (14%)	50.6
HT	24	5 (21%)	59.4
None	64	5 (8%)	49.6

Details in Tables VI, VII and VIII

-30 degrees or to its left was found in 0.2 to 1.2 per cent.^{2,3} while among two series of adults (aged 45 to 69 years and above 20 respectively) LAD (< -30 degrees) was found in as many as 4.1 and 5.3 per cent respectively.^{2,3} These series confirm that the QRS axis has a leftward tendency with age.^{2,3,6} An exceptionally high frequency of LAD (-30 degrees to -90 degrees) probably due to a genetic factor was recorded among the Navajo children (10 per cent).⁴ As far as true LAH is concerned we are aware of only two epidemiologic studies: one by Rosenbaum and associates² who found LAH in 76 out of 1658 patients (4.58 per cent) attending their cardiological service and the other by Yano and associates³ who detected LAH in 1.5 per cent of 8000 adult Japanese American men in Honolulu. The latter is the only study on general adult male population and its findings are strikingly similar to ours (1.4 per cent, Table I).

The prevalence of RBBB + LAH in the general population is practically unknown. It was not investigated in the above mentioned air forces series because most had been studied before this IVCD was recognized. The only similar and recent study is that of Rotman and colleagues⁷ who found this pattern in 0.008 per cent of aircraft personnel and applicants. Among hospitalized patients the prevalence of this BFB was

Table V Progression of ECG pattern in 5 patients with IHD

Patient No	Age (years)	Initial IVCD	Time of appearance (years)		Remarks
			BFB	CHB	
1	52	LAH	—	7	CHB during AMI (fatal outcome despite pacemaker insertion)
2	54	LAH	5 (BBBB)	—	Previous AMI in 1952
3	52	RBBB	4 (BBBB)	8	AMI in 1952 1958 and 1968 PR> since 1970 Died 19/1 de pte pacemaker insertion
4	48	RBBB	5	—	AMI in 1960 and 1972 PR> since 1972
5	47	LAH	5	—	Anginal syndrome since 1968

AMI acute myocardial infarction

found to be 1 per cent,^{4, 5} and a very similar figure (0.9 per cent) was encountered among ambulatory patients attending a cardiological center.¹² Our figure of 0.17 per cent reflects, as expected, a markedly lower (five fold) prevalence among middle aged working males than among symptomatic patients. No comparable data exist.

As to the increasing incidence of IVCD with age our data also confirm this tendency. The average age of all 123 patients with IVCD was almost 4 years higher than that of the population examined (53.5 against 49.8 years) ($p < 0.01$) and when analyzed according to age groups there is a marked increase of frequency of all types of IVCD with age (Table II). A plateau seems to be reached, however, around the age of 60.

The relative frequency of our various IVCD types appear to be, in declining order LAH, RBBB, RBBB + LAH and LBBB (TABLE I). It is generally believed that RBBB is much more frequent than LBBB especially in asymptomatic populations. Thus, in some studies RBBB has been found to be three to 13 times more frequent than LBBB.^{1, 3} This is confirmed in the present study, where RBBB is 5.5 times more frequent than LBBB (28 against 5 per cent). However, among hospital patients LBBB appears as frequently or even more frequently than RBBB.^{27, 28} Obviously the relative frequency of different IVCD is linked to the type of population examined. To our knowledge the only comparable study in which the prevalence of all four types of IVCD was examined in the same population is that of Rosenbaum and associates¹² who found a similar order of frequency (Table III) except for a total prevalence of IVCD four times higher than ours (9.69 per cent against 2.36 per cent). This may be easily explained by the difference in the population studied (symptomatic subjects versus

'healthy' adults). It is interesting however, that the distribution of the various IVCD remains similar in both studies.

As for sex preponderance among various IVCD it is interesting that while RBBB appears to be more frequent in men,^{1, 4, 13} LBBB was found to be equally distributed²⁴ or even more frequent in women.^{21, 29} The information concerning LAH is controversial and insufficient, thus while LAD has been claimed to be more frequent in men,²² LAH has been encountered more frequently in women.²⁰ Our study, as well as that of Yano and associates²² cannot add to the subject since both were confined to males.

Etiology

The etiology, clinical implications and long term prognosis of right and left BBB have been extensively commented upon in the literature but the information pertinent to LAH or RBBB + LAH is scant. The most frequent etiologies involved in IVCD are ischemic and hypertensive heart disease.^{3, 31, 32} Rarely rheumatic infective, congenital degenerative or traumatic heart disease or the 'cardiomyopathies' are implicated.^{16, 37, 41, 42} Our group of 123 patients with IVCD was clinically divided into three subgroups (1) 35 patients (28 per cent) with ischemic heart disease (IHD) (2) 24 patients (20 per cent) with hypertension (HT) but without IHD and (3) 64 patients (52 per cent) with no evidence of ischemic, hypertensive rheumatic infective, or other heart disease (Table IV).

1 Ischemic heart disease and hypertension. While IHD and HT constitute the most frequent etiologies involved in IVCD their incidence differs in various populations. In two early reviews dealing with hospital populations IHD and HT were detected in almost all patients with

Table VI Progression of ECG pattern in 5 patients with HT

Patient no	Age (years)	Initial IVCD	Time of appearance (years)		Remarks
			BFB	CHB	
1	50	LAH	5	—	—
2	63	RBBB	2	—	—
3	64	RBBB	10	—	—
4	59	RBBB	4	4	Pacemaker insertion
5	59	RBBB	Not documented	9	Pacemaker insertion

BBB and their prognosis was found to be poor accordingly.¹⁰⁻¹¹ Later studies on young and healthy aircraft personnel often failed to reveal any signs of heart disease in many subjects with IVCD and their prognosis was thus obviously much better.

However if various types of IVCD are considered within a defined population there appear to exist differences between the roles played by the ischemic etiology in each type of IVCD. Thus in our material IHD was present in five of six patients with LBBB but in only seven of 34 (21 per cent) of patients with RBBB ($p < 0.01$). Moreover even if HT is considered along with IHD these etiologies together are involved in less than half (44 per cent) the cases of RBBB (Table III). Likewise in a younger and selectively healthy population the proportion of IHD and HT was found to be as low as 11 per cent among patients with RBBB as against 16 per cent in LBBB. Indeed most reports favor a closer relationship between IHD with left than with right BBB.

The relationship of LAH to IHD was similar in our study to that of RBBB. Thus 28 and 19 per cent of patients with LAH had IHD or HT respectively when considered together practically half (47 per cent) these patients were linked with these etiologies (Table IV). Very little information is available in the literature on the clinical etiology of LAH. Thus we are aware of only two relevant studies excluding those dealing with simple LAD one revealing 71 per cent of IHD and/or HT among 128 symptomatic patients with LAH the other disclosing 33 per cent of these etiologies among 119 asymptomatic adult males.¹² The latter figure is quite lower than ours (33 versus 47 per cent) in spite of the similarities in the types of population studied for which we have no explanation.

As for RBBB + LAH here also our figures are similar to those of isolated RBBB or LAH groups

Thus two and two out of nine patients had IHD or HT respectively when considered together practically half the cases (four out of nine) were linked with these etiologies (Table IV). Similar figures emerged in the study of Rosenbaum and colleagues¹³ concerning 140 patients with RBBB + LAH 28 per cent of whom had IHD and 48 per cent either IHD or HT. In a few series of hospital patients the proportion of IHD among subjects with RBBB + LAH was obviously higher varying from 36 to 73 per cent.¹⁴

In contrast to the above mentioned investigations in which different populations are compared the advantage of our study resides in its ability to compare the role played by IHD or HT among various IVCD in the same segment of populations. This reveals interestingly that except for LBBB in which the incidence of IHD is significantly higher the role played by IHD and/or HT is practically the same in all other three types of IVCD suggesting a similar etiology for these three types.

It can be speculated that silent coronary disease may be present in some adult males with IVCD and without clinical IHD. Indeed angiographic studies have shown coronary narrowing among some patients with RBBB¹⁵ and in a higher proportion among those with LBBB.¹⁶ While to the best of our knowledge angiocardio-graphic studies have not been performed in patients with LAH or RBBB + LAH the similar frequency of clinical IHD among the latter and the RBBB group in our study suggests silent coronary disease as a cause for LAH or RBBB + LAH as well.

2 Rheumatic and infective heart disease

Valvular heart disease is often mentioned when dealing with the etiology of IVCD and has been claimed to be involved in 3 to 10 per cent of cases of BBB.¹⁷⁻¹⁹ In the series of Rosenbaum and associates¹³ a rheumatic aortic lesion was found

often than not an isolated disease of the conduction system affecting mainly both bundle branches. Although it seems self evident that this process may produce isolated BBB as well as CHB and although Mahaim¹⁰ as early as in 1931 wrote that BBB and CHB may constitute two facets of the same condition degenerative disease is rarely mentioned as a cause for isolated BBB. Furthermore Lev and Bharati¹¹ claimed in 1975 that while an idiopathic etiology certainly exists for CHB and probably for RBBB + LAD this is doubtful for isolated BBB. It is therefore interesting that our material strongly suggests a degenerative etiology for some cases of MFB although on clinical grounds only. Obviously it is impossible to point out which patient with MFB suffers from degenerative disease of the conduction system (DDCS) unless serial ECG's showing progression are available. Such progressive changes were observed in 5 of our patients of Group 3 (i.e. without IHD or HT) and were therefore considered to represent examples of a DDCS (see later). More of our patients may have had the same etiology: the slow progression of their IVCD preventing a definite diagnosis during the study.

To summarize while it is impossible on clinical grounds alone to assess the exact etiology of the IVCD in each case it appears from our material that about one third of subjects with IVCD are associated with IHD and one fifth with HT (35 and 24 of 123 respectively). Among the remaining 64 a few may constitute examples of silent coronary disease or of a state after myocarditis while at least 4 per cent (five of 123) may be ascribed to a DDCS.

Progression

Progression of conduction disturbances occurred in 15 patients all belonging to the RBBB or LAH groups thus constituting 14 per cent of 108 patients with monofascicular blocks (MFB). Progression was displayed by the appearance of an added fascicular block or CHB (Table V). P-R prolongation as a single feature was not encountered. None of the nine patients with RBBB + LAH showed further progression and likewise no progression was recorded among the six patients with LBBB (four of whom died during the follow up). Progression of IVCD is discussed separately from the ECG and etiologic point of view (Tables V and VI).

Table VIII Comparison between 1 658 outpatients (Rosenbaum et al.¹) and 5 204 Israeli working males prevalence and distribution of IVCD

Type of IVCD	No. of patients		Prevalence in population (per cent)	
	Rosenbaum et al.	Ours	Rosenbaum et al.	Ours
LAH	6 (47%)	14 (60%)	4.08	1.42
RBBB	53 (33%)	34 (88%)	3.19	0.65
RBBB + LAH	15 (9%)	11 (27%)	1.02	0.17
LBBB	17 (11%)	6 (8%)	0.90	0.12
TOTAL	161 (100%)	123 (100%)	9.09	2.36

1 Progression of ECG pattern The interrelation between BFB and CHB has been confirmed both by retrospective and prospective studies^{12,13} while the interrelation between MFB and higher degrees of IVCD has received little attention so far. While some retrospective studies mention the type of MFB preceding the occurrence of BFB or CHB^{14,15} very few prospective studies of MFB progression have been published. Thus Bhat and associates¹⁶ who followed 455 patients above the age of 60 with various IVCD for an average period of 2 years found no progression. Rotman and Triebwasser³ who followed 394 subjects with RBBB (average age 36 years) for more than 10 years found that only one (0.25 per cent) developed CHB. In contrast we found a 22.5 per cent progression among our patients with RBBB (eight of 34 Table V). These conflicting findings may be explained by the short follow up period in Bhat and colleagues' study and the younger age of the subjects followed by Rotman and Triebwasser. As for LAH to the best of our knowledge no prospective study dealing with this form of IVCD is available. In our material 9.5 per cent of LAH progressed within the 10 year follow up (seven of 74 Table V). Thus our data demonstrate that MFB progresses in a significant proportion of cases (15 of 108 14 per cent) if followed long enough. Among these 15 patients 10 progressed to bifascicular block (BFB) or BBBB only three displayed first BFB and then CHB and the remaining two progressed to CHB without documented BFB (Table V). This suggests as expected that in addition to BFB MFB is an important precursor of CHB. Interestingly the

Table VII Progression of ECG pattern in 5 patients with IVCD of degenerative origin

Patient no	Age (years)	Initial IVCD	Time of appearance (years)		Remarks
			BFB	CHB	
1	50	LAH	5	8	Pacemaker insertion
2	54	LAH	10	—	—
3	44	LAH	10	—	—
4	46	RBBB	5	—	—
5	54	RBBB	10	—	—

in 78 and 77 per cent of subjects with LAH and RBBB + LAH, respectively. None of our patients had evidence of rheumatic valvular disease, which may be attributed to differences in the type of populations studied (symptomatic subjects versus "healthy" adults).

In every large series of BBB some are ascribed to infective or viral 'myocarditis'. Thus in the material of Rosenbaum and colleagues,¹ Chagas ic myocarditis was implicated in 9.3 and 27.8 per cent of cases with LAH and RBBB + LAH, respectively. Likewise, Rotman and associates² could obtain a history of prolonged 'flu like' illness shortly before the appearance of BBB in the majority³ of their patients. The possibility of silent myocarditis as a cause of IVCD is supported by the presence of a mild diffuse abnormality of the ventricular myocardium in patients with acquired BBB.^{4,5} "It is of course conceivable that some of our asymptomatic non-progressing IVCD patients suffered from an episode of silent myocarditis in the past although a suggestive history was not obtained in any."

3 Congenital anomaly It is also possible that some IVCD discovered routinely may be congenital in nature. If this was true however they should have been occasionally recorded among otherwise healthy infants and children. With regard to RBBB it should be recalled that while secondary R waves in right chest leads have been reported in up to 98 per cent of normal children,⁶ and that a pattern of RBBB is thus frequently considered a "normal variant" in this age group Ziegler⁷ diagnosed complete RBBB in only 6.5 per cent of normal infants according to the form of ventricular deflection in precordial leads. Furthermore, others claim that an organic impairment of the right bundle is very rare in normal children and deserved special notice.^{8,9} Our impression from reviewing the literature is that an isolated congenital block of the right

bundle in children, although possible, is rare. On the other hand the frequency of LBBB or LAH in infants may be assessed more accurately because of better criteria. LBBB is extremely rare in normal infants^{10,11,12} and seen only in unusual forms of congenital heart disease. Even in young adults, as mentioned this form of IVCD is seldom encountered¹³ and it is possible to disclose an organic basis for most cases of LBBB in older age groups. Therefore a congenital etiology cannot be invoked in most cases of LBBB.¹⁴ As for LAH, although it is the most common IVCD in adults tables showing the range and mean axis of the ECG of infants and children from birth up to the age of 16 show a constant leftward tendency with age but not to the left of -20 degrees.^{15,16} Among 1,500 aviators aged 18 to 32 no severe LAD was found.¹⁷ Moller and colleagues¹⁸ described six normal children with LAD but not to the left of -45 degrees¹⁹ and the only exception to these reports is the above mentioned finding among Navajo children.²⁰ Thus it seems that like LBBB LAH and RBBB + LAH are quite rare in childhood. It should also be added here that although a familial tendency to a conduction disease has been recently reported²¹ this was observed only in adult relatives of patients with IVCD. It can be concluded from the above that the great majority of IVCD are acquired in origin except when associated with a congenital heart lesion.

4 Degenerative disease A degenerative etiology for conduction disturbances was considered by Mahaim²² and by Yater and colleagues²³ already in the early 1930s^{24,25} but studied in detail only 30 years later by Lev, Lenegre and others.^{26,27,28} The latter termed the lesion as a sclerodegenerative process, sclerosis of the left side of the heart skeleton^{29,30} or primary idiopathic heart block.³¹ In laborious histological studies they showed that chronic CHB is more

IVCD in this group was rapid and the mortality rate very high. Thus all four patients who reached the stage of BFB or BBBB did so within the first 5 years and the two who reached the stage of CHB died despite pacemaker insertion (Table VI). It seems that in this group the natural history of IVCD parallels the natural history of IHD in general.

In the second group (HT) a different pattern emerges. Even though the rate of progression appears to be similar to the previous one (Table VIII) its long term prognosis seems better. Thus while here also two of five patients reached the stage of CHB requiring pacemaker insertion, all were alive and well at the end of 10 years.

In the third group (without IHD or HT) the five patients with progressive IVCD (Table IX) most probably represent true instances of progressive degenerative disease of the conduction system (Lenegre's or Lev's disease) and may well illustrate the natural history of this condition. Indeed in contrast with previous studies our patients constitute a homogenous group well separated from the ones with IHD and HT and followed for 10 years. In these patients the rate of progression of IVCD seems the slowest (Table IX) and its long term prognosis favorable. Thus all five patients were alive and well at the end of 10 years including the one with pacemaker insertion.

Furthermore, while lack of information as to the appearance time of the initial IVCD precludes any comment on the length of the degenerative process, it can be safely speculated that more examples of DDCCS as yet unmasked are included among the 64 patients of this group. Indeed CHB has been reported to occur as long as 23 years after BFB.⁴ As to the evolution of the ECG pattern in this disease it should be noted that while the initial tracings showed LAH in three and RBBB in two patients and that all five progressed to RBBB + LAH during the study, LBBB was not encountered at any time in this group. In this respect Lenegre¹ already observed that among his cases progressing conduction disturbances began mostly as RBBB. Whinberg and associates¹⁰ noted that none of the uncomplicated LBBB progressed to CHB during a 3 year follow up period while some of the RBBB + LAH did. Among Rotman and Triebwasser's¹¹ 125 young LBBB patients only one developed CHB and this was linked to an attack

of acute myocardial infarction. The above suggests that while LBBB may often constitute a link in the progression of IVCD to CHB in IHD,^{12,13} this pattern is an infrequent manifestation of DDCCS. To summarize, the frequency of DDCCS appears to be at least 0.1 per cent (five of 204) among a population of the type studied here or 4 per cent of all types of IVCD (five of 123). It is likely to begin with an FCG pattern of RBBB or LAH in middle age or earlier and to progress to BFB and later to CHB within a few years or a few decades. LBBB does not seem to be a frequent manifestation of this disease. Its prognosis is favorable, life expectancy remaining unaffected, especially since the advent of pacemaker therapy.

Summary

The ECG tracings of 5204 working males aged 40 years and over representing a random sample of Israeli civil service employees were reviewed and 123 (2.36 per cent) displaying intraventricular conduction disturbances (IVCD) in the form of left anterior hemiblock (LAH), RBBB, RBBB + LAH and LBBB were followed for a period of 10 years (1963 to 1973). While these patients were slightly older than the population they were derived from (53.5 versus 49.8 years average age) there was no significant difference in ages between the various types of IVCD but there was a marked increase in the frequency of all IVCD with age. Left anterior hemiblock constituted the most frequent IVCD (1.42 per cent) being twice as frequent as RBBB (0.65 per cent). The prevalence of RBBB + LAH was 0.17 per cent (7 per cent of all IVCD). To the best of our knowledge this is the first time that the frequency of this condition has been assessed in an unselected male population.

The vast majority of these ECG changes seem to be acquired. Ischemic heart disease (IHD) constituted the most frequent associated condition for all types of IVCD (28 per cent), its prevalence being similar (21 to 28 per cent) in LAH, RBBB and RBBB + LAH but much higher in patients with LBBB (five of six patients). Hypertension (HT) not associated with IHD was present in 24 patients and constituted the next most frequent factor (20 per cent). No definite etiology could be demonstrated in the remaining 64 patients (52 per cent) except for five (4 per cent of all IVCD and 0.1 per cent of the

Table IX Associated conditions in 123 patients with IVCD

Type of IVCD	No of patients	Associated clinical condition (No of patients)			
		IHD*	HT*	Both	None
LAH	74	21 (28%)	14 (19%)	35 (47%)	39 (53%)
RBBB	34	7 (21%)	8 (24%)	15 (44%)	19 (56%)
RBBB + LAH	■	2 (†)	2 (†)	4 (†)	5 (†)
LBBB	6	5 (†)	~	5 (†)	1 (†)
Total	123	35 (28%)	24 (20%)	59 (48%)	64 (52%)
Average age (years)	53.5	55.8	55.8	55.8	51.3

IHD ischemic heart disease HT hypertension

† Figures too small for per cent evaluation

number of progressing cases was higher among the group with RBBB (eight of 34, 22.5 per cent) than with LAH (seven of 74, 9.5 per cent) ($p < 0.05$). This accords with retrospective studies in which a pattern of RBBB was more frequent than LAH in sinus conducted beats of patients with CHB.⁶ It also accords with Lenegre's observations that RBBB precedes LAH in cases with progressing IVCD. It follows that a pattern of RBBB in the adult may not be as innocent as suggested by studies on younger age groups.

As stated the inter relationships between BFB and CHB has been confirmed both by retrospective and prospective studies. Thus RBBB + LAH has been encountered in 34 to 60 per cent of previous ECG recordings or in sinus conducted beats of patients with established CHB.^{6,7} Among patients with RBBB + LAH studied from hospital records, high degree A-V block has been found in six to 28 per cent within an average follow up period up to 31 years.^{7,8} Truly prospective follow up studies on this subject have been few and conducted only recently. They revealed a 27 to 60 per cent progression to CHB per average year of follow up.^{6,9,10}

In our material the pattern of BFB (RBBB + LAH) could be divided in two: (a) Nine patients displaying this pattern from the beginning without further change throughout the study (the 'static type'), and (b) Thirteen patients starting with RBBB or LAH (MFB) and developing RBBB + LAH (BFB) during the study, with among these, three showing further progression to CHB (the 'dynamic type'). The lack of progression of IVCD observed in the static type is puzzling while the ratio of progression in the dynamic group (three out of

13 reaching CHB) is within the range of the above mentioned reports. But when comparing our data with others the following should be noted: first, ours is the only general population study, all others being derived from hospital records, then, our follow up period is twice as long as the longest in the literature (10 versus 4.8 years) and last, but most important it is misleading to analyze the natural history of IVCD without considering their etiologies since the latter may actually determine their rate of progression. Thus the stability of the static group could tentatively be ascribed to different etiologies, accordingly and in contrast to previous reports we have further analyzed the IVCD progression according to etiology as follows:

2 Progression and prognosis and IVCD according to etiology Progression of IVCD occurred in five of our 35 patients with IHD (14 per cent) in five of 24 with HT (21 per cent) and in five of the remaining 64 (8 per cent). Despite these small numbers a different natural history seems to emerge for each group.

As far as the group with IHD is concerned the progression of IVCD could very well represent progressing per infarction or intraparietal blocks secondary to IHD rather than intrinsic disease of the conduction system. Indeed four of these patients had sustained one or more episodes of acute myocardial infarction before or during the study, and the fifth suffered from anginal syndrome (Table VII). Furthermore in our material the only two instances of BBBB a pattern which usually indicates extensive myocardial damage with intraparietal block¹¹ were encountered in this group (patients Nos 2 and 3 Table VII). With regard to prognosis the progression of

1. Has, R. G. Lamb L. E. and Allen M. F. Electrocardiographic findings in 67375 asymptomatic subject. XX Normal values. *Am J Cardiol* 6:200 1960
2. Yano K., Peskoe S. M. Rhoads, G. G., Moore J. O. and Asgan A. Left axis deviation and left anterior hemiblock among 8000 Japanese American men. *Am J Cardiol* 35:809 1975
3. Ostrander L. D. Left axis deviation prevalence associated conditions and prognosis. *Ann Intern Med* 75:23 1971
4. Blackburn H. Vasquez C. L. and Keys A. The aging electrocardiogram. A common aging process or latent coronary artery disease? *Am J Cardiol* 20:618 1967
5. Simonson E. The effect of age on the electrocardiogram. *Am J Cardiol* 29:64 1972
6. Marcus, F. I. Goldberg S. J. Molthan M. N. Phibbs B. and Ewy G. A. Electrocardiographic axis deviation in Navajo children. (Abstr.) *Circulation* 46 (Suppl. II) 11:168 1972
7. Langley R. W. Reed J. C. and Utz D. C. Bundle branch block: a review of 100 cases. *AM HEART J* 33:730 1947
8. Mulvihill H. Hickey N. and Maurel B. Aetiology of bundle branch block. *Br Heart J* 30:34 1968
9. Bhat, P. K. Watanabe K. Rao D. B. and Lausda A. A. Conduction defects in the aging heart. *J Am Geriatr Soc* 22:517 1974
10. Yater W. Pathogenesis of bundle branch block. *Arch Intern Med* 82:1 1938
11. Rosenman R. H. Pick A. and Katz L. N. Intraventricular block: review of the literature. *Arch Intern Med* 88:196 1950
12. Grayzel, J. and Neyshaboun M. Left axis deviation etiologic factors in one hundred patients. *AM HEART J* 89:419 1975
13. Scott R. C. Left bundle branch block—a clinical assessment. Part I. *AM HEART J* 70:533 1965
14. Smith, R. F. Jackson D. H. Harthorne J. W. and Sanders C. A. Acquired bundle branch block in a healthy population. *AM HEART J* 80:746 1970
15. Lancaster M. C. and Schechter E. Acquired complete right bundle branch block without overt cardiac disease: clinical and hemodynamic study of 37 patients. *Am J Cardiol* 30:32 1972
16. Schechter E. Eber L. and Lancaster M. Meaning of left bundle branch block. (Abstr.) *Circulation* 46 (Suppl. II) 11:8 1972
17. Blount S. G. Jr. Munyan E. A. Jr. and Hoffman M. B. Hypertrophy of the right ventricular outflow tract. *Am J Med* 22:784 1957
18. Ziegler R. F. Electrocardiographic studies in normal infants and children. Springfield Ill. 1951. Charles C. Thomas, Publisher
19. Coakley J. B. Congenital absence of the right branch of the bundle of His. *Br Heart J* 13:148 1951
20. Shaffer A. H. and Reiser I. Right bundle branch system block in healthy young people. *AM HEART J* 62:487 1961
21. Agusti H. and Liebman J. Ventricular conduction disturbance in normal children. *Dis Chest* 52:26 1967
22. Walsh, S. Z. Electrocardiography in infants and children. In *Pediatric cardiology*, edited by Watson H. London 1968. Lloyd Luce Ltd.
23. Liebman J. Electrocardiography in heart disease in infants, children and adolescents. edited by Moss A. J. and Adams F. H. Baltimore 1968. The Williams & Wilkins Company
24. Moller J., Carlson E. and Ebot H. S. Left axis deviation in children. *Dis Chest* 53:453 1968
25. Greenspahn B. H. Denes P. William D. and Rosen K. R. Chronic bifascicular block: evaluation of familial factors. *Ann Intern Med* 84:521 1976
26. Mahaim I. Les maladies organiques du faisceau de His. *Tawara Paris*, 1931. Masson et Cie
27. Yater W. M. Cornell V. H. and Clayton T. Auriculo-ventricular heart block due to BBBB lesions. *Arch Intern Med* 57:137 1936
28. Zook M. and Smith H. S. Aetiology of complete heart block. *Br Med J* 2:1149 1963
29. Lev M. Anatomic basis for atrioventricular block. *Am J Med* 37:742 1964
30. Davies M. and Harris A. Pathological basis of primary heart block. *Br Heart J* 31:719 1969
31. Lev M. and Bharati S. Atrioventricular and intraventricular conduction disease. *Arch. Intern Med* 135:405 1975
32. Feigl, D. Yahini, J. and Neufeld H. N. Clinical and electrocardiographic findings in complete atrioventricular block. *Israel Med J* 85:107 1973
33. Ranganathan N. Dhurandhar R. Phillips J. H. and Wigle D. H. Bundle electrogram in bundle branch block. *Circulation* 45:287 1972
34. Wenke J. and Laxon T. Z. Prognosis of RBBB with LAD. (Abstr.) *Circulation* 40 (Suppl. III) III:212 1969
35. Kulbertus H. and Collignon P. Association of right bundle branch block with left superior or inferior intraventricular block: its relation to complete heart block and Adams-Stokes syndrome. *Br Heart J* 31:435 1969
36. Wiberg T. Götzel F. L. and Richman H. G. The significance and prognosis of bundle branch block. (Abstr.) *Circulation* 50 (Suppl. III) III:57 1974
37. Denes P. Dhingra R. C. Wu D. Chughumia R. Amat y Leon F., Wyndham C. and Rose K. M. H. Interval in patients with bifascicular block (right bundle branch block and left anterior hemiblock): clinical electrocardiographic and electrophysiologic correlation. *Am J Cardiol* 35:23 1975
38. Posenbaum M. B. and Lepeschkin E. Bilateral bundle branch block. *AM HEART J* 50:38 1955

population studied) who displayed progressive IVCD and were considered to represent examples of a degenerative disease of the conduction system (DDCS). The latter confirms that monofascicular blocks (MFB) may represent an initial stage of DDCS.

From the ECG point of view, 14 per cent of cases with MFB showed progression to bifascicular block (BFB) or complete heart block (CHB) within 10 years, regardless of etiology. This was more frequent in RBBB than in LAH (22.5 per cent versus 9.5 per cent). From the clinical point of view, the natural history of IVCD in patients with IHD parallels the natural history and prognosis of this disease. In contrast, the prognosis of IVCD in patients with isolated HT or in asymptomatic subjects, was more benign even in patients reaching the stage of CHB. The natural history of DDCS began as RBBB or LAH in middle age or earlier and progressed to CHB through the stage of BFB. This process may last from a few years to a few decades, LBBB seems to be rarely if ever encountered in its course.

REFERENCES

- Lev M. The pathology of complete atrioventricular block. *Progr Cardiovasc Dis* 6:317 1964.
- Lenegre J. Etiology and pathology of bilateral bundle branch block in relation to complete heart block. *Progr Cardiovasc Dis* 6:409 1964.
- Harris A, Davies M, Redwood D, Leatham A, and Siddons H. Aetiology of chronic heart block. A clinicopathological correlation in 65 cases. *Br Heart J* 31:206 1969.
- Lasser R P, Haft J I, and Friedberg C K. Relationship of right bundle branch block and marked left axis deviation (with left parietal or peri-infarction block) to complete heart block and syncope. *Circulation* 37:429 1968.
- Watt T B Jr, and Pruitt R D. Character cause and consequence of combined left axis deviation and right bundle branch block in human electrocardiograms. *Am Heart J* 77:460 1969.
- Scanlon P J, Pryor R, and Blount B. Right bundle branch block associated with left superior or inferior intraventricular block. Clinical setting, prognosis and relation to complete heart block. *Circulation* 42:1123 1970.
- DePasquale N P, and Bruno M S. Natural history of combined right bundle branch block and left anterior hemiblock (bilateral bundle branch block). *Am J Med* 54:297 1973.
- Kulbertus H E. The magnitude of risk of developing complete heart block in patients with LAD-RBBB (Annotation). *Am Heart J* 86:278 1973.
- Kulbertus H E. Reevaluation of the prognosis of patients with LAD-RBBB (Annotation). *Am Heart J* 92:665 1976.
- Green J J, Medalie J H, Neufeld H N, Riss E, Bachrach C A, Mount F W, and Smith H. An epidemiologic investigation of hypertension and ischemic heart disease within a defined segment of the adult male population of Israel. *Isr J Med Sci* 4:177 1968.
- Medalie J H, Neufeld H N, Riss E, Green J J, Kahn H A, and Bachrach C A. Variations in prevalence of ischemic heart disease in defined segments of the male population of Israel. *Isr J Med Sci* 4:15 1968.
- Rosenbaum M B, Elizari M V, and Lazzari J O. The hemiblocks. New concepts of intraventricular conduction based on human anatomical, physiological and clinical studies. Oldsmar, Florida 1970. Tampa Tracings.
- Trevino A J, and Beller B M. Conduction disturbances of the left bundle branch system and their relationship to complete heart block. I. A review of experimental electrophysiologic and electrocardiographic aspects. *Am J Med* 51:362 1971.
- Pryor R. Fascicular blocks and the bilateral bundle branch block syndrome. *Am Heart J* 83:441 1972.
- Rosenbaum M B, Elizari M V, Lazzari J O, Nau G J, Halpern M S, and Levi R J. The differential electrocardiographic manifestations of hemiblocks: bilateral bundle branch block and trifascicular blocks. In: *Advances in electrocardiography* edited by Schlant R C, and Hurst W. New York 1972. Grune & Stratton Inc.
- Pryor R, and Blount B G Jr. The clinical significance of true left axis deviation. Left intraventricular blocks. *Am Heart J* 72:391 1966.
- Lenegre J. Bilateral bundle branch block. *Cardiologia* 48:134 1966.
- Laiken E, Laiken N, and O'Rourke R A. A rapid method for frontal plane axis determination. *Am Heart J* 85:630 1973.
- Packard J M, Graettinger J S, and Graybiel A. Analysis of the electrocardiograms obtained from 1000 young healthy aviators. *Circulation* 10:384 1954.
- Manning G W. Electrocardiography in the selection of royal Canadian airforce aircrew. *Circulation* 10:401 1954.
- Johnson R L, Averill K H, and Lamb L E. Electrocardiographic findings in 67 375 asymptomatic subjects. VI. Right bundle branch block. *Am J Cardiol* 6:143 1960.
- Hus R G, and Lamb L E. Electrocardiographic findings in 122 043 individuals. *Circulation* 25:94 1962.
- Rotman M, and Triebwasser J H. A clinical and follow up study of right and left bundle branch block. *Circulation* 51:477 1975.
- Edmonds R E. An epidemiological assessment of bilateral bundle branch block. *Circulation* 34:1081 1966.
- Reusch C S, and Vivas J R. Clinical analysis of RBBB. *Am Heart J* 58:543 1959.
- Ostrander L D. Bundle branch block. An epidemiologic study. *Circulation* 30:872 1964.
- Lamb L E, Kable K D, and Averill K H. Electrocardiographic findings in 67 375 asymptomatic subjects. V. Left bundle branch block. *Am J Cardiol* 6:130 1960.
- Brady J I, Golden L H, and Tobin J L. A review of 3369 electrocardiograms in young male hospitalized patients. *Am Heart J* 53:821 1957.
- Grant R P. Left axis deviation. An electrocardiographic-pathologic correlation study. *Circulation* 14:733 1956.
- Stewart C B, and Manning G W. A detailed analysis of the electrocardiograms of 500 RCAF aircrew. *Am Heart J* 27:502 1944.

Serum myoglobin in acute myocardial infarction A clinical study and review of the literature

Ajit P Varki, MD *
David S Roby MD *
Harvey Watts, MD **
Jacob Zatuchni, MD ***
Philadelphia Pa

The diagnosis of acute myocardial infarction (AMI) is made conventionally on the basis of the clinical history, serial electrocardiograms and serum enzyme changes. This approach suffices in the majority of instances. However, recent enthusiasm for early intervention to reduce infarct size and the attempt to optimize coronary care utilization on a cost effective basis has raised the need for early, sensitive, and specific indicators of myocardial necrosis.

Recent reports have suggested that elevations of serum myoglobin (SMB) might provide such a parameter and permit estimation of prognosis and infarct size.¹⁻³ However, a recent editorial has questioned the value of SMB in assessing suspected myocardial injury.⁴

We report here a study of serum myoglobin in a consecutive series of patients with suspected acute myocardial infarction (AMI), and in several other noncardiac conditions. The sensitivity, specificity, and practical value of SMB are discussed in relation to a review of the literature.

From the Department of Medicine and Laboratory Department, Episcopal Hospital, Philadelphia, Pa.

Received for publication Mar 31 1978.

Reprint requests: Ajit P Varki MD, Dept of Medicine, Box 8125, Washington University School of Medicine, St Louis, Mo 63110.

Resident in Medicine, Episcopal Hospital, Philadelphia.

Head of Laboratories, Episcopal Hospital, Philadelphia.

Director, Dept of Medicine, Episcopal Hospital and Professor of Medicine, Temple University School of Medicine, Philadelphia.

Table 1 A rating system for suspicion of acute myocardial infarction (AMI)*

Criteria	Points		
	0	1	2
Chest pain	None	Atypical	Typical pain
ECG changes	No changes	Non specific ST T changes	New Q waves, evolutionary ST T changes
Enzyme changes	None	Transient slight elevation	Sequential rise and fall of levels

Interpretation: 5 to 6 points = Definite AMI; < 5 points = No definite AMI.

Materials and methods

Sixty consecutive patients admitted to an intensive care unit with the initial diagnosis of possible AMI were studied. The diagnosis of AMI was established by a rating scale including chest pain, ECG changes, and enzyme elevations (Table 1). Each case was evaluated for acute myocardial infarction by two independent observers without prior knowledge of the myoglobin data. Patients with 5 to 6 points on this rating scale were judged to have a definite AMI (Group 1) and the others were classified as having no definite MI (Group 2).

In all cases, the information which was recorded included age, sex, previous history of AMI, angina, heart failure, valvular disease, renal




Fig 1 Serum myoglobin in acute myocardial infarction ● = alive at two weeks ○ = dead at two weeks * see

Table II

Table II. Definition of clinical subsets in acute myocardial infarction*

Subset	Pulmonary† congestion	Peripheral† hypoperfusion
I	-	-
II	+	-
III	-	+
IV	+	+

After Forrester et al
†t-test for χ^2 in 1 interna

Table III Profile of patients studied

Group	Points	Number of cases	%	Sex	Age + S.D.
	1	10			
	2	19			
No definite AMI	3	8	38%	22 M	63.34 ± 14.27
	4	4		16 F	
Definite AMI	5	9		14 M	63.41 ± 12.71
	6	12	37%	8 F	

See Table I

disease diabetes mellitus liver disease peripheral vascular insufficiency alcohol abuse or seizure disorder There was also elicited information regarding recent history of unusual physical exertion musculoskeletal trauma seizures intramuscular injections alcohol or drug intake Careful inquiry was made as to the exact time of onset of the present episode of chest pain or discomfort Complete physical examination was recorded with special attention to evidence of hypoperfusion (oliguria altered mentation skin changes

low BP or tachycardia) pulmonary congestion (rales tachypnea abnormal chest x ray) presence of musculoskeletal trauma or peripheral vascular disease Clinical and hemodynamic subsets were assigned according to the classification of Forrester³ (Table II) All patients were evaluated and managed by a standard coronary care protocol which included serial enzymes and electrocardiograms and conventional blood chemistry Intramuscular Demerol (meperidine)




Fig 2 Relationship of myoglobin levels to onset symptoms in acute myocardial infarction ● = alive at two weeks ○ = dead at two weeks ○-| = died shortly after sample collection

was used for sedation and analgesia and morphine for refractory pain. Patients in clinical subsets III and IV (i.e. with clinical evidence of hypoperfusion) had Swan Ganz catheterization for measurement of pulmonary arterial wedge pressure. Management with diuretics, inotropic drugs, fluids, vasodilators and other agents followed accepted principles.⁸ A record was kept of the number, route, type and time sequence of administration of all medications. Details of cardiopulmonary resuscitations, defibrillation and other procedures were recorded.

Patients with various other conditions were also studied including pre and postoperative non cardiac surgery (Group 3), critically ill patients in the intensive care unit without myocardial disease (Group 4), patients receiving multiple intramuscular injections (Group 5), and patients with heat stroke (Group 6).

In Groups 1 and 2 (acute or suspected myocardial infarction), samples were drawn by venipuncture upon admission (Day 1) and on Days 2 and 4 simultaneously with other conventional serial studies. In those cases where the time of onset of

symptoms was reasonably certain (92 per cent of cases), the number of hours from onset was noted with each sample. Samples in the other groups were drawn at appropriate times. All samples were frozen at -20°C for analysis in batches.

Serum myoglobin was determined by radioimmunoassay employing I^{125} labelled myoglobin* based on the method of Stone and colleagues.¹ The assay was reproducible, sensitive, and specific. The normal value for serum myoglobin was 31 ± 25 ng/ml. A value of 85 ng/ml is considered the extreme upper limit of normal.

All information was coded and analyzed.

Results

The profile of the population studied for possible AMI is indicated in Table III. Thirty three per cent of patients (22 of 60) had definite AMI (Group 1) and 63 per cent (38 of 60) (Group 2) had equivocal or negative criteria. The two groups were comparable by age and sex distribution.

From Nuclear Medicine Systems Inc. Newport Beach, Cal. 92663.




Fig 3 Myoglobin levels in other conditions studied

Fig 1 shows actual myoglobin levels in the two groups. Values were significantly elevated in the group with acute myocardial infarction (172 ± 124.9 ng/ml) ($p < 0.001$). There was a significant correlation of higher peak SMb values with higher clinical subsets. As expected the immediate mortality rate (two weeks) was significantly lower in subsets I and II as compared with III and IV ($p < 0.01$) (Fig 1).

Three patients with AMI failed to show significant elevations of SMb. All were in clinical subset I and had mild transient elevations of SGOT.

The exact time of onset of symptoms was known in 92 per cent of cases. Fig 2 demonstrates SMb values as a function of total duration from the onset. Typically elevations were noted at 6 to 8 hours. Early peaks were noted in two patients (less than 2 hours) and both died. Sustained elevation of SMb into the third day was associated with increased mortality ($p < 0.1$).

Twenty one per cent of patients without definite evidence for AMI (1 to 4 points on the rating scale) showed peak myoglobin levels elevated above normal. There was no trend towards higher

values in those patients with higher point ratings. Four of these patients had possibly alternative explanations for the rise in SMb (chronic renal failure 3, trauma 1). One patient had a final diagnosis of pericarditis secondary to a post myocardial infarction syndrome.

Fig 3 shows SMb values in the other groups of patients studied. Significant elevations were seen in postoperative (non cardiac) states (58 per cent), heat stroke (100 per cent), critically ill patients in the intensive care unit without cardiac disease (27 per cent), and 50 per cent of those patients receiving frequent IM injections.

Discussion

Myoglobin is a low molecular weight heme protein synthesized and found exclusively in skeletal and cardiac muscle and is immunologically identical from the two sources. Damage to either of these tissues would theoretically elevate serum myoglobin levels. Renal clearance is rapid though variable and hence myoglobinemia following a single injury tends to be transient.

Significant myoglobinuria following AMI has

Table IV Reported studies of myoglobinemia in myocardial infarction

Reference	Assay technique	Normal values of SMb (ng/ml)*	Patient selection method
Kagen et al 1975 ²	Complement fixation assay	Not detectable	Admissions to CCU†
Jutzy et al 1975 Abstract	Radio immunoassay (RIA)	20.9 ± 23.3	CCU admissions
Stone et al 1975 ³	RIA	6.85	CCU admissions (consecutive ?)
Stuart et al 1975 ⁴ Abstract	RIA	Not detectable	Not specified
Klocke et al 1976 ¹ Abstract	RIA	25 ± 23 (5.75)	CCU admissions
Stone et al 1977	RIA	31 ± 1.3 (SE) 6.85	CCU admissions
Kollman et al 1977 ^{1a} Abstract	RIA	NS < 75	Consecutive CCU admissions
Gilkeson et al 1978	RIA	6.85	Patients with chest pain in Emergency room
Reichlin et al 1978	RIA	25 ± 23	Admissions to CCU†
Present study	RIA	< 85	Consecutive CCU admissions

bmb = Serum myoglobin values in ng/ml ± 1 SD

†CCU = coronary care unit.

‡NS = not specified

§AMI = acute myocardial infarction

been reported in several studies¹⁻⁴. However urine myoglobin levels showed extreme variability with regard to the time course of excretion and are poorly correlated with peak serum levels and severity of infarction.

Myoglobinemia following AMI was first reported by Kagen and colleagues² utilizing a complement-fixation assay which would detect up to 30 ng/ml of SMb. Elevated levels over a wide range were demonstrated in 11 of 21 patients with conventional evidence of myocardial necrosis. Higher values tended to correlate with both increased severity of infarction and greater mortality. However the assay technique tended to underestimate small quantities of myoglobin because of serum interference and normal persons had undetectable levels.

A sensitive, specific, and accurate radioimmunoassay for SMb was first reported by Stone and co-workers³. Currently accepted normal values for SMb are 31 ± 50 (2SD) ng/ml, based on 135 normal subjects studied by this group. The highest value found in this population was 85 ng/ml and this was considered the upper limit of normal³. Normal subjects studied by other groups showed similar results, with maximum values ranging from 75 to 85 ng/ml^{1,2,4}.

The available information on myoglobinemia following AMI in the English language literature is summarized in Table IV. Two factors make comparison of these studies difficult. First with one exception⁴ none of the reports indicate whether the patient populations studied constituted random samples, consecutive series or selected groups with suspected AMI. Secondly while most studies analyzed the SMb values in

Sample collection		Serum myoglobin values				
		Acute myocardial infarctions			Chest pain no AMI	
Timing	Relationship to onset of symptoms	SMB	Elevated in	Peak values (hrs)	SMB	Elevated in
On admission	NS†	300	11/21	?	Not Detectable	0/12
(3)-serial		3700	(52%)			(0%)
QIH x 6hrs	Discussed in relation to onset of symptoms	216	30/30	9 12hrs from onset	2 88	0/90
Q3H x 12hrs		6800	(100%)			
Q4H x 3days						
Variable serial in 9 patients	NS	380 ± 53	18/20	8-12hrs from admission	41 ± 6	1/91
QIH x 12hrs	NS	195 ± 47	(90%)			
4hrs-from 48hrs onset		46-200	5/5	7 10hrs from onset	Not detectable	0/2
			(100%)			(0%)
Not specified (frequent)	NS	1390	31/31	Early	16% ± 11	8/18
		± 1350	(100%)			(44%)
Variable (some serially)	NS	528	62/64	4 hrs from admission	44 ± 60	2/44
	Related to admission	± 76	(96.8%)			
Not specified	NS	> 100	8/9	?	> 75	0/13
	Related to admission		(88%)			(0%)
On admission	NS	—	5/13	—	33 8	2/53
			(38%)		(Mean)	(3.8%)
6-8hrs	NS	—	9/12	—		
			(75%)			
Not specified	NS	1368	37/39	—	16% ± 52(8)	8/19
		± 1357	(100%)		■ ± 16(11)	(42%)
On admission Day 2 & Day 3 (A M)	Discussed in relation to onset of symptoms	172	19/29	6-8hrs. from onset	63 6	8/38
		± 124	(86%)			
					± 62 38	(21%)

relation to the time elapsed after admission to the hospital a few (including the present one) attempted to relate the timing of sample collection to the onset of the symptoms of AMI. The duration of significant myoglobinemia was brief in most studies and return to normal values often occurred in less than 24 hours. Hence although the exact time of onset of symptoms is difficult to determine in some patients correlation with the duration of symptoms is probably more valid than with duration of hospitalization. In the present study it was possible to determine the time of onset of chest pain in 92 per cent of the cases.

In most studies myoglobinemia was detected as early as four hours after admission and often preceded the appearance of elevated levels of CPK and the CPK MB fraction. The value of such early detection is questionable. First confirming the diagnosis a few hours earlier is

unlikely to alter the basic management of a case of AMI. On the other hand the absence of significant elevation of SMB alone would not be sufficient to abandon intensive coronary care if there is any other evidence suggesting an AMI. Secondly in most laboratories RIA procedures are usually carried out in batches on stored samples for reasons of practicality and economy. To perform the assay on a single sample as an emergency procedure would not be cost effective except under unusual circumstances. A practical approach would be to collect and store samples for SMB assay to be done only in those cases in which conventional parameters are equivocal.

Significant elevations in SMB were noted in the large majority of cases of AMI in various series (Table IV). With increased frequency of sampling 100 per cent of cases showed myoglobinemia. However these studies used hourly

Table V Conditions in which elevated serum myoglobin levels have been reported

- 1 Acute MI (See Table IV)
- 2 Angina without infarction (See Table IV)
- 3 Rhabdomyolysis
- 4 Multiple fractures ' Muscle trauma '
- 5 Acute vascular occlusion²
- 6 Renal failure '
- 7 Myopathies type not specified
- 8 Vigorous exercise
- 9 IM injections
- 10 Open heart surgery¹ '
- 11 Non cardiac surgery
- 12 Grand mal seizures
- 13 ' Dig toxicity
- 14 Ventricular tachycardia
- 15 Widespread cancer
- 16 Pericarditis ?*
- 17 Circulatory shock *
- 19 Excessive alcohol ingestion?

Present study

sampling for SMb, which is neither practical nor desirable in practice. In the present study, a *deliberate* attempt was made to evaluate the usefulness of a restricted number of samples obtained at the same time as other routine studies. Even with such infrequent sampling, 86 per cent of cases of definite AMI showed significant elevations of SMb. It would appear that more frequent samples might be of value in individual cases where clinical suspicion of myocardial necrosis is high but other parameters are equivocal. It must be pointed out that Kagen and associates¹⁰ in an early study, suggested that there appeared to be a 'staccato phenomenon' with considerable variation in the levels of SMb in the early hours following infarction.

In the present study only three patients with definite evidence of AMI failed to show elevations of SMb. These three all in clinical subset I showed only mild transient elevations of cardiac enzymes. In one patient, sampling time (3 and 44 hours after onset of symptoms) may have missed a transient myoglobin peak. In the two others, modest evolutionary changes of SMb within the normal range were seen. However there is no data available on day to day variations of SMb in normal individuals and hence no significance can be attributed to this.

Peak values for SMb in AMI were reported to occur in a varying period ranging from 4 to 12 hours after admission to 6 to 12 hours after onset of symptoms in various series (Table IV). Actual

Table VI Conditions in which elevated serum myoglobin levels were not found

- 1 Angina without infarction (See Table IV)
- 2 Congestive heart failure without AMI '
- 3 Cardiac cath '
- 4 Bicycle stress testing¹
- 5 Moderate exercise
- 6 IM injections (5 subjects—10 c.c. saline injections)
- 7 Liver disease
- 8 Scleroderma *
- 9 Rheumatoid arthritis
- 10 Thyrotoxicosis *
- 11 Diabetic ketoacidosis
- 12 Pancreatitis

values also showed a considerable range, a few with levels as high as 3 000 to 6 000 ng/ml. Several studies attempted to correlate the peak myoglobin level with the severity and prognosis of the infarction. Significantly higher levels were noted in patients who also had congestive heart failure¹⁻². In the present series a significant correlation was noted between the height of the myoglobin peak and the severity of the infarction as defined by the clinical subsets of Forrester and co-workers³. However it must be noted that patients in subsets III and IV had renal hypoperfusion by definition, and hence might have had decreased clearance of myoglobin. It has also been suggested that severity of myoglobinemia might be used to estimate infarct size¹. In studies on experimentally induced AMI in dogs, such correlation was possible¹¹. However the transient and unpredictable nature of the myoglobin peak and the possible 'staccato phenomenon' alluded to above make it unlikely that SMb can be more reliable than currently available techniques for mapping infarct size.

The incidence of elevated SMb in patients with chest pain, but no definite AMI varies greatly, from 0 to 44 per cent in various series (Table IV). This may relate in part to variations in the diagnostic criteria for an AMI. Further, several other conditions are now known to produce elevations in SMb (see Table V). In the present study 21 per cent of patients (8 of 38) with chest pain but no definite evidence of AMI showed elevated SMb levels. Of these three patients had chronic renal failure and one had sustained musculoskeletal trauma before admission. One other patient was diagnosed as having a pericarditis probably secondary to a post myocardial infarction syn-

drome. In the other three no apparent explanation was found. It is possible that some of these patients may have had a small infarction which could not be detected by conventional methods. However, there was no trend towards increasing myoglobin levels with increasing suspicion (high point count) of AMI.

Although SMB elevations are very sensitive for AMI, they are certainly not specific. Table V lists the conditions in which elevated myoglobin levels were found by various workers. In the present study, 68 per cent of postoperative (noncardiac) patients, 50 per cent of patients receiving frequent IM injections, and 27 per cent of patients admitted to an intensive care unit for critical noncardiac illnesses showed significant elevations of SMB (Fig 3). Open heart surgery resulted in very high levels of SMB.¹¹ Other conditions in which myoglobinemia has been reported include extensive trauma, rhabdomyolysis, acute vascular occlusion of an extremity, grand mal seizures, metastatic cancer, and following ventricular tachycardia without definite evidence of myocardial infarction (Table V). Because myoglobin is normally cleared rapidly by the kidney, SMB values are difficult to interpret in the presence of acute or chronic renal failure. There is no data available at the present time which allows correlation of the severity of the renal failure with the degree of elevation of the SMB. While myoglobinuria by itself is well known to be associated with renal failure, the quantities released in AMI are not significant in this regard.

While rigorous exercise is well known to cause significant rhabdomyolysis, bicycle stress testing and moderate exercise did not appear to raise the SMB.

While Stuart and associates¹ found that five subjects given 10 cc saline injections did not show elevated SMB, other studies including the present indicate that patients receiving frequent deep IM injections can have significant myoglobinemia.¹² Stone and colleagues found that cardiac catheterization did not alter myoglobin levels.

It is evident that many factors, some of them rather non-specific, can alter myoglobin levels. The SMB in myocardial infarction should therefore be interpreted only in light of other associated conditions.

The transient and dramatic nature of the myoglobin peak suggests that a distinct second

peak might be of value in making the diagnosis of an early recurrent AMI or extension of infarction in the situation where other conventional parameters are still abnormal following the first infarction. Kollman and co-workers¹³ have reported such a case. In this situation, SMB might be distinctly advantageous.

Conclusions

The results of this study and a review of the literature permit the following conclusions and suggestions regarding myoglobinemia in acute myocardial infarction.

1. Radioimmunoassay of serum myoglobin (SMB) is a sensitive indicator of myocardial damage in the early hours following an acute myocardial infarction (AMI). Even with infrequent sampling, more than 80 per cent of patients show significant elevations of SMB. Sensitivity is higher with frequent sampling.

2. It is suggested that serum for analysis should be collected on admission and daily for two days, i.e., at the same time as other conventional studies are obtained. The specimens may be frozen and the assay performed if, in retrospect, there is significant doubt regarding the diagnosis.

3. Careful note should be made of the relationship of the timing of sample collection to the time of onset of chest pain. Elevations of SMB may be expected to peak between 4 to 12 hours following the onset of pain.

4. Elevations of SMB are nonspecific for AMI. It is probably valueless in the presence of renal failure, rhabdomyolysis, extensive trauma, postoperative states (cardiac and noncardiac), acute vascular occlusions of extremities, and following seizures. It should be interpreted with care following intramuscular injections, vigorous exercise, ventricular tachycardia, and cardiopulmonary resuscitation. Inadequate data is available regarding pericarditis and cardiomyopathies. Twenty-five per cent of critically ill patients with multiple noncardiac problems have a raised SMB which cannot be adequately explained in all instances.

5. At present, there is inadequate data to suggest that SMB is superior to any of the conventional methods for assessment of the extent of infarction. However, very high levels and sustained elevations tend to be associated with a poorer prognosis.

6. SMB may be of special value in the diagnosis

of early recurrent AMI or extension of infarction

The authors wish to acknowledge the excellent technical assistance of Elizabeth Smith BS

REFERENCES

- 1 Stone M J Waterman M R et al Serum myoglobin level as diagnostic test in patients with acute myocardial infarction *Br Heart J* 39 375 1977
- 2 Kagen L and Schiedt E et al Myoglobinemia following myocardial infarction *Am J Med* 58 177 1975
- 3 Jutzy R V Nevatt G W et al Radioimmunoassay of serum myoglobin in acute myocardial infarction *Am J Cardiol* 35 147 1975
- 4 Roberts R Myoglobinemia as index to myocardial infarction *Ann Intern Med* 87 788 1977
- 5 Forrester J S et al Medical therapy of acute myocardial infarction by application of hemodynamic subsets *N Engl J Med* 295 1356 and 1404 1976
- 6 Kagen L J Myoglobin Biochemical Physiological and Clinical Aspects New York & London 1973 Columbia University Press
- 7 Adams E C Jr and Elliott T A Urinary myoglobin in myocardial infarction *JAMA* 211 1013 1970
- 8 Levine R B Alterman M Cubner R S and Adams E G Jr Myoglobinuria in myocardial infarction *Am J Med Sci* 262 179 1971
- 9 Saranchak H J and Bernstein S H A new diagnostic test for acute myocardial infarction The detection of myoglobinuria by radioimmunoassay *JAMA* 222 1251 1974
- 10 Kessler II A and Liebson F R et al Acute myocardial diagnoses by myoglobinuria *Arch Intern Med* 135 1181 1975
- 11 Donald T C Cloonan M J et al Excretion of myoglobin in urine after acute myocardial infarction *Br Heart J* 39 29 1977
- 12 Stone M J Willerson J T et al Radioimmunoassay of myoglobin in human serum—results in patients with acute myocardial infarction *J Clin Invest* 56 1334 1975
- 13 Klocke F J Visco J P and Reichlin M Myoglobinemia as an index of myocardial infarction and/or ischemia *Circulation* 54 (Suppl II) (Abst 106) 1976
- 14 Kollmann G Shapiro H et al Serum myoglobin levels in the early diagnosis of myocardial infarction (Abstract) Chicago June 1977 The Clinical Radioimmunoassay Society
- 15 Stuart H C Palmer J et al Serum myoglobin levels in the diagnosis of myocardial infarction *Am J Cardiol* 35 171 1975
- 16 Kagen L Schiedt M and Butt A Serum myoglobin in myocardial infarction The staccato phenomenon Is acute myocardial infarction in man an intermittent event? *Am J Med* 52 86 1977
- 17 Lwebuga Mukasa J S Libby P et al The evaluation of serum myoglobin following experimental coronary occlusion *Circulation* 48 (Suppl 4) 129 1973
- 18 Jutzy R V Nelson J C et al Myoglobinemia in conditions other than myocardial infarction *Circulation* 54 (Suppl II) (Abst 108) 1976
- 19 Gilkeson B S Stone M J et al Detection of myoglobin by radioimmunoassay in human sera its usefulness and limitations as an emergency room screening test for acute myocardial infarction *AM HEART J* 95 70 1978
- 20 Reichlin M et al Radioimmunoassay for human myoglobin—Initial experience in patients with coronary heart disease *Circulation* 57 52 1978

Copyright information

The appearance of a code at the bottom of the first page of an original article in this journal indicates the copyright owner's consent that copies of the article may be made for personal or internal use or for the personal or internal use of specific clients. This consent is given on the condition however that the copier pay the stated per copy fee through the Copyright Clearance Center Inc P O Box 765 Schenectady NY 12301 518 374 4430 for copying beyond that permitted by Sections 107 or 108 of the U S Copyright Law. This consent does not extend to other kinds of copying such as copying for general distribution for advertising or promotional purposes for creating new collective works or for resale.

Infective endocarditis Part III Prevention of bacterial endocarditis

Franklin Lowy MD*
Neal H Steingibiel MD FACP
New York N Y

While antibiotic therapy of infective endocarditis has dramatically improved patient survival the morbidity and mortality of this infection remains appreciable.^{1,2} Well controlled clinical studies investigating the effectiveness of antibiotics in preventing the development of infective endocarditis are not available. Therefore the present recommendations for antibiotic prophylaxis have been based on extrapolations from several types of data: (1) the pathogenesis of infective endocarditis often involves implantation of the causative organism on damaged cardiac valves during transient bacteremia; (2) the transient bacteremia often follows particular mechanical procedures;³ (3) the species of organisms isolated during these bacteremias and those which frequently cause endocarditis have relatively predictable antibiotic susceptibilities;⁴ (4) knowledge of the bactericidal activity and clinical pharmacology of antibiotics suggests prophylactic drug regimens which would be likely to decrease the incidence or intensity of such transient bacteremias and the subsequent multiplication of the pathogen in the nidus on the cardiac valve—a reduction in the incidence of infective endocarditis would therefore be expected; (5) the prophylactic drug regimens have been modified after considering the results of studies which have evaluated antibiotic prophylaxis in animal models of endocarditis. This paper will review some

of the data and the current recommendations for the prevention of endocarditis.

Prevention of rheumatic fever

The use of antibiotics to prevent recurrent episodes of rheumatic fever by preventing recurrent Group A streptococcal throat infections must be distinguished from antimicrobial prophylaxis of bacterial endocarditis. These two subjects are often confused and it should be emphasized that antibiotics administered in order to prevent rheumatic fever are not only inadequate as preventive therapy for endocarditis but can alter the antibiotic susceptibility of viridans streptococci which are part of the indigenous mouth flora making endocarditis prophylaxis more difficult. However, reducing the incidence of rheumatic fever and resulting rheumatic valvular disease potentially reduces the population of patients at risk of developing infective endocarditis.

Large scale studies with military recruits have shown a direct relationship between elimination of Group A streptococci from the throat and reduction in the incidence of rheumatic fever.¹¹⁻¹³ During epidemics the incidence of rheumatic fever following streptococcal pharyngitis is 3 per cent.² Treatment within one to two days of infection is 95 per cent effective in reducing the subsequent rheumatic fever attack rate; therapy given one two or even three weeks after an infection will reduce the incidence of rheumatic fever by 90 per cent, 67 per cent and 42 per cent respectively.³

Prophylaxis of recurrent Group A streptococcal throat infections is recommended for patients with a past history of rheumatic fever, Sydenham's chorea or rheumatic valvular disease and represents an attempt to prevent the recurrence

From the Division of Infectious Diseases, Department of Medicine, Mount Sinai Hospital and Medical Center and the Department of Medicine, Albert Einstein College of Medicine, Bronx, N Y.

During the course of this study Dr Lowy was supported by a training grant (T01 AI 00405-07 AID) from the National Institute of Allergy and Infectious Diseases.

Received for publication July 19, 1983.

Reprint requests to: Franklin Lowy, Mount Sinai Hospital and Medical Center, 111 East 51st Street, Box 2, N Y 10022.

Table 1 Prevention of rheumatic fever* (Choices listed in order of preference)*Primary prevention—Treatment of Streptococcal Pharyngitis*

- 1 Benzathine penicillin G 12 million units IM If the patient weighs less than 60 lbs the dose is 600 000 units IM
- 2 Oral penicillin G 200 000 units 3-4 times/day for ten days
- 3 In penicillin allergic patients erythromycin 20 mg /lb /day (up to 1 Gm /day) in divided doses for ten days

Secondary Prevention—Continuous prophylaxis†

- 1 Benzathine penicillin G 12 million units IM every four weeks
- 2 Oral penicillin G 200 000 units twice a day
- 3 Oral sulfadiazine 1 gram once a day If the patient weighs less than 60 lbs the dose is 0.5 gram once a day
- 4 In cases of penicillin and sulfa allergies erythromycin 250 mg twice a day

For a more complete summary of AHA recommendations see reference 14

†Continuous prophylaxis is recommended for patients with a past history of rheumatic fever or for patients who have rheumatic valvular disease

of rheumatic fever and its life threatening cardiac sequelae.¹⁴ The length of time such antibiotic prophylaxis should be continued is uncertain. Continued prophylaxis is indicated in certain high risk groups including military recruits, women during pregnancy and in patients with frequent exposure to children.¹⁴ Benzathine penicillin G given intramuscularly is the most effective prophylactic regimen, however, parenteral administration may be associated with a higher incidence of allergic reactions.¹⁴ The recommendations of the American Heart Association for rheumatic fever prophylaxis have been briefly summarized in Table 1.¹⁴

Prevention of bacterial endocarditis

Antibiotics are generally given prior to certain dental surgical and other manipulative procedures when these procedures are performed on areas of the body colonized by organisms likely to cause infective endocarditis. The aim is to reduce the incidence or intensity of the transient bacteremia which may be associated with the procedure and to prevent colonization of damaged valves. In 1923, Lewis and Grant¹⁵ first suggested that transient bacteremia was a common event in normal individuals and that it was the presence of a

deformed aortic valve that made certain individuals uniquely susceptible to endocarditis.¹⁵ Subsequent studies demonstrated that individuals with congenital, rheumatic, or other acquired valvular disease are at increased risk of developing endocarditis.¹⁶⁻¹⁷ Okell and Elliott¹⁸ demonstrated bacteremia in 60.9 per cent of patients having tooth extractions. The incidence of bacteremia was highest in individuals with severe pyorrhea and in those having more extensive dental work.¹⁸ Bacteremia following dental or other procedures is brief. Blood cultures are generally positive for at least five minutes after the procedure and are sterile by thirty minutes. There are usually fewer than 50 bacteria per ml at the peak of bacteremia.¹⁷⁻¹⁸ Studies on bacteremia following particular procedures (Table II) show considerable variation in results primarily because of the use of differing sample schedules and blood culture media. Detailed reviews of this subject have recently been published¹⁷⁻¹⁸ and indicate that transient bacteremia involving the indigenous bacterial flora is a common event. It can be demonstrated following tooth brushing¹⁹ while chewing candy,²⁰ following sigmoidoscopy,²¹ and perhaps even after a bowel movement.²² The frequency and level of bacteremia may depend on local host factors. For example, patients with extensive gum disease, or with infected urine at the time of a urological procedure, have a higher incidence of positive blood cultures. Okell and Elliott¹⁸ found a 10.9 per cent incidence of spontaneous bacteremia in patients with extensive pyorrhea when blood cultures were taken prior to any manipulation in patients scheduled for tooth extraction.

Recommendations for antibiotic prophylaxis are based not only on the incidence of bacteremia following certain procedures but also on the ability of specific organisms to cause endocarditis. Gram positive bacteria are more likely to cause endocarditis than Gram negative organisms and this may be related to their greater adherence properties. Studies have shown that enterococci, viridans streptococci and staphylococci adhere more readily than Gram negative bacteria to aortic valvular tissue.²³ Studies are also being pursued to define specific mechanisms of adherence to host tissue.²⁴ Antibiotic prophylaxis is therefore designed to protect the vulnerable heart valve specifically from organisms that are likely to cause endocarditis and not from the

Table II Transient bacteremia following various procedures

Procedure	Incidence of bacteremia (%)	Organisms isolated	Prophylaxis
Tooth extraction ^a	60.9-84.9	Streptococci mouth anaerobes <i>S. epidermidis</i> diphtheroids	+
Dental prophylaxis ^a	0-8	Same	—
Tooth brushing ^a	0-26	Same	—
Orotracheal intubation	0	—	—
Nasotracheal intubation	16	Streptococci	—
Upper gastrointestinal endoscopy	8	Streptococci <i>S. epidermidis</i> diphtheroids	+
Sigmoidoscopy ^a	9.5	Enterococci GNR†	+/-
Barium enema	11.4	As above	+/-
Liver biopsy	13.5	<i>S. pneumoniae</i> GNR	—
Transurethral prostatectomy ^a	19.3-45.7	Enterococci GNR	+
Insertion removal of urethral catheter ^a	80-96.3	Enterococci GNP	+/-
Parturition ^a	4.9	Streptococci, aerobic & anaerobic	—
Insertion, intrauterine device	0	—	—
Cardiac catheterization ^a	0	—	—
Manipulation of septic foci ^a	38.5	<i>S. aureus</i> others	+

Symbols

+ prophylaxis recommended

+/- prophylaxis recommended by some, especially in patients with prosthetic heart valves

- prophylaxis generally not recommended

† GNR, Gram negative rods.

entire array of potential organisms isolated during a bacteremic episode

A number of factors limit the potential benefits of prophylaxis to only a proportion of the patients at risk. Up to one third of patients presenting with endocarditis have no prior history of underlying heart disease and would not be considered for prophylaxis.^{1,2} In one survey of individuals aware of having heart disease, only 21.7 per cent appreciated the importance of communicating this information to their dentists.³ In addition, recent studies have noted that only 25 to 60 per cent of patients with endocarditis had apparent foci for their bacteremia.^{4,5} The incidence of endocarditis due to the penicillin-sensitive viridans streptococci has decreased, while endocarditis caused by more antibiotic-resistant organisms such as *S. aureus*, *S. epidermidis*, and enterococci has increased.⁶ Finally, there have been some reports of endocarditis occurring despite antibiotic prophylaxis, although none of the regimens used would now be considered adequate.

The actual risk of an individual with valvular heart disease developing endocarditis following a particular procedure is unknown. Hook and Kaye roughly estimated the risk to be 1 in 533 (0.19 per cent) per tooth extraction. Taran had

Table III Cardiac disorders warranting antimicrobial prophylaxis of infective endocarditis

Rheumatic valvular disease
Congenital heart disease (except uncomplicated secundum atrial septal defect)
Prosthetic heart valves
Idiopathic hypertrophic subaortic stenosis
Previous episode of infective endocarditis
Other acquired valvular heart disease (e.g. syphilitic atherosclerotic)
Patients on hemodialysis
Mitral valve prolapse
Patients with pacemakers

Need for prophylaxis uncertain

four cases of endocarditis in 350 children with rheumatic valvular disease following tooth extractions, while Schwartz and Salzman⁷ noted no cases following 403 tooth extractions in 98 patients with rheumatic heart disease. The risk of endocarditis undoubtedly varies for a number of reasons, including the type of valvular heart disease, the age of the patient, the organism involved, and the level of bacteremia. It should be noted for comparison that the incidence of anaphylactic reactions caused by penicillin is reported to be 0.04 to 0.11 per cent.⁸ Risk similar

Table 1 Prevention of rheumatic fever* (Choices listed in order of preference)

Primary prevention—Treatment of Streptococcal Pharyngitis

- 1 Benzathine penicillin G 1.2 million units IM If the patient weighs less than 60 lbs the dose is 600 000 units IM
- 2 Oral penicillin G 200 000 units 3-4 times/day for ten days
- 3 In penicillin allergic patients erythromycin 20 mg /lb /day (up to 1 Gm /day) in divided doses for ten days

Secondary Prevention—Continuous prophylaxis†

- 1 Benzathine penicillin G 1.2 million units IM every four weeks
- 2 Oral penicillin G 200 000 units twice a day
- 3 Oral sulfadiazine 1 gram once a day If the patient weighs less than 60 lbs the dose is 0.5 gram once a day
- 4 In cases of penicillin and sulfa allergies erythromycin 250 mg twice a day

*For a more complete summary of AHA recommendations see reference 14

†Continuous prophylaxis is recommended for patients with a past history of rheumatic fever or for patients who have rheumatic valvular disease

of rheumatic fever and its life threatening cardiac sequelae.¹⁴ The length of time such antibiotic prophylaxis should be continued is uncertain. Continued prophylaxis is indicated in certain high risk groups including military recruits, women during pregnancy and in patients with frequent exposure to children.¹⁴ Benzathine penicillin G given intramuscularly is the most effective prophylactic regimen, however, parenteral administration may be associated with a higher incidence of allergic reactions.¹⁴ The recommendations of the American Heart Association for rheumatic fever prophylaxis have been briefly summarized in Table 1.¹⁴

Prevention of bacterial endocarditis

Antibiotics are generally given prior to certain dental, surgical and other manipulative procedures when these procedures are performed on areas of the body colonized by organisms likely to cause infective endocarditis. The aim is to reduce the incidence or intensity of the transient bacteremia which may be associated with the procedure, and to prevent colonization of damaged valves. In 1923, Lewis and Grant¹⁵ first suggested that transient bacteremia was a common event in normal individuals and that it was the presence of a

deformed aortic valve that made certain individuals uniquely susceptible to endocarditis.¹⁵ Subsequent studies demonstrated that individuals with congenital rheumatic, or other acquired valvular disease are at increased risk of developing endocarditis.¹⁶ Okell and Elliott¹⁷ demonstrated bacteremia in 60.9 per cent of patients having tooth extractions. The incidence of bacteremia was highest in individuals with severe pyorrhea and in those having more extensive dental work.¹⁷ Bacteremia following dental or other procedures is brief. Blood cultures are generally positive for at least five minutes after the procedure and are sterile by thirty minutes. There are usually fewer than 50 bacteria per ml at the peak of bacteremia.¹⁷ Studies on bacteremia following particular procedures (Table II) show considerable variation in results, primarily because of the use of differing sample schedules and blood culture media. Detailed reviews of this subject have recently been published,¹⁸ and indicate that transient bacteremia involving the indigenous bacterial flora is a common event. It can be demonstrated following tooth brushing¹⁹ while chewing candy,²⁰ following sigmoidoscopy,²¹ and perhaps even after a bowel movement.²² The frequency and level of bacteremia may depend on local host factors. For example, patients with extensive gum disease, or with infected urine at the time of a urological procedure have a higher incidence of positive blood cultures. Okell and Elliott¹⁷ found a 10.9 per cent incidence of spontaneous bacteremia in patients with extensive pyorrhea when blood cultures were taken prior to any manipulation in patients scheduled for tooth extraction.

Recommendations for antibiotic prophylaxis are based not only on the incidence of bacteremia following certain procedures but also on the ability of specific organisms to cause endocarditis. Gram positive bacteria are more likely to cause endocarditis than Gram negative organisms and thus may be related to their greater adherence properties. Studies have shown that *enterococci*, *viridans streptococci* and *staphylococci*, adhere more readily than Gram negative bacteria to aortic valvular tissue.²³ Studies are also being pursued to define specific mechanisms of adherence to host tissue.²⁴ Antibiotic prophylaxis is therefore designed to protect the vulnerable heart valve specifically from organisms that are likely to cause endocarditis and not from the

Table II Transient bacteremia following various procedures

Procedure	Incidence of bacteremia (%)	Organisms isolated	Prophylaxis
Tooth extraction ^{1,2,3}	60.9-84.9	Streptococci mouth anaerobes <i>S. epidermidis</i> diphtheroids	+
Dental prophylaxis ^{2,3}	0-9.8	Same	+
Tooth Brushing	0-26	Same	-
Orotracheal intubation ^{2,3}	11	-	-
Nasotracheal intubation	16	Streptococci	-
Upper gastrointestinal endoscopy	8	Streptococci <i>S. epidermidis</i> diphtheroids	-
Sigmoidoscopy	9.5	Enterococci GNR†	+/-
Barium enema ^{2,3}	11.4	As above	+/-
Liver biopsy ^{2,3}	13.5	<i>S. pneumoniae</i> GNR	-
Transurethral prostatectomy	12.3-43.7	Enterococci GNR	+
Insertion, removal of urethral catheter ^{2,3}	80-26.3	Enterococci GNR	+/-
Perturbation ^{2,3}	4.9	Streptococci aerobic & anaerobic	-
Insertion intrauterine device	0	-	-
Cardiac catheterization ^{2,3}	0	-	-
Manipulation of septic foci	38.5	<i>S. aureus</i> others	+

Symbols

+ prophylaxis recommended

+/- prophylaxis recommended by some, especially for patients with prosthetic heart valves

- prophylaxis generally not recommended

† GNR: Gram negative rods.

entire array of potential organisms isolated during a bacteremic episode.

A number of factors limit the potential benefits of prophylaxis to only a proportion of the patients at risk. Up to one-third of patients presenting with endocarditis have no prior history of underlying heart disease and would not be considered for prophylaxis.¹ In one survey of individuals aware of having heart disease, only 21.7 per cent appreciated the importance of communicating this information to their dentists. In addition, recent studies have noted that only 25 to 60 per cent of patients with endocarditis had apparent foci for their bacteremia.^{2,3} The incidence of endocarditis due to the penicillin-sensitive viridans streptococci has decreased, while endocarditis caused by more antibiotic-resistant organisms such as *S. aureus*, *S. epidermidis* and enterococci has increased. Finally, there have been some reports of endocarditis occurring despite antibiotic prophylaxis, although none of the regimens used would now be considered adequate.⁴

The actual risk of an individual with valvular heart disease developing endocarditis following a particular procedure is unknown. Hook and Kaye roughly estimated the risk to be 1 in 533 (0.19 per cent) per tooth extraction. Taran⁵ had

Table III Cardiac disorders warranting antimicrobial prophylaxis of infective endocarditis

Rheumatic valvular disease
Congenital heart disease (except uncomplicated secundum atrial septal defect)
Prosthetic heart valves
Idiopathic hypertrophic subaortic stenosis
Previous episode of infective endocarditis
Other acquired valvular heart disease (e.g. atherosclerotic)
Patients on hemodialysis
Mitral valve prolapse
Patients with pacemakers
Need for prophylaxis uncertain

four cases of endocarditis in 350 children with rheumatic valvular disease following tooth extractions, while Schwartz and Salzman⁶ noted no cases following 403 tooth extractions in 98 patients with rheumatic heart disease. The risk of endocarditis undoubtedly varies for a number of reasons, including the type of valvular heart disease, the age of the patient, the organism involved, and the level of bacteremia. It should be noted for comparison that the incidence of anaphylactic reactions caused by penicillin is reported to be 0.04 to 0.11 per cent, a risk similar

Table IV Antimicrobial prophylaxis of infective endocarditis

1	Dental procedures and upper respiratory procedures ^a
	Parenteral
A	Aqueous crystalline penicillin G 1 million units plus procaine penicillin G 600 000 units IM $\frac{1}{2}$ 1 hour before the procedure then penicillin V 500 mg p.o. q6h for 4-8 doses
B	Regimen A plus streptomycin 1 Gm IM given $\frac{1}{2}$ 1 hour before the procedure ^b
C	Vancomycin 1 Gm IV over $\frac{1}{2}$ 1 hour given $\frac{1}{2}$ 1 hour prior to the procedure ^c
	Oral
D	Penicillin V 2 Gm p.o. $\frac{1}{2}$ 1 hour prior to the procedure then 500 mg p.o. q6h for 8 doses
E	Erythromycin 1 Gm p.o. 1-2 hours before the procedure then 500 mg p.o. q6h for 8 doses
2	Gastrointestinal and genitourinary procedures
	Parenteral
F	Ampicillin 1-2 grams IM or IV (or aqueous crystalline penicillin G 1-2 million units IM or IV) plus streptomycin 10 gram IM (or gentamicin 1.5 mg/kg IM) Both antibiotics to be given $\frac{1}{2}$ 1 hour before the procedure and repeated at 12 and 24 hours with the penicillin-streptomycin regimen and every 8 h for 24h with the penicillin-gentamicin regimen ^d
G	Vancomycin 1 Gm IV over $\frac{1}{2}$ 1 hour starting $\frac{1}{2}$ 1 hour prior to the procedure plus streptomycin 1 Gm IM Both drugs may be repeated at 12 hours ^e
	Oral
	No oral regimen has been demonstrated to provide satisfactory protection

All dental procedures including cleaning but not including orthodontic adjustments. The need for prophylaxis following tonsillectomy or bronchoscopy is uncertain.

These regimens are considered the most effective and are recommended for patients with prosthetic heart valves and for individuals on long term penicillin prophylaxis for rheumatic fever.

^aThese regimens may be used in penicillin allergic patients. The parenteral regimen is preferred.

^bProphylaxis is recommended for all genitourinary procedures including urethral catheter insertion and removal. It is also recommended for gall bladder and bowel surgery. It is not routinely recommended for sigmoidoscopy, barium enema, liver biopsy or upper G.I. endoscopy except perhaps for patients with prosthetic heart valves.

^cDosage of streptomycin and gentamicin should be modified in the presence of renal insufficiency.

to that of endocarditis following tooth extraction.^{18, 19}

The recommendations for antibiotic prophylaxis for endocarditis have been extensively revised based on experimental studies using a rabbit endocarditis model. Endocarditis is produced in the rabbit by passing a polyethylene catheter across the aortic or tricuspid valves and

giving an intravenous injection of organisms after a period of 1 to 2 days.^{20, 21} Mechanical trauma to the valve leads to formation of a platelet-fibrin thrombus which serves as the nidus for infection. The virulence of the organism correlates with the likelihood of establishing an infection following the 'transient' bacteremia. Durack and Petersdorf²² have studied the more commonly recommended regimens for prophylaxis using this model. Antibiotics were given one half hour prior to the injection of organisms. Rabbits were killed at 24 hours at which time bacterial colony counts of valvular vegetations were performed. Their studies of streptococcus viridans endocarditis demonstrated that vancomycin alone, or a combination of penicillin G and streptomycin were the most effective regimens. When a lower initial bacterial inoculum was used, erythromycin was shown to have some protective value, however primarily bacteriostatic drugs such as tetracycline, clindamycin, or erythromycin were generally ineffective.²³ Similar studies were performed in rabbits inoculated with enterococci.²⁴ Vancomycin alone and vancomycin or ampicillin plus streptomycin were all effective regimens. There was considerable variation in response depending on the strain of enterococcus; these variations were not always predicted by *in vitro* sensitivity tests.²⁵ The studies in the rabbit model provide important data for selecting an appropriate prophylactic regimen but with some appreciable limitations. The pharmacokinetics of antibiotics in the rabbit are different from those in man. Endocarditis is produced in the rabbit by leaving a foreign body, the catheter, across the cardiac valve. Finally a high inoculum of bacteria 10^7 colony forming units/ml is used compared to the 10^4 to 10^5 colony forming units/ml generally encountered in the bacteremia following dental procedures.^{26, 27} The high inoculum assures that a higher percentage of animals will be infected; however it provides a greater challenge for the prophylactic regimen, making some drugs such as erythromycin which are effective at a lower inoculum, appear inadequate. Therefore regimens shown to be effective using this experimental model probably provide a wide margin of safety. Nevertheless some have suggested that antibiotic dosages for prophylaxis should be the same as those used for treatment of endocarditis.¹⁷

Present recommendations for the prevention of bacterial endocarditis

Despite some uncertainty about effectiveness antibiotic prophylaxis for bacterial endocarditis is recommended in association with certain procedures. The morbidity and mortality of the disease outweighs concern for drug side effects and for the limited protection they may provide. Prophylactic regimens suggested for dental or oropharyngeal surgery are aimed especially against viridans streptococci while those suggested for genitourinary or gastrointestinal procedures are directed primarily against the enterococcus.^{1, 2}

There are several precautions that should be taken in individuals with underlying valvular disease. Patients should be informed of the potential risks of dental gastrointestinal or genitourinary procedures. Cardiac conditions which warrant prophylaxis are listed in Table III. Good dental care is particularly important in patients with valvular heart disease. The level of bacteremia is correlated with the extent of gum disease. Oral irrigation devices should generally be avoided in patients at high risk for endocarditis because of the increased incidence of bacteremia associated with their use.³ Patients scheduled for elective valvular replacement should have any necessary dental work performed prior to cardiac surgery since the risk of developing endocarditis in the immediate postoperative period is 2 to 4 per cent.⁷ When procedures are performed on the genitourinary or biliary systems the incidence of bacteremia is reduced when the urine or bile are sterile.⁸ If tracheal intubation is required the orotracheal approach causes less bacteremia than the nasotracheal approach.⁹

The antibiotic regimens listed in Table IV are based on the recently published recommendations of the American Heart Association¹ and *The Medical Letter on Drugs and Therapeutics*.² Antibiotics given parenterally are probably more effective than those given by mouth. The recommendations represent an attempt to accommodate the practical problem created by giving parenteral therapy for outpatient procedures with the need for sustained antibiotic activity. The parenteral regimen using intramuscular penicillin G plus procaine penicillin is probably adequate for most cardiac patients undergoing dental procedures. However patients taking oral penicillin prophylaxis for rheumatic fever have a

higher incidence of relatively penicillin resistant streptococci in their oropharynx so that coverage with vancomycin or penicillin plus streptomycin is advised. In addition the latter regimens are recommended for patients with prosthetic valves. Antibiotic coverage is recommended for surgery on abscesses or infected foci and for debridement of burned tissue. The antibiotic regimen in such instances should take account of the organisms (i.e. *S. aureus*) likely to be associated with bacteremia and endocarditis.¹²

Prophylaxis in cardiac surgery

Antibiotic prophylaxis is often recommended in cardiac surgery even though large carefully controlled studies of the effectiveness of such regimens are not available. Antibiotic coverage has been suggested because of the high mortality associated with early prosthetic valve endocarditis.^{1, 3} The incidence of valvular infections is relatively low so that a large number of patients would have to be included in any study evaluating the potential benefit of prophylactic antibiotics.

The incidence of prosthetic valve endocarditis rises in patients requiring prolonged surgery and cardiopulmonary bypass.¹⁴ Although the organisms accounting for these infections vary in different institutions the most frequently isolated pathogens are *S. epidermidis*, *S. aureus*, diptheroid fungi (especially *Aspergillus* and *Candida* sp.) and Gram negative rods.^{1, 15} The patient's skin, the operating room air and the cardiopulmonary bypass machines have been identified as possible intraoperative sources of infection while intravenous and urinary catheters remain the major postoperative portals of entry for bacteremia.^{1, 16}

Two recently reported studies have compared regimens using antibiotic prophylaxis continued for 1 to 2 days versus 5 to 6 days following cardiac surgery and found no significant differences in the incidence of serious infection between the two groups.^{17, 18} One study noted more infections caused by resistant organisms with the longer regimen.¹⁸ The increase in early prosthetic valve infections caused by Gram negative organisms and methicillin resistant *S. epidermidis* noted recently may be a consequence of the selective pressure provided by prophylactic therapy.¹⁹

Antibiotic coverage is unnecessary for pace

maker insertions, closed heart surgery, and cardiac catheterization^{36 56 60} It is suggested for open heart surgery when cardiopulmonary bypass is necessary Although a penicillinase resistant semisynthetic penicillin or a cephalosporin given parenterally for 48 hours is recommended, differing local patterns of antibiotic sensitivity may warrant additional or different antibiotic coverage⁵²

REFERENCES

- Garvey G J and Neu H C Infective endocarditis—an evolving disease *Medicine* 57 105 1978
- Pelletier L L Jr and Petersdorf R G Infective endocarditis a review of 125 cases from the University of Washington Hospitals 1963 72 *Medicine* 56 287 1977
- Kaye D Cure rates and long term prognosis in Infective Endocarditis D Kaye ed Baltimore 1976 University Park Press p 201
- Weinstein L and Schlesinger J J Pathoanatomic pathophysiologic and clinical correlations in endocarditis *N Engl J Med* 291 832 1122 1974
- Hook E W and Kaye D Prophylaxis of bacterial endocarditis *J Chronic Dis* 15 635 1962
- Matsen J M and Coghlan C R Antibiotic testing and susceptibility patterns of streptococci in Streptococci and Streptococcal Diseases Recognition understanding and management L W Wannamaker J M Matsen eds New York 1972 Academic Press p 189
- Sipes J N Thompson R L and Hook E W Prophylaxis of infective endocarditis a reevaluation *Ann Rev Med* 28 371 1977
- Pelletier L L Jr Durack D T and Petersdorf R G Chemotherapy of experimental streptococcal endocarditis IV Further observations on prophylaxis *J Clin Invest* 56 319 1975
- Durack D T and Petersdorf R G Chemotherapy of experimental streptococcal endocarditis I Comparison of commonly recommended prophylactic regimens *J Clin Invest* 52 592 1973
- Durack D T Starkebaum M K and Petersdorf R G Chemotherapy of experimental streptococcal endocarditis VI Prevention of enterococcal endocarditis *J Lab Clin Med* 90 171 1977
- Denny F W Wannamaker L W Brink W R Rammelkamp C H Jr and Custer E A Prevention of rheumatic fever treatment of the preceding streptococcal infection *JAMA* 143 151 1950
- Catanzaro F J Rammelkamp C H and Chamovitz E Prevention of rheumatic fever by treatment of streptococcal infections II Factor responsible for failures *N Engl J Med* 259 51 1958
- Rammelkamp C H Hemolytic streptococcal infections in Principles of Internal Medicine G W Thorn H D Adams E Braunwald K J Isselbacher and R G Petersdorf eds New York 1977 McGraw Hill Company Inc p 819
- American Heart Association Committee on Prevention of Rheumatic Fever Prevention of rheumatic fever *Circulation* 55 1 1977
- Lewis T and Grant R T Observations relating to subacute infective endocarditis *Heart* 10 21 1923
- Lerner P I and Weinstein L Infective endocarditis in the antibiotic era *N Engl J Med* 274 199 259 323 388 1966
- Kaye D Prophylaxis of endocarditis in Infective endocarditis D Kaye ed Baltimore 1976 University Park Press p 245
- Okell C C and Elliott S D Bacteremia and oral sepsis with special reference to the etiology of subacute endocarditis *Lancet* 2 869 1935
- McEntegart M G and Porterfield J S Bacteremia following dental extractions *Lancet* 2 596 1949
- Crawford J J Sconyers J R Moriarty J D King R C and West J F Bacteremia after tooth extraction studied with the aid of pre-reduced anaerobically sterilized culture media *Appl Microbiol* 27 977 1974
- DeLeo A A Schoenkecht F D Anderson M W and Peterson J C The incidence of bacteremia following oral prophylaxis on pediatric patients *Oral Surg* 37 36 1974
- Hurwitz G A Speck W T and Keller G B Absence of bacteremia in children after prophylaxis *Oral Surg* 32 891 1971
- Sconyers J R Crawford J J and Moriarty J B Relationship of bacteremia to toothbrushing in patients with periodontitis *J Am Dent Assoc* 87 616 1974
- Berger S A Weitzman S Edberg S C and Casey J I Bacteremia after the use of an oral irrigation device *Ann Intern Med* 80 510 1974
- Berry F A Blankenbaker W L and Ball C G A comparison of bacteremia occurring with nasotracheal and orotracheal intubation *Anaesth Analg (Cleveland)* 52 873 1973
- Shull H J Jr Greene E M Allen S D Dunn G D and Schenker S Bacteremia with upper gastrointestinal endoscopy *Ann Intern Med* 83 212 1975
- LeFrock J L Ellis C A Turchik J B and Weinstein L Transient bacteremia associated with sigmoidoscopy *N Engl J Med* 289 467 1973
- LeFrock J L Ellis C A Klammer A S and Weinstein L Transient bacteremia associated with barium enema *Arch Intern Med* 135 835 1975
- LeFrock J L Ellis C A Turchik J B Zawacki J A and Weinstein L Transient bacteremia associated with percutaneous liver biopsy *J Infect Dis* 131(Suppl) S104 1975
- Bjorn C L Browning W H and Thompson L Transient bacteremia immediately following transurethral prostatic resection *J Urol* 63 155 1950
- Creedy C D and Feeney M J Routine use of antibiotics in transurethral prostatic resection a clinical investigation *J Urol* 71 615 1954
- Blade N Bacteremia and septicemia after urological operations *Proc R Soc Med* 51 331 1958
- Sullivan N M Sutter V L Mims M M Marsh V H and Finegold S M Clinical aspects of bacteremia after manipulation of the genitourinary tract *J Infect Dis* 127 49 1973
- McCormack W M Rosner M Lee Y H Rankin J S and Lin J S Isolation of genital mycoplasmas from blood obtained shortly after vaginal delivery *Lancet* 1 596 1975
- Everett E D Reller L B Droegemueller W and Greer B E Absence of bacteremia after insertion or removal of intrauterine devices *Obstet Gynecol* 47 207 1976
- Sande M A Levinson M E Luksa D S and Kaye D Bacteremia associated with cardiac catheterization *N Engl J Med* 281 1104 1969
- Richards J H Bacteremia following irritation of foci of infection *JAMA* 99 1496 1932
- Cobe H M Transitory bacteremia *Oral Surg* 7 609 1954

- 1 Weinstein L. Chemoprophylaxis for bacterial endocarditis (Letter) *N Engl J Med* 292 477 1975
- 2 Gould K., Ramirez Ronda C H Holmes R K. and Sanford J W Adherence of bacteria to heart valves in vitro *J Clin Invest* 56 1364 1975
- 3 Gibbons R J Ecology and carcinogenic potential of oral streptococci, in *Streptococci and Streptococcal Diseases* Recognition understanding and management L. W Wannamaker J M Matsen eds New York 1972, Academic Press p 371
- 4 Hilson, G R F Is chemoprophylaxis necessary? *Proc R Soc Med* 53 267 1970
- 5 Harvey W P and Capone M A Bacterial endocarditis related to cleaning and filling of teeth, *Am. J Cardiol* 7 793 1961
- 6 Weinstein L. and Ruben R H Infective endocarditis—1973 *Progr Cardiovasc Dis* 16 239 1973
- 7 Durack, D T., and Littler W A Failure of adequate penicillin therapy to prevent bacterial endocarditis after tooth extraction (Letter) *Lancet* 2 846 1974
- 8 Taran L M Rheumatic fever in its relation to dental disease *N Y J Dent* 14 107 1944
- 9 Schwartz S P and Salzman I The effects of oral surgery on the course of patients with diseases of the heart *Am J Orthod* 33 331 1942
- 10 Rudolph, A H and Price E V Penicillin reactions among patients in venereal disease clinics. *JAMA* 223 499 1973
- 11 Brown W J Simpson W G and Price E V Reevaluation of reactions to penicillin in venereal disease clinic patients, *Public Health Rep* 76 189 1961
- 12 Carson W K and Freedman L R Experimental endocarditis in rabbits resulting from placement of a polyethylene catheter in the right side of the heart *Yale J Biol Med* 42 394 1970
- 13 Durack, D T and Beeson P H Experimental bacterial endocarditis I Colonization of a sterile vegetation *Br J Exp Pathol* 53 44 1972
- 14 American Heart Association Committee on Prevention of Rheumatic Fever and Bacterial Endocarditis Prevention of bacterial endocarditis *Circulation* 56 1394 1977
- 15 Antimicrobial prophylaxis Prevention of wound infection and sepsis after surgery *Med Lett Drugs Ther* 19 37 1977
- 16 Weinstein L. and Schlesinger J Treatment of infective endocarditis—1973 *Progr Cardiovasc Dis* 16 275 1973
- 17 Wilson W H Prosthetic valve endocarditis anatomic location cause morbidity and mortality in *Infections of Prosthetic Heart Valves and Vascular Grafts*, R J Duma ed Baltimore 1977 University Park Press p 3
- 18 Finland M Current problems in infective endocarditis *Mod Concepts Cardiovasc Dis* 41 53 1972
- 19 Conte J E, Cohen S N, Roe D H and Elashoff R M Antibiotic prophylaxis and cardiac surgery *Ann Intern Med* 76 943 19 2
- 20 Goldman D A Hopkins C C Karchmer A W, Abel H M., McEnany T., Akers C, Buckley M J and Moellenberg R C, Jr Cephalothin prophylaxis in cardiac valve surgery *J Thorac Cardiovasc Surg* 73 470 1977
- 21 Johnson W D Prosthetic valve endocarditis in *Infective Endocarditis*, D Kaye ed Baltimore 1976 University Park Press p 149
- 22 Patton R, D Kenamore B and Stein W Antibiotic prophylaxis for temporary transvenous pacemakers *N Engl J Med* 281 1106 1969

Conflicts in coronary care

There appears to be no agreement as to what constitutes proper care of a patient with acute myocardial infarction. Styles of coronary care vary from the hands off peace and quiet approach advocated by Burch and associates^{1,2} to the active measure all approach of Forrester and colleagues³ and others in specialized research units. Some claim that specialized coronary care in hospital confers no advantage over management in a general hospital ward.⁴ Some suggest that many patients can best be managed at home from an early stage. The matter is confused by quoted mortality rates for the acute event which range from under 10 per cent to over 40 per cent—and the fact that some of the lowest quoted rates are from patients treated at home or in general medical wards and some of the highest rates are from specialized coronary care wards.⁵ Indeed two oft quoted articles describing advances in coronary care showed mortality rates of 26 per cent⁶ and 34 per cent.⁷ The sceptic is entitled to ask if these are really advances at all—or alternatively are some advantages cancelled by disadvantages and hazards of other therapeutic or monitoring procedures?

Despite the queries the consensus appears to be that coronary care in principle is a good thing and merits wide spread implementation. Most observers would explain the differences in quoted results as being due to differences in selection of patients or in classification of myocardial infarction. The biggest question appears to be—what type of coronary care can give greatest benefit at reasonable cost?

The coronary care we have been able to provide at this hospital appears to achieve a happy compromise between comfort efficacy and cost. The coronary care ward has 30 beds and is divided into an acute six bed area and a 24 bed subacute area. Electrocardiographic monitoring is provided for all beds in the acute area and 12 beds in the subacute area. Patients are admitted to the acute section of the ward and proceed thence in the same bed to the subacute section whence they are discharged home usually after 10 to 21 days. In the acute section patients have the privacy of a single room furnished with carpet drapes and a mural to resemble as much as possible a home or hotel room. After transfer patients are monitored with ECG for several days usually in a six bed ward where they see others disconnected from the ECG and view this when their turn comes as a sign of progress. This arrangement appears to provide the proper measure of comfort and confidence at the right time and gauged by the rough and ready measure of gift boxes of chocolate per week has achieved better acceptance than management in any other part of the hospital.

Total nursing complement of the ward is 35 nurses (18 trained and 17 trainee) nursing staff rotate through the whole ward and have the professional and personal satisfaction of being able to follow patients to discharge. There are two medical officers and one technician in the acute section of the ward. Staffing of the whole ward is only somewhat higher than other wards of the hospital while average bed occupancy

at 85 per cent is only marginally lower. In this ward and without altering staff arrangements we have been able to introduce various advances including hemodynamic monitoring (some 300 patients so managed over 5 years) and arterial counterpulsation⁸ (112 patients treated over 5 years). Mortality rate for all patients with infarction admitted direct over a recent 23 year period was 9.8 per cent while for all such patients under 65 mortality rate was 5.7 per cent.⁹

Our experience leads us to believe quite firmly that specialized coronary care is most desirable and that it is possible to provide this at a high level with good results at reasonable cost and with high patient comfort. Above all we believe that comfort cost and efficacy need not be in conflict.

Michael F O'Rourke
School of Medicine
University of New South Wales
St Vincent's Hospital
Sydney 2010
Australia

REFERENCES

- 1 Burch G E and Giles T D. A study of the effectiveness of the coronary care unit. *South Med J* 64 436 1971.
- 2 Burch G E, Oei H K and Dillenkofter R L. Survival in a coronary care unit. *South Med J* 68 947 1975.
- 3 Forrester J S, Diamond G, Chatterjee K and Swan H J C. Medical therapy of acute myocardial infarction by application of hemodynamic subset. *N Engl J Med* 295 1356 1977.
- 4 Astvad K, Fabricius Bjerre N, Kjaerulf J and Lindholm J. Mortality from acute myocardial infarction before and after establishment of a coronary care unit. *Br Med J* 1 567 1974.
- 5 Mather H G, Morgan D C and Pearson N G. Myocardial infarction: a comparison between home and hospital care for patients. *Br Med J* 1 925 1976.
- 6 Burch G E. Of home cardiac care. *AM HEART J* 93 126 1977.
- 7 Colling A, Delipiani A W, Donaldson H J and McCormack P. Teeside coronary survey: an epidemiological study of acute attacks of myocardial infarction. *Br Med J* 2 1169 1976.
- 8 Shell W E and Sobel B E. Protection of jeopardized ischemic myocardium by reduction of ventricular after load. *N Engl J Med* 291 481 1974.
- 9 O'Rourke M F, Walsh H, Fletcher M and Crowley A. Impact of the new generation coronary care unit. *Br Med J* 2 837 1976.
- 10 O'Rourke M F, Chang V P, Windsor H M, Shanahan M X, Hickie J H, Morgan J J, Gunning J F, Seldon W A, Hall G V, Mitchell G, Goldfarb D and Harrison D G. Acute severe heart failure complicating myocardial infarction: experience with 100 patients referred for consideration of mechanical left ventricular assistance. *Br Heart J* 37 169 1975.

possible and second the renal vein renin tests were performed in the supine position and after administration of oral furosemide (1 mg/Kg body weight) on the afternoon before the test. Such slight stimulation of the renal vein renin ratios may have been inadequate to demonstrate overproduction of renin by the involved kidney. Thus although there is some evidence to support the existence of such a syndrome in various animal models¹ its existence in man still remains to be conclusively proven.

EP MacCarthy MRCPI
GS Stokes, MD
Cardio Renal Unit
Kanematsu Memorial Institute
Sydney Hospital
Sydney NSW 2000
Australia

REFERENCES

- 1 Bourgoignie J, Kurz S, Catanzaro F J, Sernat P and Perry H M. Renal venous renin in hypertension. *Am J Med* 48 332 1970.
- 2 Marks L S and Maxwell M H. Renal vein renin: Value and limitations in the prediction of operative results. *Urol Clin North Am* 2 311 1975.
- 3 Stokes G S, Weber M A, Gain J, Scott A J

- Roberts P A and Sheil A G R. Diazoxide-induced renin release in diagnosis of remediable renovascular hypertension. *Aust NZ J Med* 6 96 1976.
- 4 Maxwell M H, Bleifer A H, Franklin S S and Varady P D. Co-operative study of renovascular hypertension. Demographic analysis of the study. *JAMA* 220 1195 1972.
- 5 Streeter D H P, Anderson G H and Dalakas T G. Angiotensin blockade: Its clinical significance. *Am J Med* 60 817 1976.
- 6 Keenan R E. Test for role of angiotensin in hypertension. *N Engl J Med* 291 258 1974.
- 7 Thomas R D, Ball S G and Lee M R. Failure of saralasin to predict a response to surgery in renovascular hypertension. *Lancet* 1 724 1977.
- 8 Streeter D H P, Anderson G H, Freiberg J M and Dalakas T G. Use of angiotensin II antagonist (Saralasin) in the recognition of "angiotensinogenic hypertension". *N Engl J Med* 292 657 1975.
- 9 Marks L S, Maxwell M H and Kaufman J J. Non renin mediated renovascular hypertension. A new syndrome? *Lancet* 1 615 1977.
- 10 MacCarthy P and Stokes G. Non renin mediated renovascular hypertension. *Lancet* 1 1312 1977.
- 11 Davis, J O. The pathogenesis of chronic renovascular hypertension. *Circ Res* 40 439 1977.

Towards more selective resuscitation

The reviving of the apparently dead has long been a popular subject in the public imagination particularly since the development of closed chest massage and external defibrillation. Physicians must be prepared to analyze the results in order to avoid being carried away by the excessive enthusiasm generated by even an occasional success. It is essential for due regard to be given to the most efficient employment of resources and to the suffering inflicted on the relatives of patients when prolonged attempts at resuscitation are made in the face of an inevitably hopeless outcome.

Resuscitation is more likely to be successful in coronary and intensive care units¹ and there is no doubt that in such circumstances a very energetic policy must be pursued. In the more general areas of the hospital however the position is less clear. A ten year survey of the results of resuscitation in such areas has recently been carried out at the Central Middlesex Hospital in London.² The cases studied were those treated by the hospital's cardiac arrest service excluding patients in the coronary care and intensive therapy units. Successful resuscitation was defined as survival of the patient to be discharged alive from hospital. In the ten year period there were 93 survivors out of 1 063 cardiac arrest cases. The 80 patients from the first nine years of the survey were followed up for at least one year and information was collected about their subsequent health. An actuarial life table showed an annual mortality rate of 7 per cent in the survivors a figure similar to that following uncomplicated myocardial infarction. Assessment was made of their physical condition and only four of the 80 subjects showed significant deterioration of their health or working capacity due to the arrest and all these four died

within 30 months of it. In the remaining survivors the good quality of life was impressive.

The most significant factor influencing the outcome is the primary diagnosis. The success rate ranges from 22 per cent in drug overdose cases to 20 per cent in surgical cases and 15 per cent in myocardial infarction cases. In contrast following severe generalized trauma or advanced neurological disease the success rate was less than 2 per cent. Patients whose arrest complicated such conditions as cardiac failure, pulmonary embolism or respiratory failure fell into an intermediate group of between 4 per cent and 8 per cent. There were no long term survivors after cardiac arrest as a complication of head injury or subarachnoid hemorrhage.

Thirty six per cent of the arrests occurred in the Accident and Emergency Department, 58 per cent were in the wards of the hospital and most of the remainder in the operating theatres. The overall success rate was highest in the Emergency Department but this was due entirely to the large number of cases of myocardial infarction who suffered cardiac arrest there. Of the 93 survivors of the whole series 54 had arrested due to myocardial infarction in the Emergency Department.

The majority of the patients included in this series were aged between 50 and 70 years. Because of the concentration of the more favorable diagnostic categories in this age group the success rate was highest in these two decades. In earlier decades respiratory, traumatic and neurological causes were predominant with fewer survivors. The numbers of cases of myocardial infarction in the Emergency Department were sufficiently large to show that age was without influence on

the survival rate in that particular category. Attempts at resuscitation were made in 216 patients over the age of 70 with a long term survival rate of 4.7 per cent.

Although the overall success rate in this large series was low, the subsequent general condition and life expectancy of the survivors was good. The findings suggest that greater emphasis must be placed on the circumstances of each arrest. Clearly the primary diagnosis is paramount and rather less attention should be paid to location or in particular to the age of the patient. The best service must be provided in the Emergency Department and a policy of energetic resuscitation should be mandatory there. In other parts of the hospital, and especially in certain diagnostic categories, the results of resuscitation are so poor that a much more selective approach would appear to be indicated.

*Richard Peatfield M.A. M.R.C.P.
Cardiothoracic Department
Central Middlesex Hospital
London N.W.10
England*

REFERENCES

- 1 Coskey R. L. A resuscitation program in a community hospital—five year experience. *Geriatrics* 26:66 1971.
- 2 Peatfield, R. C., Sillett R. W., Taylor D., and McNicol M. W. Survival after cardiac arrest in hospital, *Lancet* 1:1223 1977.
- 3 Beard, G. W., Hipp H. R., Robins M. and Verzelina, V. R. Initial myocardial infarction among veterans: Ten year survival. *AM HEART J* 73:317 1967.
- 4 Wildsmith J. A. W., Dennyson W. G. and Myers K. W. Results of resuscitation following cardiac arrest: A review from a major teaching hospital, *Br J Anaesth* 44:716 1972.

possible and second the renal vein renin tests were performed in the supine position and after administration of oral furosemide (1 mg/Kg body weight) on the afternoon before the test. Such slight stimulation of the renal vein renin ratios may have been inadequate to demonstrate overproduction of renin by the involved kidney. Thus although there is some evidence to support the existence of such a syndrome in various animal models⁴ its existence in man still remains to be conclusively proven.

EP McCarthy MRCPI
GS Stokes MD
Cardio Renal Unit
Kanematsu Memorial Institute
Sydney Hospital
Sydney NSW 2000
Australia

REFERENCES

- 1 Bourgoignie J, Kurz S, Catanzaro F J, Serfat P, and Perry H M. Renal venous renin in hypertension. *Am J Med* 48 332 1970
- 2 Marks L S and Maxwell M H. Renal vein renin: Value and limitations in the prediction of operative results. *Urol Clin North Am* 2 311 1975
- 3 Stokes G E, Weber M A, Gam J, Scott A J,

- Roberts J A and Sheil A G R. Diazoxide induced renin release in diagnosis of remediable renovascular hypertension. *Aust NZ J Med* 6 26 1976
- 4 Maxwell M H, Bleifer K H, Franklin S S and Varady P D. Co operative study of renovascular hypertension. Demographic analysis of the study. *JAMA* 220 1195 1972
- 5 Streeten D H P, Anderson G H and Dalakas T G. Angiotensin blockade: Its clinical significance. *Am J Med* 60 817 1976
- 6 Keenan R E. Test for role of angiotensin in hypertension. *N Engl J Med* 291 258 1974
- 7 Thomas R D, Ball S G and Lee M H. Failure of saralasin to predict a response to surgery in renovascular hypertension. *Lancet* 1 724 1977
- 8 Streeten D H P, Anderson G H, Freiberg J M and Dalakas T G. Use of angiotensin II antagonist (Saralasin) in the recognition of angiotensinogenic hypertension. *N Engl J Med* 292 657 1975
- 9 Marks L S, Maxwell M H and Kaufman J J. Non renin mediated renovascular hypertension. A new syndrome? *Lancet* 1 615 1977
- 10 McCarthy P and Stokes G. Non renin mediated renovascular hypertension. *Lancet* 1 1312 1977
- 11 Davis J O. The pathogenesis of chronic renovascular hypertension. *Circ Res* 40 439 1977

Towards more selective resuscitation

The reviving of the apparently dead has long been a popular subject in the public imagination particularly since the development of closed chest massage and external defibrillation. Physicians must be prepared to analyze the results in order to avoid being carried away by the excessive enthusiasm generated by even an occasional success. It is essential for due regard to be given to the most efficient employment of resources and to the suffering inflicted on the relatives of patients when prolonged attempts at resuscitation are made in the face of an inevitably hopeless outcome.

Resuscitation is more likely to be successful in coronary and intensive care units and there is no doubt that in such circumstances a very energetic policy must be pursued. In the more general areas of the hospital however the position is less clear. A ten year survey of the results of resuscitation in such areas has recently been carried out at the Central Middlesex Hospital in London.¹ The cases studied were those treated by the hospital's cardiac arrest service excluding patients in the coronary care and intensive therapy units. Successful resuscitation was defined as survival of the patient to be discharged alive from hospital. In the ten year period there were 93 survivors out of 1 063 cardiac arrest cases. The 80 patients from the first nine years of the survey were followed up for at least one year and information was collected about their subsequent health. An actuarial life table showed an annual mortality rate of 7 per cent in the survivors, a figure similar to that following uncomplicated myocardial infarction.² Assessment was made of their physical condition and only four of the 80 subjects showed significant deterioration of their health or working capacity due to the arrest and all these four died

within 30 months of it. In the remaining survivors the good quality of life was impressive.

The most significant factor influencing the outcome is the primary diagnosis. The success rate ranges from 22 per cent in drug overdose cases to 20 per cent in surgical cases and 15 per cent in myocardial infarction cases. In contrast following severe generalized trauma or advanced neurological disease the success rate was less than 2 per cent. Patients whose arrest complicated such conditions as cardiac failure, pulmonary embolism or respiratory failure fell into an intermediate group of between 4 per cent and 8 per cent. There were no long term survivors after cardiac arrest as a complication of head injury or subarachnoid hemorrhage.

Thirty six per cent of the arrests occurred in the Accident and Emergency Department; 58 per cent were in the wards of the hospital and most of the remainder in the operating theatres. The overall success rate was highest in the Emergency Department but this was due entirely to the large number of cases of myocardial infarction who suffered cardiac arrest there. Of the 93 survivors of the whole series 54 had arrested due to myocardial infarction in the Emergency department.

The majority of the patients included in this series were aged between 50 and 70 years. Because of the concentration of the more favorable diagnostic categories in this age group the success rate was highest in these two decades. In earlier decades respiratory, traumatic and neurological causes were predominant with fewer survivors. The numbers in cases of myocardial infarction in the Emergency Department were sufficiently large to show that age was without influence on

Table 1 Hemodynamic findings (mean \pm SD and range) before and after hyaluronidase intravenous bolus

	-30 min	-15 min	0	15 min	30 min	60 min
HR bt./min	88.6 \pm 11.4 (66-105)	86.5 \pm 9.3 (67-105)	87.3 \pm 11.9 (67-108)	87.3 \pm 10.4 (68-102)	88.4 \pm 10.1 (66-104)	88.0 \pm 13.6 (62-112)
BP mm. Hg	106.5 \pm 18.9 (75-134)	104.8 \pm 14.7 (76-130)	106.2 \pm 22.5 (74-136)	101.0 \pm 16.7 (73-124)	103.0 \pm 18.0 (72-129)	104.7 \pm 14.3 (85-128)
RAP mm. Hg	7.2 \pm 5.9 (2-19)	7.5 \pm 6.3 (2-19)	7.6 \pm 6.1 (2-19)	7.7 \pm 6.1 (2-19)	8.0 \pm 6.4 (2-20)	8.6 \pm 6.7 (2-19)
PAedP mm. Hg	18.1 \pm 3.2 (13-22)	19.2 \pm 3.5 (12-2)	18.4 \pm 3.1 (12-22)	18.7 \pm 2.9 (13-22)	19.1 \pm 3.3 (14-23)	18.7 \pm 2.5 (15-22)
CI L./min./M	2.6 \pm 0.4 (2.1-3.5)	2.7 \pm 0.6 (2.0-3.6)	2.7 \pm 0.6 (2.0-3.4)	2.8 \pm 0.5 (2.2-3.4)	2.6 \pm 0.4 (2.2-3.7)	2.6 \pm 0.5 (2.1-3.5)

cited some aspects of the drug's mechanism of action on the damaged area.

To acquire further information in this regard and to evaluate eventual undesirable hemodynamic effects we recorded hemodynamic data in eight patients after hyaluronidase administration in the course of a multicenter study on the effects of the drug on the electrocardiographic signs of necrosis in patients with acute myocardial infarction. Pulmonary arterial pressure (PAP), systemic pressure (BP), and right atrial pressure (RAP) were recorded continuously using an XM 5101 Philips apparatus with Statham P23 transducers for 30 minutes preceding the administration of the drug and for 60 minutes afterwards. Cardiac output was assessed by the thermodilution method at -30 minutes, -15 minutes, 0, +15 minutes, +30 minutes and +60 minutes with respect to administration. The hyaluronidase 500 U/hg was injected as an intravenous bolus within 8 hours from symptom onset. In five patients the catheters were left in place and the hemodynamic evaluation was repeated 6 hours later after a second dose administered in an identical fashion. Therefore the hemodynamic effects of hyaluronidase were observed after a total of 13 doses. Six patients had a pulmonary artery end-diastolic pressure (PAedP) $>$ 18 mm Hg, a value that we consider critical in identifying patients with definite left ventricular dysfunction. Three patients had a RAP $>$ 10 mm Hg and three a cardiac index (CI) $<$ 2.5 L./min./M. Two patients showed clinical signs of heart failure.

The data obtained are presented in Table 1. Only minimal changes, none of statistical significance, were observed in the hemodynamic parameters. Thus it can be concluded that the action of hyaluronidase in limiting the development of necrosis is not attributable to hemodynamic modifications involving the cardiovascular system in its entirety. The innocuousness of the drug from a hemodynamic point of view demonstrated also in patients with heart failure is important since it renders possible administration to the patients with acute myocardial infarction regardless of their hemodynamic status.

Maria Ray M.D.
Luigi Tala M.D.
Jorge A. Salerno M.D.
Piero Bobba M.D.

Division of Cardiology—S. Matteo Hospital
University of Pavia
27100 Pavia, Italy

REFERENCES

- Maroko P R, Libby P, Bloor C M, Sobel B E, and Braunwald E. Reduction by hyaluronidase of myocardial necrosis following coronary artery occlusion. *Circulation* 46:430-1972.
- Hillis L D, Askenazi J, Braunwald E, Radvany P, Muller J E, Fishbein M C, and Maroko P R. Use of changes in the epicardial QRS complex to assess interventions which modify the extent of myocardial necrosis following coronary artery occlusion. *Circulation* 54:592-1976.
- Maclean D, Fishbein M C, Maroko P R, and Braunwald E. Hyaluronidase induced reductions in myocardial infarct size. *Science* 194:199-1976.
- Maroko P R, Davidson D M, Libby P, Hagan A D, and Braunwald E. Effects of hyaluronidase administration in myocardial ischemic injury in acute infarction: a preliminary study in 24 patients. *Ann Intern Med* 82:516-1975.
- Maroko P R, Hillis L D, Muller J E, Tavazzi L, Hevndrick G R, Ray M, Chianello M, Distante A, Askenazi J, Salerno J A, Carpentier J, Reshetnyaya N I, Radvany P, Libby P, Raabe D S, Chazov E I, Bobba P, and Braunwald E. Favorable effects of hyaluronidase on electrocardiographic evidence of necrosis in patients with acute myocardial infarction. *N Engl J Med* 296:838-1977.
- Kloner R A, Fishbein M C, Maclean D, Braunwald E, and Maroko P R. Effects of hyaluronidase during the early phase of acute myocardial ischemia: an ultrastructural and morphometric analysis. *Am J Cardiol* 40:44-1977.
- Askenazi J, Hillis L D, Diaz P E, Davis M A, Braunwald E, and Maroko P R. The effect of hyaluronidase on coronary blood flow following coronary artery occlusion in the dog. *Circ Res* 40:566-1977.
- Tavazzi L, Ray M, Salerno J A, Chianello M, and Bobba P. Aspetti emodinamici e terapeutici dell'infarto miocardico acuto. Parte I. Classificazione emodinamica. *G Ital Cardiol* 7:1143-1977.

Testing antianginal therapy in favor of current practice

To the Editor

Requirements for testing efficacy of antianginal treatment include documentation of disease in patients with frequent episodes of anginal pain (severe, stable disease), pain nitro

Neurologic-cardiologic interrelationships

To the Editor

Considering the many recent articles pointing out the connections between the neurologic and cardiovascular systems, it seems as though we might need to start a new specialty of cardio neurology or neuro cardiology. I am sure there would be a fight for top billing.

This interrelationship might be the basis for many at present puzzling phenomena. For example, it has seemed quite possible to me that the sudden infant death syndrome could be a cardiac arrhythmic or apneic event secondary to a minor seizure disorder discharging through the autonomic nervous system.

In support of this I have only personally investigated two cases of sudden infant death syndrome and there was a positive family history of seizures in both cases in the mother in one and in the sister in the other.

Certainly even two swallows do not make a summer. It does seem worth investigation, however.

Brooks A. Mick MD
521 West Sandusky St
Findlay Ohio 45840

REFERENCES

1. Vaisrub B. Brain and heart—The autonomic connection. *JAMA* 234:959, 1975.
2. Hirsch C S and Martin D L. Unexpected death in young epileptics. *Neurology* 21:682, 1971.

Nitroprusside reversal of ergotamine induced ischemia

To the Editor

We would like to report briefly a severe adverse reaction to ergotamine and an equally dramatic reversal with nitroprusside administration.

A 55 year old woman was being treated by her family physician for migraine headaches, anxiety, and a possible gastric ulcer. She was prescribed Cafergot suppositories (ergotamine 2 mg and caffeine 100 mg) over a period of 7 days prior to this admission. She received one suppository daily.

She was referred for further evaluation because of a rather sudden onset of pain in both feet which had persisted during the past 48 hours prior to admission. The major physical findings revealed (1) the legs were warm (2) the ankles and feet were cool, dry and cyanotic and (3) the posterior tibial pulses were faint and the dorsalis pedis pulses were absent. Due to the absent pulses and striking ischemia, a percutaneous aortogram was performed and revealed smooth but small arteries distal to the bifurcation of the aorta. There was narrowing of the superficial femoral artery as it entered Hunter's canal. For the patient's size the arteries were definitely considered diminutive.

The diagnosis of ergotism was made and treatment was initiated with an intravenous infusion of low molecular weight dextran 15 cc/minute, heparin 5000 units intravenously every 4 hours and ganglionic blockade by an extra dural

anesthetic. Despite these measures her legs continued to be quite painful and cyanotic and the skin became purple in appearance over the toes and on the bottom of her feet in a fashion characteristic of severe ischemia.

After approximately 12 hours and a fear of gangrenous changes in both feet, it was decided to try an intrarterial infusion of sodium nitroprusside (Nipride). The solution was prepared by adding 50 mg of nitroprusside in 250 cc D₅W and it was infused in each femoral artery through an intra-arterial catheter at a rate of 30 drops/minute. Over a period of approximately 10 minutes there was a dramatic and incredible improvement in the color of her feet and both dorsalis pedis pulses became palpable. The infusion was gradually discontinued over the next 12 hours with relief of pain and continued findings of adequate perfusion.

The syndrome of vascular insufficiency secondary to ergotamine has been known to produce gangrene requiring amputation¹ and in the current case it was being considered as a distinct possibility. Intravenous nitroprusside has been previously reported to reverse ergotamine induced ischemia of all four extremities.² Our rationale for infusing nitroprusside intrarterially was based on a presumption that smaller doses would be required and hypotension avoided. It is possible that an intravenous infusion would have been equally safe and efficacious, however, it could not have been more gratifying.

Thomas I. Whitsett MD

Dept. of Medicine

University of Oklahoma College of Medicine

P.O. Box 76501

Oklahoma City, Okla. 73190

William S. Myers MD

Cardiovascular Bldg

3300 Northwest 58th St

James M. Hartsuck MD

3400 Northwest Expressway

Oklahoma City, Okla.

REFERENCES

1. Cameron E A and French E H. St. Anthony's fire rekindled: Gangrene due to therapeutic dose of ergotamine. *Br Med J* 2:28, 1960.
2. Carline N H, Denune D P, Finch C S et al. Sodium nitroprusside treatment of ergotamine induced peripheral ischemia. *JAMA* 227:308, 1974.

Evaluation of the hemodynamic effects of hyaluronidase in patients with acute myocardial infarction

To the Editor

The beneficial effect of hyaluronidase in reducing the electrocardiographic signs of ischemic damage in the initial phase of acute myocardial infarction and in limiting the subsequent development of necrosis have recently been shown both in experimental animals¹ and in man with acute myocardial infarction.² Experimental studies³ have indi-

Table 1 Hemodynamic findings (mean \pm SD and range) before and after hyaluronidase intravenous bolus

	-30 min.	-15 min	0	15 min.	30 min	60 min.
HR bt./min.	88.6 \pm 11.4 (66-105)	86.5 \pm 9.3 (6 ^o 105)	87.3 \pm 11.9 (67 108)	87.3 \pm 10.4 (68 107)	88.4 \pm 10.1 (66-104)	88.0 \pm 13.6 (6 ^o 117)
BP mm. Hg	106.5 \pm 18.9 (75 134)	104.8 \pm 14.7 (76 130)	106.2 \pm 22.5 (74 136)	101.0 \pm 16.7 (73 124)	103.0 \pm 18.0 (72 129)	104.7 \pm 14.3 (85-128)
RAP mm. Hg	7.2 \pm 5.9 (2 19)	7.5 \pm 6.3 (^o 19)	7.6 \pm 6.1 (2 19)	7.7 \pm 6.1 (2 19)	8.0 \pm 6.4 (^o 20)	8.6 \pm 6.7 (2 19)
PAedP mm Hg	18.1 \pm 3.9 (13 27)	19.2 \pm 3.5 (1 ^o 22)	18.4 \pm 3.1 (12 27)	18.7 \pm 2.9 (13-22)	19.1 \pm 3.3 (14 23)	18.7 \pm 2.5 (15 27)
CI L/min/M	2.6 \pm 0.4 (^o 1 3.5)	2.7 \pm 0.5 (2.0 3.6)	2.7 \pm 0.5 (2.0 3.4)	2.8 \pm 0.5 (2.2 3.4)	2.6 \pm 0.4 (2.2 3.7)	2.6 \pm 0.5 (^o 1 3.5)

ated some aspects of the drug's mechanism of action on the dam's ed area

To acquire further information in this regard and to evaluate eventual undesirable hemodynamic effects we recorded hemodynamic data in eight patients after hyaluronidase administration in the course of a multicenter study on the effects of the drug on the electrocardiographic signs of necrosis in patients with acute myocardial infarction. Pulmonary arterial pressure (PAP) systemic pressure (BP) and right atrial pressure (RAP) were recorded continuously using an XM 5101 Philips apparatus with Statham P3 transducers for 30 minutes preceding the administration of the drug and for 60 minutes afterwards. Cardiac output was assessed by thermodilution method at -30 minutes -15 minutes 0 +15 minutes, +30 minutes and +60 minutes with respect to administration. The hyaluronidase 500 U/Kg. was injected as an intravenous bolus within 6 hours from symptom onset. In five patients the catheters were left in place and the hemodynamic evaluation was repeated 6 hours later after a second dose administered in an identical fashion. Therefore the hemodynamic effects of hyaluronidase were observed after a total of 13 doses. Six patients had a pulmonary artery end-diastolic pressure (PAedP) >18 mm Hg a value that we consider critical in identifying patients with definite left ventricular dysfunction. Three patients had a RAP >10 mm Hg and three a cardiac index (CI) <2.5 L/min/M. Two patients showed clinical signs of heart failure.

The data obtained are presented in Table 1. Only minimal changes none of statistical significance were observed in the hemodynamic parameters. Thus it can be concluded that the action of hyaluronidase in limiting the development of necrosis is not attributable to hemodynamic modifications involving the cardiovascular system in its entirety. The innocuousness of the drug from a hemodynamic point of view demonstrated also in patients with heart failure is important since it renders possible administration to the patients with acute myocardial infarction regardless of their hemodynamic status.

Maria Ray MD
Luigi Tavazzini MD
Jo ge A. Salerno MD
Piero Bobba MD

Division of Cardiology-S. Matteo Hospital
University of Pavia
27100 Pavia Italy

REFERENCES

- 1 Maroko P R Libby P., Bloor C M Sobel, H E., and Braunwald E. Reduction by hyaluronidase of myocardial necrosis following coronary artery occlusion. *Circulation* 48 430 1972
- 2 Hillis L D Askenazi J Braunwald E Radvany P., Muller J E Fishbein M C and Maroko P R Use of changes in the epicardial QRS complex to assess interventions which modify the extent of myocardial necrosis following coronary artery occlusion. *Circulation* 54 597 1976
- 3 Maclean D Fishbein M C Maroko P R and Braunwald E. Hyaluronidase induced reductions in myocardial infarct size. *Science* 194 199 1976
- 4 Maroko P R Davidson D M Libby P Hagan A D and Braunwald E. Effects of hyaluronidase administration in myocardial ischemic injury in acute infarction: a preliminary study in 24 patients. *Ann Intern Med* 82 516 1975
- 5 Maroko P R Hillis L D Muller J E Tavazzini L Heyndrick G R Ray M Charnelle M., Distanti, A Askenazi J Salerno J A. Carpentier J Reshetnay N I Radvany P Libby P Raabe D S Chazov E I Bobba P and Braunwald E. Favorable effects of hyaluronidase on electrocardiographic evidence of necrosis in patients with acute myocardial infarction. *N Engl J Med* 296 898 1977
- 6 Kloner R A Fishbein M C Maclean D., Braunwald E and Maroko P R. Effects of hyaluronidase during the early phase of acute myocardial ischemia: an ultrastructural and morphometric analysis. *Am J Cardiol* 40 44 1977
- 7 Askenazi, J Hillis L D Diaz P E Davis M A Braunwald E and Maroko P R. The effect of hyaluronidase on coronary blood flow following coronary artery occlusion in the dog. *Circ Res* 40 566 1977
- 8 Tavazzini L Ray M Salerno J A Chimentelli M and Bobba, P. Aspetti emodinamici e terapeutici dell'infarto miocardico acuto. Parte I. Classificazione emodinamica. *G Ital Cardiol* 7 1143 1977

Testing antianginal therapy. In favor of current practice

To the Editor

Requirements for testing efficacy of antianginal treatment include documentation of disease in patients with frequent episodes of anginal pain (severe stable disease) pain retro

glyceryl dianes randomization procedures and exercise stress tests. Traditionally the history of symptoms was held adequate for evaluation of the impact of a new therapy. The complexities in analyzing life stresses, emotions, activity levels and the like have led to the suggestion that subdividing the history and rating each aspect might provide even more meaningful data before and during active therapy. Another opinion of one fed up with the subjective variability inherent in angina pectoris is that full reliance in therapeutic evaluations be placed on standardized stress test results.

It seems clear that both subjective and physiological status of the patient with ischemic heart disease must be measured. They probably provide different types of information which summate into each patient's anginal syndrome. The patient who reports pain during sexual activity but who can exercise safely to a heart rate of 160/minute in the laboratory—is he a formidable sexual athlete or is he telling his physician only of his desires?

We have recently had an opportunity to measure the subjective and objective results of randomization to treatment in reliable patients with severe angina pectoris: this is critical in evaluating the effects of any form of therapy. After randomization to placebo therapy in both 2 week and 4 month trials, patients reported mean decreases in pain frequency and nitroglycerin consumption which barely distinguished them from comparable patients randomized to active drugs. During the pre-randomization baseline observation period of one study seven of 17 patients abruptly withdrawn from propranolol reported gross increases in pain frequency and nitroglycerin consumption. In all three instances of significant alteration in subjective data, results of standardized maximal stress tests were nearly stable. In contrast those patients randomized to active drug treatment demonstrated statistically significant improvement in their performance during exercise tests as well as slightly less pain than placebo patients.

It appears as if the combination of techniques of observation allows dissection of two important but inconsistently related aspects of coronary arterial obstructive disease. Can we do without one or the other? I think not.

The diary of pain and nitroglycerin consumption, whether complex or simple, relates something of the subjective as well as functional status. In addition diaries can provide critical information about adverse drug reactions or change in disease status: onset of unstable angina before the patient or the physician may discern these alterations in the exercise laboratory.

The objective testing of functional capacity and the exercise electrocardiogram provide critical measurements which have generally been accepted as necessary to the description of the effects of therapy on resting submaximal and maximal cardiovascular physiology.

Thus it appears as if there is no short cut to the trying problem of testing effective antianginal treatment. It continues to be essential to record both subjective and objective data obtained from reliable patients undergoing suitable test protocols. With both types of information being collected, however, trials on patients with milder disease may be worth carrying out. Those with fewer attacks (e.g. 1/wk vs 5 to 10/wk) may have coronary arteries and cardiac muscles which may be more profoundly affected by certain drugs, particularly vasodilators. Such trials may have to be longer than a few weeks

and the training effect must be avoided, but the data may be more valuable than that obtained from patients with calcified thread like vessels and extensively damaged muscles.

William Shapiro MD
Chief, Cardiovascular Section
and Associate Professor of Internal Medicine
Veterans Administration Hospital
4500 S. Lancaster Road
Dallas, Texas 75216

REFERENCES

1. Feinstein A R and Wells C K A new clinical taxonomy for rating change in functional activities of patients with angina pectoris. *AM HEART J* 93:177 1977
2. Shapiro W, Carroll J and Park J Effects of randomization to double blind placebo therapy in stable angina pectoris. *Clin Res* 25:47A 1977
3. Carroll J, Park J and Shapiro W Discrepancy between subjective symptoms and functional capacity following sudden propranolol withdrawal in patients with severe angina pectoris. *Clin Res* 25:45A 1977

Prolonged repolarization and hypomagnesemia

To The Editor

We read with interest the exhaustive review by Burch and Giles of hypomagnesemia in cardiovascular diseases (*AM HEART J* 94:649 1977). They have stressed the occurrence of flat T waves and prominent U waves. A review of case reports of patients all of whom had hypomagnesemia revealed that prolonged QT interval was seen in all these cases. All of them responded to magnesium therapy. The prolonged QT interval appears to be a T + U complex where T is flat and U is prominent. This prolonged repolarization in these cases also seems to be associated with increased irritability of myocardium giving rise to ectopic activity, bigeminal rhythm and ventricular fibrillation. Another interesting phenomenon of electrical alternation of T wave and U wave had also been noted.

Therefore we feel that the occurrence of these changes should be watched for and treated promptly, especially in chronic alcoholic patients as these changes are definite antecedents of ventricular fibrillation.

Dr Shinde Suresh N MD
Reader in Medicine
Dr G S Sanani MD FRCP FACP PhD
Professor and Head
Department of Medicine
B J Medical College
Poona 411 001 India

REFERENCES

1. Ricketts H H, Denison E K and Haywood L J Unusual T wave abnormality. Repolarization alternans associated with hypomagnesemia, acute alcoholism and cardiomyopathy. *JAMA* 207:365 1969
2. Bashour T, Rios J C and Gorman F A U wave alternans and increased ventricular irritability. *Chest* 64:377 1973
3. Leach H E, Pietras R J, Gunnar R M and Tobin J R Jr Paroxysmal ventricular fibrillation in two patients with hypomagnesemia. *Circulation* 37:210 1968.

CPK MB elevations in hypothermia

To the Editor

I was rather puzzled to read the report of Carlson and associates in the March issue of the *AMERICAN HEART JOURNAL* (95:35, 1978) Creatine phosphokinase MB isoenzyme in hypothermia. Case reports and experimental studies.

In the past 50 patients subjected to cardiopulmonary bypass and hypothermic cardiac arrest myocardial temperatures have been maintained less than 20°C for periods of up to 120 minutes. All patients had CPK MB estimations performed immediately postoperatively together with LDH isoenzymes. Only one patient had CPK MB elevation greater than two per cent. This patient had no evidence of myocardial infarction by other criteria.

Our experience and the experience of many other cardiac surgeons using hypothermic cardioplegic cardiac arrest techniques is at variance with that of Carlson and associates. It appears unlikely that hypothermia itself was responsible for the CPK MB elevations in their patients.

Peter R Maggs M.D.
Section of Thoracic and
Cardiovascular Surgery
Lahey Clinic
605 Commonwealth Ave
Boston, Mass 02115

Reply

To the Editor

We thank Dr Maggs for his comments on our article Creatine phosphokinase MB isoenzyme in hypothermia (*Am Heart J* 95:35, 1978). In reply we would like to make the following observations:

In our paper we presented six patients with hypothermia and MB-CPK in their serum without clinical evidence of myocardial infarction. We presented experimental evidence that six hours of total body hypothermia were sufficient to result in a 21 per cent loss of myocardial and striated muscle CPK activity in the dog. There are fundamental differences between our observation and those Dr Maggs has presented.

Our patients and the experimental animals were subjected to prolonged hypothermia much longer than the 120 minutes experienced by Dr Maggs' patients. Certainly the duration of exposure relates to the extent of any injury.

Second, the two mechanisms of hypothermia (environmental in our cases versus bypass induced) have different patterns of cooling.

Finally, the biggest difference is that the hearts of our patients continued to perform work during hypothermia and continued to be perfused. Muscle death and consequent enzyme release occurs more readily under conditions of a high oxygen consumption. In addition, Hansson observed differing lymphatic enzyme release patterns depending on the conditions of coronary perfusion and the circumstances of hypothermic arrest.

From Dr Maggs' letter we feel the only conclusion to be drawn is that under certain conditions of hypothermic cardiac arrest restoration of cardiac function can be made without MB-CPK appearing in serum and presumably without myocardial damage. This seems even more remarkable when

the duration (2 hours) and extent (20°C) of hypothermia is considered. Under other less controlled conditions such as we observed hypothermia with continuing cardiac activity may result in diffuse myocardial damage.

C. Jeffrey Carlson M.D.

Elliot Rapaport M.D.

School of Medicine
University of California Service
San Francisco General Hospital
San Francisco, Calif 94110

REFERENCE

1. Hansson H. Efflux of enzymes in right duct lymph and serum after coronary perfusion and ischaemic arrest. *Scand. J. Thorac. Cardiovasc. Surg.* 10:15, 1976.

Recourse to a computer for teaching the proper use of nitroglycerin

To the Editor

The physician now possesses an expanded therapeutic armamentarium for combating angina pectoris including long acting vasodilators, beta adrenergic blocking drugs, exercise conditioning, and the coronary bypass operation. But we believe the proper use of sublingual nitroglycerin continues to be the mainstay of correct therapy. This looms with even greater importance now for when chest discomfort is deemed inadequately controlled, the patient is invariably directed to a costly operative procedure. Indeed the correct use of nitroglycerin may very well have obviated more drastic interventions.

The problem relates in part to the fact that nitroglycerin unlike many other medications is not taken on a fixed schedule. The decision for its use is up to the patient. Folk wisdom dictates that drugs be used sparingly lest loss of efficacy or habituation supervene. There is also a psychological need to deny that retrosternal or epigastric discomfort is related to the heart. The patient is generally aware that the prompt relief afforded by nitroglycerin confirms the cardiac source for the discomfort. Furthermore the occasional need to use nitroglycerin in public calls attention to the personal disability when among colleagues this may raise disquiet as to one continuing capacity to perform. When among family members, it may provoke anxiety and encourage unwarranted solicitude. These and similar factors militate against the free use of nitroglycerin. In fact it is a constant source of consternation that only half of our patients with angina resort to nitroglycerin appropriately.

To improve patient performance we have devised an interactive computer teaching program. The patient is seated in front of a television screen and instruction is given in the use of a few keys on a connecting typewriter key board. The program begins by asking several multiple choice or true false questions on the frequency of angina, the customary use of nitrates, and the specific indications for their use. Responses are indicated by typing numbers on the keyboard. The computer then presents information about nitroglycerin in a succession of brief written messages appearing on the televi-

This work was supported in part by Grant No. HS 00188 from the National Center for Health Services Research, United States Public Health Service.

sion screen. At intervals the patient is confronted with questions based on the material already presented. The patient is complimented for correct answers. If the response is improper, additional explanations are provided and the relevant material is reviewed. The interview is written so as to endow the machine with a friendly personality. The aim is to convey an optimistic outlook and to foster insight into factors which contribute to angina. Those who learn quickly complete the program in about 30 minutes. Others may repeatedly review certain points and require an hour or more. A pamphlet is given to the patient for review at home.

Fifty consecutive patients with angina who viewed the computer program were sent a brief questionnaire by mail three months later to determine whether a single exposure modified nitroglycerin use. Forty four of 47 patients who continued to experience angina responded. During this interval the frequency of angina was not modified; thus 21 who had at least one or more episodes daily before the program experienced the identical number after the program. The following table presents the essentials.

Table I

	Computer program (No. of patients)	
	Before	After
Taking nitroglycerin	34	41
For severe or prolonged pain only	16	9
For mild discomfort at the very onset or in anticipation	18	32

A change occurred in the basis for nitroglycerin consumption: fewer patients waited for severe pain and more took the drug in anticipation. However, these numbers do not fully convey the altered attitude fostered by the computer program. Perhaps more instructive are the following verbatim responses that communicate the new attitude.

(a) Since I viewed the computer program I have been taking nitroglycerin for no reason just to prevent my angina and I have found since doing this I have had no pain or discomfort and I even feel better. I think the secret of feeling good and without chest discomfort is to take nitroglycerin when not needed.

(b) I learned to stop counting how many I take daily—counting made me try to do without and wait for pain to pass.

(c) The nitroglycerin program has made me aware of stress situations creating in many instances an angina problem and I am now able to control the angina with the nitroglycerin where before I used it only in severe discomfort and usually ended up with a hospital visit. It is now not a last resort medication.

This experience indicates that an interactive computer teaching program can effectively supplement physician instructions on the proper use of drugs. Even patients who had been carefully and repeatedly counseled in the use of nitroglycerin were less inhibited as a result of exposure to the computer teaching program. There are a number of advantages

to the computer: it is not impatient, does not lack time, consistently presents all the material and can review numerous times with the tempo determined exclusively by the patient's speed of comprehension. An important additional reason for the computer's success is that the patient is not passive; is not merely exposed to a soliloquy but engages in a dialogue with the physician's surrogate. In short, this is a method inexpensive in both cost and time to foster a new attitude towards a most beneficial medication.

Stephen H. Rabinowitz, M.D.

Bernard Loun, M.D.

Warner V. Slack, M.D.

Cardiovascular Laboratories

Harvard School of Public Health

and The Department of Medicine

Peter Bent Brigham Hospital

and The Computer Medicine Division

Beth Israel Hospital

Boston, Mass.

REFERENCE

- Slack W V, Hicks G J, Reed C E, and VanCura L. A computer based medical history system. *N Engl J Med* 274:194, 1966.

Potential hazard of the programmable pacemaker

To the Editor

The Omni Stancor programmable pacemaker has features that are highly desirable to the physician. The rate and current output of this pacemaker can be changed at any time by a non-invasive technique involving electromagnetic pulse trains emitted by an external programmer. This adjustment in the rate and power output can be made as the patient's requirements change. By decreasing the current output the pacemaker's longevity is increased. The adjustable rate control facilitates control of complicating arrhythmias.

Prolongation of battery life is a laudable feature of the programmable pacemaker. However, it is also important to remember to increase the milliamperage when a myocardial infarction occurs.

A programmable pacemaker was implanted in an 80 year old woman on February 10, 1976 because of severe sinus bradycardia with sinus arrests. The pacemaker was reprogrammed to 4 MA with a rate of 70 on December 23, 1976. Periodic telephone transmissions of the electrocardiogram revealed perfect function of the pacemaker. During the months of September, October and November 1977 weekly transmissions were accomplished and no pacing or sensing malfunctions were noted. On December 7, 1977 she developed severe chest pain which led to her admission to the Coronary Care Unit at The Methodist Hospital. An electrocardiogram revealed perfect pacemaker function. Occasional unpaired beats however showed a new right bundle branch block with deep T wave inversions in Leads V to V. A subendocardial infarction appeared likely and this was substantiated by the increase in the CPK, SGOT and LDH. On the second hospital day pacemaker spikes were observed on a monitor lead which were not followed by QRS complexes. The patient then developed ventricular tachycardia and ventricular fibrillation and was successfully cardioverted (Fig. 1). After the restoration




Fig 1 Upper ECG panel shows perfect pacemaker function. The next two panels show the pacemaker artifact which is not followed by paced beats. The bottom panel shows the onset of ventricular tachycardia.

tion to sinus rhythm the patient remained in coma due to severe brain damage. The pacemaker was reprogrammed to 9 MA and over the next seven days the pacemaker continued to work properly. The patient finally succumbed to a complicated pneumonia.

This case is important because it reminds us to reassess the malpractice when a patient sustains a myocardial infarction. With this complication the pacing threshold increases. Similarly, the pacing threshold may have to be increased in the presence of severe electrolyte abnormalities.

Laurence Gould MD
C V Ramana Reddy MD
Department of Medicine
The Methodist Hospital
Brooklyn NY

Heart rate correction of pre-ejection period

To The Editor

The paper by Burckhardt and associates (*AM HEART J* 93:187, 1978) is an outstanding contribution to the understanding of cardiac function in hypothyroidism. Their results concur directionally with other data. There is, however, a point worthy of serious dispute in the handling of systolic time intervals (STI)—namely, heart rate correction of the pre-ejection period (PEP). They have chosen to correct the PEP by Weisler's regression equation.

There is a large and growing body of work to show that PEP should not be rate corrected. To be sure, in pooled data from resting subjects, an association will sometimes be found for PLP plotted against heart rate, though at extremely low correlation coefficients. Yet, in any individual subject, both atrial pacing and administration of atropine change heart rate without changing PEP. Thus, resting values for both heart rate and PEP are independent responses to a common factor.

Interventions changing heart rate alone or disproportionately would cause spurious, corrected PEP changes. Moreover, an exaggerated rate effect could account for most or all of the PEPc correlation.

In rate-correcting PEP, the authors have followed a common though erroneous practice. It would be helpful if they would present corresponding heart rates and uncorrected PEP values. Indeed, heart rates should always be given with any systolic time interval data—for completeness and for those who differ about rate correction (different investigators have different regression formulae). In my experience, directional results for PEP and PEPc tend to be the same, though at different significance levels, as I am confident they would be in this otherwise excellent work, but the reader should always have the heart rate data.

David H Spodick MD DSc
Professor of Medicine
University of Massachusetts
Medical School
Director
Division of Cardiology
St Vincent Hospital
Worcester, Mass 01604

REFERENCES

- 1 Cokkines D V, Heimonas E T, Demopoulos J M et al. Influence of heart rate increase on uncorrected pre-ejection period/left ventricular ejection time (PEP/LVET) ratio in normal individuals. *Br Heart J* 38:683, 1976.
- 2 Sapoznikov D, Worman J, and Elbakim M. Left ventricular pre-ejection period and pulse wave velocity during complete heart block and artificial pacing in man. *Eur J Cardiol* 1:447, 1974.
- 3 Meyer W A and Kaplan, S. Noninvasive techniques in pediatric cardiovascular disease. *Progr Cardiovasc Dis* 15:341, 1973.

Table I

	Hypothyroid		Euthyroid			Hyperthyroid	
	Without treatment	With treatment	Previously hypothyroid	Normals	Previously hyperthyroid	With treatment	Without treatment
PEP	137.5 ± 15.5 p < 0.0005	124.1 ± 15.3 p < 0.0005	92.1 ± 9.1 NS	90.7 ± 9.4	77.3 ± 13.7 p < 0.005	57.1 ± 5.6 p < 0.0005	55.0 ± 19.8 p < 0.0005
Heart rate	55.8 ± 5.5 p < 0.05	64.9 ± 7.7 NS	65.0 ± 9.6 NS	68.4 ± 13.7	76.0 ± 12.9 NS	91.8 ± 17.9 p < 0.0025	87.1 ± 19.4 p < 0.005

Data are reported as mean values ± 1 SD

- 4 Salzman S H Wolfson S Jackson B et al Epinephrine infusion in man: standardization, normal response and abnormal response in idiopathic hypertrophic subaortic stenosis *Circulation* 43 137 1971
- 5 Kraus M E and Naughton J Effect of exercise on left ventricular ejection time in patients with prolapsed mitral leaflet syndrome *Chest* 69 484 1976
- 6 Talley R C Meyer J F and McNay J L Evaluation of the pre ejection period as an estimate of myocardial contractility in dogs *Am J Cardiol* 27 384 1971
- 7 Spitaels S Arbogast R Fouron J C et al The influence of heart rate and age on the systolic and diastolic time intervals in children *Circulation* 49 1107 1974
- 8 Cardiac Mechanics: Physiological, Clinical and Mathematical Considerations edited by I Mirsky et al London 1974 John Wiley & Sons Ltd p 238
- 9 Takahashi M and Mortiz D L Systolic intervals in children with normal and diseased hearts *Am J Cardiol* 29 294 1972
- 10 Fabian J Epstein E J and Coulshed N Duration of phases of left ventricular systole using indirect methods *Br Heart J* 34 874 1972
- 11 Simon H Fricke G and Esser H Originales herzdynamische Zeitmasse und Kreislaufzeiten bei arterieller Hypertonie *Klin Wochenschr* 49 193 1971
- 12 Knapp E Aigner A Baumgartl P et al Zur Frage der Frequenzabhängigkeit systolischer Kreislaufzeiten und daraus berechneter Indizes Kreislaufforsch 61 492 1972
- 13 Atsumi T Matsuda M and Honda Y Systolic time

intervals of the normal Japanese Cardiovascular Sound Bull 2 367 1972

- 14 Higgins C B Vatner S F Franklin D et al Extent of regulation of the heart's contractile state in the conscious dog by alteration in the frequency of contraction *J Clin Invest* 52 1187 1973
- 15 Golde D and Burstin L Systolic phases of the cardiac cycle in children *Circulation* 42 1029 1970
- 16 Urbaszek W Lowe H R Rentsch W et al Die Beurteilung der Herz-Kreislauf-Regulation mit dem sog. Anspannungsindex *Z Inn Med* 15 567 1976

Reply

To the Editor

We are glad to furnish the data on heart rate and uncorrected pre-ejection period (PEP) requested by Dr Spodick (see Table I).

Significance levels for uncorrected PEP are exactly the same as for corrected values ($p < 0.0005$) with the exception of previously hyperthyroid patients who have become euthyroid on treatment ($p < 0.025$ for corrected PEP vs $p < 0.005$ for uncorrected PEP).

D Buekkhardt MD
E Raeder MD
Division of Cardiology
University Hospital Basel
CH-4004 Basel, Switzerland

Diagnostic Electrocardiography and Vectorcardiography second edition By H Harold Friedman MD New York 1977 McGraw Hill Book Company Inc 630 pages Price \$14.00

This is the second edition of Friedman's book on electrocardiography and vectorcardiography. This edition, like the first, is designed for the trainee as well as the practicing physician. The author has simplified the approach to the understanding of the principles of ECG and VCG patterns for various types of cardiac disease states. There is a lengthy and good discussion of arrhythmias which are an important aspect of heart disease. The illustrations are well selected. Beginners will especially profit from a study of this book. The author has related the structure of the heart to the resultant ECG and VCG recordings in normal and abnormal cardiac states. The legends are clearly written to explain the relatively simplified illustrations. This book is worth owning and should be carefully studied in an attempt to understand the mechanisms responsible for the various tracings. VCG is now used more extensively and should be understood by those who are responsible for the interpretation of the electrocardiogram.

Modern Cardiology By John Davis Cantwell MD Boston/London 1977 Butterworth & Co Ltd 468 pages Price \$49.95

This monograph by Cantwell summarizes and interprets the cardiology literature published since 1970. The author is in private practice and intended this book for busy practitioners who have failed to keep abreast with the medical literature as related to the practice of cardiology. This is not a critical book. It represents more an interpretation of selected aspects of the literature as viewed by the author. The book includes the major subjects of present interest such as exercise testing, echocardiography, sudden death. His bundle electrocardiography and some of the new ideas concerning diagnosis, pathophysiology and treatment. The discussion of gallop rhythm (page 11) is an example of the new ideas presented. This is an interesting book which should help the physician in clinical medicine. It is well written and a good but selected bibliography is appended to each chapter. All general physicians and practicing cardiologists can profit a great deal from this book designed to review the literature in cardiology for the past 5 to 6 years. The book is not intended to replace other books and the literature but nevertheless this is a useful publication.

Advances in Heart Disease Edited by Dan T Mason MD New York 1977 Grune & Stratton Inc 548 pages Price \$34.50

This book in a series entitled Clinical Cardiology Monographs reviews the present state of concepts and knowledge of clinical cardiology. The book has many contributors and is divided into seven parts which are devoted to afterload reduction therapy in congestive heart failure, sudden death, acute myocardial infarction (medical and surgical management), special problems in coronary artery disease, prevention and population cardiology, recent advances in echocardiography and special topics in cardiovascular medicine. The presentations and discussions are not critically presented to help readers who do not follow closely the literature nor are the discussions directed at bedside cardiology. Some discussions have practical clinical applications whereas many do

not. Twenty two of the 31 presentations are from the author's group and therefore in the main this book reflects their approach to cardiology today. Clinical cardiologists will find this book to be of little value to them at present. Many of the concepts are yet to be fully tested and others such as the use of glucose-insulin-potassium solution are yet to be established as of value in clinical medicine. Those who study this book carefully will formulate their own opinions concerning the subjects discussed.

Re-entrant Arrhythmias: Mechanisms and Treatment Edited by Henri H Kulbertus, Baltimore 1977 University Park Press, 372 pages Price \$39.50

This book contains the proceedings of a symposium held in Lege, Belgium, during September 1976. The entire symposium was concerned with variations in the re-entrant arrhythmias. The discussions include electrophysiologic explanations for the electrocardiograms commonly seen clinically. The incidence of re-entrant arrhythmias seems to be more frequent with the use of digoxin and the kaliuretic diuretics. Myocardial ischemia predisposes to these arrhythmias. The family physician internist and even the cardiologist will find the discussions difficult to follow even though the illustrations are well selected and clearly defined. Some of the illustrations over-amplify activation of the myocardium by the wave of excitation (see figure on page 77). As a whole this publication should interest primarily those involved in laboratory and clinical investigation of arrhythmias. The tracings are interesting and so important in clinical cardiology that those who interpret electrocardiograms in large hospitals and clinics should study this publication carefully. It is a very good book and a fine addition to the medical literature.

Retroprospect: Insights into Medical Discovery By Julius H Comroe Jr MD Menlo Park California 1977 Von Gehr Press

Julius Comroe has produced an excellent book. It is fascinating to read and is full of interesting and exciting historical facts about science, scientists, and the great advancements in medicine. Comroe surely devoted a considerable amount of time and effort in accumulating and supporting the many facts described in his book. The overall importance of some of the advancements in physiology and biology can be debated in some instances but their introduction to medicine and clinical practice is aptly described and the important contributors are named as Dr Comroe views them. This for example is well exemplified by the discussions of cardiac catheterization which is abused in many centers and hospitals throughout the world. The discovery of Goodpasture in the culture of influenza virus in the chicken embryo appears to this reviewer to be the advancement which later led to viral culture on tissue culture and the polio and other viral vaccines. However these few remarks are not intended as criticisms of this very fine and interesting book but merely indicate the difficulties concerned with writing a book as important as this one. The book is highly recommended to all people in the medical and scientific field. It should represent an excellent gift for birth days, Christmas or other occasions. I found it interesting to read. This aspect of medicine and science has received too little attention. Comroe rendered a good service to medicine when he produced this book. It is a very good one.

Books received

Principles of Cardiac Arrhythmias 2nd ed By Edward H. Chung MD. Baltimore 1977 The Williams & Wilkins Company 770 pages Price \$49.50

Cardiac Arrhythmias Self Assessment By Edward H. Chung MD Baltimore 1977 The Williams & Wilkins Company 466 pages Price \$22.00

Advances in Experimental Medicine and Biology vol 82 Atherosclerosis Metabolic Morphologic and Clinical Aspects Edited by George W. Manning and M. Dana Faust New York 1977 Plenum Publishing Corp 1017 pages Price \$75.00

Anaesthesia for Cardiac Surgery and Allied Procedures By M. A. Branthwaite Oxford London Edinburgh Melbourne 1977 Blackwell Scientific Publications 203 pages Price \$21.50

✓ **The Cardiovascular Care Unit A Guide for Planning and Operation** By Glenn O. Turner MD New York Chichester Brisbane and Toronto 1978 John Wiley & Sons 512 pages

Nursing Care for Myocardial Infarction By Marilyn Rubin RN PhD St Louis 1977 Warren H. Green 118 pages Price \$10.50

Announcements

Contemporary Clinical Cardiology symposium

A two day symposium entitled Contemporary Clinical Cardiology will be held at the American Heart Association National Center in Dallas Texas on November 17 and 18 1978. The symposium is sponsored by Presbyterian Medical Center and co sponsored by the Council on Clinical Cardiology of the American Heart Association and by the Division of Continuing Education of the University of Texas Health Science Center Dallas. For further information contact Presbyterian Hospital of Dallas Medical Education Office 8200 Walnut Hill Lane Dallas Texas 75231 Telephone (214) 389-4111

Cardiac Diagnosis seminar

A seminar titled *Bedsides Approach to Cardiac Diagnosis* will be held at the Rose Medical Center Denver Colorado on December 7 and 8 1978. Sponsored by the Rose Medical Center the seminar is co sponsored by the Council on Clinical Cardiology of the American Heart Association Colorado Heart Association and by the University of Colorado Medical Center. For further information contact Administrator Postgraduate Programs American Heart Association 7320 Greenville Ave Dallas Texas 75229 Telephone (214) 750-5441

First International Congress on Cardiovascular Surgery and Diseases

Drs Michael DeBaey and Eliot Corday will conduct the new world wide Congress on Cardiovascular Diseases and Surgery to be held jointly with the American Society of Contemporary Medicine and Surgery at Caesar's Palace Las Vegas Nevada on January 14 through 19 1979. Participants in the congress may receive up to 40 hours of CME credit in Category I. For further information contact Dr Rutledge Howard Director of CME American Society of Contemporary Medicine and Surgery 6 N Michigan Ave Chicago Ill 60626

Cardiovascular Nuclear Medicine symposium

A two day symposium covering Current Concepts and Their Clinical Applications will be presented at the Stanford Court Hotel San Francisco on March 29 and 30 1979. The symposium is sponsored by the Foundation for Cardiovascular Research and by Peralta Hospital. For further information contact Foundation for Cardiovascular Research 201 N El Molino Ave Suite 100 Pasadena Calif 91101 Telephone (213) 792-4173

Acknowledgment to reviewers

The Editors wish to express their thanks and appreciation to the following who have aided in the review of manuscripts during the past year

Abdul Abbasi
William Abrams
Forrest H. Adams
Clarence M. Agnew
Masood Akhtar
Philip O. Alderson
Sidney Alexander
Joseph M. Alpert
E.T. Angelakos
Mark L. Armstrong
William M. Aronow
Daniel Azarnoff
John C. Bailey
Donald W. Baker
W.P. Baker
John Baum
Benjamin Befejer
George Beller
Arthur A. Berenbaum
Robert M. Berne
Sol Bernstein
Eugene H. Blackstone
Daniel J. Bleifer
John P. Boinesu
Robert F. Bond
Robert Boucek
C.Y. Bowers
Nancy H. Boyer
Eugene Braunwald
Dorothy Brumfield
C.E. Buckley
Howard B. Burchell
C.A. Caceres
Delmar R. Caldwell
Paul Cannon
Antonio Caracta
Timothy N. Cars
Dennis J. Carlson
Agustin Castellanos, Jr.
Kanu Chatterjee
John S. Child
Rory Childers
Francis P. Chisard
Chester M. Clark
Stephen D. Clements, Jr.
Lawrence S. Cohen
Jay N. Cohn
Peter F. Cohn
James S. Cole
H. Neal Coleman, III
Hadley L. Conn, Jr.
Jay Constantine

C. Richard Conti
Gene F. Conway
Betty C. Corya
Ernest Craig
Richard S. Crampton
Michael H. Crawford
I. Sylvia Crawley
James E. Crockett
Hiram B. Curry
Anthony N. Damato
J.N.P. Davies
James W. DeClue
Anthony N. De Maria
Kenneth B. Desser
James C. Dillon
Harold T. Dodge
Philip Dow
Joseph T. Doyle
Leonard M. Dreifus
Peter R. Duca
Barry Drnzio
E.E. Eddleman, Jr.
Robert S. Elvot
Lawrence H. Ellis
Curtis R. Ellison
Karl Engelman
Doris Escher
John A. Evans
Gordon A. Ewy
David P. Faxon
G.A. Fegen
Alvan R. Feinstein
Joel M. Felner
James Fisher
Gerald F. Fletcher
W.T. Foley
Alan B. Foster
Noble O. Fowler
H.A. Foxzard
Gary S. Francis
Sidney Friedman
Gottlieb C. Friesinger
Victor F. Froelicher
Walter J. Gamble
Jack C. Geer
Layne W. Gentry
Leonard S. Gettes
Thomas C. Gibson
Ray W. Gifford
Stanley E. Gittlow
Thomas R. Glatter
Gerald Gluck

Abner Golden
Stanley S. Goodman
Tavia Gordon
Thomas Gorsuch
Alexander Gottschalk
Barry H. Gray
Joseph Greenfield, Jr.
Howard P. Gutgesell
Arthur C. Guyton
Francis J. Haddv
Arthur D. Hagan
Robert Hall
Victor E. Hall
Robert I. Hamby
Glen W. Hamilton
A. Sidney Harris
Willard S. Harris
W. Proctor Harvey
George M. Haas
John A. Haves
Robert H. Heunle
Milton R. Heytmancik
Grady H. Hendrix
Michael V. Herman
Howard H. Heyer
Eugene Z. Hirsch
Brian F. Hoffman
Irwin Hoffman
Roger Holland
William H. Hood, Jr.
Orville Horwitz
Mayne J. Hughes
James C. Hunt
Michael L. Johnson
Sarah A. Johnson
Carl E. Jones
Mark E. Josephson
Samuel Kaplan
Albert A. Kattus, Jr.
Philip Kimbel
Donald Kung
Joseph A. Kuslo
Jack J. Kleid
Michael Klein
William H. Knospe
Yihong Kong
Charles E. Kossmann
Morris Kotler
Robert Kraus
Michael M. Laks
Herbert G. Langford
Phil Lankowski

Books received

Principles of Cardiac Arrhythmias 2nd ed By Edward K Chung M D Baltimore 1977, The Williams & Wilkins Company 770 pages Price \$49 50

Cardiac Arrhythmias Self Assessment By Edward K Chung M D Baltimore 1977 The Williams & Wilkins Company 466 pages Price \$22 00

Advances in Experimental Medicine and Biology vol 82 **Atherosclerosis Metabolic Morphologic and Clinical Aspects** Edited by George W Manning and M Daria Haust New York 1977 Plenum Publishing Corp 1017 pages Price \$75 00

Anaesthesia for Cardiac Surgery and Allied Procedures By M A Branthwaite Oxford London Edinburgh Melbourne 1977 Blackwell Scientific Publications 203 pages Price \$21 50

✓ **The Cardiovascular Care Unit A Guide for Planning and Operation** By Glenn O Turner M D New York Chichester Brisbane and Toronto 1978 John Wiley & Sons 512 pages.

Nursing Care for Myocardial Infarction By Marilyn Rubin R N Ph D St Louis 1977 Warren H Green 118 pages Price \$10 50

Announcements

Contemporary Clinical Cardiology symposium

A two day symposium entitled Contemporary Clinical Cardiology will be held at the American Heart Association National Center in Dallas Texas on November 17 and 18 1978 The symposium is sponsored by Presbyterian Medical Center and co sponsored by the Council on Clinical Cardiology of the American Heart Association and by the Division of Continuing Education of the University of Texas Health Science Center Dallas For further information contact Presbyterian Hospital of Dallas Medical Education Office 8200 Walnut Hill Lane Dallas Texas 75231 Telephone (214) 369 4111

Cardiac Diagnosis seminar

A seminar titled Bedside Approach to Cardiac Diagnosis will be held at the Rose Medical Center Denver Colorado on December 7 and 8 1978 Sponsored by the Rose Medical Center the seminar is co sponsored by the Council on Clinical Cardiology of the American Heart Association Colorado Heart Association and by the University of Colorado Medical Center For further information contact Administrator Postgraduate Programs American Heart Association 7320 Greenville Ave Dallas Texas 75229 Telephone (214) 720 5441

First International Congress on Cardiovascular Surgery and Diseases

Drs Michael DeBakey and Eliot Corday will conduct the new world wide Congress on Cardiovascular Diseases and Surgery to be held jointly with the American Society of Contemporary Medicine and Surgery at Caesar's Palace Las Vegas Nevada on January 14 through 19 1979 Participants in the congress may receive up to 40 hours of CME credit in Category I For further information contact Dr Rutledge Howard Director of CME American Society of Contemporary Medicine and Surgery 11 N Michigan Ave Chicago Ill 60626

Cardiovascular Nuclear Medicine symposium

A two day symposium covering Current Concepts and Their clinical Applications will be presented at the Stanford Court Hotel San Francisco on March 29 and 30 1979 The symposium is sponsored by the Foundation for Cardiovascular Research and by Peralta Hospital For further information contact Foundation for Cardiovascular Research 201 N Fl Molino Ave Suite 100 Pasadena Calif 91101 Telephone (213) 792-4173

The role of acute myocardial infarction in sudden cardiac death—a statistician's nightmare

T Lovegrove MB ChB
P Thompson MB BS FRACP FACC
Nedlands Western Australia

Despite increasing evidence to the contrary the practice of attributing sudden cardiac death to an acute pathologic lesion in the heart remains widespread. For example in 174 consecutive death certificates completed by doctors in Perth Western Australia in 1971 for patients who died outside hospital from coronary heart disease and did not have postmortem examinations the recorded causes of death were myocardial infarction in 73 (41 per cent), coronary occlusion in 66 (38 per cent), coronary thrombosis in 10 (6 per cent) and other causes in 26 cases (15 per cent). The true frequency of myocardial infarction on postmortem examinations of persons who have died suddenly is only 13 to 28 per cent and there is some evidence that acute coronary thrombosis only rarely precipitates the terminal event.¹ The usual explanation for the paucity of acute myocardial or coronary arterial lesions at postmortem is that death has prevented the development of the inevitable pathologic abnormalities of infarction. That this explanation is scientifically inept has been emphasised and recent evidence from patients who have been resuscitated from sudden death suggests that it is probably wrong. Cobb and associates found that in 175 patients resuscitated from ventricular fibrillation outside hospital only about half had evidence of myocardial necrosis when subsequently studied closely in hospital. In order to document the cardiac pathologic findings in a

large series of sudden out of hospital cardiac deaths 500 consecutive cases which occurred in the Perth Metropolitan area between July 1973 and April 1975 were studied.² This report deals with the 351 persons who died within half an hour of the onset of symptoms.

Methods

In the Perth Metropolitan area a Coroner's autopsy is performed if the patient has not been seen by a doctor or if the attending doctor is uncertain about the cause of death. Autopsies were performed by five forensic pathologists. Cases were included when no pathological findings apart from those in the heart could be found to explain the cause of death. Shortly after the death a member of the Western Australian Police Force carrying out routine investigations on behalf of the Coroner completed a specially designed questionnaire for the purpose of this study.

Timing of deaths Precise timing of the onset of symptoms or time of death is rarely possible but in 251 cases (71.5 per cent) where death was witnessed the symptoms preceding death were known to be of less than 30 minutes duration. In 100 cases (28.5 per cent) death was not witnessed but was assumed to have occurred within 30 minutes as the person had not reported symptoms or called for aid when people were constantly within earshot.

Results

All cases had advanced coronary atherosclerosis. Evidence of recent myocardial infarction was present in 72 cases (20.5 per cent) of these cardiac rupture was present in 24 (6.8 per

From the Department of Cardiac Medicine, Queen Elizabeth II Medical Centre, Nedlands, Western Australia.

Received for publication 7 November 1977.

Reprint requests: Dr T Lovegrove, Dept of Cardiac Medicine, Queen Elizabeth II Medical Centre, Nedlands, Western Australia 6009.

Kenneth C Lasseter
Garrett Lee
Louis Lemberg
Donald Leon
Michael Lesch
Harold D Levine
Herbert J Levine
Howard P Lewis
Richard P Lewis
Albert J Libanoff
Joseph Landsay Jr
Bernard E Lipman
Henry S Loeb
Joseph R Logic
David T Lowenthal
Daniel S Lukas
Brabson Lutz
L Lutchner
Harold A Lyons
Rex N MacAlpin
Ben D McAllister
Robert McDonald
FG McMahon
Oscar Magdson
William J Mandel
George V Mann
R Davis Manning Jr
Richard H Martin
B L Martz
Daniel Mason
Barry Masse
H Page Mauck Jr
James T Mazzara
Lawrence E Meltzer
Milton Mendlowitz
Richard Meyer
Richard Miller
Gary S Mintz
Jere H Mitchell
Gordon K Moe
Neil E Moore
Douglas C Morris
Andrew G Morrow
Hilrud S Mueller
Gerald W Murphy

T K Nasto
Navin C Nanda
Onkar S Narula
John Naughton
L C Neri
R Joe Noble
Jacqueline Noonan
Donald O Nutter
Robert M Olson
Edward S Orgain
Robert A O'Rourke
Irvine H Page
Hyman W Paley
James C Parker
Alan S Pearlman
SD Peck
Oscar Pereda
Kirk L Peterson
Brendan Phibbs
Bertram Pitt
Leon Fordy
JM Pouget
Walter H Pritchard
Raymond Pruitt
Robert A Ratshin
Pratap Reddy
Michael J Reighgott
James L Reynolds
Jorge C Rios
Stanley L Robbins
Nigel K Roberts
William Roberts
John Ross, Jr
George G Rowe
Carl J Rubenstein
Richard O Russell Jr
Barry D Rutherford
David A Rytand
Don R Santschi
C Glenn Sawyer
Dante C Scarpelli
Leonard Scherlis
Sidney Schnur
Fred W Schoonmaker
Robert Schramel

H L Seese
Alfred M Sellers
Arthur Selzer
Ralph Shabetai
Stephen D Shappell
James Shaver
Walter Sheldon
John T Shepard
Kenneth I Shine
Earl K Shurey
Barry Silverman
Hugh C Smith
Harold Smulyan
Louis A Soloff
Madison E Spach
J A Spath Jr
Nick Sperelakis
Stanley Spitzer
David H Spodick
Daniel J Stechschulte
Paul D Stein
Robert G Tancredi
Robert C Tarazi
James H Thomsen
Sam A Threefoot
Bernard Towers
Naip Tuna
Philip Varnale
Galen S Wagner
Paul Walinsky
Paul F Walter
Richard Wasserburger
Thomas E Watt Jr
Louis Weinstein
Nanette Wenger
David E Williams
Merlin R Wilson
A C Witham
Stephen M Wittenberg
Kinsman E Wright
Robert Yates
Paul N Yu
Robert Zehs
Henry A Zimmerman
Harry F Zinsser

The role of acute myocardial infarction in sudden cardiac death—a statistician's nightmare

T Lovegrove MB Ch ■
P Thompson MB BS FRACP FACC
Nedlands West Australia

Despite increasing evidence to the contrary the practice of attributing sudden cardiac death to an acute pathologic lesion in the heart remains widespread. For example in 174 consecutive death certificates completed by doctors in Perth Western Australia in 1971 for patients who died outside hospital from coronary heart disease and did not have postmortem examinations the recorded causes of death were myocardial infarction in 72 (41 per cent) coronary occlusion in 66 (38 per cent) coronary thrombosis in 10 (6 per cent) and other causes in 26 cases (15 per cent). The true frequency of myocardial infarction on postmortem examinations of persons who have died suddenly is only 13 to 28 per cent and there is some evidence that acute coronary thrombosis only rarely precipitates the terminal event. The usual explanation for the paucity of acute myocardial or coronary arterial lesions at postmortem is that death has prevented the development of the inevitable pathologic abnormalities of infarction. That this explanation is scientifically inept has been emphasised¹ and recent evidence from patients who have been resuscitated from sudden death suggests that it is probably wrong. Cobb and associates found that in 175 patients resuscitated from ventricular fibrillation outside hospital only about half had evidence of myocardial necrosis when subsequently studied closely in hospital. In order to document the cardiac pathologic findings in a

large series of sudden out of hospital cardiac deaths 500 consecutive cases which occurred in the Perth Metropolitan area between July 1973 and April 1975 were studied. This report deals with the 351 persons who died within half an hour of the onset of symptoms.

Methods

In the Perth Metropolitan area a Coroner's autopsy is performed if the patient has not been seen by a doctor or if the attending doctor is uncertain about the cause of death. Autopsies were performed by five forensic pathologists. Cases were included when no pathological findings apart from those in the heart could be found to explain the cause of death. Shortly after the death a member of the Western Australian Police Force carrying out routine investigations on behalf of the Coroner completed a specially designed questionnaire for the purpose of this study.

Timing of deaths Precise timing of the onset of symptoms or time of death is rarely possible but in 251 cases (71.5 per cent) where death was witnessed the symptoms preceding death were known to be of less than 30 minutes duration. In 100 cases (28.5 per cent) death was not witnessed but was assumed to have occurred within 30 minutes as the person had not reported symptoms or called for aid when people were constantly within earshot.

Results

All cases had advanced coronary atherosclerosis. Evidence of recent myocardial infarction was present in 72 cases (20.5 per cent) of these cardiac rupture was present in 24 (6.8 per

From the Department of Cardiac Medicine ■ Elizabeth II Medical Centre, Nedlands Western Australia.
Received for publication November 7, 1977.
Reprint requests to Dr. T. Lovegrove, Department of Cardiac Medicine, Elizabeth II Medical Centre, Nedlands Western Australia 6009.




Fig 1 Pictorial presentation of 351 cases of sudden cardiac death within 30 minutes of the onset of symptoms. Note that two thirds had no acute coronary or myocardial lesion.

cent of total). Coronary thrombosis was found in 76 cases (21.6 per cent), and was associated with myocardial infarction in 31 (8.8 per cent of total). Thus coronary thrombosis was unassociated with infarction in 45 cases (59.2 per cent of cases of coronary thrombosis) and infarction was unassociated with coronary thrombosis in 41 (57 per cent of cases of infarction).

In 234 cases (66.6 per cent) there was no pathologic evidence of recent coronary thrombosis or myocardial infarction (see Fig 1).

Two hundred and sixty-two cases (74.6 per cent) had evidence of old myocardial fibrosis and recent infarction was present in 48 of these. Of 89 cases without fibrosis there were 24 cases of infarction. In 137 of the cases with fibrosis there was no past history of heart disease of which family or witnesses were aware.

Comment

Fully two thirds of the persons in the present series of 351 sudden deaths within 30 minutes of symptoms had no acute cardiac pathologic lesion

at postmortem. Only one fifth had typical pathologic features of acute myocardial infarction. These results from an Australian population are in line with reports on American populations.¹¹ Although it cannot be known from studies of this type how many patients would have subsequently developed pathologic evidence of infarction had they survived, the traditional assumption that most would have done so is probably incorrect. That most sudden cardiac deaths are due to a functional rather than structural disturbance of the myocardium and that fatal ventricular fibrillation is not necessarily due to a structural change in the myocardium is evident from experimental findings¹² and recent clinical reports.¹³ Conversely, many well developed myocardial infarctions which had caused no symptoms in life were identified at postmortem.¹⁴ In this study, electrocardiographic evidence of silent infarction is a common finding in epidemiologic studies.¹⁵ The assumptions that most sudden cardiac deaths are due to early myocardial infarction and that the majority of infarctions are symptomatic are typical procrustean errors which have greatly distorted the true incidence and effects of myocardial infarction. Community studies on the incidence of myocardial infarction and particularly analyses of the trends in mortality of the condition need to take account of these errors.

The statistical problems of the incidence of death due to ischemic heart disease was partly recognized in the 1965 reclassification of ischemic heart disease in the International Classification of Diseases,¹⁶ where category 410 (Acute myocardial Infarction) included any acute manifestation of chronic ischemic heart disease. This allowed sudden cardiac death outside hospital to be categorized under the one heading but the erroneous label of 'acute myocardial infarction' with its quite different connotations for clinician, pathologist and epidemiologist was continued. Unfortunately this confusing situation has not been corrected by the changes made in the latest (1975) revision of the Classification.

An alternative term to describe sudden cardiac death does not readily present itself. Terminology based on pathologic assumptions will simply perpetuate the errors described above. Alternative use of physiologic terms such as cardiac arrhythmia or ventricular fibrillation will be wrong when the cause of death is cardiac rupture or

acute cardiac failure. The traditional term "heart attack" has an attractive simplicity, as has been pointed out by Sidel and colleagues,¹ but its popular roots prejudice its widespread medical acceptance. To overcome this problem without making any unwarranted assumptions about the mechanism of sudden cardiac death, the term "ischemic heart attack" seems clinically, pathologically, and epidemiologically accurate.

We wish to thank the Perth City Coroner, Mr W. G. Wickens, S.M., for permission to conduct this survey and for arranging facilities and accommodation to carry it out. We are grateful to Dr W. Laurie, D.S.O., Dr A. T. Pearson, Dr D. Hamsworth, Dr J. M. N. Hilton, and Dr D. A. Pocock, who conducted the autopsies for access to their records and for advice on technical pathology problems. We thank Inspector R. H. Patterson for his practical help in assembling the data and Sergeant T. H. Bushe-Jones and the other members of the West Australian Police Force who investigated the circumstances associated with these sudden cardiac deaths, and Mrs T. Mason and Mrs. C. Worth, who carried out the secretarial work.

REFERENCES

- 1 Lovegrove T. Occlusion, infarct or thrombosis. *Lancet* 2:971, 1971.
- 2 Bache V. J., Baba N., Keller M. D., Geer J. C. and Anthony J. R. Pathology of atherosclerotic heart disease in sudden death. II. The significance of myocar-

- dial infarction. *Circulation* 51 and 52 (Suppl. III) 63, 1975.
- 3 Spain D. M. and Braden V. A. Sudden death from coronary heart disease. *Chest* 58:10, 1970.
- 4 Roberts W. L. and Buja L. M. The frequency and significance of coronary arterial thrombi and other observations in fatal acute myocardial infarction. *Am J Med* 52:475, 1972.
- 5 Schwartz C. J. and Walsh W. J. The pathologic basis of sudden death. *Prog Cardiovasc Dis* 13:465, 1971.
- 6 Cobb L. A., Baum R. S., Alvarez H. and Shaffer W. A. Resuscitation from out of hospital ventricular fibrillation: 4 years follow-up. *Circulation* 51:52 (Suppl. III) 23, 1975.
- 7 Lovegrove T. Sudden death from ischemic heart disease: A review of five hundred consecutive cases. *Med J Aust* 1:178, 1977.
- 8 Wit A. L. and Bigger J. T. Possible electrophysiological mechanisms for lethal arrhythmias accompanying myocardial infarction. *Circulation* 51:52 (Suppl. III) 96, 1975.
- 9 Margolis, J. R., Kannel W. B., S. Feinleib M. et al. Clinical features of unrecognized myocardial infarction—silent and symptomatic. *Am J Cardiol* 32:1, 1973.
- 10 International Classification of Diseases. Manual of the International Statistical Classification of Diseases, Injuries and Causes of Death, 1965 revision. World Health Organization, Geneva, 1967.
- 11 Sidel, V. W., Acton J. and LOWN H. Models for the evaluation of pre-hospital coronary care. *Am J Cardiol* 24:674, 1969.

Radionuclide assessment of ventricular performance during propranolol withdrawal prior to aortocoronary bypass surgery

Lawrence A Reduto, MD *
Harvey J Berger, MD
Alexander Geha, MD
Graeme Hammond, MD
Lawrence S Cohen, MD
Alexander Gottschalk, MD
Barry L Zaret, MD **

New Haven Conn

Propranolol's antianginal effects are believed to be due predominantly to its reduction in myocardial oxygen consumption secondary to inhibition of the positive chronotropic and inotropic actions of catecholamines. However, this decrease in adrenergic support could exacerbate regional and global ventricular dysfunction and precipitate congestive heart failure. Clinical studies on the effects of propranolol on left ventricular performance have yielded conflicting results. After intravenous administration of propranolol, a consistent negative inotropic effect at the time of cardiac catheterization has not been documented.¹⁻³ Recently, Shubrooks and colleagues⁴ failed to demonstrate a significant change in ejection fraction or regional wall motion following this mode of propranolol administration. Echocardiographic functional assessment also

has been variable after oral administration. While some studies have shown no effect, others have demonstrated a depression in ejection fraction and posterior wall motion in patients with angina pectoris.⁵⁻⁸ However, this approach is not optimal for study of patients with coronary artery disease because the assumptions required for echocardiographic calculation of ventricular volumes are not valid in the presence of regional wall motion abnormalities.⁹

Newly developed radionuclide techniques for evaluation of ventricular performance in coronary artery disease may offer significant advantages over contrast angiography and conventional M mode echocardiography. With first pass quantitative radionuclide angiocardigraphy analysis is based upon radionuclide time-activity curves and consequently is independent of the geometric assumptions inherent in volume determinations made from outlines of cavity silhouettes.¹⁰⁻¹² Reproducible first pass techniques with minimal variability have been developed and validated in this laboratory.¹³⁻¹⁵

The present study was undertaken to assess the net inotropic effects of oral propranolol upon left ventricular performance. Preoperative patients receiving chronic propranolol therapy for angina pectoris were studied during drug withdrawal. This situation was felt to represent a commonly encountered clinical model in which drug effects could be studied. Left ventricular ejection fraction, mean normalized ejection rate, and regional

From the Section of Cardiology, Department of Internal Medicine, Section of Nuclear Medicine, Department of Diagnostic Radiology, Section of Cardiothoracic Surgery, Department of Surgery, Yale University School of Medicine, New Haven, Conn.

This study was supported in part by National Heart, Lung and Blood Institute Contract N01HV52977 and National Heart, Lung and Blood Institute Grant R01HL21690-01.

Received for publication Dec 29 1977

Accepted for publication Feb 1 1978

Reprint requests: Barry L Zaret, MD, Yale University School of Medicine, Section of Cardiology, 333 Cedar Street, 87 LMP, New Haven, Conn 06510

Research Fellow, American Heart Association, Connecticut Affiliate

Established Investigator, American Heart Association

wall motion were determined using first pass radionuclide angiocardiology on multiple occasions as propranolol was tapered prior to elective aortocoronary bypass surgery

Methods

Patient population The study population consisted of 12 preoperative patients with documented coronary artery disease and clinically stable angina pectoris. All patients underwent left and right heart cardiac catheterization, coronary angiography and left ventriculography. Seventeen patients had significant (> 70 per cent) stenosis of at least two coronary arteries: one patient had significant single vessel disease. Sixteen patients were male and two female with a mean age of 52 years (range 34 to 65 years). Ten patients had both clinical and electrocardiographic evidence of previous myocardial infarction. Infarcts were transmural in five patients (defined by Q waves 0.04 sec in duration) and non-transmural in five patients (defined as persistent T wave inversions).

At the time of admission for surgery all patients had been on propranolol therapy for at least one month. There was no change in the propranolol dosage for at least two weeks prior to admission. Two patients were receiving digoxin therapy for congestive heart failure. Fourteen patients were receiving long acting nitrates, two patients were receiving diuretics. At the time of referral for surgery ten patients had New York Heart Association Class III angina and eight had Class II angina. Informed consent was obtained from each patient.

Excluded from the study population were (1) patients with unstable angina defined as recurrent pain at rest with associated ST segment or T wave changes, (2) patients in whom intra-aortic balloon counterpulsation therapy was initiated preoperatively and (3) patients with significant valvular heart disease.

Radionuclide technique and serum propranolol assay Following preoperative hospital admission three radionuclide angiocardiology studies were performed in each patient. The first study was obtained at each patient's maximal propranolol dose (mean \pm SEM 224 ± 29 mg/day, range 160 to 640 mg/day). The second study was obtained 24 to 48 hours later at an intermediate propranolol dose (99 ± 9 mg/day, range 80 to 160 mg/day) and the third study was obtained at

least 24 hours following discontinuation of propranolol. Studies were performed two to three hours after an oral dose of propranolol. The drug was administered at six hour intervals. All patients receiving nitrates or digitalis continued on their normal dosage regimen during propranolol withdrawal. Digitalis was administered orally at least 6 hours prior to each study. Nitrates were administered sublingually at least 11 hours prior to evaluation.

All radionuclide studies were performed in the Cardiovascular Nuclear Imaging Laboratory. An 18 gauge 1½ polyethylene catheter was placed in an antecubital vein for injection of radionuclide and for withdrawal of blood samples needed for determination of serum propranolol levels. Following venipuncture five to ten minutes were allowed to pass to minimize any possible contributions of sympathetic activity associated with the procedure. Prior to each radionuclide study heart rate and blood pressure were recorded. Ten ml of blood were withdrawn into glass syringes and centrifuged for 10 minutes. The serum was frozen and maintained at 0° C until propranolol levels were determined by the fluorometric method of Shand and colleagues.¹⁴ The sensitivity of this assay has been determined to be ± 5 ng/ml.

Radionuclide angiocardiology studies were performed with patients supine in the anterior position using a commercially available computerized multicrystal scintillation camera (Baird Atomic System 77 Bedford Mass.)¹ Briefly 15 to 20 mCi of technetium 99m pertechnetate dissolved in less than 1 ml of normal saline were injected rapidly and flushed with 20 ml of saline. Data were acquired in frame mode at 50 msec intervals for 20 seconds as the bolus of tracer initially passed through the central circulation. A high frequency time-activity curve was generated from a left ventricular region of interest (Fig 1). End diastolic frames were used as starting points to sum together counts at 50 msec intervals over three to five cardiac cycles forming a summed cardiac cycle. A series of background frames (equal to the number of cardiac cycles used) was selected from the left ventricular time-activity curve just prior to the first discernible left ventricular beat. The sum of the background frames was subtracted from the summed cardiac cycle forming a high count rate background corrected representative cardiac cycle.

COUNTS
1500

Fig 1 High frequency high count rate time-activity curve used to calculate left ventricular ejection fraction in a normal patient. Each peak and valley represent one cardiac cycle.

This is equivalent to a relative ventricular volume curve. Left ventricular ejection fraction was calculated directly from these data according to the formula

Ejection fraction = $\frac{\text{End diastolic counts} - \text{End systolic counts}}{\text{End diastolic counts}} \times 100$

Ejection fraction determined in this manner has been shown to correlate closely with data obtained using standard contrast angiographic techniques for calculation of ejection fraction.¹⁰

In addition, normalized mean ejection rate was determined from the same "representative" cycle. Counts during the ejection phase were fitted to a weighted least squares straight line and the slope of this line (dC/dt) was normalized to the average counts (C) during the ejection phase yielding $dC/dt/C$. Left ventricular ejection rate is analogous to dV/dt of the ventricular volume curve and has been found to be sensitive to pharmacologic changes in inotropic state.¹²

Assessment of left ventricular wall motion was determined from analog end diastolic and end systolic images also obtained from the representative cycle. Images were computer smoothed by expanding the 294 matrix points to 4,704 points using a five point linear extrapolation. A computer generated ring representing the end diastolic outer margin was superimposed upon the end systolic image (Figs 2 and 3). Regional wall motion was evaluated from this composite image and was considered normal, hypokinetic, or akinetic. In the anterior position the left ventricular silhouette was divided into anterolateral, apical, inferior, and posterobasal segments. Regional wall motion was evaluated by two observers, and the consensus was used in data analysis. Previous work in this laboratory has demonstrated excellent agreement between analyses determined by this technique and contrast angiography.¹

The variability of these radionuclide parameters has been previously determined by multiple, sequential studies in 20 stable control patients with both normal and abnormal baseline left ventricular performance. For left ventricular ejection fraction, variability averaged (\pm SD) 4.4 ± 3.6 per cent with comparable differences in both patients and normal and abnormal left ventricular performance. In the same study, left ventricular ejection rate had an intrinsic variability of 0.56 ± 4.7 sec⁻¹. Furthermore, variability was greater in those patients with normal left ventricular performance. The presence or magnitude of regional wall motion abnormalities also did not change from study to study.¹³

Statistical analysis. Data are expressed as the mean \pm standard error (SEM). Comparisons between studies in individual patients were made with a paired t test.

Results

Indices of left ventricular performance. There was no significant change in left ventricular ejection fraction measured on the three occasions during propranolol withdrawal (59.1 ± 2.4 per cent vs 60.4 ± 2.0 per cent vs 59.2 ± 2.5 per cent, $p > 0.05$) (Fig 4). Five of 18 patients had mildly to moderately abnormal ejection fraction (range 43 to 48 per cent). In this subgroup as well ejection fraction did not change significantly as propranolol was withdrawn. In the total group two patients demonstrated an increase and four a decrease in ejection fraction beyond the intrinsic variability of the technique from initial to final studies. Individual patients varied from 0 to 10 per cent during the study period (greatest increase in ejection fraction 8 per cent, greatest decrease in ejection fraction 10 per cent).

Normalized left ventricular ejection rate also did not change significantly as propranolol was




Fig 2 Serial regional wall motion studies in patient E M obtained in the anterior position. In each image the outer ring represents the computer generated end-diastolic perimeter and the image within the ring represents end-systole. Note the normal wall motion in each study. Ejection fraction (EF) and ejection rate (ER) are given below each image. PROP = propranolol.




Fig 3 Serial regional wall motion studies in patient T K. Note the posterobasal hypokinesis in each study. Abbreviations as in Fig 2.

withdrawn (2.80 ± 1.8 sec vs 2.87 ± 1.8 sec vs 2.92 ± 0.20 sec, $p > 0.05$). This was a consistent finding both in patients with abnormal (< 2.50 sec) and normal initial ejection rates. Four patients demonstrated increases and two decreases in ejection rate from initial to final studies beyond the intrinsic variability of the radionu-

clide technique. Individual patients varied from 0.10 to 1.63 sec during the study period (greatest increase in ejection rate 1.63 sec; greatest decrease 0.99 sec) (Fig 5). The greatest lability in ejection rate was noted in patients with normal left ventricular performance. The degree of variation was comparable to




Fig 4 Sequential measurements of left ventricular ejection fraction in 18 patients studied as propranolol (*PROP*) was tapered preoperatively. Data in each individual patient are represented by the thin solid lines. Mean values for the entire group are shown by the circles connected by the heavy solid line. Vertical bars represent standard errors. NS = not significant by paired t test.




Fig 5 Sequential measurements of left ventricular ejection rate in 18 patients. The format and abbreviations as in Fig 4.




Fig 6 Mean \pm SEM daily propranolol dosage for the three studies (Top) and Mean \pm SEM serum propranolol levels at the time of peak intermediate and final studies (Bottom). Note the significant decrease in serum levels at the intermediate and final studies in comparison to peak level.

that seen in normal, stable control patients¹¹

In six patients radionuclide regional wall motion was abnormal at Study 1. Three patients demonstrated akinesis and three hypokinesis of a left ventricular segment. These regional wall motion abnormalities were in close agreement with those assessed by preoperative contrast left ventricular angiography. There was no observable change in the magnitude or extent of regional wall motion abnormalities as propranolol was withdrawn in these six patients. Furthermore, no patient developed new abnormalities in regional wall motion during drug withdrawal and all patients with normal initial performance remained normal on subsequent studies. Two patients with anterior hypokinesis at left ventricular angiography demonstrated normal left ventricular regional wall motion with radionuclide angiography.

Serum propranolol levels. Serum propranolol levels significantly decreased as propranolol was withdrawn and were virtually not detectable at the time of the final study (Fig 6). The peak propranolol level at Study 1 averaged 85 ± 22 ng/ml, with a range from 15 to 371 ng/ml.

Intermediate study propranolol levels averaged 30 ± 6 ng/ml with a range from 5 to 81 ng/ml. Serum propranolol levels at the final study averaged 4 ± 2 ng/ml.

Heart rate, systolic blood pressure, heart rate increased significantly ($p < 0.001$) during preoperative propranolol withdrawal from 62.3 ± 2.3 to 67.8 ± 3.0 to 73.1 ± 2.3 beats/minute. The increase in rate changed from 0 to 20 beats/minute. Changes in heart rate were similar in patients with normal ejection fraction (11 beats/minute) and abnormal ejection fraction (10 beats/minute). Mean systolic blood pressure was not altered significantly (114.7 ± 4.3 vs 110.3 ± 3.0 vs 113 ± 3.0 mm Hg, $p > 0.05$) as the propranolol dosage was reduced.

Discussion

This study demonstrates that in patients with documented coronary artery disease preoperative propranolol withdrawal does not result in significant modification of basal global and regional left ventricular performance. The clinical situation of preoperative propranolol withdrawal provided a suitable model for study since all patients received clinically relevant drug dosages all were observed in a controlled hospital environment and all had documented coronary artery disease. The technique of quantitative first pass radionuclide angiography provided a good method of study since it is independent of ventricular geometry and correlates well with contrast angiographic data in patients with and without coronary artery disease. Furthermore sequential data have been obtained with low variability indicating the suitability of the method for this type of investigation.

Several studies have demonstrated significant negative inotropic effects following intravenous propranolol administration.^{1,15,16} However, questions still remain concerning the effect of chronic oral propranolol therapy upon ventricular performance in the basal state in man. The conflicting results of some previous studies may be due to the nature of the noninvasive techniques employed. Employing roentgenographic left heart dimensions and systolic time intervals in normal subjects, Le Winter and colleagues¹⁷ did not demonstrate any change in cardiac dimensions or the ratio of pre-ejection period to left ventricular ejection time following oral propranolol. In contrast, Frishman and asso-

ciates¹⁸ found a reduction in echocardiographic ejection fraction and posterior wall motion in patients with angina following therapy with propranolol. However, these echocardiographic techniques for the evaluation of ventricular performance have been found to be unreliable in the patient with coronary artery disease and regional ventricular dysfunction. On the other hand, this is clearly not the case with the radionuclide techniques used in the present study for assessment of ejection fraction. The contrasting efficacy of the two techniques in patients with coronary artery disease has been reported by Henning and co-workers¹⁹ who showed a poor correlation between echocardiographic and radionuclide ejection fraction in patients with regional wall motion abnormalities.

Ejection fraction is the most commonly used clinical parameter of global left ventricular performance. However, it is dependent upon variables other than intrinsic myocardial contractility such as heart rate, preload, afterload, and the presence of valvular regurgitation.²⁰ Thus, studies demonstrating changes in ejection fraction following propranolol must be interpreted in light of simultaneous alterations in these parameters as well. In the present study, systolic blood pressure, an approximate index of afterload, did not change significantly as propranolol was withdrawn. However, there was an increase in heart rate noted during propranolol withdrawal. Although this heart rate change did not affect ejection fraction, it may have resulted in concomitant alterations in both end-diastolic and end-systolic volumes.

There is wide variation in the dosage of propranolol required for clinical relief of angina.²¹ In part, this may be due to marked differences in sympathetic tone from one patient to another. However, in the basal state, beta-adrenergic support to left ventricular function is probably minimal. The most commonly used clinical criterion for determining adequacy of dosage is reduction of the resting pulse, usually to 50 to 60 beats/minute. This was the heart rate response most frequently encountered in patients in this study, all were felt to have received maximal or close to maximal beta-blocking therapy for angina by their referring physicians.

Although serum propranolol levels also demonstrate wide variability, serum levels of 50 to 100 ng/ml are regarded nevertheless as indicating a

significant degree of beta blockade²¹ Pine and colleagues²² suggested that maximal beta blockade to endogenous stimuli occurs at serum levels of 100 ng/ml. In the present study, the peak dosage of 224 ± 27 mg/day and corresponding serum levels of 85 ± 22 ng/ml may not represent maximal beta blockade but are compatible with a significant drug effect and are values commonly encountered in clinical practice.

Several studies have demonstrated a temporal disparity between serum propranolol levels and the degree of beta blockade. Faulkner and associates³ could not detect propranolol in the plasma or left atrial tissue obtained from patients undergoing bypass surgery in whom propranolol had been withdrawn 36 to 48 hours earlier. Furthermore, the norepinephrine sensitivity of left atrial tissue obtained from these patients did not significantly differ from control patients. Romagnoli and Keats²⁴ assessed the effects of isoproterenol infusion on patients with coronary artery disease 18 hours after withdrawal of chronic oral propranolol therapy. There was no significant difference in heart rate response between the propranolol treated group and a control group with coronary artery disease. Leaman and co-workers¹ failed to demonstrate any depression of heart rate, cardiac output, or triple product 36 hours following discontinuation of oral propranolol. The difficulties in relating the magnitude of beta blockade to serum propranolol levels following oral administration are further compounded by the presence of metabolites such as 4-hydroxypropranolol which also have beta blocking properties.⁶

It is conceivable therefore that in the present study while plasma propranolol levels at the final measurement were virtually undetectable there were residual beta blocking effects present at the time of this study. Nevertheless, the significant decrease in propranolol levels and concomitant increase in heart rate suggests that a substantial reduction in the effects of propranolol had occurred during the study period. The results of the present study are similar to those of Marshall and colleagues¹ who sequentially assessed the effects of increasing oral propranolol dosage upon left ventricular performance in patients with stable angina or ventricular arrhythmias. Increases in dosage occurred at intervals of at least 48 to 72 hours. While propranolol levels significantly increased and heart rate declined, there

was no significant change in left ventricular ejection fraction, ejection rate or regional wall motion noted.

It must be emphasized that the majority of the patients in this study had normal ventricular function. Only six had regional wall motion disturbances and five had abnormal ejection fraction. The effects of propranolol upon basal ventricular performance in the patient with more pronounced intrinsic myocardial dysfunction may differ considerably from those observed in the present study. Coltart and co-workers¹ noted adverse effects of intravenous propranolol only in those patients with preexisting severe myocardial dysfunction. Two patients with anterior wall hypokinesis at left ventriculography demonstrated normal regional wall motion with radionuclide angiography. It is possible that subtle changes in regional wall motion induced by propranolol in these two patients may be beyond the current resolution of the radionuclide technique employed. However, since contrast angiographic and radionuclide studies were separated by several months, direct comparison of these two studies may not be valid in these patients.

Two points require additional emphasis. The present study was performed in the basal state. No statement can be made concerning the response of the left ventricle to stress in a patient receiving propranolol. This has particular relevance to the clinical question of propranolol withdrawal prior to cardiac surgery. Although ventricular performance was unchanged in these patients preoperatively, responses to anoxic or ischemic stress or the effects of prolonged cardiopulmonary bypass might be quite different. Finally, the situation of acute myocardial infarction and sudden death developing during abrupt preoperative propranolol withdrawal has been reported.²⁵ Although this study does not address that clinical question, the data would indicate that the major change in resting myocardial oxygen requirements during propranolol withdrawal results from an increase in heart rate rather than from major changes in global or regional left ventricular pump performance.

Summary

The effects of oral propranolol upon left ventricular performance were assessed in 18 patients with angiographically documented coronary artery disease in whom propranolol was

tapered prior to elective aortocoronary bypass surgery. Left ventricular ejection fraction, ejection rate and regional wall motion were obtained on three occasions with first pass radionuclide angiocardiographic techniques. Patients were studied at peak propranolol dose (\pm SEM) 234 ± 29 mg/day serum propranolol level 85 ± 22 ng/ml, intermediate dose (99 ± 9 mg/day serum propranolol 30 ± 11 ng/ml) and 24 hours following discontinuation of propranolol therapy.

Heart rate increased significantly (62 ± 23 vs 67 ± 30 vs 73 ± 23 beats/minute $p < 0.001$) during propranolol withdrawal while systolic blood pressure did not change significantly (1147 ± 43 vs 1103 ± 30 vs 113 ± 30 mm Hg $p > 0.05$). There was no significant change in ejection fraction (59.1 ± 2.4 vs 60.4 ± 2.0 vs 59.2 ± 2.5 per cent) or ejection rate (2.60 ± 0.18 vs 2.87 ± 0.18 vs 2.92 ± 0.20 sec⁻¹) as propranolol was tapered ($p > 0.05$). No patient demonstrated a change in regional wall motion in response to propranolol withdrawal. The results of this study suggest that oral propranolol in commonly used clinical dosages does not significantly affect radionuclide measures of left ventricular performance in the basal state.

We thank Dr Ronald Leonardi of Ayerst Laboratories New York, N.Y. for obtaining the serum propranolol assays as well as Ms Linda Pytluck for technical assistance and Ms Coletta Sawyer for secretarial assistance.

REFERENCES

1. Wolfson S and Corlin R. Cardiovascular pharmacology of propranolol in man. *Circulation* 40:501 1969.
2. Robin E, Covan C, Puri P, Ganguly S, DeBoyre E, Martinez M, Stock T and Bung R. A comparative study of nitroglycerin and propranolol. *Circulation* 36:175 1967.
3. Coltart H J, Alderman E L, Robinson S C, and Harrison D. Effect of propranolol on left ventricular function: segmental wall motion and diastolic pressure-volume relation in man. *Br Heart J* 37:357 1975.
4. Shubrooks S J, Zur L M, Dinsmore H E and Hawthorne J W. Left ventricular wall motion response to intravenous propranolol. *Circulation* 52:124 1975.
5. Leaman D M, Levenson L W, Shroff H A, Babb J D, DeJoseph R L, Hayek A H and Zelis R. Persistence of biologic activity after disappearance of propranolol from the serum. *J Thorac Cardiovasc Surg* 72:67 1976.
6. Friedman W, Smithen C, Besser H, Kliffeld P and Philip T. Noninvasive assessment of clinical response to oral propranolol therapy. *Am J Cardiol* 35:635 1975.
7. Teichholz L E, Kruken T, Herman M V and Gorlin R. Problems in echocardiographic volume determination: echocardiographic-angiographic correlation in the presence or absence of asynergy. *Am J Cardiol* 37:7 1976.

8. Van Dyke D, Anger H G, Sullivan H W, Vetter W R, Yano Y, and Parker H G. Cardiac evaluation from radiotracer dynamics. *J Nucl Med* 13:585 1972.
9. Steele P, Kirch D, Le Free M and Battcock D. Measurement of right and left ventricular ejection fractions by radionuclide angiocardiography in coronary artery disease. *Chest* 70:51 1976.
10. Schellert H H, Verha J W, Johnson H H, Brock H W, Alazraki N P, Rose F J and Ashburn W L. Nontraumatic determination of left ventricular ejection fraction by radionuclide angiocardiography. *Circulation* 51:902 1975.
11. Steele P, Kirch D, Mathews M and Davies H. Measurement of left heart ejection fraction and end diastolic volume by a computerized scintigraphic technique using a wedged pulmonary arterial catheter. *Am J Cardiol* 34:199 1974.
12. Marshall H C, Berger H J, Costin J C, Freedman G S, Wolberg J, Cohen L S, Gottschalk A and Zaret H L. Assessment of cardiac performance with quantitative radionuclide angiography: sequential left ventricular ejection fraction normalized left ventricular ejection rate and regional wall motion. *Circulation* 55:870 1977.
13. Marshall R C, Berger H J, Reduto L A, Gottschalk A and Zaret H L. Variability in sequential measures of left ventricular performance assessed by radionuclide angiocardiography. *Am J Cardiol* 41:89 1978.
14. Shand D G, Nuckolls E M and Oates J A. Plasma propranolol levels in adults with observations in four children. *Clin Pharmacol Ther* 11:112 1970.
15. Dwyer E M, Wiener L and Cox J W. Effects of beta adrenergic blockade (propranolol) on left ventricular hemodynamics and the electrocardiogram during exercise-induced angina pectoris. *Circulation* 38:250 1968.
16. Miller R R, Vismara L A and Mason D T. Comparative effects of tolazamol and propranolol on cardiac and peripheral circulatory function in patients with coronary artery disease. *Clin Pharmacol Ther* 17:713 1975.
17. LeWinter M M, Crawford M H, Karlner J S and O'Rourke H A. Effects of oral propranolol in normal subjects. *Clin Pharmacol Ther* 17:709 1975.
18. Henning H, Schellert H, Crawford M H, Karlner J S, Ashburn W and O'Rourke R A. Left ventricular performance assessed by radionuclide angiocardiography and echocardiography in patients with previous myocardial infarction. *Circulation* 52:1069 1975.
19. Brutsaert D L and Sonnenblick E H. Cardiac muscle mechanics in the evaluation of myocardial contractility and pump function: problems, concepts and directions. *Prog Cardiovasc Dis* 16:337 1973.
20. Corolly M E, Kersten F and Dollery C T. The clinical pharmacology of beta adrenoceptor blocking drugs. *Prog Cardiovasc Dis* 19:703 1976.
21. Shand D G. Drug therapy: propranolol. *N Engl J Med* 293:280 1975.
22. Fine M, Favrat L, Smith S, McDonald K and Chudsey C A. Correlation of plasma propranolol concentrations with therapeutic response in patients with angina pectoris. *Circulation* 55:886 1975.
23. Faulkner S L, Hopkins J T, Boerth R C, Young J L, Jellert J B, Niem A S, Bender H W, and Shand D G. Time required for complete recovery from chronic propranolol therapy. *N Engl J Med* 283:607 1973.
24. Romagnoli A and Keats A S. Plasma and atrial propranolol after preoperative withdrawal. *Circulation* 52:1123 1975.
25. Marshall R C, Berger H J, Reduto L A, Cohen L S.

- Gottschalk A and Zaret E L Effect of oral propranolol therapy upon left ventricular performance in coronary artery disease: noninvasive assessment by sequential radionuclide angiocardiology (Abstr.) *Circulation* (Suppl III) 32: 1977
- 26 Miller H R, Olson H G, Amsterdam E A., and Mason D T Propranolol withdrawal rebound phenomenon: Exacerbation of coronary events after abrupt cessation of antianginal therapy. *N Engl J Med* 293: 416, 1975
- 27 Nellen M Withdrawal of propranolol and myocardial infarction. *Lancet* 1: 558, 1973
- 28 Alderman E L, Coltart D J, Wettach G E and Harrison D Coronary artery syndromes after sudden propranolol withdrawal. *Ann Intern Med* 81: 63, 1974

Information for authors

Most of the provisions of the Copyright Act of 1976 became effective on January 1, 1978. Therefore, all manuscripts must be accompanied by the following written statement signed by one author: "The undersigned author transfers all copyright ownership of the manuscript (title of article) to The C. V. Mosby Company in the event the work is published. The undersigned author warrants that the article is original, is not under consideration by another journal, and has not been previously published. I sign for and accept responsibility for releasing this material on behalf of any and all co-authors. Authors will be consulted when possible regarding republication of their material."

Electrophysiological studies in four patients with atrial flutter with 1:1 atrioventricular conduction

Brian M Kennelly MB ChB PhD MRCP FACC

Geoffrey K Lane BSc MB BS MRACP*

Cape Town, South Africa

Atrial flutter with sustained 1:1 atrioventricular (AV) conduction is an uncommon dysrhythmia which normally causes serious hemodynamic disturbance. It may develop as a result of treatment of atrial flutter with drugs which can accelerate AV conduction such as quinidine, procainamide, atropine and phenytoin sodium. It has been described as an uncommon complication in patients with pre-excitation syndromes particularly during electrophysiological study¹⁻³ but has also occasionally been documented as occurring spontaneously in patients without obvious evidence of pre-excitation in some of whom the arrhythmia may have been precipitated by factors increasing sympathetic tone such as physical or emotional stress, induction of anaesthesia or thyrotoxicosis. Castellanos and co-workers⁴ have suggested that patients manifesting atrial flutter with spontaneous 1:1 AV conduction may have partial AV nodal bypass tracts and this postulate has been supported by electrophysiological studies in one such patient reported by Aranda and colleagues.⁵ To investigate this hypothesis further we have performed electrophysiological studies in four patients with no electrocardiographic evidence of pre-excitation who developed atrial flutter with spontaneous 1:1 AV conduction.




Fig 1 Electrocardiograms of Case 1 during atrial flutter with 1:1 and 2:1 AV conduction and following conversion to sinus rhythm (1° lead ECG)

Patients and methods

Patient selection An electrocardiographic diagnosis of atrial flutter with 1:1 AV conduction was made in patients with a regular tachycardia exceeding 230 per minute without evidence of AV dissociation in whom the atrial rate could be shown to be unchanged during second degree AV block when present in the previous or subsequent electrocardiogram and in whom the QRS morphology when in sinus rhythm was similar to that seen during the tachyarrhythmia.

These criteria were fulfilled in four patients, in

From the Cardiac Clinic, Groote Schuur Hospital, and Department of Medicine, University of Cape Town, Cape Town, South Africa.

Received for publication June 12, 1978.

Accepted for publication Feb 2, 1979.

Reprint requests: Dr B M Kennelly, Cardiac Clinic, Groote Schuur Hospital, Observatory 7925, South Africa.

Supported by a Grant from Sandak Ltd. Present address: Cardiology Department, Fremantle Hospital, Fremantle, Western Australia 6060.

- Gottschalk A and Zaret M L Effect of oral propranolol therapy upon left ventricular performance in coronary artery disease: noninvasive assessment by sequential radionuclide angiocardiology (Abstr.) *Circulation* (Suppl III) 32: 1977
- 26 Miller R R, Olson H G, Amsterdam M A and Mason D T Propranolol withdrawal rebound phenomenon: Exacerbation of coronary events after abrupt cessation of antianginal therapy. *N Engl J Med* 293: 416, 1975
- 27 Nellen M Withdrawal of propranolol and myocardial infarction. *Lancet* 1: 558, 1973
- 28 Alderman E L, Coltart D J, Wettach G E and Harrison D Coronary artery syndromes after sudden propranolol withdrawal. *Ann Intern Med* 81: 623, 1974

Information for authors

Most of the provisions of the Copyright Act of 1976 became effective on January 1, 1978. Therefore, all manuscripts must be accompanied by the following written statement signed by one author: "The undersigned author transfers all copyright ownership of the manuscript (title of article) to The C. V. Mosby Company, in the event the work is published. The undersigned author warrants that the article is original, is not under consideration by another journal, and has not been previously published. I sign for and accept responsibility for releasing this material on behalf of any and all co-authors." Authors will be consulted, when possible, regarding republication of their material.

Table 1 Clinical data

Patient No	Sex & age	Presentation	ECG during tachyarrhythmia	Comment
1	Male 26	Angina effort dyspnea and palpitations for 2 months Right basal pneumonia	Atrial flutter 310/min with 1:1 AV conduction QRS width 0.08 sec 2:1 AV conduction after verapamil (Fig 1)	Studied 90 months after presentation. No recurrence of arrhythmia. Off therapy for 19 months
2	Male 53	Episodic palpitations for 1 year Angina and dyspnea with palpitations for 3 weeks	Atrial flutter 290/min with 1:1 AV conduction QRS width 0.12 sec (RBBB) Variable 2:1 AV block after verapamil (Fig 2)	Studied 15 months after presentation. No recurrence of arrhythmia. Off therapy for 6 months
3	Male 53	Symptoms of hyperthyroidism palpitations with angina and sweating for 8 months	Atrial flutter 290/min with 1:1 AV conduction QRS width 0.09 sec Variable 2:1 AV block after verapamil and practolol (Fig 3)	Studied 3 years after presentation. No recurrence of symptoms after treatment of thyrotoxicosis with I
4	Male 48	Recurrent palpitations and dizziness for 7 years. Sick sinus syndrome with 1:1 AV block Left axis deviation and intraventricular conduction disturbance. Congestive cardiomyopathy	Atrial flutter 40/min with 1:1 AV conduction QRS width 0.18 sec Atrial flutter 40/min with variable 2:1 AV block after digitalization (Fig 4)	Studied 2 months prior to presentation with atrial flutter and 1:1 AV conduction

of study. A tripolar electrode catheter was introduced percutaneously via the right femoral vein to record the His bundle electrogram as described by Scherlag and co-workers⁶ and a quadripolar electrode catheter (inter electrode distance 1 cm) introduced by the same route was positioned along the lateral border of the right atrium. The distal pair of electrodes was used to stimulate the right atrium and the proximal pair to record a right atrial electrogram. Standard electrocardiographic Leads I, II, III, VI and V and intracardiac electrograms were recorded at a paper speed of 100 mm/sec using an eight channel direct writing ink jet recorder.* Electric stimulation from the mid right atrium was performed for 60 second periods at progressively higher rates until second degree AV block developed. Recordings were made during the last 30 seconds of each period and time was allowed between each pacing period for the rhythm to return to the control rate. The refractory periods of the AV conducting system were then measured by the extrastimulus method.* Using a Medtronic SP 1349A pulse generator* the right atrium was paced at a cycle length slightly less

than that of the sinus node and premature atrial impulses of 2 msec duration and approximately twice diastolic threshold were introduced after every eighth paced beat. The coupling interval of the premature atrial impulse was reduced by 5 to 10 msec decrements until the atrium became refractory. In three patients repeated studies were performed at shorter paced atrial cycle lengths. After completion of these baseline measurements three of the four patients received 0.75 mg strophanthin intravenously (IV) over a period of approximately 15 minutes and both atrial pacing and atrial premature stimulation studies were repeated after 20 to 70 minutes.


Definition of terms. Standard definitions and normal values for AV conduction times (PA 27 ± 18 msec, AH 92 ± 38 msec, HV 43 ± 12 msec) were used.¹⁰

The maximal pacing rate was defined as the highest atrial pacing rate at which consistent 1:1 AV conduction could be maintained.

The pacing range was defined as the difference between the minimal and maximal atrial pacing rates per minute for each pacing study.

The Δ AH was defined as the difference between the AH intervals at the maximal and minimal atrial pacing rates.

lead II atrial flutter 290/min 1:1 response



CSM






after verapamil 15mg IV
atrial flutter 290/min with irregular ventricular response

Fig 2 Electrocardiograms of Case 2. Upper three panels show continuous rhythm strips during atrial flutter with the development of varying second degree AV block during carotid sinus massage (CSM) and subsequently after intravenous verapamil. Note wide QRS complexes during atrial flutter. Lower two panels show 12 lead ECG following conversion to sinus rhythm.

three of whom electrophysiological studies were performed 15 months to 3 years after atrial flutter with 1:1 AV conduction had first been documented. In the fourth patient the electrophysiological study had been performed because of an undiagnosed tachyarrhythmia 2 months prior to documented atrial flutter with 1:1 AV conduction.

Clinical details of the four patients are summarized in Table I and their ECGs both during atrial flutter with 1:1 AV conduction and during sinus rhythm are shown in Figs 1 to 4. It should be noted that none of the four patients had abnormally short PR intervals nor delta waves to suggest pre-excitation on their 12 lead ECG during sinus rhythm.

monitor lead





after verapamil & procainolol IV
monitor lead atrial flutter 290/min 2° AV block

Fig 3 Electrocardiograms of Case 3 during atrial flutter with 1:1 conduction and varying second degree AV block and following conversion to sinus rhythm (12 lead ECG).



after digoxin





Fig 4 Electrocardiograms of Case 4 during atrial flutter with 1:1 conduction and varying second degree AV block and following conversion to sinus rhythm (12 lead ECG). Note wide QRS complex during atrial flutter with 1:1 conduction.

Methods Informed consent was obtained from all patients for intracardiac electrophysiological studies which were performed using local anesthesia in the postabsorptive non sedated state. No patient was taking cardioactive drugs at the time




Fig 5 Graphic representation of changes in AH intervals at increasing atrial pacing rates during 1:1 AV conduction in each of the four cases both in the control state (closed circles) and following intravenous atropine (open circles). ΔH = total increase in AH interval (msec) over the range of pacing rates.

increasing rates of atrial pacing. In Cases 2 and 3 there was no significant change in the ΔAH or AH gradients after intravenous atropine. In Case 1 however the ΔAH was abnormally short (20 msec) with an AH gradient of only 17 in the control state but after intravenous atropine the ΔAH and AH gradients increased to values of 70 msec and 71 respectively. These increases were largely due to a sudden increase in the AH interval only at maximal atrial pacing rates.




Fig 6 AV function curves derived from extrastimulus studies during paced atrial rhythm (CL = cycle length) in each of the four cases. Studies performed in the control state are shown on the left hand panels and those following intravenous atropine on the right. In each panel A A coupling intervals are plotted on the abscissa and H H (closed circles) and V V (open circles) on the ordinate.

Refractory periods. For each patient the refractory periods of the atrium, AV node and ventricular specialized conducting system as determined by the extrastimulus technique are summarized in Table III. Representative AV function curves both before and after intravenous atropine from which the AV refractory periods were measured are illustrated in Fig 6.

The atrial functional refractory period in the

Table II AV conduction times and results of atrial pacing

Case No	AV conduction times (msec)					Atrial pacing data			
	Sinus cycle length	PA	AH	HV	PR	Maximal pacing rate (beats/min)	Pacing range (beats/min)	Δ AH (msec)	AH gradient
1	735	20	95	45	160	C 218 D 218	118 98	20 70	17 71
2	955	30	105	50	185	C 200 D 171	134 85	95 70	71 8 ^a
3	1005	15	130	50	185	C 207 D 207	147 132	100 85	68 64
4	— ^a	30	145	85	260	C 150	105	67	64

C = control D = following IV strophanthin

Pacing range = difference between minimal and maximal atrial pacing rates per minute

^a = junctional rhythm with occasional non consecutive sinus beats

The AH gradient was obtained by dividing the Δ AH interval by the pacing range in each study

The functional refractory period of the atrium was defined as the shortest attainable interval between two successive atrial depolarisations (A' A''). The relative refractory period (RRP) of the AV node was defined as the longest A' A' interval at which H' H' was longer than A' A'.

The functional refractory period (FRP) of the AV node was defined as the shortest interval between two successive His bundle responses propagated from the atrium

The effective refractory period (ERP) of the AV node was defined as the longest A' A' interval that failed to conduct to the bundle of His

Results

AV conduction times Three of the four patients were in sinus rhythm at the time of study and showed normal PR intervals and AV conduction times (Table II). The fourth patient was cardioverted at the beginning of the study from atrial tachycardia (210/minute) conducted with 2:1 AV block to an unstable junctional rhythm (mean ventricular rate 43/minute) with intermittent episodes of sinus bradycardia and escape capture bigeminy. Both AH and HV times were prolonged.

Atrial pacing In three of the four patients the maximal rate of pacing at which 1:1 AV conduction was maintained was determined before and after IV strophanthin. In these patients the control values were in excess of 200/minute (range 200 to 218/minute) (Table II). These rates

although fast, were considerably slower than the maximal rate at which 1:1 conduction occurred spontaneously during atrial flutter. Although intravenous strophanthin significantly prolonged the AH interval at any particular pacing rate in all three cases (Fig 5), it reduced the maximal pacing rate achieved in only one of the three (Case 2). In the fourth patient Wenckebach AV block developed at atrial pacing rates above 150/minute and in this patient the effect of intravenous strophanthin was not assessed.

The results of atrial pacing were also analyzed by plotting AV nodal conduction times (AH intervals) against the rate of pacing both in the control state and after intravenous strophanthin (Fig 5). As has been shown in normal subjects by Scherlag and colleagues,¹¹ the AH interval increased almost linearly with increasing pacing rates in three of the four patients. The total increase (Δ AH) was expressed as a function of the pacing range to give a figure representing the gradient of the AH response to rapid atrial stimulation (AH gradient). To obtain normal values AH gradients were calculated from two previously reported studies comprising 24 apparently normal subjects with normal PR intervals in whom Wenckebach AV block did not develop at pacing rates less than 120/minute.^{11, 12} In these patients values for Δ AH ranged from 35 to 160 msec and AH gradient varied from 29 to 2.76 (mean \pm SD = 1.31 ± 0.63).

In Cases 2, 3 and 4 the control values for Δ AH with AH gradients (Table II) fell within the above normal ranges, indicating a normal increase in AV nodal conduction time with

were significantly prolonged following ouabain. The authors concluded that these results were compatible with either a partial AV nodal bypass or an AV node with unusual capacity for rapid conduction.

In this study we were faced with a similar difficulty in interpretation of the data because of limited data on normal values for the responses of AV conduction to atrial pacing and for AV nodal refractory periods. In adult patients without clinical or electrocardiographic evidence of AV nodal disease previous investigators have shown that the atrial pacing rate at which Wenckebach AV block first developed ranged from (mean \pm SD) 150.0 ± 24.2 to 170.2 ± 26.8 beats/minute with two of the four patients studied by Reddy and associates¹ showing 1:1 AV conduction to rates of 200/minute. That this is an age related phenomenon has been demonstrated by Pahlam and colleagues¹⁰ who showed that 9 of 13 children under the age of 13 years developed Wenckebach AV block at atrial pacing rates only in excess of 200/minute and that under the age of 3 years 1:1 AV conduction at rates in excess of 250/minute was common. It has been suggested by these authors that adults manifesting 1:1 AV conduction at very rapid rates may have immature AV nodes without bypass tracts. Although three of the four patients in this study manifested 1:1 AV conduction at rates in excess of 200/minute in none did the rate at which Wenckebach AV block developed during paced atrial rhythm approach the maximum ventricular response achieved during spontaneous atrial flutter. A similar contrast between the rate at which 1:1 AV conduction occurred during atrial pacing and that occurring spontaneously or induced by exercise has been observed previously¹ and has been attributed to the conduction delay in the nodal tissues produced by pacing induced liberation of acetylcholine.

The limits of normality for incremental change in AH interval with atrial pacing at increasing rates are not well defined. Caracta and colleagues¹¹ quote an average normal value for Δ AH of 120 msec without tabulating the original data. Comparing the results in our four patients with those of two series of adults without ECG evidence of AV nodal disease or pre-excitation in whom suitable data on the normal response to atrial pacing is available^{1,2} only one patient (Case 1) demonstrated an abbreviated increase in the AH interval during atrial pacing (Δ AH = 20

msec, AH gradient = 17) suggesting the possibility of a partial AV nodal bypass.

In assessing the results of the extrastimulus studies in these patients the problem of definition of the normal values again arises particularly in view of the evidence that AV nodal refractory periods in man are both rate and age dependent.^{1,2} Comparison of the data for AV nodal refractory periods in this study with that of five previous studies which have examined these parameters in normal subjects at similar driven cycle lengths¹⁻⁵ showed that the values for FRP and ERP of the AV node in all four patients were within these normal limits. Only the AV nodal RRP in Case 1 appeared unusually short.

We conclude that a partial AV nodal bypass could explain the 1:1 ventricular response during atrial flutter in Case 1. However, no evidence for an AV nodal bypass tract could be found in the remaining three cases. Other possible explanations include alteration in sympathetic tone during prolonged attacks of atrial flutter affecting the conduction properties of the AV node¹ or alteration in the AV nodal functional refractory period with continuous and prolonged rapid atrial stimulation during atrial flutter. A different route of entry of the wavefront into the AV conducting system during atrial flutter could have influenced the properties of the normal AV node thus explaining discrepancies between the ventricular rate during atrial flutter compared to that observed during high right atrial overdrive pacing. Janse's³ animal work showed how the site of atrial stimulation could influence the route of entry of the atrial wavefront and hence the conduction properties of the AV node. Clinical studies also have shown the effects of varying the site of atrial pacing on AV nodal refractory periods, Δ AH and AH gradients.^{1,12} The case reported by Aranda and colleagues⁷ in whom dual AV nodal pathways were demonstrable during pacing from the high right atrium or coronary sinus but not from the mid right atrium suggests that access to an AV nodal bypass tract could have been denied to impulses arising from the sinus node or during high right atrial overdrive pacing but not during atrial flutter in Cases 2, 3 and 4. This has not however been described thus far in the presence of a normal PR interval on the resting electrocardiogram and seems less likely. Without studies of AV conduction from multiple sites within right and

Table III

		Atrium			AV node		
		CL	FRP	ERP	RRP	FRP	ERP
Case 1	C	700	260	260	360	325	260
	D	700	250	250	360	315	260
Case 2	C	900	320	285	740	395	320
		700	300	230	625	380	≥300
	D	900	330	250	800	415	≥330
Case 3		700	310	230	650	390	310
	C	900	320	280	720	≥360	≥320
		800	280	240	480	≥330	≥280
		700	290	270	585	≥335	≥290
		800	270	250	560	325	≥270
	D	900	270	250	540	330	≥270
Case 4	C	1100	280	240	725	415	≥280
		550	≥380*	≥380*	≤540	445	390

All measurements are in msec

CL = cycle length C = control D = after IV strophanthin
FRP = functional refractory period ERP = effective refractory period

* Shorter atrial coupling intervals were not attempted

control state ranged from 320 to 260 msec, tended to be shortened by reduction in paced atrial cycle length, and was the rate limiting determinant of AV conduction only in Case 3. It was not significantly altered by strophanthin. The AV nodal functional refractory period in the control state, varied from 325 to 445 msec in the three patients in whom it could be determined and its response to alteration in paced cycle length was variable. As the paced atrial cycle length was decreased the FRP (AVN) increased in one patient, and decreased in the other two. The AV nodal FRP was the rate limiting determinant of conduction in three of the four cases. The AV nodal effective refractory period (ERP) could then only be determined in three patients and ranged from 260 to 390 msec. It was not significantly altered by strophanthin and was also variably affected by reduction of the paced atrial cycle length. Refractoriness of the His Purkinje system was not a rate limiting determinant of AV conduction in any case.

The relative refractory period of the AV node in the control state was short only in Case 1 (RRP = 360 msec at CL = 700 msec). Following strophanthin the RRP remained unchanged in Case 1, but was lengthened in the other two cases. Neither reciprocating tachycardias nor changes in QRS morphology suggesting ventricular pre excitation were observed during extrastimulus studies either before or after strophanthin. No attempt

was made by ventricular premature stimulation to exclude the presence of a concealed accessory pathway with only retrograde V A conduction.

Discussion

Although over 60 cases of atrial flutter with 1:1 AV conduction have been reported previously,¹ in many of these cases the electrocardiographic diagnosis has been open to dispute particularly when the QRS complexes have been wide the rates less than 230/minute and atrial flutter with higher grades of AV block has not been demonstrated. For this reason we have used relatively rigid criteria for the diagnosis of atrial flutter with 1:1 AV conduction and although the selection of a rate of 230/minute or more as an arbitrary one it is supported by previously reported studies of atrial flutter¹¹ and also emphasizes the phenomenon of 1:1 AV conduction at rapid atrial rates, irrespective of the type of supraventricular arrhythmia.

Very few electrophysiological studies of patients with atrial flutter and 1:1 AV conduction have been reported. Durrer¹ described a 38 year old woman with a short PR interval (0.07 sec) who presented with attacks of supraventricular tachycardia with 1:1 AV conduction (rate 250/minute) in whom catheter manipulation in the right atrium during electrophysiological study resulted in a similar tachycardia requiring electrical cardioversion. Her AV conduction time during right atrial pacing was only 70 msec suggesting an AV nodal bypass. Wellens investigated a 35 year old woman with a PR interval of 12 sec who had an 18 year history of palpitations due to supraventricular tachycardia at a rate of 220/minute. He found evidence of a probable anomalous AV connection from left atrium to an area close to the tail of the AV junction. During this study atrial overdriving of the supraventricular tachycardia at 300/minute provoked atrial flutter with 1:1 AV conduction (rate 270/minute) with rapid loss of consciousness. A more detailed investigation in a 43 year old man with documented atrial flutter and 1:1 AV conduction (rate 270/minute) has been reported by Aranda and colleagues.⁵ In this patient the PR interval was 16 sec and the maximal pacing rate was 215/minute with an AH increment (Δ AH) of 35 msec and an AH gradient of 25. The onset of the AV nodal RRP was shortened at 335 msec the AV nodal FRP was 350 msec, and the AV nodal ERP was less than 280 msec. All refractory periods

Leukocyte intracellular cations in hypertension

Effect of antihypertensive drugs

Matthew A Araoye M II BS

Ibrahim M Khatir MD

Linda L. Yao MS

Edward D Freis MD

Washington II C

There is a considerable body of evidence which indicates that sodium (Na) is an important factor in the development of hypertension. Epidemiologic studies have shown that unacculturated peoples who have no access to salt do not develop hypertension in contrast to all salt eating societies where hypertension is common. Clinical studies have documented that reduction in body sodium using saluretic agents or low salt diets often lowers blood pressure. Experimental studies have shown that hypertension can be induced in susceptible strains of rats by salt loading. Most studies to date have been concerned with the assessment of total extracellular and plasma volumes and of extracellular Na concentration as methodological problems have made it difficult to measure the intracellular content of Na in man. However methods have been developed recently for determining Na and other cations in leukocytes. These represent living nucleated cells that are easily obtained by venipuncture. Recently Edmonson and associates¹ reported that the Na and water content of leukocytes (WBC) is increased in hypertensive patients. In the present study the WBC Na, potassium (K), magnesium (Mg) and water content have been determined in normal subjects and in patients with essential hypertension.

No information is presently available regarding the effect of antihypertensive drugs on intracellular cations. Therefore we have also determined intracellular water and cation changes in leukocytes (WBC) before and after treatment with four antihypertensive agents: hydrochlorothiazide (HCTZ), reserpine (RES), alpha methyl dopa (AMD) and hydralazine (HDZ).

Materials and methods

Comparison of normotensive and hypertensive subjects The study group comprised 32 normotensive men and 47 male patients with uncomplicated hypertension. The blood pressure of the hypertensive patients taken in the sitting position ranged between 130/96 and 190/128 mm Hg with an average mean blood pressure (MBP) of 128 mm Hg. MBP was estimated by taking the sum of the diastolic blood pressure and one third of the pulse pressure. The blood pressure of the normal subjects ranged between 100/70 and 160/86 mm Hg with an average MBP of 95 mm Hg. The average age of the hypertensive patients was 47 years as compared to 44 years in the normal group. No patients with renal or cardiac failure were included; the highest serum creatinine level being 2.2 mg per cent. Forty five patients had not received previous antihypertensive drug therapy while in the remainder treatment had been discontinued for 4 weeks or longer prior to drawing the blood samples.

Effects of antihypertensive agents The study group comprised 51 hypertensive patients. The following criteria were used for selecting these subjects: either no prior treatment or absence of any antihypertensive drug medication within a period of at least four weeks prior to the study. Diastolic blood pressure of 90 to 114 mm Hg.

From the Veterans Administration Hospital, and the Department of Medicine, Georgetown University, Washington, D.C.

Received for publication June 4, 1978

Accepted for publication May 12, 1978

Reprint requests: Edward D. Freis, MD, VA Hospital, 40 Irving St. NW, Washington, D.C. 20422.

left atria and coronary sinus, these suggested mechanisms must remain speculative

Summary

Electrophysiological studies of atrioventricular conduction during rapid atrial overdrive pacing and during programmed premature atrial stimulation are reported in four patients with an unusually rapid 1:1 ventricular response to atrial flutter (ventricular rates 240 to 310 per minute). Second degree AV block developed during atrial overdrive pacing at rates well below those during which 1:1 AV conduction was sustained during spontaneous atrial flutter. Although none of the four patients showed evidence of pre excitation on the standard 12 lead electrocardiogram, evidence suggesting a partial AV nodal bypass was demonstrated at electrophysiological study in one case. It is postulated that the profile of the atrial wavefront presented to the normal AV node by atrial flutter differs from that during high right atrial pacing and may account for the lower ventricular rates achieved during high right atrial overdrive pacing than during spontaneous atrial flutter in the remaining three cases.

The authors express their appreciation to the Medical Superintendent of Groote Schuur Hospital for permission to publish these findings, to Miss Alison Shennan and Mr L. W. Piller for technical help and to Miss M. Kavalsky for secretarial help.

REFERENCES

- Durrer D. Electrical aspects of human cardiac activity. A clinical-physiological approach to excitation and stimulation. *Cardiovasc Res* 2:1 1968.
- Wellens H J J. Electrical stimulation of the heart in the study and treatment of tachycardia. Baltimore 1971. University Park Press p 110.
- Bellet S. Clinical disorders of the heart beat. Philadelphia 1971. Lea & Febiger Publishers p 191.
- Castellanos A, Vagueiro M C, Befeler B and Myerburg R J. Syndrome of short PR, narrow QRS and repetitive supraventricular tachyarrhythmias: the possible occurrence of the R on T phenomenon and the limits of this syndrome. *Eur J Cardiol* 2:337 1975.
- Aranda J M, Moleiro F, Castellanos A and Befeler B. Electrophysiological studies in a patient with atrial flutter and 1:1 atrioventricular conduction. *Chest* 68:200 1975.
- Scherlag B J, Lau S H, Helfant R H, Berkowitz W D, Stein E and Damato A N. Catheter technique for recording His bundle activity in man. *Circulation* 39:13 1969.
- Krayer O, Mandoki J J and Mendez C. Studies on veratrum alkaloids. XVI. The action of epinephrine and of veratramine on the functional refractory period of the auriculo ventricular transmission in the heart-lung preparation of the dog. *J Pharmacol. Exp Ther* 103:412 1951.
- Wit A L, Weiss M B, Berkowitz W D, Rosen K M, Steiner C and Damato A N. Patterns of atrioventricular conduction in the human heart. *Circ Res* 27:34, 1970.
- Barold S S, Costes C, Cross W and Citron P. The triple pulse generator: clinical evaluation of a new multipurpose external pulse generator. *J Electrocardiol* 8:281 1975.
- Hecht H H, Kossman C E, Childers H W, Langendorf H, Lev M, Rosen K M, Pruitt R D, Truer R C, Uhley H N and Watt T B Jr. Atrioventricular and intraventricular conduction. Revised nomenclature and concepts. *Am J Cardiol* 31:232 1973.
- Scherlag B J, Narula O S, Lister J W and Samet P. Analysis of atrioventricular conduction by direct intracardiac recordings. *J Mt Sinai Hosp* 37:76, 1970.
- Damato A N, Lau S H, Helfant R H, Stein E, Berkowitz W D and Cohen S I. Study of atrioventricular conduction in man using electrode catheter recordings of His bundle activity. *Circulation* 39:287 1969.
- Lindsay J Jr and Hurst J W. The clinical features of atrial flutter and their therapeutic implications. *Chest* 66:114 1974.
- Reddy C P, Damato A N, Akhtar M, Ogunkelu J B, Caracat A R, Ruskin J N and Lau S H. Time dependent changes in the functional properties of the atrioventricular conduction system in man. *Circulation* 52:1012 1975.
- Amat y Leon F, Denes P, Wu D, Pietras R J and Rosen K M. Effects of atrial pacing site on atrial and atrioventricular nodal function. *Br Heart J* 37:56 1975.
- Pahljani D H, Miller R A and Serratto M. Patterns of atrioventricular conduction in children. *Am Heart J* 90:165 1975.
- Lister J W, Stein E, Kosowsky B D, Lau S H and Damato A N. Atrioventricular conduction in man: effect of rate, exercise, isoproterenol and atropine on the PR interval. *Am J Cardiol* 16:516 1965.
- Caracat A R, Damato A N, Gallagher J J, Josephson M E, Varghese P J, Lau S H and Westra E E. Electrophysiologic studies in the syndrome of short PR interval, normal QRS complex. *Am J Cardiol* 31:245 1973.
- Dubrow I W, Fisher E A, Amat y Leon F, Denes P, Wu D, Rosen K and Hastreiter A R. Comparison of cardiac refractory periods in children and adults. *Circulation* 51:485 1975.
- Akhtar M, Damato A N, Batsford W P, Ruskin J N and Ogunkelu J B. A comparative analysis of anterograde and retrograde conduction patterns in man. *Circulation* 52:766 1975.
- Batsford W P, Akhtar M, Caracat A R, Josephson M E, Seides F and Damato A N. Effect of atrial stimulation site on the electrophysiological properties of the atrioventricular node in man. *Circulation* 50:783, 1974.
- Denes P, Wu D, Dhingra R, Pietras R J and Rosen K M. The effects of cycle length on cardiac refractory periods in man. *Circulation* 49:32 1974.
- Jense M J. Influence of the direction of the atrial wave front on A-V nodal transmission in isolated hearts of rabbits. *Circ Res* 25:439 1969.
- Aranda J, Castellanos A, Moleiro F and Befeler B. Effects of the pacing site on A-V conduction and refractoriness in patients with short PR intervals. *Circulation* 53:33 1976.

Table III Comparison of hypertensive patients (P) with normal controls (N) by age groups

Age (yrs)	Subjects		Mean blood pressure		WBC Na content	
			Average mm Hg	Comparison of N with H	Average mEq/kg wcu	Comparison of N with H
	Type	No				
<30	N	4	89.0		20.7	
	H	3	117.0	$P < 0.025$	26.7	$P < 0.1$
30-39	N	4	89.9		15.8	
	H	6	126.2	$P < 0.005$	28.5	$P < 0.05$
40-49	N	9	100.9		21.1	
	H	17	128.8	$P < 0.005$	28.1	$P < 0.05$
50-59	N	8	94.8		20.7	
	H	19	125.2	$P < 0.005$	22.8	NS
>60	N	3	91.0		20.0	
	H	2	134.6	$P < 0.005$	17.4	NS

wcu = wet cell weight

The reproducibility of the measurement was checked by repeating the determinations one week to 3 months apart in 10 normotensive control subjects and in 16 patients with hypertension. All samples were code numbered so that the biochemist was blinded as to the identity of the samples.

Results

Comparison of normotensive and hypertensive subjects The results are illustrated in Tables I to III. Table I shows the reproducibility of the WBC cation determination. In the 10 controls (N) and in 16 patients (H) who had two blood samples one week to three months apart, there were no statistically significant differences between the values in the first determination as compared to those of the second. The r values correlating the two determinations were statistically significant ($P < 0.05$ for Na, $P < 0.005$ for K, and $P < 0.005$ for Mg).

Table II indicates that the WBC Na content was significantly higher in hypertensive patients (average 25.5 mEq/Kg wet cell weight (wcu)) than in the control group (average 19.7 mEq/Kg wcu) ($P < 0.1$). The percentage distribution of WBC sodium values are plotted in Fig. 1. The percentage of hypertensive patients at the low end of the scale of sodium concentrations is small, whereas there is a preponderance of such patients at the high end. The curve for the hypertensive patients appears shifted to the right although in the mid range of sodium values the percentage




Fig. 1 Percentage distribution of the sodium concentration of leukocytes in normal subjects (clear columns) and hypertensive patients (black columns). The distribution for the hypertensive subjects appears shifted to the right.

distribution is essentially the same in both groups. Differences in WBC K and Mg or water content and in serum Na and K, as well as in body weight, were not significant in patients as compared to the normal subjects.

Table III indicates the differences in WBC Na between normal and hypertensive subjects according to age group. It shows that whereas the MBP was significantly increased in hypertensive patients as compared to the controls of the same age in all age groups ($P < 0.025$ to $P < 0.005$), the WBC Na content was higher in hypertensive patients as compared to controls only in the age groups under 50 years ($P < 0.05$ to $P < 0.01$) and not in the older patients.

Effects of antihypertensive agents All drug regimens resulted in a significant reduction in MBP after 48 hours, two weeks, and four weeks (Table IV). Whereas the average fall in MBP was somewhat greater with HCTZ than with the other drugs (Table VI), statistically there was no significant difference between the various regimens.

WBC Na fell significantly in the patients who received HCTZ or RES (Table V). The reduction in extracellular Na was evident at 48 hours after either drug and decreased further over the subsequent 4 weeks. Neither HDZ nor AMD however produced any significant change in WBC Na. While the mean reduction in WBC Na associated with HCTZ was greater than with RES, the difference between the two was not significant.

The initial mean values of WBC Na were lower in the groups receiving HDZ or AMD than in those receiving HCTZ or RES. Since this might have influenced the results, the data were further analyzed in each drug group according to whether

Table I Reproducibility of WBC cation determinations

Variable	Mean of first determination	Mean of second determination	Significance of difference	r*
Normal controls (10)				
Na mEq/Kg	16.7	18.5	NS	87‡
wcw				
K mEq/Kg	116.2	113.7	NS	97‡
wcw				
Mg mEq/Kg	19.0	19.2	NS	81‡
wcw				
H ₂ O % wcw	64.6	65.0	NS	84‡
Hypertensive patients (16)				
Na mEq/Kg	25.0	24.2	NS	64‡
wcw				
K mEq/Kg	116.7	115.1	NS	91‡
wcw				
Mg mEq/Kg	19.9	19.5	NS	84‡
wcw				
H ₂ O % wcw	64.3	65.8	NS	50‡

*The correlation coefficient measuring the relationship between the first and second determinations

wcw = wet cell weight

‡P < 0.05

‡P < 0.05

inclusive on two or more consecutive visits or 115 to 124 mm Hg on the initial visit. Patients with diastolic blood pressure of 115 mm Hg or higher at the initial visit were begun on treatment without a second visit.

The patients were randomly assigned to one of the following drug regimens given orally: 14 patients received HCTZ 50 mg twice daily; 13 patients were given RES 0.25 mg 3 times daily for 2 days and then 0.25 mg daily; 13 received AMD 250 mg 3 times while 13 patients were given HDZ 25 mg 3 times daily. If the initial dose of HDZ or AMD failed to reduce the diastolic pressure by 5 mm Hg or more below the pretreatment level and to below 90 mm Hg diastolic, the dose was increased on succeeding visits to maximum doses of 150 mg per day HDZ and 1500 mg per day AMD.

Before initiating treatment two control blood samples for WBC and serum electrolytes were drawn one week apart, except for patients with diastolic blood pressure of 115 mm Hg or higher who had only one control blood sample. Further blood samples were drawn at 48 hours at 2 weeks and finally at 4 weeks after beginning drug administration.

Table II Comparison of 47 hypertensive patients (H) with 32 normal control subjects (N)

Variable	Subjects		Mean and standard deviation	Comparison of N and H
	Type	No		
Age (yrs)	N	32	44.0 ± 12.3	NS
	H	47	46.9 ± 8.9	
Body weight (lb)	N	27	177.2 ± 28.8	NS
	H	47	183.3 ± 47.4	
MBP (mm Hg)	N	32	94.7 ± 8.8	P < 0.01
	H	47	126.1 ± 11.3	
WBC Na (mEq/Kg wcw)*	N	32	19.7 ± 6.2	P < 0.01
	H	47	25.5 ± 7.7	
WBC K (mEq/Kg wcw)	N	32	113.1 ± 11.9	NS
	H	47	118.0 ± 11.6	
WBC Mg (mEq/Kg wcw)	N	32	19.8 ± 1.6	NS
	H	47	19.8 ± 2.3	
H ₂ O % wcw	N	32	63.2 ± 8.8	NS
	H	47	64.6 ± 3.4	
Serum Na (mEq/L)	N	31	141.7 ± 3.6	NS
	H	47	143.1 ± 3.7	
Serum K (mEq/L)	N	31	4.2 ± 0.5	NS
	H	47	4.3 ± 0.5	

wcw = wet cell weight.

Blood pressure and pulse rate in the sitting position, body weight and incidence of side effects were recorded at each visit. Mean blood pressure (MBP) was estimated by the sum of the diastolic blood pressure plus one third of the pulse pressure.

The method of Baron and Ahmed³ for measuring WBC cations and water content was used with modifications introduced by Edmondson and associates⁴ and by ourselves. A summary of the method is as follows: blood was drawn from an antecubital vein with minimal suction to avoid frothing and transferred in 8 c.c. aliquots into graduated tubes containing Dextran and heparin. The blood was allowed to sediment for 30 minutes and the WBC layer pipetted off. After centrifugation the sediment was diluted and the residual red blood cells were lysed. After a second centrifugation the WBC were transferred to a platinum crucible, weighed, dried and weighed again. They were then ashed and the cations were measured by atomic absorption spectrophotometry. The extracellular fluid volume trapped within the leukocyte mass was determined by adding ¹²⁵I-labelled human serum albumin and measuring its volume dilution. All samples were measured in duplicate.

Table V Changes in WBC cations and per cent water content during treatment

Drug	Time	Number of patients	WBC Na (mEq / Kg) %	Change	WBC K (mEq / Kg) %	Change	WBC Mg (mEq / Kg) %	Change	Percent water content	Change
HCTZ	Control	11	25.7 ± 12.7	—	1.4 ± 19.7	—	20.1 ± 2.9	—	64.9 ± 3.0	—
	48 Hours	13	19.4 ± 10.0	-7.6†	12.3 ± 17.0	-0.5	20.1 ± 2.7	0	64.4 ± 4.9	0
	8 weeks	12	14.9 ± 4.2	-8.7‡	1.4 ± 10.2	-0.1	20.0 ± 1.8	0	6.0 ± 5.1	-2.9†
	4 weeks	11	14.8 ± 4.3	-11.0‡	1.2 ± 10.6	-1.2	19.9 ± 1.4	-0.2	63.0 ± 3.1	-2.0
HDZ	Control	11	19.6 ± 5.7	—	11.8 ± 5.8	—	19.2 ± 1.9	—	63.6 ± 2.7	—
	48 Hours	11	17.7 ± 6.5	-1.8	11.9 ± 7.0	0	19.3 ± 1.7	0	62.6 ± 4.6	0
	2 Weeks	10	20.7 ± 6.5	+0.9	11.5 ± 4.6	-2.8	18.8 ± 1.4	0	64.9 ± 2.2	0
	4 Weeks	9	20.1 ± 8.6	-0.1	11.5 ± 7.0	-1.9	19.2 ± 2.2	0	63.9 ± 4.9	0
RES	Control	13	26.3 ± 10.8	—	12.0 ± 4.8	—	20.7 ± 2.4	—	65.1 ± 2.3	—
	48 Hours	13	18.4 ± 6.5	-7.9†	11.5 ± 12.0	-2.4	20.2 ± 1.3	-0.2	65.2 ± 3.5	0
	2 Weeks	13	16.5 ± 6.3	-9.9‡	11.9 ± 5.5	0	19.7 ± 1.2	-0.5	66.1 ± 2.2	+1.0
	4 Weeks	11	20.0 ± 9.1	-7.9†	11.7 ± 6.6	-1.2	19.2 ± 1.2	-0.6	67.1 ± 2.1	+2.3†
AMD	Control	13	20.7 ± 6.7	—	11.6 ± 6.0	—	19.0 ± 1.7	—	64.9 ± 2.9	—
	48 Hours	13	19.7 ± 8.6	-1.0	11.6 ± 7.3	0	19.0 ± 2.1	0	65.0 ± 2.7	0
	2 Weeks	13	17.3 ± 6.5	-4.2†	11.8 ± 4.9	+1.3	19.6 ± 1.3	0	65.2 ± 2.4	0
	4 Weeks	12	19.4 ± 8.2	-0.8	11.6 ± 5.5	0	19.2 ± 1.5	0	65.5 ± 3.4	+0.4

See Table I

†P < .05

‡P < .01

§P < .001

¶ mEq / Kg w t cell weight.

Na / Kg wct and 2 per cent cell water respectively. These authors found a somewhat higher concentration of cell potassium averaging 137 mEq / Kg wct as compared to our mean of 114 mEq / Kg wct.

Interest in the Na and water content of cells in hypertensive patients stems from the observation of Tobian and Bunion⁷ who in 1952 reported increased amounts of both in the renal arteries of hypertensive patients. The determination of intracellular cations in hypertension using cardiac or skeletal muscle brain and erythrocytes have resulted in inconclusive and conflicting results.⁸ Part of the difficulty might be due to the lack of reliable methods for measuring the extracellular space in complex tissues. Since the extracellular concentration of Na is far higher than the intracellular content only small errors in estimating the extracellular space surrounding the cells can lead to considerable deviations from the true intracellular Na content. This problem is not present with the erythrocyte but because of its unique structure and function it may not be representative of other living cells. However, WBC are nucleated cells and also are not bound to other cells so that the fluid trapped between the packed WBC can be accurately measured by mixing with an extracellular indicator.

The present results confirm the observations of Edmondson and associates⁴ that the Na content of WBC is increased in patients with essential hypertension. Edmondson and colleagues found a mean increase of 29 per cent in WBC Na of hypertensive patients which is the same as was determined in the present study. Our data however indicated that the increase is found primarily in hypertensive patients below the age of 50 whereas Edmondson and associates did not observe any age differences. Edmondson and colleagues studied fewer patients and it is possible that their series was too small to detect differences in subgroups.

The significance of the increased WBC Na in hypertension requires further clarification. Evidence for an intracellular shift of Na associated with a rise of blood pressure had been presented by Friedman and co-workers. They observed that pressor doses of pitressin, norepinephrine and angiotensin intravenously resulted in a shift of Na with variable amounts of water from the extracellular fluid into the cells. A reverse shift occurred as the pressor reaction wore off. Friedman and colleagues believed that the Na shift preceded the rise of blood pressure and was in fact instrumental in bringing about the vasoconstrictor response. However there is no certain

Table IV Mean blood pressure, body weight and serum Na and K changes during treatment

Drug	Time	Number of patients	Mean blood pressure (mm Hg)	Change**	Body weight (lb)	Change**	Serum Na (mEq/L)	Change**	Serum K (mEq/L)	Change
HCTZ	Control	14	128 ± 12	—	183 ± 52	—	144 ± 4.9	—	4.2 ± 0.5	—
	48 Hours	13	116 ± 8	-11.6§	183 ± 52	0	141 ± 4.4	-3.1†	4.0 ± 0.5	-0.2
	2 Weeks	12	109 ± 11	-18.6‡	178 ± 51	-2.5†	143 ± 3.8	-1.0	4.0 ± 0.4	-0.2
	4 Weeks	11	105 ± 12	-22.2‡	177 ± 54	-1.8	143 ± 2.7	-1.1	3.9 ± 0.4	-0.34†
HDZ	Control	11	129 ± 13	—	194 ± 38	—	140 ± 3.4	—	4.0 ± 0.5	—
	48 Hours	11	120 ± 12	-8.6§	194 ± 38	0	142 ± 4.0	+1.0	4.0 ± 0.7	0
	2 Weeks	10	120 ± 13	-10.6‡	199 ± 35	+1.2	141 ± 3.3	+0.6	4.1 ± 0.6	+0.04
	4 Weeks	9	112 ± 15	-17.9‡	198 ± 38	+0.8	141 ± 3.3	+0.4	4.0 ± 0.6	0
RES	Control	13	122 ± 10	—	198 ± 42	—	143 ± 2.8	—	4.4 ± 0.6	—
	48 Hours	13	110 ± 14	-11.4§	199 ± 41	0	144 ± 3.3	+0.6	4.2 ± 0.4	-0.05
	2 Weeks	13	112 ± 7	-9.9‡	199 ± 41	0	145 ± 3.8	+1.8	4.1 ± 0.5	-0.3
	4 Weeks	11	110 ± 8	-13.2‡	196 ± 42	-0.5	145 ± 3.4	+2.9‡	4.3 ± 0.5	-0.16
AMD	Control	13	124 ± 10	—	178 ± 45	—	145 ± 3.7	—	4.1 ± 0.3	—
	48 Hours	13	113 ± 9	-10.9§	178 ± 44	0	143 ± 2.9	-2.1†	3.8 ± 0.6	-0.24
	2 Weeks	13	109 ± 24	-15.1‡	177 ± 45	0	144 ± 3.0	-1.0	4.2 ± 0.5	+0.5
	4 Weeks	12	114 ± 17	-10.6‡	177 ± 46	0	145 ± 5.5	0	4.3 ± 0.4	+0.18

HCTZ = hydrochlorothiazide 50 mg twice daily HDZ = hydralazine 25 mg 3 times daily RES = reserpine 0.75 mg daily for 2 days and then 0.25 mg daily AMD = alpha methyl dopa 250 mg 3 times daily

When there were fewer patients at a follow up interval than were present in the control period the difference was calculated from the mean control value of the patients remaining in the study at the particular interval

†P < 0.05

‡P < 0.01

§P < 0.001

the initial level of WBC Na was low or high The median pretreatment value for all of the patients of 21.8 mEq/Kg wcv was used as the dividing line between low and high subgroups The results shown in Table VII indicate a marked difference between low and high subgroups in the patient taking HCTZ However, there was no difference in the degree of reduction seen in the low and high subgroups who were given RES Changes were small in both low and high subgroups receiving HDZ or AMD and remained insignificant even when the two groups were combined

HCTZ also resulted in 2.9 per cent (P < 0.05) reduction in the cell water content after two weeks and a 2.0 per cent reduction (P > 0.05) after four weeks Percentage of cell water increased slightly after reserpine, becoming significant (P < 0.05) at the fourth week of treatment No change was observed in cell water content until 2 weeks after RES Cell water content remained essentially unchanged after HDZ and AMD None of the drugs included HCTZ was associated with significant changes in either WBC K or Mg (Table V)

As expected serum K decreased during treatment with HCTZ although the change was small reaching the level of significance (P < 0.05) at the

fourth week after beginning the drug Serum Na showed little change after any of the drugs but occasionally the change reached the level of significance (P < 0.05) Such a decrease occurred at 48 hours after HCTZ and AMD but was not maintained and an increase occurred at the fourth week after RES However, sporadic fluctuation of this type occurring in small sample sizes probably are due to chance variation There was a mean loss of six pounds body weight after HCTZ and a mean gain of four pounds following HDZ Body weight did not change appreciably after RES or AMD

Discussion

The reproducibility of the measurements of WBC cations and water content was tested by repeating the measurements one to 12 weeks apart The correlation coefficients indicated good agreement between the two measurements in each subject despite a wide range of values between subjects The actual values for WBC sodium and water content in normal subjects agreed closely with those previously published by Baron and Ahmed³ who reported mean values of 22.2 mEq Na/kg wcv, and 64.1 per cent cell water as compared to our values of 19.7 mEq

Table V Changes in WBC cations and per cent water content during treatment

Drug	Time	Number of patients	WBC Na (mEq / Kg) †	Change	WBC K (mEq / Kg) †	Change	WBC Mg (mEq / Kg) ‡	Change	Percent water content	Change
HCTZ	Control	11	25.7 ± 12.7	—	124 ± 19.7	—	20.1 ± 2.9	—	64.9 ± 3.0	—
	48 Hours	13	19.4 ± 10.0	-7.6†	123 ± 17.0	-0.5	20.1 ± 2.7	0	64.4 ± 4.9	0
	2 weeks	12	14.9 ± 4.9	-8.7‡	124 ± 10.2	-0.1	20.0 ± 1.8	0	62.5 ± 5.1	-2.9†
	4 weeks	11	14.8 ± 4.3	-11.0†	122 ± 10.6	-1.2	19.9 ± 1.4	-0.2	63.0 ± 3.1	-2.0
HDZ	Control	11	19.6 ± 5.7	—	118 ± 5.8	—	19.2 ± 1.9	—	63.6 ± 2.7	—
	48 Hours	11	17.7 ± 6.5	-1.8	119 ± 7.2	0	19.3 ± 1.7	0	62.5 ± 4.5	0
	2 Weeks	10	20.7 ± 6.5	+0.9	116 ± 4.6	-2.8	18.8 ± 1.4	0	64.9 ± 2.2	0
	4 Weeks	9	20.1 ± 8.6	-0.1	115 ± 7.0	-1.9	19.2 ± 2.2	0	63.9 ± 4.9	0
RES	Control	13	26.3 ± 10.8	—	120 ± 4.8	—	20.7 ± 2.4	—	65.1 ± 2.3	—
	48 Hours	13	18.4 ± 6.5	-7.9†	115 ± 12.0	-2.4	20.2 ± 1.3	-0.2	65.2 ± 3.6	0
	2 Weeks	13	16.5 ± 6.3	-9.9†	119 ± 5.5	0	19.7 ± 1.2	-0.5	66.1 ± 2.2	+1.0
	4 Weeks	11	20.0 ± 9.1	-7.9†	117 ± 6.6	-1.2	19.2 ± 1.2	-0.6	67.1 ± 2.1	+2.3†
AMD	Control	13	20.7 ± 6.7	—	116 ± 6.0	—	19.2 ± 1.7	—	64.9 ± 2.9	—
	48 Hours	13	19.7 ± 6.6	-1.0	116 ± 7.3	0	19.2 ± 2.1	0	65.0 ± 2.7	0
	2 Weeks	13	17.3 ± 6.5	-4.2†	118 ± 4.9	+1.3	19.6 ± 1.3	0	65.2 ± 2.4	0
	4 Weeks	12	19.4 ± 8.2	-0.8	116 ± 5.5	0	19.2 ± 1.5	0	65.6 ± 3.4	+0.4

See Table I

†P < 0.05

‡P < 0.01

§P < 0.001

‡ mEq / Kg. wet cell weight

Na / Kg cww and 63.2 per cent cell water respectively. These authors found a somewhat higher concentration of cell potassium averaging 137 mEq / Kg cww as compared to our mean of 114 mEq / Kg cww.

Interest in the Na and water content of cells in hypertensive patients stems from the observation of Tobian and Bunion who in 1952 reported increased amounts of both in the renal arteries of hypertensive patients. The determination of intracellular cations in hypertension using cardiac or skeletal muscle brain and erythrocytes have resulted in inconclusive and conflicting results. Part of the difficulty might be due to the lack of reliable methods for measuring the extracellular space in complex tissues. Since the extracellular concentration of Na is far higher than the intracellular content only small errors in estimating the extracellular space surrounding the cells can lead to considerable deviations from the true intracellular Na content. This problem is not present with the erythrocyte but because of its unique structure and function it may not be representative of other living cells. However WBC are nucleated cells and also are not bound to other cells so that the fluid trapped between the packed WBC can be accurately measured by mixing with an extracellular indicator.

The present results confirm the observations of Edmondson and associates⁹ that the Na content of WBC is increased in patients with essential hypertension. Edmondson and colleagues found a mean increase of 29 per cent in WBC Na of hypertensive patients which is the same as was determined in the present study. Our data however indicated that the increase is found primarily in hypertensive patients below the age of 50 whereas Edmondson and associates did not observe any age differences. Edmondson and colleagues studied fewer patients and it is possible that their series was too small to detect differences in subgroups.

The significance of the increased WBC Na in hypertension requires further clarification. Evidence for an intracellular shift of Na associated with a rise of blood pressure had been presented by Friedman and co-workers.¹⁰ They observed that pressor doses of pitressin, norepinephrine and angiotensin intravenously resulted in a shift of Na with variable amounts of water from the extracellular fluid into the cells. A reverse shift occurred as the pressor reaction wore off. Friedman and colleagues believed that the Na shift preceded the rise of blood pressure and was in fact instrumental in bringing about the vasoconstrictor response. However there is no certain

Table VI Comparison between mean* changes for the 4 weeks following HCTZ and the other anti hypertensive agents

Drug regimen	Mean blood pressure (mm Hg)	WBC Na (mEq /kg)	WBC water (% wet cell weight)
HCTZ	-17.00	-9.29	-2.00
HDZ	-11.18	-0.58	+0.00
Significance	NS	‡	NS
HCTZ	-17.00	-9.29	-2.00
RES	-11.31	-8.35	+2.27
Significance	NS	NS	NS
HCTZ	-17.00	-9.29	-2.00
AMD	-11.38	-2.38	+0.50
Significance	NS	§	NS

NS = not statistically significant

Mean changes represent the average of all three determinations taken during the treatment period as compared to the pretreatment control period

mEq/Kg wet cell weight

‡P < 0.01

§P < 0.05

Table VII Influence of low and high initial WBC Na content on response to antihypertensive agents

Drug	Low initial WBC Na†			*High initial WBC Na†		
	No pts	Mean change mEq / kg wcu	P value†	No pts	mEq / kg wcu	P value
HCTZ	11	-2.7	NS	7	-18.3	< 0.1
HDZ	7	+2.2	NS	3	-3.3	NS
AMD	7	-0.7	NS	6	-4.0	NS
RES	4	-8.0	< 0.05	6	-8.0	NS
HDZ+AMD	14	+0.7	NS	9	-3.7	NS

The division between low and high WBC Na was done by taking the median value in the pretreatment period using the data from all patients. This value was 21.6 mEq Na /kg wet cell weight of WBC

†Change from pretreatment

evidence that the Na shift they observed was the cause or the effect of the pressor response, nor is it possible to relate directly the changes observed in patients with chronic hypertension to the results of acute elevation of blood pressure in animals induced by pressor hormones

The role of Na in vascular smooth muscle contraction and its possible relationship to hypertension has recently been reviewed by Haddy and Overbeck¹⁰ and by Blaustein.¹¹ The ratio (Na⁺) / (Na⁺) is important in regulating the amount of intracellular calcium. An increase in calcium ions within the cell triggers smooth muscle contraction, and smooth muscle tension is dependent on the concentration of intracellular calcium. A decrease in the (Na⁺) / (Na⁺), by either a decrease in (Na⁺) or an increase in (Na⁺), will result in a movement of calcium into cells. The above authors postulate that in hypertension total peripheral resistance is increased because of an increase of Na⁺ in vascular smooth muscle cells. The increase could occur either through passive leakage of Na⁺ into the cells or a failure of the intracellular sodium pump. They suggest that a circulating hormone, possibly the 'natriuretic hormone,' controls this change in the Na gradient. While admittedly speculative it is of interest that the present findings support this hypothesis at least with respect to the WBC.

No significant differences were observed in the WBC content of K⁺ and Mg²⁺ in the hypertensive

patients as compared to the normal subjects. Also in contrast to Edmondson and co-workers¹² who found an increased WBC water as well as Na⁺ content in hypertensive patients, we found no difference in the percentage of cell water between hypertensive and normal subjects. The reason for this discrepancy is not apparent. Similar methods were used in both studies.

While the observation of an increase in WBC Na⁺ in hypertension is of considerable interest and possible importance it should be emphasized that other body cells may not share in this change and that the observed cation abnormality in hypertensive patients may be peculiar to WBC and not to other cells. Furthermore, the distribution of WBC sodium levels in hypertensive patients may signify the presence of two populations: a larger group with normal values and a smaller group with elevated levels. Except for the preponderance of patients under age 50 we were unable to identify any other distinguishing features that would characterize the latter group. Further investigation is needed to clarify the pathogenic significance of these findings.

With respect to the changes observed after the various antihypertensive agents, it should be noted that all were effective in significantly reducing MBP. In addition to lowering the MBP, HCTZ resulted in a significant reduction in WBC Na⁺. Both blood pressure and WBC Na⁺ were significantly reduced as early as 48 hours after

administration of HCTZ and both were maintained throughout the four weeks of study. There also was a loss of WBC water after HCTZ. This reduction was not present until after the first 48 hours of treatment and was of relatively small magnitude in comparison with the loss of WBC Na.

The serum Na concentration remained constant after HCTZ throughout the period of the study. This observation is consistent with prior studies indicating that the drug produces a loss of extracellular water and Na in isotonic proportion. The result of the reduction in intracellular (WBC) Na concentration and unchanged extracellular Na concentration was a rise in the WBC extra/intracellular Na (Na/Na_i) gradient. A similar relationship between intracellular Na and MBP changes was described by Friedman and colleagues²⁰ who found in animals an increase in the Na/Na_i gradient associated with an acute fall in blood pressure.

The literature concerning the effects of the thiazide diuretics on the intracellular cations and water is conflicting. Muscle biopsies have been taken in man before and after treatment with HCTZ by two groups of investigators who report almost diametrically opposite results. Vilamil and associates²¹ found a decrease in both intracellular sodium and water following 3 to 7 weeks of treatment with HCTZ in hypertensive patients. These observations are therefore similar to the present findings in WBC. On the other hand, Bergstrom and Hultman²² found after one week of treatment with HCTZ in normal subjects a significant increase in the intracellular Na concentration of muscle. Still a third result was obtained in vascular smooth muscle of rats by Tobian and associates.²³ They found the Na and water content of small artery smooth muscle to remain unchanged following chlorothiazide.

Other types of studies suggest that the principal effect of the thiazide diuretics is on the extracellular fluid volume rather than on the water and electrolyte content of the cells. Several investigators have found that treatment with chlorothiazide or HCTZ is associated with decreased extracellular and plasma volumes.²⁴ Freis²⁵ observed that during the first 4 or 5 days following the administration of chlorothiazide all of the excess loss of Na and water in the urine could be accounted for by the decrease in extracellular fluid volume. The present results indicate that the major loss of WBC Na occurred within

the first 48 hours although there was a further small progressive loss following that interval. While there is no ready explanation for the present findings it is possible that because of their location in the circulation WBC are unusually responsive to changes in extracellular and plasma volume, a characteristic that is not shared by other body cells.

The hemodynamic response within the first week of treatment with thiazides is a reduction in cardiac output and an increase in total peripheral resistance.^{26,27} Thus latter finding would appear to be inconsistent with Friedman and colleagues' theory of a primary Na shift in vascular smooth muscle producing a decrease in total peripheral resistance. Against the Friedman and associates' hypothesis also is the fact that the reduction of blood pressure associated with HDZ or AMD was not accompanied by any significant change in WBC Na. Again such changes could occur in vascular smooth muscle and not in WBC.

It is puzzling that the administration of RES was associated with a significant reduction in WBC Na. This change was present after 48 hours and was maintained throughout the study. At present it is not clear whether the observed changes in WBC Na were related to the antihypertensive actions of HCTZ and RES or were independent effects. An increase in percentage of cell water was recorded after RES. However the change was quite small, barely reaching the level of significance and only at the fourth week of treatment. The increase therefore could have occurred by chance rather than being drug related.

None of the four drugs used in this study was associated with significant changes in WBC K or Mg (Table V) although HCTZ resulted in the well known fall in serum K. However it is doubtful that the hypokalemia reflects a similar change in total body K. The most recent studies using the total body counter failed to disclose a significant decrease in total body K during prolonged treatment of hypertensive patients with oral diuretics.^{28,29} Maronde and co-workers³⁰ collected urine and stool samples on a metabolic ward in hypertensive patients. The cumulative loss of K over 7 days of thiazide treatment indicated negligible reduction in total body stores. In all of the above studies there was a significant reduction in serum K concentration which obviously did not reflect an intracellular deficit. The present results are consistent with

other evidence that the reduction in serum concentration of K^+ is not a reflection of a major intracellular loss

Summary

Leukocyte (WBC) cations were determined in 32 normotensive control subjects and in 47 age matched patients with uncomplicated hypertension. The intracellular concentration of sodium (Na^+) which averaged 25.5 mEq/Kg wet cell weight (wcw) in the hypertensive patients was significantly higher ($P < 0.01$) than in the control subjects (average 19.7 mEq/Kg wcw). Elevated WBC Na^+ was observed only in the hypertensive patients under age 50 years. WBC potassium, magnesium and percentage water content were not significantly different in hypertensive patients as compared to the control subjects. The finding of an increased intracellular Na^+ content in hypertensive patients is consistent with recent observations relating the extracellular/intracellular Na^+ gradient to vascular smooth muscle tension and to the control of the peripheral vascular resistance.

WBC cations also were determined after treatment with hydrochlorothiazide, hydralazine, reserpine or alpha-methyldopa. Hydrochlorothiazide was associated with a reduction in WBC sodium content ($P < 0.01$). Reserpine also was associated with a lesser fall in WBC sodium ($P < 0.05$). Cell water content decreased slightly after hydrochlorothiazide ($P < 0.05$), but increased slightly following reserpine ($P < 0.05$). Changes in WBC, sodium or water were not significant following alpha-methyldopa or hydralazine. None of the drugs were associated with changes in WBC potassium or magnesium, although serum potassium concentration decreased significantly ($P < 0.05$) with hydrochlorothiazide.

REFERENCES

1. Freis E D. Salt volume and the prevention of hypertension. *Circulation* 53: 589, 1976.
2. Sasaku N. The relationship of salt intake to hypertension in the Japanese. *Geriatrics* 19: 735, 1964.
3. Wilson I M and Freis E D. Relationship between plasma and extracellular fluid volume depletion and the antihypertensive effect of chlorothiazide. *Circulation* 20: 1028, 1959.
4. Meneely G H and Dahl L K. Electrolytes in hypertension: the effects of sodium chloride. The evidence from animal and human studies. *Med Clin North Am* 45: 271, 1961.
5. Baron D N and Ahmed S A. Intracellular concentrations of water and of the principal electrolytes deter-

- mined by analysis of isolated human leucocytes. *Clin Sci* 37: 205, 1969.
6. Edmondson R P, Thomas R D, Hilton P J, Patrick J and Jones N F. Abnormal leucocyte composition and sodium transport in essential hypertension. *Lancet* 1: 1003, 1975.
7. Tobian L Jr and Bimon J. Effect of deficiency of renal tissue with or without resulting hypertension of electrolyte composition of brain and skeletal muscle. *Am J Physiol* 178: 233, 1954.
8. Weller J M. The acid-base balance and sodium distribution of the blood in essential hypertension. *J Lab Clin Med* 53: 553, 1959.
9. Friedman S M, Jamieson J D and Friedman C L. Sodium gradient, smooth muscle tone and blood pressure regulation. *Circ Res* 7: 44, 1959.
10. Haddy F J and Overbeck H W. The role of humoral agents in volume expanded hypertension. *Life Sci* 18: 935, 1976.
11. Blaustein M P. Sodium ions, calcium ions, blood pressure regulation and hypertension: a reassessment and a hypothesis. *Am J Physiol* 232: C160, 1977.
12. Freis E D. Mechanism of the antihypertensive effects of diuretics: Possible role of salt in hypertension. *Clin Pharmacol Ther* 1: 337, 1960.
13. Friedman S M, Friedman C L and Nakashima M. Sodium gradient and renopriv hypertension in the rat. *Circ Res* 7: 917, 1959.
14. Villamil M F, Yeyati N, Ereno M A, Rubianes C and Taquini A C. Effect of long term treatment with hydrochlorothiazide on water and electrolytes of muscle in hypertensive subjects. *AM HEART J* 65: 294, 1963.
15. Bergstrom J and Hultman E. The effect of thiazides, chlorthalidone and furosemide on muscle electrolytes and muscle glycogen in normal subjects. *Acta Med Scand* 180: 363, 1966.
16. Tobian L, Janacek J, Foker J and Ferreira D. Effect of chlorothiazide on renal juxtaglomerular cells and tissue electrolytes. *Am J Physiol* 202: 905, 1967.
17. Wilson I M and Freis E D. Relationship between plasma and extracellular fluid volume depletion and the antihypertensive effect of chlorothiazide. *Circulation* 20: 1028, 1959.
18. Tarazi H C, Dustan H P and Frohlich E D. Long term thiazide therapy in essential hypertension. *Circulation* 41: 709, 1970.
19. Leth A. Changes in plasma and extracellular fluid volumes in patients with essential hypertension during long term treatment with hydrochlorothiazide. *Circulation* 42: 479, 1970.
20. Dustan H P, Cumming G R, Corcoran A C and Page I II. A mechanism of chlorothiazide-enhanced effectiveness of antihypertensive ganglioplegic drugs. *Circulation* 71: 360, 1959.
21. Frohlich E D, Schnaper H W, Wilson I M and Freis E D. Hemodynamic alterations in hypertensive patients due to chlorothiazide. *N Engl J Med* 262: 1961, 1960.
22. Wilkinson P R, Hesp R, Issler H and Raftery E B. Total body and serum potassium during prolonged thiazide therapy for essential hypertension. *Lancet* 1: 1003, 1975.
23. Leenhuis M P, van Damme K J and Struyvenberg A. Effects of chlorthalidone on serum and total body potassium in hypertensive patients. *Acta Med Scand* 200: 37, 1976.
24. Maronde H F, Milgrom M and Dickey J M. Potassium loss with thiazide therapy. *AM HEART J* 78: 16, 1969.

Significance of P wave terminal force in presumably healthy middle aged men

Kolbjørn Forfang M D

Jan Enkssen M D

Oslo Norway

The finding of an abnormal P terminal force in Lead V₁ (V Ptf) a concept introduced by Morris and associates¹ in 1964 has been demonstrated in both acute and chronic left sided heart diseases.^{2,3} In most of these studies a significant correlation has been found between left ventricular filling pressure and the magnitude of V Ptf. Recently V₁Ptf was shown to correlate significantly with left atrial dimensions as measured by echocardiography in various cardiac diseases and Josephson and associates⁴ have suggested that an interatrial conduction defect may be the underlying cause for abnormal V Ptf.

The discriminative performance of V Ptf in coronary heart disease (CHD) versus normals seems to be questionable.⁵⁻⁸ Most previous studies on V₁Ptf have been performed in patients with proven heart disease. Increased V₁Ptf is however occasionally seen in routine electrocardiograms of apparently healthy individuals and the significance of this finding in relation to latent cardiac disease is not yet defined. The aims of the present study were (1) to assess the prevalence of abnormal V Ptf in presumably healthy males and (2) to evaluate the significance of this finding in relation to latent CHD and various physiological parameters.

Material and methods

The present study comprises 695 males with mean age 49.5 years range 40 to 60 years selected

among the first 1 000 of 11 014 males who participated in an epidemiological study on latent CHD.⁹ They were all working at five preselected firms or state agencies in Oslo Norway. Prior to the survey a careful selection of men thought to be healthy was performed by excluding all with known CHD other heart disease hypertension under treatment, diabetes mellitus malignancy disorders of the locomotive system preventing a near maximal bicycle exercise test and miscellaneous disorders (advanced pulmonary disease renal disease liver disease etc). The examination included a comprehensive case history complete physical examination laboratory tests chest x ray with measurement of heart volume¹ phonocardiogram resting electrocardiogram (ECG) exercise ECG during a near maximal bicycle exercise test and postexercise ECG. This examination program revealed a considerable number of cases with findings suggesting heart disease. In the men in whom the survey examination suggested the presence of CHD coronary angiography was performed as described elsewhere.¹⁰ For an angiogram to be called positive an obstruction of a major coronary artery ≥ 50 per cent had to be present and among the positives all except 5 had at least one obstruction of 75 per cent or more. The diastolic blood pressures used were measured at phase 4.

Either of the following findings revealed during the examination program was a cause for exclusion from the main study: (a) systolic murmur of grade 3 or more (b) diastolic murmur (c) heart volume 500 ml/M² or more (d) ECG patterns of myocardial infarction (e) left ventricular hypertrophy (f) left or (g) right bundle branch block (Minnesota Codes 1 1 3 1 7 1 and 7 3 respectively).

From Medical Department B, Ullevål Hospital, Rikshospitalet, Oslo Norway

Received for publication July 26 1978

Accepted for publication May 5 1978

Reprint requests: Kolbjørn Forfang, M.D., B. Rikshospitalet, Oslo 1, Norway




Fig 1 Measurements for calculation of V_{1Ptf}

ly (h) a positive WHO questionnaire on angina pectoris and (i) a positive exercise ECG

To assess the possible difference in V_{1Ptf} between normals and individuals with latent CHD, 95 of the 105 angiographed males were selected, representing all with a strong suspicion of CHD and none of the exclusion criteria (a) through (g) (see above).

The study on interobserver variation in the measurements of V_{1Ptf} was performed on ECG's from both groups. All ECG's were read separately and blindly by both authors.

ECG's were recorded with a direct writing ink jet Mingograf (Elema Schonander) with a paper speed of 50 mm per second. The estimations of V_{1Ptf} were performed according to the method of Morris and associates.¹ Measurements of amplitude were made down to the nearest 0.25 mm, and duration down to the nearest 0.1 second. The terminal force is defined as the product of the amplitude in millimeters (1 mm \approx 0.1 mV) and the duration in second of a possible negative terminal portion of the P wave (Fig 1). Abnormal V_{1Ptf} values is defined as ≤ -0.03 mm second. The measurements of V_{1Ptf} were made separately on the resting ECG's and on the ECG's recorded five minutes after the near maximal exercise test.¹¹ Except for the results on interobserver variation the measurements used refer to the readings made by one of us (K.F.).

The statistical evaluations were made by linear correlation analyses one and two way analyses of variance and multiple t tests.

Results

Abnormal V_{1Ptf} (≤ -0.03 mm second) at rest was found in 49 of the 695 presumably healthy males (7.1 per cent). Mean V_{1Ptf} was -0.0088 mm second, SD 0.0110, range 0 to -0.075 mm

second. Five minutes after exercise mean V_{1Ptf} had become more negative, mean -0.0177 mm second, SD 0.0165, range 0 to -0.075 mm second. According to the definition an abnormal V_{1Ptf} was found in 176 individuals after exercise (25.4 per cent).

Table I shows the mean values of the blood pressure parameters: maximal rate pressure product during exercise (MRPP) and heart volume in individuals with and without an abnormal V_{1Ptf} . All parameters except for heart volume showed slightly higher values in the individuals with an abnormal V_{1Ptf} at rest. None of these differences were significant. Individuals with an abnormal V_{1Ptf} after exercise however showed significantly higher systolic and diastolic blood pressure at rest, more increase in systolic blood pressure during exercise, and higher MRPP than in the individuals with normal V_{1Ptf} .

By considering V_{1Ptf} in subgroups according to various arbitrary levels of blood pressure (Table II) the sole significant result was an inverse correlation between V_{1Ptf} after exercise and increase in systolic blood pressure during exercise.

Relationship between V_{1Ptf} and fourth heart sound. The occurrence of the fourth heart sound was specially sought for in 538 of the 695 normal individuals and was demonstrated by phonocardiography in 272 (50.5 per cent). V_{1Ptf} at rest was abnormal in 12 of the 272 (4.4 per cent) as compared to 21 of the 266 (7.9 per cent) without a fourth heart sound. The corresponding figures concerning V_{1Ptf} after exercise were 62 (22.8 per cent) and 54 (19.9 per cent). None of these differences were statistically significant.

V_{1Ptf} in latent CHD. Table III presents V_{1Ptf} in relation to the angiographic findings among the 95 individuals who underwent coronary angiography. There was no difference between the mean values of these 95 and 695 normals, nor a difference in distribution of normal versus abnormal V_{1Ptf} . Neither was there any difference between individuals with normal versus abnormal angiographic findings. Hence V_{1Ptf} could not discriminate between normals and subjects with latent CHD nor between true and falsely suspect cases of CHD.

Inter observer variation. V_{1Ptf} was measured in ECG from 790 males at rest and after exercise. There was complete agreement between the two

Table I Blood pressure and heart rate parameters and heart volume in groups of individuals classified by V_1 Ptf

Parameters	V_1 Ptf at rest (mm second)					V_1 Ptf after exercise (mm second)				
	> -0.03 (n = 646)		≤ -0.03 (n = 49)		p	> -0.03 (n = 519)		≤ -0.03 (n = 176)		p
	\bar{x}	SEM	\bar{x}	SEM		\bar{x}	SEM	\bar{x}	SEM	
SBP (mm. Hg)	124.3	0.6	127.4	0.2	NS	123.8	0.7	126.9	1.3	0.03
DBP (mm Hg)	87.7	0.4	90.7	1.5	NS	87.2	0.5	89.9	0.8	0.005
SBPD (mm Hg)	50.2	0.8	94.6	2.7	NS	89.6	0.9	93.2	1.4	0.03
MRPP (beats per minutes \times mm Hg)	35394	181	36146	630	NS	35185	205	36271	370	0.01
Heart volume (mL/M)	393.9	2.0	389.9	8.0		391.8	2.3	393.3	3.7	NS

Abbreviations: SBP = systolic blood pressure; DBP = diastolic blood pressure; SBPD = systolic blood pressure difference (maximum SBP during exercise - SBP at rest); MRPP = maximum rate-pressure product during exercise.

Table II V_1 Ptf in groups of individuals classified by blood pressure

Blood pressures (mm Hg)	No	V_1 Ptf at rest (mm second)		p	V_1 Ptf after exercise (mm second)		p
		\bar{x}	SEM		\bar{x}	SEM	
SBP < 150	644	-0.0086	0.0004	NS	-0.0175	0.0007	NS
SBP \geq 150	51	-0.0104	0.0014		-0.0206	0.0024	
DBP < 100	599	-0.0084	0.0004	NS	-0.0111	0.0007	NS
DBP \geq 100	96	-0.0111	0.0013		-0.0210	0.0020	
SBPD \leq 79	209	-0.0078		NS	-0.0150		0.001
80-99	253	-0.0089			-0.0175		
100-119	176	-0.0096			-0.0204		
\geq 120	47	-0.0096			-0.0209		

Abbreviations as in Table I.

observers in 1 001 of the 1 580 measurements of V_1 Ptf. The total number of abnormal V_1 Ptf was 264 and 199 respectively. The amplitudes were merging in 1 246 and the duration in 1 049. The differences were mainly due to systematically longer durations measured by one of us (K.F.) which was obvious at the linear regression analysis made on V_1 Ptf at rest. V_1 Ptf (K.F.) = $0.993 \times V_1$ Ptf (J.E.) + 0.0013 , $r = 0.872$, $n = 790$. Mean V_1 Ptf (K.F.) = -0.0092 mm second, SD 0.0113; mean V_1 Ptf (J.E.) = -0.0080 mm second, SD 0.0099.

Discussion

The present data reemphasize the well known fact that it is hazardous to extrapolate from findings in one population with defined diseases to another comprising apparently normals. A

V_1 Ptf ≤ -0.03 mm second has been shown to correlate well with various parameters such as left ventricular filling pressure, "a" and left atrial size" in individuals with heart disease. However, the same V_1 Ptf was noted in 71 per cent of apparently healthy middle aged men at rest and in 25.4 per cent after exercise. Hence this sign can hardly be regarded as a valuable sign of heart disease and in particular not of CHD. The present study, however, has shown a weak correlation between the magnitude of V_1 Ptf and blood pressure. The mechanism may be left ventricular hypertrophy secondary to blood pressure increment and thereby reduced left ventricular compliance, left atrial contractions with increased force and thus posterior enlargement of the left atrium leading to a posterior rotation of the P wave in the horizontal plane. It is obvious

Table III Number of patients with normal and abnormal V₁P_{tf} in the various groups classified by EECG* and CA†

Findings by EECG and CA	V P _{tf} at rest (mm second)		V P _{tf} after exercise (mm second)	
	> -0.03	≤ -0.03	> -0.03	≤ -0.03
EECG -	646	49	519	176
EECG +	23	6	19	10
CA -				
EECG +	60	6	49	17
CA +				

*Exercise electrocardiogram

†Coronary angiography

however that these mechanisms only to a small extent are responsible for the occurrence of abnormal V₁P_{tf} in the present material. In a recent electrophysiological study Josephson and associates¹ have suggested that an interatrial conduction defect may be the underlying cause for the electrocardiographic patterns of left atrial enlargement such as abnormal V₁P_{tf}. This conduction defect may be caused by a variety of factors and possibly by innocent underlying causes in a number of cases according to the present study and thus it may be comprehended as an unimportant anomaly. The increase in V₁P_{tf} seen post exercise may be a physiological response to increased cardiac output.

The present study shows clearly that V₁P_{tf} is of negligible value as a tool for diagnosing asymptomatic CHD. These findings strongly support previous findings,¹⁰ and are at variance with the statements by Bethell and Nixon.⁵

The reproducibility of the measurements of V₁P_{tf} is previously found to be satisfactory.¹⁰ Although the present study shows complete concordance in the measurements in only two thirds of the cases the inter observer variation was small in most of the remaining cases. Hence the method should be acceptable for the clinical use of V₁P_{tf}.

Conclusions

At rest an abnormal V₁P_{tf} (≤ -0.03 mm second) is found in 7.1 per cent and post exercise in 25.4 per cent among middle aged males without cardiovascular disease. Possibly this finding in individuals without symptoms or signs of heart disease is due to a clinically unimportant anomaly

of the interatrial conduction. The increase in V₁P_{tf} post exercise should also be regarded as a normal finding among healthy middle aged men.

Summary

In a material comprising 695 males aged 40 to 60 years without cardiovascular disease, the prevalence of abnormal P wave terminal force in V₁ (V₁P_{tf}) (≤ -0.03 mm second) at rest was 7.1 per cent, whereas the prevalence five minutes after a near maximal exercise test was 25.4 per cent. Abnormal V₁P_{tf} was associated with a slightly higher systolic and diastolic blood pressure, maximal rise of systolic blood pressure, and maximal rate-pressure product during the exercise test. The prevalence of abnormal V₁P_{tf} was not significantly higher in another group of 95 individuals who were angiographed because of strong suspicion of latent coronary heart disease (CHD) according to exercise electrocardiogram.

An abnormal V₁P_{tf} may be considered as a possibly clinically unimportant anomaly in otherwise healthy middle aged men. V₁P_{tf} is not suitable as a tool for the diagnosis of latent CHD.

REFERENCES

- 1 Morris J J Jr, Estes E H Jr, Thompson H K Jr and McIntosh H D. P wave analysis in valvular heart disease. *Circulation* 29:242, 1964.
- 2 Gooch A S, Calatayud J B, Rogers J B and Gorman P A. Analysis of the P wave in severe aortic stenosis. *Dis Chest* 49:459, 1966.
- 3 Tarazi R C, Miller A, Frolich E D and Dustan H P. Electrocardiographic changes reflecting left atrial abnormality in hypertension. *Circulation* 34:818, 1966.
- 4 Heikkilä J. Mitral incompetence as a complication of acute myocardial infarction. *Acta Med Scand (Suppl)* 475:65, 1967.
- 5 Bethell H J N and Nixon P G F. P wave of electrocardiogram in early ischaemic heart disease. *Br Heart J* 34:1170, 1972.
- 6 Chandraratna P A N and Hodges M. Electrocardiographic evidence of left atrial hypertension in acute myocardial infarction. *Circulation* 47:493, 1973.
- 7 Heikkilä J, Hugenholz P G and Tabakin B S. Prediction of left heart filling pressure and its sequential changes in acute myocardial infarction from the terminal force of the P wave. *Br Heart J* 35:147, 1973.
- 8 Yokoyama M, Sakamoto A, Honno S and Sakakibara S. P wave changes on exercise in patients with isolated mitral stenosis. *Am Heart J* 87:15, 1974.
- 9 Forfang K and Simonson S. Correlation between P wave terminal force and hemodynamic parameters in aortic stenosis. Prediction of left ventricular end diastolic pressure. *Cardiology* 59:222, 1974.
- 10 Forfang K and Stake G. P wave terminal force and persisting ST elevations in chronic ischaemic heart disease. *Am Heart J* 92:297, 1976.
- 11 Churif II, Feitosa G S and Frankl W S. Electrocar-

diographic detection of left atrial enlargement. Correlation of P wave with left atrial dimensions on by echocardiography. *Br Heart J* 37 1284 1975

Josephson M E Kator J A and Morganroth J
Electrocardiographic left atrial enlargement. Electro-physiologic, echocardiographic and hemodynamic correlates. *Am J Cardiol* 39 967 1977

Ericksen J Enge I Forfang A and Storstein O
False positive diagnostic tests and coronary angiographic

- findings in 105 presumably healthy males. *Circulation* 54 371 1976
- 14 Amundsen P The diagnostic value of conventional radiological examination of the heart in adults. *Acta Radiol (Suppl)* 181 1959
- 15 Rose C and Blackburn H Cardiovascular Survey Methods, Geneva 1968 World Health Organization Monograph Series No 56

Copyright information

The appearance of a code at the bottom of the first page of an original article in this journal indicates the copyright owner's consent that copies of the article may be made for personal or internal use or for the personal or internal use of specific clients. This consent is given on the condition however that the copier pay the stated per copy fee through the Copyright Clearance Center Inc. P O Box 765 Schenectady N Y 12301 518 374 4430 for copying beyond that permitted by Sections 107 or 108 of the U S Copyright Law. This consent does not extend to other kinds of copying such as copying for general distribution for advertising or promotional purposes for creating new collective works or for resale.

Clinicopathologic study of the conduction systems in 10 patients with Kawasaki's disease (mucocutaneous lymph node syndrome)

Hisayoshi Fujiwara MD*

Chuichi Kawai, MD**

Yoshihiro Hamashima, MD*

Kyoto Japan

We found that in cases of Kawasaki's disease there were pathologic lesions in the atrioventricular conduction system. However, at the time we did not study whether these lesions were due to ischemia secondary to coronary stenosis or acute inflammation, itself. The atrioventricular conduction systems were examined in five cases only.

In the present work pathologic findings in the sinoatrial and atrioventricular conduction systems processed in Kawasaki's disease according to duration of illness at death were studied in the ten autopsied hearts and comparisons between the pathology and the clinical data (ECG) were made.

Materials and methods

The materials were ten unselected hearts obtained at autopsy from Japanese patients diagnosed as having Kawasaki's disease. Eight were clinically typical and two (Case 3 and 9) were not according to the guideline of diagnosis of Kawasaki's disease made by the MLNS Research Committee of the Ministry of Health and Welfare of the Japanese Government† in 1974. All hearts

had been fixed in formalin at autopsy. The major three coronary arteries were transversely and serially cut at 0.2 to 0.3 cm intervals and diagrammatically sketched. The heart was incised serially and latitudinally at 0.5 cm intervals and observed macroscopically and microscopically. Age at the time of death, sex, the suddenness of death and pathologic data of three major coronary arteries and myocardium are summarized according to duration of illness at death in Table I.

Ten tissue blocks containing the atrioventricular (AV) conduction system and eight tissue blocks containing the sinoatrial (SA) conduction system from the ten hearts were removed and serially sectioned at a thickness of 5 microns according to the methods of Lev and associates¹¹. Every fourth section from each block was stained with hematoxylin-eosin and elastic Van Gieson stains. All intervening sections were kept and processed as deemed necessary for additional hematoxylin-eosin stained sections or other special stains. For each heart the average number of histologic sections examined was about 200 to 400.

The clinical record and all available electrocardiograms of each patient were studied.

Results

The pathologic data of sinoatrial (SA) and atrioventricular (AV) conduction systems are summarized according to duration of illness at the time of death in Table II.

In the early acute stage (Case 1—duration of illness from 0 to 9 days) the inflamed and edematous changes without necrosis of the

From the Departments of Pathology and Internal Medicine, Faculty of Medicine, Kyoto University, Kyoto, Japan.

Received for publication Jan. 27, 1978.

Accepted for publication Feb. 8, 1978.

Reprint requests: Hisayoshi Fujiwara, MD, Department of Pathology, Faculty of Medicine, Kyoto University, Sakyo-ku, Kyoto 606, Japan.

Department of Pathology, Kyoto University.

Department of Internal Medicine, Kyoto University.

†MLNS Research Committee c/o Department of Pediatrics, Japan Red Cross Central Hospital, 4-1-9, Hirono, Shinjuku-ku, Tokyo, Japan.

Table I Ten autopsy cases with Kawasaki's disease

Case	Duration of illness	Age/sex	Sudden death	Coronary type	LAD	LCX	RCA	Myocarditis	Coagulation necrosis	Fibrosis
1	9D	10M/m	+	L	N	N	N	+	-	-
2	20D	7M/f	-	R	N	N	■	+	-	-
3	21D	11M/m	+	II	AS	S	AS	+	-	-
4	21D	6M/m	+	R	AS	AS	AS	+	-	-
5	24D	1Yr8M/m	+	R	AS	AS	AS	+	-	-
6	31D	10M/m	+	II	AS	AS	AS	+	+	+
7	48D	11M/f	+	R	AS	A	AS	-	+	+
8	48D	9M/f	+	B	AS	N	AS	-	-	+
9	3M	7M/f	+	B	AS	S	AS	-	-	+
10	M	2yrs/f	+	B	AS	AS	AS	-	-	+

D = days M = months Yrs = years m = male f = female LAD = left anterior descending artery LCD = left circumflex artery RCA = right coronary artery N = macroscopically normal artery ■ = artery due to thickened wall with aneurysm A = aneurysm with intimal stenosis of the lumen AS = aneurysm with severe stenosis due to thrombus

Coronary types according to the classification by S. Hiesing et al. L = left preponderance R = right preponderance B = balanced type Rupture (LAD)

*The stenosis was less than 75 per cent of the lumen.

Table II Lesions of sinoatrial and atrioventricular conduction systems in Kawasaki's disease

Case	Duration of illness	Sinoatrial nodal artery	Sinoatrial node	Atrioventricular nodal artery	Central fibrous body	Atrioventricular node	Bundle of His	Main bundle branch	Left bundle branch	Right bundle branch	Working muscles of septum			Valvulitis	
											My	Co	Ft	Mitral valve	Tricuspid valve
1	9D	ns	f	ns	f	d	f	d	d	f	+	-	-	+	+
2	20D	ns	■	ns	d	d	d	d	d	f	+	-	-	++	++
3	21D	ns	n	ns	f	f	n	n	f	n	-	+	-	+	-
4	21D	sa	d	sa	d	d	d	f	f	f	-	+	-	-	-
5	24D	ns	■	ns	d	f	f	n	f	n	+	-	-	+	+
6	31D	ns	f	ns	f	f	n	n	n	n	-	-	-	-	-
7	48D	ns	n	ss	d	d	d	n	n	n	-	+	-	-	-
8	48D	■	■	ss	o	o	n	n	n	n	-	+	+	-	-
9	3M	ss	n	ns	o	n	n	n	n	n	-	+	+	-	-
10	7M	ns	■	ns	o	o	o	o	o	o	-	-	+	-	-
Total		2/8	5/8	3/10	10/10	9/10	6/10	4/10	6/10	4/10	3/10	5/20	3/10	4/10	3/10

ns = no site seen sa = stenosis of the subarterial acute angulus ss = stenosis due to scar f = focal (less than 50 per cent) acute inflammatory changes d = diffuse (more than 50 per cent) acute inflammatory changes o = old inflammatory changes n = no findings My = myocarditis C = coagulation necrosis ■ = fibrosis

Containing the sinoatrial node and sinoatrial node butting against central fibrous body Bleeding (gonorrhoea or artifact)

conduction cells were conspicuous in the AV conduction system (Fig 1). The most numerous cells were neutrophils with lymphocytes. Plasma cells, eosinophils, and monocytes were occasionally evident. The inflammatory cells tended to be more concentrated at the perivascular area of the microvessels and the borders of the conduction system as it abuts against the adjacent tissue. In the AV nodal artery acute angitis without stenosis was noted. Both mitral and tricuspid valves

had a focal endocarditis. In the SA node and around the neighboring ganglion the inflammatory cell infiltration was focally and extensively evident.

In the most severe acute stage (Cases 2 to 6—duration of illness from 21 to 31 days) severe edematous changes with fine fibrosis in the perivascular area of the microvessels and the extensive compression of the conduction cells with degeneration and necrosis were evident in AV




Fig 1 Atrioventricular (AV) and sinoatrial (SA) conduction systems of Case 1 in the early acute stage *a* diffuse inflammation of the AV node CFB = central fibrous body (Hematoxylin and eosin stain original magnification 10 power \times 10) *b* a magnification of (a) Perivascular cell infiltration consisted of leukocytes and lymphocytes (Hematoxylin and eosin stain original magnification 40 power \times 10) *c* inflammation of stem of the left bundle branch \rightarrow means the left bundle branch (Hematoxylin and eosin stain original magnification 10 power \times 10) *d* inflammation of the right bundle branch \rightarrow means the right bundle branch (Hematoxylin and eosin stain original magnification 20 power \times 10)

conduction system in all five cases (Table II and Fig 2) The numerous inflammatory cells consisted of lymphocytes atypical lymphocytes plasma cells, large mononuclear cells fibroblasts and fibrocytes The above changes were noted throughout all of AV conduction system especially in the approach of the AV node where the inflammation was noted in all cases Inflammation of the bundle branches was severe in the stems and mild in the peripheries The greatest inflammatory changes were detected in the connective tissues fatty tissues and atrial and ventricular septal muscles abutting against the central fibrous body (Fig 2) There was no evidence of coagulation necrosis of AV conduction cells although coagulation necrosis was frequently detected in the ventricular septum (Table II) In addition to endocarditis of the valves inflammation in the root of the valve was frequently noted (Table II) In Case III severe panvalvulitis occurred (Fig 2) Angitis with

severe stenosis of the lumen occurred in the AV and SA nodal arteries (Table II) In the SA node and neighboring ganglions inflammatory changes were focally noted in three of four cases

In the end stage (cases 7 to 10—duration of illness from 48 days to 7 months) old and inflammatory changes consisting of the perivascular fibrosis of small or microvessels and fatty infiltration were conspicuous in both AV (Cases 8 and 10) and SA (Case 9) conduction systems (Figs 3 and 4) although the same evidence as in the acute stage was noted in Case 7 There was no evidence of any considerable loss of conduction cells coagulation necrosis or massive fibrosis in the AV and SA conduction systems In three out of four cases the elastic tissue of the collagenous extension of the central fibrous body was definitely increased Acute valvulitis disappeared Severe stenosis with recanalization due to a thickened wall secondary to scar formation was noted in AV and SA nodal arteries (Table II and Fig 4)




Fig 2 Atrioventricular (AV) conduction system of Case 2 in the most severe acute stage a inflammation of the AV node with severe compression of the conduction cells due to perivascular edema and cell infiltration. Severe inflammation was noted in the central fibrous body (CFB) \rightarrow means the AV node (Hematoxylin and eosin stain original magnification 5 power $\times 10$) b a magnification of (a) There was no evidence of diffuse necrosis of the conduction cells despite severe compression. Perivascular cellular infiltration consisted of mononuclear cells fibroblast and fibrocytes (Hematoxylin and eosin stain original magnification 40 power $\times 10$) c inflammation of the right bundle branch \rightarrow means right bundle branch (Hematoxylin and eosin stain original magnification 20 power $\times 10$) d the mitral valve with panvalvulitis (Hematoxylin and eosin stain original magnification 5 power $\times 10$)

Correlation between electrocardiogram (ECG) and pathology in the conduction systems ECG data on the conduction disturbances or ectopic beats are summarized in Table III. An ECG had not been taken in Cases 4 and 5 therefore such data were only available for eight cases. Prolongation of PQ interval was noted in four cases (Cases 2, 3, 8 and 10). In Cases 2 and 3 an acute pathologic lesion of the AV conduction system was detected. In Cases 8 and 10 the pathologic lesions were old and healed changes (Fig 3 and Table II). These PQ prolongations appeared in the acute stage and disappeared after the 24th day of illness in Case 8 and after the 18th day of illness in Case 10 (Table III and Fig 3). Acute pathologic lesions were probably present in the acute stage when PQ prolongations were evident. A complete AV block was seen in the ECG one

day prior to death in Case 7. Diffuse lesions of the acute stage were discovered in the AV node and bundle of His. As there was evidence of diffuse coagulation necrosis in the high posterior of the ventricular septum, the ischemia would have superimposed the inflammatory changes of the AV conduction system. Supraventricular tachycardia was present on the day of death and pathologic lesions were evident in both AV and SA conduction systems in Case 5. In Case 9 no pathologic changes of the AV conduction system or conduction disturbances in the recurrence ECG were noted. The incompatibility between pathology and ECG was noted in only one case (Case 1) in which there were acute inflammatory changes of the AV conduction system and yet no evident abnormality in the ECG (Fig 1 and Tables II and III).




Fig 3 Atrioventricular (AV) conduction system in the end stage and the electrocardiograms (ECG) in perivascular fibrosis without considerable loss of the conduction cells in the AV node of Case 8 CFB-central fibrous body (Hematoxylin and eosin stain original magnification 20 power \times 10) Right the ECG revealed PQ prolongation (PQ interval = 0.16 sec upper limits of normal control = 0.135 sec) on the 12th day of illness and normal PQ interval on the 24th day of illness b fatty infiltration in the bundle of His of Case 10 CFB = central fibrous body (Hematoxylin and eosin stain original magnification 20 power \times 10) Right The ECG revealed PQ prolongation (PQ interval 0.14 sec upper limits of normal control = 0.135 sec) on the 5th day of illness and normal PQ interval on the 18th day of illness

The pathologic lesions of SA conduction system were subclinical in three of four cases (Cases 1, 9 and 10) and in Case 6 there was evidence of a supraventricular tachycardia. In the other three cases (Cases 2, 8 and 7) there was no pathologic lesion, and no sinus arrest, second SA block, or ectopic beats. Sinus tachycardia was noted in all except Case 8 (Table III).

Discussion

Kawasaki's disease cannot be pathologically and clinically distinguished from infantile periarthritis nodosa at present.^{1, 6, 7} According to one case report of infantile periarthritis nodosa in

which the subject died after 6 months of illness,¹ the conduction systems gave evidence of pathological findings much the same as found reported in the end stage of our present work.

It is not surprising that the lesions were discovered in nine of 10 cases in the AV conduction system and in five of eight cases in the SA conduction system in autopsies of Kawasaki's disease. The death rate in cases of Kawasaki's disease is 1 to 2 per cent.⁸

The pathologic lesions could be differentiated from myocardial infarction, as the lesions began from edema and cell infiltration in the early and acute stages without coronary stenosis (Cases 1



Fig 4 Sinoatrial (SA) and atrioventricular (AV) nodal arteries with severe stenosis with reorganization due to scar formation in the end stage a the SA nodal artery of Case 9 with fatty infiltration in the SA node (Hematoxylin and eosin stain original magnification 70 power $\times 10$) b the AV nodal artery of Case 7 (Hematoxylin and eosin stain original magnification 20 power $\times 10$)

Table III Conduction disturbances or ectopic beats in ECG according to duration of illness

Case	Duration of illness				At death
	10 days	20 days	40 days	3 months	
1	0 11 (180) 0 16 (180)	0 13 (120) 0 14 (140)			9 days 20 days
3	0 14 (130)	0 14 (150) 0 17 (125)			21 days
4	no ECG				21 days
5	no ECG				24 days
6			SVT		31 days
7			CAVB		48 days
8	0 16 (140)	0 13 (110) 0 12 (135)	0 11 (170)		48 days
9	0 10 (180)	0 11 (175) 0 10 (150)		0 10 (135)	3 months
10	0 14 (140) 0 14 (150)	0 13 (105) 0 13 (95)	0 10 (150) 0 12 (100)	0 14 (125)	7 months

N numbers outside of parentheses = PQ interval (sec) n numbers within parentheses = heart rates and lined numbers = prolongation of PQ interval
SVT = supra-ventricular tachycardia CAVB = complete atrio-ventricular block

Days prior to death

Time of death

*Ten days prior to death

Forteen days prior to death

From this prior to death

and 2) and disappeared about the 48th day of illness leaving behind a mild fibrosis of the perivascular area and mild fatty infiltration without considerable loss of conduction cells. There was no evidence of coagulation necrosis of conduction cells in subjects with severe stenosis of the coronary arteries. Therefore it is concluded that the pathologic lesions of the conduction system are acute and inflammatory even if the ischemia is superimposed on the inflammatory changes in those with severe coronary stenosis.

Inflammation of the central fibrous body the

neighboring tissues atrium and valves was frequently evident and as such was analogous to that seen in acute rheumatic fever¹⁰. Aschoff bodies were not detected in our series.

All five cases with AV blocks had pathologic lesions in the AV conduction system. Cases 8 and 10 in which PQ prolongation had appeared in the acute stage and disappeared in the end stage had old and healed changes in the AV conduction system. Five of seven cases with pathologic lesions in the AV conduction system also had AV blocks in the ECG. One of two other cases had

supraventricular tachycardia Case B with no pathologic lesion had no AV block either in the acute stage or in the end stage. Our findings indicate that the ECG is a sensitive indicator of lesions of the AV conduction system. Especially there was a good correlation between PQ prolongation and acute inflammation of the AV conduction system in Kawasaki's disease.

It has been reported that PQ prolongation appears frequently in the acute stage but second or third degree AV blocks were rare in Kawasaki's disease.¹¹⁻¹³ So also was diffuse inflammation of the AV conduction system. This is attributed to the lack of diffuse necrosis of the conduction cells in the interstitial myocarditis of Kawasaki's disease.

In view of the long term prognosis of Kawasaki's disease, it is significant that the stenosis of the SA or AV nodal artery due to scar formation remains after disappearance of the acute angitis. This stenosis also remains in the three major coronary arteries.

Summary

Clinicopathologic study of the conduction systems was done on ten hearts obtained at autopsy from patients with Kawasaki's disease.

The pathologic lesions were discovered in the atrioventricular (AV) conduction system in nine out of 10 cases and in five of eight cases in the sinoatrial (SA) conduction system. The lesions of the AV conduction system were classified according to duration of illness at death. Early acute stage (0 to 9 days) was characterized by inflammation with cell infiltration and edema without coronary stenosis. The most severe acute stage (21 to 31 days) was characterized by severe compression of conduction cells without the diffuse necrosis due to severe perivascular edema and cell infiltration. In the end stage (48 days to 7 months), old changes with perivascular fibrosis and fatty infiltration without considerable loss of the conduction cells were noted. Coagulation

necrosis of the conduction cells was not evident despite the severe coronary stenosis. Lesions in the conduction system are therefore acute and inflammatory.

Pathology and electrocardiogram showed a good correlation in seven of eight cases. PQ prolongation was a sensitive indicator of acute inflammation of the AV conduction system in the present study.

Thanks are due to Drs T. Kawasaki, H. Okada, F. Hazama, K. Nishiohara, and T. Asai for pertinent discussions, A. Tsuchida for technical assistance, and M. Ohara for assistance with preparation of the manuscript.

REFERENCES

1. Fujiwara H and Hamashima Y. Pathology of the heart in Kawasaki's disease. *Pediatrics* 61:100, 1978.
2. Lev M, Widran J and Erickson E. A method for the histopathologic study of the atrioventricular node bundle and branches. *Arch Pathol* 52:73, 1951.
3. Lev M and Watne A L. Method for routine histopathologic study of human sinoatrial node. *Arch Pathol* 57:168, 1954.
4. Schlesinger M J. Relation of anatomic pattern to pathologic considerations of the coronary arteries. *Arch Pathol* 30:403, 1940.
5. Bellet S. Clinical disorders of the heart beat. Philadelphia 1971. Lea & Febiger, p. 345.
6. Tanaka N, Sekimoto K and Naoe S. Kawasaki's disease: Relationship with infantile periarthritis nodosa. *Arch Pathol Lab Med* 100:81, 1976.
7. Landing B H and Larson E J. Are infantile periarthritis nodosa with coronary artery involvement and fatal mucocutaneous lymph node syndrome the same? Comparison of 20 patients from North America with patients from Hawaii and Japan. *Pediatrics* 59:631, 1977.
8. Tang P H L and Segal A J. Polyarteritis nodosa of infancy. *J A M A* 217:1666, 1971.
9. Kawasaki T, Kosaki F, Okawa S, Shigematsu I and Yanagawa H. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. *Pediatrics* 54:271, 1974.
10. Gross L and Fried B M. Lesions in the AV conduction system occurring in rheumatic fever. *Am J Pathol* 12:31, 1936.
11. Kusakawa S and Asai T. Circulatory lesions of mucocutaneous lymph node syndrome (in Japanese). *Shonika* 16:795, 1975.
12. Kato Y and Koike S. Cardiac lesions of mucocutaneous lymph node syndrome (in Japanese). *Jap J Clin Med* 34:248, 1976.

Exercise tests, atrial pacing and myocardial lactate extraction in relation to coronary arteriography in young patients with angina pectoris

M Rajasalmi MD

J Takkenen MD

Oulu Finland

Since the introduction of selective coronary arteriography, conservative opinions have been expressed concerning the need for and use of coronary arteriography.¹ The prognostic implications of this examination and the diagnostic approach to coronary artery disease have been emphasized in comparison with the risks which have diminished with adequate facilities and greater experience.² Myocardial ischemia can be diagnosed on the basis of a typical history of angina pectoris even in the absence of any further evidence.³ In many situations however there may be cause for more extensive investigations from a purely medical standpoint or because of the patient's personal needs or the requirements of the community. The use of exercise studies and atrial pacing and even myocardial biopsies does not exclude the significance of coronary arteriography. It has also been concluded that with the use of coronary arteriograms and left ventricular biopsy alone it may be extremely difficult to separate patients aged over 40 years with left ventricular dysfunction due to ischemic heart disease from those with cardiomyopathy. Thus arteriographic studies provide a means of fulfilling the need for adequate anatomical diagnosis even in younger persons and when other methods of investigation are also used. The opinion that arteriographic evaluation is not justified in patients presumed to be at low risk is correct.

But when the symptoms jeopardize the patient's working capacity investigations must be carried out in depth even in younger patients not only for the diagnosis per se but also in order to decide upon the appropriate treatment and rehabilitation. In this study the methods used in the evaluation of possible ischemic heart disease have been applied to young patients with angina pectoris (1) to get information about possible changes in coronary arteriograms (2) to compare these with the findings in other examinations and (3) to disclose if there are any specific divergent features behind the angina pectoris symptoms in young patients.

Methods

Patients All 55 presenting patients forming this series were aged 40 or less and had been referred for examination because of angina pectoris. A basic examination was performed and other possible causes of the symptoms were excluded in the outpatient department. The patients with congenital or valvular heart disease or findings consistent with previous myocardial infarction and similarly those with hypertension anemia or diabetes are excluded from this series. Biochemical parameters including blood lipids and glucose tolerance were determined. Those patients in whom angina pectoris then seemed probable were sent for a cardiological examination. The distribution of the patients by sex and age is presented in Table I. The symptoms were recorded before the physical examination or any other measures had been undertaken. The physical activity involved in the patient's everyday work was also evaluated,⁴ since one indication for a thorough

From the Cardiology Division, Department of Internal Medicine, University of Oulu, Oulu, Finland.

Received for publication July 12, 1978.

Accepted for publication May 31, 1979.

Reprint requests: Dr. J. Takkenen, Cardiac Department, University of Oulu, SF-90021 Oulu 22, Finland.

Table 1 Classification of the 55 patients of age 40 or less comprising the present series by sex and age

	Age groups (yrs)				
	21-25	26-30	31-35	36-40	Total
Women	3	4	8	18	33
Men	3	3	8	8	22

examination had been their incapacity to perform their daily work. Sedentary work in a bank or office or some comparable position was assigned to the first category, light work including more walking and some lifting or moving of heavier objects formed the second, heavy work taken to include physically strenuous tasks in a factory or warehouse formed the third, while the fourth category, that of very hard workers, comprised mainly longshoremen, farmers, and lumber jacks.

Exercise ECG The test was conducted using an electrically braked bicycle (Godart Statham NV Bilthoven, Holland), with a load of 30 W initially increasing by 10 W/minute for women and 15 W/minute for men. The exercise was continued until the patient was exhausted or until anginal symptoms prevented further pedaling. A conventional 12 lead ECG was taken before exercise and at two and five minutes afterwards. The patients were monitored throughout, the electrodes for which were placed according to a modified CM₅ system¹⁴ on the manubrium sterni, high sacrum, and corresponding to the ECG Lead V₅ to get minimal disturbance from muscle function. A recording was made every minute at a paper speed of 50 mm/sec, the cuff blood pressure also being measured. A depression of 0.5 mm or more in the ST segment was regarded as pathologically significant.¹⁵ Serious arrhythmias were taken as natural indicators to stop the exercise. A three channel Elema Schonander Mingograph 43 was used in the exercise and pacing studies.

Blood sampling and lactate determination A Zuckers catheter¹⁶ was introduced into the coronary sinus via the cubital vein. If needed a lateral x-ray tube was used. The catheter was positioned in the coronary sinus as far as possible in such a manner that the blood sampling was not prevented, which would have meant wedging of the vein. This technique was used in an attempt

to obtain as adequate and comparable samples as possible for the measurement of lactate concentrations in the blood draining the left ventricle. This position also had a suitably low threshold for pacing by means of a Medtronic Model 5837 pulse generator. Arterial samples were collected simultaneously with coronary sinus sampling. The blood samples were immediately denatured with five volumes of ice cold 0.6 N trichloroacetic acid in closed tubes in a blender and placed in an icebath for transportation to the laboratory followed by immediate analysis by an enzymatic method.¹⁷ The normal value for lactate extraction, which is the difference between the arterial and coronary sinus concentrations calculated as a percentage of the former, is over 10 per cent.¹⁸ A lower extraction or a net accumulation of lactate in the coronary sinus blood was regarded as pathological in accordance with references in the literature.

Atrial pacing An intravenous injection of 0.6 mg of atropine sulphate was used to prevent any interference with Wenckebach's phenomenon. After the injection the heart rate was brought up to 170/minute in about 30 seconds. Blood samples and a 12 lead ECG were taken before pacing and at 2 and 4 minutes. Pacing lasted for 4 minutes in all blood samples and electrocardiograms were then taken at 3 and 5 minutes after the cessation of pacing. A three lead (V₁, V₄) ECG sample was recorded every minute during pacing and during the transition from pacing to sinus rhythm.¹ The recordings were satisfactory for a comparison to be made of any ST segment changes during and immediately after the pacing.

Coronary arteriography Judkins technique was used for coronary arteriography,¹ special care being taken not to introduce the catheter too far into the artery in order to avoid irritation and spasms. A good backflow to the aorta was regarded as an indication of good catheter position. Two to 8 ml of contrast material (Urografin 60 per cent) was injected by hand. Ostial stenosis was evaluated from a nearby ostial injection or aortography or from clear and immediate ostial wedging of the catheter. The biplane cineangiography instrumentation consisted of two Philips Maximus 100 roentgen generators with an XG 7002 cinepulse apparatus and Philips HQ type image intensifiers with Arrtekno R 90 camera¹⁹ and a Philips Angio Diagnost table. The biplane cineangiographies were taken in the frontal and 30 degree right anterior oblique positions with a

film speed of 50 frames/sec. All angiographies were evaluated by three independent cardiologists and disagreement was settled by consultation. If a spasm of the coronary artery was suspected nitroglycerine was used immediately in a new arteriography and the exposure was taken about two minutes later. The diameter of the stenosis of the coronary artery was compared with that of the same artery proximal to the narrowed segment and was expressed as a percentage of the latter. A significant change was held to be one involving a narrowing of 50 per cent or more, a degree of stenosis which is termed here obviously pathological. The dominance of a coronary artery was determined from the lateral films. Vascularization was balanced if the right coronary artery and the circumflex branch shared approximately equal parts of the posteroinferior part of the heart. In other cases one of these could be called dominant. Minor changes involved a narrowing of less than 50 per cent, or a vessel or main branch of general small size. The loading of the myocardial small vessels with contrast material and the slow disappearance of this were also recorded. The nomenclature recommended by Kretschmann and Kaltenbach⁷ is used in abbreviations.

Results

Most of the patients fall into the age groups 31 to 35 and 36 to 40 (Table I). The female patients comprise more than half of the total, most of them being in the age group 36 to 40 years. There is a clear difference between Tables I and II in that relatively more men are doing heavy or very heavy work. Housework was not included in the evaluation. Two thirds of the women (23 out of 33) were employed in sedentary or light work but these still experienced anginal symptoms at work or at home in the evening. In Table III the patients are grouped according to the findings in coronary arteriography versus family history, type of symptoms and sex, age and the duration of the symptoms. The men with obvious coronary changes are of greater age and have a significantly shorter duration of the symptoms than the women with coronary changes or the men with normal arteriograms. More prolonged anginal symptoms are found among the patients with pathological arteriograms in relation to their number. Early coronary disease means a coronary disease in the immediate members of the family and includes only men aged less than 50

Table II Patients classified by sex and physical strain of their work

	I	II	III	IV
Women	8	1	10	—
Men	1	5	11	5

Sedentary sitting work

I Light work moving and lifting

II Heavy work—factory type work

III Very heavy work—farmer lumberjack

Table III Findings in coronary arteriography in relation to the history of angina pectoris

	Pathological arteriogram		Normal arteriogram	
	Women	Men	Women	Men
Sex and number	5	6	28	16
Mean age (years)	37.2	35.5	36.2	36.2
Duration of symptoms (years)	2.4	1.7	3.2	3.9
Early coronary disease in family	4	3	14	8
Effort angina	5	6	23	16
Prolonged angina	3	3	12	11

years and women aged less than 60 years since angina pectoris becomes very common with advancing age in Finland.⁸ Even with this exclusion there is a high, evenly distributed incidence of angina pectoris in the near family in the young angina pectoris patients if the findings in coronary arteriography are ignored. Although angina pectoris was a criterion for admission to this series, five women did not have all their attacks in relation to physical stress so that only 23 women without coronary changes have a typical history of effort angina.

In the laboratory tests all patients had normal glucose tolerance. Of lipids only cholesterol and triglycerides were determined. The range of cholesterol values in five women with hypercholesterolemia was 277 to 398 mg/dl and respectively in seven men it was 289 to 461 mg/dl (normal below 270 mg/dl). The triglyceride values were evaluated in one woman (257 mg/dl) and in four of these men it was 230 to 354 mg/dl when the upper limit of normal is 150 mg/dl. All these patients except one man were in the oldest age group. Three of the men had narrowings in the coronary arteriograms which means that half of the men with obvious coronary changes had

Table IV Type, location, and degree of minor changes in six patients with a coronary arteriogram deviating from normal, but without significant stenosis

Sex and age	RC*	LC	LAD & LD	LCx	Dominance
F 40	—	kinking	—	—	Balanced
F 39	small	—	—	—	LC
F 40	small	—	below 50	—	LC
F 26	—	—	—	small	RC
M 32	small	—	—	—	LC
M 39	small	—	below 50	—	LC

RC = right coronary LC = left coronary LAD = left anterior descending branch LD = left diagonal branch LCx = left circumflex artery

hypercholesterolemia The results of coronary arteriography are presented in Tables IV and V. According to the criteria used, there are five women out of 33 and six men out of 22 with a clear narrowing of more than 50 per cent in one or more arteries, while minor changes were found in four women and two men. An obvious two or three vessel stenosis was found in four of the six men mentioned. Only one of the women had two vessel stenosis. Patients with small coronary arteries are to be found among both those with and without stenotic changes. All of these also had a slow clearance of the contrast material from the myocardium. One woman had a functional kinking of the left main coronary artery near the first bifurcation. In general the right coronary artery was affected more frequently than the left in this population. Two total occlusions were found, both in men, one in the diagonal branch of the left coronary artery. Both men had a normal resting ECG and the patient with the occlusion of the right coronary also gave a normal finding in the lactate study, but had a very low exercise capacity without ECG changes. His maximal heart rate was only 98 and in two minutes he developed angina pectoris with pallor and dizziness. The other man with the obstructed ventricular branch of left coronary artery had pathological findings in the exercise ECG, pacing ECG and lactate study, as well as an exercise capacity for a heart rate of 115 in 3 minutes. The right coronary artery was dominant in six out of the eleven patients with obvious coronary changes. No clear collaterals from the main branches of one coronary artery to the other could be seen.

The pathological and normal findings in coro-

Table V Location and degree of stenotic coronary changes in 11 patients in whom a clear change was found in arteriography. The balance between the coronaries is also recorded

Sex and age	Stenosed artery and degree of stenosis (in %)				
	RC*	LC	LAD & LD	LCx	Dominance
F 33	over 50	—	—	50	RC
F 36	over 50	—	—	—	Balanced
F 33	70	short	small	small	RC
F 38	70	short	—	—	RC
F 21	50 & 70	—	—	—	LC
M 39	over 50	—	75	below 50	Balanced
M 34	over 50	—	50	—	RC
M 39	75	—	over 50	—	RC
M 28	small	—	—	—	LC
M 35	75	—	LD 100	—	RC
M 38	100	—	—	small	LC

RC = right coronary LC = left coronary LAD = left anterior descending branch LD = left diagonal branch LCx = left circumflex artery

nary arteriography are presented in Table VI in relation to the results in other tests. Most of the patients with stenotic findings also had a clear pathology in the dynamic clinical tests. The women with normal arteriograms, on the other hand, had pathological findings in more than two thirds of the tests. The men with normal arteriograms also had more normal results in the exercise ECG and lactate test, but in the pacing ECG more of them gave an ST segment depression like the women with normal arteriograms. The data in Table VI enable the sensitivity and specificity of the exercise pacing and lactate tests to be calculated by considering the coronary arteriography as the definitive diagnostic procedure. The results are presented as percentages in Table VII. The sensitivity of these tests in the young patients with angina pectoris appears on this basis to be very high, with the pacing ECG the least specific. The specificity of the tests carried out on women was one half or two thirds of that in the tests on men.

The results of the various tests in relation to the coronary arteriogram are presented in Figs 1 and 2. Among the 11 patients with stenotic coronary changes there were five who had pathological results in all three functional tests as seen in Fig 1. In one man only the exercise ECG was




Fig 1 Venn diagram for the pathological findings in the exercise ECG pacing ECG and lactate study in patients with obvious coronary changes in coronary arteriography M = men F = women

Table VI Pathological and normal findings in patients with and without obvious stenotic coronary changes in the arteriograms Seven patients had normal results throughout

	Pathological arteriogram		Normal arteriogram	
	Women	Men	Women	Men
Exercise ECG				
Pathological	4	4	19	7
Normal	1	2	9	9
Pacing ECG				
Pathological	4	5	24	10
Normal	1	1	4	8
Lactate test				
Pathological	4	4	18	4
Normal	1	2	10	12

pathological and in another only the pacing ECG was pathological. Both had a moderate working capacity but developed angina pectoris that prevented further pedalling and both were farmers who worked during wintertime as lumberjacks. The elder, aged 34 years, had the principal stenosis in the right coronary artery but also had minor narrowings in the left anterior descending branch while the younger, aged 28 years, had a long stenotic section of 75 per cent that comprised the first third of the right coronary artery. He developed a second degree sinoventricular block during exercise and had a history of faintings with angina pectoris in the course of heavy work during previous years. Most of the patients with coronary changes had pathological results in the




Fig 2 Venn diagram for the pathological findings in the exercise ECG pacing ECG and lactate test in patients with minor changes or normal findings in coronary arteriograms. Seven patients with normal results are excluded M = men F = women

Table VII Calculated sensitivities and specificities of the exercise ECG pacing ECG and lactate test according to the criteria used. The finding of a stenosis of more than 50 per cent in a coronary lumen in the arteriogram is taken as indicative of significant coronary disease

		Sensitivity %	Specificity %
Exercise ECG	Total	72.7	40.9
	Men	66.6	36.3
	Women	80.0	35.0
Pacing ECG	Total	81.8	27.0
	Men	83.3	37.5
	Women	80.0	14.3
Lactate test	Total	72.7	47.7
	Men	66.6	68.8
	Women	80.0	38.6

lactate study but discrepancies in their exercise and pacing ECG's. Fig 2 presents the pathological results in the patients with minor coronary changes or normal coronary arteriograms. Most of them have pathological findings in the pacing ECG. All three tests were pathological in 15 out of the 37 patients included in this diagram. Seven patients are not included and must be regarded as true negatives because all their results were normal. The concept of serial testing deems a person positive only if he gives positive results in the whole series. This would suggest, according to Fig 1, a sensitivity in detecting coronary changes of 50 per cent in men and 40 per cent in women for these physiological tests. On the other hand, the power of serial tests to detect persons without




Fig 3 ST segment depressions in patients with pathological (open circles) and normal (closed circles) results in lactate tests by sex

coronary changes is apparently good in men, for the specificity, as calculated from the data in Fig 2 is 80 per cent for men in this case, whereas for women it is only 55.5 per cent. The difference is significant in clinical practice.

The ST segment changes in exercise and pacing tests are presented in Fig 3 in relation to the findings in the lactate study. There is no clear separation of patients with regard to the degree of ST depression and the result in the lactate test. The woman with a 3 mm ST depression in pacing had only an 0.5 mm depression in exercise and normal lactate response, but she had a narrowing of 70 per cent in the right coronary artery and her exercise time was only 2 minutes to angina pectoris that she also felt during pacing.

Two men and two women had evidence of mitral valve prolapse. One of the men had occlusion in the first third of the right coronary artery and the other one had a stenotic first third of the same vessel. One of the women had a small right coronary artery and a narrowing of less than 50 per cent in the left anterior descending branch. She had pathological results in ECG and lactate tests. The other woman had normal arteriograms and only ST depressions in pacing. These findings were confirmed by left ventriculograms and echocardiography.

Discussion

In epidemiological studies of angina pectoris in Finland, the prevalence in the age group 30 to 34 years in men was 0.4 per cent and in the age group

35 to 39 years it was 1.2 per cent. The corresponding figures for women were 1.6 and 2.6 per cent respectively, or about two to three times higher than for men. Our study population was selected after a tight clinical scrutiny that excluded the possible extracardiac causes of chest pain. The patients considered to have typical angina pectoris and who found themselves unable to do their work because of the symptoms were submitted with their consent to a thorough cardiological examination. Of the 71 patients referred to cardiological evaluation, four did not accept the invasive procedure, four were excluded because of diabetes, and eight patients were excluded because of hypertension. The exact prevalence of patients with this degree of angina pectoris can not be adequately presented in relation to the epidemiological numbers, but at any rate they form a minority in the young age groups. The relation of men to women corresponds to the relation of the prevalence percentages in the referenced epidemiological study. The number of patients and findings increase with age from 20 to 40 years (Table I), which is in agreement with epidemiological, clinical, and anatomicopathological findings in Finland. In the patients studied, the physical stress of their work did not bear any clear relation to the existence of the symptom, but most of the typical coronary changes were found in the people who did heavy work. Six women and seven men of the study group did smoke 10 to 20 cigarettes a day. One man and one woman of these had coronary

changes. At the time of the examination no one of the women was taking estrogen containing medication.

The sensitivity of exercise testing is higher in women but the specificity markedly better among men (Table VII). The high prevalence of false positive exercise ECG findings among healthy women and also symptomatic patients has been previously documented.^{2,7} The ability of the lactate test to distinguish men without any significant coronary changes is evident and also the sensitivity of lactate test is in agreement with previous publications.¹¹ The significance of the coronary arteriography has been questioned but it is clear in several patients of this study when both a negative exercise test and a negative lactate test made the diagnosis doubtful. In two men and one woman an occlusion or a narrowing of the right coronary artery was found but they had only a very low exercise capacity with a low angina pectoris threshold in other tests. Consequently we must be ready to go through the diagnostic algorithm recently presented by Hurst and King¹⁴ in a thorough manner even in the case of young patients. In addition to the classical angina pectoris at times of effort prolonged chest discomfort after physical stress is also an indication for a careful examination (Table III). In men the symptoms seem to be clearer and led more directly to an examination in our series of patients.

Another important fact is that even though the women had more normal findings neither mean age nor family history nor the type or duration of the symptoms served to separate those with coronary changes from others. A large proportion of the women were employed in light work and of the five women with pathological findings in coronary arteriography only one was a heavy laborer but still they had anginal symptoms even doing light work. More than 60 per cent of women with normal arteriograms showed lactate production during pacing but in men the situation was reversed a result that has been found previously.¹¹ This may suggest that angina pectoris in young people with no significant coronary changes is perhaps an entity distinct from classical coronary disease even if coronary disease exists in these patients. A few clear pathological findings in the major coronary arteries did emerge in these young patients and this argues in favor of the findings obtained in pathologic anatomy

cal studies^{11,15} and clinical studies¹⁶ that these patients actually have large vessel disease. The criteria adopted for the definition of pathological results were those commonly used and these have been evaluated on many occasions¹¹ mostly in connection with patients who are older than the present series and who had more evidence of ischemic heart disease before coronary arteriography. Our selection criteria imply a minimum of selectivity with regard to the ECG changes at rest. The 0.5 mm depression in the ST segment upon exercise is very sensitive as is shown in Table VII. The sensitivity percentages obtained in the men are within the range noted in previous studies using an ST depression of 1 mm.^{11,17} If the sensitivity data computed for an ST segment depression of 1 mm or more in the exercise test for men are 66.7 and for women are 60.0 the specificity percentages are 88.7 and 57.1 respectively. The corresponding sensitivity values in pacing tests are for men 50.0 and for women 60.0 the sensitivity percentages being 37.5 and 21.4 respectively. Compared to the data in Table VII a significantly better result is reached only in the specificity percentages for women in the exercise test. The high sensitivity of the criteria used here is reflected in the low percentages of specificity. This logical situation is tolerable in the exercise ECG but in the pacing ECG the 0.5 mm criterion is evidently useless. On the basis of results presented in Fig. 3 we are thus inclined to agree with previous investigators who found that a depression of 2 to 4 mm correlated best with a pathological result in the lactate extraction test.¹⁸ Three of our six male patients with coronary changes had an ST depression of 2 to 3 mm and two had an ST depression of 0.5 to 1 mm while one gave no ST depression either during or after pacing a result consistent with findings in older patients.¹⁹ The 16 men with normal coronary arteriograms and normal lactate extraction also had fewer ST changes but these findings do not separate them. The pathological findings in the exercise ECG and lactate test correlate well from the qualitative point of view in individual patients but in some situations the lactate extraction test is misleading because the coronary sinus drains the blood mainly from the left ventricle.²⁰ Three examples have been presented where changes in the right coronary artery were connected with low ergometric capacity and angina pectoris at a low heart rate. In the case of

patients with this degree of angina, it is proper to obtain a coronary arteriogram rather than to require a new exercise test. 'The low specificity of the exercise ECG, the pacing ECG and the myocardial lactate study for the indication of ischemia in young women is also evident here as in previous reports, where false positive results have been obtained in 30 to 67 per cent of women with angina pectoris' ^{3, 18} or without. 'The exact nature of the coronary changes recorded in arteriography remains open. In most cases they seem to be identical with the findings in older patients with atherosclerosis. In one woman aged 22 the two narrowings indicated in the right coronary artery are difficult to explain on this basis. Other possibilities are infectious lesions or some systemic disease that could not be identified in our study.' 'The case of those patients who had a very small coronary artery without any narrowings is also highly interesting. The other coronary artery was naturally the dominant one but no collateral circulation was found. A loading of the myocardium with contrast material, which was slow to disappear, was also typical.' 'It has been proposed that venous drainage or a stagnation on the venous side could be a notable factor in the ischemic heart disease.' 'Our findings are compatible with this. The pathological changes were ostial in two male and two female patients which is consistent with autopsy findings on young people who have died acutely.' 'These patients also presented practical problems in the examination as they were prone to develop bradycardia and various arrhythmias when the catheter was introduced into the ostium of the artery. The ostial narrowings were all found in the right coronary artery as were most of the narrowings found in this series but this may be only a coincidence. On the other hand the right coronary artery was also dominant in these patients and this may possibly be a cause of the accentuated symptoms that led the patients to this examination. The venn diagrams in Figs 1 and 2 show that about half of the men and women with coronary changes as well as half of the women with no coronary changes had all other three test results appear pathological. The men with normal coronary arteriograms had fewer pathological changes also in the other tests. Of the four patients with mitral prolapse three had abnormalities in the right coronary artery in agreement with some but not with most of the results.' 'Totally normal arteriographic findings and

dynamic test results were registered in two women and in five men. The exact nature of ischemic heart disease with open coronary arteries still remains unexplained,' but there is considerable evidence in favor of small vessel disease.' '.

Other possibilities are metabolic disturbances or abnormal reactivity of the coronary vessels since no clear morphological disease of the small myocardial arteries has yet been found in biopsies.' 'The generally known ominous nature of chest pain related to physical stress in any case seems to lead patients in Finland to seek all possible help in explaining their symptoms. The follow up of these patients after the thorough medical survey seems to be the only way of furnishing such an explanation and providing guidelines for the physician.

Summary

An exercise ECG and atrial pacing with a simultaneous study of myocardial lactate metabolism were used in conjunction with coronary arteriographies for the examination of 33 women and 22 men aged 40 or below whose working capacity was impaired by angina pectoris. Most of the patients fell into the age group 36 to 40. The men with coronary changes had come for examination in a shorter time than other patients. Coronary artery narrowings were found in five women and six men. The findings in other tests were pathological with greater frequency in patients with coronary stenosis. When evaluated on the basis of coronary arteriograms the exercise and lactate tests proved to be reasonably sensitive (66.6 per cent) and specific (56.3 per cent and 68.8 per cent) in men. In women the sensitivity was high (80 per cent) but the specificity low (exercise 35 per cent, pacing 14.3 per cent and lactates 38.5 per cent, respectively). The pacing ECG was also highly unspecific in men (37.5 per cent). Seven patients gave totally normal findings. The examination did not identify any specific group of patients with changes indicative of a constitutional disease of the myocardium. The coronary changes indicated that even in this age it is proper to obtain arteriograms in patients with low working capacity even in the absence of any other changes that angina pectoris itself. There are more false positive findings in women than in men in exercise tests and in many situations arteriography assures the best basis for further measures.

REFERENCES

1. Sones F M and Shirey E K. Cine coronary arteriography. *Mod Concepts Cardiovasc Dis* 31 735 1967
2. Judkins M P. Selective coronary arteriography. *Radiology* 89 815 1967
3. Werko L. Coronary arteriography: clinical aspects. In: Halonen P I and Louhja A, eds. *Thrombosis and coronary heart disease*. Basel 19 11 S Karger p 748
4. Lavesley H and Oram S. Diagnosis of doubtful angina. Comparison of radiotelemetric exercise electrocardiogram with lactate content of coronary sinus blood after pacing. *Lancet* 1 1461 1973
5. Humphries J O, Kuller L, Ross H S, Friesinger G C and Page E E. Natural history of ischemic heart disease in relation to arteriographic findings. A twelve year study of 74 patients. *Circulation* 49 489 1974
6. Picard A. Coronary arteriography for everyone? *Am J Cardiol* 38 833 1976
7. Sampson J J and Chertlin M D. Pathophysiology and differential diagnosis of cardiac pain. *Progr Cardiovasc Dis* 15 507 1973
8. Hurst J W and Logue H H. The clinical recognition and medical management of coronary atherosclerotic heart disease. In: *The Heart* ed Hurst J W, Logue H H, Schlant R C and Wenger N K. New York 19 4 McGraw Hill Book Company Inc pp 1038 1137
9. Walsh W, Rickards A F and Balcon H. Coronary arteriographic study of mild angina. *Br Heart J* 37 752, 1975
10. Richardson P J, Lavesley B, Oram S, Olsen E G J and Armstrong, P. Angina pectoris with normal coronary arteries. Transvenous myocardial biopsy in diagnosis. *Lancet* 11 677 1974
11. Kawai C and Takatsu T. Clinical and experimental studies on cardiomyopathy. *N Engl J Med* 18 597 1975
12. Gulotta S J. Coronary arteriography 1976—for whom? *Am J Cardiol* 38 531 1976
13. Wilhelmsson L, Tibblin G, Fodor J and Werko L. A multifactorial primary preventive trial in Gothenburg, Sweden. In: *Coronary heart disease and physical fitness* ed O Andrés Larsen and R O Malmberg. Denmark 1971. Ejnar Munksgaards Forlag pp 286 290
14. Redwood D R and Epstein S E. Uses and limitations of stress testing in the evaluation of ischemic heart disease. *Circulation* 45 1115 1972
15. Friesinger G C and Smith H F. Correlation of electrocardiographic studies and arteriographic findings with angina pectoris. *Circulation* 46 1173 1972
16. Zucker I R, Rothfeld H L and Bernstein A. A new multipurpose cardiac catheter. *Am J Cardiol* 15 45 1965
17. Hohorst H J L (+) Lactate determination with lactate dehydrogenase and DPN in H U Bergmayer editor. *Methods of enzymatic analysis*. New York, 1963. Academic Press pp 766 20
18. Herman M V, Elliott W C and Gorlin R. An electrocardiographic anatomic and metabolic study of zonal myocardial ischemia in coronary heart disease. *Circulation* 35 644 1967
19. Parker J O, Chiang M A, West H O and Case R B. Sequential alterations in myocardial lactate metabolism. S-T segments and left ventricular function during angina induced by atrial pacing. *Circulation* 40 113 1969
20. Robson R H, Pride H and Fluck D C. Evaluation of rapid atrial pacing in diagnosis of coronary artery disease. Evaluation of atrial pacing test. *Br Heart J* 38 498 1976
21. Kretschmann H J and Haltenbach M. Anatomy and nomenclature of coronary arteries in M Haltenbach and P Lechtlen editors. *Coronary heart disease. International Symposium held in Frankfurt January 22-24 1970*. Stuttgart 1971. Georg Thieme Verlag p 37
22. Puro A and Aromaa A. Social Insurance Institution's coronary heart disease study. Prevalence of chest pain symptoms and ECG findings in nine Finnish population groups (English summary and legends). *Kansaneläkeläi toisen julkaisuja*. AL 1 91 1975
23. Rissanen V. Aortic and coronary atherosclerosis in a Finnish autopsy series of violent deaths. *Ann Acad Sci Fenn Series A* 4 155 31 1972
24. Hekah P. Coronary angiography and clinical symptomatology. *Acta Radiol* 17(Suppl) 354 1976
25. Cumming H R, Dufresne C and Samm J. Exercise ECG changes in normal women. *CMA Journal* 109 108 1973
26. Sketch, M H, Mohiuddin S M, Lynch J D, Zenka A E and Runco V. Significant sex difference in the correlation of exercise testing and coronary arteriograms. *Am J Cardiol* 36 169 1975
27. Lesbre J Ph, Campau L, Bourassa M, Huot R, Quiret J C and Bernasconi L. Electrocardiogramme d'effort chez la femme. *Arch Mal Coeur* 69 935 1976
28. Hurst J W and King S B III. The problem of chest pain. Emphasis on the workup of myocardial ischemia. *JAMA* 236 2100 1976
29. King H G Jr, Vokonas P S, Cohn P F and Gorlin R. The anginal syndrome associated with normal coronary arteriograms. Report of six years experience. *Am J Med* 54 74 1973
30. James T N. The role of small vessel disease in myocardial infarction. *Circulation* 39 and 40 (Suppl IV) 13 1969
31. Pressens J, Van Mieghem W, Kesteloot H and De Geest H. Diagnostic value of clinical history, exercise testing and atrial pacing in patients with chest pain. *Am J Cardiol* 33 361 1974
32. Boudoulas H, Cobb T C, Leighton R F and Wilt S M. Myocardial lactate production in patients with angina like chest pain and angiographically normal coronary arteries and left ventricle. *Am J Cardiol* 34 501 1974
33. Chertlin M D, McAllister H A and Castro C M. Myocardial infarction without atherosclerosis. *JAMA* 231 91 1975
34. Tambe A, Demany M, Zimmerman H and Mascarenhas E. Angina pectoris and slow flow velocity of dye in coronary arteries. A new arteriographic finding. *Am Heart J* 84 66 1972
35. Farrer Brown G. Patterns of microvasculature in normal and diseased hearts. *Acta Cardiol Suppl* 19 p 119 1974
36. Razda V, Benichou A, Desser K H, Reich F D, Shearsh C and Graves C. Mitral valve prolapse in patients with coronary artery disease—echocardiographic angiographic correlation. *Br Heart J* 39 53 1977
37. Chesler E, Mattson R E, Lakier J H, Pocock W A, Obel P and Barlow J. Acute myocardial infarction with normal coronary arteries—a possible manifestation of the billowing mitral leaflet syndrome. *Circulation* 54 203 1976
38. Gault J H. "Preinfarction" angina in patients with normal coronary arteries. *Adv Cardiol* 15 38 1975
39. Aorhola O, Valle M, Frick M H, Viljasalo M and Ruuhimäki E. Regional myocardial perfusion abnormalities on venous 133 imaging in patients with angina pectoris and normal coronary arteries. *Am J Cardiol* 39 355 1977

Effect of verapamil on normal sinoatrial node function and on sick sinus syndrome*

Hugo A Carrasco, M D
Abdel Fuenmayor P, M D
Juan S Barboza M, M D
German Gonzalez, M D
Mérida, Venezuela

Verapamil, a derivative of papaverine was originally introduced as an antianginal drug. It was subsequently found to have potent antiarrhythmic properties, in both experimental and clinical studies.¹⁻⁴ The drug is now commonly used for treatment of reentrant atrial tachyarrhythmias, for controlling ventricular rate in atrial flutter and fibrillation, and also for tachyarrhythmias associated with preexcitation syndrome.⁵⁻⁶ Current reports on its mode of action have focused attention on the effect of this drug on sinoatrial (SAN) and atrioventricular (AVN) nodes.⁷⁻⁹ Previously, clinical studies demonstrated that a variety of supraventricular bradyarrhythmias, such as A block atrial arrest and advanced A V block¹⁰⁻¹² have been associated with administration of intravenous bolus of the drug. Since the underlying cause of some atrial tachyarrhythmias is a damaged SA node,¹³⁻¹⁵ the use of verapamil in patients with sick sinus syndrome may be potentially dangerous. Unfortunately, clinical information on the effects of this drug on human SAN function is inadequate¹⁶⁻²⁰ to establish safe therapeutic patterns.

The purpose of the present communication is to study the effect on SAN function of several concentrations of intravenous verapamil adminis-

tered in the usual clinical range measured by determination of SAN recovery time and of corrected SAN recovery time after overdrive atrial pacing.²¹⁻²³ Patients with normal SAN function and with sick sinus syndrome (SSS) were studied. beta receptor active drugs and parasympatholytic drugs were also administered to elucidate a possible mode of action in these circumstances.

Material and methods

Sixty seven patients underwent hemodynamic and electrophysiologic studies (right and left sided catheterization, pressures LV cineangiogram coronary angiogram and atrial stimulation) and were divided into three groups. Groups I and II included 15 patients with angina like chest pain, 16 patients with asymptomatic sustained sinus bradycardia over 50 per minute, 12 patients with arterial hypertension, and seven patients who underwent miscellaneous angiographic studies. Their age range was from 21 to 83 years. None of the patients were receiving antiarrhythmic agents, digitalis or diuretics. Group I patients were treated with verapamil alone in various concentrations to determine its effects on SAN function.

Group II patients received beta receptor and parasympatholytic drugs in conjunction with verapamil.

The Group III patients were previously diagnosed as having sick sinus syndrome (SSS) established by clinical findings, routine electrocardiograms, Holter monitoring,²⁴⁻²⁶ and abnormal SAN suppression tests.²⁷⁻³¹ The age range was from 28 to 65 years and included four

From the Centro Cardiovascular, Universidad de Los Andes, Hospital Universitario de Los Andes, Mérida, Venezuela.

Supported by a grant from the Consejo de Desarrollo Científico y Humánico de la Universidad de Los Andes (CDCHULA).

Received for publication Jan 16 1978.

Accepted for publication Apr 4 1978.

Reprint requests: Dr. Abdel Fuenmayor, Centro Cardiovascular, Universidad de Los Andes, Mérida, Venezuela.

Presented in part at the Seventh World Congress of Cardiology, Buenos Aires, Argentina, September 1974.




Fig 1 Lead II tracings recorded at double standardization from a patient with sick sinus syndrome. Control post pacing pause of almost two seconds and a warming up phenomenon are observed (upper strip). Isoproterenol administration normalizes SAN recovery time (second strip) but verapamil administered intravenously doubles it allowing a junctional escape rhythm to appear (third strip). Sinus rhythm resumes 17 seconds after stopping artificial atrial pacemaking (fourth strip). Atropine did not revert completely the SAN depressing effect of verapamil in this patient (lower strip).

females and three males. Four of these patients had angiographically proven coronary artery disease, two had chronic Chagas heart disease, and one had no defined etiology. Informed consent was obtained on all patients.

Routine hemodynamic and angiographic studies were carried out as planned in all patients. Thereafter (in 31 patients) a No. 5F bipolar electrocatheter (Medtronic 6700) was passed via the right femoral vein and placed in a stable position in the high right atrium. In 36 patients a No. 6F tetrapolar electrocatheter (USCI) was used. This catheter has two distal electrodes positioned for pacing and two proximal electrodes positioned in the proximities of the S-A node for intraatrial electrogram recordings. Tracings were obtained on a calibrated Hewlett Packard electrocardiograph or on a Mingograph (EM 81, Elema-Schoenander). After positioning of the

catheters a period of 30 minutes was allowed for stabilization before starting drug studies.

SAN function was measured by performing *override* atrial pacing with a 5880 A Medtronic external generator according to standard techniques at paced frequencies of 90, 110, 130, 150, and 180 per minute. Extent of SAN suppression after pacing is proportional to the duration of post pacing pause measured from the last pacing artefact to the first spontaneous P wave. Results were expressed as a percentage of control rate.

Percent SAN recovery time (% SAN rec time) =
Maximal postpacing atrial pause (insec) \times 100

Control P-P interval

Corrected SAN recovery time (CSNRT) defined as the recovery interval in excess of the sinus cycle was also calculated. Sequences without

Table I Effect of verapamil on normal SAN function

	RR (msec)	Max rec time (msec)	% SAN rec time	CSNRT (msec)	PR (msec)	% AV cond
Control (n = 7)	751 ± 41	1017 ± 42	136 ± 4	263 ± 27	180 ± 11	91 ± 3
0.10 mg/Kg 5 min post V	780 ± 61	1040 ± 63	135 ± 5	260 ± 36	210 ± 40	76 ± 9
Δ%	4 ± 5	4 ± 4	2 ± 6	4 ± 5	16 ± 8*	-37 ± 15
0.10 mg/Kg 15 min post V	728 ± 27	1020 ± 50	140 ± 4	293 ± 30	200 ± 30	70 ± 7
Δ%	-1 ± 2	1 ± 4	2 ± 2	7 ± 8	17 ± 8	-9 ± 10
0.10 mg/Kg 30 min post V	737 ± 25	1057 ± 61	143 ± 4	320 ± 39	200 ± 14	72 ± 9
Δ%	2 ± 4	5 ± 13	6 ± 5	20 ± 15	14 ± 8	-22 ± 10
Control (n = 14)	883 ± 50	1134 ± 65	129 ± 3	251 ± 27	180 ± 7	96 ± 2
0.15 mg/Kg 5 min post V	799 ± 37	1157 ± 57	144 ± 4	357 ± 37	210 ± 11	61 ± 7
Δ%	-8 ± 3*	3 ± 7	16 ± 3	52 ± 16*	16 ± 3*	-36 ± 7*
0.15 mg/Kg 15 min post V	921 ± 53	1414 ± 145	156 ± 16	494 ± 131	210 ± 30	50 ± 10
Δ%	-3 ± 7	15 ± 14	26 ± 16*	90 ± 111	16 ± 5	-43 ± 10
0.15 mg/Kg 30 min post V	884 ± 67	1348 ± 135	152 ± 11	464 ± 100	210 ± 14	11 ± 13
Δ%	-2 ± 8	16 ± 12	20 ± 8	71 ± 42*	17 ± 5	-33 ± 13
Control (n = 9)	986 ± 54	1270 ± 80	128 ± 2	285 ± 30	190 ± 1	98 ± 2
0.20 mg/Kg 5 min post V	834 ± 48	1310 ± 107	155 ± 4	473 ± 59	230 ± 13	47 ± 8
Δ%	-14 ± 5**	3 ± 8	27 ± 4***	73 ± 20	19 ± 4***	-51 ± 8**
0.20 mg/Kg 15 min post V	938 ± 51	1762 ± 265	188 ± 21	828 ± 235	230 ± 13	46 ± 8
Δ%	-5 ± 6	32 ± 17	57 ± 20	177 ± 68*	19 ± 4**	-50 ± 8
0.20 mg/Kg 30 min post V	967 ± 61	1537 ± 149	157 ± 8	570 ± 90	230 ± 40	43 ± 6
Δ%	-5 ± 6	17 ± 15	27 ± 8	83 ± 30**	-20 ± 6*	-51 ± 6*

* $p < 0.05$ * $p < 0.005$ * $p < 0.0005$

All results expressed as mean ± SEM

Abbreviations: Max rec time = maximal post pacing pause; % SAN rec time = per cent SAN recovery time; CSNRT = corrected sinus node recovery time; % AV cond = per cent AV conduction efficiency; Δ% = per cent change as compared to control; V = verapamil

clear cut sinus escape beats after pacing were discarded and were repeated. Longest maximal post pacing pauses, usually observed after pacing between 130 and 180/minute were used for comparison of results. An approximate estimation of A V conduction efficiency, expressed as per cent A V conduction, was obtained by dividing ventricular rate by paced atrial rate at 130/minute. This relationship is essentially a numerical expression of the Wenckebach phenomenon and was calculated in our experiments (together with PR changes) as a secondary objective, to obtain an approximate idea of the effect of the drugs used on A V conduction.

After a control value for SAN function was determined in all patients they were divided (as described previously) into three groups. Thirty patients (Group I) with no evidence of SAN dysfunction were given commercially available intravenous verapamil (Mandon Knoll AG) in single bolus to establish the effect of several concentrations of this drug on normal SAN function, seven patients were administered verapamil

at 0.10 mg/Kg, 14 patients at 0.15 mg/Kg and nine patients at 0.20 mg/Kg. Atrial overdrive pacing was repeated and SAN function measured at five, 15 and 30 minutes after the administration of the drug.

The next 30 patients with normal SAN function (Group II) were further subdivided in an effort to demonstrate by what means verapamil exerts its effect on this pacemaker. In six patients of Group II, the possibility of a beta blocking effect of verapamil was explored. For this purpose isoproterenol (Isuprel, Wintrop, 3 µg/minute) was administered for five minutes until heart rate response was stable. Then the infusion was stopped and an additional five to ten minute period was allowed for hemodynamic changes to return to control levels. At this time, an 0.20 mg/Kg bolus of verapamil was administered. Seven minutes later isoproterenol infusion was started again at 3 µg/minute and maintained for 10 minutes. SAN function was measured immediately before, and five minutes after, the administration of the drugs. In the next six patients of




Fig 2 Effect of verapamil on SAN function in normal subjects (panel A) and in patients with sick sinus syndrome (panel B). In panel A the effects of three different doses of verapamil (V) are depicted. Per cent changes in SAN recovery time as compared to control are represented in ordinates. These effects are already significant at 5 minutes with doses of 0.15 and 0.20 mg/Kg of the drug reaching a maximum at 15 minutes after injection and lasting for more than 30 minutes. In panel B the effect of a similar dose of verapamil (V = 0.15 mg/kg) and of atropine (A = 0.05 mg/kg) in patients with sick sinus syndrome and on subjects with normal function are compared. Prolongation of per cent recovery time in SSS patients is fourfold that seen in patients with normal SAN function being maximal at 5 minutes and lasting for more than 30 minutes. Atropine injected at this time returned per cent SAN recovery time to pre verapamil level in both groups.

Group II blocking of the beta cardiac receptor was achieved before administration of verapamil in an effort to determine if this blocking would alter the action of verapamil on SAN function. Consequently propranolol (Inderal ICI 0.1 mg/kg) was given in 100 cc of 5 per cent C.W. solution over a 10 minute period. SAN function determinations were made five and ten minutes

after the end of the intravenous solution and immediately thereafter verapamil (0.20 mg/kg) was administered intravenously. Overdrive atrial pacing was repeated at five, 15 and 30 minutes after the administration of verapamil. In the remaining 18 patients of group II effects of blocking cholinergic receptors with 0.025 mg/kg of atropine intravenously administered before

Table II Effects of isoproterenol and propranolol on verapamil induced changes in normal SAN function

	RR (msec)	Max rec time (msec)	% SAN rec time	CSNRT (msec)	PR (msec)	AV cond
Control (n = 8)	941 ± 89	1254 ± 88	136 ± 5	313 ± 35	190 ± 9	9° ± 8
5 min post Isoproterenol	576 ± 33	808 ± 64	140 ± 5	232 ± 37	140 ± 4	100 ± 0
Δ%	-26 ± 6*	-29 ± 5	4 ± 2	-31 ± 7*	-23 ± 8	13 ± 10
5 min post Verapamil	929 ± 87	1525 ± 206	162 ± 8	609 ± 145	230 ± 20	48 ± 9
Δ%	-1 ± 7	20 ± 9*	22 ± 6**	95 ± 33*	22 ± 7	-44 ± 9
5 min post Isoproterenol	773 ± 55	993 ± 81	129 ± 4	220 ± 38	170 ± 10	90 ± 8
Δ%	-15 ± 7	-21 ± 8	-7 ± 4	-24 ± 12	-11 ± 5	-2 ± 9
Control (n = 6)	948 ± 117	1266 ± 130	135 ± 5	316 ± 36	180 ± 8	93 ± 6
5 min post Propranolol	1060 ± 106	1472 ± 154	139 ± 5	404 ± 66	190 ± 10	64 ± 10
Δ%	13 ± 5*	13 ± 2**	4 ± 5	29 ± 13	9 ± 4	-78 ± 1*
10 min post Propranolol	1080 ± 125	1436 ± 154	144 ± 2	440 ± 46	190 ± 10	63 ± 3*
Δ%	17 ± 4*	13 ± 2**	9 ± 5	49 ± 21*	9 ± 4*	-27 ± 16
5 min post Verapamil	1028 ± 75	1996 ± 329	195 ± 31	1064 ± 404	240 ± 40	34 ± 7
Δ%	11 ± 6	80 ± 33	60 ± 30	225 ± 103*	35 ± 5	-60 ± 1*
15 min post Verapamil	1020 ± 102	2292 ± 517	224 ± 49	1272 ± 477	230 ± 8	3° ± 5
Δ%	9 ± 4	78 ± 36	89 ± 40*	275 ± 116	30 ± 6	-61 ± 10
30 min post Verapamil	1020 ± 63	1932 ± 350	190 ± 36	912 ± 338	220 ± 8	3° ± 5
Δ%	11 ± 7	55 ± 30	55 ± 34	177 ± 86	28 ± 6	-61 ± 10*

* p < 0.05

** p < 0.005

*** p < 0.0005

Isoproterenol = IV infusion 3 µg/min Verapamil = IV bolus 0.20 mg/kg Propranolol = IV infusion 0.1 mg/kg Other abbreviations as in Table I

verapamil in seven patients and after 0.20 mg/Kg verapamil in eleven patients were studied to test possible vagal like action of the drug SAN function was measured immediately before and five to ten minutes after administration of the drugs

The methodology followed for Group III (seven patients with SSS) was as follows: control levels of SAN function were determined 0.15 mg/Kg of verapamil were administered intravenously and SAN function redetermined at 5, 15, and 30 minutes post drug injection. Finally, atropine (0.025 mg/Kg bolus) was given 35 minutes after verapamil administration followed five minutes later by SAN function measurements (Fig 1)

Changes observed in all parameters are expressed as per cent increase or decrease from control conditions (Δ%). Normal results in our laboratory for per cent SAN recovery time is 135 ± 22 (mean ± 2 standard deviations) and for CSNRT is 289 ± 176 msec. These results are in agreement with those currently reported.^{11, 13, 21} Standard techniques (paired Student's t test correlation coefficient determinations and lineal correlation analysis) were applied in order to assess statistical significance of data

calculated in a pre programmed 9810 Hewlett Packard desk computer

Results

1 Effect of verapamil on normal SAN function (Group I) Results are summarized in Table I and in Fig 2A. Patients given 0.10 mg/Kg verapamil did not show significant changes in heart rate or SAN rec time or CSNRT evidencing no measurable effect on SAN function. Definitive prolongation of PR interval (14 to 17 per cent p < 0.05) and a decrease in AV conduction efficiency (-37 per cent p < 0.05) were observed the effect being maximal at 5 minutes and lasting for more than 30 minutes. These changes suggest an important depressant effect on AV node function.

When the drug dose was raised to 0.15 mg/kg a small but significant shortening of RR interval was observed (-8 per cent p < 0.05) five minutes post drug administration. Significant prolongation of % SAN rec time was observed at 5 minutes reaching a maximum of 26 per cent at 15 minutes (p < 0.05) and lasting for more than 30 minutes. Similar changes were also noticed in CSNRT values (maximal increase of 96 per cent at 15 minutes p < 0.05) demonstrating an early

Table III Effects of atropine on verapamil induced changes in normal SAN function

	RR (msec)	Max rec time (msec)	% SAN rec time	CSNRT (msec)	PR (msec)	% AV cond
Control (n = 7)	800 ± 46	1066 ± 67	129 ± 2	243 ± 96	0.18 ± 0.02	96 ± 4
5 min post Atropine	591 ± 39	709 ± 59	119 ± 2	114 ± 20	0.16 ± 0.02	100 ± 0
Δ%	-28 ± 4	-35 ± 9	-10 ± 2	-54 ± 4	-13 ± 2	4 ± 3
10 min post Verapamil†	606 ± 51	857 ± 97	140 ± 6	251 ± 51	0.18 ± 0.01	85 ± 7
Δ%	2 ± 3	20 ± 6	20 ± 5	129 ± 28	13 ± 4	-15 ± 7
Control (n = 11)	1010 ± 55	1315 ± 58	131 ± 3	304 ± 24	0.19 ± 0.02	90 ± 5
5 min post Verapamil	915 ± 49	1340 ± 67	150 ± 5	452 ± 40	0.22 ± 0.02	51 ± 6
Δ%	-8 ± 3	2 ± 4	20 ± 4	46 ± 11	21 ± 4	-43 ± 6
5 min post Atropine	719 ± 44	960 ± 78	134 ± 4	251 ± 38	0.18 ± 0.02	88 ± 2
Δ%	-28 ± 4	-28 ± 4	3 ± 6	-12 ± 17	-5 ± 3	10 ± 6

= p < 0.05

Δ% = p < 0.005

= p < 0.0005

Atropine = IV bolus 0.5 mg/Kg

Verapamil = IV bolus 0.20 mg/Kg

†Results obtained after administration of verapamil are compared to those seen after administration of atropine and not to control results.

Other results as in Table I

and sustained depressant effect on normal SAN function PR interval prolongation and the decrement in AV conduction were little more pronounced at this dose level. At a dose of 0.20 mg/kg the RR interval shortened to -14 per cent ($p < 0.05$) 5 minutes after injection but no significant changes were observed later. Changes in % SAN rec time were even more pronounced prolonging to 27 per cent at 5 minutes ($p < 0.05$) 51 per cent at 15 minutes and 27 per cent at 30 minutes post drug administration (both changes $p < 0.05$). CSNRT changes paralleled those observed in per cent SAN rec time reaching a maximum of 177 per cent at 15 minutes ($p < 0.05$). In contrast AV conduction efficiency decreased little more than with previous dose levels and the increase in PR interval was also similar. These changes seemed to be uniform throughout 30 minutes of observation after the drug was given.

These results indicate that verapamil exerts an important dose related depressant effect on normal SAN function. The effect is already discernible 5 minutes post drug administration is maximal at 15 minutes and still significant 30 minutes post injection. Effect of verapamil on the AV node seems to be present at a lower dosage and is maintained uniformly for 30 minutes after administration of the drug but it may be less dose dependent than the effect on SAN function. In addition to these observations there was noted an increased frequency of atrial arrhythmias such

as SA block and atrial standstill accompanied always by junctional or ventricular escapes. Advanced AV block was also observed in two patients given 0.20 mg/Kg it lasted for more than 5 minutes necessitating the use of temporary artificial pacemaking.

2 Effect of isoproterenol: propranolol and atropine on verapamil induced changes on normal SAN function (Group II). Results are summarized in Tables II and III and in Figs 3 and 4. Isoproterenol infusion maintained at a rate of 3 µg/minute over a 5 minute period caused a typical beta receptor stimulant effect that is shortening of RR interval PR interval and CSNRT. It did not alter % SAN REC time or per cent AV conduction. Once this drug was withdrawn and control condition reestablished verapamil (0.20 mg/Kg) was administered. Changes observed were similar to those previously described at 5 minutes post injection: increase in % SAN rec time and in CSNRT, lengthening of PR interval and a decrease in AV conduction efficiency. When isoproterenol infusion was restarted a complete return to control conditions was obtained for % SAN rec time and per cent AV conduction. RR interval CSNRT and PR interval showed shortening similar to that observed when isoproterenol was administered before verapamil. This response indicates that verapamil did not block cardiac beta receptors at this dosage (Fig. 3A).

In six patients administration of intravenous




Fig. 3 Effect of beta receptor active drugs on verapamil induced changes in normal SAN function. *Panel A* Administration of isoproterenol infusion ($I = 3 \mu\text{g}/\text{minute}$) does not modify significantly SAN recovery time. Verapamil injection ($V = 0.20 \text{ mg}/\text{kg}$) prolongs it after 5 minutes but it does not prevent normal response to reinfusion of isoproterenol at same previous dosage. *Panel B* Infusion of propranolol ($P = 0.1 \text{ mg}/\text{kg}$) does not prolong significantly SAN recovery time. Effects of verapamil ($V = 0.20 \text{ mg}/\text{kg}$) administered 10 minutes after stopping propranolol infusion are more than double those expected for this dose suggesting a synergistic depressant effect of these two drugs on SAN function. Dotted line at the right of the graph represents mean results obtained with a dose of $0.20 \text{ mg}/\text{kg}$ of verapamil in normal subjects without blocking of beta receptors. This is the same curve represented in Fig. 2 redrawn here for purposes of comparison of results.

propranolol ($0.1 \text{ mg}/\text{kg}$) caused significant prolongation of RR interval at 5 minutes (13 per cent) and at 10 minutes (17 per cent). It also prolonged CSNRT (29 per cent at 5 minutes, 49 per cent at 10 minutes, $p < 0.05$). PR interval (9 per cent) and per cent AV conduction (27 per cent) without modifying % SAN rec time. Five minutes after the administration of $0.20 \text{ mg}/\text{kg}$ verapamil to those patients already given propranolol the prolongation of % SAN rec time (60 per

cent $p < 0.05$) and of CSNRT (225 per cent $p < 0.05$) was twofold and threefold that observed after the administration of verapamil alone. This enhancement of verapamil effect was also observed on AV nodal function. PR prolonged to 35 per cent and AV conduction efficiency decreased to -49 per cent ($p < 0.005$). These changes increased to a maximum at 15 minutes post verapamil administration but only effects on AVN function persisted significantly up




Fig 4 Effect of atropine on verapamil induced changes in normal SAN function. *Panel A* atropine ($A = 0.0\%$ mg/Kg) administered ten minutes after injecting intravenous verapamil ($V = 0.20$ mg/Kg) shortens SAN recovery time at 4 minutes post injection. Prolongation of this parameter is observed in all patients five minutes after administration of verapamil. *Panel B* Administration of same dose of verapamil ($V = 0.20$ mg/Kg) causes expected prolongation of SAN recovery time at 5 minutes in all patients. Atropine ($A = 0.0\%$ mg/Kg) administered seven minutes after injection of verapamil shortens SAN recovery time in only four out of 11 patients. Results are expressed as per cent changes from Control (C) SAN recovery time in the ordinates in both graphs

to 30 minutes (Table II). This suggests that verapamil and propranolol have a synergistic effect on SAN and AV function which lasts up to 10 minutes for SAN and for more than 30 minutes for AVN function (Fig 3B). However verapamil induced shortening of RR interval was not observed after blocking of the beta receptors; it would seem then that this effect of verapamil must be brought about by a mechanism other than that which explains the action of the drug on SAN function. In the seven patients with normal SAN function given atropine prior to verapamil (Table II, Fig 4A) there was an initial shortening of RR and PR intervals (-28 per cent and -13 per cent $p < 0.01$) per cent SAN rec time and CSNRT also decreased (-10 per cent and -54 per cent $p < 0.01$). When 0.20 mg/Kg of verapamil was administered in these circumstances a definite prolongation of CSNRT and increase of per cent SAN rec time were observed (129 per cent and 20 per cent $p < 0.05$) along with prolonga-

tion of PR interval (13 per cent) and decrease of AV conduction efficiency (-15 per cent). Eleven patients of this same Group II received verapamil followed by atropine; in seven of these eleven patients (64 per cent) atropine failed to return to control values the prolongation of SAN rec time and of CSNRT caused by verapamil. These results suggest that the action of verapamil is not exerted via stimulation of cholinergic cardiac receptors.

3 Effect of verapamil on sick sinus syndrome (Group III) Patients with SSS (Table IV, Fig 2B) showed a somewhat prolonged RR interval. Mean % SAN rec time (212 ± 5) and CSNRT (1004 ± 359 msec) were significantly longer than normal. AV conduction efficiency was slightly lower than normal (82 per cent) and PR interval was normal. Administration of a single bolus of 0.15 mg/kg verapamil did not affect RR interval. % SAN rec time showed a threefold prolongation (305 per cent $p < 0.05$) and CSNRT a

Table IV Effects of verapamil on SAN function in patients with sick sinus syndrome

	RR (msec)	Max rec time (msec)	% SAN rec time	CSNRT (msec)	PR (msec)	% AV cond
Control (n = 7)	1029 ± 82	2033 ± 369	212 ± 51	1004 ± 359	160 ± 10	82 ± 9
5 min post Verapamil	1157 ± 143	5703 ± 1093	517 ± 149	4754 ± 1696	210 ± 20	46 ± 10
Δ%	18 ± 21	218 ± 61 *	305 ± 106	418 ± 118 *	27 ± 7 *	-40 ± 19
15 min post Verapamil	1203 ± 138	4793 ± 1760	359 ± 88	3633 ± 1663	200 ± 20	44 ± 10
Δ%	19 ± 20	164 ± 43 *	160 ± 43 *	354 ± 118 **	24 ± 7 **	-45 ± 14
30 min post Verapamil	1131 ± 127	4283 ± 1823	355 ± 119	2960 ± 1520	210 ± 20	51 ± 10
Δ%	16 ± 20	78 ± 40 *	143 ± 72 *	181 ± 83 *	27 ± 7 **	-91 ± 9
5 min post Atropine	940 ± 111	3223 ± 1862	282 ± 423	2283 ± 1768	160 ± 10	78 ± 11
Δ%	-3 ± 18	18 ± 40	60 ± 67	19 ± 41	0 ± 14	-4 ± 8

* p < 0.05

** p < 0.005

*** p < 0.0005

Verapamil = 0.15 mg/Kg

Atropine = 0.075 mg/Kg

Other abbreviations as in Table I

fourfold prolongation (418 per cent $p < 0.05$) at five minutes after verapamil. In contrast, lengthening of PR interval and decrease in AVN conduction efficiency were of the same magnitude as those caused by the same drug dose in patients with normal SAN function. This marked prolongation of % SAN rec time and of CSNRT decreased at 15 minutes post injection of verapamil but nevertheless persisted up to 30 minutes. Changes in PR interval and AV conduction efficiency were maintained at the same level for 15 minutes and showed little decrease at 30 minutes post drug administration. At this time administration of atropine induced normalization of SAN function parameters in two patients return to pre verapamil levels in one, and no response in the remaining four (two patients with Chagas disease and two with coronary artery disease). On the whole atropine returned % SAN rec time and CSNRT to pre verapamil values as it did all changes in PR interval and AV conduction efficiency (Table IV and Fig 2B). After administration of verapamil the appearance or worsening of the degree of SA block even with progression to atrial arrest and of prolonged periods of asystole needing artificial temporary pacemaking after overdrive atrial pacing were frequently observed (Fig 1). The four patients who did not respond to atropine needed temporary pacemakers left in place until definitive pacemaker implantation was undertaken.

These results indicate that the patients with SSS are at least four or five times more sensitive

to verapamil than subjects with normal SAN function. The effect is maximum at approximately five minutes and persists up to 30 minutes, frequently it is not reversed at all by atropine administration thus necessitating temporary artificial pacing. Depressant effect on AVN function seems to be of the same magnitude as that observed in subjects with normal SAN function.

Discussion

The use of overdrive atrial pacing for determining sinus node recovery time represents a useful tool for measuring over all SAN function, it is reproducible, involves few complications and is easily applied to clinical studies.^{13, 14, 15} Prolongation of CSNRT has been demonstrated in instances of SAN injury,¹⁶ in cases of sick sinus syndrome,^{11, 12} and following vagal stimulation.¹⁷ In addition, the influence of atropine^{13, 14}, isoproterenol¹⁸ and beta receptor blocking drugs on CSNRT has been described¹⁹ but little data has been gathered regarding effects of other drugs such as verapamil.²⁰ Our studies clearly demonstrated the depressant effect that verapamil exerts on normal SAN function. This is manifested by a dose related prolongation of SAN recovery time after overdrive atrial pacing.²¹ Prolongation that appears early and lasts up to 30 minutes in duration. Similar animal experimental results have been reported elsewhere.^{22, 23} In studies using selective perfusion of SAN and AVN areas, SAN function exhibited a greater sensitivity to verapamil than AVN function.²⁴

We frequently observed SA block and atrial arrest accompanying prolongation of SAN rec time after administration of the drug but it should be noted that the first effect on the heart was a significant decrease in AV conduction efficiency (Table I Fig 2A) even at doses which seem not to affect SAN function.¹ Intra atrial conduction atrial tissue and ventricular tissue properties are little or not at all affected by the drug.^{1, 2} A consensus exists that the decrease in AV conduction efficiency is the main and most useful electrophysiologic effect of verapamil and explains its efficacy in reversing arrhythmias which involve circus movement or AVN reentries.

In these circumstances the previously demonstrated SAN depressing effect must be considered an undesirable effect on the drug since it is a frequent cause of complications observed in clinical trials.³

The effects of verapamil on SAN function are not mediated via blocking of cardiac beta sympathetic receptor.⁴ Its administration did not affect the response of SAN to isoproterenol in ours (Table II Fig 3A) and other experiments.⁴ Recent studies have elucidated that the negativeotropic action and antiarrhythmic properties are best explained by its interference with the slow inward calcium current observed in phase 2 and 3 of the action potential^{5, 6} or on the slow channels itself. Generation of normal action potentials in SAN and AVN may depend mainly on the slow ionic current carried by Ca²⁺ Na⁺ or both and so these nodes are more sensitive than the rest of cardiac tissue to calcium antagonists such as verapamil. This would explain the rather selective and singular depressant effects of this drug on SAN automaticity and on AVN conduction. Importantly enough reversal of all effects of verapamil on SAN and AVN by isoproterenol may be explained by the property this drug has of enhancing slow inward current.

Beta adrenergic receptor blockers exert their antiarrhythmic action preventing catecholamines from acting on excitable cells. Also they may interact within the cell membrane to limit its permeability to calcium ions.⁷ The additive and marked depressant effects on SAN and AVN function observed in patients given verapamil after blocking with propranolol (Table II Fig 3B) can then be explained on the basis of a double interference with calcium entry to the cell

exerted by both drugs. The increased frequency of complications related to the simultaneous clinical use of these two drugs⁸ can be explained similarly.

Action of verapamil on SAN function was not blocked by previous administration of atropine nor did this drug reverse to normal verapamil induced prolongation of SAN rec time in most of our normal subjects (Table III Fig 4). Similar results were reported in several other studies^{4, 9, 10, 11} with few exceptions¹² and they seem to confirm that verapamil acts directly on SAN cell rather than indirectly through stimulation of cholinergic receptors. A possible explanation for atropine induced shortening of SAN rec time in some of our cases is that this drug inhibits the usually more preponderant influence of parasympathetic tone¹³ on SAN activity or that it improves conduction from SA node paciny cells to the atrium thereby facilitating recovery after overdrive atrial pacing.¹⁴

The slight increase in heart rate observed at 5 minutes post verapamil administration at doses of 0.15 and 0.20 mg/Kg has also been observed in previous reports.^{15, 16, 17} Its short duration and the fact that it is not observed in cases of previous beta receptor blocking nor in cases with SSS nor in experimental selective perfusion to SAN area¹⁸ suggests that it may be due to reflex sympathetic stimulation secondary to a brief decrease in peripheral resistance and in blood pressure.^{19, 20} However some authors reported these changes in heart rate without a concomitant decrease in peripheral resistance²¹ but as we did not measure hemodynamic changes post verapamil we cannot draw any conclusion on this matter.

In our study patients with SSS displayed a variety of atrial tachyarrhythmias²² susceptible to treatment with verapamil.²³ Only those patients were chosen who also showed abnormal response to overdrive atrial pacing^{24, 25} in order to be confident as to the degree of SAN dysfunction for each of them. The presence of Wenckebach phenomenon at atrial paced rates of 130/minute was also more frequent among them evidencing some degree of concomitant AV nodal disease as well.²⁶ As could be expected given the already altered SAN function²⁷ effects of verapamil are much more marked and severe on SAN function of these patients but effects on AVN function are no different from those caused

Table IV Effects of verapamil on SAN function in patients with sick sinus syndrome

	RR (msec)	Max rec time (msec)	% SAN rec time	CSNRT (msec)	PR (msec)	AV cond
Control (n = 7)	1029 ± 82	2033 ± 369	212 ± 51	1004 ± 359	160 ± 10	87 ± 9
5 min post Verapamil	1157 ± 143	5703 ± 1093	517 ± 149	4754 ± 1896	210 ± 20	46 ± 10
Δ%	18 ± 21	218 ± 61**	30 ± 106*	418 ± 118	27 ± 7*	-40 ± 1*
15 min post Verapamil	1203 ± 138	4793 ± 1760	359 ± 84	3633 ± 1663	200 ± 20	44 ± 10
Δ%	19 ± 20	164 ± 43*	160 ± 43	354 ± 118**	24 ± 7	-45 ± 14
30 min post Verapamil	1131 ± 127	4283 ± 1823	355 ± 119	2960 ± 1520	210 ± 20	61 ± 10
Δ%	16 ± 20	78 ± 40*	143 ± 72*	181 ± 83	27 ± 7	-21 ± 9
5 min post Atropine	940 ± 111	3223 ± 1862	282 ± 423	2283 ± 1768	160 ± 10	78 ± 11
Δ%	-3 ± 18	18 ± 40	60 ± 67	19 ± 41	0 ± 14	-4 ± 8

* = p < 0.05

** = p < 0.005

*** = p < 0.0005

Verapamil = 0.15 mg/Kg

Atropine = 0.025 mg/Kg

Other abbreviations as in Table I

fourfold prolongation (418 per cent, $p < 0.005$) at five minutes after verapamil. In contrast lengthening of PR interval and decrease in AVN conduction efficiency were of the same magnitude as those caused by the same drug dose in patients with normal SAN function. This marked prolongation of % SAN rec time and of CSNRT decreased at 15 minutes post injection of verapamil, but nevertheless persisted up to 30 minutes. Changes in PR interval and AV conduction efficiency were maintained at the same level for 15 minutes and showed little decrease at 30 minutes post drug administration. At this time administration of atropine induced normalization of SAN function parameters in two patients return to pre verapamil levels in one and no response in the remaining four (two patients with Chagas disease and two with coronary artery disease). On the whole atropine returned % SAN rec time and CSNRT to pre verapamil values as it did all changes in PR interval and AV conduction efficiency (Table IV and Fig 2B). After administration of verapamil the appearance or worsening of the degree of SA block even with progression to atrial arrest and of prolonged periods of asystole needing artificial temporary pacemaking after overdrive atrial pacing were frequently observed (Fig 1). The four patients who did not respond to atropine needed temporary pacemakers left in place until definitive pacemaker implantation was undertaken.

These results indicate that the patients with SSS are at least four or five times more sensitive

to verapamil than subjects with normal SAN function. The effect is maximum at approximately five minutes and persists up to 30 minutes, frequently it is not reversed at all by atropine administration thus necessitating temporary artificial pacing. Depressant effect on AVN function seems to be of the same magnitude as that observed in subjects with normal SAN function.

Discussion

The use of overdrive atrial pacing for determining sinus node recovery time represents a useful tool for measuring over all SAN function. It is reproducible, involves few complications and is easily applied to clinical studies.^{11,12} Prolongation of CSNRT has been demonstrated in instances of SAN injury,¹³ in cases of sick sinus syndrome,^{13,14} and following vagal stimulation.¹⁵ In addition the influence of atropine^{11,12} isoproterenol¹⁶ and beta receptor blocking drugs on CSNRT has been described¹⁷ but little data has been gathered regarding effects of other drugs such as verapamil.¹⁸ Our studies clearly demonstrated the depressant effect that verapamil exerts on normal SAN function. This is manifested by a dose related prolongation of SAN recovery time after overdrive atrial pacing a prolongation that appears early and lasts up to 30 minutes in duration. Similar animal experimental results have been reported elsewhere.^{19,20} In studies using selective perfusion of SAN and AVN areas SAN function exhibited a greater sensitivity to verapamil than AVN function.²¹

- of verapamil on electrophysiological properties of anomalous atrioventricular connection in Wolff Parkinson White syndrome *Br Heart J* 36 256 1974
- 7 Rosen M R, Wit A L, and Hoffman B F. Electrophysiology and pharmacology of cardiac arrhythmias VI Cardiac effects of verapamil *Am Heart J* 89 665 1975
- 8 Zipes, D P and Fischer J C. Effects of agents which inhibit the slow channel on sinus node automaticity and atrioventricular conduction in the dog *Circ Res* 34 184 1974
- 9 Inglessis G, González G, Sarrh G, García M, Ramírez, J and Fuenmayor A. Acción antiarrítmica del verapamil, *Arch Ven Cardiol* 1 207 1974
- 10 Benaim M E. Aystole after verapamil *Br Med J* 2 169 1972
- 11 Boothby C H, Garrard C S and Pickering D. Intravenous verapamil in cardiac arrhythmias *Br Med J* 2 343 1970
- 12 Sacks, H and Kennelly B M. Verapamil in cardiac arrhythmias, *Br Med J* 2 716 1972
- 13 Ferrer M I. The sick sinus syndrome. New York: Futura Publishing Co Inc 1974
- 14 Rasmussen K. Chronic sinoatrial heart block *Am Heart J* 81 38 1971
- 15 Mandel, W J, Hayakawa, H, Allen H N, Danzig R and Kermar A I. Assessment of sinus node function in patients with the sick sinus syndrome. *Circulation* 46 161 1972
- 16 Obel, I W P, Cohen E and Scott Millar R N. Chronic symptomatic sinoatrial block: a review of 34 patients and their treatment. *Chest* 65 397 1974
- 17 Rubenstein J J, Schulman C L, Yurchak P and de Sanctis R W. Clinical spectrum of the sick sinus syndrome. *Circulation* 45 5 1972
- 18 Short D S. The syndrome of alternating bradycardia and tachycardia. *Br Heart J* 16 208 1964
- 19 Husain, M H, Krasnicka J, Ryden L and Holmberg S. Action of verapamil on sinus node atrioventricular and intraventricular conduction. *Br Heart J* 35 734 1973
- 20 Roy P H, Spurrell R A J and Sowton E. The effect of verapamil on the cardiac conduction system in man. *Postgrad Med J* 50 270 1974
- 21 Mandel, W J, Hayakawa H, Danzig R and Marcus H S. Evaluation of SA node function in man by overdrive suppression. *Circulation* 44 59 1971
- 22 Narula O S, Samet P and Javier H P. Significance of the sinus node recovery time. *Circulation* 45 140 1972
- 23 Gupta P K, Lichter E, Chadda, K D and Badier, E. Appraisal of sinus nodal recovery time in patients with sick sinus syndrome. *Am J Cardiol* 34 265 1974
- 24 Corday E, Bazuka V, Lang T W, Pappelbaum S, Gold M and Bernstein H. Detection of phantom arrhythmias and evanescent electrocardiographic abnormalities. Use of prolonged direct electrocardiographic recording. *J A M A* 193 417 1966
- 25 Crook B R M, Cashman P M M, Scott F D and Raftery E H. Tape monitoring of the electrocardiogram in ambulatory patients with SA node disease. *Br Heart J* 35 1009 1973
- 26 Chadda K D, Banks V S, Bodenheimer M M and Helfant H. Corrected sinus node recovery time: Experimental physiologic and pathologic determinants. *Circulation* 51 797 1975
- 27 Singh B N and Vaughan E M. A fourth class of anti-dysrhythmic action? Effect of verapamil on ouabain toxicity on atrial and ventricular intracellular potentials and on other features of cardiac function. *Cardiovasc Res* 6 109 1972
- 28 Garvey H L. The mechanism of action of verapamil on the sinus and AV nodes. *Europ J Pharmacol* 8 159 1969
- 29 Cranefield P F, Aronson H S and Wit A L. Effect of verapamil on the normal action potential and on a calcium-dependent slow response of canine cardiac Purkinje fibers. *Circ Res* 34 204 1974
- 30 Nayler W G and Kirkler D. Verapamil and the myocardium. *Postgrad Med J* 50 441 1974
- 31 Brichard G and Zimmermann P E. Verapamil in cardiac dysrhythmias during anaesthesia. *Br J Anaesth* 42 1005 1970
- 32 Ross G and Jorgensen C R. Cardiovascular actions of isoproterenol. *J Pharmacol Exp Ther* 188 504 1967
- 33 Brooks C and Lu H H. The sinoatrial pacemaker of the heart. Springfield Illinois 1970. Charles C Thomas Publisher
- 34 Livesley B and Oram S. Mode of action of verapamil in man. *Br Med J* 2 50 1972
- 35 Grodner A S, Lahriz, H, Pool, P E and Braunwald E. Neurotransmitter control of sinoatrial pacemaker frequency in isolated rat atria and in intact rabbits. *Circ Res* 27 867 1970
- 36 Cannon D S, Rider A J, Stinson E B and Harrison D C. Electrophysiologic studies in the denervated transplanted human heart. *Am J Cardiol* 38 859 1975
- 37 Lange G. Action of driving stimuli from intrinsic and extrinsic source on the in situ cardiac pacemaker tissue. *Circ Res* 17 449 1965
- 38 Ryden L and Sætre H. The haemodynamic effect of verapamil. *Europ J Clin Pharmacol* 3 153 1971
- 39 Rosen K M, Loeb H S, Ziad M, Rahumtools S H and Gunnar R M. Cardiac conduction in patients with symptomatic sinus node disease. *Circulation* 43 836 1971
- 40 Das, G, Talmers F N, and Weisler A M. New observations on the effects of atropine on the sinoatrial and atrioventricular nodes in man. *Am J Cardiol* 36 281, 1975
- 41 Anonim D S, Godov R A, Manco J C, Tanaka A and Gallo L. Effects of acute elevation in blood pressure and of atropine on heart rate in Chagas disease. *Circulation* 38 289 1968

by the drug in patients with normal SAN and AVN function. However, this depression of AVN function acquires a different functional meaning in patients with SSS, since they depend fundamentally on presumed escape rhythms originating mainly from this AVN area. Verapamil then exerts a double deleterious effect on SSS patients, depressing even more the damaged SAN function and potentially suppressing possible and vital escape rhythms coming from the AVN area.

In four of seven patients, atropine administered intravenously when the effect of verapamil was fading away failed to reverse the depressant action on SAN function, although it normalized AV conduction in all cases. In the two cases of chronic Chagasic cardiomyopathy this unresponsiveness might be attributed to cardiac parasympathetic innervation damage⁴¹ or in all four cases to intrinsic refractoriness inherent to organic SAN damage,^{7, 11, 12} or to a more marked direct effect exerted by verapamil on these damaged SAN nodes. Evidence supporting the last point in particular is currently lacking. Partial unresponsiveness to atropine in cases of SSS may be explained by postulating that the sick sinus shows hyperresponsiveness to acetylcholine released by overdrive atrial pacing,¹⁵ and atropine administered at the usual dose level was not able to reverse all its effects.⁴² Overdrive stimulation and consequent release of acetylcholine can also increase in severity preexisting conduction blocking within the SAN.³⁴ Verapamil could cause a similar increase and simultaneously depress automaticity of SAN pacing cells. Atropine then may act only on effects of acetylcholine released, thus partially improving the recovery time. Acetylcholine causes an increase in cell membrane permeability to K⁺³⁵ which can be blocked by atropine whereas it cannot inhibit the Ca changes provoked by verapamil. In normal cells, these opposite ionic effects of verapamil and atropine may counterbalance each other. In cases of SSS, however, this balance may be upset by the presence of organic SAN damage, intranodal block and other as yet undetermined influences, and the persistence of verapamil induced depression of SAN function is therefore favored.

Summary

Sixty patients, normal with respect to SAN function, screened to exclude cardiomyopathy, and seven patients with sick sinus syndrome

underwent overdrive right atrial pacing at progressively increasing rates before and after administration of different doses of verapamil. Sinus node corrected recovery time and percent recovery time related to control PP were determined before and five, 15, and 30 minutes after the administration of the drug. Moderate prolongations of these parameters lasting for more than 30 minutes were observed with doses of 0.15 and 0.20 mg/Kg of verapamil, evidencing a depressant effect on normal SAN function, concomitant and earlier AV conduction impairment was also observed. These changes were dose related and were eliminated by administration of isoproterenol, but not by atropine intravenously. Action of the drug is probably exerted directly on SAN and AVN cells since it did not show any significant effect on beta sympathetic receptors or on cholinergic receptors.

In patients with sick sinus syndrome, effect of verapamil on SAN function is four or five times more intense, with concomitant impairment of AVN function, several of these patients had prolonged asystoles after administration of the drug which did not reverse with atropine injection. It is concluded that the marked depression of SAN function caused by verapamil in patients with sick sinus syndrome contraindicates its use for treatment of any of the atrial arrhythmias which form this syndrome. Precautions must be taken also when treating any supraventricular arrhythmia on an emergency basis since they may be caused by an as yet undiagnosed sick sinus syndrome.

The authors wish to thank all medical and paramedical personnel of the Cardiovascular Center for their cooperation in this study and Mrs. Raquel Kowalsky and Mrs. Francesca Guegack for their secretarial work.

REFERENCES

- Haas H and Hartfelder O: α -isopropyl α [(N-methyl-N-homoveratryl)- γ -amino-propyl]-3,4-dimethoxyphenylacetate. Eine Substanz mit coronargefäßerweiternden Eigenschaften. *Arzneim Forsch* 12:549, 1962.
- Mellvitz H, E. Shister H E and Hug S: Isoproterenol. Experimental data on coronary dilatation and antiarrhythmic action. *Can Med Assoc J* 90:761, 1964.
- Schamroth L, Kirkler D M and Garret C: Immediate effects of intravenous verapamil in cardiac arrhythmias. *Br Med J* 1:660, 1972.
- Diewitz M and Lange B M: Zur Behandlung Tachykarder rhythmusstörungen mit verapamil. *Med Klin* 64:1699, 1969.
- Kirkler D M and Spurrell R A J: Verapamil in the treatment of paroxysmal supraventricular tachycardia. *Postgrad Med J* 50:447, 1974.
- Spurrell R A J, Kirkler D M and Sowton E: Effects

under the artery but the vessel was not occluded. Coronary occlusion was verified by the appearance of S-T segment elevation in the epicardial electrogram obtained from the ischemic region and by cyanosis and systolic bulging of the ventricular wall distal to the ligature. The unipolar epicardial electrode consisted of a 1 cm diameter felt pad sutured to the epicardium and attached to a medicine dropper containing saline and the electrode lead by a strip of 1/4 inch umbilical tape. The epicardial electrode was referenced to the combined standard limb lead (Wilson central terminal). Ventricular arrhythmias were treated with 0.5 to 20 mg/Kg doses of intravenous lidocaine.

Hemodynamic measurements. Aortic and left ventricular pressures were measured using Statham P23Db pressure transducers connected to saline filled polyethylene (PE 260) catheters. Pressure signals and the first derivative of left ventricular pressure dP/dt were displayed on a Physiograph recorder (Narco Bio Systems Houston Texas) together with either Lead II of the electrocardiogram or the epicardial electrogram. Heart rate, left ventricular end diastolic pressure, left ventricular systolic pressure and maximum dP/dt were measured directly from the Physiograph records.

Cardiac output was measured using the saline indicator dilution technique and the continuous flow conductivity cell described by Geddes and associates.¹ The change in blood resistivity with the addition of sodium chloride ($\Delta\rho/\Delta C$) is a function of blood temperature and packed cell volume. Thus the values of $\Delta\rho/\Delta C$ at 37°C and different packed cell volumes reported previously by Geddes and co-workers¹ were corrected to blood temperature t using the expression

$$\frac{\Delta\rho}{\Delta C}_t = \frac{\Delta\rho}{\Delta C}_{37} (1 + 0.036 (37 - t))$$

Sodium heparin (10 mg/Kg) was given intravenously every 2 to 3 hours to prevent clot formation in the cell. Cardiac index, stroke index, peripheral vascular resistance and left ventricular minute work were calculated by established methods.

Induction of hypothermia. Hypothermia was induced by covering the dogs with bags of flake ice and by circulating ice water through the coils of a rubber mat under the dogs. Esophageal or blood (subclavian artery) temperature was con-



Fig 1 Representative photographs of mirror image ventricular slices taken from a dog heart after 5 hours of LAD coronary artery occlusion. The anterior wall of the left ventricle (LV) is directed towards the center of the photographs. *a* shows the opposing surfaces of the two slices after India ink perfusion. The light areas of the cut surfaces are unperfused (ischemic). *b* shows the same surfaces of the slices after incubation in NBT stain. The light areas of the cut surfaces are unstained (injured).

tinuously monitored using a thermistor (Yellow Springs Instrument Co., Yellow Springs, Ohio). When the core body temperature reached 27°C, the ice was removed and the body temperature was allowed to equilibrate. A body temperature near 26°C was maintained by bags of ice or warm overhead lights as needed.

Identification and quantitation of ischemic myocardium. In dogs with coronary occlusions, the region of myocardial ischemia was identified by perfusing a dilute India ink suspension through the patent coronary vascular bed. Cardiac perfusion was accomplished by withdrawing the left ventricular pressure catheter to the aortic root (verified by pressure measurements). A ligature was placed around the right brachiocephalic artery containing the catheter. The left subclavian artery, the precava, the post-

Protection of ischemic myocardium by whole-body hypothermia after coronary artery occlusion in dogs

Dana R Abendschein, Ph D *
Willis A Tacker, Jr M D, Ph D
Charles F Babbs, M D, M S Ph D
West Lafayette Ind

The survival of myocardium distal to an occluded coronary artery depends on a delicate balance between oxygen supply and oxygen demand. Interventions which either reduce myocardial oxygen requirements or increase myocardial oxygen availability have been found to decrease ischemic injury.

Whole body and local hypothermia have been used extensively in patients during cardiopulmonary bypass surgery to lower myocardial oxygen demand and thereby minimize the ischemic injury resulting from temporary anoxia. However the value of lowering the body temperature to decrease ischemic injury after coronary occlusion is not clear. Several investigators have concluded that hypothermia is contraindicated in recent myocardial infarction because of a high incidence of ventricular fibrillation observed in dogs. However in all of these studies a coronary artery was ligated after the animal was hypothermic when the heart is highly vulnerable to mechanical stimulation. Other studies in which coronary occlusion preceded hypothermia have shown that dogs not only tolerated moderate hypothermia (25 to 30°C) without ventricular fibrillation but also demonstrated better hemodynamic recovery following rewarming than controls. Ginks and colleagues reported a

significant reduction in ischemic injury after coronary occlusion in dogs using a combination of hypothermia, intra aortic balloon counterpulsation, intravenous propranolol and coronary reperfusion but the simultaneous use of several interventions did not permit the evaluation of hypothermia alone. The objective of the present study was to determine if moderate hypothermia without rewarming reduces ischemic injury after coronary artery occlusion in the anesthetized open chest dog.

Materials and methods

Animal preparation Twenty eight mongrel dogs of both sexes, weighing between 4 and 18 kilograms served as subjects. Anesthesia was induced by intravenous pentobarbital sodium (35.5 ± 1.7 mg/Kg) and was maintained at stage III plane II according to the criteria of Lumb by additional doses (3.5 ± 0.3 mg/Kg) given as needed. The chest was opened by median sternotomy and the heart was supported in a pericardial cradle formed by suturing the free edges of the incised pericardium to the chest wall. Ventilation was maintained through a cuffed endotracheal tube by an intermittent positive pressure ventilator using room air. Blood pH, pCO₂ and pO₂ were monitored in several dogs to determine that ventilation was adequate. The exposed heart was frequently moistened with Ringers solution containing sodium lactate to prevent desiccation.

In 23 dogs the left anterior descending coronary artery was isolated above the first major diagonal branch and was occluded with a silk suture. In five control dogs a suture was passed

From the Biomedical Engineering Center and the Department of Physiology and Pharmacology School of Veterinary Medicine Purdue University West Lafayette Ind

Received for publication Jan 20 1978

Accepted for publication May 5 1978

Reprint requests Dr Willis A Tacker Jr Biomedical Engineering Center Purdue University West Lafayette Ind 4 907

Dr Abendschein was supported by a predoctoral fellowship from the American Heart Association Indiana Affiliate Inc




Fig 3 The effect of hypothermia on heart rate, mean blood pressure and vascular resistance during periods of 5 and 10 hours of coronary artery occlusion. Time 0 indicates occlusion. Points represent the mean ($n = 5$) \pm one standard deviation. Asterisks indicate that the mean values of the hypothermic and normothermic groups differ significantly ($p < 0.05$).

ylm and eosin and were examined for signs of early myocardial necrosis.

Experimental design The left anterior descending coronary artery was occluded in 23 dogs and sham occluded in five dogs. Beginning 30 minutes later the body temperature of 12 dogs with coronary occlusions and all five sham-operated control dogs was reduced to 26°C. The body temperature of the remaining 11 dogs was maintained at 37°C. Hemodynamic data were collected immediately before occlusion and at one

hour intervals thereafter. In sham-operated dogs the intact hearts were perfused with Ringer's solution and the sliced ventricles were stained with NBT 5 hours after sham occlusion. These dogs served to determine the incidence of myocardial injury during hypothermia alone. In dogs with coronary artery occlusions the intact hearts of surviving animals were perfused with Ringer's solution and India ink to define the region of ischemia after either 5 or 10 hours of coronary occlusion (five normothermic and five hypothermic).




Fig 2 The effect of reducing body temperature to 26°C on the percentage of the ischemic myocardium with decreased dehydrogenase enzyme after either 5 or 10 hours of coronary artery occlusion. Bars represent group means ($n = 5$). Vertical lines indicate one standard deviation.

cava, and the aorta were ligated in succession. Ringers solution containing sodium lactate (37°C) was first perfused through the coronary arteries via the aortic catheter at 120 to 150 mm Hg pressure to clear the heart of blood. The atrial appendages were incised to permit drainage of fluid. Perfusion with Ringers solution was stopped when the effluent from the atrial appendages cleared (about 200 ml of perfusate was required). Then a 10 per cent mixture by volume of India ink (Pelikan drawing ink, black No. 17) in Ringers solution (37°C) was perfused at 120 to 150 mm Hg pressure until the posterior wall of the left ventricle was uniformly blackened (about 50 ml of ink perfusate was required). The hearts of dogs which did not receive coronary occlusions were perfused only with Ringers solution.

The ventricles were sectioned into five 0.5 to 1.0 cm thick transverse slices. The slices were weighed and photographs showing the mirror image surfaces were taken using Polaroid Continuous Tone (Type 46L) black and white transparency film. A red filter was used to intensify the contrast between inked and noninked myocardium. Enlarged (8 × 10) black and white prints (Kodak Velox F2 photographic paper) similar to the one shown in Fig 1a, were cut and

weighed to determine the ratio of unperfused to perfused area for each slice surface. The average ratio of areas for both surfaces of a slice was multiplied by the tissue weight to determine the weight of ischemic myocardium in each slice.

Macroscopic enzyme mapping of ischemic myocardium. Nitrobluetetrazolium (NBT) staining was used to identify injured myocardium, since histologic indices of myocardial injury may not be reliably quantitated during the first 12 hours of coronary occlusion. Viable cells containing active dehydrogenase enzymes reduce NBT forming a deep purple diformazan deposit. In contrast, injured cells irreversibly lose dehydrogenase enzymes within 2 to 4 hours from the onset of ischemia and do not form the diformazan residue.¹⁴ The ventricular slices were incubated for 30 minutes at 37°C in a preheated solution consisting of 0.5 mg/ml of NBT (ICN Pharmaceuticals Inc., Cleveland, Ohio) in 0.1 M phosphoric acid buffer (pH 7.4) without substrate.

After incubation in NBT, the slices were rephotographed. Enlarged black and white prints similar to the one shown in Fig 1b, were cut and weighed without knowledge of treatment group to determine the ratio of unstained to stained area for each slice surface. Any area with less than maximum staining was considered injured. The average ratio of both slice surfaces was used to calculate the weight of enzyme deficient myocardium in each slice. In dogs with coronary occlusions, the percentage of ischemic myocardium having decreased NBT staining was determined for the whole heart. Expression of the amount of injured (unstained) myocardium as a percentage of the ischemic (inked) myocardium reduced the effect of inevitable variations in size and homogeneity of infarcts produced in dogs.

Microscopic evaluation of injury. In several dogs with coronary occlusions the ventricular slices were prepared for light microscopy to evaluate histopathology in areas of decreased NBT staining. The slices were fixed in 10 per cent buffered neutral formalin immediately after the macroscopic analysis. Following at least one week in formalin fixative blocks containing equal portions of NBT stained and unstained tissue were embedded in paraffin and cut at a thickness of 8 to 10 μ in a plane parallel to the NBT stained surface. The sections were stained with hematoxy-




Fig 6 The effect of hypothermia on maximum left ventricular (LV) dP/dt and LV systolic pressure during periods of 5 and 10 hours of coronary artery occlusion. Time 0 indicates occlusion. Points represent the mean ($n = 5$) \pm standard deviation. The absolute values of dP/dt at time 0* were 2640 mm Hg/sec in the hypothermic group and 4680 mm Hg/sec in the normothermic group of the 5 hour study ($p < 0.05$) and 3120 mm Hg/sec in the hypothermic group and 3160 mm Hg/sec in the normothermic group of the 10 hour study ($p = N.S.$). * indicates that the mean values of the hypothermic and normothermic groups differ significantly ($p < 0.05$).

fibrillation was not significantly increased by hypothermia after coronary occlusion. Of the 23 dogs that received coronary occlusions two hypothermic dogs and one normothermic dog developed ventricular fibrillation. The data from these dogs have not been included in the following analysis. The use of lidocaine to treat arrhythmias and delay of cooling until after the intense post occlusion arrhythmic period (i.e. 30 minutes) probably contributed to the low incidence of ventricular fibrillation in these studies.

Size of the ischemic region. The ischemic region produced by ligation of the left anterior descending coronary artery was clearly visible in transverse ventricular slices after perfusing the heart with India ink solution (Fig 1a). This region was located in the anterior wall of the left ventricle including the anterior papillary muscle and reaching the adjacent lateral and septal walls. The average weight of ischemic myocardium was 13 Gm ranging from 11 to 30 Gm; the

average weight of the twenty dog hearts was 78 Gm ranging from 52 to 132 Gm. The size of the ischemic region did not differ significantly between groups in this study ($p > 0.05$).

Myocardial injury in the ischemic region. Following NBT staining portions of the ischemic region with decreased intracellular dehydrogenase enzyme were readily visible upon gross inspection of the tissue and were easily quantitated in black and white photographs of the ventricular slices (Fig 1b). Fig 2 shows the effect of moderate hypothermia on ischemic injury. The percentage of the ischemic region which did not react with NBT was significantly lower in hypothermic dogs than in normothermic dogs after either 5 or 10 hours of coronary occlusion. Five hours after coronary occlusion the injured tissue appeared grossly as a patchy pale area in the ischemic subendocardium of the hypothermic dog hearts. In contrast in the ischemic region of normothermic dog hearts the injured tissue appeared as a




Fig 4 The effect of hypothermia on stroke index cardiac index and left ventricular (LV) minute work during periods of 5 and 10 hours of coronary artery occlusion Time 0 indicates occlusion Points represent the mean ($n = 5$) \pm one standard deviation * indicates that the mean values of the hypothermic and normothermic groups differ significantly ($p < 0.05$)

mic dogs at each time period) The ischemic region was measured grossly in transverse slices of the ventricles, and the slices were stained with NBT to identify injured myocardium within the ischemic region The extent of myocardial injury was evaluated grossly and was expressed as a percentage of the ischemic region In eight hypothermic dogs and six normothermic dogs ventricular slices were prepared for histopathologic study Histochemical and hemodynamic

measurements were analyzed by unpaired Student's *t* tests

Results

The hearts of sham operated dogs subjected to 4½ hours of hypothermia contained no visible areas of decreased dehydrogenase enzyme This indicated that hypothermia alone did not produce detectable myocardial injury

The incidence of arrhythmias and ventricular

hypothermia decreased oxygen demand in ischemic myocardium. This is inferred from the following observations. First the decrease in heart rate during hypothermia implies that minute myocardial oxygen consumption was reduced because pressure was developed fewer times each minute. Blair²⁰ has reported that the direct effect of reduced temperature on the metabolic rate of the myocardium causes the decline in heart rate and a parallel decrease in oxygen consumption during cooling to 25°C. Second depressed contractility in hypothermic dogs indicated by decreases in both the maximum rate of rise of left ventricular pressure (dp/dt_{max}) and the peak systolic pressure implies that the oxygen consumption during active contraction was decreased. Reduced contractility has also been reported by Holobut and Stazka¹ and by Delin and associates² in normal dogs cooled to comparable body temperatures. However these findings conflict with reports showing a positive inotropic effect of hypothermia in normal dogs and in dogs with infarction probably because of differences in experimental conditions such as method of measuring contractility, ventricular loading and level of anesthesia.²¹ Third lower left ventricular afterload (i.e. systemic vascular resistance) in hypothermic dogs may have contributed to a reduction in myocardial oxygen demand by decreasing cardiac minute work (external power). Since oxygen utilization is known to be higher for pressure work than for volume work, hypothermic hearts probably consumed less oxygen to maintain the same cardiac index as normothermic hearts by increasing the stroke index against a reduced aortic pressure.

The finding that hypothermia increased stroke index while end diastolic pressure remained unchanged suggests that the performance of the left ventricle was improved. Enhanced performance may have resulted from decreased afterload. Our results are consistent with other studies which have shown that hypothermia improves cardiac function and does not promote heart failure in dogs with myocardial infarction¹ or cardiogenic shock.²²

Although hypothermia may only inhibit the necrosis of ischemic myocardium which upon rewarming will ultimately become infarcted, this study suggests the potential value of cooling *per se* as a means of protecting the heart until a definitive procedure such as aortocoronary

bypass can be initiated. Maroko and colleagues have shown that ischemic myocardium in dogs at normal body temperature may be salvaged if revascularization is accomplished within 3 to 4 hours after coronary occlusion. Since clinically the delay between the onset of acute ischemia and admission to surgery often exceeds 4 hours the preoperative use of whole body hypothermia might well extend the time frame within which revascularization could be successfully completed.

Summary

Anesthetized dogs were cooled to a core body temperature of 26°C or maintained at a body temperature of 37°C during periods of 5 and 10 hours of LAD coronary artery occlusion. Subsequent macroscopic dehydrogenase enzyme mapping showed that ischemic injury was 25 per cent less after 5 hours of coronary occlusion and 20 per cent less after 10 hours of occlusion in hypothermic dogs than in normothermic controls. The heart rate and left ventricular minute work in hypothermic dogs decreased to roughly half the levels measured in normothermic animals while left ventricular contractility was 10 to 40 per cent lower in hypothermic dogs than in normothermic dogs. However cardiac index and left ventricular end diastolic pressure were unchanged by whole body cooling. Thus hypothermia appeared to diminish the oxygen requirements of the ischemic myocardium without reducing the performance of the heart as a pump. Hypothermia may be useful as a therapeutic adjunct to myocardial revascularization or pharmacologic interventions.

The authors acknowledge the technical assistance of Mr William Voorhees and Mr William Schoenlein and the secretarial assistance of Mrs Jane Abeudschien and Miss Julie Deleo.

REFERENCES

1. Maroko P R, Kjekshus J A, Sobel B E, Watanabe T, Covell J W, Ross J Jr and Braunwald E. Factors influencing infarct size following experimental coronary artery occlusions. *Circulation* 43 67 1971.
2. Maroko P R, Radvany P, Braunwald E and Hale E L. Reduction of infarct size by oxygen inhalation following acute coronary occlusion. *Circulation* 52 360 1975.
3. Hurshfield J W, Jr, Brer J S, Goldstein R E, Barrett M J and Epstein S E. Reduction in severity and extent of myocardial infarction when nitroglycerin and methoxyamine are administered during coronary occlusion. *Circulation* 49 291 1974.
4. Rittenhouse E A, Mohr H, Dillard D H and

Table I Left ventricular end diastolic pressure

Time (hours)	Number of dogs in each group	Hypothermic (mean LVEDP \pm S D)	Normothermic (mean LVEDP \pm S D)	Hypothermic-normothermic	t	p
0	10	05 \pm 08	05 \pm 08	0	0	05
1	10	15 \pm 12	15 \pm 12	0	0	05
2	10	25 \pm 13	08 \pm 06	+17	17	>01
3	10	30 \pm 18	10 \pm 11	+20	16	>01
4	10	30 \pm 13	25 \pm 13	+05	09	>01
5	10	25 \pm 13	25 \pm 18	0	0	05
6	5	00 \pm 00	20 \pm 22	-20	10	>01
7	5	00 \pm 00	10 \pm 11	-10	10	>01
8	5	00 \pm 00	20 \pm 13	-20	16	>01
9	5	00 \pm 00	10 \pm 11	-10	10	>01
10	5	00 \pm 00	10 \pm 11	-10	10	>01

transmural area of greater pallor, containing fewer foci of stained myocardium. After 10 hours of coronary occlusion, the injured area extended transmurally in both groups and the pallor of the unstained tissue was increased, but, fewer foci of stained tissue were observed in the ischemic region of normothermic dog hearts.

Microscopic study of the ventricular slices after 10 hours of coronary occlusion confirmed results obtained by gross histochemical staining. Few damaged cardiac muscle cells were present in NBT unstained areas of hypothermic dog hearts whereas, in normothermic dog hearts, NBT unstained areas contained numerous damaged cardiac muscle cells. The histological features of damaged fibers after 10 hours of coronary occlusion consisted of hyalinized sarcoplasm with mild interstitial edema and neutrophilic infiltration. Qualitatively there was no difference between hypothermic and normothermic dogs in the appearance of the damaged cells. Damaged fibers could not be evaluated by light microscopy after only 5 hours of coronary occlusion.

Effects of coronary occlusion and hypothermia on hemodynamics. Approximately 2 hours of surface cooling was required to reduce the core body temperature to 26°C. Fig 3 shows that heart rate and mean blood pressure were significantly lower in hypothermic dogs than in normothermic dogs after 2 to 3 hours of coronary occlusion. Vascular resistance increased in both groups during the first 5 hours of coronary occlusion but remained lower in hypothermic dogs than in normothermic dogs.

Fig 4 shows that stroke index was increased significantly in hypothermic dogs but cardiac

index in the two groups did not differ significantly. Left ventricular minute work was typically lower in hypothermic dogs than in normothermic dogs. Fig 5 shows that both the maximum rate of rise of left ventricular pressure and the left ventricular systolic pressure were decreased by hypothermia. Table I compares the left ventricular end diastolic pressure (LVEDP) in hypothermic and normothermic dogs during 10 hours of coronary occlusion. LVEDP was not significantly different between the two groups.

Discussion

Prevention of cardiogenic shock and death after acute myocardial infarction is largely dependent upon the containment of infarct size. Since an imbalance between oxygen supply and demand in the ischemic tissue results in myocardial necrosis, interventions which improve this balance could significantly reduce the size of an infarct. Thus beta adrenergic blockade with propranolol,¹ intra aortic balloon counterpulsation² and nitroglycerin³ have been shown to decrease ischemic injury following coronary artery occlusion. In the present study whole body hypothermia appeared to decrease the extent of ischemic injury produced by either 5 or 10 hours of coronary occlusion. Histochemical staining of the sliced ventricles showed less metabolic deterioration in the ischemic region of dog hearts cooled to 26°C. Histologic findings after 10 hours of occlusion were consistent with the histochemical results indicating that the morphologic tissue damage was also less in the ischemic region of hypothermic dog hearts.

A possible explanation of these findings is that

Ouabain induced Wenckebach conduction block in canine Purkinje fibers The role of cycle length and time dependent changes in membrane potential

Gary J Anderson M D

Joseph Reiser Ph D *

Philadelphia Pa

Since Wenckebach's original description¹ of progressive conduction delay and eventual failure of conduction between atria and ventricles this type of conduction block has been described in virtually every tissue of the heart including sinus node A V junction² bundle of His³ bundle branch systems⁴ and ventricular tissue.⁵ Among the drugs likely to induce Wenckebach periods cardiac glycosides have demonstrated this well known effect in toxic doses. Clinical⁶ and experimental studies have verified that cardiac glycosides induce Wenckebach block in cardiac tissue most commonly in the A V junctional tissue of the intact heart. Cardiac glycosides have been reported to reduce membrane potential^{7,8} and thereby slow conduction velocity. This effect is most likely mediated by inhibition of the sodium-potassium ATPase pump. More recently studies have reported that cardiac glycosides induce low amplitude potentials delayed after depolarizations or transient depolarizations which are functions of both cycle length⁹ as well as degree of toxicity.¹⁰

While the phenomena of glycoside induced delayed after depolarizations¹¹ and beat to

beat reduction in maximal diastolic potential¹² have been observed it appeared to us that these changes in membrane potential may relate to the development of Wenckebach conduction block. The purpose of this report is to describe our observations on cardiac glycoside induced Wenckebach conduction block in canine Purkinje fibers. Our data suggest that Wenckebach periodicity induced by cardiac glycosides is associated with a beat to beat reduction in membrane potential and a decrease in excitability which in turn leads to failure of conduction.

Methods

Studies were conducted on adult mongrel dogs weighing 10 to 20 kilograms. After anesthesia induced by sodium pentobarbital (30 mg /Kg) the heart was removed through a lateral thorax incision. The heart was immediately placed in warm oxygenated Tyrode solution and dissected to obtain the desired Purkinje strand usually from the right bundle branch system to the papillary muscle. The Purkinje strand was then placed in a plexiglass tissue chamber and superfused with warm oxygenated Tyrode solution maintained at $37 \pm 0.5^\circ \text{C}$. After the Purkinje strand was placed in the tissue chamber the two ends of the Purkinje strands were pinned for immobilization. The composition of the Tyrode solution in millimoles was as follows:

NaCl	137.0	NaHCO ₃	12.0
KCl	2.7	Glucose	5.5
MgCl	0.5	CaCl ₂	2.7
NaH ₂ PO ₄	1.8		

From The William Loh Heart Research Institute, The Hahnemann Medical College and Hospital, Philadelphia, Pennsylvania. Supported by the Cardiovascular Research Fund, Southwestern Pennsylvania Heart Association.

Received for publication July 24, 1978.

Accepted for publication April 12, 1979.

Reprint requests: Gary J. Anderson, M.D., The William Loh Heart Research Institute, Hahnemann Medical College and Hospital, 230 North Broad Street, Philadelphia, PA 19102.

Dr. Reiser is a USPHS Postdoctoral Fellow.

- Merendino K A Deep hypothermia in cardiovascular surgery *Ann Thorac Surg* 17 63 1974
- 5 Cohn L H and Collins J J Jr Local cardiac hypothermia for myocardial protection *Ann Thorac Surg* 17 135 1974
- 6 Selman M W and Brofman H L Effect of hypothermia on survival rates following coronary occlusion in dogs *Surgery* 37 707 1955
- 7 Smith G Lawson D and Penhale B The effect of hypothermia on acute coronary occlusion *Br J Surg* 44 419 1957
- 8 Davis H C Morse I S and Dick M M Effect of pronestyl on experimental coronary occlusion in hypothermic dogs *Am J Surg* 93 453 1957
- 9 Dumond E G Guimpel A VanCitters R Cardoso S and Lin T K Acute coronary occlusion Survival study in closed chest dogs in controls with hypothermia and with lytic cocktail *J Kansas M Soc* 59 249 1958
- 10 Decortis A and Dalem J Hypothermie et infarctus experimental du myocarde chez le chien *Acta Cardiol* 13 299 1958
- 11 Freese J W Lesage A M Young W G Jr and Sealy W C The effect of core induced hypothermia of 25 and 7 C on dogs with myocardial infarction *Trans Am Soc Artif Intern Organs* 6 218 1960
- 12 Kuhn L W Weiser F M Dana J and Apter R Hemodynamic and metabolic effects of hypothermia and extracorporeal circulation in experimental myocardial infarction and shock *Circ Res* 10 916 1962
- 13 Kuhn L A Apter R Weinrauch H Jacobson T E and Meltzer L Hemodynamic and metabolic effects of the skin and blood stream cooling in experimental myocardial infarction with shock *Am J Cardiol* 12 795 1963
- 14 Bergmann H R Torres J C and Angelakos E T The effect of moderate hypothermia after acute coronary occlusion in dogs *Fed Proc* 36 620 1977
- 15 Ginks W Ross J Jr and Sybers H D Prevention of gross myocardial infarction in the canine heart *Arch Pathol* 97 380 1974
- 16 Lumb W V Small Animal Anesthesia Philadelphia 1963 Lea & Febiger Publishers
- 17 Geddes L A Perry E and Steinberg R Cardiac output using an electrically calibrated flow through conductivity cell *J Appl Physiol* 37 912 1974
- 18 Hamolsky M W and Kaplan N O Measurements of enzymes in the diagnosis of acute myocardial infarction *Circulation* 23 102 1961
- 19 Maroko P R Bernstein E F Libby P DeLana G A Covell J W Ross J Jr and Braunwald F The effects of intra aortic balloon counterpulsation on the severity of myocardial ischemic injury following acute coronary occlusion Counterpulsation and myocardial injury *Circulation* 45 1150 1972
- 20 Blair E Clinical Hypothermia New York 1964 McGraw Hill Book Company Inc p 33
- 21 Holobut W and Stazka W On dynamic heart efficiency in hypothermia *Acta Physiol Polon* 13 530 1962
- 22 Delin N A Pollock L Kjartansson K B and Schenk W G Jr Cardiac performance in hypothermia An experimental study of left ventricular power oxygen consumption and efficiency in dogs *J Thorac Cardiovas Surg* 47 774 1964
- 23 Goldberg L I Effects of hypothermia on contractility of the intact dog heart *Am J Physiol* 194 92 1958
- 24 Bader H S Effect of hypothermia on the contractile "capacity" of the myocardium *J Thorac Cardiovas Surg* 53 651 1967
- 25 Sarnoff S J Braunwald E Welch G H Jr Case R B Stainsby W N and Macruz R Hemodynamic determinants of oxygen consumption of the heart with special reference to the tension-time index *Am J Physiol* 192 148 1958
- 26 Salisbury P F Cross C E and Rieben P A Integrative study of the circulation in moderate hypothermia *Am J Cardiol* 12 184 1963
- 27 Boyer N H and Gerstein M M Induced hypothermia in dogs with acute myocardial infarction and shock *J Thorac Cardiovas Surg* 74 286 1977
- 28 Maroko P R Libby P Ginks W R Bloor C M Shell W E Sobel B E and Ross J Jr Coronary artery reperfusion I Early effects on local myocardial function and the extent of myocardial necrosis *J Clin Invest* 51 2710 1972

Quabain induced Wenckebach conduction block in canine Purkinje fibers The role of cycle length and time dependent changes in membrane potential

Gary J Anderson M.D.
Joseph Reiser Ph.D.*
Philadelphia Pa

Since Wenckebach's original description¹ of progressive conduction delay and eventual failure of conduction between atria and ventricles, this type of conduction block has been described in virtually every tissue of the heart including sinus node A V junction^{2,3} bundle of His^{4,5} bundle branch systems⁶ and ventricular tissue.⁷ Among the drugs likely to induce Wenckebach periods cardiac glycosides have demonstrated this well known effect in toxic doses. Clinical and experimental studies have verified that cardiac glycosides induce Wenckebach block in cardiac tissue most commonly in the A V junctional tissue⁸ of the intact heart. Cardiac glycosides have been reported to reduce membrane potential⁹ and thereby slow conduction velocity. This effect is most likely mediated by inhibition of the sodium-potassium ATPase pump.¹⁰ More recently studies have reported that cardiac glycosides induce low amplitude potentials delayed after depolarizations or transient depolarizations which are functions of both cycle length as well as degree of toxicity.¹¹⁻¹⁴

While the phenomena of glycoside induced delayed after depolarizations^{15,16} and beat to

beat reduction in maximal diastolic potential^{17,18} have been observed it appeared to us that these changes in membrane potential may relate to the development of Wenckebach conduction block. The purpose of this report is to describe our observations on cardiac glycoside induced Wenckebach conduction block in canine Purkinje fibers. Our data suggest that Wenckebach periodicity induced by cardiac glycosides is associated with a beat to beat reduction in membrane potential and a decrease in excitability which in turn leads to failure of conduction.

Methods

Studies were conducted on adult mongrel dogs weighing 10 to 20 kilograms. After anesthesia induced by sodium pentobarbital (30 mg/Kg) the heart was removed through a lateral thorax incision. The heart was immediately placed in warm oxygenated Tyrode solution and dissected to obtain the desired Purkinje strand usually from the right bundle branch system to the papillary muscle. The Purkinje strand was then placed in a plexiglass tissue chamber and superfused with warm oxygenated Tyrode solution maintained at $37^{\circ} \pm 0.5^{\circ} \text{C}$. After the Purkinje strand was placed in the tissue chamber the two ends of the Purkinje strands were pinned for immobilization. The composition of the Tyrode solution in millimoles was as follows:

NaCl	137.0	NaHCO ₃	12.0
KCl	2.7	Glucose	5.5
MgCl ₂	0.5	CaCl ₂	2.7
NaH ₂ PO ₄	1.8		

From The William Lickoff Cardiacular Institute, The Hahnemann Medical College and Hospital of Philadelphia, Philadelphia, Pa.
Supported by the Cardiovascular Institute Research Fund, Southwestern Pennsylvania Heart Association.

Received for publication June 24, 1978

Accepted for publication April 1, 1979

Reprint requests: Gary J. Anderson, M.D., The William Lickoff Cardiacular Institute, Hahnemann Medical College and Hospital, 30 North Broad Street, Philadelphia, PA 19107.

Dr. Reiser is U.S.P.H.S. Postdoctoral Fellow.




Fig 1 Effect of ouabain (2×10^{-6} M) on the diastolic potential (phase 4) of the Purkinje fiber paced in a train of nine stimuli at a basic cycle length (BCL) of 1 000 msec. Each train was followed by a pause of 5 seconds. After 26 minutes of ouabain superfusion a progressive increase in the diastolic slope was noted with successive beats in the stimulus train. This increase in the diastolic slope was expressed as an after depolarization following the last beat of the stimulus train (Photograph retouched)

Conventional microelectrode techniques were employed as described elsewhere.*

Glass microelectrodes were utilized with tip resistances ranging between 15 to 20 megohms. Extracellular stimulation was accomplished by placing Teflon coated stainless steel electrodes bared at the tip on one end of the Purkinje strand. Stimuli were provided by a specially constructed interval and pulse generator.* The sweep generator of the oscilloscope was synchronized to the stimulator. Current threshold requirements were determined by employing an intracellular stimulating and recording system.¹ Intracellular stimulation and recording was accomplished by utilizing a switching system in which the same microelectrode could be used for both current threshold determination and recording of intracellular action potentials. Upon activation of the switching system the microelectrode was used for current threshold determination while the amplifier of the microelectrode was shorted to ground. After termination of the current pulse the switch was again activated and the microelectrode was employed for action potential recording. Current was recorded by closing the current pulse circuit to ground via the input resistance of the oscilloscope. During the stimulation train extracellular stimulation was performed except for one or two beats in which

intracellular stimulation was performed. Extracellular stimulation intensity was maintained at twice threshold and intracellular current threshold was recorded when any given current intensity yielded activation 50 per cent of the time or more.

Data were recorded simultaneously on a Tektronix 5113 memory oscilloscope for Polaroid photography and on a Honeywell 7600 analog tape recorder for permanent data storage.

The tissue was superfused with ouabain (20×10^{-6} M) until the cells developed delayed after depolarizations at which time the membrane potential ranged from -60 mV to -75 mV. Ouabain concentration was then reduced to 1.1×10^{-6} M to sustain the desired effects.

Results

Since we will attempt to develop a postulate for Wenckebach periodicity based upon beat to beat changes in action potential parameters it would facilitate understanding of subsequent data if data dealing with beat to beat changes were presented. Fig 1 is representative of such an example. The tissue was stimulated in trains of 9 at a basic cycle length (BCL) of 1 000 msec followed by a 5 second pause and recycled again to a train of 9. Data were recorded after 26 minutes of superfusion with ouabain. The first action potential terminating the 5 second pause is seen at the left which is followed by 8 mV/sec of phase 4 depolarization. The slope of diastolic depolarization progressively increases until the ninth applied stimulus. The difference between the maximal diastolic potential of the ninth beat and the membrane potential at the point of application of the stimulus was 8 mV and the slope of diastolic depolarization increased to 18 mV/sec. Following cessation of stimuli a delayed after depolarization is seen which repolarizes to a potential of -82 mV. The progressive increase in the slope of phase 4 depolarization with successive beats effectively results in a progressive decrease in the membrane potential from which the action potential arises (or take off potential). Data similar to this has been previously reported.¹⁷

Since one of the well known effects of cardiac glycosides is inhibition of the sodium-potassium pump,¹³⁻¹⁵ it was anticipated that stimuli applied sufficiently rapidly might result in depolarization




Fig 2 Effect of cycle length on Purkinje fibers exposed to toxic concentrations of ouabain. All sequences were recorded consecutively after 35 minutes of ouabain exposure (2×10^{-6} M). Stimuli were applied in trains of ten (10) at decreasing cycle lengths (BCL) of 1000 800 500 300 respectively. Following each train of stimuli a 5 second pause was interposed. Note the progressive reduction in the maximum diastolic potential with successive beats in the trains of decreasing cycle lengths. In addition a direct relationship of cycle length and repolarizing slope of the diastolic potential during the 5 second pause is indicated.

of the cell possibly mediated by either an increase in intracellular sodium (Na_i) or outside potassium (K_o). In the studies by Hogan and colleagues: increasing the stimulation rate from 60 beats/minute to 120 beats/minute resulted in a reduction of the maximal diastolic potential of ouabain treated Purkinje fibers. When the rate was then returned to 60/minute a gradual increase in membrane potential was observed. We have extended these studies and programmed pauses into trains of stimuli to more precisely identify beat to beat changes in maximal diastolic potential and membrane potential changes in prolonged diastolic periods as dependent on cycle length of stimulation. Fig 2 shows data recorded from an experiment in which stimuli were applied in trains of ten at different basic cycle lengths. After each train of ten a pause of 5 seconds was interposed and the train of ten stimuli was repeated. Data for all cycle lengths

were recorded within 2 minutes. The Purkinje strand was initially superfused with ouabain (20×10^{-6} M) for 35 minutes. At a basic cycle length of 1 second the maximal diastolic potential of the first action potential (MDP_1) was -84 mV (Fig 2). After the sixth action potential maximal diastolic potential was reduced to -80 mV and remained at -80 mV through the tenth beat; the difference in maximal diastolic potential between the first and tenth beat ($\text{MDP}_1 - \text{MDP}_{10}$) was 4 mV. At a basic cycle length of 800 msec MDP_1 was -84 mV and MDP_{10} was -76 mV. As the basic cycle length was shortened the degree of depolarization occurring with successive stimuli was increased. The observation that shorter cycle lengths produced a more marked reduction in maximal diastolic potential was also noted at lesser degrees of toxicity. However more rapid stimulation was required to produce these changes in maximal diastolic potential.




Fig 1 Effect of ouabain ($2 \times 10^{-7} M$) on the diastolic potential (phase 4) of the Purkinje fiber paced in a train of nine stimuli at a basic cycle length (BCL) of 1 000 msec. Each train was followed by a pause of 5 seconds. After 26 minutes of ouabain superfusion a progressive increase in the diastolic slope was noted with successive beats in the stimulus train. This increase in the diastolic slope was expressed as an after depolarization following the last beat of the stimulus train (Photograph retouched).

Conventional microelectrode techniques were employed as described elsewhere.*

Glass microelectrodes were utilized with tip resistances ranging between 15 to 20 megohms. Extracellular stimulation was accomplished by placing Teflon coated stainless steel electrodes bared at the tip on one end of the Purkinje strand. Stimuli were provided by a specially constructed interval and pulse generator.* The sweep generator of the oscilloscope was synchronized to the stimulator. Current threshold requirements were determined by employing an intracellular stimulating and recording system.¹ Intracellular stimulation and recording was accomplished by utilizing a switching system in which the same microelectrode could be used for both current threshold determination and recording of intracellular action potentials. Upon activation of the switching system, the microelectrode was used for current threshold determination while the amplifier of the microelectrode was shorted to ground. After termination of the current pulse the switch was again activated, and the microelectrode was employed for action potential recording. Current was recorded by closing the current pulse circuit to ground via the input resistance of the oscilloscope. During the stimulation train, extracellular stimulation was performed except for one or two beats in which

intracellular stimulation was performed. Extracellular stimulation intensity was maintained at twice threshold and intracellular current threshold was recorded when any given current intensity yielded activation 50 per cent of the time or more.

Data were recorded simultaneously on a Tektronix 5113 memory oscilloscope for Polaroid photography and on a Honeywell 7600 analog tape recorder for permanent data storage.

The tissue was superfused with ouabain ($20 \times 10^{-7} M$) until the cells developed delayed after depolarizations at which time the membrane potential ranged from -60 mV to -75 mV. Ouabain concentration was then reduced to $1.1 \times 10^{-7} M$ to sustain the desired effects.

Results

Since we will attempt to develop a postulate for Wenckebach periodicity based upon beat to beat changes in action potential parameters it would facilitate understanding of subsequent data if data dealing with beat to beat changes were presented. Fig 1 is representative of such an example. The tissue was stimulated in trains of 9 at a basic cycle length (BCL) of 1 000 msec followed by a 5 second pause and recycled again to a train of 9. Data were recorded after 26 minutes of superfusion with ouabain. The first action potential terminating the 5 second pause is seen at the left which is followed by 8 mV/sec of phase 4 depolarization. The slope of diastolic depolarization progressively increases until the ninth applied stimulus. The difference between the maximal diastolic potential of the ninth beat and the membrane potential at the point of application of the stimulus was 8 mV and the slope of diastolic depolarization increased to 18 mV/sec. Following cessation of stimuli a delayed after depolarization is seen which repolarizes to a potential of -82 mV. The progressive increase in the slope of phase 4 depolarization with successive beats effectively results in a progressive decrease in the membrane potential from which the action potential arises (or take off potential). Data similar to this has been previously reported.¹⁷

Since one of the well known effects of cardiac glycosides is inhibition of the sodium-potassium pump,^{18,19} it was anticipated that stimuli applied sufficiently rapidly might result in depolarization




Fig 4 Ouabain induced alteration of action potential configuration (top) and phase 0 (bottom) during a stimulus train. Both sequences in this figure are representative of the same cell, recorded simultaneously, at different sweep speeds on separate oscilloscopes. After 39 minutes of ouabain exposure (1.25×10^{-6} M) the characteristic decrease in the maximum diastolic potential during the stimulus train is shown in the top trace (slow sweep speed) concomitant to the decreasing diastolic potential the action potential amplitude decreased with successive beats in the trains of 10 beats. In the lower sequence only the action potential upstroke (phase 0) is shown due to the expanded sweep speed. The initial portion of the sweeps includes the stimulus artefact. A decrease in the slope of phase 0 with successive beats is demonstrated.

beat was 88 mV and was reduced to 68 mV by the ninth. The tenth applied stimulus (not identifiable in the figure) failed to induce a propagated response and a spontaneous beat is noted early in the 5 second pause. The amplitude of this spontaneous beat is increased from the previous action potential to 93 mV and occurs after a cycle length of 1200 msec. These data demonstrated two interesting phenomena occurring in ouabain intoxicated Purkinje fibers. In fibers exposed to ouabain the first observed response is the disappearance of phase 4 during the programmed pause and the appearance of hyperpolarization. Second during intermittent trains of stimuli beat to beat depolarization is more pronounced with increasing exposure time to ouabain.

The observation that the cells exposed to ouabain depolarized on a beat to beat basis with stimulation suggests that concomitant changes in




Fig 5 Effect of ouabain on activation time of successive beats during a stimulus train. The sweep speed was expanded as in the previous figure. Only the upstroke (phase 0) of the action potential is indicated (bottom trace) and its corresponding derivative (dV/dt top trace). Stimulating and recording electrodes were sufficiently separated thus accounting for the initial latency (activation time) between the stimulus artefact and initiation of the action potential. Both an increase in the activation time and an associated decrease in dV/dt is demonstrated with successive beats reflecting a Wenckebach periodicity. Calibration of dV/dt is 100 V/sec. (Retouched from original photography).

phase 0 might be observed with an increased sweep speed. Fig 4 shows the slow and rapid sweep displays of ten sequentially applied stimuli and subsequent action potentials recorded from a Purkinje fiber after a 5 second pause. The preparation had been exposed to ouabain for 39 minutes. The Purkinje strand was stimulated at a basic cycle length of 500 msec. The maximal diastolic potential following the first beat was -73 mV and action potential amplitude was 88 mV. With each successive stimulus action potential amplitude and maximal diastolic potential decreased until the tenth action potential which had an action potential amplitude of 71 mV (Fig 4 top). At a rapid oscilloscope sweep speed (0.2 msec/cm) the successive phases 0 show progressive reduction in the rate of rise of phase 0 (dV/dt). Phases 0 of the first two beats were superimposed and thereafter showed the progressive reduction in dV/dt as well as delay in




Fig 3 Time dependence of ouabain induced alterations of membrane potential in Purkinje fibers paced by a stimulus train interrupted by a 5 second pause. The basic cycle length was maintained constant in all sequences (BCL = 600). In the control sequence no significant changes in the maximum diastolic potential are observed. At 15 minutes of ouabain exposure (2×10^{-6} M) a gradual decrease in the maximum diastolic potential with successive stimuli is noted. In addition a small after depolarization develops at the point of initiating the 5 second pause. The changes in membrane potential became exaggerated both at 30 minutes and 45 minutes of ouabain superfusion. A progressive increase of the repolarizing slope of the membrane potential (during the 5 second pause) as a function of the duration of ouabain exposure is demonstrated.

The reduction in diastolic membrane potential after exposure to cardiac glycosides is thought to be due to inhibition of the sodium pump. Increasing the exposure time to ouabain produces an expected further reduction of diastolic membrane potential both in response to abrupt increases in stimulation rate and at slower intermittent pacing (Fig 3). At a basic cycle length of 600 msec in the control state depolarization did not occur with trains of ten. Maximal diastolic potential after the first action potential was -93 mV and remained at that potential through the tenth action potential. Phase 4 depolarization was noted to some degree during the 5 second pause and resulted in a 3 mV reduction in membrane potential. With exposure to ouabain a beat to beat reduction in maximal diastolic potential was noted. At 15 minutes MDP after the first action potential was -93 mV. Following each action potential the slope of phase 4 progressively increased through the fifth action potential and

maximal diastolic potential is reduced to -90 mV by the tenth beat. During the 5 second pause membrane potential remained at -90 mV until the return of the stimulation. At 30 minutes membrane potential at the time of application of the first stimulation was -83 mV. MDP was reduced following each action potential and after the tenth action potential a delayed after depolarization was observed followed by a repolarization of membrane potential from -74 mV to -83 mV. A similar sequence of events was noted at 45 minutes. In the first train of ten beats maximal diastolic potential was reduced from -78 mV after the first beat to -66 mV after the tenth beat. However in this train the action potential amplitude of the sixth beat was reduced and continued to decrease in amplitude until the tenth beat. Repolarization following the tenth beat from -66 mV to -76 mV occurred during the 5 second pause and the train of ten was repeated. Action potential amplitude of the fifth




Fig 7 Graph showing the relationship of current threshold and take off potential with successive beats during ouabain exposure. Abscissa: duration of ouabain (2×10^{-6} M) superfusion. Ordinate (Left): magnitude of current to reach threshold (amperes). Ordinate (Right): membrane potential (mV) at which the action potential arose. Threshold current was measured at beat 3 (Δ open triangles) and beat 10 (\circ open circles) in a train of 10 beats (BCL = 700) during ouabain superfusion. Solid triangles and circles denote the corresponding take off potential of the third (TOP) and tenth (TOP) beat respectively. See text for further discussion.

follows. Initially take off potential and current threshold are similar for both the third and tenth beats TOP and I_{th} . First decreased followed by a decrease in TOP and I_{th} . I_{th} then increased followed by an increase in I_{th} . It is interesting to note that the increase in I_{th} occurred at a membrane potential of -74 mV while the increase in I_{th} occurred at a membrane potential of -60 mV. After 90 minutes Wenckebach periods occurred and trains of ten stimuli failed to elicit the full sequence of ten propagated action potentials. This response was observed in five of five experiments.

Discussion

Several hypotheses have been proposed for Wenckebach conduction and include decremental conduction encroachment upon the refractory period of the preceding impulse and elec-

tronic transmission through a site of conduction block. The mechanism for Wenckebach block however has not yet been resolved to a point of unanimous agreement.

Many recent reports have cited the electrophysiological manifestations of glycoside toxicity in Purkinje fibers. Our study has repeated many of these studies in an attempt to relate the previously identified glycoside induced changes with changes in excitability and conduction. Our data suggest that the glycoside induced Wenckebach periods are related to the delayed after depolarizations and concomitant changes in excitability. Recent reports have described changes in phase 4 of Purkinje fibers which have been termed transient depolarizations delayed after depolarizations or low amplitude potentials.^{14,15} These delayed after depolarizations were observed in the course of induction of cardiac glycoside toxic




Fig 5 Beat to beat variation in the after depolarization following ouabain superfusion. Basic cycle length is constant at 700 msec. The Purkinje fiber was exposed to ouabain for 39 minutes. With successive beats a progressive increase in the diastolic slope can be noted expressed as an after depolarization. Although external stimulation was maintained the action potential was consistently blocked concomitant with the largest after depolarization. The periodic block resulted in varying conduction patterns which tends to repeat in a cyclic fashion. See text for further discussion.

activation time. The gradual reduction in membrane potential results in a thickening of the trace following the stimulus artefact.

Fig 5 represents an example in which the recording and stimulating electrodes were more separated. These data were recorded from a Purkinje cell exposed to ouabain for 44 minutes. The basic cycle length of stimulation was 500 msec. The first applied stimulus elicits an action potential after 2.4 msec. The take off potential was -66 mV and the dV/dt was recorded to be 195 V/sec. The second applied stimulus elicits a response of 2.6 msec and its corresponding dV/dt is 167 V/sec. The increase in activation time was 0.2 msec. The third applied stimulus elicits a response after 2.9 msec and dV/dt is further reduced to 124 V/sec. The fourth applied stimulus induced a response with a conduction time of 5.7 msec and dV/dt of 73 V/sec. The fifth and sixth applied stimuli failed to induce a propagated response. The conduction pattern observed was that of Wenckebach conduction block. Fig 6 shows the relationship between the beat to beat changes in the slope and height of delayed after depolarizations and the eventual development of a blocked beat. The first action potential arises from a membrane potential of -72 mV. Following this action potential, the slope of the diastolic period results in a reduction in membrane potential to -70 mV at the point of stimulus application. Following the second action potential the

delayed after depolarization is more prominent and membrane potential is further reduced to -65 mV at the time of application of the third stimulus. Following the third action potential, the delayed after depolarization is larger and results in a further reduction in membrane potential. The stimulus is applied after the peak of the delayed after depolarization and is associated with failure to produce a propagated response to the recording electrode. This pattern of 4:3 conduction reverted to 3:2 conduction as shown in the remainder of the rhythm strip.

Changes in excitability. The observed changes in both membrane potential and phase II with successive beats suggest that changes in excitability might also occur. To test this hypothesis we designed experiments in which the current threshold for stimulation could be quantitated. Fig 7 presents data from one such experiment in which the tissue was superfused with ouabain (2×10^{-6} M) and stimulated at a basic cycle length of 700 msec in trains of ten followed by a 5 second pause. Membrane potential at the onset of the action potential, the so called take off potential (TOP) is plotted for the third (TOP₃) and tenth (TOP₁₀) action potentials as was the current threshold (I_{th}) in amperes for the third (I_{th3}) and tenth (I_{th10}) action potentials. Control take off potential of the third action potential was -92 mV. Control current threshold values for the third and tenth beats were identical at 3×10^{-7} A. Superfusion with ouabain did not significantly alter TOP or I_{th} until 40 minutes at which time TOP₃ was -91 mV and TOP₁₀ was -89 mV. I_{th3} was slightly reduced and I_{th10} was reduced even more, suggesting that the membrane potential of the tenth beat was closer to threshold and hence more excitable. Continued superfusion with ouabain resulted in further decreases in current threshold requirements until 60 minutes at which time I_{th10} began to increase and by 67 minutes was equal to that of I_{th3} . Once I_{th10} exceeded I_{th3} it remained greater although at 73 minutes I_{th3} also increased but for any given time was less than I_{th10} . Membrane take off potential of the tenth beat was less than the third after 33 minutes. Take off potential of the third beat also decreased but the exposure time required to attain any given membrane take off potential was longer than for the tenth beat.

In summary, Fig 7 shows sequential changes as

accumulation outside the membrane increases potassium conductance and that this effect is greater by the tenth beat than for the third. Current threshold may thereby increase since sodium conductance must exceed potassium conductance to produce excitation.

The observed decrease in maximal diastolic potential with increasing rate of stimulation in Purkinje cells exposed to ouabain (Fig. 2) suggests that the well known ability of cardiac glycosides to inhibit Na-K ATPase¹ plays a role in this depolarization. At slower rates of stimulation accumulation of sodium inside and/or potassium outside may not occur possibly because the sodium pump can adequately handle the required ion pumping. At higher rates of stimulation accumulation of these ions may occur which cannot be adequately transported by the available pumping sites. Such an accumulation of these ions such as K⁺ outside may lead to temporary shifts in membrane potential which with sufficient periods of quiescence may further repolarize (Fig. 3) to control levels. The positive shift in membrane potential occurring in our studies may represent the combined effects of the progressive increase in the slope of phase 4 depolarization and the local accumulation of potassium outside the membrane. An accumulation of sodium inside may also induce depolarization but the quantity of sodium flux associated with depolarization would be unlikely to shift the membrane potential several millivolts as noted in these experiments.

Our data describe physiologic responses in Purkinje cells exposed to ouabain which provide a basis for the observed progressive slowing of conduction in Wenckebach periodicity. That this mechanism is operative in the A-V junction is not necessarily implied since the electrical properties of A-V junctional cells are so dissimilar from those of Purkinje fibers.

Summary

The purpose of this study was to determine the mechanism for digitalis induced Wenckebach conduction block. Canine Purkinje cells were exposed to ouabain (2.0×10^{-6} M) and studied with conventional microelectrode techniques. When trains of stimuli were interrupted by a 5 second pause restoration of stimuli resulted in successive action potentials showing an increas-

ing slope of phase 4 depolarization which was expressed after the last beat as a delayed after depolarization. For any given state of ouabain toxicity a beat to beat reduction in maximal diastolic potential could be induced by shortening the basic cycle length. If basic cycle length remained constant continued exposure to ouabain would increase the net voltage reduction in membrane potential occurring during the train of ten beats. During the 5 second pause an increase in membrane potential was observed and this hyperpolarization was of the same magnitude as the depolarization occurring during stimulation. With successive beats as membrane potential was reduced action potential amplitude and dV/dt were concomitantly reduced and conduction slowed. Intracellular current threshold measurements showed that the reduction in membrane potential initially was associated with decreased current threshold requirements but later in toxicity current threshold was markedly increased for beats occurring late in the train. These data suggest that (1) the beat to beat reduction in membrane potential is due to both an increase in the height of the delayed after depolarization and a reduction in maximal diastolic potential, (2) trains of beats are associated with progressive prolongation of activation time with concomitant reduction in dV/dt and membrane potential and (3) failure of conduction is probably related to Purkinje segments showing decreased excitability.

REFERENCES

1. Wenckebach, K. F. Zur Analyse des unregelmässigen Pulses. *Z. Klin. Med.* 37: 376, 1899.
2. Wenckebach, K. F. Beiträge zur Kenntnis der menschlichen Herzrhythmus. *Arch. Anat. Physiol. (Physiol. Abteilung)* 9: 97, 1906.
3. Katz, L. N. and Pick, A. *Clinical Electrocardiography*. Philadelphia: 1968. Lea & Febiger, page 67.
4. Hay, J. Bradycardia and cardiac arrhythmia produced by depression of certain functions of the heart. *Lancet* 1: 139, 1906.
5. Maltz, W. Über die Unvollständige Störung der Erregungsüberleitung zwischen Vorhof und Kammer des menschlichen Herzens. *Z. Ges. Exp. Med.* 41: 180, 1954.
6. Anderson, C. J., Greenspan, K., Fisch, C. and Bailey, J. C. Electrophysiologic studies on Wenckebach structures below the A-V junction. *Am. J. Cardiol.* 32: 37, 1972.
7. Narula, O. S. and Samet, P. Wenckebach and Mobitz Type II A-V block due to block within the His bundle and bundle branch. *Circulation* 41: 947, 1970.
8. Rosenbaum, M. H., Gerardo, V. J., Lewis, R. J., Halperin, M. D., Eluzari, M. V. and Lazzari, J. O. Wenckebach periods in the bundle branch. *Circulation* 50: 59, 1969.
9. Friedberg, H. D. and Shamroff, L. The Wenckebach

ity The heights of the delayed after depolarizations have been correlated with cycle length¹⁹ Data has also been recorded¹⁹ showing that with stimuli applied in trains, the slope of phase 4 depolarization (or the ascending limb of the delayed after depolarization) progressively increased similar to that observed in Fig 1 This increase in the diastolic slope results in a decrease in the membrane potential at the time of application of the stimulus Accordingly, the take off potential is progressively reduced, and occurs with a concomitant reduction in dV/dt as shown in Fig 4 These data suggest that both the reduction in membrane potential and dV/dt may play a role in the progressive reduction in conduction velocity of successive impulses The studies of Rosen and associates²⁰ and Saunders and colleagues¹⁸ have shown data consistent with this hypothesis These studies demonstrated the relationship of the delayed after depolarizations and the success or failure of a critically timed premature impulse When the premature impulse was applied on either side of the peak of the delayed after depolarization propagation to ventricular muscle occurred However, application of the impulse close to the peak of the delayed after depolarization resulted in conduction block

As noted above cardiac glycosides reduced the take off potential by increasing the slope of phase 4 and by reducing the maximal diastolic potential This possibly relates to our observation on the biphasic current threshold response of Purkinje cells exposed to ouabain Early in the course of glycoside administration there was an initial reduction in take off potential in which the take off potential of the tenth beat was usually less negative than the third beat This may be accounted for on the basis of an increasing slope of phase 4 following the ninth action potential compared to the second Presumably threshold potential has not been likewise reduced and therefore current threshold is less for the tenth beat than for the third Later in the time course of glycoside administration the continued application of stimuli in trains of ten induced changes in membrane parameters tending to make the current threshold requirements for the tenth beat higher than the third The explanation for these phenomena might rest in the combined effects of the cardiac glycoside on the delayed after depolarizations and Na^+-K^+ pump inhibition In more

severe degrees of toxicity, the reduction in membrane potential due to increased pump inhibition with successive beats is greater and the resulting cation accumulation (either K^+ or Na^+) would be greater In such circumstances the degree of sodium inactivation may in fact be greater with the tenth beat than for the third Thus, the slight reduction in take off potential of the third beat narrows the margin between the cells' membrane potential and threshold potential, thereby reducing current threshold requirements However, with each subsequent beat, both the slope of phase 4 increases and presumably sodium inactivation is increased Concomitant with the reduction in membrane potential threshold potential is reduced Presumably the threshold potential is shifted to a greater extent, thereby increasing the separation between membrane potential and threshold potential This in turn, increases current threshold requirements The observed increase in current threshold for excitability may relate to the mechanism for conduction block in Wenckebach periods If a segment of a Purkinje strand has decreased excitability, then it would favor the development of Wenckebach periodicity This area of increased current threshold may develop if a segment of Purkinje was more susceptible to cardiac glycosides or was affected by underlying preexistent disease Our data however, do not indicate which of the two mechanisms may be responsible for the beat to beat changes in current threshold requirements for excitation From the above discussion we may note that both voltage dependent changes in excitability may occur as well as those occurring secondary to ion conductance changes and pump inhibition The relative contribution of each of these factors to the observed Wenckebach block requires further study

The finding that current threshold increased at different membrane potentials for the third and tenth beats (Fig 7) was noteworthy In all five experiments the third beat depolarized to less negative values before an increase in current threshold was observed This finding is not explained solely by sodium inactivation as postulated above Since the increase in current threshold occurs at a more negative membrane potential for the tenth beat it is suggested that a parameter for threshold potential is not membrane potential alone It is possible that K^+

Endocardial fibroelastosis Myocardial and vascular alterations associated with viral like nuclear particles

Stephen M Factor MD

Bronx, N Y

The pathogenesis of primary endocardial fibroelastosis (EFE) remains an enigma despite an increasing body of clinical, immunologic^{1,2} and experimental evidence accumulated over the past two decades implicating viral myocarditis in the development of this condition. The viruses considered to be the most likely agents include mumps and coxsackie. In general histopathologic findings in EFE have not conclusively supported an infectious etiology. Even in those cases presumed to be of infectious origin the observed lesions have included non specific foci of calcification fibrosis vascular sclerosis and rare inflammatory infiltrates.³ Since viral inflammation may resolve completely and leave only structural damage as a clue to pre existing infection (i.e. rubella) it should not be surprising that viral particles or specific lesions attributable to viruses have never been demonstrated in primary EFE.

The present report describes in detail the light microscopic and ultrastructural features of the myocardium in a case of primary EFE. A possible relationship to viral myocarditis was supported by the observation of unusual intramyocardial small vessel endothelial proliferation myocardial cellular alterations and intranuclear particles suggestive of viral associated material.

From the Department of Pathology Albert Einstein College of Medicine and the Anatomic Pathology Service The Bronx Municipal Hospital Center Bronx, N Y

Received for publication Oct 13 1977

Accepted for publication Nov 30 1977

Reprint requests: Stephen M Factor MD Asst. Professor of Pathology Department of Pathology Albert Einstein College of Medicine, 1200 Morris Ave. Bronx, N Y 10461

Case report

An 8-month-old male infant was admitted to the hospital in respiratory distress. There was no history of previous respiratory or cardiac ailments. Physical examination revealed a tachypneic febrile infant with a tachycardia of 200/minute. Auscultation of the lungs and heart was unremarkable. Hepatomegaly was present. Chest roentgenogram demonstrated a markedly enlarged cardiac silhouette. Electrocardiogram revealed left axis deviation high QRS voltage in Leads V₁ V₂ notched P waves and P mitrale. Following 4 hours of treatment with digitalis oxygen and diuretics the patient had a cardiopulmonary arrest. Resuscitation attempts were unsuccessful.

Postmortem examination was performed 16 hours after death. With the exception of pulmonary and visceral congestion abnormalities were limited to the cardiovascular system. The heart weighed 112 grams (normal 37 grams) and was globular in shape. All four chambers were dilated and both the left and right ventricular walls were hypertrophied. The left atrial and left ventricular endocardial surface was pearly white in color and measured up to 2 mm in thickness. Papillary muscles were encased in the fibroelastic tissue. Focal fibrous septa were noted to extend from the endocardium into the underlying muscle. Cardiac valves and chordae tendineae were structurally normal however the mitral and tricuspid valves were irregularly thickened. Coronary arteries were of normal caliber and arose from the aorta.

Materials and methods Routine paraffin embedded sections were prepared from all four cardiac chambers and valves. Tissue was stained with hematoxylin and eosin periodic acid and Schiff with and without pretreatment with diastase elastic van Gieson and Masson's trichrome. Specific attention was given to the degree and type of myofiber abnormalities the presence of interstitial fibrosis not associated with extension of overlying endocardial fibroelastotic tissue into the myocardium in the form of septa or involving arterio-luminal vessels the presence of inflammation and the extent if any of vascular alterations.

Sections for electron microscopy were prepared from tissue which had been fixed in 3.7 per cent formaldehyde for 4 days. Segments of fibroelastotic left ventricular endocardium and underlying myocardium were removed and diced into 1 mm

- phenomena in left bundle branch block *Am J Cardiol* 24 591 1969
- 10 Fisch C and Stone J *Digitals* Fisch C and Surawicz B eds New York 1969 Grune & Stratton Inc
- 11 Hoffman B F and Singer D H Effect of digitals on the electrical activity of cardiac fibers *Progr Cardiovasc Dis* 7 226 1964
- 12 Vassalle M Kars J and Hoffman H Toxic effects of ouabain and Purkinje fibers and ventricular muscle fibers *Am J Physiol* 203 433 1962
- 13 Glynn I M The action of cardiac glycosides on ion movement *Pharmacol Rev* 16 381 1964
- 14 Ku D Akera T Pew C L and Brody T M Cardiac Glycosides Correlations among Na⁺ K⁺ ATPase sodium pump and contractility in the guinea pig heart Naunyn-Schmiedeberg's *Arch Pharmacol* 285 185 1974
- 15 Davis L D The effect of changes in cycle length on diastolic depolarization produced by ouabain in canine Purkinje fibers *Circ Res* 32 206 1973
- 16 Saunders J H Ferrer G R and Moe G K Conduction block associated with transient depolarizations induced by acetylcholine and isolated canine Purkinje fibers *Circ Res* 23 610 1973
- 17 Rosen M R Gelband D H Merker C and Hoffman H F Mechanisms of digitalis toxicity Effect of ouabain on phase 4 of canine Purkinje fiber transmembrane potentials *Circulation* 47 681 1973
- 18 Hashimoto K and Moe G K Transient depolarizations induced by acetylcholine in specialized tissue of dog atrium and ventricle *Circ Res* 32 618 1973
- 19 Ferrer G R Saunders J H and Mendez C A cellular mechanism for the generation of ventricular arrhythmias by acetylcholine *Circ Res* 32 600 1973
- 20 Ferrer G R and Moe G K Effect of calcium on acetylcholine induced transient depolarizations in canine Purkinje tissue *Circ Res* 33 508 1973
- 21 Moore E N and Bloom M A method for intracellular stimulation and recording using a single microelectrode *J Appl Physiol* 27 734 1969
- 22 Hogan P M Wittenberg S M and Klocke F J Relationship of stimulation frequency to automaticity in the canine Purkinje fiber during ouabain administration *Circ Res* 32 377 1973
- 23 Paes de Carvalho A and de Almeida D F Spread of activity through the atrial ventricular node *Circ Res* 8 801 1960
- 24 Hoffman H F and Cranefield P F *Electrophysiology of the heart* New York 1960 McGraw Hill Book Company Inc pages 156 174
- 25 Rosenbluth A Mechanisms of Wenckebach-Luciani cycles *Am J Physiol* 194 491 1958
- 26 Decherd G M and Ruskin A The mechanism of the Wenckebach type of AV block *Br Heart J* 8 6 1946
- 27 Levy M N Martin P J Edelstein J and Goldbert L H The AV nodal Wenckebach phenomenon as a positive feedback mechanism *Progr Cardiovasc Dis* 18 601 1974
- 28 Levy M N Martin P J Ziehe H and Adler D Role of positive feedback in the atrial ventricular nodal Wenckebach phenomenon *Circ Res* 34 697
- 29 Wennemark J R and Bandura J P Microelectrode study of Wenckebach periodicity in canine Purkinje fibers *Am J Cardiol* 33 390 1974
- 30 Rosen M R Wit A L and Hoffman B F Electro physiology and pharmacology of cardiac arrhythmias IV Cardiac antiarrhythmic and toxic effects of digitalis *Am Heart J* 89 391 1975
- 31 Kunze D L Rate dependent changes in extracellular potassium in the rabbit atrium *Circ Res* 41 127 1977
- 32 Kline R and Morad M Potassium efflux and accumulation in heart muscle *Biophys J* 16 367 1966




Fig. 2 Dense interstitial collagen diffusely surround atrophic myocardial cell. Numerous clear vacuoles are present within many myofibers in some cases comprising a significant proportion of the cell diameter (arrows) (Tinchro stain, original magnification $\times 63$)

exception of one arteriole which had a round cell inflammatory infiltrate within its wall, no intramural inflammation was associated with the cellular proliferation.

Chronic inflammatory cells were diffusely scattered throughout the interstitium and were only rarely aggregated into focal collections. The infiltrate consisted predominantly of lymphocytes, histiocytes, rare plasma cells, and typical Anitschkow myocytes (Fig. 4). The cells were noted particularly beneath the endocardium around blood vessels in areas of dense interstitial fibrosis and within the mitral valve substance. Minimal inflammation was seen in the surface endocardium.

Two segments of peripheral striated muscle were available for study. Of special interest, changes similar to those in the myocardium were observed, particularly interstitial and perivascular inflammation, focal fibrosis, and partial obliteration of arterial lumens by proliferated intimal cells (Fig. 5). No other similar microscopic inflammatory changes were demonstrated in any other organs.

Electron microscopy. Ultrastructural alterations were observed in the interstitium and in individual myocytes. Endothelium of capillaries and small arterioles demonstrated a pronounced degree of cytoplasmic swelling, with numerous small projections extending into the vessel lumen in many cases leading to complete occlusion (Fig. 6). Small electron dense particles and increased numbers of surface pinocytotic vesicles were noted within the projections. Nuclei were abnormal and will be described below. The surrounding interstitium had proliferation of basal lamina, presence of increased collagen, and cellular debris.

Myocytes had in reased numbers of mitochondria, many with bizarre and irregular sizes and shapes (Fig. 7). Intracellular cytoplasmic vacuoles were frequently observed and were of two types. In the paranuclear zone, large single membrane delimited vacuoles were present containing coarsely granular electron dense material. Cytoplasmic organelles were usually absent from these structures. In the second type of vacuole, cytoplasmic material including intact or degenerated mitochondria, membranous whorls, and lysosomes were seen (Fig. 8). These vacuoles were of variable size and in some areas were clearly delimited by a double unit membrane. Similar vacuoles with a double lining have been reported in vascular smooth muscle cells and myocardium and have been interpreted as cell to cell hernias. Foci of myofibrillar degeneration with severe disruption of cellular morphology were noted (Fig. 9) and areas of myofibrilolysis were commonly observed. With the exception of clearing of the mitochondrial matrix, there was no suggestion that the alterations in the zones of degeneration were secondary to tissue autolysis.

Within otherwise hypertrophied and irregular myocardial nuclei, as well as less commonly within endothelial nuclei, diffuse and aggregated viral like particulate elements were observed (Figs. 10 and 11). These nuclear inclusions were smaller than nucleoli and were less electron dense than chromatin. They were composed of numerous round bodies measuring 25 to 85 nm in diameter. Tubular structure or crystalline arrays were never seen. Although poorly defined, there was an indication of a fuzzy coat around the outer margin of some individual bodies and in several instances a dense inner core could be discerned (Fig. 11). Particularly




Fig 1 A representative section from the left ventricular endocardial surface. The thickened endocardium (top) is composed of coarse elastic fibers (stained dark) and collagen (stained light). In this region there is minimal penetration of the fibroelastosis into the underlying myocardium. (Elastic van Gieson stain; original magnification $\times 63$)

cubes. The tissue was washed in cacodylate-sucrose buffer pH 7.4 for 2 hours, post fixed in osmium tetroxide for 2 hours, dehydrated in progressively increasing concentrations of alcohol and propylene oxide, and embedded in epoxy resin. One micron sections, stained with alkaline toluidine blue, were examined to select appropriate areas for study. Ultrathin sections were prepared with diamond knives, mounted on copper grids, and stained with uranyl acetate and lead citrate. Grids were examined in RCA EMU 3C and Siemens Elmiskop 10A electron microscopes.

Light microscopy. The left atrial and ventricular endocardial surface was composed of fine and coarse elastic fibers and collagenous tissue (Fig 1). Focally, groups of trapped vacuolated myofibers and conduction tissue were incorporated into the sclerotic endocardium. Myofibers generally were hypertrophied with increased cellular diameter and hyperchromatic

bizarre and rectangular nuclei. Clear intracytoplasmic vacuoles could be appreciated in almost every muscle cell. Intranuclear vacuoles were also present, but no typical inclusion bodies were seen. A diffuse network of loose pericellular collagen extended transmurally within the interstitium. In irregular foci, dense collagenous tissue surrounded atrophic myofibers (Fig 2). Virtually all small and medium sized blood vessels were surrounded by proliferated adventitial fibrosis which extended focally into the interstitium.

Within the superficial and midwall myocardium, many small arteries were completely occluded by vacuolated intimal cells (Fig 3). The internal elastica and the media were usually intact, however, bubbly basophilic material resembling mucopolysaccharide was present in some vessel walls. Occlusive intimal proliferation was noted in occasional small arterioles; however, it was difficult to evaluate smaller vessels. With the




Fig 4 Numerous darkly stained inflammatory cells are present within the myocardial interstitium. A small artery (A) in the center is surrounded by similar cells. The vessel lumen is partially occluded by intimal cells (Hematoxylin-eosin stain; original magnification $\times 100$)

and EFE has been derived from two models. Round heart disease of turkeys, a spontaneous myocarditis appearing in susceptible birds,¹⁰ results in cardiac hypertrophy, left ventricular dilatation, and EFE with features remarkably similar to the human disease. Microscopically, focal interstitial inflammation was observed in birds under 1 month of age with progressive condensation of subendocardial collagen and elastic tissue and diminution of inflammation as the birds matured. Ultrastructurally, various degenerative phenomena and spherical viral-like particles were described in affected and normal cells. These particles measuring 60 to 90 nm with a central dense core of 30 to 60 nm resembled avian leuko virus according to the authors. In contrast to the mechanical dilatation hypothesis, fibroelastotic deposition in the turkey heart appears to precede the development of overt ventricular dilatation.

St Geme and associates¹¹ have inoculated chick embryos with mumps virus. They described features of myocarditis which subsided following hatch, and at one year of age histological fibroelastosis was present in the endocardium of the

left ventricle. In both the chick and turkey models (similar to the human disease), EFE was present in young birds without significant evidence of myocardial inflammation.

This report represents the first study of a human case of idiopathic EFE in which extensive myocardial degeneration and vascular abnormalities consistent with viral infection have been associated with viral-like particles in endothelial and myocardial cells. Although viral culture was not performed in this case and tissue was not available for immunologic confirmation of the viral nature of the observed particles, their presence in areas of myocardial degeneration and endothelial proliferation, their lack of resemblance to known artifact or non-viral spherical microparticles,¹² and their morphologic similarity to confirmed viral structures¹³ or supposed viral-related material¹⁴ support the view that they are of viral origin.

At the light microscopic level, several alterations suggested an infectious etiology. Extensive interstitial fibrosis was associated with mononuclear inflammation. Degenerative changes were prominent with myofiber atrophy and extensive



Fig 3 An intramyocardial artery is completely occluded by vacuolated intimal cells (IC). A portion of the internal elastic membrane (arrow) may be seen. Surrounding the vessel there is relatively acellular perivascular fibrosis (PVF) with collagen (C) extending into the myocardial interstitium. Myofibers are atrophic (Elastic van Gieson stain; original magnification $\times 250$).

within endothelial nuclei; the viral-like particles were not aggregated but were focally dispersed throughout the nucleoplasm. Additionally, the structures were also present along the outer nuclear envelope and were within cytoplasmic fragments located in the interstitium.

Discussion

Renewed interest in the infectious etiology of endocardial fibroelastosis was stimulated by Noren and associates¹ in 1963. They described a group of patients having cutaneous delayed hypersensitivity to mumps virus antigen associated with an increased frequency of maternal exposure to mumps virus during the first trimester of pregnancy. This immunologic and epidemiologic study and subsequent reports²⁻⁴ reversed a trend of approximately 25 years during which time mechanical and hemodynamic forces were invoked by most investigators⁵⁻⁷ to explain the pathogenesis of this disorder. Although observers in the 1930s had interpreted pathologic features seen in EFE such as myocardial fibrosis, calcification, rare inflammatory foci, and vascular sclerosis as indicative of *in utero* infection, these abnormalities were subsequently discounted as non-

specific alterations. Despite the fact that many of the theories invoked to explain the development of EFE had basic conceptual flaws (see Schryer and Karnauchow⁸ for a review), it was not until the techniques of clinical immunology, electron microscopy, and experimental viral endomyocarditis were applied to the problem that *in utero* infection of the heart regained its primacy as the cause of EFE.

Evidence supporting the infectious etiology of EFE has come from several observations. Hutchins and Vie⁹ reported on a group of 64 children in whom 41 had coexisting interstitial (probably viral) myocarditis and idiopathic EFF. These authors noted that with longer survival times the myocarditis subsided while the fibroelastosis increased in severity. A more direct clinical association between viral infection and EFE has been documented in cases of postnatal viral myocarditis attributed to mumps, poliovirus type 2,¹⁰ and coxsackie B virus,¹¹ in which the development of EFE occurred following a variable time period.

Experimental evidence relating viral infection



Fig 7 Two markedly hypertrophied and bizarre mitochondria (M and M') are observed in this myocardial cell. Mitochondrial cristae are disorganized. There appears to be partial fusion of the enlarged mitochondrion at the arrow. The myocardial nucleus contains viral like particles (V) which are seen better in Fig 11 (Original magnification $\times 8000$)

cellular vacuolization. The most striking abnormality observed was the presence of intramyocardial vessels completely occluded by intimal proliferation. Although occasional vascular abnormalities have been described in EFE, occlusive lesions are rare. Numerous studies have documented the propensity of several cardiotrophic viruses to infect endothelium; however, the role of vascular occlusion in the development of myocardial damage and EFE remains speculative. Finally, the fact that myofiber degeneration and vascular endothelial proliferation were found in skeletal muscle supports our contention that the EFE resulted from infection with virus. It is unlikely that abnormal mechanical or hemodynamic forces could have produced the extra cardiac lesions.

Ultrastructurally, hypertrophied cells with irregular nuclei and increased numbers of mitochondria with bizarre and giant forms were observed. Numerous intracellular double membrane delimited vacuoles containing cytoplasmic components were frequently noted. These vacuoles have recently been described in vascular smooth muscle cells by Joris and Majno. These

authors provide evidence that the vacuoles represent cell to cell herniae with the protrusion of one cellular plasma membrane into an invaginated adjacent cell producing the double membrane lined space. Joris and Majno propose that these vacuoles arise as a result of pathological wall tension or spasm in vessels. In the heart these vacuoles are probably indicative of abnormalities of contraction resulting from the endocardial sclerosis and interstitial fibrosis associated with cellular hypertrophy.

Myofiber degeneration consisted of focal myofibrilolysis and severe cytoplasmic disruption. These features were not invariably associated with nuclear or cytoplasmic viral like material. Occasional aggregates of electron dense particles were noted in degenerated cells; however, they most probably were ribosomal particles.

The striking proliferation of endothelial cells within capillary and arteriolar lumens extended the light microscopic observation of a similar process occurring in larger vessels. Occasional endothelial cells had associated intranuclear viral like particles. As an indication of cellular degeneration, many of these small vessels were




Fig 5 This section of skeletal muscle is infiltrated by darkly stained inflammatory cells which are also present within the wall of a distorted artery (A). The vascular lumen is obliterated by vacuolated cells identical to those seen in the myocardial vessels. (Hematoxylin-eosin stain, original magnification $\times 100$)




Fig 6 This small interstitial blood vessel is composed of three endothelial cells (E). The vessel lumen (L) is almost entirely obliterated by proliferated endothelial cytoplasmic projections (P). Small electron-dense particles are present within the projections, the endothelial cytoplasm, and focally in the extracellular space (arrow). Reduplicated basement membrane (BM) and cytoplasmic fragments (CF) surround the vessel. (Original magnification $\times 20,000$)



Fig 10 This myocardial cell nucleus contains two aggregated groups of viral like particles (V) Individual non aggregated particles are also present (arrows) The difference in structure and electron density between the viral like particles and the nuclear chromatin and nucleolus can be clearly seen (Original magnification $\times 37,000$)

surrounded by cytoplasmic debris within the interstitium. Viral like particles were occasionally observed in these structures.

We interpret the aggregates of nuclear particles observed in endothelial and myocardial cells as probably of viral origin. Their size and morphology are suggestive of coxsackie virus as well as being similar to the particles described in round heart disease of turkeys.⁹ Their presence in or near degenerating myocardial cells and hyperplastic endothelium is support for their relationship to the development of EFE in this case. Of course it may always be argued that they are the result of a secondary viral infection of an already diseased myocardium and this cannot be easily refuted. On the other hand their similarity to coxsackie virus which is known to be clinically associated with EFE,⁹ suggests a primary relationship.

Finally we may speculate on the pathogenesis of EFF in this case and in general. If in fact the described particles represent viral related material how do they result in fibroelastosis of the endocardium? If the virus has an affinity for cardiac endothelium it may directly infect the

endocardium producing damage and subsequent healing by proliferation of collagen and elastic tissue. Alternatively obliteration of multiple vascular channels may lead to scarring of the endocardium as a secondary phenomenon. In this regard it may be pertinent that experimental ablation of cardiac lymphatic vessels may produce EFE.¹¹ Although cardiac lymphatics were not clearly involved in experimental mumps induced EFE,⁴ we could not rule out the possibility that some of the occluded vessels in our case represented lymphatics.

Diverse and unrelated cardiac conditions have been associated with EFE. These include congenital heart disease,² myocardial infarction,¹ Hurler's syndrome and cardiac glycogenosis. Congenital heart disease is frequently the result of *in utero* viral infection,¹² and microvascular alterations may be a prominent feature in the myocardium.³ In the other conditions which are clearly non viral in origin vascular abnormalities are obvious in myocardial infarction but they are also present in Hurler's syndrome¹ and Pompe's disease.³ Thus although speculative it is conceivable that intramyocardial occlusive vas-



Fig 8 This large intracellular myocardial vacuole contains flocculent and electron dense granular material a degenerated mitochondrion (M) and membranous structures. The double membrane surrounding the vacuole can be seen at the arrows suggesting that the vacuole represents an intracellular hernia (Original magnification $\times 36,000$)



Fig 9 There is severe degeneration of the myocardial cell in the lower portion of the field with similar but less severe changes noted in the cell on the right. There is absence or dissolution of myofilaments and complete disorganization of an intercalated disk (ID). Membranous material and electron-dense granular particles (arrow) are present beneath the still intact sarcolemma. The interstitium contains collagen fibers (C). (Original magnification $\times 9,500$)



Fig 10 This myocardial cell nucleus contains two aggregated groups of viral like particles (v). Individual non aggregated particles are also present (arrows). The difference in structure and electron density between the viral like particles and the nuclear chromatin and nucleolus can be clearly seen. (Original magnification $\times 3,000$)

surrounded by cytoplasmic debris within the interstitium. Viral like particles were occasionally observed in these structures.

We interpret the aggregates of nuclear particles observed in endothelial and myocardial cells as probably of viral origin. Their size and morphology are suggestive of coxsackie virus as well as being similar to the particles described in round heart disease of turkeys. Their presence in or near degenerating myocardial cells and hyperplastic endothelium is support for their relationship to the development of EFE in this case. Of course it may always be argued that they are the result of a secondary viral infection of an already diseased myocardium and this cannot be easily refuted. On the other hand their similarity to coxsackie virus which is known to be clinically associated with EFE suggests a primary relationship.

Finally we may speculate on the pathogenesis of EFE in this case and in general. If in fact the described particles represent viral related material how do they result in fibroelastosis of the endocardium? If the virus has an affinity for cardiac endothelium it may directly infect the

endocardium producing damage and subsequent healing by proliferation of collagen and elastic tissue. Alternatively obliteration of multiple vascular channels may lead to scarring of the endocardium as a secondary phenomenon. In this regard it may be pertinent that experimental ablation of cardiac lymphatic vessels may produce EFE. Although cardiac lymphatics were not clearly involved in experimental mumps induced EFE we could not rule out the possibility that some of the occluded vessels in our case represented lymphatics.

Diverse and unrelated cardiac conditions have been associated with EFE. These include congenital heart disease²², myocardial infarction²³, Hurler's syndrome²⁴ and cardiac glycogenosis²⁵. Congenital heart disease is frequently the result of *in utero* viral infection^{26,27} and microvascular alterations may be a prominent feature in the myocardium²⁸. In the other conditions which are clearly non viral in origin vascular abnormalities are obvious in myocardial infarction²⁹ but they are also present in Hurler's syndrome³⁰ and Pompe's disease³¹. Thus although speculative it is conceivable that intramyocardial occlusive vas-



Fig 8 This large intracellular myocardial vacuole contains flocculent and electron dense granular material a degenerated mitochondrion (*M*) and membranous structures. The double membrane surrounding the vacuole can be seen at the arrow suggesting that the vacuole represents an intracellular hernia. (Original magnification $\times 36,000$)



Fig 9 There is severe degeneration of the myocardial cell in the lower portion of the field with similar but less severe changes noted in the cell on the right. There is absence or dissolution of myofibrils and complete disorganization of an intercalated disk (*ID*). Membranous material and electron dense granular particles (arrows) are present beneath the still intact sarcolemma. The interstitium contains collagen fibers (*C*). (Original magnification $\times 9,500$)

- 3 Carstens, P H II Postnatal mumps virus infection associated with endocardial fibroelastosis Arch Pathol 88 399 1967
- 4 Mehrizi, A Hutchins G M Medeiros D N Jr and Row R d. Enterovirus infection and endocardial fibroelastosis, Circulation 32 150 1965
- 5 Frühling E L Korn R Lavillaureix J Surjus A and Fousseau J La myo-endocardite chronique fibroelastique du nouveau-né et du nourrisson (fibroelastose) Ann Anat Pathol 7 27 1967
- 6 Noren G R Adams, P Jr and Anderson R C Postive skin reactivity to mumps virus antigen in endocardial fibroelastosis J Pediatr 62 604 1963
- 7 St Geme J W Jr Noren C R and Adams I Jr Proposed embryopathic relation between mumps virus and primary endocardial fibroelastosis N Engl J Med 275 339 1966
- 8 St Geme J W Jr Davis C W C and Noren G R An overview of primary endocardial fibroelastosis and chronic viral cardiomyopathy Perspect Biol Med 17 49 1974
- 9 Noren G R Staley N A Jankus E F and Stevenson J E Myocarditis in round heart disease of turkeys A light and electron microscopic study Virehows Arch Pathol Anat 352 280 1971
- 10 Staley N A Noren G R and Jankus E F Virus like particles associated with myocarditis of turkeys Am J Vet Res 33 808 1972
- 11 St Geme J W Jr Davis C W C Peralta H J Faras, N E Yamanchi T and Cooper M D The biologic perturbations of persistent embryonic mumps virus infection Pediatr Res 7 541 1973
- 12 Farber S and Hubbard J Fetal endomyocarditis: Intrauterine infection as the cause of congenital cardiac anomalies Am J Med Sci 186 700 1933
- 13 Kugel M A and Stoloff E G Dilatation and hypertrophy of the heart in infants and in young children Am J Dis Child 45 878 1933
- 14 Strohm G Malformations of the heart of the newborn Con ential lesions suggestive of an inflammatory origin Arch Pathol 17 311 1934
- 15 Roberts J T A case of congenital aortic atresia with hypoplasia of ascending aorta normal origin of coronary arteries, left ventricular hypoplasia and mitral stenosis, Am Heart J 12 448 1916
- 16 House R K Diffuse interstitial myocarditis in children Am J Pathol 24 1935 1918
- 17 Joris I and Majno G Cell-to-cell herniae in the arterial wall I The pathogenesis of vacuoles in the normal wall Am J Pathol 87 35 1971
- 18 Page E The occurrence of inclusions within membrane limited structures that run longitudinally in the cells of mammalian heart muscle J Ultrastruct Res 17 63 1967
- 19 De la Iglesia F A and Lumb C Ultrastructural and circulatory alterations of the myocardium in experimental coronary artery narrowing Lab Invest 21 329 1969
- 20 Caspo Z Dusek, J and Horvath G Peculiar myofibrillar changes near the intercalated disc in isoproterenol induced cardiac muscle cell injury J Mol Cell Cardiol 6 9 1974
- 21 Gross, P Concept of fetal endocarditis A general review with report of an illustrated case Arch Pathol 31 163 1941
- 22 Johnson F R Anoxia as a cause of endocardial fibroelastosis in infancy Arch Pathol 54 237 1952
- 23 Andersen D H and Kelly J Endocardial fibroelastosis I Endocardial fibroelastosis associated with congenital malformations of the heart Pediatrics 18 513 1956
- 24 Black Schaffer B Infantile endocardial fibroelastosis A suggested etiology Arch Pathol 63 281 1957
- 25 Ferrans V J, Thiedemann K U, Maron B J Jones M and Roberts, W C Spherical microparticles in human myocardium An ultrastructural study Lab Invest 35 349 1976
- 26 Rabin F R Hassan S A Jensen A B and Melnick J L Coxsackie virus B3 myocarditis in mice An electron microscopic immunofluorescent and virus assay study Am J Pathol 44 5 1964
- 27 Bialock Z R Rabin E W and Melnick, J L Adenovirus myocarditis in mice An electron microscopic study Exp Mol Pathol 9 84 1968
- 28 Sohal R S Burch G F Chu K C, Leiderman P and Colcolough H L Ultrastructural changes in cardiac capillaries of coxsackie virus B infected mice Lab Invest 19 399 1968
- 29 Sohal R S and Burch G E Electron microscopic study of the endocardium in coxsackie virus by infected mice Am J Pathol 55 133 1969
- 30 Hay S Morphologic aspects of nuclear bodies in a case of bronchiolar alveolar carcinoma of the lung Hum Pathol 8 774 1977
- 31 Cogrove G E Jr and Kaup D H Endocardial sclerosis in infants and children Am J Clin Pathol 16 322 1966
- 32 Overman J R, Peers J H and Kilham L Pathology of mumps virus meningoencephalitis in mice and hamsters Arch Pathol 55 457 1953
- 33 Miller A J Pick R and Katz L N Ventricular endomyocardial changes after impairment of cardiac lymph flow in dogs Br Heart J 25 187 1963
- 34 Hutchins G M and Bannan G A Development of endocardial fibroelastosis following myocardial infarction Arch Pathol 91 113 1971
- 35 Goldfischer S Colloff Schiller B Biempica L and Wolinsky H Lysosomes and the sclerotic arterial lesion in Hunter's syndrome Hum Pathol 8 633 1975
- 36 Hernandez A Jr Marchetti V Goldring D, Kassane L Jr and Hargmann A F Jr Cardiac glycogenesis hemodynamic angiocardigraphic and electron microscopic findings—report of a case J Pediatr 68 400 1966
- 37 Williamson A P Simonsen L and Blattner R J Specific organ defects in early chick embryos following inoculation with influenza A virus Proc Soc Exp Biol Med 92 334 1956
- 38 Heath H D Shear H H Imigawa D T Jones M H and Adams J M Teratogenic effects of herpes simplex vaccinia influenza A (NWS) and distemper virus infections on early chick embryos Proc Soc Exp Biol Med 92 675 1966
- 39 Bulkley B H Weisfeldt M L and Hutchins G M Isometric cardiac contraction A possible cause of the disorganized myocardial pattern of idiopathic hypertrophic subaortic stenosis N Engl J Med 296 135 1977



Fig 11 A high magnification view of the nucleus seen in Fig 7 demonstrates a loosely aggregated group of viral like particles (V) Several of the individual particles (arrows) appear to be composed of an outer shell and a small central electron dense core (Original magnification $\times 40,000$)

cular disease represents a common denominator for the development of EFE. In the future known cases of primary EFE should be studied with particular attention to the myocardial small vessels. Additionally electron microscopy and immunologic techniques should be employed to confirm the presence of viral material.

Summary

Although clinical immunologic and experimental evidence exists implicating *in utero* viral infection of the myocardium in the development of primary endocardial fibroelastosis, the infectious etiology of this condition remains somewhat controversial. To date specific features of viral myocarditis and morphological demonstration of viral particles have not been described in EFE. The present case is the first in which extensive light microscopic and ultrastructural analysis of the myocardium revealed abnormalities consistent with a primary viral myocarditis associated with typical EFE. These alterations consisted of chronic myocardial inflammation, extensive interstitial fibrosis, severe degenerative changes in myocardial cells, and marked proliferation of endothelial cells in large and small intramyocar-

dial vessels leading to vascular occlusions. In support of the infectious etiology of this disease, similar features were noted in skeletal muscle. Most interestingly, viral like particles were observed in many myocardial and endothelial nuclei. Although we are not absolutely certain of the viral nature of these particles, their appearance suggests viral associated material. We propose that the presence of these particles in this case in association with the other morphological alterations is support for the viral etiology of EFE. The prominent vascular occlusion observed in the myocardium may be an important clue to the pathogenesis of fibroelastosis as either a primary or secondary disease.

I would like to express my appreciation to Dr. Luis Biempica for his extremely helpful comments and suggestions, to Mrs. Stella Biempica for her fine technical assistance, and to Ms. Constance Verutes for her excellent secretarial aid in preparing this manuscript.

REFERENCES

1. Hutchins G. M. and Vie S. A. The progression of interstitial myocarditis to idiopathic endocardial fibroelastosis. *Am J Pathol* 66:483, 1972.
2. Schryer M. J. P. and Karnachow P. N. Endocardial fibroelastosis: Etiologic and pathogenetic considerations in children. *Am Heart J* 88:557, 1974.



Fig 1 Cross section of left anterior descending coronary artery with Teflon felt embolus lodged at a point of branching 0.5 cm from the ostium (black arrows) (Embolus measures 0.4 cm in greatest diameter) (Original magnification approximately $\times 2$)




Fig 2 Photomicrograph of the Teflon felt embolus within the coronary artery (Hematoxylin and eosin original magnification $\times 60$)

Autopsy findings The heart weighed 580 grams with marked left ventricular hypertrophy. The prosthetic valve was in place. There were no thrombi on the surface of the disc or on the cage of the prosthesis. The coronary arteries were cross sectioned at 3 mm intervals. There was a complete occlusion of left anterior descending coronary artery by an embolus of fibrillar foreign material 5 mm from the left coronary ostium (Fig 1). Microscopically, the embolus was composed of relatively uniform fibers, oriented along the long axis of the vessel (Fig 2). The embolic material was histologically identical to fibers of Teflon taken from a piece of Teflon felt used to buttress sutures on the Björk-Shiley valve (Fig 3). The remaining coronary arteries had moderate atherosclerosis with no significant luminal narrowing.

The myocardium was cut transversely at 1 cm intervals and the slices were stained with nitro blue tetrazolium (NBT) (Fig 4). This revealed a large non-staining area in the anterior wall and anterior septum indicating recent myocardial infarct. Microscopically there was extensive eosinophilia of the fibers, disruption of the cross striations, loss of nuclei and margination of polymorphonuclear leukocytes in capillaries near the necrotic muscle. These findings confirmed the presence of a large anterior myocardial infarction less than 24 hours old. Both the age and distribution of the infarct correspond with an occlusive embolus to the left anterior descending coronary artery.

All sections of the myocardium contained small patches of granulation tissue with loss of muscle fibers and a predom-

Teflon felt embolism of coronary arteries after cardiac surgery A case report

Carlos D Bedetti M D
Ralph D Siewers, M D
Harold A Dunsford, M D
Pittsburgh Pa

Teflon felt and mattress sutures buttressed with a small pledget of Dacron or Teflon cloth are commonly used in cardiac surgery. In cardiac valve replacement they are sometimes used to attach the valve prosthesis to the valvular ring and to avoid tearing of the sutures through the annulus. In the case reported here, a piece of Teflon embolized to the left anterior descending coronary artery resulting in complete occlusion and extensive acute myocardial infarction 10 days after the insertion of a Bjork Shiley aortic valve prosthesis. Only two previous documented cases of Teflon embolism of coronary arteries causing myocardial necrosis have been reported.^{1,2} These cases were characterized by multiple embolization of small intramural coronary arteries and arterioles after replacement of individual valve cusps by cusps made of Teflon. This case is unique in that Teflon embolism caused occlusion of an extramural coronary artery resulting in extensive acute myocardial infarction in the occluded artery distribution. This unusual complication has been not previously described with the use of the Bjork Shiley tilting disc valve.

Case report

M G was a 48 year old female with a known heart murmur for 18 years asymptomatic until 2½ years before admission when she developed substernal pressure sensation with exertion. She was treated with digitalis and diuretics. She was admitted to the Departments of Pathology and Surgery, Presbyterian-University Hospital and University of Pittsburgh School of Medicine, Pittsburgh, Pa.

Received for publication Oct. 21, 1977

Accepted for publication Nov. 1, 1977

Reprint requests: Carlos D Bedetti M D, Presbyterian-University Hospital, Department of Pathology, 230 Lothrop Street, Pittsburgh, Pa. 15213

tion progressive shortness of breath, ankle edema and nocturnal dyspnea. She was known to have thalassemia minor and adult onset diabetes mellitus. A left nephrectomy had been done seven years previously for cystic disease and an enlarged liver by biopsy was found to have micronodular cirrhosis and fatty metamorphosis. She had been treated with daily digoxin and diuretics. Blood pressure was 110/60 mm Hg, pulse was regular and she was in no preoperative distress. The heart was clinically enlarged; there was a III/VI holosystolic murmur at the cardiac base radiating to the carotids and a II/VI blowing diastolic murmur present at the low left sternal border and apex of the heart. There was mild hepatosplenomegaly. An electrocardiogram showed a sinus rhythm and nonspecific ST and T wave abnormalities. Chest x ray revealed slight cardiomegaly. Cardiac catheterization showed calcific aortic stenosis and moderate aortic insufficiency. The left ventricular end-diastolic pressure was 18 mm Hg with a cardiac index of 3.02 L/min/M². The coronaries were angiographically normal.

The operation was done with moderate hypothermia and continuous coronary perfusion with a beating heart. The aortic valve had three definite well suspended leaflets with thickened, rolled edges, commissural fusion and calcium deposits. The valve was totally excised removing a portion of the ring beneath the left coronary sinus. This was repaired with two mattress sutures buttressed with Teflon felt. A No. 23 Bjork Shiley aortic valve was placed with interrupted mattress sutures each buttressed with Teflon felt placing these from the ventricular side of the ring through the ring and the sewing ring of the prosthesis.

The postoperative course initially was uncomplicated. She was anticoagulated and ready for discharge on the tenth postoperative day when she developed severe crushing chest pain, tachycardia and mild hypotension. ECGs revealed acute changes of an anterolateral myocardial infarction. The hypotension worsened, ventricular arrhythmias occurred and in spite of pharmacologic support, intra-aortic balloon counterpulsation and respiratory support, she died within 24 hours of the onset of her chest pain. It was suspected clinically that in spite of her anticoagulation with Coumadin which had been in the therapeutic range since her seventh postoperative day, she had suffered a prosthetic thrombus with an embolus to the left coronary artery.

embolism of coronary arteries resulting in myocardial necrosis.^{1,2} These were late complications following individual aortic leaflet replacement by Teflon prosthetic leaflets. The emboli involved multiple small intramural coronary arteries.

Coronary embolism of Teflon material has not been previously reported following the use of Teflon felt buttressed sutures for placement of a Bjork Shiley tilting disc valve. Henze and associates³ reviewed the cause of death and major pathology of the patients following 161 aortic valve replacements with the Bjork Shiley tilting disc valve. Eight of the 161 patients died within 30 days of operation (hospital mortality rate 5 per cent) and 12 patients died after 30 days (7 per cent). Myocardial failure (nine cases) was the prominent cause of death in this series. They encountered no thromboembolic complications in survivors with anticoagulation treatment after insertion of the Bjork Shiley valve in the aortic position. In the case reported here a piece of Teflon felt embolized to the left anterior descending coronary artery resulting in total occlusion and extensive acute myocardial infarction in the distribution of the occluded artery. The source of the embolus was the Teflon felt used to buttress sutures used to hold the valve. These Teflon pledgets lie on the ventricular side in the outflow stream of the left ventricle. The reason for the detachment of a fragment of Teflon felt in this case is unexplained. The clinical and pathologic findings clearly established that the embolism of the occluded artery occurred on the tenth postoperative day and not at the time of surgery. This case demonstrates that the use of Teflon or similar synthetic material in cardiac valve replacement, even with the improved valve prosthesis, should be regarded as a potential embolic source and a rare cause of coronary occlusion.

Summary

A case is presented of fatal coronary embolism of Teflon felt used to buttress sutures in the placement of a Bjork Shiley aortic valve prosthesis. The embolism occurred on the tenth postoperative day lodging in the left anterior descending branch of the left coronary artery 5.5 cm from the ostium causing a large anterior myocardial infarct. The patient died in less than 24 hours following the infarct. A review of the literature indicates that this is the first reported case of clinically significant embolism of Teflon felt used in the placement of a Bjork Shiley aortic valve.

REFERENCES

1. Aguino T I and Skusnes O K. Teflon embolism of coronary arteries: A case report. *Arch Pathol* 80:625 1965.
2. Gonzalez-Crussi F., Mandy M., Johnson J. and Green R. Teflon embolism of coronary arteries. *J Thorac Cardiovasc Surg* 54:53 1967.
3. Nachlas M. M. and Shnitka T. K. Macroscopic identification of early myocardial infarcts by alterations in dehydrogenase activity. *Am J Pathol* 42:379 1963.
4. Henson D. E., Najafi H., Callaghan R., Coogan P., Julian O. C. and Eisenstein R. Myocardial lesions following open heart surgery. *Arch Pathol* 88:473 1969.
5. Morales A. R., Fine G. and Taber R. E. Cardiac surgery and myocardial necrosis. *Arch Pathol (Chicago)* 83:71 1967.
6. Wenger N. K. The heart. third edition. Hurst J. W. ed. New York 1974. pg 114. McGraw-Hill Book Company Inc.
7. Wenger N. K. and Bauer S. Coronary embolism. Review of the literature and presentation of 15 cases. *Am J Med* 25:549 1958.
8. Gobel F. L., Hawkin H. M., Hanson R. and Wang Y. Acute myocardial infarction secondary to thromboembolism from a fractured prosthetic aortic valve. *Circulation* 38:67 1968.
9. Lamkin E. H., Oebler C. and Balslev M. D. Coronary embolization with myocardial infarction. Late complication in a patient with Starr Edwards mitral valve prosthesis. *JAMA* 194:1019 1965.
10. Henze A., Carlsson S. and Bjork V. O. Mortality and pathology following aortic valve replacement with the Bjork Shiley tilting disc valve. *Scand J Thorac Cardiovasc Surg* 7:7 1973.



Fig 3 Photomicrograph of a Teflon felt pledget taken from the patient's aortic valve prosthesis (Hematoxylin and eosin original magnification $\times 60$)



Fig 4 Gross photograph of slices of ventricular myocardium stained with nitro blue tetrazolium (NBT) the pale non staining area (between arrows) is the recent myocardial infarct involving the anterior wall of the left ventricle and anterior portion of the septum

nantly mononuclear infiltrate. These tiny infarcts were approximately two weeks old corresponding to the time of open heart surgery. Multiple foci of cardiac ischemia have been reported in the literature and have been ascribed to open heart surgery.

Other findings included micronodular cirrhosis of the liver, compensatory hypertrophy of the right kidney with mild arteriosclerosis, fatty infiltration of the pancreas and chronic non specific thyroiditis.

Discussion

Coronary embolism is an infrequent cause of myocardial infarction and is listed in standard textbooks as a rare cause of coronary artery disease. Coronary emboli most frequently occlude the left coronary artery particularly its left anterior descending branch. Wenger and Bauer⁷ found 11 cases of coronary artery embolism in 17 469 consecutive autopsy cases at Mt Sinai Hospital, New York for a general necropsy incidence of 0.06 per cent. Despite anticoagulation therapy, thrombosis of the prosthetic valve after cardiac valve replacement is still an important complication and a potential source of systemic or pulmonary embolism. Cases of coronary embolism and myocardial infarction from thrombus following insertion of a Starr Edwards prosthesis have been reported.⁸ Also embolic material such as calcium suture and foreign bodies have been described in small intramural coronary arteries as incidental autopsy findings after open heart surgery.⁹ Two documented cases have been found in the literature of Teflon




Fig 1 Diagram illustrating the operative procedures carried out in the child described RPA and LPA = right and left main pulmonary arteries RA = right atrium LA = left atrium

Table 1 Hemodynamic data in patient T H

Age of study (months)	3		10		19		60		84	
	P	O	P	O	P	O	P	O	P	O
Superior vena cava	—	—	—	—	3	70	5	33	—	—
Right atrial mean	6	4	3	50	3	10	5	33	—	—
Right ventricle	85/10	94	110	—	110/10	86	125/5	44	80/50	60
Pulmonary artery	—	—	—	—	—	—	—	—	—	—
Pulmonary vein	—	97	—	—	8	97	—	—	—	—
Left atrial mean	12	94	9	95	8	97	—	—	—	—
Left ventricle	85/9	93	—	—	—	—	—	—	—	—
Aorta	—	—	150/90	80	110/60	86	125/78	44	170/40	60
qP qS	—	—	—	—	17.1	—	15.4	—	—	—

Abbreviations: P = pressure in mm Hg O = oxygen saturation in per cent qP qS = pulmonary to aortic flow ratio

main pulmonary artery where pressures were elevated. With apparent occlusion of the right subclavian artery by the catheter the child became severely hypoxic and heart beats ceased.

DR ROBERTS: Doctor Chandra, could you summarize the finding at necropsy?

DR. CHANDRA: The findings at necropsy (A 11176) are summarized in Figs 2 to 4. There was corrected or L transposition and common ventricle. The aorta arose anterior to the pulmonary trunk from a small coarsely trabeculated subaortic chamber (right ventricular type). The anatomic left ventricle was on the right. Both

Complex congenital heart disease A multiplicity of therapeutic options

Lewis P Scott, MD*

Roma S Chandra, MD**

William C Roberts, MD***

Washington DC and Bethesda Md

DR ROBERTS In this report, a boy with cyanotic congenital cardiac disease will be presented and problems manifested in him will be discussed. Dr Scott will describe his patient.

DR SCOTT T H (CHNMC No 299 3972) a 7 year old black boy who died in December 1976 was noted to have cyanosis and a precordial murmur at 2 weeks of age. Shortly thereafter signs of congestive heart failure developed. At 3 months of age cardiac catheterization (Table I) provided a diagnosis of transposition of the great arteries with single ventricle. The pulmonary trunk was banded at this time with reduction of the systolic pressure in this artery from 85 to 45 mm Hg (Fig 1). Despite this procedure, however, the child failed to thrive and cyanosis increased. Inadequate intracardiac mixing of blood was considered the reason and accordingly a Rash-

kind atrial septostomy was performed at 8 months of age (Fig 1). The transatrial pressure difference was reduced by this procedure from 9 to 3 mm Hg.

Because of persistent growth failure and cyanosis catheterization was repeated at 19 months of age (Table I). Subsequently, growth continued to be slow, exercise tolerance poor and polycythemia increased. Still another catheterization at 5 years of age disclosed severe reduction in systemic arterial saturation compared to previous studies (Table I). Although the pulmonary trunk was not entered by the catheter, the pressure in the distal pulmonary artery by clinical examination was believed to be low. Accordingly a left subclavian to pulmonary arterial anastomosis was performed (Fig 1). The distal portion of this left subclavian artery, however, thrombosed almost immediately and then a right subclavian to right pulmonary arterial anastomosis was done (Fig 1). This second shunt remained open as evidenced by the development of a continuous murmur over the precordium. Nevertheless cyanosis persisted and polycythemia worsened. Multiple hospitalizations for phlebotomies followed. During the next several months fever periodically appeared and a diastolic basal precordial murmur suggesting aortic regurgitation developed. Blood cultures were always negative and the cause of the recurring fever was never determined.

The last hospitalization was at age 7 years for another cardiac catheterization. Its purpose was to again try to measure the pulmonary arterial pressure and resistance. The right subclavian artery was entered retrogradely from the femoral artery. The catheter was advanced into the right

From the Division of Pediatric Cardiology, Department of Child Health and Development and Department of Pathology, Children's Hospital National Medical Center, Washington DC. The Departments of Pediatrics and Pathology, George Washington University School of Medicine, Washington DC, and the Pathology Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland.

Received for publication Nov 15 1977.

Reprint requests: William C Roberts, MD, Chief Pathology Branch, NIH, National Heart Lung and Blood Institute, Bethesda, Md 20014.

Chief, Department of Cardiology, Children's Hospital National Medical Center and Professor, Department of Child Health and Development, George Washington University School of Medicine, Washington DC.

Chairman, Department of Anatomical Pathology, Children's Hospital National Medical Center and Associate Professor of Pathology and of Child Health and Development, George Washington University School of Medicine, Washington DC.

Chief Pathology Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, and Clinical Professor of Pathology and Medicine (Cardiology), George Washington University, Washington DC.




Fig 1 Diagram illustrating the operative procedures carried out in the child described RPA and LPA = right and left main pulmonary arteries RA = right atrium LA = left atrium

Table 1 Hemodynamic data in patient T H

Age at study (months)	3		10		19		60		84	
	P	O	P	O	P	O	P	O	P	O
Superior vena cava	—	—	—	—	3	70	5	33	—	—
Right atrial mean	6	47	8	50	3	70	8	33	—	—
Right ventricle	85/10	88	110	—	110/10	86	125/5	44	80/50	60
Pulmonary artery	—	—	—	—	—	—	—	—	—	—
Pulmonary vein	—	97	—	—	8	97	—	—	—	—
Left atrial mean	12	94	9	95	8	97	—	—	—	—
Left ventricle	55/9	93	—	—	—	—	—	—	—	—
Aorta	—	—	150/90	80	110/60	86	125/28	44	120/40	60
qP qS	—	—	—	—	171	—	154	—	—	—

Abbreviat P = pressure in mm Hg O = oxygen saturation in per cent qP qS = pulmonary artery to-system cardiac output

main pulmonary artery where pressures were elevated. With apparent occlusion of the right subclavian artery by the catheter the child became severely hypoxic and heart beats ceased.

DR ROBERTS: Doctor Chandra, could you summarize the finding at necropsy?

DR CHANDRA: The findings at necropsy (A 11176) are summarized in Figs 2 to 4. There was corrected or L transposition and common ventricle. The aorta arose anterior to the pulmonary trunk from a small coarsely trabeculated subaortic chamber (right ventricular type). The anatomic left ventricle was on the right. Both

Complex congenital heart disease A multiplicity of therapeutic options

Lewis P Scott, MD*

Roma S Chandra, MD**

William C Roberts MD***

Washington DC and Bethesda Md

DR ROBERTS In this report, a boy with cyanotic congenital cardiac disease will be presented and problems manifested in him will be discussed. Dr Scott will describe his patient.

DR SCOTT T H (CHNMC No 299 3972) a 7 year old black boy who died in December 1976 was noted to have cyanosis and a precordial murmur at 2 weeks of age. Shortly thereafter signs of congestive heart failure developed. At 3 months of age, cardiac catheterization (Table I) provided a diagnosis of transposition of the great arteries with single ventricle. The pulmonary trunk was banded at this time with reduction of the systolic pressure in this artery from 85 to 45 mm Hg (Fig 1). Despite this procedure however the child failed to thrive and cyanosis increased. Inadequate intracardiac mixing of blood was considered the reason and accordingly a Rash-

kind atrial septostomy was performed at 9 months of age (Fig 1). The transatrial pressure difference was reduced by this procedure from 9 to 3 mm Hg.

Because of persistent growth failure and cyanosis, catheterization was repeated at 19 months of age (Table I). Subsequently, growth continued to be slow, exercise tolerance poor, and polycythemia increased. Still another catheterization at 5 years of age disclosed severe reduction in systemic arterial saturation compared to previous studies (Table I). Although the pulmonary trunk was not entered by the catheter, the pressure in the distal pulmonary artery, by clinical examination, was believed to be low. Accordingly, a left subclavian to pulmonary arterial anastomosis was performed (Fig 1). The distal portion of this left subclavian artery however thrombosed almost immediately and then a right subclavian to right pulmonary arterial anastomosis was done (Fig 1). This second shunt remained open as evidenced by the development of a continuous murmur over the precordium. Nevertheless cyanosis persisted and polycythemia worsened. Multiple hospitalizations for phlebotomies followed. During the next several months fever periodically appeared and a diastolic basal precordial murmur suggesting aortic regurgitation developed. Blood cultures were always negative and the cause of the recurring fever was never determined.

The last hospitalization was at age 7 years for another cardiac catheterization. Its purpose was to again try to measure the pulmonary arterial pressure and resistance. The right subclavian artery was entered retrogradely from the femoral artery. The catheter was advanced into the right

From the Division of Pediatric Cardiology, Department of Child Health and Development and Department of Pathology, Children's Hospital National Medical Center, Washington DC. The Departments of Pediatrics and Pathology, George Washington University School of Medicine, Washington DC, and the Pathology Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland.

Received for publication Nov 15 1977.

Reprint requests: William C Roberts MD, Chief Pathology Branch, NIH National Heart Lung and Blood Institute, Bethesda, Md 20014.

Chief, Department of Cardiology, Children's Hospital National Medical Center and Professor, Department of Child Health and Development, George Washington University School of Medicine, Washington DC.

Chairman, Department of Anatomical Pathology, Children's Hospital National Medical Center and Associate Professor of Pathology and of Child Health and Development, George Washington University School of Medicine, Washington DC.

Chief Pathology Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland and Clinical Professor of Pathology and Medicine (Cardiology), Georgetown University, Washington DC.




Fig 3 Diagram showing the change in intracardiac blood flow which occurred before any cardiac operation (left) and after complete occlusion of the pulmonary trunk by the banding procedure (right)

DR ROBERTS As I understand it Dr Scott you did the last cardiac catheterization on this child to see if the pulmonary arterial pressure was elevated and indeed you did find that the pressure in this artery was quite elevated. Yet at necropsy the pulmonary arteries in both lungs were devoid of changes suggestive of pulmonary hypertension. Indeed many of the pulmonary arteries showed changes suggestive of pulmonary hypotension rather than hypertension. What is your explanation for the finding of pulmonary hypertension in this child at the final catheterization?

DR SCOTT It is apparent from the necropsy findings that there was no pulmonary blood flow entering the lesser circuit from the right ventricular outflow tract. The only perfusion of the pulmonary circuit was through the right subclavian anastomosis and bronchial vessels. With the catheter in the right subclavian artery pulmonary blood flow apparently was severely decreased. In all probability near occlusion of the right subclavian artery by the catheter produced acute hypoxia which caused severe spastic constriction of the smaller pulmonary arteries and arterioles resulting in severe elevation of the pulmonary arterial pressure.

DR ROBERTS Dr Scott I believe you were quite concerned with the increasing polycythemia in this child during his last several years and consequently several therapeutic phlebotomies were performed. What are your indications today for doing phlebotomy in individuals with cyanotic congenital heart disease?

DR SCOTT With rising hematocrit the resulting

increased viscosity in blood can induce intravascular thrombosis in both pulmonary and systemic vessels. When a child develops hematocrit values above 65 per cent we usually recommend phlebotomy. By reducing viscosity the tendency for intravascular thrombosis is reduced and in addition the stroke work of the ventricle is reduced and consequently cardiac output improves.

DR ROBERTS Dr Scott suppose that in this patient the banding procedure had been ideal, i.e. the pulmonary arterial pressure distal to the band was normal and that growth and development progressed well. Had that occurred what would have been your subsequent plan for this child?

DR SCOTT There are several options open to the cardiologist and cardiovascular surgeon today. None of these options however are truly optimal and I would not recommend any of them as long as the patient was relatively asymptomatic and grew normally. In the event that deterioration began a total corrective operation wherein a ventricular septum would be created assuming of course that two well developed atrioventricular valves existed should be considered. At the same time one would have to remove the band on the pulmonary trunk. A second option would be a modified Fontan operation: the tricuspid valve orifice would be closed and a conduit connected from the right atrial appendage to the distal pulmonary artery. To carry out such a procedure pulmonary vascular resistance would have to be low and the function of the single ventricle would have to be excellent. Before performing the Fontan operation the right pulmonary artery




Fig 2 Diagram summarizing the operative procedures carried out on the pulmonary trunk and main right (RPA) and left (LPA) pulmonary arteries and their consequences

atrioventricular valves entered the large ventricle which anatomically was left ventricular in type. The coronary arteries were mirror image of normal (Fig 4). On the ventricular aspects of each of the three cusps of the aortic valve small bumps composed mainly of fibrous tissue but also some calcific deposits, were present. The pulmonary trunk was totally occluded by fibrous tissue at the site of the banding. The distal portion of the left subclavian artery also was occluded by fibrous tissue (resulting from organization of thrombus) just proximal to its anastomosis to the left main pulmonary artery. The right subclavian artery was wide open. Histologic examination of sections from both lungs showed entirely normal pulmonary arteries and arterioles.

DR ROBERTS: This child's course and therapeutic interventions raise questions regarding management of patients with cyanotic congenital heart disease secondary to complex malformations. This boy's early course was characterized by evidence of excessive pulmonary blood flow and consequently the pulmonary trunk was banded. His course thereafter was characterized by evidence of inadequate pulmonary blood flow and consequently attempts (Blalock-Taussig anastomoses) were made to increase pulmonary blood flow. Dr Scott, I am aware that the banding of the pulmonary trunk in this child was

done before the child presented to you. If however, we could start again in this child what would be the initial operative procedure you would recommend and why?

DR SCOTT: Our major concern in a child presenting with pulmonary overflow associated with single ventricle and transposition is to control congestive heart failure and to prevent growth failure the usual major presenting problems in this situation. Over the long run of course prevention of the development of pulmonary vascular disease is essential. Consequently banding of the pulmonary trunk remains an excellent procedure to reduce congestive cardiac failure and prevent growth failure. In the presence of moderately elevated left atrial pressures however, we would perform atrial septostomy at the time of the initial cardiac catheterization. There appears to be a relationship between the elevation of the left atrial pressure and the rapidity with which the pulmonary vascular disease develops.

DR ROBERTS: Dr Scott, why does pulmonary vascular disease develop so rapidly as a rule in the child with single ventricle and transposed great arteries?

DR SCOTT: There are multiple factors. The high pressure and flow through the pulmonary arteries are certainly major contributors to the induction of these vascular changes. Just as important however are the left atrial pressure and the presence of hypoxic blood in the bronchial circulation.

DR ROBERTS: The banding of the pulmonary trunk in this child diminished the pulmonary arterial systolic pressure measured at the time of operation from approximately 85 to 45 mm Hg. Yet by the time necropsy was performed nearly six years later the pulmonary trunk was totally obstructed at the site of the band. Dr Scott, do you have an explanation for this acquired atresia of the pulmonary trunk at the site of banding?

DR SCOTT: I have never observed a patient previously in whom banding of the pulmonary trunk progressed to total occlusion of its lumen. It is recognized that total obstruction to right ventricular outflow may occur in a patient with tetralogy of Fallot who has had a systemic to pulmonary arterial shunt created operatively. What caused the especially severe fibrosis around the band in the present patient with eventual total occlusion of the pulmonary trunk is unclear.

Coagulation for cardiologists

Stanford Wessler M D
Sanford N Gitel Ph D
New York N Y

Vascular patency depends upon the balance between at least six subtly interrelated systems each of which in itself is exceedingly complex. These include the endothelium and its subjacent structures the platelets the coagulation and fibrinolytic systems the inhibitors of these latter systems and the flow characteristics of blood within the circulation. Alterations of the rather delicate balance among these hemostatic systems can result in serious hemorrhage or major thromboembolism. In the discussion that follows the focus will be directed to the issue of thrombosis and its management.

Basic aspects of hemostasis as they relate to thrombosis

The endothelium and the platelet. Intact endothelial cells prevent platelet aggregation by at least two mechanisms. They act as a physical barrier between thrombocytes and subendothelial structures such as collagen, which can initiate platelet aggregation; they also have the capacity to synthesize a prostaglandin, prostacyclin (PGI_2), that is a potent inhibitor of platelet aggregation.

Damage or disruption of the integrity of the endothelial cell by a variety of agents can initiate thrombosis, a phenomenon that may potentiate the earliest phase of atherosclerosis. Though platelets do not attach to intact endothelial cells, they do adhere to exposed collagen when the endothelial barrier is disrupted, whereupon the

platelet undergoes a series of changes termed the release reaction. Included in this reaction is the release from platelet storage pools of ADP which causes additional reversible thrombocyte aggregation and further release of ADP thus sustaining the initial platelet aggregation¹ that is still reversible. Platelet aggregation moreover results in the release of phospholipid (platelet factor 3), an element essential to the coagulation process.

The exposed subendothelial structures in addition to their effect on platelet function also activate the clotting sequence leading to the production of thrombin, a serine protease that forms fibrin from fibrinogen. Thrombin can also induce irreversible platelet aggregation by initiating the synthesis of thromboxane A_2 ¹⁰ as well as platelet actomyosin contraction¹¹ which along with the production of fibrin consolidates the platelet plug. This description of platelet function has relevance to the prevention of arterial thrombosis.

The coagulation system. The coagulation system has been depicted as a series of proenzyme to activated enzyme transformations¹² that involve biochemical amplification. Such a sequence allows a relatively few molecules of a clot initiator to produce a biochemically explosive amount of thrombin in a short period of time.

Blood clotting can be precipitated either by contact activation (the intrinsic system, Fig 1) or by traumatic release of tissue thromboplastin (the extrinsic system, Fig 1). The two systems converge at factor X and continue along a common pathway to fibrin formation.

In the intrinsic system clotting is initiated by the adsorption of factor XII onto a foreign surface such as collagen¹³. Both kallikrein and

The relationship of the various clotting factors can be followed by referring to Fig 1.

From the Department of Medicine, New York University School of Medicine, New York, N Y.

Supported by National Heart, Lung, and Blood Institute Grant No. 2 R01 HL 18333 and National Institute of Health, Dept. of Health, Education, and Welfare.

Received for publication April 24, 1978.

Reprint requests: Stanford Wessler, MD, Professor of Medicine, School of Medicine, New York University, 550 First Avenue, New York, N Y 10016.




Fig 4 Drawings showing the various intrathoracic cardiovascular malformations observed in the patient described. The aorta arises anteriorly and from a small subaortic chamber. The large ventricle located mainly on the right side has the interior lining of an anatomic left ventricle. The coronary arteries are mirror image of normal.

should be anastomosed to the superior vena cava. Had the Blalock-Taussig anastomoses already been performed, a third operative option would be to reanastomose or close off the anastomoses and perform a Waterston type shunt between ascending aorta and pulmonary artery.

DR ROBERTS: Dr Scott, I understand that a basal diastolic blowing murmur was audible in this child during the last few months of life. What was your explanation for this murmur?

DR SCOTT: I initially thought that the diastolic murmur was produced by insufficiency of the pulmonic valve. As the aortic diastolic pressure began to fall, however, it was apparent that this murmur was due to runoff through the aortic valve. On several occasions, this patient had fever for rather protracted periods. Multiple blood cultures were obtained, but all were negative. Short-term courses of antibiotics for upper respiratory tract and ear infections probably allowed

cure of the probable associated infective endocarditis, which caused the aortic regurgitation.

DR ROBERTS: At necropsy, there were lesions on each of the three aortic valve cusps which were consistent with healed infective endocarditis. Occurrence of infective endocarditis in children is quite unusual. Those with endocarditis in childhood nearly always have underlying congenital heart disease, but, in contrast to this child, it is usually of the acyanotic variety.

REFERENCES

1. Roberts W C, Friesinger C C, Cohen L S, Mason D T, and Ross H S. Acquired pulmonic atresia. Total obstruction to right ventricular outflow after systemic to pulmonary arterial anastomoses for cyanotic congenital cardiac disease. *Am J Cardiol* 24:33, 1969.
2. Roberts W C, and Buchbinder N A. Healed left-sided infective endocarditis. A clinicopathologic study of 39 patients. *Am J Cardiol* 40:876, 1977.
3. Arnett F N, and Roberts W C. Active infective endocarditis. A clinicopathologic analysis of 137 necropsy patients. *Curr Probl Cardiol* 11:1976 (October).

Coagulation for cardiologists

Stanford Wessler M.D.
Sanford N. Gitel Ph.D.
New York, N.Y.

Vascular patency depends upon the balance between at least six subtly interrelated systems each of which in itself is exceedingly complex. These include the endothelium and its subjacent structures, the platelets, the coagulation and fibrinolytic systems, the inhibitors of these latter systems, and the flow characteristics of blood within the circulation. Alterations of the rather delicate balance among these hemostatic systems can result in serious hemorrhage or major thromboembolism. In the discussion that follows, the focus will be directed to the issue of thrombosis and its management.

Basic aspects of hemostasis as they relate to thrombosis

The endothelium and the platelet. Intact endothelial cells prevent platelet aggregation by at least two mechanisms. They act as a physical barrier between thrombocytes and subendothelial structures such as collagen which can initiate platelet aggregation; they also have the capacity to synthesize a prostaglandin, prostacyclin (PGI₂), that is a potent inhibitor of platelet aggregation.

Damage or disruption of the integrity of the endothelial cell by a variety of agents can initiate thrombosis, a phenomenon that may potentiate the earliest phase of atherosclerosis. Though platelets do not attach to intact endothelial cells, they do adhere to exposed collagen when the endothelial barrier is disrupted, whereupon the

platelet undergoes a series of changes termed the release reaction. Included in this reaction is the release from platelet storage pools of ADP which causes additional reversible thrombocyte aggregation and further release of ADP thus sustaining the initial platelet aggregation; that is still reversible. Platelet aggregation moreover results in the release of phospholipid (platelet factor 3), an element essential to the coagulation process.¹

The exposed subendothelial structures in addition to their effect on platelet function also activate the clotting sequence leading to the production of thrombin, a serine protease that forms fibrin from fibrinogen. Thrombin can also induce irreversible platelet aggregation by initiating the synthesis of thromboxane A₂¹⁰ as well as platelet actomyosin contraction¹¹ which along with the production of fibrin consolidates the platelet plug. This description of platelet function has relevance to the prevention of arterial thrombosis.

The coagulation system. The coagulation system has been depicted as a series of proenzyme to activated enzyme transformations¹² that invoke biochemical amplification.¹³ Such a sequence allows a relatively few molecules of a clot initiator to produce a biochemically explosive amount of thrombin in a short period of time.

Blood clotting can be precipitated either by contact activation (the intrinsic system, Fig. 1) or by traumatic release of tissue thromboplastin (the extrinsic system, Fig. 1). The two systems converge at factor X and continue along a common pathway to fibrin formation.

In the intrinsic system, clotting is initiated by the adsorption of factor XII onto a foreign surface such as collagen. Both kallikrein and

¹The relative types of the various clotting factors can be followed by referring to Fig. 1.

From the Department of Medicine, New York University School of Medicine, New York, N.Y.

Supported by National Heart, Lung, and Blood Institute Grant No. 2 R01 HL 18333, National Institutes of Health, Department of Health, Education and Welfare.

Received for publication April 24, 1978.

Reprint requests: Stanford Wessler, M.D., Professor of Medicine, School of Medicine, New York University, 550 First Avenue, New York, N.Y. 10016.




Fig 1 Relationships of the various clotting factors. Abbreviations: *HMW kininogen* = high molecular weight kininogen; *PL* = phospholipid; *TPL* = tissue thromboplastin. The subscript *a* indicates that the protein has been activated. Vitamin K-dependent zymogens are Factors VII, IX, X, and II (Prothrombin). XIIa, XIa, IXa, Xa, and thrombin can be inhibited by antithrombin III, and the rate of this inhibition is accelerated by heparin. Factors V and VIII attain maximum cofactor activity after activation by thrombin.

high molecular weight kininogen are required for the rapid surface activation of factor XII to an activated serine protease XIIa.^{15,17} In addition, high molecular weight kininogen increases the reactivity of XIIa in the conversion of factor XI to its activated form XIa.

XIa itself a serine protease converts factor IX to an activated serine protease IXa. Then factors VIII and IXa form a complex which results in the activation of factor X.¹⁸ Both phospholipid, made available by aggregated platelets, and Ca⁺⁺ are essential to activate factor X at a maximum rate.¹⁹ Subsequently, the serine protease Xa, in the presence of factor V, Ca⁺⁺, and phospholipid, converts prothrombin to thrombin.^{20,21}

The extrinsic system is triggered by the release of tissue thromboplastin, a protein-phospholipid mixture that activates factor VII.²² Together they serve as cofactors with Ca⁺⁺ for the activation of factor X. Once Xa is formed, thrombin production proceeds as described above.

Thrombin is the final serine protease formed in the coagulation sequence. It cleaves fibrinogen to fibrin, induces platelet aggregation, and activates factor XIII to XIIIa, a transamidase that covalently

links fibrin monomers into a fibrin mesh in the presence of Ca⁺⁺. Thrombin is also capable of activating factors VIII¹ and V¹⁸ from either inactive or partially active forms to highly reactive molecules. Thus, for the coagulation system to function at its maximum potential, minute amounts of thrombin are required.

In general, coagulation can be viewed as a series of zymogen activations to serine proteases that are enhanced by Ca⁺⁺, phospholipids, and regulatory proteins. The sequential activation contributes to an amplification of the thrombotic stimulus¹² so that a sufficient amount of thrombin is produced to form a stable thrombus. These biochemical reactions also have therapeutic implications.

The fibrinolytic system. Plasminogen, a proenzyme normally present in plasma, can be converted to the active enzyme plasmin. This conversion is induced by an activator present in most body tissues including endothelial cells. The release of this activator is mediated by either XIIa, thrombin, or hypoxia. Plasmin, a serine protease enzymatically, cleaves fibrin into soluble fragments. Besides degrading fibrin, plasmin can also degrade fibrinogen, prothrombin, and factors

VIII and V. Thus it might appear that the use of a fibrinolytic agent could be a double edged sword removing thrombi once their physiological role in hemostasis had been completed yet causing hemorrhage because of the degradation of clotting proteins other than fibrin that are essential to the integrity of the vascular tree—a dilemma that is amenable to solution but posed in different ways and to different degrees by all pharmacological agents that affect the hemostatic balance.

Inhibitory systems Normal human plasma contains several serine protease inhibitors capable of neutralizing activated clotting species. The only inhibitor in this group whose concentration and activity have been correlated with a thrombotic disorder is antithrombin III. This α_2 globulin with a molecular weight of 63 000 has a major role in maintaining the fluidity of the blood.¹ In purified systems antithrombin III inhibits thrombin and Xa. At significantly slower reaction rates this α_2 globulin also inhibits XIIIa, XIa and IXa. Antithrombin III forms an undissociable complex with activated clotting factors in which one molecule of antithrombin III forms a covalent ester linkage at the active site of the protease.

Although antithrombin III will also inhibit the serine protease plasmin, other inhibitors such as α_2 macroglobulin² and a specific plasmin inhibitor α_2 plasmin inhibitor are more effective in preventing the action of circulating plasmin. Since plasmin is readily blocked in the circulation only plasmin produced or localized within the thrombus facilitates clot dissolution. Several mechanisms whereby this may occur have been postulated.

These inhibitors also have important therapeutic roles.

Blood flow Although the relationship between various parameters of blood flow and thrombosis are still being unravelled there are some generalizations that can be provided. Retarded blood flow while it cannot cause intravascular coagulation does facilitate the thrombotic process once it is initiated. Stasis can occur not only in veins but also in arteries at bends and bifurcations. If a platelet or other thrombus is effective in halting or nearly halting the flow of blood such static movement will facilitate the thrombotic process by mechanically protecting it from being washed away by fluid blood. From fluid mechanics it can

be proposed that in areas of retarded flow thrombus evolution would be favored in the plasma phase within the static red cell network because thrombin and other serine proteases would be protected from dilution to subcritical concentrations from inflow of plasma inhibitors and from clearance of proteases by the liver whereas nascent fibrin would be protected from premature dispersion. It is formulations such as this that justify efforts at least in the peripheral venous circulation where such an approach is feasible to reduce or prevent thrombosis by mechanical devices that accelerate venous blood flow either in place of or in conjunction with antithrombotic agents.

The pharmacology of antithrombotic agents

There are presently available several classes of drugs which have been used to inhibit or control thrombosis. These include platelet antiaggregants such as aspirin, dipyridamole (Persantine) and sulfinpyrazone (Anturane), vitamin K antagonists such as warfarin (Coumadin), antithrombin III potentiators such as heparin, plasminogen activators such as streptokinase and urokinase, depleters of fibrinogen such as anicrod and the dextrans which have a variety of potentially antithrombotic actions.

Platelet antiaggregants

Aspirin This drug has been shown to inhibit prostaglandin synthesis in platelets. Aspirin acetylates a protein prostaglandin cyclooxygenase³ thereby irreversibly inhibiting this enzyme and blocking synthesis of prostaglandin endoperoxides which are potent platelet aggregants. Aspirin also partially blocks the production of thromboxane A₂, another potent platelet aggregant.

On the other hand aspirin also blocks prostaglandin synthesis in endothelial cells. One of these endothelial prostaglandins, PGI₂, is a potent platelet antiaggregant. By blocking the synthesis of PGI₂ one may possibly counteract the anticoagulant effect of aspirin on the platelet. Whether these two opposite effects can be separated by a proper choice of dose is presently unknown. The value of aspirin as an antithrombotic agent may be determined by the results of ongoing trials.

As stated previously, aspirin inhibition is irreversible⁴ accounting for the duration of the effect of this compound on platelet function for the




Fig. 1 Relationships of the various clotting factors. Abbreviations: HMW kinogen = high molecular weight kininogen; PL = phospholipid; TPL = tissue thromboplastin. The subscript *a* indicates that the protein has been activated. Vitamin K-dependent zymogens are Factors VII, IX, X, and II (Prothrombin). VII_a, IX_a, X_a, and thrombin can be inhibited by antithrombin III and the rate of this inhibition is accelerated by heparin. Factors I and VIII attain maximum cofactor activity after activation by thrombin.

high molecular weight kininogen are required for the rapid surface activation of factor XII to an activated serine protease XII_a. In addition, high molecular weight kininogen increases the reactivity of XII_a in the conversion of factor XI to its activated form XI_a.

XI_a itself a serine protease converts factor IX to an activated serine protease IX_a. Then factors VIII and IX_a form a complex which results in the activation of factor X. Both phospholipid made available by aggregated platelets and Ca⁺⁺ are essential to activate factor X at a maximum rate.¹ Subsequently, the serine protease X_a, in the presence of factor V, Ca⁺⁺, and phospholipid, converts prothrombin to thrombin.¹

The extrinsic system is triggered by the release of tissue thromboplastin, a protein-phospholipid mixture that activates factor VII. Together they serve as cofactors with Ca⁺⁺ for the activation of factor X. Once X_a is formed, thrombin production proceeds as described above.

Thrombin is the final serine protease formed in the coagulation sequence. It cleaves fibrinogen to fibrin, induces platelet aggregation, and activates factor XIII to XIII_a, a transamidase that covalently

links fibrin monomers into a fibrin mesh in the presence of Ca⁺⁺. Thrombin is also capable of activating factors VIII and V from either inactive or partially active forms to highly reactive molecules. Thus, for the coagulation system to function at its maximum potential, minute amounts of thrombin are required.

In general, coagulation can be viewed as a series of zymogen activations to serine proteases that are enhanced by Ca⁺⁺, phospholipids, and regulatory proteins. The sequential activation contributes to an amplification of the thrombotic stimulus, so that a sufficient amount of thrombin is produced to form a stable thrombus. These biochemical reactions also have therapeutic implications.

The fibrinolytic system. Plasminogen, a proenzyme normally present in plasma, can be converted to the active enzyme plasmin. This conversion is induced by an activator present in most body tissues, including endothelial cells. The release of this activator is mediated by either VII_a, thrombin, or hypoxia. Plasmin, a serine protease, enzymatically cleaves fibrin into soluble fragments. Besides degrading fibrin, plasmin can also degrade fibrinogen, prothrombin, and factors

Dextran In its original form dextran is a branched polysaccharide of about 200 000 glucose units with a molecular weight of approximately 40 million. The glucose units in the main chain are bound together through 16 glucosidic linkages; those in shorter branches through 14 linkages. By means of partial hydrolysis and subsequent fractionation native dextran can be converted to polysaccharides of any desired range of molecular weight. In general it is fair to say that clinical complications increase with higher average molecular weight, broader molecular weight distribution and a more pronounced degree of branching of the molecule. The two most important preparations currently in use are a 70 000 molecular weight preparation with the trade name Macrodex or Dextran 70 and a 40 000 molecular weight compound known as Rheoma, crodex or Dextran 40.

Fibrin deposited in the presence of dextran is morphologically different from fibrin in normal clots, resulting in a decrease in its mechanical strength and an increase in its porosity.¹¹ These properties favor both the inability of the fibrin clot to withstand shear stress in flowing blood and the rate at which fibrinolysis can occur. Dextran also decreases platelet aggregability. On the other hand dextran increases the rate of blood flow which may particularly in cardiac patients precipitate pulmonary edema. The drug may also induce allergic reactions.

Venoms Various snake venoms have striking effects on the coagulation and fibrinolytic systems. The venom from the Malayan pit viper contains a protein anserod that is capable of converting plasma fibrinogen to fibrin.¹² However since factor XIII is not activated the resulting fibrin cannot form a stabilized precipitate. Accordingly the unstabilized thrombus can be readily broken up and promptly removed from the circulation.¹³ In man the intravenous administration of anserod produces a rapid decrease in plasma fibrinogen which results in an hypocoagulable state that can prevent thrombosis but also produces hemorrhage at venipuncture sites as well as easy bruising. Although used abroad the drug has not yet received FDA approval and consequently is not presently available for clinical use in the United States.

Clinical status of antithrombotic agents

Platelet antiaggregants On the basis of the role of the platelet in hemostasis and the failure

of heparin or the coumarin drugs to prevent arterial thrombosis it is natural that increasing knowledge of the pharmacology of several platelet antiaggregating agents should suggest that these drugs may have important therapeutic implications for the prevention of arterial thrombosis. Most of the studies have been conducted in vitro or in animals but in recent years some of these agents have been subjected to clinical trials, several of them still ongoing. Thus although there is little question that the issue of preventing arterial thrombosis with platelet antiaggregants is currently an exciting area of antithrombotic clinical investigation, the published data require that enthusiasm be tempered with patience.

Aspirin There have been several reports on the use of aspirin in patients with transient ischemic attacks (TIA). The goals were cessation of subsequent TIA, prevention of stroke (for which TIA is prodromal) and a decrease in mortality rate (much of which comes from heart disease rather than from cerebrovascular accidents). These publications consist of case reports, retrospective and prospective trials.¹⁴

One stimulus for these trials has come from a variety of reports suggesting that aspirin users have a remarkably low incidence of coronary artery disease. In one of these studies¹⁵ the incidence of TIA was significantly reduced but comparable advantages for stroke and mortality rate were not obtained. In addition the soundness of the trial design itself has been questioned.¹⁶ Further trials involving aspirin are currently in progress however and when they are reported a more definite answer to the value of aspirin may emerge than is presently available.

As in TIA the benefit of aspirin in myocardial infarction is still being evaluated in regard to recurrent infarction and mortality rate. Two completed trials showed favorable trends but did not reach statistical significance.^{17,18} Two secondary prevention trials now in progress are evaluating the efficacy of aspirin among patients who have recovered from acute myocardial infarction. Their findings are awaited with great interest.

On the other hand in arteriovenous shunts among patients on hemodialysis¹⁹ and in hemodialyzers²⁰ aspirin does appear to have significantly reduced the incidence of thrombosis.

Aspirin in combination with dipyridamole has corrected platelet consumption observed among patients with prosthetic heart valves.²¹ The role of aspirin alone on this effect is unknown and

lifetime of the thrombocyte (seven to ten days). Presumably the effect on endothelial cells is also irreversible and would be lost only when new endothelial cells replace the aspirin affected ones.

Sulfinpyrazone This drug is a uricosuric agent used in the treatment of gout. The compound is a potent competitive inhibitor of platelet prostaglandin synthetase activity.³¹ However, unlike aspirin the effect is only transient. The *in vitro* effect of this agent is most marked when aggregation is induced by dilute collagen suspensions.³² The effect of sulfinpyrazone on endothelial prostaglandin synthesis, specifically PGI₂, has not yet been determined.

Dipyridamole This compound *in vitro* inhibits ADP induced platelet aggregation³³ as well as the platelet release reaction.³⁴ The drug blocks platelet cyclic AMP phosphodiesterase activity, thereby inhibiting the conversion of cyclic AMP to AMP.³⁵ The mechanism whereby dipyridamole inhibits platelet aggregation is still to be determined.

Heparin Heparin is a glycosaminoglycan widely distributed in animal tissues that is chemically heterogeneous and exhibits polydispersion in molecular weight. A property of the heparin molecule essential to its anticoagulant activity is the presence of N sulfate groups on the 2 amino 2 deoxy hexose components as well as O sulfate moieties on the L iduronic acid and the amino hexose residues. As an illustration of the complex nature of heparin, electrofocusing of the compound has identified 21 components in a single heparin sample.

The function of heparin as an anticoagulant is to accelerate antithrombin III neutralization of the clotting serine proteases. Thus heparin has a major role in preventing thrombosis initiated via the intrinsic clotting system as well as in the final common pathway leading to fibrin gel formation and irreversible platelet aggregation. In this role heparin acts as a catalyst³⁶⁻³⁹ requiring antithrombin III for its efficacy and increasing the rate of the inhibitor-protease reaction without being consumed and without altering the final products of the reaction.⁴⁰

Coumarin compounds Two comprehensive reviews of the mechanism of action of coumarin compounds and their effect on coagulation have recently been published.^{41,42} Warfarin (one of the more frequently used coumarin drugs in this country) acts as an anticoagulant by inhibiting

the carboxylation of glutamic acid to γ carboxy glutamic acid residues. The presence of γ carboxyglutamic acid imparts two essential properties to the K dependent clotting zymogens: the proteins bind Ca²⁺ in the physiologic range and also bind to a negatively charged phospholipid surface in the presence of Ca²⁺. In man the noncarboxylated proteins are released into the circulation. Thus, warfarin alters the synthesis of four K dependent zymogens: factors II, VII, IX and X. Although the prothrombin time reflects changes in factors II, VII, and X and is used effectively as a guide to dosage of the oral anticoagulants, the warfarin induced changes in these zymogens have never been correlated with the prevention of thrombosis in man or experimental animals. Recently, several additional vitamin K dependent proteins have been isolated from plasma.⁴³⁻⁴⁶ One is capable of being activated to a protease that resembles the K dependent clotting factors and can degrade factor V⁴⁷ thus inhibiting coagulation, a second appears to have an effect on the heparin-antithrombin III reaction.⁴⁸ The clinical roles of these recently identified proteins are yet to be determined.

Fibrinolytic agents For almost 50 years it has been known that streptococci produced an enzyme that lysed fibrin⁴⁹ and for nearly 20 years it has been known that this material streptokinase can potentiate the dissolution of thrombi in man. It was also recognized that urokinase, an enzyme produced by the kidney and found in human urine, has the capacity to potentiate the dissolution of clots.

Both proteins, as activators of the fibrinolytic system, act by combining with plasminogen to form a 1:1 complex of activator and plasminogen which by proteolytic cleavage converts plasminogen to plasmin.⁵⁰ Dissolution of the thrombus probably results from the action of either the activator or the formed plasmin within the thrombus. The enzymatic effect of plasmin on zymogens in flowing blood is usually feeble because of the presence of plasmin inhibitors in the circulation. Immunological problems complicate the use of streptokinase. Moreover, in patients with recent streptococcal infection a large loading dose of the drug may be required to overcome the immunological inhibition of streptokinase action and, in some of these patients streptokinase may be ineffective in therapeutic doses. Streptokinase is more readily and more inexpensively produced than urokinase.

prior to therapy that is increased after heparin administration will demonstrate that heparin is circulating. One study has claimed that if the partial thromboplastin time is not maintained above a given level in heparinized patients the likelihood of thrombosis is increased.⁸ Nevertheless in an individual patient there is as yet no technique for determining the minimum amount of heparin necessary to prevent further thrombosis. The issue is further complicated particularly in the first few days of therapy by the fact that it is not possible to distinguish progression of thrombosis from fracture of a leg vein thrombus and its subsequent passage to the lung—a phenomenon unaffected by anticoagulant drugs.

Hemorrhage while it complicates dosage schedule at the same time simplifies the decision making process for in reality risk of hemorrhage controls dosage at least after 48 hours of heparinization. It is rare in a hemostatically competent patient to encounter spontaneous hemorrhage during the first 48 hours^{9,10} of a regimen of 30 000 to 40 000 units of heparin per day. Subsequently the risk is real and unpredictable even by the partial thromboplastin time. This risk can be aggravated by the administration of aspirin or other platelet antiaggregants by heparin associated thrombocytopenia and by trauma from surgery, invasive vascular procedures, intramuscular injections¹¹ and the occasional reported and unreported minor injuries that hospitalized patients may sustain. Some protection from the consequences of hemorrhage can be obtained by minimizing these traumatic events and by frequent hematocrit determinations and platelet counts.

It is for the reasons just mentioned that the dose of heparin in the majority of patients should be reduced after 48 hours to the range of 20 000 to 25 000 units/day provided the thrombotic episode is not progressing as determined by clinical and laboratory finding. If anticoagulation is to be continued beyond the hospital stay warfarin therapy can be initiated. In this regard it is probably desirable to overlap the oral anti-coagulant with heparin for six days after the prothrombin time has reached the therapeutic level. These recommendations are not ideal but are dictated by current limitations in our knowledge of the pathogenesis of venous thromboembolism and the pharmacology of heparin. It is believed that this regimen together with the

precautions recommended will protect the vast majority of patients from further venous thromboembolism and diminish significantly the amount of hemorrhage induced by heparin—presently a major source of in hospital drug related deaths in reasonably healthy patients.¹² As research advances in both these areas the clinical guidelines will be sharpened.

In patients with massive acute pulmonary embolism investigators have recommended as much as 120 000 units/day for the first 24 hours of treatment.^{13,14} Others have stated that 60 000 units are adequate.^{15,16} Since there are no guides from clinical trials these large dosage schedules should be reserved for patients with massive pulmonary embolism and shock. Such high dosages should be reduced to the medium dose range 12 to 24 hours after therapy is instituted and then further reduced as clinical progress dictates. The risk of bleeding on the highest regimen is reported to be low in the first 24 hours^{17,18} and there appears to be little purpose in doing clotting assays in this situation.¹⁹ These observations may merely demonstrate that large amounts of heparin may not produce hemorrhage within the first few hours of administration rather than reflecting the amount of heparin actually required to prevent further thrombosis in these patients.

METHODS OF ADMINISTRATION. There are at present three accepted methods whereby heparin is administered: subcutaneous injection, intermittent intravenous injection and continuous intravenous injection.

Subcutaneous injection has been used almost exclusively for low dose heparin regimens. This method results in a prolonged low plasma level of heparin.^{20,21}—a situation which is required to minimize bleeding intraoperatively and postoperatively while maintaining an antithrombotic effect. For medium dose regimens both intermittent and continuous intravenous injections have been used. Data regarding the relative frequency of bleeding complications with these two regimens have been conflicting. Two studies concluded that there was a greater incidence of bleeding with intermittent intravenous than with continuous intravenous administration.^{22,23} Two other reports found no difference in hemorrhagic complications between continuous and intermittent intravenous therapy.^{24,25} In all of the studies however the units of heparin/24

Table 1 Heparin regimens

Dose (USP units/24 hrs)	Route	Clinical indications
Low dose 10 15 000	Subcutaneous	(1) Elective abdomino thoracic surgery (2) Acute myocardial infarction (3) Disseminated intravascular coagulation
Medium dose 20 60 000	Intravenous (continuous or intermittent)	(1) Active venous thromboembolism (2) Disseminated intravascular coagulation
High dose 60 000 100 000*	Intravenous (continuous)	(1) Massive pulmonary embolism with shock

*See text for limitation of duration in days of the larger doses

whether correction of increased platelet consumption can be correlated with an antithrombotic effect is still questioned

Sulfinpyrazone Several reports have indicated a favorable effect of sulfinpyrazone on recurrences of TIA^{8, 28} and in one of these trials a survival benefit was noted.²⁹ Sulfinpyrazone also appeared in this latter trial to have a survival benefit among patients with a previous myocardial infarct. A large TIA trial utilizing sulfinpyrazone is still ongoing.

Recently a randomized, double blind multi center trial comparing sulfinpyrazone (200 mg four times daily) with a placebo has demonstrated a significant reduction in sudden cardiac deaths among treated patients compared to the control group during the first year after myocardial infarction.³⁰ Although the basis for the benefit has not been established, the results are very striking.

Among patients with prosthetic mitral valves sulfinpyrazone has returned shortened platelet survival times toward normal³¹ although a significant antithrombotic effect has not yet been demonstrated.

Dipyridamole In a single trial of dipyridamole among patients with cerebrovascular disease no benefit was recognized.³² Similarly in a large number of trials of this drug among patients with coronary artery disease no benefit has been found. In patients with mitral valve disease

shortened platelet survival has been returned to normal, but an antithrombotic benefit has only been demonstrated when dipyridamole was used with another antithrombotic agent.³³

Heparin

Dose Heparin has been employed most effectively to prevent venous thromboembolism in low doses prior to the onset of intravascular coagulation and in larger doses to prevent progression after a thromboembolic event has occurred. Table I lists currently accepted dose regimens, routes of administration, and indications for therapy. Details on the efficacy and safety of the low dose regimens on a variety of conditions have been recently published in this Journal³⁴ and elsewhere.³⁵ What requires discussion here is the use of heparin at higher doses after the thrombotic event.

Once deep venous thrombosis or pulmonary embolism has occurred low dose heparin regimens are inadequate. For patients in whom the extensiveness of thrombosis is not great, as estimated clinically or with laboratory guides a treatment range of 20 000 to 60 000 units/day encompasses most of the reports.³⁶ In the majority of these studies heparin was given by intermittent intravenous injection, in many by constant infusion. Most of the regimens were in the narrower range of 30 000 to 45 000 units/day. Some investigators have used body weight in determining the daily dose, but most have not. Some reports recommend lower doses for older women, others do not. Although many investigators use some clotting assay as a guide to dosage several do not. Clearly it is difficult to provide definitive dose recommendations in the absence of firm clinical data. Moreover the decision making process is further complicated by the fact that the antithrombotic effect and the hemorrhagic risk do not proceed in parallel and as will be seen it is the latter which is usually the more critical of the two in determining dose.

Our interpretation of the literature suggests that 30 000 to 40 000 USP units/day by the intravenous route (either by continuous infusion or by bolus on a four hourly schedule) will be antithrombotic in the large majority of patients. This recommendation assumes that the quantity of plasma antithrombin III is normal—a determination that can be made prior to the institution of therapy by any one of several available assays.^{37, 38} In addition a normal partial thromboplastin time

that long term anticoagulation not be attempted if however underlying heart disease is recognized then long term anticoagulation appears justified although such a view is still controversial

Fibrinolytic agents Streptokinase or urokinase have been tried in a host of conditions including acute myocardial infarction stroke peripheral arterial occlusion retinal artery occlusion priapism DIC and thrombosed valve prosthesis with inconclusive or negative results In two clinical trials among patients with pulmonary embolism these thrombolytic agents showed improvement in angiographic and hemodynamic measurements^{11,12} Similarly lysis has been accelerated in patients with extensive deep venous thrombosis¹³ and in other studies thrombolytic agents cleared at least temporarily partially occluded arteriovenous cannulae¹⁴ Thrombolytic agents are primarily effective against recent thrombi

Current recommendations are for their use primarily in acute massive pulmonary embolism or extensive venous thrombosis How well these recommendations will withstand the test of time cannot be judged at present For it is clear that thrombolytic agents entail a substantial risk of hemorrhage should not be used concurrently with heparin or the coumarin compounds and particularly for streptokinase present the added problem of allergic reactions Following discontinuance of fibrinolytic therapy moreover heparinization is usually necessary to prevent rethrombosis The practical problems involved in the safe and effective administration of these drugs for the limited clinical situations in which they may be helpful adjuncts strongly suggest that their use for the present be limited to institutions with knowledgeable coagulation laboratory support

Dextran Both Dextran 40 and Dextran 70 have been used to prevent venous thromboembolism and effective results have been obtained in surgical patients Whether it is superior to heparin or warfarin has not been established although it may have a special role in orthopedic surgery and in patients with trauma^{15,17}

General comment

The impact of thromboembolism on mortality and morbidity is impressive It is involved substantively in deaths from cardiovascular cerebrovascular and renal disease it contributes to

occlusions of arteries veins microcirculatory vessels and wherever blood comes into contact with a foreign surface In atherosclerosis thrombosis plays a role in the terminal vascular occlusion¹⁸ in the enlargement of the plaque¹⁹ and possibly in the origin of the atheroma itself²⁰

A broad armamentarium of pharmacologic agents is now available to prevent or treat thromboembolic episodes It is possible somewhat arbitrarily to divide these compounds into three groups (1) drugs that inhibit the coagulation cascade so that insufficient thrombin is formed to initiate or propagate a thrombus (heparin and warfarin) (2) compounds that inhibit or remove clotting constituents essential to the formation of thrombi (platelet antiaggregants dextran and anicrod) and (3) agents that destroy already formed thrombi (streptokinase and urokinase) The choice dose duration and regulation of drug therapy—or in some instances the choice of drug combinations or drug sequences—may depend on the result desired the morphology of the thrombus the vascular bed involved the sex age and hemostatic competency of the patient the presence of other concurrent disease states and finally the risk-benefit ratio of each agent in any particular clinical setting Fortunately this decision making process is often easy but at other times particularly where knowledge is still incomplete definitive solutions may remain elusive None of these agents however effective will remove the factors causing thrombosis nor will they invariably prevent previously formed thrombi on endocardium arteries and veins from embolizing to distal portions of the circulation

It is clear that several of these problems can only be resolved by further insights into the molecular events that either initiate intravascular coagulation or account for the antithrombotic actions of chemically diverse compounds Despite the complexity expense duration and at times the frustration of clinical trials they remain in many instances an important court of last appeal complicated though they may be by unanticipated errors in design low event rates ethical and legal considerations and retrospectively premature decisions to test a particular compound in a given condition That trials are initiated when knowledge of the pharmacologic effects of the agent to be tested are incomplete and the apparent vagaries of the natural history of the underlying disease process not entirely

hours were less in the continuous compared to the intermittent groups. One may conclude, from the available data that either technique may produce hemorrhagic complications if full dosage schedules are maintained beyond 48 hours.

Since it has been demonstrated that the rate of heparin clearance is increased following pulmonary embolism,^{116, 117} it is suggested that, when using intermittent intravenous therapy for this condition, heparin be administered every four hours. If, however, a regimen of intermittent therapy every six hours is used, some assay should be performed on a plasma sample obtained 5½ hours post heparin administration to insure the maintenance of an antithrombotic effect for the entire period between injections.

One observation that may complicate the management of heparin therapy is the possibility of a heparin induced decrease in the quantity of antithrombin III. It has recently been reported that some patients receiving either continuous or intermittent intravenous heparinization exhibited a plasma inhibitor decrease to levels as low as 67 per cent of initial levels.¹¹⁸ During therapy, however, these patients are adequately anticoagulated even if antithrombin III is depressed by heparin. If, however, this observation is a general phenomenon it will cause difficulty in the interpretation of assays used to monitor therapy. Since the anticoagulant action of heparin is dependent on the quantity of antithrombin III in plasma,¹¹⁹ assays such as the partial thromboplastin time and the whole blood clotting time may fail to reflect the anticoagulant effect of the drug. Attempts to attain therapeutic levels of heparin as judged by these assays, may result in excess heparinization with the concomitant risk of hemorrhage, when heparin is actually functioning optimally without a dose increase.

When heparin is discontinued the drug induced depression of antithrombin III returns to normal in 24 to 48 hours. During this time period the patient may be at potential risk of thrombosis,¹²⁰ providing another reason for overlapping warfarin with heparin.

Oral anticoagulants: Coumarin compounds have had some success in diminishing the recurrence of TIA, but have had no clear cut effect in reducing the subsequent incidence of stroke or death.¹²¹

By far the largest number of trials have involved the use of the oral anticoagulants in the

treatment of acute myocardial infarction. The data from these trials have been evaluated in a variety of ways.¹²²⁻¹²⁴ If one assumes that on average, 20 per cent of patients hospitalized for acute myocardial infarction will die and that of these deaths 1 per cent result from pulmonary and 1 per cent from systemic emboli and that oral anticoagulants can prevent 80 per cent of these thromboembolic catastrophes, then a small but meaningful benefit could be achieved among the 500,000 patients annually hospitalized for acute myocardial infarction in this country.¹²⁴ What effect the trend to early hospital discharge of patients with uncomplicated acute myocardial infarction¹²⁵ may have on patient selection, or the duration or value of oral anticoagulants in this disorder remains to be determined.

Data are available to suggest that oral anticoagulants will diminish systemic emboli in patients with significant mitral stenosis¹²⁶ as well as with prosthetic valves.¹²⁷ In the latter situation this prophylactic gain is claimed to be augmented by supplementation with dipyridamole¹²⁸ or aspirin.¹²⁹ At the same time, improvements in valve prostheses are believed to have resulted in a decrease in their intrinsic thrombogenicity.

Oral anticoagulants of course, share with heparin a place in the prevention of venous thromboembolism.

The contraindication to oral anticoagulants dosage laboratory control and the management of major hemorrhage, have been covered in prior reviews.¹³⁰ It is reasonable to initiate warfarin therapy without a loading dose¹³¹ and it is critical to appreciate that there are an ever increasing number of drugs that may potentiate or antagonize the anticoagulant action of the coumarin compounds.¹³² When patients on anticoagulants have other drugs deleted from or added to their therapeutic regimen frequent prothrombin time determinations will permit appropriate coumarin dose regulation. Finally, it must be recognized that there are occasional patients who are congenitally resistant to coumarin therapy.¹³³

The cardiologist is frequently confronted with the decision as to whether to anticoagulate the patient with episodic or fixed atrial fibrillation or with the other arrhythmias associated with systemic embolism. If thorough investigation reveals no underlying heart disease in a patient (particularly a young individual) with atrial fibrillation the risk/benefit ratio would suggest

- Seegers, W H The inhibition of blood clotting An unidentified substance which acts in conjunction with heparin to prevent the conversion of prothrombin into thrombin *Am J Physiol* 125 683 1939
34. Waugh, P F., and Fitzgerald M A Quantitative aspects of antithrombin and heparin in plasma *Am J Physiol* 184 7 1956
 35. Monkhouse F C France E III and Seegers W H Studies on the antithrombin and heparin cofactor activities of a fraction adsorbed from plasma by aluminum hydroxide *Circ Res* 3 397 1955
 36. Abildgaard, U Highly purified antithrombin III with heparin cofactor activity prepared by disc electrophoresis *Scand J Clin Lab Invest* 18 89 1968
 37. Seegers W H and Marciniak F Inhibition of auto prothrombin C activity with plasma *Nature* 193 1188 1962
 38. Yin E T and Wessler S Heparin accelerated inhibition of activated factor X by its natural plasma inhibitor *Biochim Biophys Acta* 201 387 1970
 39. Biggs R Denson K W E Akman N Borrett R and Hadden M Antithrombin III antifactor Xa and heparin *Br J Haematol* 18 283 1970
 40. Yin E T Wessler S and Stoll P J Rabbit plasma inhibitor of the activated species of blood coagulation factor X. Purification and some properties *J Biol Chem* 246 3794 1971
 41. Rosenberg R D Chemistry of the hemostatic mechanism and its relationship to the action of heparin *Fed Proc* 30 10 1971
 42. Owen W G Pemick G D Yoder E and Poole B L Evidence for an ester bond between thrombin and heparin cofactor *Thrombos. Haemostas* 35 8 1976
 43. Collen D DeCook, F and Verstraete M Immunochemical distinction between antiplasmin and alpha antitrypsin *Thromb Res* 7 245 1975
 44. Moroi, M and Aoki N Isolation and characterization of a plasmin inhibitor from human plasma A novel proteinase inhibitor which inhibits activator induced clot lysis *J Biol Chem* 251 956 1976
 45. Alkjaersug N Fletcher A P and Sherry S The mechanism of clot dissolution by plasmin *J Clin Invest* 38 1086 1959
 46. Ambrus C M and Markus G Plasmin antiplasmin complex as a reservoir of fibrinolytic enzyme *Am J Physiol* 199 491 1960
 47. Chesterman C N Allington M J and Sharp A A Relationship of plasminogen activator to fibrin *Nature* 238 15 1972
 48. Fry D L Hemodynamic injury in Th Thrombotic Process in Atherosclerosis Chandler A B Eurenus K McMillan G C Nelson C B Schwartz C J and Wessler S eds New York 1978 Plenum Press p 351
 49. Wessler S The role of stasis in thrombosis, in *Thrombosis* Sherry S Brinkhaus, K M Geyten E and Stengle J M eds Washington DC 1969 National Academy of Science # 461
 50. Roth G J Stanford N and Majerus F W Acetylation of prostaglandin synthase by aspirin *Proc Natl Acad Sci USA* 72 3073 1975
 51. McDonald J W III, Ali, M Nagai G R Barnett, H and Barnett H J M Inhibition of platelet prostaglandin synthetase and platelet release reaction by sulfin pyrazone *Blood* 45 1033 1975
 52. McDonald J W D Ali, M Barnett W H Nagai G R and Barnett H J M Effects of sulfinpyrazone on platelet release reaction and prostaglandin synthesis *Stroke* 7 11 1976
 53. Emmons P R Harrison M J G Honour A J., and Mitchell J R A Effect of dipyridamole on human platelet behavior *Lancet* 2 603 1965
 54. Curran M F Nishizawa F E and Mustard J F Effect of dipyridamole compounds on platelet function *J Lab Clin Med* 77 958 1971
 55. Zucker M H and Peterson J Effect of acetylsalicylic acid and other non steroidal anti inflammatory agents and dipyridamole on human blood platelets *J Lab Clin Med* 76 66 1970
 56. Mills, D C H and Smith J B The influence on platelet aggregation of drugs that affect the accumulation of adenosine 3',5' cyclic monophosphate in platelets *Biochem J* 121 185 1971
 57. Nader H B McDuffie E M and Dietrich C I Heparin fractionated by electrofocusing Presence of 21 components of different molecular weights *Biochem Biophys. Res. Commun* 57 488 1974
 58. Markwardt, F and Walsmann P The reaction between hirudin and thrombin *Hoppe Seyler's Z Physiol. Chem.* 312 65 1973
 59. Hentell H H and Klugerman M The nature of heparin antithrombin action *Thromb Diath Haemorrh* 18 167 1967
 60. Gitel, S N Evidence for a catalytic role of heparin in anticoagulation reactions, in *Heparin Structure function and clinical implications*, Bradshaw R A., and Wessler S eds. New York 1975 Plenum Press p 243
 61. Suttie J W and Jackson C M Prothrombin structure activation and biosynthesis *Physiol. Rev* 57 1 1977
 62. Stenflo J and Suttie J W Vitamin K dependent formation of γ -carboxyglutamic acid in *Annual Reviews of Biochemistry* Vol 46 Snell E E Boyer P D Meister A and Richardson C C., eds Palo Alto CA 1977 Annual Reviews Inc pg 157
 63. Stenflo J A new vitamin K-dependent protein Purification from bovine plasma and preliminary characterization *J Biol Chem* 251 355 1976
 64. DeSciropi R G Hermanson M A Yates S G., and Davie E W A comparison of human prothrombin factor IX (Christmas factor) factor X (Stuart factor) and protein III *Biochemistry* 16 698 1977
 65. Kissel W Ericsson L H and Davie E W Proteolytic activation of protein C from bovine plasma *Biochemistry* 15 493 1976
 66. Boyer G J Bang N U Ferroni J W., and Benson M D Plasma amyloid P-component inhibits heparin activity *Blood* 50 (Suppl 1) 260 1977
 67. Kissel W., Canfield W M Ericsson L H and Davie E W Anticoagulant properties of bovine plasma protein C following activation by thrombin *Biochemistry* 16 5824 1977
 68. Killeit S W and Garner R L The fibrinolytic activity of hemolytic streptococci *J Exp Med* 58 485 1933
 69. Johnson A J and McCarty W R The lysis of artificially induced intravascular clots in man by intravenous infusions of streptokinase *J Clin Invest* 38 1697 1959
 70. MacFarlane R G and Pilling J Fibrinolytic activity of normal urine *Nature* 159 79 1947
 71. Reddy, K N N and Markus G Mechanism of activation of human plasminogen by streptokinase Presence of active center in streptokinase plasminogen complex *J Biol Chem* 247 1683 1972

unravelling, only adds further difficulty to the decision making process. However, one cannot always wait until all questions have been answered, and under similar conditions, therapeutic triumphs have occurred in other fields. In any event, progress with antithrombotic therapy continues to be made, even though firm data are only available in certain areas, and the physician is still confronted with difficult decisions where clear therapeutic formulations have yet to be achieved.

REFERENCES

- Deykin D. Emerging concepts of platelet function. *N Engl J Med* 290:137-174.
- Moncada S, Higgs E A and Vane J R. Human arterial and venous tissues generate prostacyclin (prostaglandin X), a potent inhibitor of platelet aggregation. *Lancet* 1:18-177.
- Weksler B D, Marcus A J and Jaffe E A. Synthesis of prostaglandin I₂ (prostacyclin) by cultured human and bovine endothelial cells. *Proc Natl Acad Sci USA* 74:3922-1977.
- Moncada S, Herman A G, Higgs E A and Vane J R. Differential formation of prostacyclin (PGX or PGI₂) by layers of the arterial wall. An experimental explanation for the antithrombotic properties of vascular endothelium. *Thromb Res* 11:323-1977.
- The Thrombotic Process in Atherosclerosis. Chandler A B, Eurenus K, McMillan G C, Nelson C B, Schwartz C J and Wessler S eds. New York 1978. Plenum Press.
- Stemerman M B and Spaet T H. The subendothelium and thrombogenesis. *Bull NY Acad Med* 48:289-1972.
- Baumgartner H R and Haudenschild C. Adhesion of platelets to subendothelium. *Ann NY Acad Sci* 201:22-1972.
- Holmsen H, Day H J and Stormorken H. The blood platelet release reaction. *Scand J Haematol* 3:29-1969.
- Marcus A J. Platelet function. *N Engl J Med* 280:1213-1969.
- Smith J B and Willis A L. Aspirin selectively inhibits prostaglandin production in human platelets. *Nature (New Biol)* 231:235-1971.
- Lüscher E F, Probst E and Bettex Galland M. Thromboxenin: Structure and function. *Ann NY Acad Sci* 201:122-1972.
- MacFarlane R G. An enzyme cascade in the blood clotting mechanism and its function as a biochemical amplifier. *Nature* 202:498-1964.
- Davie E W and Ratnoff O D. Waterfall sequence for intrinsic blood clotting. *Science* 145:130-1964.
- Wilner G D, Nossel H L and LeRoy E C. Activation of Hageman factor by collagen. *J Clin Invest* 47:2608-1968.
- Saito H, Ratnoff O D, Waldmann R and Abraham J P. Fitzgerald trait: Deficiency of a hitherto unrecognized agent Fitzgerald Factor participating in surface mediated reaction of clotting fibrinolysis generation of kinins and the property of diluted plasma enhancing vascular permeability (PF/DIL). *J Clin Invest* 55:1082-1975.
- Lau C Y, Scott C F, Bagdasarian A, Pierce J V, Kaplan A P and Coleman R W. Potentiation of the function of Hageman factor fragments by high molecular weight kininogen. *J Clin Invest* 60:7-1977.
- Meier H L, Pierce J V, Coleman R W and Kaplan A P. Activation and function of human Hageman factor: the role of high molecular weight kininogen and prekallikrein. *J Clin Invest* 60:18-1977.
- Osterud H and Rapaport S I. Synthesis of the intrinsic factor X activator. Inhibition of the function of formed activator by antibodies to factor VIII and factor IX. *Biochemistry* 15:1854-1970.
- Marcus A J, Zucker Franklin D, Safir L B and Ullman H L. Studies on human platelet granules and membranes. *J Clin Invest* 45:14-1966.
- Jobin F and Esnouf M P. Studies on the formation of the prothrombin converting complex. *Biochem J* 102:666-1967.
- Barton P G, Jackson C M and Hanahan D J. Relationship between factor V and activated factor V in the generation of prothrombinase. *Nature* 214:93-1967.
- Jesty J and Nemerson Y. Purification of factor VII from bovine plasma. Reaction with tissue factor and activation of factor X. *J Biol Chem* 249:609-1974.
- Bjorklid E, Storm E, Osterud B and Prydz H. The interaction of the protein and phospholipid components of tissue thromboplastin (factor III) with factors VII and X. *Scand J Haematol* 14:65-1975.
- Lorand L, Rule N G, Ong H H, Foranetto R, Jacobsen A, Downey J, Onier N and Bruner Lorand J. Amino specificity in transpeptidation. Inhibition of fibrin cross linking. *Biochemistry* 7:1214-1968.
- Rapaport S I, Schiffman S, Patch M J and Ames E B. The importance of activation of antihemophilic globulin and proaccelerin by traces of thrombin in the generation of intrinsic prothrombinase. *Blood* 21:991-1963.
- Ware A G and Seegers W H. Serum A C globulin. Formation from plasma A C globulin role in blood coagulation partial purification properties and quantitative determination. *Am J Physiol* 152:567-1948.
- Rapaport S I, Hjort P F and Patch M J. Rabbit factor V. Different effects of thrombin and venom as source of error in assay. *Am J Physiol* 211:147-1966.
- Prentice C R M, Ratnoff O D and Breckenridge R T. Experiments on the nature of the prothrombin converting principle. Alteration of proaccelerin by thrombin. *Br J Haematol* 13:898-1967.
- Warren B A. Fibrinolytic activity of vascular endothelium. *Br Med Bull* 20:213-1967.
- Harpel P C and Rosenberg R D. A Macroglobulin and antithrombin heparin cofactor. Modulation of hemostatic and inflammatory reactions. In: Progress in Hemostasis and Thrombosis, vol 3. Spaet T H ed. New York 1976. Grune & Stratton. pg 145.
- Gitel S N, Stephenson R and Wessler S. The activated factor X antithrombin III reaction rate. A measure of the increased thrombotic tendency induced by estrogen containing oral contraceptives. *Haemostas* 7:10-1978.
- Abildgaard U, Fagerhol M K and Fegberg O. Comparison of progressive antithrombin activity and the concentration of three thrombin inhibitors in human plasma. *Scand J Clin Lab Invest* 26:349-1970.
- Brinkhous K M, Smith H P, Warner F D, and

- intermittent heparin in pulmonary embolism *Ann Rev Respir Dis* 113 148 1976 (Abstract)
- Chiu H M van Aken W G Hirsh J Regoeczi E and Homer A A Increased heparin clearance in experimental pulmonary embolism *J Lab Clin Med* 90 904 1977
- Hirsh J van Aken W M Galus A S Dollery C T, Cade J F and Yung W L Heparin kinetics in venous thrombosis and pulmonary embolism *Circulation* 53 691 1976
- Marciniak E and Gockerman J P Heparin induced decrease in circulating antithrombin III *Lancet* 2 581 1977
- Gitel E N and Wessler E Antithrombin III concentrates for clinical use in International Workshop on Technology of Protein Separation and Improvement of Blood Plasma Fractionation Department of Health Education & Welfare 1978 p 307
- Whitnall J P, Carbridge M B and Elveback L R Carotid and vertebral basilar transient ischemic attacks Effect of anticoagulants hypertension and cardiac disorders on survival and stroke occurrence—a population study *Ann Neurol* 3 107 1978
- Gifford R H and Feinstein A H A critique of methodology in studies of anticoagulant therapy for acute myocardial infarction *N Engl J Med* 280 351 1969
- Wessler S The anticoagulant dilemma—a prescription for its resolution *Am J Med Sci* 274 106 1977
- Chalmers T C Matta R J Smith H Jr and Kunzler A Evidence favoring the use of anticoagulants in the hospital phase of acute myocardial infarction *N Engl J Med* 297 1091 1977
- Wessler S Kleiger K E Cornfield J and Teitelbaum S L Coumarin therapy in acute myocardial infarction A Hobson's choice *Arch Intern Med* 134 74 1974
- McNeer J F Wagner G S Ginsburgh P B Wallace A G McConis C B Conley M J and Rosati R A Hospital discharge one week after acute myocardial infarction *N Engl J Med* 298 229 1978
- Prentice C R M Long term anticoagulant treatment *Prescribers J* 16 116 19 1978
- Abernathy W S and Wells P W III Thromboembolic complications of rheumatic heart disease *Cardiovasc Clin* 5 131 1973
- Altman R, Bouillon F and Rouvier J Aspirin and prophylaxis of thromboembolic complications in patients with substitute heart valves *J Thorac Cardiovasc Surg* 72 127 1976
- A Guide to Anticoagulant Therapy Wessler S and Alexander H eds American Heart Association Dallas 1970
- O'Reilly R A and Aggeler P M Studies on coumarin anticoagulant drugs Initiation of warfarin therapy without a loading dose *Circulation* 38 169 1968
- Koch Waser J, and Sellers E M Drug interactions with coumarin anticoagulants *N Engl J Med* 285 Part I p 487 and Part II p 547 1971
- O'Reilly R A The second reported kindred with hereditary resistance to oral anticoagulant drugs *N Engl J Med* 282 1448 1970
- Urokinase pulmonary embolism trial—Phase I results *JAMA* 214 2163 1970
- Sasahara A A Bell W R, and Simon H L The phase II urokinase-streptokinase pulmonary embolism trial *Thromb Diath. Haemorrh* 33 464 1975
- Porter J M and Goodnight J H Jr The chemical use of fibrinolytic agents *Am J Surg* 134 217 1977
- Gonzalez F M and Locke T H Use of streptokinase in occluded arteriovenous shunts *Thromb Diath. Haemorrh (Suppl)* 47 119 19 1977
- Gruber U F Dextran and the prevention of postoperative thromboembolic complications *Surg Clin North Am* 55 619 1975
- Chandler A B Chapman I and Erhardt L R Coronary thrombosis in myocardial infarction Report of a workshop on the role of coronary thrombosis in the pathogenesis of acute myocardial infarction *Am J Cardiol* 34 823 1974
- Chandler A B and Pope J T Arterial thrombosis and atherogenesis a survey of the frequency of incorporation of thrombi into atherosclerotic plaques in Blood and Arterial Wall in Atherogenesis and Arterial Thrombosis Hautvast J G A J Hermus R J J and Van Dethaer F, eds Leiden 1975 E J Brill p 110

- 72 Muzaffar T Z, Stalker A L, Bryce W A J and Dhall D P Structural alterations in fibrin clots with dextran Thromb Diath Haemorrh 28 257 1972
- 73 Dhall T M, Bryce W A J and Dhall D P Effects of dextran on the molecular structure and tensile behavior of human fibrin Thromb Haemostas 35 736 1976
- 74 Reid H A Defibrination by *Aghistrodon rhodostoma* venom in Animal Toxins Russel F F and Saunders P R eds Oxford 1967 Pergamon Press p 323
- 75 Bell W R, Pitney W R, Oakley C M and Goodwin J F Therapeutic defibrination in the treatment of thrombotic disease Lancet 1 490 1968
- 76 Harrison M J G, Marshall J, Meadows J C and Russell R W R Effect of aspirin in amaurosis fugax Lancet 2 743 1971
- 77 Mundall J, Quintero P, vonKaulla K N, Harmon R and Austin J Transient monocular blindness and increased platelet aggregability treated with aspirin A case report Neurology 22 280 1972
- 78 Dyken M I, Kolar J J and Jones F H Differences in the occurrence of carotid transient ischemic attacks associated with antiplatelet aggregation therapy Stroke 4 732 1973
- 79 Fields W S, Lemak N A, Frankowski R F and Hardy R J Controlled trial of aspirin in cerebral ischemia Stroke 8 301 1977
- 80 Hass W K Aspirin for the limping brain Stroke 8 299 1977
- 81 Elwood P C, Cochrane A I and Burr M L A randomized controlled trial of acetylsalicylic acid on the secondary prevention of mortality from myocardial infarction Br Med J 1 436 1974
- 82 Klumt C R, Doub P H and Doub N H Clinical trial in thrombosis Secondary prevention of myocardial infarction Thromb Haemostas 35 49 1976
- 83 Andrassy K, Ritz E, Schoeffner W, Hahn G and Walter K The influence of acetylsalicylic acid on platelet adhesiveness and thrombotic fistula complications in hemodialyzed patients Klin Wochenschr 3 168 1971
- 84 Stewart J H, Farrell P C and Dyon M Reduction of platelet/fibrin deposition in haemodialyzers by aspirin administration Aust N Z Med J 5 117 1975
- 85 Harker L A In vivo evaluation of antithrombotic therapy in man Thromb Diath Haemorrh Suppl 160 pg 481 1974
- 86 Evans G Effect of drugs that suppress platelet surface interaction on incidence of amaurosis fugax and transient cerebral ischemia Surg Forum 23 239 1972
- 87 Blakeley J A and Gent M Platelets drugs and longevity in a geriatric population in Platelets Drugs and Thrombosis Hirsh J, Cade J F and Gallus A S eds Basel 1975 S Karger AG p 284
- 88 Steele P, Carroll J, Overfield D and Genton E Effect of sulfinpyrazone on platelet survival time in patients with transient cerebral ischemic attacks Stroke 8 396 1977
- 89 Sulfinpyrazone in the prevention of cardiac death after myocardial infarction The anturane reinfarction trial N Engl J Med 298 289 1978
- 90 Welby H S and Genton E Altered platelet function in patients with prosthetic mitral valves Effects of sulfinpyrazone therapy Circulation 42 967 1970
- 91 Acheson J, Danta G and Hutchinson E C Controlled trial of dipyridamole in cerebral vascular disease Br Med J 1 614 1969
- 92 Sullivan M J, Harken D E and Gorlin R L Pharmacologic control of thromboembolic complications of cardiac valve replacements N Engl J Med 284 1391 1971
- 93 Wessler S and Gitel S N Low dose heparin Is the risk worth the benefit? AM HEART J (In press)
- 94 Special report Prevention of venous thromboembolism in surgical patients by low dose heparin Circulation 55 423A 1977
- 95 Wessler S and Gitel S N Control of heparin therapy in Progress in Hemostasis and Thrombosis, Spaet, T ed New York 1976 Grune & Stratton p 311
- 96 Fagerhol M K and Abildgaard U Immunological studies on human antithrombin III Scand J Haematol 7 10 1970
- 97 Gitel S N and Wessler S Plasma antithrombin III A quantitative assay of biological activity Thrombosis Res 7 5 1975
- 98 Abildgaard U, Loe M and Odegaard O R A simple amidolytic method for the determination of functionally active antithrombin III Scand J Clin Lab Invest. 36 109 1976
- 99 Basu D, Gallus A, Hirsh J and Cade J A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time N Engl J Med 287 324 1972
- 100 DeTakats G Vascular surgery Philadelphia 1959 WB Saunders Company p 181
- 101 Mant M J, Thong K L, Birtwhistle R V, O'Brien D, Hammond G W and Grace M G Hemorrhagic complications of heparin therapy Lancet 1 1133 1977
- 102 Domenet J G, Evans D W and Stephenson H Anticoagulants in congestive heart failure Br Med J 4 866 1966
- 103 Coon W W and Willis P W III Thromboembolic complications during anticoagulant therapy Arch Surg 105 209 1972
- 104 Potter J and Jick H Drug related deaths among medical inpatients JAMA 237 879 1977
- 105 Bauer G Clinical experience of a surgeon in the use of heparin Am J Cardiol 14 29 1964
- 106 Kernohan R J and Todd C Heparin therapy in thromboembolic disease Lancet 1 621 1966
- 107 Crone, E The diagnosis and treatment of pulmonary embolism Surg Clin North Am 46 551 1966
- 108 Sutton G C The management of pulmonary embolism in Thromboembolism Aetiology Advances in Prevention and Management Nicotides A N ed Lancaster England 1975 Medical & Technical Publishing Co p 287
- 109 Gurewich V, Thomas D P and Stuart R K Some guidelines for heparin therapy of venous thromboembolic disease JAMA 199 116 1967
- 110 Yin E T, Wessler S and Butler J V Plasma heparin A unique practical submicrogram sensitive assay J Lab Clin Med 81 298 1973
- 111 Johnson E A, Kirkwood T B, Stirling Y., Perez Requero J L, Ingram G I C, Bangham D R and Brozovic M Four heparin preparations Anti Xa potentiating effect of heparin after subcutaneous injection Thromb Haemostas. 35 586 1976
- 112 Thomas, D P, Sagar S, Stamataks J D, Maffei F H A, Erdi A and Kakkar V V Plasma heparin levels after administration of calcium and sodium salts of heparin Thrombosis Res 9 241 1976
- 113 Salzman E W, Deykin D, Shapiro R M and Rosenberg R Management of heparin therapy Controlled prospective trial N Engl J Med 292 1046 1971
- 114 Glazer R L and Crowell E B Randomized prospective trial of continuous vs intermittent heparin therapy JAMA 236 1365 1976
- 115 Bynum L J and Wilson J E III Continuous vs

Table 1 Uses of diuretics (see text for details)

Indication	Agent		
	Thiazides Chlorthalidone Metolazone	Furosemide Ethacrynic Acid	Spironolactone Triamterene
Edema forming states (CHF, cirrhosis, nephrosis)	+	++	+
Hypertension	++	+	+
Hypercalcemia	-	++	-
Hypercalciuria	++	-	-
Diabetes Insipidus	+	-	-
Syndrome of inappropriate secretion of ADH	-	+	-
Renal tubular acidosis	+	+	-
Renal failure	-	+	-

tration of these drugs reduces urinary calcium excretion and makes them useful in the treatment of patients with idiopathic hypercalciuria and renal calculi.¹ Agents in this group impair urinary diluting capacity (by their effect on the ascending limb or diluting segment of the nephron) and thus have been useful in the treatment of diabetes insipidus, especially of the nephrogenic type.² Finally, since these drugs increase urinary hydrogen ion excretion,³ they may be employed in the treatment of renal tubular acidosis.

Side effects of this group of diuretics are numerous but usually mild. Hypokalemia is common and may be attributed to multiple factors including increased urine flow rate and increased delivery of sodium or poorly resorbable anions (bicarbonate or phosphate) to more distal sites where potassium is secreted. Hypokalemia is often clinically insignificant except in the edema forming states where exaggerated secondary aldosteronism may contribute to the potassium deficit.⁴ Treatment though less than ideal may be indicated when deficits are severe. The therapeutic alternatives include reduction of diuretic dose (counterproductive), increase in dietary potassium (ineffective), administration of supplemental oral potassium (unpalatable) or addition of one of the potassium sparing diuretics (reliable but expensive). Accompanying the hypokalemia there is often a mild hypochloremic alkalosis caused both by indirect and direct factors,⁵ which unlike the situation with the organomercurials does not impair the action of the diuretics.

Hyperuricemia is also common and results from a decrease in urinary excretion of uric acid.⁶

Occasionally clinical gout is evoked by the diuretics and requires treatment with standard agents. In this regard it is pertinent to warn of the potential hazard of treating diuretic induced hyperuricemia with allopurinol. This combination of drugs has been reported to cause serious life threatening reactions and should be avoided. Mild thrombocytopenia has been described⁷ which is usually reversible on discontinuing the drugs. Less common side effects of these agents include hyponatremia resulting from a combination of salt losses, excessive anti-diuretic hormone release, potassium depletion and impairment in diluting capacity,⁸ hyperglycemia usually mild,⁹ azotemia from excess diuresis and consequent volume depletion or from acute interstitial nephritis,¹⁰ and various allergic reactions common to all sulfonamides (skin rash, photosensitivity, narrow depression). Rarely reported complications of therapy include paradoxical edema,¹¹ hemolytic anemia,¹² or allergic pneumonitis.¹³ Despite this imposingly long list the distal tubular diuretics have been employed usefully and safely over the past 30 years.

Ethacrynic acid and furosemide

These agents are loop of Henle diuretics. Ethacrynic acid is an aryloxyacetic acid derivative developed in the search for a potent inhibitor of sulfhydryl containing enzyme systems.¹⁴ After ingestion and rapid absorption the drug is chemically modified to its active form, ethacrynic-cysteine.¹⁵ Furosemide is a sulfonamide analogue akin to the thiazides yet its renal actions are similar to ethacrynic acid.¹⁶ It too is rapidly absorbed but acts without modification on the

Appraisal and reappraisal of cardiac therapy

Edited by Arthur C DeGraff and Julian Frieden

Diuretics

Philip D Lief, M D

Bronx N Y

The development of clinically useful diuretic agents has been an important advance of the past 30 years. Until then, the organomercurials were the most commonly employed diuretics, but their usefulness was limited by the need for parenteral administration.¹ However, the finding in the 1940's that benzoyl and heterocyclic sulfonamides were inhibitors of carbonic anhydrase² and could increase urinary sodium excretion³ stimulated a search for other compounds which might act as potent oral diuretics. The purpose of this report is to describe the mechanisms of action, clinical uses, and side effects of some of these orally administered agents.

A diuretic, by definition, is a compound which increases the flow of urine by any means. Thus a diuresis may be obtained by aminophylline or glucocorticoids, which increase glomerular filtration rate, by maneuvers such as plasma volume expansion or by a wide variety of agents which increase cardiac output. However, this discussion will be limited to compounds which act directly on the kidney, specifically on the renal tubule to increase the excretion of salt and water.

Thiazides: chlorthalidone and metolazone

The agents in this group are distal tubule potassium wasting diuretics. Though differing chemically from each other, they have similar effects on the nephron. Chlorothiazide developed first, and hydrochlorothiazide, the most widely used benzothiadiazine compounds, were discovered as carbonic anhydrase inhibiting analogues of sulfanilamide.⁴ Chlorthalidone is a non sulfonamide phthalimidine and metolazone is a quina-

zoline derivative of sulfonamide. After oral administration, the drugs are absorbed rapidly and then filtered and secreted (via the organic acid secretory pathway) into the renal tubular lumen.⁵ There they exert their primary effect by inhibiting active sodium transport in the cortical portion of the ascending limb and in the distal convoluted tubule where approximately 10 per cent of the filtered sodium is normally reabsorbed. In addition, these compounds have varying degrees of carbonic anhydrase inhibitory activity, but this action does not account for a significant portion of their diuretic effect. Differences in potency of these agents relate principally to their duration of action. Thus the benzothiadiazines exert their effect for 6 to 12 hours while metolazone, due to strong protein binding and considerable enterohepatic recycling,⁶ exerts a diuretic effect for 24 to 48 hours. The dose response curve for these drugs is flat above the recommended maximal dose (1500 mg/day chlorothiazide, 150 to 200 mg/day hydrochlorothiazide, 200 mg/day chlorthalidone, 10 to 20 mg/day metolazone), and the use of additional drug increases side effects without a significant increase in the diuretic action.⁷

The distal tubule diuretics are useful in a wide variety of conditions (Table I). They are employed in the edema forming states (congestive heart failure, cirrhosis and nephrotic syndrome) to directly increase urinary sodium excretion. However, if volume depletion is present or develops during treatment, distal salt delivery may be reduced. Under these circumstances the agents may become less effective in promoting a diuresis. Distal diuretics are also useful in the treatment of hypertension because of their relatively long duration of action. They exert both renal (diuretic) and non renal (vasodilatory) effects each of which contributes to the lowering of blood pressure.⁸ The chronic adminis-

From the Renal Division, Department of Medicine, Albert Einstein College of Medicine and Montefiore Hospital and Medical Center, Bronx, N Y.

Received for publication June 30, 1978.

Reprint requests: Philip D Lief, M.D., Renal Division, Montefiore Hospital and Medical Center, 111 E 210th St, Bronx, N Y 10467.

REFERENCES

- 1 Vogel, A. The discovery of the organic mercurial diuretics. *Am Heart J* 39 681 1950
- 2 Mann T and Kedlin D. Sulfanilamide as a specific inhibitor of carbonic anhydrase. *Nature (London)* 148 164 1940
- 3 Schwartz, W H. The effect of sulfanilamide on salt and water excretion in congestive heart failure. *N Engl J Med* 240 173 1949
- 4 Beyer K. H. Chlorothiazide and other diuretic agents. *Ann N Y Acad Sci* 71 371 1958
- 5 Goldberg M. The renal physiology of diuretics. In: *Handbook of Physiology* section 8. Renal Physiology. Washington D C 1913. American Physiological Society p 1003
- 6 Lowenthal, D T and Shear L. Use of a new diuretic agent (Metolazone) in patients with edema and ascites. *Arch. Intern Med* 132 38 1973
- 7 Gifford, R W. A guide to the practical use of diuretics. *JAMA* 235 1890 19 6
- 8 Conway J and Palmero H. The vascular effects of the thiazide diuretics. *Arch Intern Med* 111 203 1963
- 9 Costanza L S and Weiner I M. On the hypocalcemic action of chlorothiazide. *J Clin Invest* 54 678 1974
- 10 Yendt, E R, Gayne R J A and Coham M. The effects of thiazides in idiopathic hypercalcemia. *Am J Med Sci* 251 449 1966
- 11 Yendt, E R, Guay G F and Garcia B A. The use of thiazides in the prevention of renal calculi. *Can Med Assoc J* 103 614 1970
- 12 Crawford J D and Kennedy C C. Chlorothiazide in diabetes insipidus. *Nature* 183 891 1959
- 13 Lief P D and Mutz B. Stimulation of hydrogen ion secretion by diuretics in turtle urinary bladder: a mechanism for diuretic induced alkalosis. *American Society of Nephrology*, 10th Annual Meeting 1977 p 113A
- 14 Kassirer J P and Harrington J H. Diuretics and potassium metabolism: a reassessment of the need effectiveness and safety of potassium therapy. *Kidney Int* 11 505 1971
- 15 Ayrasman J H and Ayrasman L F. A study of the hyperurcemia induced by hydrochlorothiazide and acetazolamide separately and in combination. *J Clin Invest* 40 1961 1961
- 16 Young J L, Roswell H H and Nuss A S. Severe aldopurinnal hypersensitivity. Association with thiazides and prior renal compromise. *Arch Intern Med* 134 553 1974
- 17 Ball P. Thrombocytopenia and purpura in patients receiving chlorothiazide and hydrochlorothiazide. *JAMA* 173 663 1960
- 18 Fishman M P, Vorherr H, Kleeman C R and Telfer N. Diuretic induced hyponatremia. *Ann Intern Med* 75 853 1971
- 19 Weller J M and Borondy P E. Effects of benzothiazine drugs on carbohydrate metabolism. *Metabolism* 14 708 1965
- 20 Lyons H, Pinn, V W, Cortell S, Cohen J J and Harrington J T. Allergic interstitial nephritis causing reversible renal in four patients with idiopathic nephrotic syndrome. *N Engl J Med* 228 174 1973
- 21 MacGregor G A, Tasker P R W and De Warden H E. Diuretic induced edema. *Lancet* 1 489 1975
- 22 Vela J M, Blum L and Dosik H. Thiazide induced hemolytic anemia. *JAMA* 236 1723 19 6
- 23 Beaudry C and Laplante L. Severe allergic pneumonitis from hydrochlorothiazide. *Ann Intern Med* 78 251 1973
- 24 Beyer R H, Baer J E, Michaelson J F and Russo H F. Renotropic characteristics of ethacrynic acid: a phenoxycetic saluretic-diuretic agent. *J Pharmacol Exp Ther* 147 1 1965
- 25 Burg M and Green N. Effect of ethacrynic acid on the thick ascending limb of Henle's loop. *Kidney Int* 4 301 1973
- 26 Fischett J H and Goldberg M. The acute effects of furosemide on acid and electrolyte excretion in man. *J Lab Clin Med* 71 666 1968
- 27 Anderson J., Godfrey B E, Hill D M et al. A comparison of the effects on hydrochlorothiazide and furosemide in the treatment of hypertensive patient. *Q J Med* 40 541 1971
- 28 Suki, W N. Acute treatment of hypercalcemia with furosemide. *N Engl J Med* 283 835 19 6
- 29 Hantman D, Rosner N, Zohman H and Schreier R. Rapid correction of hyponatremia in the syndrome of inappropriate secretion of antidiuretic hormone. *Ann Intern Med* 78 870 1973
- 30 Pillay V h, G Schwartz F D, Aimi K., and Hark R M. Transient and permanent deafness following treatment with ethacrynic acid in renal failure. *Lancet* 1 77 1968
- 31 Wauters J P. Unusual complication of high dose furosemide. *Br Med J* 4 674 19 5
- 32 Malach, M and Berman N. Furosemide and chloral hydrate. Adverse drug interaction. *JAMA* 232 638 1975
- 33 Mitchell J R., Potter W Z, Hunson J A and Jollow D J. H. patic necrosis caused by furosemide. *Nature* 251 508 1974
- 34 Leide G W. Aldosterone antagonists. *Arch Intern Med* 102 998 19 8
- 35 Mammel M A, Berner G J, Wagnild J P and Weiner M W. An effect of spironolactone on urinary acidification in normal man. *Arch Intern Med* 134 4 1974
- 36 Lief P D and Mutz B. Inhibition of H⁺ secretion by amiloride in turtle urinary bladder: dependence on sodium transport. *Clin Res* 25 440a 19 7
- 37 Louaux, D L. Spironolactone and endocrine dysfunction. *Ann Intern Med* 85 650 19 6

renal tubule. Both agents exert their primary effect by inhibiting active chloride transport in the thick ascending portion of Henle's loop and are thus capable of inhibiting more than 20 per cent of the filtered salt load. Moreover, unlike the distal tubule drugs, the loop diuretics have an almost infinite dose response pattern and in large doses (300 to 600 mg ethacrynic acid, 1000 to 1500 mg furosemide) are effective even in the presence of renal insufficiency.⁷ Thus they are extremely potent diuretics with a rapid onset (30 to 60 minutes) of effect, limited only by a relatively short (4 to 6 hours) duration of action.

The loop diuretics are most useful in the severe edema-forming states (Table I) where their potency almost always insures a substantial diuresis. However, they may continue to promote salt and water losses in the face of severe volume depletion, a characteristic that also makes them potentially more dangerous. Because of their shorter duration of action, they are probably no more effective than thiazides in the treatment of hypertension,¹⁸ although this fact has been ignored by most clinicians. Unlike the distal diuretics which reduce urinary calcium, the loop diuretics promote renal calcium excretion and are employed in the treatment of hypercalcemia.²² Like the thiazides they promote urinary hydrogen excretion and are used in the management of renal tubular acidosis. Finally, since these agents act on the ascending limb of Henle's loop (the concentrating segment) to impair urinary concentration, they have been used, with infusions of hypertonic saline, for the rapid correction of hyponatremia in the syndrome of inappropriate secretion of antidiuretic hormone.⁹

Side effects of the loop diuretics are similar to those of the thiazides with a few important differences. They do not cause hypercalcemia. Ethacrynic acid, which is not a sulfonamide, is less frequently associated with hypersensitivity reactions and hyperglycemia than furosemide but does produce more gastrointestinal side effects. Both drugs cause transient nerve deafness, especially when employed in high doses in azotemic patients; occasionally the deafness is long lasting after ethacrynic acid.²⁰ Less commonly reported adverse reactions for furosemide include agranulocytosis,²¹ interaction with chloral hydrate,² and hepatic necrosis.²³ Despite these side effects the loop agents have been widely used to effect a rapid and reliable diuresis.

Spironolactone and triamterene

These agents in this group are distal tubular potassium sparing diuretics. Spironolactone is a specific competitive inhibitor of the cellular binding of aldosterone.²⁴ Its action is thus directly related to the circulating level of endogenous mineralocorticoid. In contrast, triamterene a pteridine derivative is not dependent on circulating levels of aldosterone and has a different mechanism of action from spironolactone. Nonetheless these agents have identical effects on urinary composition.⁶ The drugs are absorbed and act in their native state in the distal nephron, to inhibit sodium reabsorption and to block potassium and hydrogen ion excretion. They are weak natriuretic drugs when used alone, capable of inhibiting only the 2 to 3 per cent of the filtered salt load which is delivered to the distal nephron (even less during volume depletion).

Since the distal tubule potassium sparing agents are not potent natriuretic drugs they are employed in the edema-forming states and in hypertension (Table I), principally in combination with the other diuretics for a small additive diuresis and to prevent hypokalemia. However, spironolactone alone in higher doses (400 to 600 mg/day) may be useful in the management of primary aldosteronism.

The major side effects of the potassium sparing agents related to their tubular actions are hyperkalemia and less commonly, metabolic acidosis.^{25, 26} These complications are particularly frequent either in patients receiving potassium supplementation or with renal insufficiency; thus these agents are contraindicated under these circumstances. Gynecomastia and hirsutism are troublesome side effects of spironolactone²⁷ and both drugs in this class cause mild gastrointestinal upset in occasional patients. Nonetheless the distal potassium sparing agents when used properly, have added a significantly useful component to modern diuretic therapy.

In summary, the last 30 years has seen the development of many useful oral diuretic agents active at different sites in the renal tubule. Rational use of these agents in the edema-forming states in hypertension or in other special situations requires knowledge of their pharmacology, mechanism of action and side effects. With understanding and careful use diuretics have become some of the most valuable widely used drugs in the modern therapeutic armamentarium.

more advantageous than right sided A-V sequential pacing. If a quadripolar electrode were to be used in the coronary sinus site differences in the positions of the electrode pairs may further accentuate the stimulus threshold differences for the two chambers, with the proximal and distant pairs being used for atrial and ventricular stimulation respectively. Thus the technique here described with possible further refinements and an appropriately designed pacing device may obviate the necessity of two electrode insertions for the purposes of sequential A-V pacing.

R. H. Wald M.D. F.R.C.P.(C)
M. B. Waxman M.D. F.R.C.P.(C)
J. F. Bonet M.D.
Department of Medicine
University of Toronto
Division of Cardiology
Toronto General Hospital
Toronto Ontario Canada

REFERENCES

- Samet P, Castillo C and Bernstein W: Hemodynamic sequelae of atrial ventricular and sequential atrioventricular pacing in cardiac patients. *Am Heart J* 72:725 1968
- Lumbard D, Dreifus L.S. and Berkovits B.V. Specific pacemaker design for intractable cardiac arrhythmias (Abstr.) *Circulation* 37 and 48 (Suppl. IV) IV 194 1973
- Fields, J. Berkovits B. V. and Matloff J. M. Surgical experience with temporary and permanent A-V sequential demand pacing. *J Thorac Cardiovasc Surg* 65:865 1973
- Rubensfire M., Berkovits, B., and Malinowski, E. Single catheter electrode technique for temporary bifocal A-V sequential pacing (Abstr.) *Circulation* 47 and 48 (Suppl. IV) IV 710 1973
- Castellanos A. Berkovits, B. V. Castillo C. A., and Befeler B. Sextapolar catheter electrode for temporary sequential atrioventricular pacing. *Cardiovasc Res* 8:712 1974
- Kramer D. H. and Moss, A. J. Permanent percutaneous atrial pacing from the coronary vein. *Circulation* 42:427 1970.
- Furman S., and Fisher J. D. Cardiac pacing and pacemakers. V. Technical aspects of implantation and equipment. *Am Heart J* 94:250 1977
- Lester J. W., Klotz D. H., Jomam S. L., Stuckey J. H. and Hoffman B. F. Effect of pacemaker site on cardiac output and ventricular activation in dogs with complete heart block. *Am J Cardiol* 18:494 1964
- Daggett W. M., Bismarck J. A., Powell W. J. Jr., and Austen W. G. Relative contributions of the atrial systolic ventricular systole interval and of patterns of ventricular activation to ventricular function during electrical pacing of the dog heart. *Circ Res* 27:69 1970

A reevaluation of intravenous quinidine*

Quinidine is an effective and widely used antiarrhythmic agent usually given orally for long term arrhythmia control. Although lidocaine and procainamide are generally recognized as agents of choice for emergency control of most ventricular tachyarrhythmias, some arrhythmias are refractory to these agents. Furthermore many supraventricular arrhythmias respond poorly to lidocaine and procainamide. Thus clinical situations often arise in which the need for rapid achievement of therapeutic quinidine levels necessitates parenteral therapy. The intramuscular (IM) route has been the preferred mode of parenteral quinidine therapy largely due to sporadic reports of unfavorable reactions to quinidine by the intravenous route. Recent studies on the pharmacokinetics of IM drug administration as well as recent experience with intravenous quinidine suggest that the question of the optimum parenteral route for quinidine should be reconsidered.

Intramuscular administration of many agents results in slow unpredictable and sometimes incomplete drug absorption. Poorly water soluble drugs are often prepared for injection in irritating oily solvent vehicles. After injection the

drugs may precipitate at the injection site resulting in considerable local pain and tissue damage as well as poor drug absorption. Although total quinidine bioavailability by the IM route is comparable to that observed after oral administration of quinidine sulfate absorption is erratic and occasionally non linear. Furthermore quinidine injections are associated with moderate to severe pain and substantial increases in serum creatine phosphokinase.

It is widely perpetuated dogma that intravenous quinidine is too hazardous to be acceptable. Specific hazards are thought to include profound hypotension, exacerbation of malignant arrhythmias and cardiac arrest. Some clinicians have stated that intravenous quinidine is never or hardly ever indicated because of these risks.

Two large series and a number of case reports appear to constitute the evidence upon which these recommendations rest (Table 1). Critical assessment of these cases indicates that most of the patients with adverse reactions to intravenous quinidine were virtually moribund before the drug was given. Their arrhythmias were complicated by severe congestive heart failure, hypotension or shock. Moreover the patients often were receiving digitalis and some appeared to have overt digitalis toxicity. In five cases quinidine was infused too rapidly and electrocardiographic (ECG) signs of toxicity were not heeded. The mode of death was not always documented, and even the authors acknowledged that death may have occurred despite rather than because of quinidine.

This work was done in part during the tenure of research grant in aid award from the American Heart Association Western Massachusetts Division to Dr. Greenblatt. Dr. Greenblatt is an Associate Professor of Medicine at the Massachusetts General Hospital and is a member of the faculty of the Harvard Medical School. Dr. Woo is the recipient of a research fellowship (HL-05723) from the United States Public Health Service.

Sequential atrioventricular pacing with a single bipolar electrode catheter

Electrophysiologic and hemodynamic considerations have perhaps never found a better technologic interface than the highly specialized sequential atrioventricular mode of cardiac pacing. Although the exact extent of its applicability is yet to be established its usefulness in the management of certain select clinical problems has been well documented.^{1,2} One of the drawbacks of the technique has been the necessity of separate atrial and ventricular electrodes. A specially designed six polar catheter has been one proposed solution to this problem,³ but experience with it is still limited. Despite the recent development of specialized atrial pacing electrodes the coronary sinus remains one of the best and most reliable permanent atrial pacing sites.⁴ Since the left ventricle can also be paced from an electrode in the coronary sinus we tested the possibility of sequential A-V pacing via a single bipolar electrode catheter placed in the coronary sinus. The feasibility of this undertaking depended on a sufficient difference between the left atrial and left ventricular pacing thresholds from the coronary sinus site to allow selective

stimulation of the two chambers with a reasonable margin of safety. Fig 1 demonstrates this technique in a patient in whom a bipolar electrode catheter had been temporarily inserted into the coronary sinus during a diagnostic procedure being carried out for a different purpose. The atrial pacing threshold was found to be about one fourth of the ventricular threshold. The bipolar electrode was connected to two isolated stimulators set at 15 times the pacing threshold of each chamber and triggered sequentially by a digital timing device such that the lower voltage stimulus was followed by the higher one after a variable delay which effectively determined the resulting A-V delay. So long as this delay was less than the atrial refractory period the atrium would not be restimulated with the ventricular impulse. The application of this technique resulted in successful A-V sequential pacing at variable rates and atrioventricular delays.

Previous evidence showing that left ventricular pacing resulted in better cardiac output than right ventricular pacing⁵ may possibly render this mode hemodynamically




Fig 1 Simultaneous tracings of electrocardiographic Leads 1, 2, and 3 and stimulus timing signals (bottom). The QRS configuration during normal sinus rhythm (panel A) and during atrial pacing via the coronary sinus electrode (panel B) are identical. In panel C the left ventricle is paced through the same electrode utilizing a higher current. In panels D, E, and F low and high intensity stimuli are applied in pairs with delays of 100, 150, and 200 msec respectively. With delays of 100 and 150 msec (panels D and E) the QRS configuration is intermediate between the sinus and ventricular paced configurations and is the result of different degrees of fusion between ventricular and supraventricular activations. When the spontaneous P-R interval is exceeded (delay 200 msec, panel F) the QRS configuration is again identical to that during sinus rhythm or atrial pacing. In this instance the ventricular stimulus is too late to affect the ventricular depolarization pattern resulting from conduction of the atrial impulse.

effects were encountered ECG changes characteristic of quinidine effects occurred in all patients these rapidly reversed following termination of the infusion as did other symptoms and signs. Results from other laboratories are similar. Conrad and colleagues infused quinidine at a rate of 0.5 to 1.0 mg/Kg/minute to nine hospitalized patients with out significant adverse effects. Ueda and associates and Hirschfeld and co-workers described intravenous infusion of quinidine gluconate at 3 to 4 mg/Kg/minute to 27 cardiac patients, 12 of whom had underlying conduction defects. They noted no increase in the degree of block or in ventricular ectopic activity. Mild asymptomatic decreases in blood pressure occurred in 15 patients this responded to elevation of the legs and slowing or termination of the infusion. Two patients had more severe hypotension with nausea and dyspnea. The syndromes resolved without sequelae with termination of the infusion. Therapeutic serum levels (3 to 7 µg/ml) were achieved within 22 minutes in 15 of the 16 patients who received 2.6 to 4.4 mg/Kg of quinidine base. Potentially toxic serum quinidine concentrations did not occur in any patient.

Many other reports are available documenting the safe use of intravenous quinidine in the context of more general evaluations of antiarrhythmic therapy.

Quinidine administration by any route is not without risk and the risk is especially great in certain susceptible individuals. For patients needing parenteral therapy intravenous infusions are clearly preferred to IM injections. The IM route is painful and characterized by erratic and unreliable absorption. Furthermore it is impossible to halt further drug absorption if untoward ECG or hemodynamic reactions develop following IM injection. Rapid intravenous infusion of quinidine with resulting plasma concentrations in the known toxic range would certainly be expected to carry unacceptable hazard. Because quinidine is rapidly and extensively distributed to tissues, potentially toxic serum concentrations are not likely to be reached during a slow controlled infusion of a therapeutic dose at 0.3 to 0.4 mg/Kg/minute. If untoward ECG or hemodynamic effects do develop in susceptible individuals during the infusion they can be reversed readily by stopping the infusion. Thus well controlled slow intravenous infusion, with due regard for plasma levels achieved appears to represent a safe and reliable mode of quinidine administration for patients needing parenteral therapy.

Elaine Woo M.D.

David J. Greenblatt M.D.

Clinical Pharmacology Unit

Massachusetts General Hospital

Boston, Mass 02114

REFERENCES

- Greenblatt D J and Koch Weser J. Intramuscular injection of drugs. *N Engl J Med* 295:547 1976
- Greenblatt D J, Pfeifer H J, Ochs H R, Franke K, MacLaughlin D S, Smith T W, and Koch Weser J. Pharmacokinetics of quinidine in humans after intravenous, intramuscular and oral administration. *J Pharmacol Exp Ther* 202:365 1977
- Friedberg C K. *Diseases of the Heart* 3rd ed., Philadelphia 1956 W B Saunders Company p 553.
- Goldberg L I. *Pharmacology of cardiovascular drugs*, in *The Heart Arteries and Veins*, 3rd ed. edited by J W Hurst R B Logue R C Schlant and N K Wenger New York, 1974 McGraw-Hill, p 104
- Cohen S J. *Current concepts in quinidine therapy* in *Drugs in Cardiology* vol 1 edited by E Donoso New York, 1975 Stratton Intercontinental Medical Book Corporation pp 17-35
- Selzer A. The use and abuse of quinidine. *Heart Lung* 1:755 1972
- Sokolow M. The present status of therapy of the cardiac arrhythmias with quinidine. *AM HEART J* 42:711 1951
- Hepburn J. and Rykert H. Use of quinidine sulfate intravenously in ventricular tachycardia. *AM HEART J* 14:620 1937
- Rakov H L. Ventricular fibrillation in acute coronary artery thrombosis during the intravenous administration of quinidine sulfate. *Ann Intern Med* 16:571 1942
- Armbrust C A, Jr., and Levine S A. Paroxysmal ventricular tachycardia: study of 107 cases. *Circulation* 1:28 1959
- Acerno L J and Gubner R. Utility and limitations of intravenous quinidine in arrhythmias. *AM HEART J* 41:733 1951
- Chapman D W. Observations on two patients with paroxysmal ventricular tachycardia treated by the intravenous administration of quinidine lactate. *AM HEART J* 30:776 1945
- Rosenman J E F., and Lunthall H. Paroxysmal ventricular tachycardia: its favorable prognosis in absence of acute cardiac damage and its treatment with parenterally administered quinidine dihydrochloride. *AM HEART J* 22:219 1941
- Strong G F and Munroe D S. Paroxysmal ventricular tachycardia with report of an unusual case. *AM HEART J* 19:486 1940
- Ferris M I, Harvey R M, Werko L., Dredale D T., Courmand A., and Richards D W Jr. Some effects of quinidine sulfate on the heart and circulation in man. *AM HEART J* 36:816 1948
- Gaughan G E, Low B., Langman J., Voukydis P. and Besser H W. Acute oral testing for determining antiarrhythmic drug efficacy. I. Quinidine. *Am J Cardiol* 38:677 1976
- Koster R W and Wellens H J J. Quinidine induced ventricular flutter and fibrillation without digitalis intoxication. *Am J Cardiol* 38:519 1976
- Reynolds E W and Van der Ark C R. Quinidine syncope and delayed repolarization syndromes. *Mod Concepts Cardiovasc Dis* 45:117 1976
- Ochs H H., Greenblatt D J., Woo E., Franke K. and Smith T W. Reduced clearance of quinidine in elderly humans. *Clin Res* 25:513A 1977
- Greenblatt D J., Pfeifer H J., Ochs H R., Franke K., Smith T W. and Koch Weser J. Pharmacokinetics of parenteral quinidine in humans. *Clin Pharmacol Ther* 21:105 1977
- Conrad K A, Molk B L. and Chudsey C A. Pharmacokinetic studies of quinidine in patients with arrhythmias. *Circulation* 55:1 1977
- Ueda C T, Hirschfeld D S., Scheinman M M., Rowland M., Williamson B J. and Dzundzo B S. Disposition kinetics of quinidine. *Clin Pharmacol Ther* 19:30 1976
- Hirschfeld D S., Ueda C T, Rowland M. and Scheinman M M. Clinical and electrophysiological effects of intravenous quinidine in man. *Br Heart J* 39:309 1976
- Rutkowski M M., Doyle E F. and Cohen S N. Drug therapy of heart disease in pediatric patients: a therapeutic challenge of supraventricular tachyarrhythmias in infants and children. *AM HEART J* 86:567 1973

Table I Reports of adverse reactions to intravenous quinidine

Ref erence	Number of fatalities/ total cases	Characteristics of patients with adverse reactions			Quinidine dose and rate of injection	Adverse reactions
		Age	Disease state(s)*	Clinical status prior to quinidine administration		
8	0/9	?	IHD PVT	Hypotension	Infusion of 15 mg/min to maximum total of 2300 mg	Transiently exacerbated hypo- tension in one patient after 650 mg
9	1/1	57	Acute MI PVT	Semi mor- bund Cyanotic Dyspneic	450 mg as a bolus follow- ing 1.8 gm given in prior 24 hours	Agitation then collapse
10	4/34	50	RHD Severe CHF PVT	Moribund	600 mg over 20 min	No details given
		55	Uremic coma RHD	Comatose	300 mg given over a few minutes	Respirations ceased
		58	Acute MI	Extreme shock	1200 mg over 30 min	No details given
		51	RHD AF	Shock	100 mg time not specified	No details given
11	4/44	66	Hypertension CHF Digitalis toxicity PVT	Not stated	650 mg over 30 min	Progressive AV block then asystole
		50	Hypertension PVT Possible digitalis toxicity	Not stated	130 mg over 10 min	Progressive AV block then asystole
		50	Hypertension CHF PVT Digitalis toxicity	Not stated	400 mg over 27 min	Progressive AV block then ventricular fibrillation
		60	Hypertension Severe CHF AF Possible digitalis toxicity	Coma	650 mg as a bolus	Progressive AV block then asystole
12	0/2	52	IHD PVT	Stable	900 mg over 300 min	Seizure then recovery
		47	PVT	Stable	650 mg as a bolus	No ill effects
13	0/1	?	PVT	Stable	450 mg as a bolus	Transient unconsciousness then recovery
14	0/1	41	PVT	Stable	2650 mg time not speci- fied	Seizure transient unconscious- ness then recovery

CHF = congestive heart failure IHD = ischemic heart disease MI = myocardial infarction PVT = paroxysmal ventricular tachycardia RHD = rheumatic heart disease AF = atrial fibrillation

Finally it is clear that quinidine administration by any route can produce hypotension 'a paradoxical increase in ectopic activity' or even life threatening ventricular tachyarrhythmias in particular susceptible individuals. It may well be that some of the intravenous quinidine fatalities reported in the older clinical literature were due to the patient's sensitivity to quinidine *per se* rather than to the route of administration.

Recent evidence suggests that contrary to popular dogma well controlled and monitored intravenous infusions of quinidine at appropriately slow rates constitute a safe and reliable mode of quinidine administration. We have infused quinidine lactate at a rate of 33 mg/Kg/minute to a large series of healthy subjects aged 20 to 70 years. Most subjects experienced perioral paresthesias and some individuals reported nausea but no important adverse hemodynamic

a need to define responsibility and accountability. And this is the responsibility of the medical profession and good government even though the government is run by laymen and not by physicians. If the doctors won't assume this responsibility the U.S. Government will—and should—and must.

The answer to these problems is better education and practices in the medical schools and hospitals and the consideration of ethics, morals, and considerate practice in the medical curriculum.

There is a need for better training in bedside medicine and cardiology with greater compassionate consideration of the sick man's dollar. Excellent bedside cardiology is much more difficult but more rewarding to the physician than excelling in a single procedure or the operation of one gadget. The master cardiologist does not routinely need these expensive and hazardous examinations and tests. However he knows when he needs them and uses them selectively. Good well-trained and master clinicians can obtain the necessary clinical information at the bedside much more thoughtfully, less expensively and without risk to the patient. But who is to train elegant or master bedside cardiologists? Bedside clinicians are disappearing and new ones are not appearing to replace them. Surely those who must depend upon catheters,

treadmills, Holter monitors, vectorcardiograms, echocardiograms, coronary care units, etc. for management of the cardiac patient cannot train bedside cardiologists. The need in cardiology is not for more gadgets, more tests, and more costs but rather for more and better clinical education. What the master cardiologist can do for his patient at the bedside with little cost to the U.S. Government, insurance companies, and patients and their families is astounding. There is a need to value merit and good practice and not measure success by money, material things, or political and administrative advancement. These are problems that can best be resolved by the medical profession itself.

George E. Burch, M.D.

Tulane University School of Medicine
and Charity Hospital of Louisiana
New Orleans, La.

REFERENCES

1. Containing the rising cost of medical care under social security. WHO Chronicle 31:408, 1977.
2. Greenberg D. S. Carter and health care. N Engl J Med 297:1299, 1977.

Favorable effects of prolonged nitroglycerin infusion in patients with acute myocardial infarction

The prognosis of acute myocardial infarction has been closely related to the extent of cardiac damage. Necrosis is a dynamic process and in the early period of acute myocardial infarction cells which are still in reversible injury can either progress to necrosis or retain viability. Experimentally it has been shown that after coronary occlusion pharmacological interventions may decrease the development of myocardial necrosis quantified histologically and enzymatically. These interventions which protect the ischemic myocardium in laboratory animals also hasten the decline of elevated precordial ST segment in animals and in patients. Nitroglycerin accelerates the fall of ST segment elevations in patients with acute myocardial infarction suggesting that the extent of myocardial damage may be decreased. In those patients the favorable effects of nitroglycerin on ischemia were demonstrated with an infusion maintained for only a few hours; a longer infusion might be considered as a real treatment and could reduce complications and mortality of acute myocardial infarction.

Seventy-four patients with acute myocardial infarction (admitted within 24 hours of the onset of chest pain) were randomized to control (35 patients) or to nitroglycerin treatment (39 patients) groups. Patients with initial cardiogenic shock and patients not in clinical shock but with systolic arterial pressure less than 90 mm Hg were excluded from this study. Nitroglycerin was initially infused at a rate of 15 µg/minute and the dose was slowly increased every 10 minutes until a fall in systolic arterial pressure of 70 mm Hg was obtained. The first 12 patients were treated during 24 hours

since there were only few side effects. Nitroglycerin infusion was maintained for 5 to 7 days in the 27 other patients. Infusion began 10.1 ± 0.9 hours after the onset of chest pain and the average rate of nitroglycerin infusion was 50.8 ± 3.7 µg/minute. All patients with anterior acute myocardial infarction (nitroglycerin and 22 control patients) were studied by 30 lead precordial mapping; the maps recorded on admission and 7 days later were comparatively analyzed according to Maroko's scoring system. The admission maps were similar in the two groups of patients. Vulnerable sites were defined as sites with ST segment elevation >1.5 mm and persistent R wave on initial map.

Q waves appeared in 56.2 ± 14.0 per cent of the vulnerable sites in control patients versus 30.0 ± 7.3 per cent in nitroglycerin patients. The sum of R wave voltages (ΣR) in these sites fell more in the control group than in the nitroglycerin group (64.0 ± 12.7 per cent versus 32.4 ± 8.1 per cent, $p < 0.05$). The incidence of premature ventricular complexes was nearly similar in the two groups but ventricular fibrillation (VF) and ventricular tachycardia (VT) were less frequent in the nitroglycerin group (VF 0, VT four) than in the control group (VF three, VT eight). The hospital mortality rate was reduced in the nitroglycerin group: only two of 39 nitroglycerin patients died (two of 24 anterior infarctions, 0 of 15 inferior infarctions) versus eight of 35 control patients (six of 22 anterior infarctions, two of 13 inferior infarctions, $p < 0.01$).

This preliminary study concerns a limited number of patients and does not provide quantitative information

- 25 Hejtmancik M R and Herrmann G R A study of paroxysmal ventricular tachycardia *Ann Intern Med* 28 989 1948
- 26 Stempfen E and Katz K H Quinidine and potassium in treatment of refractory paroxysmal ventricular tachycardia *AM HEART J* 24 555 1942
- 27 Clagett A H Jr Intravenous use of quinidine with

- particular reference to ventricular tachycardia *Am J Med Sci* 220 381 1950
- 28 Fisher J D Cohen H L Mehra R Altschuler H Escher D J W and Furman E Cardiac pacing and pacemakers II Serial electrophysiologic-pharmacologic testing for control of recurrent tachyarrhythmias *Am HEART J* 93 658 1977

Of testing, treating, and charging

It is interesting that only in recent years has cardiology become so expensive and so many expensive tests have become routine. In the past special procedures were used only when absolutely indicated and they were not used routinely. The two step test, a mild stress test, was used only when definitely necessary because of its hazard and the additional cost. The two step test is now replaced by the treadmill test which is much more stressful, much more dangerous, a great deal more expensive and used almost routinely by some cardiologists but its value is yet to be established. It certainly is yet to be shown to be so routinely indicated. It has not been shown to be more informative clinically or quantitatively than Master's two step test nor more informative than a good history, physical examination, and minimal simple and inexpensive laboratory studies. Nevertheless patients are now strongly advised and led to believe that no cardiac evaluation is complete or thorough without a treadmill stress test, vector cardiogram, echocardiogram, Holter monitor recording, radioisotopic cardiac scan, blood gas analyses, respiratory function study, apex cardiogram, phonocardiogram, His bundle electrogram, and even cardiac and coronary angiography. These tests result in charges of several hundred dollars to the patient. And even if the U.S. Government, state or municipal governments, and insurance carriers pay for these tests, the total cost is still borne by people often by sick people too ill to work to earn the money to pay for even part of medical services. Who is to control or stop this? And is there no limit? Can one provide such services and charge them to others without prior consideration or consent of even third party payers? Surely no physician would allow the U.S. Government insurance company or patient to visit any retail store (medical or other) and charge purchases to him without prior consent regardless of how these purchases improved the health, happiness or psychic state of the purchaser. Why then can physicians and others order tests and consultations at random even when these procedures are not fully justified on the basis of established medical value, absolute medical needs or standards of practice and merely bill the payer for them? Would any person or patient open his charge account at any department store to his doctor or any clinic or medical institution? Then why open an unlimited charge account for all and any medical tests, procedures and consultations? This is what prevails to an excessive extent in American medicine today—modern medicine. This practice is especially common among large clinical group practices and hospital groups.

The policy of testing, consulting, treating, etc. without regard to cost or prior permission of the payer on an elective

basis is most unusual in the present civilization and society or of any time in the history of man. This policy would be comparable to one allowing the U.S. Government and insurance companies to pay for retail goods in all department stores to provide happiness and good health for all people in response to the judgment of social workers or others. Purchase of anything that would make people happy would certainly better their health. It would only be necessary to bill the U.S. Government (the American people) and insurance companies (the policy holders) and the bills would be paid without question except that the price for each item would be limited to the level indicated in a price code established by HEW or any other third party agency. Why are the costs for medicine given different consideration than those for food, clothing, housing, transportation, entertainment, vacations, etc.? All these items can improve the health, well being and happiness of people.

With pressure to sell medical material and equipment by manufacturers and with the scare instilled through the press about sudden death, the great killer, and periodic health examinations and cardiac check-ups, patients are often frightened so much that they even enter bankruptcy in order not to die. This is not necessary and should not be permitted in America. The patient and his family, with their inadequate knowledge, cannot decide alone about the need for tests and treatment, especially when they listen to the arguments presented and are faced with the American tradition of considering that good things cost a lot. But who is to control this uncontrolled practice which is spreading like a medical economic plague? Remember much of this originates and is initiated by the U.S. Government research supported programs and by other government agencies and their policies and regulations as well as by insurance companies. Surely special facilities must be available for occasional special and rare and well selected needs. But who is to control the introduction of expensive devices by manufacturers whose primary responsibility and business is to make money? The indications use claims of value, charges and quality of service and marketing policies of apparatus, procedures and tests need definition and careful consideration by the medical profession. The physicians should control the use of these procedures and tests and if they don't, then the U.S. Government should and eventually will. Not only is there a great need to control tests, procedures, equipment and apparatus but there is even greater need to decide what is a fair charge to be made to patients without their prior consent. There is a need to justify at least all hazardous and expensive studies at all times. More controls! But whose fault? There is

Main determinant of ECG voltage measurements

To the Editor

The paper by Toshima and colleagues on Correlations between electrocardiographic vectorcardiographic and echocardiographic findings in patients with left ventricular overload which appeared in the November 1977 issue of the AMERICAN HEART JOURNAL (94:547 1977) is very interesting.

It demonstrates a close correlation between voltage measurements and wall thickness in patients with pressure overload but not in patients with volume overload. On the other hand a close correlation was found between voltage measurements and cavity size in volume overload but not in pressure overload. I am surprised that the authors do not give the explanation which is to be found in the papers to which they refer for these findings. The main determinant of electrocardiographic voltage measurements is not ventricular wall thickness but muscle mass which can be estimated from echocardiographic measurements of wall thickness and cavity size. In compensated pressure overload cavity enlargement does not occur and wall thickness is the main dimension contributing to ventricular mass. In volume overload both wall thickness and cavity size increase. Wall thickness may only be modestly increased but it is cavity size which is the main dimension contributing to ventricular muscle mass. Voltage measurements were greater in patients with volume overload than in those with pressure overload and had the authors calculated muscle mass they would have found that this was also greater in volume overload.

David Bennett MD MRCP
Cardiac Department
The Radcliffe Infirmary
Oxford OX2 6HE
England

Reply

To the Editor

I would like to thank Dr Bennett for his letter regarding our article in AM HEART J (94:547 1977). We agree that the main determinant of electrocardiographic and vectorcardiographic voltage measurement is ventricular mass. However we chose not to emphasize this since our main interest was to investigate the differences in vectorcardiographic features between patients with left ventricular (LV) hypertrophy and dilatation. Our study demonstrated that QRS voltage was related to LV wall thickness in patients without LV cavity dilatation and to LV cavity size in patients without LV wall thickening. These findings could be considered to have a similar meaning—that LV mass is the main determinant of QRS voltage—which was not fully mentioned in our reports. It is quite likely however that other factors such as myocardial fibrosis, Brody effect proximity effect and so on play some role in the augmented QRS voltage. Thus correlations between LV mass and maximum magnitude of the spatial

QRS vector ($r = 0.58$) or SV + RV or RV ($r = 0.60$) were not high in our study.

Hironori Toshima MD
Yoshinori Koga MD
3rd Department of Internal Medicine
Kurume University Medical School
67 Asahimachi
Kurume 830 Japan

Lactate production after left ventricular angiography in coronary artery disease

To the Editor

The effects of contrast medium on hemodynamic and myocardial function are well known; however little is known of its effects on myocardial metabolism. In an attempt to study this problem we have determined the percentage of lactic acid extraction [arterial (LA)—coronary sinus lactic acid concentration (LV) $\times 100$ /arterial concentration (LA)] during left ventricular angiography in 32 subjects. The samples were obtained at basal state immediately after the intravenous injection of contrast medium (0.8 cc/kg of meglumine diatrizoate) at maximum increase of left ventricular end-diastolic pressure (LVEDP continuously monitored) and 20 minutes after the injection.

The patients who were all male and aged between 30 to 66




Fig 1 Maximum change of myocardial extraction ratio of lactate after left ventricular angiography (A) in normal subjects and in CAD patients (B = basal values)

however these results suggest that prolonged nitroglycerin infusion reduces significantly electrocardiographic extension and hospital mortality rate of acute myocardial infarction

J P Derrida MD

R Sal MD

P Chiche MD FACC

Hopital Tenon

4 rue de la Chune

Paris 75020

France

REFERENCES

- 1 Hillis L D and Braunwald E Myocardial ischemia N Engl J Med 296 1093 1977
- 2 Maroko P R Hillis L D Muller J E et al

Favorable effects of hyaluronidase on electrocardiographic evidence of necrosis in patients with acute myocardial infarction N Engl J Med 296 898 1977

- 3 Derrida J P Sal R Hourdebaigt Larrusse P et al Cartographie précordiale à la phase aiguë de l'infarctus myocardique Tentative de limitation de la nécrose par les dérivés nitrés oraux et intraveineux Coeur Med Int 15 423 1976
- 4 Flaherty J T Come P C Baird M G et al Effects of intravenous nitroglycerin on left ventricular function and ST segment changes in acute myocardial infarction Br Heart J 38 612 1976
- 5 Chiche P Derrida J P and Sal R Traitement de l'infarctus myocardique récent par la Trinitrine en perfusion prolongée N Presse Med 6 4119 1977

Copyright information

The appearance of a code at the bottom of the first page of an original article in this journal indicates the copyright owner's consent that copies of the article may be made for personal or internal use or for the personal or internal use of specific clients. This consent is given on the condition, however, that the copier pay the stated per copy fee through the Copyright Clearance Center, Inc., P.O. Box 765, Schenectady, N.Y. 12301 518 374 4430 for copying beyond that permitted by Sections 107 or 108 of the U.S. Copyright Law. This consent does not extend to other kinds of copying, such as copying for general distribution for advertising or promotional purposes, for creating new collective works, or for resale.




Fig 2 High power view of endocardial lesion showing acute inflammatory cells cellular debris necrotic material fibrin and erythrocytes portion of normal myocardium (lower right) (Hematoxylin and eosin stain)

tended to rupture easily exuding creamy purulent contents. Microscopically the outer surfaces of these masses were covered by attenuated endothelial cells the bulk of each cystic lesion consisted of acute inflammatory cells cellular debris necrotic material platelets fibrin and exudate (Fig 2). There was no microscopic evidence of bacteria viral inclusions fungi or neoplastic cells. At the point of attachment of these cystic lesions to the ventricular wall the mural endocardium showed no evidence of thickening inflammation or edema.

The types of lesions which most commonly affect the endocardium are bland or infected vegetations mural thrombi with or without secondary infection and abscesses which may be primary or secondary to myocardial infection. The lesions described in our patient do not belong to any of these three categories. The usual endocardial vegetation is irregular rigid and friable but in the present case the mural endocardial lesions were globular soft cystic and otherwise intact until ruptured at autopsy. All of these lesions appeared to be at the same stage of maturity and probably were present for no more than five to seven days. A few scattered polymorphonuclear leukocytes among the myofibers of the ventricular wall probably resulted from seepage from the cystic lesions. Occasional scattered necrotic muscle fibers were noted but not in direct relationship to the cysts. No myocardial abscesses were found. Of particular interest was the entirely normal condition of the cardiac valves.

The proximate initiating mechanism of these endocardial "pseudocysts" remains uncertain. The ulcerating carcinoma and terminal bronchopneumonia may represent remote portals of entry of invading organisms however the endocardial lesions may have begun as non bacterial vegetations

which subsequently underwent secondary infection or ischemic necrosis or both. There were however no lesions in any transitional stages of this process. Furthermore non bacterial vegetations most commonly begin on the cardiac valves which was not true in this case. The uniform stage of maturity of the "pseudocysts" suggests a single episodic event as the primary cause.

Persaud and Milstoc and Berger¹ reported the only three similar cases of endocardial pseudocysts in the English literature. The clinical background in their cases was one of chronic debilitating illness the lesions were identical both grossly and microscopically with those mentioned above. In the two cases of Persaud, burns and bronchiectasis were present in one instance streptococci were cultured from the endocardial lesions and in the second case cytomegalovirus was observed both in the lesions but also in most organs of the body. It would be impossible from a practical viewpoint to determine whether such organisms found in these lesions were primary causes or only secondary invaders. The single case reported by Milstoc and Berger presented such endocardial lesions together with a myocardial abscess which may have been a primary cause or possibly a secondary complication of the few adjacent endocardial lesions.

A review of the limited case material suggests that this type of endocardial lesion develops in the presence of debilitating illness which is remote from rather than approximate to the heart and endocardium.

The electrocardiographic changes in the present case suggest acute anteroapical myocardial infarction though autopsy revealed only scattered microscopic areas of individual fiber necrosis and a few inflammatory cells in the myocardium. Recent studies suggest such foci of myocytolysis can be

years (mean 50 years) were divided into two groups: the first group consisted of ten normal subjects (studied because of chest pain of uncertain etiology) and was considered as control; the second group consisted of 22 patients having typical angina (with 75 per cent or greater luminal obstruction in at least one of the major coronary artery branches). All subjects underwent cardiac catheterization and coronary angiography.

Production of lactic acid in the coronary sinus or extraction of less than 10 per cent was considered to be a sign of myocardial energy deficiency and of anaerobic glycolysis.

In the first group only one patient showed production of lactate after ventricular angiography; another one showed an extraction of less than 10 per cent.

In the second group (CAD patients) all of them except one showed either less than 10 per cent extraction or production of lactate (Fig 1).

Atrial pacing (140 beats/minute \times 10 minutes) performed in 12 patients of the CAD group resulted in marked lactate production only in seven patients; whereas three patients showed a reduction of lactate and two patients showed no change.

The increase of lactic acid production after left ventricular angiography does not show a correlation with either the degree of coronary occlusion (using Gensini's scores) or with ejection fraction or with variation of LVEDP.

It seems likely that the perfusion of coronary capillary bed by contrast medium could be the determining factor in the onset of anaerobic metabolism.

The practical interest of our observation is the availability of a reliable method to assess myocardial metabolism by a single routine procedure like left ventricular angiography.

Odoardo Visioli M.D. Ph.D.

Francesco Cuccini M.D.

Stefano Bongroni B.S.D.

Roberto Ferrari M.D.

Cattedra di Malattie dell'Apparato Cardiovascolare

Università degli Studi di Parma

Via Gramsci 14 Parma

Italy

REFERENCES

1. Rahumtoola S H, Duffy J P and Swan H J C. Ventricular performance after angiography. *Circulation* 35:70 1967.
2. Hammermeister K E and Warbasse J R. Immediate hemodynamic effects of cardiac angiography in man. *Am J Cardiol* 31:307 1973.
3. Brundage II H and Cheitlin M D. Ventricular function curves from the cardiac response to angiographic contrast: a sensitive detector of ventricular dysfunction in coronary artery disease. *AM HEART J* 88:281 1974.
4. Gensini G G. *Coronary arteriography*. New York 1975 Futura Publishing Company.

Unusual cystic endocardial lesions

To the Editor

An unusual form of cystic endocardial lesion found in association with chronic debilitating illness may require special attention from echocardiographers especially as their instruments become more sensitive.

An illustrative case was a 78 year-old white female who



Fig 1 Endocardial pseudocysts with abscess formation confined to the areas of the trabeculae carneae of the left ventricle.

complained of shortness of breath and was found on hospital admission to have a right lower quadrant mass, melena, an iron deficiency anemia, a white blood cell count of 38 000 and serial electrocardiograms compatible with acute anteroseptal myocardial infarction. Chest x-ray revealed only cardiac enlargement and bilateral pulmonary congestion. Shortly after admission the patient developed hypotension, increased pulmonary congestion, oliguria and eventually coma; she died on the third hospital day.

At autopsy a fungating, moderately well differentiated adenocarcinoma of the caecum, approximately 7 cm in length, was identified together with microscopic metastases to regional lymph nodes and liver. Extensive pelvic thromboses were associated with recent embolism to the smaller pulmonary arteries.

The heart weighed 340 grams and showed occlusive coronary atherosclerosis with microscopic foci of patchy fibrosis. All valvular structures were normal. On the left ventricular endocardium there were numerous discrete, round and ovoid, soft, grayish-yellow, fluctuant masses, 0.1 to 2.0 cm in diameter, filling the recesses of the trabeculae carneae (Fig 1). These lesions were smooth, globular, soft, easily compressible and



Fig 2 High power view of endocardial lesion showing acute inflammatory cells cellular debris necrotic material, fibrin and erythrocytes portion of normal myocardium (lower right) (Hematoxylin and eosin stain)

tended to rupture easily exuding creamy purulent contents. Microscopically the outer surfaces of these masses were covered by attenuated endothelial cells the bulk of each cystic lesion consisted of acute inflammatory cells cellular debris necrotic material platelets fibrin and exudate (Fig 2). There was no microscopic evidence of bacteria viral inclusions fungi or neoplastic cells. At the point of attachment of these cystic lesions to the ventricular wall the mural endocardium showed no evidence of thickening inflammation or edema.

The types of lesions which most commonly affect the endocardium are bland or infected vegetations mural thrombi with or without secondary infection and abscesses which may be primary or secondary to myocardial infection. The lesions described in our patient do not belong to any of these three categories. The usual endocardial vegetation is irregular rigid and friable but in the present case the mural endocardial lesions were globular soft cystic and otherwise intact until ruptured at autopsy. All of these lesions appeared to be at the same stage of maturity and probably were present for no more than five to seven days. A few scattered polymorphonuclear leukocytes among the myofibers of the ventricular wall probably resulted from seepage from the cystic lesions. Occasionally scattered necrotic muscle fibers were noted but not in direct relation, up to the cysts. No myocardial abscesses were found. Of particular interest was the entirely normal condition of the cardiac valves.

The proximate initiating mechanism of these endocardial pseudocysts remains uncertain. The ulcerating carcinoma and terminal bronchopneumonia may represent remote portals of entry of invading organisms however the endocardial lesions may have begun as non bacterial vegetations

which subsequently underwent secondary infection or ischemic necrosis or both. There were however no lesions in any transitional stages of this process. Furthermore non bacterial vegetations most commonly begin on the cardiac valves which was not true in this case. The uniform stage of maturity of the pseudocysts suggests a single episodic event as the primary cause.

Persaud and Milstoc and Berger² reported the only three similar cases of endocardial pseudocysts in the English literature. The clinical background in their cases was one of chronic debilitating illness the lesions were identical both grossly and microscopically with those mentioned above. In the two cases of Persaud, burns and bronchiectasis were present in one instance streptococci were cultured from the endocardial lesions and in the second case cytomegalovirus was observed both in the lesions but also in most organs of the body. It would be impossible from a practical viewpoint to determine whether such organisms found in these lesions were primary causes or only secondary invaders. The single case reported by Milstoc and Berger presented such endocardial lesions together with a myocardial abscess which may have been a primary cause or possibly a secondary complication of the few adjacent endocardial lesions.

A review of the limited case material suggests that this type of endocardial lesion develops in the presence of debilitating illness which is remote from rather than approximate to the heart and endocardium.

The electrocardiographic changes in the present case suggest acute anteroseptal myocardial infarction though autopsy revealed only scattered microscopic areas of individual fiber necrosis and a few inflammatory cells in the myocardium. Recent studies suggest such foci of myocytolysis can be

years (mean 50 years) were divided into two groups the first group consisted of ten normal subjects (studied because of chest pain of uncertain etiology) and was considered as control the second group consisted of 22 patients having typical angina (with 75 per cent or greater luminal obstruction in at least one of the major coronary artery branches) All subjects underwent cardiac catheterization and coronary angiography

Production of lactic acid in the coronary sinus or extraction of less than 10 per cent was considered to be a sign of myocardial energy deficiency and of anaerobic glycolysis

In the first group only one patient showed production of lactate after ventricular angiography another one showed an extraction of less than 10 per cent

In the second group (CAD patients) all of them except one showed either less than 10 per cent extraction or production of lactate (Fig 1)

Atrial pacing (140 beats/minute \times 10 minutes) performed in 12 patients of the CAD group resulted in marked lactate production only in seven patients whereas three patients showed a reduction of lactate and two patients showed no change

The increase of lactic acid production after left ventricular angiography does not show a correlation with either the degree of coronary occlusion (using Gensini's scores) or with ejection fraction or with variation of LVEDP

It seems likely that the perfusion of coronary capillary bed by contrast medium could be the determining factor in the onset of anaerobic metabolism

The practical interest of our observation is the availability of a reliable method to assess myocardial metabolism by a single routine procedure like left ventricular angiography

Odoardo Visoli M D Ph D

Francesco Cuccini M D

Stefano Bongrani B S D

Roberto Ferrari M D

Cattedra di Malattie dell'Apparato Cardiovascolare

Università degli Studi di Parma

Via Gramsci 14 Parma

Italy

REFERENCES

- 1 Rahumtoola S H Duffy J P and Swan H J C Ventricular performance after angiography *Circulation* 35 70 1967
- 2 Hammermeister K E and Warbasse J R Immediate hemodynamic effects of cardiac angiography in man *Am J Cardiol* 31 307 1973
- 3 Brundage II H and Cheitlin M D Ventricular function curves from the cardiac response to angiographic contrast a sensitive detector of ventricular dysfunction in coronary artery disease *Am HEART J* 88 281 1974
- 4 Gensini G G Coronary arteriography New York 1975 Futura Publishing Company

Unusual cystic endocardial lesions

To the Editor

An unusual form of cystic endocardial lesion found in association with chronic debilitating illness may require special attention from echocardiographers especially as their instruments become more sensitive

An illustrative case was a 78 year old white female who



Fig 1 Endocardial pseudocysts with abscess formation confined to the areas of the trabeculae carneae of the left ventricle

complained of shortness of breath and was found on hospital admission to have a right lower quadrant mass melena an iron deficiency anemia a white blood cell count of 38 000 and serial electrocardiograms compatible with acute anteroseptal myocardial infarction Chest x ray revealed only cardiac enlargement and bilateral pulmonary congestion Shortly after admission the patient developed hypotension increased pulmonary congestion oliguria and eventually coma she died on the third hospital day

At autopsy a fungating moderately well differentiated adenocarcinoma of the caecum approximately 7 cm in length was identified together with microscopic metastases to regional lymph nodes and liver Extensive pelvic thromboses were associated with recent embolism to the smaller pulmonary arteries

The heart weighed 340 grams and showed occlusive coronary atherosclerosis with microscopic foci of patchy fibrosis All valvular structures were normal On the left ventricular endocardium there were numerous discrete round and ovoid soft grayish yellow fluctuant masses 0.1 to 2.0 cm in diameter filling the recesses of the trabeculae carneae (Fig 1) These lesions were smooth globular soft easily compressible and

37 other patients who had positive tests and no symptoms at all. That included pain or other kinds of anginal equivalents that were usual for that particular patient as determined by his history. Unusual equivalents were excluded as best we could by questioning the patients. While patients with angina may have the same pain pattern with each episode studies like ours (and those performed with Holter monitoring) question how consistent such a pattern is. Finally the pain threshold factor should not be glibly dismissed by the observation that since all patients had a "chest pain syndrome" the pain threshold could be simply discovered by historical features. Because of psychological factors denial and subcultural norms influencing the kinds of symptoms that are most acceptable for patients to admit the relatively soft data that is obtained by history taking is not as valid for statistical analysis as is harder data such as the response to Achilles tendon pain etc., as measured by some standardized test. Since we did not do these more sophisticated tests we were not prepared to defend any conclusions regarding pain threshold based only on the kind of soft data cited.

4. In his final paragraph Dr. Lass apparently agrees with our conclusions, and he suggests that other noninvasive techniques may help unravel the problems of defective anginal warning systems. This appears inconsistent since from the tone of his letter it would seem that if the patient had a positive exercise test associated with a radionuclide scan or any other noninvasive procedure Dr. Lass would still question the adequacy of the history. Was the patient a kerd if there was a numb sensation between the third and fourth toes on his left foot? And so on ad nauseam. From the point of view of clinical relevancy this is obviously not that pertinent. Either one accepts the concept of a defective warning system whatever its etiology and however it is defined or one does not. If one does accept it then the role of angina as a useful warning symptom needs to be re-emphasized to the patient. The patient without angina or its equivalents during some or all ischemic episodes may require a much more cautious approach in regard to recommendations about stressful activities, physical training programs etc. This is the implication of our study and we hope to have more data in this regard in future reports.

Peter F. Cohn, M.D.
Director, Clinical Cardiology Service
Dept. of Medicine
Cardiovascular Division
Harvard Medical School
Peter Bent Brigham Hospital
721 Huntington Ave.
Boston, Mass. 02115

Retrograde Wenckebach effect in VT

To the Editor

I was interested to read the Letter to the Editor by Drs. Cotoi, Georgescu and Corlea, that appeared in the May 1978 issue of AMERICAN HEART JOURNAL. Retrograde Wenckebach phenomenon in ventricular tachycardia (95:6:1978).

In 1971 my associates and I reported this phenomenon clearly documented in a male physician with ventricular tachycardia of 57 days duration.
Fordy L., Holker J. and Levy H. Paroxysmal ventricu-

lar tachycardia of prolonged duration. Analysis of retrograde Wenckebach effect by polygraphs and electrokymogram. Review of present therapy. Am J Med 10:254 1951.

It was gratifying to learn of another manifestation of this phenomenon which we reported so many years ago.

Leon Fordy, M.D.
1150 Park Ave.
New York, N.Y. 10028

Lenegre's disease in youth

To the Editor

We have read with interest the case report by Dianzumba and colleagues entitled "Lenegre's disease in youth" describing a 22-year-old, apparently healthy man who presented with symptomatic AV block. We recently saw a 20-year-old otherwise healthy female who presented with intermittent




Fig 1 Panel A ECG on admission. Sinus tachycardia 125 per minute with high degree AV block and intermittent complete AV block. The ventricular rate is 31 per minute. The QRS morphology suggests RBBB and left anterior fascicular block. Panel B ECG a few hours after admission. The AV block has disappeared. The QRS pattern now suggests RBBB and left posterior fascicular block.

associated with ECG patterns of transmural infarction *

Since the endocardial lesions were not suspected during life in the present case no special diagnostic techniques were used. Physicians who regularly interpret echocardiographic studies should be aware of this lesion and identification of such pseudocysts during life should prompt the physician to search for occult malignant disease and possibly for sites of chronic infection in the patient.

The prognostic significance of these cystic endocardial lesions remains in doubt since to date they have been identified by autopsy only in a setting of other serious life threatening illness. It is quite possible that such lesions may heal as the underlying illness improves; all evidence of their previous existence may disappear during the healing process. Identification of these lesions by echocardiographic technique during life might not necessarily imply a negative prognosis.

Solange Abu Nassar MD
Associate Attending Pathologist
John T. Flynn MD
Chief of Medicine
Beekman Downtown Hospital
170 William St
New York NY 10038

REFERENCES

- 1 Persaud V. Two unusual cases of mural endocarditis with a review of the literature. *Am J Clin Pathol* 53:832-1970.
- 2 Milstoc M and Berger A. True bacterial mural endocarditis. *Chest* 59:103-1971.
- 3 Duren D and Mecker A. Focal myocytolysis mimicking the electrocardiographic pattern of transmural anteroapical myocardial infarction. *Chest* 59:506-1976.

Silent or asymptomatic myocardial ischemia

To the Editor

I read with much interest the article in the April 1978 issue of *AM HEART J* entitled "Silent myocardial ischemia during and after exercise testing in patients with coronary artery disease" by Drs Lindsey and Cohn (*AM HEART J* 95:441-1978). I fail to understand how the authors can conclude from the data they presented in their article that there may be silent or asymptomatic myocardial ischemia just as there may be silent myocardial infarction. Their initial statement that they studied the exercise responses of 232 consecutive patients with chest pain syndromes negates the word "silent." Only 122 of these 232 patients with coronary artery disease and an abnormal ECG response to exercise testing were reported upon. Their two step test was considered positive if there were new or additional J point depression greater than 0.5 mm, while exercise tests performed on a bicycle were required to have 0.1 mm ST segment depression.

In their discussion Lindsey and Cohn state: "A majority of the patients in both groups had a history of angina that could be described as typical, but this occurred as frequently and with the same severity in both subgroups. Once again the word 'silent' does not seem indicated. In their conclusion they admit that three of the 44 pain free patients did have an anginal equivalent, mainly dyspnea. In regard to their third conclusion, I fail to understand the comment: 'We did not conduct pain threshold tests to determine if our pain free group actually had a higher than normal pain threshold.' This

seems obviated by the fact that all patients had a chest pain syndrome. The threshold could simply have been discovered by review of records and/or speaking to the patients involved. Their fourth comment that their patients may have experienced truly unusual anginal equivalents once again could have been discovered by the appropriate history. It is well known that patients with angina pectoris or its equivalent often have the same response with each episode of coronary insufficiency.

Although a considerable number of patients with coronary artery disease may have ECG evidence of exercise induced myocardial ischemia without angina or its usual equivalents, I do not see how the authors can make this conclusion from their study. I agree that there may be a group of non-responders, but their non-response may be a result of inadequate history, inadequate testing, and failure to use the ancillary methods of exercise testing at our disposal.

The use of systolic time intervals, phonocardiograms, echocardiography, radionuclide imaging, and real time radionuclide cineangiography may help unravel the mystery of the defective warning system.

Joseph P. Liss Jr MD FACC
Chief, Exercise Laboratory
Director, Cardiac Rehabilitation
Saint Francis Hospital and Medical Center
Hartford, Conn 06105

Reply

To the Editor

Several points in the letter from Dr. Liss require clarification.

1. Dr. Liss objects to our term "silent" because all of the patients had a chest pain syndrome and a majority of them had typical angina as well. In our paper we specifically noted that "silent" referred to the absence of symptoms during a positive exercise test. This was done in order to make the point that not all episodes of ischemia are associated with pain. The analogy might be made to the individual who has had angina who has suffered an infarction with pain and then suffers one without pain or any of his other usual symptoms. We would interpret that second infarction as being a "silent" one and believe that most cardiologists would agree.

2. The 122 patients reported from our consecutive series were those who had positive tests and coronary artery disease, as clearly stated in the text. We did not discuss the other 48 patients in our series without heart disease who had positive or negative tests nor did we discuss the 62 patients with coronary disease who had negative tests. Correlating the presence or absence of pain during a negative test in patients with coronary disease presents a difficult set of problems in defining an ischemic episode; hence our decision to limit our discussion in the present report to those patients with clearly positive tests and angiographically determined coronary artery disease. The criteria for positive tests that we used are the standard ones employed for the two types of tests and as noted, similar numbers of both kinds of tests (two step test and bicycle) were performed in the subgroup with and without pain during positive tests, thereby negating the methodology of the test as a discriminating factor.

3. Three patients had dyspnea which was their usual anginal equivalent and nine others experienced fatigue which may or may not have been their usual anginal equivalent. These patients were given special mention because there were

Book reviews

Congenital Malformations of the Heart and Great Vessels
Synopsis ■ Pathology Embryology and Natural History
By Hans Baski Baltimore 1977 Urban & Schwarzenberg 264 pages

The title of this book defines its contents very well. The author is from the Faculty of Pathology of the University of Vienna Austria and the contents of this small but elegant book describe his own experiences and material from his department. The book is divided into two parts: one concerned primarily with embryology of the heart and the second with specific malformations. Although it contains nothing new, the book summarizes concisely and extremely well in 264 pages the congenital anomalies of the heart and great vessels. Readers will appreciate the book because of its brevity. There are 793 references cited. This book is worth owning by anyone who is concerned with cardiology.

Angina Pectoris Edited by Desmond G. Julian M.D. New York, 1977 Churchill Livingstone 272 pages Price \$75.00

This is a useful and clinically oriented book on angina pectoris edited by Julian and written by 18 contributors. The subject is concisely discussed including the history, pathophysiology, diagnosis and medical and surgical management of angina pectoris. Each chapter has appended a selected bibliography. Angina pectoris is an important aspect of medicine and one of the most common diseases of man. Every physician, regardless of his specialty, must contend with angina pectoris. This is a very good up-to-date review of the disease presented in a practical clinical manner for the average physician's benefit. This is a highly recommended book for all practicing physicians, especially general practicing physicians and internists.

Chest Pain: An Integrated Diagnostic Approach Edited by Donald L. Levene with Ronald F. Billings, Geoffrey M. Davies, John Edmeads, and Fredric G. Saibil Philadelphia 1977 Lea & Febiger Publishers 903 pages Price \$11.00

Chest pain is an interesting and important subject. The editors and contributors discuss the neurological and psychological aspects of chest pain including pain arising from intrathoracic structures, chest wall nerves and spinal cord, extrathoracic structures, and emotional disorders. A section is devoted to pain in children. This paperback book of 903 pages is brief. It can serve as a good review of chest pain for all

physicians. Undergraduate medical students and housestaff should find this a source for rapid review of chest pain. The book reminds physicians of the many causes of chest pain and the extreme importance of careful evaluation of pain in the chest. A rapid and casual diagnosis can certainly lead to considerable errors in diagnosis, expense to patients, and mistreatment. Chest pain is one of the most common complaints of patients. All of the eight contributors are from Toronto, Canada. The book is written for the practicing physician. Some discussions are too brief and inadequate, for example, the presentation of the post-cardiotomy syndrome on page 51. This is an extremely important and common syndrome which responds dramatically to proper therapy when administered early and responds relatively poorly when treated late. The practicing physician should appreciate this book.

Second Henry Ford Hospital International Symposium on Cardiac Surgery Edited by Julius C. Davis, M.D. New York 1977 Appleton-Century-Crofts Inc. 732 pages Price \$65.50

This symposium must have been an outstanding one to attend. The many participants were from various parts of the world and included surgeons presently engaged in cardiovascular surgery. The subjects discussed are extremely interesting and the history of cardiac surgery which advanced so rapidly during the last 25 to 30 years is nicely described by those responsible for cardiac surgery. Those who witnessed these advancements can appreciate this publication most and those who entered medicine recently certainly should read and enjoy this book.

The book is divided into 17 sections, all interesting, each consisting of brief summaries of important aspects of cardiac surgery. Among the sections are reflections on the development of cardiac surgery, diagnosis, extracorporeal circulation, anesthesia, congenital anomalies and surgery for them, cardiac valve surgery and replacement, myocardial revascularization, management of pump failure, and others. The papers are relatively short but well written and clearly describe the authors' contributions and thoughts. The book is nicely printed and bound. The illustrations are clear and the photographs interesting. This publication is an excellent history of cardiac surgery for a 25-year period up to about 1975. This is a valuable publication of the proceedings of what must have been a very good and well-organized symposium.




Fig 2 His bundle electrocardiogram (HBE) showing normal AH and prolonged HV intervals

symptomatic trifascicular block who conforms with the criteria for Lenegre's disease

Case report

The patient is a 20 year old apparently healthy female brought to the hospital because of recurrent episodes of dizziness of one week's duration. The family history and past medical history were negative. The physical examination on admission revealed peripheral pulse of 30 per minute and blood pressure of 170/90 mm Hg. The rest of the examination including the cardiovascular system was unremarkable. The initial electrocardiogram revealed sinus rhythm with atrial rate of 125 per minute, high degree AV block and intermittent complete AV block. The ventricular rate was 31 per minute. The QRS complexes had a pattern of RBBB and left anterior fascicular block (Fig 1A). A temporary transvenous pacemaker was inserted. The chest x ray, cardiac fluoroscopy, echocardiogram and other laboratory data revealed no abnormalities. The electrocardiographic monitoring in the CCU revealed intermittent nature of the AV block with symptoms appearing during the period of AV block. On the sixth hospital day a permanent pacemaker was implanted. The twelve lead ECG during normal AV conduction showed regular sinus rhythm 80 per minute, PR interval 1.6 second, RBBB and left posterior hemiblock (Fig 1B). A His bundle electrocardiogram during

this time showed normal AH and prolonged HV intervals (Fig 2) indicating infranodal conduction delay. Eight months after admission the patient now has returned to normal activity without symptoms. The standard ECG after pacemaker suppression with chest wall stimulation shows persistent RBBB, left posterior hemiblock and intermittent high degree AV block.

The clinical and electrocardiographic data along with alteration in His bundle ECG suggest the etiology as Lenegre's disease. To our knowledge this case represents the youngest patient with documented heart block possibly secondary to Lenegre's disease.

P K Mathew MD FACC
T Mariano MD
A Ostro MD
Department of Medicine
University of Rochester
School of Medicine and Dentistry
St Mary's Hospital
Rochester NY 14611

REFERENCE

1. Dianzumba S B, Singer D H, Meyers S, Barresi V, Belic N and Smith J M. Lenegre's disease in youth. *AM HEART J* 94:479 1977.

Author index*

A

- ABENDSCHEIN DANA R TACKER WILLIS A JR AND BABBS CHARLES F Protection of ischemic myocardium by whole body hypothermia after coronary artery occlusion in dogs 17
- ARTALIO BELINDE (See Brunson et al) 419 (Letter to Editor)
- ANTABIAN ACOP HAMBY ROBERT I KRAMER ROBERT J AND WISOFF B GEORGE Unusual complications of coronary bypass surgery 17
- — — HOFFMAN IRWIN AND KRAMER ROBERT J Coronary ectasia: Incidence and results of coronary bypass surgery 309
- (See Hamby et al) 195
- AKHTAR MASOOD (See Reddy et al) 316
- ALDERMAN MICHAEL H SELIGMANN ARTHUR W AND DAVIS TONI K Hypertension control: an alternate view from Gimbels 471 (Letter to Editor)
- ALOSILLA CARLO (See Lim et al) 463
- ALTER BARRY R TREASURE ROBERT L MARTIN HAL A HUNTER STEPHEN H MURGO JOSEPH P AND MCGRANAHAN GEORGE M JR Echocardiographic detection of a subannular aortic aneurysm 579
- ALVAREZ SERGIO (See Benchimol et al) 347
- AMAT Y LEON FERNANDO BLASDELL ALISON TEAGUE STEVE ROSEY KENNETH V AND DENES PABLO Effects of bundle branch block on experimental A to ventricular tachycardia 67
- AMERSON JOHN A MILLER JOSE HENMAN MICHAEL V AND TEICHGOLD LOUIS E The ventricular A wave: a new echocardiographic index of late diastolic filling of the left ventricle 615
- AMITAI NOGA (See Lewis et al) 636
- ANDERSON CARY J AND REISER JOSEPH Ouabain induced Wenckebach conduction block in canine Purkinje fibers: The role of cycle length and time dependent changes in membrane potential 781
- AOAI KYUZO KONDO SHITA MOCHIZUKI AKAHITO YOSHI DA TADASHI KATO SEITSUKO KATO KAZUAKI AND TAIKAWA KIYOHARU Anti-hypertensive effect of cardiovascular C₂ antagonist in hypertensive patients in the absence and presence of beta adrenergic blockade 718
- APPLEFELD MARK M Reply 566 (Letter to Editor)
- ARAKAWA TAKEHI (See Hambe et al) 517
- ARANI DIAVAT T GREENE DAVID G AND KLOCKE FRANK J Coronary artery fistulas emptying into left heart chambers 438
- ARAQYI MATTHEW A KHAIRI IBRAHIM M YAO LINDA J AND FREIS EDWARD D Leukocyte intracellular cations in hypertension: Effect of antihypertensive drugs 31
- ARAVANTIS CHRIST Smoking and the causes of CHD 493 (Letter to Editor)
- ARTIAS JOSE C GOLDBERG STANLEY J SPITARS SILJA E C AND DE VILLFELF VOLKERT H An evaluation of range gated pulsed Doppler echocardiography for detecting pulmonary outflow tract obstruction in the transposition of the great vessels 46
- ARONOW WILBERT S (See Feitlin DeVicario and Aronow) 337
- ARYANPURI IJAI (See Sassi Arvanpur and Shakibi) 135 (Letter to Editor)
- ATKINS JAMES M (See Sutherland O'Brien and Atkins) 311

B

- BABB CHARLES F (See Abend-schein Tacker and Babbs)

- BAKIR ASAD A PATEL SURESH K SCHWARTZ MELVIN M AND LEWIS EDMUND J Isolated dissecting aneurysm of the renal artery 97
- BARBOZA M JUAN S (See Carrasco et al) 760
- BAROLDI GEORGIO Coronary stenosis: Ischemic or nonischemic factor? 139
- Reply 562 (Letter to Editor)
- BASSLER THOMAS J Statistics: marathon and CHD 560 (Letter to Editor)
- BAUER SPOMENOK (See Kopman et al) 444
- BEDETTI CARLOS D SIEWERS RALPH D AND DUNSFORD HAROLD A Teflon felt embolism of coronary arteries after cardiac surgery: A case report 801
- BEEVERS D G (See Ferras et al) 97
- BEVELER BENJAMIN Reply 564 (Letter to Editor)
- BEMIS CHARLES E (See Iskandrian et al) 603
- BENCHIMOL ALBERTO REYN'S PHILIPPE ALVAREZ SERGIO DESSER KENNETH B AND MCCULLOUGH KAREN Noninvasive assessment of left internal mammary-coronary bypass patency using the external Doppler probe 347
- BENNETT DAVID Main determinant of ECG voltage measurements 830 (Letter to Editor)
- BERGER HARVEY J (See Reduto et al) 714
- BIRING THOMAS (See Starr et al) 37
- BYRMAN WILLIAM JR WHITMAN VICTOR, STANGER PALL AND RUDOLPH ABRAHAM M Congenital tricuspid incompetence simulating pulmonary atresia with intact ventricular septum: a report of two cases 655
- BLACK MARTIN (See Keeler et al) 677
- BLANKENHORN DAVID H (See Sanmarco Brooks and Blankenhorn) 470
- BLASDELL ALISON (See Amat y Leon et al) 67
- BOSSA PIERO (See Rav et al) 700 (Letter to Editor)
- BODDY K (See Ferras et al) 97
- BODEN GUNTHER (See Ochs et al) 349
- (See Ochs et al) 507
- BOERTH ROBERT C HAMMERMEISTER KARL E AND WARBASSE J RICHARD Comparative influence of ouabain, norepinephrine and heart rate on myocardial oxygen consumption and inotropic state in dogs 357
- BONET J F (See Wald Waxman and Bonet) 873 (Annot)
- BONGRANI STEFANO (See Visoli et al) 830 (Letter to Editor)
- BOLASSA MARTIAL G (See Sami et al) 303
- BOYE KEVIN H (See Fowler et al) 533
- BRASO EMMAUEL L (See Fouad et al) 646
- BROOKS HAROLD L (See Sheppard et al) 9
- BROOKS SAMUEL H (See Sanmarco Brooks and Blankenhorn) 470
- BROWN J J (See Ferras et al) 97
- BUNSON SANDRA C NUDEL DOV H GOOTMAN NORMAN AND ARTALIO BELINDE Truncus arteriosus in a family 419 (Letter to Editor)
- BULKLEY BERNARDINE H AND HUTCHINS GROVER M Pompe's disease presenting as hypertrophic myocardopathy with Wolff Parkinson White syndrome 216
- (See Ross et al) 10
- BURCH GEORGE E Of how non-invasive is non-invasive 130 (Annot)
- Of the myocardium and myotonia atrophica (dystrophica myotonica) 272 (Annot)
- Of discoveries, 416 (Annot)
- Of atherosclerosis in infants and children and viral infections 558 (Annot)
- Of the venous pumps and congestive heart failure 697 (Annot)
- Of testing treating and charging 837 (Annot)

1979 Pediatric Cardiology Examination

The Sub Board of Pediatric Cardiology of the American Board of Pediatrics will offer its next written examination on Friday July 13 1979. To sit for the examination the following criteria must be met: (1) Certification by the American Board of Pediatrics; (2) Two years of full time graduate training in an approved pediatric cardiology program; (3) Letters of recommendation from individuals able to attest to the applicant's fellowship training. Candidates who achieve a qualifying score on the written examination will be eligible for the oral examination. The oral portion of the examination will be held in October 1979 in San Francisco. A candidate must be successful on both the written and oral portions of the examination in order to be certified.

The registration period for the examination will extend from October 1 1978 to January 31 1979. Please contact the American Board of Pediatrics to receive an application for the examination. The application fee for the written portion of the examination is \$300 (\$150 registration and \$150 examination). An additional fee of \$150 will be payable upon receipt of an appointment for the oral portion of the examination. Direct inquiries to: American Board of Pediatrics Suite 402 NCNB Plaza 136 E Rosemary St Chapel Hill N C 27514. Telephone (919) 929 0461.

Third Symposium on Echocardiology

The Third Symposium on Echocardiology will be held at the Erasmus University Rotterdam The Netherlands on June 20 through 22 1979. The main program will consist of lectures by invited speakers selected contributions and a poster session. A commercial and scientific exhibition will be held in conjunction with the meeting. For registration information or further details please write: 3rd Symposium on Echocardiology Thoraxcenter EE 2302 A P O Box 1738 3000 DR Rotterdam The Netherlands Attn: Mr C T Lancée.

Florence International Meeting on Myocardial Infarction

An International Meeting on topics related to myocardial infarction will be held in Florence Italy from May 8 through

11 1979. The meeting will be divided into a series of lectures given by invited speakers and a sharing of original communications by participants. Communications selected by the Scientific Committee will be published together with the lectures in a volume issued by *Excerpta Medica* Amsterdam in 1979. For information regarding this meeting, please write: Florence International Meeting on Myocardial Infarction Organizing and Scientific Secretariat Istituto di Patologia Medica II dell'Università di Firenze Viale Morgagni 85 Firenze Italy Tel (055) 43 27 58.

Sexuality and the Cardiovascular Patient

A two day national course entitled *Sexuality and the Cardiovascular Patient* will be conducted in Baltimore Md on April 27 and 28 1979. The course will be co sponsored by the American Heart Association Council on Clinical Cardiology American Heart Association-Maryland Affiliate Inc and the American Heart Association-Central Maryland Chapter Inc. The purpose of the course will be to present to physicians cardiovascular nursing specialists and other allied health professionals the currently available information on the psychological and physiological aspects of sexuality of the various types of cardiovascular patients and the impact of this knowledge on cardiovascular rehabilitation. For further information regarding this course please contact: Michaeline K Silverstein Program Director American Heart Association-Central Maryland Chapter P O Box 17025 Baltimore MD 21203.

Symposium on Infarct Size

A symposium on *Infarct Size* organized by Dr D Durrer of Amsterdam and by Dr F L Meijer of Utrecht will be held in Utrecht The Netherlands on April 9 and 10 1979. Topics will include: Fundamental and diagnostic aspects of myocardial ischemia Arrhythmias in ischemia and infarction Pump failure and infarct size and Reduction of infarct size. Deadline for registration is February 1 1979. Registration fee is 150 Dutch florins which includes luncheons. For further information contact: Dr Frits L Meijer Department of Cardiology University Hospital 3500 CG Utrecht The Netherlands.

- GELBAND HENRY (See Garcia et al.) 662
 GIBSON EDWARD S (See Sackett et al.) 472 (Letter to Editor)
 GIBSON THOMAS C Blood pressure levels in acute myocardial infarction 475
 GILL SCHWARTZ (See Sakuma et al.) 384
 GIORGIANNI SALVATORE J Jr Steroids in myocardial disease 974 (Letter to Editor)
 GITEL SANFORD N (See Wessler and Gitel) 811
 GLAGOV SEYMOUR (See Lamberti et al.) 496
 GLOS D (See Lawson Gloss and Jick) 52
 GLOCKE MARMADUKE (See Lange et al.) 144
 GOLDBERG STANLEY J (See Arijas et al.) 467
 GOLDBOURT URI (See Siegmán Igra et al.) 669
 GOWES JOSEPH A (See Reddy et al.) 316
 GONZALEZ GERMAN (See Carrasco et al.) 760
 GOOTMAN NORMAN (See Brunson et al.) 419 (Letter to Editor)
 GORDON A G Lymphatic drainage of the brain and catarrh 84 (Letter to Editor)
 GOTTSMAN MERVIN M (See Lewis et al.) 636
 GOTTECHALK ALEXANDER (See Reduto et al.) 714
 GOLD LAWRENCE AND REDDY C V RANAMA Potential hazard of the programmable pacemaker 04 (Letter to Editor)
 GRAHAM DAVID I (See Jones and Graham) 270 (Annot.)
 GRAHAM IAN M Surgical versus medical treatment in disease of the left main coronary artery 1
 GRAMIAK RAYMOND (See See Nanda and Gramiak) 157
 GRECO V (See Puletti et al.) 561 (Letter to Editor)
 GREENBLATT DAVID J (See Ochs et al.) 389
 — (See Ochs et al.) 507
 — (See Woo and Greenblatt) 89 (Annot.)
 GREENE DAVID G (See Arani, Greene and Klocke) 438
 GROSHEN ROBERTSON MARSHA (See Viden et al.) 203
 GUYTHORP WARREN G More on BP measurement and cuff size 4.3 (Letter to Editor)
 GUTHANER DIANA F (See Cipriano and Guthaner) 166
- H**
- HALBERSLEVEN DAVID Ischemic myocardial disease and alterations in the ECG 2.6 (Letter to Editor)
 HALON DAVID A (See Lewis et al.) 636
 HAMASHIMA YOSHIHIRO (See Fujiwara, Kawai and Hamashima) 744
 HAMBY ROBERT I ANTIBABIAN AGOP ROBERTS GERALD AND KRAMER ROBERT J Postextrasystolic aortic pressure pulse response in coronary artery disease 185
 — (See Antablian et al.) 17
 — (See Antablian et al.) 309
 HAMMERMEISTER KARL E (See Boerth Hammermeister and Warbasse) 355
 HAMMOND GRAEME (See Reduto et al.) 714
 HAN JAOK (See Fondacaro Han and Yoon) 81
 HARNATZ JEROLD S (See Ochs et al.) 507
 HARSHEY JOHN S (See Ross et al.) 10
 HARSTON WILLIAM E JR ROBERTSON ROSE M AND FRIESINGER GOTTLIEB C Echocardiographic evaluation of porcine heterograft valves in the mitral and aortic positions 449
 HARTSLUCK JAMES M (See Whitsett Myers and Hartsluck) 70 (Letter to Editor)
 HAYNES R BRIAN (See Sackett et al.) 477 (Letter to Editor)
 HERMAN MICHAEL V (See Ambrose et al.) 615
 HESS T SCHOLTYK G AND RIESSEN W The prevention and reversal of digoxin intoxication with specific antibodies 486
 HIBI NORIO (See Kambe et al.) 19
 HIRAMORI KATSUHIRO SUMITOSHI TETSUYA MOTOGI SAERO HONDA TAKASHI KIMATA SHINICHI HIROSAWA KOHICHIRO KAWAI HISAOHI KONDO AKIRA IWAASA MASARU AND MITOSHI KAZUO Rapid sensitive detection of myoglobinemia by improved counterimmunoelectrophoresis in cases of acute myocardial infarction, 187

- HIROSAWA KOHICHIRO (See Hiramori et al.) 187
 HIRSCHMANN J V Pericardial constriction 110
 HOFFMAN IRWIN (See Antablian et al.) 309
 HONDA TAKASHI (See Hiramori et al.) 187
 HOOD WILLIAM H JR (See Weiner et al.) 458
 HOWELL, JOEL (See Lamberti et al.) 496
 HUEYER DAVID C (See Weiner et al.) 458
 HUMPHREY STEPHEN H (See Alter et al.) 525
 HUMPHRIES WILLIAM C JR (See Kessler et al.) 627
 HURZELER, PHILIP (See Furman and Hurzeler) 276 (Letter to Editor)
 HU SAH SHAFRAT SCHWARTZ JOEL M FRIEDMAN SANDOR A AND CHLA SEGUNDINA N Arterial thrombosis in essential thrombocythemia 31
 HUTCHINS GROVER M (See Ross et al.) 170
 — (See Bulkley and Hutchins) 746
- I**
- ISKANDRIAN ABDULLMASSIH S KIMBIRIS DEMETRIOS BEMIS CHARLES E AND SPOL BERNARD L Coronary artery to pulmonary artery fistulas 605
 IWAASA MASARU (See Hiramori et al.) 187

J

- JACOBELLIS G F (See Puletti et al.) 561 (Letter to Editor)
 JAMES T N (See Urthaler Walker and James) 481
 JICK H (See Lawson Gloss and Jick) 57
 JOHNSON ALFRED L LAIKEN STUART L AND SHABETAI RALPH Noninvasive diagnosis of ischemic cardiomyopathy by fluorocarbon detection of coronary artery calcification 571
 JOHNSON ARNOLD L (See Sackett et al.) 477 (Letter to Editor)
 JOHNSON LEWIS W (See Smulyan et al.) 596
 JONES JOHN V AND GRAHAM DAVID I Hypertension and the cerebral circulation—its relevance to the elderly 20 (Annot.)
 JONES RICHARD A (See Ross et al.) 170
 JORDAN DAVID (See Zonerach et al.) 286

K

- KAFFETZAKIS E M (See Mir and Kafetzakis) 350
 KAMBE TADASHI SUZUKI SHOHACHI KATO TADAYUKI HIBI NORIO FUKUI YOICHI ARAKAWA TAKEMI NISHINURA KINYA MIWA ARATA AND SAKAMOTO NOBUTO Origin of the basal systolic murmurs in mitral stenosis A study with intracardiac phonocardiography 519
 KAMPFMAN KENNETH (See Lamberti et al.) 496
 KAPILA RAJENDRA (See Lange et al.) 144
 KARREMAN GEORGE (See Starr et al.) 37
 KARSH DENNIS L UMBACH RICHARD E COHEN LAWRENCE S AND LANGOU RENE A Prolonged benefit of nitroglycerin ointment on exercise tolerance in patients with angina pectoris 587
 KATHOLI RICHARD E NOLAN STANTON P AND MCGUIRE LOCKHART B The management of anticoagulation during noncardiac operations in patients with prosthetic heart valves A prospective study 163
 KATO KATSUAKI (See Aoki et al.) 218
 KATO TETSUKO (See Aoki et al.) 218
 KATO TADAYUKI (See Kambe et al.) 519
 KAWAI CHUICHI (See Fujiwara, Kawai and Hamashima) 744
 KAWAI HISAOHI (See Hiramori et al.) 187
 KAY JEROME HAROLD ZUBIATE PABLO MENDEZ MICHAEL A VANSTROM NEAL AND YOKOMASA TARO Mitral valve repair for significant mitral insufficiency 553
 KEANE JOHN F FYLER DONALD C AND NADAS ALEXANDER S Hazards of cardiac catheterization in children with primary pulmonary vascular obstruction 556 (Annot.)

- BURCH PHILIP R J Reply 423 (Letter to Editor)
BURKHARDT D AND RAEDER E Reply 706 (Letter to Editor)

C

- CARLSON C JEFFREY AND RAPAPORT ELLIOT Reply 703 (Letter to Editor)
CARRASCO HUGO A FUENMAYOR P ABDEL BARBOZA M JUAN S AND GONZALEZ GERMAN Effect of verapamil on normal sinoatrial node function and on sick sinus syndrome 760
CASEY JOAN I AND MILLER MICHAEL H Infective endocarditis Part II Current therapy 263
— (See Miller and Casey) 123
CASTELLANOS AGUSTIN (See Garcia et al) 662
CHAROT MICHEL (See Sami et al) 303
CHAITMAN BERNARD R (See Sami et al) 303
CHANDRA ROMA B (See Scott Chandra and Roberts) 806
CHARPIN DENIS (See Sami et al) 303
CHAWLA KAMAL K (See Kramer et al) 381
CHICHE P (See Derrida Sal and Chiche) 833 (Annot)
CHIERCHIA S (See Maseri et al) 554 (Annot)
CHOU TE CHUAN AND WENZKE FRANK The importance of R on T phenomenon 191
CHUA SEGUNDINA N (See Hussain et al) 31
CIPRIANO PAUL R AND GUTHANER DIANA F Organized left atrial mural thrombus demonstrated by coronary angiography 166
COHEN LAWRENCE S (See Karsh et al) 587
— (See Reduto et al) 714
COHN PETER F Reply 838 (Letter to Editor)
CONNORS DEAN M (See Ledbetter Wells and Connors) 580
COTTRELL JAMES E AND TURNDORF HERMAN Intravenous nitroglycerin 550
COUSINEAU DANIEL LAPOINTE LÉONARD AND DE CHAMPLAIN JACQUES Circulating catecholamines and systolic time intervals in normotensive and hypertensive patients with and without left ventricular hypertrophy 227
CRAMPTON RICHARD S Another link between the left stellate ganglion and the long QT syndrome 130 (Annot)
CRUZ JAIRO II (See Saksena et al) 384
CUCCHINI FRANCESCO (See Visioh et al) 835 (Letter to Editor)

D

- DALE JOHN AND MYHRE ERIK Intravascular hemolysis in the late course of aortic valve replacement Relation to valve type size and function 24
— (See Kvarstein and Dale) 624
DAMATO ANTHONY N (See Reddy et al) 316
DAVIES D L (See Ferriss et al) 97
DAVIES M J ROBERTSON W B WOOLF N AND POPPLE A Pathogenesis of myocardial infarction 561 (Letter to Editor)
DAVIS TONI K (See Alderman Sehgmann and Davis) 421 (Letter to Editor)
DE CHAMPLAIN JACQUES (See Cousineau Lapointe and de Champlain) 227
DE VILLENEUVE VOLKERT H (See Aretas et al) 467
DELVICARIO MICHAEL (See Ferlinz DelVicario and Aronow) 337
DENES PABLO (See Amat y Leon et al) 62
DERRIDA J P SAL R AND CHICHE P Favorable effects of prolonged nitroglycerin infusion in patients with acute myocardial infarction 833 (Annot)
DESSER KENNETH B (See Benchemol et al) 347
DHATT MALKIAT S (See Reddy et al) 316
DOLGIN MARTIN (See Shah et al) 407
DOMBY W ROGER AND WHITCOMB MICHAEL E Pleural effusion as a manifestation of Dressler's syndrome in the distant post infarction period 243
DRAYER DENNIS (See Romankiewicz et al) 518
DUNBAR SCOTT (See Fowler et al) 533

- DUNSFORD HAROLD A (See Bedetti Siewers and Dunsford) 802
DUSTAN HARRIET P (See Fouad et al) 646

E

- EICH ROBERT II (See Smulyan et al) 596
EMERSON PETER A Preventing thromboembolism after myocardial infarction Effect of low dose heparin or smoking 129 (Annot)
ERIKSSON JAN (See Forfang and Eriksson) 739
ERWIN STANLEY W (See Mirvis and Erwin) 529

F

- FACTOR STEPHEN M Endocardial fibroelastosis Myocardial and vascular alterations associated with viral like nuclear particles 701
FENOGLO JOHN (See Schatz Fenoglio and Krongrad) 23
FERGUSON THOMAS II (See Kopman et al) 444
FERLINZ JACK DELVICARIO MICHAEL AND ARONOW WILBERT S Effects of rapid digitalization on total and regional myocardial performance in patients with coronary artery disease 337
FERRARI ROBERTO (See Visioh et al) 835 (Letter to Editor)
FERRIS J B BEEVERS D G BODDY K BROWN J J DAVIES D L FRASER R KREMER D LEVER A F AND ROBERTSON J I S The treatment of low renin (primary) hyperaldosteronism 97
FLYNN JOHN T (See Nassar and Flynn) 836 (Letter to Editor)
FONDALORO JOSEPH D HAN JAKO AND YOON MYUNG S Effects of verapamil on ventricular rhythm during acute coronary occlusion 81
FORESTER DONALD Chest thumping to terminate ventricular tachycardia 564 (Letter to Editor)
FORFANG KOLBJÖRN AND ERIKSSON JAN Significance of P wave terminal force in presumably healthy middle aged men 739
FOSTER JAMES R (See Reddy et al) 316
FOUAD FATMA M TARAZI ROBERT C DUSTAN HARRIET P AND BRAVO EMANUEL L Hemodynamics of essential hypertension in young subjects 646
FOWLER NOBLE BOVE KEVIN E DUNBAR SCOTT AND MEYER RICHARD Fatigue dyspnea and abdominal swelling in a 13 year old boy 533
FRANKLIN JOHN E JR (See Romankiewicz et al) 518
FRASER R (See Ferriss et al) 97
FRED HERBERT L Mutton's law 273 (Annot)
FREIS EDWARD D (See Aronow et al) 731
FRIEDMAN HARVEY M (See Litman and Friedman) 610
FRIEDMAN SANDOR A (See Hussain et al) 31
FRIESINGER GOTTLIEB C (See Harston Robertson and Friesinger) 448
FUENMAYOR P ABDEL (See Carrasco et al) 760
FUJIWARA HISAYOSHI KAWAI CHUICHI AND HAMASHIMA YOSHINOBU Clinicopathologic study of the conduction systems in 10 patients with Kawasaki disease (mucocutaneous lymph node syndrome) 744
FUKUI YOICHI (See Kambe et al) 512
FURMAN SEYMOUR AND HURZELER PHILIP Reply 2 6 (Letter to Editor)
FYLER DONALD C (See Keane Flyler and Nadas) 506 (Annot)

G

- GAMBEL ROBERT (See Saksena et al) 384
GARCIA OTTO L CASTELLANOS AGUSTIN SUNC RUEY J AND GFLAND HENRY Exposure of concealed right bundle branch block in Wolff Parkinson White type B by pacing from the vicinity of the A V node 662
GFDDES L A AND WHISTLER S J The error in indirect blood pressure measurement with the incorrect size of cuff 4
GEHA ALEXANDER (See Reduto et al) 714

- MILLER, MICHAEL H AND CASEY JOAN I Infective endocarditis New diagnostic techniques 193
— (See Casey and Miller) 63
MOLLY PAUL Replv 560 (Letter to Editor)
MIR M AFZAL AND KAFETZKIS E M Assessment of percutaneous maleate in angiographically proven intractable angina A double-blind trial 350
MIRVIS DAVID M AND ERWIN STANLEY W Ventricular pre-excitation and prolonged Q-T interval syndromes in a patient with mitral valve prolapse 523
MIWA ARATA (See Kambe et al) 519
MIYOSHI KAZUO (See Hiramori et al) 187
MOCHIZUKI AKIHIRO (See Aoki et al) 218
MORRIS GEORGE C JR (See Lie et al) 239
MOTEGI SAORO (See Hiramori et al) 187
MURGO JOSEPH P (See Alter et al) 575
MYERS WILLIAM S (See Whitsett Myers and Hartsuck) 100 (Letter to Editor)
MYHRE ERIK (See Dale and Myhre) 24

N

- NADAS ALEXANDER S (See Keane Fyler and Nadas) 551 (Annot)
NAGASAWA KOICHI (See Vyden et al) 203
NANDA NAVIN C (See Sze Nanda and Gramiak) 157
NASSAR SOLANGE ABU AND FLYNN JOHN T Unusual cystic endocardial lesions 836 (Letter to Editor)
NEUFELD HENRY N (See biegan Igra et al) 669
NIARCHOS ANDREAS P TAHMOORES I PARVIS AND TARAZI ROBERT C Comparison of heart rate and blood pressure response to amyl nitrite isoproterenol and standing before and during acute beta adrenergic blockade with intravenous propranolol 47
NI HIMURA KINYA (See Kambe et al) 512
NOLAN STANTON P (See Kathleen Nolan and McGuire) 163
NORDLANDER R (See Lofmark Nordlander and Ornmu) 153
NUDEL DOV B (See Brunson et al) 419 (Letter to Editor)

O

- OCHS HERMAN R REENBLATT DAVID J BODEN CUNTH ER AND SMITH THOMAS W Spironolactone 389
— — — AND HARMATZ JEROLD S Dose independent pharmacokinetics of digoxin in humans 507
ORINIS E (See Lofmark Nordlander and Ornmu) 153
ORourke MICHAEL F Conflicts in coronary care 696 (Annot)
OSBORN ROGER C JR (See Smythman Osborn and Atkula) 363
OSTROV A (See Mathew Manano and Ostrov) 839 (Letter to Editor)

P

- PARK JANET (See Shapiro and Park) 417 (Annot)
PARKER FREDERICK B (See Smulyan et al) 596
PARODI O (See Mason et al) 5:4 (Annot)
PARSONS WILLIAM H JR Effect of probucol in hyperlipidemic patients during two years of administration 713
PAZAL NOEMI Oral ISDN—long acting nitrate 474 (Letter to Editor)
PATIL RAJESH H (See Kramer et al) 381
PATIL SURESH H (See Bakir et al) 9
PEATFIELD RICHARD Towards more selective resuscitation 698 (Annot)
PHILLIPS DANIEL F (See Lim et al) 463
POFF R L (See Markiewicz and Popp) 5:5 (Annot)
POPPY A (See Davies et al) 561 (Letter to Editor)
PORDY LYON Retrograde Wenckebach effect in VT 839 (Letter to Editor)
POTTS JAMES L (See Smulyan et al) 596

- POAR F (See Puletti et al) 581 (Letter to Editor)
PRASQUIER RICHARD (See Werner Schiller and Prasquier) 180
PROUDFIT WILLIAM J (See Lim et al) 463
PULETTI M JACOBELLIS G F GRECO V AND POZZAR F Acid gas induced MI 561 (Letter to Editor)

II

- RABER M B Sensing the cardiac electrogram 275 (Letter to Editor)
RABINOWITZ STEPHEN H LOWEN BERNARD AND SLACK WARNER V Recourse to a computer for teaching the proper use of nitroglycerin 703 (Letter to Editor)
RACHWILEWITZ ELIEZER A (See Lewis et al) 636
RAEDER P (See Burckhardt and Raeder) 106 (Letter to Editor)
RAJASALMI M AND TAKKILNEN J Exercise tests atrial pacing and myocardial lactate extraction in relation to coronary arteriography in young patients with angina pectoris 751
RAMOS MARCOS U Reply 275 (Letter to Editor)
— Reply 279 (Letter to Editor)
RAPAPORT ELLIOT (See Carlson and Rapaport) 703 (Letter to Editor)
RATHOD RAMESH (See Kramer et al) 381
RAY MARIA TAVAZZI LUIGI SALERNO JORGE A AND BOBBA PIERO Evaluation of the hemodynamic effects of hyaluronidase in patients with acute myocardial infarction 700 (Letter to Editor)
REDDY C PRATAP DAMATO ANTHONY N AKHTAR MASOOD DHARTI MALKIAT S GONIES JOSEPH A AND FOSTER JAMES R Study of the temporal effects on conduction and refractoriness of the His-Purkinje system in man 318
REDDY C V RAMANA (See Gould and Reddy) 704 (Letter to Editor)
REDUTO LAWRENCE A BERGER HARVEY J GEHA ALEXANDER AND HAYMOND GRAEF COHEN LAWRENCE S GOTTSCHALK ALEXANDER AND ZARPT BARRY L Radionuclide assessment of ventricular performance during propranolol withdrawal prior to aortocoronary bypass surgery 714
REIDENBERG MARCUS (See Romankiewicz et al) 518
REISER JOSEPH (See Anderson and Reiser) 781
REYNS PHILIPPE (See Benrhoul et al) 347
RHEE JAI I (See Zonerach et al) 286
RIESEN W (See Hess Scholtysik and Riesen) 486
ROBERTS GERALD (See Hambro et al) 185
ROBERTS JAMES C JR Serum myoglobin tests by RIA 420 (Letter to Editor)
ROBERTS ROBIN S (See Sackett et al) 422 (Letter to Editor)
ROBERTS WILLIAM C (See Scott Chandra and Roberts) 806
ROBERTSON J I S (See Ferrus et al) 97
ROBERTSON ROSE M (See Harston Robertson and Friesen) 448
ROBERTSON W B (See Davies et al) 561 (Letter to Editor)
ROBY DAVID S (See Varki et al) 680
ROMANKIEWICZ JOHN A REIDENBERG MARCUS DRAYER DENNIS AND FRANKLIN JOHN E JR The noninterference of aluminum hydroxide gel with quinidine sulfate absorption. An approach to control quinidine induced diarrhea 518
ROSE GEOFFREY Population screening for myocardial ischemia 47
ROSE KENNETH M (See Amat y Leon et al) 62
ROSS RICHARD S BULKLEY BERNARDINE H HUTCHINS GROVER M HARSHLEY JOHN S JONES THORNE C KRAHS HENRY LIEBMAN JEROME THORNE C MICHAEL WEINBERG SIDNEY B WEECH A ASHLEY AND WEECH ALEXANDER A JR Idiopathic familial myocardialopathy in three generations A clinical and pathological study 170

- KENNELLY BRIAN M AND LANE GEOFFREY K Electrophysiological studies in four patients with atrial flutter with 1:1 atrioventricular conduction 723
- KESSLER KENNETH M HUMPHRIES WILLIAM C JR BLACK MARTIN AND SPANN JAMES F Quinidine pharmacokinetics in patients with cirrhosis or receiving propranolol 627
- KHAN MUSHTAQ (See Sakseena et al) 384
- KHATRI IBRAHIM M (See Arayae et al) 731
- KIMATA SHINICHI (See Hiramori et al) 187
- KIMBIRIS DEMETRIOS (See Iskandrian et al) 605
- KINOSHITA SHINJI Variations in the critical cycle length inducing rate dependent bundle branch block 54
- KLEID JACK J (See Massie Kleid and Schiller) 543
- KLEYN J H Quality of early ECG tracings 421 (Letter to Editor)
- KLOCKE FRANCIS J (See Arani Greene and Klocke) 438
- KOGA YOSHINOBU (See Toshima and Koga) 835 (Letter to Editor)
- KONDO AMIRA (See Hiramori et al) 187
- KONDO SHUTA (See Aoki et al) 218
- KOPMAN ERICUMANT A WEYGANDT GLENN R BAUER SPOMENKO AND FERGUSON THOMAS B Arterial hypoxemia following the administration of sublingual nitroglycerin 444
- KRALIOS ALEXANDROS C TSAGARIS THEOFILIS J AND KUIDA HIROSHI Comparison of rhythm and rate induced myocardial O_2 consumption changes before and after coronary occlusion 372
- KRAMER NEIL E RATHOD RAMESH CHAWLA KAMAL K PATEL RAMESH AND TOWNE WILLIAM D Echo cardiographic diagnosis of left ventricular mural thrombi occurring in cardiomyopathy 387
- (See Sakseena et al) 384
- KRAMER ROBERT J (See Antablian et al) 17
- (See Hamby et al) 19a
- (See Antablian et al) 309
- KRASNOW NORMAN AND STEIN RICHARD A Hypertrophic cardiomyopathy in the aged 326
- KRAUS HENRY (See Ross et al) 170
- KREMER D (See Ferriss et al) 97
- KRONGRAD FHUD (See Schatz Fenoglio and Krongrad) 235
- KUIDA HIROSHI (See Kralios Tsagaris and Kuida) 372
- AVARSTEIN BERNT AND DALF JON Leukocyte function after aortic valve replacement 624

L

- LABABIDI ZUHDI The O point and diastolic impedance wave form 277 (Letter to Editor)
- LABBATE A (See Maseri et al) 554 (Annot)
- LAIKEN STUART L (See Johnson Laiken and Shabetai) 521
- LAMBERTI JOHN J SILVER MELAYNE HOWELL JOEL KAMPAN KENNETH AND GLAGOV SEYMOUR Transmural gradients of experimental myocardial ischemia Limited correlation of ultrastructure with epicardial S T segment elevation 496
- LANE GEOFFREY K (See Kennelly and Lane) 723
- LANGE MICHAEL SALAMI JOHN S MIDDLETON JOHN R SEN PURNENDU KAPILA RAJENDRA GUCKE MARMADUKE AND LOURIA DONALD B Infective endocarditis in heroin addicts Epidemiological observations and some unusual cases 144
- LANGOU RENE A (See Karsh et al) 587
- LAPOINTE LEONARD (See Cousineau Lapointe and de Champlain) 227
- LAWRIE GERALD M (See Lie et al) 29a
- LAWSON D H GLOSS D AND JICK H Adverse reactions to methyl dopa with particular reference to hypotension 572
- LEDBETTER MARION K WELLS DAVID H AND CONNORS DEAN M Common pulmonary vein atresia 580
- LESCHIN A AND SCHMITZ L E Exaggerated impedance waveform—a noninvasive assay 275 (Letter to Editor)

- LEV MAURICE Setting the record straight on TAPVC 134 (Letter to Editor)
- LEVER A F (See Ferriss et al) 97
- LEWIS BASIL S RACHIMILEWITZ ELIEZER A AMITAI NOGA HALON DAVID A AND GOTSMAN MEYRIN S Left ventricular function in β thalassemia and the effect of multiple transfusions 636
- LEWIS EDMUND J (See Bakir et al) 92
- LIE J T LAWRIE GERALD M MORRIS GEORGE C JR AND WINTERS WILLIAM I Hemorrhagic myocardial infarction associated with aortocoronary bypass revascularization 295
- LIERMAN JEROME (See Ross et al) 170
- LIEF PHILIP D Diuretics 824
- LIM JUAN S PROUDFIT WILLIAM L SHELDON WILLIAM C ALOSILLA CARLOS PHILLIPS DANIEL F AND LOOP FLOYD D Perioperative myocardial infarction related to coronary bypass surgery 463
- LISS JOSEPH P JR Silent or asymptomatic myocardial ischemia 838 (Letter to Editor)
- LITMAN GEORGE I AND FRIEDMAN HARVEY M Mitral and mitral valve prolapse syndrome 610
- LITTMANN L (See Tenczer and Littmann) 134 (Letter to Editor)
- LOFMARK R NORDLANDER R AND ORINIUS M The temperature course in acute myocardial infarction 153
- LOOP FLOYD D (See Lim et al) 463
- LOURIA DONALD B (See Lange et al) 144
- LOVEGROVE T AND THOMPSON P The role of acute myocardial infarction in sudden cardiac death—a statistical nightmare 711
- LOWN BERNARD (See Rabinowitz Lown and Slack) 103 (Letter to Editor)
- LOWY FRANKLIN AND STEIGEBEL NPAH H Infective endocarditis Part III Prevention of bacterial endocarditis 689
- LUCERI RICHARD M Nocturnal angina 421 (Letter to Editor)

M

- McCABE CAROLYN (See Weiner et al) 458
- MACCARTHY E P AND STROKES G B Renal vein renin and saralasin testing in renovascular hypertension 69a (Annot)
- McCULLOUGH KAREN (See Benchimol et al) 317
- McGRANAHAN GEORGE M JR (See Alter et al) 52a
- McGUIRE LOCKHART B (See Katholi Nolan and McGuire) 163
- McMILLAN DONALD E Diabetic angiopathy—its lessons in vascular physiology 401
- MAGGS PETER R CPK MB elevations in hypothermia 703 (Letter to Editor)
- MANN GEORGE V Coronary heart disease—the doctor's dilemma 569
- MARIANO T (See Mathew Mariano and Ostrov) 839 (Letter to Editor)
- MARKEWICZ W AND POPP R L Effect of transducer placement on echocardiographic mitral valve motion 555 (Annot)
- MARSHALL GEORGE Roll over test 132 (Annot)
- MARTIN HAL A (See Alter et al) 575
- MASERI ATTILIO LABBATE A CHIENCHIA S AND PAROLI P Coronary artery spasm—diagnostic and therapeutic implications 554 (Annot)
- MASSIE BARRY KLEID JACK J AND SCHILLER NELSON E Echocardiography in ischemic heart disease Present status and future prospects 543
- MATTHEW P K MARIANO T AND OSTROV A Lenegre's disease in youth 839 (Letter to Editor)
- MELLER JOSE (See Ambrose et al) 615
- MENDEZ MICHAEL A (See Kay et al) 253
- MEYER RICHARD (See Fowler et al) 533
- MICK BROOKS A Neurologic-cardiologic interrelationships 700 (Letter to Editor)
- MIDDLETON JOHN R (See Lange et al) 144

- TOWNE WILLIAM D (See Kramer et al) 381
 — (See Saksena et al) 384
 TRACY GERALD P (See Smulyan et al) 596
 TREASURE ROBERT L (See Alter et al) 525
 TREHAN NARESH (See Shah et al) 407
 TROUT KILGORE ■ (See Sackett et al) 492 (Letter to Editor)
 TSAGARIS THEOFILLOS J (See Krahos Tsagaris and Kuida) 379
 TUCCI JOSEPH R (See Tommaso and Tucci) 274 (Letter to Editor)
 TURCK W P G Observations on Q fever endocarditis 564 (Letter to Editor)
 TURNDORF HERMAN (See Cottrell and Turndorf) 550

U

- UMBACH RICHARD ■ (See Karsh et al) 587
 URTHALER F WALKER A A AND JAMES T N The effect of aging on ventricular contractile performance 481

V

- VANSTROM NEAL (See Kay et al) 253
 VARAI AJIT P ROBY DAVID S WATTS HARVEY AND ZATUCHNI JACOB Serum myoglobin in acute myocardial infarction A clinical study and review of the literature 680
 VINOLI ODOARDO CLCCHINI FRANCESCO BONGRANI STEFANO AND FERRARI ROBERTO Leftate production after left ventricular angiography in coronary artery disease 835 (Letter to Editor)
 VYDEN JOHN K SELLERS ALVIN NAGASAWA KOICHI TAKANO TERLO GROSETH ROBERTSON MARSHA AND SWAN H J C Peripheral hemodynamics in anephric patients with hypertension 203

W

- WALD H W WAXMAN M B AND BONET J F Sequential stenoventricular pacing with a single bipolar electrode catheter 878 (Annot)
 WALKER A A (See Urthaler Walker and James) 481
 WARBASE J RICHARD (See Boerth Hammermeister and Warbase) 35
 WARLOW CHARLES Venous thromboembolism after stroke 283
 WATTS HARVEY (See Varki et al) 680
 WAYMAN M B (See Wald Wayman and Bonet) 878 (Annot)
 WEECH A ASHLEY (See Ross et al) 10

- WEECH ALEXANDER A JR (See Ross et al) 170
 WEINBERG SIDNEY B (See Ross et al) 170
 WEINER DONALD A MCCLARE CAROLYN HUETER DAVID C RYAN THOMAS J AND HOOD WILLIAM B JR The predictive value of anginal chest pain as an indicator of coronary disease during exercise testing 458
 WELLS DAVID H (See Ledbetter Wells and Connors) 580
 WENZKE FRANK (See Chou and Wenzke) 191
 WERNER JEFFREY A SCHILLER NELSON B AND PRASQUIER RICHARD Occurrence and significance of echocardiographically demonstrated tricuspid valve prolapse 180
 WESSLER STANFORD AND GITEL SANFORD ■ Coagulation for cardiologists 811
 WEXLER BERNARD C Myocardial infarction in young vs old male rats Pathophysysiologic changes 70
 WEYGANDT GLENN R (See Kopman et al) 444
 WHEATLEY CHARLES E Acute idiopathic pericarditis and calcific aortic stenosis unusual fatal disease combination 87
 WHISTLER S J (See Geddes and Whistler) 4
 WHITCOMB MICHAEL ■ (See Dombey and Whitcomb) 243
 WHITMAN VICTOR (See Betman et al) 655
 WHITSETT THOMAS L MYERS WILLIAM S AND HARTSUCK, JAMES M Nitroprusside reversal of ergotamine induced ischemia 700 (Letter to Editor)
 WINTERS WILLIAM L (See Lie et al) 295
 WIDOFF B GEORGE (See Aintablian et al) 17
 WOO ELAINE AND GREENBLATT DAVID J A reevaluation of intravenous quinidine 829 (Annot)
 WOOLF N (See Davies et al) 561 (Letter to Editor)

Y

- YAHINI JOSEPH M (See Siegman Igra et al) 669
 YAO LINDA L (See Araiye et al) 731
 YOKOYAMA TAKO (See Kay et al) 253
 YOON MYUNG S (See Fondacaro Han and Yoon) 81
 YOSHIDA TADASHI (See Aoki et al) 218

Z

- ZARET BARRY L (See Reduto et al) 714
 ZATUCHNI JACOB (See Varki et al) 680
 ZONERAICH OLGA ZONERAICH SAMUEL, RHEE JAI J AND JORDAN DAVID Atrial flutter Electrocardiographic vectorcardiographic and echocardiographic correlation 986
 ZONERAICH SAMUEL (See Zoneraich et al) 286
 ZUBIATE PABLO (See Kay et al) 253

- ROSSI L Intramural ramification of the left bundle branch 271 (Annot)
- RUDOLPH ABRAHAM M (See Berman et al) 655
- RYAN THOMAS J (See Weiner et al) 438
- B
- SACKETT DAVID L HAYNES R BRIAN GIBSON EDWARD S TAYLOR D WAYNE ROBERTS ROBIN S JOHN SON ARNOLD L AND TROUT KILGORE S Reply 422 (Letter to Editor)
- SAFAR AG M Orthostatic hypertension in normotensives and borderline hypertensive patients 563 (Letter to Editor)
- SAINANI G S (See Suresh N and Samani) 702 (Letter to Editor)
- SAKAMOTO NOBUO (See Kambe et al) 512
- SAKSENA FRANKLIN B KRAMER NEIL E TOWNF WILLIAM D KHAN MUSHTAQ GAMBLE ROBERT CRUZ JAIRO M AND GILL SUKHIT Infective aneurysm of the left ventricle angiographic and echocardiographic features 384
- SAL R (See Derrida Sal and Chiche) 833 (Annot)
- SALAKI JOHN S (See Lange et al) 144
- SALERNO JORGE A (See Ray et al) 700 (Letter to Editor)
- SAMI MAGDI CHAITMAN BERNARD R BOURASSA MARTIAL G CHARPIN DENIS AND CHABOT MICHEL Long term follow up of aneurysmectomy for recurrent ventricular tachycardia or fibrillation 303
- SANMARCO MIGUEL E BROOKS SAMUEL H AND BLANKEN HORN DAVID H Reproducibility of a consensus panel in the interpretation of coronary angiograms 430
- SBARBARO JAMES A (See Sheppard et al) 9
- SCHATZ JOHN FENOGGIO JOHN AND KRONGRAD EHUD Electrophysiologic histologic correlation of the cardiac specialized conduction system in two cases of single ventricle and levotransposition of the great arteries 235
- SCHILLER NELSON B (See Werner Schiller and Prasquier) 180
- (See Massie Kleid and Schiller) 543
- SCHNITZER L E (See Leschin and Schnitzer) 275 (Letter to Editor)
- SCHOENFELD MYRON R Dissertation on a Roast Pig Updated 134 (Letter to Editor)
- SCHOLTYSIK G (See Hess Scholtysik and Riesen) 486
- SCHWARTZ JOEL M (See Hussain et al) 31
- SCHWARTZ MELVIN M (See Bakir et al) 92
- SCOTT LEWIS P CHANDRA ROYA S AND ROBERTS WILLIAM C Complex congenital heart disease A multiplicity of therapeutic options 806
- SEGAL BERNARD L (See Ishandrian et al) 605
- SELIKMAN ARTHUR W (See Alderman Seligmann and Day) 421 (Letter to Editor)
- SELLERS ALVIN (See Vyden et al) 203
- SEN PURNENDU (See Lange et al) 144
- SHABETAI RALPH (See Johnson Laiken and Shabetai) 521
- SHAH ABID A (See Sheppard et al) 9
- SHAH ANKUMAR DOLGIN MARTIN TICF DAVID A AND TPEHAN NARESH Complications due to cloth wear in cloth covered Starr Edwards aortic and mitral valve prostheses—and their management 407
- SHAKIMI JAMI G (See Siassi Aryanpur and Shakimi) 175 (Letter to Editor)
- SHAPIRO WILLIAM AND PARK JANET The effect of a new beta blocking agent levo bunolol on exercise induced or augmented ventricular arrhythmias 417 (Annot)
- Testing antianginal therapy In favor of current practice 701 (Letter to Editor)
- SHELburne JAMES C (See Starr et al) 37
- SHELDON WILLIAM C (See Lim et al) 463
- SHEPPARD J M SHAH ABID A SBARBARO JAMES A AND BROOKS HAROLD L Distinctive echocardiographic pattern of posterior wall endocardial motion in aortic stenosis 9
- SHORT DAVID AND STOWERS MARY Spontaneous changes in the severity of angina pectoris 415 (Annot)
- AND — The carbon copy pain of myocardial infarction 417 (Annot)
- SIASSI BIJAN ARYANPUR IRAJ AND SHAKIMI JAMI G Additional angiocardiograms for Tetralogy of Fallot 135 (Letter to Editor)
- SIEGMAN IGRA YARDENA YAHINI JOSEPH H GOLDBOURT URI AND NEUFELD HENRY N Intraventricular conduction disturbances A review of prevalence etiology and progression for ten years with a stable population of Israeli adult males, 669
- SIEWERS RALPH D (See Bedetti Siewers and Dunsford) 802
- SILVER HFLAYNE (See Lamberti et al) 496
- SLACK WARNER V (See Rabinowitz Lowm and Slack) 603 (Letter to Editor)
- SMITH THOMAS W (See Ochs et al) 389
- SMITHERMAN THOMAS C OSBORN ROGER C JR AND ATKINS JAMES M Cardiac dose response relationship for intravenously infused glucagon in normal intact dogs and men 363
- SNULYAN HAROLD EICH ROBERT H JOHNSON LEWIS W PARKER FRIDERICK B POTTS JAMES L AND TRACY GERALD P An evaluation of the results of left ventricular aneurysmectomy Use of a simplified method for analysis of the left ventriculogram 596
- SPANN JAMES F (See Kessler et al) 627
- SITAEELS SILJA E C (See Arenas et al) 467
- SPODICK DAVID H Heart rate correction of pre ejection period 703 (Letter to Editor)
- STANCER PAUL (See Berman et al) 605
- STARR ISAAC KARREMAN GEORGE BLIRING THOMAS AND SHELburne JAMES C Blind study on the relations between the extent of coronary arteriosclerosis and the strength of the myocardial contraction as measured by invasive and noninvasive tests 37
- STEICIGEL NFAL II (See Lowm and Steigberg) 689
- STEIN RICHARD A (See Krasnow and Stein) 376
- STOKES G S (See MacCarthy and Stokes) 697 (Annot)
- STOWERS MARY (See Short and Stowers) 415 (Annot)
- (See Short and Stowers) 417 (Annot)
- SUMIYOSHI TETSUYA (See Hiramoto et al) 187
- SUNC RUFY J (See Garcia et al) 662
- SURFEN N SHINDOF AND SAINANI G S Prolonged repolarization and hypomagnesemia 702 (Letter to Editor)
- SLZUKI SHOHACHI (See Kambe et al) 512
- SWAN H J C (See Vyden et al) 203
- SZF KARL C NANDA NAVIN C AND GRANIAH RAYMOND Systolic flutter of the mitral valve 157
- T
- TACKER WILLIS A JR (See Abend chem Tacker and Babbs) 772
- TAHMOORESSI FARVIS (See Niarchos Tahmooressi and Tarazi) 47
- TAKANO TERUO (See Vyden et al) 203
- TAKIKAWA KIYOHARU (See Aoki et al) 218
- TAKAUNEN J (See Rajasalmi and Takunen) 701
- TARAZI ROBERT C (See Niarchos Tahmooressi and Tarazi) 47
- (See Fouad et al) 646
- TAVAZZI LUIGI (See Ray et al) 700 (Letter to Editor)
- TAYLOR D WAYNE (See Sackett et al) 492
- TEACUF STEVE (See Amat y Leon et al) 62
- TEICHHOLZ LOUIS E (See Ambrose et al) 615
- TEICHER J AND LITTMANN L More on jugular venous pulse (JVP) tracings and cannon waves 134 (Letter to Editor)
- THOMSON I (See Lovegrove and Thompson) 711
- THORNFY C MICHAEL (See Ross et al) 170
- TICF DAVID A (See Shah et al) 407
- TOMMASO CARLO AND TUCCI JOSEPH R Diagnosing magnesium deficiency 274 (Letter to Editor)
- TOSHIMA HIROKORI AND KOGA YOSHIOHRI Reply 830 (Letter to Editor)

- Atriosinus, truncus in a family (Brunson et al) 419 (Letter to Editor)
- Artery(ies) calcification coronary noninvasive diagnosis of ischemic cardiomyopathy by fluoroscopic detection of (Johnson Laiken and Shabetai) 571
- coronary left main disease of the surgical versus medical treatment in (Graham) 1
- Teflon felt embolism of after cardiac surgery a case report (Bedetti Siewers and Dunsford) 807
- to pulmonary artery fistulas (Iskandran et al) 605
- disease coronary effects of rapid digitalization on total and regional myocardial performance in patients with (Ferinzi Del'Vicario and Aronow) 334
- lactate production after left ventricular angiography in (Visoli et al) 835 (Letter to Editor)
- postextrasystolic aortic pressure pulse response in (Hamby et al) 190
- fistulas coronary emptying into left heart chambers (Arani Greene and Hlocke) 438
- pulmonary coronary artery to (Iskandran et al) 605
- great levotransposition of the electrophysiologic histologic correlation of the cardiac specialized conduction system in two cases of single ventricle and (Schatz Fenoglio and Krongrad) 235
- occlusion coronary in dogs protection of ischemic myocardium by whole body hypothermia after (Abend schen Tacker and Babb) 72
- renal, isolated dissecting aneurysm of the (Bakr et al) 92
- spasm coronary—diagnostic and therapeutic implications (Masen et al) 554 (Annot)
- Asymptomatic or silent myocardial ischemia (Liss) 838 (Letter to Editor)
- Reply (Cohn) 838
- Atherosclerosis in infants and children and viral infections of (Burch) 558 (Annot)
- Atresia common pulmonary vein (Ledbetter Wells and Connors) 580
- pulmonary congenital tricuspid incompetence simulating with intact ventricular septum a report of two cases (Berman et al) 555
- Atrial flutter Electrocardiographic vectorcardiographic and echocardiographic correlation (Zonerach et al) 286
- with 1:1 atrioventricular conduction electrophysiological studies in four patients with (Kennelly and Lane) 723
- mural thrombus organized left demonstrated by coronary angiography (Ciprino and Guthaner) 166
- pacing exercise tests and myocardial lactate extraction in relation to coronary arteriography in young patients with angina pectoris (Rajasaama and Takkunen) 51
- Atrioventricular (A V) conduction 1:1 electrophysiological studies in four patients with atrial flutter with (Kennelly and Lane) 723
- node exposure of concealed right bundle branch block in Wolff Parkinson White type B by pacing from the vicinity of the (Garcia et al) 66
- pacing sequential with a single bipolar electrode catheter (Wald Waxman and Bonet) 878 (Annot)
- reentrant tachycardia effects of bundle branch block on experimental (Amat y Leon et al) 6
- Augmented or exercise induced ventricular arrhythmias effect of a new beta blocking agent levo bunolol on (Shapiro and Park) 417 (Annot)

B

- Bacterial endocarditis prevention of Infective endocarditis Part III (Lowy and Steigbigel) 689
- Basal systolic murmurs in mitral stenosis origin of A study with intracardiac phonocardiography (Kambe et al) 517
- Beta adrenergic blockade antihypertensive effect of cardiovascular Ca antagonist in hypertensive patients in the absence and presence of (Aoki et al) 218

Beta adrenergic blockade—continued

- with intravenous propranolol comparison of heart rate and blood pressure response to amyl nitrite isoproterenol and standing before and during acute (Niarchoos, Tahmooressi and Tarazi) 47
- blocking agent new levo bunolol on exercise induced or augmented ventricular arrhythmias the effect of a (Shapiro and Park) 417 (Annot)
- thalassemia left ventricular function in and the effect of multiple transfusions (Lewis et al) 636
- Bipolar electrode catheter single sequential atrioventricular pacing with a (Wald Waxman and Bonet) 878 (Annot)
- Block right bundle branch in Wolff Parkinson White type B exposure of concealed by pacing from the vicinity of the A V node (Garcia et al) 662
- Wenckebach conduction ouabain induced in canine Purkinje fibers the role of cycle length and time dependent changes in membrane potential (Anderson and Reiser) 81
- Blockade beta adrenergic antihypertensive effect of cardiovascular Ca antagonist in hypertensive patients in the absence and presence of (Aoki et al) 218
- Blood pressure and heart rate response to amyl nitrite isoproterenol and standing before and during acute beta adrenergic blockade with intravenous propranolol comparison of (Niarchoos Tahmooressi and Tarazi) 47
- levels in acute myocardial infarction (Gibson) 475
- measurement and cuff size more on (Güntheroth) 473 (Letter to Editor)
- indirect with the incorrect size of cuff the error in (Geddes and Whistler) 4
- Book reviews 137 280 425 567 707 841
- Books received 138 281 426 567 708
- Borderline hypertensive patients and normotensives orthostatic hypertension in (Salar) 563 (Letter to Editor)
- Brain lymphatic drainage of and catarrhea (Gordon) 274 (Letter to Editor)
- Branch block bundle effects of on experimental A V reentrant tachycardia (Amat y Leon et al) 62
- rate dependent variations in the critical cycle length inducing (Kinoshita) 54
- right bundle in Wolff Parkinson White type B exposure of concealed by pacing from the vicinity of the A V node (Garcia et al) 662
- left bundle intramural ramification of the (Rossi) 971 (Annot)
- Bundle branch block on experimental A V reentrant tachycardia effects of (Amat y Leon et al) 62
- right in Wolff Parkinson White type B exposure of concealed by pacing from the vicinity of the A V node (Garcia et al) 662
- variations in the critical cycle length inducing rate dependent (Kinoshita) 54
- left intramural ramification of the (Rossi) 271 (Annot)
- Bypass coronary and left internal mammary patency using the external Doppler probe non invasive assessment of (Benchoual et al) 317
- revascularization aortocoronary hemorrhagic myocardial infarction associated with (Lie et al) 293
- surgery aortocoronary radionuclide assessment of ventricular performance during propranolol withdrawal prior to (Reduto et al) 714
- coronary incidence and results of in connection with coronary ectasia (Auntabian et al) 309
- perioperative myocardial infarction related to (Lam et al) 463
- unusual complications of (Auntabian et al) 17

C

- Ca antagonist cardiovascular in hypertensive patients antihypertensive effect of in the absence and presence of beta adrenergic blockade (Aoki et al) 218

Subject index*

A

- A wave ventricular the new echocardiographic index of late diastolic filling of the left ventricle (Ambrose et al) 615
- Abdominal swelling fatigue and dyspnea in a 13 year old boy (Fowler et al) 533 (CPC)
- Acid gas induced MI (Puletti et al) 561 (Letter to Editor)
- Acknowledgment to reviewers 709
- Acute myocardial infarction blood pressure levels in (Gibson) 475
- evaluation of the hemodynamic effects of hyaluronidase in patients with (Rav et al) 700 (Letter to Editor)
- favorable effects of prolonged nitroglycerin infusion in patients with (Derrida Sal and Chiche) 833 (Annot)
- in sudden cardiac death role of—a statistician's night mare (Lovegrove and Thompson) 711
- rapid sensitive detection of myoglobinemia by improved counterimmunoelectrophoresis in cases of (Hiramon et al) 187
- serum myoglobin in a clinical study and review of the literature (Varki et al) 680
- the temperature course in (Lofmark Nordlander and Ornnäs) 153
- Adverse reactions to methyldopa with particular reference to hypotension (Lawson Gloss and Jick) 572
- Aged hypertrophic cardiomyopathy in the (Krasnow and Stem) 326
- Aging on ventricular contractile performance the effect of (Urthaler Walker and James) 481
- Alterations in the ECG ischemic myocardial disease and (Halbersleben) 276 (Letter to Editor)
- Alternate view of hypertension control from Cumbels (Alderman Seligmann and Davis) 421 (Letter to Editor)
- Reply (Sackett et al) 422
- Aluminum hydroxide gel noninterference of with quinidine sulfate absorption an approach to control quinidine induced diarrhea (Romankiewicz et al) 518
- Amyl nitrite isoproterenol and standing before and during acute beta adrenergic blockade with intravenous propranolol comparison of heart rate and blood pressure response to (Nasrchos Tahmooreesi and Tarazi) 47
- Aneuphric patients with hypertension peripheral hemodynamics in (Viden et al) 203
- Aneurysm infective of the left ventricle angiographic and echocardiographic features (Saksena et al) 384
- isolated dissecting of the renal artery (Bakir et al) 92
- subannular aortic echocardiographic detection of a (Alter et al) 523
- Aneurysmectomy left ventricular an evaluation of the results of use of a simplified method for analysis of the left ventriculogram (Smulyan et al) 596
- long term follow up of for recurrent ventricular tachycardia or fibrillation (Sami et al) 303
- Angina intractable assessment of perhexiline maleate in angiographically proven a double blind trial (Mir and Kafetzakis) 350
- nocturnal (Luceri) 421 (Letter to Editor)
- pectoris exercise tests atrial pacing and myocardial lactate extraction in relation to coronary arteriography in young patients with (Rajalalmi and Takkunen) 731
- prolonged benefit of nitroglycerin treatment on exercise tolerance in patients with (Karsh et al) 587
- spontaneous changes in the severity of (Short and Stowers) 415 (Annot)
- Anginal chest pain predictive value of as an indicator of coronary disease during exercise testing (Werner et al) 458
- Angiocardiograms additional for Tetralogy of Fallot (Sias, Arvanpur and Shakkil) 13s (Letter to Editor)
- Angiograms coronary reproducibility of a consensus panel in the interpretation of (Sanmarco Brooks and Blankenhorn) 430
- Angiographic and echocardiographic features of infective aneurysm of the left ventricle (Saksena et al) 384
- Angiographically proven intractable angina assessment of perhexiline maleate in a double blind trial (Mir and Kafetzakis) 350
- Angiography coronary organized left atrial mural thrombus demonstrated by (Cipriano and Guthaner) 166
- ventricular left lactate production after in coronary artery disease (Visoli et al) 835 (Letter to Editor)
- Angiopathy diabetic—its lessons in vascular physiology (McMillan) 401
- Announcements 138 282 426 568 708 842
- Antianginal therapy testing in favor of current practice (Shapiro) 701 (Letter to Editor)
- Antibodies prevention and reversal of digoxin intoxication with specific (Hess Scholtz and Riesen) 496
- Anticoagulation during noncardiac operations in patients with prosthetic heart valves management of a prospective study (Katholi Nolin and McGowan) 163
- Antihypertensive drugs effect of with leukocyte intracellular cations in hypertension (Araoz et al) 731
- effect of cardiovascular Ca²⁺ antagonist in hypertensive patients in the absence and presence of a adrenergic blockade (Aoki et al) 218
- Aortic and mitral valve prostheses Starr Edward cloth covered complications due to cloth wear in and their management in (Shah et al) 407
- aneurysm subannular echocardiographic detection of a (Alter et al) 523
- pressure pulse response postextrasystolic in coronary artery disease (Hambly et al) 194
- stenosis calcific and acute idiopathic pericarditis unusual fatal disease combination (Wheatley) 87
- distinctive echocardiographic pattern of posterior wall endocardial motion in (Sheppard et al) 9
- valve replacement intravascular hemolysis in the late course of Relation to valve type size and function (Dale and Myhre) 24
- leukocyte function after (Klarstein and Dyle) 674
- Aortocoronary bypass revascularization hemorrhagic myocardial infarction associated with (Lie et al) 297
- surgery radionuclide assessment of ventricular performance during propranolol withdrawal prior to (Reduto et al) 714
- Arrhythmia ventricular exercise induced or augmented effect of a new beta blocking agent levo bunolol on (Shapiro and Park) 417 (Annot)
- Arterial hypoxemia following the administration of sublingual nitroglycerin (Kopman et al) 444
- thrombosis in essential thrombocythemia (Hussain et al) 31
- Arteriography coronary in young patients with angina pectoris exercise tests atrial pacing and myocardial lactate extraction in relation to (Rajalalmi and Takkunen) 731
- Arteriosclerosis coronary and the strength of the myocardial contraction as measured by invasive and noninvasive tests blind study on the relations between the extent of (Starr et al) 37

Coronary—continued

- arteriography calibration: noninvasive diagnosis of ischemic cardiomyopathy by fluoroscopic detection of (Johnson, Lanken and Shabetai) 571
- disease: effects of rapid digitalization on total and regional myocardial performance in patients with (Ferlinz, DelVecchio and Aronow) 337
- lactate production after left ventricular angiography in (Viscoli et al.) 83a (Letter to Editor)
- portocaval systolic aortic pressure pulse response in (Hamby et al.) 19
- stent: emptying into left heart chambers (Arani, Greene and Hlocke) 438
- left main disease: of the surgical versus medical treatment in (Graham) 1
- occlusion in dogs: protection of left main myocardium by whole body hypothermia after (Abend, Chein, Tarker and Babbs) 7
- spasm—diagnostic and therapeutic implications (Masera et al.) 504 (Annot.)
- Teflon felt embolism of after cardiac surgery: a case report (Bedetti, Siemers and Dunsford) 807
- to pulmonary artery fistulas (Iskandran et al.) 80b
- bypass and left internal mammary patency using the external Doppler probe: noninvasive assessment of (Benchumol et al.) 347
- surgery: incidence and results in connection with coronary occlusion (Antablian et al.) 309
- perioperative myocardial infarction related to (Lim et al.) 463
- unusual complication of (Antablian et al.) 17
- late effects in (O'Rourke) 696 (Annot.)
- disease during exercise testing: predictive value of anginal chest pain as an indicator of (Weiner et al.) 458
- ectasia: incidence and results of coronary bypass surgery (Antablian et al.) 309
- heart disease—the doctor's dilemma (Mann) 68
- smoking and the causes of (Aravakis) 473 (Letter to Editor)
- Reply (Burch) 423
- statistics and marathoners (Bassler) 580 (Letter to Editor)
- Reply (Milby) 580
- occlusion: acute effects of verapamil on ventricular rhythm during (Fondacaro, Han and Yoon) 81
- comparison of rhythm and rate induced myocardial O₂ consumption changes before and after (Krahn, Tassaris and Kunda) 37
- stenosis: ischemic or non ischemic factor? (Baroldi) 129
- Correction of the pre-ejection period heart rate (Spodick) 66 (Letter to Editor)
- Reply (Burckhardt and Raeder) 66
- Counterimmunoelectrophoresis: improved rapid sensitive detection of myoglobinemia by in cases of acute myocardial infarction (Hiramoto et al.) 18
- CPK MB elevations in hypothermia (Maggs) 63 (Letter to Editor)
- Reply (Carlson and Rapaport) 703
- Critical cycle length inducing rate dependent bundle branch block variations in the (Hiroshita) 54
- Cuff size and BP measurement: more on (Gunteroth) 423 (Letter to Editor)
- of incorrect error in indirect blood pressure measurement with (Geddes and Whitler) 4
- Current practice in use of in testing autonomic therapy (Shapiro) 61 (Letter to Editor)
- therapy for infective endocarditis. Part II (Casey and Miller) 703
- Cycle length and time dependent changes in membrane potential: the role of ouabain induced Wenckebach conduction block in canine Purkinje fibers (Anderson and Brice) 8
- critical, inducing rate dependent bundle branch block variations in the (Hiroshita) 54
- Cystic endocardial lesions, unusual (Abu Nasar and Flynn) 82 (Letter to Editor)
- dilatation of the great vessels: evaluation of range gated pulsed Doppler echocardiography for detecting pulmonary outflow tract obstruction in (Arens et al.) 467
- Death cardiac sudden: role of acute myocardial infarction in—a statistician's nightmare (Lovegrove and Thompson) 711
- Deficiency magnesium: diagnosing (Tommaso and Tucci) 24 (Letter to Editor)
- Determinant: main of ECG voltage measurements (Bennett) 835 (Letter to Editor)
- Reply (Foshima and Koga) 835
- Diabetic angiopathy—its lessons in vascular physiology (McMillan) 401
- Diagnosing magnesium deficiency (Tommaso and Tucci) 274 (Letter to Editor)
- Diarrhea: quindine induced: an approach to control the noninterference of aluminum hydroxide gel with quindine sulfate absorption (Romankiewicz et al.) 518
- Diastolic filling of the left ventricle: new echocardiographic index of late the ventricular A wave (Ambrose et al.) 615
- impedance waveform: the O point and (Lababidi) 77 (Letter to Editor)
- Reply (Ramos) 278
- Digitalization: effects of rapid on total and regional myocardial performance in patients with coronary artery disease (Ferlinz, DelVecchio and Aronow) 337
- Digoxin: dose independent pharmacokinetics of in humans (Ochs et al.) 507
- intoxication with specific antibodies: prevention and reversal of (Hess, Scholtz and Riesen) 48b
- Discoveries, of (Burch) 416 (Annot.)
- Disease: Lenegre's in youth (Mathew, Mariano and Ostrov) 839 (Letter to Editor)
- Dissecting aneurysm of the renal artery: isolated (Bakur et al.) 92
- Dissertation on a Roast Pig Updated (Schoenfeld) 134 (Letter to Editor)
- Diuretics (Leaf) 874
- Doctors' dilemma—coronary heart disease (Mann) 569
- Doppler echocardiography: range gated pulsed for detecting pulmonary outflow tract obstruction in dilatation of the great vessels: an evaluation of (Arens et al.) 467
- probe: noninvasive assessment of left internal mammary coronary bypass patency using the external (Benchumol et al.) 347
- Dose independent pharmacokinetics of digoxin in humans (Ochs et al.) 507
- Drainage of the brain and catarrhea lymphatic (Gordon) 274 (Letter to Editor)
- Dressler's syndrome in the distant post infarction period: pleural effusion as a manifestation of (Dombv and Whitcomb) 243
- Dyspnea: fatigue and abdominal swelling in a 13 year-old boy (Fowler et al.) 533 (CPI)
- Dystrophic myotonia (myotonia atrophica) of the myocardium and (Burch) 272 (Annot.)

E

- Early ECG tracings: quality of (Kleyn) 421 (Letter to Editor)
- Echocardiographic and angiographic features of infective aneurysm of the left ventricle (Saksena et al.) 384
- detection of a subaortic aortic aneurysm (Alter et al.) 525
- diagnosis of left ventricular mural thrombus occurring in cardiomyopathy (Kramer et al.) 381
- electrocardiographic and vectorcardiographic correlation in atrial flutter (Zonerach et al.) 286
- evaluation of porcine heterograft valves in the mitral and aortic positions (Harston, Robertson and Friesen) 448

- Cannon waves more on jugular venous pulse (JVP) tracings and (Tenczer and Littmann) 134 (Letter to Editor)
- Carbon copy print of myocardial infarction the (Short and Stowers) 417 (Annot)
- Cardiac catheterization in children with primary pulmonary vascular obstruction hazards of (Keane Fyler and Nadas) 556 (Annot)
- death sudden role of acute myocardial infarction in—a statistician's nightmare (Lovegrove and Thompson) 711
- dose response relationship for intravenously infused glucagon in normal intact dogs and men (Smitherman, Osborn and Atkins) 363
- electrogram sensing the (Raber) 275 (Letter to Editor) Reply (Furman and Hürzeler) 276
- specialized conduction system electrophysiologic—histologic correlation of the in two cases of single ventricle and levotransposition of the great arteries (Schätz Fenoglio and Krongrad) 235
- surgery Teflon felt embolism of coronary arteries after a case report (Bedetti Sievers and Dunsford) 802
- Cardiologic-neurologic interrelationships (Mick) 700 (Letter to Editor)
- Cardiologists conglomeration for (Wessler and Gitel) 811
- Cardiomyopathy echocardiographic diagnosis of left ventricular mural thrombi occurring in (Kramer et al) 381
- in the aged hypertrophic (Krasnow and Stein) 326
- ischemic noninvasive diagnosis of by fluoroscopic detection of coronary artery calcification (Johnson Laiken and Shabetan) 521
- Cardiovascular Ca²⁺ antagonist in hypertensive patients anti hypertensive effect of in the absence and presence of beta adrenergic blockade (Aoki et al) 218
- Care coronary conflicts in (O'Rourke) 696 (Annot)
- Cataract lymphatic drainage of the brain and (Gordon) 274 (Letter to Editor)
- Catecholamines circulating and systolic time intervals in normotensive and hypertensive patients with and without left ventricular hypertrophy (Cousineau Lapointe and de Champlain) 227
- Catheter single bipolar electrode sequential atrioventricular pacing with a (Wald Waxman and Bonet) 828 (Annot)
- Catheterization cardiac in children with primary pulmonary vascular obstruction hazards of (Keane Fyler and Nadas) 556 (Annot)
- Cations leukocyte intracellular in hypertension effect of antihypertensive drugs (Arroyo et al) 731
- Causes of CHD smoking and the (Aravanis) 423 (Letter to Editor) Reply (Burch) 423
- Cerebral circulation the and hypertension—its relevance to the elderly (Jones and Graham) 270 (Annot)
- Charging testing and treating of (Burch) 832 (Annot)
- Chest pain anginal predictive value of as an indicator of coronary disease during exercise testing (Weiner et al) 459
- thumping to terminate ventricular tachycardia (Forester) 564 (Letter to Editor) Reply (Befeler) 564
- Children and infants and viral infections of atherosclerosis in (Burch) 558 (Annot)
- with primary pulmonary vascular obstruction hazards of cardiac catheterization in (Keane Fyler and Nadas) 556 (Annot)
- Circulating catecholamines and systolic time intervals in normotensive and hypertensive patients with and without left ventricular hypertrophy (Cousineau Lapointe and de Champlain) 227
- Circulation cerebral the and hypertension—its relevance to the elderly (Jones and Graham) 270 (Annot)
- Cirrhosis or receiving propranolol quinidine pharmacokinetics in patients with (Kessler et al) 627
- Clinical pathologic conference Pompe disease presenting as hypertrophic cardiomyopathy with Wolff Parkinson White syndrome (Bulkley and Hutchins) 246
- Clinical pathologic conference—continued
- Fatigue dyspnea and abdominal swelling in a 13-year old boy (Fowler et al) 533 (CPC)
- Complex congenital heart disease a multiplicity of therapeutic options (Scott Chandra and Roberts) 806
- Cloth covered Starr Edwards aortic and mitral valve prostheses complications due to cloth wear in and their management in (Shah et al) 407
- Cloth wear in cloth covered Starr Edwards aortic and mitral valve prostheses complications due to and their management (Shah et al) 407
- Coagulation for cardiologists (Wessler and Gitel) 811
- Common pulmonary vein atresia (Ledbetter Well and Connors) 580
- Complex congenital heart disease a multiplicity of therapeutic options (Scott Chandra and Roberts) 806
- Complications due to cloth wear in cloth covered Starr Edwards aortic and mitral valve prostheses—and their management (Shah et al) 407
- of coronary bypass surgery unusual (Amatlian et al) 17
- Computer for teaching the proper use of nitroglycerin recourse to a (Rabinowitz Lowm and Slack) 103 (Letter to Editor)
- Conduction and refractoriness of the His Purkinje system in man study of the temporal effects on (Reddy et al) 316
- atrioventricular 11 electrophysiological studies in four patients with atrial flutter with (Kennelly and Lane) 723
- block Wenckebach quasiblock induced in canine Purkinje fibers the role of cycle length and time dependent changes in membrane potential (Anderson and Reiser) 781
- disturbances intraventricular a review of prevalence etiology and progression for ten years within a stable population of Israeli adult males (Siegmán Igra et al) 669
- system(s) cardiac specialized electrophysiologic histologic correlation of the in two cases of single ventricle and levotransposition of the great arteries (Schätz Fenoglio and Krongrad) 235
- in 10 patients with Kawasaki's disease (mucocutaneous lymph node syndrome) clinicopathologic study of (Fujimura Kawai and Hamashima) 744
- Conflicts in coronary care (O'Rourke) 696 (Annot)
- Congenital heart disease complex a multiplicity of therapeutic options (Scott Chandra and Roberts) 806
- tricuspid incompetence simulating pulmonary atresia with intact ventricular septum a report of two cases (Berman et al) 600
- Congestive heart failure of the venous pumps and (Burch) 697 (Annot)
- Consensus panel reproducibility of a in the interpretation of coronary angiograms (Sanmarco Brooks and Blankenhorn) 430
- Constriction pericardial (Hirschmann) 110
- Contractile performance ventricular the effect of aging on (Urthaler Walker and James) 491
- Contraction myocardial strength of as measured by invasive and noninvasive tests blind study on the relations between the extent of coronary arteriosclerosis and (Starr et al) 37
- Coronary angiograms reproducibility of a consensus panel in the interpretation of (Sanmarco Brooks and Blankenhorn) 430
- angiography organized left atrial mural thrombus demonstrated by (Cipriano and Guthaner) 166
- arteriography in young patients with angina pectoris exercise tests atrial pacing and myocardial lactate extraction in relation to (Rajasingh and Takkunen) 751
- arteriosclerosis and the strength of the myocardial contraction as measured by invasive and noninvasive tests blind study on the relations between the extent of (Starr et al) 37

- Hazard potential, of the programmable pacemaker (Gould and Reddy) 404 (Letter to Editor)
- Heart chambers left coronary artery fistulas emptying into (Arani, Greene and Klocke) 438
- disease complex congenital a multiplicity of therapeutic options (Scott Chandra and Roberts) 806
- coronary—the doctor's dilemma (Mann) 569
- ischemic echocardiography in present status and future prospectives (Massey Kleid and Schiller) 543
- failure congenital of the venous pumps and (Burch) 697 (Annot)
- rate and blood pressure response to amyl nitrite isoproterenol and standing before and during acute beta adrenergic blockade with intravenous propranolol comparison of (Niarchos Tahmooreza and Tara) 47
- correction of pre ejection period (Spodick) 705 (Letter to Editor)
- Reply (Burckhardt and Raeder) 66
- norepinephrine and ouabain on myocardial oxygen consumption and inotropic state in dogs comparative influence of (Boerth Hammermester and Warbasse) 355
- valves prosthetic management of anticoagulation during noncardiac operations in patients with A prospective study (Katholi Nolan and McGuire) 163
- Hemodynamic effects of hyaluronidase in patients with acute myocardial infarction evaluation of (Ray et al) 700 (Letter to Editor)
- Hemodynamics of essential hypertension in young subjects (Fouad et al) 646
- peripheral in anephric patients with hypertension (Vysden et al) 203
- Hemolysis intravascular in the late course of aortic valve replacement Relation to valve type size and function (Dale and Myhre) 24
- Hemorrhagic myocardial infarction associated with aorto coronary bypass revascularization (Lee et al) 299
- Heparin low dose or smoking—effect of in preventing thromboembolism after myocardial infarction (Emerson) 179 (Annot)
- Heroin addicts infective endocarditis in epidemiological observations and some unusual cases (Lange et al) 144
- Heterograft valves porcine in the mitral and aortic positions echocardiographic evaluation of (Harston Robert son and Friesinger) 448
- His Purkinje system in man study of the temporal effects on conduction and refractormess of the (Reddy et al) 318
- Hyaluronidase in patients with acute myocardial infarction evaluation of the hemodynamic effects of (Ray et al) 700 (Letter to Editor)
- Hyperaldosteronism the treatment of low renin (primary) (Ferriss et al) 97
- Hyperlipidemic patients effect of probucol in during two years of administration (Parsons) 213
- Hypertension and the cerebral circulation—its relevance to the elderly (Jones and Graham) 270 (Annot)
- control an alternate view from Gumbels (Alderman Seligmann and Davis) 471 (Letter to Editor)
- Reply (Sackett et al) 477
- essential hemodynamics of in young subjects (Fouad et al) 646
- leukocyte intracellular cations in effect of antihypertensive drugs (Aracoy et al) 731
- orthostatic in normotensives and borderline hypertension patients (Safar) 563 (Letter to Editor)
- peripheral hemodynamics in anephric patients with (Vysden et al) 203
- reno ocular renal vein renin and saralasin testing in (MacCarthy and Stokes) 69 (Annot)
- Hypertension and normotensives patients with and without left ventricular hypertrophy circulating catecholamines and systolic time intervals in (Cousineau Lapointe and de Champlain) 277
- Hypertensive—continued
- patients antihypertensive effect of cardiovascular Ca antagonist in the absence and presence of beta adrenergic blockade (Aoki et al) 218
- borderline and normotensives orthostatic hypertension in (Safar) 563 (Letter to Editor)
- Hypertrophic cardiomyopathy in the aged (Krasnow and Stett) 376
- myocardial pathy with Wolff Parkinson White syndrome Pompe disease presenting as (Bulkley and Hutchins) 216
- Hypertrophy left ventricular circulating catecholamines and systolic time intervals in normotensive and hypertensive patients with and without (Cousineau Lapointe and de Champlain) 277
- Hypomagnesemia and prolonged repolarization (Suresh N and Samani) 10 (Letter to Editor)
- Hypotension adverse reactions to methyldopa with particular reference to (Lawson Gloss and Jick) 512
- Hypothermia CPG MB elevations in (Mag s) 63 (Letter to Editor)
- Reply (Carlson and Rapaport) 703
- whole body protection of ischemic myocardium by after coronary artery occlusion in dogs (Abendschein Tacker and Babbs) 712
- Hypoxemia arterial following the administration of sublingual nitroglycerin (Hopman et al) 444
- I
- Idiopathic familial myocardial pathy in three generations A clinical and pathologic study (Ross et al) 110
- pericarditis acute and calcific aortic stenosis unusual fatal disease combination (Wheatley) 87
- Impedance waveform diastolic the O point and (Lababidi) 277 (Letter to Editor)
- Reply (Ramos) 279
- examined—a noninvasive assist (Leschin and Schnitzler) 215 (Letter to Editor)
- Reply (Ramos) 275
- Importance of R on T phenomenon the (Chou and Wenzke) 191
- Incompetence congenital tricuspid simulating pulmonary atresia with intact ventricular septum a report of two cases (Berman et al) 660
- Indirect blood pressure measurement with the incorrect size of cuff the error in (Geddes and Whistler) 4
- Infants and children and viral infections of atherosclerosis in (Burch) 558 (Annot)
- Infarction acute myocardial, blood pressure levels in (Gibson) 415
- evaluation of the hemodynamic effects of hyaluronidase in patients with (Ray et al) 700 (Letter to Editor)
- favorable effects of prolonged nitroglycerin infusion in patients with (Dernda Sal and Chiche) 833 (Annot)
- in sudden cardiac death role of—a statistician's nightmare (Lovegrove and Thompson) 711
- rapid sensitive detection of myoglobinemia by improved counterimmunoelectrophoresis in cases of (Harmoni et al) 187
- serum myoglobin in clinical study and review of the literature (Vark et al) 680
- the temperature course in (Lofmark Nordlander and Ormuss) 151
- myocardial hemorrhagic associated with aortocoronary bypass revascularization (Lee et al) 299
- in young vs old male rats Pathophysiologic changes (Wexler) 70
- pathogenesis of (Davies et al) 561 (Letter to Editor)
- Reply (Baroldi) 562
- peroperative related to coronary bypass surgery (Lin et al) 463
- preventing thromboembolism after effect of low-dose heparin or smoking (Emerson) 179 (Annot)

Subject index

Echocardiographic—continued

- index of late diastolic filling of the left ventricle a new the ventricular A wave (Ambrose et al) 615
- mitral valve motion effect of transducer placement on (Markiewicz London and Popp) 555 (Annot)
- pattern of posterior wall endocardial motion in aortic stenosis distinctive (Sheppard et al) 9
- Echocardiographically demonstrated tricuspid valve prolapse occurrence and significance of (Werner Schiller and Prasquier) 180
- Echocardiography in ischemic heart disease present status and future prospects (Masse Kleid and Schiller) 543
- range gated pulsed Doppler an evaluation of for detecting pulmonary outflow tract obstruction in d transposition of the great vessels (Areias et al) 467
- Ectasia coronary incidence and results of coronary bypass surgery (Antablian et al) 309
- Effect of aging on ventricular contractile performance the (Orthaler Walker and James) 481
- Effusion pleural as a manifestation of Dressler's syndrome in the distant postinfarction period (Dombay and Whitcomb) 243
- Elderly relevance of hypertension and the cerebral circulation to the (Jones and Graham) 270 (Annot)
- Electrocardiogram (ECG) ischemic myocardial disease and alterations in the (Halbersleben) 276 (Letter to Editor)
- Electrocardiographic vectorcardiographic and echocardiographic correlation in atrial flutter (Zonerach et al) 286
- tracings quality of early (Kleyn) 421 (Letter to Editor)
- voltage measurements main determinant of (Bennett) 835 (Letter to Editor)
- Reply (Toshima and Koga) 835
- Electrode catheter single bipolar sequential atrioventricular pacing with a (Wald Waxman and Bonet) 828 (Annot)
- Electrogram cardiac sensing the (Raber) 275 (Letter to Editor)
- Reply (Furman and Hurler) 276
- Electrophysiological-histologic correlation of the cardiac specialized conduction system in two cases of single ventricle and levotransposition of the great arteries (Schatz Fenoglio and Kronegrad) 235
- Electrophysiological studies in four patients with atrial flutter with 1:1 atrioventricular conduction (Kennelly and Lane) 723
- Elevations CPK MB in hypothermia (Maggs) 703 (Letter to Editor)
- Reply (Carlson and Rapaport) 703
- Embolism Teflon felt of coronary arteries after cardiac surgery a case report (Bedetti Siewers and Dunsford) 802
- Endocardial fibroelastosis myocardial and vascular alterations associated with viral like nuclear particles (Factor) 791
- lesions unusual cystic (Abu Nassar and Flynn) 836 (Letter to Editor)
- motion in aortic stenosis posterior wall distinctive echocardiographic pattern of (Sheppard et al) 11
- Endocarditis bacterial prevention of Infective endocarditis Part III (Lowy and Steigbigel) 689
- infective in heroin addicts epidemiological observations and some unusual cases (Lange et al) 144
- new diagnostic techniques (Miller and Casey) 123
- Part II Current therapy (Casey and Miller) 263
- Part III Prevention of bacterial endocarditis (Lowy and Steigbigel) 689
- Q fever observations on (Turck) 564 (Letter to Editor)
- Reply (Applefeld) 566
- Epicardial ST segment elevation limited correlation of ultrastructure with transmural gradients of experimental myocardial ischemia (Lamberti et al) 496
- Ergotamine induced ischemia nitroprusside reversal of (Whitsett Myers and Hartsuck) 700 (Letter to Editor)

- Essential hypertension hemodynamics of in young subjects (Foad et al) 646
- thrombocytopenia arterial thrombosis in (Hussain et al) 31
- Exaggerated impedance waveform—a noninvasive assist (Leschin and Schnitzer) 275 (Letter to Editor)
- Reply (Ramos) 275
- Exercise induced or augmented ventricular arrhythmias effect of a new beta blocking agent levo bunolol on (Shapiro and Park) 417 (Annot)
- testing predictive value of anginal chest pain as an indicator of coronary disease during (Weiner et al) 458
- tests atrial pacing and myocardial lactate extraction in relation to coronary arteriography in young patients with angina pectoris (Rajasaalmi and Takkunen) 751
- tolerance in patients with angina pectoris prolonged benefit of nitroglycerin ointment on (Harsh et al) 587

F

- Failure heart congestive of the venous pumps and (Burch) 697 (Annot)
- Fallot tetralogy of additional angiocardiograms for (Siam Arjanpur and Shakibi) 135 (Letter to Editor)
- Familial myocardiopathy idiopathic in three generations A clinical and pathologic study (Ross et al) 170
- Fatigue dyspnea and abdominal swelling in a 13 year old boy (Fowler et al) 533 (CPC)
- Favorable effects of prolonged nitroglycerin infusion in patients with acute myocardial infarction (Derrida Sal and Chiche) 833 (Annot)
- Fever Q endocarditis observations on (Turck) 564 (Letter to Editor)
- Reply (Applefeld) 566
- Fibrillation or recurrent ventricular tachycardia long term follow up of aneurysmectomy for (Sami et al) 303
- Fibroelastosis endocardial myocardial and vascular alterations associated with viral like nuclear particles (Factor) 791
- Fistulas coronary artery emptying into left heart chambers (Arani Greene and Klocke) 438
- to pulmonary artery (Iskandrian et al) 605
- Fluoroscopic detection of coronary artery calcification noninvasive diagnosis of ischemic cardiomyopathy by (Johnson Laiken and Shabetai) 521
- Flutter atrial Electrocardiographic vectorcardiographic and echocardiographic correlation (Zonerach et al) 286
- with 1:1 atrioventricular conduction electrophysiological studies in four patients with (Kennelly and Lane) 723
- of the mitral valve systolic (Sze Nanda and Gramiak) 157

G

- Ganglion left stellate and the long Q T syndrome another link between the (Crampton) 130 (Annot)
- Gas induced MI acid (Puletti et al) 561 (Letter to Editor)
- Gel aluminum hydroxide noninterference of with quinidine sulfate absorption an approach to control quinidine induced diarrhea (Romankiewicz et al) 518
- Gumbel an alternate view from in hypertension control (Alderman Seligmann and Davis) 471 (Letter to Editor)
- Reply (Sackett et al) 422
- Glucagon intravenously infused in normal intact dogs and men cardiac dose response relationship for (Smitherman O born and Atkins) 363
- Great vessels d transposition of evaluation of range gated pulsed Doppler echocardiography for detecting pulmonary outflow tract obstruction in (Areias et al) 467

- Maleate perhexiline assessment of in angiographically proven intractable angina a double blind trial (Mir and Kafetzakis) 300
- Mammary left internal, and coronary bypass patency using the external Doppler probe non invasive assessment of (Benchmol et al) 347
- Marathoning statistics and CHD (Bassler) 560 (Letter to Editor)
- Reply (Milvy) 560
- MB elevations, CPK in hypothermia (Maggs) '03 (Letter to Editor)
- Reply (Carlson and Rapaport) '03
- Measurement(s) BP and cuff size more on (Güntheroth) 493 (Letter to Editor)
- ECG voltage main determinant of (Bennett) 835 (Letter to Editor)
- Reply (Toshima and Hoga) 835
- Medical versus surgical treatment in disease of the left main coronary artery (Graham) 1
- Membrane potential role of cycle length and time dependent changes in ouabain induced Wenckebach conduction block in canine Purkinje fibers (Anderson and Reuser) 781
- Methyldopa adverse reactions to with particular reference to hypotension (Lawson Gloss and Jack) 579
- Middle aged men significance of P wave terminal force in presumably healthy (Forfang and Erikssen) 39
- Migraine and the mitral valve prolapse syndrome (Litman and Friedman) 810
- Mitral and aortic positions echocardiographic evaluation of porcine heterograft valves in the (Harston Robert son and Friesinger) 448
- valve prostheses Starr Edwards, cloth covered complications due to cloth wear in and their management in (Shah et al) 407
- insufficiency mitral valve repair for significant (Kay et al) 253
- stenosis origin of the basal systolic murmurs in A study with intracardiac phonocardiography (Hambe et al) 819
- valve motion echocardiographic effect of transducer placement on (Markiewicz London and Popp) 555 (Annot)
- prolapse syndrome and migraine (Litman and Friedman) 810
- ventricular pre excitation and prolonged Q T interval syndromes in a patient with (Mirvis and Erwin) 579
- repair for significant mitral insufficiency (Kay et al) 253
- astolic flutter of the (Sze Nanda and Gramiak) 157
- More selective resuscitation towards (Peatfield) 698 (Annot)
- Mucocutaneous lymph node syndrome (hawasaki's disease) clinicopathologic study of the conduction systems in 10 patients with (Fujwara Kawai and Hama shima) 44
- Mural thrombi left ventricular occurring in cardiomyopathy echocardiographic diagnosis of (Kramer et al) 381
- thrombus, organized left atrial demonstrated by coronary angiography (Cipriano and Guthaner) 166
- Mutton's law (Fred) 73 (Annot)
- Myocardial and vascular alterations associated with viral like nuclear particles in endocardial fibroelastosis (Factor) 91
- contraction strength of as measured by invasive and noninvasive tests, blind study on the relations between the extent of coronary atherosclerosis and (Starr et al) 37
- disease ischemic and alterations in the ECG (Halbersleben) '76 (Letter to Editor)
- steroids in (Giorganni) '4 (Letter to Editor)
- infarction (VI) acid gas-induced (Puletti et al) 561 (Letter to Editor)
- acute blood pressure levels in (Gibson) 4 5
- evaluation of the hemodynamic effects of hyaluronidase in patients with (Ray et al) 00 (Letter to Editor)
- Myocardial infarction acute—continued
- favorable effects of prolonged nitroglycerin infusion in patients with (Dermda Sal and Chiche) 833 (Annot)
- in sudden cardiac death role of—a statistician's night mare (Lovegrove and Thompson) 711
- rapid sensitive detection of myoglobinemia by improved counterimmunoelectrophoresis in cases of (Hiramon et al) 187
- serum myoglobin in a clinical study and review of the literature (Varki et al) 680
- the temperature course in (Lofmark Nordlander and Örnquist) 153
- hemorrhagic associated with aortocoronary bypass revascularization (Lee et al) 297
- in young vs old male rats Pathophysiologic changes (Wexler) 0
- pathogenesis of (Davies et al) 561 (Letter to Editor)
- Reply (Baroldi) 567
- perioperative related to coronary bypass surgery (Lim et al) 467
- preventing thromboembolism after effect of low-dose heparin or smoking (Emerson) '79 (Annot)
- the carbon-copy pain of (Short and Stowers) 417 (Annot)
- ischemia asymptomatic or silent (Lass) 838 (Letter to Editor)
- Reply (Cohn) 838
- experimental transmural gradients of limited correlation of ultrastructure with epicardial S-T segment elevation (Lamberti et al) 496
- population screening for (Rose) 427
- lactate extraction exercise tests and atrial pacing in relation to coronary arteriography in young patients with angina pectoris (Rajasalmi and Takkunen) 751
- oxygen consumption and inotropic state in dogs comparative influence of ouabain norepinephrine and heart rate on (Boerth Hammermeister and Warbasse) 355
- changes before and after coronary occlusion comparison of rhythm and rate induced (Kralios Tsagaris and Kudva) 379
- performance total and regional effects of rapid digitalization on in patients with coronary artery disease (Fertiz Delvicano and Aronow) 337
- Myocardial path hypertrophic with Wolf Parkinson White syndrome Pompe's disease presenting as (Bulkley and Hutchins) 246
- idiopathic familial in three generations A clinical and pathologic study (Ross et al) 170
- Myocardium and myotonia atrophica (*dystrophica myotonia*) of the (Burch) 2, 7 (Annot)
- ischemic protection of by whole-body hypothermia after coronary artery occlusion in dogs (Abendschein Tacker and Babbs) '2
- Myoglobin serum in acute myocardial infarction a clinical study and review of the literature (Varki et al) 680
- tests by RIA (Roberts) 420 (Letter to Editor)
- Mvoglobulinemia rapid sensitive detection of by improved counterimmunoelectrophoresis in cases of acute myocardial infarction (Hiramon et al) 187
- Mvotonia atrophica (*dystrophica myotonia*) of the myocardium and (Burch) 272 (Annot)
- N
- Neurologic-cardiologic interrelationships (Mick) '00 (Letter to Editor)
- Nitrite long acting-oral ISDN (Pascal) 424 (Letter to Editor)
- Nitroglycerin infusion prolonged in patients with acute myocardial infarction favorable effects of (Dermda Sal and Chiche) 833 (Annot)
- intravenous (Cottrell and Turndorf) 550
- ointment prolonged benefit of on exercise tolerance in patients with angina pectoris (Karsh et al) 587

- Infarction myocardial—continued
the carbon copy pain of (Short and Stowers) 417
(Annot)
- Infections viral of atherosclerosis in infants and children and (Burch) 558 (Annot)
- Infective aneurysm of the left ventricle angiographic and echocardiographic features (Saksena et al) 384
endocarditis in heroin addicts epidemiological observations and some unusual cases (Lange et al) 144
new diagnostic techniques (Miller and Casey) 123
Part II Current therapy (Casey and Miller) 263
Part III Prevention of bacterial endocarditis (Lovy and Steigbigel) 689
- Inotropic state and myocardial oxygen consumption in dogs comparative influence of ouabain norepinephrine and heart rate on (Boerth Hammermeister and Warbasse) 355
- Insufficiency mitral mitral valve repair for significant (Kay et al) 253
- Intoxication digoxin prevention and reversal of with specific antibodies (Hess Scholtysik and Riessen) 486
- Intracardiac phonocardiography a study with Origin of the basal systolic murmurs in mitral stenosis (Kambe et al) 512
- Intracellular cations leukocyte in hypertension effect of antihypertensive drugs (Araoye et al) 731
- Intractable angina assessment of perhexiline maleate in angiographically proven a double blind trial (Mir and Kafetzakis) 350
- Intramural ramification of the left bundle branch (Rossi) 271 (Annot)
- Intraventricular conduction disturbances a review of prevalence etiology and progression for ten years within a stable population of Israeli adult males (Siegmán Igra et al) 689
- Intravascular hemolysis in the late course of aortic valve replacement Relation to valve type size and function (Dalk and Myhre) 24
- Intravenous nitroglycerin (Cottrell and Turndorf) 550
quinidine a reevaluation of (Woo and Greenblatt) 829 (Annot)
- Intravenously infused glucagon in normal intact dogs and men cardiac dose response relationship for (Smitherman Osborn and Atkins) 363
- Ischemia ergotamine induced nitroprusside reversal of (Whitsett Myers and Hartsuck) 700 (Letter to Editor)
myocardial asymptomatic or silent (Liss) 838 (Letter to Editor)
Reply (Cohn) 838
experimental transmural gradients of limited correlation of ultrastructure with epicardial S T segment elevation (Lamberti et al) 496
population screening for (Rose) 427
- Ischemic cardiomyopathy noninvasive diagnosis of by fluoroscopic detection of coronary artery calcification (Johnson Laiken and Shabetai) 521
- heart disease echocardiography in present status and future perspectives (Massie Kleid and Schiller) 543
myocardial disease and alterations in the ECG (Halbersleben) 276 (Letter to Editor)
myocardium protection of by whole body hypothermia after coronary artery occlusion in dogs (Abendschein Tacker and Babbs) 772
or non ischemic factor coronary stenosis (Baroldi) 139
- ISDN oral-long acting nitrite (Pascal) 424 (Letter to Editor)
- Isoproterenol amyl nitrite and standing before and during acute beta adrenergic blockade with intravenous propranolol comparison of heart rate and blood pressure response to (Niarchos Tahmooressi and Tarazi) 47
- Israeli adult males a review of prevalence etiology and progression of intraventricular conduction disturbances for ten years within a stable population of (Siegmán Igra et al) 689
- Jugular venous pulse (JVP) tracings and cannon waves more on (Tenczer and Littmann) 134 (Letter to Editor)
- Kawasaki's disease (mucocutaneous lymph node syndrome) clinicopathologic study of the conduction systems in 10 patients with (Fujisawa Kawai and Hama shima) 744
- Lactate extraction myocardial exercise tests and atrial pacing in relation to coronary arteriography in young patients with angina pectoris (Rajasalmi and Takkunen) 751
production after left ventricular angiography in coronary artery disease (Visoli et al) 835 (Letter to Editor)
- Left bundle branch intramural ramification of the (Rossi) 271 (Annot)
heart chambers coronary artery fistulas emptying into (Arani Greene and Klocke) 438
main coronary artery surgical versus medical treatment in disease of the (Graham) 1
stellate ganglion and the long Q T syndrome another link between the (Crampton) 130 (Annot)
ventricular aneurysmectomy an evaluation of the results of use of a simplified method for analysis of the left ventriculogram (Smulyan et al) 596
angiography lactate production after in coronary artery disease (Visoli et al) 835 (Letter to Editor)
function in beta thalassemia and the effect of multiple transfusions (Lewis et al) 636
hypertrophy circulating catecholamines and systolic time intervals in normotensive and hypertensive patients with and without (Cousineau Lapointe and de Champlain) 227
ventriculogram use of a simplified method for analysis of the an evaluation of the results of left ventricular aneurysmectomy (Smulyan et al) 596
- Lenegre's disease in youth (Mathew Mariano and Ostrov) 839 (Letter to Editor)
- Lesions, unusual cystic endocardial (Abu Naasar and Flynn) 836 (Letter to Editor)
- Leukocyte function after aortic valve replacement (Kvarstein and Dale) 624
intracellular cations in hypertension effect of antihypertensive drugs (Araoye et al) 731
- Levo bunolol new beta blocking agent the effect of on exercise induced or augmented ventricular arrhythmias (Shapiro and Park) 417 (Annot)
- Levotransposition of the great arteries electrophysiologic-histologic correlation of the cardiac specialized conduction system in two cases of single ventricle and (Schatz Fenoglio and Hongrad) 235
- Long acting nitrite-oral ISDN (Pascal) 424 (Letter to Editor)
- Low renin (primary) hyperaldosteronism the treatment of (Ferriss et al) 97
- Lymph node syndrome mucocutaneous (Kawasaki's disease) clinicopathologic study of the conduction systems in 10 patients with (Fujisawa Kawai and Hama shima) 744
- Lymphatic drainage of the brain and catarrhea (Gordon) 274 (Letter to Editor)
- Magnesium deficiency diagnosing (Tomimiso and Tucci) 274 (Letter to Editor)
- Main determinant of ECG voltage measurements (Bennett) 831 (Letter to Editor)
Reply (Toshima and Koga) 835

- Posterior wall endocardial motion in aortic stenosis: diurnal time to echocardiographic pattern of (Sheppard et al) 9
- Potential hazard of the programmable pacemaker (Gould and Reddy) 704 (Letter to Editor)
- Predictive value of anginal chest pain as an indicator of coronary disease during exercise testing (Weiner et al) 458
- Pre-ejection period heart rate correction of (Spodick) 100 (Letter to Editor)
- Reply (Burckhardt and Raeder) 706
- Pre-excitation ventricular and prolonged Q T interval syndromes in a patient with mitral valve prolapse (Mirvis and Erwin) 599
- Pressure levels blood in acute myocardial infarction (Gibson) 47
- Measurement blood indirect with the incorrect size of cuff the error in (Geddes and Whistler) 4
- Pulse response postextrasystolic aortic in coronary artery disease (Hamby et al) 195
- Prevention and reversal of digoxin intoxication with specific antibodies (Hess Scholtysik and Riesen) 496
- of bacterial endocarditis. Infective endocarditis. Part III (Lowe and Steingabel) 639
- Primary (low renin) hyperaldosteronism: the treatment of (Ferriss et al) 97
- pulmonary vascular obstruction hazards of cardiac catheterization in children with (Keane Fyler and Nadas) 556 (Annot)
- Probulon in hyperlipidemic patients during two years of administration effect of (Parsons) 713
- Programmable pacemaker potential hazard of the (Gould and Reddy) 704 (Letter to Editor)
- Prolapse syndrome mitral valve and mitrains (Litman and Friedman) 610
- value tri-liquid occurrence and significance of echocardiographically demonstrated (Werner Schiller and Praeger) 180
- Prolonged nitro glycerin infusion in patients with acute myocardial infarction favorable effects of (Derrida Sal and Chiche) 833 (Annot)
- repolarization and hypomagnesemia (Suresh N and Samani) 707 (Letter to Editor)
- Proper use of nitroglycerin recourse to a computer for teaching the (Rabinowitz Lowin and Slack) 706 (Letter to Editor)
- Propranolol intravenous comparison of heart rate and blood pressure response to amyl nitrite isoproterenol, and standing before and during acute beta adrenergic blockade with (Natchos Tahmooreza and Tarazi) 47
- quinidine pharmacokinetics in patients with cirrhosis or receiving (Kessler et al) 67
- withdrawal prior to aortocoronary bypass surgery radionuclide assessment of ventricular performance during (Reduto et al) 714
- Protheses valve complications due to cloth wear in cloth coated Starr Edwards aortic and mitral and their management (Shah et al) 407
- Prosthetic heart valves management of anticoagulation during non cardiac operations in patients with A prothetix study (Katholi Nolan and McGuire) 163
- Pulmonary artery catheter coronary artery to (I kandrian et al) 600
- atrial congenital tricuspid incompetence simulating with intact interatrial septum: a report of two cases (Bern et al) 600
- outflow tract obstruction in d transposition of the great vessels: evaluation of range gated pulsed Doppler echocardiography for detecting (Arenas et al) 47
- vascular obstruction primary hazards of cardiac catheterization in children with (Keane Fyler and Nadas) 556 (Annot)
- vein atria common (Ledbetter Wells and Connors) 540
- ulse response post extrasystolic aortic pressure in coronary artery disease (Hamby et al) 19
- Pulse-continued
- tracings jugular venous (JVP) and cannon waves more on (Tenczer and Luttmann) 134 (Letter to Editor)
- Pumps, venous, of the and congestive heart failure (Burch) 697 (Annot)
- Purkinje fibers canine ouabain induced Wenckebach conduction block in the role of cycle length and time dependent changes in membrane potential (Anderson and Reser) 781
- Q
- Q fever endocarditis observations on (Turk) 564 (Letter to Editor)
- Reply (Applefeld) 566
- Q T interval syndrome prolonged and ventricular pre excitation syndrome in a patient with mitral valve prolapse (Mirvis and Erwin) 529
- syndrome long another link between the left stellate ganglion and the (Crampton) 130 (Annot)
- Quality of early ECG tracings (Kleyn) 471 (Letter to Editor)
- Quinidine induced diarrhea an approach to control The noninterference of aluminum hydroxide gel with quinidine sulfate absorption (Romankiewicz et al) 518
- intravenous a reevaluation of (Woo and Greenblatt) 829 (Annot)
- pharmacokinetics in patients with cirrhosis or receiving propranolol (Kessler et al) 82
- sulfate absorption the noninterference of aluminum hydroxide gel with an approach to control quinidine induced diarrhea (Romankiewicz et al) 518
- P
- R on T phenomenon the importance of (Lhou and Wenzke) 191
- Radionuclide assessment of ventricular performance during propranolol withdrawal prior to aortocoronary bypass surgery (Reduto et al) 714
- Range gated pulsed Doppler echocardiography for detecting pulmonary outflow tract obstruction in d transposition of the great vessel an evaluation of (Arenas et al) 47
- Rate and rhythm induced myocardial O consumption changes before and after coronary occlusion comparison of (Khalos Tsagaris and Kuda) 372
- Rats young vs of male pathophysiologic changes in myocardial infarction in (Wexler) 8
- Reactions to methyldopa adverse with particular reference to hypotension (Lawson Glass and Jack) 679
- Recourse to a computer for teaching the proper use of nitroglycerin (Rabinowitz Lowin and Slack) 703 (Letter to Editor)
- Reevaluation of intravenous quinidine a (Woo and Greenblatt) 829 (Annot)
- Refractormess and conduction of the His Purkinje system in man study of the temporal effect on (Reddy et al) 316
- Renal artery isolated dissecting aneurysm of the (Bakir et al) 97
- renin and saralasin testing in renovascular hypertension (MacCarthy and Stokes) 691 (Annot)
- Renal renal vein and saralasin testing in renovascular hypertension (MacCarthy and Stokes) 697 (Annot)
- Renovascular hypertension renal vein renin and saralasin testing in (MacCarthy and Stokes) 691 (Annot)
- Repolarization prolonged and hypomagnesemia (Suresh N and Samani) 707 (Letter to Editor)
- Reproducibility of a consensus panel in the interpretation of coronary angiograms (Sanmarco Brooks and Blankenhorn) 470
- Resuscitation selective towards more (Peatfield) 698 (Annot)
- Retrograde Wenckebach effect in VT (Pordy) 839 (Letter to Editor)
- Revascularization aortocoronary bypass hemorrhagic myocardial infarction associated with (Lae et al) 295

- Nitroglycerin continued
proper use of recourse to a computer for teaching (Rabinowitz Low and Slack) 703 (Letter to Editor)
sublingual arterial hypoxemia following the administration of (Kopman et al) 444
- Nitroprusside reversal of ergotamine induced ischemia (Whitsett Myers and Hartsuck) 700 (Letter to Editor)
- Nocturnal angina (Luceri) 421 (Letter to Editor)
- Noncardiac operations in patients with prosthetic heart valves: management of anticoagulation during A prospective study (Katholi Nolan and McGuire) 163
- Non invasive assessment of left internal mammary coronary bypass patency using the external Doppler probe (Benchimol et al) 347
assist-exaggerated impedance waveform a (Lechin and Schnitzer) 275 (Letter to Editor)
Reply (Ramos) 275
diagnosis of ischemic cardiomyopathy by fluoroscopic detection of coronary artery calcification (Johnson Laiken and Shabetai) 521
is non invasive or how (Burch) 130 (Annot)
- Norepinephrine ouabain and heart rate on myocardial oxygen consumption and inotropic state in dogs: comparative influence of (Boerth Hammermeister and Warbasse) 355
- Normotensive(s) and borderline hypertensive patients orthostatic hypertension in (Safar) 563 (Letter to Editor)
and hypertensive patients with and without left ventricular hypertrophy: circulating catecholamines and systolic time intervals in (Cousineau Lapointe and de Champlain) 227
- Nuclear particles viral like myocardial and vascular alterations associated with in endocardial fibroelastosis (Factor) 791
- O
- O point and diastolic impedance waveform the (Lababidi) 277 (Letter to Editor)
Reply (Ramos) 279
- Observations on Q fever endocarditis (Turck) 564 (Letter to Editor)
Reply (Applefeld) 566
- Occlusion coronary: acute effects of verapamil on ventricular rhythm during (Fondacaro Han and Yoon) 81
artery in dogs: protection of ischemic myocardium by whole body hypothermia after (Abendschein Tacker and Babbs) 772
comparison of rhythm and rate induced myocardial O consumption changes before and after (Kralios Tsagaris and Kuida) 372
- Of atherosclerosis in infants and children and viral infections (Burch) 558 (Annot)
discovers (Burch) 416 (Annot)
how non invasive is non invasive? (Burch) 130 (Annot)
testing treating and charging (Burch) 832 (Annot)
the myocardium and myotonia atrophica (*Dystrophica myotonia*) (Burch) 272 (Annot)
the venous pumps and congestive heart failure (Burch) 697 (Annot)
- Ointment nitroglycerin prolonged benefit of on exercise tolerance in patients with angina pectoris (Karsh et al) 587
- Oral ISDN-long acting nitrate (Pascal) 424 (Letter to Editor)
- Orthostatic hypertension in normotensives and borderline hypertensive patients (Safar) 563 (Letter to Editor)
- Ouabain induced Wenckebach conduction block in canine Purkinje fibers: the role of cycle length and time dependent changes in membrane potential (Anderson and Reiser) 781
norepinephrine and heart rate on myocardial oxygen consumption and inotropic state in dogs: comparative influence of (Boerth Hammermeister and Warbasse) 355
- Outflow tract obstruction pulmonary in d transposition of the great vessels: evaluation of range gated pulsed Doppler echocardiography for detecting (Arias et al) 467
- O consumption changes myocardial before and after coronary occlusion: comparison of rhythm and rate induced (Kralios Tsagaris and Kuida) 372
- P
- P wave terminal force in presumably healthy middle aged men: significance of (Forfang and Ericksen) 439
- Pacemaker programmable: potential hazard of the (Gould and Reddy) 704 (Letter to Editor)
- Pacing atrial exercise tests and myocardial lactate extraction in relation to coronary arteriography in young patients with angina pectoris (Rajasalmi and Takkunen) 751
from the vicinity of the A V node: exposure of concealed night bundle branch block in Wolff Parkinson White type B by (Garcia et al) 662
sequential retroventricular with a single bipolar electrode catheter (Wald Waxman and Bonet) 874 (Annot)
- Pain of myocardial infarction: the carbon copy (Short and Stowers) 417 (Annot)
- Patency left internal mammary coronary bypass: non invasive assessment of using the external Doppler probe (Benchimol et al) 347
- Pathogenesis of myocardial infarction (Davies et al) 561 (Letter to Editor)
Reply (Baroldi) 562
- Pectoris angina: exercise tests: atrial pacing and myocardial lactate extraction in relation to coronary arteriography in young patients with (Rajasalmi and Takkunen) 751
prolonged benefit of nitroglycerin ointment on exercise tolerance in patients with (Karsh et al) 587
spontaneous changes in the severity of (Short and Stowers) 415 (Annot)
- Perhexiline maleate in angiographically proven intractable angina: assessment of a double blind trial (Mir and Kafetzakis) 350
- Pericardial constriction (Hirschmann) 110
- Pericarditis idiopathic acute and calcific aortic stenosis: unusual fatal disease combination (Wheatley) 87
- Penoperative myocardial infarction related to coronary bypass surgery (Lum et al) 463
- Peripheral hemodynamics in anephric patients with hypertension (Viden et al) 203
- Pharmacokinetics dose independent of digoxin in humans (Ochs et al) 507
quinidine in patients with cirrhosis or receiving propranolol (Kessler et al) 627
- Phenomenon the importance of R on T (Chou and Wenzke) 191
- Phonocardiography intracardiac: a study with Origin of the basal systolic murmurs in mitral stenosis (Kambe et al) 512
- Physiology vascular lesions of diabetic angiopathy in (McMillan) 401
- Pig Roast Dissertation on an updated (Schoenfeld) 134 (Letter to Editor)
- Pleural effusion as a manifestation of Dressler's syndrome in the distant post infarction period (Dombi and Whitcomb) 243
- Pompe's disease presenting as hypertrophic cardiomyopathy with Wolff Parkinson White syndrome (Bulkley and Hutchins) 246
- Population screening for myocardial ischemia (Rose) 427
- Porcine heterograft valves in the mitral and aortic positions: echocardiographic evaluation of (Harston Robertson and Friesinger) 448
- Postextrasystolic aortic pressure pulse response in coronary artery disease (Hamby et al) 113
- Post infarction period: distant pleural effusion as a manifestation of Dressler's syndrome in the (Dombi and Whitcomb) 243

- Thrombus, mural organized left atrial demonstrated by coronary angiography (Cipriano and Guthaner) 166
- Thumpin, chest to terminate ventricular tachycardia (Forster) 564 (Letter to Editor)
- Reply (Befeler) 564
- Time dependent changes and cycle length in membrane potential the role of ouabain induced Wenckebach conduction block in canine Purkinje fibers (Anderson and Reiser) 781
- Towards more selective resuscitation (Peatfield) 698 (Annot)
- Tracings, ECG early equality of (Kleven) 421 (Letter to Editor)
- Transducer placement on echocardiographic mitral valve motion effect of (Markiewicz London and Popp) 505 (Annot)
- Transfusions, multiple left ventricular function in beta thalassemia and the effect of (Lewis et al) 636
- Transmural gradients of experimental myocardial ischemia limited correlation of ultrastructure with epicardial S-T segment elevation (Lamberti et al) 496
- Treating testin and charging of (Burch) 839 (Annot)
- Tricuspid incompetent congenital, simulating pulmonary atresia with intact ventricular septum a report of two cases (Berman et al) 655
- Valve prolapse occurrence and significance of echocardiographically demonstrated (Werner Schiller and Prasquer) 180
- Truncus arteriosus in a family (Brunson et al) 419 (Letter to Editor)

U

- Ultrastructure with epicardial S-T segment elevation limited correlation of transmural gradients of experimental myocardial ischemia (Lamberti et al) 496
- Unusual complications of coronary bypass surgery (Aimablan et al) 17
- cystic endocardial lesions (Abu Nassar and Flynn) 838 (Letter to Editor)

V

- Valve(s) mitral systolic flutter of the (Sze Nanda and Gramiak) 157
- motion mitral echocardiographic effect of transducer placement on (Markiewicz London and Popp) 555 (Annot)
- porcine homograft in the mitral and aortic positions echocardiographic evaluation of (Harston Robert son and Friesinger) 448
- prolapse mitral ventricular pre-excitation and prolonged Q-T interval syndromes in a patient with (Mirvis and Erwin) 579
- syndrome mitral, and migraine (Latman and Friedman) 610
- tricuspid occurrence and significance of echocardiographically demonstrated (Werner Schiller and Prasquer) 180
- prostheses complications due to cloth wear in cloth-covered Starr Edwards aortic and mitral and their management (Shah et al) 40
- prosthetic heart management of anticoagulation during noncardiac operations in patients with A prospective study (Katholi, Nolan and McGuire) 163
- repair mitral for significant mitral insufficiency (Kav et al) 753
- replacement, aortic intra aortic hemolysis in the late course of Relation to valve type size and function (Dai and Myhre) 24
- leukocyte function after (Kvarstein and Dale) 64
- type size and function in relation to intravascular hemolysis in the late course of aortic valve replacement (Dai and Myhre) 24
- vascular and myocardial alterations associated with viral like nuclei at patiens in endocardial fibroelastosis (Faccior) 91

Vascular-continued

- obstruction primary pulmonary hazard of cardiac catheterization in children with (Keane Fyler and Nadas) 556 (Annot)
- physiology lessons of diabetic angiopathy in (McMillan) 401
- Vectorcardiographic electrocardiographic and echocardiographic correlation in atrial flutter (Zonerach et al) 286
- Vein atresia common pulmonary (Ledbetter Wells and Connors) 580
- renin renal and saralasin testing in renovascular hypertension (MacCarthy and Stokes) 697 (Annot)
- Venous pulse jugular (IVP) tracings and cannon waves more on (Tenczer and Littmann) 134 (Letter to Editor)
- pumps and congestive heart failure of the (Burch) 697 (Annot)
- thromboembolism after stroke (Warlow) 763
- Ventricle left infective aneurysm of the angiographic and echocardiographic features (Saksens et al) 384
- new echocardiographic index of late diastolic filling of the ventricular A wave (Ambrose et al) 615
- Ventricular A wave the a new echocardiographic index of late diastolic filling of the left ventricle (Ambrose et al) 615
- aneurysmectomy left an evaluation of the results of use of a simplified method for analysis of the left ventricular urogram (Smulyan et al) 696
- angiography left lactate production after in coronary artery disease (Visiohi et al) 835 (Letter to Editor)
- arrhythmias exercise induced or augmented effect of a new beta blocking agent levo bunolol on (Shapiro and Park) 417 (Annot)
- contractile performance the effect of aging on (Urthaler Walker and James) 481
- function left in beta thalassemia and the effect of multiple transfusions (Lewis et al) 636
- mural thrombi left occurring in cardiomyopathy, echocardiographic diagnosis of (Kramer et al) 381
- performance during propranolol withdrawal prior to aortic coronary bypass surgery radionuclide assessment of (Reduto et al) 714
- pre-excitation and prolonged Q-T interval syndromes in a patient with mitral valve prolapse (Mirvis and Erwin) 579
- rhythm during acute coronary occlusion effects of verapamil on (Fondacaro Han and Yoon) 81
- septum intact congenital tricuspid incompetence simulating pulmonary atresia with a report of two cases (Berman et al) 655
- tachycardia(s) chest thumping to terminate (Forester) 564 (Letter to Editor)
- Reply (Befeler) 564
- or fibrillation recurrent long term follow up of aneurysmectomy for (Sam et al) 303
- (VT) retrograde Veneckebach effect in (Pordy) 839 (Letter to Editor)
- Ventriculogram left use of a simplified method for analysis of the evaluation of the results of left ventricular aneurysmectomy (Smulyan et al) 696
- Verapamil on normal sinoatrial node function and on sick sinus syndrome effect of (Carrauso et al) 60
- on ventricular rhythm during acute coronary occlusion effects of (Fondacaro Han and Yoon) 81
- Viral infections of atherosclerosis in infants and children and (Burch) 558 (Annot)
- like nuclear particles myocardial and vascular alterations associated with in endocardial fibroelastosis (Faccior) 91
- Voltage measurements ECG main determinant of (Bennett) 835 (Letter to Editor)
- Reply (Toshima and Koga) 835

- Rhythm and rate induced myocardial O_2 consumption changes before and after coronary occlusion comparison of (Kralios Tsagaris and Kuda) 372
- RIA serum myoglobin tests by (Roberts) 420 (Letter to Editor)
- Right bundle branch block in Wolff Parkinson White type B exposure of concealed by pacing from the vicinity of the A V node (Garcia et al) 662
- Rorst Pig Updated Dissertation on a (Schoenfeld) 134 (Letter to Editor)
- Roll over test (Marshall) 132 (Annot)

S

- Saralasin testing and renal vein renin in renovascular hypertension (MacCarthy and Stokes) 697 (Annot)
- Selective resuscitation towards more (Peatfield) 698 (Annot)
- Sensing the cardiac electrogram (Raber) 275 (Letter to Editor)
- Reply (Furman and Hurler) 276
- Septum intact ventricular congenital tricuspid incompetence simulating pulmonary atresia with a report of two cases (Berman et al) 655
- Sequential atrioventricular pacing with a single bipolar electrode catheter (Wald Waxman and Bonet) 828 (Annot)
- Serum myoglobin in acute myocardial infarction a clinical study and review of the literature (Varki et al) 680
- tests by RIA (Roberts) 420 (Letter to Editor)
- Setting the record straight on TAPVC (Lev) 134 (Letter to Editor)
- Severity of angina pectoris spontaneous changes in the (Short and Stowers) 415 (Annot)
- Sick sinus syndrome effect of verapamil on normal sinoatrial node function and on (Carrasco et al) 760
- Silent or asymptomatic myocardial ischemia (Liss) 838 (Letter to Editor)
- Reply (Cohn) 838
- Single ventricle and levotransposition of the great arteries electrophysiologic histologic correlation of the cardiac specialized conduction system in two cases of (Schatz Fenoglio and Krongrad) 235
- Sinoatrial node function normal and on sick sinus syndrome effect of verapamil on (Carrasco et al) 760
- Sinus syndrome sick effect of verapamil on normal sinoatrial node function and on (Carrasco et al) 760
- Smoking and the causes of CHD (Aravanis) 423 (Letter to Editor)
- Reply (Burch) 423
- or low dose heparin—effect of in preventing thromboembolism after myocardial infarction (Emerson) 129 (Annot)
- Spasm coronary artery—diagnostic and therapeutic implications (Maser et al) 554 (Annot)
- Spirolactone (Ochs et al) 389
- Spontaneous changes in the severity of angina pectoris (Short and Stowers) 415 (Annot)
- Standing amyl nitrite and isoproterenol before and during acute beta adrenergic blockade with intravenous propranolol comparison of heart rate and blood pressure response to (Niarchos Tahmooressi and Tarazi) 47
- Starr Edwards aortic and mitral valve prostheses cloth covered complications due to cloth wear in and their management in (Shah et al) 407
- Statistics marathon and CHD (Bassler) 560 (Letter to Editor)
- Reply (Milvy) 560
- Stellate ganglion left and the long Q T syndrome another link between the (Crampton) 130 (Annot)
- Stenosis aortic calcific and acute idiopathic pericarditis unusual fatal disease combination (Wheatley) 87
- distinctive echocardiographic pattern of posterior wall endocardial motion in (Sheppard et al) 9
- coronary ischemic or non ischemic factor? (Baroldi) 139

Stenosis—continued

- mitral origin of the basal systolic murmurs in A study with intracardiac phonocardiography (Hambe et al) 512
- Steroids in myocardial disease (Giorganni) 274 (Letter to Editor)
- S T segment elevation epicardial limited correlation of ultrastructure with transmural gradients of experimental myocardial ischemia (Lamberti et al) 496
- Stroke venous thromboembolism after (Warlow) 293
- Subannular aortic aneurysm echocardiographic detection of a (Alter et al) 52
- Sublingual nitroglycerin arterial hypoxemia following the administration of (Kopman et al) 444
- Surgical versus medical treatment in disease of the left main coronary artery (Graham) 1
- Syndrome Q T long another link between the left stellate ganglion and the (Crampton) 130 (Annot)
- Systolic flutter of the mitral valve (Sze Nanda and Gramiak) 157
- murmurs basal in mitral stenosis origin of A study with intracardiac phonocardiography (Hambe et al) 512
- time intervals and circulating catecholamines in normotensive and hypertensive patients with and without left ventricular hypertrophy (Cousineau Lapointe and de Champlain) 227

T

- Tachycardia(s) A V reentrant effects of bundle branch block on experimental (Amat y Leon et al) 62
- recurrent ventricular or fibrillation long term follow up of aneurysmectomy for (Sami et al) 303
- ventricular chest thumping to terminate (Forester) 564 (Letter to Editor)
- Reply (Befeler) 564
- (VT) retrograde Wenckebach effect in (Pordy) 839 (Letter to Editor)
- TAPVC setting the record straight on (Lev) 134 (Letter to Editor)
- Teaching the proper use of nitroglycerin recourse to a computer for (Rabinowitz Lowen and Slack) 701 (Letter to Editor)
- Teflon felt embolism of coronary arteries after cardiac surgery a case report (Bedetti Siewers and Dunsford) 802
- Temperature course in acute myocardial infarction the (Lofmark Nordlander and Orinius) 153
- Terminal force P wave in presumably healthy middle aged men significance of (Forfang and Friksen) 739
- Terminate ventricular tachycardias chest thumping to (Forester) 564 (Letter to Editor)
- Reply (Befeler) 564
- Test roll over (Marshall) 132 (Annot)
- Testing antitangential therapy in favor of current practice (Shapiro) 701 (Letter to Editor)
- treatment and charging of (Burch) 832 (Annot)
- Tetralogy of Fallot additional angiograms for (Sias Arjampour and Shakibi) 135 (Letter to Editor)
- Therapeutic options a multiplicity of in complex congenital heart disease (Scott Chandra and Roberts) 806
- Therapy current for infective endocarditis Part II (Casey and Miller) 263
- testing antitangential in favor of current practice (Shapiro) 701 (Letter to Editor)
- Thrombomural left ventricular occurring in cardiomyopathy echocardiographic diagnosis of (Kramer et al) 381
- Thrombocytopenia essential arterial thrombosis in (Hussain et al) 31
- Thromboembolism after myocardial infarction preventing effect of low dose heparin or smoking (Emerson) 129 (Annot)
- after stroke venous (Warlow) 293
- Thrombotic arterial in essential thrombocythemia (Hussain et al) 31

